id,document_id,text,text_bound_annotations,events,relations,equivalences,attributes,normalizations
0,PMC-1310901-05-MATERIALS_AND_METHODS,"Expression analysis
To analyze the IRF-4 transcriptional level, RNA was extracted from cells using the commercial RNAzol-kit (Paesel, Frankfurt, Germany). An aliquot of 1 mug total RNA was used for cDNA synthesis as described previously (27). RNA expression analysis for IRF-4 and the reference gene beta-actin was carried out by semi-quantitative PCR as described previously (3,27). PCR products were verified by automated sequencing. PCR primers and conditions for expression analysis of DNMT or MBP (DNMT1 DNMT3A, DNMT3B, MeCP, MBD1, MBD2 and MBD4) were published elsewhere (28).
For analysis of IRF-4 protein expression, a standard immunoblotting assay was performed as described previously (29). Briefly, protein lysates were generated by incubating 1 x 106 cells in 100 microl RIPA buffer (1% NP-40, 0.5% sodiumdesoxycholate, 0.1% SDS, 100 microg/ml phenylmethylsulfonyl fluoride, 10 microl/ml protease-inhibitory-mix, 1 micromol/ml sodiumorthovanadate in phosphate-buffered saline) for 30 min on ice. After centrifugation, protein concentration of the supernatant was determined by BCA-method (Pierce, Rockford, IL) as recommended. Protein lysates (70-100 microg) were electrophoresed on polyacrylamide gels and transferred to a PVDF-membrane (Immobilon P, 0.45 microm; Millipore, Eschborn, Germany). Membranes were blocked with 2.5% blocking reagent (Boehringer Mannheim, Germany) in TBST buffer (4.44 g/l Tris-HCL, 2.65 g/l TrisOH, 8.07 g/l NaCl, 0.2 g/l KCl and 500 microl/l Tween-20 in H2O) and subsequently incubated with primary antibody as indicated and horseradish peroxidase-conjugated secondary antibody, anti-mouse or anti-goat IgG (DAKO, Hamburg, Germany), respectively. The membranes were then developed with an ECL detection kit (Amersham Pharmacia Biotech, Freiburg, Germany). The primary antibodies were goat anti-IRF-4/ICSAT (M-17) (Santa Cruz Biotechnology, Santa Cruz, CA) and mouse anti-beta-actin (AC-74) (Sigma).","[{'offsets': [[35, 40]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[271, 276]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[300, 310]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[502, 508]], 'text': ['(DNMT1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[509, 515]], 'text': ['DNMT3A'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[517, 523]], 'text': ['DNMT3B'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[525, 529]], 'text': ['MeCP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[531, 535]], 'text': ['MBD1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[537, 541]], 'text': ['MBD2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[546, 550]], 'text': ['MBD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[599, 604]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1837, 1842]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1843, 1848]], 'text': ['ICSAT'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1850, 1854]], 'text': ['M-17'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1914, 1924]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[41, 56]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T16'}, {'offsets': [[243, 257]], 'text': ['RNA expression'], 'type': 'Transcription', 'id': 'T17'}, {'offsets': [[467, 477]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[613, 623]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T19'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T17', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T18', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T19', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],"[{'id': '*', 'ref_ids': ['T12', 'T14', 'T13']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}]",[]
1,PMC-2791889-15-Experimental_Procedures,"Immunoblotting
Differentiated CD4+ T cells were rested for 5 hr in 1% FCS-containing medium and restimulated as described for specific experiments. Cell lysates were prepared, equal amounts of protein were separated by SDS-PAGE, and phosphorylated or total ERK and actin were detected as described before (Beinke et al., 2004).","[{'offsets': [[30, 33]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[257, 260]], 'text': ['ERK'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[265, 270]], 'text': ['actin'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
2,PMC-2664230-11-RESULTS,"PTX upregulates CREB phosphorylation and activation after LPS stimulation
Phosphorylation of nuclear CREB was used as a marker for CREB activation. LPS stimulation caused a negligible increase in CREB phosphorylation when compared to control (Figure 4A). PTX alone caused a marked increase in CREB phosphorylation (P < 0.01 vs. HBSS). When LPS and PTX exposure occurred simultaneously, CREB phosphorylation was significantly higher than with LPS stimulation alone (543 +/- 92 vs. 100 +/- 0; P < 0.01). In addition, the amount of CREB phosphorylation seen with concomitant LPS and PTX treatment was less than that seen with PTX alone, although this difference was not statistically significant (P = 0.08).
To determine if CREB-DNA binding was affected by PTX in a manner similar to CREB phosphorylation, an EMSA was performed. Exposure of LPS-stimulated cells to PTX similarly increased CREB DNA-binding compared to LPS alone (Figure 4B).","[{'offsets': [[886, 890]], 'text': ['CREB'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[876, 885]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T2'}, {'offsets': [[895, 902]], 'text': ['binding'], 'type': 'Binding', 'id': 'T3'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T3', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
3,PMC-3245220-07-Results,"M-CSF Induces Phosphorylation of NF-kappaB Ser276 in a PKC-dependent Fashion
Since M-CSF did not regulate NF-kappaB activation by influencing IkappaBalpha, we next sought to determine if M-CSF affected NF-kappaB p65 by post-translational mechanisms. Thus, we examined the phosphorylation of NF-kappaB p65 with specific phospho-NFkappaB p65 (Ser276 and Ser536) antibodies. M-CSF induced the phosphorylation of Ser276 but not Ser536 of NF-kappaB p65 in MDMs. Compared to vehicle, the general PKC inhibitor Ro-31-8220 reduced Ser276 phosphorylation, but not Ser536, phosphorylation in M-CSF-stimulated cells (Figure 5B). Furthermore, M-CSF-stimulated NF-kappaB p65 phosphorylation at residue Ser276 in RAW 264.7 cells was also PKC dependent (Figure 5C). These studies suggested that PKC(s) regulated Ser276 phosphorylation but not Ser536 in both human MDMs and mouse macrophages after M-CSF stimulation.
We next performed cellular fractionation to identify the cellular location of phosphorylated NF-kappaB p65 in Raw 264.7 cells. Non-phosphorylated NF-kappaB p65 was located in both cytosolic and nuclear fractions, but phosphorylated Ser276 and Ser536 NF-kappaB p65 was primarily located in nuclear fraction after M-CSF stimulation (Figure 5D). Notably, constitutive phosphorylation of Ser536 NF-kappaB p65 was found in these cells. Importantly, Ro-31-8220 reduced M-CSF-induced Ser276 phosphorylation of NF-kappaB p65 in both the cytosolic and nuclear fractions, while M-CSF-induced NF-kappaB p65 Ser536 phosphorylation was present in the nucleus regardless of PKC inhibition. These observations indicate that M-CSF-induced Ser276 and Ser536 are regulated differently by conventional PKC activation in mononuclear phagocytes. The purity of the cytosol and nuclear cell fractions was confirmed by immunoblotting with GAPDH and Lamin B, respectively (Figure 5D).","[{'offsets': [[142, 154]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[212, 215]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[301, 304]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[444, 447]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[658, 661]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1004, 1007]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1057, 1060]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1161, 1164]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1302, 1305]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1414, 1417]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1493, 1496]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[193, 201]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[219, 248]], 'text': ['post-translational mechanisms'], 'type': 'Protein_modification', 'id': 'T15'}, {'offsets': [[272, 287]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T16'}, {'offsets': [[378, 385]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[390, 405]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T18'}, {'offsets': [[409, 415]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T19'}, {'offsets': [[424, 430]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T20'}, {'offsets': [[515, 522]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T21'}, {'offsets': [[523, 529]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T22'}, {'offsets': [[530, 545]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T23'}, {'offsets': [[555, 561]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T24'}, {'offsets': [[563, 578]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T25'}, {'offsets': [[637, 647]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[662, 677]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T27'}, {'offsets': [[689, 695]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T28'}, {'offsets': [[728, 737]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T29'}, {'offsets': [[787, 796]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T30'}, {'offsets': [[797, 803]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T31'}, {'offsets': [[804, 819]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T32'}, {'offsets': [[828, 834]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T33'}, {'offsets': [[888, 899]], 'text': ['stimulation'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[967, 975]], 'text': ['location'], 'type': 'Localization', 'id': 'T35'}, {'offsets': [[979, 993]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T36'}, {'offsets': [[1032, 1046]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T37'}, {'offsets': [[1065, 1072]], 'text': ['located'], 'type': 'Localization', 'id': 'T38'}, {'offsets': [[1076, 1112]], 'text': ['both cytosolic and nuclear fractions'], 'type': 'Entity', 'id': 'T39'}, {'offsets': [[1118, 1132]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T40'}, {'offsets': [[1133, 1139]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[1144, 1150]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T42'}, {'offsets': [[1179, 1186]], 'text': ['located'], 'type': 'Localization', 'id': 'T43'}, {'offsets': [[1190, 1197]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T44'}, {'offsets': [[1266, 1281]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T45'}, {'offsets': [[1285, 1291]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T46'}, {'offsets': [[1356, 1363]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T47'}, {'offsets': [[1370, 1377]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[1378, 1384]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[1385, 1400]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T50'}, {'offsets': [[1475, 1482]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[1497, 1503]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T52'}, {'offsets': [[1504, 1519]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[1547, 1557]], 'text': ['regardless'], 'type': 'Regulation', 'id': 'T54'}, {'offsets': [[1616, 1623]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[1624, 1630]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[1635, 1641]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T56'}, {'offsets': [[1646, 1655]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T57'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T19']}}, {'trigger': 'T17', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T20']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T22']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T25', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T24']}}, {'trigger': 'T26', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T27', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T28']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T30', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T32', 'id': 'E16', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T31']}}, {'trigger': 'T30', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T32', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T33']}}, {'trigger': 'T34', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T34', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T35', 'id': 'E21', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T36', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T37', 'id': 'E23', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T38', 'id': 'E24', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T39']}}, {'trigger': 'T40', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T41']}}, {'trigger': 'T40', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T42']}}, {'trigger': 'T43', 'id': 'E27', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T44']}}, {'trigger': 'T45', 'id': 'E28', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T46']}}, {'trigger': 'T47', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T48', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T50', 'id': 'E31', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T49']}}, {'trigger': 'T51', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T53', 'id': 'E33', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T52']}}, {'trigger': 'T54', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T13', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T55']}}, {'trigger': 'T13', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T56']}}, {'trigger': 'T57', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T57', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}]",[]
4,PMC-3148254-09-Materials_and_Methods,"Somatic cell gene targeting
The generation of HOIP-deficient cells was accomplished using a homologous recombination approach described previously [7], [8]. Segments of Rnf31 gene sequence used in the targeting construct (Fig. 1A) were amplified by PCR from A20.2J genomic DNA. The oligonucleotide primers used to generate the 5' flank (1224 bp) were 5'-ttttctagagcggtggcttaagtgaccc-3' and 5'-tattctagatgcagcatctgagaaagcaagc-3'. The 3' flank (6032 bp) primers were 5'-aaaaccggtgtatgcttctttacgggagaaaaatattag-3' and 5'-tataccggtatgaagccaaaggaacactgagag-3'. Restriction endonuclease sites in the oligonucleotide primers allowed insertion of the PCR products into the targeting vector. A20.2J cells were transfected (by electroporation [7]) with the targeting construct and subcloned in medium containing 600 microg/ml G418 sulfate. Homologous recombination in G418-resistant clones was detected by PCR of genomic DNA, as described [7]. Oligonucleotide primers used for screening were 5'-cttcctgatctcagctttaccgtcac-3' (homologous to genomic sequence; approximate position noted in Fig. 1) and 5'-caatccatcttgttcagccat-3' (homologous to sequence in NeoR). Clones in which one copy of Rnf31 had been disrupted were transiently transfected with an expression plasmid encoding Cre, in order to remove NeoR. G418-sensitive subclones were subjected to a second round of targeting to disrupt the remaining copy of Rnf31. G418-resistant clones were tested for homologous recombination by PCR and HOIP protein expression by Western blot.","[{'offsets': [[46, 50]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[169, 174]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1180, 1185]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1404, 1409]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1485, 1489]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[51, 60]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T6'}, {'offsets': [[1195, 1204]], 'text': ['disrupted'], 'type': 'Negative_regulation', 'id': 'T7'}, {'offsets': [[1498, 1508]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
5,PMC-2626671-06-RESULTS_AND_DISCUSSION,"Runx3 controls multiple aspects of the CTL differentiation program, in part through induction of Eomes
Because Runx3 is highly expressed in peripheral CD8+ T cells, and because of the T-bet-Runx3 cooperation we observed earlier in CD4+ T cells (15), we examined the role of Runx3 in effector CTL differentiation. We isolated CD8+ T cells from Runx3-/- (KO) mice of the outbred ICR background and their WT Runx3+/+ littermates by positive selection with anti-CD8 magnetic beads (Figs. S1 and S2, available at http://www.jem.org/cgi/content/full/jem.20081242/DC1). Strikingly, Runx3-/- CD8+ T cells were strongly impaired in their ability to differentiate into effector CTLs, as judged by expression of perforin, granzyme B, and IFN-gamma (Fig. 3). Compared with WT T cells, perforin mRNA and protein expression were essentially undetectable in Runx3-/- T cells at day 6 of culture (Fig. 3, A and B). Runx3-/- T cells also had no detectable Eomes expression; in contrast, T-bet expression was unimpaired (Fig. 3 A). Furthermore, Runx3 was required for maximal production of IFN-gamma, but not TNF or IL-2, by CD8+ T cells restimulated at day 6 (Fig. 3 C).
We previously reported that Th1 cell differentiation was regulated through a feed-forward loop in which T-bet is up-regulated early and induces Runx3, after which T-bet and Runx3 cooperate to induce IFN-gamma and silence IL-4, thus promoting stable differentiation toward the Th1 lineage (15, 22). Because (a) Runx3 appeared necessary for Eomes induction (Fig. 3 A), (b) the kinetics of Eomes expression paralleled those of perforin expression (Fig. 2), and (c) overexpression of Eo-VP16 in either WT or T-bet-deficient T cells led to an increase in both perforin and IFN-gamma expression (Fig. 2, B and D), we asked whether CTL differentiation was also potentially regulated by a feed-forward loop involving these same two classes of Runx and T-box transcription factors. Specifically, we asked whether Runx3, which was necessary for Eomes induction, then cooperated with Eomes to regulate transcription of the effector CTL markers perforin, IFN-gamma, and granzyme B.
To test this hypothesis, we used chromatin immunoprecipitation (ChIP) assays to ask whether Eomes and Runx3 bound regulatory regions of the Prf1, Ifng, and Gzmb genes (Fig. 3 D). Both proteins associated with gene regulatory regions in differentiated CTLs. Runx3 bound to the Prf1 and Gzmb transcription start sites (TSS); to a known IL-2 responsive enhancer located near -1 kb of the Prf1 gene (23); to the distal CTL-specific DNase I hypersensitive site 9 in the Prf1 locus (24); to the Ifng promoter near the TSS, as previously reported for Th1 cells (10); and to several DNase I hypersensitive sites in the Ifng locus (Fig. 3 D and not depicted) (25). Eomes bound primarily to the Prf1 TSS and the -1 kb enhancer; this binding was substantially greater than that observed at the promoter of the Il2rb gene, a known direct target of Eomes (8), and comparable to that observed at the Ifng TSS, a known target of T-box proteins in both Th1 and CD8+ T cells (Fig. 3 D) (17).
To determine whether Runx3 controlled the expression of CTL effector genes through its induction of Eomes, we retrovirally expressed Runx3 and Eo-VP16 in CD8+ T cells from Runx3-/- mice. Because of the limited number of CD8+ T cells in these mice, and because we saw no difference between Runx3-/- CD8+CD4- SP and CD8+CD4+ DP cells in our previous experiments, we used total Runx3-/- CD8+ T cells without further fractionation as recipients for retroviral transduction. Reconstitution of Runx3-/- CD8+ T cells with Runx3 restored expression of Eomes as well as perforin, granzyme B, and IFN-gamma (Fig. 4, A and B). In addition, Runx3-/- T cells showed a compensatory up-regulation of Runx1, which was suppressed upon reconstitution with Runx3, indicating that Runx1 is a target of repression by Runx3. Notably, Eo-VP16 did not up-regulate perforin expression when expressed in Runx3-/- cells, even though it restored the capacity to induce IFN-gamma expression upon TCR restimulation (Fig. 4, A and B). This result suggests strongly that perforin expression requires Runx3 and Eomes.
As expected from their defect in perforin and granzyme B expression, Runx3-/- CD8+ T cells showed defective cytolytic activity in a mixed lymphocyte reaction (12). However, TCR-stimulated Runx3-/- CD8+ cells were as effective as WT cells in killing tumor cells in a redirected CTL assay (12). Furthermore, CD8+ cells from the peritoneal cavity of Runx3-/- mice immunized with certain tumor cells effectively killed these targets (13). Therefore, although activation of the perforin/granzyme B machinery is defective in Runx3-/- CD8+ cells, these cells are not entirely devoid of cytolytic activity and could still effectively kill targets, possibly by alternative mechanisms such as the Fas-Fas ligand pathway.","[{'offsets': [[0, 5]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 102]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[111, 116]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[151, 154]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[184, 189]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[190, 195]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[231, 234]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[274, 279]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[325, 328]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[343, 348]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[405, 410]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[458, 461]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[575, 580]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[584, 587]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[701, 709]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[711, 721]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[727, 736]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[773, 781]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[843, 848]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[899, 904]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[939, 944]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[970, 975]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1027, 1032]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1072, 1081]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1091, 1094]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1098, 1102]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1107, 1110]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1258, 1263]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1298, 1303]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1317, 1322]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1327, 1332]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1353, 1362]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1375, 1379]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1464, 1469]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1493, 1498]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1541, 1546]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1578, 1586]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1634, 1641]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1658, 1663]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1709, 1717]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1722, 1731]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1958, 1963]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1989, 1994]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2027, 2032]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2087, 2095]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2097, 2106]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2112, 2122]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2216, 2221]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2226, 2231]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2264, 2268]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2270, 2274]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2280, 2284]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2381, 2386]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2400, 2404]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2409, 2413]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2509, 2513]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2589, 2593]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2613, 2617]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2735, 2739]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2780, 2785]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2809, 2813]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2923, 2928]], 'text': ['Il2rb'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2960, 2965]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3010, 3014]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3069, 3072]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3120, 3125]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3199, 3204]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3232, 3237]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3242, 3249]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3253, 3256]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3271, 3276]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3319, 3322]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[3388, 3393]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[3397, 3400]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[3401, 3404]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[3413, 3416]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[3417, 3420]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[3474, 3479]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[3483, 3486]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[3587, 3592]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[3596, 3599]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[3614, 3619]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[3643, 3648]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[3660, 3668]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[3670, 3680]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[3686, 3695]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[3728, 3733]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[3784, 3789]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[3837, 3842]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[3860, 3865]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[3895, 3900]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[3911, 3918]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[3939, 3947]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[3977, 3982]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[4040, 4049]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[4138, 4146]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[4167, 4172]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[4177, 4182]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[4217, 4225]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[4230, 4240]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[4253, 4258]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[4262, 4265]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[4372, 4377]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[4381, 4384]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[4490, 4493]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[4531, 4536]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[4657, 4665]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[4666, 4676]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[4703, 4708]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4712, 4715]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4871, 4874]], 'text': ['Fas'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4875, 4885]], 'text': ['Fas ligand'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[84, 93]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T117'}, {'offsets': [[127, 136]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T118'}, {'offsets': [[687, 697]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T119'}, {'offsets': [[799, 809]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T120'}, {'offsets': [[827, 839]], 'text': ['undetectable'], 'type': 'Positive_regulation', 'id': 'T121'}, {'offsets': [[945, 955]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T122'}, {'offsets': [[976, 986]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T123'}, {'offsets': [[991, 1001]], 'text': ['unimpaired'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[1037, 1045]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T125'}, {'offsets': [[1058, 1068]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T126'}, {'offsets': [[1267, 1279]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T127'}, {'offsets': [[1290, 1297]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T128'}, {'offsets': [[1346, 1352]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T129'}, {'offsets': [[1367, 1374]], 'text': ['silence'], 'type': 'Negative_regulation', 'id': 'T130'}, {'offsets': [[1479, 1488]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T131'}, {'offsets': [[1499, 1508]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T132'}, {'offsets': [[1547, 1557]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T133'}, {'offsets': [[1587, 1597]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T134'}, {'offsets': [[1616, 1630]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[1664, 1673]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T136'}, {'offsets': [[1682, 1685]], 'text': ['led'], 'type': 'Positive_regulation', 'id': 'T137'}, {'offsets': [[1692, 1700]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T138'}, {'offsets': [[1732, 1742]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T139'}, {'offsets': [[1975, 1984]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T140'}, {'offsets': [[1995, 2004]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T141'}, {'offsets': [[2036, 2044]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T142'}, {'offsets': [[2045, 2058]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T143'}, {'offsets': [[2232, 2237]], 'text': ['bound'], 'type': 'Binding', 'id': 'T144'}, {'offsets': [[2238, 2256]], 'text': ['regulatory regions'], 'type': 'Entity', 'id': 'T145'}, {'offsets': [[2303, 2316]], 'text': ['Both proteins'], 'type': 'Anaphora', 'id': 'T113'}, {'offsets': [[2317, 2327]], 'text': ['associated'], 'type': 'Binding', 'id': 'T146'}, {'offsets': [[2387, 2392]], 'text': ['bound'], 'type': 'Binding', 'id': 'T147'}, {'offsets': [[2414, 2439]], 'text': ['transcription start sites'], 'type': 'Entity', 'id': 'T148'}, {'offsets': [[2786, 2791]], 'text': ['bound'], 'type': 'Binding', 'id': 'T149'}, {'offsets': [[2814, 2817]], 'text': ['TSS'], 'type': 'Entity', 'id': 'T150'}, {'offsets': [[2826, 2840]], 'text': ['-1 kb enhancer'], 'type': 'Entity', 'id': 'T151'}, {'offsets': [[2886, 2890]], 'text': ['that'], 'type': 'Binding', 'id': 'T152'}, {'offsets': [[2907, 2915]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T153'}, {'offsets': [[2950, 2956]], 'text': ['target'], 'type': 'Binding', 'id': 'T154'}, {'offsets': [[2989, 2993]], 'text': ['that'], 'type': 'Binding', 'id': 'T155'}, {'offsets': [[3015, 3018]], 'text': ['TSS'], 'type': 'Entity', 'id': 'T156'}, {'offsets': [[3028, 3034]], 'text': ['target'], 'type': 'Binding', 'id': 'T157'}, {'offsets': [[3186, 3195]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T158'}, {'offsets': [[3222, 3231]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T159'}, {'offsets': [[3620, 3628]], 'text': ['restored'], 'type': 'Positive_regulation', 'id': 'T160'}, {'offsets': [[3629, 3639]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T161'}, {'offsets': [[3767, 3780]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T162'}, {'offsets': [[3791, 3796]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T114'}, {'offsets': [[3801, 3811]], 'text': ['suppressed'], 'type': 'Negative_regulation', 'id': 'T163'}, {'offsets': [[3881, 3891]], 'text': ['repression'], 'type': 'Negative_regulation', 'id': 'T164'}, {'offsets': [[3927, 3938]], 'text': ['up-regulate'], 'type': 'Positive_regulation', 'id': 'T165'}, {'offsets': [[3948, 3958]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T166'}, {'offsets': [[3964, 3973]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T167'}, {'offsets': [[4005, 4007]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T115'}, {'offsets': [[4008, 4016]], 'text': ['restored'], 'type': 'Positive_regulation', 'id': 'T168'}, {'offsets': [[4033, 4039]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T169'}, {'offsets': [[4050, 4060]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T170'}, {'offsets': [[4147, 4157]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T171'}, {'offsets': [[4158, 4166]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T172'}, {'offsets': [[4201, 4206]], 'text': ['their'], 'type': 'Anaphora', 'id': 'T116'}, {'offsets': [[4207, 4213]], 'text': ['defect'], 'type': 'Positive_regulation', 'id': 'T173'}, {'offsets': [[4241, 4251]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T174'}, {'offsets': [[4639, 4649]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T175'}, {'offsets': [[4690, 4699]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T176'}]","[{'trigger': 'T117', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T2', 'T1']}}, {'trigger': 'T118', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T119', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T119', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T119', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T120', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T121', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T122', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T123', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T124', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T125', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T23']}}, {'trigger': 'T126', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T125', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'T23']}}, {'trigger': 'T126', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T125', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T23']}}, {'trigger': 'T126', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T127', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T128', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T129', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T32', 'T30']}}, {'trigger': 'T129', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T32', 'T31']}}, {'trigger': 'T130', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'T30']}}, {'trigger': 'T130', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'T31']}}, {'trigger': 'T131', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T34']}}, {'trigger': 'T132', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T133', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T134', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T135', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T136', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T137', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'E27']}}, {'trigger': 'T138', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T137', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'E27']}}, {'trigger': 'T138', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E34']}}, {'trigger': 'T139', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T139', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T140', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T42']}}, {'trigger': 'T141', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T142', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'T42']}}, {'trigger': 'T143', 'id': 'E38', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T142', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'T44']}}, {'trigger': 'T142', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'T42']}}, {'trigger': 'T143', 'id': 'E41', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T142', 'id': 'E42', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'T44']}}, {'trigger': 'T142', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'T42']}}, {'trigger': 'T143', 'id': 'E44', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T142', 'id': 'E45', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'T44']}}, {'trigger': 'T144', 'id': 'E46', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T48', 'T50', 'T145']}}, {'trigger': 'T144', 'id': 'E47', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T48', 'T51', 'T145']}}, {'trigger': 'T144', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T48', 'T52', 'T145']}}, {'trigger': 'T144', 'id': 'E49', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T50', 'T145']}}, {'trigger': 'T144', 'id': 'E50', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T51', 'T145']}}, {'trigger': 'T144', 'id': 'E51', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T52', 'T145']}}, {'trigger': 'T146', 'id': 'E52', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T146', 'id': 'E53', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T147', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T53', 'T54', 'T148']}}, {'trigger': 'T147', 'id': 'E55', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T53', 'T55', 'T148']}}, {'trigger': 'T149', 'id': 'E56', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T60', 'T61', 'T150']}}, {'trigger': 'T149', 'id': 'E57', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T60', 'T61', 'T151']}}, {'trigger': 'T152', 'id': 'E58', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T60', 'T62', 'T153']}}, {'trigger': 'T154', 'id': 'E59', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T62', 'T63', 'T153']}}, {'trigger': 'T155', 'id': 'E60', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T60', 'T64', 'T156']}}, {'trigger': 'T157', 'id': 'E61', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T64', 'T156']}}, {'trigger': 'T158', 'id': 'E62', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T67', 'T66']}}, {'trigger': 'T159', 'id': 'E63', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T159', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T160', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E66', 'T82']}}, {'trigger': 'T161', 'id': 'E66', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T160', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E68', 'T82']}}, {'trigger': 'T161', 'id': 'E68', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T160', 'id': 'E69', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E70', 'T82']}}, {'trigger': 'T161', 'id': 'E70', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T160', 'id': 'E71', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E72', 'T82']}}, {'trigger': 'T161', 'id': 'E72', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T86']}}, {'trigger': 'T162', 'id': 'E73', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T163', 'id': 'E74', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T88', 'T89']}}, {'trigger': 'T164', 'id': 'E75', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T90', 'T91']}}, {'trigger': 'T165', 'id': 'E76', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E77', 'T92']}}, {'trigger': 'T166', 'id': 'E77', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T93']}}, {'trigger': 'T167', 'id': 'E78', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T92']}}, {'trigger': 'T168', 'id': 'E79', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E80', 'T92']}}, {'trigger': 'T169', 'id': 'E80', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E81']}}, {'trigger': 'T170', 'id': 'E81', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T95']}}, {'trigger': 'T171', 'id': 'E82', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T96']}}, {'trigger': 'T172', 'id': 'E83', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E82', 'T97']}}, {'trigger': 'T172', 'id': 'E84', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E82', 'T98']}}, {'trigger': 'T173', 'id': 'E85', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E86', 'T97']}}, {'trigger': 'T174', 'id': 'E86', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T99']}}, {'trigger': 'T173', 'id': 'E87', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E86', 'T98']}}, {'trigger': 'T173', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E89', 'T97']}}, {'trigger': 'T174', 'id': 'E89', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T100']}}, {'trigger': 'T173', 'id': 'E90', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E89', 'T98']}}, {'trigger': 'T175', 'id': 'E91', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T107']}}, {'trigger': 'T175', 'id': 'E92', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T108']}}, {'trigger': 'T176', 'id': 'E93', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E91']}}, {'trigger': 'T176', 'id': 'E94', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E92']}}]","[{'id': 'R1', 'head': {'ref_id': 'T113', 'role': 'Subject'}, 'tail': {'ref_id': 'T48', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T113', 'role': 'Subject'}, 'tail': {'ref_id': 'T49', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T114', 'role': 'Subject'}, 'tail': {'ref_id': 'T88', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T115', 'role': 'Subject'}, 'tail': {'ref_id': 'T92', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T116', 'role': 'Subject'}, 'tail': {'ref_id': 'T97', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T116', 'role': 'Subject'}, 'tail': {'ref_id': 'T98', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E35', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E46', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E47', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E48', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E49', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E50', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E51', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E76', 'value': ''}, {'id': 'M16', 'type': 'Speculation', 'ref_id': 'E83', 'value': ''}, {'id': 'M17', 'type': 'Speculation', 'ref_id': 'E84', 'value': ''}, {'id': 'M18', 'type': 'Negation', 'ref_id': 'E85', 'value': ''}, {'id': 'M19', 'type': 'Negation', 'ref_id': 'E87', 'value': ''}, {'id': 'M20', 'type': 'Negation', 'ref_id': 'E88', 'value': ''}, {'id': 'M21', 'type': 'Negation', 'ref_id': 'E90', 'value': ''}]",[]
6,PMC-3279418-11-Materials_and_Methods,"Generation of BMDC
BMDC were developed as previously reported [54], [55]. Cells were collected after 10-12 days of culture. The cell yield was 2-3x107 cells/mouse with 80-95% BMDC.",[],[],[],[],[],[]
7,PMC-2889865-15-Materials_and_methods,"Reverse transcription quantitative PCR (RT-qPCR)
RT-qPCR was used to determine gene expression levels of il-6 and cxcl8 in response to PMA following inhibition of NF-kappaB, JNK and PKC. The following primer sequences were used, il-6: forward- TGTGAAAGCAGCAAAGAGGCACTG, reverse- ACAGCTCTGGCTTGTTCCTCACTA; cxcl8: forward- ACCACACTGCGCCAACACAGAAAT, reverse- AAACTTCTCCACAACCCTCTGCAC. Thermocycling conditions for CYBR Green (Quanta, USA) consisted of a denaturation step for 10 min at 95 degreesC followed by 60 cycles of 95degreesC for 1s and 60degreesC for 30s. Gene expression was analysed using Stratagene (Mx3000p(TM)) (AH diagnostics). The obtained Ct values were normalized against 18S. Initially, all measured 18S Ct values were used to calculate a mean Ct value that was used to determine the deltaCt values for each sample. Gene expression patterns for il-6 and cxcl8 were then normalized with regard to the samples 18S deltaCt.","[{'offsets': [[105, 109]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[114, 119]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[229, 233]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[305, 310]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[861, 865]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[870, 875]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[84, 94]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[120, 134]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T8'}, {'offsets': [[139, 148]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[837, 847]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T9', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T10', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T10', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}]",[]
8,PMC-3148254-00-TIAB,"HOIL-1L Interacting Protein (HOIP) Is Essential for CD40 Signaling
CD40 is a cell surface receptor important in the activation of antigen-presenting cells during immune responses. In macrophages and dendritic cells, engagement of CD40 by its ligand CD154 provides signals critical for anti-microbial and T cell-mediated immune responses, respectively. In B cells, CD40 signaling has a major role in regulating cell proliferation, antibody production, and memory B cell development. CD40 engagement results in the formation of a receptor-associated complex that mediates activation of NF-kappaB, stress-activated protein kinases, and other signaling molecules. However, the mechanisms that link CD40 to these signaling events have been only partially characterized. Known components of the CD40 signaling complex include members of the TNF receptor-associated factor (TRAF) family of proteins. We previously showed that the TRAF family member TRAF2 mediates recruitment of HOIL-1L-interacting protein (HOIP) to the cytoplasmic domain of CD40, suggesting that HOIP has a role in the CD40 signaling pathway. To determine the role of HOIP in CD40 signaling, we used somatic cell gene targeting to generate mouse B cell lines deficient in HOIP. We found that the CD40-induced upregulation of CD80 and activation of germline immunoglobulin epsilon transcription were defective in HOIP-deficient cells. We also found that the CD40-mediated activation of NF-kappaB and c-Jun kinase was impaired. Recruitment of IkappaB kinase proteins to the CD40 signaling complex was undetectable in HOIP-deficient cells, potentially explaining the defect in NF-kappaB activation. Restoration of HOIP expression reversed the defects in cellular activation and signaling. These results reveal HOIP as a key component of the CD40 signaling pathway.","[{'offsets': [[0, 27]], 'text': ['HOIL-1L Interacting Protein'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[29, 33]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[52, 56]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[67, 71]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[230, 234]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[242, 248]], 'text': ['ligand'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[249, 254]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[364, 368]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[482, 486]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[694, 698]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[942, 947]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[972, 999]], 'text': ['HOIL-1L-interacting protein'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1001, 1005]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1036, 1040]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1058, 1062]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1081, 1085]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1130, 1134]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1138, 1142]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1234, 1238]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1258, 1262]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1287, 1291]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1374, 1378]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1419, 1423]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1577, 1581]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1673, 1677]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1769, 1773]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1800, 1804]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[216, 226]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T28'}, {'offsets': [[487, 497]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T29'}, {'offsets': [[948, 956]], 'text': ['mediates'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[957, 968]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T31'}, {'offsets': [[1014, 1032]], 'text': ['cytoplasmic domain'], 'type': 'Entity', 'id': 'T32'}, {'offsets': [[1221, 1230]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1263, 1270]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1271, 1283]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1361, 1370]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[1379, 1388]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[1582, 1591]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1658, 1669]], 'text': ['Restoration'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1678, 1688]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T40'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T5', 'T7']}}, {'trigger': 'T29', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T30', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T11']}}, {'trigger': 'T31', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T12', 'T14', 'T32']}}, {'trigger': 'T33', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T34', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T20']}}, {'trigger': 'T35', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T36', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T37', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T38', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T39', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T40', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}, {'id': '*', 'ref_ids': ['T12', 'T13']}]",[],[]
9,PMC-3245220-32-Caption-Figure_8,"NF-kappaB p65 Ser276 is essential in regulating NF-kappaB activity.
(A) Raw 264.7 cell line was transiently transfected with pNF-kappaB-SEAP along with empty vector or plasmid encoding either NF-kappaB p65 WT or NF-kappaB p65 276S/A. The cells were transfected for 18-24 hours, serum starved for 4 hours, and then incubated with 10 microM of Ro-31-8220 for 30 minutes prior to treatment with 100 ng/ml of M-CSF for 2 hours and SEAP secretion in the medium was measured. (B) NF-kappaB p65-/- cell line was transiently transfected with pNF-kappaB-SEAP along with empty vector or plasmid encoding either NF-kappaB p65 WT, NF-kappaB p65 276S/A, or NF-kappaB p65 536S/A. The cells were cultured for 24 hours and then serum starved for 4 hours. Cells were then incubated in fresh DMEM medium for 2 hours and SEAP secretion in the medium was measured. The results shown are fold change over empty vector + pTAL-SEAP. (C) NF-kappaB p65-/- cell line was transiently transfected with pNF-kappaB-SEAP with either empty vector or plasmid encoding either NF-kappaB p65 WT or NF-kappaB p65 276S/A. The cells were transfected for 24 hours and serum starved for 4 hours, and then incubated with 10 microM of Ro-31-8220 for 30 minutes prior to treatment with 10 ng/ml of TNFalpha. The supernatant were collected after 2 hours of treatment and SEAP secretion in the medium was measured. The results shown are the fold change over empty vector + pNF-kappaB-SEAP. Data shown are mean +/- S.E.M for at least three independent experiments performed in duplicate.","[{'offsets': [[10, 13]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[202, 205]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[222, 225]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[484, 487]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[611, 614]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[629, 632]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[654, 657]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[924, 927]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1052, 1055]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1072, 1075]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1254, 1262]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[108, 119]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[517, 528]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[957, 968]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T14'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T14', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]",[],[],[],[]
10,PMC-2065877-06-Results,"LMP1 Upregulates IL10 and Constitutively Activates Stat3
To identify cytokines that may contribute to the increased survival and growth of lymphomas, the expression levels of a panel of cytokines were screened on CD19+ MACS-purified B cells, using an RPA probe set for IL4, IL5, IL10, IL13, IL15, IL9, IL2, IL6, and IFNgamma. Expression levels were quantified with a phosphorimager and normalized to the ribosomal housekeeping gene L32. None of the tested cytokines were detected in wild-type lymphocytes, therefore cytokine:L32 ratios were set to 1 in the mouse B cell lymphoma line 967. Transcription of IL10, IL15, and IFNgamma were reproducibly detected in LMP1 transgenic lymphocytes and lymphoma cells and was higher than in the B cell lymphoma cell lines 967 and K46mu (Figure 5A). There was no significant difference in the expression of IL15 and IFNgamma between LMP1 transgenic lymphocytes and lymphoma cells, suggesting that upregulation of IL15 and IFNgamma is induced by LMP1 expression in healthy lymphocytes but is not a unique property of malignant lymphocytes. Strikingly, IL10, a B lymphocyte stimulatory cytokine, was increased 1.5- to 5-fold in the wild-type and LMP1 transgenic lymphoma cells compared to LMP1 transgenic lymphocytes (Figure 5A). Production of IL15 and IFNgamma has been associated with induction of cytotoxic effector responses in cells latently infected with EBV [33,34]. However, transformation and growth properties induced by EBV are associated with the upregulation of IL10 [35-38]; hence, the effects of IL10 upregulation on the growth properties of the lymphoma cells were further examined. Immunoblot analysis indicated that LMP1 transgenic lymphocytes and wild-type and LMP1 transgenic lymphoma cells had corresponding increased levels of phosphorylated alpha and beta isoforms of activated Stat3, a target of the IL10 receptor (Figure 5B). However, when comparing the same lymphomas, there was no correlation between the levels of IL10 induction and the levels of Stat3 activation. This suggests that the activation of Stat3 is not solely induced by IL10 or that Stat3 activation may be constitutive. Additionally, there was no correlation between the levels of LMP1 expression and the levels of IL10 induction (Figures 1A and 5A). This indicates that the induction of IL10 is a general property associated with enhanced survival and may only be indirectly affected by LMP1. Neutralizing antibodies to IL10 did not affect the survival of lymphoma cells as determined by the MTS assay (unpublished data), suggesting constitutive activation of Stat3. This was confirmed by immunoblot analysis such that in the presence of anti-IL10 neutralizing antibodies, pStat3 levels remained activated in lymphoma cells isolated from wild-type and LMP1 transgenic lymphomas (Figure 5C). Exogenous addition of IL10 enhanced pStat3 activation above constitutive levels, indicating that lymphoma cells are responsive to IL10 treatment (Figure 5C). This means that although the lymphoma cells have constitutive Stat3 activation, it may be further enhanced by IL10 induction. The neutralizing effect of the anti-IL10 antibody was confirmed by pre-incubation of IL10 with anti-IL10 antibody compared to a rat IgG1 isotype control (Figure 5C).
Nuclear translocation of pStat3 is a consequence of activation, and nuclear pStat3 was not detected by immunohistochemistry staining of spleen sections from control mice. However, nuclear pStat3 was detectable in LMP1 transgenic mice and wild-type lymphomas and was detected more homogeneously in LMP1 transgenic lymphomas (Figure 5D). The constitutive activation of pStat3 and abundant nuclear Stat3 suggests that Stat3 signaling contributes to LMP1-mediated lymphoma development.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 21]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[51, 56]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[213, 217]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[269, 272]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[274, 277]], 'text': ['IL5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[279, 283]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[285, 289]], 'text': ['IL13'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[291, 295]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[297, 300]], 'text': ['IL9'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[302, 305]], 'text': ['IL2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[307, 310]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[316, 324]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[432, 435]], 'text': ['L32'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[525, 528]], 'text': ['L32'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[606, 610]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[612, 616]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[622, 630]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[661, 665]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[846, 850]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[855, 863]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[872, 876]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[904, 918]], 'text': ['lymphoma cells'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[952, 956]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[961, 969]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[984, 988]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1090, 1094]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1183, 1187]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1226, 1230]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1281, 1285]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1290, 1298]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1512, 1516]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1548, 1552]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1671, 1675]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1717, 1721]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1838, 1843]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1861, 1865]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1979, 1983]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2012, 2017]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2067, 2072]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2098, 2102]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2111, 2116]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2210, 2214]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2244, 2248]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2317, 2321]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2417, 2421]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2450, 2454]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2590, 2595]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2673, 2677]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2703, 2709]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2782, 2786]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2843, 2847]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2857, 2863]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2951, 2955]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3041, 3046]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3089, 3093]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3141, 3145]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3190, 3194]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3205, 3209]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3296, 3302]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3347, 3353]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3459, 3465]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3484, 3488]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3568, 3572]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3638, 3644]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3666, 3671]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3686, 3691]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3717, 3721]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5, 16]], 'text': ['Upregulates'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[41, 50]], 'text': ['Activates'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[445, 465]], 'text': ['the tested cytokines'], 'type': 'Anaphora', 'id': 'T69'}, {'offsets': [[471, 479]], 'text': ['detected'], 'type': 'Gene_expression', 'id': 'T73'}, {'offsets': [[589, 602]], 'text': ['Transcription'], 'type': 'Transcription', 'id': 'T74'}, {'offsets': [[716, 722]], 'text': ['higher'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[832, 842]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[936, 948]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[973, 980]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[989, 999]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[1137, 1146]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1267, 1277]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[1496, 1508]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[1553, 1565]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[1766, 1775]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T84'}, {'offsets': [[1786, 1800]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T85'}, {'offsets': [[1828, 1837]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[1847, 1853]], 'text': ['target'], 'type': 'Regulation', 'id': 'T87'}, {'offsets': [[1945, 1956]], 'text': ['correlation'], 'type': 'Regulation', 'id': 'T88'}, {'offsets': [[1984, 1993]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[2018, 2028]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T90'}, {'offsets': [[2053, 2063]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[2087, 2094]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[2176, 2187]], 'text': ['correlation'], 'type': 'Regulation', 'id': 'T93'}, {'offsets': [[2215, 2225]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[2249, 2258]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[2304, 2313]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[2405, 2413]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[2423, 2435]], 'text': ['Neutralizing'], 'type': 'Negative_regulation', 'id': 'T98'}, {'offsets': [[2576, 2586]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[2726, 2735]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[2848, 2856]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[2864, 2874]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[3047, 3057]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T103'}, {'offsets': [[3059, 3061]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T70'}, {'offsets': [[3077, 3085]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[3109, 3128]], 'text': ['neutralizing effect'], 'type': 'Negative_regulation', 'id': 'T105'}, {'offsets': [[3271, 3278]], 'text': ['Nuclear'], 'type': 'Entity', 'id': 'T106'}, {'offsets': [[3279, 3292]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T107'}, {'offsets': [[3308, 3319]], 'text': ['consequence'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[3323, 3333]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T109'}, {'offsets': [[3339, 3346]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T110'}, {'offsets': [[3362, 3370]], 'text': ['detected'], 'type': 'Localization', 'id': 'T111'}, {'offsets': [[3451, 3458]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T112'}, {'offsets': [[3470, 3480]], 'text': ['detectable'], 'type': 'Localization', 'id': 'T113'}, {'offsets': [[3537, 3545]], 'text': ['detected'], 'type': 'Localization', 'id': 'T114'}, {'offsets': [[3624, 3634]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T115'}]","[{'trigger': 'T71', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T2', 'T1']}}, {'trigger': 'T72', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T1']}}, {'trigger': 'T73', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T73', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T73', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T73', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T73', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T73', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T73', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T73', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T73', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T74', 'id': 'E12', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T74', 'id': 'E13', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T74', 'id': 'E14', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T75', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T75', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T75', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T76', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T76', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T77', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T77', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T78', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E23']}}, {'trigger': 'T79', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T78', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E23']}}, {'trigger': 'T80', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T81', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T81', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T82', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T83', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T84', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T85', 'id': 'E31', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T86', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T87', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T88', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E36']}}, {'trigger': 'T90', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T89', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T91', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T92', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T41']}}, {'trigger': 'T93', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'E41']}}, {'trigger': 'T95', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T94', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T96', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T97', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T46']}}, {'trigger': 'T98', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T99', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T100', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T101', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T52']}}, {'trigger': 'T102', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T103', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T104', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T105', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T107', 'id': 'E52', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T60', 'T106']}}, {'trigger': 'T108', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E52', 'E54']}}, {'trigger': 'T109', 'id': 'E54', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T111', 'id': 'E55', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T61', 'T110']}}, {'trigger': 'T113', 'id': 'E56', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T62', 'T112']}}, {'trigger': 'T114', 'id': 'E57', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T62', 'T112']}}, {'trigger': 'T115', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T115', 'id': 'E59', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}]","[{'id': 'R1', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T70', 'role': 'Subject'}, 'tail': {'ref_id': 'T103', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E22', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E24', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E38', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E38', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E39', 'value': ''}, {'id': 'M16', 'type': 'Speculation', 'ref_id': 'E43', 'value': ''}, {'id': 'M17', 'type': 'Speculation', 'ref_id': 'E45', 'value': ''}, {'id': 'M18', 'type': 'Speculation', 'ref_id': 'E50', 'value': ''}, {'id': 'M19', 'type': 'Negation', 'ref_id': 'E55', 'value': ''}]",[]
11,PMC-2626671-15-MATERIALS_AND_METHODS,"Northern and Western blot analyses.
RNA isolation and Northern blot analysis was performed as previously described (29). In brief, 10 mug of total RNA was loaded per lane and transferred to positively charged nylon membranes (Hybond-N+; GE Healthcare), which was confirmed by ethidium bromide staining of ribosomal RNA species on the membrane. Membranes were hybridized with 1 ng/ml alpha-[32P]dCTP-labeled trichloroacetic acid precipitable probe in ExpressHyb hybridization buffer (Clontech Laboratories, Inc.). All cDNA probes were confirmed to have the appropriate single-copy specificity under these conditions using genomic Southern blot analysis. Band intensities were acquired by phosphorimaging analysis.
For Western analysis, whole-cell protein lysates were obtained from CD8+ T cells at the time points indicated in the figures during clonal expansion in 100 U/ml IL-2 with lysis buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% NP-40) by resuspending samples in 10 mul per 106 cells and incubating on ice for 30 min in the presence of protease inhibitors. Immunoblot analysis was performed with the antibodies indicated in the figures after SDS-PAGE (10-30 mug of total protein was loaded per well). Quantification of detected protein was performed with an Intelligent Dark Box unit (LAS-3000; Fujifilm) and normalized for loading with the amount of RNA Pol-II detected in each lane.","[{'offsets': [[781, 784]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[874, 878]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
12,PMC-1447668-05-Results,"The Transactivation Functions of HTLV-I Tax Are Suppressed by Foxp3
Previous studies by Bettelli and colleagues have demonstrated that Foxp3 can repress both the basal levels of NF-kappaB activation as well as tumor necrosis factor-alpha-stimulated NF-kappaB activation [15]. Our next step was to determine whether Foxp3 could also suppress the activation of NF-kappaB caused by a strong viral transactivator protein. HTLV-I encodes a multifunctional transactivator protein, Tax, capable of activating both the NF-kappaB and CREB pathways [24-29]. Since the HTLV-I Tax protein can function at multiple levels in both the cytoplasm and the nucleus to stimulate activation of NF-kappaB [28,29], we hypothesized that overexpression of Foxp3 may interfere with this process. However, since Tax-dependent HTLV-I gene expression is independent of NF-kappaB [18], we also hypothesized that Foxp3 would not affect Tax-dependent activation of the HTLV-I LTR. To test these hypotheses, we overexpressed HTLV-I Tax, full-length Foxp3, and/or deltaFKH in HEK 293T cells cotransfected with an HTLV-I LTR or NF-kappaB reporter vector. As shown in Figure 4A, HTLV-I Tax strongly up-regulated NF-kappaB-dependent transcriptional activation (~60-fold). Interestingly, overexpression of Foxp3, but not deltaFKH, suppressed Tax-mediated activation of NF-kappaB-dependent transcription. These observations further suggest that the carboxyl-terminal FKH domain is required for inhibiting activation of NF-kappaB in the presence of Tax in HEK 293T cells, strikingly similar to the requirements of Foxp3 inhibition of basal NF-kappaB activation shown in Figure 2B. Transactivation of the HTLV-I LTR was stimulated about 55-fold by overexpression of Tax (Figure 4B), while transfection of Foxp3 suppressed Tax-dependent HTLV-I LTR activation, although HTLV-I LTR activation in the presence or absence of Tax is independent of NF-kappaB or NF-AT (another transcriptional activator known to interact with Foxp3). Furthermore, overexpression of deltaFKH also led to suppression of HTLV-I transactivation by Tax to a similar extent as full-length Foxp3 (Figure 4B). The suppressive effects shown in Figure 4A and 4B were not the result of Foxp3 down-regulating the expression of the transfected Tax plasmid as determined by real-time RT-PCR (Figure 4C). These results strongly suggest that Foxp3 interacts with transcriptional regulators in addition to NF-kappaB and NF-AT, and that the carboxyl-terminal FKH domain, and therefore localization to the nucleus, are not required for inhibition of Tax-mediated HTLV-I LTR activation (even in HEK 293T cells).
To determine whether Foxp3 inhibited the transactivation functions of Tax by directly associating with this viral protein, we generated an expression vector in which HTLV-I Tax was fused in-frame to the carboxyl terminus of the Gal4 DNA-binding domain (Gal4-BD). This Gal4-BD-Tax fusion protein activated transcription of a synthetic promoter containing five Gal4 binding sites, while Gal4-BD was insufficient to stimulate transcription by itself (Figure 4D). Transactivation of the Gal4-resposive promoter by Gal4-BD-Tax remained relatively unaffected by overexpression of either EGFP (control), Foxp3, or deltaFKH, suggesting that Foxp3 does not repress Tax transactivation by directly interfacing with the HTLV-I Tax protein. To confirm that Foxp3 had a direct effect on HTLV-I replication, we transfected HEK 293T cells with a well-characterized HTLV-I infectious molecular clone (termed ACH) [30] in the presence of full-length Foxp3, deltaFKH, or control vector. ACH has been previously shown to direct the expression of viral antigens, produce infectious virus, and transform CD4+ T cells both in vitro and in vivo [31,32]. After 24 h, the amount of viral antigen expression, in this case Tax mRNA, was detected by a sensitive real-time RT-PCR assay. As illustrated in Figure 5, the level of Tax mRNA synthesized from ACH was down-regulated in the presence of Foxp3 compared to the level produced in the presence of the control vector. deltaFKH did not have a discernable affect on Tax expression. These data indicate that Foxp3 is capable of repressing the expression of Tax from an infectious HTLV-I molecular clone.","[{'offsets': [[40, 43]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 67]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[135, 140]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[210, 237]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[315, 320]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[475, 478]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[565, 568]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[732, 737]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[786, 789]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[883, 888]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[906, 909]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1000, 1003]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1017, 1022]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1031, 1039]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1151, 1154]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1269, 1274]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1284, 1292]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1305, 1308]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1510, 1513]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1575, 1580]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1726, 1729]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1765, 1770]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1782, 1785]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1880, 1883]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1979, 1984]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2018, 2026]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2080, 2083]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2119, 2124]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2211, 2216]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2267, 2270]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2362, 2367]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2567, 2570]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2649, 2654]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2698, 2701]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2801, 2804]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2856, 2860]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2881, 2885]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2896, 2907]], 'text': ['Gal4-BD-Tax'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3013, 3017]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3138, 3149]], 'text': ['Gal4-BD-Tax'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3225, 3230]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3235, 3243]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3261, 3266]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3284, 3287]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3344, 3347]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3373, 3378]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3561, 3566]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3568, 3576]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3711, 3714]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3824, 3827]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3927, 3930]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3995, 4000]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4071, 4079]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4117, 4120]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4158, 4163]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4207, 4210]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[714, 728]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[979, 992]], 'text': ['overexpressed'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[1251, 1265]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[1708, 1722]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[1749, 1761]], 'text': ['transfection'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[1965, 1973]], 'text': ['interact'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[2000, 2014]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[2217, 2232]], 'text': ['down-regulating'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[2237, 2247]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[2368, 2377]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T68'}, {'offsets': [[2503, 2515]], 'text': ['localization'], 'type': 'Localization', 'id': 'T69'}, {'offsets': [[2523, 2530]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[2714, 2725]], 'text': ['associating'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[2731, 2749]], 'text': ['this viral protein'], 'type': 'Anaphora', 'id': 'T57'}, {'offsets': [[3184, 3198]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[3316, 3327]], 'text': ['interfacing'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[3785, 3798]], 'text': ['viral antigen'], 'type': 'Anaphora', 'id': 'T58'}, {'offsets': [[3799, 3809]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T74'}, {'offsets': [[3936, 3947]], 'text': ['synthesized'], 'type': 'Transcription', 'id': 'T75'}, {'offsets': [[3961, 3975]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[4023, 4031]], 'text': ['produced'], 'type': 'Transcription', 'id': 'T77'}, {'offsets': [[4107, 4113]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[4121, 4131]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[4178, 4188]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[4193, 4203]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T81'}]","[{'trigger': 'T59', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T60', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T60', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T60', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T61', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T61', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T62', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T63', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T64', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T65', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T66', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T29']}}, {'trigger': 'T67', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T68', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T69', 'id': 'E14', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T31', 'T70']}}, {'trigger': 'T71', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T34']}}, {'trigger': 'T72', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T72', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T73', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T45', 'T43']}}, {'trigger': 'T74', 'id': 'E19', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T75', 'id': 'E20', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T76', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T52']}}, {'trigger': 'T77', 'id': 'E22', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T78', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T53']}}, {'trigger': 'T79', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T80', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T55']}}, {'trigger': 'T81', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}]","[{'id': 'R1', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T34', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T58', 'role': 'Subject'}, 'tail': {'ref_id': 'T50', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}]",[]
13,PMC-3245220-20-Materials_and_Methods,"Western Blot Analysis
Cells were washed with PBS and resuspended in cell lysis buffer. (Cell Signaling Technology) and incubated for 10 minutes on ice then centrifuged to remove the insoluble fraction. The protein concentration was determined by the BCA protein assay (Bio-Rad, Hercules, CA). Cell lysates were separated by SDS-PAGE on 10% polyacrylamide gels and then transferred onto nitrocellulose membranes and subjected to Western blotting. The immunoblotted proteins were detected by ECL reagent (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).",[],[],[],[],[],[]
14,PMC-2065877-10-Materials_and_Methods,"Transgenic mice.
Generation of LMP1 mice under the Ig heavy chain promoter and enhancer have been described previously and were maintained as heterozygotes on a Balbc background [26]. LMP1 mice were genotyped by Southern blot and PCR analysis of tail DNA as described previously [26]. Spleen and liver sections were fixed in 4% paraformaldehyde and embedded in paraffin, and 5-mum sections were stained with hematoxylin and eosin for histopathological analysis. Lymphomas were passaged by intraperitoneal injection of 1 x 108 splenocytes into SCID mice and sacrificed upon development of an extended abdomen. Animals were housed in the Association for Assessment and Accreditation for Animal Care-approved animal facility at the University of North Carolina at Chapel Hill. All protocols were approved by the Institutional Animal Care and Use Committee.","[{'offsets': [[31, 35]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[184, 188]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
15,PMC-2065877-24-Caption-Figure_6,"LMP1 Activates Akt Signaling and Deregulates the Rb Cell Cycle Pathway
(A and B) Immunoblot analysis of purified B cells (CD19+) from the spleens of WT and LMP1 transgenic mice for Akt signaling, probing for (A) activated pAkt and downstream targets, including inactivated pGSK3alpha/beta, and (B) activated p-mTOR, and total levels of FoxO1. Arrows indicate the positions of alpha and beta isoforms of GSK3. The white line indicates that intervening lanes have been spliced out.
(C) Immunoblot analysis for cell cycle proteins regulating the Rb pathway, probing for activated pRb, and total levels of Cdk2 and the Cdk inhibitor p27. Actin was used as a loading control.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[15, 18]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 51]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[122, 126]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[156, 160]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[181, 184]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[222, 226]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[273, 283]], 'text': ['pGSK3alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[284, 288]], 'text': ['beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[308, 314]], 'text': ['p-mTOR'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[336, 341]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[403, 407]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[543, 545]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[577, 580]], 'text': ['pRb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[602, 606]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[629, 632]], 'text': ['p27'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[242, 249]], 'text': ['targets'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[261, 272]], 'text': ['inactivated'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[298, 307]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[567, 576]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T20'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}]",[]
16,PMC-2065877-00-TIAB,"EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B Cell Lymphomas
Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. The lymphoma cells have deregulated cell cycle markers, and inhibitors of Akt, NFkappaB, and Stat3 block the enhanced viability of LMP1 transgenic lymphocytes and lymphoma cells in vitro. Lymphoma cells are independent of IL4/Stat6 signaling for survival and proliferation, but have constitutively activated Stat3 signaling. These same targets are also deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas.","[{'offsets': [[4, 29]], 'text': ['Latent Membrane Protein 1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[40, 43]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[59, 64]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[85, 110]], 'text': ['Latent membrane protein 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[112, 116]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[192, 196]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[458, 461]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[477, 482]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[515, 519]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[606, 609]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[610, 615]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[692, 697]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[857, 860]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[876, 881]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[30, 39]], 'text': ['Activates'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[444, 454]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[709, 727]], 'text': ['These same targets'], 'type': 'Anaphora', 'id': 'T15'}, {'offsets': [[737, 748]], 'text': ['deregulated'], 'type': 'Regulation', 'id': 'T18'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T2', 'T1']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T1']}}, {'trigger': 'T17', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]","[{'id': 'R1', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}]",[]
17,PMC-2791889-05-Results,"IL-10 Production Is Maintained by High TCR Signal Strength and IL-12
We next investigated whether repeated strong TCR activation is a compensatory signal for IL-12-induced STAT4 signaling in the induction of IL-10 in Th1 cells. For this, CD4+ T cells were differentiated for 2 consecutive weeks with high antigen doses in the presence or absence of IL-12 throughout (Figures 4A-4D). High antigen dose and IL-12 cooperated to induce maximal IL-10 production (Figures 4A and 4B), given that this combination resulted in the highest numbers of IL-10-producing Th1 cells. Repeated high antigen dose stimulation in the absence of exogenously added IL-12 resulted in the production of IL-10 by Th1 cells, suggesting that repeated strong TCR triggering may overcome the need for IL-12 for IL-10 induction (Figures 4C and 4D). However, IL-10 induction under these conditions was abrogated when IL-12p40-deficient DCs were used as APCs (Figure 4E). Thus, IL-12 is essential during both primary and secondary antigenic stimulation for production of IL-10 by Th1 cells.
To determine the requirements for stability of the IL-10-producing Th1 cells, we differentiated CD4+ T cells for 1 week with high antigen doses with or without IL-12 (Figures 4A and 4C), washed them, and then restimulated them for an additional week with a low antigen dose, in the absence or presence of IL-12 (Figure 4F). Th1 cells induced in the first week to produce IL-10 by culture with high antigen doses and IL-12 lost their ability to express IL-10 when recultured with low doses of OVA, which could be compensated for, to some extent, by addition of IL-12 to the secondary cultures (Figure 4F), again suggesting that antigen dose and IL-12 signals cooperate for the induction of IL-10. Finally, DO11.10 CD4+ cells that were exposed to low doses of antigen and IL-12 during the primary differentiation phase produced high amounts of IFN-gamma but little IL-10, but they could be induced to produce IL-10 when both high antigen dose and IL-12 were present during the recall phase (Figure S4). Thus, high antigen dose and IL-12 are required for sustaining the induction of IL-10 production by Th1 cells.","[{'offsets': [[0, 5]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[63, 68]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[158, 163]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 177]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[208, 213]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[238, 241]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[349, 354]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[405, 410]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[440, 445]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[541, 546]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[643, 648]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[679, 684]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[772, 777]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[782, 787]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[828, 833]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[886, 894]], 'text': ['IL-12p40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[946, 951]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1039, 1044]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1110, 1115]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1155, 1158]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1219, 1224]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1364, 1369]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1430, 1435]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1475, 1480]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1511, 1516]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1551, 1554]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1619, 1624]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1703, 1708]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1748, 1753]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1772, 1775]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1829, 1834]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1901, 1910]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1922, 1927]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1966, 1971]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2004, 2009]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2088, 2093]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2139, 2144]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[6, 16]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[20, 30]], 'text': ['Maintained'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[195, 204]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[425, 431]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[446, 456]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[547, 556]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[649, 657]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[665, 675]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[763, 767]], 'text': ['need'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[788, 797]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[834, 843]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[871, 880]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[895, 904]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[955, 964]], 'text': ['essential'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[1025, 1035]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[1116, 1125]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[1393, 1400]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[1422, 1429]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[1481, 1485]], 'text': ['lost'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[1503, 1510]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[1571, 1582]], 'text': ['compensated'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[1607, 1615]], 'text': ['addition'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1717, 1726]], 'text': ['cooperate'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[1735, 1744]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[1876, 1884]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[1947, 1954]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[1958, 1965]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[2126, 2135]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[2145, 2155]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T66'}]","[{'trigger': 'T38', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'T2']}}, {'trigger': 'T40', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T41', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T8']}}, {'trigger': 'T42', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T43', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T44', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T45', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T46', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T13']}}, {'trigger': 'T47', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T48', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T49', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E13']}}, {'trigger': 'T50', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T51', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T17']}}, {'trigger': 'T52', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T53', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T54', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T24']}}, {'trigger': 'T55', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T56', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T26']}}, {'trigger': 'T57', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T58', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T27']}}, {'trigger': 'T59', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T60', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T61', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T62', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T62', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T63', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T35']}}, {'trigger': 'T64', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T65', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T36']}}, {'trigger': 'T66', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}]",[]
18,PMC-2626671-17-Caption-Figure_1,"Kinetics of gene expression during CD8+ T cell differentiation. (A) Kinetics of Prf1, Gzmb, Tbx21 (T-bet), and Eomes mRNA expression in differentiating P14 CD8+ T cells analyzed by Northern blotting. RNA from day 7 Th1 cells was used as a control. Sizes of mRNA transcripts are indicated. (B) Quantification of relative mRNA amounts by phosphorimager analysis. (C) Kinetics of protein expression in differentiating P14 CD8+ T cells analyzed by immunoblotting. Sizes of protein bands are indicated. (D) Relative protein amounts quantified from the Western blots. (E) Intracellular staining for granzyme B, IFN-gamma, and TNF. Granzyme B staining was specific relative to an isotype control (not depicted). Cells were restimulated with PMA and ionomycin for 4 h. (F) FACS-based assay to measure cytolytic activity of P14 CD8+ T cells against EL4 targets loaded with 0 (-) or 1 (+) muM Gp33 peptide (effector-to-target ratio = 5:1). Percentage of Annexin V+ (apoptotic) target cells in the CD8-negative EL4 target population (dot plots) was determined (histograms). Cytolytic activity was blocked by incubation with 2 mM EGTA (not depicted), confirming involvement of the granule exocytosis (perforin-granzyme B) pathway. Data are representative of at least five (A-E) or three (F) independent experiments.","[{'offsets': [[35, 38]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[80, 84]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[86, 90]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[92, 97]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[99, 104]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[111, 116]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[156, 159]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[419, 422]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[593, 603]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[605, 614]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 623]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[625, 635]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[819, 822]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[944, 953]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[987, 990]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1189, 1197]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1198, 1208]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[117, 132]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T18'}, {'offsets': [[580, 588]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[636, 644]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T20'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T18', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]",[],"[{'id': '*', 'ref_ids': ['T4', 'T5']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}]",[]
19,PMC-3148254-10-Materials_and_Methods,"Retroviral transduction
A retroviral vector (pMIP) was used for the stable transduction of cells with HOIP and IKKgamma cDNA constructs. pMIP was constructed by replacing the IRES and GFP encoding sequences in pMIG [31] with the IRES and puromycin resistance gene from pIRESpuro2 (Clontech). FLAG-tagged mouse HOIP cDNA was inserted into the multiple cloning site of pMIP. A pMIP construct encoding mouse IKKgamma with an amino terminal birch profilin peptide (BP)-tag was also prepared. Retroviral particles were generated by transient transfection of 293T cells with pMIP, pMIP-HOIP, or pMIP-IKKgamma and the packaging vector pCL-Eco [32]. Two days after transfection, culture supernatants were harvested and filtered. A20.2J or HOIP-deficient cells were added to 24-well plates (2.5x105 cells/well) with 1 ml virus-containing supernatant and 8 microg/ml polybrene. Plates were centrifuged at 500 x g for 2 hrs at room temperature. Cells were cultured in B cell culture medium for 48 hrs, after which the transduced cells were selected in 3 microg/ml puromycin.","[{'offsets': [[102, 106]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[111, 119]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[310, 314]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[405, 413]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[580, 584]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[594, 602]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[731, 735]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[736, 745]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T8'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]",[],[],[],[]
20,PMC-2664230-05-MATERIALS_AND_METHODS,"SDS-PAGE and Immunoblotting (I-kappaBalpha, NF-kappaB p65, and CREB)
Following stimulation, PBMCs were washed with ice-cold PBS and centrifuged to collect a cell pellet. The pellet was resuspended in ice-cold SDS sample buffer supplemented with 100 mM dithiothreitol. Cytoplasmic and nuclear extracts were isolated with NE-PER nuclear and cytoplasmic extraction reagents with 1x Halt Protease Inhibitor Cocktail according to the manufacturer's instructions. Protein concentrations were determined with the BCA protein reagent kit for each sample according to a standardized curve for albumin. Cell lysates were collected by boiling the samples in a 100degreesC water bath for 5 minutes. Ten mug of protein per sample was separated by SDS-polyacrylamide gel electrophoresis through 8-16% tris-glycine polyacrylamide gradient gels and transferred to nitrocellulose membranes. The membranes were blocked with 5% milk in Tris-buffered saline/Tween 20 (Fischer Scientific, Pittsburgh, PA) for 1 hour. Cytoplasmic extracts were incubated with phosphorylated I-kappaBalpha antibody (1:200), while nuclear extracts were incubated with either phosphorylated NF-kappaB p65 antibody (1:500) or phosphorylated CREB antibody (1:500) overnight at 4degreesC in separate experiments. The membranes were washed with Tris-buffered saline/Tween 20 and incubated for 1 hour at room temperature with the secondary antibody, horseradish peroxidase-linked anti-rabbit IgG diluted 1:2000 in blocking solution. After repeated washing of the membrane, the Supersignal West Pico Chemiluminescent Kit was applied for antibody detection per the manufacturer's instructions.
Western blot data is presented as a percentage of LPS stimulation. The percentage of LPS stimulation was calculated by dividing the mean band pixel total for each treatment arm divided by the mean pixel total of samples stimulated with LPS and multiplying by 100. Thus, LPS stimulation is reported as 100% and each of the treatment arms is reported as a percent of LPS stimulation.","[{'offsets': [[29, 42]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 57]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[63, 67]], 'text': ['CREB'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1052, 1065]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1159, 1162]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1037, 1051]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T6'}, {'offsets': [[1134, 1148]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T7'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],[],[]
21,PMC-3245220-19-Materials_and_Methods,"Annexin V/PI Apoptosis Assay
Cell apoptosis assay was performed as described previously [51] using the Annexin V-FITC apoptosis detection kit (BD PharMingen, San Diego, CA). Briefly, human monocytes (5x106) were incubated with inhibitors for 30 minutes in X-vivo medium and restimulated with 100 ng/ml M-CSF overnight. The cells were removed from the culture dish using Accutase (eBioscience, San Diego, CA) and stained with Annexin V-FITC and PI and analyzed by flow cytometry (FACSCalibur; BD PharMingen). Annexin V-FITC and PI double negative cells were considered non-apoptotic cells for statistical analysis.","[{'offsets': [[0, 9]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[103, 112]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[425, 434]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[508, 517]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
22,PMC-2065877-20-Caption-Figure_2,"LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion
(A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains.
(B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results.
(C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[119, 123]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[164, 168]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[182, 185]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[310, 314]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[379, 383]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[581, 585]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[619, 623]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[624, 627]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[654, 658]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[659, 662]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[796, 800]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[909, 913]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[937, 941]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
23,PMC-1447668-17-Materials_and_Methods,"Western blot analysis.
HEK 293T cells were plated at a density of 5 x 105 cells/well in six-well culture plates (BD Biosciences) 1 d prior to transfection with the appropriate plasmid DNA (2 mug total) using FuGene 6 transfection reagent (Roche). Cells were harvested 24 h posttransfection for whole-cell lysates in RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Igepal (NP-40), 0.5% sodium deoxycholate, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 1x Complete Mini Protease Inhibitor [Roche]). Protein concentration was determined by Lowry assay (Bio-Rad, Hercules, California, United States) and colorimetric reactions were read using a VersaMax microplate reader (Molecular Devices, Sunnyvale, California, United States) at an absorbance of 750 nm. Size fractionation was performed on 20 mug of protein/sample by SDS-PAGE, and the protein was transferred to nitrocellulose or PVDF membranes and subjected to immunoblotting using the indicated antibodies. Foxp3 was detected using rabbit anti-human Foxp3 polyclonal antibody (ab4728 or ab10563; Abcam, Cambridge, United Kingdom) and anti-rabbit IgG-HRP secondary antibody (Cell Signaling Technology, Beverly, Massachusetts, United States). NF-kappaB p65 and CREB-1 were detected using rabbit anti-human polyclonal (p65) or monoclonal antibody (CREB-1; 48H2) (Cell Signaling Technology). Beta-actin was detected using a mouse monoclonal antibody (AC-15; Sigma, St. Louis, Missouri, United States). For coimmunoprecipitation analysis, cell lysates were precleared with 30 mul of protein A/G plus-agarose beads (Santa Cruz Biotechnology, Santa Cruz, California, United States) and then incubated with mouse monoclonal anti-HA antibody (6E2; 1:100; Cell Signaling Technology) and 30 mul of protein A/G plus-agarose beads overnight. The immunoprecipitates were washed four times with RIPA buffer, resuspended in SDS sample buffer, and heated at 95 degreesC for 5 min. Proteins were then treated as described for Western blot analysis.","[{'offsets': [[957, 962]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1000, 1005]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1201, 1204]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1209, 1215]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1266, 1269]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1295, 1301]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1338, 1348]], 'text': ['Beta-actin'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
24,PMC-1310901-11-RESULTS,"Methylation-sensitive enzymes do not cut specific sites in the IRF-4 promoter in hematopoietic cells
To further investigate promoter methylation as a regulatory mechanism of IRF-4 gene expression, restriction-PCR-assays were performed (20,24), where only methylated DNA would not be cut enabling subsequent PCR amplification and vice versa. Genomic DNA from leukemic cells Jurkat, CML-T1, U-937, K-562, EM-2 and BV-173 was digested with the methylation-sensitive enzymes HpaII, Bsh1236I and HaeII-isochizomer Bsp143II. EcoRI, which has no recognition site within the IRF-4 promoter, and the methylation-resistant enzyme MspI served as controls. Two separate amplification reactions were performed, generating two fragments, F1 and F2 (Figure 3A). After digestion with HpaII and Bsp143II a sufficient PCR amplification of F1 and F2 was detected in DNA from IRF-4-negative Jurkat, CML-T1, U-937, K-562 and EM-2 cells, suggesting a promoter methylation (and restriction protection) at the respective recognition sites (Figure 3B and C). Notably, in IRF-4-positive SD-1 cells digestion with the methylation-sensitive enzymes completely inhibited amplification of F1 and F2. In IRF-4-positive BV-173 cells a HpaII, but not a Bsh1236I digestion, significantly reduced the amplifiable DNA message of F2 (Figure 3C), whereas amplification of F1 was not affected (Figure 3B). This implied that IRF-4 transcription in SD-1 and BV-173 cells is associated with less promoter methylation (in BV-173 especially at HpaII sites) as compared with the tested IRF-4-negative cells.","[{'offsets': [[63, 68]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[174, 179]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[567, 572]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[856, 861]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1046, 1051]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1173, 1178]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1385, 1390]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1541, 1546]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[185, 195]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[862, 870]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[1052, 1060]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[1179, 1187]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[1391, 1404]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T13'}, {'offsets': [[1547, 1555]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T14'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}]",[]
25,PMC-2889865-03-Results,"Induction of inflammatory responses
The ability of PMA and HK E. coli to induce an inflammatory response in Jurkat T-cells was evaluated using a multiplex cytokine assay following 24 h stimulation. The cytokine profile revealed an enhanced induction of the pro-inflammatory cytokines IL-2, IL-6, TNF and the chemokine CXCL8. The levels of the anti-inflammatory cytokine IL-10 were unaffected by PMA but were significantly decreased by HK E. coli (Table 1). These results confirmed that PMA and HK E. coli induced an inflammatory response in the Jurkat T-cells. It is interesting to note that PMA was 120-fold more effective at inducing CXCL8 than HK E. coli. PMA-dependent induction of AP-1 and down-regulation of NF-kappaB suggests an involvement of AP-1 in CXCL8 regulation. Determination of the time course of cytokine induction in response to PMA showed that CXCL8 was already released between 2-6 h, while TNF and IL-6 were released between 6-24 h (figure 3). These results indicated that the cytokines were differentially regulated and that the release was not associated with the early transient induction of NF-kappaB. The temporal induction of AP-1 correlated to the CXCL8 levels and preceded the TNF and IL-6 release. This suggests an association between CXCL8 release and AP-1 signalling.","[{'offsets': [[284, 288]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[290, 294]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[318, 323]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[370, 375]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[636, 641]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[759, 764]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[863, 868]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[919, 923]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1176, 1181]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1214, 1218]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1265, 1270]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[231, 239]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[240, 249]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[381, 391]], 'text': ['unaffected'], 'type': 'Regulation', 'id': 'T15'}, {'offsets': [[422, 431]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[614, 623]], 'text': ['effective'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[627, 635]], 'text': ['inducing'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[736, 747]], 'text': ['involvement'], 'type': 'Regulation', 'id': 'T19'}, {'offsets': [[765, 775]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T20'}, {'offsets': [[881, 889]], 'text': ['released'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[929, 937]], 'text': ['released'], 'type': 'Localization', 'id': 'T22'}, {'offsets': [[994, 1007]], 'text': ['the cytokines'], 'type': 'Anaphora', 'id': 'T12'}, {'offsets': [[1028, 1037]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[1219, 1226]], 'text': ['release'], 'type': 'Localization', 'id': 'T24'}, {'offsets': [[1271, 1278]], 'text': ['release'], 'type': 'Localization', 'id': 'T25'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T23', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T24', 'id': 'E13', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T25', 'id': 'E14', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]","[{'id': 'R1', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}]",[]
26,PMC-2065877-18-Materials_and_Methods,"Antibodies.
FITC-conjugated goat anti-mouse IgM, rat IgG2akappa anti-mouse IgD (clone 11-26), rat IgG1kappa anti-mouse kappa (clone 187.1), rat IgG2bkappa anti-mouse lambda (clone JC5-1); PE-conjugated goat anti-mouse IgG; un-conjugated goat anti-mouse kappa and anti-mouse lambda were purchased from Southern Biotech. APC-conjugated rat IgG2akappa anti-mouse CD19 (clone 6D5), PE-conjugated mouse IgG2akappa anti-LMP1 (clone S12), un-conjugated mouse IgG2a anti-Rb (clone 2), and anti-Cdk2 (clone 55) were purchased from BD Bioscience. PE-conjugated rat IgG2akappa anti-mouse CD5 (clone 53-7.3) was purchased from eBioscience. Rat anti-LMP1 (clones 8G3, 1G6, 7E10, and 7G8) was purchased from Ascenion. Rabbit anti-pAkt (Ser473), anti-pGSK3alpha/beta (Ser21/9), anti-pStat3 (Tyr705), anti-pStat6 (Tyr641), anti-pmTOR (Ser2448), anti-Stat6, anti-Akt, anti-FoxO1, and anti-p27 were purchased from Cell Signaling. Rabbit anti-Stat3 (H-190), anti-IkappaBalpha (C-21), and goat anti-beta actin (I-19) were purchased from Santa Cruz Biotechnology. Mouse IgG1kappa anti-GSK3 was purchased from Upstate Biotechnology. Rabbit anti-pRb (Thr373) was purchased from EMD Biosciences.","[{'offsets': [[360, 364]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[414, 418]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[463, 465]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[486, 490]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[577, 580]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[637, 641]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[716, 720]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[736, 746]], 'text': ['pGSK3alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[747, 751]], 'text': ['beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[768, 774]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[790, 796]], 'text': ['pStat6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[812, 817]], 'text': ['pmTOR'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[834, 839]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[846, 849]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[856, 861]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[872, 875]], 'text': ['p27'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[924, 929]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[944, 956]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[979, 989]], 'text': ['beta actin'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1064, 1068]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1123, 1126]], 'text': ['pRb'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
27,PMC-2889865-17-Caption-Figure_1,"AP-1 activation following long-term exposure of Jurkat T-cells to PMA. Jurkat T-cells were transfected with luciferase reporter plasmids containing the AP-1 cis-elements. (A) Time-dependent AP-1 activation in response to PMA. (B) HK E. coli does not activate AP-1. (C) Dose-dependent activation of AP-1 were performed using PMA alone (grey bars) and in combination with calcium ionophore (CaI 955 muM, black bars). (D) TCR-/- deficient cells responded to PMA (162 nM) by up-regulating AP-1 activity. Statistical significance from the control was determined using Student's t-test. (n = 4). Controls were arbitrarily set to 1.","[{'offsets': [[108, 118]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
28,PMC-1310901-00-TIAB,"Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region
Although the bcr-abl translocation has been shown to be the causative genetic aberration in chronic myeloid leukemia (CML), there is mounting evidence that the deregulation of other genes, such as the transcription factor interferon regulatory factor 4 (IRF-4), is also implicated in the pathogenesis of CML. Promoter methylation of CpG target sites or direct deletions/insertions of genes are mechanisms of a reversible or permanent silencing of gene expression, respectively. Therefore, we investigated whether IRF-4 promoter methylation or mutation may be involved in the regulation of IRF-4 expression in leukemia cells. Whereas promoter mutations or structural rearrangements could be excluded as a cause of altered IRF-4 expression in hematopoietic cells, the IRF-4 promoter methylation status was found to significantly influence IRF-4 transcription. First, treatment of IRF-4-negative lymphoid, myeloid and monocytic cell lines with the methylation-inhibitor 5-aza-2-deoxycytidine resulted in a time- and concentration-dependent increase of IRF-4 mRNA and protein levels. Second, using a restriction-PCR-assay and bisulfite-sequencing we identified specifically methylated CpG sites in IRF-4-negative but not in IRF-4-positive cells. Third, we clearly determined promoter methylation as a mechanism for IRF-4 down-regulation via reporter gene assays, but did not detect an association of methylational status and mRNA expression of DNA methyltransferases or methyl-CpG-binding proteins. Together, these data suggest CpG site-specific IRF-4 promoter methylation as a putative mechanism of down-regulated IRF-4 expression in leukemia.","[{'offsets': [[19, 49]], 'text': ['interferon regulatory factor 4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[158, 161]], 'text': ['bcr'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[162, 165]], 'text': ['abl'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[367, 397]], 'text': ['interferon regulatory factor 4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[399, 404]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[658, 663]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[734, 739]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[866, 871]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[911, 916]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[982, 987]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1023, 1028]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1194, 1199]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1339, 1344]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1365, 1370]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1456, 1461]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1687, 1692]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1756, 1761]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[0, 15]], 'text': ['Down-regulation'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[55, 65]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[305, 317]], 'text': ['deregulation'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[321, 332]], 'text': ['other genes'], 'type': 'Anaphora', 'id': 'T18'}, {'offsets': [[720, 730]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T22'}, {'offsets': [[740, 750]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[858, 865]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T24'}, {'offsets': [[872, 882]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[972, 981]], 'text': ['influence'], 'type': 'Regulation', 'id': 'T26'}, {'offsets': [[988, 1001]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T27'}, {'offsets': [[1029, 1037]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1134, 1142]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[1182, 1190]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[1345, 1353]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[1371, 1379]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T32'}, {'offsets': [[1462, 1477]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1741, 1755]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T34'}, {'offsets': [[1762, 1772]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T35'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T20', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T21', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T23', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T24', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T25', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T26', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T27', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T28', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T29', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T30', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T32', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T33', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T34', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T35', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}]","[{'id': 'R1', 'head': {'ref_id': 'T18', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T4', 'T5']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}]",[]
29,PMC-2065877-27-Caption-Table_1,Summary of Analysis Performed on Wild-Type and LMP1 Transgenic Lymphomas,"[{'offsets': [[47, 51]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[52, 62]], 'text': ['Transgenic'], 'type': 'Gene_expression', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
30,PMC-3245220-15-Materials_and_Methods,"Electrophoresis of the Mobility Shift Analysis (EMSA)
Nuclear extracts were isolated from MDMs by using a nuclear extraction kit according to the manufacturer's instruction from Active Motif (Carlsbad, CA). Briefly, MDMs were lysed in hypotonic lysis buffer (20 mM Hepes, pH 7.5; 5 mM NaF, 10 microM Na2MoO4 0.5% NP-40 and 0.1 mM EDTA), and then nuclei were resuspended in lysis buffer supplemented with 0.5 mM DTT and 0.2 mM PMSF. The NF-kappaB consensus oligonucleotides (sense: AGTTGAGGGGACTTTCCCAGGC; antisense: GCCTGGGAAAGTCCCCTCAACT) labeled with 32P by T4 polynucleokinase (Promega, Madison, WI) were incubated with nuclear extracts in binding buffer (10 mM Tris pH 7.6, 1 mM DTT, 0.5 mM EDTA, 2 microg polydI-dC and 10% Glycerol) at 30degreesC for 30 minutes. The free DNA and DNA-protein mixtures were resolved in 5% native polyacrylamide gels in 0.5x TBE buffer (45 mM Tris, 45 mM boric acid and 1 mM EDTA, pH 8.3) by electrophoresis. The gel was dried and subjected to autoradiography analysis.",[],[],[],[],[],[]
31,PMC-3148254-02-Results,"Generation of HOIP-deficient B cells via targeted disruption of Rnf31, the gene encoding HOIP
In our previous study, we demonstrated that HOIP is recruited to the CD40 signaling complex in two mouse B cell lines [6]. Similar results were obtained with mouse splenocytes, indicating that the interaction of CD40 with HOIP is not limited to transformed B cell lines (unpublished observations). We also found that the recruitment of HOIP to CD40 was TRAF2-dependent and that overexpression of a truncated HOIP mutant partially inhibited CD40-mediated NF-kappaB activation. These results support the hypothesis that HOIP plays a role in CD40 signal transduction. To further define the role and evaluate the importance of HOIP in CD40 signaling, we used somatic cell gene targeting to disrupt the gene encoding HOIP in the mouse B cell line A20.2J. This cell line has been particularly useful in the characterization of CD40 signaling mechanisms due to the relative ease with which its genome can be modified by homologous recombination [7], [8], [9]. We used a targeting vector capable of undergoing homologous recombination with Rnf31 (the gene encoding HOIP) to disrupt the coding sequence of the gene in exon 5 (Fig. 1A). Following introduction of the vector, the neomycin-resistant clones that arose were screened by PCR amplification of genomic DNA to identify cells containing a disrupted Rnf31 allele. To remove the selectable marker gene cassette from the disrupted Rnf31 allele, recombinant cell lines were transiently transfected with a plasmid that encodes Cre recombinase. This step allowed us to perform a second round of targeting and drug selection, generating cells in which both copies of Rnf31 were disrupted. Two independent clonal cell lines were chosen for further analysis. HOIP protein expression was undetectable in both cell lines, as determined by Western blot analysis of cell lysates (Fig. 1B), demonstrating that the targeting process was successful. In the text that follows, the two gene-targeted cell lines are referred to as HOIP-deficient cells.
To enable us to confirm that any signaling or functional defects observed in HOIP-deficient cells were due to disruption of the Rnf31 gene, both HOIP-deficient cell lines were transduced with a retrovirus encoding FLAG-tagged wild-type HOIP, thus restoring HOIP protein expression (Fig. 1B). These cells are referred to as HOIP-reconstituted cells. In the experiments that follow, responses by these cells were compared to those of A20.2J cells and HOIP-deficient cells transduced with a retroviral vector (pMIP) lacking a cDNA insert (empty vector).","[{'offsets': [[14, 18]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[64, 69]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[89, 93]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[138, 142]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[306, 310]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[316, 320]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[430, 434]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[438, 442]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[447, 452]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[502, 506]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[534, 538]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[612, 616]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[633, 637]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[717, 721]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[725, 729]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[806, 810]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[915, 919]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1126, 1131]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1151, 1155]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1391, 1396]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1470, 1475]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1564, 1579]], 'text': ['Cre recombinase'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1702, 1707]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1792, 1796]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2054, 2058]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2153, 2157]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2204, 2209]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2221, 2225]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2312, 2316]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2333, 2337]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2399, 2403]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2525, 2529]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[19, 28]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[50, 60]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T34'}, {'offsets': [[146, 155]], 'text': ['recruited'], 'type': 'Binding', 'id': 'T35'}, {'offsets': [[291, 302]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T36'}, {'offsets': [[415, 426]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[453, 462]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T38'}, {'offsets': [[780, 787]], 'text': ['disrupt'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[1381, 1390]], 'text': ['disrupted'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1460, 1469]], 'text': ['disrupted'], 'type': 'Negative_regulation', 'id': 'T41'}, {'offsets': [[1713, 1722]], 'text': ['disrupted'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[1805, 1815]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2059, 2068]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T44'}, {'offsets': [[2158, 2167]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T45'}, {'offsets': [[2186, 2196]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T46'}, {'offsets': [[2226, 2235]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T47'}, {'offsets': [[2323, 2332]], 'text': ['restoring'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[2346, 2356]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[2404, 2417]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T50'}, {'offsets': [[2530, 2539]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T51'}]","[{'trigger': 'T33', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T34', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T35', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T36', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T5', 'T6']}}, {'trigger': 'T37', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T7', 'T8']}}, {'trigger': 'T38', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T9']}}, {'trigger': 'T39', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T40', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T41', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T42', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T43', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T44', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T45', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T46', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T47', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T48', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T49', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T50', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T51', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}, {'id': '*', 'ref_ids': ['T18', 'T19']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}]",[]
32,PMC-3279418-15-Materials_and_Methods,"In vitro cytokine secretion by BMDC
The BMDC were cultured in triplicate wells of 24-well or 96-well plates at 106 or 105 cells/mL, respectively, in RPMI-1640 complete medium. The cells were washed and stimulated with 100 ng/mL LPS or 25 microg/mL poly I:C. After 24 hours, supernatants were harvested for ELISA analysis. The presence of nitrite in the supernatants was determined using the Griess reagent.",[],[],[],[],[],[]
33,PMC-2065877-26-Caption-Figure_8,"Analysis of Akt, NFkappaB, and Stat3 Pathways in Contribution to the Growth and Survival of Lymphoma Cells
(A-D) Immunoblot analysis of wild-type and LMP1 transgenic lymphomas for Akt, NFkappaB, and Stat3 signaling after treatment with (A) an Akt inhibitor, triciribine, (B) an NFkappaB inhibitor, BAY11-7085, and the Stat3 inhibitors (C) cucurbitacin I and (D) AG490, at the indicated concentrations. Arrows indicate the positions of alpha and beta isoforms of Stat3. Actin was used as a loading control.","[{'offsets': [[12, 15]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[31, 36]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[150, 154]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[180, 183]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[199, 204]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[243, 246]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[318, 323]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[462, 467]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[247, 256]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T9'}, {'offsets': [[324, 334]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T10'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]",[],[],[],[]
34,PMC-1447668-13-Materials_and_Methods,"Isolation of primary human CD4+ T cells.
CD4+ T cells were isolated from cryopreserved healthy donor PBMCs by negative selection with the CD4+ T Cell Isolation Kit II (Miltenyi Biotech, Bergisch Gladbach, Germany) according to manufacturer's guidelines. Purity of negatively selected CD4+ T cells was consistently higher than 96% as determined by flow cytometry.","[{'offsets': [[27, 30]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 44]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[138, 141]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[284, 287]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
35,PMC-2664230-13-DISCUSSION,"The exposure of inflammatory cells to a variety of extracellular stimuli results in the initiation of transcriptional and posttranscriptional events, which culminate in the production of pro-inflammatory mediators.11-14 TNF-alpha is released very early following shock and is considered an important mediator of the inflammatory cascade, since it regulates the synthesis of several other critical cytokines and chemokines.15 A clear relationship between increased TNF-alpha synthesis and the development of shock and multiple organ dysfunction has been observed in animal models of sepsis.15-17
Because of its importance in orchestrating multiple steps of the inflammatory response, strategies aimed at decreasing TNF-alpha levels or attenuating its production seem attractive. PDE inhibitors have been shown to downregulate TNF-alpha production in distinct human cell populations. We have previously shown that, in general, TNF-alpha levels continue to increase after LPS exposure and that concomitant infusion of phosphodiesterase inhibitors can markedly decrease TNF-alpha levels.18-19 In this in vitro study, we verified the sustained attenuation of LPS-induced TNF-alpha expression over time in an isolated human mononuclear cell population.
The mechanisms by which PTX, a non-specific phosphodiesterase inhibitor, significantly and consistently decreases TNF-alpha production have not been completely elucidated. It has been postulated that drugs that increase intracellular cAMP exert their anti-inflammatory effects through the activation of PKA. This classic pathway has been challenged as the sole mechanism involved in the modulation of inflammation by cAMP-enhancing drugs, and alternative mechanisms involving PKA-independent pathways have been proposed.6-8 In this series of experiments, we observed a significant attenuation of TNF-alpha production in LPS-stimulated human mononuclear cells following PTX administration, independent of PKA activation.
We used a nonspecific phosphodiesterase inhibitor, PTX, in the present study because it has been used clinically in the treatment of a variety of conditions in which inflammation is an important component of the pathophysiology of the disease process.19 Additionally, the use of PTX in sepsis as an adjunct to other treatments to maintain adequate organ function has been explored based upon its effects on TNF-alpha synthesis. However, the reported beneficial effects of PTX are not only related to the downregulation of TNF-alphabut also to PTX's hemorrheologic properties, its ability to reduce neutrophil activation, and its beneficial effects on microcirculation, cardiac performance, and organ injury.20-25 Herein, we demonstrated that the downregulatory effects of PTX in human mononuclear cells involves modulation of pathways that involve NF-kappaB and CREB, two major transcription factors involved in the inflammatory cascade.
NF-kappaB/Rel constitutes a family of transcriptional factors involved in the regulation of numerous cytokine genes and immune responses in different cell populations. The most abundant form of NF-kappaB is the p50-p65 heterodimer.26 The inactive form of NF-kappaB exists in the cytoplasm bound to an inhibitory complex containing I-kappaBalpha. Following cellular stimulation with LPS and chemotactic factors, NF-kappaB inducible kinase phosphorylates and activates the I-kappaB kinase (IKK) complex consisting of IKK-1 and IKK-2, which in turn phosphorylates the I-kappaBalpha subunit. Phosphorylation, ubiquitination, and subsequent degradation of I-kappaBalpha results in NF-kappaB nuclear translocation. This allows the transcription factor to bind to promoter regions of specific pro-inflammatory genes and influence transcription.27,28 Because a number of potential kappaB sites are present in the nucleotide sequences of the TNF-alpha gene, NF-kappaB is considered to be a critical transcriptional factor involved in TNF-alpha gene expression and protein synthesis.29,30
In this set of experiments, we demonstrated that PTX downregulates cytoplasmic I-kappaBalpha phosphorylation, nuclear NF-kappaB p65 phosphorylation/translocation, as well as NF-kappaB DNA-binding after LPS stimulation, suggesting that PTX exerts its function proximal to or at the level of I-kappaBalpha phosphorylation.
Previous studies that have evaluated the effects of cAMP-elevating drugs on I-kappaBalpha and NF-kappaB have reported conflicting results. Haddad et al. reported results similar to ours with respect to the effects of PTX on I-kappaBalpha and NF-kappaB in pulmonary epithelial cells.31 Conversely, Neumann et al. proposed that increased intracellular cAMP stabilizes the interaction between I-kappaBalpha and NF-kappaB, therefore reducing NF-kappaB activation.32 In contrast, Takahashi et al. showed no difference in I-kappaBalpha degradation in Jurkat T-lymphocytes in the presence and absence of forskolin, an alternative cAMP inducing compound. This group also demonstrated that forskolin did not inhibit the DNA-binding activity of NF-kappaB and that CREB was not involved in forskolin-induced decrease in p65 transcriptional activity.33 Similar results were reported by Ollivier et al. using THP-1 cells and endothelial cells treated with forskolin or dibutyryl cAMP, two agents known to function through cAMP elevation and subsequent PKA activation.9 The differences between our results and those mentioned above may be explained by the use of different cell types and exogenous stimulants. It is also possible that PTX exerts its anti-inflammatory effects on the NF-kappaB pathway independent of PKA, as suggested by the continued attenuation of LPS-induced TNF-alpha production by PTX in the presence or absence of PKA inhibition observed in this study. This hypothesis is currently under investigation in our laboratory. Furthermore, we utilized a broad PKA inhibitor in this study in addition to H89, but did not examine the effect of specific inhibition of various PKA isoforms. This information may yield more insight into the mechanism by which PTX exerts its down-regulatory effects.
PDE inhibitors may also downregulate NF-kappaB transcriptional activity by altering the competitive binding of CREB and NF-kappaB to the promoter regions of pro-inflammatory genes. Herein, we showed that the activation and DNA binding activity of CREB is upregulated in a dose-dependent manner by PTX. Of note, the increase in CREB activity was slightly alleviated by the addition of LPS, suggesting competition between PTX-induced CREB-associated gene transcription and those factors, such as NF-kappaB, which may be upregulated by LPS exposure. This competition has been postulated to involve the recruitment of the co-activator CBP and its homologue p30034, suggesting an alternative mechanism that may be involved in the anti-inflammatory actions of PTX. Future studies are planned to delineate the validity of this potential mechanism.
The effects of PTX on other transcription factors, such as AP-1, c-fos, and c-jun, cannot be ruled out by our experiments. Activation of AP-1 and its components (c-fos and c-jun) by agents that enhance mononuclear cell activity has been implicated in TNF-alpha expression. Moreover, AP-1 and CREB recognize a similar DNA binding sequence in the promoter region of the TNF-alpha gene35. Given these relationships, it is conceivable that PTX may exert some of its anti-inflammatory actions by affecting AP-1 activation and favoring CREB binding, thus inhibiting TNF-alpha gene transcription. Additional studies are necessary to elucidate the complex interactions between CREB, NF-kappaB, and AP-1 following LPS exposure and PDE inhibition. Furthermore, the effect of PTX on the cGMP pathway after LPS stimulation has not been explored, although we plan to do so in the future.
In summary, we have demonstrated that PDE inhibition of human mononuclear cells downregulates TNF-alpha production, at least in part, through a PKA-independent mechanism. In addition, PTX attenuates the activity of NF-B while upregulating CREB activation after LPS stimulation, which may result in modulation of pro-inflammatory mediator synthesis. Therefore, PTX may serve as a potential adjunct therapeutic for the treatment of conditions in which TNF-alpha production plays a significant role.","[{'offsets': [[220, 229]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[464, 473]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[714, 723]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[825, 834]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[925, 934]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1066, 1075]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1166, 1175]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1361, 1370]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1843, 1852]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2374, 2383]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2489, 2498]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[3116, 3119]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3120, 3123]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3236, 3249]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3420, 3425]], 'text': ['IKK-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3430, 3435]], 'text': ['IKK-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3470, 3483]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3556, 3569]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3838, 3847]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3930, 3939]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[4063, 4076]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4112, 4115]], 'text': ['p65'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4274, 4287]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4381, 4394]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4529, 4542]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4695, 4708]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4821, 4834]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5114, 5117]], 'text': ['p65'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5669, 5678]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[6733, 6736]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[6755, 6759]], 'text': ['p300'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[7008, 7013]], 'text': ['c-fos'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[7019, 7024]], 'text': ['c-jun'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[7105, 7110]], 'text': ['c-fos'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[7115, 7120]], 'text': ['c-jun'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[7194, 7203]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[7311, 7320]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[7503, 7512]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[7912, 7921]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[8268, 8277]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[233, 241]], 'text': ['released'], 'type': 'Localization', 'id': 'T22'}, {'offsets': [[253, 262]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[454, 463]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[474, 483]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[703, 713]], 'text': ['decreasing'], 'type': 'Negative_regulation', 'id': 'T26'}, {'offsets': [[734, 745]], 'text': ['attenuating'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[746, 749]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T21'}, {'offsets': [[750, 760]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[812, 824]], 'text': ['downregulate'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[835, 845]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[954, 962]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[1057, 1065]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[1139, 1150]], 'text': ['attenuation'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1158, 1165]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1176, 1186]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[1351, 1360]], 'text': ['decreases'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[1371, 1381]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[1828, 1839]], 'text': ['attenuation'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1853, 1863]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[1906, 1915]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[1936, 1947]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T41'}, {'offsets': [[2363, 2370]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T42'}, {'offsets': [[2384, 2393]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2471, 2485]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T44'}, {'offsets': [[3451, 3465]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T45'}, {'offsets': [[3493, 3508]], 'text': ['Phosphorylation'], 'type': 'Phosphorylation', 'id': 'T46'}, {'offsets': [[3510, 3524]], 'text': ['ubiquitination'], 'type': 'Ubiquitination', 'id': 'T47'}, {'offsets': [[3541, 3552]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T48'}, {'offsets': [[3918, 3926]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T49'}, {'offsets': [[3940, 3955]], 'text': ['gene expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[4037, 4050]], 'text': ['downregulates'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[4077, 4092]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T73'}, {'offsets': [[4116, 4131]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T74'}, {'offsets': [[4132, 4145]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T75'}, {'offsets': [[4288, 4303]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T76'}, {'offsets': [[4346, 4353]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T77'}, {'offsets': [[4511, 4518]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[4660, 4670]], 'text': ['stabilizes'], 'type': 'Regulation', 'id': 'T79'}, {'offsets': [[4675, 4686]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T80'}, {'offsets': [[4835, 4846]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T81'}, {'offsets': [[4878, 4886]], 'text': ['presence'], 'type': 'Regulation', 'id': 'T82'}, {'offsets': [[4891, 4898]], 'text': ['absence'], 'type': 'Regulation', 'id': 'T83'}, {'offsets': [[5642, 5653]], 'text': ['attenuation'], 'type': 'Negative_regulation', 'id': 'T84'}, {'offsets': [[5661, 5668]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T85'}, {'offsets': [[5679, 5689]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T86'}, {'offsets': [[5704, 5723]], 'text': ['presence or absence'], 'type': 'Regulation', 'id': 'T87'}, {'offsets': [[7066, 7076]], 'text': ['Activation'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[7089, 7103]], 'text': ['its components'], 'type': 'Anaphora', 'id': 'T71'}, {'offsets': [[7180, 7190]], 'text': ['implicated'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[7204, 7214]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[7240, 7249]], 'text': ['recognize'], 'type': 'Binding', 'id': 'T91'}, {'offsets': [[7260, 7280]], 'text': ['DNA binding sequence'], 'type': 'Entity', 'id': 'T92'}, {'offsets': [[7492, 7502]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[7518, 7531]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T94'}, {'offsets': [[7898, 7911]], 'text': ['downregulates'], 'type': 'Negative_regulation', 'id': 'T95'}, {'offsets': [[7922, 7932]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T96'}, {'offsets': [[7966, 7977]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[8278, 8288]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T98'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T24', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T25', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T27', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T28', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T29', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T30', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T31', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T32', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T33', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T34', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T35', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T36', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T37', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T38', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T39', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T40', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T41', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T42', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T43', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T44', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T45', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T46', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T47', 'id': 'E26', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T48', 'id': 'E27', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T49', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T50', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T72', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T73', 'id': 'E31', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T72', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T74', 'id': 'E33', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T72', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T75', 'id': 'E35', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T76', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T77', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T78', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T79', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T80', 'id': 'E40', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T81', 'id': 'E41', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T82', 'id': 'E42', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T83', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T84', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E45']}}, {'trigger': 'T85', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T86', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T87', 'id': 'E47', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T88', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T88', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T89', 'id': 'E50', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T90', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T91', 'id': 'E52', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T67', 'T92']}}, {'trigger': 'T93', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E54']}}, {'trigger': 'T94', 'id': 'E54', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T95', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T96', 'id': 'E56', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T97', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E55']}}, {'trigger': 'T98', 'id': 'E58', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}]","[{'id': 'R1', 'head': {'ref_id': 'T21', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T71', 'role': 'Subject'}, 'tail': {'ref_id': 'T64', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T71', 'role': 'Subject'}, 'tail': {'ref_id': 'T65', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E28', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E43', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}]",[]
36,PMC-2889865-01-Background,"Cytokines and chemokines are important in immune cell recruitment and in regulation of inflammatory responses [1]. T-cells produce a broad range of inflammatory mediators, including IL-2, IL-6, TNF and CXCL8, all of which are important in cell proliferation, differentiation, communication and initiation of inflammatory responses [2]. Elevated levels of pro-inflammatory cytokines and chemokines, such as TNF, IL-6 and CXCL8, are associated with several human diseases including cystic fibrosis [3-5], pulmonary fibrosis [6,7] and AIDS [8,9]. Induction of CXCL8 has been suggested to be mediated through NF-kappaB in cooperation with AP-1 [10,11], however the precise mechanism is not fully elucidated, and treatment strategies aimed at inhibiting CXCL8 have failed [12]. Persistent production of IL-6 and CXCL8 leads to chronic inflammation and enhanced survival of lymphocytes increasing serum cytokine/chemokine levels. This forms the basis of several autoimmune disorders including plasmacytosis and hyperplasia [13]. To develop viable CXCL8 based treatment strategies, it is necessary to identify the signalling pathways regulating CXCL8 and determine how this is coupled to NF-kappaB, AP-1 and IL-6.
The signalling pathways leading to NF-kappaB and AP-1 activation are overlapping, where both are involved in the induction and regulation of cytokines/chemokines. NF-kappaB is activated in response to stress, such as oxidative stress, bacterial toxins, viruses and UV light [14], and is essential for differentiation, proliferation and survival of many cell types including T-lymphocytes [15]. AP-1 activation requires Fos (c-Fos, FosB, Fra-1, Fra-2) and Jun (c-Jun, v-Jun, JunB, JunD) through the formation of homo- and hetero-dimers [16,17], and regulates transcription of a broad range of genes involved in immune responses [18-21]. Both AP-1 and NF-kappaB binding sites have been identified in the promoter region of IL-6 and CXCL8 [12,22], however, the mechanism by which these interleukins are regulated in T-cells is still not clear. CXCL8 is a C-X-C chemokine with properties enabling it to recruit T-cells and basophils and to activate neutrophils and monocytes [23]. IL-6 is a cytokine that possesses both pro- and anti-inflammatory characteristics and that plays a key role in haematopoiesis and acute-phase responses [24,25].
The present study suggests that the regulation of CXCL8 and IL-6 is uncoupled. Using Jurkat T-cells exposed to PMA and heat killed (HK) Escherichia coli MG1655 in combination with inhibitors of NF-kappaB, JNK and PKC, we demonstrated that NF-kappaB regulates IL-6 expression while the regulation of CXCL8 more closely correlated to AP-1 activity. These results indicate that inhibition of NF-kappaB is not an effective strategy in countering the high CXCL8 activities in diseases such as cystic fibrosis, AIDS and pulmonary fibrosis.","[{'offsets': [[182, 186]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[188, 192]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[202, 207]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[411, 415]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[420, 425]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[557, 562]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[749, 754]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[798, 802]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[807, 812]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1041, 1046]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1138, 1143]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1201, 1205]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1631, 1636]], 'text': ['c-Fos'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1638, 1642]], 'text': ['FosB'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1644, 1649]], 'text': ['Fra-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1651, 1656]], 'text': ['Fra-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1667, 1672]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1674, 1679]], 'text': ['v-Jun'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1681, 1685]], 'text': ['JunB'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1687, 1691]], 'text': ['JunD'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1928, 1932]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1937, 1942]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2048, 2053]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2184, 2188]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2395, 2400]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2405, 2409]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2604, 2608]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2644, 2649]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2677, 2681]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2796, 2801]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[123, 130]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[148, 170]], 'text': ['inflammatory mediators'], 'type': 'Anaphora', 'id': 'T31'}, {'offsets': [[544, 553]], 'text': ['Induction'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[588, 596]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[738, 748]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[784, 794]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[1127, 1137]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T40'}, {'offsets': [[1626, 1629]], 'text': ['Fos'], 'type': 'Anaphora', 'id': 'T32'}, {'offsets': [[1662, 1665]], 'text': ['Jun'], 'type': 'Anaphora', 'id': 'T33'}, {'offsets': [[1705, 1741]], 'text': ['formation of homo- and hetero-dimers'], 'type': 'Binding', 'id': 'T41'}, {'offsets': [[1984, 2002]], 'text': ['these interleukins'], 'type': 'Anaphora', 'id': 'T34'}, {'offsets': [[2007, 2016]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T42'}, {'offsets': [[2381, 2391]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T43'}, {'offsets': [[2594, 2603]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[2609, 2619]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[2630, 2640]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T46'}, {'offsets': [[2776, 2786]], 'text': ['countering'], 'type': 'Negative_regulation', 'id': 'T47'}]","[{'trigger': 'T35', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T35', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T35', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T36', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T37', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T38', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T39', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T39', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T40', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T41', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T17']}}, {'trigger': 'T41', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T18']}}, {'trigger': 'T41', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T19']}}, {'trigger': 'T41', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T20']}}, {'trigger': 'T41', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T17']}}, {'trigger': 'T41', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T18']}}, {'trigger': 'T41', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T19']}}, {'trigger': 'T41', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T20']}}, {'trigger': 'T41', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T17']}}, {'trigger': 'T41', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T18']}}, {'trigger': 'T41', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T19']}}, {'trigger': 'T41', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T20']}}, {'trigger': 'T41', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T41', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T18']}}, {'trigger': 'T41', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T19']}}, {'trigger': 'T41', 'id': 'E25', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T20']}}, {'trigger': 'T42', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T42', 'id': 'E27', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T43', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T43', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T44', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T45', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T46', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T47', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}]","[{'id': 'R1', 'head': {'ref_id': 'T31', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T31', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T31', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T14', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T15', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T16', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T17', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T19', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R11', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T20', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R12', 'head': {'ref_id': 'T34', 'role': 'Subject'}, 'tail': {'ref_id': 'T21', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R13', 'head': {'ref_id': 'T34', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E33', 'value': ''}]",[]
37,PMC-3245220-24-Materials_and_Methods,"Ethics Statement
All research involving human blood (Buffy coat) were ordered from American Red cross and have been approved by the Ohio State University review board (ARC IRB Protocol #2001-26).",[],[],[],[],[],[]
38,PMC-2791889-01-Introduction,"Interleukin-10 (IL-10) is a cytokine with broad anti-inflammatory properties that inhibits macrophage and dendritic cell (DC) function (Moore et al., 2001). IL-10 limits the immune and inflammatory responses to pathogens and gut flora and prevents damage to the host (Moore et al., 2001; O'Garra and Vieira, 2004), but when dysregulated may result in chronic infection (Brooks et al., 2006; Ejrnaes et al., 2006; Moore et al., 2001). IL-10 is expressed by T helper 2 (Th2) cells, B cells, DCs, and macrophages (Moore et al., 2001), and also by Th1 cells (Anderson et al., 2007; Assenmacher et al., 1994; Del Prete et al., 1993; Gerosa et al., 1996; Jankovic et al., 2007; Pohl-Koppe et al., 1998) and (reviewed in O'Garra and Vieira, 2007; Trinchieri, 2007), certain regulatory (Treg) T cells (Moore et al., 2001; O'Garra and Vieira, 2004; Roncarolo et al., 2006), and Th17 cells (Awasthi et al., 2007; Fitzgerald et al., 2007; McGeachy et al., 2007; Stumhofer et al., 2007).
In vitro human CD4+ and CD8+ T cell clones, or mouse CD4+ T cells that produce both interferon-gamma (IFN-gamma) and IL-10, can be differentiated by T cell receptor (TCR)-stimulation in the presence of IL-12 (Chang et al., 2007; Gerosa et al., 1996; Jeannin et al., 1996; Meyaard et al., 1996; Windhagen et al., 1996). Furthermore, Th1 cell clones coproducing IFN-gamma and IL-10 have been isolated from bronchoalveolar lavage (BAL) of active pulmonary tuberculosis (TB) patients (Gerosa et al., 1999). IL-10 production by Th1 cells was also reported in animals infected with Toxoplasma gondii (Jankovic et al., 2002; Shaw et al., 2006) or with Leishmania major (Anderson et al., 2007) and shown to be required for regulation of the immune response in these infections (Anderson et al., 2007; Jankovic et al., 2007). The relative amounts of IL-10 and IFN-gamma produced by Th1 cells may influence the balance between clearance and persistent infection with certain pathogens (Moore et al., 2001; Trinchieri, 2007), thus determining whether chronic infection or immunopathology ensues.
Th1, Th2, and Th17 cell responses differentiate along distinct signaling pathways (Glimcher and Murphy, 2000; Ivanov et al., 2007; Stockinger and Veldhoen, 2007). Th1 cell development requires signal transducer and activator of transcription (STAT)1 activation, induced by type I IFN or IFN-gamma, the transcription factor T-box 21 (T-bet), and IL-12-induced STAT4 signaling, which can couple with IL-18-induced IRAK and NF-kappaB transcription factors to drive the high amounts of IFN-gamma required to eradicate intracellular pathogens (Glimcher and Murphy, 2000). Th2 cell development, with expression of IL-4, IL-5, and IL-13, requires IL-4, STAT6, and the transcription factor GATA binding protein (GATA)-3 (Glimcher and Murphy, 2000). The development of Th17 cells requires IL-6, TGF-beta, and the STAT3-dependent expression of the transcription factor RORgammat (Ivanov et al., 2007; Stockinger and Veldhoen, 2007).
Th1 and Th2 cell responses can also be induced by varying the dose of antigen presented to the naive T cell by the antigen-presenting cell (APC). Whereas high doses of antigen, with sustained TCR signaling and extracellular-signal regulated (ERK) mitogen-activated protein kinase (MAPK) phosphorylation, result in Th1 cells producing IFN-gamma via an IL-12-independent mechanism, low doses of antigen, with transient ERK1 and ERK2 activation, favor Th2 responses and IL-4 secretion (Constant et al., 1995; Hosken et al., 1995; Jorritsma et al., 2003; Yamane et al., 2005).
Because Th1 and Th2 cells cross regulate each other's development and function and can suppress Th17 cell responses, and all differentiate along distinct signaling pathways (Glimcher and Murphy, 2000; Stockinger and Veldhoen, 2007), IL-10 produced by all these Th cells may thus act as a feedback regulator to control the pathology associated with an overexuberant, albeit efficacious, inflammatory response. Whether IL-10 production by these different Th cell subsets is induced by independent and/or common mechanisms is unknown.
Here, we showed that in vitro differentiation of IL-10-producing Th1 cells from naive CD4+ T cells required IL-12-induced STAT4 signaling, strong TCR activation (high antigen dose), and sustained ERK1 and ERK2 phosphorylation. Furthermore, we showed that activation of ERK1 and ERK2 is a requirement for production of IL-10 by Th1, Th2, and Th17 cell subsets. This common but highly regulated pathway for IL-10 induction and maintenance ensures its function as a feedback loop to control damage to the host and also allows a protective response to ensue as opposed to chronic infection.","[{'offsets': [[3, 14]], 'text': ['erleukin-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[16, 21]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[157, 162]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[434, 439]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[991, 994]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1000, 1003]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1029, 1032]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1060, 1076]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1078, 1087]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1093, 1098]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1178, 1183]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1336, 1345]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1350, 1355]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1479, 1484]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1817, 1822]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1827, 1836]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2254, 2311]], 'text': ['signal transducer and activator of transcription (STAT)1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2334, 2344]], 'text': ['type I IFN'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2348, 2357]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2384, 2392]], 'text': ['T-box 21'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2394, 2399]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2406, 2411]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2420, 2425]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2459, 2464]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2473, 2477]], 'text': ['IRAK'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2543, 2552]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2669, 2673]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2675, 2679]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2685, 2690]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2701, 2705]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2707, 2712]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2743, 2772]], 'text': ['GATA binding protein (GATA)-3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2841, 2845]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2847, 2855]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2865, 2870]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2920, 2929]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3318, 3327]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3335, 3340]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3401, 3405]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3410, 3414]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3451, 3455]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3790, 3795]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3974, 3979]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4138, 4143]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4175, 4178]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4197, 4202]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4211, 4216]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4285, 4289]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4294, 4298]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4358, 4362]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4367, 4371]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4407, 4412]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4494, 4499]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[443, 452]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[1047, 1054]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[1324, 1335]], 'text': ['coproducing'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[1485, 1495]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[1837, 1845]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[2311, 2321]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[2323, 2330]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[2465, 2472]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[2517, 2522]], 'text': ['drive'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[2532, 2539]], 'text': ['amounts'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[2655, 2665]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[2692, 2700]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[2871, 2880]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[2881, 2891]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[3288, 3294]], 'text': ['result'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[3308, 3317]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T69'}, {'offsets': [[3341, 3352]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T70'}, {'offsets': [[3415, 3425]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[3427, 3432]], 'text': ['favor'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[3456, 3465]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T73'}, {'offsets': [[3796, 3804]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[3836, 3863]], 'text': ['act as a feedback regulator'], 'type': 'Regulation', 'id': 'T75'}, {'offsets': [[3980, 3990]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[4029, 4036]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[4144, 4153]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T78'}, {'offsets': [[4299, 4314]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T79'}, {'offsets': [[4344, 4354]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[4377, 4388]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[4393, 4403]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T82'}, {'offsets': [[4500, 4509]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T83'}]","[{'trigger': 'T54', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T55', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T55', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T56', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T56', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T57', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T58', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T58', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T59', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T60', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T18']}}, {'trigger': 'T60', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T19']}}, {'trigger': 'T61', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T25', 'T24']}}, {'trigger': 'T62', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E9']}}, {'trigger': 'T63', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T64', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T64', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T64', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T65', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T30']}}, {'trigger': 'T65', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T31']}}, {'trigger': 'T65', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T32']}}, {'trigger': 'T65', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T30']}}, {'trigger': 'T65', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T31']}}, {'trigger': 'T65', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T32']}}, {'trigger': 'T65', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T29', 'T30']}}, {'trigger': 'T65', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T29', 'T31']}}, {'trigger': 'T65', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T29', 'T32']}}, {'trigger': 'T66', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T35']}}, {'trigger': 'T67', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T68', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T69', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T70', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T38']}}, {'trigger': 'T71', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T71', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T72', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E32']}}, {'trigger': 'T73', 'id': 'E35', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T72', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E33']}}, {'trigger': 'T74', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T75', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T42']}}, {'trigger': 'T76', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T77', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T78', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T79', 'id': 'E42', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T79', 'id': 'E43', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T80', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T80', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T81', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E44']}}, {'trigger': 'T82', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T81', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E45']}}, {'trigger': 'T83', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}, {'id': '*', 'ref_ids': ['T8', 'T9']}, {'id': '*', 'ref_ids': ['T20', 'T21']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E38', 'value': ''}]",[]
39,PMC-2065877-14-Materials_and_Methods,"Flow cytometry.
One million splenocytes were stained with the appropriate primary antibody unconjugated or conjugated to FITC, PE, or APC diluted in stain buffer (PBS with 3% FBS). For BrdU detection, the FITC-BrdU flow kit was used as instructed by the manufacturer (BD Bioscience). Briefly, cells were exposed to EMA (Molecular Probes) for exclusion of dead cells, stained for surface antigens, fixed in paraformaldehyde, and permeabilized with saponin. To expose BrdU epitopes, cells were treated with Dnase and stained with FITC-conjugated anti-BrdU antibody. Flow cytometry was performed on FACScalibur using the CellQuest program (Becton Dickinson). Further analysis was conducted on the Summit v4.2 program (Dako).",[],[],[],[],[],[]
40,PMC-2065877-02-Results,"High Levels of LMP1 Expression Correlates with the Development of Lymphoma
LMP1 expression in IgLMP1 mice was directed to B cells under the control of the Ig heavy chain promoter and enhancer. It has previously been shown that in these transgenic mice, LMP1 expression was restricted to B220+ B cells with lymphoma detected in greatly enlarged spleens [23,26]. To investigate whether LMP1 expression contributes to lymphoma development, B cells were purified from splenocytes by positive selection using anti-CD19 MACS magnetic beads, and equivalent amounts of B cells were analyzed by immunoblotting. LMP1 was detectable in LMP1 transgenic B cells, but upon development of lymphoma, LMP1 expression was stronger in 5/7 lymphomas analyzed with concomitant appearance of degradation products (Figure 1A). To determine whether the higher level of LMP1 detected was due to an expansion of malignant lymphocytes, expression of LMP1 in the spleen was further evaluated by immunohistochemical staining. Immunohistochemistry analysis of spleen sections detected LMP1 in the plasma membrane of cells in both the follicular white pulp and circulating lymphocytes in the red pulp (Figure 1B). LMP1 expression was heterogeneous with strong LMP1 staining interspersed amongst a background of cells staining weakly for LMP1. Upon development to lymphoma, LMP1 expression was more abundantly detected with multiple foci of intense LMP1 staining. This demonstrates that the increased LMP1 detected by immunoblotting upon malignant progression reflects an increase in LMP1 expression and an accumulation of cells expressing high levels of LMP1. This correlation between high LMP1 expression and the development of lymphoma suggests that progression to lymphoma results from increased levels of LMP1.","[{'offsets': [[15, 19]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[75, 79]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[253, 257]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[384, 388]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[509, 513]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[602, 606]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[625, 629]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[684, 688]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[845, 849]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[923, 927]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1055, 1059]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1183, 1187]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1229, 1233]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1306, 1310]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1342, 1346]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1417, 1421]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1469, 1473]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1552, 1556]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1623, 1627]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1659, 1663]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1778, 1782]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[0, 11]], 'text': ['High Levels'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[20, 30]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[80, 90]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[130, 147]], 'text': ['under the control'], 'type': 'Regulation', 'id': 'T25'}, {'offsets': [[258, 268]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T26'}, {'offsets': [[273, 283]], 'text': ['restricted'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[389, 399]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[611, 621]], 'text': ['detectable'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[689, 699]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[704, 712]], 'text': ['stronger'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[829, 841]], 'text': ['higher level'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[909, 919]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[1046, 1054]], 'text': ['detected'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[1188, 1198]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[1222, 1228]], 'text': ['strong'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[1295, 1301]], 'text': ['weakly'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[1347, 1357]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[1367, 1377]], 'text': ['abundantly'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1409, 1416]], 'text': ['intense'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[1459, 1468]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1540, 1548]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[1557, 1567]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[1597, 1607]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[1608, 1619]], 'text': ['high levels'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[1654, 1658]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[1664, 1674]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[1758, 1767]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[1768, 1774]], 'text': ['levels'], 'type': 'Gene_expression', 'id': 'T49'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T24', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T25', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T27', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T28', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T29', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T30', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T31', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T32', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T33', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T34', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T35', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T36', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T37', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T38', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T39', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T40', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T41', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T42', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T43', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T44', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T45', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T46', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T47', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T48', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T49', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}]",[]
41,PMC-2889865-24-Caption-Table_1,Jurkat T-cells were stimulated with 162 nM PMA and 5 x 107 CFU/ml HK E. coli for 24 h.,[],[],[],[],[],[]
42,PMC-3148254-14-Materials_and_Methods,"Immunoprecipitations
Immunoprecipitation of CD40 was performed by activated receptor capture, as previously described [6]. Briefly, 3x107 cells (A20.2J and derivatives) were incubated for 60 minutes at room temperature with 10 microl magnetic protein G beads (Dynal) pre-coated with 10 microg goat anti-rat IgG (Jackson), and 10 microg anti-CD40 (1C10) or an isotype control antibody (mAb72). Cells/beads were then pelleted by centrifugation and lysed in buffer containing 1% Triton X100. Beads were washed with lysis buffer to remove unbound material. In some experiments, material associated with the beads was dephosphorylated with lambda phosphatase (New England BioLabs) as per manufacturer's instructions. Beads were resuspended in 2X SDS-PAGE sample buffer and heated for 5 minutes at 95degreesC. Material eluted from the beads was fractionated by SDS-PAGE and transferred to PVDF membranes for Western blotting. In some experiments, cells were cultured for 6 hrs with 25 microM antennapedia-linked SMAC-N7 peptide (Calbiochem) or an appropriate volume of the solvent used for the peptide (DMSO). After incubation, cells (in peptide- or DMSO-containing medium) were stimulated with antibody-coated beads as outlined above.","[{'offsets': [[44, 48]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
43,PMC-2065877-22-Caption-Figure_4,"Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture
(A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe.
(B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out.
(D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.","[{'offsets': [[14, 18]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 73]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 79]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[132, 135]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[164, 168]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[183, 187]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[216, 219]], 'text': ['L32'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[224, 229]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[374, 378]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[409, 415]], 'text': ['pStat6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[441, 445]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[524, 527]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[695, 699]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[740, 743]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[772, 775]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[866, 870]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[399, 408]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T17'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
44,PMC-2664230-00-TIAB,"Insights into the Regulation of TNF-alpha Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition
OBJECTIVE
The objective of this study was to determine the effect of nonspecific phosphodiesterase inhibition on transcription factor activation and tumor necrosis factor-alpha (TNF-alpha) production in lipopolysaccharide (LPS)-stimulated human mononuclear cells.
INTRODUCTION
The production of TNF-alpha following LPS stimulation is one of the key steps in bacterial sepsis and inflammation. The mechanism by which phosphodiesterase inhibition alters TNF-alpha production in the presence of LPS remains unclear.
METHODS
Human mononuclear cells were stimulated with LPS (1 mug/mL), in the presence and absence of Pentoxifylline (PTX; 20 mM), a nonspecific phosphodiesterase inhibitor. Western blotting of phosphorylated cytoplasmic I-kappaBalpha, nuclear factor-kappaB p65 (NF-kappaB), and nuclear cAMP-response element binding protein (CREB) was performed. DNA binding of NF-kappaB and CREB was verified by electrophoretic mobility shift assay. TNF-alpha levels were determined in the supernatant of stimulated cells in the presence and absence Protein kinase A inhibition by an enzyme-linked immunosorbent assay (ELISA).
RESULTS
PTX was demonstrated to significantly reduce cytoplasmic I-kappaBalpha phosphorylation, nuclear p65 phosphorylation, and the DNA binding activity of NF-kappaB. In contrast, PTX markedly enhanced the phosphorylation and DNA binding activity of CREB. Cells concomitantly treated with PTX and LPS secreted similar levels of TNF-alpha in the presence and absence Protein kinase A inhibition.
DISCUSSION
The increased level of cAMP that results from phosphodiesterase inhibition affects cytoplasmic and nuclear events, resulting in the attenuation of NF-kappaB and the activation of CREB transcriptional DNA binding through pathways that are partially Protein kinase A-independent.
CONCLUSION
PTX-mediated phosphodiesterase inhibition occurs partially through a Protein kinase A-independent pathway and may serve as a useful tool in the attenuation of LPS-induced inflammation.","[{'offsets': [[32, 41]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[287, 314]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[316, 325]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[433, 442]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[590, 599]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[870, 883]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[907, 910]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1084, 1093]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1326, 1339]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1365, 1368]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1590, 1599]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[18, 28]], 'text': ['Regulation'], 'type': 'Regulation', 'id': 'T12'}, {'offsets': [[42, 52]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[197, 203]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[327, 337]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[419, 429]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[443, 452]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[583, 589]], 'text': ['alters'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[600, 610]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[611, 629]], 'text': ['in the presence of'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[843, 857]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T21'}, {'offsets': [[1307, 1313]], 'text': ['reduce'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1340, 1355]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T23'}, {'offsets': [[1369, 1384]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T24'}, {'offsets': [[1563, 1571]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T25'}, {'offsets': [[1607, 1615]], 'text': ['presence'], 'type': 'Regulation', 'id': 'T26'}, {'offsets': [[1620, 1627]], 'text': ['absence'], 'type': 'Regulation', 'id': 'T27'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T15', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T19', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T20', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T23', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T22', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T24', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T25', 'id': 'E15', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T26', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T27', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}]",[]
45,PMC-2626671-19-Caption-Figure_3,"Key role for Runx3 in effector CTL differentiation. (A) Western analysis of Runx3, Eomes, T-bet, and perforin expression in Runx3+/+ versus Runx3-/- CD8+ SP T cells differentiated for 6 d. beta-Actin was used as a loading control. (B) Northern blot analysis of Prf1 mRNA expression in Runx3+/+ versus Runx3-/- CD8+ T cells differentiated for 6 d. beta-Actin was used as a loading control. (C) Expression of granzyme B, IFN-gamma, TNF, and IL-2 by resting or restimulated (6 h) Runx3+/+ versus Runx3-/- CD8+ SP T cells differentiated for 6 d. The vertical gray line indicates the granzyme B MFI for WT GFP+ cells. Results in A-C are representative of two independent experiments. (D) ChIP analysis of binding of endogenous Runx3 and Eomes to the Prf1 locus. Enrichment of the indicated genomic regions was evaluated by real-time PCR of DNA from immunoprecipitated and input chromatin. The data are the means of duplicate measurements from two chromatin preparations from two independent CD8+ T cell differentiations. The efficiency of recovery of input for the -1-kb region of Prf1 was 0.97% for the Runx3 ChIP and 0.5% for the Eomes ChIP.","[{'offsets': [[13, 18]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[76, 81]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 88]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[90, 95]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[101, 109]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[124, 129]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[140, 145]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[149, 152]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[189, 199]], 'text': ['beta-Actin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[261, 265]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[285, 290]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[301, 306]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[310, 313]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[347, 357]], 'text': ['beta-Actin'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[407, 417]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[419, 428]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[430, 433]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[439, 443]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[477, 482]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[493, 498]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[502, 505]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[579, 589]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[601, 604]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[722, 727]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[732, 737]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[745, 749]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[986, 989]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1076, 1080]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1099, 1104]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1127, 1132]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[110, 120]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[266, 281]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T32'}, {'offsets': [[393, 403]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[700, 707]], 'text': ['binding'], 'type': 'Binding', 'id': 'T34'}]","[{'trigger': 'T31', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T31', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T31', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T32', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T33', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T33', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T33', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T33', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T34', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T26']}}, {'trigger': 'T34', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T25', 'T26']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}]",[]
46,PMC-2626671-11-MATERIALS_AND_METHODS,"FACS-based cytotoxicity assay.
To measure cytotoxicity, EL4 thymoma target cells were loaded with 0 or 1 muM Gp33 peptide for 2 h before a 2-h coincubation with P14 CD8+ T cells at the effector-to-target ratios indicated in the figures in 96-well round-bottom plates. After the coincubation period, cells were stained with Annexin V-FITC and anti-CD8-allophycocyanin. Data analysis was performed with FlowJo software (Tree Star, Inc.); EL4 target cells (CD8-negative events) were gated, and the percentage of Annexin V+ target cells was determined.","[{'offsets': [[165, 168]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[323, 332]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[347, 350]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[454, 457]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[509, 518]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
47,PMC-3245220-30-Caption-Figure_6,"Inhibition of M-CSF-induced PKC reduces NF-kappaB-regulated genes in both MDMs and RAW 264.7 cells.
MDMs (A and C) and RAW 264.7 (B) cells were pretreated with Ro-31-8220 or solvent control DMSO for 30 minutes prior to M-CSF stimulation for the indicated times. Total RNA was isolated and converted to cDNA. Real-time RT PCR was performed using primers for IkappaBalpha, BCL-xl or GAPDH. Data are expressed as relative fold increase of IkappaBalpha or BCL-xl gene expression upon treatment over non-stimulated cells. Data represent the mean +/- S.E.M for three independent experiments.","[{'offsets': [[357, 369]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[371, 377]], 'text': ['BCL-xl'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[436, 448]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[452, 458]], 'text': ['BCL-xl'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[424, 432]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[464, 474]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T6'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T6', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
48,PMC-1447668-01-Introduction,"Immunological tolerance to self-antigens is the result of the deletion of self-reactive T lymphocytes in the thymus (central tolerance) and suppression of the activation of potentially self-reactive T lymphocytes in the periphery (peripheral tolerance) [1]. Suppression of pathogenic T cell responses is mediated by naturally arising CD4+CD25+ T regulatory cells (Tregs) [2,3]. Deficiencies in Treg development and function have been linked to the severe autoimmune disorder known as immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) [4]. In addition, recent studies have provided strong evidence that dysregulation of Treg development and/or function may be a significant factor in the pathogenesis of several autoimmune disorders (e.g., multiple sclerosis [5], myasthenia gravis [6], and type 1 diabetes [7]) and virus-induced immunologic disorders (e.g., human T lymphotropic virus type I [HTLV-I]-associated myelopathy/tropical spastic paraparesis [HAM/TSP], and HIV-induced AIDS [8-10]).
The transcription factor Foxp3 is a 431-amino acid (48-kDa) protein expressed at very high levels in CD4+CD25hi T cells and has previously been shown to be absolutely critical for Treg development and function [11-14]. Foxp3 contains a proline-rich amino-terminal domain reported to function as a nuclear factor of activated T cells (NF-AT) and nuclear factor-kappaB (NF-kappaB) binding domain, a central region containing a zinc finger and leucine zipper potentially important for protein-protein interactions, and a carboxyl-terminal forkhead (FKH) domain required for nuclear localization and DNA-binding activity [14-16]. Functional inactivation of Foxp3 by genetic mutations affecting the Foxp3 coding region, as demonstrated in IPEX, or repression of Foxp3 expression by the HTLV-I-encoded transactivator protein Tax, as recently reported in patients with HAM/TSP, results in loss of regulatory activity in CD4+CD25hi T cells [4,8,17]. Although it is clear that Foxp3 regulates T cell proliferation and cytokine production, very little is known concerning the molecular mechanisms of Foxp3 function.
The first evidence to indicate how Foxp3 promotes the development and function of regulatory T cells came from a report by Ziegler and colleagues [16], which suggested that Foxp3 could inhibit transcriptional activation by physically interacting with forkhead binding sites located immediately adjacent to critical cis-acting NF-AT binding sites found in various cytokine promoters (e.g., IL-2 promoter). That study also demonstrated that Foxp3 could repress activation of a synthetic reporter vector containing an SV40 promoter and three tandem copies of a forkhead binding site. These results provided additional evidence suggesting that Foxp3 transcriptional repression was mediated by binding in a sequence-specific manner to promoters containing forkhead binding sites. A recent study by Bettelli and colleagues [15] further demonstrated that Foxp3 could inhibit NF-AT as well as NF-kappaB activation, although the mechanism of suppression was shown to involve direct protein-protein interactions between NF-AT or NF-kappaB and Foxp3 rather than binding of Foxp3 to promoter elements adjacent to cis-acting NF-AT or NF-kappaB sites. Collectively, these data suggested that Foxp3 may function as a transcriptional repressor, potentially through the formation of both DNA-protein and protein-protein interactions.
In the present study, we expanded upon these observations by defining additional requirements of Foxp3-mediated repression of NF-kappaB activation, and investigated whether Foxp3 could target additional signaling pathways by examining transcriptional activation of NF-kappaB-dependent and NF-kappaB-independent retroviral pathogens. The characterization of the molecular targets of Foxp3 and the mechanism(s) utilized by Foxp3 to support Treg development and function will aid in our understanding of the role Tregs play in the pathogenesis of human autoimmune disease.","[{'offsets': [[334, 337]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[338, 342]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1048, 1053]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1124, 1127]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1128, 1132]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1242, 1247]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1676, 1681]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1717, 1722]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1780, 1785]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1842, 1845]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1936, 1939]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1940, 1944]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1991, 1996]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2113, 2118]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2164, 2169]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2302, 2307]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2518, 2522]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2568, 2573]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2769, 2774]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2977, 2982]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3162, 3167]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3191, 3196]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3307, 3312]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3543, 3548]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3619, 3624]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3828, 3833]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3867, 3872]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1057, 1090]], 'text': ['a 431-amino acid (48-kDa) protein'], 'type': 'Anaphora', 'id': 'T28'}, {'offsets': [[1091, 1100]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[1464, 1478]], 'text': ['leucine zipper'], 'type': 'Entity', 'id': 'T31'}, {'offsets': [[1491, 1500]], 'text': ['important'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[1521, 1533]], 'text': ['interactions'], 'type': 'Binding', 'id': 'T33'}, {'offsets': [[1541, 1580]], 'text': ['carboxyl-terminal forkhead (FKH) domain'], 'type': 'Entity', 'id': 'T34'}, {'offsets': [[1581, 1589]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1594, 1601]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T36'}, {'offsets': [[1602, 1614]], 'text': ['localization'], 'type': 'Localization', 'id': 'T37'}, {'offsets': [[1623, 1630]], 'text': ['binding'], 'type': 'Binding', 'id': 'T38'}, {'offsets': [[1660, 1672]], 'text': ['inactivation'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[1703, 1712]], 'text': ['affecting'], 'type': 'Regulation', 'id': 'T40'}, {'offsets': [[1723, 1736]], 'text': ['coding region'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[1766, 1776]], 'text': ['repression'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[1786, 1796]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2314, 2321]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T44'}, {'offsets': [[2322, 2348]], 'text': ['transcriptional activation'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[2363, 2374]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T46'}, {'offsets': [[2492, 2510]], 'text': ['cytokine promoters'], 'type': 'Anaphora', 'id': 'T29'}, {'offsets': [[2523, 2531]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T47'}, {'offsets': [[2818, 2825]], 'text': ['binding'], 'type': 'Binding', 'id': 'T48'}, {'offsets': [[3118, 3130]], 'text': ['interactions'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[3180, 3187]], 'text': ['binding'], 'type': 'Binding', 'id': 'T50'}, {'offsets': [[3382, 3391]], 'text': ['formation'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[3432, 3444]], 'text': ['interactions'], 'type': 'Binding', 'id': 'T52'}]","[{'trigger': 'T30', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T32', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E3', 'T6', 'T31']}}, {'trigger': 'T33', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E5', 'T6', 'T34']}}, {'trigger': 'T37', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T36']}}, {'trigger': 'T35', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E7', 'T6', 'T34']}}, {'trigger': 'T38', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T39', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'E9']}}, {'trigger': 'T40', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T41']}}, {'trigger': 'T42', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T10']}}, {'trigger': 'T43', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T44', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E14']}}, {'trigger': 'T45', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T17', 'T47']}}, {'trigger': 'T46', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T50', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T52', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}]","[{'id': 'R1', 'head': {'ref_id': 'T28', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T29', 'role': 'Subject'}, 'tail': {'ref_id': 'T47', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}]",[]
49,PMC-2889865-19-Caption-Figure_3,"CXCL8, IL-6 and TNF expression following long-term stimulation with PMA. Jurkat T-cells were either treated with media (white bars) or stimulated with PMA (black bars) and incubated for 1 h, 2 h, 6 h and 24 h. Aged media was added following each centrifugation step representative to the stimulation time (see Materials and methods). Cytokine levels (A) CXCL8, (B) IL-6 and (C) TNF were detected by ELISA. Statistical significance from the control was determined using Student's t-test. (n = 3).","[{'offsets': [[0, 5]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[7, 11]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[354, 359]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[365, 369]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[20, 30]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[31, 40]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T6'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T6', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
50,PMC-2889865-11-Materials_and_methods,"Multiplex cytokine assay
Quantification of the levels of cytokines IL-2, IL-6, IL-10 and TNF and the chemokine CXCL8 was performed on culture supernatants using multiplexed biomarker immunoassay kits according to manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA). A Bio-Plex(TM) 200 readout System was used (Bio-Rad), which utilizes Luminex(R) xMAP(TM) fluorescent bead-based technology (Luminex Corp., Austin). Levels were automatically calculated from standard curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad).","[{'offsets': [[67, 71]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[73, 77]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[79, 84]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[111, 116]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
51,PMC-2626671-02-RESULTS_AND_DISCUSSION,"A cell culture system to monitor effector CTL differentiation
We used a simple cell culture system to examine the kinetics of effector gene expression during CD8+ T cell differentiation. Naive CD8+ T cells from P14 TCR transgenic mice were activated for 2 d with anti-CD3 and anti-CD28 or with splenic APCs in the presence of Gp33 peptide, and were cultured in media containing 100 U/ml of recombinant human IL-2 (rhIL-2). We used TCR transgenic mice for these experiments because they provide a reliable source of CD8+ T cells that are truly naive; however, we chose not to stimulate cells with antigen in most experiments so as to avoid contamination with proteins and nucleic acids derived from APCs. There were only minor differences in gene expression during differentiation induced by antigen/APC versus anti-CD3/anti-CD28, and the major conclusions presented in this report are the same for both activating conditions.
Under our culture conditions, activated CD8+ T cells expanded exponentially and accumulated for >8 d. We limited our analysis to the first 6-8 d after activation, a period that coincides with clonal expansion of CD8+ T cells after activation in vivo.","[{'offsets': [[158, 161]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[193, 196]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[268, 271]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[281, 285]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[408, 412]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[414, 420]], 'text': ['rhIL-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[515, 518]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[815, 818]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[824, 828]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[966, 969]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1138, 1141]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T11'}]",[],[],"[{'id': '*', 'ref_ids': ['T5', 'T6']}]",[],[]
52,PMC-2791889-11-Experimental_Procedures,"Isolation of CD4+ T Cells and of Splenic DC and Cell Culture for T Cell Phenotype Differentiation
T cells were sorted for CD4+CD62Lhi, CD4+CD62LhiCD25-, or CD4+CD44loCD25- to >98% on a Moflo cytometer (Cytomation) as before (Shoemaker et al., 2006; Veldhoen et al., 2009). In most cases, experiments were reproduced with each type of purified CD4+ T cell population with similar results obtained. Splenic DCs were prepared as described (Hosken et al., 1995), and sort purified CD11c+ cells were added to the T cell culture. Purified DO11.10 CD4+ T cells (1 x 105 cells/ml) were cultured as before (Hosken et al., 1995), in a total volume of 1 ml cRPMI medium in a 48-well plate, with splenic DCs (2 x 104 cells/ml), and varying amounts of OVA and of IL-12. APC-independent differentiation of naive CD4+ T cells into Th1 and Th2 cells used stimulation with anti-CD3 and anti-CD28 and appropriate cytokine conditions, and control Th1 and Th2 cells were cultured as described before (Hosken et al., 1995; Shoemaker et al., 2006). Culture conditions for Th17 cells were as described before (Veldhoen et al., 2006). Importantly, Th1 and Th2 cells could be differentiated in cRPMI or IMDM (Hosken et al., 1995; Shoemaker et al., 2006; Veldhoen et al., 2006), but Th17 cells were only differentiated optimally in IMDM (Veldhoen et al., 2009). When indicated, U0126 or PD184352 (MEK inhibitors), SB203580 (p38 inhibitor), CT99021 (GSK3beta inhibitor), or a similar amount of DMSO were present in the culture. More details of specific culture conditions are provided in Figures S6 and S7.","[{'offsets': [[13, 16]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[122, 125]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[126, 131]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[135, 138]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[139, 144]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[146, 150]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[156, 159]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[160, 164]], 'text': ['CD44'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[166, 170]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[343, 346]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[477, 482]], 'text': ['CD11c'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[541, 544]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[739, 742]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[750, 755]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[798, 801]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[861, 864]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[874, 878]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1371, 1374]], 'text': ['MEK'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1398, 1401]], 'text': ['p38'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1423, 1431]], 'text': ['GSK3beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1375, 1385]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T21'}, {'offsets': [[1402, 1411]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1432, 1441]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T23'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}]",[],[],[],[]
53,PMC-3245220-03-Results,"PKC Inhibition Reduces NF-kappaB Activity in Human MDMs and RAW 264.7 Cells
Since NF-kappaB is activated by PKC in several cell types [36], we next determined if M-CSF-induced NF-kappaB transcriptional activity was dependent on PKC activation and if calcium, a co-factor for conventional PKC isoform activation, was important. In addition, because of the number of conventional PKCs existing within mononuclear cells, pharmacological inhibitors of PKC family activation was used to determine the relationship of PKC activation to M-CSF-induced cellular survival. MDMs were transfected with the pNF-kappaB-SEAP reporter and then treated with the general PKC inhibitor, Ro-31-8220; the conventional PKCalpha/beta inhibitor Go-6976; or the intracellular calcium blocker BAPTA/AM. Ro-31-8220 significantly suppressed M-CSF-induced NF-kappaB activity compared to cells treated with M-CSF alone (Figure 2A). In addition, Go-6976 and BAPTA/AM also blocked NF-kappaB activity in M-CSF-treated MDMs. Trypan blue exclusion analysis did not indicate cell death suggesting that this suppression was not due to non-specific toxicity. These data indicate that M-CSF mediated NF-kappaB activation through calcium-dependent conventional PKC activation.
We next investigated whether PKC inhibition affected NF-kappaB activity in the mouse macrophage cell line, RAW 264.7. Similar to MDMs, PKC inhibitors Ro-31-8220, Go-6976 and BAPTA/AM reduced M-CSF-induced NF-kappaB activity in a dose-dependent manner in RAW 264.7 macrophages (Figure 2B). To ensure that PKC specifically regulated NF-kappaB p65 and not the closely related family member, c-Rel, we co-transfected c-Rel and NF-kappaB-SEAP constructs into the Raw 264.7 cell line and measured NF-kappaB activity in response to M-CSF. There was no increased NF-kappaB activity in cells expressing c-Rel (Figure S1). These observations indicate that PKC functioned upstream of NF-kappaB p65 in MDMs and RAW 264.7 cells.","[{'offsets': [[697, 705]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[706, 710]], 'text': ['beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1578, 1581]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1625, 1630]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1831, 1836]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1920, 1923]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[711, 720]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T7'}, {'offsets': [[1558, 1567]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T8'}, {'offsets': [[1820, 1830]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[1887, 1897]], 'text': ['functioned'], 'type': 'Regulation', 'id': 'T10'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
54,PMC-3279418-03-Results,"Phenotyping splenic DC and BMDC from WT and cpdm mice
DC are heterogeneous and can be categorized into multiple subtypes based on surface markers [13]. To determine if the Sharpin mutation affects DC development in lymphoid tissues, mouse spleens were examined for the distribution of conventional DC (cDC; CD11c+CD8alpha+ and CD11c+CD8alpha-) [13] and plasmacytoid DC (pDC; CD11c-PDCA-1+) [14]. The percentages for splenic cDC and pDC were both reduced in cpdm mice when compared with WT controls (Fig. 2A). However, when gated on CD11c+ cDC, the percentages of CD8alpha+ and CD8alpha- cells were not affected by SHARPIN deficiency (Fig. 2A). Since the spleen of cpdm mice is markedly enlarged and contains three times as many cells (Fig. 1C), the different percentages of splenic cDC and pDC between WT and mutant mice reflect the increased number of total spleen cells rather than a reduction in cDC and pDC numbers. These data indicate that the Sharpin mutation does not affect the distribution of the examined DC subsets in the spleen.
BMDC from in vitro cultures functionally resemble non-lymphoid tissue DC and monocyte-derived inflammatory DC [15], [16]. The yields of BMDC from WT and cpdm mice were similar. BMDC were CD11c+ and MHC II+ with low expression of co-stimulatory molecules CD40, CD80, and CD86. The TLR3 ligand poly I:C and the TLR4 ligand LPS each activate overlapping but different signaling pathways and were used to induce DC maturation [17], [18]. Incubation with the TLR agonists for 24 hours resulted in increased expression of CD40, CD80, and CD86 on BMDC; however, there was no difference in the expression levels of these markers between WT and cpdm BMDC (Fig. 2B). Thus, SHARPIN deficiency did not influence the expression of co-stimulatory molecules by BMDC.","[{'offsets': [[172, 179]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[307, 312]], 'text': ['CD11c'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[313, 321]], 'text': ['CD8alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[327, 332]], 'text': ['CD11c'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[333, 341]], 'text': ['CD8alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[375, 380]], 'text': ['CD11c'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[381, 387]], 'text': ['PDCA-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[614, 621]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[949, 956]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1228, 1233]], 'text': ['CD11c'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1295, 1299]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1301, 1305]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1311, 1315]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1321, 1325]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1350, 1354]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1557, 1561]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1563, 1567]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1573, 1577]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1704, 1711]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[180, 188]], 'text': ['mutation'], 'type': 'Negative_regulation', 'id': 'T21'}, {'offsets': [[622, 632]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[957, 965]], 'text': ['mutation'], 'type': 'Negative_regulation', 'id': 'T23'}, {'offsets': [[1326, 1332]], 'text': ['ligand'], 'type': 'Binding', 'id': 'T24'}, {'offsets': [[1355, 1361]], 'text': ['ligand'], 'type': 'Binding', 'id': 'T25'}, {'offsets': [[1521, 1529]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[1533, 1542]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[1543, 1553]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1609, 1619]], 'text': ['difference'], 'type': 'Regulation', 'id': 'T29'}, {'offsets': [[1627, 1637]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[1648, 1661]], 'text': ['these markers'], 'type': 'Anaphora', 'id': 'T20'}, {'offsets': [[1712, 1722]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T31'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T24', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T25', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T26', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T27', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T26', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T27', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T26', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T27', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T28', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T28', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T29', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T30', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T29', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T30', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T29', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T30', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T31', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]","[{'id': 'R1', 'head': {'ref_id': 'T20', 'role': 'Subject'}, 'tail': {'ref_id': 'T16', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T20', 'role': 'Subject'}, 'tail': {'ref_id': 'T17', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T20', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}]",[]
55,PMC-2065877-25-Caption-Figure_7,"Akt, NFkappaB, and Stat3 Signaling Are Required for the Growth and Survival of Lymphoma Cells
MTS assay of splenocytes from (A and B) WT or (C and D) LMP1 transgenic lymphomas and (E and F) LMP1 transgenic lymphoctyes. Splenocytes were cultured with or without inhibitors of NFkappaB (BAY11), mTOR (rapamycin), Akt (triciribine), MEK1/2 (U0126), p38 (SB202190), or Stat3 (cucurbitacin I and AG490) at the indicated concentrations. The results are the mean +/- SEM of triplicate samples. Shown are the results for (A and B) WT lymphoma 1, (C and D) LMP1 transgenic lymphoma 2, and (E and F) one out of two LMP1 transgenic mice analyzed. This analysis was repeated with LMP1 transgenic lymphoma 4 yielding similar results.","[{'offsets': [[0, 3]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[19, 24]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[150, 154]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[190, 194]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[293, 297]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[311, 314]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[330, 334]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[335, 336]], 'text': ['2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[365, 370]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[548, 552]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[605, 609]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[668, 672]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[261, 271]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T13'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]",[],[],[],[]
56,PMC-3245220-09-Results,"Identification of PKCalpha as the Upstream Activator of NF-kappaB in Myeloid Cells
Even though the PKC family consists of 10 members, finding that PKCalpha/beta inhibitors and intracellular calcium inhibitors reduced M-CSF-induced NF-kappaB activity, suggested PKCalpha was involved in NF-kappaB activation after M-CSF treatment. To confirm the role of PKCalpha in NF-kappaB activation in macrophages, constructs for either wildtype (WT)-PKCalpha or kinase-deficient (KD)-PKCalpha was co-transfected with the pNF-kappaB-SEAP reporter gene and SEAP secretion was measured. As shown in Figure 7A, MDMs co-transfected with pNF-kappaB-SEAP and WT-PKCalpha had a 1.8-fold increase in NF-kappaB transcriptional activity after M-CSF activation compared with NS cells (p = 0.05), similar to M-CSF-treated cells expressing only pNF-kappaB-SEAP. Transfecting human macrophages with the KD-PKCalpha construct significantly reduced M-CSF-induced NF-kappaB activity compared to WT-PKCalpha transfected cells (p = 0.016). Similarly, RAW 264.7 cells transfected with WT-PKCalpha had 2.5-fold more NF-kappaB transcriptional activity after M-CSF activation compared to unstimulated RAW 264.7 cells (NS) transfected with WT-PKCalpha (Figure 7B). Expression of the KD-PKCalpha construct into RAW 264.7 cells reduced M-CSF-induced NF-kappaB activity to 1.5-fold (p = 0.045) compared to cells transfected with WT PKCalpha.
Cell survival was also examined in MDMs expressing either WT-PKCalpha or KD-PKCalpha constructs by Annexin V-FITC and PI staining. As expected, M-CSF increased MDM survival as measured by the percent of Annexin V/PI negative cells. Similarly, expression of WT-PKCalpha protected cells from apoptosis. In contrast, expression of KD-PKCalpha decreased M-CSF-induced cell survival (p<0.01) (Figure 7C).
Next, we examined the effect of expressing the PKCalpha constructs on NF-kappaB phosphorylation. As shown in Figure 7D, expression of KD-PKCalpha in RAW 264.7 cells did not affect the constitutive phosphorylation at Ser536 of NF-kappaB p65, but attenuated the phosphorylation at Ser276. Expression of WT-PKCalpha did not effect the phosphorylation of either residue with or without M-CSF stimulation. These observations demonstrate that PKCalpha is important in M-CSF-regulated cell survival and NF-kappaB activation and likely regulated through phosphorylation of Ser276 of NF-kappaB p65.
To further validate the impact that PKCalpha played in M-CSF-induced NF-kappaB transcriptional activity, we next employed PKCalpha siRNA treatment of MDM or RAW cells. A pool of specific PKCalpha siRNA were transfected into MDM or Raw 264.7 cells in the presence or absence or M-CSF. Reducing native PKCalpha expression decreased M-CSF-induced NF-kappaB transcriptional activity in both MDM (Figure 7E) (p = 0.012) and Raw 264.7 cells (Figure 7F) (p = 0.01). We also examined cell survival of the MDMs by Annexin V-FITC and PI staining after PKCalpha siRNA transfection. As shown in Figure 7G, M-CSF-induced MDM survival was reduced in the cells transfected with PKCalpha siRNA compared with cells transfected with control siRNA (p = 0.047). In Figure 7H, we confirmed that PKCalpha siRNA transfection decreased PKCalpha protein expression in both MDM and Raw 264.7 cells. Our results indicated that PKCalpha regulated NF-kappaB activation and M-CSF-regulated cell survival.","[{'offsets': [[147, 155]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[156, 160]], 'text': ['beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[261, 269]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[353, 361]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[438, 446]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[472, 480]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[643, 651]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[879, 887]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[968, 976]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1055, 1063]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1206, 1214]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1249, 1257]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1392, 1400]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1463, 1471]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1478, 1486]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1501, 1510]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1605, 1614]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1662, 1670]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1733, 1741]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1849, 1857]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1939, 1947]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2038, 2041]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2106, 2114]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2239, 2247]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2387, 2390]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2428, 2436]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2514, 2528]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2579, 2593]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2692, 2700]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2897, 2906]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2934, 2948]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3055, 3069]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3166, 3180]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3204, 3212]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3292, 3300]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[161, 171]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[450, 466]], 'text': ['kinase-deficient'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[485, 499]], 'text': ['co-transfected'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[600, 614]], 'text': ['co-transfected'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[876, 878]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T41'}, {'offsets': [[977, 988]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[1035, 1046]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[1186, 1197]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[1246, 1248]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T45'}, {'offsets': [[1372, 1383]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[1442, 1452]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[1475, 1477]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[1618, 1626]], 'text': ['negative'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[1645, 1655]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[1730, 1732]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[1834, 1844]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[1936, 1938]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[1975, 1981]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T54'}, {'offsets': [[1999, 2014]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T55'}, {'offsets': [[2018, 2024]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T56'}, {'offsets': [[2047, 2057]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[2062, 2077]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T58'}, {'offsets': [[2081, 2087]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[2089, 2099]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[2123, 2129]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T61'}, {'offsets': [[2134, 2149]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T62'}, {'offsets': [[2153, 2167]], 'text': ['either residue'], 'type': 'Anaphora', 'id': 'T36'}, {'offsets': [[2168, 2183]], 'text': ['with or without'], 'type': 'Regulation', 'id': 'T63'}, {'offsets': [[2348, 2363]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T64'}, {'offsets': [[2367, 2373]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T65'}, {'offsets': [[2676, 2684]], 'text': ['Reducing'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[2701, 2711]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[3194, 3203]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T68'}, {'offsets': [[3221, 3231]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T69'}]","[{'trigger': 'T37', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T37', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T38', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T39', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T40', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T41', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T42', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T43', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T44', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T45', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T46', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T47', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T48', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T49', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T50', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T51', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T52', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T53', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T54', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E18']}}, {'trigger': 'T55', 'id': 'E20', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T22', 'T56']}}, {'trigger': 'T57', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'E18']}}, {'trigger': 'T58', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T22', 'T59']}}, {'trigger': 'T60', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T61', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E23']}}, {'trigger': 'T62', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T22', 'T56']}}, {'trigger': 'T61', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'E23']}}, {'trigger': 'T62', 'id': 'E27', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T22', 'T59']}}, {'trigger': 'T63', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T63', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T64', 'id': 'E30', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T65']}}, {'trigger': 'T66', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T67', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T68', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'T33']}}, {'trigger': 'T69', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}]","[{'id': 'R1', 'head': {'ref_id': 'T36', 'role': 'Subject'}, 'tail': {'ref_id': 'T56', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T36', 'role': 'Subject'}, 'tail': {'ref_id': 'T59', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E29', 'value': ''}]",[]
57,PMC-1310901-07-MATERIALS_AND_METHODS,"Bisulfite treatment
DNA was extracted as described above. Bisulfite treatment of DNA, leading to conversion of unmethylated cytosine to uracil residues and no change of methylated cytosine residues, was performed as described as follows. Briefly, 1 microg of DNA and 2 microg of poly(dA-dT)(poly(dA-dT) copolymers (Amersham Pharmacia Biotech) were denaturated for 20 min at 42degreesC in 0.3 M NaOH in a volume of 50 microl. Fresh solutions of 30 microl of 10 mM hydrochinon (Sigma) and 530 microl of 3 M sodium bisulfite (pH 5.0; Sigma) were added, the solution was gently mixed, overlayed with mineral oil and incubated in the dark for 12-13 h at 50degreesC. The aqueous phase was recovered using the 'Wizard DNA clean-up system' (Promega, Mannheim, Germany). The purified DNA was subsequently mixed with 1 M NaOH to a final concentration of 0.3 M and incubated for 20 min at 37degreesC to ensure complete desulfonisation. DNA was ethanol precipitated in the presence of 1/10 vol of 3 M sodium acetate, washed with 70% ethanol and resuspended in 50 microl H2O. Subsequent PCR amplification of 4 microl bisulfite-treated DNA was used for cloning of two fragments of the IRF-4 promoter (BS-I and BS-II) into pCR2.1 vector with the 'TOPO TA cloning kit' (Invitrogen) (see Figure 3A). The primers used for PCR amplification of the BS-I and BS-II fragments contain the putative altered sequence of the sense strand due to bisulfite treatment (converted cytosine residues are written in bold letters): BS-I-forward 5'-TATTTGGATTTTTAGGGAGTTTTTTTT-3', BS-I-reverse 5'-ACCCAACTCCCTTAAACTATTAAACT-3' (187 bp); BS-II-forward 5'-AGTTTAATAGTTTAAGGGAGTTGGGT-3', BS-II-reverse 5'-CTCACCCTAAACTCAAAACTAAAAAC-3' (674 bp). After bacterial amplification of the cloned PCR fragments by standard procedures, eight clones from each sample were sequenced with an automated sequencer (ABI Prism 377, Applied Biosystems).","[{'offsets': [[1171, 1176]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
58,PMC-3245220-33-Caption-Figure_9,Proposed model for M-CSF-induced monocyte survival via PKC regulation by activating NF-kappaB p65 phosphorylation at Ser276.,"[{'offsets': [[94, 97]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[73, 83]], 'text': ['activating'], 'type': 'Positive_regulation', 'id': 'T2'}, {'offsets': [[98, 113]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T3'}, {'offsets': [[117, 123]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T4'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T3', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T4']}}]",[],[],[],[]
59,PMC-3279418-13-Materials_and_Methods,"BMDC-T cell in vitro interaction
WT and cpdm BMDC (5x104) were stimulated with medium, 1 microg/mL LPS, 25 microg/mL and 5 microg/mL Pam3CYS. 24 hours later, cells were collected and washed with PBS. Allogeneic naive CD4+ T cells were isolated from spleens of BALB/c mice by negative selection kit (Invitrogen) and were then added at 2.5x105 and co-cultured with activated BMDC. After 5 days, supernatant was collected and the secretion of IFNgamma, IL4, IL2, and IL17A measured by ELISA. Negative controls are 1) stimulated BMDC without co-culture with allogeneic CD4+ T cells; 2) allogeneic CD4+ T cells without co-culture with stimulated BMDC. Both negative controls show no production of aforementioned cytokines.","[{'offsets': [[440, 448]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[450, 453]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[455, 458]], 'text': ['IL2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[464, 469]], 'text': ['IL17A'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[427, 436]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[678, 688]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[692, 716]], 'text': ['aforementioned cytokines'], 'type': 'Anaphora', 'id': 'T5'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T6', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T7', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T7', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T7', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]","[{'id': 'R1', 'head': {'ref_id': 'T5', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T5', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T5', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T5', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}]",[]
60,PMC-1447668-20-Materials_and_Methods,"Statistical analyses.
The Mann-Whitney U test was used to compare the data between patients with HAM/TSP and AC.",[],[],[],[],[],[]
61,PMC-2626671-08-MATERIALS_AND_METHODS,"Antibodies and reagents.
The following antibodies used for intracellular or surface stains were obtained from eBioscience: anti-IL-2, anti-IFN-gamma, anti-TNF, anti-granzyme B, anti-CD8, anti-CD25, and anti-CD44. Anti-CD69 was purchased from BD. For ChIP experiments, the anti-Eomes antibody was obtained from Abcam and the anti-Runx3 antibody was produced by the Groner laboratory. The following antibodies were used for immunoblotting: antiperforin (Abcam), anti-Eomes (Abcam), and anti-Pol-II (Santa Cruz Biotechnology, Inc.). The T-bet antibody was provided by L. Glimcher (Harvard School of Public Health, Boston, MA).
The following reagents were used for the experiments presented in this report: Annexin V-FITC Apoptosis Detection Kit (BD), CD8 Negative Isolation Kit (Invitrogen), CD8 MicroBeads (Miltenyi Biotec), and SYBR Green PCR Core Reagents (Applied Biosystems). The Gp33 peptide (KAVYNFATC) was synthesized by the Tufts University Core Facility, and 10 mM of stock solutions was prepared in DMSO.","[{'offsets': [[128, 132]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[139, 148]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[155, 158]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[165, 175]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[182, 185]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[192, 196]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[207, 211]], 'text': ['CD44'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[218, 222]], 'text': ['CD69'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[277, 282]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[329, 334]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[442, 450]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[465, 470]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[534, 539]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[703, 712]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[748, 751]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[789, 792]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
62,PMC-3245220-13-Materials_and_Methods,"Cell Culture
The murine macrophage cell line RAW 264.7 was purchased from ATCC (Manassas, VA). RAW 264.7 cells were maintained in RPMI supplemented with 5% FBS and antibiotic-antimycotic (1000 U/ml penicillin, 1000 microg/ml streptomycin sulfate, and 250 ng/ml amphotericin B) at 37degreesC. Mouse embryonic fibroblasts (MEFs) cell line lacking specific NFkappaB signaling subunits NF-kappaB p65 (p65-/- cell line) [50] were cultured in DMEM medium supplemented with 10% FBS and antibiotic-antimycotic solution.","[{'offsets': [[392, 395]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[397, 400]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
63,PMC-2065877-08-Results,"LMP1 Promotes Tumor Growth and Survival through Activation of Akt, NFkappaB, and Stat3 Pathways
To explore which pathways were required for the enhanced growth and survival of LMP1-induced lymphomas, splenocytes from wild-type and LMP1 transgenic mice were cultured in the presence of inhibitors for Akt, NFkappaB, Stat3, mTOR, or MAPK and assayed for growth and survival by the MTS assay. As previously shown, wild-type lymphocytes were not viable in culture and could not be tested with the inhibitors. However, the enhanced viability of LMP1 transgenic lymphocytes was effectively blocked by treatment with triciribine, BAY11-7085, cucurbitacin I, and slightly with SB203580, but not by treatment with rapamycin, U0126, or AG490 (Figure 7). Triciribine inhibits the activation of Akt and at 20 muM has been shown to induce growth arrest in cancer cells with aberrant Akt activity [46]. The effects of triciribine on cell growth of the transgenic lymphocytes and lymphomas were apparent as low as 1 muM, suggesting that activation of Akt is required for the survival and growth of LMP1 transgenic lymphocytes and lymphoma cells (Figure 7). The effects of the inhibitors were assessed by identifying phosphorylated Akt, Stat3, and total levels of IkappaBalpha (Figure 8). Treatment with triciribine effectively blocked phosphorylation of Akt, and phosphorylated Akt was no longer detected past 5 muM. Phosphorylated Stat3 and IkappaBalpha were still present at 25 muM. These findings suggest that triciribine specifically targets Akt and that Akt activation is required for the enhanced viability of the transgenic lymphocytes and lymphoma cells.
Inhibition of NFkappaB signaling rapidly induces cell death of EBV-transformed lymphocytes [17,18]. BAY11-7085, an inhibitor of NFkappaB signaling, also greatly decreased the viability of the LMP1 transgenic lymphocytes and lymphoma cells at doses as low as 1 muM, and at 5 muM the cells were completely nonviable (Figure 7). This is well within the reported IC50 of 10 muM. Phosphorylated Akt, Stat3, and total IkappaBalpha were still present up to treatment with 15 muM and then were no longer detected (Figure 8). This finding suggests that inhibition of NFkappaB can induce cell death in LMP1 transgenic lymphocytes and lymphoma cells without significant effects on activation of Akt or Stat3.
Cucurbitacin I inhibits activation of Stat3 by suppressing the activation of its kinase JAK2. It has been shown to selectively inhibit the growth of tumors with constitutively activated Stat3 [47]. Similarly, LMP1 transgenic lymphocytes and lymphoma cells were susceptible to cucurbitacin I treatment starting at 0.1 muM, a dose that corresponds closely to the reported IC50 of 500 nM (Figure 7) [47]. Phosphorylated Akt, Stat3, and total IkappaBalpha were not detectable past 1 muM and at higher doses all protein levels were greatly decreased, indicative of the total loss of viability (Figure 8). A second reported inhibitor of Stat3, AG490, had no effect on growth (Figure 7), but activation of Akt, Stat3, or levels of IkappaBalpha were also not affected (Figure 8). These findings suggest that inhibition of Stat3 can induce cell death in LMP1 transgenic lymphocytes and lymphoma cells, but Stat3 inhibition also has considerable crossover effects on Akt and NFkappaB signaling.
LMP1 has also been shown to activate JNK and p38 MAPK pathways [13,48], and LMP1 transgenic lymphocytes were mildly susceptible to growth inhibition by SB202190, an inhibitor of p38 MAPK, but not U0126, an inhibitor of MEK1/2 activity. However, effects of SB202190 were only apparent at high doses (>10 muM), much higher than the reported IC50 of 0.35 muM, suggesting that p38 MAPK does not significantly contribute to the enhanced viability in LMP1 transgenic lymphocytes or lymphoma cells (Figure 7). Interestingly, both wild-type and LMP1 transgenic lymphomas were similarly susceptible to triciribine, BAY11-7085, and cucurbitacin I treatments, but not SB202190, AG490, or U0126 treatment, suggesting that activation of Akt, NFkappaB, and Stat3 but not MAPK pathways are characteristics associated with malignant transformation (Figure 7). rapamycin, an inhibitor of mTOR, did not affect the viability of the transgenic lymphocytes or lymphoma cells, confirming that mTOR is not targeted by Akt activation in LMP1 transgenic lymphocytes or malignant lymphoma cells (Figure 7).","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 65]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[81, 86]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[176, 180]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[231, 235]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[300, 303]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 320]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[322, 326]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[540, 544]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[783, 786]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[870, 873]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1036, 1039]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1083, 1087]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1216, 1219]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1221, 1226]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1248, 1260]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1339, 1342]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1363, 1366]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1417, 1422]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1427, 1439]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1531, 1534]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1544, 1547]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1840, 1844]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2038, 2041]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2043, 2048]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2060, 2072]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2240, 2244]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2332, 2335]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2339, 2344]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2384, 2389]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2434, 2438]], 'text': ['JAK2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2532, 2537]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2555, 2559]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2763, 2766]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2768, 2773]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2785, 2797]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2977, 2982]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3045, 3048]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3050, 3055]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3070, 3082]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3160, 3165]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3191, 3195]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3243, 3248]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3303, 3306]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3331, 3335]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3407, 3411]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3550, 3554]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3555, 3556]], 'text': ['2'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3776, 3780]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3868, 3872]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4055, 4058]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4074, 4079]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4202, 4206]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4302, 4306]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4326, 4329]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4344, 4348]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[285, 295]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[756, 764]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[769, 779]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[1022, 1032]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[1201, 1215]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T62'}, {'offsets': [[1312, 1319]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1320, 1335]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T64'}, {'offsets': [[1348, 1362]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T65'}, {'offsets': [[1381, 1389]], 'text': ['detected'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[1402, 1416]], 'text': ['Phosphorylated'], 'type': 'Phosphorylation', 'id': 'T67'}, {'offsets': [[1523, 1530]], 'text': ['targets'], 'type': 'Regulation', 'id': 'T68'}, {'offsets': [[1548, 1558]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T69'}, {'offsets': [[2023, 2037]], 'text': ['Phosphorylated'], 'type': 'Phosphorylation', 'id': 'T70'}, {'offsets': [[2084, 2091]], 'text': ['present'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[2144, 2152]], 'text': ['detected'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[2307, 2314]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[2318, 2328]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[2361, 2369]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[2370, 2380]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[2522, 2531]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[2748, 2762]], 'text': ['Phosphorylated'], 'type': 'Phosphorylation', 'id': 'T78'}, {'offsets': [[2807, 2817]], 'text': ['detectable'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[2849, 2860]], 'text': ['all protein'], 'type': 'Anaphora', 'id': 'T57'}, {'offsets': [[2881, 2890]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[2964, 2973]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[3097, 3105]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T82'}, {'offsets': [[3146, 3156]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[3249, 3259]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T84'}, {'offsets': [[3537, 3546]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[4189, 4198]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T86'}, {'offsets': [[4314, 4322]], 'text': ['targeted'], 'type': 'Regulation', 'id': 'T87'}]","[{'trigger': 'T58', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T58', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T58', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T59', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T60', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T61', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T62', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T62', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T63', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T64', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T65', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T66', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T67', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T67', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T68', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T69', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T70', 'id': 'E17', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T70', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T71', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T71', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T71', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T72', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T72', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T72', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T73', 'id': 'E25', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T74', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T73', 'id': 'E27', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T74', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T75', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T76', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T77', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T78', 'id': 'E32', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T78', 'id': 'E33', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T79', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T79', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T79', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T80', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T80', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T80', 'id': 'E39', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T81', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T82', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T83', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T84', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T85', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T85', 'id': 'E45', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T86', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T87', 'id': 'E47', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}]","[{'id': 'R1', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T34', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T35', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T36', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E25', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E27', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E27', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E35', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E36', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E41', 'value': ''}, {'id': 'M14', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}]",[]
64,PMC-2889865-08-Materials_and_methods,"Chemicals
The following chemicals were used in the present study: PMA (Phorbol 12-myristate 13-acetate, (Sigma #P1585, USA)); NF-kappaB activation inhibitor (NAI), (InSolution(TM) NF-kappaB Activation Inhibitor, Calbiochem #481407, USA); JNK inhibitor, (InSolution(TM) JNK Inhibitor II, Calbiochem #420128, USA); PKC Inhibitor, (InSolution(TM) Bisindolylmaleimide I, Calbiochem #203293, USA); Calcium Ionophore, (Calcium Ionophore A23187 mixed calcium magnesium salt, Sigma #C5149, USA).",[],[],[],[],[],[]
65,PMC-3279418-07-Discussion,"The present report showed that null mutations of the mouse Sharpin gene did not affect the steady-state distribution of splenic DC subsets nor the development and phenotype of BMDC. However, loss of SHARPIN significantly diminished the capacity of BMDC to secrete inflammatory cytokines and nitric oxide. The attenuated cytokine production was not due to the presence of anti-inflammatory inhibitors, and can be largely explained by selective inactivation of NF-kappaB signaling. Stimulated cpdm BMDC exhibited Th2-biased T cell-polarizing capabilities, consistent with the Th2 cytokine-dominant phenotype in cpdm mice. Together, these results indicate an indispensible role of SHARPIN in regulating DC immunological functions, disruption of which may contribute to the development of immune diseases.
Since WT and cpdm mice are both specific pathogen-free, the nature of the trigger of the severe inflammation in cpdm mice is not obvious. One such initiating factor could be endogenous apoptotic and/or necrotic cells that can release danger-associated molecular patterns (DAMPs) to launch and amplify an inflammatory response [32]. Such 'sterile' inflammation could be initiated and take place in all organs and tissues affected in cpdm mice, thus causing multi-organ inflammatory disorders. This hypothesis is supported by several recent studies. Fibroblasts of cpdm mice are highly sensitive to TNFalpha-induced cell death and the cpdm phenotype can be partially rescued by deletion of TNF [7], [8], suggesting that deficiency of SHARPIN compromises the anti-apoptotic mechanisms in cpdm mice resulting in cell death-induced inflammatory disease. Apoptosis of keratinocytes is a prominent feature of the skin lesions in cpdm mice [33] and this is mediated by caspase-dependent mitochondrial pathways [34]. These induced and/or intrinsic apoptotic cells can release various types of DAMPs that exert their pro-inflammatory properties by activating DC through pattern recognition receptors [32], [35], such as HMGB1 recognized by TLR2/4 [36], [37].
Consistent with the impaired Th1 immune response in cpdm mice [5], stimulated BMDC weakly polarized Th1 differentiation, but strongly supported the development of Th2 effector cells. Combined with the dramatic effect of IL12 treatment on the phenotype of these mice [5], this suggests that the Th2-biased systemic inflammation in cpdm mice is caused by reduced IL12P70 production from DC. The importance of IL12P70 in regulating Th1 and Th2 immune responses in mice was clearly demonstrated in IL12P35- and IL12P40-deficient mice [38], [39] and through clinical studies in human patients [40]-[42].
NF-kappaB, TBK/IRF3, and MAPK signaling are important pathways activated by LPS or poly I:C and disruption of either pathway may lead to decreased cytokine expression. NF-kappaB activation was selectively inhibited in LPS and poly I:C stimulated cpdm BMDC compared to wild type, while activation of TBK1/IRF3, ERK1/2, or p38 was not, indicating that disrupted NF-kappaB signaling in cpdm DC is responsible for the defective cytokine expression. These results seem to contradict a recent study that found increased levels of NF-kappaB activation and IL1 transcription in cpdm mice [43]. This difference can probably be attributed to the different cells and tissues used in these studies, and may point to cell- and tissue- type specific functions of SHARPIN. This is consistent with recent reports of tissue-specific effects of NF-kappaB signaling [44]. Ubiquitous activation of NF-kappaB by removing inhibitors such as A20 and ITCH through genetic manipulation results in widespread inflammation, consistent with the role of NF-kappaB in the production of pro-inflammatory mediators [45], [46]. However, selective inhibition of NF-kappaB activation in parenchymal cells of the skin, liver, and intestine results in chronic inflammation driven by NF-kappaB competent leukocytes [47]-[50]. This indicates that a balance between the pro-inflammatory role of NF-kappaB in leukocytes and the anti-inflammatory role in parenchymal cells is critical in the maintenance of tissue homeostasis. Experiments with mice with cell- and tissue-specific deletion of Sharpin, currently under way, will help to elucidate the role of SHARPIN in inflammation.
Despite defective NF-kappaB activation in the absence of Sharpin expression, there was no significant change in splenic DC populations or expression of co-stimulatory molecules on BMDC. Different NF-kappaB subunits involved in the canonical and non-canonical branches of the NF-kappaB signaling pathway have distinct functions to control specific aspects of DC development and function [51], [52]. The non-canonical pathway (p100 processing to produce p52) appears to be intact in SHARPIN-deficient cells [7], [9] suggesting that the NF-kappaB heterodimer p52/RELB is sufficient to maintain the normal regulation of DC homeostasis and maturation.
The molecular basis by which the Sharpin mutation causes reduced NF-kappaB activation in BMDC remains to be determined. LPS and poly I:C used here are well-defined ligands that specifically engage TLR4 and TLR3, respectively. The expression profile of surface TLR4 complexes is similar between WT and cpdm BMDC suggesting that defective NF-kappaB activation is not a result of differential TLR expression on target cells. LPS engages TLR4 to activate MYD88-dependent and TRIF-dependent pathways, whereas TLR3 stimulated by poly I:C only triggers TRIF-dependent signaling [53]. The defective NF-kappaB activation by both stimuli suggests that the Sharpin mutation interferes with the protein adaptors or kinases shared by both signaling pathways, such as RIP1 and TRAF6 [18]. Recent studies demonstrated that SHARPIN interacts with HOIP to form LUBAC that exerts its linear-ubiquitin-chain-ligase activity on NF-kappaB signaling players RIP1 and NEMO [7], an essential step for intact TNFalpha-stimulated NF-kappaB activation. The Sharpin null mutation disrupts the ubiquitylation process and abrogates the TNFalpha-induced NF-kappaB signaling pathway. Since TNFR and TLR partially share their downstream signaling cascades, a similar ubiquitin-mediated regulation may hold true for SHARPIN in LPS- and poly I:C-induced NF-kappaB activation.
In summary, the present study identified an indispensible role of SHARPIN in the production of pro-inflammatory mediators and TLR-induced NF-kappaB signaling. The impaired Th1-stimulating ability of Sharpin-deficient DC may account for the Th2-dominant inflammatory phenotype of cpdm mice. The balance between Th1 and Th2 differentiation is critical for immune homeostasis. A better understanding of how such balance is maintained will help design cytokine treatment for human diseases with Th2-biased cytokine secretion similar to the mouse cpdm, such as allergies and hypereosinophilic syndromes.","[{'offsets': [[59, 66]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[199, 206]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[678, 685]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1399, 1407]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1490, 1493]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1534, 1541]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2012, 2017]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2032, 2036]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2037, 2038]], 'text': ['4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2545, 2552]], 'text': ['IL12P35'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2558, 2565]], 'text': ['IL12P40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2665, 2669]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2949, 2953]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2954, 2958]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2960, 2964]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2965, 2966]], 'text': ['2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3399, 3406]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3569, 3572]], 'text': ['A20'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3577, 3581]], 'text': ['ITCH'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4200, 4207]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4265, 4272]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4347, 4354]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4715, 4719]], 'text': ['p100'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4742, 4745]], 'text': ['p52'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4771, 4778]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4846, 4849]], 'text': ['p52'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4850, 4854]], 'text': ['RELB'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4970, 4977]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5134, 5138]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5143, 5147]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5371, 5375]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[5388, 5393]], 'text': ['MYD88'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[5408, 5412]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[5441, 5445]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[5483, 5487]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5583, 5590]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5691, 5695]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5700, 5705]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5745, 5752]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5768, 5772]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5873, 5877]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5882, 5886]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5921, 5929]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5967, 5974]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[6043, 6051]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6219, 6226]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6344, 6351]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6477, 6484]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[31, 45]], 'text': ['null mutations'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[191, 195]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[728, 738]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[742, 747]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T12'}, {'offsets': [[1478, 1486]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[1520, 1530]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[2018, 2028]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T18'}, {'offsets': [[2566, 2575]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[2935, 2945]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[2975, 2982]], 'text': ['was not'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[4188, 4196]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[4336, 4343]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[4355, 4365]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[4779, 4788]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[4978, 4986]], 'text': ['mutation'], 'type': 'Negative_regulation', 'id': 'T65'}, {'offsets': [[5127, 5133]], 'text': ['engage'], 'type': 'Binding', 'id': 'T66'}, {'offsets': [[5363, 5370]], 'text': ['engages'], 'type': 'Binding', 'id': 'T67'}, {'offsets': [[5446, 5456]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[5591, 5599]], 'text': ['mutation'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[5753, 5762]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T70'}, {'offsets': [[5792, 5798]], 'text': ['exerts'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[5799, 5802]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T57'}, {'offsets': [[5803, 5841]], 'text': ['linear-ubiquitin-chain-ligase activity'], 'type': 'Ubiquitination', 'id': 'T72'}, {'offsets': [[5975, 5988]], 'text': ['null mutation'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[5989, 5997]], 'text': ['disrupts'], 'type': 'Negative_regulation', 'id': 'T74'}, {'offsets': [[5998, 6024]], 'text': ['the ubiquitylation process'], 'type': 'Anaphora', 'id': 'T58'}, {'offsets': [[6485, 6494]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T75'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T7', 'T8']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T19', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T59', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T59', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T59', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T59', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T60', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T60', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T60', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T60', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T61', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T62', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T63', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T64', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T65', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T66', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T66', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T67', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T68', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T69', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T70', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T47', 'T48']}}, {'trigger': 'T71', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T72', 'id': 'E29', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T49', 'T47']}}, {'trigger': 'T71', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T72', 'id': 'E31', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T50', 'T47']}}, {'trigger': 'T73', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T74', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E32']}}, {'trigger': 'T74', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E32']}}, {'trigger': 'T75', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}]","[{'id': 'R1', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T47', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T58', 'role': 'Subject'}, 'tail': {'ref_id': 'T72', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}]",[]
66,PMC-1447668-11-Materials_and_Methods,"Patients and cell preparation.
PBMCs were prepared by centrifugation over Ficoll-Hypaque gradients (BioWhittaker, Walkersville, Maryland, United States) from eight HAM/TSP patients and eight ACs, and the cells were viably cryopreserved in liquid nitrogen until tested. HAM/TSP was diagnosed according to WHO guidelines [49]. HTLV-I seropositivity was determined by ELISA (Abbott Laboratories, Abbott Park, Illinois, United States), with confirmation by Western blot analysis (Genelabs Technologies, Redwood City, California, United States). Blood samples were obtained after informed consent as part of a clinical protocol reviewed and approved by the NIH institutional review panel.",[],[],[],[],[],[]
67,PMC-1447668-07-Results,"CREB Is a Target for Transcriptional Repression by Foxp3
Although Foxp3 could down-regulate Tax-dependent transactivation of the HTLV-I LTR (Figure 4B) and inhibit Tax expression from an infectious molecular clone (Figure 5), Foxp3 failed to modulate Tax function in the absence of the viral promoter (Figure 4D). These results led us to hypothesize that Foxp3 acts on HTLV-I gene expression by interacting with proteins important for driving HTLV-I LTR activity in vivo. Previous studies have demonstrated that the Tax-responsive elements within the HTLV-I LTR play a crucial role in driving Tax-mediated transactivation of the HTLV-I LTR [18]. The Tax-responsive elements have been shown to resemble CREB binding sites, bind CREB in vitro and in vivo, and facilitate HTLV-I LTR activation both in the presence and in the absence of Tax [35,36]. Ching and colleagues [18] demonstrated that addition of a dominant-negative CREB expression vector resulted in nearly complete inhibition of Tax-mediated activation of the HTLV-I LTR, while blocking NF-kappaB activation by addition of a dominant-negative IKKbeta expression vector had no effect on Tax transactivation of the HTLV-I LTR. Therefore, we hypothesized that Foxp3 may inhibit Tax transactivation of the HTLV-I LTR via disruption of the CREB signaling pathway. To test this possibility, HEK 293T cells were transfected with an HTLV-I LTR or synthetic CREB reporter vector along with a control expression vector (EGFP) or expression vectors encoding Foxp3 or deltaFKH. As shown in Figure 6A, Foxp3 down-regulated basal activation of the HTLV-I LTR and transcription of a synthetic CREB reporter vector, suggesting that Foxp3 down-regulates HTLV-I LTR activation by targeting the CREB pathway. Deletion of the FKH domain of Foxp3 dampened the suppressive effect of Foxp3, but did not completely abrogate suppression, as is seen with NF-kappaB-responsive promoters in HEK 293T cells. Like NF-kappaB activation, CREB transcriptional activation was also suppressed by expression of Foxp3, and to a similar extent deltaFKH, in healthy donor CD4+ T cells (Figure 6B). Similarly, Foxp3 and deltaFKH also repressed basal HTLV-I LTR activation in primary human CD4+ T cells (Figure 6C). To our knowledge, this is the first evidence implicating CREB as a molecular target of Foxp3. As observed with NF-kappaB activation, deltaFKH was a more potent inhibitor of CREB activation in CD4+ T cells than in HEK 293T cells, further indicating that a cell type-specific mechanism of action may govern the function of this Foxp3 mutant.
To determine whether Foxp3 functioned by directly signaling through CREB, we utilized expression vectors encoding CREB-1 or c-Jun (a member of the activator protein 1 family of transcription factors) fused in-frame to the Gal4-BD (Gal4-BD-CREB-1 and Gal4-BD-c-Jun). As shown in Figure 6D, activation of a Gal4-responsive reporter vector by Gal4-BD-CREB-1 was down-regulated by Foxp3 compared to control vector (EGFP), indicating that Foxp3 functions by directly or indirectly interacting with CREB-1. However, Foxp3 failed to markedly affect transcriptional activation of Gal4-BD-c-Jun (c-Jun has also been demonstrated to bind to the HTLV-I LTR) and Gal4-BD-Tax (see Figure 5). Importantly, the mechanism of Foxp3-mediated inhibition of CREB-dependent transcription was not due to a block in CREB-1 protein expression, as determined by Western blot analysis (Figure 6E). Although these results demonstrate that Foxp3 functions as a co-repressor of CREB activation (in addition to NF-kappaB and NF-AT), we were unable to detect a direct physical interaction between CREB-1 and Foxp3 by coimmunoprecipitation or mammalian two-hybrid analysis (unpublished data). Therefore, our data suggest that Foxp3 may interfere with CREB signaling at an upstream event, such as phosphorylation of CREB or recruitment/function of coactivator proteins CREB-binding protein (CBP)/p300.","[{'offsets': [[51, 56]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[66, 71]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[92, 95]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[164, 167]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[226, 231]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[251, 254]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[355, 360]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[593, 596]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[834, 837]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[988, 991]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1102, 1109]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1145, 1148]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1216, 1221]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1234, 1237]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1506, 1511]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1515, 1523]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1548, 1553]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1675, 1680]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1779, 1784]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1820, 1825]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2034, 2039]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2065, 2073]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2092, 2095]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2129, 2134]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2139, 2147]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2208, 2211]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2321, 2326]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2367, 2375]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2407, 2411]], 'text': ['CREB'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2426, 2429]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2595, 2600]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2688, 2694]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2698, 2703]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2721, 2740]], 'text': ['activator protein 1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2796, 2800]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2805, 2819]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2824, 2837]], 'text': ['Gal4-BD-c-Jun'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2879, 2883]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2914, 2928]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2951, 2956]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3008, 3013]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3067, 3073]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3084, 3089]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3146, 3159]], 'text': ['Gal4-BD-c-Jun'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3161, 3166]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3225, 3236]], 'text': ['Gal4-BD-Tax'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3283, 3288]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3367, 3373]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3486, 3491]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3640, 3646]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3651, 3656]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3768, 3773]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3910, 3930]], 'text': ['CREB-binding protein'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3932, 3935]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3937, 3941]], 'text': ['p300'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[156, 163]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[168, 178]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T59'}, {'offsets': [[242, 250]], 'text': ['modulate'], 'type': 'Regulation', 'id': 'T60'}, {'offsets': [[395, 406]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1110, 1120]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[1749, 1757]], 'text': ['Deletion'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1765, 1775]], 'text': ['FKH domain'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[2020, 2030]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[2394, 2403]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[2412, 2422]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[2660, 2670]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T68'}, {'offsets': [[3050, 3061]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[3197, 3201]], 'text': ['bind'], 'type': 'Binding', 'id': 'T70'}, {'offsets': [[3358, 3363]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[3382, 3392]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[3620, 3631]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T73'}, {'offsets': [[3778, 3787]], 'text': ['interfere'], 'type': 'Negative_regulation', 'id': 'T74'}, {'offsets': [[3798, 3807]], 'text': ['signaling'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[3811, 3828]], 'text': ['an upstream event'], 'type': 'Anaphora', 'id': 'T56'}, {'offsets': [[3865, 3876]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T76'}, {'offsets': [[3889, 3909]], 'text': ['coactivator proteins'], 'type': 'Anaphora', 'id': 'T57'}]","[{'trigger': 'T58', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T2']}}, {'trigger': 'T59', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T60', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T5']}}, {'trigger': 'T61', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T62', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T63', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T19', 'T64']}}, {'trigger': 'T65', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T65', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T66', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T28']}}, {'trigger': 'T67', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T68', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T68', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T69', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T41', 'T42']}}, {'trigger': 'T70', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T71', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T72', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T73', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T50', 'T51']}}, {'trigger': 'T74', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T52']}}, {'trigger': 'T75', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T74', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T52']}}, {'trigger': 'T75', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T76', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T76', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}]","[{'id': 'R2', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T53', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T55', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T53', 'T54']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E20', 'value': ''}]",[]
68,PMC-2065877-12-Materials_and_Methods,"MTS assay.
The 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) cell cytotoxicity/proliferation assays were performed using the CellTiter 96 aqueous one-solution cell proliferation assay (Promega), according to manufacturer's instructions. For IL4 studies, splenocytes were cultured for 3 d in the presence or absence of 100 ng/ml IL4. Cells were seeded on day 3 in triplicate in a 96-well plate at 2.5 x 106 cells/ml at 100 mul per well. MTS reagent was added for 4 h and absorbance was read at 540 nm; values plotted were subtracted from blanks. For neutralization assays, splenocytes were seeded at 5 x 106 cells/ml at 100 mul per well on day of harvest and IL4, rat IgG1 anti-mouse IL4, or rat IgG1 isotype control (R&D Systems) were added at the concentrations indicated in the figures. Cultures were pulsed for 4 h with MTS reagent 1 d post-seeding. For inhibitor studies, splenocytes were seeded at 1 x 107 cells/ml at 100 mul per well on day of harvest, and inhibitors were added at the concentrations indicated in the figures. The inhibitors BAY11-7085, rapamycin, triciribine, U0126, SB202190, and cucurbitacin I were purchased from EMD Biosciences. For non-malignant splenocyte cultures, B cell activation was induced with 10 mug/ml of goat F(ab') anti-mouse IgM (Jackson ImmunoResearch). Cultures were pulsed for 4 h with MTS reagent 1 d post-seeding.","[{'offsets': [[302, 305]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[389, 392]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[719, 722]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[744, 747]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
69,PMC-3245220-22-Materials_and_Methods,"RNA Isolation and Quantitative Real-time PCR
MDMs or RAW 264.7 cells were serum-starved overnight or for 2 hours, respectively, prior to incubating with inhibitors for 30 minutes. The cells were restimulated with 100 ng/ml M-CSF and total mRNA was extracted from cells with Trizol (Invitrogen) and 1-2 microg of total RNA was used to synthesized cDNA using SuperScript III (Invitrogen). Quantitative real-time (qRT)-PCR was performed using SYBR Green Master Mix (Applied BioSystems, Carlsbad, CA). The reactions were performed using an ABI PRIZM 7700 machine with software Sequence Detector version 1.7 (Applied Biosystems). The target gene values were normalized to the values of GAPDH as a housekeeping gene and expressed as relative fold increase 2(-deltadeltaCt) over the non-stimulated samples (NS).",[],[],[],[],[],[]
70,PMC-2791889-07-Results,"IL-10 Production by Th2 and Th17 Cells Also Requires ERK1 and ERK2 Activation
To address whether IL-10 production by Th2 and Th17 cells was also dependent on ERK1 and ERK2 activation, we differentiated these cells with anti-CD3 and anti-CD28 in the absence of APCs (Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006), in the presence or absence of the MEK inhibitor (PD184352). We showed that ERK1 and ERK2 activation is a common pathway required for induction of IL-10 in different Th cell subsets because IL-10 production by both Th2 and Th17 cells was markedly inhibited in the presence of the MEK inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast, inhibitors of p38 MAPK or of GSK-3beta activation did not affect the expression of IL-10 by these subsets (Figure S5B). Activation of the ERK1 and ERK2 signaling pathway is therefore a common requirement for the induction of IL-10 production by Th1, Th2, and Th17 cells.","[{'offsets': [[0, 5]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[53, 57]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[62, 66]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[97, 102]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[158, 162]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[167, 171]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[224, 227]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[237, 241]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[371, 374]], 'text': ['MEK'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[412, 416]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[421, 425]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[483, 488]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[526, 531]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[616, 619]], 'text': ['MEK'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[696, 704]], 'text': ['p38 MAPK'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[711, 720]], 'text': ['GSK-3beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[765, 770]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[820, 824]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[829, 833]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[907, 912]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[6, 16]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[44, 52]], 'text': ['Requires'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[67, 77]], 'text': ['Activation'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[103, 113]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[145, 154]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[172, 182]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[375, 384]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[426, 436]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[457, 465]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[470, 479]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[532, 542]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[583, 592]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[620, 629]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[682, 692]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T34'}, {'offsets': [[721, 731]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[740, 746]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[751, 761]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[874, 885]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[894, 903]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[913, 923]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T40'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E3']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E5']}}, {'trigger': 'T23', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T24', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T25', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E8']}}, {'trigger': 'T26', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T25', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E10']}}, {'trigger': 'T26', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T27', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T28', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E12']}}, {'trigger': 'T30', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T29', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T31', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T32', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E19']}}, {'trigger': 'T33', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T34', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T35', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T34', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T35', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T36', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E20']}}, {'trigger': 'T37', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T36', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E22']}}, {'trigger': 'T38', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T39', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T40', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}]",[]
71,PMC-3148254-12-Materials_and_Methods,"GLepsilon transcript assay
The CD40-simulated activation of GLepsilon transcription was evaluated as previously reported [33]. Briefly, 1x106 cells were stimulated overnight with anti-CD40 antibody (10 microg/ml) or an isotype control antibody, with or without 500 U/ml mouse IL-4 (BD Biosciences). RNA was isolated using Trizol (Invitrogen), and reverse-transcribed (Superscript III kit, Invitrogen). Quantitative PCR for GLepsilon and Hprt1 was performed using SYBR GREEN master mix (Applied Biosystems), and an Applied Biosystems 7900HT Fast Real-Time PCR instrument. Expression of GLepsilon in each sample was normalized to the expression of Hprt1.","[{'offsets': [[0, 9]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[31, 35]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[60, 69]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[276, 280]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[423, 432]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[437, 442]], 'text': ['Hprt1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[585, 594]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[646, 651]], 'text': ['Hprt1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[36, 45]], 'text': ['simulated'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[46, 56]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[70, 83]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T11'}, {'offsets': [[571, 581]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[632, 642]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
72,PMC-2889865-18-Caption-Figure_2,NF-kappaB down-regulation by PMA and up-regulation by heat killed E. coli MG1655 following long-term stimulation. Transfection of Jurkat T-cells was performed using luciferase reporter plasmids containing NF-kappaB cis-elements. (A) Time-dependent stimulation of Jurkat T-cells using PMA. NF-kappaB activation was evaluated using HK E. coli in a (B) dose- and (C) time-dependant manner. Calcium ionophore increased NF-kappaB activity following PMA exposure (E) and resulted in a negative regulation in response to HK E. coli stimulation (D). Statistical significance from the control was determined using Student's t-test. (n = 4). Controls were arbitrarily set to 1.,"[{'offsets': [[165, 175]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
73,PMC-3245220-01-Introduction,"Monocytes are produced in the bone marrow and circulate in blood for 24-48 hours [1]. In the absence of serum, monocytes die via apoptosis [1], [2]. Macrophage colony-stimulating factor (M-CSF) stimulates mononuclear phagocyte survival and differentiation [3]. Importantly, M-CSF-mediated cell survival and activation is associated with a variety of human diseases, including atherosclerosis, transplant vascular sclerosis and breast cancer metastasis [4], [5], [6].
We previously identified that NF-kappaB activation is important in M-CSF-induced monocyte survival [7]. In addition to its role in mononuclear phagocyte survival, the transcription factor NF-kappaB regulates numerous genes that play important roles in cellular signaling, stress response, cell growth, survival, differentiation and inflammation [8]. There are five members in the NF-kappaB family: RelA/p65, p50, p52, c-Rel and RelB. The most common activating complex is the p50/p65 heterodimer, driven by the activation domain in the NF-kappaB p65 subunit. NF-kappaB p65 regulates important developmental processes [9], [10]. Mice lacking NF-kappaB p65 die in utero and have extensive liver damage via enhanced apoptosis [9]. Embryonic macrophages from NF-kappaB p65 null mice are susceptible to TNFalpha-induced apoptosis which is rescued by overexpressing the NF-kappaB p65 subunit [10]. Moreover, inhibiting NF-kappaB induces cell death in many cell types and cytokine-independent survival is mediated by constitutively active NF-kappaB in murine macrophages [11].
In monocytes and macrophages, NF-kappaB is an important transcriptional factor for expression of cytokines and cell surface receptors [12]. However, unlike resting T-cells, NF-kappaB is constitutively present in the nuclei of primary monocytes and monocytic cell lines in the absence of exogenous stimuli as demonstrated by mobility shift analysis [13]. Similarly, constitutively active NF-kappaB was observed in human alveolar macrophages [14].
In the classic/canonical pathway, the NF-kappaB p50/p65 complex is sequestered in the cytosol by IkappaBalpha [15]. Upon stimulation by cytokines or UV radiation, IkappaBalpha is phosphorylated, ubiquitinated, and degraded, releasing NF-kappaB p50/p65 to translocate to the nucleus and transactivate target genes. After its release from IkappaBalpha, NF-kappaB p65 can undergo post-translational modification to activate gene transcription. The role of NF-kappaB p65 phosphorylation on NF-kappaB transcriptional activity varies by stimulus, time of stimulation and cell type [16]. Previous research shows that phosphorylation of NF-kappaB p65 at Ser276, Ser529 or Ser536 plays an important role in regulating transcriptional activity of NF-kappaB [17]. In TNFalpha-treated murine fibroblasts, Ser276 of NF-kappaB p65 is phosphorylated by MSK1 to enhance NF-kappaB transcriptional activity [18]. In macrophages treated with endotoxin, NF-kappaB transcription activity is associated with phosphorylation on Ser276 and Ser536 that is regulated through protein kinase A (PKA) and IKKbeta respectively[16], [19]. In human T cells, NF-kappaB p65 is constitutively phosphorylated on Ser536 to facilitate NF-kappaB p65 nuclear translocation following cellular stimulation [20]. Accumulating evidence reveals that NF-kappaB p65 phosphorylation at Ser276 is crucial for its transcriptional activity. Upon nuclear translocation, phosphorylation of Ser276 on NF-kappaB p65 by PKA recruits the transcription co-activator, p300 to potentiate NF-kappaB-regulated gene transcription [21]. However, other studies show that PKA inhibits NF-kappaB-regulated gene expression by stabilizing IkappaBalpha [22], [23]. Interestingly, the serine/threonine kinase Pim-1 directly phosphorylates NF-kappaB p65 at Ser276 by stabilizing to prevent ubiquitin-proteasome degradation [24]. Several other phosphorylation sites are also described to enhance NF-kappaB gene transactivation [25].
Here, we investigate the role of protein kinase C (PKC) in M-CSF-stimulated NF-kappaB activation. PKC proteins are multifunctional kinases that differ in structure, function and co-factor requirement [26]. PKCs are involved in diverse cell responses, including cell growth, survival, differentiation and development [27]. The 12 closely related enzymes of the PKC family are divided into three classes: conventional (cPKCs: alpha betaI betaII and gamma require Ca2+ and diacylglycerol (DAG); novel (nPKCs: delta, epsilon, eta, theta and mu) require DAG; and atypical (aPKCs: xi, iota and lambda) require neither Ca2+ nor DAG. Monocytes and macrophages predominantly express conventional PKC isoforms (PKCalpha PKCbetaI and PKCbetaII) and novel PKCs (PKCdelta and PKCepsilon). Conventional PKCs regulate differentiation of the human promyelocytic leukemia cell line HL60 to macrophages [28]. PKCalpha induces IL-1alpha, iNOS and TNFalpha mRNA production after lipopolysaccharide (LPS) exposure [29]. In addition, accumulating evidence suggests that conventional PKCs like PKCalpha have anti-apoptotic functions. For example, PKCalpha is overexpressed in a variety of tumor cells including gliomas, liver, and lung [30], [31]. In epithelial cells, inhibition of PKCalpha induces PKCdelta-dependent apoptosis [31]. Interestingly, in human monocytes and premonocytic THP-1 leukemia cells, novel PKCs like PKCdelta have the opposite effect on cell survival, Voss et al showed that PKCdelta directly phosphorylates caspase-3 and promotes etoposide-induced apoptosis [32]. Moreover, knockout mouse studies suggest that another novel PKC, PKCepsilon is critically involved in early LPS-mediated signaling in activated macrophages [33].
Previously, we reported that M-CSF promotes monocyte survival through the activation of the PI3-K/AKT pathway [3]. In addition to AKT activation, M-CSF stimulates PKC in human monocytes and increases NF-kappaB DNA binding [34]. However, whether PKC and/or NF-kappaB activation is critical in M-CSF-stimulated mononuclear phagocyte survival and/or differentiation is unclear. In other cells, PKC plays an important role in NF-kappaB activation and cell survival [35], however the specific mechanisms of this activation and the biological effects on cellular phenotype are not known. Therefore, we focused at understanding the role of PKC in the regulation of NF-kappaB activation and M-CSF-induced monocyte survival.
Here we demonstrates that M-CSF upregulated the NF-kappaB transcription and cell survival in human and mouse macrophages. This activity was reduced by the conventional, but not novel, PKC inhibitors, dominant negative PKCalpha constructs or PKCalpha siRNA. Conventional PKC regulated NF-kappaB-regulated gene expression and phosphorylation of Ser276 of NF-kappaB p65 occurred in an M-CSF-dependent fashion correlating with its maximal transcriptional activity. Furthermore, PKCalpha-regulated phosphorylation of Ser276 of NF-kappaB p65 plays an important role in regulating its activity in mononuclear phagocytes and murine embryonic fibroblasts.","[{'offsets': [[865, 869]], 'text': ['RelA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[870, 873]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[875, 878]], 'text': ['p50'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[880, 883]], 'text': ['p52'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[885, 890]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[895, 899]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[943, 946]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[947, 950]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1013, 1016]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1036, 1039]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1118, 1121]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1232, 1235]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1265, 1273]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1341, 1344]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2031, 2034]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2035, 2038]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2080, 2092]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2146, 2158]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2227, 2230]], 'text': ['p50'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2231, 2234]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2320, 2332]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2344, 2347]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2446, 2449]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2622, 2625]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2796, 2799]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2821, 2825]], 'text': ['MSK1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3059, 3066]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3119, 3122]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3190, 3193]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3298, 3301]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3440, 3443]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3492, 3496]], 'text': ['p300'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3653, 3665]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3721, 3726]], 'text': ['Pim-1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3761, 3764]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4367, 4372]], 'text': ['alpha'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4373, 4379]], 'text': ['betaI'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4379, 4385]], 'text': ['betaII'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4390, 4395]], 'text': ['gamma'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4449, 4454]], 'text': ['delta'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4456, 4463]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4465, 4468]], 'text': ['eta'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[4470, 4475]], 'text': ['theta'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[4480, 4482]], 'text': ['mu'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[4518, 4520]], 'text': ['xi'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[4522, 4526]], 'text': ['iota'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[4531, 4537]], 'text': ['lambda'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[4644, 4652]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[4653, 4661]], 'text': ['PKCbetaI'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[4666, 4675]], 'text': ['PKCbetaII'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[4693, 4701]], 'text': ['PKCdelta'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[4706, 4716]], 'text': ['PKCepsilon'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[4834, 4842]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[4851, 4860]], 'text': ['IL-1alpha'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[4862, 4866]], 'text': ['iNOS'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[4871, 4879]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[5014, 5022]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[5067, 5075]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[5203, 5211]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[5220, 5228]], 'text': ['PKCdelta'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[5344, 5352]], 'text': ['PKCdelta'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[5419, 5427]], 'text': ['PKCdelta'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[5452, 5461]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[5574, 5584]], 'text': ['PKCepsilon'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[6587, 6613]], 'text': ['dominant negative PKCalpha'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[6628, 6642]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[6750, 6753]], 'text': ['p65'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[6919, 6922]], 'text': ['p65'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[1100, 1107]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1236, 1240]], 'text': ['null'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[1312, 1326]], 'text': ['overexpressing'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[2099, 2103]], 'text': ['Upon'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[2162, 2176]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T42'}, {'offsets': [[2197, 2205]], 'text': ['degraded'], 'type': 'Protein_catabolism', 'id': 'T43'}, {'offsets': [[2303, 2306]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T36'}, {'offsets': [[2307, 2314]], 'text': ['release'], 'type': 'Localization', 'id': 'T44'}, {'offsets': [[2360, 2391]], 'text': ['post-translational modification'], 'type': 'Protein_modification', 'id': 'T45'}, {'offsets': [[2450, 2465]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T46'}, {'offsets': [[2593, 2608]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T47'}, {'offsets': [[2629, 2635]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T48'}, {'offsets': [[2637, 2643]], 'text': ['Ser529'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[2647, 2653]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[2776, 2782]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T51'}, {'offsets': [[2803, 2817]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T52'}, {'offsets': [[2969, 2984]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[2988, 2994]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T54'}, {'offsets': [[2999, 3005]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[3006, 3010]], 'text': ['that'], 'type': 'Anaphora', 'id': 'T37'}, {'offsets': [[3014, 3023]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[3141, 3155]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T57'}, {'offsets': [[3159, 3165]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[3194, 3201]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[3202, 3215]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T60'}, {'offsets': [[3302, 3317]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T61'}, {'offsets': [[3321, 3327]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[3401, 3416]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T63'}, {'offsets': [[3420, 3426]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[3444, 3446]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[3641, 3652]], 'text': ['stabilizing'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[3736, 3750]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T67'}, {'offsets': [[3768, 3774]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[4843, 4850]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[4885, 4895]], 'text': ['production'], 'type': 'Transcription', 'id': 'T103'}, {'offsets': [[5079, 5092]], 'text': ['overexpressed'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[5189, 5199]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T105'}, {'offsets': [[5437, 5451]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T106'}, {'offsets': [[6661, 6670]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T107'}, {'offsets': [[6711, 6726]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T108'}, {'offsets': [[6730, 6736]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T109'}, {'offsets': [[6775, 6784]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T110'}, {'offsets': [[6870, 6879]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T111'}, {'offsets': [[6880, 6895]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T112'}, {'offsets': [[6899, 6905]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T113'}]","[{'trigger': 'T38', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T40', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T41', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T42', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T41', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T43', 'id': 'E7', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T44', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T45', 'id': 'E9', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T46', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T47', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T48']}}, {'trigger': 'T47', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T49']}}, {'trigger': 'T47', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T50']}}, {'trigger': 'T52', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T25', 'T26', 'T51']}}, {'trigger': 'T53', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T54']}}, {'trigger': 'T53', 'id': 'E16', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T55']}}, {'trigger': 'T56', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T27']}}, {'trigger': 'T56', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T27']}}, {'trigger': 'T57', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T58']}}, {'trigger': 'T60', 'id': 'E20', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T29', 'T59']}}, {'trigger': 'T61', 'id': 'E21', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T30', 'T62']}}, {'trigger': 'T63', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T31', 'T64']}}, {'trigger': 'T65', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T66', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T67', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T35', 'T34', 'T68']}}, {'trigger': 'T102', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T86']}}, {'trigger': 'T103', 'id': 'E27', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T87']}}, {'trigger': 'T102', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T86']}}, {'trigger': 'T103', 'id': 'E29', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T102', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T86']}}, {'trigger': 'T103', 'id': 'E31', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T104', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}, {'trigger': 'T105', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T92']}}, {'trigger': 'T106', 'id': 'E34', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T96', 'T95']}}, {'trigger': 'T107', 'id': 'E35', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T108', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T100', 'T109']}}, {'trigger': 'T110', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T111', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T112', 'id': 'E39', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T101', 'T113']}}]","[{'id': 'R1', 'head': {'ref_id': 'T36', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T37', 'role': 'Subject'}, 'tail': {'ref_id': 'T53', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T2', 'T1']}]",[],[]
74,PMC-3245220-10-Results,"PKC is Essential in Regulating NF-kappaB Activity
M-CSF-dependent PKC activity facilitated NF-kappaB p65 phosphorylation at Ser276 but not Ser536. To confirm the role of PKC and p65 Ser276 phosphorylation on NF-kappaB activity, we co-transfected the NF-kappaB-SEAP construct with either WT NF-kappaB p65 or NF-kappaB p65 276S/A constructs in Raw 264.7 cells, then treated cells with the PKC inhibitor Ro-31-8220 in the absence or presences of M-CSF. As expected in cells transfected with vector control, inhibiting PKC reduced M-CSF-stimulated NF-kappaB activity compared to cells treated with M-CSF and the vehicle DMSO (p = 0.001) (Figure 8A). In contrast, expressing WT NF-kappaB p65 (p65 WT) increased NF-kappaB activity, while the general PKC inhibitor Ro-31-8220 decreased this NF-kappaB activity (p = 0.001). Notably, the introduction of NF-kappaB p65 276 S/A construct significantly reduced NF-kappaB activity compared with the WT NF-kappaB p65 construct (p = 0.005) and M-CSF treatment was unable to overcome this inhibition.
Furthermore, we co-transfected the NF-kappaB-SEAP construct along with either the WT NF-kappaB p65, NF-kappaB p65 276S/A or NF-kappaB p65 536S/A constructs into a NF-kappaB p65-/- murine fibroblast cell line and measured NF-kappaB activity. As predicted, expression of WT NF-kappaB p65 (p65 WT) in NF-kappaB p65-/- cell line constitutively activated NF-kappaB compared to cells transfected with vector control without any stimulation (Figure 8B). In comparison, transfecting the NF-kappaB p65 276S/A construct reduced NF-kappaB activity by 5-fold (p = 0.006, WT NF-kappaB p65 vs. NF-kappaB p65 276S/A), while expressing the NF-kappaB p65 536S/A construct increased NF-kappaB activity in the p65-/- cells to levels similar to WT NF-kappaB p65 transfected cells.
Since M-CSF-induced PKC activation regulated NF-kappaB activity via Ser276 residue of NF-kappaB p65 in primary human MDMs and RAW 264.7 cells, we next examined if this occurred in NF-kappaB p65-/- fibroblasts in response to a native stimulus for these cells, TNFalpha. NF-kappaB activity was measured in the WT NF-kappaB p65 or NF-kappaB p65 276S/A transfected cells treated with TNFalpha in the absence or presence of Ro-31-8220 (Figure 8C). As expected, TNFalpha increased NF-kappaB activity in NF-kappaB p65-/- cells expressing WT p65 and (p = 0.001) PKC inhibitors decreased NF-kappaB activity to the non-stimulated (NS) level (p = 0.007). Introducing NF-kappaB p65 276 S/A constructs significantly reduced NF-kappaB activity compared with the WT NF-kappaB p65 construct (p = 0.001). Notably, TNFalpha failed to increase NF-kappaB activity in the NF-kappaB p65-/- cells expressing NF-kappaB p65 276S/A constructs. These observations are similar to macrophages overexpressing the NF-kappaB p65 276S/A (Figure 8A). Our data demonstrate that Ser276 of NF-kappaB p65 is essential in regulating NF-kappaB activity and suggests that PKC regulates NF-kappaB activity by modulating the phosphorylation of NF-kappaB p65 at Ser276 residue.","[{'offsets': [[101, 104]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[178, 181]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[300, 303]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[317, 320]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[683, 686]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[688, 691]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[855, 858]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[949, 952]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1130, 1133]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1145, 1148]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1169, 1172]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1208, 1211]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1317, 1320]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1322, 1325]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1343, 1346]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1524, 1527]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1607, 1610]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1625, 1628]], 'text': ['p65'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1669, 1672]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1726, 1729]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1773, 1776]], 'text': ['p65'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1892, 1895]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1986, 1989]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2055, 2063]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2117, 2120]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2134, 2137]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2176, 2184]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2252, 2260]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2303, 2306]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2330, 2333]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2462, 2465]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2557, 2560]], 'text': ['p65'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2593, 2601]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2657, 2660]], 'text': ['p65'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2691, 2694]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2789, 2792]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2859, 2862]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3007, 3010]], 'text': ['p65'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[79, 90]], 'text': ['facilitated'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[105, 120]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T40'}, {'offsets': [[124, 130]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[139, 145]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T42'}, {'offsets': [[182, 188]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T43'}, {'offsets': [[189, 204]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T44'}, {'offsets': [[231, 245]], 'text': ['co-transfected'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[659, 669]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[829, 841]], 'text': ['introduction'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[1051, 1065]], 'text': ['co-transfected'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[1211, 1214]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[1290, 1300]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[1346, 1349]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T51'}, {'offsets': [[1497, 1509]], 'text': ['transfecting'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[1644, 1654]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[1729, 1732]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[1777, 1788]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[1989, 1992]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[2145, 2156]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[2306, 2309]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[2316, 2326]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T59'}, {'offsets': [[2440, 2451]], 'text': ['Introducing'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[2660, 2663]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[2670, 2680]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[2760, 2774]], 'text': ['overexpressing'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[2963, 2973]], 'text': ['modulating'], 'type': 'Regulation', 'id': 'T64'}, {'offsets': [[2978, 2993]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T65'}, {'offsets': [[3014, 3020]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T66'}]","[{'trigger': 'T39', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T40', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T41']}}, {'trigger': 'T39', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T42']}}, {'trigger': 'T44', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T43']}}, {'trigger': 'T45', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T45', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T46', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T47', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T48', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T48', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T49', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T50', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T51', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T52', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T53', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T54', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T55', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T56', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T57', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T57', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T58', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T59', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T60', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T61', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T62', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T63', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T64', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T65', 'id': 'E29', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T38', 'T66']}}]",[],"[{'id': '*', 'ref_ids': ['T5', 'T6']}, {'id': '*', 'ref_ids': ['T13', 'T14']}]","[{'id': 'M2', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}]",[]
75,PMC-3279418-01-Introduction,"SHARPIN was originally identified in post-synaptic densities of excitatory synapses in the brain of rats [1], but this protein is widely expressed in a variety of tissues [2]. Two allelic, autosomal recessive mutations in the Sharpin gene occurred spontaneously in two inbred strains of mice, C57B/KaLawRij-Sharpincpdm/Sharpincpdm and CBy.Ocb3/Dem-Sharpincpdm-Dem/Sharpincpdm-Dem, resulting in premature termination of mRNA synthesis and absence of a functional protein product [2]. Despite different genetic backgrounds, both mutations cause similar inflammatory disease with severe chronic progressive dermatitis and defective development of secondary lymphoid organs [2]-[4]. The dermatitis becomes clinically apparent at about four weeks of age. There are accumulations of eosinophils, neutrophils and macrophages in the skin of Sharpincpdm/Sharpincpdm mutant mice (hereafter referred to as cpdm mice) associated with increased expression of Th2 cytokines in the skin and in the supernatants of activated splenocytes [5]. The mice have an impaired delayed type hypersensitivity response and decreased secretion of IFNgamma [5], indicating a defect in Th1 immune responses and a bias towards a Th2 immune response. Systemic treatment of cpdm mice with recombinant IL12 caused complete remission of the dermatitis [5]. Neutralization of IL5 by antibody treatment or crosses with IL5-deficient mice reduced the number of circulating and cutaneous eosinophils, but failed to reduce the onset and severity of the dermatitis [6].
Recently, three independent groups identified SHARPIN as an essential component of the linear ubiquitin chain assembly complex (LUBAC) that regulates TNFalpha-induced canonical NF-kappaB signaling [7]-[9]. SHARPIN-deficient mouse embryonic fibroblast (MEF) were sensitized to TNFalpha-induced apoptosis and cell death was implicated as a factor in the dermatitis of cpdm mice [7]-[9].
Dendritic cells (DC) have a sentinel role in sensing pathogen or danger signals and initiate and direct activation of the adaptive immune response [10]. Activated and mature DC can carry processed antigenic peptides, migrate to lymphoid organs, and induce T-cell-mediated immune responses or tolerance. DC direct the differentiation of CD4+ T cells, and hence the type of immune response, through the selective secretion of cytokines. We hypothesized that defective cytokine secretion by DC contributed to the Th2-biased inflammatory phenotype in SHARPIN-deficient mice. The studies reported here found that lack of SHARPIN protein in BMDC caused defective expression of pro-inflammatory mediators and impaired NF-kappaB activation upon ligand stimulation. The ability of cpdm BMDC to stimulate Th1 cytokine production in allogeneic CD4+ T cells was compromised. Taken together, these results reveal that SHARPIN is a novel regulatory molecule in DC biology and suggest that the dysregulated function of SHARPIN-deficient DC plays a role in the cpdm phenotype.","[{'offsets': [[0, 7]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[226, 233]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1118, 1126]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1339, 1342]], 'text': ['IL5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1381, 1384]], 'text': ['IL5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1574, 1581]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1678, 1686]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1734, 1741]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1804, 1812]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2460, 2467]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2529, 2536]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2818, 2825]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2917, 2924]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[114, 126]], 'text': ['this protein'], 'type': 'Anaphora', 'id': 'T14'}, {'offsets': [[137, 146]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[199, 218]], 'text': ['recessive mutations'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[381, 390]], 'text': ['resulting'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[404, 415]], 'text': ['termination'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[419, 423]], 'text': ['mRNA'], 'type': 'Anaphora', 'id': 'T15'}, {'offsets': [[424, 433]], 'text': ['synthesis'], 'type': 'Transcription', 'id': 'T21'}, {'offsets': [[438, 445]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[449, 477]], 'text': ['a functional protein product'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[1095, 1104]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T23'}, {'offsets': [[1105, 1114]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[1321, 1335]], 'text': ['Neutralization'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[1385, 1394]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T26'}, {'offsets': [[1742, 1751]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[2468, 2477]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[2521, 2525]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[2925, 2934]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T30'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T18', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'E2']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E2']}}, {'trigger': 'T22', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T23', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T25', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T26', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T27', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T30', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]","[{'id': 'R1', 'head': {'ref_id': 'T14', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}]",[],[],[]
76,PMC-2664230-07-MATERIALS_AND_METHODS,"Role of PKA on LPS-induced mononuclear cell TNF-alpha production
To evaluate the role of PKA on TNF-alpha production in mononuclear cells and its involvement in the attenuation of LPS-induced TNF-alpha production observed following PTX treatment, H89, a specific PKA inhibitor, was utilized. Isolated mononuclear cells were incubated according to the treatment groups described above in the presence and absence of pretreatment with H89 (10 muM) for 1 hour at 37degreesC. The dose of H89 was chosen based on previous work which demonstrated specific and complete inhibition of PKA at this concentration.10 Since the activity of this inhibitor is both specific and consistent at this specified dose, we did not include experiments with additional PKA inhibitors with this set of experiments. The TNF-alpha concentration in the supernatant was measured quantitatively by ELISA. The results are expressed in pg/mL.","[{'offsets': [[44, 53]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[96, 105]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[192, 201]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[795, 804]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[0, 4]], 'text': ['Role'], 'type': 'Regulation', 'id': 'T5'}, {'offsets': [[19, 26]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[54, 64]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[81, 85]], 'text': ['role'], 'type': 'Regulation', 'id': 'T8'}, {'offsets': [[106, 116]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[146, 157]], 'text': ['involvement'], 'type': 'Regulation', 'id': 'T10'}, {'offsets': [[165, 176]], 'text': ['attenuation'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[184, 191]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[202, 212]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T13'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T11', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T12', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T13', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],[],[]
77,PMC-2626671-18-Caption-Figure_2,"Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.","[{'offsets': [[14, 22]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[24, 34]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[40, 49]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[64, 69]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[74, 79]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[109, 118]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[137, 142]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[151, 156]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[168, 173]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[193, 196]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[307, 316]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[399, 408]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[447, 451]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[456, 460]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[486, 491]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[502, 505]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[603, 613]], 'text': ['Eomes-VP16'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[615, 622]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[641, 644]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[839, 849]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[854, 863]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[878, 883]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[891, 896]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[975, 984]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1021, 1028]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1041, 1044]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1164, 1167]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1169, 1178]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[0, 10]], 'text': ['Regulation'], 'type': 'Regulation', 'id': 'T29'}, {'offsets': [[50, 60]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[119, 129]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[157, 166]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[317, 327]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[461, 476]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T34'}, {'offsets': [[492, 501]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T35'}, {'offsets': [[592, 602]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[864, 874]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[985, 995]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T38'}]","[{'trigger': 'T29', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T4']}}, {'trigger': 'T30', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T29', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T5']}}, {'trigger': 'T29', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T4']}}, {'trigger': 'T30', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T29', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T5']}}, {'trigger': 'T29', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T4']}}, {'trigger': 'T30', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T29', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T5']}}, {'trigger': 'T31', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T32', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T33', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T34', 'id': 'E13', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T34', 'id': 'E14', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T35', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T36', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T37', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T37', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T38', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}]",[],"[{'id': '*', 'ref_ids': ['T17', 'T18']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E14', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E17', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E19', 'value': ''}]",[]
78,PMC-1310901-13-RESULTS,"In vitro methylation of an IRF-4 promoter-reporter construct decreases its activity
To provide evidence for a direct effect of methylational status on IRF-4 promoter activity we performed reporter gene assays with IRF-4 promoter constructs before and after their in vitro methylation. A complete methylation of these constructs was checked via restriction assays with methylation-sensitive endonucleases (Figure 5A). Intriguingly, methylation of the IRF-4 promoter significantly decreased promoter activity in IRF-4-positive SD-1 cells by 85.0% (Figure 5B). The silencing effect of CpG methylation was not restricted to IRF-4-positive cells, since in vitro methylation led to a 92.9% abrogation of promoter activity in IRF-4-negative Jurkat cells (Figure 5C). In contrast, control methylation of a reporter construct with a different promoter (FasL) as well as an empty vector had no effect on the reporter activity (data not shown). These data proved a direct association between methylation and activity of the IRF-4 promoter.","[{'offsets': [[27, 32]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[151, 156]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[214, 219]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[450, 455]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[510, 515]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[620, 625]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[719, 724]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[844, 848]], 'text': ['FasL'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1013, 1018]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[479, 488]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T10'}, {'offsets': [[489, 497]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T11'}, {'offsets': [[516, 524]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[626, 634]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[684, 694]], 'text': ['abrogation'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[698, 706]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[725, 733]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T16'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T11']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T14', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T15']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}]",[]
79,PMC-1447668-19-Materials_and_Methods,"Flow cytometric analysis of Foxp3 protein expression.
Cryopreserved PBMCs from HAM/TSP patients or HTLV-I-infected ACs were thawed and washed with FACS buffer (1x PBS, 0.1% NaN3, 5% FBS). Cells (1.5 x 106) were fixed by sequential formaldehyde/methanol fixation as follows. Cells were carefully resuspended in FACS buffer and fixed with 100 mul of reagent A (Fix & Perm kit; Caltag Laboratories, Burlingame, California, United States) at room temperature for 3 min followed by 2 ml of 70% methanol for 5 min at 4 degreesC. Cells were washed twice and permeabilized with 100 mul of reagent B (Fix & Perm kit) and stained for intracellular Foxp3 with mouse anti-human Foxp3 monoclonal antibody (0.5 mug of ab22510; Abcam) or the appropriate isotype control for 30 min. Cells were washed twice and stained with Cy5-conjugated goat anti-mouse immunoglobulin F(ab')2 secondary antibody (Caltag Laboratories) for an additional 30 min. Cells were washed twice and stained for surface CD4 expression with PE-labeled anti-CD4 (BD) and CD25 expression with FITC-labeled anti-CD25 (BD). Cells were washed twice and analyzed on a FACSCalibur (BD). Data analysis was performed using FlowJo (Tree Star, Ashland, Oregon, United States).","[{'offsets': [[28, 33]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[638, 643]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[666, 671]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[977, 980]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1013, 1016]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1026, 1030]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1065, 1069]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[42, 52]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[981, 991]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[1031, 1041]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T9', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T10', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
80,PMC-2889865-05-Results,"NF-kappaB inhibition due to PKC-dependent Bcl10 degradation
Western blot analysis revealed an up-regulation of phosphorylated-PKC after 24 h treatment of Jurkat T-cells with PMA or HK E. coli (figure 7a), while IkappaBbeta levels remained unaffected (figure 7b). Bcl10 is a signalling protein that acts upstream of NF-kappaB in concert with CARMA1 and MALT1 and has been suggested to directly regulate NF-kappaB activity in T-cells [27]. Therefore, Bcl10 activation was evaluated in both control and PMA stimulated cells after 10 min, 1 h, 6 h, and 24 h using western blot analysis. The Bcl10 levels decreased following treatment with PMA, while in control cells, Bcl10 returned to higher levels by 24 h (figure 7c). This suggests that Bcl10 is involved in the PMA dependent inhibition of NF-kappaB activation.","[{'offsets': [[42, 47]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[211, 222]], 'text': ['IkappaBbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[263, 268]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[341, 347]], 'text': ['CARMA1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[352, 357]], 'text': ['MALT1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[449, 454]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[587, 592]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[664, 669]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[736, 741]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[32, 41]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T10'}, {'offsets': [[48, 59]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T11'}, {'offsets': [[239, 249]], 'text': ['unaffected'], 'type': 'Regulation', 'id': 'T12'}, {'offsets': [[455, 465]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[600, 609]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[670, 688]], 'text': ['returned to higher'], 'type': 'Positive_regulation', 'id': 'T15'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
81,PMC-2065877-21-Caption-Figure_3,"LMP1 Promotes B Cell Survival and Proliferation In Vitro
(A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where ""n"" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas.
(B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d.
(C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[98, 102]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[201, 204]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[404, 408]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[448, 452]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[496, 500]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[532, 536]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[641, 644]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[714, 718]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[770, 773]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[828, 832]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
82,PMC-3148254-06-Discussion,"Our results indicate that the protein HOIP is critical for CD40-induced signals that regulate B cell function. Our data show that HOIP-dependent cellular responses include CD40-mediated upregulation of CD80 expression and synthesis of germline RNA transcripts from the immunoglobulin heavy chain locus, two events that are important for T-cell-dependent antibody-mediated immune responses. At the molecular level, our data indicate that HOIP functions downstream of TRAF2 in the CD40 signaling pathway and that HOIP has a key role in promoting the recruitment of the IKK complex to CD40. Consistent with this, CD40-induced activation of NF-kappaB is dependent on the presence of HOIP. In addition, our data show that HOIP facilitates the activation of JNK in response to CD40 engagement. Together, our findings provide support for the conclusion that HOIP is a key component of the CD40 signaling pathway. Given the importance of CD40 signaling in both cellular and humoral immune responses, our results indicate that HOIP has a critical role in the regulation of the immune system.
The functional properties of HOIP have only been partially characterized. Initial studies showed that HOIP and the related protein HOIL-1 are components of a large (~600 kDa) protein complex capable of synthesizing linear polyubiquitin chains [5]. Subsequent studies showed that a HOIP-containing complex can interact with IKKgamma and facilitate activation of NF-kappaB via the canonical pathway [16]. These data, considered together with ours, suggest that a HOIP-containing complex mediates recruitment of IKKgamma to the CD40 signaling complex. In addition, CD40-associated HOIP could play a role in activating IKKgamma after its recruitment to the signaling complex [16]. The higher molecular weight forms of IKKgamma we observed in CD40 immunoprecipitates would be consistent with the presence of post-transcriptional modifications including phosphorylation and ubiquitination, which have been suggested to reduce or enhance IKKgamma activity, respectively [16], [17].
The mechanisms by which HOIP mediates recruitment of the IKK complex to CD40 and by which HOIP is recruited to CD40 remain unclear. A previous study indicates that HOIP may mediate direct contacts with the IKK complex [16], suggesting that it functions as an adaptor for the recruitment of the IKK complex to CD40. However, the ubiquitin ligase activity of HOIP suggests that it is more than a simple adapter molecule. As IKKgamma appears capable of binding linear polyubiquitin [18], [19], it is possible that HOIP directs formation of linear polyubiquitin chains on a CD40-associated factor, and it is these chains that serve to recruit IKKgamma to the CD40 signaling complex. The molecular interactions necessary for recruitment of HOIP itself to the CD40 signaling complex also remain to be fully characterized. We previously showed that the recruitment of HOIP to the signaling complex is TRAF2-dependent [8]. Potentially, TRAF2 and HOIP directly interact, but it is possible that the ubiquitin ligase activity of TRAF2 [20] (or TRAF2-associated proteins, such as the cIAPs [21]) generates K63-linked polyubiquitin chains to which HOIP can bind and thus associate with the CD40 signaling complex [22].
While our previous work indicated a potentially important link between TRAF2 and HOIP in CD40 signaling, the signals and functions tested here are dependent upon TRAF6 as well as TRAF2. In previous experiments with TRAF-deficient A20.2J cells, we found that the activation of NF-kappaB by CD40 could be mediated by either TRAF2 or TRAF6, while activation of JNK by CD40 was largely dependent on TRAF6 alone [8]. HOIP deficiency compromises the CD40-mediated activation of both NF-kappaB and JNK, indicating that signals mediated by both TRAF2 and TRAF6 likely pass through HOIP. Our previous work also demonstrated that the CD40-mediated activation of NF-kappaB and JNK, while TRAF6-dependent, was not compromised by the disruption of the binding site for TRAF6 in the cytoplasmic domain of CD40 or deletion of the receptor binding domain (the TRAF-C domain) in TRAF6 [8]. These observations indicate that TRAF6 need not directly bind CD40 in order to mediate certain signals, suggesting the assembly of a signaling complex not directly associated with the receptor. If such a complex exists, our results indicate that the absence of HOIP compromises its function as well.
Although the experiments presented here focus on CD40, our results and those of other groups [16], [22] support the possibility that HOIP is important in many signaling pathways in which TRAF2 or TRAF6 are involved, including those associated with various members of the TNF receptor superfamily and the Toll-like receptors. The potential importance of HOIP in immune function and TNFR family signaling is further supported by the recent discovery that HOIP interacts with a protein known as SHARPIN (SHANK-associated RH domain interacting protein in postsynaptic density), which appears capable of working together with HOIP and HOIL to mediate the assembly of linear polyubiquitin [14], [23], [24]. Interestingly, mice with a spontaneous mutation in the gene encoding SHARPIN (chronic proliferative dermatitis (cpdm) mice) exhibit chronic inflammation of the skin and internal organs, defective development of secondary lymphoid tissue, and defects in the production of switched immunoglobulin isotypes [17], [25]. The apparently intimate functional link between SHARPIN and HOIP strongly suggests that at least part of the cpdm phenotype stems from defects in the regulation or function of HOIP.","[{'offsets': [[38, 42]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[59, 63]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[130, 134]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 176]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[202, 206]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[437, 441]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[466, 471]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[479, 483]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[511, 515]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[582, 586]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[610, 614]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[717, 721]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[771, 775]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[851, 855]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[882, 886]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[930, 934]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1018, 1022]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1112, 1116]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1185, 1189]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1214, 1220]], 'text': ['HOIL-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1406, 1414]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1592, 1600]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1645, 1649]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1661, 1665]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1698, 1706]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1797, 1805]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1821, 1825]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2014, 2022]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2082, 2086]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2130, 2134]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2148, 2152]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2169, 2173]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2222, 2226]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2367, 2371]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2415, 2419]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2480, 2488]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2569, 2573]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2697, 2705]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2793, 2797]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2919, 2923]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2952, 2957]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2986, 2991]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2996, 3000]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3077, 3082]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3194, 3198]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3336, 3341]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3346, 3350]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3354, 3358]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3427, 3432]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3444, 3449]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3554, 3558]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3587, 3592]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3596, 3601]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3630, 3634]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3660, 3665]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3677, 3681]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3709, 3713]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3802, 3807]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3812, 3817]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3838, 3842]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3889, 3893]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3942, 3947]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4021, 4026]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4056, 4060]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4127, 4132]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4171, 4176]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4200, 4204]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4399, 4403]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4487, 4491]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4571, 4575]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4625, 4630]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4634, 4639]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4791, 4795]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4891, 4895]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4930, 4937]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[4939, 5009]], 'text': ['SHANK-associated RH domain interacting protein in postsynaptic density'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5059, 5063]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[5068, 5072]], 'text': ['HOIL'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[5208, 5215]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[5503, 5510]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[5515, 5519]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[5631, 5635]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[135, 144]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T88'}, {'offsets': [[177, 185]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[186, 198]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T90'}, {'offsets': [[207, 217]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[452, 462]], 'text': ['downstream'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[526, 530]], 'text': ['role'], 'type': 'Regulation', 'id': 'T93'}, {'offsets': [[534, 543]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[548, 559]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T95'}, {'offsets': [[776, 786]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T96'}, {'offsets': [[1392, 1400]], 'text': ['interact'], 'type': 'Binding', 'id': 'T97'}, {'offsets': [[1568, 1576]], 'text': ['mediates'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[1577, 1588]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T99'}, {'offsets': [[1650, 1660]], 'text': ['associated'], 'type': 'Binding', 'id': 'T100'}, {'offsets': [[1679, 1683]], 'text': ['role'], 'type': 'Regulation', 'id': 'T101'}, {'offsets': [[1687, 1697]], 'text': ['activating'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[1713, 1716]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T83'}, {'offsets': [[1717, 1728]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T103'}, {'offsets': [[1886, 1920]], 'text': ['post-transcriptional modifications'], 'type': 'Anaphora', 'id': 'T84'}, {'offsets': [[1931, 1946]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T104'}, {'offsets': [[1951, 1965]], 'text': ['ubiquitination'], 'type': 'Ubiquitination', 'id': 'T105'}, {'offsets': [[1967, 1972]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T85'}, {'offsets': [[1996, 2002]], 'text': ['reduce'], 'type': 'Negative_regulation', 'id': 'T106'}, {'offsets': [[2006, 2013]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[2087, 2095]], 'text': ['mediates'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[2096, 2107]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T109'}, {'offsets': [[2156, 2165]], 'text': ['recruited'], 'type': 'Binding', 'id': 'T110'}, {'offsets': [[2298, 2300]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T86'}, {'offsets': [[2301, 2324]], 'text': ['functions as an adaptor'], 'type': 'Positive_regulation', 'id': 'T111'}, {'offsets': [[2333, 2344]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T112'}, {'offsets': [[2508, 2515]], 'text': ['binding'], 'type': 'Binding', 'id': 'T113'}, {'offsets': [[2680, 2685]], 'text': ['serve'], 'type': 'Positive_regulation', 'id': 'T114'}, {'offsets': [[2689, 2696]], 'text': ['recruit'], 'type': 'Binding', 'id': 'T115'}, {'offsets': [[2764, 2773]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T116'}, {'offsets': [[2778, 2789]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T117'}, {'offsets': [[2904, 2915]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T118'}, {'offsets': [[2958, 2967]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T119'}, {'offsets': [[3010, 3018]], 'text': ['interact'], 'type': 'Binding', 'id': 'T120'}, {'offsets': [[3203, 3207]], 'text': ['bind'], 'type': 'Binding', 'id': 'T121'}, {'offsets': [[3217, 3226]], 'text': ['associate'], 'type': 'Binding', 'id': 'T122'}, {'offsets': [[3682, 3692]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T123'}, {'offsets': [[3986, 3996]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[4004, 4016]], 'text': ['binding site'], 'type': 'Entity', 'id': 'T125'}, {'offsets': [[4064, 4072]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T126'}, {'offsets': [[4080, 4103]], 'text': ['receptor binding domain'], 'type': 'Entity', 'id': 'T127'}, {'offsets': [[4195, 4199]], 'text': ['bind'], 'type': 'Binding', 'id': 'T128'}, {'offsets': [[4388, 4395]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T129'}, {'offsets': [[4896, 4905]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T130'}, {'offsets': [[4911, 4920]], 'text': ['a protein'], 'type': 'Anaphora', 'id': 'T87'}, {'offsets': [[5490, 5494]], 'text': ['link'], 'type': 'Binding', 'id': 'T131'}, {'offsets': [[5590, 5597]], 'text': ['defects'], 'type': 'Negative_regulation', 'id': 'T132'}, {'offsets': [[5605, 5615]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T133'}]","[{'trigger': 'T104', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T105', 'id': 'E2', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T88', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T3']}}, {'trigger': 'T89', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T4']}}, {'trigger': 'T90', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T91', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T92', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T7']}}, {'trigger': 'T93', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T9']}}, {'trigger': 'T94', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T95', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T96', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T97', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T98', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T99', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T100', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T23', 'T24']}}, {'trigger': 'T101', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T24']}}, {'trigger': 'T102', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T103', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T106', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'E1']}}, {'trigger': 'T106', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'E2']}}, {'trigger': 'T107', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'E1']}}, {'trigger': 'T107', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'E2']}}, {'trigger': 'T108', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T29']}}, {'trigger': 'T109', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T110', 'id': 'E25', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T31', 'T32']}}, {'trigger': 'T111', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T33']}}, {'trigger': 'T112', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T113', 'id': 'E28', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T114', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T115', 'id': 'E30', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T116', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T117', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T118', 'id': 'E33', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T119', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T41']}}, {'trigger': 'T120', 'id': 'E35', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T42', 'T43']}}, {'trigger': 'T121', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T122', 'id': 'E37', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T123', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T124', 'id': 'E39', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T64', 'T125']}}, {'trigger': 'T126', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T65', 'T127']}}, {'trigger': 'T128', 'id': 'E41', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T66', 'T67']}}, {'trigger': 'T129', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T130', 'id': 'E43', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T74', 'T75']}}, {'trigger': 'T131', 'id': 'E44', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T80', 'T81']}}, {'trigger': 'T132', 'id': 'E45', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T133', 'id': 'E46', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T82']}}]","[{'id': 'R1', 'head': {'ref_id': 'T83', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T84', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T86', 'role': 'Subject'}, 'tail': {'ref_id': 'T33', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T87', 'role': 'Subject'}, 'tail': {'ref_id': 'T75', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T75', 'T76']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E28', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E45', 'value': ''}]",[]
83,PMC-1447668-09-Discussion,"In the present study, we show that Foxp3 functions as a potent repressor of NF-kappaB- and CREB-dependent transcriptional activation. Furthermore, the carboxyl-terminal FKH domain appears to be dispensable for mediating these effects, at least in T cell populations. This observation may become important in light of recent reports suggesting that Foxp3 expression in thymic epithelial cells was crucial for directing development of T cells in the thymus [42]. Interestingly, the majority of the genetic mutations associated with IPEX, a severe autoimmune disorder caused by functional inactivation of Foxp3, map to the carboxyl-terminal FKH domain or the leucine zipper domain in the central region of the protein. Only one mutation associated with IPEX to date has been mapped to the amino-terminal proline-rich region [43]. It is possible that the FKH domain has a complex tertiary structure that is particularly sensitive to misfolding caused by genetic mutations and that an intact FKH domain is absolutely critical for promoting Foxp3 function in the nucleus, whereas the structure of the amino-terminal proline-rich region may tolerate certain mutations as long as the NF-kappaB/NF-AT binding motif remains unaltered. This motif may also include the zinc finger domain. A logical region that may be targeted by the amino-terminal proline-rich region of Foxp3 is the Rel homology domain found in both NF-kappaB and NF-AT family proteins. A region that may also be important with respect to Foxp3 function is the leucine zipper domain, as demonstrated by the number of mutations associated with IPEX that have been mapped in this region of Foxp3. The role of this domain in Foxp3 function remains uncharacterized, but may play a role in dimer formation as it does in other Foxp family members [44].
Because the pathogenesis of a number of retroviral-induced immunologic disorders such as HIV-1/AIDS and HTLV-I/HAM/TSP have been associated with dysregulation of Foxp3 expression [8,45], we also examined the role of Foxp3 in retroviral gene expression. HIV-1 LTR activation in CD4+ T cells is critically dependent on two tandem NF-kappaB sites located between nucleotide positions -102 and -81 within the HIV-1 enhancer region, whereas HTLV-I LTR activation in the presence or absence of the HTLV-I-encoded transactivator protein Tax is independent of NF-kappaB [18]. To our knowledge for the first time, Foxp3 was shown to have a direct effect on HIV-1 LTR transcription. Deletion of the NF-kappaB sites within the HIV-1 enhancer region reduced the responsiveness of the HIV-1 LTR to Foxp3-mediated suppression. In addition, the FKH domain of Foxp3 was required for this inhibitory effect in HEK 293T cells, but not in Jurkat T cells, similar to Foxp3-mediated suppression of a synthetic NF-kappaB reporter. The direct effect of Foxp3 down-regulating HIV-1 gene expression correlates well with recently reported evidence indicating that higher regulatory activity of CD4+CD25+ T cells from HIV-1-infected patients was associated with lower HIV-1 viral loads in these patients [46].
Foxp3 also affected two well-known functions of HTLV-I Tax: transactivation of the NF-kappaB pathway and, most surprisingly, transactivation of the HTLV-I LTR. Transactivation of the HTLV-I LTR by Tax involves the interaction of ATF/CREB factors with Tax in the nucleus. Binding of Tax enhances ATF/CREB dimerization and promotes assembly of Tax-ATF/CREB complexes onto specific sequences in the viral promoter known as Tax-responsive elements. This series of steps allows Tax to recruit coactivator proteins CBP/p300 to the viral promoter and facilitate a high level of viral gene expression [24-26]. Transactivation of the NF-kappaB pathway by Tax was inhibited by overexpression of full-length Foxp3, but not deltaFKH, as seen with basal activation of the HIV-1 LTR and a synthetic NF-kappaB reporter in HEK 293T cells. However, Tax-mediated transactivation of the HTLV-I LTR was inhibited by overexpression of both full-length Foxp3 as well as deltaFKH in both HEK 293T cells and CD4+ T cells. We demonstrated that Foxp3 did not directly affect the functioning of Tax, but rather Foxp3 targeted the transcription factors required for Tax transactivation (i.e., NF-kappaB and a then-unknown cellular factor, which we identified in this study as CREB). The negative effect of Foxp3 on HTLV-I gene expression was confirmed utilizing an HTLV-I infectious molecular clone.
Importantly, we demonstrated that HTLV-I-infected individuals with the highest levels of Foxp3 protein expression within the CD4+CD25+ T cells population exhibited lower proviral loads than did individuals with the lowest levels of Foxp3 protein expression. Previous studies have demonstrated that the HTLV-I proviral load directly correlates with HTLV-I Tax mRNA load, the frequency of immunopathogenic virus-specific CD8+ T cells, and disease severity in patients with HAM/TSP [47]. These results have important implications on the utility of Foxp3 in controlling viral gene expression and thus pathogenesis of HAM/TSP. Therefore, Foxp3 becomes an attractive target for the development of novel therapeutic applications directed at modulating the expression of this important regulatory protein, especially in light of recent observations that the expression of Foxp3 can also be down-regulated by HTLV-I Tax [8].
As the activation of the HTLV-I LTR depends primarily on ATF/CREB proteins (whether in the presence or the absence of Tax), we investigated whether Foxp3 could interact with this additional cellular signaling pathway. While the DNA-binding activity of CREB is, in most cases, constitutive, the transactivation potential of CREB is regulated by the phosphorylation of CREB and recruitment of CBP/p300 [48]. Our data demonstrate that Foxp3 interferes with the latter of these two processes and that the recruitment of the coactivator protein p300, and resulting transcriptional activation are blocked by Foxp3. This may be the result of the physical interaction we detected between Foxp3 and p300. With respect to HTLV-I LTR activity, while full-length Foxp3 inhibited both basal and Tax-dependent transcription by ~50%, deltaFKH appeared less effective in suppressing basal activation (~25% inhibition) compared to Tax-dependent activation (~50% inhibition). The effect of deltaFKH on basal activation of the HTLV-I LTR in HEK 293T cells was very similar to that shown for a synthetic CREB reporter, suggesting that the FKH domain of Foxp3 is important at some level. As observed with NF-kappaB activation, the Foxp3 mutant lacking the FKH domain was a stronger inhibitor of CREB activation in CD4+ T cells than in HEK 293T epithelial cells. Therefore, it appears that in CD4+ T cells, the FKH domain is dispensable for the proper functioning of Foxp3 with respect to both NF-kappaB and CREB activation.
In summary, this is, to our knowledge, the first direct evidence implicating a role for the Treg-specific transcription factor Foxp3 in regulating retroviral gene expression. In addition, we identify the CREB pathway as a molecular target of Foxp3. Since CREB has been shown to regulate multiple genes involved in transcription (e.g., JunD, c-Fos, signal transducer of activated T cells 3 [STAT3]), cell cycle (e.g., p15INK4b, cyclin A, cyclin D1), and immune regulation (e.g., IL-2, IL-6, T-cell receptor alpha) (reviewed in [48]), the findings presented in this report broaden the potential range of signaling pathways under the control of the regulatory protein Foxp3. Our evidence stresses the importance of Foxp3 expression and Treg function in the development and maintenance of protective immunity against HIV-1 and HTLV-I. Based on recent findings, Foxp3 may limit HIV-1 and HTLV-I transcription by interfering with activation of NF-kappaB and CREB pathways. However, observing that this inhibitory effect is not absolute, a low level of viral gene expression may persist in CD4+ T cells (in particular regulatory T cells, which are known reservoirs of HIV-1 and HTLV-I) and result in the accumulation of viral proteins that either stimulate NF-kappaB and/or CREB activation or directly inhibit Foxp3 expression or function. The imbalance of NF-kappaB and CREB activation caused by these viral gene products may be a crucial step in the pathogenesis of virus-induced immunological disorders such as AIDS and HAM/TSP. Future studies will be directed at identifying and characterizing cellular proteins that interact with Foxp3 both in the nucleus and cytoplasm, in order to better address how Foxp3 functions to guide the development and function of regulatory T cells in health and disease.","[{'offsets': [[35, 40]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[348, 353]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[602, 607]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1035, 1040]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1360, 1365]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1496, 1501]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1645, 1650]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1679, 1684]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1966, 1971]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2020, 2025]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2081, 2084]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2334, 2337]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2409, 2414]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2589, 2594]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2648, 2653]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2751, 2756]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2834, 2839]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2972, 2975]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2976, 2980]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3087, 3092]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3142, 3145]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3284, 3287]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3338, 3341]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3369, 3372]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3429, 3432]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3560, 3563]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3596, 3599]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3600, 3604]], 'text': ['p300'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3733, 3736]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3784, 3789]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3799, 3807]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3919, 3922]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4018, 4023]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4035, 4043]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4071, 4074]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4106, 4111]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4155, 4158]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4171, 4176]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4225, 4228]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4365, 4370]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4548, 4553]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4584, 4587]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4588, 4592]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4691, 4696]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4814, 4817]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4878, 4881]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5004, 5009]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5092, 5097]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5323, 5328]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5366, 5369]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5493, 5496]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5523, 5528]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5766, 5769]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5770, 5774]], 'text': ['p300'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[5807, 5812]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5915, 5919]], 'text': ['p300'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5977, 5982]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[6055, 6060]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[6065, 6069]], 'text': ['p300'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[6126, 6131]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[6157, 6160]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[6194, 6202]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[6289, 6292]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[6347, 6355]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[6508, 6513]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[6585, 6590]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[6668, 6671]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[6746, 6749]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6820, 6825]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[7005, 7010]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[7120, 7125]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[7213, 7217]], 'text': ['JunD'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[7219, 7224]], 'text': ['c-Fos'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[7226, 7266]], 'text': ['signal transducer of activated T cells 3'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[7268, 7273]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[7295, 7303]], 'text': ['p15INK4b'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[7305, 7313]], 'text': ['cyclin A'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[7315, 7324]], 'text': ['cyclin D1'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[7356, 7360]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[7362, 7366]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7368, 7389]], 'text': ['T-cell receptor alpha'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7543, 7548]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[7590, 7595]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[7735, 7740]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[7961, 7964]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[8181, 8186]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[8506, 8511]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[8578, 8583]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[354, 364]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[586, 598]], 'text': ['inactivation'], 'type': 'Negative_regulation', 'id': 'T96'}, {'offsets': [[1306, 1314]], 'text': ['targeted'], 'type': 'Binding', 'id': 'T97'}, {'offsets': [[1322, 1356]], 'text': ['amino-terminal proline-rich region'], 'type': 'Entity', 'id': 'T98'}, {'offsets': [[1518, 1539]], 'text': ['leucine zipper domain'], 'type': 'Entity', 'id': 'T99'}, {'offsets': [[1664, 1675]], 'text': ['this domain'], 'type': 'Anaphora', 'id': 'T89'}, {'offsets': [[1727, 1738]], 'text': ['play a role'], 'type': 'Regulation', 'id': 'T100'}, {'offsets': [[1742, 1757]], 'text': ['dimer formation'], 'type': 'Binding', 'id': 'T101'}, {'offsets': [[1761, 1763]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T90'}, {'offsets': [[1764, 1768]], 'text': ['does'], 'type': 'Regulation', 'id': 'T102'}, {'offsets': [[1949, 1962]], 'text': ['dysregulation'], 'type': 'Regulation', 'id': 'T103'}, {'offsets': [[1972, 1982]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T104'}, {'offsets': [[3301, 3312]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T105'}, {'offsets': [[3358, 3365]], 'text': ['Binding'], 'type': 'Binding', 'id': 'T106'}, {'offsets': [[3408, 3416]], 'text': ['promotes'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[3417, 3425]], 'text': ['assembly'], 'type': 'Binding', 'id': 'T108'}, {'offsets': [[3567, 3574]], 'text': ['recruit'], 'type': 'Binding', 'id': 'T109'}, {'offsets': [[3754, 3768]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T110'}, {'offsets': [[3983, 3997]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T111'}, {'offsets': [[4530, 4537]], 'text': ['highest'], 'type': 'Positive_regulation', 'id': 'T112'}, {'offsets': [[4562, 4572]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T113'}, {'offsets': [[4674, 4680]], 'text': ['lowest'], 'type': 'Negative_regulation', 'id': 'T114'}, {'offsets': [[4705, 4715]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T115'}, {'offsets': [[5193, 5203]], 'text': ['modulating'], 'type': 'Regulation', 'id': 'T116'}, {'offsets': [[5208, 5218]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[5222, 5255]], 'text': ['this important regulatory protein'], 'type': 'Anaphora', 'id': 'T91'}, {'offsets': [[5309, 5319]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T118'}, {'offsets': [[5341, 5355]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T119'}, {'offsets': [[5751, 5762]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T120'}, {'offsets': [[5813, 5823]], 'text': ['interferes'], 'type': 'Negative_regulation', 'id': 'T121'}, {'offsets': [[5829, 5862]], 'text': ['the latter of these two processes'], 'type': 'Anaphora', 'id': 'T92'}, {'offsets': [[5876, 5887]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T122'}, {'offsets': [[5966, 5973]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T123'}, {'offsets': [[5984, 5988]], 'text': ['This'], 'type': 'Anaphora', 'id': 'T93'}, {'offsets': [[6000, 6006]], 'text': ['result'], 'type': 'Positive_regulation', 'id': 'T124'}, {'offsets': [[6023, 6034]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T125'}, {'offsets': [[6598, 6605]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T126'}, {'offsets': [[6610, 6620]], 'text': ['FKH domain'], 'type': 'Entity', 'id': 'T127'}, {'offsets': [[7156, 7164]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T128'}, {'offsets': [[7165, 7179]], 'text': ['multiple genes'], 'type': 'Anaphora', 'id': 'T94'}, {'offsets': [[7596, 7606]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T129'}, {'offsets': [[8173, 8180]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T130'}, {'offsets': [[8187, 8197]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T131'}, {'offsets': [[8492, 8500]], 'text': ['interact'], 'type': 'Binding', 'id': 'T132'}]","[{'trigger': 'T123', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T57']}}, {'trigger': 'T95', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T96', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T97', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T98']}}, {'trigger': 'T100', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E6', 'T6', 'T99']}}, {'trigger': 'T101', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T102', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E6', 'T6', 'T99']}}, {'trigger': 'T103', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T104', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T105', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T106', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T107', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E11']}}, {'trigger': 'T108', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T109', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T26', 'T27']}}, {'trigger': 'T109', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T26', 'T28']}}, {'trigger': 'T110', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T110', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T111', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T111', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T112', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T113', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T114', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T115', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T116', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T117', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T118', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T119', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T50']}}, {'trigger': 'T120', 'id': 'E28', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T120', 'id': 'E29', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T121', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T55']}}, {'trigger': 'T121', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T55']}}, {'trigger': 'T122', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T124', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'E34']}}, {'trigger': 'T125', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T58', 'T59']}}, {'trigger': 'T124', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E34']}}, {'trigger': 'T124', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E34']}}, {'trigger': 'T126', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T66', 'T127']}}, {'trigger': 'T128', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T128', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T128', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T128', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T128', 'id': 'E42', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T128', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T128', 'id': 'E44', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T128', 'id': 'E45', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T128', 'id': 'E46', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T129', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T130', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T131', 'id': 'E49', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T86']}}, {'trigger': 'T132', 'id': 'E50', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T87']}}]","[{'id': 'R1', 'head': {'ref_id': 'T89', 'role': 'Subject'}, 'tail': {'ref_id': 'T99', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T90', 'role': 'Subject'}, 'tail': {'ref_id': 'T89', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T91', 'role': 'Subject'}, 'tail': {'ref_id': 'T48', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T92', 'role': 'Subject'}, 'tail': {'ref_id': 'T120', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T72', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T73', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T75', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T76', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R11', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T77', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R12', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T78', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R13', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R14', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T80', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R15', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T81', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T75', 'T74']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E33', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E35', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E36', 'value': ''}]",[]
84,PMC-2791889-03-Results,"IL-10 Production by Th1 Cells Is Dependent on STAT4 but Not on STAT6, IFN-gamma, or IL-4 Signaling
To further elucidate the mechanisms required for the development of Th1 cells producing IL-10, we investigated the role of STAT4, one of the signaling pathways activated by IL-12 (Murphy et al., 2000). Naive CD4+ D011.10 T cells deficient in STAT4 (Ouyang et al., 1998) were cultured in the presence of IL-12 and OVA. Again, IL-10-producing Th1 cells were differentiated at the high antigen dose in the presence of IL-12 in DO11.10 T cells (Figure 2A). In contrast, in the absence of STAT4, the percentage of cells expressing IFN-gamma was dramatically diminished as expected and resulted in an increase in the percentage of cells expressing IL-4, but not IL-10 (Figure 2A), suggesting that STAT4 contributes to IL-10 expression by Th1 cells.
Because IL-10 expression is associated with an IL-4-induced Th2 cell phenotype, we investigated whether the differentiation of the IL-10-producing Th1 cells depended on signaling through the IL-4 receptor via STAT6 activation (Glimcher and Murphy, 2000; Murphy et al., 2000). The absence of STAT6 did not impair the differentiation of IL-10-producing Th1 cells in the presence of IL-12 and OVA (Figure 2A). In fact, a higher percentage of STAT6-deficient cells compared with WT cells produced both IL-10 and IFN-gamma (Figure 2A), which may be the result of the loss of Th2 cell control over a Th1 cell response. As expected, lack of STAT6 abrogated both IL-4 and IL-10 production by T cells developed with IL-4 or with low antigen dose (Figures 2B and 2C). However, in the absence of STAT4 signaling, IL-10 and IL-4 production by Th2 cells was if anything increased (Figures 2B and 2C). Thus, in contrast to what was observed under Th1 conditions, IL-10 expression by Th2 cells depended on STAT6, but not on STAT4, signaling (Figures 2B and 2C).
To investigate whether the inability of STAT4-deficient T cells to produce IL-10 might be due to the absence of IFN-gamma, as suggested before (Shaw et al., 2006), we differentiated DO11.10 or DO11.10 IFN-gamma-deficient naive CD4+ T cells in the presence of IL-12 and increasing doses of OVA. The secretion of IL-10 as induced by high antigen dose, and IL-12 was not affected by an absence of IFN-gamma (Figure 2D), showing that the expression of IL-10 by Th1 cells is independent of IFN-gamma. In the absence of IFN-gamma, we observed an increase in the secreted IL-4 as expected (data not shown).
We also tested for any potential role of IL-4 in the development of Th1 cells producing IL-10 by culturing DO11.10 or DO11.10 IL-4-deficient naive CD4+ T cells with IL-12 and increasing doses of antigen. As observed in the absence of STAT6 (Figure 2A), IL-4 deficiency had no effect on the development of Th1 cells producing IL-10 (Figure 2E), but compromised the development of Th2 cells producing IL-10 (Figure 2F). Thus, our data suggested that IL-10 production by Th1 or Th2 cells was dependent on the specific signaling pathways required for their differentiation, given that STAT4 is required for the induction of IL-10 production by Th1 cells and STAT6 for Th2 cells.","[{'offsets': [[0, 5]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[46, 51]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[63, 68]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[70, 79]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[84, 88]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[187, 192]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[222, 227]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[272, 277]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[307, 310]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[341, 346]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[402, 407]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[412, 415]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[424, 429]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[514, 519]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[583, 588]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[625, 634]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[741, 745]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[755, 760]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[790, 795]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[811, 816]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[850, 855]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[889, 893]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[973, 978]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1033, 1037]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1051, 1056]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1133, 1138]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1177, 1182]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1222, 1227]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1232, 1235]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1281, 1286]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1340, 1345]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1350, 1359]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1476, 1481]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1497, 1501]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1506, 1511]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1549, 1553]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1627, 1632]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1644, 1649]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1654, 1658]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1791, 1796]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1833, 1838]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1851, 1856]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1929, 1934]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1964, 1969]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2001, 2010]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2090, 2099]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2116, 2119]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2148, 2153]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2178, 2181]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2200, 2205]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2243, 2248]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2283, 2292]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2337, 2342]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2374, 2383]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2403, 2412]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2454, 2458]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2530, 2534]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2577, 2582]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2615, 2619]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2636, 2639]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2654, 2659]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2723, 2728]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2742, 2746]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2814, 2819]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[2888, 2893]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[2937, 2942]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3070, 3075]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3109, 3114]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3143, 3148]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[6, 16]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T70'}, {'offsets': [[33, 42]], 'text': ['Dependent'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[177, 186]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[214, 218]], 'text': ['role'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[259, 268]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[328, 337]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[430, 439]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[572, 579]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T77'}, {'offsets': [[614, 624]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T78'}, {'offsets': [[652, 662]], 'text': ['diminished'], 'type': 'Negative_regulation', 'id': 'T79'}, {'offsets': [[694, 702]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[730, 740]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[796, 807]], 'text': ['contributes'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[817, 827]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T83'}, {'offsets': [[856, 866]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[979, 988]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T85'}, {'offsets': [[1057, 1067]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[1122, 1129]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T87'}, {'offsets': [[1183, 1192]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T88'}, {'offsets': [[1203, 1221]], 'text': ['in the presence of'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[1287, 1296]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T90'}, {'offsets': [[1326, 1334]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[1468, 1472]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T92'}, {'offsets': [[1482, 1491]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[1512, 1522]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[1659, 1669]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[1699, 1708]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[1797, 1807]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T97'}, {'offsets': [[1821, 1829]], 'text': ['depended'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[1916, 1925]], 'text': ['inability'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[1935, 1944]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T100'}, {'offsets': [[1956, 1963]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T101'}, {'offsets': [[1979, 1982]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[1990, 1997]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T103'}, {'offsets': [[2100, 2109]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T104'}, {'offsets': [[2187, 2196]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T105'}, {'offsets': [[2209, 2216]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T106'}, {'offsets': [[2257, 2265]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T107'}, {'offsets': [[2272, 2279]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T108'}, {'offsets': [[2323, 2333]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[2359, 2370]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T110'}, {'offsets': [[2392, 2399]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[2429, 2437]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T112'}, {'offsets': [[2445, 2453]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T113'}, {'offsets': [[2522, 2526]], 'text': ['role'], 'type': 'Regulation', 'id': 'T114'}, {'offsets': [[2567, 2576]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T115'}, {'offsets': [[2620, 2629]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T116'}, {'offsets': [[2712, 2719]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T117'}, {'offsets': [[2747, 2757]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T118'}, {'offsets': [[2804, 2813]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T119'}, {'offsets': [[2878, 2887]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T120'}, {'offsets': [[2943, 2953]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T121'}, {'offsets': [[3096, 3105]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T122'}, {'offsets': [[3115, 3125]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T123'}]","[{'trigger': 'T70', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T71', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T72', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T73', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T7']}}, {'trigger': 'T74', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'T8']}}, {'trigger': 'T75', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T76', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T77', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T78', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T79', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'E8']}}, {'trigger': 'T80', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E8']}}, {'trigger': 'T81', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T80', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E8']}}, {'trigger': 'T81', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T82', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T19']}}, {'trigger': 'T83', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T84', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T85', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T86', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T87', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T88', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T89', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T28']}}, {'trigger': 'T89', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T29']}}, {'trigger': 'T90', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T91', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T91', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T92', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T93', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E27']}}, {'trigger': 'T94', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T93', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E27']}}, {'trigger': 'T94', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T95', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T95', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T96', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T96', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T97', 'id': 'E36', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T98', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T99', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E40']}}, {'trigger': 'T101', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T100', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T102', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'E42']}}, {'trigger': 'T103', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T104', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T105', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T106', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T107', 'id': 'E46', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T51', 'E47']}}, {'trigger': 'T108', 'id': 'E47', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T109', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T110', 'id': 'E49', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T54']}}, {'trigger': 'T111', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T112', 'id': 'E51', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E52', 'E50']}}, {'trigger': 'T113', 'id': 'E52', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T114', 'id': 'E53', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'T57']}}, {'trigger': 'T115', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T116', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T117', 'id': 'E56', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T118', 'id': 'E57', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T119', 'id': 'E58', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T120', 'id': 'E59', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T121', 'id': 'E60', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T122', 'id': 'E61', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T67']}}, {'trigger': 'T123', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T122', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T69']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E37', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E41', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E46', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E49', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E53', 'value': ''}]",[]
85,PMC-3279418-17-Materials_and_Methods,"Immunoblots
After adding stimulating ligands, 100 ng/mL LPS or 25 microg/mL poly I:C, BMDC were collected and lysed at 0-, 15-, 30-, and 60-minute time points. Immunoblots were performed with antibodies (Cell Signaling Technology) against p-IKK1/2(#2697), p-IkappaBalpha (#9246), IkappaBalpha (#4814), p-TBK1(#5483), p-p38 (#9216), p38 (#9212), p-ERK1/2 (#4376), and ERK1/2 (#4695). Beta-actin (sc-47778, Santa Cruz Biotechnology) was used as loading control.","[{'offsets': [[241, 245]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[246, 247]], 'text': ['2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[258, 270]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[280, 292]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[304, 308]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[347, 351]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[352, 353]], 'text': ['2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[367, 371]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[372, 373]], 'text': ['2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[383, 393]], 'text': ['Beta-actin'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
86,PMC-3245220-17-Materials_and_Methods,"Transient Transfection of Primary Human Monocytes
Monocytes were transfected using the human monocyte Amaxa nucleofector kit (Lonza Walkersville Inc, Walkersville, MD) as previously described [51]. Briefly, monocytes were resuspended in Amaxa Nucleofactor solution at a density of 20x106 cells/ml, and 2 microg of total plasmid DNA 100 nM of PKCalpha siRNA or control siRNA was added and transfected using program Amaxa Y-01. For co-transfection studies, PKCalpha or NF-kappaB p65 constructs were mixed at a ratio of 5:1 with the reporter plasmid. Immediately after transfection, cells were washed with 1 ml of RPMI medium containing 2 mM glutamine and 10% FBS or serum free LGM medium (Lonza Walkersville Inc.) then plated at 4x105 cells/well in 24-well plates. The original medium was replaced by serum free LGM medium without or with M-CSF (100 ng/ml) one hour later. The next day, cell-free supernatants were collected for the SEAP analysis. Cells were stained with Annexin V/propidium iodide (PI). For the inhibition studies, cells were pre-incubated with inhibitor for 30 minutes in X-vivo medium prior to the addition of M-CSF.","[{'offsets': [[342, 356]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[455, 463]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[477, 480]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[970, 979]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
87,PMC-3148254-04-Results,"HOIP mediates CD40-stimulated NF-kappaB and JNK activation
The results described above show that HOIP plays an important role in CD40-mediated effector functions of B cells. It follows that HOIP is likely a key mediator of CD40 signaling. To test this hypothesis, we stimulated A20.2J and HOIP-deficient cells with CD154 (CD40 ligand) expressed by HI5 insect cells [7], [8] and measured activation of the NF-kappaB and JNK pathways, two of the major transcriptional regulators activated by CD40 [4]. Cell-associated CD154 was used as the stimulus in these experiments as it typically provides more robust, and therefore more readily detected, activation signals than does anti-CD40 antibody. Activation of the canonical NF-kappaB pathway is initiated with the phosphorylation of IkappaB proteins by the IkappaB kinase complex (IKK). In resting cells, IkappaB proteins are responsible for sequestering NF-kappaB subunits in the cytoplasm. Phosphorylation by the IKK complex targets IkappaB proteins for ubiquitination and degradation, allowing NF-kappaB to enter the nucleus and activate gene expression. CD40-mediated phosphorylation and degradation of IkappaBalpha in HOIP-deficient cells was dramatically impaired relative to that observed in parental A20.2J cells (Fig. 4). We also assayed activation of the stress-activated protein kinase JNK in response to CD40 engagement (Fig. 4). CD40-mediated JNK activation in HOIP-deficient cells was impaired as measured by phosphorylation of Thr183 and Tyr185 in JNK. CD40-induced activation of NF-kappaB and JNK in HOIP-reconstituted cells was normal, demonstrating that the defects observed in gene-deficient cells were due to the absence of HOIP expression.","[{'offsets': [[0, 4]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 18]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[97, 101]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[129, 133]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[190, 194]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[223, 227]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 320]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[322, 333]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[490, 494]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[516, 521]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[901, 919]], 'text': ['NF-kappaB subunits'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1104, 1108]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1153, 1165]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1169, 1173]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1362, 1366]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1388, 1392]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1420, 1424]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1514, 1518]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1562, 1566]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1690, 1694]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[335, 344]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[505, 515]], 'text': ['associated'], 'type': 'Binding', 'id': 'T22'}, {'offsets': [[872, 883]], 'text': ['responsible'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[888, 900]], 'text': ['sequestering'], 'type': 'Negative_regulation', 'id': 'T24'}, {'offsets': [[1109, 1117]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[1118, 1133]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T26'}, {'offsets': [[1138, 1149]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T27'}, {'offsets': [[1174, 1183]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[1207, 1215]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[1367, 1377]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T30'}, {'offsets': [[1425, 1434]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T31'}, {'offsets': [[1567, 1580]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[1695, 1705]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T24', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T25', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T12']}}, {'trigger': 'T26', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T25', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T12']}}, {'trigger': 'T27', 'id': 'E8', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T28', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T29', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T29', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T30', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T32', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T33', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}]",[],"[{'id': '*', 'ref_ids': ['T7', 'T8']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}]",[]
88,PMC-2664230-03-MATERIALS_AND_METHODS,"Human Peripheral Blood Mononuclear Cell Isolation and Stimulation
Human mononuclear cells were isolated from the peripheral blood of four healthy human volunteers. The sample size was chosen from our previously published work, which demonstrated reliable results.10 Cell isolation and all subsequent experiments were conducted under sterile and pyrogen-free conditions. Blood collected in heparin tubes was incubated with Dextran T500 and the red cells were sedimented for 40 minutes at room temperature. The resultant serum was then washed with HBSS and separated by Percoll gradient centrifugation according to the manufacturer's instructions. Cell viability was assessed by trypan blue dye exclusion, with purity of greater than 95%. Isolated cells were resuspended in RPMI 1640 supplemented with 10% FBS and 5 mM HEPES at a concentration of 1 x 107cells/mL. Each subsequent experiment listed below was conducted on samples of 5 x 106 cells per treatment group. Isolated cells were stimulated with either HBSS as a negative control, LPS (1 mug/mL), PTX (20 mM), or concomitant LPS / PTX, at the above-mentioned concentrations, for 30 minutes at 37degreesC. Cells were placed on ice for 10 minutes to stop the reaction and the samples were then stored at -70degreesC for further analysis. The stimulation times and concentrations of LPS and PTX utilized in this study were determined in previous pilot studies done in our laboratory, which examined the effects of increasing concentrations of PTX on LPS-induced TNF-alpha production. LPS at a concentration of 1 mug/mL and PTX at a concentration of 20 mM were the minimum concentrations necessary to produce a reproducible and reliable up-regulation and down-regulation in TNF-alpha production, respectively, in quantitative assays (data not shown).","[{'offsets': [[1514, 1523]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1725, 1734]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1506, 1513]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T3'}, {'offsets': [[1524, 1534]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T4'}, {'offsets': [[1688, 1701]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[1706, 1721]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T6'}, {'offsets': [[1735, 1745]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T3', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T7', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T6', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}]",[],[],[],[]
89,PMC-3279418-08-Materials_and_Methods,"Ethics Statement
All mouse work was carried out in strict accordance with protocols approved by the Institutional Animal Care and Use Committees.",[],[],[],[],[],[]
90,PMC-2626671-01-INTRODUCTION,"Naive CD8+T cells differentiate into effector CTLs with the ability to lyse antigen-bearing target cells by exocytosis of lytic granules containing perforin and granzymes, and to produce inflammatory cytokines such as IFN-gamma and TNF upon restimulation through the TCR (1,2). In vivo experiments have elucidated many critical parameters governing the development and evolution of primary CTL responses (3,4). In this study, we have used in vitro systems such as those developed to study CD4+T cell differentiation to define the molecular basis of effector CTL differentiation (5,6).The T-box transcription factors Eomesodermin (Eomes) and T-bet are needed for important aspects of effector and memory CTL differentiation (7). In uninfected mice, compound deletion of theTbx21(encoding T-bet) andeomesodermingenes is associated with a selective loss of CD8+T cells with an IL-2Rbeta-high, memory phenotype (8). Mice deficient for both T-bet and Eomes in T cells have impaired expression of cytolytic mediators, manifest poor cytolytic activity, and fail to control acute lymphocytic choriomeningitis virus infection (9). Nevertheless, the specific roles of T-bet and Eomes in clonal expansion and CTL differentiation have not yet been resolved: in particular, it is not known whether these transcription factors function redundantly to control effector CD8+T cell differentiation, and whether they do so directly by targeting specific effector cytokine and cytolytic genes.Runx proteins, a family of three DNA-binding transcription factors, control thymocyte differentiation and the CD4/CD8 lineage decision (10-13). Runx3 and perforin mRNA are expressed by double-positive (DP) thymocytes and CD8+single-positive (SP) thymocytes but not in CD4+SP cells (14). Although Runx3 is not expressed in naive CD4+T cells, its expression is up-regulated during Th1 cell differentiation, and Runx3 influences Th1 cell differentiation and function through direct regulation of theIl4andIfngcytokine genes (15,16). In contrast, all three Runx proteins are expressed in mature CD8+T cells (10,12), and Runx3-deficient CD8+T cells show reduced cytolytic activity (12,13). We therefore tested whether Runx3 influenced cytolytic T cell differentiation.In this report, we show that Runx3 and T-box factors synergistically regulate CTL differentiation and function. T-bet is induced quickly upon TCR stimulation and is required for early programming of cytokine production (17), whereas Eomes is induced later during differentiation and sustains IFN-gamma expression. Runx3 is required for Eomes and perforin expression, and both Eomes and Runx3 bind at thePrf1locus; in contrast, perforin expression is unaffected in T-bet-deficient cells. T cells lacking Runx3 show decreased expression of IFN-gamma and granzyme B, and Runx3 also binds the promoter regions of theIfngandGzmbgenes. Collectively, these results provide evidence for a complex transcriptional network in which Runx3 is a primary regulator ofGzmbexpression but synergizes with T-bet and Eomes, respectively, to promote transcription of theIfngandPrf1genes.","[{'offsets': [[6, 9]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 156]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[218, 227]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[232, 235]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[489, 492]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[616, 628]], 'text': ['Eomesodermin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[630, 635]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[641, 646]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[772, 777]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[787, 792]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[797, 809]], 'text': ['eomesodermin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[854, 857]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[874, 883]], 'text': ['IL-2Rbeta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[936, 941]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[946, 951]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1158, 1163]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1168, 1173]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1354, 1357]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1584, 1587]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1588, 1591]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1618, 1623]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1628, 1636]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1695, 1698]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1742, 1745]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1770, 1775]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1802, 1805]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1883, 1888]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1970, 1973]], 'text': ['Il4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1976, 1980]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2065, 2068]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2090, 2095]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2106, 2109]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2187, 2192]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2266, 2271]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2349, 2354]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2470, 2475]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2529, 2538]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2551, 2556]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2573, 2578]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2583, 2591]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2613, 2618]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2623, 2628]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2640, 2644]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2664, 2672]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2701, 2706]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2740, 2745]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2775, 2784]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2789, 2799]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2805, 2810]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2849, 2853]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2856, 2860]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2959, 2964]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2990, 2994]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3025, 3030]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3035, 3040]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3087, 3091]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3094, 3098]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[179, 186]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[187, 209]], 'text': ['inflammatory cytokines'], 'type': 'Anaphora', 'id': 'T58'}, {'offsets': [[757, 765]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[917, 926]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1394, 1398]], 'text': ['they'], 'type': 'Anaphora', 'id': 'T59'}, {'offsets': [[1417, 1426]], 'text': ['targeting'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[1646, 1655]], 'text': ['expressed'], 'type': 'Transcription', 'id': 'T65'}, {'offsets': [[1783, 1792]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T66'}, {'offsets': [[1815, 1818]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T60'}, {'offsets': [[1819, 1829]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[1833, 1845]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1953, 1963]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T69'}, {'offsets': [[2096, 2105]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[2358, 2365]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[2479, 2486]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[2520, 2528]], 'text': ['sustains'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[2539, 2549]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[2560, 2568]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[2592, 2602]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[2629, 2633]], 'text': ['bind'], 'type': 'Binding', 'id': 'T77'}, {'offsets': [[2673, 2683]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T78'}, {'offsets': [[2687, 2697]], 'text': ['unaffected'], 'type': 'Regulation', 'id': 'T79'}, {'offsets': [[2707, 2716]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[2732, 2739]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[2751, 2760]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[2761, 2771]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T83'}, {'offsets': [[2816, 2821]], 'text': ['binds'], 'type': 'Binding', 'id': 'T84'}, {'offsets': [[2826, 2842]], 'text': ['promoter regions'], 'type': 'Entity', 'id': 'T85'}, {'offsets': [[2978, 2987]], 'text': ['regulator'], 'type': 'Regulation', 'id': 'T86'}, {'offsets': [[2994, 3004]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[3059, 3066]], 'text': ['promote'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[3067, 3080]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T89'}]","[{'trigger': 'T61', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T61', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T62', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T62', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T63', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T63', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T64', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T64', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T65', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T65', 'id': 'E10', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T66', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T67', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T68', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T69', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T27']}}, {'trigger': 'T69', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T29', 'T27']}}, {'trigger': 'T70', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T71', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T72', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T73', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T36']}}, {'trigger': 'T74', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T75', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T38']}}, {'trigger': 'T76', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T75', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T38']}}, {'trigger': 'T76', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T77', 'id': 'E25', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T41', 'T43']}}, {'trigger': 'T77', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T42', 'T43']}}, {'trigger': 'T78', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T79', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'E29']}}, {'trigger': 'T80', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T81', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T82', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'E30']}}, {'trigger': 'T83', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T82', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E30']}}, {'trigger': 'T83', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T84', 'id': 'E35', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T50', 'T85']}}, {'trigger': 'T84', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T51', 'T85']}}, {'trigger': 'T86', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'T52']}}, {'trigger': 'T87', 'id': 'E38', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T88', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'T54']}}, {'trigger': 'T89', 'id': 'E40', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T88', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T55']}}, {'trigger': 'T89', 'id': 'E42', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}]","[{'id': 'R1', 'head': {'ref_id': 'T58', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T58', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T16', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T17', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T60', 'role': 'Subject'}, 'tail': {'ref_id': 'T25', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T6', 'T7']}, {'id': '*', 'ref_ids': ['T9', 'T10']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}]",[]
91,PMC-1447668-15-Materials_and_Methods,"Foxp3 and HTLV-I Tax expression analysis by real-time RT-PCR.
Real-time RT-PCR analysis of Foxp3 and HTLV-I Tax expression was performed as previously described [8,47]. Briefly, total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, California, United States) according to manufacturer's guidelines, and cDNA was synthesized by reverse transcription using TaqMan Gold RT-PCR Kit using random hexamer primers (Applied Biosystems, Foster City, California, United States). Foxp3 and HTLV-I Tax mRNA expression was quantified by real-time PCR using ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The normalized values in each sample were calculated as the relative quantity of Foxp3 or HTLV-I Tax mRNA expression divided by the relative quantity of HPRT mRNA expression. The values were calculated by the following formula: normalized Foxp3 or HTLV-I Tax expression = 2Ct value of HPRT - Ct value of Foxp3 or HTLV-I Tax.","[{'offsets': [[0, 5]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 20]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[91, 96]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[108, 111]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[484, 489]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[501, 504]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[703, 708]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[719, 722]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[775, 779]], 'text': ['HPRT'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[861, 866]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[877, 880]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[907, 911]], 'text': ['HPRT'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[926, 931]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[942, 945]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[21, 31]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[112, 122]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[505, 520]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T17'}, {'offsets': [[723, 738]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T18'}, {'offsets': [[780, 795]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T19'}, {'offsets': [[881, 891]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T17', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T19', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T20', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T20', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}]",[]
92,PMC-2065877-16-Materials_and_Methods,"PCR analysis of kappa chain rearrangement.
DNA was isolated from splenocytes using the Dneasy Tissue Kit (Qiagen), with Rnase treatment. PCR reactions contained 100 ng of genomic DNA, 0.2 muM each primer, 0.2 mM dNTPs, and 2.5 U Taq DNA polymerase (NEB) performed in 1X ThermoPol buffer (NEB). Primers used were Vkappacon and Jkappa5-1degrees and have been described previously [74]. PCR conditions were 94 degreesC for 2 min, 40 cycles of 94 degreesC for 30 s, 63 degreesC for 90 s, and 72 degreesC for 1 min, followed by 1 cycle of 72 degreesC for 5 min.","[{'offsets': [[229, 247]], 'text': ['Taq DNA polymerase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
93,PMC-2065877-04-Results,"LMP1 Promotes B Cell Survival and Proliferation In Vitro
Primary B cell cultures can be maintained through CD40 ligation and supplementation with IL4 [32]. To investigate whether LMP1 affects primary B cell survival and proliferation, splenocytes were cultured in the presence or absence of IL4 and analyzed by MTS as a metabolic marker, by ethidium monoazide (EMA) exclusion for viability, and by 5-bromo-2'-deoxy-uridine (BrdU) incorporation for proliferation. In the MTS assay, as expected, splenocytes from wild-type mice did not survive even with the addition of IL4 due to a lack of CD40 ligation (Figure 3A). In contrast, LMP1 splenocytes had increased metabolism even in the absence of IL4, which was further enhanced upon addition of IL4. Wild-type and LMP1 transgenic lymphoma cells had high levels of MTS activity even in the absence of IL4 (Figure 3A). The LMP1 transgenic lymphoma cells had approximately 4-fold higher MTS activity than the normal transgenic lymphocytes and were at least 2-fold higher than the control lymphoma. As previously published, lymphoma usually develops in mice over 12 mo of age and all mice are sacrificed by 18-20 mo. The ages of the transgenic mice with or without lymphoma ranged between 6 and 20 mo old. There was no correlation between age and MTS activity.
EMA exclusion of CD19+ gated B cells prepared from two wild-type and two LMP1 transgenic mice indicated a 2-fold increase in viability in the LMP1 transgenic lymphocytes compared to wild-type lymphocytes. Two examples of LMP1 transgenic lymphoma cells had greatly increased viability that was not increased by IL4 treatment, indicating that the lymphoma cells are independent of IL4 co-stimulation (Figure 3B). Enhancement in MTS activity was observed in LMP1 transgenic lymphoma cells by the addition of IL4; however, EMA exclusion did not reveal a similar increase. This could reflect a difference for IL4 requirement in the metabolic activity versus the viability of LMP1 transgenic lymphoma cells. Although expression of LMP1 could enhance survival of non-malignant primary lymphocytes, BrdU incorporation revealed that LMP1 expression alone was not sufficient to induce proliferation in culture (unpublished data). Only lymphoma cells had detectable levels of BrdU incorporation detected by flow cytometry (Figure 3C). Interestingly, LMP1 lymphoma cells had significantly higher levels of proliferation in comparison to the spontaneous lymphoma that developed in an LMP1-negative littermate (25% versus 4%). This higher level of proliferation was observed in lymphomas that express both high (Table 1, LMP1-L2 and LMP1-L3) and low (Table 1, LMP1-L5) levels of LMP1, suggesting that even small amounts of LMP1 is sufficient to induce dramatic effects in proliferation. The level of proliferation was not enhanced upon IL4 addition, confirming the IL4 independence observed in the viability studies (Figure 3C; Table1).","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[107, 111]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[146, 149]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[179, 183]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[291, 294]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 571]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[589, 593]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[629, 633]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[694, 697]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[743, 746]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[762, 766]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[848, 851]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[869, 873]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1322, 1326]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1378, 1382]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1447, 1451]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1526, 1530]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1615, 1618]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1684, 1687]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1760, 1764]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1810, 1813]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1909, 1912]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1975, 1979]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2030, 2034]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2129, 2133]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2344, 2348]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2476, 2480]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2612, 2616]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2624, 2628]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2651, 2655]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2670, 2674]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2714, 2718]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2827, 2830]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2856, 2859]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[112, 120]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T35'}, {'offsets': [[581, 585]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[594, 602]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[683, 690]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[837, 844]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[2016, 2026]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[2134, 2144]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[2481, 2489]], 'text': ['negative'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[2584, 2591]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2597, 2601]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[2637, 2640]], 'text': ['low'], 'type': 'Positive_regulation', 'id': 'T45'}]","[{'trigger': 'T35', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T36', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T37', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T38', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T39', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T40', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T45', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}]",[]
94,PMC-1310901-15-DISCUSSION,"Many genetic lesions are known to influence gene expression of tumor suppressor genes. Whereas mutations and deletions or insertions have permanent effects, reversible mechanisms are gene methylation, or expression and activation of transcription factors, respectively. We studied a putative cause for absent IRF-4 expression in leukemia cells and first focused on genetic aberrations of the promoter. We observed no genetic alterations in the IRF-4 promoter, which can account for the lack of IRF-4 expression: The detected base pair changes at position -1081 (T to C substitution), at position -1068 (A to C substitution) and at position -116 (A to C substitution) are unlikely responsible for absent IRF-4-expression since the first two mutations were found both in IRF-4-positive and -negative cells whereas the latter change was not detected consistently in all IRF-4-negative or -positive cells and may thus be a polymorphism. All three substitutions did not change any known putative transcription factor binding sites (30,31) and also do not affect any restriction sites or primer binding sites of the used assays. However, permanent genetic variations in the IRF-4 coding sequence, such as deletions or mutations resulting in stop-codons have not been excluded by sequence analysis. Since IRF-4 expression in cell lines and CML can be induced by demethylation and successful IFN-alpha therapy (3), respectively, the existence of such genetic aberrations seems unlikely.
We then investigated whether the previously described down-regulation of IRF-4 expression in human myeloid leukemias was due to a differential hypermethylation of the promoter, since the presented re-expression due to AzadC-treatment might also be a result of activation of positive transcriptional regulators of IRF-4. Methylation of CpG sites is a common mechanism of silencing genes in leukemia and has also been shown for another IRF, IRF-7 (35) and for PU.1 (36), an interacting partner of IRF-4. To elucidate the relevance of this mechanism for the regulation of IRF-4 expression, various leukemic cells were treated with demethylating agents and promoters were sequenced after bisulfite treatment. We found that IRF-4 expression could indeed be connected to the methylation status of distinct CpG motifs in the IRF-4 promoter. In Figure 4A, those CpG sites are shown (bottom line), whose hypermethylation may account for the absence of IRF-4 expression in the respective cells. One of them (#54) is adjacent to an identified regulatory element (NFkappaB-site), indicating a possible involvement of this site. At two further CpG sites (#48, 45) the methylation status in IRF-4-positive was lower than that of IRF-4-negative cells. These CpG sites are located in an NFkappaB and an SP1 element (31) and thus may also play a role in regulation of IRF-4 expression. It has been shown that NFkappaB elements play an important role in IRF-4 induction as IRF-4 expression depends on binding of the transactivator c-Rel to these elements in the IRF-4 promoter (31,37). Furthermore, methylation of the central CpG in the NFkappaB element inhibits binding of the NFkappaB protein complexes (38), promoting the significance of the observed methylation differences in IRF-4-positive and -negative cells.
Via in vitro methylation and reporter gene assays we could clearly appoint the silencing of the IRF-4 promoter to a methylation effect, which may thus be the mechanism of IRF-4 deregulation in vivo. One possible cause for the aberrant methylation in tumorigenesis is an increased level of DNMTs during the pathogenetic process. In colon, lung and hematologic malignancies, overexpression of DNMT1, a maintenance DNMT, has been detected (39-41). Furthermore, it has been shown that CML cells in the acute phase exhibited elevated levels of the three known DNMTs, while CML cells in chronic phase expressed normal levels of DNMTs if compared with normal bone marrow cells (25). Interestingly, a positive correlation between DNMT1 expression levels and hypermethylation of p15INK4b has been detected in AML (25). In this work, we did not detect significant mRNA expression differences of selected DNMT or MBP, making it an unlikely cause for the observed methylation and thus IRF-4 expression differences in leukemia cells.
The finding that IRF-4 expression is silenced by promoter hypermethylation might represent a mechanism that accounts for the previously observed loss of IRF-4 expression in CML. Indeed, several clinical trials with leukemia patients and patients with myelodysplastic syndromes demonstrated the potential clinical benefit of a treatment with demethylating agents (42-45).
The expression of another IRF, IFN consensus sequence binding protein (ICSBP/IRF-8), is impaired in myeloid leukemias especially CML (27,46,47). But in contrast to IRF-4, the loss of this IRF could not be reverted in ICSBP-negative cell lines (EM-2, CML-T1, K-562 and LAMA-84) by treatment with AzadC (Figure 6) and AzadC has no effect on ICSBP levels in ICSBP-positive U-937 cells (Figure 6). These data suggest a distinct regulatory mechanism for these two IRFs.
IRF-4, similar to many other classical tumor suppressor genes p15INK4b, p16INK4a or p53, may thus be a subject of alterations in the promoter methylation status leading to expression changes, which might contribute to the initiation and/or progression of cancer. Still, the obvious functional diversity of IRF-4 remains remarkable and cannot be fully explained by the IRF-4 promoter methylation status. For example, IRF-4 is primarily known for its oncogenic features. In multiple myeloma (MM) a translocation on chromosome 14q was reported to lead to a fusion gene of immunoglobulin heavy-chain (IgH) and IRF-4 resulting in a subsequent overexpression of IRF-4 (48,49). In addition, abundant IRF-4 expression was found to be a marker for various subsets of lymphomas, such as diffuse large B-cell lymphomas, primary effusion lymphoma, and marginal zone lymphoma, and adult T-cell leukemia (11,31,50-52). This draws a more complex picture of the role of IRF-4. Down-regulation of IRF-4 may promote leukemogenesis in myeloid cell context (3), which was recently confirmed in IRF-4-/- ICSBP-/- double knock-out mice (53), while IRF-4 up-regulation may induce a growth advantage in lymphomas or MM (48).
Taken together, our data suggest that IRF-4 promoter methylation regulates IRF-4 expression, and that aberrant expression of IRF-4 in certain types of leukemia may be a consequence of IRF-4 promoter hypermethylation.","[{'offsets': [[309, 314]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[444, 449]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[494, 499]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[703, 708]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[769, 774]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[867, 872]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1168, 1173]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1298, 1303]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1384, 1393]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1552, 1557]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1792, 1797]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1918, 1923]], 'text': ['IRF-7'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1937, 1941]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1974, 1979]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2048, 2053]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2198, 2203]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2297, 2302]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2422, 2427]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2656, 2661]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2694, 2699]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2830, 2835]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2915, 2920]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2934, 2939]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2992, 2997]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3023, 3028]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3242, 3247]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3374, 3379]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3449, 3454]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3669, 3674]], 'text': ['DNMT1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4000, 4005]], 'text': ['DNMT1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4048, 4056]], 'text': ['p15INK4b'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4251, 4256]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4316, 4321]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4452, 4457]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4701, 4739]], 'text': ['IFN consensus sequence binding protein'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4741, 4746]], 'text': ['ICSBP'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4747, 4752]], 'text': ['IRF-8'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4834, 4839]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4887, 4892]], 'text': ['ICSBP'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[5009, 5014]], 'text': ['ICSBP'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[5025, 5030]], 'text': ['ICSBP'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[5135, 5140]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[5197, 5205]], 'text': ['p15INK4b'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5207, 5215]], 'text': ['p16INK4a'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5219, 5222]], 'text': ['p53'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5441, 5446]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5503, 5508]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5551, 5556]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5704, 5730]], 'text': ['immunoglobulin heavy-chain'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5732, 5735]], 'text': ['IgH'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5741, 5746]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5791, 5796]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5828, 5833]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6089, 6094]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6115, 6120]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6209, 6214]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[6218, 6223]], 'text': ['ICSBP'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[6261, 6266]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[6374, 6379]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[6411, 6416]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[6461, 6466]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[6520, 6525]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[302, 308]], 'text': ['absent'], 'type': 'Negative_regulation', 'id': 'T65'}, {'offsets': [[315, 325]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T66'}, {'offsets': [[486, 490]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T67'}, {'offsets': [[500, 510]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T68'}, {'offsets': [[680, 691]], 'text': ['responsible'], 'type': 'Positive_regulation', 'id': 'T69'}, {'offsets': [[696, 702]], 'text': ['absent'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[709, 719]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T71'}, {'offsets': [[775, 783]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[789, 797]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T73'}, {'offsets': [[873, 881]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[886, 894]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[965, 971]], 'text': ['change'], 'type': 'Regulation', 'id': 'T76'}, {'offsets': [[991, 1025]], 'text': ['transcription factor binding sites'], 'type': 'Entity', 'id': 'T77'}, {'offsets': [[1050, 1056]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[1061, 1078]], 'text': ['restriction sites'], 'type': 'Entity', 'id': 'T79'}, {'offsets': [[1082, 1102]], 'text': ['primer binding sites'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[1304, 1314]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[1344, 1351]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[1533, 1548]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[1558, 1568]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[1600, 1603]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T85'}, {'offsets': [[1676, 1689]], 'text': ['re-expression'], 'type': 'Gene_expression', 'id': 'T86'}, {'offsets': [[1729, 1735]], 'text': ['result'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1951, 1962]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T88'}, {'offsets': [[2034, 2044]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[2054, 2064]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[2204, 2214]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[2395, 2402]], 'text': ['account'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[2411, 2418]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[2428, 2438]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[2662, 2670]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[2808, 2812]], 'text': ['role'], 'type': 'Regulation', 'id': 'T96'}, {'offsets': [[2816, 2826]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[2836, 2846]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T98'}, {'offsets': [[2871, 2888]], 'text': ['NFkappaB elements'], 'type': 'Entity', 'id': 'T99'}, {'offsets': [[2897, 2911]], 'text': ['important role'], 'type': 'Regulation', 'id': 'T100'}, {'offsets': [[2921, 2930]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[2940, 2950]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[2951, 2958]], 'text': ['depends'], 'type': 'Positive_regulation', 'id': 'T103'}, {'offsets': [[2962, 2969]], 'text': ['binding'], 'type': 'Binding', 'id': 'T104'}, {'offsets': [[3001, 3015]], 'text': ['these elements'], 'type': 'Anaphora', 'id': 'T63'}, {'offsets': [[3087, 3090]], 'text': ['CpG'], 'type': 'Entity', 'id': 'T105'}, {'offsets': [[3098, 3114]], 'text': ['NFkappaB element'], 'type': 'Entity', 'id': 'T106'}, {'offsets': [[3115, 3123]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T107'}, {'offsets': [[3124, 3131]], 'text': ['binding'], 'type': 'Binding', 'id': 'T108'}, {'offsets': [[3248, 3256]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[3262, 3270]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T110'}, {'offsets': [[3357, 3366]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[3380, 3388]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T112'}, {'offsets': [[3455, 3467]], 'text': ['deregulation'], 'type': 'Regulation', 'id': 'T113'}, {'offsets': [[3651, 3665]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T114'}, {'offsets': [[4006, 4016]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T115'}, {'offsets': [[4257, 4267]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T116'}, {'offsets': [[4322, 4332]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[4444, 4448]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T118'}, {'offsets': [[4458, 4468]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T119'}, {'offsets': [[4674, 4684]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T120'}, {'offsets': [[4758, 4766]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T121'}, {'offsets': [[4845, 4849]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T122'}, {'offsets': [[4853, 4861]], 'text': ['this IRF'], 'type': 'Anaphora', 'id': 'T64'}, {'offsets': [[4875, 4883]], 'text': ['reverted'], 'type': 'Negative_regulation', 'id': 'T123'}, {'offsets': [[4893, 4901]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T124'}, {'offsets': [[4999, 5005]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T125'}, {'offsets': [[5015, 5021]], 'text': ['levels'], 'type': 'Gene_expression', 'id': 'T126'}, {'offsets': [[5031, 5039]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T127'}, {'offsets': [[5307, 5317]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T128'}, {'offsets': [[5318, 5325]], 'text': ['changes'], 'type': 'Regulation', 'id': 'T129'}, {'offsets': [[5747, 5756]], 'text': ['resulting'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[5773, 5787]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T131'}, {'offsets': [[5834, 5844]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T132'}, {'offsets': [[6096, 6111]], 'text': ['Down-regulation'], 'type': 'Negative_regulation', 'id': 'T133'}, {'offsets': [[6234, 6243]], 'text': ['knock-out'], 'type': 'Gene_expression', 'id': 'T134'}, {'offsets': [[6267, 6280]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[6401, 6410]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T136'}, {'offsets': [[6417, 6427]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T137'}, {'offsets': [[6447, 6457]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T138'}, {'offsets': [[6505, 6516]], 'text': ['consequence'], 'type': 'Positive_regulation', 'id': 'T139'}]","[{'trigger': 'T65', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T66', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T67', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T68', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T69', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T70', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T71', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T72', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T73', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T74', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T75', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T76', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T77']}}, {'trigger': 'T78', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T79']}}, {'trigger': 'T78', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T80']}}, {'trigger': 'T81', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T82', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T9']}}, {'trigger': 'T83', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T84', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T85', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T86', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T87', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T88', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T14']}}, {'trigger': 'T89', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T90', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T91', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T92', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T93', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T94', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T95', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T96', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T97', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T98', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T100', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E34', 'T25', 'T99']}}, {'trigger': 'T101', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T102', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T103', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E37']}}, {'trigger': 'T104', 'id': 'E37', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T24', 'T25', 'T99']}}, {'trigger': 'T107', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E39', 'T25', 'T105']}}, {'trigger': 'T108', 'id': 'E39', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T106']}}, {'trigger': 'T109', 'id': 'E40', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T110', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T111', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T27', 'T112']}}, {'trigger': 'T113', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T114', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T115', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T116', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T117', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T118', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T119', 'id': 'E49', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T120', 'id': 'E50', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T121', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E50']}}, {'trigger': 'T122', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T123', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E52']}}, {'trigger': 'T124', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T125', 'id': 'E55', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T126', 'id': 'E56', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T127', 'id': 'E57', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T128', 'id': 'E58', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T129', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T130', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E61']}}, {'trigger': 'T131', 'id': 'E61', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T132', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T133', 'id': 'E63', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T134', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T134', 'id': 'E65', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T135', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T136', 'id': 'E67', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E68']}}, {'trigger': 'T137', 'id': 'E68', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T138', 'id': 'E69', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T139', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E69']}}]","[{'id': 'R1', 'head': {'ref_id': 'T63', 'role': 'Subject'}, 'tail': {'ref_id': 'T99', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T64', 'role': 'Subject'}, 'tail': {'ref_id': 'T35', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T35', 'T36', 'T37']}, {'id': '*', 'ref_ids': ['T49', 'T50']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E19', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E26', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E30', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E41', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E43', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E53', 'value': ''}, {'id': 'M14', 'type': 'Negation', 'ref_id': 'E54', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E55', 'value': ''}, {'id': 'M16', 'type': 'Negation', 'ref_id': 'E64', 'value': ''}, {'id': 'M17', 'type': 'Negation', 'ref_id': 'E65', 'value': ''}, {'id': 'M18', 'type': 'Speculation', 'ref_id': 'E67', 'value': ''}, {'id': 'M19', 'type': 'Speculation', 'ref_id': 'E70', 'value': ''}]",[]
95,PMC-2889865-25-Caption-Table_2,"Jurkat T-cells were treated with 10 nM NAI, 10 muM JNK-I or10 nM PKC-I for 2 h followed by induction with 162 nM PMA for 24 h.",[],[],[],[],[],[]
96,PMC-1447668-03-Results,"The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells
To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.","[{'offsets': [[130, 135]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[225, 230]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[301, 306]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[329, 334]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[401, 406]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[532, 547]], 'text': ['deltaFKH mutant'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[682, 697]], 'text': ['deltaFKH mutant'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[794, 799]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[868, 873]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[982, 987]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1138, 1143]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1156, 1164]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1279, 1284]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1289, 1297]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1503, 1508]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1643, 1648]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1653, 1661]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1710, 1713]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1771, 1774]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1804, 1809]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1814, 1822]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1875, 1878]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1962, 1967]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2093, 2098]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2212, 2220]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2354, 2359]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[231, 238]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[243, 253]], 'text': ['FKH domain'], 'type': 'Entity', 'id': 'T29'}, {'offsets': [[408, 413]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T27'}, {'offsets': [[414, 423]], 'text': ['localizes'], 'type': 'Localization', 'id': 'T30'}, {'offsets': [[450, 457]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T31'}, {'offsets': [[466, 470]], 'text': ['bind'], 'type': 'Binding', 'id': 'T32'}, {'offsets': [[557, 565]], 'text': ['localize'], 'type': 'Localization', 'id': 'T33'}, {'offsets': [[573, 580]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T34'}, {'offsets': [[597, 605]], 'text': ['interact'], 'type': 'Binding', 'id': 'T35'}, {'offsets': [[719, 726]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T36'}, {'offsets': [[727, 739]], 'text': ['localization'], 'type': 'Localization', 'id': 'T37'}, {'offsets': [[874, 885]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T38'}, {'offsets': [[999, 1003]], 'text': ['bind'], 'type': 'Binding', 'id': 'T39'}, {'offsets': [[1038, 1045]], 'text': ['prevent'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1046, 1058]], 'text': ['localization'], 'type': 'Localization', 'id': 'T41'}, {'offsets': [[1066, 1073]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T42'}, {'offsets': [[1074, 1083]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[1108, 1122]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[1303, 1312]], 'text': ['expressed'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[1333, 1342]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[1775, 1785]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[1832, 1837]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[1887, 1897]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[2051, 2058]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[2059, 2071]], 'text': ['localization'], 'type': 'Localization', 'id': 'T51'}, {'offsets': [[2196, 2208]], 'text': ['localization'], 'type': 'Localization', 'id': 'T52'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T29']}}, {'trigger': 'T30', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T31']}}, {'trigger': 'T32', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T33', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T34']}}, {'trigger': 'T35', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T37', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T36']}}, {'trigger': 'T38', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T39', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T40', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E8']}}, {'trigger': 'T41', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T10', 'T42']}}, {'trigger': 'T43', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T44', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T44', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T45', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T45', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T46', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T46', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T47', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T48', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T20']}}, {'trigger': 'T49', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T48', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T21']}}, {'trigger': 'T51', 'id': 'E22', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T50']}}, {'trigger': 'T52', 'id': 'E23', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}]","[{'id': 'R1', 'head': {'ref_id': 'T27', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E21', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}]",[]
97,PMC-2626671-13-MATERIALS_AND_METHODS,"Retroviral transduction of primary CD8+ T cells.
For transduction experiments, viral supernatants were generated by calcium phosphate transfection of Phoenix cells and concentration by overnight centrifugation at 6,000 g. At ~42 h after the initial TCR activation of 106 CD8+ T cells per well in 12-well plates, the culture media was removed and replaced with complete media supplemented with 8 mug/ml polybrene containing fresh plus concentrated virus. The plates were centrifuged at 700 g for 1 h at RT before returning to 37degreesC for an additional 5 h. Retroviral constructs for Eomes-VP16 and the MIG control empty vector were a gift from S.L. Reiner (University of Pennsylvania, Philadelphia, PA) (8).","[{'offsets': [[271, 274]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[585, 595]], 'text': ['Eomes-VP16'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
98,PMC-2889865-13-Materials_and_methods,"Western blot analysis
Following stimulation, Jurkat T-cells were centrifuged at 1000 x g for 8 min and lysed on ice for 2 h using sodium hydroxide with the addition of a protease inhibitor cocktail (Roche, Mannheim). The cells were further centrifuged at 8000 x g, 4degreesC for 10 min and the supernatants were transferred to new tubes. Cytoplasmic proteins (~8 mug) were separated by SDS-PAGE (10%) followed by western blotting using anti-IkappaBbeta, phospho-PKC (pan)(zeta Thr410)(190D10), anti-Bcl10 (Cell Signalling Technology, Boston) and beta-actin (Abcam, Cambridge). Detection was performed following incubation with ECL(TM) Anti-rabbit IgG, horseradish peroxidase linked whole antibodies (Amersham Biosciences, Buckinghamshire) and developed using ECL(TM) Western Blotting Detection Reagents (GE Healthcare, UK).","[{'offsets': [[546, 556]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
99,PMC-2065877-23-Caption-Figure_5,"LMP1 Upregulates IL10 Expression and Constitutively Activates Stat3
(A) Relative expression of IL10, IL15, and IFNgamma mRNA in WT and LMP1 transgenic B cells (CD19+), as detected with an Rnase protection assay. Mouse lymphoma cell lines 967 and K46mu were used as controls. Expression levels were quantified with a phosphorimager and values were normalized to the ribosomal housekeeping gene L32. The cytokine:L32 ratio was set to 1 in the mouse B cell lymphoma line 967.
(B and C) Immunoblot analysis of activated pStat3 in purified B cells (CD19+) from WT and LMP1 transgenic mice (B) at the time of harvest, and (C) 4 h after culture with or without IL10, a neutralizing antibody to IL10, or a rat IgG1 isotype control. (C) Shown are the results for WT lymphoma 1 and LMP1 transgenic lymphoma 1. Arrows indicate the positions of the alpha and beta isoforms of Stat3. Actin was used as a loading control.
(D) Immunohistochemistry detection of activated nuclear pStat3 in the spleens of WT and LMP1 transgenic mice. Scale bar, 20 mum.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 21]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[62, 67]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[95, 99]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[101, 105]], 'text': ['IL15'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[111, 119]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[135, 139]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[160, 164]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[393, 396]], 'text': ['L32'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[411, 414]], 'text': ['L32'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[516, 522]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[544, 548]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[563, 567]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[654, 658]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[687, 691]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[772, 776]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[864, 869]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[964, 970]], 'text': ['pStat3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[996, 1000]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[5, 16]], 'text': ['Upregulates'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[22, 32]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[52, 61]], 'text': ['Activates'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[81, 91]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T23'}, {'offsets': [[506, 515]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[946, 955]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T25'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T1']}}, {'trigger': 'T23', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T23', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T24', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}]",[]
100,PMC-2791889-09-Discussion,"IL-10 expression by cells of the innate and adaptive immune systems reflects the importance of this cytokine in the tight regulation of the immune response, to minimize pathology during infection. IL-10 expression by Th1 cells has been reported to regulate the immune response in leishmaniasis and toxoplasmosis. However, in many situations, IL-10 is not produced by Th1 cells in response to antigenic stimulation. Our goal was to address the molecular signals that determine whether Th1 cells develop to produce IL-10 (Trinchieri, 2007). Here, we showed that Th1 cells required high-antigen-dose-induced ERK1 and ERK2 phosphorylation and IL-12-induced STAT-4 activation to produce IL-10. Our findings that ERK1 and ERK2 activation was a common pathway required for the production of IL-10 by Th1, Th2, and Th17 cell subsets, which differentiate along distinct pathways, such that IL-10 provides a highly regulated feedback loop to avoid the extremes of excessive inflammation or chronic infections and also allow a protective response to diverse pathogens.
In certain viral or parasitic infections (Anderson et al., 2007; Brooks et al., 2006; Ejrnaes et al., 2006), high amounts of stimulation may lead to the chronic nonhealing infection shown to be regulated by IL-10. During the course of infection, after initial triggering with antigen, T cells migrate to the tissue encountering high doses of antigen and factors produced by the innate immune response. Under these conditions, we speculate that Th1 cells will be induced to express high amounts of IL-10, in keeping with reports that IL-10-producing Th1 cells were found in CD4+ clones isolated from BAL but not blood of TB patients (Gerosa et al., 1999). Similarly, the immune response to a clinical isolate of L. major, which produces heavily infected nonhealing lesions, was found to be regulated by IL-10 derived from Foxp3- Th1 cells that coproduce IL-10 and IFN-gamma (Anderson et al., 2007), and the immune response during T. gondii infection was found also to be regulated by Foxp3- Th1 cells (Jankovic et al., 2007). It is likely that IL-10 production by Th1 cells is evoked under conditions of high inflammation and antigenic stimulation, whereas regulatory CD4+ T cells producing IL-10 may operate to regulate the immune response under conditions in which the pathogen is clinically controlled, such as in infection with L. major (Friedlin strain) (Belkaid et al., 2002; Suffia et al., 2006). We now also reported that CD4+ T cells cultured with high antigen dose and IL-12 differentiate into canonical Th1 effector cells, which, in addition to expressing large amounts of IFN-gamma and IL-10, lose their IL-2 expression as described before in certain chronic infection models (Sallusto et al., 2004). Our demonstration that loss of IL-2 is accompanied by production of IL-10 offers potential additional mechanisms whereby effector T cell responses may be dampened during chronic disease.
Using an in vivo transfer model of DO11.10 TCR transgenic cells (Castro et al., 2000), we showed that IL-10-producing Th1 cells were differentiated in the presence of high doses of OVA protein and LPS. We showed here that this induction of IL-10 in Th1 cells in vivo was markedly, but not totally, reduced in STAT4-deficient T cells as observed during T. gondii infection (Jankovic et al., 2002). A high antigenic activation during T. gondii infection or high antigen doses delivered in the presence of LPS, as seen in our system, may compensate for an absolute requirement for IL-12 in the induction of IL-10 by Th1 cells.
In our in vitro system, repeated stimulation of Th1 cells with high antigen doses allowed the development of Th1 cells producing IL-10 in an IL-12-dependent manner. IL-10 production by Th1 cells induced by high antigen dose and IL-12 was independent of IFN-gamma, in keeping with previous findings (Jankovic et al., 2002). However, a role for IFN-gamma in mediating IL-10 reactivation by Th1 cells during secondary infection with T. gondii has been suggested (Shaw et al., 2006). We have found that CD4+ T cells exposed to a high dose of antigen do not express IL-10 upon restimulation, but can be induced to produce IL-10 upon re-exposure to a high dose of antigen in the recall phase in the absence of added IL-12. However, this is dependent on the induction of IL-12 by antigen-presenting DCs. The combination of both high antigen dose and IL-12 resulted in the highest levels of IL-10 production and correlated with the high levels of ERK1 and ERK2 activation. The increased expression of IFN-gamma observed during the secondary phase will induce increased IL-12 production by DCs and suggests that repeated high-level TCR activation feeds back to upregulate IL-12 production by DC. It is thus likely that in T. gondii infection in vivo (Shaw et al., 2006), the requirement for IFN-gamma to induce IL-10, was for feedback upregulation of IL-12 by DCs, which in turn induced IL-10 in the Th1 cells.
Although IL-10 may be differentially regulated in Th1 and Th2 cells as has been reported (Chang et al., 2007; Wang et al., 2005), some studies suggest the existence of common pathways, but the molecular basis for these is as yet unclear. Costimulatory OX-40 signals have been shown to negatively regulate IL-10 production (Ito et al., 2005) both in Th1 and Th2 cells, whereas ICOS signaling has been suggested to induce IL-10 (Ito et al., 2007; Witsch et al., 2002) in both Th1 and Th2 cells. However, in some cases, ICOS signaling also regulates IL-4 production and Th2 responses (Greenwald et al., 2005). We now provide a common mechanism of ERK1 and ERK2 activation for the regulation of IL-10 production in Th1, Th2, and Th17 cells, although each subset differentiates along a distinct and subset-specific transcriptional pathway. This reinforces the fact that IL-10 is not a Th cell-subset-specific cytokine, but instead is produced in a tightly regulated fashion during each differentiation pathway. Of note, a role for ERK1 and ERK2 activation in the induction of IL-10 production has already been described for macrophages and DC (Agrawal et al., 2006; Hacker et al., 1999).
Differential transcriptional regulation of IL-10 in Th1 and Th2 cells has been suggested (Chang et al., 2007; Wang et al., 2005), and extensive histone acetylation of the IL-10 gene is detectable in fully polarized Th2 cells, but not Th1 cells (Chang et al., 2007). We provide evidence that IL-10 is produced in canonical Th1 cells and that its expression correlates with the expression of T-bet and the highest IFN-gamma production, in keeping with our observations that high-dose antigen stimulation and IL-12 signaling are required for IL-10 and IFN-gamma expression. It has also been shown that maintenance of IL-10 expression is conditional on IL-12 or IL-4 unless the IL-10 gene is imprinted by GATA-3 (Chang et al., 2007), which can remodel the IL-10 locus, thus explaining the highest amounts of IL-10 produced by Th2 cells (Chang et al., 2007; Shoemaker et al., 2006). We show here that high antigen dose and IL-12 drastically downregulate Gata-3 expression, suggesting that additional factors are in place to induce IL-10 expression in Th1 cells, albeit transiently. Expression of c-maf was greatly diminished by high antigen doses in T cells and yet was unexpectedly maintained by IL-12 and present in Th17 cells. That c-maf expression is common to IL-10-producing Th1, Th2, and Th17 cells and, like IL-10, is dependent on ERK activation in Th1 and Th17 cells for its expression is of interest because c-Maf has been shown to be an essential transcription factor for IL-10 expression in macrophages (Cao et al., 2005).
In summary, we show that although Th1, Th2, and Th17 CD4+ T cell subsets differentiate along distinct signaling and transcriptional pathways, they can all be induced to make IL-10. ERK1 and ERK2 activation is required for IL-10 production by all these Th cell subsets. With regard to the expression of IL-10 by Th1 cells, our data provide a mechanism for how IL-10 expression is induced and then amplified and regulated by the levels of antigen and IL-12 encountered in the environment. This provides a mechanism whereby a Th1 cell responds to extrinsic signals, reflecting increased inflammation in the tissue, to tightly regulate the production of IL-10 so as to allow a protective response to eradicate a pathogen with minimal damage to the host and also prevent chronic infection. Moreover, our findings have important implications for the regulation of IL-10 production during an inflammatory Th1 response in infection and may be of relevance for the design of vaccines and for strategies in immunotherapy in infectious diseases.","[{'offsets': [[0, 5]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[197, 202]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[342, 347]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[513, 518]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[605, 609]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[614, 618]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[639, 644]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[653, 659]], 'text': ['STAT-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[682, 687]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[707, 711]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[716, 720]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[784, 789]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[881, 886]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1265, 1270]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1555, 1560]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1591, 1596]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1631, 1634]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1860, 1865]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1879, 1884]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1911, 1916]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1921, 1930]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2041, 2046]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2101, 2106]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2225, 2228]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2248, 2253]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2487, 2490]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2536, 2541]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2641, 2650]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2655, 2660]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2673, 2677]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2801, 2805]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2838, 2843]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3059, 3064]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3138, 3141]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3197, 3202]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3266, 3271]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3535, 3540]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3561, 3566]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3710, 3715]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3722, 3727]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3746, 3751]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3809, 3814]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3834, 3843]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3924, 3933]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3947, 3952]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4080, 4083]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4142, 4147]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4198, 4203]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4291, 4296]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4345, 4350]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4424, 4429]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4464, 4469]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4520, 4524]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4529, 4533]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4574, 4583]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4642, 4647]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4744, 4749]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4863, 4872]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4883, 4888]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4923, 4928]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4959, 4964]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4992, 4997]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5235, 5240]], 'text': ['OX-40'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[5288, 5293]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[5359, 5363]], 'text': ['ICOS'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5403, 5408]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5500, 5504]], 'text': ['ICOS'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5530, 5534]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5627, 5631]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5636, 5640]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5674, 5679]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5848, 5853]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[6009, 6013]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[6018, 6022]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[6054, 6059]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[6209, 6214]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[6310, 6317]], 'text': ['histone'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[6337, 6342]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[6457, 6462]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[6556, 6561]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[6578, 6587]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[6672, 6677]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[6705, 6710]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[6715, 6724]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[6780, 6785]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[6815, 6820]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[6824, 6828]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[6840, 6845]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[6867, 6873]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[6918, 6923]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[6970, 6975]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[7084, 7089]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[7115, 7121]], 'text': ['Gata-3'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[7192, 7197]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[7257, 7262]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[7358, 7363]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[7396, 7401]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[7426, 7431]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[7477, 7482]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[7500, 7503]], 'text': ['ERK'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[7579, 7584]], 'text': ['c-Maf'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[7644, 7649]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[7749, 7752]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[7870, 7875]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[7877, 7881]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[7886, 7890]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[7918, 7923]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[7998, 8003]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[8055, 8060]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[8145, 8150]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[8346, 8351]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[8554, 8559]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[6, 16]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T116'}, {'offsets': [[203, 213]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[355, 363]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T118'}, {'offsets': [[377, 391]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T119'}, {'offsets': [[505, 512]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T120'}, {'offsets': [[570, 578]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T121'}, {'offsets': [[619, 634]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T122'}, {'offsets': [[645, 652]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T123'}, {'offsets': [[660, 670]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T124'}, {'offsets': [[674, 681]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T125'}, {'offsets': [[721, 731]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T126'}, {'offsets': [[753, 761]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T127'}, {'offsets': [[770, 780]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T128'}, {'offsets': [[887, 928]], 'text': ['provides a highly regulated feedback loop'], 'type': 'Regulation', 'id': 'T129'}, {'offsets': [[1520, 1527]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[1531, 1538]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T131'}, {'offsets': [[1597, 1606]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T132'}, {'offsets': [[1901, 1910]], 'text': ['coproduce'], 'type': 'Gene_expression', 'id': 'T133'}, {'offsets': [[2107, 2117]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T134'}, {'offsets': [[2238, 2247]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T135'}, {'offsets': [[2613, 2623]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T136'}, {'offsets': [[2662, 2666]], 'text': ['lose'], 'type': 'Negative_regulation', 'id': 'T137'}, {'offsets': [[2678, 2688]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T138'}, {'offsets': [[2793, 2797]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T139'}, {'offsets': [[2824, 2834]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T140'}, {'offsets': [[3184, 3193]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T141'}, {'offsets': [[3255, 3262]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T142'}, {'offsets': [[3272, 3281]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T143'}, {'offsets': [[3519, 3530]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T144'}, {'offsets': [[3548, 3557]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T145'}, {'offsets': [[3700, 3709]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T146'}, {'offsets': [[3752, 3762]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T147'}, {'offsets': [[3776, 3783]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T148'}, {'offsets': [[3819, 3830]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T149'}, {'offsets': [[3937, 3946]], 'text': ['mediating'], 'type': 'Positive_regulation', 'id': 'T150'}, {'offsets': [[3953, 3965]], 'text': ['reactivation'], 'type': 'Positive_regulation', 'id': 'T151'}, {'offsets': [[4134, 4141]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T152'}, {'offsets': [[4179, 4186]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T153'}, {'offsets': [[4190, 4197]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T154'}, {'offsets': [[4307, 4311]], 'text': ['this'], 'type': 'Anaphora', 'id': 'T113'}, {'offsets': [[4315, 4324]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T155'}, {'offsets': [[4332, 4341]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T156'}, {'offsets': [[4430, 4438]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T157'}, {'offsets': [[4470, 4480]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T158'}, {'offsets': [[4534, 4544]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T159'}, {'offsets': [[4550, 4559]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T160'}, {'offsets': [[4560, 4570]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T161'}, {'offsets': [[4625, 4631]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T162'}, {'offsets': [[4632, 4641]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T163'}, {'offsets': [[4648, 4658]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T164'}, {'offsets': [[4733, 4743]], 'text': ['upregulate'], 'type': 'Positive_regulation', 'id': 'T165'}, {'offsets': [[4750, 4760]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T166'}, {'offsets': [[4847, 4858]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T167'}, {'offsets': [[4876, 4882]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T168'}, {'offsets': [[4907, 4919]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T169'}, {'offsets': [[4951, 4958]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T170'}, {'offsets': [[5020, 5029]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T171'}, {'offsets': [[5268, 5287]], 'text': ['negatively regulate'], 'type': 'Negative_regulation', 'id': 'T172'}, {'offsets': [[5294, 5304]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T173'}, {'offsets': [[5396, 5402]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T174'}, {'offsets': [[5520, 5529]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T175'}, {'offsets': [[5535, 5545]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T176'}, {'offsets': [[5641, 5651]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T177'}, {'offsets': [[5660, 5670]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T178'}, {'offsets': [[5680, 5690]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T179'}, {'offsets': [[5912, 5920]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T180'}, {'offsets': [[5934, 5943]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T181'}, {'offsets': [[6000, 6004]], 'text': ['role'], 'type': 'Regulation', 'id': 'T182'}, {'offsets': [[6023, 6033]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T183'}, {'offsets': [[6041, 6050]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T184'}, {'offsets': [[6060, 6070]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T185'}, {'offsets': [[6195, 6205]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T186'}, {'offsets': [[6466, 6474]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T187'}, {'offsets': [[6507, 6510]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T114'}, {'offsets': [[6511, 6521]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T188'}, {'offsets': [[6542, 6552]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T189'}, {'offsets': [[6588, 6598]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T190'}, {'offsets': [[6692, 6700]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T191'}, {'offsets': [[6725, 6735]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T192'}, {'offsets': [[6765, 6776]], 'text': ['maintenance'], 'type': 'Positive_regulation', 'id': 'T193'}, {'offsets': [[6786, 6796]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T194'}, {'offsets': [[6800, 6811]], 'text': ['conditional'], 'type': 'Positive_regulation', 'id': 'T195'}, {'offsets': [[6976, 6984]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T196'}, {'offsets': [[7102, 7114]], 'text': ['downregulate'], 'type': 'Negative_regulation', 'id': 'T197'}, {'offsets': [[7122, 7132]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T198'}, {'offsets': [[7185, 7191]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T199'}, {'offsets': [[7198, 7208]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T200'}, {'offsets': [[7243, 7253]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T201'}, {'offsets': [[7275, 7285]], 'text': ['diminished'], 'type': 'Negative_regulation', 'id': 'T202'}, {'offsets': [[7344, 7354]], 'text': ['maintained'], 'type': 'Positive_regulation', 'id': 'T203'}, {'offsets': [[7402, 7412]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T204'}, {'offsets': [[7432, 7441]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T205'}, {'offsets': [[7487, 7496]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T206'}, {'offsets': [[7504, 7514]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T207'}, {'offsets': [[7541, 7544]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T115'}, {'offsets': [[7545, 7555]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T208'}, {'offsets': [[7609, 7618]], 'text': ['essential'], 'type': 'Positive_regulation', 'id': 'T209'}, {'offsets': [[7650, 7660]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T210'}, {'offsets': [[7854, 7861]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T211'}, {'offsets': [[7865, 7869]], 'text': ['make'], 'type': 'Gene_expression', 'id': 'T212'}, {'offsets': [[7891, 7901]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T213'}, {'offsets': [[7905, 7913]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T214'}, {'offsets': [[7924, 7934]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T215'}, {'offsets': [[7984, 7994]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T216'}, {'offsets': [[8061, 8071]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T217'}, {'offsets': [[8075, 8082]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T218'}, {'offsets': [[8092, 8101]], 'text': ['amplified'], 'type': 'Positive_regulation', 'id': 'T219'}, {'offsets': [[8106, 8115]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T220'}, {'offsets': [[8319, 8327]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T221'}, {'offsets': [[8332, 8342]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T222'}, {'offsets': [[8540, 8550]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T223'}, {'offsets': [[8560, 8570]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T224'}]","[{'trigger': 'T116', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T117', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T118', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T119', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T120', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T121', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'E8']}}, {'trigger': 'T125', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T122', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T121', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'E10']}}, {'trigger': 'T122', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T121', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'E12']}}, {'trigger': 'T124', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T123', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T7']}}, {'trigger': 'T126', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T126', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T127', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E14']}}, {'trigger': 'T128', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T127', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T129', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T13']}}, {'trigger': 'T130', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T131', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T132', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T133', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T133', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T134', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T135', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T136', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T136', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T137', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T138', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T139', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T140', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T141', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T142', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'E35']}}, {'trigger': 'T143', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T144', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T37']}}, {'trigger': 'T145', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T146', 'id': 'E38', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T147', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T148', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T42']}}, {'trigger': 'T149', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'T43']}}, {'trigger': 'T150', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'T44']}}, {'trigger': 'T151', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T152', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T153', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T154', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T155', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'E48']}}, {'trigger': 'T156', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T157', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E50', 'T51']}}, {'trigger': 'T158', 'id': 'E50', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T159', 'id': 'E51', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T159', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T160', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E54']}}, {'trigger': 'T161', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T162', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E56', 'E53']}}, {'trigger': 'T163', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T164', 'id': 'E57', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T165', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T166', 'id': 'E59', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T167', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E61', 'T58']}}, {'trigger': 'T168', 'id': 'E61', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T169', 'id': 'E62', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T170', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T61', 'E62']}}, {'trigger': 'T171', 'id': 'E64', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T172', 'id': 'E65', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E66']}}, {'trigger': 'T173', 'id': 'E66', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T174', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T175', 'id': 'E68', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E69']}}, {'trigger': 'T176', 'id': 'E69', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T177', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T177', 'id': 'E71', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}, {'trigger': 'T178', 'id': 'E72', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'T69']}}, {'trigger': 'T179', 'id': 'E73', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T178', 'id': 'E74', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'T70']}}, {'trigger': 'T180', 'id': 'E75', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T181', 'id': 'E76', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E75']}}, {'trigger': 'T182', 'id': 'E77', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E78', 'E79']}}, {'trigger': 'T184', 'id': 'E78', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E82']}}, {'trigger': 'T183', 'id': 'E79', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T182', 'id': 'E80', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E78', 'E81']}}, {'trigger': 'T183', 'id': 'E81', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T185', 'id': 'E82', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T186', 'id': 'E83', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T187', 'id': 'E84', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T188', 'id': 'E85', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T189', 'id': 'E86', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T190', 'id': 'E87', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T191', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E89']}}, {'trigger': 'T192', 'id': 'E89', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T191', 'id': 'E90', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E91']}}, {'trigger': 'T192', 'id': 'E91', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T193', 'id': 'E92', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E93']}}, {'trigger': 'T194', 'id': 'E93', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T195', 'id': 'E94', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E92', 'T86']}}, {'trigger': 'T195', 'id': 'E95', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E92', 'T87']}}, {'trigger': 'T196', 'id': 'E96', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}, {'trigger': 'T197', 'id': 'E97', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E98', 'T92']}}, {'trigger': 'T198', 'id': 'E98', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T93']}}, {'trigger': 'T199', 'id': 'E99', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E100']}}, {'trigger': 'T200', 'id': 'E100', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T94']}}, {'trigger': 'T201', 'id': 'E101', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T95']}}, {'trigger': 'T202', 'id': 'E102', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E101']}}, {'trigger': 'T203', 'id': 'E103', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E101', 'T96']}}, {'trigger': 'T204', 'id': 'E104', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T97']}}, {'trigger': 'T205', 'id': 'E105', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T98']}}, {'trigger': 'T206', 'id': 'E106', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E104', 'E107']}}, {'trigger': 'T207', 'id': 'E107', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T100']}}, {'trigger': 'T206', 'id': 'E108', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T99', 'E107']}}, {'trigger': 'T208', 'id': 'E109', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T97']}}, {'trigger': 'T209', 'id': 'E110', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E111', 'T101']}}, {'trigger': 'T210', 'id': 'E111', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T102']}}, {'trigger': 'T211', 'id': 'E112', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E113']}}, {'trigger': 'T212', 'id': 'E113', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T104']}}, {'trigger': 'T213', 'id': 'E114', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T105']}}, {'trigger': 'T213', 'id': 'E115', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T106']}}, {'trigger': 'T214', 'id': 'E116', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E117', 'T105']}}, {'trigger': 'T215', 'id': 'E117', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T107']}}, {'trigger': 'T214', 'id': 'E118', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E117', 'T106']}}, {'trigger': 'T216', 'id': 'E119', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T108']}}, {'trigger': 'T217', 'id': 'E120', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T109']}}, {'trigger': 'T218', 'id': 'E121', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E120']}}, {'trigger': 'T219', 'id': 'E122', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E120', 'T110']}}, {'trigger': 'T220', 'id': 'E123', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E120', 'T110']}}, {'trigger': 'T221', 'id': 'E124', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E125']}}, {'trigger': 'T222', 'id': 'E125', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T111']}}, {'trigger': 'T223', 'id': 'E126', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E127']}}, {'trigger': 'T224', 'id': 'E127', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T112']}}]","[{'id': 'R1', 'head': {'ref_id': 'T113', 'role': 'Subject'}, 'tail': {'ref_id': 'T153', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T114', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T115', 'role': 'Subject'}, 'tail': {'ref_id': 'T97', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E41', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E42', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E44', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E58', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E67', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E99', 'value': ''}]",[]
101,PMC-2626671-04-RESULTS_AND_DISCUSSION,"Distinct kinetics of T-bet and Eomes expression during CTL differentiation
The T-box transcription factors T-bet and Eomes have been linked to the regulation of genes encoding effector cytokines (e.g., Ifng) and genes important for cytolytic function (e.g., Prf1 and GzmB) (20). We investigated the kinetics of expression of these transcription factors in our in vitro cultures (Fig. 1, A-D). T-bet mRNA and protein were not detectable in naive CD8+ T cells, but were strongly induced upon TCR priming (day 2) and remained expressed through day 6 of differentiation (Fig. 1, A and C; quantified in Fig. 1, B and D). In contrast, Eomes expression was low or undetectable at both the mRNA and protein levels in naive CD8+ T cells, and TCR priming in culture had only a modest effect on its expression at day 2 (Fig. 1, A and C). Strong induction of Eomes mRNA and protein was only observed at day 4 and later (Fig. 1, A and C). T-bet mRNA expression slightly preceded the expression of GzmB mRNA; similarly, Eomes mRNA and protein were expressed ~1 d ahead of the reexpression of perforin mRNA and protein, respectively (Fig. 1, B and D).
This detailed kinetic analysis suggested that, under our culture conditions, T-bet and Eomes contribute to distinct aspects of gene transcription during CTL differentiation. T-bet is required early for IFN-gamma production, and our data suggested that Eomes might not function during this early period but rather might contribute later to the control of perforin expression. Our data seemed most consistent with a model in which TCR signals induce T-bet, which in turn induces IFN-gamma (17) and possibly granzyme B; subsequently, Eomes is induced during the period of clonal expansion in IL-2 and activates perforin expression.","[{'offsets': [[21, 26]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[31, 36]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[107, 112]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[117, 122]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[202, 206]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[258, 262]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[267, 271]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[393, 398]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[445, 448]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[629, 634]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[715, 718]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[847, 852]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[926, 931]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[984, 988]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1006, 1011]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1078, 1086]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1214, 1219]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1224, 1229]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1311, 1316]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1339, 1348]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1389, 1394]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1491, 1499]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1585, 1590]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1614, 1623]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1642, 1652]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1668, 1673]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1726, 1730]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1745, 1753]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[37, 47]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[133, 139]], 'text': ['linked'], 'type': 'Regulation', 'id': 'T35'}, {'offsets': [[147, 157]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[161, 166]], 'text': ['genes'], 'type': 'Anaphora', 'id': 'T29'}, {'offsets': [[212, 217]], 'text': ['genes'], 'type': 'Anaphora', 'id': 'T30'}, {'offsets': [[311, 321]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[325, 352]], 'text': ['these transcription factors'], 'type': 'Anaphora', 'id': 'T31'}, {'offsets': [[425, 435]], 'text': ['detectable'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[477, 484]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[514, 522]], 'text': ['remained'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[523, 532]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[635, 645]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[650, 669]], 'text': ['low or undetectable'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[774, 780]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[784, 787]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T32'}, {'offsets': [[788, 798]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[834, 843]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[932, 947]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T47'}, {'offsets': [[970, 980]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[1034, 1043]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[1062, 1074]], 'text': ['reexpression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[1320, 1328]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[1349, 1359]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[1456, 1466]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[1480, 1487]], 'text': ['control'], 'type': 'Regulation', 'id': 'T54'}, {'offsets': [[1500, 1510]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[1578, 1584]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T56'}, {'offsets': [[1592, 1597]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T33'}, {'offsets': [[1606, 1613]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[1677, 1684]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[1735, 1744]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1754, 1764]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T60'}]","[{'trigger': 'T34', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T34', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T35', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T3']}}, {'trigger': 'T36', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T35', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T4']}}, {'trigger': 'T35', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T3']}}, {'trigger': 'T36', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T35', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T4']}}, {'trigger': 'T35', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T3']}}, {'trigger': 'T36', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T35', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T4']}}, {'trigger': 'T37', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T37', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T38', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T39', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T40', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T41', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T42', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T43', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T44', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T45', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T46', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T47', 'id': 'E23', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T48', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T49', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T50', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T51', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T19']}}, {'trigger': 'T52', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T53', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T21']}}, {'trigger': 'T54', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T55', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T56', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T57', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T24', 'T23']}}, {'trigger': 'T57', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T25', 'T23']}}, {'trigger': 'T58', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T59', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T26']}}, {'trigger': 'T60', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}]","[{'id': 'R1', 'head': {'ref_id': 'T29', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T30', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T30', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T31', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T31', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E29', 'value': ''}]",[]
102,PMC-1310901-03-MATERIALS_AND_METHODS,"Cell culture and stimulation
All cell lines were maintained at 5% CO2 in RPMI 1640 medium with 1% glutamine (Gibco/BRL Eggenstein, Germany) supplemented with 10% fetal calf serum (Gibco/BRL), 1% penicillin/streptomycin (Biochrom, Berlin, Germany). When indicated, cells were treated with 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) (Sigma, Taufkirchen, Germany) for different time periods. Owing to their chemical instability fresh substances were re-added every 24 h.",[],[],[],[],[],[]
103,PMC-3245220-05-Results,"M-CSF-Induces PKCalpha Kinase Activity
Since our data suggested that conventional PKCs were involved in activating NF-kappaB in response to M-CSF in primary human macrophages, we next investigated whether the conventional PKC, PKCalpha was a downstream target of M-CSF in human MDMs. PKCalpha was immunoprecipitated from human MDMs at the indicated time points (Figure 4), and then a PKC kinase assay was performed using a fluorescein-tagged peptide as a substrate. As shown in Figure 4 (upper panel), the peptide substrate was maximally phosphorylated within 10 minutes of stimulation (1.8-fold over resting cells, lower panel), and then returned to basal levels by 15 minutes. This effect was not seen in M-CSF-stimulated monocytes when isogenic antibodies (IgG) were used for immunoprecipitation. Western blots of identical samples using an antibody recognizing PKCalpha demonstrated that equal amounts of PKCalpha were assayed (Figure 4, middle panel).","[{'offsets': [[14, 22]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[227, 235]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[242, 259]], 'text': ['downstream target'], 'type': 'Regulation', 'id': 'T3'}]","[{'trigger': 'T3', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
104,PMC-2791889-13-Experimental_Procedures,"In Vivo Studies
BALB/c mice were injected intravenously (i.v.) with a red blood cell-depleted single-cell spleen suspension (2.5 x 107 cells) (Castro et al., 2000) from DO11.10 WT or STAT-deficient mice. After 48 hr, they were injected subcutaneously with PBS or with OVA protein (5 mg) plus LPS (5 mug). The inguinal lymph nodes were removed 48 hr later. A single-cell suspension (1 x 106 cells) was restimulated for 24 or 48 hr with 1 muM or 3 muM of OVA and with BrefeldinA for the last 6 hr. Half of the supernatant was removed before the addition of BrefeldinA for use in an ELISA assay. The cells were fixed and stained as before. Those positive for KJ1-26-Bio and for CD4-PerCP were gated, and IFN-gamma and IL-10 staining was examined for this population and analyzed as before.","[{'offsets': [[183, 187]], 'text': ['STAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[268, 271]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[453, 456]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[656, 662]], 'text': ['KJ1-26'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[675, 678]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[701, 710]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[715, 720]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[188, 197]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T8'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
105,PMC-3148254-07-Materials_and_Methods,"Cell lines
The mouse B cell line A20.2J has been previously described [26], [27]. Cells were grown in RPMI 1640, 10% FCS, 10 microM 2-ME, 2 mM L-glutamine, and antibiotics. HI-5 insect cells (Invitrogen) expressing CD154 have been described [28].","[{'offsets': [[215, 220]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[204, 214]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
106,PMC-3245220-31-Caption-Figure_7,"PKCalpha regulates phosphorylation of NF-kappaB p65 at Ser276.
(A) MDM or (B) RAW 264.7 cells were transiently transfected with pNF-kappaB-SEAP along with either WT-PKCalpha or the kinase-deficient (KD)-PKCalpha construct at a 1:5 ratio. Cells were serum starved and stimulated with M-CSF and then SEAP secretion in the medium was measured. Data is from of three independent experiments. The p-value of cells transfected with KD compared to those transfected with WT was 0.05. (C) MDMs were removed from the plate using accutase and apoptosis of MDMs was measured by flow cytometry using Annexin V-FITC and propidium iodine (PI). (D) Whole cell lysates from the transfected RAW 264.7 cells were subjected to Western blot analysis with phospho-Ser276 or phospho-Ser536 NF-kappaB p65 antibodies. Blots were immunoblotted with PKCalpha to determine equal protein expression for the PKCalpha constructs. beta-actin served as a loading control. Shown is a representative blot from three independent experiments. (E) MDM or (F) RAW 264.7 cells were transiently transfected with a pNF-kappaB-SEAP along with either 100 nM PKCalpha siRNA or control siRNA for 20-24 hours. Cells were serum starved for 2-4 hours and stimulated with 100 ng/ml M-CSF for 6 hours for MDM or RAW 264.7 for 2 hours and then SEAP secretion in the medium was measured. Shown is data of three independent experiments. (G) MDMs were removed from the plate using accutase and apoptosis of MDMs was measured by Annexin V-FITC and propidium iodine (PI) staining and analyzed by flow cytometry. (H) Whole cell lysates from the transfected MDM and RAW 264.7 cells were subjected to Western blot analysis with PKCalpha antibody. beta-actin served as a loading control. Shown is a representative blot from at least three independent experiments.","[{'offsets': [[0, 8]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[48, 51]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[165, 173]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[203, 211]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[588, 597]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[824, 832]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[879, 887]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[900, 910]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1115, 1129]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1474, 1483]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1688, 1698]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[9, 18]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T12'}, {'offsets': [[19, 34]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T13'}, {'offsets': [[55, 61]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T14'}, {'offsets': [[111, 122]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[181, 197]], 'text': ['kinase-deficient'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[860, 870]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[1055, 1066]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T18'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T14']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]",[],[],[],[]
107,PMC-3279418-19-Caption-Figure_1,"In vivo and in vitro features of SHARPIN.
(A) COILS and MotifScan programs were used to predict the presence of CC (coiled-coil) domain, UBL (ubiquitin-like) domain and ZFRBP (zinc-finger Ran-Binding protein 2) domain which form similar motif patterns in the SHARPIN protein of human, mouse and rat origins. (B) Eight week-old females of WT and cpdm mice. The mutant mice (above) develop progressive skin inflammation starting at about four weeks. (C) Extramedullary hematopoiesis causes marked enlargement of the spleen of cpdm mice. (D) BMDC were incubated in the absence or presence of 100 ng/ml LPS for 4 hours. The mRNA level of Sharpin was measured by qRT-PCR and presented relative to the mRNA expression in non-stimulated WT BMDC. Bars represent the mean +/- s.d. of 3 mice. * P<0.05; ** P<0.001. (E) Fibroblast (NIH3T3) and macrophages (RAW264.7) cells were transfected with the expression plasmid pFLAG-SHARPIN. After 48 hours, cells were fixed and probed with anti-FLAG and FITC-conjugated secondary antibody. Nuclei were stained with DAPI. In both transfected cell lines, FLAG-SHARPIN was found to be cytoplasm-localized.","[{'offsets': [[33, 40]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[259, 266]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[634, 641]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[913, 920]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1089, 1096]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[620, 630]], 'text': ['mRNA level'], 'type': 'Transcription', 'id': 'T6'}, {'offsets': [[1113, 1122]], 'text': ['cytoplasm'], 'type': 'Entity', 'id': 'T7'}, {'offsets': [[1123, 1132]], 'text': ['localized'], 'type': 'Localization', 'id': 'T8'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T7']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
108,PMC-3279418-05-Results,"Impaired cytokine production by cpdm BMDC is correlated with selective defects in NF-kappaB signaling
There are a number of possible explanations for the defective cytokine secretion in stimulated cpdm BMDC, including 1) reduced surface expression of the LPS receptor complex, 2) increased production of anti-inflammatory mediators, 3) increased expression of negative regulators of TLR pathways, and 4) impaired TLR-induced signaling activation.
We determined the surface expression of the LPS receptor complex that comprises TLR4, the accessory proteins CD14 and myeloid differentiation factor 2 (MD2/LY96) [19]. Flow cytometric analysis shows that the expression levels of CD14 and TLR4/MD2 between WT and cpdm BMDC were similar (Fig. 5A). We then quantified the secretion of the suppressive cytokines IL10 that can inhibit IL12 secretion in an autocrine manner [20], [21]. The supernatants from LPS-stimulated cpdm BMDC contained significantly lower levels of IL10 than stimulated WT BMDC (Fig. 5B), suggesting that IL10 was not responsible for decreased secretion of IL12P70 by cpdm BMDC. Increased expression of a negative regulator of TLR signaling such as A20 [22] may also suppress cytokine secretion. However, the transcript level of A20 was lower in LPS-activated cpdm BMDC than WT controls (Fig. 5C), thereby ruling out overexpression of A20 as a factor in the reduced cytokine production.
The transcription of TLR3/4-induced proinflammatory intermediates is tightly regulated by cellular signaling pathways, in particular NF-kappaB, TBK1/IRF3, and MAPK [23]-[27]. We next determined if disrupted NF-kappaB, TBK1/IRF3, and/or MAPK signaling may underlie the impaired cytokine production from stimulated Sharpin-deficient BMDC. Stimulus-induced phosphorylation of the IkappaB kinase (IKK1/2) is an essential step in NF-kappaB signaling, allowing phosphorylation and proteasome-mediated degradation of the NF-kappaB inhibitor IkappaBalpha to release the NF-kappaB transcription factors into the nucleus. The amount of phosphorylated IKK1/2 (p-IKK1/2) and IkappaBalpha (p-IkappaBalpha) following incubation with LPS or poly I:C was severely decreased in cpdm BMDC as compared with WT controls (Fig. 6). The cpdm BMDC exhibited similar levels of TBK1, ERK1/2, and p38 phosphorylation to those of WT cells (Fig. 6). These results indicate that the absence of functional SHARPIN decreased NF-kappaB activation but did not affect TBK1/IRF3, ERK1/2, and p38 signaling in BMDC.","[{'offsets': [[527, 531]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[556, 560]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[565, 597]], 'text': ['myeloid differentiation factor 2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[599, 602]], 'text': ['MD2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[603, 607]], 'text': ['LY96'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[676, 680]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[685, 689]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[690, 693]], 'text': ['MD2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[805, 809]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[964, 968]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1020, 1024]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1164, 1167]], 'text': ['A20'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1244, 1247]], 'text': ['A20'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1350, 1353]], 'text': ['A20'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1423, 1427]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1428, 1429]], 'text': ['4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1546, 1550]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1551, 1555]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1620, 1624]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1625, 1629]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1715, 1722]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1795, 1799]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1800, 1801]], 'text': ['2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1936, 1948]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2043, 2047]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2048, 2049]], 'text': ['2'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2053, 2057]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2058, 2059]], 'text': ['2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2065, 2077]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2081, 2093]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2254, 2258]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2260, 2264]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2265, 2266]], 'text': ['2'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2377, 2384]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2435, 2439]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2440, 2444]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2446, 2450]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2451, 2452]], 'text': ['2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[655, 665]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[766, 775]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[948, 953]], 'text': ['lower'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[954, 960]], 'text': ['levels'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[1094, 1103]], 'text': ['Increased'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[1104, 1114]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[1224, 1240]], 'text': ['transcript level'], 'type': 'Transcription', 'id': 'T45'}, {'offsets': [[1252, 1257]], 'text': ['lower'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[1332, 1346]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[1723, 1732]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[1848, 1856]], 'text': ['allowing'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[1857, 1872]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T50'}, {'offsets': [[1888, 1896]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[1897, 1908]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T52'}, {'offsets': [[2028, 2042]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[2150, 2159]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[2276, 2291]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T55'}, {'offsets': [[2355, 2362]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T56'}]","[{'trigger': 'T39', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T39', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T42', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T43', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T44', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T45', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T46', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T47', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T48', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T49', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T50', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T49', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T52', 'id': 'E16', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T51', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T53', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T53', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T53', 'id': 'E20', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T54', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T54', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T54', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T55', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T55', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T55', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T56', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}]",[],"[{'id': '*', 'ref_ids': ['T3', 'T4', 'T5']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}]",[]
109,PMC-2664230-12-RESULTS,"Effect of PTX on TNF-alpha production in the presence of PKA inhibition
The role of PKA in PTX-induced downregulation of TNF-alpha production in LPS-stimulated mononuclear cells was assessed by treating mononuclear cells with H89, a PKA inhibitor, prior to LPS and PTX exposure. The addition PTX to LPS-stimulated cells resulted in a reduction in TNF-alpha, similar to that observed in our previous experiments (529 pg/mL +/- 112 vs. 37 pg/mL +/- 10; P < 0.01). Pre-incubation of cells with H89 prior to LPS and PTX exposure did not result in any significant modulation of TNF-alpha production when compared to that demonstrated with PTX alone (P = 0.2; Figure 5). These results suggest that downregulation of TNF-alpha production by PTX in LPS-stimulated mononuclear cells is, at least in part, PKA-independent.","[{'offsets': [[17, 26]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[121, 130]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[347, 356]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[573, 582]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[710, 719]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[0, 6]], 'text': ['Effect'], 'type': 'Regulation', 'id': 'T6'}, {'offsets': [[27, 37]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[38, 56]], 'text': ['in the presence of'], 'type': 'Regulation', 'id': 'T8'}, {'offsets': [[76, 80]], 'text': ['role'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[95, 102]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[103, 117]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[131, 141]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[320, 328]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[334, 343]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[533, 539]], 'text': ['result'], 'type': 'Regulation', 'id': 'T15'}, {'offsets': [[559, 569]], 'text': ['modulation'], 'type': 'Regulation', 'id': 'T16'}, {'offsets': [[583, 593]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[692, 706]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[720, 730]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[800, 811]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T20'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T9', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T11', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T12', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T14', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T16', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T17', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T19', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T20', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}]",[]
110,PMC-2889865-16-Materials_and_methods,"Statistical analysis
Statistical significant differences were determined using two-tailed Student's t-test (*p < 0.05; **p < 0.01; ***p < 0.001).",[],[],[],[],[],[]
111,PMC-3279418-12-Materials_and_Methods,"Phenotype of BMDC and splenic DC subsets
The phenotype of BMDC was determined before and after 24 hour culture in the presence of 100 ng/mL LPS. The cells were incubated in PBS with 0.1% NaN3, 1% BSA and 10% normal rabbit serum for 20 minutes on ice, washed and incubated for 30 minutes on ice with Alex Fluor-labeled anti-CD11c (MCD11C20, CALTAG) in combination with PE- anti-CD40 (3/23, BD Biosciences), PE-anti-CD80 (16-10A1, eBioscience), PE-anti-CD86 (P03.1, eBioscience), PE-anti-CD14 (Sa2.8, eBioscience) and biotinylated anti-TLR4 (BioLegend). The cells incubated with biotinylated anti-TLR4/MD-2 were washed twice and incubated for 30 minutes on ice with avidin-PE. To isolate splenic DC, spleens were collagenase digested and subject to Percoll gradient centrifugation. The bands at the 35-55% interface were collected to stain with PE-anti-CD11c (HL3, BioLegend), APC-anti-PDCA-1 (927, BioLegend) and FITC-anti-CD8alpha (53-6.7, BD BioScience). The cells were washed twice, fixed in 2% paraformaldehyde, and stored at 4degreesC until analysis. Flow cytometry was performed in an Excel (Coulter) instrument. Dead cells were omitted from the analysis by gating on forward and 90degrees light scatter, and 10,000 cells were analyzed by FlowJo software.",[],[],[],[],[],[]
112,PMC-3245220-08-Results,"M-CSF-dependent PKC Regulates NF-kappaB-targeted Genes
NF-kappaB induces a number of downstream genes, including the IkappaB family. Among the IkappaB molecules, IkappaBalpha is highly induced by NF-kappaB activation [40]. Having shown that PKC regulated NF-kappaB activity in M-CSF-stimulated MDMs, we next determined whether inhibition of PKC activity decreased expression of NF-kappaB-regulated genes. We treated both MDMs and RAW 264.7 cells with the PKC inhibitor Ro-31-8220 for 30 minutes and then stimulated with M-CSF. IkappaBalpha gene was measured by qRT-PCR. As shown in Figures 6A and 6B, M-CSF enhanced IkappaBalpha gene expression and PKC inhibition by Ro-31-8220 decreased IkappaBalpha gene expression in both MDMs and RAW 264.7 cells (p<0.01), demonstrating that PKC affected NF-kappaB-regulated gene expression in macrophages.
To further define the role of PKC in mediating human MDM survival in response to M-CSF, we examined the expression of the anti-apoptotic gene BCL-xL, which is also regulated by NF-kappaB. As shown in Figure 6C, Ro-31-8220 reduced M-CSF-stimulated BCL-xL expression compared to cells treated with M-CSF and the vehicle control DMSO (p<0.05).","[{'offsets': [[162, 174]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[527, 539]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[616, 628]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[688, 700]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[986, 992]], 'text': ['BCL-xL'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1091, 1097]], 'text': ['BCL-xL'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[185, 192]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[607, 615]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[634, 644]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[678, 687]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T12'}, {'offsets': [[706, 716]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[948, 958]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[962, 985]], 'text': ['the anti-apoptotic gene'], 'type': 'Anaphora', 'id': 'T7'}, {'offsets': [[994, 999]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T8'}, {'offsets': [[1008, 1017]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T15'}, {'offsets': [[1066, 1073]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[1080, 1090]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[1098, 1108]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T16', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T17', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]","[{'id': 'R1', 'head': {'ref_id': 'T7', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T8', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}]",[]
113,PMC-3245220-12-Materials_and_Methods,"Materials
Recombinant human M-CSF was purchased from R&D Systems (Minneapolis, MN). Ro-31-8220, Go-6976, Rotterin, and BAPTA/AM were obtained from Calbiochem (San Diego, CA). Low endotoxin RPMI and X-vivo serum free medium were obtained from Lonza Walkersville Inc (Walkersville, MD). Fetal bovine serum (FBS, certified <0.06 endotoxin units/ml endotoxin levels) was purchased from Atlanta Biological (Lawrenceville, GA). All other cell culture reagents were obtained through Invitrogen (Carlsbad, CA). PKCalpha NF-kappaB p65, Lamin B, beta-actin, and GAPDH antibodies, anti-mouse and rabbit IgG-HRP conjugated antibodies, and PKCalpha siRNA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-NFkappaB p65 (Ser276 or Ser536) antibodies were purchased from Cell Signaling Technology (Danvers, MA). DNA constructs pTAL-SEAP and pNF-kappaB-SEAP were obtained from Clontech (Mountian View, CA). Expression vectors containing CMV-p65 WT, CMV-p65 276S/A and CMV-p65 536S/A were cloned in pBa5e Puro vector or pFLAG-CMV-2 vector as described previously [49]. Kinase deficient CMV-PKCalpha (KD-PKCalpha) or wild type pCMV-PKCalpha (WT-PKCalpha) were generous gifts from Alexandra C. Newton (University of California, San Diego, CA). IkappaBalpha (NFKBIA) and GAPDH primers for real-time RT-PCR were obtained from SABiosciences (Frederick, MD). A pool of mouse or human PKCalpha specific siRNA were purchased from Santa Cruz Biotechnology (Santa cruz, CA).","[{'offsets': [[627, 641]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[944, 947]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[956, 959]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[975, 978]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1092, 1100]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1105, 1113]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1133, 1141]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1146, 1154]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1244, 1256]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1380, 1403]], 'text': ['PKCalpha specific siRNA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1071, 1087]], 'text': ['Kinase deficient'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[1102, 1104]], 'text': ['KD'], 'type': 'Negative_regulation', 'id': 'T12'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],[],[]
114,PMC-3279418-25-Caption-Figure_7,"Stimulated cpdm BMDC induced Th2-biased cytokine production from naive CD4+ T cells.
WT and cpdm BMDC (5x104 cells in 0.1 mL complete medium; MHC haplotype: H-2b) were incubated with medium, 100 ng/mL LPS, 25 microg/mL poly I:C or 5 microg/mL Pam3CYS. After 24 hours, cells were washed with PBS and incubated with freshly isolated allogeneic naive CD4+ T cells (2.5x105 cells in 0.1 mL complete medium; MHC haplotype: H-2d). After 5 days, supernatants were collected and the secretion of IFNgamma, IL4, and IL2 were measured by ELISA. Negative controls are 1) stimulated BMDC without co-culture with allogeneic CD4+ T cells; 2) allogeneic CD4+ T cells without co-culture with stimulated BMDC. Samples from both negative controls had no detectable production of the aforementioned cytokines (not shown). Results are analyzed based on 2-4 mice per group. * P<0.05.","[{'offsets': [[488, 496]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[498, 501]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[507, 510]], 'text': ['IL2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[475, 484]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[747, 757]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[761, 789]], 'text': ['the aforementioned cytokines'], 'type': 'Anaphora', 'id': 'T4'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T6', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T6', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]","[{'id': 'R1', 'head': {'ref_id': 'T4', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T4', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T4', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}]",[]
115,PMC-1310901-06-MATERIALS_AND_METHODS,"Methylation-specific restriction-PCR-assay
DNA was extracted with a commercial kit (Qiagen) as recommended. Since the restriction ability of several endonucleases is inhibited by methylation of their target sequence, we used methylation-sensitive enzymes HpaII and HaeII-isochizomer Bsp143II and Bsh1236I (MBI Fermentas, St Leon-Rot, Germany) (20,24). As control the methylation-resistant enzyme MspI and an enzyme with no recognition site in the target promoter, EcoRI, were used. DNA (0.8 microg) was digested by 40 U the respective enzyme for 6 h and, to ensure complete cleavage, additional 20 U for 16 h. Thereafter 100 ng of digested DNA was used to a PCR amplification of two fragments (F1 and F2) spanning part of the IRF-4 promoter (30) (GenBank U52683; see Figure 3A). The sequences of the primers were F1-forward: 5'-TTGAGATGGAGTCTTGCTCTGT-3', F1-reverse: ATCACTTCCAGACTTCAGTTCACCT-3' (341 bp); F2-forward: 5'-AAGGTGAACTGAAGTCTGGAAGTGA-3', F2-reverse: 5'-CCAGGACCTCAGGAGGCCAGTCA-3' (474 bp). The PCR conditions were described elsewhere (3). PCR was performed with an annealing temperature of 62degreesC and 35 cycles. When DNA was methylated at specific sites, the sensitive enzymes were not able to digest the DNA and amplification took place; in case of no methylation, DNA was digested and no product was generated. The PCR products were electrophoresed on a 3% agarose gel, were stained with ethidium bromide and photographed. PCR products were verified by automated sequencing.","[{'offsets': [[726, 731]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
116,PMC-2065877-11-Materials_and_Methods,"Isolation and growth of B cells.
Splenocytes were prepared by homogenizing spleen tissue with two frosted slides and debris was filtered through a 100-mum cell strainer. Erythrocytes were lysed using 0.8% ammonium chloride solution (StemCell Technologies) for 10 min on ice and washed twice with PBS. B cells were isolated using CD19-MACS beads according to the manufacturer's instructions (Miltenyi Biotec) and grown in Iscove's medium supplemented with heat-inactivated 10% fetal bovine serum and antibiotic/antimycotic (GIBCO). Splenocytes isolated from SCID-passaged lymphomas consisted of 80%-90% B cells as determined by flow cytometry, and were hence not further purified with CD19-MACS beads. Splenocytes were seeded at 1.25 x 106 cells/ml and where applicable, recombinant mouse IL4 was added at 100 ng/ml, recombinant mouse IL10 at 10 ng/ml, and rat IgG1 anti-mouse IL10 and rat IgG1 isotype control at 10 mug/ml (R&D Systems). For BrdU incorporation assays, splenocytes were pulsed for 24 h with 10 muM BrdU 1 d post-harvest.","[{'offsets': [[329, 333]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[684, 688]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[788, 791]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[834, 838]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[876, 880]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
117,PMC-2791889-00-TIAB,"Interleukin-10 Production by Th1 Cells Requires Interleukin-12-Induced STAT4 Transcription Factor and ERK MAP Kinase Activation by High Antigen Dose
Summary
CD4+ T cells producing interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) are reported in chronic infections. However, the signals that direct the development of IL-10-producing T helper 1 (Th1) cells are undefined. We showed that development of IL-10-producing Th1 cells required high T cell receptor (TCR) ligation, sustained ERK1 and ERK2 MAP kinases phosphorylation, and IL-12-induced STAT4 transcription factor activation. Repeated TCR triggering led to enhanced IL-10 production by Th1 cells, and continued IL-12 action and high-dose TCR signaling were required for the development and maintenance of IL-10-producing Th1 cells. Although Th1, Th2, and Th17 cells require the activation of distinct STATs for their differentiation, activation of ERK1 and ERK2 was a common requirement for production of IL-10 by all Th cell subsets. IL-10 expression also correlated with c-maf expression. Despite having distinct functions in protection against pathogens, all Th cells share the important task of controlling overexuberant immune responses by means of IL-10 production.","[{'offsets': [[0, 14]], 'text': ['Interleukin-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[48, 62]], 'text': ['Interleukin-12'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 76]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[102, 105]], 'text': ['ERK'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[157, 160]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[180, 194]], 'text': ['interleukin-10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[196, 201]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[207, 223]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[225, 234]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[324, 329]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[408, 413]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[490, 494]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[499, 503]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[537, 542]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[551, 556]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[630, 635]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[675, 680]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[769, 774]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[912, 916]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[921, 925]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[969, 974]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[999, 1004]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1037, 1042]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1218, 1223]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[15, 25]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[39, 47]], 'text': ['Requires'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[63, 70]], 'text': ['Induced'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[117, 127]], 'text': ['Activation'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[170, 179]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[330, 339]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[414, 423]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[516, 531]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T32'}, {'offsets': [[543, 550]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[578, 588]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[621, 629]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[636, 646]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[721, 729]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[775, 784]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[898, 908]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[939, 950]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[955, 965]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[1005, 1015]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[1043, 1053]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[1224, 1234]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T44'}]","[{'trigger': 'T25', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T26', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E3']}}, {'trigger': 'T27', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T2']}}, {'trigger': 'T26', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E5']}}, {'trigger': 'T28', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T29', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T29', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T30', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T31', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T32', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T32', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T33', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T14']}}, {'trigger': 'T34', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T35', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T36', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T37', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T38', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T39', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T39', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T40', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E18']}}, {'trigger': 'T41', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T40', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E19']}}, {'trigger': 'T42', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T43', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T44', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}]",[],"[{'id': '*', 'ref_ids': ['T6', 'T7']}, {'id': '*', 'ref_ids': ['T8', 'T9']}]",[],[]
118,PMC-3245220-28-Caption-Figure_4,"M-CSF activates PKCalpha in human MDMs.
MDMs treated with M-CSF (100 ng/ml) for varying amounts of time were lysed and immunoprecipitated using anti-PKC antibody or control IgG antibody. One half of the samples was used to analyze PKC kinase activity using a fluorescein tagged peptide and visualized by agarose gel electrophoresis (top panel), while the other half was subjected to Western blot analysis to confirm equal amounts of PKCalpha were immunoprecipitated from each sample (middle panel). The kinase assay was quantitated using Quantity One software (Bio-Rad) (bottom panel). Data represents the average fold increase of PKCalpha activity in non-stimulated samples compared to M-CSF-treated MDM +/- S.E.M for three independent experiments. NS: non-stimulated. * The p-values of M-CSF stimulated compared to non-stimulated were <=0.05.","[{'offsets': [[16, 24]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[433, 441]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[631, 639]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[6, 15]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T4'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
119,PMC-2065877-07-Results,"LMP1 Activates Akt Signaling and Deregulates the Rb Cell Cycle Pathway
LMP1 transformation of rodent fibroblasts requires activation of PI3K and Akt [5]. Additionally, activated pAkt is frequently detected in NPC and the neoplastic Reed-Sternberg cells of classical HD [39,40]. To determine if Akt signaling is activated in LMP1 transgenic mice, pAkt and several of its targets were assessed by immunoblotting of splenic CD19+ MACS-purified B cells. LMP1 transgenic B cells had increased levels of pAkt compared to wild-type lymphocytes; however, progression to lymphoma in both LMP1-positive and -negative lymphoma cells did not further increase pAkt levels. The Akt target glycogen synthase kinase 3 (GSK3) is inactivated by phosphorylation; however, increased phosphorylated GSK3 was not detected in the transgenic lymphocytes and was almost absent in the lymphoma samples (Figure 6A). This finding indicates that GSK3 is not a target of activated Akt in the LMP1 transgenic lymphocytes and lymphoma cells. Similarly, activation of Akt without phosphorylation of GSK3 has been previously shown in EBV-positive HD [40]. In contrast, the wild-type lymphocytes lacked activated Akt but did have detectable phosphorylated GSK3. This further suggests that additional pathways are involved in the regulation of GSK3.
To identify other potential Akt targets, immunoblot analysis for p-mTOR was performed. Activated p-mTOR was not increased in LMP1 transgenic lymphocytes or lymphoma cells, indicating that this pathway is not affected by LMP1-induced Akt activation and does not contribute to lymphoma development (Figure 6B). Akt is also known to phosphorylate and induce the degradation of the pro-apoptotic Forkhead family of transcription factors, leading to cell cycle progression and survival in some human tumors [41,42]. Immunoblot analysis of splenic B cells did not consistently detect p-FoxO1 levels, a signal that targets FoxO1 for degradation. Hence, degradation of FoxO1 was assessed by detection of total FoxO1 levels. Immunoblot analysis indicated that total FoxO1 levels were greatly decreased in wild-type and LMP1 transgenic lymphomas (Figure 6B), suggesting that inhibition of the Forkhead signaling pathway is an important target of Akt in lymphoma development. However, considering that Akt activation did not induce FoxO1 degradation in LMP1 transgenic B cells, Akt may not be the sole regulator of FoxO1, and it may be that progression to lymphoma requires modulation of multiple pathways.
The Forkhead family of transcription factors is known to induce the expression of the Cdk inhibitor p27 [43,44]. LMP1-transformed rodent fibroblasts have decreased expression of p27, upregulation of Cdk2, and subsequent phosphorylation and inactivation of the tumor suppressor gene Rb [45]. To investigate whether LMP1 affected cell cycle regulation through the Rb pathway in B cells, immunoblot analyses for pRb, Cdk2, and p27 were performed on splenic CD19+ MACS-purified B cells. LMP1 transgenic B cells had enhanced levels of pRb with concomitant stabilization of total Rb levels and Cdk2 compared to wild-type B lymphocytes (Figure 6C). Progression to lymphoma in both wild-type and LMP1 transgenic lymphoma cells led to increased levels of Rb, correspondingly high levels of Cdk2, and decreased levels of p27 (Figure 6C). These data indicate that the Rb pathway is deregulated in LMP1 transgenic lymphocytes and that lymphoma cells are distinguished by loss of FoxO1 and decreased p27.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[15, 18]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 51]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[71, 75]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[145, 148]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[178, 182]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[294, 297]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[324, 328]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[346, 350]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[421, 425]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[450, 454]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[498, 502]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[579, 583]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[647, 651]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[664, 667]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[675, 701]], 'text': ['glycogen synthase kinase 3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[703, 707]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[778, 782]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[917, 921]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[951, 954]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[962, 966]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1035, 1038]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1066, 1070]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1178, 1181]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1221, 1225]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1308, 1312]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1342, 1345]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1379, 1385]], 'text': ['p-mTOR'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1411, 1417]], 'text': ['p-mTOR'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1439, 1443]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1534, 1538]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1547, 1550]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1623, 1626]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1894, 1899]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1930, 1935]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1975, 1980]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2016, 2021]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2071, 2076]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2124, 2128]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2250, 2253]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2305, 2308]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2335, 2340]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2356, 2360]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2381, 2384]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2418, 2423]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2610, 2613]], 'text': ['p27'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2623, 2627]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2688, 2691]], 'text': ['p27'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2709, 2713]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2792, 2794]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2824, 2828]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2872, 2874]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2919, 2922]], 'text': ['pRb'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2924, 2928]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2934, 2937]], 'text': ['p27'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2964, 2968]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2993, 2997]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3040, 3043]], 'text': ['pRb'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3084, 3086]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3098, 3102]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3198, 3202]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3256, 3258]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3291, 3295]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3321, 3324]], 'text': ['p27'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3367, 3369]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3396, 3400]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3477, 3482]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3497, 3500]], 'text': ['p27'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[113, 121]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[122, 132]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[168, 177]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[478, 487]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[638, 646]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[668, 674]], 'text': ['target'], 'type': 'Binding', 'id': 'T75'}, {'offsets': [[712, 723]], 'text': ['inactivated'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[753, 762]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[763, 777]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T78'}, {'offsets': [[931, 937]], 'text': ['target'], 'type': 'Binding', 'id': 'T79'}, {'offsets': [[941, 950]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1021, 1031]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[1047, 1062]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T82'}, {'offsets': [[1168, 1177]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[1206, 1220]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T84'}, {'offsets': [[1294, 1304]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T85'}, {'offsets': [[1346, 1353]], 'text': ['targets'], 'type': 'Binding', 'id': 'T86'}, {'offsets': [[1401, 1410]], 'text': ['Activated'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1426, 1435]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[1502, 1514]], 'text': ['this pathway'], 'type': 'Anaphora', 'id': 'T69'}, {'offsets': [[1522, 1530]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[1539, 1546]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T90'}, {'offsets': [[1551, 1561]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[1922, 1929]], 'text': ['targets'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[2097, 2106]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[2309, 2319]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[2328, 2334]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[2341, 2352]], 'text': ['degradation'], 'type': 'Negative_regulation', 'id': 'T96'}, {'offsets': [[2405, 2414]], 'text': ['regulator'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[2578, 2588]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T98'}, {'offsets': [[3021, 3029]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[3229, 3232]], 'text': ['led'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[3236, 3245]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[3276, 3287]], 'text': ['high levels'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[3301, 3310]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T103'}, {'offsets': [[3469, 3473]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T104'}, {'offsets': [[3487, 3496]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T105'}]","[{'trigger': 'T70', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T71', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T72', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T73', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T74', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T75', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T16']}}, {'trigger': 'T76', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T77', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T78', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T79', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T19', 'T20']}}, {'trigger': 'T80', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T81', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T82', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T83', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T84', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T85', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T86', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T87', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T88', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T89', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E21']}}, {'trigger': 'T90', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T31']}}, {'trigger': 'T91', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T92', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T93', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T94', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T95', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'E25']}}, {'trigger': 'T96', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T97', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T45', 'T44']}}, {'trigger': 'T98', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T99', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T99', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T100', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T101', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T102', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T103', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T104', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T105', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}]","[{'id': 'R1', 'head': {'ref_id': 'T69', 'role': 'Subject'}, 'tail': {'ref_id': 'T87', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T16', 'T17']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E17', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E28', 'value': ''}]",[]
120,PMC-2626671-07-RESULTS_AND_DISCUSSION,"Runx3 and T-box factors control a complex program of transcriptional regulation during CTL differentiation
Collectively, these data provide evidence that Runx3, together with T-box factors, orchestrates a complex program of transcriptional regulation in differentiating CTL (Fig. 4 C). Runx3 is present in naive CD8+ T cells before activation (12). It represses Runx1 and has a positive role in the induction of Eomes, granzyme B, perforin, and IFN-gamma. Runx3 binds to promoters and putative regulatory regions of the latter three genes, suggesting a direct effect on gene expression. Additional experiments are needed to determine whether Eomes and Runx1 are also direct target genes of Runx3.
Surprisingly, Runx3 contributed to the optimal expression of TNF, IL-2, and IFN-gamma at day 4 (Fig. S2). For TNF and IL-2, the requirement for Runx3 subsides by day 6 (Fig. 3 C), possibly because of compensation by Runx1, which is derepressed in Runx3-/- cells (Fig. 4 A). Runx3 continues to be required for IFN-gamma expression even at day 6, perhaps because of its role in the induction of Eomes expression (Fig. 4 A).
An unexpected finding was that the two T-box transcription factors, T-bet and Eomes, are up-regulated with very different kinetics in CD8+ T cells under our culture conditions and have nonredundant roles in the subsequent expression of key effector proteins (Fig. 4 C). T-bet is needed early to confer on activated CD8+ T cells the competence to produce IFN-gamma upon restimulation, but its function is less important at later times. Eomes, which is induced late and functions downstream of Runx3, may substitute for T-bet in promoting the acute expression of IFN-gamma in restimulated CTLs (8). Indeed, T-bet and Eomes both contribute to perforin expression in NK cells (8, 26), and Eomes induces granzyme B as effectively as T-bet in developing Th2 cells (7); thus, the relative roles of these T-box transcription factors vary depending on cell type.
Surprisingly, however, Eomes and T-bet appeared nonredundant in their ability to induce two other markers of CTL function, Prf1 and Gzmb (Fig. 4 C). Rather, T-bet and Eomes were involved in regulating granzyme B and perforin expression, respectively: up-regulation of T-bet and Eomes mRNA and protein closely preceded up-regulation of Gzmb and Prf1 mRNA and protein, respectively. T-bet had no role in perforin expression under our culture conditions, and Eo-VP16 did not affect granzyme B expression when expressed in T-bet-/- or Runx3-/- cells. Because conventional Eomes-deficient mice die before precursor cells can be isolated for bone marrow transfers (27) and because T cells conditionally deficient in Eomes have only recently been described (9), we were unable to introduce Runx3 into Eomes-deficient CD8+ T cells to test formally whether Eomes cooperated with Runx3 to induce perforin expression.
Collectively, our data are consistent with a transcriptional network in which preexisting Runx3 cooperates with the induced T-box factors T-bet and Eomes and IL-2Rbeta signals (unpublished data) to orchestrate CTL differentiation (Fig. 4 C). Our data recall the ""feed-forward"" interaction between T-bet and Runx3 that we previously described in CD4+ (Th1) T cells (15) but are distinct in two respects: in differentiating Th1 cells, T-bet is induced by TCR signals and IFN-gamma, and in turn induces Runx3 (15), whereas in differentiating CD8+ T cells, preexisting Runx3 is required to induce the T-box transcription factor Eomes. Whole-genome experiments in these and other systems will be required to establish whether cooperation between T-box and Runx family transcription factors is a general feature of cellular differentiation programs.","[{'offsets': [[0, 5]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[154, 159]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[286, 291]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[312, 315]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[362, 367]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[412, 417]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[419, 429]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[431, 439]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[445, 454]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[456, 461]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[642, 647]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[652, 657]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[690, 695]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[711, 716]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[758, 761]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[763, 767]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[773, 782]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[807, 810]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[815, 819]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[841, 846]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[913, 918]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[944, 949]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[971, 976]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1006, 1015]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1090, 1095]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1187, 1192]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1197, 1202]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1253, 1256]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1389, 1394]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1434, 1437]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1473, 1482]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1554, 1559]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1611, 1616]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1637, 1642]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1680, 1689]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1724, 1729]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1734, 1739]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1759, 1767]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1804, 1809]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1818, 1828]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1847, 1852]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1996, 2001]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2006, 2011]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2096, 2100]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2105, 2109]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2130, 2135]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2140, 2145]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2174, 2184]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2189, 2197]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2241, 2246]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2251, 2256]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2308, 2312]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2317, 2321]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2354, 2359]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2375, 2383]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2429, 2436]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2452, 2462]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2492, 2497]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2504, 2509]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2541, 2546]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2683, 2688]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2756, 2761]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2767, 2772]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2783, 2786]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[2821, 2826]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[2843, 2848]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[2859, 2867]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[2970, 2975]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3018, 3023]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3028, 3033]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3038, 3047]], 'text': ['IL-2Rbeta'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3177, 3182]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[3187, 3192]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[3225, 3228]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[3313, 3318]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[3349, 3358]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[3380, 3385]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[3419, 3422]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[3445, 3450]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[3504, 3509]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[295, 302]], 'text': ['present'], 'type': 'Gene_expression', 'id': 'T86'}, {'offsets': [[349, 351]], 'text': ['It'], 'type': 'Anaphora', 'id': 'T81'}, {'offsets': [[352, 361]], 'text': ['represses'], 'type': 'Negative_regulation', 'id': 'T87'}, {'offsets': [[372, 391]], 'text': ['has a positive role'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[399, 408]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[462, 467]], 'text': ['binds'], 'type': 'Binding', 'id': 'T90'}, {'offsets': [[471, 480]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T91'}, {'offsets': [[494, 512]], 'text': ['regulatory regions'], 'type': 'Entity', 'id': 'T92'}, {'offsets': [[516, 538]], 'text': ['the latter three genes'], 'type': 'Anaphora', 'id': 'T82'}, {'offsets': [[560, 566]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T93'}, {'offsets': [[575, 585]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[674, 680]], 'text': ['target'], 'type': 'Binding', 'id': 'T95'}, {'offsets': [[717, 728]], 'text': ['contributed'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[744, 754]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T97'}, {'offsets': [[825, 836]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[847, 855]], 'text': ['subsides'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[929, 940]], 'text': ['derepressed'], 'type': 'Negative_regulation', 'id': 'T100'}, {'offsets': [[993, 1001]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[1016, 1026]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[1061, 1064]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T83'}, {'offsets': [[1065, 1069]], 'text': ['role'], 'type': 'Regulation', 'id': 'T103'}, {'offsets': [[1077, 1086]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[1096, 1106]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T105'}, {'offsets': [[1208, 1220]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T106'}, {'offsets': [[1398, 1404]], 'text': ['needed'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[1465, 1472]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T108'}, {'offsets': [[1561, 1566]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T84'}, {'offsets': [[1570, 1577]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T109'}, {'offsets': [[1587, 1607]], 'text': ['functions downstream'], 'type': 'Regulation', 'id': 'T110'}, {'offsets': [[1646, 1655]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T111'}, {'offsets': [[1666, 1676]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T112'}, {'offsets': [[1745, 1755]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T113'}, {'offsets': [[1768, 1778]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T114'}, {'offsets': [[1810, 1817]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T115'}, {'offsets': [[2054, 2060]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T116'}, {'offsets': [[2061, 2078]], 'text': ['two other markers'], 'type': 'Anaphora', 'id': 'T85'}, {'offsets': [[2163, 2173]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T117'}, {'offsets': [[2198, 2208]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T118'}, {'offsets': [[2224, 2237]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T119'}, {'offsets': [[2282, 2290]], 'text': ['preceded'], 'type': 'Positive_regulation', 'id': 'T120'}, {'offsets': [[2291, 2304]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T121'}, {'offsets': [[2360, 2371]], 'text': ['had no role'], 'type': 'Regulation', 'id': 'T122'}, {'offsets': [[2384, 2394]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T123'}, {'offsets': [[2445, 2451]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T124'}, {'offsets': [[2463, 2473]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T125'}, {'offsets': [[2479, 2488]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T126'}, {'offsets': [[2547, 2556]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T127'}, {'offsets': [[2670, 2679]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T128'}, {'offsets': [[2773, 2782]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T129'}, {'offsets': [[2852, 2858]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[2868, 2878]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T131'}, {'offsets': [[2996, 3003]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T132'}, {'offsets': [[3157, 3168]], 'text': ['interaction'], 'type': 'Regulation', 'id': 'T133'}, {'offsets': [[3322, 3329]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T134'}, {'offsets': [[3372, 3379]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[3454, 3462]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T136'}, {'offsets': [[3466, 3472]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T137'}]","[{'trigger': 'T86', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T87', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T5', 'T3']}}, {'trigger': 'T88', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T3']}}, {'trigger': 'T89', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T88', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T3']}}, {'trigger': 'T89', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T88', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T3']}}, {'trigger': 'T89', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T88', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T3']}}, {'trigger': 'T89', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T90', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T7', 'T10', 'T91']}}, {'trigger': 'T90', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T8', 'T10', 'T91']}}, {'trigger': 'T90', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T9', 'T10', 'T91']}}, {'trigger': 'T90', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T7', 'T10', 'T92']}}, {'trigger': 'T90', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T8', 'T10', 'T92']}}, {'trigger': 'T90', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T9', 'T10', 'T92']}}, {'trigger': 'T93', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T10']}}, {'trigger': 'T94', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T93', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T10']}}, {'trigger': 'T94', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T93', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T10']}}, {'trigger': 'T94', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T95', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T11', 'T13']}}, {'trigger': 'T95', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T12', 'T13']}}, {'trigger': 'T96', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T14']}}, {'trigger': 'T97', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T96', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T14']}}, {'trigger': 'T97', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T96', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T14']}}, {'trigger': 'T97', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T98', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T18', 'T20']}}, {'trigger': 'T98', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T19', 'T20']}}, {'trigger': 'T99', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T21']}}, {'trigger': 'T99', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T21']}}, {'trigger': 'T100', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T101', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T23']}}, {'trigger': 'T102', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T103', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T23']}}, {'trigger': 'T104', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T105', 'id': 'E40', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T106', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T106', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T107', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'T29']}}, {'trigger': 'T108', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T109', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T110', 'id': 'E46', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T32', 'T33']}}, {'trigger': 'T111', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T32']}}, {'trigger': 'T112', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T111', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T34']}}, {'trigger': 'T113', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'T36']}}, {'trigger': 'T114', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T113', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'T37']}}, {'trigger': 'T115', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T40', 'T39']}}, {'trigger': 'T115', 'id': 'E54', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T40', 'T41']}}, {'trigger': 'T116', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T44', 'T42']}}, {'trigger': 'T116', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T44', 'T43']}}, {'trigger': 'T116', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T45', 'T42']}}, {'trigger': 'T116', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T45', 'T43']}}, {'trigger': 'T117', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'T46']}}, {'trigger': 'T118', 'id': 'E60', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T117', 'id': 'E61', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T47']}}, {'trigger': 'T118', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T119', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T119', 'id': 'E64', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T120', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E66', 'E63']}}, {'trigger': 'T121', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T120', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E68', 'E64']}}, {'trigger': 'T121', 'id': 'E68', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T122', 'id': 'E69', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E70', 'T54']}}, {'trigger': 'T123', 'id': 'E70', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T124', 'id': 'E71', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E72', 'T56']}}, {'trigger': 'T125', 'id': 'E72', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T126', 'id': 'E73', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T127', 'id': 'E74', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T128', 'id': 'E75', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T129', 'id': 'E76', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T130', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E78', 'T65']}}, {'trigger': 'T131', 'id': 'E78', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T130', 'id': 'E79', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E78', 'T66']}}, {'trigger': 'T132', 'id': 'E80', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T132', 'id': 'E81', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}, {'trigger': 'T133', 'id': 'E82', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T72', 'T72']}}, {'trigger': 'T133', 'id': 'E83', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T72', 'T73']}}, {'trigger': 'T133', 'id': 'E84', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T73', 'T72']}}, {'trigger': 'T133', 'id': 'E85', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T73', 'T73']}}, {'trigger': 'T134', 'id': 'E86', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T75', 'T76']}}, {'trigger': 'T135', 'id': 'E87', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T77', 'T75']}}, {'trigger': 'T136', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E89', 'T79']}}, {'trigger': 'T137', 'id': 'E89', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}]","[{'id': 'R1', 'head': {'ref_id': 'T81', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T82', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T82', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T82', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T83', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T84', 'role': 'Subject'}, 'tail': {'ref_id': 'T32', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T44', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T45', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E17', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E19', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E24', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E35', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E38', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E47', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E49', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E71', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E77', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E79', 'value': ''}]",[]
121,PMC-3245220-21-Materials_and_Methods,"Analysis of PKCalpha Kinase Activity
Human MDMs were starved for 2 hours before stimulation with M-CSF (0-60 minutes), then washed with cold PBS and removed from the plates. The cells were resuspended in lysis buffer (20 mM Tris, 5 mM MgCl2, 1 mM EGTA, 20 mM beta-glycerol phosphate, 1 mM PMSF 2 microg/ml aprotinin and 2 microg/ml leupeptin, pH 7.5), sonicated and centrifuged to obtain whole cell lysates, which were then immunoprecipitated with anti-PKCalpha antibody and protein G-agarose (Invitrogen). Immune complexes were washed twice, and PKCalpha activity was analyzed by non-radioactive Peptag assay kit (Promega). Briefly, kinase buffer, activator, peptide protection solution and Peptag peptide were incubated with the immune complexes at 30degreesC for 30 minutes. Reactions were stopped by boiling for 10 minutes and samples were separated on 0.8% agarose gel. Phosphorylated peptide migrated toward the anode (+), while non-phosphorylated peptide migrated toward the cathode (-). Fluorescein-tagged peptides were visualized by UV light.","[{'offsets': [[12, 20]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[547, 555]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
122,PMC-2626671-16-MATERIALS_AND_METHODS,"Online supplemental material.
Fig. S1 shows the characterization of peripheral CD8+ T cells from Runx3-/- mice. Fig. S2 shows effector protein expression by Runx3 WT and KO cells at day 4 of in vitro culture. Primer sequences used for ChIP experiments are shown in Table S1. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081242/DC1.","[{'offsets': [[79, 82]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 102]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[157, 162]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
123,PMC-1447668-10-Materials_and_Methods,"Cell culture.
HEK 293T cells were cultured in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, California, United States). Jurkat T cells and primary human CD4+ T cells were cultured in RPMI-1640 medium (Invitrogen). Media were supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mug/ml streptomycin (Cambrex, East Rutherford, New Jersey, United States), and 10% fetal bovine serum (Atlanta Biologicals, Norcross, Georgia, United States).","[{'offsets': [[163, 166]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
124,PMC-1447668-06-Results,"Increased Foxp3 Protein Expression Is Associated with Low HTLV-I Proviral Load
Since Foxp3 is expressed almost exclusively within CD4+CD25+ T cells, a major viral reservoir for HTLV-I [33], it was important to determine whether there was an association between Foxp3 and HTLV-I replication in infected patients. We therefore quantitated the Foxp3 protein expression in CD4+CD25+ T cells by flow cytometry and the HTLV-I proviral load (a surrogate marker of viral replication) by real-time PCR from eight patients with HAM/TSP and eight asymptomatic carriers (ACs). The data from this analysis is summarized in Table 1. As expected, patients with HAM/TSP exhibited significantly higher proviral loads (indicated as HTLV-I proviral DNA copies/100 cells) (34.68 +/- 23.19) compared to ACs (4.75 +/- 5.47) (p = 0.0008). The percentage of Foxp3+ cells within the CD4+CD25+ T cell population was significantly greater in ACs (43.23 +/- 12.95) than in HAM/TSP patients (18.59 +/- 5.77) (p = 0.0033). These data suggest that high levels of Foxp3 protein expression are associated with reduced HTLV-I replication in vivo. They also support our recent reports that high proviral loads, which have been shown to correlate with high Tax mRNA in HTLV-I-infected patients, are associated with reduced Foxp3 expression [8,34].","[{'offsets': [[10, 15]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[85, 90]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[130, 133]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[134, 138]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[261, 266]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[341, 346]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[369, 372]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[373, 377]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[834, 839]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[858, 861]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[862, 866]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1032, 1037]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1221, 1224]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1287, 1292]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[0, 9]], 'text': ['Increased'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[24, 34]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[94, 103]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[355, 365]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[1017, 1021]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[1046, 1056]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[1216, 1220]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[1279, 1286]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1293, 1303]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T22', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
125,PMC-2889865-22-Caption-Figure_6,Involvement of PKC and JNK in cytokine expression. Jurkat T-cells were incubated with PKC- and JNK inhibitors for 1 h followed by stimulation with PMA (162 nM) for 24 h. (A) CXCL8 expression was inhibited in a dose-dependent manner by both inhibitors. (B) JNK-I revealed a stronger inhibitory effect on IL-6 expression than the PKC-I. (C) TNF expression was not affected by either inhibitor. Statistical significance from the positive control (PMA) was determined using Student's t-test. (n = 3).,"[{'offsets': [[174, 179]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[303, 307]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[180, 190]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T3'}, {'offsets': [[195, 204]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T4'}, {'offsets': [[215, 224]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T5'}, {'offsets': [[282, 299]], 'text': ['inhibitory effect'], 'type': 'Negative_regulation', 'id': 'T6'}, {'offsets': [[308, 318]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T3', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T7', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],[],[]
126,PMC-2664230-06-MATERIALS_AND_METHODS,"NF-kappaB and CREB Electrophoretic Mobility Shift Assay (EMSA)
The non-radioactive LightShift Chemiluminescent EMSA Kit was used to detect DNA-protein interactions. The NF-kappaB 3' biotin end-labeled DNA oligonucleotide used as a probe for the EMSA was a 42-bp double stranded construct (5'-TTGTTACAA-GGGGACTTTCCGCTGGGGACTTTCCAGGGAGGC - 3') containing two tandemly repeated NF-kappaB binding sites (underlined). Specificity was determined by a competition assay with the addition of 200 molar excess of unlabeled double stranded NF-kappaB oligonucleotide. The CREB 3' biotin end-labeled DNA oligonucleotide used as a probe for the EMSA was a 23-bp double stranded construct (5'-TTT TCG AGC TCTGACGTCAGA-GC - 3') containing the CRE consensus sequence (underlined). Specificity was determined by a competition assay with the addition of 200 molar excess of unlabeled double stranded CREB oligonucleotide.
Nuclear extracts (10 mug) were incubated with 5 nM NF-kappaB or CREB probe (NF-kB: 1x binding buffer, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 0.1% NP40, 10% glycerol, and 50 ng/mul poly dI-dC, CREB: 1x binding buffer, 20 mM Tris, pH 7.5, 50 mM KCl, 1 mM EDTA, 1 mM DTT, 0.10% NP40, 6% glycerol, 0.1 mg/mL BSA and 50 ng/mul poly dI-dC) and were then electrophoresed through a 6% DNA retardation gel at 100V for 90 minutes. The gels were electrophoretically transferred at 380mA for 1 hour on ice to a positively charged nylon membrane and immediately cross-linked for 15 minutes with a UV transilluminator equipped with a 312 nm bulb. Streptavidin-horseradish peroxidase conjugate and the LightShift Chemiluminescent Substrate were used to detect the biotin end-labeled DNA. The nylon membranes were exposed to x-ray film for 1-3 minutes for detection.",[],[],[],[],[],[]
127,PMC-2791889-06-Results,"IL-10 Production by Th1 Cells Requires ERK1 and ERK2 Activation
Our data showed that the maintenance of IL-10 induction in Th1 cells required stimulation with high antigen dose, which to some extent could be compensated for by the addition of IL-12. Signaling through the TCR with high doses of antigen induced stronger ERK1 and ERK2 activation than that induced by low antigen dose, not only in naive CD4+ T cells (data not shown) as previously demonstrated (Jorritsma et al., 2003) but also in CD4+ T cells restimulated with the same high and low antigen doses (Figure 5A). Although the apparent peak and amount of ERK1 and ERK2 activation varied slightly between experiments, a consistent finding was that high antigen dose differentiated Th1 cells always showed enhanced and prolonged ERK1 and ERK2 activation in the presence of IL-12, regardless of whether they were restimulated with high or low antigen dose (Figure 5B).
We then investigated whether ERK1 and ERK2 activation was required for the induction of IL-10 in Th1 cells by using U0126 (Figure 5C), a compound that blocks downstream ERK activation. To ensure that only T cell signaling was being affected by U0126, we used an APC-free system in which the T cells were differentiated in the presence of increasing doses of anti-CD3 and a constant amount of IL-12. As in the APC-driven cultures, stronger TCR stimulation together with IL-12 led to higher percentages of cells producing both IL-10 and IFN-gamma after 1 week of culture (Figure 5C). Addition of U0126 to the cultures abrogated the production of IL-10 at all doses of anti-CD3 (Figure 5C). Because U0126 inhibits the MEK5-catalyzed activation of ERK5, as well as the MEK1- and MEK2-catalyzed activation of ERK1 and ERK2 (Bain et al., 2007; Mody et al., 2001), we also used the more specific, structurally unrelated MEK1 and MEK2 inhibitor PD184352 at concentrations in which it inhibits MEK1 and MEK2 but not MEK5 (Bain et al., 2007; Mody et al., 2001). PD184352 caused a similar inhibition of IL-10 production by Th1 cells in a dose-dependent fashion (Figure 5D and Figure S5A). Upon addition of inhibitors to other signaling pathways, including a p38 MAPK inhibitor, SB203580, or the GSK3beta inhibitor, CT99021 (Bain et al., 2007), no effect on IL-10 production was observed (Figure S5B). Our data thus suggested that IL-10 production by Th1 cells in response to high antigen dose and IL-12 requires ERK1 and ERK2 signaling, but not the activation of the p38 or the GSK3beta pathways.","[{'offsets': [[0, 5]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[39, 43]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[48, 52]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[104, 109]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[243, 248]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[320, 324]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[329, 333]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[402, 405]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[496, 499]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[617, 621]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[626, 630]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[789, 793]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[798, 802]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[833, 838]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[957, 961]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[966, 970]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1016, 1021]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1291, 1294]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1320, 1325]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1397, 1402]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1453, 1458]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1463, 1472]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1572, 1577]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1599, 1602]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1643, 1647]], 'text': ['MEK5'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1672, 1676]], 'text': ['ERK5'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1693, 1697]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1703, 1707]], 'text': ['MEK2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1732, 1736]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1741, 1745]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1841, 1845]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1850, 1854]], 'text': ['MEK2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1913, 1917]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1922, 1926]], 'text': ['MEK2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1935, 1939]], 'text': ['MEK5'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2020, 2025]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2175, 2183]], 'text': ['p38 MAPK'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2212, 2220]], 'text': ['GSK3beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2274, 2279]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2347, 2352]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2414, 2419]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2429, 2433]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2438, 2442]], 'text': ['ERK2'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2484, 2487]], 'text': ['p38'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2495, 2503]], 'text': ['GSK3beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[6, 16]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[30, 38]], 'text': ['Requires'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[53, 63]], 'text': ['Activation'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[89, 100]], 'text': ['maintenance'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[110, 119]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[133, 141]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[231, 239]], 'text': ['addition'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[303, 310]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[334, 344]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[355, 362]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[631, 641]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T56'}, {'offsets': [[766, 774]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[779, 788]], 'text': ['prolonged'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[803, 813]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[971, 981]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[986, 994]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[1003, 1012]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[1438, 1447]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[1544, 1553]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[1558, 1568]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[1630, 1638]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[1648, 1657]], 'text': ['catalyzed'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[1658, 1668]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1708, 1717]], 'text': ['catalyzed'], 'type': 'Positive_regulation', 'id': 'T69'}, {'offsets': [[1718, 1728]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[1855, 1864]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[1904, 1912]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[2006, 2016]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[2026, 2036]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[2184, 2193]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[2221, 2230]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[2264, 2270]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T77'}, {'offsets': [[2280, 2290]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T78'}, {'offsets': [[2353, 2363]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[2377, 2391]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[2420, 2428]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[2466, 2476]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T82'}]","[{'trigger': 'T46', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E4']}}, {'trigger': 'T82', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T48', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T47', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E6']}}, {'trigger': 'T48', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T47', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E4']}}, {'trigger': 'T82', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T47', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E6']}}, {'trigger': 'T49', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T50', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T51', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T52', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T53', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T54', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T53', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T54', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T55', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T55', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T56', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T56', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T57', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T14']}}, {'trigger': 'T59', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T14']}}, {'trigger': 'T59', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T58', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T58', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T60', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T60', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T61', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E28']}}, {'trigger': 'T62', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T61', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E29']}}, {'trigger': 'T63', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T63', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T64', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T65', 'id': 'E36', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T66', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T67', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'T25']}}, {'trigger': 'T66', 'id': 'E39', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T69', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T27']}}, {'trigger': 'T66', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T69', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T28']}}, {'trigger': 'T66', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T69', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E49', 'T27']}}, {'trigger': 'T66', 'id': 'E45', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T69', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E49', 'T28']}}, {'trigger': 'T68', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T70', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T70', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T71', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T71', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T72', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T72', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T72', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T73', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T74', 'id': 'E56', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T75', 'id': 'E57', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T76', 'id': 'E58', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T77', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E57']}}, {'trigger': 'T78', 'id': 'E60', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T77', 'id': 'E61', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E58']}}, {'trigger': 'T79', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T80', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T41']}}, {'trigger': 'T81', 'id': 'E64', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E63', 'E3']}}, {'trigger': 'T81', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E63', 'E8']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E30', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E32', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E54', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E59', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E61', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E64', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E64', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E65', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E65', 'value': ''}]",[]
128,PMC-3148254-18-Caption-Figure_4,"CD40-induced activation of NF-kappaB and JNK is defective in HOIP-deficient cells.
CD40-mediated signaling was defective in HOIP-deficient cells (HOIP-/- + pMIP), but intact in parental cells transduced with an empty retroviral vector (A20.2J + pMIP) and in HOIP-deficient cells transduced with a retroviral vector encoding HOIP (HOIP-/- + HOIP). Cells were activated with CD154-expressing insect cells for the times indicated. As a negative control, cells were stimulated with insect cells lacking CD154 (5 minute time point only). Western blots of whole-cell lysates were probed with the indicated antibodies. Phospho-IkappaBalpha (pIkappaBalpha) and phospho-JNK (pJNK) blots were stripped and reprobed for total IkappaBalpha and total JNK, respectively (anti-JNK antibodies recognize p46 and p54 isoforms). IkappaBalpha blots were also reprobed for actin to demonstrate equal lane loading. Molecular weights are indicated at right. Similar results were obtained in a second experiment and in two additional experiments with a second HOIP-deficient clone.","[{'offsets': [[0, 4]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[61, 65]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 87]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[124, 128]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[258, 262]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[324, 328]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[330, 334]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[340, 344]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[373, 378]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[499, 504]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[612, 632]], 'text': ['Phospho-IkappaBalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[634, 647]], 'text': ['pIkappaBalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[715, 727]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[810, 822]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1036, 1040]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[66, 75]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[129, 138]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[263, 272]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[379, 389]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[491, 498]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[1041, 1050]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T21'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]",[],"[{'id': '*', 'ref_ids': ['T11', 'T12']}]",[],[]
129,PMC-3148254-11-Materials_and_Methods,"CD80 upregulation and flow cytometry
Cells (5x104 in 2 ml) were cultured in 24-well plates for 3 days with 5 microg/ml anti-CD40 or an isotype control antibody. Cells were stained for flow cytometry with FITC-anti-CD80 or an appropriate control antibody as described [28]. Data acquired with a FACScan flow cytometer (BD Biosciences) were analyzed with WinMDI 2.8 (Scripps Research Institute, San Diego, CA).","[{'offsets': [[0, 4]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[5, 17]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
130,PMC-2889865-04-Results,"Cooperative induction of cytokines by AP-1 and NF-kappaB
To further characterize the involvement of NF-kappaB in cytokine regulation, we treated cells with an NF-kappaB activation inhibitor (NAI). The results showed that NAI selectively down-regulated NF-kappaB activation (figures 4a and 4b) and did not alter AP-1 activity (figures 4c and 4d). Exposure of Jurkat T-cells to NAI resulted in a modest reduction of CXCL8 following PMA exposure, while it did not alter the CXCL8 release following HK E. coli exposure (figure 5a). NAI did not affect TNF expression (figure 5b) indicating that NF-kappaB is not the main regulator of CXCL8 or TNF following either PMA or HK E. coli exposure in Jurkat T-cells. In contrast, NAI resulted in a complete inhibition of IL-6 following PMA exposure and a 45% inhibition following HK E. coli exposure (figure 5c), suggesting an involvement of NF-kappaB in IL-6 regulation.
Ca2+ was observed to increase AP-1 activity (figure 1c) and reduce NF-kappaB activity (figure 2e); therefore, we exposed T-cells to a PKC inhibitor together with PMA to determine its effect on cytokine expression. Inhibition of PKC reduced CXCL8 release from 7 ng/ml to 3 ng/ml while it had a modest effect on IL-6 and TNF (figure 6a-c). This prompted us to test the effect of JNK inhibition on PMA-induced cytokine expression. JNK is involved in the regulation of a multitude of different transcription factors, including the phosphorylation and activation of c-Jun, c-Fos and p53, leading to cellular apoptosis [26]. Inhibition of the JNK pathways resulted in a down-regulation of both CXCL8 and IL-6, while no clear effect was observed on TNF expression (figure 6a-c). Analysis of mRNA levels using RT-qPCR (table 2) showed that PMA induced both il-6 and cxcl8 mRNA (5.1-fold and 111.8 fold respectively). Addition of the NF-kappaB inhibitor NAI and the JNK inhibitor reduced the il-6 expression below basal levels. In contrast, while the cxcl8 levels were suppressed by the same treatments the levels remained elevated above basal level.","[{'offsets': [[414, 419]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[471, 476]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[629, 634]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[759, 763]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[893, 897]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1150, 1155]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1220, 1224]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1471, 1476]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1478, 1483]], 'text': ['c-Fos'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1488, 1491]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1598, 1603]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1608, 1612]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1759, 1763]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1768, 1773]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1893, 1897]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1952, 1957]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[401, 410]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[420, 429]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[461, 466]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T20'}, {'offsets': [[477, 484]], 'text': ['release'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[485, 494]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[616, 625]], 'text': ['regulator'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[642, 651]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[745, 755]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[764, 773]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[797, 807]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[808, 817]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[865, 876]], 'text': ['involvement'], 'type': 'Regulation', 'id': 'T29'}, {'offsets': [[898, 908]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T30'}, {'offsets': [[1142, 1149]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T31'}, {'offsets': [[1156, 1163]], 'text': ['release'], 'type': 'Localization', 'id': 'T32'}, {'offsets': [[1210, 1216]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T33'}, {'offsets': [[1437, 1452]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T34'}, {'offsets': [[1457, 1467]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1560, 1568]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[1574, 1589]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[1746, 1753]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1774, 1778]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T39'}, {'offsets': [[1881, 1888]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1898, 1908]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T41'}, {'offsets': [[1958, 1964]], 'text': ['levels'], 'type': 'Transcription', 'id': 'T42'}, {'offsets': [[1970, 1980]], 'text': ['suppressed'], 'type': 'Negative_regulation', 'id': 'T43'}, {'offsets': [[2004, 2014]], 'text': ['the levels'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[2015, 2023]], 'text': ['remained'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[2024, 2032]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T45'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T20', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T21', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T24', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T26', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T27', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T30', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T33', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T34', 'id': 'E17', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T34', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T34', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T35', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T35', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T35', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T36', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T37', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T36', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T37', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T38', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T39', 'id': 'E28', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T38', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T39', 'id': 'E30', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T40', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T41', 'id': 'E32', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T42', 'id': 'E33', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T43', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T44', 'id': 'E35', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T45', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}]","[{'id': 'R1', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T42', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E35', 'value': ''}]",[]
131,PMC-3279418-21-Caption-Figure_3,"Defective production of pro-inflammatory mediators from stimulated cpdm BMDC.
(A-D) Cultured WT and cpdm BMDC (1x105 cells in 0.1 ml complete medium) were washed and stimulated with medium, 100 ng/ml LPS or 25 microg/ml poly I:C for 24 hours. Supernatants were collected for ELISA of IL12P70, IL6, and GMCSF, and for quantification of nitric oxide (NO). (E-F) Gradient numbers (1x104, 2x104, and 4x104 cells in 0.1 mL complete medium) of BMDC were used for100 ng/mL LPS stimulation. After 24 hours, the amounts of IL12P70 and IL6 from the supernatant were measured. (G) The cpdm mice rescued by Sharpin-containing BAC had complete remission of the inflammatory phenotype [2]. BMDC developed from cpdm and rescued cpdm mice were plated (1x106 cells in 0.3 mL) and stimulated with 100 ng/mL LPS. After 24 hours, supernatants were collected for analysis of IL12P70 production. Data are representative of three independent experiments. * P<0.01; ** P<0.005.","[{'offsets': [[293, 296]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[302, 307]], 'text': ['GMCSF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[526, 529]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[595, 602]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
132,PMC-1310901-12-RESULTS,"Specific CpG sites in the IRF-4 promoter are methylated in hematopoietic cells
In order to exactly map the methylation sites within the IRF-4 promoter, we treated DNA of Jurkat, CML-T1, U-937, K-562 and EM-2 cells as well as of SD-1, RPMI-8226 and BV-173 control cells with bisulfite, which chemically converts unmethylated cytosine to uracil, whereas it has no effect on methylated cytosine, i.e. in CpG (34). This technique is especially useful for detection of unknown methylation patterns. PCR amplification, cloning and sequencing of the bisulfite-treated DNA showed a specific methylation pattern of the analyzed 62 CpG sites in all cell lines (Figure 4 and Table 1). In general, the methylational status ranged from one cell line with a nearly non-methylated IRF-4 promoter (SD-1, IRF-4-positive) to a completely methylated IRF-4 promoter in CML-T1 (IRF-4-negative). Interestingly, the percentage of CpG methylation in the IRF-4 promoter from IRF-4-positive cells was very low (mean 24%) as compared with IRF-4-negative cells (mean 94%) (Figure 4A and Table 1). A 5'-region (R1) with 13 hypermethylated CpG sites (mean number of methylated clones 5.5 of 8 with 77% methylated CpGs) was found in most cells (except SD-1 and RPMI-8226) and a 3'-region (R3) of 6 hypomethylated CpG sites (mean number of methylated clones 1.7 of 8 with 33% methylated CpGs) was found in most cells (except CML-T1 and U-937) (Figure 4A and Table 1).
Intriguingly, a stretch of 13 CpG sites (#10-22; R2) was detected in between these regions, which were highly methylated in IRF-4-negative (mean number of methylated clones 7.1 of 8 with 89% methylated CpGs) but totally non-methylated in IRF-4-positive cells (Figure 4A and B). Furthermore, three CpG sites at the 5' end (#54, 56, 58) and two CpG motifs at the 3' end (#1, 2) showed this direct correlation between high methylation status and absence of IRF-4 expression. In addition, two CpG sites located in a NFkappaB (#48) and a SP1 element (#45) are less methylated in IRF-4-positive than in IRF-4-negative cells (mean number of methylated clones: 1/8 versus 8/8). These results indicate the involvement of CpG methylation in the regulation of IRF-4 expression in leukemic cells.","[{'offsets': [[26, 31]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[136, 141]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[766, 771]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[788, 793]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[831, 836]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[857, 862]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[930, 935]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[950, 955]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1012, 1017]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1560, 1565]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1674, 1679]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1890, 1895]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2010, 2015]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2033, 2038]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2185, 2190]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[794, 802]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[863, 871]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[956, 964]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[1018, 1026]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[1566, 1574]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[1680, 1688]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[1879, 1886]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1896, 1906]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[2016, 2024]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[2039, 2047]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[2171, 2181]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T26'}, {'offsets': [[2191, 2201]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T27'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T23', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T25', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T26', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T27', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}]",[]
133,PMC-1447668-00-TIAB,"Foxp3 Represses Retroviral Transcription by Targeting Both NF-kappaB and CREB Pathways
Forkhead box (Fox)/winged-helix transcription factors regulate multiple aspects of immune responsiveness and Foxp3 is recognized as an essential functional marker of regulatory T cells. Herein we describe downstream signaling pathways targeted by Foxp3 that may negatively impact retroviral pathogenesis. Overexpression of Foxp3 in HEK 293T and purified CD4+ T cells resulted in a dose-dependent and time-dependent decrease in basal levels of nuclear factor-kappaB (NF-kappaB) activation. Deletion of the carboxyl-terminal forkhead (FKH) domain, critical for nuclear localization and DNA-binding activity, abrogated the ability of Foxp3 to suppress NF-kappaB activity in HEK 293T cells, but not in Jurkat or primary human CD4+ T cells. We further demonstrate that Foxp3 suppressed the transcription of two human retroviral promoters (HIV-1 and human T cell lymphotropic virus type I [HTLV-I]) utilizing NF-kappaB-dependent and NF-kappaB-independent mechanisms. Examination of the latter identified the cAMP-responsive element binding protein (CREB) pathway as a target of Foxp3. Finally, comparison of the percent Foxp3+CD4+CD25+ T cells to the HTLV-I proviral load in HTLV-I-infected asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis suggested that high Foxp3 expression is associated with low proviral load and absence of disease. These results suggest an expanded role for Foxp3 in regulating NF-kappaB- and CREB-dependent cellular and viral gene expression.","[{'offsets': [[0, 5]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[196, 201]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[334, 339]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[410, 415]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[441, 444]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[718, 723]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[809, 812]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[851, 856]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1159, 1164]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1201, 1206]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1207, 1210]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1211, 1215]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1390, 1395]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1511, 1516]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[392, 406]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[576, 584]], 'text': ['Deletion'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[592, 631]], 'text': ['carboxyl-terminal forkhead (FKH) domain'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[633, 641]], 'text': ['critical'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[646, 653]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T19'}, {'offsets': [[654, 666]], 'text': ['localization'], 'type': 'Localization', 'id': 'T20'}, {'offsets': [[675, 682]], 'text': ['binding'], 'type': 'Binding', 'id': 'T21'}, {'offsets': [[1385, 1389]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[1396, 1406]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T6', 'T17']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E4', 'T6', 'T17']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T19']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E6', 'T6', 'T17']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T23', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]",[],[],[],[]
134,PMC-1447668-18-Materials_and_Methods,"Transcription factor DNA-binding analysis (TF-ELISA).
CREB-1 and ATF-2 DNA-binding activity was analyzed with the TransFactor Profiling (Inflammation 1) Kit (BD Biosciences) according to the manufacturer's protocol. Nuclear extracts were prepared from HEK 293T cells transfected with a control vector (EGFP) or Foxp3 expression vector (1,000 ng) in the presence or absence of forskolin (10 muM for 4 h) using the TransFactor Extraction Kit (BD Biosciences). Protein concentration was determined using a Biophotometer (Eppendorf, Hamburg, Germany). Nuclear extracts (20 mug) were incubated in preblocked wells containing plate-bound double-stranded oligonucleotides corresponding to an ATF/CREB consensus sequence (...TGACATCA...). Wells were washed, incubated with the appropriate primary antibody, washed, incubated with secondary antibody (HRP-labeled), washed again, and finally developed with TMB substrate. Colorimetric reactions were read using a VersaMax microplate reader (Molecular Devices) at an absorbance of 655 nm.","[{'offsets': [[54, 60]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[65, 70]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[311, 316]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[75, 82]], 'text': ['binding'], 'type': 'Binding', 'id': 'T4'}, {'offsets': [[317, 327]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T5'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
135,PMC-3148254-16-Caption-Figure_2,"CD40-mediated CD80 upregulation is defective in HOIP-deficient cells.
Cells were incubated for 72 hrs with an isotype control antibody (left) or anti-CD40 antibody (right) and then stained for expression of CD80 (filled profiles indicate staining with anti-CD80 antibody; open profiles are staining with an isotype control antibody). Transduction of both HOIP-deficient (HOIP-/-) clones with a retrovirus encoding FLAG-HOIP reversed defective CD80 upregulation, while transduction with an empty vector (pMIP) did not. Similar results were obtained in a second experiment.","[{'offsets': [[0, 4]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 18]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[48, 52]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[207, 211]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[355, 359]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[371, 375]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[419, 423]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[443, 447]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[5, 13]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[19, 31]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[35, 44]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[53, 62]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T12'}, {'offsets': [[193, 203]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[360, 369]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[424, 432]], 'text': ['reversed'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[433, 442]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[448, 460]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T17'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T16', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T17', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
136,PMC-3279418-16-Materials_and_Methods,"Immunofluorescence
Fibroblast and macrophage cells were transfected with pFLAG-SHARPIN. 48 hours later, cells were washed briefly with PBS, then fixed in cold methanol at -20degreesC for 10 minutes and cold acetone at -20degreesC for 1 minute. Incubate cells with PBS+1% BSA for 15 minutes to block non-specific binding. Fixed cells were then incubated with anti-FLAG (1:100) as the primary antibody at room temperature for 1 hour, followed by three 5-minute washes. Cells were further incubated with goat anti-rabbit IgG-FITC (1:100) as the secondary antibody at room temperature for 30 minutes, followed by three 5-minute washes. Cells were then examined using inverse fluorescence microscope.","[{'offsets': [[79, 86]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
137,PMC-2791889-02-Results,"IL-12 and High Doses of Antigen Induce the Development of Th1 Cells Producing IL-10
To study the differentiation of Th1 cells coproducing IFN-gamma and IL-10, we cultured purified TCR-transgenic DO11.10 naive CD4+ T cells with purified DCs as APCs and increasing doses of ovalbumin peptide 323-339 (OVA). Culture with high doses of antigen for 7 days gave rise to Th1 cells expressing IFN-gamma upon restimulation (Constant et al., 1995; Hosken et al., 1995), but not IL-10 (Figure S1A available online). Culture with low antigen doses under the same conditions led to the differentiation of Th2 cells, which expressed both IL-4 and IL-10 upon restimulation (Figure S1A). Culture of naive CD4+ T cells in an APC-free system by stimulation with anti-CD3 and anti-CD28 antibodies in the presence of IL-12 resulted in IFN-gamma-producing Th1 cells, a proportion of which coproduced IL-10, as did Th2 cells resulting from culture in IL-4 (Figure S1B).
To investigate whether the lack of IL-10 produced by Th1 cells resulted from inhibition of IL-10 production by DCs and high antigen dose or alternatively required IL-12, we cultured naive CD4+ T cells with increasing doses of antigen presented by DC in the presence of IL-12. At low doses of antigen, IL-12 abrogated the development of Th2 cells and induced IFN-gamma expression but only low levels of IL-10 expression, suggesting that IL-12 per se was not sufficient to induce significant IL-10 production in Th1 cells (Figure 1A). Strikingly, as the antigen dose was increased, Th1 populations driven with IL-12 now contained higher numbers of IL-10-producing cells (Figure 1A) and produced more IL-10 protein upon restimulation (Figures 1A and 1B). Thus, the development of Th1 cells producing IL-10 required both IL-12 and high doses of antigen. Th1 cells differentiated to produce large amounts of IL-10 and IFN-gamma and lost their capacity to produce IL-2 (Figure 1B). Because the presence of IL-12 reduced the proliferation of CD4+ T cells at both high and low antigen doses (Table S1), and only the former showed IL-10 production, the development of high IL-10-producing cells is most likely not related to limited IL-2. Naive CD4+ T cells from DO11.10/recombination-activating gene 1 (Rag1)-deficient animals, cultured with high doses of antigen in the presence of IL-12, also resulted in IL-10 expression by Th1 cells, showing that this expression was not dependent on the presence of effector or memory T cells or Treg cells (Figure S2). Although it has been suggested that TGF-beta can induce IL-10 in CD4+ T cells (Kitani et al., 2003; Schiott et al., 2000), we found that in developing Th1 and Th2 cells this was not the case (data not shown). In fact, neutralization of TGF-beta led to increased IL-10 production by both T cell subsets (Figure S3). Thus, the development of IL-10-producing Th1 cells only depended on the presence of IL-12 together with high antigen dose and not on other soluble factors such as IL-2 or TGF-beta or on the presence of other T cell types.","[{'offsets': [[0, 5]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[78, 83]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[138, 147]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[152, 157]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[209, 212]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[272, 281]], 'text': ['ovalbumin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[299, 302]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[385, 394]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[468, 473]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[624, 628]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[633, 638]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[689, 692]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[749, 752]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[762, 766]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[797, 802]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[815, 824]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[879, 884]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[929, 933]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[983, 988]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1039, 1044]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1111, 1116]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1136, 1139]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1217, 1222]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1249, 1254]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1306, 1315]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1350, 1355]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1384, 1389]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1438, 1443]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1556, 1561]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1594, 1599]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1646, 1651]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1745, 1750]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1765, 1770]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1851, 1856]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1861, 1870]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1906, 1910]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1948, 1953]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1983, 1986]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2070, 2075]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2112, 2117]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2172, 2176]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2184, 2187]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2210, 2241]], 'text': ['recombination-activating gene 1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2243, 2247]], 'text': ['Rag1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2323, 2328]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2347, 2352]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2534, 2542]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2554, 2559]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2563, 2566]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2734, 2742]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2760, 2765]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2838, 2843]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2897, 2902]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2976, 2980]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2984, 2992]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[68, 77]], 'text': ['Producing'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[126, 137]], 'text': ['coproducing'], 'type': 'Gene_expression', 'id': 'T59'}, {'offsets': [[356, 360]], 'text': ['rise'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[374, 384]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[609, 618]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[803, 811]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[825, 834]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[868, 878]], 'text': ['coproduced'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[975, 979]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[989, 997]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[1011, 1019]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1025, 1035]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[1045, 1055]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T70'}, {'offsets': [[1298, 1305]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[1316, 1326]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[1356, 1366]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T73'}, {'offsets': [[1419, 1425]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[1444, 1454]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[1600, 1609]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[1632, 1640]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T77'}, {'offsets': [[1641, 1645]], 'text': ['more'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[1735, 1744]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[1751, 1759]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1826, 1833]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[1875, 1879]], 'text': ['lost'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[1898, 1905]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T83'}, {'offsets': [[2076, 2086]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[2118, 2127]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T85'}, {'offsets': [[2164, 2171]], 'text': ['limited'], 'type': 'Negative_regulation', 'id': 'T86'}, {'offsets': [[2249, 2258]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T87'}, {'offsets': [[2335, 2343]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[2353, 2363]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T89'}, {'offsets': [[2391, 2406]], 'text': ['this expression'], 'type': 'Anaphora', 'id': 'T56'}, {'offsets': [[2415, 2424]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T90'}, {'offsets': [[2547, 2553]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[2716, 2730]], 'text': ['neutralization'], 'type': 'Negative_regulation', 'id': 'T92'}, {'offsets': [[2750, 2759]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T93'}, {'offsets': [[2766, 2776]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[2844, 2853]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[2869, 2877]], 'text': ['depended'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[2946, 2967]], 'text': ['other soluble factors'], 'type': 'Anaphora', 'id': 'T57'}]","[{'trigger': 'T58', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T59', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T59', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T60', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T61', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T60', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T61', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T62', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T62', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T63', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T15']}}, {'trigger': 'T64', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T63', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T15']}}, {'trigger': 'T65', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T66', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T67', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T68', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E17']}}, {'trigger': 'T69', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T70', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T71', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T24']}}, {'trigger': 'T72', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T71', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T24']}}, {'trigger': 'T73', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T74', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T27']}}, {'trigger': 'T75', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T76', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T77', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T78', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T79', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T80', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T33']}}, {'trigger': 'T81', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T81', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T82', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T83', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T84', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T85', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T86', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T87', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T88', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T45']}}, {'trigger': 'T89', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T90', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T91', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T48', 'T47']}}, {'trigger': 'T92', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T93', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E42']}}, {'trigger': 'T94', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T95', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T96', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T53']}}, {'trigger': 'T96', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T54']}}, {'trigger': 'T96', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T55']}}]","[{'id': 'R1', 'head': {'ref_id': 'T56', 'role': 'Subject'}, 'tail': {'ref_id': 'T89', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T54', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T55', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T6', 'T7']}, {'id': '*', 'ref_ids': ['T43', 'T44']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E40', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E41', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E48', 'value': ''}]",[]
138,PMC-2664230-02-MATERIALS_AND_METHODS,"This study was approved by the Human Research Protections Program and the Institutional Review Board. Written consent to participate in the study was obtained from all volunteers prior to blood donation.Heparinized Vacutainers were purchased from Becton Dickinson (San Jose, CA). 1.5-mL Eppendorf centrifuge tubes were purchased from Fisher Scientific (Pittsburg, PA). Hank's balanced salt solution (HBSS) and RPMI 1640 were obtained from Irvine Scientific (Santa Ana, CA). LPS fromEscherichia coliserotype 0111:B4 and PTX were purchased from Sigma (St. Louis, MO). The PKA inhibitor, N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoguinolinesulfonamide-2HCl] (H89), was purchased from Calbiochem (La Jolla, CA). Antibodies for phosphorylated CREB (serine 133), phosphorylated I-kappaBalpha (serines 32 and 36), phosphorylated NF-kappaB p65 subunit (serine 276), and secondary antibodies were purchased from Cell Signaling (Beverly, MA).Dextran T500 and Percoll were received from GE Healthcare/Amersham Biosciences (Piscataway, NJ). The enzyme-linked immunosorbent assay (ELISA) for TNF-alpha was obtained from Quantikine R&D Systems (Minneapolis, MN).Tris-glycine and DNA retardation gels, nitrocellulose membranes, and western blot running buffers were obtained from Invitrogen (Carlsbad, CA). NE-PER(R)nuclear and cytoplasmic extraction reagents, the BCA protein reagent kit, the Supersignal West Pico Chemiluminescent Kit, and the LightShift Chemiluminescent EMSA Kit were purchased from Pierce (Rockland, IL). CREB and NF-kappaB DNA oligonucleotide probes were synthesized by IDT (Coralville, IA). Nylon membranes were purchased from Roche Applied Sciences (Indianapolis, IN). Western blot band quantification was performed with the UN-SCAN-IT Gel Digitizing software (Silk Scientific, Orem, UT).","[{'offsets': [[736, 740]], 'text': ['CREB'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[770, 783]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[830, 833]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1077, 1086]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[721, 735]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T5'}, {'offsets': [[742, 752]], 'text': ['serine 133'], 'type': 'Entity', 'id': 'T6'}, {'offsets': [[755, 769]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T7'}, {'offsets': [[785, 795]], 'text': ['serines 32'], 'type': 'Entity', 'id': 'T8'}, {'offsets': [[800, 802]], 'text': ['36'], 'type': 'Entity', 'id': 'T9'}, {'offsets': [[805, 819]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[843, 853]], 'text': ['serine 276'], 'type': 'Entity', 'id': 'T11'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T6']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T8']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T9']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T11']}}]",[],[],[],[]
139,PMC-3245220-16-Materials_and_Methods,"Transient Transfection of RAW 264.7 Cells
RAW 264.7 cells were seeded in 12-well plates in RPMI medium containing 5% FBS one day prior to transfection, Secreted alkaline phosphatase (SEAP) reporter plasmids pTAL-SEAP or pNF-kappaB-SEAP were transfected into cells using Qiagene Effectene or Attractene transfection kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. For co-transfection studies, PKCalpha or NF-kappaB p65 constructs were mixed at a ratio of 5:1 with the reporter plasmid. For siRNA transfection, 100 nM of PKCalpha siRNA or control siRNA were used. Cells were incubated with the transfection reagents for 16-24 hours, washed and starved in RPMI without FBS for 4 hours. Samples were then stimulated with 100 ng/ml M-CSF for 4 hours at which point the medium was collected for the SEAP analysis. For inhibition studies, cells were pre-incubated with inhibitors for 30 minutes before M-CSF treatment. On average, we realized 30-40% transfection efficiency as confirmed by GFP expression in Raw 264.7 cells.","[{'offsets': [[413, 421]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[435, 438]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[540, 554]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1004, 1007]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[388, 403]], 'text': ['co-transfection'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[1008, 1018]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T6'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
140,PMC-3148254-03-Results,"HOIP is required for CD40-mediated CD80 upregulation and activation of germline epsilon transcription
Engagement of CD40 on B cells upregulates expression of CD80 [10], a cell surface protein that promotes activation of T cells interacting with B cells and other APC. To begin evaluating potential contributions of HOIP to CD40 signaling, we assayed the upregulation of CD80 induced by engagement of CD40 on parental A20.2J, HOIP-deficient, and HOIP-reconstituted cells (Fig. 2). Compared to the parental cell line, the CD40-stimulated upregulation of CD80 was dramatically reduced in all HOIP-deficient cells tested. In contrast, upregulation of CD80 was restored in HOIP-reconstituted cells, confirming that the defect in CD80 upregulation in the HOIP-deficient cells was due to the disruption of Rnf31.
CD40 signals in B cells can also contribute to the activation of DNA recombination in the immunoglobulin heavy chain locus [11], [12]. This process, known as immunoglobulin class switching (or isotype switching), allows B cells, initially expressing IgM, to switch to IgA, IgG, or IgE depending on the class of antibody most appropriate for a particular immune response. Switching to IgE can be induced by the combination of IL-4 and CD40 signals. The gene rearrangement necessary for IgE production is preceded by the production of non-coding RNA transcripts from germline sequences in the IgE heavy chain locus [13]. To determine whether HOIP is required in the initiation of the class switching process, the relevant B cell lines were stimulated through CD40 in the presence of IL-4 and tested for production of germline epsilon (GLepsilon) transcripts (Fig. 3). Anti-CD40 antibody stimulation alone or together with IL-4 induced GLepsilon transcription in parental A20.2J cells as expected. In contrast, only low levels of GLepsilon expression were detected in HOIP-deficient cells stimulated with either anti-CD40 antibody alone or anti-CD40 and IL-4. Normal levels of GLepsilon expression were induced in HOIP-reconstituted cells stimulated with anti-CD40 antibody alone or together with IL-4. Collectively, these data demonstrate that HOIP has a critical role in cellular responses to CD40 signaling.","[{'offsets': [[0, 4]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 25]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[35, 39]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[71, 87]], 'text': ['germline epsilon'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[116, 120]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[158, 162]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 319]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[323, 327]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[370, 374]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[400, 404]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[425, 429]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[445, 449]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[520, 524]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[552, 556]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[589, 593]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[647, 651]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[668, 672]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[724, 728]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[749, 753]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[799, 804]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[806, 810]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1231, 1235]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1240, 1244]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1446, 1450]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1563, 1567]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1587, 1591]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1621, 1637]], 'text': ['germline epsilon'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1639, 1648]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1726, 1730]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1739, 1748]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1833, 1842]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1871, 1875]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1957, 1961]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1980, 1989]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2017, 2021]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2100, 2104]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2148, 2152]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2198, 2202]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[8, 16]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[26, 34]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[40, 52]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[57, 67]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[88, 101]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T43'}, {'offsets': [[102, 112]], 'text': ['Engagement'], 'type': 'Binding', 'id': 'T44'}, {'offsets': [[132, 143]], 'text': ['upregulates'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[144, 154]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[354, 366]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[375, 382]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[386, 396]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[450, 463]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T50'}, {'offsets': [[525, 535]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[536, 548]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[574, 581]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[594, 603]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[631, 643]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[673, 686]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T56'}, {'offsets': [[714, 720]], 'text': ['defect'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[729, 741]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[754, 763]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[774, 777]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[785, 795]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1607, 1617]], 'text': ['production'], 'type': 'Transcription', 'id': 'T62'}, {'offsets': [[1731, 1738]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[1749, 1762]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T64'}, {'offsets': [[1843, 1853]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[1876, 1885]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[1990, 2000]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[2006, 2013]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[2022, 2035]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T69'}]","[{'trigger': 'T39', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T40', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T39', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T1']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T42', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T43', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T44', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T45', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E8']}}, {'trigger': 'T46', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T47', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T48', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E13']}}, {'trigger': 'T49', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T50', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T51', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T13']}}, {'trigger': 'T52', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T53', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'E18']}}, {'trigger': 'T54', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T55', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T56', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T57', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'E23']}}, {'trigger': 'T58', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T59', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T60', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E25']}}, {'trigger': 'T61', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T62', 'id': 'E26', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T63', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T64', 'id': 'E28', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T65', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T66', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T67', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T68', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T69', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}]",[],"[{'id': '*', 'ref_ids': ['T27', 'T28']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E26', 'value': ''}]",[]
141,PMC-2889865-20-Caption-Figure_4,"Inhibition of NF-kappaB activity by NAI. Jurkat T-cells were transfected with luciferase reporter plasmids containing either NF-kappaB or AP-1 cis-acting elements. The cells were incubated with NF-kappaB activation inhibitor (NAI) for 1 h followed by stimulation with PMA (162 nM, A and C) or HK E. coli (5 x 107 CFU/ml, B and D) for 24 h. (A, B) NF-kappaB, but not (C, D) AP-1 was inhibited. Statistical significance from the positive control (PMA/HK E. coli) was determined using Student's t-test. (n = 4). Controls were set to 1.","[{'offsets': [[78, 88]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
142,PMC-2065877-15-Materials_and_Methods,"Rnase protection assay.
Total RNA was isolated from CD19+ MACS-purified B cells using the Rneasy midi purification kit with Dnase treatment, according to the manufacturer's instructions (Qiagen). The mCK-1 probe template set (BD Biosciences) was labeled using the In Vitro Transcription Kit according to the manufacturer's instructions (BD Biosciences). Briefly, 50 ng of mCK-1 probe set was labeled with [alpha-32P]UTP using T7 RNA polymerase and purified using Sephadex G-50 columns (NucAway Spin column, Ambion). The labeled probe was quantitated using a scintillation counter, and 6 x 105 cherenkov cpm was used to hybridize to 4 mug of total RNA using the RPA kit (BD Biosciences). Samples were denatured at 90 degreesC and hybridized at 56 degreesC overnight. Single-stranded RNA was digested with a mixture of Rnase A and T1, and precipitated using isopropanol. Protected probes were resolved on a denaturing 4.75% acrylamide gel, dried, and imaged using a phosphorImager (Molecular Dynamics). Densitometry was performed using the ImageQuant TL v2005 software (GE Healthcare).","[{'offsets': [[52, 56]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[817, 824]], 'text': ['Rnase A'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[829, 831]], 'text': ['T1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
143,PMC-1447668-14-Materials_and_Methods,"Transient expression and luciferase assays.
HEK 293T cells were plated at a density of 5 x 105 cells/well in six-well culture plates (BD Biosciences, San Diego, California, United States) 1 d prior to transfection with the appropriate plasmid DNA (~2 mug total) using FuGene 6 transfection reagent (Roche, Basel, Switzerland). Jurkat T cells were plated at 1 x 106 cells/well in six-well culture plates the day of transfection with the appropriate plasmid DNA (~2 mug total) using FuGene 6 transfection reagent. Primary human CD4+ T cells (2 x 106) were nucleofected with the specified plasmid DNA (5 mug total) using the Human T Cell Nucleofection Kit (Amaxa, Gaithersburg, Maryland, United States). Forskolin (10 muM; Calbiochem, San Diego, California, United States) was added in some experiments 20 h posttransfection. Cells were harvested 24 h posttransfection and luciferase activity was analyzed using the Dual-luciferase Reporter Assay System (Promega) and a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, California, United States) according to manufacturer's guidelines. pGL4-TKhRluc2 was used as an internal control to normalize for transfection efficiency. Nucleofected CD4+ T cells were also monitored for transfection efficiency and cell viability 24 h posttransfection as follows. Transfection efficiency was routinely ~30% as determined by flow cytometric analysis of EGFP expression. Cell viability, determined by staining with 7-amino-actinomycin D (7-AAD; BD Biosciences), was routinely ~70%. Both transfection efficiency and cell viability in nucleofected CD4+ T cells was independent of the plasmids used.","[{'offsets': [[25, 35]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[526, 529]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[870, 880]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[918, 928]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1210, 1213]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1604, 1607]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
144,PMC-2626671-20-Caption-Figure_4,"Runx3 controls Eomes, perforin, granzyme B, and IFN-gamma expression in effector CTLs. Runx3+/+ or Runx3-/- CD8+ T cells were activated and transduced with retroviruses bearing an empty IRES-GFP cassette (GFP) or also encoding Eomes-VP16 (Eo-VP16) or Myc-Runx3 (Runx3). The frequency of transduced cells in the cultures was equivalent for all constructs (~75-90% GFP+ cells; not depicted). (A) Protein expression in whole-cell extracts (day 6) was analyzed by immunoblotting. Overexpression of Eomes-VP16 cannot be detected with the Eomes antibody, as the C-terminal epitope is within the region that has been replaced with the VP16 transactivation domain. (B) Expression of granzyme B and IFN-gamma after culture for 6 d and restimulation for 4 h with PMA and ionomycin was determined by intracellular staining. The percentage of positively stained cells is shown above the gate; the mean fluorescence intensity (MFI) of granzyme B staining for the total population is shown below the gate. The vertical gray lines indicate the MFI for WT GFP+ cells. Results are representative of at least two independent experiments. (C) Schematic diagram of the transcriptional network involving Runx3 and T-box factors. T-bet is induced by TCR signals and is essential for early IFN-gamma expression. Runx3 is present in naive CD8+ T cells and represses Runx1 and induces Eomes, perforin, granzyme B, and IFN-gamma expression. Eomes may participate in sustaining late IFN-gamma expression, whereas Runx3 and Eomes (but not T-bet) may cooperate to activate perforin expression. The dotted line indicates the partial effect of T-bet deficiency on Gzmb mRNA but not granzyme B protein expression.","[{'offsets': [[0, 5]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[15, 20]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[22, 30]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[32, 42]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[48, 57]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[87, 92]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[99, 104]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[108, 111]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[191, 194]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[227, 237]], 'text': ['Eomes-VP16'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[239, 246]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[251, 254]], 'text': ['Myc'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[255, 260]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[262, 267]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[494, 504]], 'text': ['Eomes-VP16'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[533, 538]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[628, 632]], 'text': ['VP16'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[675, 685]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[690, 699]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[922, 932]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1040, 1043]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1183, 1188]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1208, 1213]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1267, 1276]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1289, 1294]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1315, 1318]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1342, 1347]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1360, 1365]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1367, 1375]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1377, 1387]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1393, 1402]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1415, 1420]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1456, 1465]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1486, 1491]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1496, 1501]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1511, 1516]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1544, 1552]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1613, 1618]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1633, 1637]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1651, 1661]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[6, 14]], 'text': ['controls'], 'type': 'Regulation', 'id': 'T41'}, {'offsets': [[58, 68]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[476, 490]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[661, 671]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[933, 941]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[1217, 1224]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[1247, 1256]], 'text': ['essential'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[1277, 1287]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[1298, 1305]], 'text': ['present'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[1332, 1341]], 'text': ['represses'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[1352, 1359]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[1403, 1413]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[1425, 1436]], 'text': ['participate'], 'type': 'Regulation', 'id': 'T53'}, {'offsets': [[1466, 1476]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[1535, 1543]], 'text': ['activate'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[1553, 1563]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[1603, 1609]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T57'}, {'offsets': [[1619, 1629]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[1670, 1680]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T59'}]","[{'trigger': 'T41', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T42', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T41', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T1']}}, {'trigger': 'T42', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T1']}}, {'trigger': 'T42', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T1']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T44', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T45', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T46', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T47', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T23']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T50', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T25']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T25']}}, {'trigger': 'T52', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T51', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T25']}}, {'trigger': 'T52', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T51', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T25']}}, {'trigger': 'T52', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T51', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T25']}}, {'trigger': 'T52', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T53', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T32']}}, {'trigger': 'T54', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T55', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T34']}}, {'trigger': 'T56', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T55', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T35']}}, {'trigger': 'T55', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T36']}}, {'trigger': 'T57', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'E34']}}, {'trigger': 'T59', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T58', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T57', 'id': 'E35', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'E34']}}, {'trigger': 'T59', 'id': 'E36', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}]",[],"[{'id': '*', 'ref_ids': ['T10', 'T11']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E26', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E28', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E30', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E31', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E36', 'value': ''}]",[]
145,PMC-2065877-09-Discussion,"This study defines the oncogenic properties of LMP1 in promoting B cell lymphomagenesis. LMP1 transgenic mice have a higher incidence of lymphoma [26] and the progression to lymphoma correlates with higher expression levels of LMP1 (Figure 1A and 1B), suggesting that LMP1 is directly involved in tumor development. Table 1 summarizes the biological and molecular properties that were identified in wild-type and LMP1 transgenic lymphomas. Although many of the molecular properties studied were similar between wild-type and LMP1 transgenic lymphomas, there were distinguishing biological properties, namely the ability of LMP1 transgenic lymphomas to induce higher levels of survival and proliferation. Interestingly, although LMP1 transgenic mice develop lymphomas in the same B-1a cell type as spontaneous wild-type lymphomas (Figure 2), some signaling effects induced by LMP1 may explain the enhanced promotion to lymphomagenesis. Since CD40-deficient mice have decreased numbers of IgMhighIgDlow cells, a phenotype associated with B-1, marginal zone, and memory B cells, the mimicry of CD40 signaling by LMP1 could possibly contribute to the expansion of B-1 cells [20]. It is noteworthy that expression of LMP1 in transgenic mice has been shown to inhibit the formation of GCs [23,49], preventing typical B-2 cells from antigen-driven selection and expansion. The lack of GC reactions may contribute to the bias of LMP1 transgenic mice towards B-1 cell lymphomas. Interestingly, LMP2 signaling also favors development of B-1 cells, but this occurs in the absence of transformation. These results suggest that the mimicry of B cell receptor signaling by LMP2 promotes B-1 cell differentiation but not transformation [24,50,51]. This promotion of B-1 differentiation may account for the ability of LMP2 to exacerbate autoimmunity and bypass anergy induction [52,53]. In contrast, the preponderance of tumors of B-1a origin does not reflect effects of LMP1 signaling on B cell differentiation, as splenic B cells from healthy LMP1 transgenic mice contain similar numbers of B-1 and B-2 cells as wild-type mice. In support of this lack of effect, the differentiation of B-1 versus B-2 cells is thought to be independent of CD40 signaling [54].
B-1 cells constitute the predominant lymphocyte population in the peritoneal and pleuropericardial cavities, while B-2 cells are mainly found in the spleen, lymph node, and peripheral blood. B-1 cells produce the main source of IgM and IgA antibodies in serum, which are involved in T cell-independent responses to common microbial antigens. Importantly, B-1 cells have the unique capacity to self replenish and are also predisposed to transformation [28,29]. Clonal expansion of B-1 cells can be detected in aging mice above 18 mo of age, and B-1 cells are thought to be the murine progenitor of B cell chronic lymphocytic leukemia [30]. The data presented in this study indicate that although LMP1 is expressed in all B lymphocytes in the transgenic mice, malignancy develops in this specific subset of B cells. The elevated expression of LMP1 in B-1a cells and the activation of specific pathways apparently induce malignant growth. These same pathways can also become sporadically activated in aged mice and also result in lymphoma development. This is similar to EBV-associated cancers in vivo, where pathways that are activated by LMP1 are also activated in the less prevalent EBV-negative forms of the cancers [40,55-58]. Thus, the contribution of EBV and LMP1 to tumor development is apparently the continuous activation of pathways that can also be sporadically activated and contribute to tumor development.
The lymphomas were marked by the upregulation of IL10, constitutive activation of Stat3 signaling, and a requirement for activation of Akt, NFkappaB, and Stat3 pathways (Figures 5 and 7). Induction of IL10 is associated with the transformation of B-1 lymphomas in mice [59,60] and is frequently associated with EBV-positive B cell malignancies acting as a B cell growth factor [35-38]. In addition, LMP1 has been shown to stimulate IL10 expression in Burkitt lymphoma cell lines [61,62]. This suggests that although Stat3 is constitutively activated in the lymphoma cells, the induction of IL10 may further enhance Stat3 activation or may contribute to other IL10-responsive signaling pathways.
LMP1 activates both the canonical and non-canonical pathways of NFkappaB signaling [14,63-65], and inhibition of NFkappaB blocked the survival of LMP1 transgenic lymphocytes and LMP1-positive and -negative lymphoma cells. NFkappaB and PI3K signaling are crucial for CD40-induced proliferation, and mice deficient for cRel or the p85 regulatory subunit of PI3K are unresponsive to mitogenic stimuli, including CD40 ligation [66-68]. We have previously shown that cRel is specifically activated in both wild-type and LMP1 transgenic lymphomas, suggesting that activation of cRel is associated with B cell transformation [27]. Our observations suggest that similar to CD40-induced proliferation, LMP1 induces proliferation through PI3K-mediated activation of Akt and activation of NFkappaB components such as cRel. CD40 also induces downregulation of the cell cycle inhibitor p27 through a PI3K-dependent manner, and the LMP1 lymphoma cells also had decreased levels of p27 with phosphorylation of Rb and increased Cdk2 (Figure 6C) [66]. Although LMP1 has been shown to deregulate the Rb pathway in epithelial cells [69], to our knowledge this is the first demonstration of this property in B lymphocytes.
The requirement for Akt activation was confirmed by the striking inhibition of lymphoma viability by triciribine, an Akt inhibitor. However, the activated pAkt did not lead to phosphorylation and inactivation of the downstream target GSK3 (Figure 6A). This effect has also been described in EBV-positive HD biopsies [40]. In contrast, rapamycin, U0126, and SB202190 did not affect the survival of LMP1 transgenic lymphocytes or the wild-type and LMP1 transgenic lymphoma cells (Figure 7A, 7C, and 7E). This lack of effect by rapamycin confirmed the absence of activated p-mTOR levels (Figure 6B). These findings suggest that other Akt targets contribute to malignant progression. One key target is likely the inhibition of the Fox01 transcription factors. Repression of the pro-apoptotic transcription factor FoxO1 in a PI3K-dependent manner can inhibit expression of bcl6, a transcription factor necessary for GC formation [49,70]. It has been shown that overstimulation of CD40 signaling with agonistic antibodies inhibits GC formation [71]. Similarly, due to mimicry of CD40 signaling, transgenic LMP1 mice are also defective in GC formation [23,49]. The constitutive signaling by LMP1 likely blocks GC formation through downregulation of bcl6. Interestingly, clinical studies indicate that expression of LMP1 and bcl6 are mutually exclusive in non-HD and classical HD [72,73]. Thus, the LMP1 transgenic lymphomas mirror aspects of EBV-induced HD. Although the activation of Akt and the lack of Fox01 in the lymphoma cells suggest that LMP1 affects bcl6 and GC formation through this pathway, regulation of other Forkhead targets involved in cell cycle progression, such as p27 and CyclinD2, likely contribute to malignant transformation. Indeed, loss of FoxO1 expression in lymphoma cells correlated with a loss of p27 (Figure 6B and 6C). CyclinD2 has also been shown to be upregulated by LMP1 through release of FoxO1-mediated repression [70].
In summary, in this transgenic model of lymphomagenesis, LMP1 promotes malignancy in B-1a cells, a population that is predisposed to clonal expansion with age. The malignant lymphocytes were distinguished by constitutively active Stat3 signaling, decreased p27, and activated Akt and NFkappaB pathways, properties that are associated with promoting the growth and survival of B lymphocytes. Importantly, Akt, NFkappaB, and Stat3 pathways were critically required for the growth and survival of malignant lymphocytes as well as healthy LMP1 transgenic lymphocytes. The growth of EBV-transformed lymphocytes also requires activation of NFkappaB, and these studies provide insight into how LMP1 contributes to EBV-associated transformation. The transgenic lymphomas mirror multiple aspects of EBV-induced tumors and suggest that in vivo these properties of LMP1 are major factors in the development of cancer.","[{'offsets': [[47, 51]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[89, 93]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 231]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[268, 272]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[413, 417]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[525, 529]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[623, 627]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[728, 732]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[875, 879]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[941, 945]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1091, 1095]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1109, 1113]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1212, 1216]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1421, 1425]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1485, 1489]], 'text': ['LMP2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1659, 1663]], 'text': ['LMP2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1802, 1806]], 'text': ['LMP2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1955, 1959]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2029, 2033]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2225, 2229]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2941, 2945]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3087, 3091]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3383, 3387]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3509, 3513]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3713, 3717]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3746, 3751]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3799, 3802]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3818, 3823]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3865, 3869]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4063, 4067]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4096, 4100]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4180, 4185]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4254, 4258]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4279, 4284]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4323, 4327]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4359, 4363]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4505, 4509]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4537, 4541]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4625, 4629]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4676, 4680]], 'text': ['cRel'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4688, 4691]], 'text': ['p85'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4768, 4772]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4821, 4825]], 'text': ['cRel'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4874, 4878]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4931, 4935]], 'text': ['cRel'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5024, 5028]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5052, 5056]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5115, 5118]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5165, 5169]], 'text': ['cRel'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5171, 5175]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5232, 5235]], 'text': ['p27'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5277, 5281]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5326, 5329]], 'text': ['p27'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5354, 5356]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[5371, 5375]], 'text': ['Cdk2'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5403, 5407]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5441, 5443]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5582, 5585]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5679, 5682]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[5717, 5721]], 'text': ['pAkt'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5796, 5800]], 'text': ['GSK3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5959, 5963]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[6008, 6012]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[6132, 6138]], 'text': ['p-mTOR'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[6193, 6196]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[6289, 6294]], 'text': ['Fox01'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[6371, 6376]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[6430, 6434]], 'text': ['bcl6'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6537, 6541]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[6635, 6639]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[6662, 6666]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[6746, 6750]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[6804, 6808]], 'text': ['bcl6'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[6870, 6874]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[6879, 6883]], 'text': ['bcl6'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[6953, 6957]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[7040, 7043]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[7060, 7065]], 'text': ['Fox01'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[7101, 7105]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[7114, 7118]], 'text': ['bcl6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7239, 7242]], 'text': ['p27'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7247, 7255]], 'text': ['CyclinD2'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[7320, 7325]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[7381, 7384]], 'text': ['p27'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[7405, 7413]], 'text': ['CyclinD2'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[7455, 7459]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[7479, 7484]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[7568, 7572]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[7741, 7746]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[7768, 7771]], 'text': ['p27'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[7787, 7790]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[7915, 7918]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[7934, 7939]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[8046, 8050]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[8198, 8202]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[8365, 8369]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[199, 205]], 'text': ['higher'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[206, 216]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T101'}, {'offsets': [[946, 955]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T102'}, {'offsets': [[1198, 1208]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T103'}, {'offsets': [[2949, 2958]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T104'}, {'offsets': [[3064, 3072]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T105'}, {'offsets': [[3073, 3083]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T106'}, {'offsets': [[3697, 3709]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[3852, 3861]], 'text': ['Induction'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[4086, 4095]], 'text': ['stimulate'], 'type': 'Positive_regulation', 'id': 'T109'}, {'offsets': [[4101, 4111]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T110'}, {'offsets': [[4204, 4213]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T111'}, {'offsets': [[4241, 4250]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T112'}, {'offsets': [[4271, 4278]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T113'}, {'offsets': [[4285, 4295]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T114'}, {'offsets': [[4662, 4671]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T115'}, {'offsets': [[4773, 4781]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T116'}, {'offsets': [[4842, 4851]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T117'}, {'offsets': [[4917, 4927]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T118'}, {'offsets': [[5057, 5064]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T119'}, {'offsets': [[5101, 5111]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T120'}, {'offsets': [[5123, 5133]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T121'}, {'offsets': [[5137, 5156]], 'text': ['NFkappaB components'], 'type': 'Anaphora', 'id': 'T97'}, {'offsets': [[5181, 5188]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T122'}, {'offsets': [[5189, 5203]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T123'}, {'offsets': [[5306, 5315]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[5335, 5350]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T125'}, {'offsets': [[5361, 5370]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T126'}, {'offsets': [[5566, 5577]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T127'}, {'offsets': [[5586, 5596]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T128'}, {'offsets': [[5683, 5692]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T129'}, {'offsets': [[5707, 5716]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[5730, 5734]], 'text': ['lead'], 'type': 'Positive_regulation', 'id': 'T131'}, {'offsets': [[5738, 5753]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T132'}, {'offsets': [[5758, 5770]], 'text': ['inactivation'], 'type': 'Negative_regulation', 'id': 'T133'}, {'offsets': [[6111, 6118]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T134'}, {'offsets': [[6122, 6131]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[6250, 6256]], 'text': ['target'], 'type': 'Regulation', 'id': 'T136'}, {'offsets': [[6271, 6281]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T137'}, {'offsets': [[6318, 6328]], 'text': ['Repression'], 'type': 'Negative_regulation', 'id': 'T138'}, {'offsets': [[6408, 6415]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T139'}, {'offsets': [[6416, 6426]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T140'}, {'offsets': [[6786, 6800]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T141'}, {'offsets': [[6856, 6866]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T142'}, {'offsets': [[6897, 6906]], 'text': ['exclusive'], 'type': 'Negative_regulation', 'id': 'T143'}, {'offsets': [[7026, 7036]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T144'}, {'offsets': [[7052, 7056]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T145'}, {'offsets': [[7106, 7113]], 'text': ['affects'], 'type': 'Regulation', 'id': 'T146'}, {'offsets': [[7144, 7148]], 'text': ['this'], 'type': 'Anaphora', 'id': 'T98'}, {'offsets': [[7149, 7156]], 'text': ['pathway'], 'type': 'Regulation', 'id': 'T147'}, {'offsets': [[7158, 7168]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T148'}, {'offsets': [[7172, 7194]], 'text': ['other Forkhead targets'], 'type': 'Anaphora', 'id': 'T99'}, {'offsets': [[7312, 7316]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T149'}, {'offsets': [[7326, 7336]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T150'}, {'offsets': [[7355, 7365]], 'text': ['correlated'], 'type': 'Positive_regulation', 'id': 'T151'}, {'offsets': [[7373, 7377]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T152'}, {'offsets': [[7440, 7451]], 'text': ['upregulated'], 'type': 'Positive_regulation', 'id': 'T153'}, {'offsets': [[7758, 7767]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T154'}]","[{'trigger': 'T100', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T101', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T102', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T103', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T104', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T105', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T106', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T107', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T108', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T109', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T30']}}, {'trigger': 'T110', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T111', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T112', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T113', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T114', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T115', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T115', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T116', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T117', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T118', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T119', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T47']}}, {'trigger': 'T120', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T119', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T47']}}, {'trigger': 'T121', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T122', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T50']}}, {'trigger': 'T123', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T124', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T125', 'id': 'E28', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T126', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T127', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T128', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T129', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T130', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T131', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E33']}}, {'trigger': 'T132', 'id': 'E35', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T131', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'E33']}}, {'trigger': 'T133', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T134', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T135', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T136', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'T65']}}, {'trigger': 'T137', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T138', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T139', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E42']}}, {'trigger': 'T140', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T141', 'id': 'E45', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T142', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T142', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T143', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E46', 'E46']}}, {'trigger': 'T143', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E46', 'E47']}}, {'trigger': 'T143', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E46']}}, {'trigger': 'T143', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E47']}}, {'trigger': 'T144', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T145', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T146', 'id': 'E54', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T80', 'E55']}}, {'trigger': 'T147', 'id': 'E55', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T78', 'T79']}}, {'trigger': 'T148', 'id': 'E56', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T148', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T82']}}, {'trigger': 'T149', 'id': 'E58', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T150', 'id': 'E59', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T151', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E61', 'E58']}}, {'trigger': 'T152', 'id': 'E61', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T153', 'id': 'E62', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T154', 'id': 'E63', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T90']}}]","[{'id': 'R1', 'head': {'ref_id': 'T97', 'role': 'Subject'}, 'tail': {'ref_id': 'T49', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T98', 'role': 'Subject'}, 'tail': {'ref_id': 'T78', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T99', 'role': 'Subject'}, 'tail': {'ref_id': 'T81', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T99', 'role': 'Subject'}, 'tail': {'ref_id': 'T82', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E14', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E36', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E54', 'value': ''}]",[]
146,PMC-2626671-03-RESULTS_AND_DISCUSSION,"Distinct expression kinetics of perforin and granzyme B during CTL development in culture
Our experiments revealed clear differences in the kinetics of perforin, granzyme B, and cytokine expression during CD8+ T cell activation (Fig. 1). Naive T cells showed detectable expression of perforin mRNA as well as perforin protein (Fig. 1, A-D). Relative to its expression in naive T cells, perforin (Prf1) mRNA expression did not increase appreciably at day 2 but showed a reproducible decrease at day 4, followed by robust reexpression between days 4 and 8 (Fig. 1, A-D). In contrast, granzyme B (Gzmb) mRNA was low or undetectable in naive T cells but was strongly up-regulated by day 2 after stimulation and increased progressively until day 6 (Fig. 1, A and B); similarly, granzyme B protein was expressed by day 4 and remained high until day 6 (Fig. 1 E). As expected, a small fraction of naive T cells expressed the cytokines IFN-gamma and TNF in response to stimulation, and this capacity increased significantly in differentiated cells (Fig. 1 E; see also Fig. 2 A).
We evaluated antigen-dependent cytolytic function in a short-term assay in which target cell death was measured within 2 h (Fig. 1 F). By limiting the duration of TCR stimulation, this strategy minimizes cytolysis secondary to new gene expression during the period of the assay. Naive T cells did not display significant cytolytic function in this short-term assay (unpublished data), most likely because they express immature (unprocessed) forms of perforin and lack the capacity to degranulate (18, 19). Even after activation for 2 or 4 d, the cells showed poor cytolytic activity (Fig. 1 F), in striking contrast to their capacity for efficient cytokine production (Fig. 1 E). Only cells cultured until day 6 displayed robust cytotoxicity, as judged by their ability to induce apoptosis in a large number of target cells (Fig. 1 F).
These results show that after a strong priming stimulus through TCRs and co-stimulatory receptors in vitro, granzyme B expression and the ability to produce effector cytokines are programmed early, whereas perforin expression and cytolytic function are induced later, during the phase of clonal expansion in IL-2. Therefore, the two major effector functions of CTL, cytokine production and cytolytic activity, are not intrinsically coregulated.","[{'offsets': [[32, 40]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[45, 55]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[152, 160]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[162, 172]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[205, 208]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[284, 292]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[309, 317]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[386, 394]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[396, 400]], 'text': ['Prf1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[582, 592]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[594, 598]], 'text': ['Gzmb'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[773, 783]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[928, 937]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[942, 945]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1521, 1529]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2015, 2025]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2113, 2121]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2215, 2219]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[9, 19]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[187, 197]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[270, 280]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[353, 356]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T19'}, {'offsets': [[357, 367]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[402, 417]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T25'}, {'offsets': [[426, 434]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[482, 490]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[520, 532]], 'text': ['reexpression'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[609, 628]], 'text': ['low or undetectable'], 'type': 'Transcription', 'id': 'T29'}, {'offsets': [[663, 675]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[707, 716]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[819, 832]], 'text': ['remained high'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[904, 913]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[978, 991]], 'text': ['this capacity'], 'type': 'Anaphora', 'id': 'T20'}, {'offsets': [[992, 1001]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1481, 1488]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[2026, 2036]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[2122, 2132]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[2160, 2167]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T38'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T23', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T24', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T26', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T27', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T30', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T33', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T33', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T34', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T34', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T35', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T36', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T37', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T38', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}]","[{'id': 'R1', 'head': {'ref_id': 'T19', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T20', 'role': 'Subject'}, 'tail': {'ref_id': 'T33', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T8', 'T9']}, {'id': '*', 'ref_ids': ['T10', 'T11']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}]",[]
147,PMC-2626671-12-MATERIALS_AND_METHODS,"Cytokine and surface marker staining.
To assess cytokine production, cells were restimulated with 10 nM PMA + 1 muM ionomycin for 6 h (unless indicated otherwise in the figures), and intracellular cytokine stains were performed as previously described (28). To detect expression of surface molecules, cells were washed in PBS, resuspended in FACS wash buffer (3% FBS, 0.1% sodium azide, 30 mM Hepes, 1x PBS) containing the antibodies indicated in the figures at previously optimized concentrations, incubated for 15 min at room temperature (RT), washed, and resuspended in 2% formaldehyde fixative solution before acquisition on a FACSCalibur (BD).",[],[],[],[],[],[]
148,PMC-2065877-03-Results,"LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion
To determine if LMP1 signaling affects B cell differentiation and to immunophenotype the lymphomas that arise from LMP1 expression, surface Ig expression of heavy chains (IgM, IgG, IgD) and light chains (kappa, lambda) were analyzed by flow cytometry. Similar numbers of naive (IgM+IgD+IgG-) splenic B cells with a strong bias towards kappa light chain were detected from wild-type or LMP1 transgenic mice, indicating that LMP1 signaling does not affect B cell maturation (unpublished data). Flow cytometry analysis of the SCID-passaged wild-type and LMP1 transgenic lymphomas revealed an IgMhighIgDlow phenotype (Figure 2A), indicative of marginal zone, B-1, or memory B cells. B-1 cells are further separated into CD5+ (B-1a) and CD5- (B-1b) subsets. To differentiate between these cell types, lymphoma cells were further analyzed for the B-1a marker CD5. All (5/5) of the tested LMP1 transgenic lymphomas displayed an IgMhighIgDlowCD5+ phenotype (Figure 2A), an expression pattern that distinguishes B-1a cells. Interestingly, a spontaneous wild-type lymphoma also developed in B-1a cells (Figure 2A). These cells are an interesting population that is self replenishing with an increased likelihood to become malignant in aged mice [30]. Analysis of LMP1 transgenic mice before the development of lymphoma showed similar numbers of splenic B-1a (CD19+CD5+) and B-1b or B-2 populations (CD19+CD5-), indicating that LMP1 does not affect B cell differentiation (Figure 2B).
Due to allelic exclusion, mature B cells that have been exposed to antigen will typically express only one heavy chain isotype (IgG, IgE, or IgA) and either a kappa or lambda light chain. Interestingly, 2/5 LMP1 transgenic lymphomas analyzed (lymphomas 2 and 4) were doubly positive for low levels of both kappa and lambda light chains (Figure 2A). Previous characterization of the LMP1 lymphomas had revealed that the lymphomas were clonal as determined by Ig heavy chain rearrangement [26], and analysis of kappa chain rearrangement (Figure S1) of the samples analyzed in this study confirmed clonality. To further assess light chain expression, the passaged samples were tested by immunoblotting for kappa and lambda light chains (Figure 2C). Interestingly, very low levels of expression of both light chains were detected by flow cytometry. The low levels of expression may reflect a limitation of the total number of light chains that can be expressed on the surface of a B cell. In agreement with the flow cytometry analysis, LMP1 transgenic lymphomas 2 and 4 were also positive for kappa and lambda light chains by immunoblot analysis (Figure 2C), confirming that these lymphomas express both light chains. A previous study of mice that developed leukemia due to an expansion of self-reactive B-1a cells determined that the B-1a leukemias were also doubly positive for kappa and lambda light chains [31]. These findings indicate that expression of LMP1 in B-1a cells promotes the development of malignancy and can result in the aberrant escape from allelic exclusion.","[{'offsets': [[0, 4]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 83]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[178, 182]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[448, 452]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[486, 490]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[614, 618]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[779, 782]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[795, 798]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[916, 919]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[945, 949]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[997, 1000]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1316, 1320]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1412, 1416]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1417, 1420]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1452, 1456]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1457, 1460]], 'text': ['CD5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1480, 1484]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1744, 1748]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1919, 1923]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2569, 2573]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2992, 2996]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[183, 193]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[2978, 2988]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}]",[],[],[],[]
149,PMC-3245220-11-Discussion,"NF-kappaB transcriptional activity is important in regulating intracellular signaling, stress response, proliferation, survival, differentiation and inflammation [8]. To regulate gene transcription, NF-kappaB p50/p65 heterodimers translocate to the nucleus from the cytoplasm, however, their translocation is not sufficient to activate gene transcription. Post-translational modification of NF-kappaB heterodimers such as phosphorylation or acetylation also contributes to its transcriptional activity [41], [42], [43]. Because NF-kappaB constitutively translocates to the nucleus in monocytic lineage [13] and activates gene transcription and survival in murine macrophages [11], we sought to determine how M-CSF affected NF-kappaB transcriptional activity in human MDMs and whether this activation regulated their survival. The present study demonstrated that M-CSF stimulated PKCalpha kinase upstream of NF-kappaB transcriptional activity in primary human MDMs and RAW 264.7 cells. We showed inhibition of conventional PKCs by PKC inhibitors, kinase deficient PKCalpha or PKCalpha siRNA blocked M-CSF-induced cell survival and NF-kappaB-regulated gene expression. This block correlated with a reduction in M-CSF-induced phosphorylation of NF-kappaB p65 at Ser276. Consistent with these findings the dominant negative PKCalpha constructs also inhibited NF-kappaB p65 phosphorylation at Ser276 but not at Ser536 resulting in reduced NF-kappaB transcriptional activation and M-CSF-induced MDM survival. A simplified proposed cartoon model in Figure 9 demonstrates that M-CSF induced monocytes survival is regulated by activating NF-kappaB p65 phosphorylation at Ser276 via PKC. Finally, in a NF-kappaB p65-/- fibroblast cell line, we confirmed that the Ser276 residue of NF-kappaB p65 is important and essential for PKC modulation of NF-kappaB activity. More compelling is that we observed a similar regulation between two different cell lineages in our study.
Post-translational modification of NF-kappaB p65 regulates its activating or repressing effects on gene expression. Among the seven reported putative NF-kappaB p65 phosphorylation sites, five increase nuclear translocation, DNA binding and NF-kappaB transcriptional activity [17]. Similar to our finding, Zhong et al. found that in response to LPS, NF-kappaB p65 is phosphorylated at the highly conserved Ser276 residue by the catalytic subunit of PKA [16]. In addition to PKA, Ser276 can be phosphorylated by MSK1 in the nucleus upon TNFalpha treatment [18]. Phosphorylation of NF-kappaB p65 at Ser536 occurs in response to many inflammatory stimuli as well as kinases, IKKalpha, IKKbeta and RSK1 [17], [18], [19], [20], [21]. Notably, in addition to phosphorylating Ser276 of NF-kappaB, our study revealed that M-CSF also modulated the phosphorylation of the NF-kappaB p65 subunit at Ser536, however, PKC inhibitors or kinase deficient PKCalpha constructs did not affect this phosphorylation event. Moreover, mutant constructs containing a point mutation at Ser536 of NF-kappaB p65 did not reduce NF-kappaB activity in cells lacking endogenous NF-kappaB p65, while the NF-kappaB p65 276S/A construct did reduce NF-kappaB activity in these cells. Therefore, specific post-translational modification of NF-kappaB p65 is likely to regulate transcriptional activation in response to specific stimuli [15], [43].
It is notable that M-CSF activated NF-kappaB p65 Ser276 phosphorylation and transcriptional activation in a PKCalpha-dependent manner. PKCalpha is a member of the conventional PKC family of protein kinases that are critical for cell growth, differentiation and cell death. PKCalpha primarily modulates anti-apoptotic and proliferation signals following cytokine treatment in various cell types [42]. Expression of PKCalpha attenuates apoptosis in many different cell types, while PKCalpha inhibition generally potentiates apoptosis [42]. In our studies using conventional PKC inhibitors and dominant negative PKCalpha constructs, PKCalpha was critical in M-CSF-induced macrophage survival by inducing Ser276 phosphorylation of NF-kappaB p65 in both primary human MDMs and Raw 264.7 cells. We also demonstrated PKC inhibition downregulated NF-kappaB-induction of the anti-apoptotic gene BCL-xL. Consistent with our finding, others reported NF-kappaB regulated the gene expression of many anti-apoptotic proteins including other BCL-2 family members and inhibitor of apoptosis (IAP) proteins which are regulators of apoptosis and function upstream of caspases [44]. It has been shown that phosphorylation of p65 at Ser276 prevents its degradation by ubiquitin-mediated proteolysis and promotes cell survival in HeLa cells [24]. In addition to BCL-xL expression as examined in this study, we are evaluating the possibility that PKCalpha-regulated NF-kappaB activity upregulates additional anti-apoptotic genes in an M-CSF-dependent fashion to modulate cell survival.
The use of inhibitors and siRNA in our study has not ruled out that other conventional PKCs might also be important in M-CSF-induced NF-kappaB activation and macrophage survival. In contrast to the actions of PKCalpha activation of other conventional PKC isoforms, like PKCbetaI/betaII, appear necessary for macrophage apoptosis. The PKCbetaI/betaII isoforms are expressed in apoptotic U937 myelomonocytic cells [45]. The human myeloid cell line HL-525 which is devoid of endogenous PKCbetaII is resistant to TNFalpha-induced apoptosis [46]. Re-expression of PKCbetaII in HL-525 cells restores their susceptibility to TNFalpha-induced apoptosis implying that PKCbetaII is pro-apoptotic and may be required to induce macrophage apoptosis.
Recent studies demonstrated that NF-kappaB transcriptional activity can be regulated by phosphorylation of the NF-kappaB p65 subunit in the absence of IkappaBalpha degradation [47]. By this pathway, phosphorylation of NF-kappaB regulates its interaction with other components of the basal transcriptional machinery without affecting its capability to bind DNA [21]. Since NF-kappaB can bind the promoters of numerous gene targets, post-translational modification of NF-kappaB p65 may affect its interaction with other proteins, refining the expression of gene targets. We did not find that PKC was involved in IkappaBalpha degradation or NF-kappaB p65 nuclear translocation induced by M-CSF, but that M-CSF-induced phosphorylation of NF-kappaB p65 at Ser276 was dramatically reduced by the conventional PKC inhibitor and kinase deficient PKCalpha and by siRNA towards PKCalpha. Current studies are underway to delineate the protein complexes formed by activated NF-kappaB and other transcriptional co-activators in response to M-CSF and PKC activation. Recently studies indicated that the non-canonical pathway was activated during human monocyte-macrophage differentiation [48]. During this process, expression of IKKalpha among other proteins, is elevated leading to increased p52 NF-kappaB (relB) expression through partial proteolytic degradation of the p100 NF-kappaB protein. Thus, it is possible that M-CSF regulates monocyte survival through both the canonical and non-canonical NF-kappaB pathways, which will be a focus in future research.
We previously showed that M-CSF reduced caspase-3 and -9 activity and prevented monocyte apoptosis [3]. This study reveals that treatment of monocytes with conventional PKC inhibitors, or overexpression of kinase-deficient PKCalpha blocked M-CSF-induced cell survival. Our data revealed that conventional PKCs are upstream of NF-kappaB activation in response to M-CSF and mediate post-translational activation of NF-kappaB p65 by phosphorylating Ser276 to regulate gene transcription and cell survival. Thus, our observation may provide insight in potential therapeutic targets for inflammatory diseases.","[{'offsets': [[209, 212]], 'text': ['p50'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[213, 216]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[286, 291]], 'text': ['their'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[879, 887]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1063, 1071]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1075, 1089]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1252, 1255]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1302, 1328]], 'text': ['dominant negative PKCalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1365, 1368]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1639, 1642]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1702, 1705]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1781, 1784]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2006, 2009]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2121, 2124]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2320, 2323]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2471, 2475]], 'text': ['MSK1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2496, 2504]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2550, 2553]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2632, 2640]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2642, 2649]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2654, 2658]], 'text': ['RSK1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2832, 2835]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2899, 2907]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3041, 3044]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3117, 3120]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3142, 3145]], 'text': ['p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3274, 3277]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3416, 3419]], 'text': ['p65'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3479, 3487]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3506, 3514]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3644, 3652]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3785, 3793]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3851, 3859]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3962, 3988]], 'text': ['dominant negative PKCalpha'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4001, 4009]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4108, 4111]], 'text': ['p65'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4257, 4263]], 'text': ['BCL-xL'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4577, 4580]], 'text': ['p65'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4619, 4628]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[4712, 4718]], 'text': ['BCL-xL'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[4796, 4804]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[5144, 5152]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[5205, 5213]], 'text': ['PKCbetaI'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[5214, 5220]], 'text': ['betaII'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[5269, 5277]], 'text': ['PKCbetaI'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[5278, 5284]], 'text': ['betaII'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[5418, 5427]], 'text': ['PKCbetaII'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[5444, 5452]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[5494, 5503]], 'text': ['PKCbetaII'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[5553, 5561]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[5594, 5603]], 'text': ['PKCbetaII'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[5794, 5797]], 'text': ['p65'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[5824, 5836]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[6149, 6152]], 'text': ['p65'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[6283, 6295]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[6321, 6324]], 'text': ['p65'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[6417, 6420]], 'text': ['p65'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[6511, 6519]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[6527, 6532]], 'text': ['siRNA'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[6541, 6549]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[6888, 6896]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[6952, 6955]], 'text': ['p52'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[6967, 6971]], 'text': ['relB'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[7031, 7035]], 'text': ['p100'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[7262, 7271]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[7276, 7278]], 'text': ['-9'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[7445, 7453]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[7645, 7648]], 'text': ['p65'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[230, 241]], 'text': ['translocate'], 'type': 'Localization', 'id': 'T29'}, {'offsets': [[249, 256]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T30'}, {'offsets': [[292, 305]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T31'}, {'offsets': [[868, 878]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[1046, 1062]], 'text': ['kinase deficient'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1196, 1205]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T34'}, {'offsets': [[1215, 1222]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1223, 1238]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T36'}, {'offsets': [[1259, 1265]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T37'}, {'offsets': [[1345, 1354]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1369, 1384]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T39'}, {'offsets': [[1388, 1394]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T40'}, {'offsets': [[1406, 1412]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[1618, 1628]], 'text': ['activating'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[1643, 1658]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T43'}, {'offsets': [[1662, 1668]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T44'}, {'offsets': [[1705, 1708]], 'text': ['-/-'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[1961, 1992]], 'text': ['Post-translational modification'], 'type': 'Protein_modification', 'id': 'T46'}, {'offsets': [[2290, 2304]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[2327, 2341]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T48'}, {'offsets': [[2366, 2372]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[2439, 2445]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[2453, 2467]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T51'}, {'offsets': [[2491, 2495]], 'text': ['upon'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[2521, 2536]], 'text': ['Phosphorylation'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[2557, 2563]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T54'}, {'offsets': [[2571, 2585]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[2785, 2794]], 'text': ['modulated'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[2799, 2814]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T57'}, {'offsets': [[2847, 2853]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[2882, 2898]], 'text': ['kinase deficient'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[3003, 3017]], 'text': ['point mutation'], 'type': 'Regulation', 'id': 'T60'}, {'offsets': [[3021, 3027]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T61'}, {'offsets': [[3088, 3095]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[3229, 3260]], 'text': ['post-translational modification'], 'type': 'Protein_modification', 'id': 'T63'}, {'offsets': [[3396, 3405]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[3420, 3426]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T90'}, {'offsets': [[3427, 3442]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T91'}, {'offsets': [[3488, 3497]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[3771, 3781]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T93'}, {'offsets': [[3860, 3870]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T94'}, {'offsets': [[4063, 4071]], 'text': ['inducing'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[4072, 4078]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T96'}, {'offsets': [[4079, 4094]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T97'}, {'offsets': [[4196, 4209]], 'text': ['downregulated'], 'type': 'Negative_regulation', 'id': 'T98'}, {'offsets': [[4220, 4229]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[4558, 4573]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T100'}, {'offsets': [[4584, 4590]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T101'}, {'offsets': [[4591, 4599]], 'text': ['prevents'], 'type': 'Negative_regulation', 'id': 'T102'}, {'offsets': [[4600, 4603]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T88'}, {'offsets': [[4604, 4615]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T103'}, {'offsets': [[4616, 4618]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[4629, 4637]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T105'}, {'offsets': [[4638, 4649]], 'text': ['proteolysis'], 'type': 'Protein_catabolism', 'id': 'T106'}, {'offsets': [[4719, 4729]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T107'}, {'offsets': [[5298, 5307]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T108'}, {'offsets': [[5397, 5403]], 'text': ['devoid'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[5480, 5490]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T110'}, {'offsets': [[5761, 5776]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T129'}, {'offsets': [[5813, 5820]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T130'}, {'offsets': [[5837, 5848]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T131'}, {'offsets': [[6104, 6135]], 'text': ['post-translational modification'], 'type': 'Protein_modification', 'id': 'T132'}, {'offsets': [[6157, 6163]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T133'}, {'offsets': [[6164, 6167]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T128'}, {'offsets': [[6168, 6179]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T134'}, {'offsets': [[6271, 6279]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T135'}, {'offsets': [[6296, 6307]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T136'}, {'offsets': [[6325, 6332]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T137'}, {'offsets': [[6333, 6346]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T138'}, {'offsets': [[6347, 6354]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T139'}, {'offsets': [[6380, 6387]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T140'}, {'offsets': [[6388, 6403]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T141'}, {'offsets': [[6424, 6430]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T142'}, {'offsets': [[6448, 6455]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T143'}, {'offsets': [[6494, 6510]], 'text': ['kinase deficient'], 'type': 'Negative_regulation', 'id': 'T144'}, {'offsets': [[6874, 6884]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T145'}, {'offsets': [[6922, 6930]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T146'}, {'offsets': [[6942, 6951]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T147'}, {'offsets': [[6973, 6983]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T148'}, {'offsets': [[6984, 6991]], 'text': ['through'], 'type': 'Positive_regulation', 'id': 'T149'}, {'offsets': [[7012, 7023]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T150'}, {'offsets': [[7254, 7261]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T151'}, {'offsets': [[7428, 7444]], 'text': ['kinase-deficient'], 'type': 'Negative_regulation', 'id': 'T152'}, {'offsets': [[7594, 7601]], 'text': ['mediate'], 'type': 'Positive_regulation', 'id': 'T153'}, {'offsets': [[7621, 7631]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T154'}, {'offsets': [[7652, 7667]], 'text': ['phosphorylating'], 'type': 'Phosphorylation', 'id': 'T155'}, {'offsets': [[7668, 7674]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T156'}]","[{'trigger': 'T29', 'id': 'E1', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T30']}}, {'trigger': 'T29', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T30']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T32', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T33', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T34', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T35', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T36', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T37']}}, {'trigger': 'T38', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T8']}}, {'trigger': 'T39', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T40']}}, {'trigger': 'T38', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T8']}}, {'trigger': 'T39', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T41']}}, {'trigger': 'T42', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T43', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T44']}}, {'trigger': 'T45', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T46', 'id': 'E16', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T47', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T48', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T16', 'T49']}}, {'trigger': 'T51', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T16', 'T17', 'T50']}}, {'trigger': 'T52', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T18']}}, {'trigger': 'T53', 'id': 'E21', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T19', 'T54']}}, {'trigger': 'T55', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T56', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T23', 'T58']}}, {'trigger': 'T59', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T60', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T61']}}, {'trigger': 'T62', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T63', 'id': 'E28', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T89', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T91', 'id': 'E30', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T64', 'T90']}}, {'trigger': 'T92', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T65']}}, {'trigger': 'T93', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T94', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T95', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'T71']}}, {'trigger': 'T97', 'id': 'E35', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T72', 'T96']}}, {'trigger': 'T98', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E37']}}, {'trigger': 'T99', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T100', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T74', 'T101']}}, {'trigger': 'T102', 'id': 'E39', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'E38']}}, {'trigger': 'T104', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'E42']}}, {'trigger': 'T103', 'id': 'E41', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T105', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'T75']}}, {'trigger': 'T106', 'id': 'E43', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T107', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T108', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T108', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T82']}}, {'trigger': 'T109', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T110', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T129', 'id': 'E49', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T111']}}, {'trigger': 'T130', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T131', 'id': 'E51', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T112']}}, {'trigger': 'T132', 'id': 'E52', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T113']}}, {'trigger': 'T133', 'id': 'E53', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'E52']}}, {'trigger': 'T134', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T113']}}, {'trigger': 'T135', 'id': 'E55', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T136', 'id': 'E56', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T114']}}, {'trigger': 'T135', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T139', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T138', 'id': 'E59', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T115', 'T137']}}, {'trigger': 'T140', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T141', 'id': 'E61', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T116', 'T142']}}, {'trigger': 'T143', 'id': 'E62', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E63']}}, {'trigger': 'T144', 'id': 'E63', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T117']}}, {'trigger': 'T143', 'id': 'E64', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'T118']}}, {'trigger': 'T145', 'id': 'E65', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T120']}}, {'trigger': 'T146', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E65']}}, {'trigger': 'T147', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E68', 'E65']}}, {'trigger': 'T148', 'id': 'E68', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T121']}}, {'trigger': 'T149', 'id': 'E69', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'E70']}}, {'trigger': 'T150', 'id': 'E70', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T123']}}, {'trigger': 'T151', 'id': 'E71', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T124']}}, {'trigger': 'T151', 'id': 'E72', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T125']}}, {'trigger': 'T152', 'id': 'E73', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T126']}}, {'trigger': 'T153', 'id': 'E74', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E75']}}, {'trigger': 'T154', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T127', 'E76']}}, {'trigger': 'T155', 'id': 'E76', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T127', 'T156']}}]","[{'id': 'R1', 'head': {'ref_id': 'T88', 'role': 'Subject'}, 'tail': {'ref_id': 'T74', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T128', 'role': 'Subject'}, 'tail': {'ref_id': 'T113', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T121', 'T122']}]","[{'id': 'M2', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E53', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E55', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}]",[]
150,PMC-3245220-26-Caption-Figure_2,"Inhibition of PKC reduces NF-kappaB activity in M-CSF stimulated macrophages.
(A) Human MDMs transfected with pNF-kappaB-SEAP were pre-incubated with inhibitors; Ro-31-8220, Go-6976, or BAPTA/AM for 30 minutes prior to 6 hours M-CSF stimulation. (B) RAW 264.7 cells transfected with the pNF-kappaB-SEAP construct were pre-incubated with inhibitors for 30 minutes prior to 2 hours of stimulation with mouse recombinant M-CSF. The NF-kappaB activity was analyzed by measuring SEAP production in the medium and data are expressed as fold increase of SEAP activity over that in pTAL-SEAP transfected resting cells. The graph represents mean +/- S.E.M for three independent experiments. *The p-values of cells treated with inhibitors/M-CSF compared to vehicle/M-CSF were <=0.05.",[],[],[],[],[],[]
151,PMC-1447668-02-Results,"Foxp3 Suppresses NF-kappaB Dependent Transcriptional Activation
To ascertain the molecular mechanisms by which Foxp3 functions to promote the regulatory function of CD4+CD25hi T cells, we first confirmed the function of Foxp3 as a repressor of activation of NF-kappaB, previously implicated as a target of other forkhead/winged-helix family transcription factors (e.g., Foxj1 and Foxo3a) [19,20]. We analyzed the effect of Foxp3 overexpression on NF-kappaB activation in HEK 293T cells in dose-response and time course analyses. Transfection of HEK 293T cells with an NF-kappaB luciferase reporter vector in the presence or absence of increasing concentrations of a Foxp3 expression vector or a control vector (enhanced green fluorescent protein [EGFP]) was performed, and cells were harvested after 24 h to assay for luciferase activity and Foxp3 mRNA expression. Results indicated that as the concentration of Foxp3 transfected into cells increases (from 50 to 2,400 ng), the level of NF-kappaB activation decreases proportionally (Figure 1A). Foxp3 mRNA was also assayed to monitor activity of the Foxp3 expression vector (Figure 1B). Since NF-kappaB activation was partially affected by transfection of high concentrations of the control vector, we determined the fold inhibition of NF-kappaB activation by Foxp3 compared to the control vector at each concentration (Figure 1A). Fold inhibition of NF-kappaB activation was directly proportional to the level of Foxp3 mRNA expression detected by real-time RT-PCR. To determine the level of Foxp3-mediated suppression of NF-kappaB activation over time, HEK 293T cells were transfected with an NF-kappaB luciferase reporter vector and an expression vector encoding Foxp3 or EGFP (control vector) and harvested over 4 d. As shown in Figure 1C, NF-kappaB activation was suppressed by overexpression of Foxp3 at all time points. Extending these results from established, in vitro HEK cell lines to primary human lymphocytes, overexpression of Foxp3 in purified CD4+ T cells from three healthy donors also down-regulated the steady-state level of NF-kappaB activation (Figure 1D). These results recapitulate those from Bettelli and colleagues [15] demonstrating that Foxp3 functions, in part, to block NF-kappaB-dependent transcription in human cell lines as well as in primary human CD4+ T cells.","[{'offsets': [[0, 5]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[111, 116]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[165, 168]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[169, 173]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[220, 225]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[370, 375]], 'text': ['Foxj1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[380, 386]], 'text': ['Foxo3a'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[423, 428]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[578, 588]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[666, 671]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[720, 745]], 'text': ['green fluorescent protein'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[818, 828]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[842, 847]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[912, 917]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1046, 1051]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1101, 1106]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1311, 1316]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1465, 1470]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1543, 1548]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1655, 1665]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1716, 1721]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1851, 1856]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1991, 1996]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2009, 2012]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2214, 2219]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2331, 2334]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[429, 443]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[672, 682]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[848, 863]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T29'}, {'offsets': [[895, 908]], 'text': ['concentration'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[941, 950]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[1107, 1117]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T32'}, {'offsets': [[1471, 1486]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T33'}, {'offsets': [[1689, 1699]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[1833, 1847]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1973, 1987]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T36'}]","[{'trigger': 'T27', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T28', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T29', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T30', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T31', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T32', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T33', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T34', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T35', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T36', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
152,PMC-1310901-02-MATERIALS_AND_METHODS,"Cell lines
K-562, Jurkat and U-937 were obtained from the ATCC (American Type Culture Collection, Rockville, USA) and EM-2, LAMA-84, CML-T1, BV-173, SD-1 and RPMI-8226 from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). All cell lines, except BV-173, SD-1 and RPMI-8226, were IRF-4-negative.","[{'offsets': [[324, 329]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[330, 338]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}]",[]
153,PMC-3279418-04-Results,"Production of proinflammatory mediators by cpdm BMDC is impaired
Incubation with LPS or poly I:C resulted in secretion of IL6, IL12P70, and GMCSF from both WT and cpdm BMDC; however, BMDC from cpdm mice produced significantly less of all three cytokines compared with WT BMDC (Fig. 3A-C, E-F). The amount of nitric oxide generated by mutant BMDC was also significantly reduced compared with WT cells (Fig. 3D), indicating severely disrupted production of proinflammatory mediators from Sharpin-deficient BMDC. In vivo complementation with a Sharpin gene-containing BAC reversed the phenotype of the mutant mice [2], and BMDC generated from these rescued mice secreted significantly more IL12P70 than BMDC from cpdm mice (Fig. 3G), supporting a necessary role of SHARPIN for the production of IL12P70. In addition, the transcript levels of the inflammatory cytokines Il6, Il12p40, Gmcsf, and Ifnb were examined, and these were all significantly reduced in stimulated cpdm BMDC when compared with WT controls (Fig. 4).","[{'offsets': [[122, 125]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[140, 145]], 'text': ['GMCSF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[486, 493]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[541, 548]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[762, 769]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[866, 869]], 'text': ['Il6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[871, 878]], 'text': ['Il12p40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[880, 885]], 'text': ['Gmcsf'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[891, 895]], 'text': ['Ifnb'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[97, 105]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[109, 118]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[203, 211]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[226, 230]], 'text': ['less'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[234, 253]], 'text': ['all three cytokines'], 'type': 'Anaphora', 'id': 'T10'}, {'offsets': [[494, 503]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T15'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T13', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T14', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T15', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]","[{'id': 'R1', 'head': {'ref_id': 'T10', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T10', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}]",[]
154,PMC-2889865-06-Discussion,"NF-kappaB and AP-1 are critical regulators of inflammatory responses, proliferation and differentiation of T-cells [28-30], however, the signal transduction and subsequent cytokine/chemokine expression is not fully understood. The aim of the present study was to investigate IL-6 and CXCL8 regulation by NF-kappaB and AP-1 in Jurkat T-cells.
Our results demonstrated that PMA induced AP-1 activation, indicating a specific activation of the MAPK pathway. Furthermore, we demonstrated that PMA dependent AP-1 activation in T-cells was delayed (>2 h) and increased following long-term treatment. MAPK is one of the main signalling pathways in T-cells that regulate cell- and transcriptional activation [31,32]. Several studies [20,33,34] have indicated the importance of AP-1 in T-cell activation and the induction of inflammatory responses [35], including pro-inflammatory cytokine release. In contrast to AP-1, NF-kappaB activity rapidly increased (1 min) during PMA exposure followed by a down-regulation to the lowest levels at 6 h. This is in line with Park and colleagues [36] who demonstrated a rapid increase in NF-kappaB activity following short-term stimulation with PMA, but prolonged challenge resulted in a persistent inhibition of NF-kappaB. They showed that the inhibition of NF-kappaB was due to PKC-dependent degradation of IkappaB kinase beta and gamma in response to PMA. Interestingly, the HK E. coli exposure induced NF-kappaB activation without affecting AP-1 activity. Wang and colleagues [37] reported an elevated inflammatory response by obtaining expression of IL-6 following the exposure of T-cells to peptidoglycan. Reduction in NF-kappaB by calcium ionophore following HK E. coli stimulation may be due to the Ca2+ binding protein calmodulin (CaM), which has been shown to negatively regulate c-Rel when activated [38]. The regulation of NF-kappaB and AP-1 observed in the present study was in agreement with earlier studies.
T-cells produce a broad range of pro- and anti-inflammatory cytokines, including IL-2, IL-6, CXCL8, TNF and IL-10, in response to infections or other stress factors [39]. The assessment of Jurkat T-cell inflammatory responses (Table 1) revealed an enhanced IL-2 expression upon exposure to PMA or HK E. coli due to PKC activation [40]. In addition to the transcription factor NF-kappaB, AP-1 binding sites have been identified in the IL-6 promoter region, indicating multiple regulation [22]. AP-1 and NF-kappaB have also been demonstrated to regulate CXCL8 expression during induction of inflammatory responses in T-cells [12]. Furthermore, IL-6 and CXCL8 gene-expression is associated with an early immune response in Jurkat T-cells [41]. In the present study, both PMA and HK E. coli resulted in comparable increases in IL-6 while PMA was more potent at activating CXCL8 release. PMA and HK E. coli treatment also induced TNF expression. TNF is one of the first cytokines induced by T-cells [42] and its expression is regulated by calcineurin, NFAT and ATF-2/Jun [20]. However, PMA-stimulated Jurkat T-cells showed no difference in IL-10 expression indicating an induced inflammatory response. HK E. coli treatment resulted in a significant reduction of IL-10 expression. The anti-inflammatory cytokine IL-10 is known to inhibit T-cell activation, proliferation and the expression of pro-inflammatory cytokines, such as IL-2, IL-5 and INF-gamma [39,43] and regulate inflammatory responses by inducing T-cell anergy [44].
The time course analysis of cytokine expression showed a correlation between AP-1 and the chemokine CXCL8 where CXCL8 expression was significantly elevated already at 2-6 h after PMA exposure. The CXCL8 expression did not correlate with the early NF-kappaB activation (1 min) or with the down-regulation of NF-kappaB at 2 h post exposure. Both IL-6 and TNF expression were up regulated between 6-24 h. During this period, NF-kappaB increased from its minimum level at 6 h. PKC has been shown to be associated with the activation of AP-1, but not with NF-kappaB activation of the IL-2 promoter [45]. Mutation of the NF-kappaB site did not affect IL-2 expression, whereas mutation of the AP-1 site or PKC depletion almost revoked IL-2 release. These observations indicate that the MAPK pathway and the transcription factor AP-1 play an important role in the induction of inflammatory responses in Jurkat T-cells [12,20,22]. The obtained results signify that CXCL8 was primarily regulated through the MAPK pathway.
The NF-kappaB activation inhibitor (NAI) showed specificity against NF-kappaB and resulted in a complete IL-6 inhibition following induction with PMA and significant IL-6 reduction after HK E. coli treatment. CXCL8 was highly up regulated by PMA and the addition of NAI resulted in a minor reduction in CXCL8 expression. Furthermore, CXCL8 expression was not affected by NAI following HK E. coli treatment, indicating a lack of correlation between CXCL8 and NF-kappaB. Further analysis of CXCL8 expression revealed a down-regulation by PKC- and JNK- inhibitors, suggesting an involvement of AP-1 via PKC and JNK, respectively. Analysis of gene expression further confirmed that il-6 and cxcl8 were upregulated by PMA. Expression of il-6 dropped below basal levels following inhibition of NF-kappaB and JNK whereas cxcl8 remained elevated above basal levels (16.5-fold and 7.1-fold respectively) following the same treatment. Furthermore, inhibition of PKC did not result in a significant decrease of il-6 or cxcl8, which is in accordance with protein data (figure 6). These results suggest that NF-kappaB is involved in IL-6 regulation and release while it is not required for the expression of CXCL8 in Jurkat T cells.
The transcription factor NF-kappaB is responsible for a rapid immune response which is followed by an increase in transcription of IkappaB thus inhibiting NF-kappaB [46]. Activation of NF-kappaB in Jurkat T-cells is dependent on Bcl10 activation, which in turn is regulated by PKC. Recent studies have established the importance of a protein complex consisting of CARMA1, Bcl10 and MALT1 (CBM), in the induction of NF-kappaB. Investigating Bcl10, Scharschmidt and colleagues [47] demonstrated that it is a critical regulator of NF-kappaB activity. Down-regulation of Bcl10 from signals transduced via the TCR/CD28 and PKC resulted in a concomitant down-regulation of NF-kappaB. They suggested that Bcl10 is initially activated by TCR/PKC but that continued activation (>1 h) promotes its degradation. Narayan and colleagues [27] suggested that deletion in any of the three CBM complex proteins impairs antigen-receptor dependent activation of NF-kappaB. They showed that NF-kappaB activation via Akt requires CARMA1 and acts in cooperation with PKC following short-term exposure (30 min) of Jurkat T-cells with PMA. Akt phosphorylates and thus activates Bcl10. These studies indicate that PKC is crucial for NF-kappaB activation following short-term treatment through signals via membrane bound receptors such as the TCR and the co-stimulatory receptor CD28. Thus, the CBM complex proteins play a key role in this signalling process. PMA diffuses into the cytosol and directly activates PKC since it is an analogue to diacylglycerol [48]. Several studies have demonstrated that inhibition of PKC blocks NF-kappaB and AP-1 activity, suggesting a direct regulation of these transcription factors by PKC [49,50]. PKC is activated at an early stage following T-cell stimulation and is therefore an important regulator of downstream inflammatory signalling pathways leading to cytokine expression [50]. We have shown that phosphorylated-PKC is up regulated in response to PMA and HK E. coli, indicating an association between PKC and the transcription factors AP-1 and NF-kappaB. Bcl10 levels were down-regulated following extended treatment of Jurkat T-cells with PMA. In the control groups, a loss of Bcl10 occurred after 6 h, followed by an increase after 24 h, which is in accordance with the observed NF-kappaB activity (figure 7). These results are supported by an earlier study [47], demonstrating that prolonged PKC activation by PMA leads to an inhibition of Bcl10 and NF-kappaB.
It has been shown that NF-kappaB is an important transcription factor complex involved in almost every aspect of cell regulation including apoptosis, differentiation, proliferation and initiation of immune responses [51-53]. NF-kappaB is constitutively active in many human malignancies, which makes it an attractive therapeutic target [54]. Elevated CXCL8 levels during chronic inflammation result in an enhanced recruitment of immune cells to the site of infection, which may lead to the development of autoimmune diseases following secretion of pro-inflammatory cytokines. In HIV infected persons, serum CXCL8 levels are elevated and this could recruit more T-cells potentially leading to a more rapid progression of the disease since there will be more T-cells available to infect.","[{'offsets': [[275, 279]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[284, 289]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1339, 1358]], 'text': ['IkappaB kinase beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1363, 1368]], 'text': ['gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1585, 1589]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1820, 1825]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2034, 2038]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2040, 2044]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2046, 2051]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2061, 2066]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2210, 2214]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2387, 2391]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2505, 2510]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2595, 2599]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2604, 2609]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2776, 2780]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2821, 2826]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3009, 3014]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3088, 3093]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3210, 3215]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3259, 3264]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3376, 3380]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3382, 3386]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3391, 3400]], 'text': ['INF-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3577, 3582]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3821, 3825]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4056, 4060]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4122, 4126]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4205, 4209]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4594, 4598]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4655, 4659]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4792, 4797]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4823, 4828]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4937, 4942]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4978, 4983]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5167, 5171]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5176, 5181]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5221, 5225]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5303, 5308]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5489, 5493]], 'text': ['il-6'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5497, 5502]], 'text': ['cxcl8'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5609, 5613]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5684, 5689]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5938, 5943]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[6073, 6079]], 'text': ['CARMA1'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[6081, 6086]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[6091, 6096]], 'text': ['MALT1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[6149, 6154]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[6276, 6281]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[6318, 6322]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[6407, 6412]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[6718, 6724]], 'text': ['CARMA1'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[6863, 6868]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[7062, 7066]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[7784, 7789]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[7907, 7912]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[8172, 8177]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[8544, 8549]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[8800, 8805]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[290, 300]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T30'}, {'offsets': [[1314, 1323]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T31'}, {'offsets': [[1324, 1335]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T32'}, {'offsets': [[1369, 1383]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[1571, 1581]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[1590, 1599]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1800, 1819]], 'text': ['negatively regulate'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[2201, 2209]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[2215, 2225]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[2261, 2264]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[2429, 2439]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T40'}, {'offsets': [[2511, 2521]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[2615, 2625]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[2763, 2772]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[2810, 2820]], 'text': ['activating'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[2827, 2834]], 'text': ['release'], 'type': 'Localization', 'id': 'T45'}, {'offsets': [[3064, 3084]], 'text': ['showed no difference'], 'type': 'Regulation', 'id': 'T46'}, {'offsets': [[3094, 3104]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[3197, 3206]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[3216, 3226]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T49'}, {'offsets': [[3834, 3844]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[3850, 3862]], 'text': ['up regulated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[4038, 4048]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[4061, 4069]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T53'}, {'offsets': [[4076, 4084]], 'text': ['Mutation'], 'type': 'Regulation', 'id': 'T54'}, {'offsets': [[4092, 4106]], 'text': ['NF-kappaB site'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[4115, 4121]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[4127, 4137]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[4147, 4155]], 'text': ['mutation'], 'type': 'Regulation', 'id': 'T58'}, {'offsets': [[4163, 4172]], 'text': ['AP-1 site'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[4197, 4204]], 'text': ['revoked'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[4210, 4217]], 'text': ['release'], 'type': 'Localization', 'id': 'T61'}, {'offsets': [[4571, 4579]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[4599, 4609]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T96'}, {'offsets': [[4620, 4629]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[4660, 4669]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T98'}, {'offsets': [[4779, 4788]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[4798, 4808]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T100'}, {'offsets': [[4829, 4839]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T101'}, {'offsets': [[4848, 4856]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T102'}, {'offsets': [[4864, 4873]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T103'}, {'offsets': [[4984, 4994]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T104'}, {'offsets': [[5006, 5021]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T105'}, {'offsets': [[5065, 5076]], 'text': ['involvement'], 'type': 'Regulation', 'id': 'T106'}, {'offsets': [[5085, 5088]], 'text': ['via'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[5187, 5198]], 'text': ['upregulated'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[5207, 5217]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[5226, 5233]], 'text': ['dropped'], 'type': 'Negative_regulation', 'id': 'T110'}, {'offsets': [[5309, 5326]], 'text': ['remained elevated'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[5477, 5485]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T112'}, {'offsets': [[5597, 5605]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T113'}, {'offsets': [[5614, 5624]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T114'}, {'offsets': [[5629, 5636]], 'text': ['release'], 'type': 'Localization', 'id': 'T115'}, {'offsets': [[5653, 5661]], 'text': ['required'], 'type': 'Regulation', 'id': 'T116'}, {'offsets': [[5670, 5680]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[5944, 5954]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T118'}, {'offsets': [[5973, 5982]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T119'}, {'offsets': [[6257, 6272]], 'text': ['Down-regulation'], 'type': 'Negative_regulation', 'id': 'T120'}, {'offsets': [[6426, 6435]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T121'}, {'offsets': [[6451, 6476]], 'text': ['that continued activation'], 'type': 'Anaphora', 'id': 'T92'}, {'offsets': [[6484, 6492]], 'text': ['promotes'], 'type': 'Positive_regulation', 'id': 'T122'}, {'offsets': [[6493, 6496]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T93'}, {'offsets': [[6497, 6508]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T123'}, {'offsets': [[6553, 6561]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[6572, 6602]], 'text': ['the three CBM complex proteins'], 'type': 'Anaphora', 'id': 'T94'}, {'offsets': [[6829, 6843]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T125'}, {'offsets': [[6853, 6862]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T126'}, {'offsets': [[7802, 7816]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T127'}, {'offsets': [[7899, 7903]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T128'}, {'offsets': [[7948, 7956]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T129'}, {'offsets': [[8146, 8151]], 'text': ['leads'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[8158, 8168]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T131'}, {'offsets': [[8535, 8543]], 'text': ['Elevated'], 'type': 'Positive_regulation', 'id': 'T132'}, {'offsets': [[8817, 8825]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T133'}]","[{'trigger': 'T30', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T30', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T32', 'id': 'E4', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T31', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T32', 'id': 'E6', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T33', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T33', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T34', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T35', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T36', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T37', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T38', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T39', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T40', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T41', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T42', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T42', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T43', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T44', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T45', 'id': 'E21', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T46', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T47', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T48', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T49', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T50', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T51', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T52', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T27', 'T53']}}, {'trigger': 'T54', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T55']}}, {'trigger': 'T56', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E29']}}, {'trigger': 'T57', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T58', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T29', 'T59']}}, {'trigger': 'T60', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E32']}}, {'trigger': 'T61', 'id': 'E34', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T95', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T96', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T95', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T98', 'id': 'E38', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T97', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T99', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T100', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T101', 'id': 'E42', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T102', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T103', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T104', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T105', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E45']}}, {'trigger': 'T106', 'id': 'E47', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E45']}}, {'trigger': 'T107', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E47']}}, {'trigger': 'T108', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T108', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T109', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}, {'trigger': 'T110', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T111', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T112', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T112', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T113', 'id': 'E56', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T114', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T113', 'id': 'E58', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T115', 'id': 'E59', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T116', 'id': 'E60', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E61']}}, {'trigger': 'T117', 'id': 'E61', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T118', 'id': 'E62', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T119', 'id': 'E63', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E62']}}, {'trigger': 'T120', 'id': 'E64', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T81', 'T82']}}, {'trigger': 'T121', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T122', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'E65']}}, {'trigger': 'T123', 'id': 'E67', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T124', 'id': 'E68', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T124', 'id': 'E69', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T124', 'id': 'E70', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T125', 'id': 'E71', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T126', 'id': 'E72', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T127', 'id': 'E73', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T87']}}, {'trigger': 'T128', 'id': 'E74', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T129', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T130', 'id': 'E76', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E77']}}, {'trigger': 'T131', 'id': 'E77', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T132', 'id': 'E78', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T90']}}, {'trigger': 'T133', 'id': 'E79', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}]","[{'id': 'R1', 'head': {'ref_id': 'T92', 'role': 'Subject'}, 'tail': {'ref_id': 'T121', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T93', 'role': 'Subject'}, 'tail': {'ref_id': 'T83', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T77', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T78', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T94', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E43', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E48', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E53', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E54', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E55', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E56', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E58', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E60', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E60', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E65', 'value': ''}]",[]
155,PMC-3245220-04-Results,"NF-kappaB and PKC(s) Mediate Human MDM Survival in Response to M-CSF Stimulation
Since PKC and NF-kappaB are critical in cell survival [37], [38], we hypothesized that M-CSF promoted cell survival through PKC in human MDMs. To detect apoptosis, the expression of cleaved caspase-3, a marker of apoptosis, was analyzed in the presence or absence of M-CSF and PKC inhibitors. In MDMs pretreated with PKC inhibitors (Ro-31-8220, Go-6976, or BAPTA/AM) and stimulated with M-CSF, cleaved caspase-3 was elevated to levels of cells treated with vehicle alone (Figure 3A). In contrast, cells incubated with M-CSF and vehicle had less cleaved caspase-3 than cells incubated with vehicle alone or M-CSF with PKC inhibitors. These data supported the hypothesis that M-CSF-induced NF-kappaB activity was regulated by conventional PKCs, not novel PKCs.
To confirm that PKC inhibition decreased cell survival, cells were treated with M-CSF in the absence or presence of PKC inhibitors and then also examined for apoptosis by Annexin V/PI staining. PKC inhibitors in the presence of M-CSF reduced the number of Annexin V/PI negative MDMs compared to cells treated with M-CSF alone (Figure 3B). These observations further suggested that MDM survival is promoted by M-CSF and critically involves conventional PKCs and NF-kappaB activity.","[{'offsets': [[271, 280]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[483, 492]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[634, 643]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1011, 1020]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1096, 1105]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[249, 259]], 'text': ['expression'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[263, 270]], 'text': ['cleaved'], 'type': 'Protein_catabolism', 'id': 'T7'}, {'offsets': [[475, 482]], 'text': ['cleaved'], 'type': 'Protein_catabolism', 'id': 'T8'}, {'offsets': [[497, 505]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[621, 625]], 'text': ['less'], 'type': 'Negative_regulation', 'id': 'T10'}, {'offsets': [[626, 633]], 'text': ['cleaved'], 'type': 'Protein_catabolism', 'id': 'T11'}, {'offsets': [[1109, 1117]], 'text': ['negative'], 'type': 'Negative_regulation', 'id': 'T12'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T9', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T11', 'id': 'E6', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],[],[]
156,PMC-2889865-12-Materials_and_methods,"Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed on supernatants from challenged Jurkat T-cells to quantify IL-6, CXCL8 and TNF (BD OptEIA Human IL-6 Elisa Set, BD OptEIA Human CXCL8 Elisa Set and BD OptEIA Human TNF Elisa Set, Biosciences, USA) according to the manufacturer's instructions. Briefly, Jurkat T-cells were stimulated with PMA (162 nM) for 1 h, centrifuged (1000 x g, 8 min) and the supernatants were collected and stored at -80degreesC until use. Following centrifugation, the cells were resuspended in 1 h aged media, where cells have been grown in, containing PMA. The same procedure was performed to collect media after 2 h and 6 h. The final collection of media was performed after 24 h.","[{'offsets': [[121, 125]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[127, 132]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[158, 162]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[190, 195]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[226, 229]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
157,PMC-2791889-12-Experimental_Procedures,"Cytokine Detection by ICS and ELISA
At day 5 or 7, cells were restimulated with immobilized anti-CD3 (2 mug/ml) and anti-CD28 (2 mug/ml) (4 hr with BrefeldinA [10 mug/ml] in the last 2 hr) or with PdBU and Ionomycin (5 hr with BrefeldinA [1 mug/ml]). After ICS FACS, data were collected on a FACSCalibur (Becton Dickinson) and analyzed with FlowJo (Tree Star). For ELISA, cells were similarly restimulated for 48 hr and supernatant was collected and analyzed for IL-4, IL-10, and IFN-gamma as described before (Shoemaker et al., 2006).","[{'offsets': [[97, 100]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[121, 125]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[463, 467]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[469, 474]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[480, 489]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
158,PMC-3279418-23-Caption-Figure_5,"Normal TLR4 and MD2 expression and decreased IL10 secretion and A20 expression by cpdm BMDC.
(A) Unstimulated WT and cpdm BMDC (5x105) were labeled with PE-labeled anti-TLR4/MD2 or anti-CD14 and then subject to flow cytometry analysis. Unstained cells serve as negative controls. (B) Cultured WT and cpdm BMDC (1x105 cells in 0.1 ml complete medium) were washed and stimulated with medium, 100 ng/ml LPS or 25 microg/ml poly I:C for 24 hours. Supernatants were collected for ELISA of IL10. (C) Cultured WT and cpdm BMDC (5x105 cells in 0.2 ml complete medium) were washed and stimulated with 100 ng/ml LPS or 25 microg/ml poly I:C. At 0, 1, and 2 hours, total RNA was extracted and subject to qRT-PCR to measure the production of A20.","[{'offsets': [[7, 11]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[16, 19]], 'text': ['MD2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[45, 49]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[64, 67]], 'text': ['A20'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[484, 488]], 'text': ['IL10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[730, 733]], 'text': ['A20'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[0, 6]], 'text': ['Normal'], 'type': 'Negative_regulation', 'id': 'T7'}, {'offsets': [[20, 30]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[35, 44]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T9'}, {'offsets': [[50, 59]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[68, 78]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[716, 726]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T12'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T9', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T11', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}]",[]
159,PMC-2626671-09-MATERIALS_AND_METHODS,"Isolation and culture of primary CD8+ T cells.
CD8+ T cells from 4-8-wk-old Tcra-/- x P14 TCR transgenic (Taconic), C57BL/6J WT, or Tbx21-/- (The Jackson Laboratory) mice were purified (>95% purity) by negative selection (Invitrogen) from pooled spleen and lymph node cells. CD8+ T cells from Runx3-/- mice on the ICR background were purified by positive selection (Miltenyi Biotec). All mice were maintained in specific pathogen-free barrier facilities and used according to protocols approved by the Immune Disease Institute and the Harvard Medical School Animal Care and Use Committees. For stimulation, purified CD8+ T cells were cultured at 106 cells/ml (10 ml) in T25 flasks coated with 1 mug/ml each of anti-CD3 (clone 2C11) and anti-CD28 (clone 37.51) by pretreatment with 300 mug/ml goat anti-hamster IgG. After 48 h, cells were removed from the TCR stimulation and recultured at a concentration of 5 x 105 cells/ml in media supplemented with 100 U/ml rhIL-2. Every 24 h, viable cells were counted and readjusted to 5 x 105 cells/ml with fresh media containing the corresponding amount of rhIL-2.","[{'offsets': [[47, 50]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[76, 80]], 'text': ['Tcra'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[132, 137]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[275, 278]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[293, 298]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[616, 619]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[715, 718]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[741, 745]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1098, 1104]], 'text': ['rhIL-2'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
160,PMC-2889865-00-TIAB,"Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells
Background
Activator protein (AP)-1 and nuclear factor (NF)-kappaB largely control T-cell activation, following binding of foreign antigens to the T-cell receptor leading to cytokine secretion. Elevated levels of pro-inflammatory cytokines and chemokines such as TNF, IL-6 and CXCL8 are associated with several human diseases including cystic fibrosis, pulmonary fibrosis and AIDS. The aim of this study was to investigate the role of the transcription factors, AP-1 and NF-kappaB, in IL-6 and CXCL8 regulation in Jurkat T-cells.
Results
Phorbol myristate acetate (PMA) exposure resulted in an up-regulation of AP-1 and down-regulation of NF-kappaB activity, however, exposure to heat killed (HK) Escherichia. coli MG1655 resulted in a dose-dependent increase in NF-kappaB activity without affecting AP-1. The cytokine profile revealed an up-regulation of the chemokine CXCL8 and the pro-inflammatory cytokines TNF, IL-2 and IL-6 following treatment with both PMA and HK E. coli, while the levels of the anti-inflammatory cytokine IL-10 were not affected by PMA but were significantly down-regulated by HK E. coli. AP-1 activation was significantly increased 2 h after PMA exposure and continued to increase thereafter. In contrast, NF-kappaB responded to PMA exposure by a rapid up-regulation followed by a subsequent down-regulation. Increased intracellular Ca2+ concentrations countered the down-regulation of NF-kappaB by PMA, while similar treatment with calcium ionophore resulted in a reduced NF-kappaB activity following induction with HK E. coli. In order to further study NF-kappaB activation, we considered two up-stream signalling proteins, PKC and Bcl10. Phosphorylated-PKC levels increased in response to PMA and HK E. coli, while Bcl10 levels significantly decreased following PMA treatment. Using an NF-kappaB activation inhibitor, we observed complete inhibition of IL-6 expression while CXCL8 levels only decreased by 40% at the highest concentration. Treatment of Jurkat T-cells with PMA in the presence of JNK-inhibitor suppressed both CXCL8 and IL-6 while PKC-inhibitor primarily decreased CXCL8 expression.
Conclusion
The present study shows that NF-kappaB regulated IL-6 but not CXCL8. This complex regulation of CXCL8 suggests that there is a need to further evaluate the signalling pathways in order to develop new treatment for diseases with elevated CXCL8 levels, such as AIDS and autoimmune diseases.","[{'offsets': [[341, 345]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[350, 355]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[558, 562]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[567, 572]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[943, 948]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[989, 993]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[998, 1002]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1104, 1109]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1734, 1739]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1818, 1823]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1956, 1960]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1978, 1983]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2129, 2134]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2139, 2143]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2184, 2189]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2262, 2266]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2275, 2280]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2309, 2314]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2450, 2455]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[500, 504]], 'text': ['role'], 'type': 'Regulation', 'id': 'T20'}, {'offsets': [[573, 583]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[912, 925]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[1119, 1127]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[1158, 1172]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T24'}, {'offsets': [[1845, 1854]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[1942, 1952]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T26'}, {'offsets': [[1961, 1971]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T27'}, {'offsets': [[1996, 2005]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[2113, 2123]], 'text': ['suppressed'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[2174, 2183]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T30'}, {'offsets': [[2190, 2200]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[2252, 2261]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T32'}, {'offsets': [[2295, 2305]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T33'}, {'offsets': [[2441, 2449]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T34'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T20', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T21', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T22', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T23', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T25', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T26', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T27', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T29', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T30', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T31', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T32', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T32', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T33', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T34', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E18', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}]",[]
161,PMC-3245220-14-Materials_and_Methods,"Purification of Peripheral Blood Monocytes and Monocyte-Derived Macrophages (MDMs)
Monocytes were isolated from source leukocyte packs obtained from the American Red Cross as described previously [51]. Monocytes used in real time PCR experiments and transfection experiments were purified by positive selection using CD14 Monocyte Isolation Kit from Miltenyi Biotech (Auburn, CA) (>90% pure). In some experiments, monocytes were isolated by clumping method (70% pure). To obtain monocyte-derived macrophages (MDMs), monocytes were cultured in RPMI-1640 medium containing 10% FBS, and 10 microg/ml polymyxin B and 20 ng/ml M-CSF.","[{'offsets': [[317, 321]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
162,PMC-3279418-14-Materials_and_Methods,"RNA expression by BMDC
BMDC were cultured at 106 cells/mL in 10 mL of RPMI-1640 complete medium in the presence or absence of 100 ng/mL LPS or 25 microg/mL poly I:C. After 1 and 2 hours, RNA was isolated with TRI-reagent (Sigma) according to the manufacturer's instructions. The expression of Il6, Il12p40, Gmcsf, and Sharpin mRNA was determined by qRT-PCR. Primers and probes were purchased from Applied Biosystems. Reverse transcription was performed at 42degreesC for 60 minutes with the final denaturation step at 90degreesC for 5 minutes in 30 microl containing 0.5 microg of total RNA. dNTPs, oligo(dT)15 primer, recombinant RNasin Ribonuclease Inhibitor, and M-MLV Reverse Transcriptase (all from Promega, Madison, WI) were used according to the manufacturer's instruction. Reverse transcription was done in a PTC-200 Peltier Thermal Cycler (MJ Research, Watertown, MA). qRT-PCR was performed in ABI Prism 7700 Sequence Detection System with TaqMan(R) Gene Expression Assays (Applied Biosystems, Foster City, CA) for mouse Actb, IL6, IL12p40, Ifnbeta, Gmcsf, and Sharpin according to the manufacturer's protocol. The endogenous standard for normalization of the target gene was beta-actin. Relative gene expression was calculated using the 2-deltadeltaCt method [56].","[{'offsets': [[293, 296]], 'text': ['Il6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[298, 305]], 'text': ['Il12p40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[307, 312]], 'text': ['Gmcsf'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[318, 325]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[666, 693]], 'text': ['M-MLV Reverse Transcriptase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1030, 1034]], 'text': ['Actb'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1036, 1039]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1041, 1048]], 'text': ['IL12p40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1050, 1057]], 'text': ['Ifnbeta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1059, 1064]], 'text': ['Gmcsf'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1070, 1077]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1185, 1195]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[279, 289]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T13'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
163,PMC-3148254-01-Introduction,"CD40 signaling in professional antigen-presenting cells, including B cells, macrophages, and dendritic cells, is critical for the efficient activation of humoral and cell-mediated immune responses [1], [2], [3]. CD40 signaling is activated in a T cell-dependent manner, as the ligand for CD40, CD154, is expressed primarily by activated T cells. CD40 engagement leads to the activation of various signaling molecules, including stress-activated protein kinases and the transcription factor NF-kappaB, which upregulate the expression of cytokines and other factors that promote immune responses. The mechanism by which CD40 induces these signaling pathways has not been completely defined. The cytoplasmic domain of CD40 does not appear to have intrinsic enzymatic activity, but is able to mediate signaling through the recruitment of several intracellular proteins. Members of the TNF receptor-associated factor (TRAF) family, including TRAF1, TRAF2, TRAF3, and TRAF6, appear to be particularly important for the initiation and regulation of CD40 signaling [4]. These proteins function in part as adaptor molecules, binding to the cytoplasmic tail of CD40 and recruiting other proteins to the receptor-associated complex. Some of the TRAFs also function as E3 ubiquitin ligases, and this enzymatic activity may contribute to signal propagation and regulation. Among the multiple TRAFs that associate with CD40, TRAF3 can function as a negative regulator of signaling, while TRAF2 and TRAF6 promote the activation of downstream signaling pathways [4].
We recently demonstrated that HOIL-1L interacting protein (HOIP), a ubiquitin ligase that can catalyze the assembly of linear polyubiquitin chains [5], is recruited to CD40 in a TRAF2-dependent manner following engagement of CD40 by agonistic antibody [6]. These and other findings led us to hypothesize that HOIP functions downstream of TRAF2 in the CD40 signaling pathway and that HOIP is necessary for the activation of NF-kappaB and possibly other signaling molecules. To test this hypothesis, we employed somatic cell gene targeting to ablate expression of HOIP in a mouse B cell line that has proven to be a useful model for B cell CD40 signaling [7], [8], [9]. We found that the CD40-induced upregulation of CD80 (a costimulatory molecule for T cells) was defective in HOIP-deficient cells. Similarly, the CD40 and IL-4 driven production of germline transcripts from the immunoglobulin epsilon heavy chain locus, an event that precedes immunoglobulin gene rearrangement and isotype switching, was defective in the absence of HOIP. We also found that the CD40-mediated activation of NF-kappaB and the stress-activated protein kinase c-Jun kinase (JNK) was defective in HOIP-deficient cells. Consistent with impaired NF-kappaB activation, association of the IkappaB kinase (IKK) complex with CD40 was undetectable in HOIP-deficient cells. Together, our results indicate that HOIP plays a critical role in the activation of signaling pathways that regulate cellular responses to CD40 engagement.","[{'offsets': [[0, 4]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[212, 216]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[288, 292]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[294, 299]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[346, 350]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[618, 622]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[715, 719]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[937, 942]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[944, 949]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[951, 956]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[962, 967]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1042, 1046]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1151, 1155]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1405, 1409]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1411, 1416]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1474, 1479]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1484, 1489]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1581, 1608]], 'text': ['HOIL-1L interacting protein'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1610, 1614]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1719, 1723]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1729, 1734]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1776, 1780]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1860, 1864]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1889, 1894]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1902, 1906]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1934, 1938]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2113, 2117]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2189, 2193]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2237, 2241]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2266, 2270]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2327, 2331]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2364, 2368]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2373, 2377]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2583, 2587]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2612, 2616]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2726, 2730]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2848, 2852]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2873, 2877]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2931, 2935]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3034, 3038]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[304, 313]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[351, 361]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T45'}, {'offsets': [[693, 711]], 'text': ['cytoplasmic domain'], 'type': 'Entity', 'id': 'T46'}, {'offsets': [[819, 830]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T47'}, {'offsets': [[1062, 1076]], 'text': ['These proteins'], 'type': 'Anaphora', 'id': 'T41'}, {'offsets': [[1116, 1123]], 'text': ['binding'], 'type': 'Binding', 'id': 'T48'}, {'offsets': [[1131, 1147]], 'text': ['cytoplasmic tail'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[1366, 1384]], 'text': ['the multiple TRAFs'], 'type': 'Anaphora', 'id': 'T42'}, {'offsets': [[1385, 1389]], 'text': ['that'], 'type': 'Anaphora', 'id': 'T43'}, {'offsets': [[1390, 1399]], 'text': ['associate'], 'type': 'Binding', 'id': 'T50'}, {'offsets': [[1706, 1715]], 'text': ['recruited'], 'type': 'Binding', 'id': 'T51'}, {'offsets': [[1735, 1744]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T52'}, {'offsets': [[1752, 1761]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[1762, 1772]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T54'}, {'offsets': [[1865, 1885]], 'text': ['functions downstream'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[2092, 2098]], 'text': ['ablate'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[2099, 2109]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[2242, 2249]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[2250, 2262]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[2314, 2323]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[2332, 2341]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[2572, 2579]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[2731, 2740]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[2795, 2806]], 'text': ['association'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[2878, 2887]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T65'}, {'offsets': [[3039, 3049]], 'text': ['engagement'], 'type': 'Binding', 'id': 'T66'}]","[{'trigger': 'T44', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T45', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T47', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T46']}}, {'trigger': 'T48', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T8', 'T13', 'T49']}}, {'trigger': 'T48', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T9', 'T13', 'T49']}}, {'trigger': 'T48', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T10', 'T13', 'T49']}}, {'trigger': 'T48', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T11', 'T13', 'T49']}}, {'trigger': 'T50', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T15']}}, {'trigger': 'T50', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T16']}}, {'trigger': 'T50', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T17']}}, {'trigger': 'T51', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T18', 'T20']}}, {'trigger': 'T52', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T21']}}, {'trigger': 'T53', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E14']}}, {'trigger': 'T54', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T55', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T24', 'T23']}}, {'trigger': 'T56', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T57', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T58', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T29']}}, {'trigger': 'T59', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T60', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T61', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T62', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T63', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T64', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T65', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T66', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}]","[{'id': 'R1', 'head': {'ref_id': 'T41', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T41', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T41', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T41', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T42', 'role': 'Subject'}, 'tail': {'ref_id': 'T15', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T42', 'role': 'Subject'}, 'tail': {'ref_id': 'T16', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T42', 'role': 'Subject'}, 'tail': {'ref_id': 'T17', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T43', 'role': 'Subject'}, 'tail': {'ref_id': 'T42', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T18', 'T19']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}]",[]
164,PMC-3245220-29-Caption-Figure_5,"M-CSF-induced PKC activity does not regulate IkappaBalpha degradation but regulates the phosphorylation of NF-kappaB p65 at Ser276.
(A) MDMs were pretreated with cycloheximide (CHX) in the absence or presence of Ro-31-8220 for 30 minutes prior to M-CSF stimulation for the indicated times. Whole cell lysates were subjected to Western blotting with anti-IkappaBalpha antibody. Data are representative of three independent experiments. (B) MDMs were pretreated with either vehicle or Ro-31-8220 for 30 minutes before the addition of M-CSF for 10 minutes. Whole cell lysates were resolved by SDS-PAGE and phospho-Ser276 or phospho-Ser536 of NF-kappaB p65 was detected using phospho-specific antibodies to either residue of NF-kappaB p65. (C) Whole cell lysates of RAW 264.7 cells treated with vehicle control or Ro-31-8220 in the absence or presence of M-CSF were subjected to Western blot analysis with phospho-Ser276 or phospho-Ser536 NF-kappaB p65 antibodies. (D) Cytosolic and nuclear fractions of RAW 264.7 were obtained from the treated cells and immunoblotted for phospho-NF-kappaB. The purity of the cytosolic and nuclear fractions was confirmed by immunoblotting with GAPDH and Lamin B, respectively. Shown are representative blots from three independent experiments.","[{'offsets': [[45, 57]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[117, 120]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[649, 652]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[731, 734]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[36, 44]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T5'}, {'offsets': [[58, 69]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T6'}, {'offsets': [[74, 83]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T7'}, {'offsets': [[88, 103]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T8'}, {'offsets': [[124, 130]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T9'}, {'offsets': [[603, 610]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[611, 617]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T11'}, {'offsets': [[621, 628]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T12'}, {'offsets': [[629, 635]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T13'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T9']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T11']}}, {'trigger': 'T12', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T13']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}]",[]
165,PMC-1310901-08-MATERIALS_AND_METHODS,"In vitro methylation and reporter gene assays
The IRF-4 promoter-reporter gene construct was generously provided by J. Hiscott (31). Constructs were methylated in vitro with CpG Methylase (M.Sss I) as recommended by the manufacturer (NE Biolabs) and complete methylation was checked via restriction analysis (Figure 5A). Reporter gene assays using the dual luciferase assay (Promega) were performed similar to previous reports (29). Briefly, 5 nM of the reporter construct and the transfection control construct expressing the renilla luciferase gene were transientlyco-expressed via electroporation. The control construct served as an internal reference for transfection efficiency. Forty-eight hours after transfection, luciferase activity was measured with a LB 96 P microlumat (EG&G Berthold, Bad Wildbad, Germany). IRF-4 promoter activation was quantified as a ratio of measured firefly light units (flu) relative to renilla (rlu). Each experiment was carried out at least three times.","[{'offsets': [[50, 55]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[174, 187]], 'text': ['CpG Methylase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[189, 196]], 'text': ['M.Sss I'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[357, 367]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[535, 545]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[722, 732]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[820, 825]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[512, 522]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[570, 579]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[826, 834]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T10'}, {'offsets': [[835, 845]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T11'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T9', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T10']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]",[],[]
166,PMC-2626671-00-TIAB,"Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs
Activation of naive CD8+ T cells with antigen induces their differentiation into effector cytolytic T lymphocytes (CTLs). CTLs lyse infected or aberrant target cells by exocytosis of lytic granules containing the pore-forming protein perforin and a family of proteases termed granzymes. We show that effector CTL differentiation occurs in two sequential phases in vitro, characterized by early induction of T-bet and late induction of Eomesodermin (Eomes), T-box transcription factors that regulate the early and late phases of interferon (IFN) gamma expression, respectively. In addition, we demonstrate a critical role for the transcription factor Runx3 in CTL differentiation. Runx3 regulates Eomes expression as well as expression of three cardinal markers of the effector CTL program: IFN-gamma, perforin, and granzyme B. Our data point to the existence of an elaborate transcriptional network in which Runx3 initially induces and then cooperates with T-box transcription factors to regulate gene transcription in differentiating CTLs.","[{'offsets': [[0, 5]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[113, 116]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[327, 335]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[500, 505]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[528, 540]], 'text': ['Eomesodermin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[542, 547]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[621, 643]], 'text': ['interferon (IFN) gamma'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[743, 748]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[773, 778]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[789, 794]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[883, 892]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[894, 902]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[908, 918]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1001, 1006]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[487, 496]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[515, 524]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[550, 577]], 'text': ['T-box transcription factors'], 'type': 'Anaphora', 'id': 'T15'}, {'offsets': [[583, 591]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T19'}, {'offsets': [[644, 654]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[779, 788]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[795, 805]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[817, 827]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[831, 853]], 'text': ['three cardinal markers'], 'type': 'Anaphora', 'id': 'T16'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T4']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T5']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T9']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T9']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T9']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T21', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T9']}}, {'trigger': 'T23', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]","[{'id': 'R1', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T5', 'T6']}]",[],[]
167,PMC-3245220-23-Materials_and_Methods,"Statistical Analysis
Statistical comparisons were performed using analysis of variance testing (Minitab software, State Park, PA or SPSS16 software, SPSS Inc. Chicago, IL). Statistical significance was defined as p<=0.05.",[],[],[],[],[],[]
168,PMC-2065877-13-Materials_and_Methods,"Immunohistochemistry.
Paraffin-embedded spleen sections were deparaffinized in Histoclear (National Diagnostics) and rehydrated in graded ethanol. Sections were antigen retrieved by microwaving in citrate buffer (pH 6.0) for 15 min (LMP1 staining) and 10 min (pStat3 staining). For LMP1 staining, sections were blocked with 1% BSA and 0.1% cold fish skin gelatin followed with streptavidin/biotin block (Vector Labs). Rat IgG anti-LMP1 (clones 8G3 and 1G6, Ascenion) were used at 1:10 dilution from tissue culture supernatants, followed with 8 mug/ml biotinylated mouse F(ab') anti-rat IgG (H+L) pre-adsorbed to mouse serum (Jackson ImmunoResearch) and 2 mug/ml streptavidin-alkaline phosphatase conjugate (Jackson ImmunoResearch). Stains were developed with BCIP/NBT and counterstained in Nuclear Fast Red (Dako). Phospho-Stat3 was detected with 4 mug/ml of pStat3 antibody (Tyr705, Cell Signaling) and detected with anti-rabbit Poly-HRP IHC detection kit (Chemicon).","[{'offsets': [[233, 237]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[282, 286]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[431, 435]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[823, 828]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
169,PMC-2889865-09-Materials_and_methods,"Heat killed (HK) Escherichia coli
E. coli MG1655 were grown on Luria-Bertani (LB) agar and incubated at 37degreesC overnight. One colony was inoculated into 10 ml LB broth and incubated on a shaker (200 rpm) at 37degreesC overnight. The bacteria were centrifuged for 10 min at 3000 x g, washed with 3 ml phosphate buffered saline (PBS; 8 g NaCl, 1.16 g Na2HPO4, 0.2 g KH2PO4, 0.2 g KCl, pH7) and resuspended in 50 mul PBS. The bacteria were killed by heating to 70degreesC for 1 h. To ensure that the bacteria were killed; 10 mul of the heat-killed suspension was spread on a LB plate and incubated overnight at 37degreesC.",[],[],[],[],[],[]
170,PMC-3148254-15-Caption-Figure_1,"HOIP gene targeting.
(A) Regions of Rnf31 gene sequence (bottom) used in the HOIP gene targeting vector (top) are shown. Arrows (F and R) indicate approximate positions of sequences homologous to oligonucleotides used for PCR-mediated detection of homologous recombination. Homologous recombination of the vector with Rnf31 resulted in a small chromosomal deletion and the in-frame insertion of neomycin phosphotransferase (NeoR) into the amino-terminal HOIP coding sequence. A diphtheria toxin (DT) cassette in the vector facilitates the negative selection of cells in which random chromosomal insertion of the vector takes place. LoxP sequences allow the Cre-mediated deletion of the NeoR coding sequence. The SV40pA sequence helps to ensure disruption of gene expression after deletion of the NeoR sequence. (B) Anti-HOIP and anti-FLAG Western blots of cell lysates from A20.2J cells and HOIP-deficient (HOIP-/-) clones. A partial decrease in HOIP protein expression is evident in cells following disruption of one copy of Rnf31 (HOIP-/+). HOIP expression in clones reconstituted with an empty retroviral vector (pMIP) or a retroviral vector encoding FLAG-tagged HOIP is also shown. Approximate molecular weight of HOIP is 120 kD.","[{'offsets': [[0, 4]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 41]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[77, 81]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[318, 323]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[454, 458]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[891, 895]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[907, 911]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[946, 950]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1026, 1031]], 'text': ['Rnf31'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1033, 1037]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1043, 1047]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1166, 1170]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1218, 1222]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[896, 905]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[934, 942]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[959, 969]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[990, 999]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[1000, 1010]], 'text': ['disruption'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[1048, 1058]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T19'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'E5']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],[],[]
171,PMC-1447668-08-Results,"Foxp3 Antagonizes CREB Transcriptional Activation by Disrupting Coactivator Recruitment
Stimulation of CREB-dependent transcription by reagents that activate adenylate cyclase and increase cAMP levels (e.g., forskolin) increase the transactivation potential of CREB through phosphorylation of serine 133 by protein kinase A, which permits binding and recruitment of coactivators CBP/p300 to the promoter [37,38]. Phosphorylation of serine 133 does not, however, affect the DNA-binding activity of CREB in most cases [39-41]. Addition of forskolin to HEK 293T cells stimulated activation of a CREB reporter vector about 65 fold (Figure 7A). Overexpression of Foxp3 was capable of down-regulating forskolin-induced CREB transcriptional activation. The functional interaction between Foxp3 and CREB did not affect the DNA-binding activity of CREB-1, but did show a modest decrease in activating transcription factor 2 (ATF-2) DNA-binding activity in the presence of forskolin as determined by transcription factor ELISA (Figure 7B).
While Foxp3 has been shown to bind to and repress activation of both NF-kappaB and NF-AT, exactly how Foxp3 functions to bring about this affect has not been elucidated. To determine how Foxp3 blocks CREB-dependent transcription, we examined whether Foxp3 was capable of (1) disrupting the recruitment of coactivator proteins and/or (2) preventing phosphorylation of CREB at serine 133 (which is a prerequisite for coactivator recruitment). Since both of these events are required for CREB-dependent gene expression, we hypothesized that Foxp3 may affect CREB activation at both steps. To determine whether Foxp3 can disrupt the function/recruitment of the coactivator protein p300, we introduced a Gal4 reporter vector and a Gal4-BD-CREB-1 expression vector into HEK 293T cells in the absence or presence of Foxp3, p300, and/or control expression vectors (Figure 7C). As expected, p300 overexpression stimulated transcription of the Gal4-BD-CREB-1 fusion protein. Foxp3, again, repressed basal levels of Gal4-BD-CREB-1 activation by more than 2-fold, while effectively neutralizing Gal4-BD-CREB-1 activation in the presence of p300. We next analyzed the effect of Foxp3 on phosphorylation of CREB at serine 133 in forskolin-treated HEK 293T cells by Western blot analysis. Overexpression of Foxp3 failed to reduce the detectable levels of CREB phosphorylation using a phosphospecific antibody for CREB-1 (unpublished data). However, when we attempted to determine whether Foxp3 could physically interact with the coactivator protein p300, we found that p300 immunoprecipitated Foxp3 when both proteins were overexpressed in HEK 293T cells (Figure 7D). Collectively, these results suggest that Foxp3 antagonizes CREB-dependent gene expression by directly interacting with coactivator p300 and interfering with its function and/or recruitment to CREB-responsive promoter sequences.","[{'offsets': [[0, 5]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[379, 382]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[383, 387]], 'text': ['p300'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[658, 663]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[781, 786]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[839, 845]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[881, 914]], 'text': ['activating transcription factor 2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[916, 921]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1036, 1041]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1132, 1137]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1217, 1222]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1280, 1285]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1568, 1573]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1637, 1642]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1707, 1711]], 'text': ['p300'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1729, 1733]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1756, 1770]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1839, 1844]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1846, 1850]], 'text': ['p300'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1912, 1916]], 'text': ['p300'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1964, 1978]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1995, 2000]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2035, 2049]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2113, 2127]], 'text': ['Gal4-BD-CREB-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2158, 2162]], 'text': ['p300'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2195, 2200]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2322, 2327]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2428, 2434]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2503, 2508]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2564, 2568]], 'text': ['p300'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2584, 2588]], 'text': ['p300'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2608, 2613]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2724, 2729]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2814, 2818]], 'text': ['p300'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[331, 338]], 'text': ['permits'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[339, 346]], 'text': ['binding'], 'type': 'Binding', 'id': 'T38'}, {'offsets': [[640, 654]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[761, 772]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T40'}, {'offsets': [[804, 810]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T41'}, {'offsets': [[819, 826]], 'text': ['binding'], 'type': 'Binding', 'id': 'T42'}, {'offsets': [[869, 877]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T43'}, {'offsets': [[927, 934]], 'text': ['binding'], 'type': 'Binding', 'id': 'T44'}, {'offsets': [[1060, 1064]], 'text': ['bind'], 'type': 'Binding', 'id': 'T45'}, {'offsets': [[1771, 1781]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[1867, 1877]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[1917, 1931]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[1932, 1942]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[1943, 1956]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T50'}, {'offsets': [[2009, 2018]], 'text': ['repressed'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[2050, 2060]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[2100, 2112]], 'text': ['neutralizing'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[2128, 2138]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[2304, 2318]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[2526, 2534]], 'text': ['interact'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[2589, 2607]], 'text': ['immunoprecipitated'], 'type': 'Binding', 'id': 'T57'}, {'offsets': [[2614, 2618]], 'text': ['when'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[2619, 2632]], 'text': ['both proteins'], 'type': 'Anaphora', 'id': 'T35'}, {'offsets': [[2638, 2651]], 'text': ['overexpressed'], 'type': 'Gene_expression', 'id': 'T59'}, {'offsets': [[2785, 2796]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[2823, 2834]], 'text': ['interfering'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[2840, 2843]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T36'}, {'offsets': [[2860, 2871]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T62'}]","[{'trigger': 'T37', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T38', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T37', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T38', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T39', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T40', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E6']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T5']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T45', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T46', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T47', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T47', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T50', 'id': 'E17', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T22']}}, {'trigger': 'T52', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T53', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T22']}}, {'trigger': 'T54', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T55', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T56', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T29', 'T30']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T31', 'T32']}}, {'trigger': 'T58', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E26']}}, {'trigger': 'T59', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T58', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E28']}}, {'trigger': 'T59', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T60', 'id': 'E29', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T34']}}, {'trigger': 'T61', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E29']}}, {'trigger': 'T62', 'id': 'E31', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}]","[{'id': 'R1', 'head': {'ref_id': 'T35', 'role': 'Subject'}, 'tail': {'ref_id': 'T31', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T35', 'role': 'Subject'}, 'tail': {'ref_id': 'T32', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T36', 'role': 'Subject'}, 'tail': {'ref_id': 'T34', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T7', 'T8']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E23', 'value': ''}]",[]
172,PMC-1447668-12-Materials_and_Methods,"Plasmids.
Expression vectors encoding human Foxp3 (pCMV-Foxp3-IRES-EGFP) and human Foxp3 lacking the forkhead (FKH) domain (pCMV-deltaFKH-IRES-EGFP) were generous gifts from S. Ziegler (Benaroya Research Institute). pEGFP-C2 was provided by I. Lipinski (NIDDK/NIH). pcDNA3 was provided by K. T. Jeang (NIAID/NIH). pCMV4-Tax was a generous gift from W. Greene (University of California San Francisco). pGL4-luc2 and pGL4-TKhRluc2 were purchased from Promega (Madison, Wisconsin, United States). pUC18 was purchased from Stratagene (La Jolla, California, United States). HIV-1 wt LTR and HIV-1 delta-kappaB LTR luciferase reporter vectors were constructed by cloning the XhoI/HindIII LTR fragments from pHIV-CAT and pdelta-kappaB-HIV-CAT (AIDS Research and Reference Reagent Program, NIAID/NIH) into the multiple cloning site of pGL4-luc2. NF-kappaB, HTLV-I LTR, and CREB luciferase reporter and pCMV-p300-HA expression vectors were generously provided by B. Wigdahl (Drexel University College of Medicine). HTLV-I pACH infectious molecular clone has been described previously [30]. pFR-luc, pFA-CMV, pFA2-CREB-1, and pFA2-c-Jun were purchased from Stratagene. pFA-Tax (encoding a fusion protein consisting of the Gal4 DNA-binding domain fused in-frame to HTLV-I Tax) was constructed by PCR amplification of HTLV-I Tax using pCMV4-Tax as a template and BamHI/BglII-tagged primers. The amplified insert was digested and ligated into the BamHI/BglII sites of pFA-CMV. Plasmid contents were confirmed by DNA sequencing.","[{'offsets': [[44, 49]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[56, 61]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 88]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[320, 323]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[609, 619]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[706, 709]], 'text': ['CAT'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[732, 735]], 'text': ['CAT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[870, 880]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[899, 903]], 'text': ['p300'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1104, 1110]], 'text': ['CREB-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1121, 1126]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1163, 1166]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1212, 1216]], 'text': ['Gal4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1261, 1264]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1313, 1316]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1329, 1332]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[10, 20]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[89, 96]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[101, 122]], 'text': ['forkhead (FKH) domain'], 'type': 'Entity', 'id': 'T19'}, {'offsets': [[907, 917]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T19']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]",[],[],[],[]
173,PMC-2626671-10-MATERIALS_AND_METHODS,"Isolation of CD8+ T cells from Runx3-/- mice.
Runx3-deficient T cells fail to silence CD4 expression normally (Fig. S1) (12, 13). We therefore further fractionated the positively selected CD8+ T cells from Runx3 KO mice into CD8+CD4- SP or CD8+CD4+ DP cells by separation using anti-CD4 magnetic beads. This yielded a Runx3 KO SP ""enriched"" population that contained 75% CD8+CD4- cells and a KO DP enriched population that contained 85% CD8+CD4+ cells (Fig. S1). The cells were stimulated with anti-CD3+ anti-CD28 for 2 d before removing them from the TCR stimulus and culturing them in media containing 100 U/ml IL-2. As previously reported, TCR-induced proliferation of Runx3-/- CD8+ T cells was severely impaired, irrespective of CD4 expression (Fig. S1) (12, 13). However, the Runx3-/- cells showed cell-surface expression patterns indicative of activated cells, including up-regulation of CD25 and CD69 (Fig. S1). As expected from their ability to up-regulate CD25, Runx3-/- CD8+ T cells responded to IL-2 supplementation after day 2 and efficiently expanded until day 6 of the culture period, albeit at slower rates compared with WT cells (Fig. S1). Although a fraction of the KO DP cells silenced CD4 expression after activation, the ratio of SP/DP cells in each enriched population remained constant thereafter, and we did not observe any major differences between these two populations throughout the culture period, indicating that in terms of effector CTL differentiation and under our culture conditions, Runx3-/- CD8+ T cells that also coexpress CD4 are indistinguishable from those that do not. The data presented in Fig. S2 are from Runx3 KO SP cells, whereas those shown in Figs. 3 and 4 are from total Runx3 KO CD8 cells.","[{'offsets': [[31, 36]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[46, 51]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[86, 89]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[188, 191]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[206, 211]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[225, 228]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[229, 232]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[240, 243]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[244, 247]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[283, 286]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[318, 323]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[371, 374]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[375, 378]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[437, 440]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[441, 444]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[499, 502]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[509, 513]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[613, 617]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[672, 677]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[681, 684]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[733, 736]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[781, 786]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[894, 898]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[903, 907]], 'text': ['CD69'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[965, 969]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[971, 976]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[980, 983]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1006, 1010]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1204, 1207]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1517, 1522]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1526, 1529]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1559, 1562]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1648, 1653]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1719, 1724]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1728, 1731]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[52, 61]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[78, 85]], 'text': ['silence'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[90, 100]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[737, 747]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[877, 890]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[953, 964]], 'text': ['up-regulate'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1195, 1203]], 'text': ['silenced'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[1208, 1218]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[1549, 1558]], 'text': ['coexpress'], 'type': 'Gene_expression', 'id': 'T44'}]","[{'trigger': 'T36', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T37', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E1']}}, {'trigger': 'T38', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T39', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T40', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T40', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}]",[]
174,PMC-2664230-08-MATERIALS_AND_METHODS,"Statistical Analysis
The experimental results obtained in this study were derived from four separate experiments with healthy volunteer donors. Each assay was performed in duplicate or triplicate where appropriate. Data is presented as the mean +/- SEM. Statistical differences between groups were determined by one-way analysis of variance (ANOVA) with a Bonferroni correction. Statistical significance was defined as P < 0.05.",[],[],[],[],[],[]
175,PMC-2791889-08-Results,"c-maf Expression Correlates with IL-10 Production in Th1, Th2, and Th17 Cells
To investigate further the downstream factors involved in regulating IL-10 production, we differentiated DO11.10 CD4+ T cells with increasing doses of OVA, in the presence or absence of IL-12, and quantified the expression of cytokines and transcription factors by real-time RT-PCR. Low-dose antigen resulted in transcription of Il4 and this was abrogated by both high antigen doses and IL-12 (Figure 6A). A low amount of transcription of Ifngamma was induced by IL-12 when cells were differentiated with low antigen dose, but this effect of IL-12 was markedly upregulated with increasing doses of antigen (Figure 6A). A low amount of Il10 transcription was observed at low doses of antigen accompanying Il4 expression (Th2 cell response), and this was abrogated by increased doses of antigen as was Il4 expression (Figure 6A). At low doses of antigen, IL-12 had little effect to increase IL-10 mRNA expression (Figure 6A) in keeping with the protein data (Figure 1A). However, IL-12 induced a high amount of Il10 transcription as well as Ifngamma expression with increased antigen doses (Figure 6A), again in keeping with the protein data (Figure 1A).
CD4+ T cells differentiated with increasing doses of antigen did not express high amounts of Tbx-21 (T-bet) mRNA, unless they were cocultured with IL-12 (Figure 6B). In contrast, high amounts of GATA-3 mRNA expression were only observed under Th2 cell differentiation conditions (low-dose antigen) (Figure 6B), and this expression was markedly downregulated by both increasing antigen dose and coculture in IL-12 (Figure 6B). Differentiation of T cells under low antigen dose led to expression of c-maf, in keeping with the Th2 cell profile (Ho et al., 1996), which was almost completely abrogated by increasing doses of antigen (Figure 6B). Interestingly, IL-12 sustained the high expression of c-Maf mRNA even at the highest antigen dose (Figure 6B). Moreover, IL-12 maintenance of c-maf expression required STAT4 activation (data not shown).
In Th17 cells that expressed IL-17a as well as IL-10 mRNA (Figure 6C), T-bet and GATA-3 mRNA were undetectable (data not shown), whereas that of ROR-gammat was high (Figure 6C) (Ivanov et al., 2007). Th17 cells also expressed high amounts of c-maf (Figure 6C), confirming a recent report (Bauquet et al., 2009). c-Maf is therefore expressed in all IL-10-expressing T cell populations tested (Figures 6B and 6C) and may not be just a Th2 cell-specific transcription factor as originally thought (Ho et al., 1996). We showed also that like Il10 expression, c-maf expression was inhibited in Th1 and Th17 cells in the presence of the MEK1 and MEK2 inhibitor (PD184352), whereas T-bet and RORgammat expression was hardly affected (Figure 6D).","[{'offsets': [[0, 5]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[33, 38]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[147, 152]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[191, 194]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[229, 232]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[264, 269]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[407, 410]], 'text': ['Il4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[465, 470]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[517, 525]], 'text': ['Ifngamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[541, 546]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 625]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[713, 717]], 'text': ['Il10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[782, 785]], 'text': ['Il4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[878, 881]], 'text': ['Il4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[931, 936]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[967, 972]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1056, 1061]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1087, 1091]], 'text': ['Il10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1117, 1125]], 'text': ['Ifngamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1231, 1234]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1324, 1330]], 'text': ['Tbx-21'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1332, 1337]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1378, 1383]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1426, 1432]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1638, 1643]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1728, 1733]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1888, 1893]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1927, 1932]], 'text': ['c-Maf'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1994, 1999]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2015, 2020]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2041, 2046]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2105, 2111]], 'text': ['IL-17a'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2123, 2128]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2147, 2152]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2157, 2163]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2221, 2231]], 'text': ['ROR-gammat'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2318, 2323]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2388, 2393]], 'text': ['c-Maf'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2424, 2429]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2614, 2618]], 'text': ['Il10'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2631, 2636]], 'text': ['c-maf'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2707, 2711]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2716, 2720]], 'text': ['MEK2'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2751, 2756]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2761, 2770]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[6, 16]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[39, 49]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T51'}, {'offsets': [[136, 146]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T52'}, {'offsets': [[153, 163]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[378, 386]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[390, 403]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T55'}, {'offsets': [[415, 419]], 'text': ['this'], 'type': 'Anaphora', 'id': 'T46'}, {'offsets': [[424, 433]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[500, 513]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T57'}, {'offsets': [[530, 537]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[605, 616]], 'text': ['this effect'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[639, 650]], 'text': ['upregulated'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[718, 731]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T61'}, {'offsets': [[786, 796]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[822, 826]], 'text': ['this'], 'type': 'Anaphora', 'id': 'T47'}, {'offsets': [[831, 840]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[882, 892]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[948, 954]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T65'}, {'offsets': [[958, 966]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[973, 988]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T67'}, {'offsets': [[1062, 1069]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1092, 1105]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T69'}, {'offsets': [[1126, 1136]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T70'}, {'offsets': [[1300, 1307]], 'text': ['express'], 'type': 'Transcription', 'id': 'T71'}, {'offsets': [[1433, 1448]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T72'}, {'offsets': [[1546, 1561]], 'text': ['this expression'], 'type': 'Anaphora', 'id': 'T48'}, {'offsets': [[1575, 1588]], 'text': ['downregulated'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[1707, 1710]], 'text': ['led'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[1714, 1724]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[1791, 1796]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T49'}, {'offsets': [[1819, 1828]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[1894, 1903]], 'text': ['sustained'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[1913, 1923]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T78'}, {'offsets': [[2000, 2011]], 'text': ['maintenance'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[2021, 2031]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T80'}, {'offsets': [[2032, 2040]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[2047, 2057]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[2095, 2104]], 'text': ['expressed'], 'type': 'Transcription', 'id': 'T83'}, {'offsets': [[2164, 2168]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T84'}, {'offsets': [[2174, 2186]], 'text': ['undetectable'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[2236, 2240]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[2292, 2301]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[2407, 2416]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T88'}, {'offsets': [[2430, 2440]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T89'}, {'offsets': [[2619, 2629]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[2637, 2647]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[2652, 2661]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T92'}, {'offsets': [[2721, 2730]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[2771, 2781]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[2793, 2801]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T95'}]","[{'trigger': 'T50', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T51', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T52', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T53', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T54', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T55', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T56', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T8']}}, {'trigger': 'T57', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T58', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T10']}}, {'trigger': 'T59', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T11']}}, {'trigger': 'T60', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T61', 'id': 'E12', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T62', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T63', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T63', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T64', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T65', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T15']}}, {'trigger': 'T66', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T67', 'id': 'E19', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T68', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T17']}}, {'trigger': 'T69', 'id': 'E21', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T68', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T17']}}, {'trigger': 'T70', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T71', 'id': 'E24', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T72', 'id': 'E25', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T73', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T25']}}, {'trigger': 'T74', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T75', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T76', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T77', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T27']}}, {'trigger': 'T78', 'id': 'E31', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T79', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T29']}}, {'trigger': 'T80', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T81', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'E33']}}, {'trigger': 'T82', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T83', 'id': 'E36', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T83', 'id': 'E37', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T84', 'id': 'E38', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T84', 'id': 'E39', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T85', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T85', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T86', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T87', 'id': 'E43', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T88', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T89', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T90', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T91', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T92', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E46', 'E49']}}, {'trigger': 'T93', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T92', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E46', 'E51']}}, {'trigger': 'T93', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T92', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E49']}}, {'trigger': 'T92', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'E51']}}, {'trigger': 'T94', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T94', 'id': 'E55', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T95', 'id': 'E56', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'E49']}}, {'trigger': 'T95', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'E51']}}, {'trigger': 'T95', 'id': 'E58', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E55', 'E49']}}, {'trigger': 'T95', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E55', 'E51']}}]","[{'id': 'R1', 'head': {'ref_id': 'T46', 'role': 'Subject'}, 'tail': {'ref_id': 'T54', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T47', 'role': 'Subject'}, 'tail': {'ref_id': 'T61', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T48', 'role': 'Subject'}, 'tail': {'ref_id': 'T72', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T75', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T21', 'T22']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E56', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E58', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E59', 'value': ''}]",[]
176,PMC-3148254-13-Materials_and_Methods,"NF-kappaB and JNK activation assays
For activation of CD40 signaling, 5x104 HI5 insect cells or HI5 insect cells expressing mouse CD154 (CD40 ligand) were added to 1x106 B cells. Cells were centrifuged for 1 minute at 400 x g (to promote contact between ligand cells and B cells) then incubated at 37degreesC for times indicated in Fig. 4. Following stimulation, cells were chilled on ice for 2 minutes. Cell pellets were dissolved in 2X SDS-PAGE loading buffer, sonicated, and heated for 5 minutes at 95degreesC. Total cell lysates (1x105 cell equivalents per lane) were fractionated by SDS-PAGE and blotted to polyvinylidine fluoride (PVDF) membranes. Membranes were probed with antibodies as indicated in Fig. 4. Chemiluminescent detection (Pierce Biotechnology) was used for the visualization of bands on Western blots. Images of blots were recorded with a low-light imaging system (LAS4000, Fuji Medical Systems) and on X-ray film.","[{'offsets': [[54, 58]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[130, 135]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 148]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[113, 123]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T4'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]",[],[]
177,PMC-3279418-22-Caption-Figure_4,"Decreased mRNA levels of inflammatory cytokines from cpdm BMDC.
Cultured WT and cpdm BMDC (5x105 cells in 0.2 ml complete medium) were washed and stimulated with 100 ng/ml LPS (A,C,E,G) or 25 microg/ml poly I:C (B,D,F,H). At 0, 1 and 2 hours, total RNA was extracted and subject to qRT-PCR to measure the expression of Il12p40 (A,B), Il6 (C,D), Gmcsf (E,F), and Ifnb (G,H) mRNA. Bars represent mean +/- SD. Data are representative of two independent experiments.","[{'offsets': [[319, 326]], 'text': ['Il12p40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[334, 337]], 'text': ['Il6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[345, 350]], 'text': ['Gmcsf'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[362, 366]], 'text': ['Ifnb'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[305, 315]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T5'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T5', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
178,PMC-2065877-01-Introduction,"Epstein-Barr virus (EBV) is a ubiquitous gamma-herpesvirus that infects humans predominantly at an early age with greater than 90% of the adult population infected with EBV [1]. EBV is linked to the development of both B lymphocyte and epithelial cell malignancies, including Burkitt lymphoma, Hodgkin disease (HD), and nasopharyngeal carcinoma (NPC), and cancers linked to immunosuppression, including post-transplant lymphoma and AIDS-associated lymphomas [2,3]. In vitro infection of B lymphocytes with EBV induces permanent growth transformation, and this ability to affect cell growth regulation likely contributes to the development of cancer.
Many of the viral proteins expressed in transformed cells, including the EBV nuclear antigens and latent membrane proteins, have profound effects on cell growth regulation and are required for EBV latent infection and B cell transformation [1]. Latent membrane protein 1 (LMP1) is considered the major oncoprotein of EBV, as it transforms rodent fibroblasts to tumorigenicity in nude mice and is expressed in HD, NPC, and immunosuppression-associated tumors [4-8]. In B lymphocytes, LMP1 mimics CD40 signaling, and both LMP1 and CD40 are essential for EBV-mediated B cell transformation [9-11]. While CD40 interacts with CD40 ligand expressed on activated T cells to induce B cell activation and differentiation, LMP1 acts as a constitutive signal through ligand-independent oligomerization. LMP1 and CD40 interact with the same tumor necrosis factor receptor-associated factors (TRAFs) leading to activation of NFkappaB, c-Jun N terminal kinase (JNK), and p38 MAPK signaling pathways [12-16]. Activation of NFkappaB is required for EBV-induced B cell transformation and its inhibition rapidly results in cell death [17,18]. Recent studies indicate that LMP1 also activates phosphatidylinositol 3 kinase (PI3K)/Akt signaling and that this activation is required for LMP1-mediated transformation of rodent fibroblasts [5,19].
In vitro, primary B cells can be maintained by CD40 ligation in combination with IL4 treatment. In vivo, CD40 signaling is necessary for germinal center (GC) formation such that mice deficient for CD40 or CD40L are unable to form GCs in response to T cell-dependent antigens [20,21]. Both the membrane proximal and distal cytoplasmic regions of CD40 that bind TRAF6 and TRAFs2/3/5, respectively, are necessary for GC formation, but either region is sufficient to induce extrafollicular B cell differentiation and restore low affinity antibody production [22]. Functionally, LMP1 can rescue CD40-deficient mice and restore immunoglobulin (Ig) class switching, most likely because LMP1 recruits similar TRAF molecules, TRAFs 1/2/3/5 and TRAF6, through the C-terminal activation regions 1 and 2 domains, respectively. However, LMP1 is unable to restore affinity maturation and GC formation [23].
Several EBV transforming proteins have been studied in transgenic mouse models, however, only LMP1 induces tumor development when expressed under the control of the Ig heavy chain promoter and enhancer [24-26]. The LMP1 transgenic mice (IgLMP1) express LMP1 in B lymphocytes, and in mice older than 12 mo, lymphoma develops with increased incidence (40%-50%) compared to wild-type control mice (11%), suggesting that LMP1 contributes to tumor development [26]. The LMP1 lymphomas have rearranged Ig genes and have activated Akt, JNK, p38, and NFkappaB, with specific activation of the NFkappaB family member cRel [27].
In this study, the LMP1 transgenic lymphocytes and lymphomas were further characterized and their growth properties in vitro were determined. To obtain pure populations of malignant lymphocytes and to enable more detailed biochemical analyses, examples of primary lymphomas were inoculated and passaged in SCID mice. Interestingly, lymphoma development was restricted to B-1a lymphocytes, a self-replenishing population of cells that are prone to malignancy [28,29]. LMP1 transgenic lymphocytes had increased viability in vitro and viability was increased by the addition of IL4. In contrast, both LMP1-positive and -negative lymphoma cells were independent of IL4 co-stimulation for survival and proliferation in vitro with a complete absence of activated Stat6, the IL4 target. The lymphomas were also distinguished by constitutive activation of Stat3 and deregulation of the Rb cell cycle pathway. Inhibition of the PI3K/Akt, NFkappaB, and Stat3 signaling pathways blocked the enhanced growth of both LMP1 transgenic and malignant lymphocytes, suggesting that these pathways are required for their growth and survival. These appear to be the same targets that are deregulated in wild-type B-1a lymphomas that arise spontaneously through age predisposition. This study reveals that LMP1 promotes malignancy in cells with the inherent ability to proliferate and that the Akt, NFkappaB, and Stat3 signaling pathways are required for its growth stimulatory effects.","[{'offsets': [[895, 920]], 'text': ['Latent membrane protein 1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[922, 926]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1133, 1137]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1145, 1149]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1170, 1174]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1179, 1183]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1251, 1255]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1271, 1282]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1363, 1367]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1442, 1446]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1451, 1455]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1479, 1500]], 'text': ['tumor necrosis factor'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1572, 1577]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1804, 1808]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1861, 1864]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1916, 1920]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2022, 2026]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2056, 2059]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2080, 2084]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2172, 2176]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2180, 2185]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2320, 2324]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2335, 2340]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2345, 2351]], 'text': ['TRAFs2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2352, 2353]], 'text': ['3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2354, 2355]], 'text': ['5'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2549, 2553]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2565, 2569]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2654, 2658]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2692, 2699]], 'text': ['TRAFs 1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2700, 2701]], 'text': ['2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2702, 2703]], 'text': ['3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2704, 2705]], 'text': ['5'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2710, 2715]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2799, 2803]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2962, 2966]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3083, 3087]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3121, 3125]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3285, 3289]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3333, 3337]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3392, 3395]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3476, 3480]], 'text': ['cRel'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3506, 3510]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3954, 3958]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4062, 4065]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4085, 4089]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4148, 4151]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4244, 4249]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4255, 4258]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4335, 4340]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4365, 4367]], 'text': ['Rb'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4411, 4414]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4430, 4435]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4491, 4495]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4771, 4775]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4859, 4862]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4878, 4883]], 'text': ['Stat3'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[975, 977]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T58'}, {'offsets': [[1046, 1055]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[1256, 1265]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1283, 1292]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[1425, 1440]], 'text': ['oligomerization'], 'type': 'Binding', 'id': 'T63'}, {'offsets': [[1456, 1464]], 'text': ['interact'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[2027, 2035]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[2158, 2167]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[2268, 2285]], 'text': ['membrane proximal'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[2290, 2316]], 'text': ['distal cytoplasmic regions'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[2330, 2334]], 'text': ['bind'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[2558, 2564]], 'text': ['rescue'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[2570, 2579]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[2659, 2667]], 'text': ['recruits'], 'type': 'Binding', 'id': 'T72'}, {'offsets': [[2729, 2760]], 'text': ['C-terminal activation regions 1'], 'type': 'Entity', 'id': 'T73'}, {'offsets': [[2765, 2774]], 'text': ['2 domains'], 'type': 'Entity', 'id': 'T74'}, {'offsets': [[2998, 3007]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[3008, 3025]], 'text': ['under the control'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[3113, 3120]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T77'}, {'offsets': [[3382, 3391]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[3435, 3445]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[4223, 4230]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[4234, 4243]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[4259, 4265]], 'text': ['target'], 'type': 'Regulation', 'id': 'T82'}, {'offsets': [[4321, 4331]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[4628, 4644]], 'text': ['the same targets'], 'type': 'Anaphora', 'id': 'T59'}, {'offsets': [[4654, 4665]], 'text': ['deregulated'], 'type': 'Regulation', 'id': 'T84'}]","[{'trigger': 'T60', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T61', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T7', 'T8']}}, {'trigger': 'T62', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T63', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T64', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T64', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T65', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T66', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T66', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T69', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T22', 'T23', 'T67']}}, {'trigger': 'T69', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T22', 'T24', 'T68']}}, {'trigger': 'T69', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T22', 'T25', 'T68']}}, {'trigger': 'T69', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T22', 'T26', 'T68']}}, {'trigger': 'T70', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T71', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T72', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T29', 'T30', 'T73']}}, {'trigger': 'T72', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T29', 'T31', 'T73']}}, {'trigger': 'T72', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T29', 'T32', 'T73']}}, {'trigger': 'T72', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T29', 'T33', 'T73']}}, {'trigger': 'T72', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T29', 'T34', 'T74']}}, {'trigger': 'T75', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T76', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T77', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T78', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T79', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T80', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T81', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T82', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T48', 'T49']}}, {'trigger': 'T83', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T84', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T84', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}]","[{'id': 'R1', 'head': {'ref_id': 'T58', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T52', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T53', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T1', 'T2']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E30', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E31', 'value': ''}]",[]
179,PMC-2889865-23-Caption-Figure_7,"NF-kappaB inhibition by PMA correlated to PKC-dependent Bcl10 degradation. Levels of intracellular protein were assessed following 24 h stimulation with PMA (162 nM) or HK E. coli (5 x 107 CFU/ml). (A) Phospho-PKC increased in response to PMA and HK E. coli stimulation. (B) IkappaB decreased following stimulation with HK E. coli indicating NF-kappaB activation. (C) Bcl10 activation was inhibited following long-term stimulation with PMA, which explains the inhibitory effect of PMA on NF-kappaB activation. beta-actin was used as a loading control. (n = 3).","[{'offsets': [[56, 61]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[368, 373]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[510, 520]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[46, 55]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T4'}, {'offsets': [[62, 73]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T5'}, {'offsets': [[374, 384]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[389, 398]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T7'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T7', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}]",[],[],[],[]
180,PMC-1310901-14-RESULTS,"mRNA expression of DNA methyltransferases and methyl-CpG-binding proteins may not be associated with IRF-4 promoter methylation
Since abundance of DNMT and MBP contribute to promoter regulation via methylation (25,26,28), we studied their mRNA expression to investigate a possible mechanism for the observed methylation differences in the IRF-4 promoter. To this end, we did not detect a significant difference in DNMT (DNMT1, DNMT3A and DNMT3B) or MBP (MBD1, MBD2, MBD4 and MeCP) mRNA expression between IRF-4-positive and -negative cells (Figure 5D). In fact, all analyzed cells had moderate to high mRNA levels of these tested DNMT/MBPs and differences in expression were not correlated with IRF-4 status. These results indicate a distinct cause of the methylation differences in IRF-4-positive and -negative cells rather than changes in the DNMT and MBP mRNA transcription.","[{'offsets': [[101, 106]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[339, 344]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[420, 425]], 'text': ['DNMT1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[427, 433]], 'text': ['DNMT3A'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[438, 444]], 'text': ['DNMT3B'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[454, 458]], 'text': ['MBD1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[460, 464]], 'text': ['MBD2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[466, 470]], 'text': ['MBD4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[475, 479]], 'text': ['MeCP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[505, 510]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[695, 700]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[783, 788]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[174, 182]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[183, 193]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[481, 496]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T19'}, {'offsets': [[511, 519]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[525, 533]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[602, 613]], 'text': ['mRNA levels'], 'type': 'Transcription', 'id': 'T22'}, {'offsets': [[617, 634]], 'text': ['these tested DNMT'], 'type': 'Anaphora', 'id': 'T13'}, {'offsets': [[635, 639]], 'text': ['MBPs'], 'type': 'Anaphora', 'id': 'T14'}, {'offsets': [[659, 669]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T23'}, {'offsets': [[789, 797]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[803, 811]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[841, 849]], 'text': ['the DNMT'], 'type': 'Anaphora', 'id': 'T15'}, {'offsets': [[854, 857]], 'text': ['MBP'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[863, 876]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T26'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T17']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T19', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T20', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T22', 'id': 'E12', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T22', 'id': 'E13', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E14', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E15', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E16', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T22', 'id': 'E17', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T23', 'id': 'E18', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T23', 'id': 'E19', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T23', 'id': 'E20', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T23', 'id': 'E21', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T23', 'id': 'E22', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T23', 'id': 'E23', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T23', 'id': 'E24', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T24', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T25', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T26', 'id': 'E27', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T26', 'id': 'E28', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T26', 'id': 'E29', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T26', 'id': 'E30', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T26', 'id': 'E31', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T26', 'id': 'E32', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T26', 'id': 'E33', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]","[{'id': 'R1', 'head': {'ref_id': 'T13', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T13', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T13', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T14', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T14', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T14', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T14', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R11', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R12', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R13', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R14', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}]",[]
181,PMC-3245220-25-Caption-Figure_1,"M-CSF induces NF-kappaB transcriptional activity in macrophages.
(A) Nuclei were extracted from human MDMs treated without or with M-CSF for 15 or 30 minutes. NF-kappaB DNA binding activity was analyzed by EMSA Shown is a representative blot from three independent experiments. NS: non-stimulated. (B) Human MDMs transiently transfected with pTAL-SEAP or pNF-kappaB-SEAP constructs were treated with M-CSF in X-vivo medium and incubated for 6 hours before the collection of medium. NF-kappaB activity was analyzed by measuring the amount of SEAP secreted into the medium and data are expressed as fold increase of SEAP activity over that in pTAL-SEAP transfected resting cells. (C) RAW 264.7 cells were transiently transfected with pTAL-SEAP or pNF-kappaB-SEAP construct. Cells were serum starved for 4 hours prior to 2 hours stimulation with mouse recombinant M-CSF (100 ng/ml). Culture media was collected to measure SEAP production. Data are expressed mean +/- S.E.M, for three independent experiments.",[],[],[],[],[],[]
182,PMC-2889865-10-Materials_and_methods,"Cell culturing, transfection and stimulation
Jurkat T-cells (wild type and TCR deficient- TCR-/-) were maintained in 90% RPMI 1640 medium (PAA laboratories, Austria) with 1.5 mM L-glutamine (Invitrogen, USA), 10% foetal bovine serum (Invitrogen, USA) and 1% antibiotic-antimycotic (Invitrogen, USA) and incubated in a stable environment of 5% CO2 at 37degreesC.
The cells were centrifuged at 1000 x g for 8 min and resuspended in fresh media to a final cell density of 1.6 x 107 cells/ml in a 24-well plate. Reporter plasmid (pNFkappaB-Luc, pAP1 (PMA)-TA-Luc, pNFkappaB-SEAP), internal control plasmid (pRL) (Promega, USA) and lipofectamine 2000 (Invitrogen, USA) were added to each well at 0.54 mug/well, 0.06 mug/well and 1.5 mul/well, respectively. Initially, the reporter plasmid and pRL were mixed separately with OptiMEM (Gibco, USA). After 5 min of incubation at room temperature, lipofectamine 2000 was added and the mixture was incubated further for 20 min at room temperature. The transfection was allowed to proceed overnight at 37degreesC, after which, the cells were centrifuged, the media removed and fresh pre-warmed media added. The cells were pre-incubated with NF-kappaB, JNK and PKC inhibitors and stimulated in 24-well plates with different concentrations of PMA, HK E. coli MG1655 and Calcium Ionophore A23187.
The cells were lysed and luciferase activity (NF-kappaB and AP-1) was measured using the Dual-Luciferase(R) reporter assay system (Promega, USA) according to the manufacturer's instructions on a TD 20/20 luminometer (Turner Designs, Sunnyvale, CA). Secreted alkaline phosphatase (NFkappaB-SEAP, figure 4a, b) levels were measured using Great EscAPe(TM) SEAP Detection Kit (Clontech, USA).","[{'offsets': [[1357, 1367]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1368, 1376]], 'text': ['activity'], 'type': 'Positive_regulation', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
183,PMC-3279418-02-Results,"Characterization of Sharpin
Orthologs of SHARPIN protein are found in various species, including human, mouse and rat. Motif prediction programming, using COILS [11] and MotifScan [12], suggests that SHARPIN contains a coiled-coil (CC) domain, a ubiquitin-like (UBL) domain, and a zinc-finger Ran-binding protein 2 (ZFRBP) domain. These functional motifs constitute similar domain profiles that are present in the SHARPIN protein of all three origins (Fig. 1A), suggesting that SHARPIN exerts highly conserved functions across species. Spontaneous mutations in the mouse Sharpin gene results in a complex inflammatory phenotype characterized by severe dermatitis (Fig. 1B), systemic inflammation and an enlarged spleen (Fig. 1C) caused by extramedullary hematopoiesis [3]. The endogenous expression of Sharpin mRNA in BMDC was determined by quantitative real time-PCR (qRT-PCR) following culture in medium only or after stimulation with LPS. Sharpin mRNA was present in BMDC generated from WT mice (Fig. 1D) and its level was modestly decreased by LPS stimulation. There was a significant reduction of Sharpin mRNA (6-7-fold) in BMDC generated from cpdm mice. Transfection of Flag-tagged Sharpin in fibroblasts (NIH3T3) and macrophages (RAW264.7) indicated cytoplasmic localization of the SHARPIN protein (Fig. 1E).","[{'offsets': [[20, 27]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 48]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[200, 207]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[414, 421]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[478, 485]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[571, 578]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[802, 809]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[942, 949]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1102, 1109]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1188, 1195]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1289, 1296]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[548, 557]], 'text': ['mutations'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[788, 798]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T14'}, {'offsets': [[959, 966]], 'text': ['present'], 'type': 'Transcription', 'id': 'T15'}, {'offsets': [[1012, 1021]], 'text': ['its level'], 'type': 'Anaphora', 'id': 'T12'}, {'offsets': [[1035, 1044]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[1089, 1098]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[1257, 1268]], 'text': ['cytoplasmic'], 'type': 'Entity', 'id': 'T18'}, {'offsets': [[1269, 1281]], 'text': ['localization'], 'type': 'Localization', 'id': 'T19'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T11', 'T18']}}]","[{'id': 'R1', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T15', 'role': 'Object'}, 'type': 'Coreference'}]",[],[],[]
184,PMC-3148254-19-Caption-Figure_5,"IKK recruitment to the CD40 signaling complex is defective in HOIP-deficient cells.
(A) SMAC peptide treatment reduces recruitment of cIAP1 to CD40 and may modify HOIP recruitment. A20.2J cells were incubated for six hours with membrane-permeable SMAC-N7 peptide or 1.5% DMSO (solvent used for the peptide). Following the incubation, cell lysates were prepared, fractionated by SDS-PAGE, and evaluated by Western blot (lanes 1 and 2). Cells incubated with DMSO or SMAC-N7 were also stimulated with magnetic beads coated with anti-CD40 or an isotype control antibody. Immunoprecipitated (IP) material bound to the beads was loaded in lanes 3-5. Samples of the cell lysates after immunoprecipitation appear in lanes 6-8. Western blots were probed with antibodies specific for cIAP1, TRAF2, TRAF3, and HOIP (approximate molecular weights indicated on left). Similar results were obtained in two additional experiments. (B) CD40 was isolated by immunoprecipitation (as in (A)) from A20.2J cells and HOIP-deficient cells transduced with an empty retroviral vector (pMIP) or a retroviral vector encoding HOIP. Material immunoprecipitated with an isotype control antibody (isotype) or anti-CD40 antibody was examined by Western blotting for CD40, TRAF2, TRAF3, cIAP1, HOIP, IKKalpha/beta, and IKKgamma (right panels). HOIP expression was required for coprecipitation of IKK proteins with CD40. Cell lysates from unstimulated cells are shown in the left panels. Similar results were obtained in a second experiment and in two experiments with a second HOIP-deficient clone. (C) To further evaluate HOIP-dependent recruitment of IKKgamma to CD40, A20.2J cells or HOIP-deficient (HOIP-/-) A20.2J cells were transduced with an empty retroviral vector or a retroviral construct encoding BP epitope-tagged IKKgamma (noted in the figure as pMIP and IKKgamma, respectively). Lysates (lanes 1-3) and immunoprecipitation (IP) samples (lanes 4-11) from the cell lines were fractionated by SDS-PAGE and evaluated by Western blotting with antibodies to the BP tag (IKKgamma, upper panel) and TRAF2. The anti-CD40 IP sample in lane 11 was treated with lambda phosphatase; the sample in lane 10 was mock-treated. Protein samples (minus those treated with phosphatase) were also fractionated on a separate gel (lower acrylamide concentration) for the evaluation of TRAF3 and HOIP (bottom two panels). Similar results were obtained in two additional experiments.","[{'offsets': [[62, 66]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[134, 139]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[143, 147]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[163, 167]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[774, 779]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[781, 786]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[788, 793]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[799, 803]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[920, 924]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[995, 999]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1098, 1102]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1234, 1238]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1240, 1245]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1247, 1252]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1254, 1259]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1261, 1265]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1267, 1275]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1276, 1280]], 'text': ['beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1286, 1294]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1311, 1315]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1381, 1385]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1544, 1548]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1590, 1594]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1620, 1628]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1632, 1636]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1654, 1658]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1670, 1674]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1793, 1801]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1826, 1830]], 'text': ['pMIP'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1835, 1843]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2045, 2053]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2072, 2077]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2342, 2347]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2352, 2356]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[67, 76]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T35'}, {'offsets': [[111, 118]], 'text': ['reduces'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[119, 130]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[156, 162]], 'text': ['modify'], 'type': 'Regulation', 'id': 'T38'}, {'offsets': [[168, 179]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T39'}, {'offsets': [[1000, 1009]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1316, 1326]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[1549, 1558]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[1595, 1604]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T43'}, {'offsets': [[1605, 1616]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T44'}, {'offsets': [[1659, 1668]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T45'}]","[{'trigger': 'T35', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T36', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T37', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T2', 'T3']}}, {'trigger': 'T38', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T39', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T40', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T23']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T45', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}]",[]
185,PMC-2791889-10-Experimental_Procedures,"Mice, Cytokines, Antibodies, and Other Reagents
BALB/c DO11.10 mice transgenic for OVA-specific TCR WT or crossed back with Rag1-, IL-4-, IFN-gamma-, STAT4-, and STAT6-deficient mice were used as a source of antigen-specific T cells (Murphy et al., 1990; Ouyang et al., 1998; Shoemaker et al., 2006) and were bred and maintained under SPF conditions at the NIMR, London, Home Office, UK, Animals (Scientific Procedures) Act 1986 or at the Washington University School of Medicine. Female mice were used at 8-12 weeks old, and animal protocols were approved according to the Animals (Scientific Procedures) Act 1986, Home Office, UK. Reagents, including antibodies for T cell and DC preparation, purification and culture, media, cytokines, and cytokine mAbs have been described (Hosken et al., 1995; Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006). LPS (S. minnesota) was from Alexis, chicken ovalbumin protein (OVA protein) was from from Sigma-Aldrich, and ovalbumin peptide323-339 (OVA) (endotoxin-free) was from Biosynthesis. U0126 was from BioMol International. PD184352 (MEK inhibitors), SB203580 (p38 inhibitor), and CT99021 (GSK3beta inhibitor) were kind gifts from P. Cohen and N. Shpiro, University of Dundee, UK.","[{'offsets': [[83, 86]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[124, 128]], 'text': ['Rag1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[131, 135]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[138, 147]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[150, 155]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[162, 167]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[914, 923]], 'text': ['ovalbumin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[933, 936]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[979, 988]], 'text': ['ovalbumin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1097, 1100]], 'text': ['MEK'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1124, 1127]], 'text': ['p38'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1153, 1161]], 'text': ['GSK3beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[168, 177]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[1101, 1111]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[1128, 1137]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[1162, 1171]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T16'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T16', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]",[],"[{'id': '*', 'ref_ids': ['T7', 'T8']}]",[],[]
186,PMC-3245220-02-Results,"M-CSF Induces NF-kappaB Transcriptional Activity in Human Monocyte-Derived Macrophages (MDMs) and Mouse Macrophage Cell Line, RAW 264.7
To determine if M-CSF induced NF-kappaB DNA binding in human macrophages, we performed EMSA analysis on nuclear lysates from M-CSF-treated MDMs. Similar to previous reports [11], nuclear NF-kappaB constitutively bound DNA in non-stimulated monocytes (Figure 1A). Interestingly, adding M-CSF did not alter NF-kappaB DNA binding by EMSA. In contrast, after transiently transfecting human MDMs with pNF-kappaB-SEAP constructs containing four NF-kappaB consensus binding sequences, M-CSF treatment of the transfected cells resulted in a 2.3-fold increase in SEAP release in the culture media compared to PBS (vehicle)-treated transfected MDMs (Figure 1B). As a control, the pTAL-SEAP construct lacking NF-kappaB binding sites was used. Cells transfected with the pTAL-SEAP construct did not produce SEAP in the absence or presence of M-CSF (Figure 1B).
We next investigated whether M-CSF induced NF-kappaB activity in the mouse macrophage cell line, RAW 264.7. RAW 264.7 cells were transfected with either the NF-kappaB-SEAP reporter or control pTAL-SEAP construct. As shown in Figure 1C, M-CSF treatment of RAW 264.7 cells increased NF-kappaB reporter activity by 2.5-fold over that of non-treated cells. Together, our data demonstrate that M-CSF induced NF-kappaB transcriptional activity in macrophages.","[{'offsets': [[1266, 1275]], 'text': ['NF-kappaB'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1256, 1265]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T2'}, {'offsets': [[1285, 1293]], 'text': ['activity'], 'type': 'Positive_regulation', 'id': 'T3'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T3', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
187,PMC-2664230-04-MATERIALS_AND_METHODS,"Effect of PTX on LPS-induced TNF-alpha production by mononuclear cells
The concentration of TNF-alpha was quantitatively determined by ELISA in the media of cells exposed to the treatments described above after stimulation for up to a maximum of 18 hours, at 3-hour intervals. The results are expressed in pg/mL.","[{'offsets': [[29, 38]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[92, 101]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[21, 28]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T3'}, {'offsets': [[39, 49]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T4'}]","[{'trigger': 'T3', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
188,PMC-3245220-18-Materials_and_Methods,"Secreted Alkaline Phosphatase (SEAP) Analysis
Secreted alkaline phosphatase activity was analyzed by GreatEscape SEAP kit according to the manufacturer's instruction. Briefly, medium was diluted in the dilution buffer and heated to 65degreesC to inactivate endogenous phosphatases then incubated with the substrate for 30 minutes. The chemiluminence signal was recorded using a luminometer.",[],[],[],[],[],[]
189,PMC-1310901-01-INTRODUCTION,"Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with a typical three phased course (chronic, accelerated and blastic phase) reflecting the loss of differentiation and malignant progress which inevitably leads to death after the blastic phase (1,2). The hallmark genetic aberration of CML is a reciprocal chromosomal translocation t(9;22) leading to expression of a bcr-abl fusion gene, an aberrant activated tyrosine kinase (2). Treatment with interferon alpha (IFN-alpha) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5-33% of CML patients (1,2). Recently, we described an impaired expression of the interferon regulatory factor 4 (IRF-4) in CML, correlating with poor response to IFN-alpha treatment (3). The cause of the silencing of IRF-4 level remained unclear.
Interferon regulatory factors (IRFs) are a family of transcriptional regulators defined by a characteristic homology in their DNA-binding domain. They play an important role in the regulation of various genes (such as IFNs, interleukins, MHC class I/II), apoptosis and differentiation/maturation (4-6). IRF-4 (ICSAT/Pip/MUM1/LSIRF) is one member with very restricted expression pattern: Predominately B- and activated T-lymphocytes are IRF-4 positive (7-11). In contrast to other IRFs, expression of IRF-4 cannot be induced by IFNs, but by antigen stimulation, crosslinking of T- or B-cell receptors or phorbol-myristate-acetate (10,11). Consistent with the restriction of expression to immunocompetent cells, mice with deletion of IRF-4 failed to develop mature and functionally active B- and T-lymphocytes (12), and the impaired expression of IRF-4 in CML was predominately found in T-cells (3). These data suggest a crucial role for IRF-4 in the function of immune cells.
Methylation of dinucleotide cytosine-guanosine motifs (CpG), especially in CpG islands located in promoter regions, is one of the mechanisms of gene regulation in mammals and a common event of gene silencing in human neoplasias (13,14). As opposed to normal cells, hypermethylation of CpG islands is a frequently observed phenomenon in every cancer type. De novo DNA methylation of genes such as cell cycle, DNA repair, apoptosis and tumor suppressor genes is therefore thought to be involved in tumorigenesis (15-17). Examples for such aberrated genes are MGMT, DAPK, p14ARF, p15INK4b, p16INK4a, BRCA1, CDH13 and APAF-1 (17-19). In CML, methylation is known to regulate expression of the c-abl, the bcr gene and others (20-23), and the extent of methylation in the c-abl promoter has been shown to be associated with advanced disease (24). Hypermethylation due to overexpression of DNA methyltransferases (DNMTs) remains one possible explanation for de novo methylation in tumorigenesis. Recently, DNMTs have been shown to be up-regulated in hematopoietic malignancies (25). Methyl-CpG-binding proteins (MBPs) are thought to inhibit the binding of transcriptional factors to the promoter and are therefore discussed as one mechanism of transcription inhibition by hypermethylation (26).
In this work, we studied mechanisms of IRF-4 gene expression silencing in leukemic cells. We analyzed the IRF-4 promoter region for genetic aberrations and methylational status in IRF-4-positive and -negative hematopoietic cells.","[{'offsets': [[388, 407]], 'text': ['bcr-abl fusion gene'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[467, 483]], 'text': ['interferon alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[485, 494]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[670, 700]], 'text': ['interferon regulatory factor 4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[702, 707]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[751, 760]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[806, 811]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1139, 1144]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1146, 1151]], 'text': ['ICSAT'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1152, 1155]], 'text': ['Pip'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1156, 1160]], 'text': ['MUM1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1161, 1166]], 'text': ['LSIRF'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1272, 1277]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1336, 1341]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1568, 1573]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1681, 1686]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1772, 1777]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2368, 2372]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2374, 2378]], 'text': ['DAPK'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2380, 2386]], 'text': ['p14ARF'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2388, 2396]], 'text': ['p15INK4b'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2398, 2406]], 'text': ['p16INK4a'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2408, 2413]], 'text': ['BRCA1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2415, 2420]], 'text': ['CDH13'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2425, 2431]], 'text': ['APAF-1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2500, 2505]], 'text': ['c-abl'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2511, 2514]], 'text': ['bcr'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2577, 2582]], 'text': ['c-abl'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3138, 3143]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3205, 3210]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3279, 3284]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[361, 368]], 'text': ['leading'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[372, 382]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[643, 651]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T34'}, {'offsets': [[652, 662]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[793, 802]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[1203, 1213]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[1278, 1286]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[1322, 1332]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[1352, 1359]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[1556, 1564]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T41'}, {'offsets': [[1667, 1677]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[2473, 2481]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T43'}, {'offsets': [[2482, 2492]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[3149, 3159]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[3160, 3169]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T46'}, {'offsets': [[3285, 3293]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[3299, 3307]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T48'}]","[{'trigger': 'T32', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T33', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T34', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T36', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T37', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T38', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T39', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T40', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T41', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T42', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T43', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T44', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T43', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T44', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T45', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T46', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T47', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T48', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}, {'id': '*', 'ref_ids': ['T4', 'T5']}, {'id': '*', 'ref_ids': ['T8', 'T9', 'T10', 'T11', 'T12']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}]",[]
190,PMC-3279418-20-Caption-Figure_2,"Effect of Sharpin mutation on DC subpopulations and maturation.
(A) Spleens from WT and cpdm mice were isolated and subject to collagenase and DNase digestion. The obtained splenic homogenates were centrifuged over a Percoll gradient (35% and 55% density) for 15 minutes. The bands at the 35%-medium and the 35-55% interface were pooled, washed and stained with a combination of various antibodies to stain different DC subsets, conventional CD11c+CD8alpha+, CD11c+CD8alpha- and plasmacytoid DC (CD11c-PDCA-1+).The top panels were gated on FSChiSSClo cells to show separate populations of CD11c+PDCA-1- and CD11c-PDCA-1+ cells. Further gating on the CD11c+PDCA-1- subpopulation gave the bottom panel that showed two distinct pools of CD11c+CD8alpha+ and CD11c+CD8alpha- cells. Percentages were calculated based on the parental population and were additionally shown as bar graphs (n = 2) (B). (C) WT and cpdm BMDC (5x105) cells were stimulated with medium, 100 ng/ml LPS or 25 microg/ml poly I:C for 24 hours. The cells were labeled with PE-labeled anti-CD40, anti-CD80, and anti-CD86, and subjected to flow cytometry analysis. The populations shown in histograms were gated on CD11c+ cells. Unstained cells served as negative controls. Results are representative of two independent experiments.","[{'offsets': [[10, 17]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 26]], 'text': ['mutation'], 'type': 'Negative_regulation', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
191,PMC-3279418-18-Materials_and_Methods,"Statistical analysis
Data are expressed as mean +/- SD. The statistical significance of differences of means between experimental groups was determined by Students' t-test.",[],[],[],[],[],[]
192,PMC-2791889-04-Results,"High Antigen Doses and STAT4 Are Required for the In Vivo Generation of IL-10-Producing Th1 Cells
To address the mechanisms regulating IL-10 production by Th1 cells in vivo, we transferred DO11.10 cells into BALB/c recipient mice and immunized the recipients with very high doses of OVA-protein with or without added lipopolysacharide (LPS). T cells were recovered from the inguinal lymph nodes 3 days after priming and restimulated in vitro with OVA peptide for 48 hr. This in vivo immunization induced IL-10 and IFN-gamma production, and the amount of IL-10 production was enhanced by addition of LPS in the immunization (Figure 3A) and with higher doses of OVA (3 muM versus 1 muM, data not shown). To test the role of STAT4 and STAT6 signaling in the in vivo development of IL-10-producing Th1 cells, we transferred STAT4- or STAT6-deficient or WT DO11.10 cells into recipient BALB/c mice and immunized with OVA-protein plus LPS as before. In vivo expression of both IL-10 and IFN-gamma was markedly reduced but not completely abrogated in the absence of STAT4 signaling (Figures 3B and 3C), suggesting the existence of compensatory mechanisms that were absent in the in vitro system. Signaling through STAT6 had no effect on IL-10 production by Th1 cells as shown by intracellular cytokine staining (ICS) and by immunoassay in STAT6-deficient T cells (Figures 3B and 3C).","[{'offsets': [[23, 28]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[72, 77]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[135, 140]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[283, 286]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[447, 450]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[504, 509]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[514, 523]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[554, 559]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[660, 663]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[722, 727]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[732, 737]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[778, 783]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[820, 825]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[830, 835]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[912, 915]], 'text': ['OVA'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[971, 976]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[981, 990]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1059, 1064]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1207, 1212]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1230, 1235]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1332, 1337]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[78, 87]], 'text': ['Producing'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[124, 134]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[141, 151]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[496, 503]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[524, 534]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T26'}, {'offsets': [[560, 570]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T27'}, {'offsets': [[575, 583]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[784, 793]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[836, 845]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T30'}, {'offsets': [[952, 962]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[1004, 1011]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[1020, 1040]], 'text': ['completely abrogated'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1220, 1226]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T34'}, {'offsets': [[1236, 1246]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[1338, 1347]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T36'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T24', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T25', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T25', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T26', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T27', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T28', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T9']}}, {'trigger': 'T29', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T30', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T30', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T32', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T33', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T33', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T34', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T35', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T36', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E18', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}]",[]
193,PMC-3148254-05-Results,"HOIP is necessary for association of the IKK complex with CD40
The marked defects in CD40-mediated cell activation and signaling displayed by HOIP-deficient cells suggested that HOIP mediates recruitment of critical components of the CD40 signaling apparatus to the receptor. Previously, we demonstrated that HOIP is recruited to the CD40 signaling complex in a TRAF2-dependent manner, suggesting that HOIP functions downstream of TRAF2 [6]. Studies by others suggest that the TRAF2-associated proteins cIAP1 and cIAP2 play a role in the recruitment of HOIP to TNFR1 and CD40 [14]. Therefore, we determined whether the association of HOIP with CD40 in A20.2J cells was altered by treatment of cells with an inhibitor of cIAP activity, a membrane-permeable peptide derived from the apoptosis regulator SMAC [15]. We found that pretreatment of cells with the SMAC peptide dramatically reduced the amount of cIAP1 associated with the CD40 signaling complex in cells stimulated with anti-CD40 antibody-coated beads (Fig. 5A). SMAC peptide treatment also resulted in a slight but reproducible decrease in the amount of the major HOIP form recovered by CD40 immunoprecipitation, along with an apparent increase in higher molecular weight species recognized by anti-HOIP antibody. In contrast, treatment with the SMAC peptide did not alter the amount or molecular weight of HOIP present in cell lysates. These data suggest that SMAC peptide treatment specifically alters the characteristics of CD40-associated HOIP rather than the entire cellular pool of this protein. Together, these results support the idea that the cIAP proteins influence the recruitment and post-translational modification state of CD40-associated HOIP.
To test the possibility that HOIP is responsible for the recruitment of other critical signaling proteins to CD40, we immunoprecipitated CD40 signaling complexes from HOIP-deficient and HOIP-reconstituted cells (Fig. 5B). As described previously, CD40 signaling complexes immunoprecipitated from A20.2J cells contained HOIP as well as TRAF2, TRAF3, IKKalpha/beta, and IKKgamma [6]. The amounts of TRAF2, TRAF3, and cIAP1 in CD40 immunoprecipitates from HOIP-deficient cells were similar to those from parental A20.2J cells, indicating that HOIP is not required for the association of these proteins with CD40. In contrast, IKKalpha/beta and IKKgamma were not detectable in CD40 immunoprecipitates recovered from HOIP-deficient cells (Fig. 5B,C). The amounts of IKKalpha/beta and IKKgamma in CD40 immunoprecipitates from HOIP-reconstituted cells were similar to those detected in samples prepared from parental cells, demonstrating that the defects in IKK recruitment we observed were due specifically to the absence of HOIP expression. These data indicate that HOIP is required for recruitment of the NF-kappaB-activating complex to the CD40 signaling complex.
As shown here and in our previous study [6], IKKgamma present in CD40 immunoprecipitates appears to have a higher molecular weight than that found in cell lysates. To confirm that this higher molecular weight species was indeed IKKgamma, we generated A20.2J cell lines containing a stably integrated retroviral vector that encoded an epitope-tagged version of mouse IKKgamma. Cell lysates and CD40 immunoprecipitates prepared from these cells were analyzed by Western blotting for the epitope tag (Fig. 5C). This analysis produced a pattern of bands that was essentially the same as that obtained using an antibody specific for native IKKgamma (compare panels B and C in Fig. 5). Moreover, analysis of cells expressing epitope tagged-IKKgamma confirmed that recruitment of IKKgamma to CD40 requires HOIP. To determine what was responsible for the increased molecular weight of IKKgamma in CD40 immunoprecipitates, the protein samples were incubated with lambda phosphatase, which removes phosphates attached to tyrosine, threonine, or serine residues in proteins. This treatment reduced much of CD40-associated IKKgamma to an apparent molecular weight similar to that of the protein in cell lysates (Fig. 5C). However, at least one band of significantly higher molecular weight remained after phosphatase treatment, suggesting that CD40-associated IKKgamma is subject to at least one other modification in addition to phosphorylation. Overall, these data demonstrate that HOIP is required for the association of IKKgamma with CD40, and suggest that this event is coupled to post-translational modifications of IKKgamma.","[{'offsets': [[0, 4]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[58, 62]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[85, 89]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[142, 146]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[178, 182]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[309, 313]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[362, 367]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[402, 406]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[431, 436]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[477, 482]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[503, 508]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[513, 518]], 'text': ['cIAP2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[553, 557]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[561, 566]], 'text': ['TNFR1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[571, 575]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[634, 638]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[644, 648]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[905, 910]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1124, 1128]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1147, 1151]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1367, 1371]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1487, 1491]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1503, 1507]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1612, 1616]], 'text': ['cIAP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1697, 1701]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1713, 1717]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1748, 1752]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1828, 1832]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1886, 1890]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1905, 1909]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2038, 2042]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2054, 2059]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2061, 2066]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2068, 2076]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2077, 2081]], 'text': ['beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2087, 2095]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2116, 2121]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2123, 2128]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2134, 2139]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2143, 2147]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2172, 2176]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2259, 2263]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2323, 2327]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2342, 2350]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2351, 2355]], 'text': ['beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2360, 2368]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2392, 2396]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2431, 2435]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2480, 2488]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2489, 2493]], 'text': ['beta'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2498, 2506]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2510, 2514]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2539, 2543]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2738, 2742]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2780, 2784]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2925, 2933]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2945, 2949]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3108, 3116]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3246, 3254]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3273, 3277]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3515, 3523]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3614, 3622]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3653, 3661]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3665, 3669]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3679, 3683]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3757, 3765]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3769, 3773]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3975, 3979]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3991, 3999]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4212, 4216]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4228, 4236]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4352, 4356]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4392, 4400]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4406, 4410]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4490, 4498]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[8, 17]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[22, 33]], 'text': ['association'], 'type': 'Binding', 'id': 'T80'}, {'offsets': [[147, 156]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[317, 326]], 'text': ['recruited'], 'type': 'Binding', 'id': 'T82'}, {'offsets': [[368, 377]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T83'}, {'offsets': [[407, 427]], 'text': ['functions downstream'], 'type': 'Regulation', 'id': 'T84'}, {'offsets': [[483, 493]], 'text': ['associated'], 'type': 'Binding', 'id': 'T85'}, {'offsets': [[526, 530]], 'text': ['role'], 'type': 'Regulation', 'id': 'T86'}, {'offsets': [[538, 549]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T87'}, {'offsets': [[619, 630]], 'text': ['association'], 'type': 'Binding', 'id': 'T88'}, {'offsets': [[669, 676]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[883, 890]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T90'}, {'offsets': [[911, 921]], 'text': ['associated'], 'type': 'Binding', 'id': 'T91'}, {'offsets': [[1050, 1058]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[1088, 1096]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T93'}, {'offsets': [[1134, 1143]], 'text': ['recovered'], 'type': 'Binding', 'id': 'T94'}, {'offsets': [[1196, 1204]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[1232, 1239]], 'text': ['species'], 'type': 'Anaphora', 'id': 'T76'}, {'offsets': [[1240, 1250]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T96'}, {'offsets': [[1327, 1332]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[1457, 1463]], 'text': ['alters'], 'type': 'Regulation', 'id': 'T98'}, {'offsets': [[1492, 1502]], 'text': ['associated'], 'type': 'Binding', 'id': 'T99'}, {'offsets': [[1626, 1635]], 'text': ['influence'], 'type': 'Regulation', 'id': 'T100'}, {'offsets': [[1640, 1651]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T101'}, {'offsets': [[1656, 1687]], 'text': ['post-translational modification'], 'type': 'Protein_modification', 'id': 'T102'}, {'offsets': [[1702, 1712]], 'text': ['associated'], 'type': 'Binding', 'id': 'T103'}, {'offsets': [[1756, 1767]], 'text': ['responsible'], 'type': 'Regulation', 'id': 'T104'}, {'offsets': [[1776, 1787]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T105'}, {'offsets': [[1891, 1900]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T106'}, {'offsets': [[1910, 1923]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[2271, 2279]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[2288, 2299]], 'text': ['association'], 'type': 'Binding', 'id': 'T109'}, {'offsets': [[2303, 2317]], 'text': ['these proteins'], 'type': 'Anaphora', 'id': 'T77'}, {'offsets': [[2436, 2445]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T110'}, {'offsets': [[2544, 2557]], 'text': ['reconstituted'], 'type': 'Positive_regulation', 'id': 'T111'}, {'offsets': [[2727, 2734]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T112'}, {'offsets': [[2743, 2753]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T113'}, {'offsets': [[3588, 3598]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T114'}, {'offsets': [[3638, 3649]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T115'}, {'offsets': [[3670, 3678]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T116'}, {'offsets': [[3980, 3990]], 'text': ['associated'], 'type': 'Binding', 'id': 'T117'}, {'offsets': [[4217, 4227]], 'text': ['associated'], 'type': 'Binding', 'id': 'T118'}, {'offsets': [[4298, 4313]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T119'}, {'offsets': [[4360, 4368]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T120'}, {'offsets': [[4377, 4388]], 'text': ['association'], 'type': 'Binding', 'id': 'T121'}, {'offsets': [[4429, 4439]], 'text': ['this event'], 'type': 'Anaphora', 'id': 'T78'}, {'offsets': [[4443, 4450]], 'text': ['coupled'], 'type': 'Positive_regulation', 'id': 'T122'}, {'offsets': [[4454, 4486]], 'text': ['post-translational modifications'], 'type': 'Protein_modification', 'id': 'T123'}]","[{'trigger': 'T79', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T80', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T81', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T82', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T83', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T7']}}, {'trigger': 'T84', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T8', 'T9']}}, {'trigger': 'T85', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T10', 'T11']}}, {'trigger': 'T85', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T10', 'T12']}}, {'trigger': 'T86', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T11']}}, {'trigger': 'T87', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T14']}}, {'trigger': 'T86', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T12']}}, {'trigger': 'T86', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T11']}}, {'trigger': 'T87', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T13', 'T15']}}, {'trigger': 'T86', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T12']}}, {'trigger': 'T88', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T89', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T90', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T91', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T92', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T93', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T92', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T95', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T94', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T19', 'T20']}}, {'trigger': 'T96', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T97', 'id': 'E25', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T98', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T99', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T22', 'T23']}}, {'trigger': 'T100', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T24']}}, {'trigger': 'T101', 'id': 'E29', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T100', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T24']}}, {'trigger': 'T102', 'id': 'E31', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T103', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T25', 'T26']}}, {'trigger': 'T104', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'T27']}}, {'trigger': 'T105', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T106', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T107', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T108', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'T42']}}, {'trigger': 'T109', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T37', 'T43']}}, {'trigger': 'T108', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'T42']}}, {'trigger': 'T109', 'id': 'E40', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T38', 'T43']}}, {'trigger': 'T108', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T42']}}, {'trigger': 'T109', 'id': 'E42', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T39', 'T43']}}, {'trigger': 'T110', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T111', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T112', 'id': 'E45', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T113', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T114', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T115', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T63', 'T64']}}, {'trigger': 'T116', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T65']}}, {'trigger': 'T117', 'id': 'E50', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T68', 'T69']}}, {'trigger': 'T118', 'id': 'E51', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T70', 'T71']}}, {'trigger': 'T119', 'id': 'E52', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T120', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'T72']}}, {'trigger': 'T121', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T73', 'T74']}}, {'trigger': 'T122', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E56', 'E54']}}, {'trigger': 'T123', 'id': 'E56', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}]","[{'id': 'R1', 'head': {'ref_id': 'T76', 'role': 'Subject'}, 'tail': {'ref_id': 'T19', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T77', 'role': 'Subject'}, 'tail': {'ref_id': 'T37', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T77', 'role': 'Subject'}, 'tail': {'ref_id': 'T38', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T77', 'role': 'Subject'}, 'tail': {'ref_id': 'T39', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T78', 'role': 'Subject'}, 'tail': {'ref_id': 'T121', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E33', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E37', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E39', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E41', 'value': ''}]",[]
194,PMC-3245220-00-TIAB,"M-CSF Induces Monocyte Survival by Activating NF-kappaB p65 Phosphorylation at Ser276 via Protein Kinase C
Macrophage colony-stimulating factor (M-CSF) promotes mononuclear phagocyte survival and proliferation. The transcription factor Nuclear Factor-kappaB (NF-kappaB) is a key regulator of genes involved in M-CSF-induced mononuclear phagocyte survival and this study focused at identifying the mechanism of NF-kappaB transcriptional activation. Here, we demonstrate that M-CSF stimulated NF-kappaB transcriptional activity in human monocyte-derived macrophages (MDMs) and the murine macrophage cell line RAW 264.7. The general protein kinase C (PKC) inhibitor Ro-31-8220, the conventional PKCalpha/beta inhibitor Go-6976, overexpression of dominant negative PKCalpha constructs and PKCalpha siRNA reduced NF-kappaB activity in response to M-CSF. Interestingly, Ro-31-8220 reduced Ser276 phosphorylation of NF-kappaBp65 leading to decreased M-CSF-induced monocyte survival. In this report, we identify conventional PKCs, including PKCalpha as important upstream kinases for M-CSF-induced NF-kappaB transcriptional activation, NF-kappaB-regulated gene expression, NF-kappaB p65 Ser276 phosphorylation, and macrophage survival. Lastly, we find that NF-kappaB p65 Ser276 plays an important role in basal and M-CSF-stimulated NF-kappaB activation in human mononuclear phagocytes.","[{'offsets': [[56, 59]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[692, 700]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[701, 705]], 'text': ['beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[743, 769]], 'text': ['dominant negative PKCalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[785, 799]], 'text': ['PKCalpha siRNA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[918, 921]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1033, 1041]], 'text': ['PKCalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1175, 1178]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1259, 1262]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[60, 75]], 'text': ['Phosphorylation'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[79, 85]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T11'}, {'offsets': [[706, 715]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T12'}, {'offsets': [[725, 739]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[875, 882]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[883, 889]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[890, 905]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T16'}, {'offsets': [[1045, 1054]], 'text': ['important'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[1082, 1089]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[1179, 1185]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T19'}, {'offsets': [[1186, 1201]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T20'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T11']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T16', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T6', 'T15']}}, {'trigger': 'T17', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T20', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T19']}}]",[],[],[],[]
195,PMC-3279418-00-TIAB,"SHARPIN Is Essential for Cytokine Production, NF-kappaB Signaling, and Induction of Th1 Differentiation by Dendritic Cells
Spontaneous mutations of the Sharpin (SHANK-associated RH domain-interacting protein, other aliases: Rbckl1, Sipl1) gene in mice result in systemic inflammation that is characterized by chronic proliferative dermatitis and dysregulated secretion of T helper1 (Th1) and Th2 cytokines. The cellular and molecular mechanisms underlying this inflammatory phenotype remain elusive. Dendritic cells may contribute to the initiation and progression of the phenotype of SHARPIN-deficient mice because of their pivotal role in innate and adaptive immunity. Here we show by flow cytometry that SHARPIN- deficiency did not alter the distribution of different DC subtypes in the spleen. In response to TOLL-like receptor (TLR) agonists LPS and poly I:C, cultured bone marrow-derived dendritic cells (BMDC) from WT and mutant mice exhibited similar increases in expression of co-stimulatory molecules CD40, CD80, and CD86. However, stimulated SHARPIN-deficient BMDC had reduced transcription and secretion of pro-inflammatory mediators IL6, IL12P70, GMCSF, and nitric oxide. Mutant BMDC had defective activation of NF-kappaB signaling, whereas the MAPK1/3 (ERK1/2) and MAPK11/12/13/14 (p38 MAP kinase isoforms) and TBK1 signaling pathways were intact. A mixed lymphocyte reaction showed that mutant BMDC only induced a weak Th1 immune response but stimulated increased Th2 cytokine production from allogeneic naive CD4+ T cells. In conclusion, loss of Sharpin in mice significantly affects the immune function of DC and this may partially account for the systemic inflammation and Th2-biased immune response.","[{'offsets': [[0, 7]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[152, 159]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[161, 207]], 'text': ['SHANK-associated RH domain-interacting protein'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[224, 230]], 'text': ['Rbckl1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[232, 237]], 'text': ['Sipl1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[585, 592]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[707, 714]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1011, 1015]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1017, 1021]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1027, 1031]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1053, 1060]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1146, 1149]], 'text': ['IL6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1160, 1165]], 'text': ['GMCSF'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1258, 1263]], 'text': ['MAPK1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1264, 1265]], 'text': ['3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1267, 1271]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1272, 1273]], 'text': ['2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1279, 1285]], 'text': ['MAPK11'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1286, 1288]], 'text': ['12'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1289, 1291]], 'text': ['13'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1292, 1294]], 'text': ['14'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1325, 1329]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1562, 1569]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[135, 144]], 'text': ['mutations'], 'type': 'Negative_regulation', 'id': 'T24'}, {'offsets': [[593, 602]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[716, 726]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T26'}, {'offsets': [[1061, 1070]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[1080, 1087]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[1088, 1101]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T29'}, {'offsets': [[1106, 1115]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[1554, 1558]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T31'}]","[{'trigger': 'T24', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T25', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T26', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T27', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T28', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E4']}}, {'trigger': 'T29', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T28', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E4']}}, {'trigger': 'T29', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T28', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E4']}}, {'trigger': 'T30', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E4']}}, {'trigger': 'T30', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3', 'T5', 'T4']}, {'id': '*', 'ref_ids': ['T14', 'T16']}, {'id': '*', 'ref_ids': ['T15', 'T17']}]",[],[]
196,PMC-2889865-02-Results,"Regulation of AP-1 and NF-kappaB activation
The transcription factors NF-kappaB and AP-1 play key roles in the initiation of an inflammatory response by inducing the expression and secretion of chemokines and cytokines that attract and activate immune cells. However, the signal transduction pathways and subsequent inflammatory cytokine induction by these transcription factors is not fully elucidated. The present study is aimed at determining the involvement of AP-1 and NF-kappaB in cytokine induction and regulation. PMA treatment resulted in an up-regulation of AP-1 after 2 h exposure and continued to increase throughout the analysis period (figure 1a). HK E. coli treatment did not affect AP-1 activation in Jurkat T-cells (figure 1b). To determine the involvement of associated pathways, we exposed cells to Ca2+ ionophore with or without PMA and observed a modest involvement of Ca2+ in PMA-dependent AP-1 activation (figure 1c) while Ca2+ alone did not alter AP-1 activity (data not shown). Furthermore, AP-1 activity decreased in a TCR-deficient Jurkat cell line when exposed to PMA compared to the parent cell line indicating that regulation of AP-1 was only partially T-cell receptor dependent (figure 1d).
NF-kappaB levels showed a transient increase at 1 min after exposure to PMA (figure 2a). However, 1 h after exposure the NF-kappaB levels began to drop reaching the lowest levels by 6 h, after which they increased again by 24 h. Exposure of Jurkat T-cells to HK E. coli resulted in a dose-dependent NF-kappaB activation, with the highest activity observed at a relative concentration of 5 x 107 CFU/ml (figure 2b). The time-dependent activation of NF-kappaB by HK E. coli was assessed further using the optimal concentration obtained from figure 2b and showed that the NF-kappaB activity increased after 3 h of exposure (figure 2c). Furthermore, increased intracellular Ca2+ reversed the PMA dependent NF-kappaB inhibition (figure 2d) and reduced the HK E. coli -dependent NF-kappaB activation (figure 2e).",[],[],[],[],[],[]
197,PMC-3148254-17-Caption-Figure_3,"GLepsilon transcription is defective in CD40-stimulated HOIP-deficient cells.
A20.2J and HOIP-deficient cells transduced with an empty retroviral vector (A20.2J + pMIP and HOIP-/- + pMIP, respectively), or HOIP-deficient cells transduced with a HOIP-encoding retrovirus (HOIP-/- + HOIP) were cultured overnight with agonistic anti-CD40 or an isotype control antibody (iso), with or without IL-4. RNA was isolated from the cells, reverse-transcribed, and then subjected to quantitative PCR to determine levels of GLepsilon transcripts. Results were normalized to the levels of Hprt1 transcripts in each sample. Symbols indicate the values from duplicate cultures (a line indicates the mean of the two values). Similar results were obtained in a second experiment and in an additional experiment with a second HOIP-deficient clone.","[{'offsets': [[0, 9]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[40, 44]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[56, 60]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[89, 93]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[172, 176]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[206, 210]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[245, 249]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[271, 275]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[281, 285]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[390, 394]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[512, 521]], 'text': ['GLepsilon'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[576, 581]], 'text': ['Hprt1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[808, 812]], 'text': ['HOIP'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[10, 23]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T14'}, {'offsets': [[27, 36]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[61, 70]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[94, 103]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[211, 220]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[522, 533]], 'text': ['transcripts'], 'type': 'Transcription', 'id': 'T19'}, {'offsets': [[582, 593]], 'text': ['transcripts'], 'type': 'Transcription', 'id': 'T20'}, {'offsets': [[813, 822]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T21'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}]",[]
198,PMC-1310901-10-RESULTS,"Increase of IRF-4 expression in hematopoietic cells after demethylating treatment
We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).","[{'offsets': [[12, 17]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[172, 177]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[222, 227]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[613, 618]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[722, 727]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[929, 934]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1139, 1144]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1207, 1212]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1287, 1292]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1400, 1405]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1510, 1515]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1619, 1624]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[0, 8]], 'text': ['Increase'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[18, 28]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[178, 188]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[599, 609]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[619, 632]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T17'}, {'offsets': [[728, 741]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T18'}, {'offsets': [[746, 753]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[846, 855]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[935, 946]], 'text': ['transcripts'], 'type': 'Transcription', 'id': 'T21'}, {'offsets': [[1213, 1221]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[1277, 1283]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[1293, 1303]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[1386, 1395]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[1406, 1416]], 'text': ['mRNA level'], 'type': 'Transcription', 'id': 'T26'}, {'offsets': [[1502, 1509]], 'text': ['control'], 'type': 'Regulation', 'id': 'T27'}, {'offsets': [[1516, 1526]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T24', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T25', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T26', 'id': 'E14', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T27', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T28', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}]",[]
199,PMC-2889865-07-Conclusion,"In the present study, IL-6 release was found to be associated with NF-kappaB activity while CXCL8 release more closely correlated with AP-1 activity. Treatment of Jurkat T-cells with PMA was more potent than HK E. coli at elevating the CXCL8 levels. PMA induced AP-1 activation and down-regulated NF-kappaB while HK E. coli up-regulated NF-kappaB without affecting AP-1 activity. In addition, the temporal induction pattern of AP-1 correlated to the release of CXCL8 while IL-6 followed the NF-kappaB activity. Likewise, blocking NF-kappaB activation resulted in a complete inhibition of IL-6 while the CXCL8 levels remained elevated as shown both at the protein and mRNA level. Furthermore, the CXCL8 release was down-regulated by inhibition of JNK activity. The present study indicates that in Jurkat T-cells, IL-6 is regulated through NF-kappaB while CXCL8 regulation is independent of NF-kappaB and closely associated with AP-1 activation.","[{'offsets': [[22, 26]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[92, 97]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[236, 241]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[461, 466]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[473, 477]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[588, 592]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[603, 608]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[696, 701]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[812, 816]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[854, 859]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[27, 34]], 'text': ['release'], 'type': 'Localization', 'id': 'T11'}, {'offsets': [[98, 105]], 'text': ['release'], 'type': 'Localization', 'id': 'T12'}, {'offsets': [[222, 231]], 'text': ['elevating'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[450, 457]], 'text': ['release'], 'type': 'Localization', 'id': 'T14'}, {'offsets': [[551, 559]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[574, 584]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[616, 624]], 'text': ['remained'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[625, 633]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[702, 709]], 'text': ['release'], 'type': 'Localization', 'id': 'T19'}, {'offsets': [[714, 728]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[820, 829]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[860, 870]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T22'}, {'offsets': [[874, 885]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T23'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T14', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T15', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T16', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T17', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T20', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T21', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T22', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T23', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}]",[]
200,PMC-2065877-17-Materials_and_Methods,"Immunoblot analysis.
Whole cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.1% sodium deoxycholate) supplemented with 2 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 1:100 protease/phosphatase inhibitor cocktails (Sigma). Crude lysates were centrifuged at 13,000 rpm for 10 min at 4 degreesC and the supernatants were collected for further analysis. Protein concentrations were determined with the Bio-Rad DC protein assay system. Lysates were boiled in the presence of 2.5% beta-mecaptoethanol, separated by denaturing SDS-PAGE, and transferred to 0.45-mum Optitran membranes (Schleicher & Schuell) in a Bio-Rad transfer unit. Membranes were immunoblotted with the appropriate primary antibody followed by horseradish peroxidase-tagged secondary antibodies (Amersham Biosciences and Dako) and detected with the SuperSignal West Pico System (Pierce).","[{'offsets': [[822, 832]], 'text': ['peroxidase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
201,PMC-3279418-09-Materials_and_Methods,"Mice
Specific-pathogen free colonies of C57BL/KaLawRij-Sharpincpdm/RijSunJ (JR#7599) and WT mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and were maintained in a barrier facility. Normal littermate controls were either +/+ or +/Sharpincpdm. These control animals were phenotypically indistinguishable and are referred to as WT. Sex-matched WT and mutant mice were used at 6-10 weeks of age. For some experiments, cpdm mice were crossed with transgenic mice with a bacterial artificial chromosome (BAC) containing the Sharpin gene (FVB/NJ-Tg(RP24-173I23)1Sun/Sun, JR#8279). These mice were backcrossed onto the C57BL/KaLawRij-Sharpincpdm/RijSunJ background and N4 mice were used in the experiments reported here. All mouse work was carried out in strict accordance with the approved protocols by the Institutional Animal Care and Use Committee.","[{'offsets': [[536, 543]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
202,PMC-2664230-09-RESULTS,"The effects of PTX on LPS-induced TNF-alpha production
To determine the duration of PDE inhibition on TNF-alpha production after LPS stimulation, time course studies were conducted. In accordance with prior work, PTX had a rapid and sustained effect on TNF-alpha production in vitro (Figure 1).","[{'offsets': [[34, 43]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[102, 111]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[253, 262]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[4, 11]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T4'}, {'offsets': [[26, 33]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[44, 54]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[112, 122]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[133, 144]], 'text': ['stimulation'], 'type': 'Positive_regulation', 'id': 'T8'}, {'offsets': [[243, 249]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[263, 273]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T9', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T10', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
203,PMC-1447668-16-Materials_and_Methods,"Real-time PCR.
Real-time PCR analysis of HTLV-I (Tax) proviral load was performed as previously described [47,50]. DNA was extracted from 1 x 106 cells using Puregene DNA Isolation Kit (Gentra, Minneapolis, Minnesota, United States), and 100 ng of the sample DNA solution was analyzed by this system. The HTLV-I proviral DNA load was calculated by the following formula: copy number of HTLV-I (pX) per 100 cells = (copy number of pX)/(copy number of beta-actin/2) x 100.","[{'offsets': [[49, 52]], 'text': ['Tax'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[450, 460]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
204,PMC-2889865-21-Caption-Figure_5,"Involvement of NF-kappaB in cytokine regulation. Cytokine/chemokine levels were determined using ELISA following incubation of Jurkat T-cells with NAI (1 h) and stimulation (24 h). (A) CXCL8 expression was partially inhibited following PMA stimulation (grey bars), whereas the levels were not altered following stimulation with HK E. coli (black bars), this indicates an induction mainly regulated by AP-1. (B) TNF expression was not affected by NAI. (C) IL-6 release was completely inhibited by NAI following PMA exposure, indicating regulation through NF-kappaB since IL-6 expression was significantly increased in response to HK E. coli than PMA. Statistical significance from the positive control (PMA/HK E. coli) was determined using Student's t-test. (n = 3).","[{'offsets': [[185, 190]], 'text': ['CXCL8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[455, 459]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[570, 574]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[191, 201]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[216, 225]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T6'}, {'offsets': [[273, 283]], 'text': ['the levels'], 'type': 'Anaphora', 'id': 'T4'}, {'offsets': [[293, 300]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T7'}, {'offsets': [[371, 380]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T8'}, {'offsets': [[388, 397]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[460, 467]], 'text': ['release'], 'type': 'Localization', 'id': 'T10'}, {'offsets': [[483, 492]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[535, 545]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T12'}, {'offsets': [[575, 585]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[604, 613]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T14'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T11', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T12', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T13', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T14', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}]","[{'id': 'R1', 'head': {'ref_id': 'T4', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}]",[]
205,PMC-3279418-24-Caption-Figure_6,"Inhibition of NF-kappaB signaling in cpdm BMDC.
WT and cpdm BMDC (2x106 cells in 0.5 mL complete medium) were stimulated with 100 ng/mL LPS (A) or 25 microg/mL poly I:C (B). At 0, 15, 30, and 60 minutes, whole-cell lysates were obtained and subject to immunoblots with antibodies against proteins involved in NF-kappaB, TBK1/IRF3, ERK1/2, and p38 signaling pathways. Beta-actin was used as loading control. (C) Cellular levels of p-IKK1/2 and p-IkappaBalpha in LPS- or poly I:C-stimulated BMDC were quantitated with ImageJ (NIH) and presented as trend lines. Results are representative of at least two independent experiments.","[{'offsets': [[320, 324]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[325, 329]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[331, 335]], 'text': ['ERK1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[336, 337]], 'text': ['2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[367, 377]], 'text': ['Beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[432, 436]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[437, 438]], 'text': ['2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[445, 457]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
206,PMC-2626671-14-MATERIALS_AND_METHODS,"ChIP and real-time PCR analysis.
20 x 106 CD8+ T cells per immunoprecipitation were fixed by adding a 1/10th volume of fixation solution (11.1% formaldehyde, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Hepes) to 1 volume of culture media and were incubated for 10 or 30 min at RT. Fixation was stopped with 120 mM glycine on ice for 5 min. Fixed cells were washed 2x with cold PBS, 1x with cold solution I (10 mM Tris [pH 7.5], 10 mM EDTA, 0.5 mM EGTA, 1% Triton X-100), and 1x with cold solution II (10 mM Tris [pH 7.5], 1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl). After washes, cell pellets were resuspended at 40 x 106 cells/ml in ChIP lysis buffer (150 mM NaCl, 25 mM Tris [pH 7.5], 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate plus protease and phosphatase inhibitors), and chromatin was sheared with a sonicator to yield 0.5-1-kb DNA fragments. After preclearing the sheared chromatin with protein A-sepharose beads and removing 5% as input chromatin, immunoprecipitation was performed by adding optimized antibody amounts (per 20 x 106 cell equivalents: 2.5 mug anti-Eomes, 1:100 dilution anti-Runx3), followed by overnight incubation at 4degreesC; protein A-sepharose beads were added for the last 3 h of the incubation period. Beads were washed 2x with RIPA buffer (50 mM Tris [pH 8], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% deoxycholate), 1x with high salt buffer (50 mM Tris [pH 8], 500 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS), and 1x with TE buffer. After the last wash, DNA was eluted by resuspending the beads in elution buffer (1% SDS, 100 mM NaHCO3). Both input and ChIP chromatin were then treated with RNase A (5 mug total) for 1 h at 37degreesC, followed by the addition of proteinase K (100 mug total) and overnight incubation at 65degreesC to reverse cross-linking. DNA was then purified with QIAquick columns (Gel Extraction Kit; QIAGEN) according to the manufacturer's instructions and resuspended in a 50-mul volume. For real-time PCR detection of immunoprecipitated targets using the SYBR Green PCR Kit, a standard curve was obtained with serial dilutions of input DNA for each sample, and 1 mul ChIP DNA was used per PCR reaction (performed in duplicates). Melt curves and agarose gels were analyzed to ensure amplification of specific target sequences. Refer to Table S1 (available at http://www.jem.org/cgi/content/full/jem.20081242/DC1) for a list of primer sets. The data are presented as the number of immunoprecipitated target sequences relative to input chromatin, assuming two copies of target sequence per cell equivalent used for the ChIP.","[{'offsets': [[42, 45]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1067, 1072]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1094, 1099]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
207,PMC-1310901-09-RESULTS,"Absence of IRF-4 expression in leukemia cells is not due to promoter alterations
We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression.","[{'offsets': [[11, 16]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[123, 128]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[234, 239]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[333, 340]], 'text': ['bcr-abl'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[372, 379]], 'text': ['bcr-abl'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[452, 459]], 'text': ['bcr-abl'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[505, 512]], 'text': ['bcr-abl'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[608, 615]], 'text': ['bcr-abl'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[682, 687]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[735, 740]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[912, 917]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[942, 947]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1258, 1263]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[0, 7]], 'text': ['Absence'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[17, 27]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[53, 56]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[115, 119]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[129, 139]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[240, 250]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[341, 349]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[380, 387]], 'text': ['positve'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[460, 467]], 'text': ['positve'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[513, 521]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[616, 624]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[724, 731]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[741, 751]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T26'}, {'offsets': [[918, 926]], 'text': ['positive'], 'type': 'Gene_expression', 'id': 'T27'}, {'offsets': [[948, 956]], 'text': ['negative'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1251, 1257]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T29'}, {'offsets': [[1264, 1274]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T30'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T23', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T24', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T25', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T26', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T27', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T28', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T29', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T30', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}]",[]
208,PMC-2065877-05-Results,"Wild-Type and LMP1 Transgenic Lymphoma Cells Do Not Require IL4 and Stat6 Signaling
To investigate whether IL4 independence was due to endogenous IL4 expression, IL4 transcription was assessed by an Rnase protection assay (RPA). IL4 transcription was detectable with control RNA and faintly in the mouse lymphoma cell line K46mu (Figure 4A). However, IL4 transcription was not detectable in CD19+ MACS-purified B cells from wild-type lymphocytes (unpublished data), LMP1 transgenic lymphocytes, or lymphoma cells, although the GAPDH and L32 controls were effectively protected (Figure 4A). Activated Stat6 (pStat6), a target of the IL4 receptor pathway, was detected in the wild-type and LMP1 transgenic lymphocytes (Figure 4B). In contrast, pStat6 was barely detected in either the wild-type or LMP1 transgenic lymphoma cells. However, the pathway was not disabled, as treatment of the lymphoma cells with IL4 induced Stat6 phosphorylation (Figure 4C).
Although wild-type lymphocytes cannot be maintained in culture with IL4 supplementation alone (Figure 3A), slight enhancement in MTS activity could be detected if the cells were analyzed at an earlier time point, at 1 d (Figure 4D) versus 3 d (Figure 3A) post-harvest. The enhancement of MTS activity induced by IL4 in wild-type lymphocytes could be neutralized by the addition of IL4 antibody (Figure 4D). However, neutralizing antibodies to IL4 did not affect the MTS activity of LMP1 transgenic lymphoma cells (Figure 4E). In summary, the wild-type and LMP1 transgenic lymphoma cells grew independently of IL4 treatment and did not require Stat6 signaling.","[{'offsets': [[14, 18]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[60, 63]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[68, 73]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[107, 110]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[146, 149]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[162, 165]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[229, 232]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[351, 354]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[391, 395]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[466, 470]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[527, 532]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[537, 540]], 'text': ['L32'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[600, 605]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[607, 613]], 'text': ['pStat6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[632, 644]], 'text': ['IL4 receptor'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[688, 692]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[796, 800]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[907, 910]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[919, 924]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1022, 1025]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1266, 1269]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1335, 1338]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1397, 1400]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1436, 1440]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1510, 1514]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1563, 1566]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1597, 1602]], 'text': ['Stat6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[150, 160]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[166, 179]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T29'}, {'offsets': [[233, 246]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T30'}, {'offsets': [[355, 368]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T31'}, {'offsets': [[590, 599]], 'text': ['Activated'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[618, 624]], 'text': ['target'], 'type': 'Regulation', 'id': 'T33'}, {'offsets': [[911, 918]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[925, 940]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T35'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T29', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T30', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T31', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T32', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T33', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T34', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T18']}}, {'trigger': 'T35', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],"[{'id': '*', 'ref_ids': ['T13', 'T14']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}]",[]
209,PMC-2664230-01-INTRODUCTION,"The bacterial membrane component lipopolysaccharide (LPS) is capable of initiating phosphorylation and activation of multiple host intracellular protein kinases and transcription factors. Transcription factor activation, which results in the modulation of gene transcription and protein synthesis, is a critical element in the defense mechanism of the host immune system.1,2
LPS-induced transcription factor activation has been shown to be a key regulator of tumor necrosis factor-alpha (TNF-alpha) production.3 TNF-alpha is a potent pro-inflammatory cytokine involved in a wide spectrum of cellular responses. Furthermore, TNF-alpha synthesis can be attenuated in immune cells exposed to phosphodiesterase (PDE) inhibition after challenge by a variety of pro-inflammatory stimulants.4 The signaling mechanisms affected by PDE inhibition, which ultimately lead to the downregulation of TNF-alpha production, have not been well characterized in inflammatory cells.
Classically, it has been demonstrated that PDE inhibition results in the intracellular accumulation of the second messenger cyclic adenosine-3,5-monophosphate (cAMP) and subsequent activation of Protein kinase A (PKA).5 PKA activation then leads to the phosphorylation of the transcription factor cAMP-response element binding protein (CREB), transmission of signals into the nucleus, and the subsequent modulation of gene transcription.6 This apparently simple linear cascade does not fully explain the mechanism by which an elevation in the intracellular cAMP level exerts wide-ranging effects on multiple cellular functions. There is a growing body of evidence suggesting that cAMP may function through both PKA-dependent and -independent mechanisms.6-8
LPS-induced activation of the transcription factor nuclear factor-kappaB (NF-kappaB) has also been the focus of a great deal of research. It has been clearly demonstrated that agents that increase intracellular cAMP also inhibit NF-kappaB-dependent pro-inflammatory gene transcription, particularly of the TNF-alpha gene.9
Controversy exists regarding the exact mechanism(s) by which PDE inhibition down-regulates TNF-alpha production. Possibilities include, but are not limited to, inhibition of NF-kappaB DNA binding activity, downregulation of NF-kappaB transcriptional activity, increased CREB activation, and competition between NF-kappaB and CREB for common co-activators such as CREB binding protein (CBP). It is also not known whether these processes rely solely upon the activation of PKA.
Therefore, the objective of the present study is to determine the effects of nonspecific PDE inhibition with 1-[5-oxohexyl]-3,7-dimethylxanthine (Pentoxifylline; PTX) on NF-kappaB and CREB activation in vitro in human mononuclear cells. With the use of specific inhibitors, we also investigated the role of PKA in LPS-induced TNF-alpha production.","[{'offsets': [[459, 486]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[488, 497]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[512, 521]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[624, 633]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[886, 895]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2027, 2036]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2135, 2144]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2846, 2855]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[446, 455]], 'text': ['regulator'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[499, 509]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[634, 643]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[651, 661]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T12'}, {'offsets': [[856, 860]], 'text': ['lead'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[868, 882]], 'text': ['downregulation'], 'type': 'Negative_regulation', 'id': 'T14'}, {'offsets': [[896, 906]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[1942, 1949]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[1960, 1969]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[1992, 2005]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T18'}, {'offsets': [[2120, 2134]], 'text': ['down-regulates'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[2145, 2155]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[2819, 2823]], 'text': ['role'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[2838, 2845]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[2856, 2866]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T16', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T17', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T20', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T21', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T22', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T23', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}]",[]
210,PMC-1447668-04-Results,"Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB
If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].","[{'offsets': [[0, 5]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[91, 96]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[188, 193]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[653, 656]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[702, 707]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[717, 725]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[978, 983]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[988, 996]], 'text': ['deltaFKH'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1048, 1053]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1458, 1461]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1533, 1538]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1619, 1624]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1787, 1792]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1965, 1970]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[194, 208]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[672, 686]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[1104, 1116]], 'text': ['interactions'], 'type': 'Binding', 'id': 'T17'}, {'offsets': [[1539, 1553]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T18'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
211,PMC-2626671-05-RESULTS_AND_DISCUSSION,"Perforin and granzyme B expression are not appreciably regulated by T-bet
To test the model outlined in the previous paragraph directly, we compared the expression of IFN-gamma, perforin, and granzyme B in CD8+ T cells from WT and Tbx21 (T-bet)-deficient mice. As expected (17, 21), naive Tbx21-/- CD8+ T cells produced IFN-gamma poorly upon activation (Fig. 2 A). Notably, this deleterious effect of T-bet deficiency was only observed in differentiating CD8+ T cells until day 4 of culture but was almost completely mitigated by day 6 (Fig. 2 A). This most likely reflected compensation by Eomes, which was strongly induced between days 4 and 6 (Fig. 1). In contrast, T-bet-deficient T cells cultured for 6 d showed no defect in perforin mRNA expression (Fig. 2 B, compare lanes 1 and 4). We consistently observed a modest reduction in GzmB mRNA in T-bet-deficient T cells (Fig. 2 B, compare lanes 1 and 4), which did not translate into a decrease in expression of granzyme B protein (Fig. 2 C).
To examine the role of Eomes, we transduced naive CD8+ T cells from WT and Tbx21-/- mice with retroviruses containing internal ribosome entry site (IRES)-GFP that were either empty or encoded a strongly transactivating version of Eomes (Eo-VP16) (8), and expanded them for 6 d under our culture conditions. Eo-VP16, but not the empty GFP retrovirus, increased perforin expression in both WT and T-bet-deficient CD8+ T cells (Fig. 2 B, lanes 2, 3, 5, and 6). As expected, Eo-VP16 also rescued the early defect in IFN-gamma production observed in T-bet-deficient CD8+ T cells (Fig. 2 D). However, Eo-VP16 did not induce GzmB mRNA expression in either WT or T-bet-deficient cells; thus, the partial T-bet dependence of GzmB mRNA expression cannot be compensated for by Eo-VP16.","[{'offsets': [[0, 8]], 'text': ['Perforin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[13, 23]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[68, 73]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[167, 176]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[178, 186]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[192, 202]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[206, 209]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[231, 236]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[238, 243]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[289, 294]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[298, 301]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[320, 329]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[401, 406]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[455, 458]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[591, 596]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[669, 674]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[730, 738]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[837, 841]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[850, 855]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[966, 976]], 'text': ['granzyme B'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1020, 1025]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1047, 1050]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1072, 1077]], 'text': ['Tbx21'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1151, 1154]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1227, 1232]], 'text': ['Eomes'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1234, 1241]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1304, 1311]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1331, 1334]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1357, 1365]], 'text': ['perforin'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1392, 1397]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1408, 1411]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1468, 1475]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1509, 1518]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1542, 1547]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1558, 1561]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1592, 1599]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1615, 1619]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1652, 1657]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1693, 1698]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1713, 1717]], 'text': ['GzmB'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1763, 1770]], 'text': ['Eo-VP16'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[24, 34]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[55, 64]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[153, 163]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T45'}, {'offsets': [[245, 254]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T46'}, {'offsets': [[311, 319]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[407, 417]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[598, 603]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T42'}, {'offsets': [[617, 624]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[675, 684]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[720, 726]], 'text': ['defect'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[739, 754]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T52'}, {'offsets': [[824, 833]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[856, 865]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[940, 948]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[952, 962]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[1347, 1356]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[1366, 1376]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[1398, 1407]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[1481, 1488]], 'text': ['rescued'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[1499, 1505]], 'text': ['defect'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1519, 1529]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[1548, 1557]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1608, 1614]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[1620, 1635]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T65'}, {'offsets': [[1658, 1667]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[1699, 1709]], 'text': ['dependence'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[1718, 1733]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T68'}]","[{'trigger': 'T43', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T43', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T44', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'T3']}}, {'trigger': 'T44', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T3']}}, {'trigger': 'T45', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T45', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T45', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T46', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T47', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T48', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T49', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T50', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T51', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E12']}}, {'trigger': 'T52', 'id': 'E14', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T53', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T18', 'E16']}}, {'trigger': 'T54', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T55', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T56', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T57', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T27']}}, {'trigger': 'T58', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T59', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T60', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T32']}}, {'trigger': 'T61', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E25']}}, {'trigger': 'T62', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T63', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T64', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T36']}}, {'trigger': 'T65', 'id': 'E27', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T66', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T67', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T39']}}, {'trigger': 'T68', 'id': 'E30', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}]","[{'id': 'R1', 'head': {'ref_id': 'T42', 'role': 'Subject'}, 'tail': {'ref_id': 'T15', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T8', 'T9']}, {'id': '*', 'ref_ids': ['T25', 'T26']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}]",[]
212,PMC-3148254-08-Materials_and_Methods,"Antibodies
Mouse anti-birch profilin antibody (4A6 [29]), rat anti-mouse CD40 (1C10 [30]) and a rat isotype control antibody (mAb72, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) were isolated from hybridoma supernatants. FITC-labeled anti-mouse CD80 and an isotype control Ab were from eBiosciences. Rabbit anti-HOIP Ab [6] was the kind gift of Dr. Betty Eipper (University of Connecticut Health Center, Farmington, Connecticut). Goat anti-rat IgG, and HRP-labeled secondary Abs were from Jackson ImmunoResearch Laboratories, Inc. All other antibodies used were described previously [6].",[],[],[],[],[],[]
213,PMC-1310901-04-MATERIALS_AND_METHODS,"Sequencing of the IRF-4 promoter
For analysis of the IRF-4 promoter region for permanent aberrations such as insertions/deletions or mutation, we PCR-amplified two fragments from genomic DNA, which was extracted from depicted cell lines with a commercial kit (Qiagen, Hilde, Germany) as recommended. The primers were 1-forward: 5'-TTGAGATGGAGTCTTGCTCTGT-3', 1-reverse: 5'-CCAGGACCTCAGGAGGCCAGTCA-3'; 2-forward: 5'-AGCGGTGAAACTGAGAGTGCGAGGT-3', 2-reverse: 5'-GCCACATCGCTGCAGTTTAG-3'. The products were cloned with the 'TOPO TA cloning kit' (Invitrogen, Groningen, The Netherlands). After bacterial amplification of the cloned PCR fragments by standard procedures, at least three clones from each sample were sequenced with an automated sequencer (ABI Prism 377, Applied Bio-systems, Foster City, USA) as recommended by the manufacturer.","[{'offsets': [[18, 23]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[53, 58]], 'text': ['IRF-4'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
214,PMC-2065877-19-Caption-Figure_1,"High LMP1 Expression Correlates with the Development of Lymphoma
LMP1 expression is shown by (A) immunoblotting of purified B cells (CD19+) and (B) immunohistochemistry staining of spleen tissue from wild-type (WT) and LMP1 transgenic mice.
(A) Lymphomas are identified with a number (1-7). Arrows indicate the LMP1-specific band and its degradation products as well as a non-specific band. Actin was used as a loading control.
(B) White and red pulps are shown, but this architecture is lost upon development of lymphoma. Scale bar, 20 mum.","[{'offsets': [[5, 9]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[65, 69]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[133, 137]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[219, 223]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[311, 315]], 'text': ['LMP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[0, 4]], 'text': ['High'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[10, 20]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[70, 80]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],[],[]
215,PMC-2889865-14-Materials_and_methods,"RNA extraction
Jurkat T-cells were treated with NF-kappaB, JNK and PKC inhibitors for 2 h in 6-well plates followed by stimulation with 162 nM PMA for 24 h. At sampling the cells were pelleted followed by RNA extraction using 100 mul TRI-reagent (Sigma, USA). This was followed by addition of 100 mul chloroform/isoamylalcohol (24/1). The solutions were mixed by vortexing followed by centrifugation at 12,000 rpm for 15 min at 4degreesC. The upper phase was transferred to a new tube followed by addition of 100 mul iso-propanol and incubated at room temperature for 10 min. RNA was then pelleted by centrifugation at 12,000 rpm for 15 min at 4degreesC and washed with 70% ethanol. The RNA pellet was dissolved in 25 mul RNase free water and the yield and ratio (A260/A280) was determined using NanoVue (GE Healthcare, UK). The samples were stored at -80degreesC until further use.",[],[],[],[],[],[]
216,PMC-3279418-10-Materials_and_Methods,"Constructs and transfection
The complementary DNA (cDNA) of the mouse Sharpin gene was cloned and amplified from RAW264.7 RNA extracts. The primer sequences were forward, 5'-CC ATG GCG ATG TCG CCG CCC GCC GGC GGT; reverse, 5'- AAG CTT CTA GGT GGA AGC TGC AGC AAG A. The Sharpin cDNA was cloned into expression vector pFLAG-CMV-2. Murine fibroblasts and macrophages were were used to express recombinant SHARPIN protein. Cells (2x104) were seeded in 96-well treated plates the day before transfection. After overnight incubation, 200 ng pFLAG-SHARPIN plasmids were transfected with 0.5 ul Lipofectamine 2000. 24 hours later, cells were incubated with fresh culture medium. After another 24 hours, cells were lysed to confirm the FLAG-SHARPIN expression by immunoblots with anti-FLAG. Cells with no transfection and transfected with empty vector pFLAG-CMV-2 were used as negative control in all transfection experiments.","[{'offsets': [[70, 77]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[270, 277]], 'text': ['Sharpin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[403, 410]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[542, 549]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[733, 740]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[383, 390]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[741, 751]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}]",[]
217,PMC-3279418-06-Results,"Th2-biased immunogenicity of stimulated cpdm BMDC
The defective IL12 production (Fig. 3A) and Th2-dominant cytokine profile in cpdm mice [5] suggest that the absence of SHARPIN affects the ability of cpdm BMDC to induce T cell differentiation into effector cells. Co-culture of allogeneic naive CD4+ T cells with WT BMDC stimulated with LPS or poly I:C elicited robust IFNgamma production, whereas the concentration of IFNgamma in cpdm BMDC-T cell cultures was significantly lower after LPS stimulation (Fig. 7A), indicating impaired Th1-polarizing abilities of cpdm BMDC. In addition to TLR3/4 agonists, the TLR2 ligand Pam3CYS was used since it has been shown to induce both Th1 and Th2 responses [28]-[30]. Pam3CYS-matured WT BMDC induced robust IFNgamma production at a significantly higher level than cpdm BMDC (Fig. 7A). The reduced Th1 differentiation following Pam3CYS stimulation is consistent with the recent report of decreased IL12 production in cpdm macrophages following TLR2 stimulation [31]. In contrast, more Th2-specific IL4 cytokine was produced in the cpdm BMDC co-cultures than the WT control (Fig. 7B), suggesting Th2-skewed immunogenicity of cpdm BMDC. The production of Th17-specific cytokine IL17A following LPS stimulation of dendritic cells was similar between stimulated WT and cpdm BMDC cocultures (data not shown). Despite the distinct Th1- and Th2-stimulating abilities of WT and cpdm BMDC, they were equally effective in IL2 production from BMDC-T cell co-cultures except for poly I:C stimulation where WT BMDC induced more IL2 than cpdm BMDC (Fig. 7C). The Th2-biased stimulating capability of cpdm BMDC when co-cultured with allogeneic naive CD4+ T cells is consistent with the Th2-dominant cytokine phenotype observed in cpdm mice.","[{'offsets': [[169, 176]], 'text': ['SHARPIN'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[369, 377]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[419, 427]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[588, 592]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[593, 594]], 'text': ['4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[609, 613]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[621, 628]], 'text': ['Pam3CYS'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[710, 717]], 'text': ['Pam3CYS'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[749, 757]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[869, 876]], 'text': ['Pam3CYS'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[985, 989]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1039, 1042]], 'text': ['IL4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1217, 1222]], 'text': ['IL17A'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1453, 1456]], 'text': ['IL2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1556, 1559]], 'text': ['IL2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[158, 165]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[353, 361]], 'text': ['elicited'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[378, 388]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[402, 415]], 'text': ['concentration'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[475, 480]], 'text': ['lower'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[595, 603]], 'text': ['agonists'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[614, 620]], 'text': ['ligand'], 'type': 'Binding', 'id': 'T22'}, {'offsets': [[734, 741]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[758, 768]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[1056, 1064]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[1180, 1190]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T26'}, {'offsets': [[1223, 1232]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[1457, 1467]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1543, 1550]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[1551, 1555]], 'text': ['more'], 'type': 'Positive_regulation', 'id': 'T30'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T6', 'T7']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T8']}}, {'trigger': 'T24', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T25', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T26', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T27', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T28', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T29', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T30', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}]",[]
218,PMC-2791889-14-Experimental_Procedures,"Real-Time Quantitative RT-PCR
Cells were harvested and restimulated in the presence of immobilized anti-CD3 (2 mug/ml) plus anti-CD28 (2 mug/ml) for 3 hr or immediately lysed. RNA was extracted and reverse-transcribed and cDNA was analyzed for the expression of cytokines and transcription factors by real-time PCR assay as before (Shoemaker et al., 2006). Target gene mRNA expression was quantified either with SYBR Green (Applied Biosystems) or with Master Mix (Applied Biosystems) and normalized to ubiquitin or HPRT mRNA levels, respectively.","[{'offsets': [[104, 107]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[129, 133]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[502, 511]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[515, 519]], 'text': ['HPRT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[520, 531]], 'text': ['mRNA levels'], 'type': 'Transcription', 'id': 'T5'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
219,PMC-2664230-10-RESULTS,"PTX decreases LPS-induced NF-kappaB activation
Since phosphorylation leads to ubiquitination and degradation of I-kappaBalpha and subsequent nuclear translocation of NF-kappaB, we first examined the effects of PTX on I-kappaBalpha. Cytoplasmic I-kappaBalpha phosphorylation was markedly increased following LPS stimulation when compared to control (100 +/- 0 vs. 20 +/- 18; P < 0.05). The addition of PTX significantly downregulated LPS-induced I-kappaBalpha phosphorylation (P = 0.02; Figure 2)
In a similar fashion, nuclear NF-kappaB p65 phosphorylation was increased following LPS stimulation (100 +/- 0 vs. 38 +/- 20; P < 0.01). PTX similarly decreased LPS-induced NF-kappaB p65 nuclear phosphorylation, a marker of NF-kappaB activation and nuclear translocation (100 +/- 0 vs. 40 +/- 6; P =0.03; Figure 3A).
EMSAs were then performed to verify the PTX-induced alterations in nuclear phosphorylation resulted in similar effects on the DNA binding activity of NF-kappaB. The addition of PTX to LPS-stimulated mononuclear cells resulted in comparable downregulation of DNA binding activity, similar to the observed downregulation of NF-kappaB phosphorylation (Figure 3B).","[{'offsets': [[112, 125]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[217, 230]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 257]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[445, 458]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[536, 539]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[679, 682]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[69, 74]], 'text': ['leads'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[97, 108]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T8'}, {'offsets': [[199, 206]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[258, 273]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[287, 296]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[297, 306]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[419, 432]], 'text': ['downregulated'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[437, 444]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[459, 474]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T15'}, {'offsets': [[540, 555]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T16'}, {'offsets': [[560, 569]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[570, 579]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[647, 656]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[661, 668]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[691, 706]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T21'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T9', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T12', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T13', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T15', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T17', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T18', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T19', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T20', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T21', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
220,PMC-3245220-06-Results,"M-CSF-Dependent Activation of PKC Does Not Regulate the Classical NF-kappaB p65 Activation Pathway
Canonical activation of NF-kappaB occurs via phosphorylation and degradation of IkappaBalpha leading to the release and nuclear translocation of the NF-kappaB p50/p65 heterodimer to transactivate target genes [37], [39]. Since conventional PKC activity was important in regulating M-CSF-induced NF-kappaB activation, we next investigated whether IkappaBalpha degradation was regulated by PKC. Cells were treated with cyclohexamide (CHX) to inhibit protein synthesis of IkappaBalpha, and its degradation was followed. As shown in Figure 5A, PKC inhibition with Ro-31-8220 did not alter M-CSF-induced IkappaBalpha degradation, suggesting that M-CSF-induced PKC activity augmented NF-kappaB transcriptional activity by an alternative pathway, like post-translational modification of NF-kappaB p65.","[{'offsets': [[76, 79]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[179, 191]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[258, 261]], 'text': ['p50'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[262, 265]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[445, 457]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 580]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[698, 710]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[889, 892]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[43, 51]], 'text': ['Regulate'], 'type': 'Regulation', 'id': 'T10'}, {'offsets': [[80, 90]], 'text': ['Activation'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[144, 159]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T12'}, {'offsets': [[164, 175]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T13'}, {'offsets': [[458, 469]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T14'}, {'offsets': [[474, 483]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T15'}, {'offsets': [[539, 546]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[555, 564]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[678, 683]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[690, 697]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[711, 722]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T20'}, {'offsets': [[767, 776]], 'text': ['augmented'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[815, 837]], 'text': ['an alternative pathway'], 'type': 'Anaphora', 'id': 'T9'}, {'offsets': [[844, 875]], 'text': ['post-translational modification'], 'type': 'Protein_modification', 'id': 'T22'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T17', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T19', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T20', 'id': 'E11', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T21', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T22', 'id': 'E13', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]","[{'id': 'R1', 'head': {'ref_id': 'T9', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}]",[]
221,PMC-3245220-27-Caption-Figure_3,"Inhibition of PKC or NF-kappaB induces apoptosis in MDMs.
(A) MDMs were pre-incubated in RPMI medium containing inhibitors (Ro-31-8220: 5 microM, Go-6976: 5 microM, BAPTA/AM: 2.5 microM) for 30 minutes prior to the addition of M-CSF. As a control, untreated cells were incubated with dimethyl sulfoxide (DMSO). Cell lysates were resolved by SDS-PAGE and immunoblotted with antibody recognizing the active cleaved form of caspase-3. The blots were reblotted with beta-actin that served as a loading control. The ratio of active caspase-3 bands (17 kD and 19 kD) to beta-actin control was determined by densitometry analysis (bottom panel). Data represents the mean +/- S.E.M from two independent donors. (B) Apoptosis of the treated MDMs was also measured by Annexin V-FITC and propidium iodine (PI) staining and analyzed by flow cytometry. The percentage of surviving cells (Annexin V/PI negative) for the cells treated with vehicle/M-CSF was arbitrarily set as 100. Data shown represent the mean +/- S.E.M from three independent experiments. *The p-values of inhibitors/M-CSF compared to vehicle/M-CSF were <=0.05.","[{'offsets': [[462, 472]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[527, 536]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[564, 574]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[758, 767]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[875, 884]], 'text': ['Annexin V'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[520, 526]], 'text': ['active'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[888, 896]], 'text': ['negative'], 'type': 'Negative_regulation', 'id': 'T7'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],[],[]
0,PMC-3359311-21-Caption-Figure_3,"Airway cells do not strongly upregulate caspase-1 activity in response to inflammasome stimuli.
S9 and IB3-1 cells were examined for caspase-1 activation following inflammasome stimulation with P. aeruginosa (MOI = 10) and ATP (5 mM). Cells were primed with LPS for 5 hours where appropriate. A representative histogram of % caspase-1-active cells is shown in (A) and the averaged values are shown in (B) (n = 3 separate experiments). (C) IB3-1 cells (5x104 cells/well) were pre-treated for 1 hour with increasing concentrations of z-YVAD-fmk (10-30 microM) prior to stimulation with P. aeruginosa (MOI = 50). Cell culture supernatants were collected after 6 hours and assayed for IL-6 by ELISA (n = 3).","[{'offsets': [[681, 685]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
1,PMC-1920263-11-RESULTS,"The A3G promoter is not inducible in T cells
According to the current knowledge, APOBEC3G plays a role in the innate defence against pathogens like HIV-1. The latter has evolved a mechanism to counteract A3G activity by expressing the regulatory protein Vif (4). Vif induces proteasomal degradation of A3G and additionally inhibits A3G activity by further mechanisms (8, 37-43). To investigate whether the overexpression of HIV-1 proteins also influences A3G promoter activity, we either expressed HIV-1 Vif or the HIV-1 Tat protein, the latter has been shown to activate different viral and cellular promoters (44,45). In addition, increasing amounts of the plasmid pNL4-3, containing the full-length genome of HIV-1, were transfected. These constructs or the empty vector pcDNA3.1 were cotransfected with the 1025 bp construct into A3.01 T cells. Luciferase assays showed that the transcriptional activity of the A3G promoter was not significantly altered in the presence of Vif, Tat or HIV-1NL4-3 (Figure 4A), suggesting that HIV-1 is not modulating A3G expression on the transcriptional level.
It has been shown that the amount of A3G mRNA in T cells is increased in response to mitogenic stimulation with phorbol ester (46-48). In addition, interferons have been described to upregulate A3G expression in hepatocytes and macrophages (46,48). To investigate whether these stimuli interfere with A3G promoter activity in T cells, we transfected A3.01 T cells with the 1025 bp promoter or the empty vector pGL3-Basic (vector) and treated the cells with phorbol ester (TPA). The luciferase assay showed that the ~15-fold increased transcriptional activity of the 1025 bp promoter relative to the empty vector was not further enhanced by TPA treatment (Figure 4B), although the functional activity of TPA was confirmed by induction of the SV40 promoter-containing reporter plasmid pGL3-Control (data not shown). Similarly, treatment of A3.01 T cells transfected with the A3G promoter deletion constructs with IFN-alpha or IFN-gamma showed no effect (Figure 4C). Interestingly, a control plasmid (pGL2-CVX) containing two IFN-responsive GAS (gamma activated sequence) elements upstream of the luciferase reporter gene was only induced by IFN-alpha in these cells (Figure 4C). Since two reports describe A3G upregulation by interferons in hepatocytes (47,48), we additionally performed the experiment in the hepatic cell line HepG2. In line with these publications, we observed an induction of the A3G promoter by approximately 2-fold after IFN-alpha or IFN-gamma stimulation (Figure 4D) with IFN-gamma being slightly more potent. For both interferon types, induction of A3G promoter activity was observed for all deletion constructs except for the 60 bp fragment, indicating that the responsible region is located within the 60 nt present in the 120 bp, but not in the 60 bp fragment.","[{'offsets': [[4, 7]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[81, 89]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[204, 207]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[254, 257]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[263, 266]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[302, 305]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[332, 335]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[455, 458]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[504, 507]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[521, 524]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[849, 859]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[915, 918]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[977, 980]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[982, 985]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1053, 1056]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1135, 1138]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1292, 1295]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1399, 1402]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1580, 1590]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1971, 1974]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2009, 2018]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2022, 2031]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2192, 2202]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2237, 2246]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2302, 2305]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2496, 2499]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2539, 2548]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2552, 2561]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2591, 2600]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2669, 2672]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[8, 16]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T31'}, {'offsets': [[24, 33]], 'text': ['inducible'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[193, 203]], 'text': ['counteract'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[220, 230]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[267, 274]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[287, 298]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T36'}, {'offsets': [[323, 331]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[488, 497]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[1042, 1052]], 'text': ['modulating'], 'type': 'Regulation', 'id': 'T39'}, {'offsets': [[1057, 1067]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[1158, 1167]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1281, 1291]], 'text': ['upregulate'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[1296, 1306]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[1622, 1631]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[1632, 1647]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T45'}, {'offsets': [[1648, 1656]], 'text': ['activity'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[1726, 1734]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[2306, 2318]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[2479, 2488]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[2500, 2508]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T50'}]","[{'trigger': 'T32', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T31']}}, {'trigger': 'T33', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'E3']}}, {'trigger': 'T34', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T5']}}, {'trigger': 'T36', 'id': 'E5', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T37', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'T5']}}, {'trigger': 'T38', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T38', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T39', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T40', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T41', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T42', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T43', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T44', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T45', 'id': 'E15', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T46', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T47', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T48', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T49', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T26', 'T50']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}]",[]
2,PMC-2222968-08-Discussion,"The current study reveals that FOXP3 induction, an important step in iTreg commitment, is inhibited by GATA3, which is the key regulator for polarization toward Th2 cells. After differentiation, the effector Th2 cells become refractory to conversion into a FOXP3+ phenotype.
In accordance with other studies, we found that CD4+CD25- cells were able to up-regulate FOXP3 [12,27]. Already-committed cells such as memory T cells and Th1 cells showed only moderate and transient FOXP3 induction, which is not sufficient to change the phenotype toward a regulatory T cell profile. In contrast, naive T cells could efficiently up-regulate FOXP3 when treated with TGF-beta to induce iTreg cells [10,28-34], suggesting that FOXP3 plays an important role in the early differentiation process and may act in a way similar to that known for the Th1/Th2 decision factors T-bet and GATA3. This commitment is characterized by competitive expression of these factors [35,36], which we also observed in differentiating FOXP3+ iTreg cells including a phase of co-expression, which turns into nonoverlapping expression upon completed differentiation. In this competitive process TGF-beta appeared to be mandatory for the induction of FOXP3, possibly by keeping the expression of GATA3 and T-bet low [37,38]. In contrast, differentiating naive T cells in the absence of polarization factors (Th0) such as IL-4, IL-12, or TGF-beta showed only a transient FOXP3 expression and failed to generate a population of FOXP3-expressing cells, but GATA3 and T-bet were up-regulated (unpublished data). Interestingly, as we and others previously described, FOXP3-promoting factors, such as dexamethasone [39], CTLA-4 [40], and estrogens [41], are also known as inhibitors of GATA3 expression [42-45]. Therefore GATA3 not only induces differentiation into Th2 cells but also inhibits FOXP3 expression and commitment into iTreg cells.
The Th2 cytokine IL-4 but not IL-13 (unpublished data) was able to inhibit TGF-beta-mediated FOXP3 induction and therefore prevented conversion into the regulatory phenotype. To prove the inhibitory effect of IL-4 on inducible or natural Treg commitment in vivo, we treated mice with IL-4 and anti-IL-4. This has been shown to increase the effect of the cytokine in vivo [19]. Only the IL-4/IL-4 mAb complex resulted in a decrease of the amount of natural or inducible Treg (CD25+ and Foxp3+) cells 7 d after treatment. Our results suggest that IL-4 is only interfering with the differentiation of naive T cells into iTreg cells. But since a distinction of nTreg and iTreg cells is currently not possible, because iTreg cells also transiently express CD25 after activation, we cannot exclude that IL-4 may also inhibit Foxp3 expression in nTreg cells in vivo or that additional effects may contribute to the observed drop in Foxp3 expression. IL-4 has already been shown to negatively regulate the development of naive T cells into Th1 or the IL-17-producing T cells (Th17) [46,47]. Similar effects have been recently described for IL-6, which, combined with TGF-beta, inhibits the generation of iTreg cells and induces differentiation into the Th17 cells by an unknown mechanism [48,49]. Thus the polarization into iTreg cells is negatively regulated by the effector cytokines IL-4 and IL-6.
IL-4 has been previously shown to induce the generation of FOXP3+ Treg cells out of CD4+CD25- [50]. In those experiments, the concentrations of IL-4 used were low, and as we also observed, IL-4 at low concentration slightly enhanced FOXP3 expression. Importantly, these concentrations were not sufficient to induce GATA3 expression. IL-4 may favor proliferation of nTreg cells [47] or directly regulate FOXP3 expression in a STAT-dependent fashion [51].
Since IL-13 does not effectively reduce FOXP3 and fails to induce GATA3, we hypothesized that the IL-4-dependent inhibition of FOXP3 could be mediated by GATA3. In fact, GATA3-inducing IL-4 concentrations repressed TGF-beta-mediated FOXP3 expression, whereas IL-4 as well as TGF-beta signaling were intact. This result suggested a competitive mechanism between GATA3 and FOXP3 transcription factors in determining lineage commitment during the early phase of differentiation. Accordingly, we investigated naturally high GATA3-expressing cells and confirmed the absence of FOXP3. Protein transduction of GATA3 into naive T cells inhibited FOXP3 induction in human, differentiating, naive T cells. This inhibitory effect of GATA3 was further confirmed in BALB/c transgenic mice, expressing GATA3 in T cells (DO11.10:CD2-GATA3 transgenic mice). In line with the transient overexpression of GATA3 in human T cells, cells of these mice failed to induce FOXP3 expression upon exposure with antigen in the presence of TGF-beta. Strikingly, the DO11.10:CD2-GATA3 mice do have peripheral FOXP3+ cells, which however displayed a 10%-25% lower frequency compared to wild-type DO11.10 mice. Thus GATA3 restrains the development of certain Treg subsets, presumably the inducible, peripheral population and not those of thymic origin. Thymic T cells undergo a different maturation process, which may explain the insensitivity of nTreg to GATA3 overexpression [52]. In contrast to the Th2-differentiating and iTreg-inhibiting function of GATA3 in peripheral T cells, GATA3 acts in the thymus together with other transcription factors such as the Repressor of GATA3 (ROG) in the differentiation process toward CD8 cells [53,54] or participates in complex transcriptional feedback network to regulate sympathoadrenal differentiation [55]. Therefore, the role of GATA3 appears to be tissue specific and cannot be generalized.
Our study demonstrates that GATA3 repressed FOXP3 expression directly by binding to the FOXP3 promoter region. A palindromic GATA-site is located 303 bp upstream of the TSS in a highly conserved region, which we have previously identified as the FOXP3 promoter [24]. Site-specific mutation of this site increased the activity of the promoter constructs, thus revealing the repressive nature of this GATA element in memory T cells, which naturally express GATA3, whereas no difference was seen in naive T cells, which do not express GATA3. This palindromic GATA element is bound by GATA3 protein as proven with pull-down experiments. Furthermore, it is shown by ChIP that GATA3 binds this element also in intact cells. It is known that GATA3 can induce transcription by chromatin remodeling [56], by directly transactivating promoters [36], or, as shown in the current study, acts as a repressor of gene expression [21,57-59]. Therefore keeping GATA3 expression low might be required to induce efficient FOXP3+ iTreg cell generation.
The molecular interactions enabling GATA3 to inhibit FOXP3 are not identified yet, but the GATA-binding site is located adjacent to positive, inducing sites, composed of AP-1-NFATc2 sites [24], and GATA3 may compete with the binding of AP-1/NFAT to the promoter (unpublished observations).
In summary, we demonstrated that FOXP3 is negatively regulated by cytokines such as IL-4. GATA3 acts as an inhibitor of FOXP3 expression in early T cell differentiation, as well as in differentiated Th2 cells by directly binding and repressing the FOXP3 promoter. We therefore describe a new mechanism of how Il-4 avoids tolerance induction by repressing FOXP3 expression. These findings will give new perspectives toward understanding molecular mechanisms of iTreg induction and thus pathways of peripheral tolerance induction, particularly in allergy and asthma.","[{'offsets': [[31, 36]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[103, 108]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[257, 262]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[323, 326]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[327, 331]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[364, 369]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[475, 480]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[633, 638]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[657, 665]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[716, 721]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[859, 864]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[869, 874]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1003, 1008]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1161, 1169]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1216, 1221]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1261, 1266]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1271, 1276]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1386, 1390]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1392, 1397]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1402, 1410]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1435, 1440]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1491, 1496]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1519, 1524]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1529, 1534]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1627, 1632]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1680, 1686]], 'text': ['CTLA-4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1745, 1750]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1781, 1786]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1853, 1858]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1920, 1924]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1933, 1938]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1978, 1986]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1996, 2001]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2112, 2116]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2187, 2191]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2201, 2205]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2289, 2293]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2294, 2298]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2378, 2382]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2388, 2393]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2448, 2452]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2654, 2658]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2700, 2704]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2722, 2727]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2828, 2833]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2846, 2850]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2946, 2951]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3035, 3039]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3062, 3070]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3281, 3285]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3290, 3294]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3296, 3300]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3355, 3360]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3380, 3383]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3384, 3388]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3440, 3444]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3485, 3489]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3529, 3534]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3611, 3616]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3629, 3633]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3699, 3704]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3756, 3761]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3790, 3795]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3816, 3821]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3848, 3852]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3877, 3882]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3904, 3909]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3920, 3925]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3935, 3939]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3965, 3973]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3983, 3988]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4009, 4013]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4025, 4033]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4111, 4116]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4121, 4126]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[4270, 4275]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[4322, 4327]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[4353, 4358]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[4388, 4393]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[4472, 4477]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[4538, 4543]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[4564, 4567]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[4568, 4573]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[4637, 4642]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[4698, 4703]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[4761, 4769]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[4795, 4798]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[4799, 4804]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[4829, 4834]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[4934, 4939]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[5174, 5179]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[5273, 5278]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[5302, 5307]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[5381, 5399]], 'text': ['Repressor of GATA3'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[5401, 5404]], 'text': ['ROG'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[5444, 5447]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[5595, 5600]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[5686, 5691]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[5702, 5707]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[5746, 5751]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[5904, 5909]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[6113, 6118]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[6190, 6195]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[6239, 6244]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[6329, 6334]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[6393, 6398]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[6602, 6607]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[6661, 6666]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[6727, 6732]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[6744, 6749]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[6889, 6894]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[6927, 6931]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[6932, 6936]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[7014, 7019]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[7065, 7069]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[7071, 7076]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[7101, 7106]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[7229, 7234]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[7290, 7294]], 'text': ['Il-4'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[7336, 7341]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[37, 46]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T125'}, {'offsets': [[90, 99]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T126'}, {'offsets': [[352, 363]], 'text': ['up-regulate'], 'type': 'Positive_regulation', 'id': 'T127'}, {'offsets': [[481, 490]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T128'}, {'offsets': [[621, 632]], 'text': ['up-regulate'], 'type': 'Positive_regulation', 'id': 'T129'}, {'offsets': [[924, 934]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T130'}, {'offsets': [[938, 951]], 'text': ['these factors'], 'type': 'Anaphora', 'id': 'T121'}, {'offsets': [[1043, 1056]], 'text': ['co-expression'], 'type': 'Gene_expression', 'id': 'T131'}, {'offsets': [[1090, 1100]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T132'}, {'offsets': [[1247, 1257]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T133'}, {'offsets': [[1277, 1280]], 'text': ['low'], 'type': 'Negative_regulation', 'id': 'T134'}, {'offsets': [[1340, 1347]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T135'}, {'offsets': [[1351, 1371]], 'text': ['polarization factors'], 'type': 'Anaphora', 'id': 'T122'}, {'offsets': [[1441, 1451]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T136'}, {'offsets': [[1497, 1507]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T137'}, {'offsets': [[1540, 1552]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T138'}, {'offsets': [[1633, 1642]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T139'}, {'offsets': [[1731, 1741]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T140'}, {'offsets': [[1751, 1761]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T141'}, {'offsets': [[1844, 1852]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T142'}, {'offsets': [[1859, 1869]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T143'}, {'offsets': [[1970, 1977]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T144'}, {'offsets': [[2002, 2011]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T145'}, {'offsets': [[2646, 2653]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T146'}, {'offsets': [[2714, 2721]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T147'}, {'offsets': [[2728, 2738]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T148'}, {'offsets': [[2793, 2803]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T149'}, {'offsets': [[2820, 2824]], 'text': ['drop'], 'type': 'Negative_regulation', 'id': 'T150'}, {'offsets': [[2834, 2844]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T151'}, {'offsets': [[2952, 2961]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T152'}, {'offsets': [[3520, 3528]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T153'}, {'offsets': [[3535, 3545]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T154'}, {'offsets': [[3560, 3580]], 'text': ['these concentrations'], 'type': 'Anaphora', 'id': 'T123'}, {'offsets': [[3604, 3610]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T155'}, {'offsets': [[3617, 3627]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T156'}, {'offsets': [[3690, 3698]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T157'}, {'offsets': [[3705, 3715]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T158'}, {'offsets': [[3783, 3789]], 'text': ['reduce'], 'type': 'Negative_regulation', 'id': 'T159'}, {'offsets': [[3809, 3815]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T160'}, {'offsets': [[3863, 3873]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T161'}, {'offsets': [[3892, 3900]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T162'}, {'offsets': [[3926, 3934]], 'text': ['inducing'], 'type': 'Positive_regulation', 'id': 'T163'}, {'offsets': [[3955, 3964]], 'text': ['repressed'], 'type': 'Negative_regulation', 'id': 'T164'}, {'offsets': [[3974, 3982]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T165'}, {'offsets': [[3989, 3999]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T166'}, {'offsets': [[4265, 4269]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T167'}, {'offsets': [[4276, 4286]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T168'}, {'offsets': [[4311, 4318]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T169'}, {'offsets': [[4378, 4387]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T170'}, {'offsets': [[4394, 4403]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T171'}, {'offsets': [[4527, 4537]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T172'}, {'offsets': [[4619, 4633]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T173'}, {'offsets': [[4681, 4687]], 'text': ['failed'], 'type': 'Negative_regulation', 'id': 'T174'}, {'offsets': [[4691, 4697]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T175'}, {'offsets': [[4704, 4714]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T176'}, {'offsets': [[5180, 5194]], 'text': ['overexpression'], 'type': 'Positive_regulation', 'id': 'T177'}, {'offsets': [[5692, 5701]], 'text': ['repressed'], 'type': 'Negative_regulation', 'id': 'T178'}, {'offsets': [[5708, 5718]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T179'}, {'offsets': [[5731, 5738]], 'text': ['binding'], 'type': 'Binding', 'id': 'T180'}, {'offsets': [[5752, 5767]], 'text': ['promoter region'], 'type': 'Entity', 'id': 'T181'}, {'offsets': [[6105, 6112]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T182'}, {'offsets': [[6182, 6189]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T183'}, {'offsets': [[6230, 6235]], 'text': ['bound'], 'type': 'Binding', 'id': 'T184'}, {'offsets': [[6335, 6340]], 'text': ['binds'], 'type': 'Binding', 'id': 'T185'}, {'offsets': [[6608, 6618]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T186'}, {'offsets': [[6619, 6622]], 'text': ['low'], 'type': 'Negative_regulation', 'id': 'T187'}, {'offsets': [[6736, 6743]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T188'}, {'offsets': [[6899, 6906]], 'text': ['compete'], 'type': 'Negative_regulation', 'id': 'T189'}, {'offsets': [[6916, 6923]], 'text': ['binding'], 'type': 'Binding', 'id': 'T190'}, {'offsets': [[6944, 6952]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T191'}, {'offsets': [[7023, 7043]], 'text': ['negatively regulated'], 'type': 'Negative_regulation', 'id': 'T192'}, {'offsets': [[7047, 7056]], 'text': ['cytokines'], 'type': 'Anaphora', 'id': 'T124'}, {'offsets': [[7077, 7097]], 'text': ['acts as an inhibitor'], 'type': 'Negative_regulation', 'id': 'T193'}, {'offsets': [[7107, 7117]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T194'}, {'offsets': [[7202, 7209]], 'text': ['binding'], 'type': 'Binding', 'id': 'T195'}, {'offsets': [[7214, 7224]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T196'}, {'offsets': [[7235, 7243]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T197'}, {'offsets': [[7325, 7335]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T198'}, {'offsets': [[7342, 7352]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T199'}]","[{'trigger': 'T125', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T126', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'T2']}}, {'trigger': 'T127', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T128', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T129', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T8', 'T9']}}, {'trigger': 'T130', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T130', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T131', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T131', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T132', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T132', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T133', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T133', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T134', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T14']}}, {'trigger': 'T134', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T14']}}, {'trigger': 'T135', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T135', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T135', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T136', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T137', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T138', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T138', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T139', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T25', 'T26']}}, {'trigger': 'T140', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T26']}}, {'trigger': 'T141', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T142', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T28']}}, {'trigger': 'T143', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T144', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T30']}}, {'trigger': 'T145', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'T32']}}, {'trigger': 'T144', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T31']}}, {'trigger': 'T146', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T147', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'E31']}}, {'trigger': 'T148', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T149', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T150', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T151', 'id': 'E36', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T152', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T153', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T57']}}, {'trigger': 'T154', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T155', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'T57']}}, {'trigger': 'T156', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T157', 'id': 'E42', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E43']}}, {'trigger': 'T158', 'id': 'E43', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T159', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T63', 'T62']}}, {'trigger': 'T160', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T64', 'T62']}}, {'trigger': 'T161', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T66', 'T65']}}, {'trigger': 'T162', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E46', 'T67']}}, {'trigger': 'T163', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T69', 'T68']}}, {'trigger': 'T164', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E50', 'E48']}}, {'trigger': 'T165', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'T70']}}, {'trigger': 'T166', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T167', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E53']}}, {'trigger': 'T168', 'id': 'E53', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T169', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T170', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E56', 'T78']}}, {'trigger': 'T171', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T172', 'id': 'E57', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T173', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T174', 'id': 'E59', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E58']}}, {'trigger': 'T175', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E61']}}, {'trigger': 'T176', 'id': 'E61', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T177', 'id': 'E62', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}, {'trigger': 'T178', 'id': 'E63', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E64', 'E65']}}, {'trigger': 'T179', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T99']}}, {'trigger': 'T180', 'id': 'E65', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T98', 'T100', 'T181']}}, {'trigger': 'T182', 'id': 'E66', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T102']}}, {'trigger': 'T183', 'id': 'E67', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T103']}}, {'trigger': 'T184', 'id': 'E68', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T104']}}, {'trigger': 'T185', 'id': 'E69', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T105']}}, {'trigger': 'T186', 'id': 'E70', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T107']}}, {'trigger': 'T187', 'id': 'E71', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E70']}}, {'trigger': 'T188', 'id': 'E72', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T110', 'T109']}}, {'trigger': 'T189', 'id': 'E73', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E74', 'T111']}}, {'trigger': 'T190', 'id': 'E74', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T110', 'T112', 'T191']}}, {'trigger': 'T189', 'id': 'E75', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'T111']}}, {'trigger': 'T190', 'id': 'E76', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T110', 'T113', 'T191']}}, {'trigger': 'T192', 'id': 'E77', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T114', 'T115']}}, {'trigger': 'T193', 'id': 'E78', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E79', 'T116']}}, {'trigger': 'T194', 'id': 'E79', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T117']}}, {'trigger': 'T195', 'id': 'E80', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T116', 'T118', 'T197']}}, {'trigger': 'T196', 'id': 'E81', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T118', 'T116', 'T197']}}, {'trigger': 'T198', 'id': 'E82', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E83', 'T119']}}, {'trigger': 'T199', 'id': 'E83', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T120']}}]","[{'id': 'R1', 'head': {'ref_id': 'T121', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T121', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T122', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T122', 'role': 'Subject'}, 'tail': {'ref_id': 'T19', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T122', 'role': 'Subject'}, 'tail': {'ref_id': 'T20', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T123', 'role': 'Subject'}, 'tail': {'ref_id': 'T57', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T124', 'role': 'Subject'}, 'tail': {'ref_id': 'T115', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T94', 'T95']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E14', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E32', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E34', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E40', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E42', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E44', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E47', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E67', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E73', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E75', 'value': ''}]",[]
3,PMC-2806624-17-MATERIALS_AND_METHODS,"Real-time PCR.
PCR primers and probes were designed based on the sequences reported in GenBank with the Primer Express software version 1.2 (Applied Biosystems) as follows: FOXP3 forward primer, 5'-GAAACAGCACATTCCCAGAGTTC-3'; FOXP3 reverse primer, 5'-ATGGCCCAGCGGATGAG-3'; EF-1a forward primer, 5'-CTGAACCATCCAGGCCAAAT-3'; and EF-1a reverse primer, 5'-GCCGTGTGGCAATCCAAT-3', as previously described (Mantel et al., 2007). GATA3 forward primer, 5'-GCGGGCTCTATCACAAAATGA-3'; and GATA3 reverse primer 5'-GCTCTCCTGGCTGCAGACAGC-3' (Mantel et al., 2007). T-bet forward primer, 5'-GATGCGCCAGGAAGTTTCAT-3'; T-bet reverse primer, 5'-GCACAATCATCTGGGTCACATT-3'; RORC2 forward primer, 5'-CAGTCATGAGAACACAAATTGAAGTG-3'; and RORC2 reverse primer 5'-CAGGTGATAACCCCGTAGTGGAT-3'. The prepared cDNAs were amplified using SYBR green PCR master mix (Fermentas) according to the recommendations of the manufacturer in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems).
RUNX1 and RUNX3 mRNA was detected by using TaqMan Gene Expression Assays from Applied Biosystems and used according to the manufacturer's instruction using TaqMan master mix using a 7000 real-time PCR system (Applied Biosystems). PCR amplification of the housekeeping gene encoding elongation factor (EF)-1alpha or by using the 18S rRNA Gene Expression Assay (Applied Biosystems) was performed to allow normalization between samples. Relative quantification and calculation of the range of confidence was performed using the comparative deltadeltaCT method (Applied Biosystems). The percentage of FOXP3 mRNA in siRNA-mediated RUNX knockdown cells was calculated in relation to cells, which were transfected with scrambled control siRNA. Arbitrary units show the 2-(deltact) values multiplied by 10,000 incorporating the ct values of the gene of interest and the housekeeping gene.","[{'offsets': [[173, 178]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[226, 231]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[273, 278]], 'text': ['EF-1a'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[327, 332]], 'text': ['EF-1a'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[422, 427]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[477, 482]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[549, 554]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[599, 604]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[651, 656]], 'text': ['RORC2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[711, 716]], 'text': ['RORC2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[963, 968]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[973, 978]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1245, 1274]], 'text': ['elongation factor (EF)-1alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1291, 1299]], 'text': ['18S rRNA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1560, 1565]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1589, 1593]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[979, 983]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T17'}, {'offsets': [[1566, 1570]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T18'}, {'offsets': [[1580, 1588]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[1594, 1603]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T20'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}]",[],[],[],[]
4,PMC-3062687-09-Results,"NleH1 inhibits RPS3 S209 phosphorylation in vivo
We previously utilized a gnotobiotic piglet infection model to determine that piglets infected with deltanleH1 mutant died more rapidly than those infected with wild-type E. coli O157:H7. Piglets infected with deltanleH1 displayed clinical disease consistent with a robust inflammatory response, but with reduced bacterial colonization and little diarrhea9. While seemingly paradoxical, based on our cell culture data (Fig. 6d), we hypothesized that NleH1 blocked RPS3 S209 phosphorylation in vivo, thereby preventing RPS3 nuclear translocation in infected piglets. We isolated piglet colons at necropsy, and subjected them to immunohistochemistry using our phospho-RPS3 antibody. Consistent with in vitro data, piglets infected with wild-type E. coli O157:H7 exhibited diffuse and low intensity phospho-RPS3 staining, whereas in piglets infected with deltanleH1 mutant, phospho-RPS3 expression was florid and intense (Fig. 6f). These data demonstrate that NleH1 inhibits RPS3 S209 phosphorylation both in vitro and in vivo, which might benefit the bacterium in colonization and transmission.","[{'offsets': [[0, 5]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[15, 19]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[149, 159]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[259, 269]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[499, 504]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[513, 517]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[567, 571]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[853, 857]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[901, 911]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[928, 932]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1006, 1011]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1021, 1025]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[6, 14]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[20, 24]], 'text': ['S209'], 'type': 'Entity', 'id': 'T14'}, {'offsets': [[25, 40]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T15'}, {'offsets': [[505, 512]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[518, 522]], 'text': ['S209'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[523, 538]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T18'}, {'offsets': [[556, 566]], 'text': ['preventing'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[572, 579]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T20'}, {'offsets': [[580, 593]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[831, 834]], 'text': ['low'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[845, 852]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T23'}, {'offsets': [[920, 927]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T24'}, {'offsets': [[959, 966]], 'text': ['intense'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[1012, 1020]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T26'}, {'offsets': [[1026, 1030]], 'text': ['S209'], 'type': 'Entity', 'id': 'T27'}, {'offsets': [[1031, 1046]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T28'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T14']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T5']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T6', 'T17']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E3']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T20']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T23', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T25', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T9']}}, {'trigger': 'T26', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T11']}}, {'trigger': 'T28', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T12', 'T27']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
5,PMC-2222968-29-Caption-Figure_5,"Effect of IL-4 on FOXP3 Induction
(A) A statistical analysis was performed with six donors on day 5 (TGF-beta (10 ng/ml) and with or without IL-4 (100 ng/ml)); Shown is the mean, and error bars indicated the SD of six donors. Statistical analysis was performed using the Dunnett test. Statistical significance is indicated by asterisks (*p <= 0.05, **p <= 0.01, Dunnett).
(B) CD4+CD45RA+ cells were activated in the presence of a constant concentration of TGF-beta (5 ng/ml) with an increasing concentration of IL-4, as indicated. Cells were harvested for mRNA quantification after 5 d.
(C) CD4+CD45RA+ cells were stimulated in vitro with plate-bound anti-CD3/CD28, TGF-beta (10ng/ml), and IL-4 (100 ng/ml) as indicated. After 1 h, cell lysates were prepared and analyzed by Western blot for phosphorylated SMAD2 and STAT6. Total STAT6 and GAPDH served as internal control.
(D) Intracellular GATA3 and FOXP3 staining are shown after exposure of CD4+CD45RA+ T cells to IL-4 as described for panel B. Data are representative of three independent experiments.","[{'offsets': [[10, 14]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 23]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[101, 109]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[141, 145]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[376, 379]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[380, 386]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[456, 464]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[511, 515]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[591, 594]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[595, 601]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[656, 659]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[660, 664]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[666, 674]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 694]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[807, 812]], 'text': ['SMAD2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[817, 822]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[830, 835]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[840, 845]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[892, 897]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[902, 907]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[945, 948]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[949, 955]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[968, 972]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[0, 6]], 'text': ['Effect'], 'type': 'Regulation', 'id': 'T24'}, {'offsets': [[24, 33]], 'text': ['Induction'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[483, 493]], 'text': ['increasing'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[792, 806]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T27'}, {'offsets': [[908, 916]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T28'}]","[{'trigger': 'T24', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T25', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T26', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T27', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T27', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T28', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T28', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
6,PMC-3333881-07-MATERIALS_AND_METHODS,"In vitro translation
HA-IkappaB-alpha, p65 and Tat were expressed under the T7 promoter and in vitro translated using the TnT quick coupled transcription/translation system (Promega), as previously reported (50). Details are described in Supplementary Data.","[{'offsets': [[21, 37]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[39, 42]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[47, 50]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[56, 65]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T4'}, {'offsets': [[66, 71]], 'text': ['under'], 'type': 'Positive_regulation', 'id': 'T5'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T4', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T5', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T5', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T5', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}]",[],[],[],[]
7,PMC-3062687-16-Methods,"LC-MS/MS Analysis
GST or GST-RPS3 was incubated with recombinant IKKbeta protein as described above in an in vitro kinase assay reaction conducted without 32P-gamma-ATP labeling. The reaction was separated by SDS-PAGE, and the protein gel was stained with Colloidal Blue (Invitrogen). The corresponding protein fragments were excised and subjected to trypsin digestion and LC-MS/MS at the Yale Cancer Center Mass Spectrometry Resource (New Haven, CT).","[{'offsets': [[25, 33]], 'text': ['GST-RPS3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[65, 72]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
8,PMC-2222968-23-Materials_and_Methods,"ChIP.
ChIP analysis was performed according to the manufacturer's protocol (Upstate Biotechnology) with the following modifications. iTreg and Th2 cells were fixed with 1% formaldehyde for 10 min at room temperature. The chromatin was sheared to 200-1000 bp of length by sonication with five pulses of 10 s at 30% power (Bandelin). The chromatin was pre-cleared for 2 h with normal mouse IgG beads and then incubated with anti-GATA3-agarose beads (HG3-31; Santa Cruz Biotechnology) for 2 h. Washing and elution buffers were used according to the protocol of Upstate Biotechnology. Crosslinks were reversed by incubation at 65 degreesC for 4 h in the presence of 0.2 M NaCl, and the DNA was purified by phenol/chloroform extraction. The amount of DNA was determined by conventional PCR. The PCR addressed for the FOXP3 promoter region -246 to -511 and was performed using the following primers: 5'-gtgccctttacgagt catctg-3' and 5'-gtgccctttacgagtcatctg-3'. The PCR products were visualized using an ethidium bromide gel.","[{'offsets': [[427, 432]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[812, 817]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
9,PMC-2800179-21-Caption-Figure_1,"Degraded CGN induced colon inflammation in rats.
Histograms showing the effect of degraded CGN on: colon length (A); macroscopic (B) and histological (C) inflammation score of colon; Myeloperoxidase (MPO) activity (D). Control rats (white bars); 10 kDa degraded CGN-treated rats (grey bars); 40 kDa degraded CGN-treated rats (black bars). * p<0.05 from control. ** p<0.01 from control. Histological analysis of colon from control rats (E), and from 40 kDa dCGN-treated rats (F).",[],[],[],[],[],[]
10,PMC-2800179-09-Materials_and_Methods,"RT-PCR Analysis
Total RNA from monocytes was isolated using TRIzol Reagent(TM) (Invitrogen). cDNA was generated on 1 microg of total RNA in a reaction volume of 20 microl, using M-MLV reverse transcriptase (Invitrogen). PCR was done in the linear range of amplification (determined for each primer pair-cDNA combination). Standard PCR reactions were performed with 1 microl of the cDNA solution, 50 microM of each primer solution, 10 mM of each dNTP, 25 mM MgCl2, 10X Goldstar DNA polymerase reaction buffer, and 0.5 units of Goldstar DNA polymerase (Eurogentec, Seraing, Belgium). First PCR cycle consisted of 1 min at 92degreesC, 1 min at 58degreesC and 1 min at 72degreesC; then each PCR cycle consisted of 40 sec at 92degreesC, 40 sec at 58degreesC and 50 sec at 72degreesC. cDNA for beta-actin was amplified for 28 cycles using the oligos: sense 5'-GGCATCGTGATGGACTCCG-3' and antisense 5'GCTGGAAGGTGGACAGCGA-3'. cDNA for TNF-alpha was amplified for 35 cycles using the oligos: sense 5'-AAGCCTGTAGCCCATGTTGT-3' and antisense 5'-CAGATAGATGGGCTCATACC-3'. cDNA for ICAM-1 was amplified for 35 cycles using the oligos sense 5'-GTAGCAGCCGCAGTCATAATGG-3' and antisense 5'-A TGCTGTTGTATCTGACTGAGG-3'.","[{'offsets': [[788, 798]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[926, 935]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1066, 1072]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
11,PMC-1920263-16-Caption-Figure_1,"Sequence of the A3G promoter and the downstream region. The first 1000 bp upstream of the major TSS are shown in lower case, the first 800 bp of the transcribed sequence are shown in upper case. Introns are removed, but their positions are indicated. Arrows refer to transcriptional start sites and their observed frequency is given by the numbers above. The primer binding sites for 5'-RACE analysis and cloning of the luciferase reporter constructs are underlined and the names of the primers are annotated. Gray and black arrowheads define the regions designated E1 and E2 which were cloned into vector pGL3-Promoter and used as EMSA probes. The ATG start codon and the identified Sp1/Sp3 transcription factor binding site are shown in bold.","[{'offsets': [[16, 19]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[267, 294]], 'text': ['transcriptional start sites'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[420, 430]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
12,PMC-2806624-08-MATERIALS_AND_METHODS,"Mice.
CbfbF/F CD4-cre and Foxp3GFP mice have previously been described (Bettelli et al., 2006; Naoe et al., 2007). Cd45.1 and Rag2-/- mice were purchased from Jackson ImmunoResearch Laboratories and Taconic, respectively. For the in vivo Foxp3 conversion assay, naive CD4+ T cells from Cbfb CD4-cre or control mice (harboring a Foxp3-IRES-GFP allele) were adoptively transferred into Rag-deficient mice. 5 x 106 cells were used per transfer. 6 wk later, TCRbeta+CD4+ gated cells from the spleen, mesenteric lymph node (MLN), and lamina propria of the small intestine were analyzed for Foxp3-GFP expression. All analyses and experiments were performed on animals at 6-8 wk of age. Animals were housed under specific pathogen-free conditions at the animal facility of the Skirball Institute, and experiments were performed in accordance with approved protocols for the New York University Institutional Animal Care and Usage Committee.","[{'offsets': [[6, 10]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 17]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[18, 21]], 'text': ['cre'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[26, 31]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[31, 34]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[115, 121]], 'text': ['Cd45.1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[126, 130]], 'text': ['Rag2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[238, 243]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[268, 271]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[286, 290]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[291, 294]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[295, 298]], 'text': ['cre'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[328, 333]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[339, 342]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[384, 387]], 'text': ['Rag'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[454, 461]], 'text': ['TCRbeta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[462, 465]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[585, 594]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[388, 397]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[595, 605]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T20', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}]",[],[],[],[]
13,PMC-2674207-08-Materials_and_Methods,"GR-GATA-3 In Vitro Competition Assay for Importin-alpha (Far-Western ELISA)
Immunoprecipitated importin-alpha (anti-importin-alpha, Santa Cruz Biotechnology) from HuT-78 cells was separated by SDS-PAGE and purified from the excised gel by electroelution [36]. Similarly, GATA-3 was isolated from nonstimulated HuT-78 cells or cells stimulated for 30 min with anti-CD3/CD28 and GR was isolated from FP (10-8 M, 30 min) stimulated HuT-78 cells. These proteins were subsequently refolded in glycine solution. 100 microl of importin-alpha solution (100 ng/ml in TBS) was added to 96-well plates coated with goat anti-importin-alpha antibody. After 1 h incubation, GATA-3 (100 ng/ml in TBS) from stimulated or unstimulated cells were added to the importin-alpha-coated wells. GR (10 or 100 ng/ml in TBS) from stimulated or unstimulated cells were added to some wells. After a further 1 h incubation, the plate was washed and incubated with primary antibodies (a mixture of rabbit anti-GATA-3 and mouse anti-GR, Santa Cruz Biotechnology) for 1.5 h, and then incubated with secondary antibodies. FITC swine anti-rabbit IgG (Dako, Cambridge, UK) was used for the detection of GATA-3, and rhodamine donkey anti-mouse IgG (Novus, Littleton, Colorado, USA) was used for the detection of GR. FITC and rhodamine levels were measured with a fluorescent micro-plate reader (Bioline, London, UK).","[{'offsets': [[0, 2]], 'text': ['GR'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[3, 9]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[271, 277]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[377, 379]], 'text': ['GR'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[660, 666]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[771, 773]], 'text': ['GR'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1168, 1174]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1276, 1278]], 'text': ['GR'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
14,PMC-2222968-14-Materials_and_Methods,"Cloning of the FOXP3 promoter and construction of mutant constructs.
The FOXP3 promoter was cloned into the pGL3 basic vector (Promega Biotech) to generate the pGL3 FOXP3 -511/+176 [24]. Site-directed mutagenesis in the FOXP3 promoter region were introduced using the QuickChange kit (Stratagene), according to the manufacturer's instructions. The following primer and its complementary strand were used: GTT TCT CAT GAG CCC TAT TAA GTC ATT CTT ACC TCT CAC CTC TGT GGT GA.","[{'offsets': [[15, 20]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[73, 78]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[165, 170]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[220, 225]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
15,PMC-2800179-00-TIAB,"Degraded Carrageenan Causing Colitis in Rats Induces TNF Secretion and ICAM-1 Upregulation in Monocytes through NF-kappaB Activation
Carrageenan (CGN) is a high molecular weight sulphated polysaccharide derived from red seaweeds. In rodents, its degraded forms (dCGN) can induce intestinal inflammation associated with macrophage recruitment and activation. The aim of this study was: 1) to analyze the size-dependent effects of dCGN on colon inflammation in vivo, and 2) to correlate these effects with monocyte/macrophage proliferation, cytokine production and expression of various cell surface antigens including ICAM-1 adhesion molecule. Peripheral blood monocytes (PBM) and THP-1 monocytic cells were cultured in the presence of either 10 or 40 kDa, dCGN. The 40 kDa, but not the 10 kDa dCGN, induced colitis in in vivo. Degraded CGN inhibited THP-1 cell proliferation in vitro, arresting the cells in G1 phase. In addition, dCGN increased ICAM-1 expression in both PBM and THP-1 cells with a major effect seen after 40 kDa dCGN exposure. Also, dCGN stimulated monocyte aggregation in vitro that was prevented by incubation with anti-ICAM-1 antibody. Finally, dCGN stimulated TNF-alpha expression and secretion by both PBM and THP-1 cells. All these effects were linked to NF-kappaB activation. These data strongly suggest that the degraded forms of CGN have a pronounced effect on monocytes, characteristic of an inflammatory phenotype.","[{'offsets': [[53, 56]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[71, 77]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[617, 623]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[624, 641]], 'text': ['adhesion molecule'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[946, 952]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1182, 1191]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[45, 52]], 'text': ['Induces'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[57, 66]], 'text': ['Secretion'], 'type': 'Localization', 'id': 'T8'}, {'offsets': [[78, 90]], 'text': ['Upregulation'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[104, 111]], 'text': ['through'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[936, 945]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[953, 963]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[1171, 1181]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[1192, 1202]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[1207, 1216]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T15'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T9', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T11', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T12', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T14', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T13', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T15', 'id': 'E12', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],[],[]
16,PMC-3062687-25-Methods,"Immunohistochemistry
Gnotobiotic piglets were infected with E. coli O157:H7 strains as described previously9. Spiral colon specimens were collected at necropsy and embedded in paraffin. Paraffin sectioning and immunohistochemical staining using phospho-RPS3 antibody were performed by Histoserv Inc.",[],[],[],[],[],[]
17,PMC-2800179-15-Results,"Degraded CGN Induced-TNF-alpha Production by Monocytes In Vitro
In order to study the capacity of dCGN to stimulate TNF-alpha production, peripheral blood monocytes were cultivated in the presence of dCGN (0.1 to 1 mg/ml). Very low levels of TNF-alpha were induced in PBM after stimulation with native CGN (Fig. 2A). Addition of 0.1 mg/ml 10 kDa dCGN resulted in approximately a 60-fold increase in TNF-alpha production by PBM. This was a dose-dependent effect that reached a 180-fold increase when cells were exposed to 1 mg/ml of 10 kDa dCGN (Fig. 2A). A 250-fold increase in TNF-alpha production was detected at 1 mg/ml 40 kDa dCGN (Fig. 2A). TNF-alpha production increased in time reaching a maximum level at 8 hours of culture (Figure 2B). After 24 h, the amount of secreted TNF-alpha was still one third of the total TNF-alpha. Lipopolysaccharide (LPS), a known activator of immune cells also induced TNF-alpha production with similar kinetics as dCGN (Fig. 2B). However, the amount of TNF-alpha produced by LPS was 4-fold less than the one produced by dCGN and it was not detected after 8 hours of culture (Fig. 2B). Similarly, monocytic THP-1 cells cultivated in the presence of variable concentration of dCGN showed an increase in TNF-alpha production (Fig. 2C). This increase in TNF-alpha production was significantly smaller (about 10-fold) than the one presented by PBM (Fig. 2A). No TNF-alpha was released from THP-1 cells exposed to native CGN (not shown). TNF-alpha production by THP-1 cells was not dose dependent to the amount of dCGN used. Also there was no difference between the two forms (10 and 40 kDa) of dCGN (Fig. 2C). Interestingly, TNF-alpha release from THP-1 cells stimulated with dCGN reached a maximum level at 32 h, while stimulation with LPS reached a maximum level at 56 h (Fig. 2D).","[{'offsets': [[21, 30]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[116, 125]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[242, 251]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[399, 408]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[578, 587]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[646, 655]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[780, 789]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[823, 832]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[907, 916]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[992, 1001]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1240, 1249]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1289, 1298]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1396, 1405]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1471, 1480]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1659, 1668]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[13, 20]], 'text': ['Induced'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[31, 41]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[106, 115]], 'text': ['stimulate'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[126, 136]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[257, 264]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[278, 289]], 'text': ['stimulation'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[351, 359]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[387, 395]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[409, 419]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T26'}, {'offsets': [[444, 453]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T27'}, {'offsets': [[454, 460]], 'text': ['effect'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[566, 574]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[588, 598]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[656, 666]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[667, 676]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[771, 779]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T32'}, {'offsets': [[899, 906]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[917, 927]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[1002, 1010]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[1011, 1013]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[1039, 1046]], 'text': ['the one'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[1047, 1055]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[1056, 1058]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1228, 1236]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1250, 1260]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[1272, 1285]], 'text': ['This increase'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1299, 1309]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[1410, 1418]], 'text': ['released'], 'type': 'Localization', 'id': 'T43'}, {'offsets': [[1481, 1491]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[1520, 1529]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T45'}, {'offsets': [[1669, 1676]], 'text': ['release'], 'type': 'Localization', 'id': 'T46'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T20', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T21', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T22', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T24', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T26', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T27', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T30', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T33', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T34', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T35', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T36', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T37', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T38', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T39', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T40', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T41', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T42', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T43', 'id': 'E26', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T44', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T45', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T46', 'id': 'E29', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]","[{'id': 'R1', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}]",[]
18,PMC-3359311-25-Caption-Figure_7,"Bay11-7082 inhibits pro-IL-1beta production in response to P. aeruginosa.
PMA-differentiated THP-1 cells were treated with 10 microM CFTRinh172 or 20 microM Bay11-7082 and harvested after (A) 4 hours (n = 3) or (B) 0.5, 1, and 1.5 hours (n = 3) stimulation with PAO1. One representative blot is shown with a graph of the averaged fluorescence intensity values over 3 experiments.",[],[],[],[],[],[]
19,PMC-3333881-18-Caption-Figure_1,"Tat counteracts the post-activation turn off of NF-kappaB in single round HIV-1-infection. Jurkat cells (5 x 107) were transfected with siRNA Tat or siRNA control (2 nmol), or left untransfected; 24 h later, cells were infected with HXB2-pseudotyped NL4-3.Luc.R-E- virions (500 ng of p24) and harvested at the indicated time. (A) Tat expression was measured in total RNA by real-time PCR, while the luciferase activity was measured in whole cell extracts. (B) Nuclear extracts (10 microg) were analysed for the p65 and p50 binding to the NF-kappaB double-stranded oligonucleotide using the NF-kappaB Transcription Factor ELISA Assay kit (Cayman). (C) The expression of p65 and IkappaB-alpha was analysed by 12% SDS-PAGE and western blotting of nuclear or cytosolic extracts (20 microg) using anti-p65 and anti-IkappaB-alpha antibodies. Histone H1 and Hexokinase II were detected with specific antibodies as markers of nuclear and cytosolic extracts, respectively. Densitometry values (D) of the bands were expressed as fold increase above the control (mock). (D) IKK activity was measured in cytosolic extracts (100 microg) by using HTScan IKK Kinase Assay (Cell Signaling Technology). Values (mean +/- SE, n = 3) are shown.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[136, 145]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[284, 287]], 'text': ['p24'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[330, 333]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[399, 409]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[511, 514]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[519, 522]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[669, 672]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[677, 690]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[851, 864]], 'text': ['Hexokinase II'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[334, 344]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[523, 530]], 'text': ['binding'], 'type': 'Binding', 'id': 'T12'}, {'offsets': [[655, 665]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
20,PMC-2800179-25-Caption-Figure_5,"Degraded CGN induced monocytes aggregation in vitro.
Monocytes were incubated in the absence (A) or the presence of 1 mg/ml 10 kDa dCGN (B), 1 mg/ml 40 kDa dCGN (C), or 1 mg/ml 40 kDa dCGN plus 2.5 microg/ml anti-ICAM-1 antibody (D). Cells were observed by phase contrast inverse microscopy at 150X magnification. Inserts in A and B show a close up of cells at 300X magnification. E: Number of monocyte aggregates in 24 wells plate of PBM cell cultured with nothing (control), with 10 kDa degraded CGN (C10), or with 40 kDa degraded CGN (C40). Some cultures had also 2.5 microg/ml anti-ICAM-1 antibody. Data are mean +/- SEM.",[],[],[],[],[],[]
21,PMC-1920263-05-MATERIALS_AND_METHODS,"Luciferase assay
For transient transfection of A3.01 and U937 cells, DMRIE-C transfection reagent (Life Technologies) was used (36). Cells were seeded in 6-well tissue culture plates (5 x 105 cells per well) in 1.5 ml Opti-MEM (Life Technologies) containing 0.5 microg firefly luciferase reporter plasmid and 3.5 microl DMRIE-C. After 4-5 h of incubation, 1.5 ml complete RPMI medium were added. HepG2 and Huh7 cell lines were transfected using LipofectAMINE Plus as recommended by the manufacturer (Life Technologies). Briefly, exponential growing cells (1.5 x 106) were transfected with 5 microl LipofectAMINE, 6 microl PLUS reagent and the required amount of plasmid DNA in a final volume of 1 ml Opti-MEM. Following 4 h of incubation, cells were washed in PBS and 3 ml of complete DMEM medium were added.
For cotransfection of reporter plasmids and siRNA into HeLa cells, HiPerfect transfection reagent (Qiagen) was used according to the manufacturer's protocol for cotransfection of adherent cells with siRNA and plasmid DNA.
Two days after transfection of the respective cell lines, cells were harvested in 100 microl (suspension cells) or 300 microl (adherent cells) of Passive Lysis Buffer (Promega) and luciferase assay was performed using the Dual Luciferase Assay System (Promega) according to the manufacturer's instructions. As an internal control, 50 ng (adherent cells) or 100 ng (suspension cells) of ph-RG-TK plasmid (Promega), which constitutively expresses renilla luciferase was cotransfected in every sample and firefly luciferase activities were normalized to renilla luciferase activities. Mean values (+/-SD) of a representative experiment performed in triplicate are shown in the figures. For stimulation of cells, final concentrations of 20 ng/ml TPA (Sigma) or 30 ng/ml IFN-alpha or 30 ng/ml IFN-gamma (Tebu-Bio) were applied approximately 15 h before harvesting for luciferase assay.","[{'offsets': [[0, 10]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[277, 287]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1212, 1222]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1484, 1494]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1541, 1551]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1590, 1600]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1797, 1806]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1819, 1828]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1894, 1904]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1466, 1475]], 'text': ['expresses'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
22,PMC-3062687-10-Results,"NleH1 steers the IKKbeta substrate specificities
NleH1 is an autophosphorylated serine-threonine kinase, which depends on the lysine 159 (K159)9. To explore the mechanism by which NleH1 inhibits RPS3 S209 phosphorylation, we first performed an in vitro kinase assay with purified wild-type His-NleH1 protein and a mutant His-NleH1 (K159A) protein, confirming that NleH1 is autophosphorylated and the K159A is an NleH1 kinase-dead mutant (Fig. 7a). To examine whether the kinase activity is required for NleH1 to inhibit IKKbeta phosphorlyation of RPS3 on S209, we ectopically expressing either wild-type or K159A NleH1 in 293T cells. Wild-type NleH1 expression significantly reduced TNF-induced RPS3 S209 phosphorylation, whereas the K159A mutant failed to do so (Fig. 7b). Thus NleH1 kinase activity is required to protect RPS3 from IKKbeta-mediated phosphorylation.
Citrobacter rodentium is a mouse pathogen that shares pathogenic strategies with E. coli 39, most notably for our investigation, C. rodentium NleH inhibited RPS3 nuclear translocation and RPS3-dependent NF-kappaB luciferase activity to an extent equivalent to E. coli NleH1 (ref. 9). We assayed RPS3 S209 phosphorylation in HeLa cells infected with different C. rodentium strains. In uninfected cells, TNF-treatment stimulated a ~3.5-fold increase in RPS3 S209 phosphorylation (Fig. 7c). Such augmentation of RPS3 phosphorylation was reduced by about 60% by wild-type C. rodentium infection (Fig. 7c). However, RPS3 phosphorylation was enhanced when cells were infected with a C. rodentium strain lacking NleH (Fig. 7c, deltanleH). We further examined the role of NleH1 kinase activity using the C. rodentium deltanleH strain as a background on which to express either wild-type or K159A E. coli NleH1. Complementing deltanleH mutant with wild-type NleH1 almost abolished TNF-induced RPS3 S209 phosphorylation whereas complementing with K159A failed to inhibit RPS3 phosphorylation (Fig. 7c). Collectively, these results demonstrate that NleH1 kinase activity is required to block RPS3 S209 phosphorylation.
We next examined whether the inhibitory activity of NleH1 is sufficiently robust to impair the strong nuclear translocation of RPS3 trigged by the constitutively-active IKKbeta (IKKbeta [SSEE]) (Fig. 2d). We found that ectopically expressing either wild-type or SSEE IKKbeta proteins, triggered more RPS3 nuclear translocation than the kinase-dead IKKbeta (SSAA) protein (Fig. 7d). RPS3 nuclear accumulation was substantially retarded by infecting cells with wild-type E. coli O157:H7 (Fig. 7d). In contrast, infecting with either deltanleH1 or deltaescN strains only slightly impaired RPS3 nuclear translocation in either IKKbeta- or IKKbeta (SSEE)-expressing cells (Fig. 7d). As expected, E. coli infections did not affect the RPS3 nuclear translocation in IKKbeta (SSAA)-expressing cells, where NF-kappaB signaling was low (Fig. 7d). Thus, during infection NleH1 is sufficiently potent to inhibit RPS3 nuclear translocation even in cells expressing constitutively-activated IKKbeta.
We examined whether NleH1 could directly phosphorylate IKKbeta thus inhibiting IKKbeta-mediated RPS3 S209 phosphorylation. We performed in vitro kinase assays using immunoprecipitated Flag-IKKbeta (K44A) as substrate and recombinant His-NleH1 as kinase, so that IKKbeta autophosphorylation would not obscure NleH1-induced phosphorylation. However, we did not observe any detectable 32P incorporation in IKKbeta (Supplementary Fig. 13), thus ruling out this possibility.
We then tested the hypothesis that NleH1 could alter the IKKbeta substrate specificities. To this end, we performed in vitro kinase assays using both CK2 and IKK substrates for IKKbeta. As expected, IKKbeta phosphorylated RPS3 (Fig. 7e, lane 7) and GST-IkappaBalpha (1-54) protein (Fig. 7e, lane 9), demonstrating it harbors either CK2 or IKK substrate specificity. Preincubation of IKKbeta with NleH1 reduced IKKbeta-mediated RPS3 phosphorylation, i.e. the CK2 kinase specificity, but not IKKbeta-mediated GST-IkappaBalpha phosphorylation, i.e. the IKK kinase specificity (Fig. 7e). Control experiments revealed no NleH1-mediated phosphorylation or autophosphorylation of RPS3 or GST-IkappaBalpha (Fig. 7e). Taken together, NleH1 blocks the CK2 substrate specificity of IKKbeta thus inhibiting the IKKbeta-mediated RPS3 S209 phosphorylation thus representing a novel strategy by E. coli O157:H7 to alter the host innate immune response.","[{'offsets': [[0, 5]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 24]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 54]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[180, 185]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[195, 199]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[290, 299]], 'text': ['His-NleH1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[321, 330]], 'text': ['His-NleH1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[364, 369]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[412, 417]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[503, 508]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[520, 527]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[547, 551]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[613, 618]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[644, 649]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[695, 699]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[779, 784]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[824, 828]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[834, 841]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1010, 1014]], 'text': ['NleH'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1025, 1029]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1056, 1060]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1081, 1091]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1136, 1141]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1163, 1167]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1319, 1323]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1377, 1381]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1479, 1483]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1573, 1577]], 'text': ['NleH'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1588, 1597]], 'text': ['deltanleH'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1632, 1637]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1677, 1686]], 'text': ['deltanleH'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1764, 1769]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1785, 1794]], 'text': ['deltanleH'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1817, 1822]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1840, 1843]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1852, 1856]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1929, 1933]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2006, 2011]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2049, 2053]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2128, 2133]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2203, 2207]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2245, 2252]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2254, 2261]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2338, 2350]], 'text': ['SSEE IKKbeta'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2376, 2380]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2424, 2431]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2458, 2462]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2607, 2617]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2621, 2630]], 'text': ['deltaescN'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2662, 2666]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2699, 2706]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2711, 2718]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2805, 2809]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2835, 2842]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2936, 2941]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2976, 2980]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3053, 3060]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3082, 3087]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3117, 3124]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3141, 3148]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3158, 3162]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3246, 3265]], 'text': ['Flag-IKKbeta (K44A)'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3295, 3304]], 'text': ['His-NleH1'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3324, 3331]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3370, 3375]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3465, 3472]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3567, 3572]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3589, 3596]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3709, 3716]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3731, 3738]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3754, 3758]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3781, 3797]], 'text': ['GST-IkappaBalpha'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[3915, 3922]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[3928, 3933]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[3942, 3949]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[3959, 3963]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[4022, 4029]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[4039, 4055]], 'text': ['GST-IkappaBalpha'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[4148, 4153]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[4205, 4209]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[4213, 4229]], 'text': ['GST-IkappaBalpha'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[4257, 4262]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[4303, 4310]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[4331, 4338]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[4348, 4352]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[61, 79]], 'text': ['autophosphorylated'], 'type': 'Phosphorylation', 'id': 'T89'}, {'offsets': [[111, 118]], 'text': ['depends'], 'type': 'Regulation', 'id': 'T90'}, {'offsets': [[126, 136]], 'text': ['lysine 159'], 'type': 'Entity', 'id': 'T91'}, {'offsets': [[186, 194]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T92'}, {'offsets': [[200, 204]], 'text': ['S209'], 'type': 'Entity', 'id': 'T93'}, {'offsets': [[205, 220]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T94'}, {'offsets': [[373, 391]], 'text': ['autophosphorylated'], 'type': 'Phosphorylation', 'id': 'T95'}, {'offsets': [[400, 405]], 'text': ['K159A'], 'type': 'Entity', 'id': 'T96'}, {'offsets': [[418, 429]], 'text': ['kinase-dead'], 'type': 'Negative_regulation', 'id': 'T97'}, {'offsets': [[490, 498]], 'text': ['required'], 'type': 'Regulation', 'id': 'T98'}, {'offsets': [[512, 519]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[528, 543]], 'text': ['phosphorlyation'], 'type': 'Phosphorylation', 'id': 'T100'}, {'offsets': [[555, 559]], 'text': ['S209'], 'type': 'Entity', 'id': 'T101'}, {'offsets': [[650, 660]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[675, 682]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T103'}, {'offsets': [[687, 694]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[700, 704]], 'text': ['S209'], 'type': 'Entity', 'id': 'T105'}, {'offsets': [[705, 720]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T106'}, {'offsets': [[747, 753]], 'text': ['failed'], 'type': 'Negative_regulation', 'id': 'T107'}, {'offsets': [[757, 759]], 'text': ['do'], 'type': 'Anaphora', 'id': 'T86'}, {'offsets': [[804, 812]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[816, 823]], 'text': ['protect'], 'type': 'Negative_regulation', 'id': 'T109'}, {'offsets': [[842, 850]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T110'}, {'offsets': [[851, 866]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T111'}, {'offsets': [[1015, 1024]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T112'}, {'offsets': [[1030, 1037]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T113'}, {'offsets': [[1038, 1051]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T114'}, {'offsets': [[1061, 1070]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T115'}, {'offsets': [[1092, 1100]], 'text': ['activity'], 'type': 'Positive_regulation', 'id': 'T116'}, {'offsets': [[1168, 1172]], 'text': ['S209'], 'type': 'Entity', 'id': 'T117'}, {'offsets': [[1173, 1188]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T118'}, {'offsets': [[1307, 1315]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T119'}, {'offsets': [[1324, 1328]], 'text': ['S209'], 'type': 'Entity', 'id': 'T120'}, {'offsets': [[1329, 1344]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T121'}, {'offsets': [[1361, 1373]], 'text': ['augmentation'], 'type': 'Positive_regulation', 'id': 'T122'}, {'offsets': [[1382, 1397]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T123'}, {'offsets': [[1402, 1409]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[1484, 1499]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T125'}, {'offsets': [[1504, 1512]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T126'}, {'offsets': [[1565, 1572]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T127'}, {'offsets': [[1722, 1729]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T128'}, {'offsets': [[1830, 1839]], 'text': ['abolished'], 'type': 'Negative_regulation', 'id': 'T129'}, {'offsets': [[1844, 1851]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T130'}, {'offsets': [[1857, 1861]], 'text': ['S209'], 'type': 'Entity', 'id': 'T131'}, {'offsets': [[1862, 1877]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T132'}, {'offsets': [[1921, 1928]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T133'}, {'offsets': [[1934, 1949]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T134'}, {'offsets': [[2031, 2039]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[2043, 2048]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T136'}, {'offsets': [[2054, 2058]], 'text': ['S209'], 'type': 'Entity', 'id': 'T137'}, {'offsets': [[2059, 2074]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T138'}, {'offsets': [[2105, 2124]], 'text': ['inhibitory activity'], 'type': 'Anaphora', 'id': 'T87'}, {'offsets': [[2160, 2166]], 'text': ['impair'], 'type': 'Negative_regulation', 'id': 'T139'}, {'offsets': [[2178, 2185]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T140'}, {'offsets': [[2186, 2199]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T141'}, {'offsets': [[2208, 2215]], 'text': ['trigged'], 'type': 'Positive_regulation', 'id': 'T142'}, {'offsets': [[2223, 2244]], 'text': ['constitutively-active'], 'type': 'Positive_regulation', 'id': 'T143'}, {'offsets': [[2263, 2267]], 'text': ['SSEE'], 'type': 'Positive_regulation', 'id': 'T144'}, {'offsets': [[2361, 2370]], 'text': ['triggered'], 'type': 'Positive_regulation', 'id': 'T145'}, {'offsets': [[2381, 2388]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T146'}, {'offsets': [[2389, 2402]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T147'}, {'offsets': [[2412, 2423]], 'text': ['kinase-dead'], 'type': 'Negative_regulation', 'id': 'T148'}, {'offsets': [[2433, 2437]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T149'}, {'offsets': [[2463, 2470]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T150'}, {'offsets': [[2471, 2483]], 'text': ['accumulation'], 'type': 'Localization', 'id': 'T151'}, {'offsets': [[2502, 2510]], 'text': ['retarded'], 'type': 'Negative_regulation', 'id': 'T152'}, {'offsets': [[2667, 2674]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T153'}, {'offsets': [[2675, 2688]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T154'}, {'offsets': [[2720, 2724]], 'text': ['SSEE'], 'type': 'Positive_regulation', 'id': 'T155'}, {'offsets': [[2726, 2736]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T156'}, {'offsets': [[2794, 2800]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T157'}, {'offsets': [[2810, 2817]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T158'}, {'offsets': [[2818, 2831]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T159'}, {'offsets': [[2844, 2848]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T160'}, {'offsets': [[2850, 2860]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T161'}, {'offsets': [[2968, 2975]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T162'}, {'offsets': [[2981, 2988]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T163'}, {'offsets': [[2989, 3002]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T164'}, {'offsets': [[3017, 3027]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T165'}, {'offsets': [[3043, 3052]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T166'}, {'offsets': [[3103, 3116]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T167'}, {'offsets': [[3125, 3129]], 'text': ['thus'], 'type': 'Positive_regulation', 'id': 'T168'}, {'offsets': [[3130, 3140]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T169'}, {'offsets': [[3149, 3157]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T170'}, {'offsets': [[3163, 3167]], 'text': ['S209'], 'type': 'Entity', 'id': 'T171'}, {'offsets': [[3168, 3183]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T172'}, {'offsets': [[3332, 3351]], 'text': ['autophosphorylation'], 'type': 'Phosphorylation', 'id': 'T173'}, {'offsets': [[3384, 3399]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T174'}, {'offsets': [[3444, 3461]], 'text': ['32P incorporation'], 'type': 'Phosphorylation', 'id': 'T175'}, {'offsets': [[3739, 3753]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T176'}, {'offsets': [[3846, 3848]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T88'}, {'offsets': [[3875, 3896]], 'text': ['substrate specificity'], 'type': 'Regulation', 'id': 'T177'}, {'offsets': [[3934, 3941]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T178'}, {'offsets': [[3950, 3958]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T179'}, {'offsets': [[3964, 3979]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T180'}, {'offsets': [[4030, 4038]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T181'}, {'offsets': [[4056, 4071]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T182'}, {'offsets': [[4154, 4162]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T183'}, {'offsets': [[4163, 4178]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T184'}, {'offsets': [[4182, 4201]], 'text': ['autophosphorylation'], 'type': 'Phosphorylation', 'id': 'T185'}, {'offsets': [[4316, 4326]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T186'}, {'offsets': [[4339, 4347]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T187'}, {'offsets': [[4353, 4357]], 'text': ['S209'], 'type': 'Entity', 'id': 'T188'}, {'offsets': [[4358, 4373]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T189'}]","[{'trigger': 'T89', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T90', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E1', 'T3', 'T91']}}, {'trigger': 'T92', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T4']}}, {'trigger': 'T94', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T93']}}, {'trigger': 'T95', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T97', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['T9', 'T9', 'T96']}}, {'trigger': 'T98', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T99', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T100', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T12', 'T101']}}, {'trigger': 'T102', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T103', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E10']}}, {'trigger': 'T104', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T106', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T15', 'T105']}}, {'trigger': 'T107', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T108', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T109', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T110', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T18']}}, {'trigger': 'T111', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T112', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T19']}}, {'trigger': 'T114', 'id': 'E20', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T20', 'T113']}}, {'trigger': 'T112', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T19']}}, {'trigger': 'T115', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T21']}}, {'trigger': 'T116', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T118', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T117']}}, {'trigger': 'T119', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T121', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T120']}}, {'trigger': 'T122', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T123', 'id': 'E28', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T124', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T125', 'id': 'E30', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T126', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'E32']}}, {'trigger': 'T127', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T128', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T129', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'T34']}}, {'trigger': 'T130', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T35']}}, {'trigger': 'T132', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T36', 'T131']}}, {'trigger': 'T133', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T134', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T135', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T136', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T138', 'id': 'E41', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T39', 'T137']}}, {'trigger': 'T139', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'E40']}}, {'trigger': 'T142', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'T42']}}, {'trigger': 'T141', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T41', 'T140']}}, {'trigger': 'T143', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T144', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T145', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T44']}}, {'trigger': 'T147', 'id': 'E48', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T45', 'T146']}}, {'trigger': 'T148', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T149', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T151', 'id': 'E51', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T47', 'T150']}}, {'trigger': 'T152', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T154', 'id': 'E53', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T50', 'T153']}}, {'trigger': 'T155', 'id': 'E54', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T156', 'id': 'E55', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T156', 'id': 'E56', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T157', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T159', 'id': 'E58', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T53', 'T158']}}, {'trigger': 'T160', 'id': 'E59', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T161', 'id': 'E60', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T162', 'id': 'E61', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T55']}}, {'trigger': 'T164', 'id': 'E62', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T56', 'T163']}}, {'trigger': 'T165', 'id': 'E63', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T166', 'id': 'E64', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T167', 'id': 'E65', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T168', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'E65']}}, {'trigger': 'T169', 'id': 'E67', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E68', 'T58']}}, {'trigger': 'T170', 'id': 'E68', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E69', 'T60']}}, {'trigger': 'T172', 'id': 'E69', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T61', 'T171']}}, {'trigger': 'T173', 'id': 'E70', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T174', 'id': 'E71', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T175', 'id': 'E72', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T176', 'id': 'E73', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T71', 'T70']}}, {'trigger': 'T176', 'id': 'E74', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T72', 'T70']}}, {'trigger': 'T177', 'id': 'E75', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T178', 'id': 'E76', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E77', 'T74']}}, {'trigger': 'T179', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E80', 'T75']}}, {'trigger': 'T178', 'id': 'E78', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E79', 'T74']}}, {'trigger': 'T181', 'id': 'E79', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E81', 'T77']}}, {'trigger': 'T180', 'id': 'E80', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T182', 'id': 'E81', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T183', 'id': 'E82', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E83', 'T79']}}, {'trigger': 'T184', 'id': 'E83', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T183', 'id': 'E84', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E85', 'T79']}}, {'trigger': 'T184', 'id': 'E85', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T183', 'id': 'E86', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E87', 'T79']}}, {'trigger': 'T185', 'id': 'E87', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T183', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E89', 'T79']}}, {'trigger': 'T185', 'id': 'E89', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T186', 'id': 'E90', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E91']}}, {'trigger': 'T187', 'id': 'E91', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E92', 'T84']}}, {'trigger': 'T189', 'id': 'E92', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T85', 'T188']}}]","[{'id': 'R1', 'head': {'ref_id': 'T86', 'role': 'Subject'}, 'tail': {'ref_id': 'T103', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T87', 'role': 'Subject'}, 'tail': {'ref_id': 'T136', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T88', 'role': 'Subject'}, 'tail': {'ref_id': 'T71', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E37', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E42', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E66', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E72', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E76', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E78', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E82', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E84', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E86', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E88', 'value': ''}]",[]
23,PMC-3062687-01-INTRODUCTION,"Nuclear Factor-kappa B (NF-kappaB) regulates crucial cellular functions and diverse stimuli activate this pleiotropic transcription factor, which in turn regulates a vast array of genetic targets1-3. The best-known mammalian NF-kappaB subunits are Rel proteins, including RelA (p65), RelB, c-Rel, p50, and p52 (refs. 4,5). However, we recently demonstrated that ribosomal protein S3 (RPS3) is a key non-Rel subunit of certain native NF-kappaB complexes6. RPS3 is defined as a ""specifier"" subunit of NF-kappaB, because it facilitates high affinity DNA binding thus determining the regulatory specificity of NF-kappaB for selected target genes7. RPS3 regulation of NF-kappaB governs key physiological processes, including immunoglobulin kappa light chain gene expression and receptor editing in B cells6,8, cytokine production in T cells6, and in host defense against enterohemorrhagicEscherichia coli(EHEC)9. In particular, theE. coliO157:H7 type III secretion system (T3SS) effector protein NleH1 selectively blocks NF-kappaB target gene transcription by attenuating RPS3 nuclear translocation, without affecting p65 localization9. Nonetheless, how specific NF-kappaB activating signals induce RPS3 nuclear translocation is unknown.Extra-ribosomal functions have been ascribed to ribosomal proteins10. Besides binding RNA within the 40S ribosomal subunit, RPS3 participates in transcription6, DNA repair11,12, and apoptosis13. Whether or not RPS3 is phosphorylated had been controversial14-18. Since kinase cascades play a critical role in NF-kappaB regulation, we tested whether RPS3 is phosphorylated in the context of NF-kappaB activation and sought to identify the responsible kinase19. Additionally, we aimed to define a regulatory role for the C-terminal tail of RPS3 whose function was unknown.Here we show that the Inhibitor of kappaB (IkappaB) kinase beta (IKKbeta) phosphorylated RPS3 at serine 209 (S209). RPS3 S209 phosphorylation enhanced its association with importin-alpha, mediating RPS3 entry into the karyopherin pathway for nuclear translocation. Furthermore, theE. coliNleH1 effector specifically inhibited RPS3 S209 revealing howE. coliO157:H7 inhibits this important innate immune response mechanism.","[{'offsets': [[272, 276]], 'text': ['RelA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[278, 281]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[284, 288]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[290, 295]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[297, 300]], 'text': ['p50'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[306, 309]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[362, 382]], 'text': ['ribosomal protein S3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[384, 388]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[403, 406]], 'text': ['Rel'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[455, 459]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[644, 648]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[720, 752]], 'text': ['immunoglobulin kappa light chain'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[991, 996]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1067, 1071]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1113, 1116]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1194, 1198]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1356, 1360]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1442, 1446]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1580, 1584]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1769, 1773]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1823, 1864]], 'text': ['Inhibitor of kappaB (IkappaB) kinase beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1866, 1873]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1890, 1894]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1917, 1921]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1999, 2003]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2089, 2094]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2127, 2131]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[758, 768]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1055, 1066]], 'text': ['attenuating'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[1072, 1079]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T30'}, {'offsets': [[1080, 1093]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T31'}, {'offsets': [[1103, 1112]], 'text': ['affecting'], 'type': 'Regulation', 'id': 'T32'}, {'offsets': [[1117, 1129]], 'text': ['localization'], 'type': 'Localization', 'id': 'T33'}, {'offsets': [[1187, 1193]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1199, 1206]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T35'}, {'offsets': [[1207, 1220]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T36'}, {'offsets': [[1310, 1317]], 'text': ['binding'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[1450, 1464]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T38'}, {'offsets': [[1588, 1602]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T39'}, {'offsets': [[1875, 1889]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T40'}, {'offsets': [[1898, 1908]], 'text': ['serine 209'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[1922, 1926]], 'text': ['S209'], 'type': 'Entity', 'id': 'T42'}, {'offsets': [[1927, 1942]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T43'}, {'offsets': [[1943, 1951]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[1956, 1967]], 'text': ['association'], 'type': 'Binding', 'id': 'T45'}, {'offsets': [[1989, 1998]], 'text': ['mediating'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[2043, 2050]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T47'}, {'offsets': [[2051, 2064]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T48'}, {'offsets': [[2117, 2126]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[2132, 2136]], 'text': ['S209'], 'type': 'Entity', 'id': 'T50'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T29', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T13']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T14', 'T30']}}, {'trigger': 'T32', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T13']}}, {'trigger': 'T33', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T34', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T36', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T16', 'T35']}}, {'trigger': 'T37', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T38', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T39', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T40', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T23', 'T21', 'T41']}}, {'trigger': 'T43', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T42']}}, {'trigger': 'T44', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E12']}}, {'trigger': 'T45', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T46', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'E13']}}, {'trigger': 'T48', 'id': 'E16', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T25', 'T47']}}, {'trigger': 'T49', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T27', 'T26', 'T50']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}, {'id': '*', 'ref_ids': ['T7', 'T8']}, {'id': '*', 'ref_ids': ['T21', 'T22']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}]",[]
24,PMC-2222968-02-Results,"FOXP3 Induction in T Cell Subsets
It is assumed that FOXP3 expression can be induced in nonregulatory T cells, which is an important step in iTreg cell differentiation. However, it is not known if all CD4+ T cells have the same capacity to express FOXP3. To investigate whether FOXP3 can be expressed by any T cell subset or if expression is restricted to a distinct lineage, FOXP3 mRNA expression was analyzed in freshly isolated T cells such as CD25-depleted CD4+ cells, CD45RA+ naive or CD45RO+ memory T cells (Figure 1A), as well as T cells driven in vitro toward Th1, Th2, or iTreg phenotypes (Figure 1B; phenotype on Figure S1). The CD4+CD25-, CD45RA+, CD45RO+, and CD4+CD45RO+CD25- were able to significantly induce FOXP3 mRNA up to 30-fold upon TCR activation and addition of TGF-beta. Th1 cells showed only a 10-fold increase. In contrast, Th2 cells stimulated under the same conditions did not increase FOXP3 expression. The in vitro generated iTreg cells were unable to further up-regulate FOXP3, which was already at high levels under the resting conditions (Figure 1B, right panel).
Th2 cells are known to produce IL-4 upon activation, which may interact with TGF-beta signaling and thus prevent FOXP3 induction. However, the neutralization of IL-4 with a blocking IL-4 antibody did not rescue FOXP3 expression in the differentiated Th2 cells (unpublished data). These data demonstrated that Th2 cells have a limited capacity to express FOXP3 (Figure 1B). The inability of Th2 cells to express FOXP3 was also documented at the single-cell level, confirming that Th2 cells lack FOXP3 expression (Figure 2A). Only iTreg cells expressed FOXP3 in resting conditions. Interestingly, we observed that resting iTreg cells express FOXP3 but show low CD25 surface expression. Repeated exposure to TGF-beta did not further increase the FOXP3 expression in the iTreg lineage but transiently induced FOXP3 expression in Th1 cells. Naturally occurring Th2 cells such as CRTH2+ T cells, T cells isolated according to their IL-4 secretion, or an IL-4-producing T cell clone (BR8) were also lacking FOXP3 expression (Figure 2B). Furthermore TGF-beta-mediated FOXP3 induction failed in these cells in contrast to the naive T cells (Figure 2B). Because IL-4 is the key Th2 cytokine, the expression of IL-4 and FOXP3 in freshly isolated CD4+ T cells was analyzed by fluorescence activated cell sorting (FACS). IL-4-expressing cells were most abundant among CD45RO+CD25- cells, which did not co-express FOXP3 (Figure 3A, left panel). In contrast, CD45RO+CD25+ cells abundantly expressed FOXP3, while lacking IL-4 (Figure 3A, right panel). As shown in Figure 3B, the frequency of the IL-4+ cells was always below 1% in the FOXP3+ cells close to the background. The IL-4+ cells were confined to the FOXP3- cells, as shown for the CD45RO+CD25-, CD45RO+CD25+, and CD45RO+CD25+high cells (Figure 3B). In addition, neither the Th2 clone (BR8) nor CRTH2 cells significantly expressed FOXP3 (Figure 3C). Cells enriched for their IL-4 secretion using the magnetic cell isolation technology contained some FOXP3-expressing cells, but importantly, the expression did not overlap. Taken together, these data indicate that FOXP3 was not expressed by Th2 cells and was not inducible in those cells.","[{'offsets': [[0, 5]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[53, 58]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[201, 204]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[248, 253]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[278, 283]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[376, 381]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[447, 451]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[461, 464]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[473, 479]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[490, 496]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[639, 642]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[643, 647]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[650, 656]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[659, 665]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[672, 675]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[676, 682]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[683, 687]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[723, 728]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[784, 792]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[913, 918]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1001, 1006]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1127, 1131]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1173, 1181]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1209, 1214]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1257, 1261]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1278, 1282]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1307, 1312]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1450, 1455]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1507, 1512]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1590, 1595]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1647, 1652]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1736, 1741]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1755, 1759]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1801, 1809]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1839, 1844]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1901, 1906]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1970, 1975]], 'text': ['CRTH2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2022, 2026]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2044, 2048]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2096, 2101]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2138, 2146]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2156, 2161]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2248, 2252]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2296, 2300]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2305, 2310]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2331, 2334]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2404, 2408]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2451, 2457]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2458, 2462]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2496, 2501]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2540, 2546]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2547, 2551]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2580, 2585]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2601, 2605]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2676, 2680]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2715, 2720]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2757, 2761]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2790, 2795]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2821, 2827]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2828, 2832]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2835, 2841]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2842, 2846]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2853, 2859]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2860, 2864]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[2934, 2939]], 'text': ['CRTH2'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[2970, 2975]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3014, 3018]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3089, 3094]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3203, 3208]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[6, 15]], 'text': ['Induction'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[59, 69]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T71'}, {'offsets': [[77, 84]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[240, 247]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T73'}, {'offsets': [[291, 300]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[328, 338]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[342, 352]], 'text': ['restricted'], 'type': 'Regulation', 'id': 'T76'}, {'offsets': [[382, 397]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T77'}, {'offsets': [[716, 722]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[904, 912]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[919, 929]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T80'}, {'offsets': [[989, 1000]], 'text': ['up-regulate'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[1119, 1126]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T82'}, {'offsets': [[1201, 1208]], 'text': ['prevent'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[1215, 1224]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T84'}, {'offsets': [[1239, 1253]], 'text': ['neutralization'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[1300, 1306]], 'text': ['rescue'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[1313, 1323]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[1442, 1449]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T88'}, {'offsets': [[1473, 1482]], 'text': ['inability'], 'type': 'Negative_regulation', 'id': 'T89'}, {'offsets': [[1499, 1506]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[1585, 1589]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T91'}, {'offsets': [[1596, 1606]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T92'}, {'offsets': [[1637, 1646]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T93'}, {'offsets': [[1728, 1735]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T94'}, {'offsets': [[1751, 1754]], 'text': ['low'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[1768, 1778]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T96'}, {'offsets': [[1826, 1834]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[1845, 1855]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T98'}, {'offsets': [[1893, 1900]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[1907, 1917]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T100'}, {'offsets': [[2027, 2036]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T101'}, {'offsets': [[2049, 2058]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[2088, 2095]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T103'}, {'offsets': [[2102, 2112]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T104'}, {'offsets': [[2162, 2171]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T105'}, {'offsets': [[2172, 2178]], 'text': ['failed'], 'type': 'Negative_regulation', 'id': 'T106'}, {'offsets': [[2282, 2292]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T107'}, {'offsets': [[2409, 2419]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T108'}, {'offsets': [[2485, 2495]], 'text': ['co-express'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[2570, 2579]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T110'}, {'offsets': [[2593, 2600]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[2960, 2969]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T112'}, {'offsets': [[3019, 3028]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T113'}, {'offsets': [[3095, 3105]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T114'}, {'offsets': [[3217, 3226]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T115'}, {'offsets': [[3252, 3261]], 'text': ['inducible'], 'type': 'Positive_regulation', 'id': 'T116'}]","[{'trigger': 'T70', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T71', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T72', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T73', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T74', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T75', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T76', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T77', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T78', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T18', 'T19']}}, {'trigger': 'T79', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T80', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T81', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T82', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T83', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T22']}}, {'trigger': 'T84', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T85', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T86', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E16']}}, {'trigger': 'T87', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T88', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T89', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T90', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T91', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T92', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T93', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T94', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T95', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T96', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T97', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T34']}}, {'trigger': 'T98', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T99', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T100', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T101', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T102', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T103', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T104', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T105', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T42', 'T41']}}, {'trigger': 'T106', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T107', 'id': 'E38', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T107', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T108', 'id': 'E40', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T109', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T110', 'id': 'E42', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T111', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T112', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T113', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T114', 'id': 'E46', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T115', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T116', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E14', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E38', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E39', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E41', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E48', 'value': ''}]",[]
25,PMC-2806624-05-RESULTS,"Role of CBFbeta in the induction of Foxp3
CBFbeta, a common cofactor of all RUNX proteins, stabilizes and increases the binding of the runt domain to target DNA sequences. To target all Runx proteins that might be involved in the induction of Foxp3, we used mice in which loxP-flanked Cbfb alleles were inactivated in T cells through expression of a CD4-cre transgene. Retinoic acid and TGF-beta synergize in the induction of Foxp3 in naive T cells (Kang et al., 2007). To investigate whether Runx-mediated induction of Foxp3 is dependent on the expression of CBFbeta, naive CD4+ CD8- T cells from CbfbF/F CD4-cre and control CbfbF/+ CD4-cre mice were stimulated with anti-CD3/28 mAbs, retinoic acid, and increasing concentrations of TGF-beta. After 3 d in culture, the cells were restimulated with PMA and ionomycin and analyzed for intracellular Foxp3 and IFN-gamma expression. TGF-beta induced Foxp3 in CbfbF/+ CD4-cre cells in a dose dependent manner, and this was significantly reduced in CbfbF/F CD4-cre cells. Retinoic acid enhanced Foxp3 expression even in 20 pg/ml of TGF-beta and more than 95% of the CD4+ T cells from CbfbF/+ CD4-cre mice became Foxp3+ in 100 and 500 pg/ml TGF-beta doses. The induction of Foxp3 was again significantly lower in CbfbF/F CD4-cre CD4+ T cells even in the presence of retinoic acid, demonstrating that deficiency in Runx binding to DNA affects the TGF-beta induction of Foxp3 in T reg cells (Fig. 5 A). There was no difference in the induction of Foxp3 when endogenous IL-4 and IFN-gamma were neutralized (Fig. S6).
The importance of RUNX transcription factors for the in vivo conversion of naive CD4+ T cells into iT reg cells was examined. Control CbfbF/F or CbfbF/F CD4-cre naive T cells, harboring a Foxp3-IRES-GFP allele were adoptively transferred into Rag2-/- mice. 6 wk later, CD4+ T cells in spleen, mesenteric lymph node, and lamina propria of the small intestine were analyzed for Foxp3-GFP expression (Fig. 5 B). There was a consistently lower percentage of CD4+ T cells that had developed Foxp3 expression in the mesenteric lymph node and lamina propria of mice transferred with CbfbF/F CD4-cre cells compared with control cells (Fig. 5, B and C). These data affirm the significance of RUNX proteins for the in vivo generation of CD4+ Foxp3+ T cells.","[{'offsets': [[8, 15]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 41]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[42, 49]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[76, 80]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[186, 190]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[243, 248]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[285, 289]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[350, 357]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[387, 395]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[426, 431]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[493, 497]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[520, 525]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[560, 567]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[575, 578]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[580, 583]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[598, 602]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[606, 613]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[626, 630]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[634, 641]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[673, 676]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[677, 679]], 'text': ['28'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[734, 742]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[848, 853]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[858, 867]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[880, 888]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[897, 902]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[906, 910]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[914, 921]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[994, 998]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1002, 1009]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1040, 1045]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1077, 1085]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1111, 1114]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1129, 1133]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1137, 1144]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1157, 1162]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1185, 1193]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1218, 1223]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1257, 1261]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1265, 1272]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1273, 1276]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1358, 1362]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1390, 1398]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1412, 1417]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1489, 1494]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1511, 1515]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1520, 1529]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1576, 1580]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1639, 1642]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1692, 1696]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[1703, 1707]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[1711, 1718]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[1746, 1751]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[1757, 1760]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[1801, 1805]], 'text': ['Rag2'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[1827, 1830]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[1934, 1943]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2012, 2015]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2044, 2049]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2134, 2138]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2142, 2149]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2241, 2245]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2285, 2288]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2290, 2295]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[0, 4]], 'text': ['Role'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[23, 32]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T67'}, {'offsets': [[214, 222]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T68'}, {'offsets': [[230, 239]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T69'}, {'offsets': [[303, 314]], 'text': ['inactivated'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[334, 344]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T71'}, {'offsets': [[396, 405]], 'text': ['synergize'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[413, 422]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T73'}, {'offsets': [[498, 506]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[507, 516]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[529, 538]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[546, 556]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T77'}, {'offsets': [[868, 878]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T78'}, {'offsets': [[889, 896]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[960, 964]], 'text': ['this'], 'type': 'Anaphora', 'id': 'T65'}, {'offsets': [[983, 990]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[1031, 1039]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[1046, 1056]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T82'}, {'offsets': [[1205, 1214]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T83'}, {'offsets': [[1248, 1253]], 'text': ['lower'], 'type': 'Negative_regulation', 'id': 'T84'}, {'offsets': [[1363, 1370]], 'text': ['binding'], 'type': 'Binding', 'id': 'T85'}, {'offsets': [[1378, 1385]], 'text': ['affects'], 'type': 'Regulation', 'id': 'T86'}, {'offsets': [[1399, 1408]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1458, 1468]], 'text': ['difference'], 'type': 'Regulation', 'id': 'T88'}, {'offsets': [[1476, 1485]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T89'}, {'offsets': [[1535, 1546]], 'text': ['neutralized'], 'type': 'Negative_regulation', 'id': 'T90'}, {'offsets': [[1944, 1954]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[2050, 2060]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T92'}, {'offsets': [[2225, 2237]], 'text': ['significance'], 'type': 'Positive_regulation', 'id': 'T93'}, {'offsets': [[2271, 2281]], 'text': ['generation'], 'type': 'Gene_expression', 'id': 'T94'}]","[{'trigger': 'T66', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T67', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T68', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T5']}}, {'trigger': 'T69', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T70', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T71', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T72', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T9']}}, {'trigger': 'T73', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T74', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T11']}}, {'trigger': 'T75', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T76', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E12']}}, {'trigger': 'T77', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T78', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T78', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T79', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T26', 'T25']}}, {'trigger': 'T80', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T81', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T32']}}, {'trigger': 'T82', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T83', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T84', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T85', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T86', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'E21']}}, {'trigger': 'T87', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T44', 'T43']}}, {'trigger': 'T88', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E26']}}, {'trigger': 'T89', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T90', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T88', 'id': 'E27', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E28']}}, {'trigger': 'T90', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T91', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T92', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T93', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T62']}}, {'trigger': 'T94', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T93', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'T62']}}, {'trigger': 'T94', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}]","[{'id': 'R1', 'head': {'ref_id': 'T65', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E14', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E27', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E29', 'value': ''}]",[]
26,PMC-2800179-10-Materials_and_Methods,"NF-kB Transcription Reporter Gene Assay
The plasmid 3XMHC-luc (a generous gift from Drs. J. Westwick and D.A. Brenner, University of North Carolina, Chapel Hill) contains three copies of NF-kappaB-responsive element from the MHC class I locus, placed upstream of the luciferase gene. Human monocytic THP-1 cells were transiently transfected as previously described [30], and then cultured for 4 h alone or with increasing concentration of either C10 or C40. Luciferase activity was determined using a luminometer (Monolight 2010 Luminometer, Ann Arbor, MI).","[{'offsets': [[267, 277]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[458, 468]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
27,PMC-1134658-12-Methods,"Antibodies used for flow cytometric analysis and immunoblot analysis
Antibodies against the human BMP-receptors Act-RIA, BMP-RIB, BMPR-II, Act-RIIA and Act-RIIb were purchased from R & D Systems (Abingdon, UK). Detection of the BMP-6-protein has been tried with the following antibodies: goat polyclonal anti-BMP-6 (Santa Cruz, San Diego, CA, USA), monoclonal mouse anti-BMP-6 and polyclonal goat anti-BMP-6 from R & D Systems (Abingdon, UK), and mouse monoclonal anti-BMP-6 (Chemicon International Inc, Temecula, CA, USA).
Characterisation of BMP-signalling pathways was done by use of anti-phospho-Smad1, -5, -and 8 polyclonal antibody (Chemicon, Temecula, CA, USA). Expression levels of Id1-3 proteins were detected with polyclonal rabbit antibody and detection was blocked with blocking peptide from Santa Cruz Biotechnology (Santa Cruz, San Diego, CA, USA). As secondary antibodies served anti-mouse, anti-goat or anti-rabbit IgG- horseradish peroxidase (HRP) from Dakocytomation AS (Copenhagen, Denmark) for immunoblot analysis. Anti-beta-actin was from Santa-Cruz. From Becton Dickinson (San Jose, CA), we purchased anti-CD19-PE, anti-CD19-FITC. The antibodies used for cell sorting were anti-CD19 PC5 from Immunotech SA (Marseille, France) and anti-CD27 PE from Becton Dickinson, Biosciences Pharmingen (San Diego, CA, USA).","[{'offsets': [[112, 119]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[121, 128]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[130, 137]], 'text': ['BMPR-II'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 147]], 'text': ['Act-RIIA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[152, 160]], 'text': ['Act-RIIb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[228, 233]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[309, 314]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[371, 376]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[402, 407]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[469, 474]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[600, 605]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[607, 609]], 'text': ['-5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[616, 617]], 'text': ['8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 693]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[694, 695]], 'text': ['3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1040, 1050]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1128, 1132]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1142, 1146]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1200, 1204]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1257, 1261]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[669, 686]], 'text': ['Expression levels'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[769, 776]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T22'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}]",[]
28,PMC-2222968-25-Caption-Figure_1,"Th2 Cells Cannot Induce FOXP3 Expression
(A) Human T cells were activated with plate-bound anti-CD3/CD28 with or without TGF-beta as indicated on the x-axis of (B). Cells were harvested after 5 days and FOXP3 mRNA was quantified by real-time PCR. Bars show the mean +/- SD of 4 independent experiments.
(B) In vitro differentiated Th1, Th2, or iTreg cells were activated with anti-CD3/CD28, TGF-beta, or anti-IL-4 as indicated. The phenotype of these cells was confirmed by FACS and proliferation analysis (Figure S1). Bars show the mean +/- SD of four independent experiments.","[{'offsets': [[24, 29]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[96, 99]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[100, 104]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[121, 129]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[203, 208]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[381, 384]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[385, 389]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[391, 399]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[409, 413]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[17, 23]], 'text': ['Induce'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[30, 40]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T11'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}]",[]
29,PMC-3359311-12-Materials_and_Methods,"CF and control subject PBMCs
The diagnosis of CF was established by typical clinical features, increased sweat chloride concentrations (>60 mmol/l), and detection of CF-inducing mutations. All patients with CF were clinically stable at the time of blood donation, and we excluded any subjects who were receiving systemic corticosteroids due to potential immunomodulatory activity. Control samples were provided by healthy adult volunteers. In previously published work we have demonstrated that TLR-mediated inflammatory responses are stable in humans from birth to 60 years old [63], therefore did not age-match the CF patients and control subjects. Peripheral blood was collected in sodium heparin tubes (BD Biosciences) and PBMCs were isolated using density gradient centrifugation on Ficoll-Paque(TM) Plus (GE Healthcare). The layer containing PBMCs was isolated, washed twice in PBS and resuspended in complete RPMI. Cells were enumerated by trypan blue exclusion using the Countess automated cell counter (Invitrogen). For derivation of macrophages from monocytes, monocytes were allowed to adhere to plastic for 2 hours in RPMI 1640 after which non-adherent cells were removed. Monocytes were allowed to differentiate in RPMI 1640 supplemented with 10% human AB serum for 10 days.",[],[],[],[],[],[]
30,PMC-1134658-05-Results,"BMP-6 induces phosphorylation of Smad1/5/8
Upon ligand binding, the type II receptor transphosphorylates and activates the type I receptor. Type I receptors can signal via several pathways. We examined the effect of BMP-6 on Smad phosphorylation, as the activation of Smad is considered to be a major signalling pathway for BMPs [17]. B cells were cultured in serum-free media over night and then treated with BMP-6 for various time points. Total protein lysates were prepared, and the amounts of the phosphorylated forms of Smad1/5/8 were determined by western blot analysis. Interestingly, treatment with 500 ng/ml BMP-6 induced phosphorylation of Smad. The BMP-6 induced phosphorylation was high at the earliest time point tested (15 minutes), and remained high for at least 48 hours (Figure 5). A similar phosphorylation was observed in Ramos cells, but not in HL60 cells (Figure 6). Furthermore, we also tested whether other known downstream signalling pathways of BMP-6 could be triggered by BMP-6 in human B cells. However, we did not observe any significant changes in the level of phospho-STAT3 or phospho-p38 upon BMP-6 treatment of B cells (data not shown).","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[33, 38]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[39, 40]], 'text': ['5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[41, 42]], 'text': ['8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[216, 221]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[410, 415]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[525, 530]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[531, 532]], 'text': ['5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[533, 534]], 'text': ['8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[617, 622]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[660, 665]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[970, 975]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[998, 1003]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1098, 1103]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1115, 1118]], 'text': ['p38'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1124, 1129]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[6, 13]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[14, 29]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T19'}, {'offsets': [[501, 515]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T20'}, {'offsets': [[623, 630]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[631, 646]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T22'}, {'offsets': [[650, 654]], 'text': ['Smad'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[666, 673]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[674, 689]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T24'}, {'offsets': [[1066, 1073]], 'text': ['changes'], 'type': 'Regulation', 'id': 'T25'}, {'offsets': [[1090, 1097]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T26'}, {'offsets': [[1107, 1114]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T27'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T1']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T1']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T20', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T10']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T21', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T10']}}, {'trigger': 'T22', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T21', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T10']}}, {'trigger': 'T22', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T23', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T11']}}, {'trigger': 'T24', 'id': 'E17', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T23', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T11']}}, {'trigger': 'T24', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T23', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T11']}}, {'trigger': 'T24', 'id': 'E21', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T25', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T16']}}, {'trigger': 'T26', 'id': 'E23', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T25', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T16']}}, {'trigger': 'T27', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]","[{'id': 'R1', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T8', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}]",[]
31,PMC-3359311-08-Results,"Disruption of CFTR activity does not increase IL-1beta production in PBMCs and THP-1 cells
A previous study has indicated a role for chloride ion concentration in suppression of NLRP3 inflammasome activation [34]. To determine whether CFTR dysfunction alters IL-1beta production, THP-1 cells and PBMCs from CF patients and healthy controls were treated with the CFTR inhibitor, CFTRinh172, prior to simulation with live P. aeruginosa. Treatment with CFTRinh172 did not alter IL-1beta or IL-8 production in control subjects or CF patients (Fig. 8a-b). Similarly, IL-1beta production was not different in monocyte-derived macrophages or THP-1 reporter cells treated with CFTRinh172 (Fig. 8c-d). IL-8 (Fig. 8e) and NF-kappaB activity (Fig. 8f) were also unchanged in CFTRinh172-treated THP-1 reporter cells.","[{'offsets': [[46, 54]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[259, 267]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[475, 483]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[562, 570]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[37, 45]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[55, 65]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[252, 258]], 'text': ['alters'], 'type': 'Regulation', 'id': 'T7'}, {'offsets': [[268, 278]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[469, 474]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T9'}, {'offsets': [[492, 502]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[571, 581]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T11'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}]",[]
32,PMC-3333881-13-RESULTS,"Tat counteracts the IkappaB-alpha inhibition of p65 by competing the repressor binding
We further investigated the physical interaction of Tat with IkappaB-alpha using in vitro translated proteins in coimmunoprecipitation assays. For mapping the interaction domains, we used the following Tat mutants: Tat T,N(23,24)A, Tat C(22,25,27)A, Tat K(50,51)A and Tat R(49-57)A (Figure 3A). IkappaB-alpha coimmunoprecipitated with all Tat proteins, except Tat R(49-57)A (Figure 3B). These results indicated that the arginine-rich domain of Tat was involved in the binding to IkappaB-alpha, which was consistent with previous observations (50,51). Moreover, Tat associating with IkappaB-alpha competed the binding of IkappaB-alpha to p65 in a dose-dependent manner (Figure 3C, lanes 3-5), while Tat R(49-57)A, which lacked the binding site for IkappaB-alpha, did not associate with IkappaB-alpha and did not compete the binding of IkappaB-alpha to p65 (Figure 3C, lanes 6-8).
Next, we evaluated whether Tat counteracted the IkappaB-alpha-mediated inhibition of p65 binding to DNA by incubating in vitro translated p65 and IkappaB-alpha proteins with the NF-kappaB probe in presence or absence of Tat followed by EMSA. The p65 DNA binding activity was inhibited by IkappaB-alpha and restored in a dose-dependent manner by wild-type Tat, and not by Tat R(49-57) (Figure 3D). Further, we analysed the Tat effect on the IkappaB-alpha repression of p65 transcriptional activity by transfecting p50-/-p65-/-MEFs with the NF-kappaB-Luc reporter together with expression vectors of p65 and IkappaB-alpha, in presence or absence of Tat. IkappaB-alpha inhibited the p65-dependent expression of the luciferase gene, which was restored in a dose-dependent manner by wild-type Tat, and not by Tat R(49-57)A (Figure 3E). Altogether these results indicated that Tat counteracts the IkappaB-alpha repression of the p65 DNA-binding and transcriptional activity by associating with IkappaB-alpha and competing the repressor binding to p65.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[20, 33]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[48, 51]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 142]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[148, 161]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[289, 292]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[302, 317]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[319, 335]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[337, 350]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[355, 368]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[382, 395]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[426, 429]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[447, 460]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[531, 534]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[566, 579]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[648, 651]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[669, 682]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[707, 720]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[724, 727]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[785, 798]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[834, 847]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[872, 885]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[921, 934]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[938, 941]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[993, 996]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1014, 1027]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1051, 1054]], 'text': ['p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1104, 1107]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1112, 1125]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1186, 1189]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1212, 1215]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1254, 1267]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1321, 1324]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1337, 1349]], 'text': ['Tat R(49-57)'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1388, 1391]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1406, 1419]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1434, 1437]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1479, 1482]], 'text': ['p50'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1485, 1488]], 'text': ['p65'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1515, 1518]], 'text': ['Luc'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1564, 1567]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1572, 1585]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1613, 1616]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1618, 1631]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1646, 1649]], 'text': ['p65'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1678, 1688]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1754, 1757]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1770, 1783]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1837, 1840]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1857, 1870]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[1889, 1892]], 'text': ['p65'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[1954, 1967]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2007, 2010]], 'text': ['p65'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4, 15]], 'text': ['counteracts'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[34, 44]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[55, 64]], 'text': ['competing'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[65, 78]], 'text': ['the repressor'], 'type': 'Anaphora', 'id': 'T54'}, {'offsets': [[79, 86]], 'text': ['binding'], 'type': 'Binding', 'id': 'T59'}, {'offsets': [[124, 135]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[396, 416]], 'text': ['coimmunoprecipitated'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[507, 527]], 'text': ['arginine-rich domain'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[539, 547]], 'text': ['involved'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[555, 562]], 'text': ['binding'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[652, 663]], 'text': ['associating'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[683, 691]], 'text': ['competed'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[696, 703]], 'text': ['binding'], 'type': 'Binding', 'id': 'T67'}, {'offsets': [[806, 812]], 'text': ['lacked'], 'type': 'Negative_regulation', 'id': 'T68'}, {'offsets': [[817, 824]], 'text': ['binding'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[825, 829]], 'text': ['site'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[857, 866]], 'text': ['associate'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[898, 905]], 'text': ['compete'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[910, 917]], 'text': ['binding'], 'type': 'Binding', 'id': 'T73'}, {'offsets': [[997, 1009]], 'text': ['counteracted'], 'type': 'Negative_regulation', 'id': 'T74'}, {'offsets': [[1037, 1047]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[1055, 1062]], 'text': ['binding'], 'type': 'Binding', 'id': 'T76'}, {'offsets': [[1220, 1227]], 'text': ['binding'], 'type': 'Binding', 'id': 'T77'}, {'offsets': [[1241, 1250]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T78'}, {'offsets': [[1272, 1280]], 'text': ['restored'], 'type': 'Negative_regulation', 'id': 'T79'}, {'offsets': [[1632, 1641]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[1650, 1659]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[1660, 1670]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T82'}, {'offsets': [[1705, 1713]], 'text': ['restored'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[1841, 1852]], 'text': ['counteracts'], 'type': 'Negative_regulation', 'id': 'T84'}, {'offsets': [[1871, 1881]], 'text': ['repression'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[1897, 1904]], 'text': ['binding'], 'type': 'Binding', 'id': 'T86'}, {'offsets': [[1937, 1948]], 'text': ['associating'], 'type': 'Binding', 'id': 'T87'}, {'offsets': [[1972, 1981]], 'text': ['competing'], 'type': 'Negative_regulation', 'id': 'T88'}, {'offsets': [[1982, 1995]], 'text': ['the repressor'], 'type': 'Anaphora', 'id': 'T55'}, {'offsets': [[1996, 2003]], 'text': ['binding'], 'type': 'Binding', 'id': 'T89'}]","[{'trigger': 'T56', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'E3']}}, {'trigger': 'T57', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T2']}}, {'trigger': 'T58', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T1']}}, {'trigger': 'T59', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T60', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T4', 'T5']}}, {'trigger': 'T61', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T11', 'T12']}}, {'trigger': 'T61', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T11', 'T13']}}, {'trigger': 'T63', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E9', 'T14', 'T62']}}, {'trigger': 'T64', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T15']}}, {'trigger': 'T65', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T66', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E10']}}, {'trigger': 'T67', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T18', 'T19']}}, {'trigger': 'T68', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T16', 'T70']}}, {'trigger': 'T69', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T16', 'T21', 'T70']}}, {'trigger': 'T71', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T20', 'T22']}}, {'trigger': 'T72', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T20']}}, {'trigger': 'T73', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T23', 'T24']}}, {'trigger': 'T74', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T25']}}, {'trigger': 'T75', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T26']}}, {'trigger': 'T76', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T77', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T78', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T32']}}, {'trigger': 'T79', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T33']}}, {'trigger': 'T79', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T34']}}, {'trigger': 'T80', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T44']}}, {'trigger': 'T81', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T45']}}, {'trigger': 'T82', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T83', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T47']}}, {'trigger': 'T83', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T48']}}, {'trigger': 'T84', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E32']}}, {'trigger': 'T85', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'T50']}}, {'trigger': 'T87', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T49', 'T52']}}, {'trigger': 'T84', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E34']}}, {'trigger': 'T88', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T49']}}, {'trigger': 'T86', 'id': 'E35', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T89', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T52', 'T53']}}]","[{'id': 'R1', 'head': {'ref_id': 'T54', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T55', 'role': 'Subject'}, 'tail': {'ref_id': 'T52', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E29', 'value': ''}]",[]
33,PMC-2800179-23-Caption-Figure_3,"Degraded CGN induced THP1 cell cycle arrest in G1 phase.
THP-1 cells in exponential growth phase were incubated in the presence or absence of carrageenan for 24 h before being stained with propidium iodide. Cell DNA content was then analyzed by flow cytometry. A: Histograms of cells treated with medium only (control), 10 kDa dCGN (C10), or 40 kDa dCGN (C40). B: Percentage of cells in each phase of the cell cycle when treated with medium only (control), different concentrations of 10 kDa dCGN (C10), of 40 kDa dCGN (C40), or of native CGN (Native).",[],[],[],[],[],[]
34,PMC-2222968-09-Materials_and_Methods,"Mice.
Normal B6 mice were purchased from the Jackson Laboratories (Bar Harbor, Maine). Transgenic DO11.10 mice, expressing a T cell receptor for OVA323-339 peptide in the context of H-2d, were backcrossed with mice expressing GATA-3, driven by the human CD2 locus control region (CD2-GATA3) [22], resulting in DO11.10xCD2-GATA3 mice. Mice used for experiments were backcrossed on a BALB/c background for a minimum of eight generations and used at an age of 8-12 wk. Mice were housed under specific pathogen-free conditions and all animal studies were performed according to institutional and state guidelines.","[{'offsets': [[226, 232]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[254, 257]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[280, 283]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[284, 289]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[318, 321]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[322, 327]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[215, 225]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
35,PMC-3359311-23-Caption-Figure_5,"PBMCs from CF patients do not produce increased amounts of IL-1beta.
PBMCs from CF patients (n = 17-20) and healthy controls (n = 15-19) were primed with LPS (10 ng/ml) overnight and stimulated with P. aeruginosa PAO1 (MOI = 1), P. aeruginosa PAO1 lacking exsA (MOI = 1), ATP (5 mM), or Poly(dA:dT) (1 microg/ml) for 24 hours. P. aeruginosa lacking exsA was used as a type III secretion control in comparison with wild-type P. aeruginosa. Supernatants were assayed for (A) IL-1beta and (B) IL-8.","[{'offsets': [[59, 67]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[256, 260]], 'text': ['exsA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[349, 353]], 'text': ['exsA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[473, 481]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[30, 37]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[38, 47]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[248, 255]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T7'}, {'offsets': [[341, 348]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T8'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}]",[]
36,PMC-2222968-00-TIAB,"GATA3-Driven Th2 Responses Inhibit TGF-beta1-Induced FOXP3 Expression and the Formation of Regulatory T Cells
Transcription factors act in concert to induce lineage commitment towards Th1, Th2, or T regulatory (Treg) cells, and their counter-regulatory mechanisms were shown to be critical for polarization between Th1 and Th2 phenotypes. FOXP3 is an essential transcription factor for natural, thymus-derived (nTreg) and inducible Treg (iTreg) commitment; however, the mechanisms regulating its expression are as yet unknown. We describe a mechanism controlling iTreg polarization, which is overruled by the Th2 differentiation pathway. We demonstrated that interleukin 4 (IL-4) present at the time of T cell priming inhibits FOXP3. This inhibitory mechanism was also confirmed in Th2 cells and in T cells of transgenic mice overexpressing GATA-3 in T cells, which are shown to be deficient in transforming growth factor (TGF)-beta-mediated FOXP3 induction. This inhibition is mediated by direct binding of GATA3 to the FOXP3 promoter, which represses its transactivation process. Therefore, this study provides a new understanding of tolerance development, controlled by a type 2 immune response. IL-4 treatment in mice reduces iTreg cell frequency, highlighting that therapeutic approaches that target IL-4 or GATA3 might provide new preventive strategies facilitating tolerance induction particularly in Th2-mediated diseases, such as allergy.","[{'offsets': [[0, 5]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[35, 44]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 58]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[339, 344]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[659, 672]], 'text': ['interleukin 4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[674, 678]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[727, 732]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[841, 847]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[895, 932]], 'text': ['transforming growth factor (TGF)-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[942, 947]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1008, 1013]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1021, 1026]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1199, 1203]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1305, 1309]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1313, 1318]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[27, 34]], 'text': ['Inhibit'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[45, 52]], 'text': ['Induced'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[59, 69]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[481, 491]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[492, 495]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[496, 506]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[718, 726]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T23'}, {'offsets': [[826, 840]], 'text': ['overexpressing'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[882, 891]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[933, 941]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[948, 957]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[959, 974]], 'text': ['This inhibition'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[978, 986]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[997, 1004]], 'text': ['binding'], 'type': 'Binding', 'id': 'T29'}, {'offsets': [[1027, 1035]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T30'}, {'offsets': [[1298, 1304]], 'text': ['target'], 'type': 'Regulation', 'id': 'T31'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T2']}}, {'trigger': 'T20', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T21', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T22', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'T5']}}, {'trigger': 'T24', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T26', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T9']}}, {'trigger': 'T27', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E12']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T11', 'T12', 'T30']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]","[{'id': 'R1', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T25', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T5', 'T6']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
37,PMC-1942070-06-Results,"3.3Antigen receptor regulated signalling pathways in PKD-null DT40 B cells
To further explore the contribution of PKD kinases to DT40 B cell biology we investigated whether specific BCR-regulated signalling events were defective in the PKD-null B cells. Initial experiments revealed that surface expression of the BCR was reduced in PKD1/3-/- (and in PKD1/3-/-:Flag-PKD3+ve) cells compared to wild-type DT40 B cells (Fig. 3A and data not shown). Nevertheless, BCR-crosslinking of PKD1/3-/- cells was sufficient to induce the activation of a number of signalling cascades, similar to that observed in wild-type cells (Fig. 3B). Hence, BCR-induced activation of the Akt, mTOR/p70 S6 kinase (as shown by S6 ribosomal protein phosphorylation) and MAPK signalling pathways was clearly detectable in PKD1/3-null B cells (Fig. 3B). Furthermore, enhanced tyrosine phosphorylation of multiple cellular proteins as well as an increase in intracellular calcium levels was also observed following BCR stimulation of PKD1/3-null B cells (data not shown). We did observe that the strength of BCR (but not phorbol ester)-induced regulation of the Erk1-RSK1 signalling pathway was reduced in PKD1/3-/- B cells compared to wild-type B cells (Fig. 3B). One interpretation of this data is that PKD enzymes may modulate Erk activation. Indeed, PKD enzymes have previously been linked to the growth factor-regulated Erk signalling in fibroblast and endothelial cell lines [33-35]. However, BCR-induced Erk phosphorylation was also reduced in PKD1/3-/--Flag-PKD3+ B cells (data not shown) suggesting that reduced BCR levels on the surface of PKD1/3-/- (and PKD1/3-/--Flag-PKD3+) B cells may itself impact on the strength of activation of this specific intracellular signalling pathway.
To search for other potential PKD targets that may show defective regulation in PKD1/3-/- DT40 B cells, we used a PKD substrate phospho-antibody that recognises consensus phosphorylation sequences targeted by PKD enzymes (LxRxxpS/T) [36]. As shown in Fig. 3C, phorbol ester- and BCR-induced phosphorylation of cellular substrates detected by this phospho-antibody was similar in wild-type and PKD1/3-/- cells and is therefore independent of PKD enzymes. However, pretreatment of both wild-type and PKD1/3-/- DT40 B cells with GF109203X, a bisindoylmaleimide derivative that inhibits PKCs prevented the induction of proteins that contain phosphorylated LxRxxS/T motifs. Thus loss of PKD1/3 enzymes does not globally disrupt the phosphorylation of cellular proteins that contain LxRxxpS/T motifs. This result is perhaps not surprising as LxRxxS/T motifs also act as good substrates for other serine/threonine kinases such as MAPKAPK2. However these experiments do provide further evidence that phosphospecific antisera are not sufficiently selective to be designated kinase specific substrate antisera.
BCR-induced signalling pathways culminate in the activation of gene transcription events that control B cell survival, proliferation and function. In this context, it has been proposed that PKD family members control of gene transcription through activation of the NFkappaB transcription factor. Thus, PKD-mediated activation of NFkappaB occurs downstream of a variety of different signals, including mROS/oxidative stress, lysophosphatidic acid and the Bcr-Abl oncogene [17,21,23,30,37]. Furthermore, expression of an activated PKD1 mutant enhances HPK1-mediated NFkappaB activation [38]. In B cells, NFkappaB is known to be regulated via DAG and PKCbeta [39,40] but whether PKDs are key intermediaries for NFkappaB regulation has not been explored.
The data (Fig. 4A) show that NFkappaB transcriptional activity was strongly induced in both wild-type and PKD1/3-/- DT40 B cells in response to either phorbol ester or BCR stimulation. In contrast, BCR and phorbol ester-induced NFkappaB transcriptional activity was abolished in PKCbeta-/- DT40 B cells (Fig. 4A), although strong activation of PKD kinases (as assessed by autophosphorylation of PKD1 at S916) was observed in the PKCbeta-/- cells (Fig. 4B). Thus, PKD kinases are neither essential nor sufficient to mediate BCR-induced NFkappaB activation in DT40 B cells and hence do not participate in DAG/PKC mediated control of NFkappaB.","[{'offsets': [[333, 337]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[338, 339]], 'text': ['3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[351, 355]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[356, 357]], 'text': ['3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[366, 370]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[480, 484]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[485, 486]], 'text': ['3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[664, 667]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[669, 673]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[701, 721]], 'text': ['S6 ribosomal protein'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[794, 798]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[799, 800]], 'text': ['3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1004, 1008]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1009, 1010]], 'text': ['3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1132, 1136]], 'text': ['Erk1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1137, 1141]], 'text': ['RSK1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1176, 1180]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1181, 1182]], 'text': ['3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1521, 1525]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1526, 1527]], 'text': ['3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1536, 1540]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1620, 1624]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1625, 1626]], 'text': ['3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1635, 1639]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1640, 1641]], 'text': ['3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1650, 1654]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1844, 1848]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1849, 1850]], 'text': ['3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2157, 2161]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2162, 2163]], 'text': ['3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2262, 2266]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2267, 2268]], 'text': ['3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2446, 2450]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2451, 2452]], 'text': ['3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2687, 2695]], 'text': ['MAPKAPK2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3319, 3335]], 'text': ['Bcr-Abl oncogene'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3394, 3398]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3415, 3419]], 'text': ['HPK1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3513, 3520]], 'text': ['PKCbeta'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3722, 3726]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3727, 3728]], 'text': ['3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3895, 3902]], 'text': ['PKCbeta'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4011, 4015]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4045, 4052]], 'text': ['PKCbeta'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[638, 645]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[646, 656]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[722, 737]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T47'}, {'offsets': [[780, 790]], 'text': ['detectable'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[801, 805]], 'text': ['null'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[2438, 2442]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[3367, 3393]], 'text': ['expression of an activated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[3988, 4007]], 'text': ['autophosphorylation'], 'type': 'Phosphorylation', 'id': 'T52'}, {'offsets': [[4019, 4023]], 'text': ['S916'], 'type': 'Entity', 'id': 'T53'}, {'offsets': [[4029, 4037]], 'text': ['observed'], 'type': 'Positive_regulation', 'id': 'T54'}]","[{'trigger': 'T45', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T46', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T45', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T46', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T45', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T46', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T47', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T48', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E9']}}, {'trigger': 'T49', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T48', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E11']}}, {'trigger': 'T49', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T48', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E9']}}, {'trigger': 'T48', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E11']}}, {'trigger': 'T48', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'E9']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'E11']}}, {'trigger': 'T50', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T50', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T52', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T43', 'T53']}}, {'trigger': 'T54', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}]",[]
38,PMC-2806624-01-INTRODUCTION,"Regulatory T (T reg) cells expressing the transcription factor forkhead box P3 (FOXP3, human; Foxp3, mouse) play an essential role in controlling immune responses to autoantigens, allergens, tumor antigens, transplantation antigens, and infectious agents (Hori et al., 2003;Akdis, 2006). Foxp3 is a member of the forkhead/winged-helix family of transcriptional regulators, and its expression in T reg cells is essential for their development and function (Fontenot et al., 2003;Williams and Rudensky, 2007). A spontaneous mutation of the X-linkedFoxp3gene inscurfymice causes an autoimmune-like disease, whereas the mutation in humans leads to immunodysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome that is also a severe multiorgan autoimmune disease with hyper-IgE (Ziegler, 2006).Although the essential role of Foxp3 in central and peripheral tolerance has been extensively studied, its regulation, cooperation with other transcription factors, and how it functions in inducible T reg (iT reg) cells to suppress various target genes is mostly not yet understood. It is known that Foxp3 cooperates with the nuclear factor of activated T cells (NFAT) or nuclear factor-kappa B (NF-kappaB) to regulate the transcription of different target genes (Schubert et al., 2001;Bettelli et al., 2005;Wu et al., 2006). The Th2 cytokine IL-4 inhibits FOXP3 expression during T cell priming. GATA3 binds to theFOXP3promoter and can repress the FOXP3 trans-activation process directly in Th2 cells (Mantel et al., 2007). It was further demonstrated that both Th1 and Th2 transcription factors T-bet and GATA3 oppose peripheral induction of Foxp3+T reg cells in mice through STAT1-, STAT4-, and STAT6-dependent pathways (Wei et al., 2007). Although natural T reg (nT reg) cells that differentiate in the thymus are characterized by their stable Foxp3 expression, the generation of iT reg cells specific for allergens, alloantigens, and autoantigens in the periphery has been associated with a transient Foxp3+phenotype (Fontenot et al., 2003;Hori et al., 2003). The crucial role of TGF-beta in their generation has been demonstrated.The RUNX gene family (Runt-related transcription factor, acute myeloid leukemia [AML], core-binding factor-alpha [CBFalpha], and polyoma enhancer-binding protein-2alpha [PEBP2alpha]) contains three members, RUNX1 (AML1/CBFA2/PEBP2alphaB), RUNX2 (AML3/CBFA1/ PEBP2alphaA), and RUNX3 (AML2/CBFA3/PEBP2alphaC). They are essential transcriptional regulators of different developmental pathways. RUNX2 is mostly important for bone development and osteoblast differentiation (Komori et al., 1997). RUNX1 plays an important role in hematopoiesis during development, and RUNX3 has important functions in thymogenesis and neurogenesis (Wang et al., 1996;Inoue et al., 2002;Levanon et al., 2002). RUNX1 and RUNX3 also work together in the establishment of lineage specification of T lymphocytes (Taniuchi et al., 2002;Egawa et al., 2007).RUNX1is a frequent target for chromosomal translocations associated with leukemias (Look, 1997), andRUNX3methylation and silencing is observed in various human epithelial cancers (Blyth et al., 2005).RUNX family members share the Runt domain, which is responsible for DNA binding (Ito, 1999). The Runt domain-containing protein constitutes the alpha-chain partner of the heterodimeric CBF complex. RUNX proteins heterodimerize with the non-DNA-binding partner, CBFbeta, which increases the affinity for DNA binding and stabilizes the complex by preventing ubiquitin-dependent degradation (Wang et al., 1993). The CBF complexes regulate the expression of cellular genes through binding to promoters or enhancer elements. The effects of the RUNX-CBFbeta complex regulation are clearly cell lineage and stage specific. They include the crucial choices between cell-cycle exit and continued proliferation, as well as between cell differentiation and self-renewal (Blyth et al., 2005).Because of the involvement of RUNX mutations in different autoimmune diseases and the known interaction with TGF-beta, we investigated the impact of RUNX1 and RUNX3 on the expression of FOXP3 and subsequently on the development and function of iT reg cells. This study demonstrates that RUNX1 and RUNX3 induced by TGF-beta are involved in the development and suppressive function of Foxp3+iT reg cells.","[{'offsets': [[63, 78]], 'text': ['forkhead box P3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[80, 85]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[94, 99]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[288, 293]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[546, 551]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[834, 839]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1103, 1108]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1346, 1350]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1360, 1365]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1400, 1405]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1418, 1423]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1452, 1457]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1600, 1605]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1610, 1615]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1647, 1652]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1681, 1686]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1689, 1694]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1701, 1706]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1851, 1856]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2009, 2014]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2088, 2096]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2143, 2147]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2346, 2351]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2353, 2357]], 'text': ['AML1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2358, 2363]], 'text': ['CBFA2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2364, 2375]], 'text': ['PEBP2alphaB'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2378, 2383]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2385, 2389]], 'text': ['AML3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2390, 2395]], 'text': ['CBFA1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2397, 2408]], 'text': ['PEBP2alphaA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2415, 2420]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2530, 2535]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2631, 2636]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2702, 2707]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2826, 2831]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2836, 2841]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2967, 2972]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3067, 3072]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3167, 3171]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3352, 3355]], 'text': ['CBF'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3428, 3435]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3523, 3532]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3580, 3583]], 'text': ['CBF'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3706, 3710]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3711, 3718]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3977, 3981]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4056, 4064]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4096, 4101]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4106, 4111]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4133, 4138]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4234, 4239]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4244, 4249]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4261, 4269]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4330, 4335]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[27, 37]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[377, 380]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T55'}, {'offsets': [[381, 391]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[906, 909]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T56'}, {'offsets': [[910, 920]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T59'}, {'offsets': [[1351, 1359]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[1366, 1376]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[1406, 1411]], 'text': ['binds'], 'type': 'Binding', 'id': 'T62'}, {'offsets': [[1423, 1431]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T63'}, {'offsets': [[1440, 1447]], 'text': ['repress'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[1458, 1474]], 'text': ['trans-activation'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[1616, 1622]], 'text': ['oppose'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[1634, 1643]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[1707, 1716]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1857, 1867]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T69'}, {'offsets': [[3379, 3393]], 'text': ['heterodimerize'], 'type': 'Binding', 'id': 'T70'}, {'offsets': [[3644, 3651]], 'text': ['binding'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[4039, 4050]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T72'}, {'offsets': [[4086, 4092]], 'text': ['impact'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[4119, 4129]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[4250, 4257]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T75'}]","[{'trigger': 'T57', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T58', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T59', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T60', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T8']}}, {'trigger': 'T61', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T62', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T10', 'T11', 'T63']}}, {'trigger': 'T64', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E6']}}, {'trigger': 'T65', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T66', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T13']}}, {'trigger': 'T67', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T66', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T14']}}, {'trigger': 'T68', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T16']}}, {'trigger': 'T68', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T17']}}, {'trigger': 'T68', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T18']}}, {'trigger': 'T68', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T16']}}, {'trigger': 'T68', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T17']}}, {'trigger': 'T68', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T18']}}, {'trigger': 'T69', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T70', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T71', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T72', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T46', 'T47']}}, {'trigger': 'T73', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T48']}}, {'trigger': 'T74', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T73', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T49']}}, {'trigger': 'T75', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T51', 'T53']}}, {'trigger': 'T75', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T52', 'T53']}}]","[{'id': 'R1', 'head': {'ref_id': 'T55', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T56', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T1', 'T2', 'T3']}, {'id': '*', 'ref_ids': ['T23', 'T26', 'T24', 'T25']}, {'id': '*', 'ref_ids': ['T27', 'T29', 'T30', 'T28']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E22', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E24', 'value': ''}]",[]
39,PMC-2674207-01-Introduction,"Inflammation in allergic diseases such as asthma, rhinitis, and atopic dermatitis is mediated via expression of the cytokines interleukin (IL)-4, IL-5, and IL-13 from T helper-2 (Th2) cells. IL-4 and IL-13 regulate the expression of IgE from B lymphocytes, whereas IL-5 plays a key role in eosinophilic inflammation [1]. Th2 cytokines are regulated by the zinc finger transcription factor GATA-3, which is predominantly expressed in Th2 cells [2],[3]. GATA-3 determines Th2 cell differentiation and selectively activates the promoters of IL-4, IL-5, and IL-13 through chromatin remodelling [4]-[7]. The key role of GATA-3 in allergic airway inflammation has been demonstrated in mice by the reduced release of Th2 cytokines in animals treated with dominant-negative mutants of GATA-3 and by local application of antisense oligonucleotides to GATA-3 [8],[9]. Furthermore, conditional knock-out of the Gata3 gene in mice reduces expression of Th2 cytokines in vitro and in vivo [10], and similar results have been reported in isolated murine CD4+ lymphocytes [11]. Finally, knockdown of GATA-3 expression using siRNA in human T cells results in loss of anti-CD3/CD28-mediated Th2 cytokine expression [12].
In order for GATA-3 to regulate gene expression, it must translocate from the cytoplasm into the nucleus to access its target genes. Enhanced nuclear expression of GATA-3 following T cell receptor activation was first demonstrated in murine T cells [13] and was recently confirmed in human T cells following T cell receptor and co-receptor stimulation [12]. GATA-3 contains a classical nuclear import signal [14] and is transported into the nucleus by the nuclear import protein importin-alpha (also known as karyopherin-alpha) [12]. Deletion of a region encompassing the GATA-3 nuclear localisation sequence (NLS) region in murine and human cells prevents its nuclear localisation [12],[14]. The affinity of the importin-alpha-NLS interaction is regulated by phosphorylation [15], and we have shown that p38 mitogen-activated protein kinase (MAPK) plays a critical role in phosphorylating GATA-3 to enhance its interaction with importin-alpha and subsequent transport into the nucleus [12].
Corticosteroids are highly effective in the treatment of allergic inflammation, with marked suppression of Th2 cytokines in airways of patients with asthma [16]. Corticosteroids mediate their anti-inflammatory effects through binding to glucocorticoid receptors (GRs), which then translocate to the nucleus where they interact with glucocorticoid response elements (GREs) in the promoter regions of steroid-sensitive genes. Alternatively, activated GR interacts with coactivator molecules to suppress the expression of inflammatory genes by inhibiting the action of proinflammatory transcription factors such as nuclear factor-kappaB (NF-kappaB) through the recruitment of co-repressor molecules such as histone deacetylase-2 [17],[18].
Nuclear localisation and retention of GR is mediated through the nuclear localisation sequences NL1 and NL2 [19], by nuclear retention signals [20], and by control of nuclear export via a chromosomal region maintenance 1 (CRM-1) dependent pathway [21]. NL1, which is similar to the SV40 NLS, binds to importin-alpha [22]. NL1 is activated both by glucocorticoid agonists such as dexamethasone and fluticasone propionate (FP) and by glucocorticoid antagonists such as mifepristone (RU486) [23]. NL1 can be mutated, and the resulting GR still translocates to the nucleus in response to ligands, but via interaction with importin 7, an event that requires an as-yet unknown component [23]. NL2 is poorly defined, residing in the ligand-binding domain, and much less is known about its mechanism of GR import [24]. A variety of other factors are also important for the regulation of GR activation and nuclear import including chaperones such as Hsp90 and other immunophilins [24]-[26] and FK506-binding proteins that may be linked to dynein and/or peptidylprolyl isomerase [27],[28].
However, the molecular basis for the inhibition of Th2 cytokines by corticosteroids is not well understood, because the genes encoding IL-4, IL-5, and IL-13 do not have any recognisable GRE sequence [29] and are only partly regulated by NF-kappaB in human cells [30]-[32]. Using overexpression and CAT-reporter genes, Lavender and colleagues [33] have shown that GR reduced GATA-3-mediated IL-5 and -13 promoter activity in human CD4+ T cells. The authors postulated that local recruitment of GR may alter the ability of GATA-3 either to bind to its target site, to cause transcriptional up-regulation, or to maintain an environment that is permissive for transcription.
We therefore investigated the effects of a synthetic corticosteroid, FP, on GATA-3 phosphorylation and nuclear translocation in a T lymphocyte cell line (HuT-78) and in peripheral blood mononuclear cells activated by anti-CD3 and anti-CD28 antibodies in vitro. We also studied the effects of inhaled fluticasone therapy on GATA-3 subcellular localization in peripheral blood mononuclear cells (PBMCs) from patients with asthma.","[{'offsets': [[126, 144]], 'text': ['interleukin (IL)-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[146, 150]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[156, 161]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[191, 195]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[200, 205]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[265, 269]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[389, 395]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[452, 458]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[538, 542]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[544, 548]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[554, 559]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[615, 621]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[777, 783]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[842, 848]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[900, 905]], 'text': ['Gata3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1040, 1043]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1085, 1091]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1217, 1223]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1368, 1374]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1562, 1568]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1776, 1782]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2094, 2100]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2433, 2457]], 'text': ['glucocorticoid receptors'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2459, 2462]], 'text': ['GRs'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2645, 2647]], 'text': ['GR'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2900, 2921]], 'text': ['histone deacetylase-2'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2971, 2973]], 'text': ['GR'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3121, 3153]], 'text': ['chromosomal region maintenance 1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3155, 3160]], 'text': ['CRM-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3465, 3467]], 'text': ['GR'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3551, 3561]], 'text': ['importin 7'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3728, 3730]], 'text': ['GR'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3812, 3814]], 'text': ['GR'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4148, 4152]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4154, 4158]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4164, 4169]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4311, 4314]], 'text': ['CAT'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4376, 4378]], 'text': ['GR'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4387, 4393]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4403, 4407]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4412, 4415]], 'text': ['-13'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4443, 4446]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4506, 4508]], 'text': ['GR'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4534, 4540]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4760, 4766]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5007, 5013]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[397, 402]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T47'}, {'offsets': [[420, 429]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[511, 520]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[525, 534]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[1072, 1081]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[1092, 1102]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[1253, 1255]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T48'}, {'offsets': [[1261, 1272]], 'text': ['translocate'], 'type': 'Localization', 'id': 'T58'}, {'offsets': [[1301, 1308]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[1312, 1318]], 'text': ['access'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[1319, 1322]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T49'}, {'offsets': [[1323, 1329]], 'text': ['target'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1346, 1353]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[1354, 1364]], 'text': ['expression'], 'type': 'Localization', 'id': 'T63'}, {'offsets': [[1375, 1384]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[1502, 1511]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[1624, 1635]], 'text': ['transported'], 'type': 'Localization', 'id': 'T66'}, {'offsets': [[1645, 1652]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[2070, 2074]], 'text': ['role'], 'type': 'Regulation', 'id': 'T68'}, {'offsets': [[2078, 2093]], 'text': ['phosphorylating'], 'type': 'Phosphorylation', 'id': 'T69'}, {'offsets': [[2104, 2111]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[2112, 2115]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T50'}, {'offsets': [[2116, 2127]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[2422, 2429]], 'text': ['binding'], 'type': 'Binding', 'id': 'T72'}, {'offsets': [[2465, 2470]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T51'}, {'offsets': [[2476, 2487]], 'text': ['translocate'], 'type': 'Localization', 'id': 'T73'}, {'offsets': [[2495, 2502]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T74'}, {'offsets': [[2509, 2513]], 'text': ['they'], 'type': 'Anaphora', 'id': 'T52'}, {'offsets': [[2514, 2522]], 'text': ['interact'], 'type': 'Binding', 'id': 'T75'}, {'offsets': [[2635, 2644]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[2648, 2657]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T77'}, {'offsets': [[2854, 2865]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T78'}, {'offsets': [[2933, 2940]], 'text': ['Nuclear'], 'type': 'Entity', 'id': 'T79'}, {'offsets': [[2941, 2953]], 'text': ['localisation'], 'type': 'Localization', 'id': 'T80'}, {'offsets': [[2958, 2967]], 'text': ['retention'], 'type': 'Localization', 'id': 'T81'}, {'offsets': [[2977, 2985]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[3089, 3096]], 'text': ['control'], 'type': 'Regulation', 'id': 'T83'}, {'offsets': [[3100, 3107]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T84'}, {'offsets': [[3108, 3114]], 'text': ['export'], 'type': 'Localization', 'id': 'T85'}, {'offsets': [[3162, 3171]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T86'}, {'offsets': [[3186, 3189]], 'text': ['NL1'], 'type': 'Entity', 'id': 'T87'}, {'offsets': [[3225, 3230]], 'text': ['binds'], 'type': 'Binding', 'id': 'T88'}, {'offsets': [[3455, 3464]], 'text': ['resulting'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[3474, 3486]], 'text': ['translocates'], 'type': 'Localization', 'id': 'T90'}, {'offsets': [[3494, 3501]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T91'}, {'offsets': [[3502, 3516]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[3534, 3545]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T93'}, {'offsets': [[3577, 3585]], 'text': ['requires'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[3731, 3737]], 'text': ['import'], 'type': 'Localization', 'id': 'T95'}, {'offsets': [[3780, 3789]], 'text': ['important'], 'type': 'Regulation', 'id': 'T96'}, {'offsets': [[3798, 3808]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T97'}, {'offsets': [[3815, 3825]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[4237, 4246]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T99'}, {'offsets': [[4379, 4386]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T100'}, {'offsets': [[4394, 4402]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[4425, 4433]], 'text': ['activity'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[4491, 4502]], 'text': ['recruitment'], 'type': 'Localization', 'id': 'T103'}, {'offsets': [[4513, 4518]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T104'}, {'offsets': [[4551, 4555]], 'text': ['bind'], 'type': 'Binding', 'id': 'T105'}, {'offsets': [[4714, 4721]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T106'}, {'offsets': [[4767, 4782]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T107'}, {'offsets': [[4787, 4794]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T108'}, {'offsets': [[4795, 4808]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T109'}, {'offsets': [[4965, 4972]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T110'}, {'offsets': [[5026, 5038]], 'text': ['localization'], 'type': 'Localization', 'id': 'T111'}]","[{'trigger': 'T53', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T54', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T10', 'T8', 'T55']}}, {'trigger': 'T54', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T9', 'T8', 'T55']}}, {'trigger': 'T54', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T11', 'T8', 'T55']}}, {'trigger': 'T56', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T57', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T58', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T18', 'T59']}}, {'trigger': 'T60', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T61', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T63', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T19', 'T62']}}, {'trigger': 'T64', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T65', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T66', 'id': 'E13', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T20', 'T67']}}, {'trigger': 'T68', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T69', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T70', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T71', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T72', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T73', 'id': 'E19', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T23', 'T74']}}, {'trigger': 'T75', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T76', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T77', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T78', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T25', 'T26']}}, {'trigger': 'T80', 'id': 'E24', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T27', 'T79']}}, {'trigger': 'T81', 'id': 'E25', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T82', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E27']}}, {'trigger': 'T83', 'id': 'E27', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T82', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E27']}}, {'trigger': 'T85', 'id': 'E29', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T27', 'T84']}}, {'trigger': 'T86', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T28']}}, {'trigger': 'T88', 'id': 'E31', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T27', 'T87']}}, {'trigger': 'T89', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T90', 'id': 'E33', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T30', 'T91']}}, {'trigger': 'T92', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'E35']}}, {'trigger': 'T93', 'id': 'E35', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T30', 'T31']}}, {'trigger': 'T94', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T95', 'id': 'E37', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T96', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T97', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T98', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T99', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T99', 'id': 'E42', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T99', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T100', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T38']}}, {'trigger': 'T101', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T39']}}, {'trigger': 'T100', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'T38']}}, {'trigger': 'T101', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E49', 'T39']}}, {'trigger': 'T102', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T102', 'id': 'E49', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T103', 'id': 'E50', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T104', 'id': 'E51', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E52', 'E50']}}, {'trigger': 'T105', 'id': 'E52', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T106', 'id': 'E53', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E54']}}, {'trigger': 'T107', 'id': 'E54', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T106', 'id': 'E55', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T109', 'id': 'E56', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T45', 'T108']}}, {'trigger': 'T110', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T111', 'id': 'E58', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}]","[{'id': 'R1', 'head': {'ref_id': 'T47', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T48', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T50', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T51', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T52', 'role': 'Subject'}, 'tail': {'ref_id': 'T51', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T23', 'T24']}, {'id': '*', 'ref_ids': ['T28', 'T29']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E51', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E53', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E55', 'value': ''}]",[]
40,PMC-2222968-18-Materials_and_Methods,"TAT-GATA3 transduction.
CD4+CD45RA+ cells were cultured in AIMV medium and transduced with 20 nM, 10 nM, or 500 nM of full-length or truncated GATA3 over the course of 4 h. After 4 h, the cells were washed and activated with soluble anti-CD3 and anti-CD28 and TGF-beta (10 ng/ml). Each day, the TAT proteins were freshly added to the medium. FOXP3 expression was measured after 5 d by intracellular staining.","[{'offsets': [[0, 3]], 'text': ['TAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[4, 9]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[24, 27]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[28, 34]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[143, 148]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[238, 241]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[251, 255]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[260, 268]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[295, 298]], 'text': ['TAT'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[342, 347]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[348, 358]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T11'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
41,PMC-1920263-18-Caption-Figure_3,"Luciferase activities of A3G promoter constructs in different cell lines. (A) A3G promoter 5' deletion constructs of different sizes were cloned into pGL3-Basic luciferase reporter plasmids. Numbering is relative to the major TSS. A putative Sp1/Sp3 consensus site (gray square) is depicted. (B) A3.01 T cells were transiently transfected with the A3G promoter deletion constructs. Numbers on the x-axis refer to the length of the A3G promoter fragments in bp. (C) A3G promoter plasmids were transfected into U937, HepG2 and Huh7 cell lines. Numbers in the legends refer to the length of the A3G promoter fragments in bp. After 48 h, cells were harvested for luciferase assay. Firefly luciferase activities were normalized to coexpressed renilla luciferase activities. Mean values (+/-SD) of a representative experiment performed in triplicate are shown.","[{'offsets': [[0, 10]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[25, 28]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[78, 81]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[161, 171]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[348, 351]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 434]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[465, 468]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[592, 595]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[659, 669]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[685, 695]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[746, 756]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[11, 21]], 'text': ['activities'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[29, 37]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[726, 737]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T14'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['T1', 'T2', 'T13']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],[],[]
42,PMC-3359311-04-Results,"CD14 positive monocytes from CF patients and controls show similar increases in caspase-1 activity upon inflammasome stimulation
Monocytes were identified in PBMC populations using CD14 as a phenotyping marker. CD14 positive monocytes from CF patients and healthy controls showed a significant increase in caspase-1 activation upon stimulation with LPS+ATP, PAO1, and LPS+Poly(dA:dT) (Fig. 4a) but this activation was not different between CF and control subjects (Fig. 4b).","[{'offsets': [[181, 185]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
43,PMC-2674207-18-Results,"Effect on MKP-1
Dexamethasone inhibits p38 MAPK function in a cell type-specific manner through the rapid induction of the dual kinase phosphatase MKP-1 (MAPK phosphatase-1), and this effect lasts for up to 24 h [28]. FP (10-8 M) treatment of HuT-78 cells activated by anti-CD3/CD28 in vitro significantly decreased p38 MAPK phosphorylation (Figure 3A) and activity measured by phosphorylation of the downstream target ATF-2 (Figure 3B). This effect was detected at 30 min and lasted for at least 14 h (Figure 3B). FP (10-8 M) also significantly reduced GATA-3 serine phosphorylation induced by anti-CD3/CD28 stimulation in both a time- and concentration-dependent manner (Figure 3C). This reduction in GATA-3 phosphorylation was also seen with lower concentrations of FP. We found that FP significantly induced MKP-1 mRNA in both a time- and concentration-dependent manner, reaching a plateau at 10-8 M after 10 min (Figure 3D and 3E). However, the effects of FP on GATA-3 nuclear import, importin-alpha association and IL-4 mRNA expression are seen at 10,000-fold lower concentrations (10-12 M, see Figure 2).
Using an in vitro competition assay (Figure 4A) utilizing purified activated GATA-3, importin-alpha, and activated GR, we demonstrated that activated GR significantly increased GR-importin-alpha association in the presence and absence of activated GATA-3 (Figure 4B). This effect is not mutual, since activated GATA-3 did not block GR-importin-alpha association (Figure 4C). These data also suggest that both activated GR and phospho-GATA-3 can directly associate with importin-alpha (Figure 4D) and that activated GR attenuates the phospho-GATA-3/importin-alpha interaction in a concentration-dependent manner (Figure 4E). Together, this suggests that ligand-activated GR may compete with phospho-GATA-3 for importin-alpha and thereby limit GATA-3 nuclear import.
Other possible interpretations of our results could include an effect of FP on GATA-3 nuclear export and/or degradation. Leptomycin B, which inhibits nuclear export, did not affect the ability of FP to block GATA-3 nuclear localization (Figure 5A). Additionally, FP had no effect on whole cell GATA-3 expression during the time course of these experiments (Figure 5B). Nor did addition of FP subsequent to anti-CD3/CD28 nuclear translocation affect GATA-3 nuclear residency (Figure 5C), suggesting that activated GR does not enhance GATA-3 nuclear export. Finally, the effect of FP on GATA-3 nuclear import was not nonspecific, since FP (10-8 M) had no effect on p65 nuclear translocation measured at 60 min (Figure 5D).","[{'offsets': [[10, 15]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[147, 152]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[154, 172]], 'text': ['MAPK phosphatase-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[419, 424]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[554, 560]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[703, 709]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[812, 817]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[967, 973]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1021, 1025]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1189, 1195]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1227, 1229]], 'text': ['GR'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1262, 1264]], 'text': ['GR'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1289, 1291]], 'text': ['GR'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1360, 1366]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1423, 1429]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1444, 1446]], 'text': ['GR'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1531, 1533]], 'text': ['GR'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1546, 1552]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1627, 1629]], 'text': ['GR'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1653, 1659]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1782, 1784]], 'text': ['GR'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1810, 1816]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1854, 1860]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1956, 1962]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2085, 2091]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2171, 2177]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2326, 2332]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2390, 2392]], 'text': ['GR'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2410, 2416]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2462, 2468]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2540, 2543]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[106, 115]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T32'}, {'offsets': [[306, 315]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[378, 393]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T34'}, {'offsets': [[412, 418]], 'text': ['target'], 'type': 'Binding', 'id': 'T35'}, {'offsets': [[546, 553]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T36'}, {'offsets': [[561, 567]], 'text': ['serine'], 'type': 'Entity', 'id': 'T37'}, {'offsets': [[568, 583]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T38'}, {'offsets': [[584, 591]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[655, 664]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T40'}, {'offsets': [[685, 699]], 'text': ['This reduction'], 'type': 'Negative_regulation', 'id': 'T41'}, {'offsets': [[710, 725]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T42'}, {'offsets': [[804, 811]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[818, 822]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T44'}, {'offsets': [[857, 866]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T45'}, {'offsets': [[950, 957]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T46'}, {'offsets': [[974, 981]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T47'}, {'offsets': [[982, 988]], 'text': ['import'], 'type': 'Localization', 'id': 'T48'}, {'offsets': [[1005, 1016]], 'text': ['association'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[1026, 1041]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T50'}, {'offsets': [[1130, 1141]], 'text': ['competition'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[1179, 1188]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[1217, 1226]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[1252, 1261]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[1279, 1288]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[1307, 1318]], 'text': ['association'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[1319, 1349]], 'text': ['in the presence and absence of'], 'type': 'Regulation', 'id': 'T57'}, {'offsets': [[1350, 1359]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[1413, 1422]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1438, 1443]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[1462, 1473]], 'text': ['association'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1521, 1530]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[1566, 1575]], 'text': ['associate'], 'type': 'Binding', 'id': 'T63'}, {'offsets': [[1617, 1626]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[1630, 1640]], 'text': ['attenuates'], 'type': 'Negative_regulation', 'id': 'T65'}, {'offsets': [[1645, 1652]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T66'}, {'offsets': [[1675, 1686]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T67'}, {'offsets': [[1706, 1715]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T68'}, {'offsets': [[1772, 1781]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T69'}, {'offsets': [[1789, 1796]], 'text': ['compete'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[1817, 1820]], 'text': ['for'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[1848, 1853]], 'text': ['limit'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[1861, 1868]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T73'}, {'offsets': [[1869, 1875]], 'text': ['import'], 'type': 'Localization', 'id': 'T74'}, {'offsets': [[1940, 1946]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T75'}, {'offsets': [[1963, 1970]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T76'}, {'offsets': [[1971, 1977]], 'text': ['export'], 'type': 'Localization', 'id': 'T77'}, {'offsets': [[1985, 1996]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T78'}, {'offsets': [[2051, 2057]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T79'}, {'offsets': [[2079, 2084]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[2092, 2099]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T81'}, {'offsets': [[2100, 2112]], 'text': ['localization'], 'type': 'Localization', 'id': 'T82'}, {'offsets': [[2150, 2156]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T83'}, {'offsets': [[2178, 2188]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[2319, 2325]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T85'}, {'offsets': [[2333, 2340]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T86'}, {'offsets': [[2341, 2350]], 'text': ['residency'], 'type': 'Localization', 'id': 'T87'}, {'offsets': [[2380, 2389]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[2402, 2409]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[2417, 2424]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T90'}, {'offsets': [[2425, 2431]], 'text': ['export'], 'type': 'Localization', 'id': 'T91'}, {'offsets': [[2446, 2452]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[2469, 2476]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T93'}, {'offsets': [[2477, 2483]], 'text': ['import'], 'type': 'Localization', 'id': 'T94'}, {'offsets': [[2530, 2536]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T95'}, {'offsets': [[2544, 2551]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T96'}, {'offsets': [[2552, 2565]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T97'}]","[{'trigger': 'T32', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T33', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T34', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T36', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T38', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T37']}}, {'trigger': 'T39', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T40', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T41', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T42', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T43', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T44', 'id': 'E12', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T45', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T46', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T47']}}, {'trigger': 'T46', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T49', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T46', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T50', 'id': 'E19', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T51', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T51', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T52', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T53', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T54', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T55', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T12']}}, {'trigger': 'T56', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T57', 'id': 'E27', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E28']}}, {'trigger': 'T58', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T59', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T60', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T15']}}, {'trigger': 'T61', 'id': 'E31', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T62', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T63', 'id': 'E33', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T63', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T64', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T65', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T19']}}, {'trigger': 'T67', 'id': 'E37', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T66', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T68', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T69', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T70', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T21']}}, {'trigger': 'T71', 'id': 'E42', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T72', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E41']}}, {'trigger': 'T74', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T23', 'T73']}}, {'trigger': 'T75', 'id': 'E45', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T77', 'id': 'E46', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T76']}}, {'trigger': 'T75', 'id': 'E47', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E48']}}, {'trigger': 'T78', 'id': 'E48', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T79', 'id': 'E49', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E50']}}, {'trigger': 'T80', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T82', 'id': 'E51', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T25', 'T81']}}, {'trigger': 'T83', 'id': 'E52', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E53']}}, {'trigger': 'T84', 'id': 'E53', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T85', 'id': 'E54', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E55']}}, {'trigger': 'T87', 'id': 'E55', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T27', 'T86']}}, {'trigger': 'T88', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T89', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E58', 'T28']}}, {'trigger': 'T91', 'id': 'E58', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T29', 'T90']}}, {'trigger': 'T92', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E60']}}, {'trigger': 'T94', 'id': 'E60', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T30', 'T93']}}, {'trigger': 'T95', 'id': 'E61', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E62']}}, {'trigger': 'T97', 'id': 'E62', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T31', 'T96']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E27', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E41', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E49', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E52', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E54', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E61', 'value': ''}]",[]
44,PMC-2800179-05-Materials_and_Methods,"Cell Culture
All tissue culture reagents were from Invitrogen (Cergy Pontoise, France). THP-1 human monocytic cells were maintained in RPMI-1640 supplemented with 10% FCS, 2 mM L -glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin at 37degreesC in a 5% CO2 incubator. Human peripheral blood mononuclear cells were obtained from heparinized blood by Ficoll-Hypaque density gradient. Monocytes were then isolated by adherence to culture flasks as described [28]. For cell aggregation, monocytes were cultured in the presence or absence of C10 or C40 for 72 h. Cell colonies were monitored under an inverted phase contrast microscope coupled through a video camera to a computer. In some wells, neutralizing monoclonal antibody to ICAM-1 (2.5 microg/ml) (Tebu, Le Perray en Yvelines, France) was added.",[],[],[],[],[],[]
45,PMC-2674207-04-Materials_and_Methods,"Cell Culture and PBMC Isolation
A human T cell line (HuT-78) was purchased from ECACC European Collection of Cell Culture (Wiltshire, UK) were cultured as previously described [12]. PBMCs were isolated by density centrifugation over Ficoll-Hypaque (density, 1.077 g/ml; Amersham Biosciences, Amersham, UK) as previously described [34]. Cells were stimulated with anti-CD3/CD28 (1 microg/ml each) for 1 h at 37degreesC to stimulate Th2 cytokine release in the presence or absence of FP (10-12 to 10-8M). Cytospins were prepared and GATA-3 localization determined by confocal microscopy as previously described [12].","[{'offsets': [[531, 537]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[538, 550]], 'text': ['localization'], 'type': 'Localization', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
46,PMC-2222968-10-Materials_and_Methods,"Isolation of CD4+ T cells.
CD4+ T cells were isolated from blood of healthy human volunteers using the anti-CD4 magnetic beads (Dynal, Hamburg, Germany) as previously described [60]. The purity of CD4+ T cells was initially tested by FACS and was >= 95%. Monoclonality of T cell clones was confirmed by TCR-chain mapping and was identified to be Vbeta8 positive. The clones were characterized by high IL-4 secretion.","[{'offsets': [[13, 16]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[27, 30]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[108, 111]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[197, 200]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[401, 405]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[396, 400]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[406, 415]], 'text': ['secretion'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],[],[]
47,PMC-2800179-19-Results,"Degraded CGN Induce IkappaB Degradation and NF-kappaB Activation
The expression of genes encoding for ICAM-1 and TNF-alpha is controlled by the nuclear factor NF-kappaB. Site-specific phosphorylation of the inhibitor IkappaB leads to its degradation by proteasome and to a consequential activation of the NF-kappaB pathway. Using a reporter plasmid for NF-kappaB activation, it was confirmed that dCGN induced a strong activation of NF-kappaB, as reflected by an increase in luciferase activity (Fig. 7A). Both forms of dCGN used induced NF-kappaB activation in a dose dependent manner. However, the effect was more strongly induced by the 40 kDa dCGN (Fig. 7A). These results were further confirmed by directly detecting NF-kappaB in the cell nucleus by Western blotting (Fig. 7C) and by FACS (Fig. 7D). These assays also allowed us to determine what NF-kappaB subunits were activated by dCGN. Both forms (10 or 40 kDa) of dCGN induced activation of the p50 and p65 subunits of NF-kappaB. This nuclear factor was present in low levels in the cell nucleus and increased considerably after treatment with dCGN. Western blots suggested the the 40 kDa form of dCGN induced a stronger activation of NF-kappaB (Fig. 7C). A more sentive assay for nuclear factor activation is flow cytometry of nuclei stained with specific antibodies for the nuclear factor of interest. In agreement with the previous data, FACS analysis of nuclei from THP-1 cells showed that there was a basal level of nuclear NF-kappaB (Fig. 7D). Again, both forms (10 or 40 kDa) of dCGN induced an increase of the p50 and p65 subunits of NF-kappaB in the nucleus of these cells. The 40 kDa degraded CGN gave a stronger increase of NF-kappaB (Fig. 7D). These data strongly suggest that the heterodimer p50/p65 is the NF-kappaB isoform activated by degraded CGN in monocytes. In addition, degradation of the inhibitor IkappaBalpha was also observed in cells treated with dCGN (Fig. 7B). No significant IkappaBalpha degradation was detected within two hours of dCGN treatment, but IkappaBalpha was markedly degraded by four hours of dCGN treatment (Fig. 7B). We focused on IkappaBalpha subunit, since it masks the nuclear localisation sequence of p65, it is the most rapidly degraded subunit and the most studied one.","[{'offsets': [[102, 108]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[113, 122]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[475, 485]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[852, 870]], 'text': ['NF-kappaB subunits'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[955, 958]], 'text': ['p50'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[963, 966]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1578, 1581]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1586, 1589]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1870, 1879]], 'text': ['inhibitor'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1880, 1892]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1964, 1976]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2042, 2054]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2134, 2146]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2208, 2211]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[69, 79]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[126, 136]], 'text': ['controlled'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[463, 471]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[929, 936]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[937, 947]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[1551, 1558]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[1562, 1570]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[1851, 1862]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T24'}, {'offsets': [[1977, 1988]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T25'}, {'offsets': [[2068, 2076]], 'text': ['degraded'], 'type': 'Protein_catabolism', 'id': 'T26'}, {'offsets': [[2162, 2164]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T15'}, {'offsets': [[2165, 2170]], 'text': ['masks'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[2175, 2204]], 'text': ['nuclear localisation sequence'], 'type': 'Entity', 'id': 'T28'}, {'offsets': [[2213, 2215]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[2236, 2244]], 'text': ['degraded'], 'type': 'Protein_catabolism', 'id': 'T29'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T18', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T23', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T24', 'id': 'E14', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T25', 'id': 'E15', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T26', 'id': 'E16', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T27', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T14', 'T13', 'T28']}}, {'trigger': 'T29', 'id': 'E18', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]","[{'id': 'R1', 'head': {'ref_id': 'T15', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}]",[]
48,PMC-2800179-27-Caption-Figure_7,"Degraded CGN activated the NF-kB pathway in monocytes.
A: THP-1 cells were transfected with a NF-kappaB reporter plasmid driving expression of luciferase. Cells were then treated with various concentrations of 10 kDa (triangles), or 40 kDa dCGN (squares). B: THP-1 cells treated with 1 mg/ml of 10 kDa dCGN (C10), or with 1 mg/ml of 40 kDa dCGN (C40) were lysed after various periods of time. Proteins in cell extracts were resolved by SDS-PAGE and then Western blotted for IkappaBalpha or alpha-tubulin as loading control. C: Degraded carrageenans (dCGN) induced activation of NF-kappaB. THP-1 cells were treated with nothing (control), or with 1 mg/ml of 10 kDa dCGN (C10), or with 1 mg/ml of 40 kDa dCGN (C40) for 30 minutes at 37degreesC. Nuclei were isolated and lysed. Proteins in nuclear extracts were resolved by SDS-PAGE and then Western blotted for NF-kappaB p50 subunit (p50) or NF-kappaB p65 subunit (p65). Lower panels show Western blots of nuclear ERK revealing equivalent amount of protein in each sample. Data are representative of three separate experiments. D: Degraded carrageenan (dCGN) induced activation of NF-kappaB. Nuclei isolated from THP-1 cells were fluorescence-stained for NF-kappaB p50 subunit or NF-kappaB p65 subunit before (filled area) or after cells were treated with 1 mg/ml of 10 kDa dCGN (C10), or with 1 mg/ml of 40 kDa dCGN (C40) for 30 minutes at 37degreesC. Dashed line corresponds to nuclei stained only with secondary fluorescence antibody. Fluorescence intensity was analyzed by flow cytometry as described.","[{'offsets': [[143, 153]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[474, 486]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[869, 872]], 'text': ['p50'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[882, 885]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[900, 903]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[913, 916]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1213, 1216]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1238, 1241]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[121, 128]], 'text': ['driving'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[129, 139]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],"[{'id': '*', 'ref_ids': ['T3', 'T4']}, {'id': '*', 'ref_ids': ['T5', 'T6']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
49,PMC-2806624-22-MATERIALS_AND_METHODS,"ChIP.
Human naive CD4+ T cells were cultured either with IL-2 only or with IL-2, anti-CD2/3/28, and TGF-beta for 72 h, and protein-DNA complexes were fixed by cross-linking with formaldehyde in a final concentration of 1.42% for 15 min. Formaldehyde was quenched with 125 mM glycine for 5 min, and cells were subsequently harvested. The ChIP assay was performed as described in the fast chromatin immunoprecipitation method (Nelson et al., 2006). Cells were lysed with immunoprecipitation buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, NP-40 [0.5% vol/vol]) containing phosphatase (Roche) and protease inhibitors cocktails (Roche), the nuclear pellet was washed, the chromatin was sheared by sonication and incubated with antibodies for RUNX1 (H-65 X; Santa Cruz Biotechnology, Inc.), RUNX3 (H-50 X; Santa Cruz Biotechnology, Inc.), CBFbeta (PEBP2beta; FL-182 X; Santa Cruz Biotechnology, Inc.), and as controls normal rabbit IgG (Santa Cruz Biotechnology, Inc.), anti-human RNA polymerase II antibody, and mouse control IgG (both from SA Biosciences). The cleared chromatin was incubated with protein A agarose beads and, after several washing steps, DNA was isolated with 10% (wt/vol) Chelex 100 resin. Samples were treated with proteinase K at 55degreesC for 30 min. The proteinase K was then inactivated by boiling the samples for 10 min. The purified DNA was used in a real-time PCR reaction. Specific primers for the FOXP3 promoter, spanning the region from -87 to -3, FOXP3 promoter forward primer 5'-AGAGGTCTGCGGCTTCCA-3', FOXP3 promoter reverse primer 5'-GGAAACTGTCACGTATCAAAAACAA-3', or control GAPDH primer (SA Biosciences) for the RNA polymerase II were used. A negative control PCR for each immunoprecipitation using IGX1A negative control primer targeting ORF-free intergenic DNA (SA Biosciences) was used. The fold enrichment in site occupancy was calculated incorporating IgG control values and input DNA values using the ChampionChIP qPCR data analysis file (SA Biosciences).","[{'offsets': [[18, 21]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 61]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[75, 79]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[86, 89]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[90, 91]], 'text': ['3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[92, 94]], 'text': ['28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[100, 108]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[746, 751]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[794, 799]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[842, 849]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[984, 1001]], 'text': ['RNA polymerase II'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1103, 1112]], 'text': ['protein A'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1240, 1252]], 'text': ['proteinase K'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1283, 1295]], 'text': ['proteinase K'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1432, 1437]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1484, 1489]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1540, 1545]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1614, 1619]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1652, 1669]], 'text': ['RNA polymerase II'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
50,PMC-2806624-07-DISCUSSION,"This study demonstrates that RUNX transcription factors 1 and 3 play an important role in the generation of FOXP3+ iT reg cells by TGF-beta. TGF-beta mediates RUNX induction and FOXP3 is efficiently up-regulated by RUNX1 and RUNX3 in human CD4+ T cells. There are three putative RUNX binding sites in the proximal FOXP3 promoter. One binding site was predicted as a binding site for RUNX2. Promoter enzyme immunoassay results showed that binding of RUNX1 and RUNX3 also occurred at this site (as well as at the other two), which were initially identified as RUNX1 binding sites. This finding is not surprising because RUNX proteins bind to promoter or enhancer elements of their target genes via the runt domain, which is conserved between members of the RUNX family. The RUNX protein that actually induces the expression of FOXP3 might therefore be dependent on the availability of the specific RUNX family member at certain stages of T cell development. RUNX proteins are able to increase or inhibit transcriptional activity of their target genes depending on the cell type and the target gene (Otto et al., 2003). Mutation of only one of the three binding sites had only a little effect on the promoter activity; however, when two binding sites were mutated, the FOXP3 promoter activity dropped to a greater extent. The most striking effect was observed when all three binding sites were mutated. We therefore assume that these binding sites have partially redundant functions, but binding to at least two sites seems to be necessary for full promoter activation.
TGF-beta promotes or inhibits the proliferation, differentiation, and survival of a wide array of different cells. It is also produced in activated T cells and it inhibits T cell proliferation (Kehrl et al., 1986; Siegel and Massague, 2003). It was shown that TGF-beta is mandatory for the maintenance of peripheral T reg cells and their expression of Foxp3 (Marie et al., 2005; Rubtsov and Rudensky, 2007). RUNX transcription factors are targets of the TGF-beta superfamily and they are involved in the TGF-beta pathway. They interact directly with regulatory SMADs (Miyazawa et al., 2002; Ito and Miyazono, 2003). TGF-beta can activate RUNX genes at the transcriptional level, and at the posttranscriptional level through activation or stabilization of RUNX proteins (Jin et al., 2004). It was shown that RUNX2 regulates the expression of TGF-beta type I receptor (Ji et al., 2001), suggesting that other mechanisms for their function could be involved. The fusion proteins RUNX1-EVI1 and RUNX1-ETO block TGF-beta inhibition of leukemic cell growth. RUNX3 plays an important role in TGF-beta-mediated growth control in epithelial cells, as loss of RUNX3 leads to decreased sensitivity to TGF-beta and hyperproliferation of the gastric mucosa (Blyth et al., 2005). The present study demonstrates that RUNX3 expression is more dominant in circulating human T reg cells and tonsil T reg cells compared with RUNX1. This could be dependent on the stage of the cells and organ from which they were isolated.
We observed that single siRNA interference of either RUNX1 or RUNX3 alone shows a slight decrease in Foxp3+ T reg cell induction, which could be caused by redundancy of these proteins. For this reason, we decided to use CbfbetaF/F CD4-cre mice. Foxp3 induction by TGF-beta is reduced in CD4+ T cells of CbfbF/F CD4-cre mice compared with CbfbF/+ CD4-cre mice. Retinoic acid is secreted by a subset of dendritic cells in the gut-associated lymphoid tissue. It inhibits the IL-6-driven induction of Th17 cells and facilitates the differentiation of naive T cells to Foxp3+ T reg cells (Mucida et al., 2007). We observed an increased number of Foxp3+ cells by retinoic acid and TGF-beta compared with TGF-beta treatment alone in CbfbF/+ CD4-cre mice and CbfbF/F CD4-cre mice. In addition, we showed a defective in vivo generation of T reg cells from Cbfb-deficient CD4+ T cells in Rag2-/- mice. These data in mice confirm the human data that RUNX proteins play an important role for TGF-beta-dependent FOXP3 induction, as well as in the suppressive capacity of iT reg cells. As an additional support for this concept, the overexpression of RUNX1 induced increased FOXP3 protein expression without any requirement of TGF-beta and anti-CD3 and anti-CD28 stimulation in human primary CD4+ cells. In both human and mouse systems, reduced Foxp3 expression was associated with reduced T reg cell suppressive activity.
In a recent study, the role of Runx-CBFbeta was investigated in nT reg cell development in the thymus (Rudra et al., 2009). It was reported that Foxp3 expression in nT reg cells is unstable in the absence of Runx-CBFbeta complexes. Cbfb-deficient nT reg cells progressively lose Foxp3 upon division, and there is no evidence of increased death of Cbfb-deficient nT reg cells in that study. The experiments in Cbfb-deficient CD4-cre T cells in mice and the knockdown experiments in humans in this study suggest that the induction of Foxp3 expression is a major contributing factor in the in vivo conversion experiment. Here, we observed that there is a twofold increased Foxp3+ iT reg cell generation in vivo. This is in the same range with previously published studies targeting different mechanisms in Foxp3 induction (Maynard et al., 2007; Sun et al., 2007). Whether the diminished capacity of Cbfb-deficient CD4-cre T cells in the generation of Foxp3 may be caused by peripheral expansion of Cbfb-deficient non-T reg cells or survival problems faced by Cbfb-deficient iT reg cells after Foxp3 induction remains to be elucidated.
The involvement of RUNX proteins in autoimmune diseases has been previously suggested (Alarcon-Riquelme, 2003). A mutation in the RUNX1 binding site in the promoter of programmed cell death 1 gene (PDCD-1) has been implicated in systemic lupus erythematosus pathogenesis (Prokunina et al., 2002). Polymorphisms that alter RUNX1 binding to other genes have also been described in rheumatoid arthritis linkage at 5q31 in Japanese patients (Tokuhiro et al., 2003) and in a psoriasis linkage at 17q25 (Prokunina et al., 2002; Helms et al., 2003). RUNX3-deficient mice spontaneously develop inflammatory bowel disease and hyperplastic gastritis-like lesions (Brenner et al., 2004). These disease symptoms resemble those occurring after depletion of Foxp3-expressing T reg cells (Sakaguchi, 2004). Derepression of Th2 cytokines might also account for some of the observed disease symptoms, as it was shown that T-bet first induces Runx3 in Th1 cells and then partners with Runx3 to direct lineage-specific gene activation. Runx3/Cbfbeta are both required for the activation of the Ifng gene and silencing of the Il4 gene in Th1 cells (Djuretic et al., 2007; Naoe et al., 2007). Runx proteins also play an essential role during T lymphocyte differentiation in the thymus (Taniuchi et al., 2002). Runx1 regulates the transitions of developing thymocytes from the CD4- CD8- double-negative stage to the CD4+ CD8+ double-positive stage and from the DP stage to the mature single-positive stage (Egawa et al., 2007). Runx1 and Runx3 deficiencies caused marked reductions in mature thymocytes and T cells of the CD4+ helper and CD8+ cytotoxic T cell lineages. In addition, inactivation of both Runx1 and Runx3 at the double-positive stages resulted in a severe blockage in the development of CD8+ mature thymocytes. These results indicate that Runx proteins have important roles at multiple stages of T cell development and in the homeostasis of mature T cells, and suggest that they may play a role in nT reg cell development, which remains to be elucidated. Furthermore, it was shown that Runx1 activates IL-2 and IFN-gamma gene expression in conventional CD4+ T cells by binding to their respective promoter. RUNX1 interacts physically with Foxp3 protein, and it was demonstrated that this interaction might be responsible for the suppression of IL-2 and IFN-gamma production and up-regulation of T reg cell-associated molecules (Ono et al., 2007).
It has been shown that Foxp3 also influences Th17 differentiation. Specifically, Foxp3 physically interacts with RORgammat, and this interaction inhibits RORgammat function (Zhou et al., 2008). This relationship of RORgammat and Foxp3 and probably yet unknown mechanisms might be the basis of the observation that the differentiation of Th17 cells and T reg cells is often reciprocal (Bettelli et al., 2006). Recently, data suggests that Runx1 may also be involved in regulating Il17 transcription, functioning in complex with RORgammat to activate transcription (Zhang et al., 2008).
The Runx3-deficient mice develop spontaneous Th2-dominated autoimmune colitis and asthma (Brenner et al., 2004; Fainaru et al., 2005). Cbfbf/f Cd4 mice also show a spontaneous Th2 dominated disease, with increased serum IgA, IgG1, and IgE titers and lymphocyte and eosinophil infiltration of the lung (Naoe et al., 2007). All these phenotypes were previously attributed to a loss of Th2 silencing whereas our findings additionally suggest that loss of T reg function plays a role. We have shown a link between Foxp3 induction in iT reg cells and RUNX1 and RUNX3. RUNX proteins play a central role in pathways regulating cell growth and differentiation, and their interaction with the TGF-beta pathway is of particular interest.
Foxp3 protein interacts not only with RUNX proteins but also with several other transcriptional partners, such as NFAT and possibly NF-kappaB; with histone acetyl transferases, such as TIP60; and histone deacetyl transferase (HDAC) complexes, such as HDAC7 and HDAC9 (Wu et al., 2006; Sakaguchi et al., 2008). NFAT forms a complex with AP-1 and NF-kappaB and regulates the expression of IL-2, IL-4, IFN-gamma, and CTLA4 in conventional T cells, which leads to the activation and differentiation to effector T cells (Dolganov et al., 1996; Hu et al., 2007). The NFAT-AP-1 complex also binds to the Foxp3 promoter after TCR triggering and regulates its gene expression positively (Mantel et al., 2006). It was shown that NFAT and Smad3 cooperate to induce Foxp3 expression through its enhancer (Tone et al., 2008), but no TGF-beta response element was identified in the Foxp3 gene or in the surrounding regions. The initial induction of RUNX1 and RUNX3 and the subsequent binding of these transcription factors to the Foxp3 promoter that we showed here might explain the relatively late induction of Foxp3 mRNA that peaks 24-48 h after stimulation. The interaction of Foxp3 and NFAT is dependent on their cooperative binding to DNA (Wu et al., 2006). RUNX1 alone, or together with its interacting partners p300 and CREB-binding protein, may cooperate with the NFAT transcription complex to activate the IL-2 promoter (Sakaguchi et al., 2008). Similar to this interaction, NFAT may also cooperate with RUNX1 or RUNX3 to activate Foxp3, but further studies are necessary to elaborate on this concept.
In conclusion, our findings elucidate the role of RUNX proteins in iT reg cell development and function. The induction of the transcription factors RUNX1 and RUNX3 by TGF-beta and the subsequent up-regulation of Foxp3 play a role in iT reg cell generation and its suppressive capacity.","[{'offsets': [[29, 57]], 'text': ['RUNX transcription factors 1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 63]], 'text': ['3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[108, 113]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[141, 149]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[159, 163]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[178, 183]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[215, 220]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[225, 230]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[240, 243]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[314, 319]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[383, 388]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[449, 454]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[459, 464]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[618, 622]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[755, 759]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[772, 776]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[825, 830]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[896, 900]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[956, 960]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1266, 1271]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1567, 1575]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1827, 1835]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1919, 1924]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1975, 1979]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2183, 2191]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2205, 2209]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2322, 2326]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2374, 2379]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2408, 2432]], 'text': ['TGF-beta type I receptor'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2543, 2553]], 'text': ['RUNX1-EVI1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2558, 2567]], 'text': ['RUNX1-ETO'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2574, 2582]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2619, 2624]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2652, 2660]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2717, 2722]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2757, 2765]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2869, 2874]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2973, 2978]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3124, 3129]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3133, 3138]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3172, 3177]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3291, 3298]], 'text': ['Cbfbeta'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3302, 3309]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3316, 3321]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3335, 3343]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3358, 3361]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3374, 3378]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3382, 3389]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3409, 3413]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3417, 3424]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3543, 3547]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3635, 3640]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3712, 3717]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3746, 3754]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3769, 3777]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3797, 3801]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3805, 3812]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3822, 3826]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3830, 3837]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3918, 3922]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3933, 3936]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3949, 3953]], 'text': ['Rag2'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4010, 4014]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4051, 4059]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4070, 4075]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4208, 4213]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4232, 4237]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4284, 4292]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4302, 4305]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4315, 4319]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4349, 4352]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4402, 4407]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4511, 4515]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4516, 4523]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4625, 4630]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[4693, 4700]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[4712, 4716]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[4759, 4764]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[4827, 4831]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[4889, 4893]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[4904, 4911]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[5012, 5017]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[5150, 5155]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[5283, 5288]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[5376, 5380]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[5391, 5398]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[5428, 5433]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[5475, 5479]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[5536, 5540]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[5570, 5575]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[5631, 5635]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[5780, 5803]], 'text': ['programmed cell death 1'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[5810, 5816]], 'text': ['PDCD-1'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[5934, 5939]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[6155, 6160]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[6356, 6361]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[6517, 6522]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[6537, 6542]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[6579, 6584]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[6629, 6634]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[6635, 6642]], 'text': ['Cbfbeta'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[6687, 6691]], 'text': ['Ifng'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[6718, 6721]], 'text': ['Il4'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[6784, 6788]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[6901, 6906]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[6967, 6970]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[6972, 6975]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[7006, 7009]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[7011, 7014]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[7118, 7123]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[7128, 7133]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[7212, 7215]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[7228, 7231]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[7294, 7299]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[7304, 7309]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[7392, 7395]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[7444, 7448]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[7691, 7696]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[7707, 7711]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[7716, 7725]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[7758, 7761]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[7812, 7817]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[7844, 7849]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[7949, 7953]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[7958, 7967]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[8075, 8080]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[8133, 8138]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[8165, 8174]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T128'}, {'offsets': [[8206, 8215]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T129'}, {'offsets': [[8267, 8276]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T130'}, {'offsets': [[8281, 8286]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T131'}, {'offsets': [[8490, 8495]], 'text': ['Runx1'], 'type': 'Protein', 'id': 'T132'}, {'offsets': [[8531, 8535]], 'text': ['Il17'], 'type': 'Protein', 'id': 'T133'}, {'offsets': [[8579, 8588]], 'text': ['RORgammat'], 'type': 'Protein', 'id': 'T134'}, {'offsets': [[8641, 8646]], 'text': ['Runx3'], 'type': 'Protein', 'id': 'T135'}, {'offsets': [[8772, 8776]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T136'}, {'offsets': [[8780, 8783]], 'text': ['Cd4'], 'type': 'Protein', 'id': 'T137'}, {'offsets': [[9147, 9152]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T138'}, {'offsets': [[9183, 9188]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T139'}, {'offsets': [[9193, 9198]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T140'}, {'offsets': [[9200, 9204]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T141'}, {'offsets': [[9321, 9329]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T142'}, {'offsets': [[9365, 9370]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T143'}, {'offsets': [[9403, 9407]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T144'}, {'offsets': [[9550, 9555]], 'text': ['TIP60'], 'type': 'Protein', 'id': 'T145'}, {'offsets': [[9701, 9705]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T146'}, {'offsets': [[9752, 9756]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T147'}, {'offsets': [[9758, 9762]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T148'}, {'offsets': [[9764, 9773]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T149'}, {'offsets': [[9779, 9784]], 'text': ['CTLA4'], 'type': 'Protein', 'id': 'T150'}, {'offsets': [[9931, 9935]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T151'}, {'offsets': [[9962, 9967]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T152'}, {'offsets': [[10093, 10098]], 'text': ['Smad3'], 'type': 'Protein', 'id': 'T153'}, {'offsets': [[10119, 10124]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T154'}, {'offsets': [[10233, 10238]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T155'}, {'offsets': [[10300, 10305]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T156'}, {'offsets': [[10310, 10315]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T157'}, {'offsets': [[10381, 10386]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T158'}, {'offsets': [[10463, 10468]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T159'}, {'offsets': [[10531, 10536]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T160'}, {'offsets': [[10614, 10619]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T161'}, {'offsets': [[10669, 10673]], 'text': ['p300'], 'type': 'Protein', 'id': 'T162'}, {'offsets': [[10678, 10682]], 'text': ['CREB'], 'type': 'Protein', 'id': 'T163'}, {'offsets': [[10766, 10770]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T164'}, {'offsets': [[10864, 10869]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T165'}, {'offsets': [[10873, 10878]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T166'}, {'offsets': [[10891, 10896]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T167'}, {'offsets': [[11012, 11016]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T168'}, {'offsets': [[11110, 11115]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T169'}, {'offsets': [[11120, 11125]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T170'}, {'offsets': [[11129, 11137]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T171'}, {'offsets': [[11174, 11179]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T172'}, {'offsets': [[150, 158]], 'text': ['mediates'], 'type': 'Positive_regulation', 'id': 'T181'}, {'offsets': [[164, 173]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T182'}, {'offsets': [[199, 211]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T183'}, {'offsets': [[438, 445]], 'text': ['binding'], 'type': 'Binding', 'id': 'T184'}, {'offsets': [[632, 636]], 'text': ['bind'], 'type': 'Binding', 'id': 'T185'}, {'offsets': [[700, 711]], 'text': ['runt domain'], 'type': 'Entity', 'id': 'T186'}, {'offsets': [[799, 806]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T187'}, {'offsets': [[811, 821]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T188'}, {'offsets': [[850, 859]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T189'}, {'offsets': [[1431, 1444]], 'text': ['binding sites'], 'type': 'Entity', 'id': 'T190'}, {'offsets': [[1485, 1492]], 'text': ['binding'], 'type': 'Binding', 'id': 'T191'}, {'offsets': [[1527, 1536]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T192'}, {'offsets': [[1546, 1554]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T193'}, {'offsets': [[1555, 1565]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T194'}, {'offsets': [[1682, 1684]], 'text': ['It'], 'type': 'Anaphora', 'id': 'T173'}, {'offsets': [[1693, 1701]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T195'}, {'offsets': [[1839, 1848]], 'text': ['mandatory'], 'type': 'Positive_regulation', 'id': 'T196'}, {'offsets': [[1905, 1915]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T197'}, {'offsets': [[2006, 2013]], 'text': ['targets'], 'type': 'Regulation', 'id': 'T198'}, {'offsets': [[2046, 2050]], 'text': ['they'], 'type': 'Anaphora', 'id': 'T174'}, {'offsets': [[2055, 2063]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T199'}, {'offsets': [[2089, 2093]], 'text': ['They'], 'type': 'Anaphora', 'id': 'T175'}, {'offsets': [[2094, 2102]], 'text': ['interact'], 'type': 'Binding', 'id': 'T200'}, {'offsets': [[2196, 2204]], 'text': ['activate'], 'type': 'Positive_regulation', 'id': 'T201'}, {'offsets': [[2223, 2238]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T202'}, {'offsets': [[2291, 2301]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T203'}, {'offsets': [[2380, 2389]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T204'}, {'offsets': [[2394, 2404]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T205'}, {'offsets': [[2709, 2713]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T206'}, {'offsets': [[2875, 2885]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T207'}, {'offsets': [[3101, 3113]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T208'}, {'offsets': [[3160, 3168]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T209'}, {'offsets': [[3190, 3199]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T210'}, {'offsets': [[3322, 3331]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T211'}, {'offsets': [[3347, 3354]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T212'}, {'offsets': [[3692, 3701]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T213'}, {'offsets': [[3923, 3932]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T214'}, {'offsets': [[4032, 4046]], 'text': ['important role'], 'type': 'Positive_regulation', 'id': 'T215'}, {'offsets': [[4060, 4069]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T216'}, {'offsets': [[4076, 4085]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T217'}, {'offsets': [[4190, 4204]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T218'}, {'offsets': [[4214, 4221]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T219'}, {'offsets': [[4222, 4231]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T220'}, {'offsets': [[4246, 4256]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T221'}, {'offsets': [[4269, 4280]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T222'}, {'offsets': [[4394, 4401]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T223'}, {'offsets': [[4408, 4418]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T224'}, {'offsets': [[4631, 4641]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T225'}, {'offsets': [[4717, 4726]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T226'}, {'offsets': [[4754, 4758]], 'text': ['lose'], 'type': 'Negative_regulation', 'id': 'T227'}, {'offsets': [[4832, 4841]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T228'}, {'offsets': [[4894, 4903]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T229'}, {'offsets': [[4999, 5008]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T230'}, {'offsets': [[5018, 5028]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T231'}, {'offsets': [[5140, 5149]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T232'}, {'offsets': [[5289, 5298]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T233'}, {'offsets': [[5353, 5363]], 'text': ['diminished'], 'type': 'Negative_regulation', 'id': 'T234'}, {'offsets': [[5381, 5390]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T235'}, {'offsets': [[5414, 5424]], 'text': ['generation'], 'type': 'Gene_expression', 'id': 'T236'}, {'offsets': [[5441, 5447]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T237'}, {'offsets': [[5480, 5489]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T238'}, {'offsets': [[5541, 5550]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T239'}, {'offsets': [[5576, 5585]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T240'}, {'offsets': [[5616, 5627]], 'text': ['involvement'], 'type': 'Regulation', 'id': 'T241'}, {'offsets': [[5928, 5933]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T242'}, {'offsets': [[5940, 5947]], 'text': ['binding'], 'type': 'Binding', 'id': 'T243'}, {'offsets': [[6161, 6170]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T244'}, {'offsets': [[6343, 6352]], 'text': ['depletion'], 'type': 'Negative_regulation', 'id': 'T245'}, {'offsets': [[6362, 6372]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T246'}, {'offsets': [[6529, 6536]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T247'}, {'offsets': [[6565, 6573]], 'text': ['partners'], 'type': 'Binding', 'id': 'T248'}, {'offsets': [[6652, 6660]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T249'}, {'offsets': [[6669, 6679]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T250'}, {'offsets': [[6701, 6710]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T251'}, {'offsets': [[7134, 7146]], 'text': ['deficiencies'], 'type': 'Negative_regulation', 'id': 'T252'}, {'offsets': [[7273, 7285]], 'text': ['inactivation'], 'type': 'Negative_regulation', 'id': 'T253'}, {'offsets': [[7697, 7706]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T254'}, {'offsets': [[7731, 7741]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T255'}, {'offsets': [[7774, 7781]], 'text': ['binding'], 'type': 'Binding', 'id': 'T256'}, {'offsets': [[7818, 7827]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T257'}, {'offsets': [[7888, 7904]], 'text': ['this interaction'], 'type': 'Anaphora', 'id': 'T176'}, {'offsets': [[7914, 7925]], 'text': ['responsible'], 'type': 'Positive_regulation', 'id': 'T258'}, {'offsets': [[7934, 7945]], 'text': ['suppression'], 'type': 'Negative_regulation', 'id': 'T259'}, {'offsets': [[7968, 7978]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T260'}, {'offsets': [[8150, 8159]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T261'}, {'offsets': [[8180, 8196]], 'text': ['this interaction'], 'type': 'Anaphora', 'id': 'T177'}, {'offsets': [[8197, 8205]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T262'}, {'offsets': [[8520, 8530]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T263'}, {'offsets': [[8536, 8549]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T264'}, {'offsets': [[8647, 8656]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T265'}, {'offsets': [[9153, 9162]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T266'}, {'offsets': [[9294, 9299]], 'text': ['their'], 'type': 'Anaphora', 'id': 'T178'}, {'offsets': [[9300, 9311]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T267'}, {'offsets': [[9379, 9388]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T268'}, {'offsets': [[9680, 9695]], 'text': ['forms a complex'], 'type': 'Binding', 'id': 'T269'}, {'offsets': [[9724, 9733]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T270'}, {'offsets': [[9738, 9748]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T271'}, {'offsets': [[9949, 9954]], 'text': ['binds'], 'type': 'Binding', 'id': 'T272'}, {'offsets': [[9968, 9976]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T273'}, {'offsets': [[10002, 10011]], 'text': ['regulates'], 'type': 'Positive_regulation', 'id': 'T274'}, {'offsets': [[10012, 10015]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T179'}, {'offsets': [[10021, 10031]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T275'}, {'offsets': [[10112, 10118]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T276'}, {'offsets': [[10125, 10135]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T277'}, {'offsets': [[10287, 10296]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T278'}, {'offsets': [[10335, 10342]], 'text': ['binding'], 'type': 'Binding', 'id': 'T279'}, {'offsets': [[10346, 10373]], 'text': ['these transcription factors'], 'type': 'Anaphora', 'id': 'T180'}, {'offsets': [[10387, 10395]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T280'}, {'offsets': [[10450, 10459]], 'text': ['induction'], 'type': 'Transcription', 'id': 'T281'}, {'offsets': [[10516, 10527]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T282'}, {'offsets': [[10549, 10558]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T283'}, {'offsets': [[10580, 10587]], 'text': ['binding'], 'type': 'Binding', 'id': 'T284'}, {'offsets': [[10648, 10659]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T285'}, {'offsets': [[10683, 10690]], 'text': ['binding'], 'type': 'Binding', 'id': 'T286'}, {'offsets': [[10753, 10761]], 'text': ['activate'], 'type': 'Positive_regulation', 'id': 'T287'}, {'offsets': [[10771, 10779]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T288'}, {'offsets': [[10882, 10890]], 'text': ['activate'], 'type': 'Positive_regulation', 'id': 'T289'}, {'offsets': [[11071, 11080]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T290'}, {'offsets': [[11157, 11170]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T291'}]","[{'trigger': 'T181', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T4']}}, {'trigger': 'T182', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T183', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T7']}}, {'trigger': 'T183', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T8']}}, {'trigger': 'T184', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T10', 'T12']}}, {'trigger': 'T184', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T10', 'T13']}}, {'trigger': 'T185', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T14', 'T186']}}, {'trigger': 'T187', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T16']}}, {'trigger': 'T188', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T189', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T18']}}, {'trigger': 'T191', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T190']}}, {'trigger': 'T192', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E11']}}, {'trigger': 'T194', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T193']}}, {'trigger': 'T195', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T196', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T22']}}, {'trigger': 'T197', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T198', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T199', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T200', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T201', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T25']}}, {'trigger': 'T202', 'id': 'E21', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T203', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T25']}}, {'trigger': 'T204', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T28']}}, {'trigger': 'T205', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T206', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T207', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T207', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T208', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T208', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T209', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E28']}}, {'trigger': 'T210', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T209', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E29']}}, {'trigger': 'T211', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T44', 'T45']}}, {'trigger': 'T212', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T213', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T53', 'T54']}}, {'trigger': 'T213', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T53', 'T55']}}, {'trigger': 'T214', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T215', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T63']}}, {'trigger': 'T217', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T216', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T64']}}, {'trigger': 'T218', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T219', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'T66']}}, {'trigger': 'T220', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T221', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T222', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T68']}}, {'trigger': 'T223', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E47']}}, {'trigger': 'T224', 'id': 'E47', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T225', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T226', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T227', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T78', 'E49']}}, {'trigger': 'T228', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T229', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T230', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E54']}}, {'trigger': 'T231', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T82']}}, {'trigger': 'T232', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T233', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T234', 'id': 'E57', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T236', 'id': 'E58', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T87']}}, {'trigger': 'T235', 'id': 'E59', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T237', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T238', 'id': 'E61', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T239', 'id': 'E62', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T240', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T90']}}, {'trigger': 'T241', 'id': 'E64', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}, {'trigger': 'T242', 'id': 'E65', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E66']}}, {'trigger': 'T243', 'id': 'E66', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T94']}}, {'trigger': 'T244', 'id': 'E67', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T95']}}, {'trigger': 'T245', 'id': 'E68', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E69']}}, {'trigger': 'T246', 'id': 'E69', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T96']}}, {'trigger': 'T247', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T98', 'T97']}}, {'trigger': 'T248', 'id': 'E71', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T97', 'T99']}}, {'trigger': 'T249', 'id': 'E72', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'T100']}}, {'trigger': 'T250', 'id': 'E73', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T102']}}, {'trigger': 'T249', 'id': 'E74', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'T101']}}, {'trigger': 'T249', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'T100']}}, {'trigger': 'T251', 'id': 'E76', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T103']}}, {'trigger': 'T249', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'T101']}}, {'trigger': 'T252', 'id': 'E78', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T110']}}, {'trigger': 'T252', 'id': 'E79', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T111']}}, {'trigger': 'T253', 'id': 'E80', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T114']}}, {'trigger': 'T253', 'id': 'E81', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T115']}}, {'trigger': 'T254', 'id': 'E82', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E83', 'E84']}}, {'trigger': 'T255', 'id': 'E83', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T119']}}, {'trigger': 'T256', 'id': 'E84', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T118']}}, {'trigger': 'T254', 'id': 'E85', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E86', 'E84']}}, {'trigger': 'T255', 'id': 'E86', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T120']}}, {'trigger': 'T257', 'id': 'E87', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T122', 'T123']}}, {'trigger': 'T258', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E89', 'E87']}}, {'trigger': 'T259', 'id': 'E89', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E92']}}, {'trigger': 'T258', 'id': 'E90', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E91', 'E87']}}, {'trigger': 'T259', 'id': 'E91', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E93']}}, {'trigger': 'T260', 'id': 'E92', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T124']}}, {'trigger': 'T260', 'id': 'E93', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T125']}}, {'trigger': 'T261', 'id': 'E94', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T127', 'T128']}}, {'trigger': 'T262', 'id': 'E95', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T129', 'E94']}}, {'trigger': 'T263', 'id': 'E96', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E97', 'T132']}}, {'trigger': 'T264', 'id': 'E97', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T133']}}, {'trigger': 'T265', 'id': 'E98', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T135']}}, {'trigger': 'T266', 'id': 'E99', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T138']}}, {'trigger': 'T267', 'id': 'E100', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T141', 'T142']}}, {'trigger': 'T268', 'id': 'E101', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T143', 'T144']}}, {'trigger': 'T268', 'id': 'E102', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T143', 'T145']}}, {'trigger': 'T269', 'id': 'E103', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T146']}}, {'trigger': 'T270', 'id': 'E104', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E105', 'E103']}}, {'trigger': 'T271', 'id': 'E105', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T147']}}, {'trigger': 'T270', 'id': 'E106', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E107', 'E103']}}, {'trigger': 'T271', 'id': 'E107', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T148']}}, {'trigger': 'T270', 'id': 'E108', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E109', 'E103']}}, {'trigger': 'T271', 'id': 'E109', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T149']}}, {'trigger': 'T270', 'id': 'E110', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E111', 'E103']}}, {'trigger': 'T271', 'id': 'E111', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T150']}}, {'trigger': 'T272', 'id': 'E112', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T151', 'T152', 'T273']}}, {'trigger': 'T274', 'id': 'E113', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E114', 'E112']}}, {'trigger': 'T275', 'id': 'E114', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T152']}}, {'trigger': 'T276', 'id': 'E115', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E116', 'T153']}}, {'trigger': 'T277', 'id': 'E116', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T154']}}, {'trigger': 'T278', 'id': 'E117', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T156']}}, {'trigger': 'T278', 'id': 'E118', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T157']}}, {'trigger': 'T279', 'id': 'E119', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T156', 'T158', 'T280']}}, {'trigger': 'T279', 'id': 'E120', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T157', 'T158', 'T280']}}, {'trigger': 'T281', 'id': 'E121', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T159']}}, {'trigger': 'T282', 'id': 'E122', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T160']}}, {'trigger': 'T283', 'id': 'E123', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E122', 'E124']}}, {'trigger': 'T284', 'id': 'E124', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T160']}}, {'trigger': 'T285', 'id': 'E125', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T161', 'T162']}}, {'trigger': 'T286', 'id': 'E126', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T163']}}, {'trigger': 'T287', 'id': 'E127', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T164', 'T161', 'T288']}}, {'trigger': 'T287', 'id': 'E128', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T164', 'T162', 'T288']}}, {'trigger': 'T289', 'id': 'E129', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T167']}}, {'trigger': 'T290', 'id': 'E130', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T169', 'T171']}}, {'trigger': 'T290', 'id': 'E131', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T170', 'T171']}}, {'trigger': 'T291', 'id': 'E132', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T172']}}]","[{'id': 'R1', 'head': {'ref_id': 'T173', 'role': 'Subject'}, 'tail': {'ref_id': 'T21', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T174', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T175', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T176', 'role': 'Subject'}, 'tail': {'ref_id': 'T257', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T177', 'role': 'Subject'}, 'tail': {'ref_id': 'T261', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T178', 'role': 'Subject'}, 'tail': {'ref_id': 'T141', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T179', 'role': 'Subject'}, 'tail': {'ref_id': 'T152', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T180', 'role': 'Subject'}, 'tail': {'ref_id': 'T156', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T180', 'role': 'Subject'}, 'tail': {'ref_id': 'T157', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T92', 'T93']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E60', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E64', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E88', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E90', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E96', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E127', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E128', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E129', 'value': ''}]",[]
51,PMC-1920263-00-TIAB,"Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene
APOBEC3G (A3G), a member of the recently discovered family of human cytidine deaminases, is expressed in peripheral blood lymphocytes and has been shown to be active against HIV-1 and other retroviruses. To gain new insights into the transcriptional regulation of this restriction factor, we cloned and characterized the promoter region of A3G. Transcriptional start sites were identified by 5'-rapid amplification of cDNA ends analysis. Luciferase reporter assays demonstrated that a 1025 bp A3G promoter sequence (from -959 to +66 relative to the major transcriptional start site) displayed constitutive promoter activity. In T cells, the A3G promoter was not inducible by mitogenic stimulation, interferon treatment or expression of HIV-1 proteins. Using a series of 5' deletion promoter constructs in luciferase reporter assays, we identified a 180 bp region that was sufficient for full promoter activity. Transcriptional activity of this A3G core promoter was dependent on a GC-box (located at position -87/-78 relative to the major transcriptional start site) and was abolished after mutation of this DNA element. Electrophoretic mobility shift assays and chromatin immunoprecipitation assays demonstrated that the identified GC-box represented a binding site for the ubiquitous transcription factors specificity protein (Sp) 1 and Sp3.","[{'offsets': [[0, 3]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 11]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[54, 62]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[68, 76]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[78, 81]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[408, 411]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[506, 516]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[709, 712]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[873, 883]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1376, 1402]], 'text': ['specificity protein (Sp) 1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1407, 1410]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[12, 20]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T13'}, {'offsets': [[27, 40]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T14'}, {'offsets': [[160, 169]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[318, 328]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T16'}, {'offsets': [[332, 355]], 'text': ['this restriction factor'], 'type': 'Anaphora', 'id': 'T12'}, {'offsets': [[713, 721]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[730, 739]], 'text': ['inducible'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[1301, 1307]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T19'}, {'offsets': [[1322, 1329]], 'text': ['binding'], 'type': 'Binding', 'id': 'T20'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T2']}}, {'trigger': 'T15', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T17']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T8', 'T10', 'T19']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T8', 'T11', 'T19']}}]","[{'id': 'R1', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T4', 'T5']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}]",[]
52,PMC-2222968-06-Results,"GATA3 Is a Negative Regulator of FOXP3 Expression
FOXP3 expression decreased once GATA3 expression is high; therefore, we hypothesized a potential role for GATA3 in repressing FOXP3. Besides GATA3's well-known positive effect on gene regulation, GATA3's repressive capabilities were previously shown to restrict Th1 commitment by inhibiting STAT4 expression [2,21], and therefore GATA3 prevents differentiation into Th1 cells. To investigate whether GATA3 can directly inhibit FOXP3 induction, we transduced GATA3 or a truncated GATA3 lacking the DNA-binding domain in human primary CD4+CD45RA+ T cells using a TAT-fused, recombinantly expressed GATA3. After transduction, the cells were activated with soluble anti-CD3/CD28 in the presence or absence of TGF-beta. TAT-GATA3 was successfully transduced in a homogeneous and dose-dependent manner into human CD4+ T cells (Figure 7A, upper panel). TAT-GATA3 reduced FOXP3 expression in a dose-dependent manner, whereas a DNA-binding domain truncated version (TAT-deltaDBD-GATA3) did not affect FOXP3 expression as compared with expression in untransduced cells (Figure 7A). In addition, we analyzed the inhibitory effect of GATA3 on FOXP3 in transgenic DO11.10 mice, constitutively overexpressing GATA3 under the control of the CD2 locus control region (DO11.10xCD2-GATA3). The thymic selection into the CD4 lineage is largely intact in DO11.10xCD2-GATA3 (RW Hendriks, unpublished data). These mice develop lymphomas at an older age, but signs of autoimmune disease were not described [22]. To investigate the effect of GATA3 on iTreg, CD4+CD62L+CD25- cells were isolated, activated with OVA in the presence or absence of TGF-beta, and Foxp3 expression was analyzed after 4 d. The naive CD4+CD25- cells were Foxp3- (unpublished data). As described for the human cells, TGF-beta dramatically up-regulated Foxp3 in the DO11.10 littermate control mice. In contrast, cells from the CD2-GATA3xDO11.10 mice showed dramatically reduced Foxp3 expression when activated with TGF-beta and OVA (Figure 7B). All mice produced similar amounts of TGF-beta; in addition, Smad7 was equally expressed [23] in T cells of both mice strains (Figure 7C), indicating intact TGF-beta signaling.
Taken together, these results demonstrated a repressive role of IL-4-induced GATA3 transcription factor in the generation of iTreg cells.","[{'offsets': [[0, 5]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[33, 38]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[50, 55]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[82, 87]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[156, 161]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[176, 181]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[191, 196]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[246, 251]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[341, 346]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[380, 385]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[450, 455]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[477, 482]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[508, 513]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[529, 534]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[583, 586]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[587, 593]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[611, 651]], 'text': ['TAT-fused, recombinantly expressed GATA3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[716, 719]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[720, 724]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[755, 763]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[765, 774]], 'text': ['TAT-GATA3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[857, 860]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[896, 905]], 'text': ['TAT-GATA3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[914, 919]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1020, 1025]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1042, 1047]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1172, 1177]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1181, 1186]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1245, 1250]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1276, 1279]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1310, 1313]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1314, 1319]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1352, 1355]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1393, 1396]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1397, 1402]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1568, 1573]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1584, 1587]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1588, 1593]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1594, 1598]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1670, 1678]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1684, 1689]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1735, 1738]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1739, 1743]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1756, 1761]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1817, 1825]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1852, 1857]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1926, 1929]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1930, 1935]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1977, 1982]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2014, 2022]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2081, 2089]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2104, 2109]], 'text': ['Smad7'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2200, 2208]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2284, 2288]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2297, 2302]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[11, 29]], 'text': ['Negative Regulator'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[39, 49]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[56, 66]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[67, 76]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[88, 98]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[102, 106]], 'text': ['high'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[147, 151]], 'text': ['role'], 'type': 'Regulation', 'id': 'T62'}, {'offsets': [[165, 175]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[330, 340]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[347, 357]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[469, 476]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[483, 492]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[535, 542]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T68'}, {'offsets': [[547, 565]], 'text': ['DNA-binding domain'], 'type': 'Entity', 'id': 'T69'}, {'offsets': [[906, 913]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[920, 930]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T71'}, {'offsets': [[969, 987]], 'text': ['DNA-binding domain'], 'type': 'Entity', 'id': 'T72'}, {'offsets': [[988, 997]], 'text': ['truncated'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[1035, 1041]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T74'}, {'offsets': [[1048, 1058]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T75'}, {'offsets': [[1151, 1168]], 'text': ['inhibitory effect'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[1230, 1244]], 'text': ['overexpressing'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[1558, 1564]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[1690, 1700]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[1839, 1851]], 'text': ['up-regulated'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1969, 1976]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[1983, 1993]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T82'}, {'offsets': [[1999, 2008]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[2053, 2061]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[2122, 2131]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T85'}, {'offsets': [[2289, 2296]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T86'}]","[{'trigger': 'T56', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T57', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T58', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T59', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E5']}}, {'trigger': 'T60', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T61', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T62', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T5']}}, {'trigger': 'T63', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T64', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T8']}}, {'trigger': 'T65', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T66', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T11']}}, {'trigger': 'T67', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T68', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T14', 'T69']}}, {'trigger': 'T70', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T23']}}, {'trigger': 'T71', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T73', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T72']}}, {'trigger': 'T74', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E16']}}, {'trigger': 'T75', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T76', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T27']}}, {'trigger': 'T77', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T78', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T36']}}, {'trigger': 'T79', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T80', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T46', 'T45']}}, {'trigger': 'T81', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T48']}}, {'trigger': 'T82', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T83', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T50']}}, {'trigger': 'T84', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T85', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T86', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T55', 'T54']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E19', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E22', 'value': ''}]",[]
53,PMC-3062687-21-Methods,"Immunofluorescence Microscopy
Confocal microscopy was performed as previously described6. Briefly, cells were fixed with 4 % paraformaldehyde in PBS and then Cellspin mounted onto slides. The fixed cells were then permeabilized with 0.05 % Triton X-100 in PBS and stained with FITC-conjugated rabbit anti-RPS3 antibodies (Primm Biotech), or AlexaFluor 594-conjugated rat anti-Flag antibodies (BD) for 40 min together with 1 mug/ml of Hoechst 33342 (Sigma) for 5 min at 25 degreesC. The slides were then rinsed with PBS three times and cover mounted for fluorescence microscopy.",[],[],[],[],[],[]
54,PMC-1134658-16-Methods,"Cell proliferation
For estimation of DNA synthesis, CD19+ cells (7.5 x 104 cells/0.2 ml) or Ramos cells (1 x 104 cells/0.2 ml) were cultured in triplicate in microtiter wells. The cells were pulsed with 3.7 x 104Bq [3H]thymidine (Amersham, Buckinghamshire, UK) for the last 16 h of a 72-h incubation. The cells were harvested using an automated cell harvester (Packard Instrument Company, Meriden, CT, USA) and [3H]thymidine incorporation was determined in a scintillation counter (TopCount, Packard Instrument Company Inc., Meriden, CT).","[{'offsets': [[52, 56]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
55,PMC-2806624-13-MATERIALS_AND_METHODS,"Cloning of the FOXP3 promoter, construction of mutant FOXP3 promoter, and RUNX expression plasmids.
The FOXP3 promoter was cloned into the pGL3 basic vector (Promega Biotech) to generate pGL3 FOXP3 -511/+176 (Mantel et al., 2006). Site-directed mutagenesis for the three putative RUNX binding sites in the FOXP3 promoter region was introduced using the QuickChange kit (Stratagene), according to the manufacturer's instructions and confirmed by sequencing the DNA. The following primers and their complementary strands were used: foxp runx-333, forward 5'-CACTTTTGTTTTAAAAACTGTCCTTTCTCATGAGCCCTATTATC-3'; foxp runx-333 reverse 5'-GATAATAGGGCTCATGAGAAAGGACAGTTTTTAAAACAAAAGTG-3'; foxp runx-287 forward 5'-CCTCTCACCTCTGTCCTGAGGGGAAGAAATC-3'; foxp runx-287 reverse 5'-GATTTCTTCCCCTCAGGACAGAGGTGAGAGG-3'; foxp runx-53 forward 5'-GCTTCCACACCGTACAGCGTCCTTTTTCTTCTCGGTATAAAAG-3'; foxp runx-53 reverse 5'-CTTTTATACCGAGAAGAAAAAGGACGCTGTACGGTGTGGAAGC-3'.
The human RUNX1 fragment from the Addgene plasmid 12504 (Biggs et al., 2006) pFlagCMV2-AML1B was sub-cloned in the pEGFPN1 vector (Clontech Laboratories). The RUNX3 vector pCMV human RUNX3, which was a gift from K. Ito (Institute of Molecular and Cell Biology, Proteos, Singapore) was subcloned into pEGFPN1 vector (Clontech Laboratories; Yamamura et al., 2006).","[{'offsets': [[15, 20]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 59]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 78]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[104, 109]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[192, 197]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[306, 311]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[955, 960]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1104, 1109]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1128, 1133]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[79, 89]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],[],[]
56,PMC-3062687-05-Results,"IkappaBalpha degradation and RPS3 nuclear translocation
Importin-alpha regulates the nuclear import of NF-kappaB Rel subunits23, 24. RPS3 harbors a nuclear localization signal (NLS) sequence and its nuclear translocation occurs in parallel to, but independently of, p65 translocation6. We envisioned that RPS3 could also utilize the importin-alpha/beta pathway. Consistent with this notion, RPS3 association with importin-alpha, but not importin-beta, was enhanced in TNF-stimulated cells (Fig. 3a). Therefore, we examined whether RPS3 binding to importin-alpha is essential for nuclear translocation during NF-kappaB activation.
Since IkappaBalpha degradation is a prerequisite to unmask the NLS of p65, and both RPS3 and IkappaBalpha bind to p65 in the cytoplasmic inhibitory complex, we tested whether IkappaBalpha degradation is required for the liberation of RPS3. We measured the association of RPS3 with importin-alpha in 293T cells overexpressing wild-type IkappaBalpha or an IkappaBalpha mutant (SSAA) resistant to IKKbeta-induced phosphorylation and degradation. In cells transfected with wild-type IkappaBalpha, TNF stimulation augmented the interaction of RPS3 and importin-alpha to a similar degree as in non-transfected cells. By contrast, we observed that the RPS3-importin-alpha association was abolished by the presence of non-degradable IkappaBalpha (Fig. 3b).
To examine whether IkappaBalpha is the only cytoplasmic barrier precluding RPS3 nuclear translocation, we measured both RPS3-importin-alpha association and nuclear RPS3 after reducing IkappaBalpha expression. Compared with nonspecific siRNA, siRNA targeting of IkappaBalpha completely depleted IkappaBalpha in Jurkat cells (Fig. 3c, input). Nevertheless, the RPS3-importin-alpha association was not augmented (Fig. 3c), nor was significant nuclear RPS3 detected (Fig. 3d). Moreover, cells treated with sodium pervanadate (Pv) to induce IkappaBalpha degradation through an IKK-independent mechanism25-27 did not show increased association between RPS3 and importin-alpha (Fig. 3e and Supplementary Fig. 3b) or nuclear accumulation of RPS3, despite complete IkappaBalpha degradation (Supplementary Fig. 3c). We further examined whether a subsequent NF-kappaB activation signal independently promotes the importin-alpha association and nuclear transport of RPS3 after IkappaBalpha degradation. We found that TNF stimulation following Pv treatment was required for the RPS3-importin-alpha association, comparable to TNF stimulation alone (Fig. 3e). Thus, IkappaBalpha phosphorylation and degradation itself is required but not sufficient to cause RPS3 association with importin-alpha followed by nuclear translocation. Rather, an additional signal, potentially IKKbeta phosphorylation of RPS3, is required.","[{'offsets': [[0, 12]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[29, 33]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[113, 116]], 'text': ['Rel'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[133, 137]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[266, 269]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[305, 309]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[391, 395]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[531, 535]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[636, 648]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[700, 703]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[714, 718]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[723, 735]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[744, 747]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[805, 817]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[864, 868]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[901, 905]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[965, 977]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[984, 996]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1024, 1031]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1109, 1121]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1168, 1172]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1275, 1279]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1355, 1367]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1398, 1410]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1454, 1458]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1499, 1503]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1543, 1547]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1563, 1575]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1621, 1626]], 'text': ['siRNA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1640, 1652]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1673, 1685]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1738, 1742]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1827, 1831]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1915, 1927]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2025, 2029]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2112, 2116]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2135, 2147]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2333, 2337]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2344, 2356]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2444, 2448]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2530, 2542]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2622, 2626]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2736, 2743]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2763, 2767]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[13, 24]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T46'}, {'offsets': [[34, 41]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T47'}, {'offsets': [[42, 55]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T48'}, {'offsets': [[71, 80]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T49'}, {'offsets': [[85, 92]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[93, 99]], 'text': ['import'], 'type': 'Localization', 'id': 'T51'}, {'offsets': [[195, 198]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T45'}, {'offsets': [[199, 206]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T52'}, {'offsets': [[207, 220]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T53'}, {'offsets': [[270, 283]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T54'}, {'offsets': [[396, 407]], 'text': ['association'], 'type': 'Binding', 'id': 'T55'}, {'offsets': [[536, 543]], 'text': ['binding'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[565, 574]], 'text': ['essential'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[579, 586]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[587, 600]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T59'}, {'offsets': [[649, 660]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T60'}, {'offsets': [[666, 678]], 'text': ['prerequisite'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[682, 688]], 'text': ['unmask'], 'type': 'Regulation', 'id': 'T62'}, {'offsets': [[693, 696]], 'text': ['NLS'], 'type': 'Entity', 'id': 'T63'}, {'offsets': [[736, 740]], 'text': ['bind'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[818, 829]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T65'}, {'offsets': [[833, 841]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[850, 860]], 'text': ['liberation'], 'type': 'Localization', 'id': 'T67'}, {'offsets': [[886, 897]], 'text': ['association'], 'type': 'Binding', 'id': 'T68'}, {'offsets': [[1005, 1009]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[1011, 1020]], 'text': ['resistant'], 'type': 'Negative_regulation', 'id': 'T70'}, {'offsets': [[1032, 1039]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[1040, 1055]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T72'}, {'offsets': [[1060, 1071]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T73'}, {'offsets': [[1139, 1148]], 'text': ['augmented'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[1153, 1164]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T75'}, {'offsets': [[1295, 1306]], 'text': ['association'], 'type': 'Binding', 'id': 'T76'}, {'offsets': [[1311, 1320]], 'text': ['abolished'], 'type': 'Negative_regulation', 'id': 'T77'}, {'offsets': [[1344, 1354]], 'text': ['degradable'], 'type': 'Protein_catabolism', 'id': 'T78'}, {'offsets': [[1443, 1453]], 'text': ['precluding'], 'type': 'Negative_regulation', 'id': 'T79'}, {'offsets': [[1459, 1466]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[1467, 1480]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T81'}, {'offsets': [[1519, 1530]], 'text': ['association'], 'type': 'Binding', 'id': 'T82'}, {'offsets': [[1554, 1562]], 'text': ['reducing'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[1576, 1586]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[1664, 1672]], 'text': ['depleted'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[1758, 1769]], 'text': ['association'], 'type': 'Binding', 'id': 'T86'}, {'offsets': [[1778, 1787]], 'text': ['augmented'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1819, 1826]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T88'}, {'offsets': [[1832, 1840]], 'text': ['detected'], 'type': 'Localization', 'id': 'T89'}, {'offsets': [[1908, 1914]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T90'}, {'offsets': [[1928, 1939]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T91'}, {'offsets': [[1995, 2004]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[2005, 2016]], 'text': ['association'], 'type': 'Binding', 'id': 'T93'}, {'offsets': [[2088, 2095]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T94'}, {'offsets': [[2096, 2108]], 'text': ['accumulation'], 'type': 'Localization', 'id': 'T95'}, {'offsets': [[2148, 2159]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T96'}, {'offsets': [[2268, 2276]], 'text': ['promotes'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[2296, 2307]], 'text': ['association'], 'type': 'Binding', 'id': 'T98'}, {'offsets': [[2312, 2319]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T99'}, {'offsets': [[2320, 2329]], 'text': ['transport'], 'type': 'Localization', 'id': 'T100'}, {'offsets': [[2357, 2368]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T101'}, {'offsets': [[2427, 2435]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[2464, 2475]], 'text': ['association'], 'type': 'Binding', 'id': 'T103'}, {'offsets': [[2543, 2558]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T104'}, {'offsets': [[2563, 2574]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T105'}, {'offsets': [[2616, 2621]], 'text': ['cause'], 'type': 'Positive_regulation', 'id': 'T106'}, {'offsets': [[2627, 2638]], 'text': ['association'], 'type': 'Binding', 'id': 'T107'}, {'offsets': [[2659, 2667]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[2671, 2678]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T109'}, {'offsets': [[2679, 2692]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T110'}, {'offsets': [[2744, 2759]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T111'}]","[{'trigger': 'T46', 'id': 'E1', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T48', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T47']}}, {'trigger': 'T49', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T51', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T3', 'T50']}}, {'trigger': 'T53', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T52']}}, {'trigger': 'T54', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T56', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T57', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'E7']}}, {'trigger': 'T59', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T58']}}, {'trigger': 'T60', 'id': 'E10', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T61', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E10']}}, {'trigger': 'T62', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T63']}}, {'trigger': 'T64', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T11', 'T13']}}, {'trigger': 'T64', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T12', 'T13']}}, {'trigger': 'T65', 'id': 'E15', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T66', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T67', 'id': 'E17', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T68', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T69', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T70', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E19']}}, {'trigger': 'T71', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T19']}}, {'trigger': 'T70', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'E19']}}, {'trigger': 'T71', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T19']}}, {'trigger': 'T72', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T73', 'id': 'E25', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T74', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T75', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T76', 'id': 'E28', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T77', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'E30']}}, {'trigger': 'T78', 'id': 'E30', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T79', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T24']}}, {'trigger': 'T81', 'id': 'E32', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T25', 'T80']}}, {'trigger': 'T82', 'id': 'E33', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T83', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T84', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T85', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T31', 'T29']}}, {'trigger': 'T86', 'id': 'E37', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T87', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'E36']}}, {'trigger': 'T89', 'id': 'E39', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T33', 'T88']}}, {'trigger': 'T90', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T91', 'id': 'E41', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T92', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'E40']}}, {'trigger': 'T93', 'id': 'E43', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T92', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'E40']}}, {'trigger': 'T95', 'id': 'E45', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T36', 'T94']}}, {'trigger': 'T96', 'id': 'E46', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T97', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E48']}}, {'trigger': 'T98', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T97', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E50']}}, {'trigger': 'T100', 'id': 'E50', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T38', 'T99']}}, {'trigger': 'T101', 'id': 'E51', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T102', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E53']}}, {'trigger': 'T103', 'id': 'E53', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T104', 'id': 'E54', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T105', 'id': 'E55', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T106', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E57', 'E54']}}, {'trigger': 'T108', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E59']}}, {'trigger': 'T106', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E57', 'E55']}}, {'trigger': 'T107', 'id': 'E59', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T110', 'id': 'E60', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T42', 'T109']}}, {'trigger': 'T111', 'id': 'E61', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}]","[{'id': 'R1', 'head': {'ref_id': 'T45', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E18', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E31', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E33', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E38', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E39', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E42', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E44', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E47', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E49', 'value': ''}]",[]
57,PMC-2674207-13-Materials_and_Methods,"Time-Lapse Microscopy
HuT-78 cells expressing GATA-3-GFP were maintained at 37degreesC in growth medium in a closed FCS2 perfusion chamber (Bioptechs, Butler, Pennsylvania, USA) combined with an objective heater (Bioptechs) on the stage a Zeiss Axiovert 200 microscope (Thornwood, New York, USA). Observations were made by 40x1.0 NA oil-immersion objective lens, and fluorescence and phase contrast images were gathered using a Hamamatsu ORCA-ER charged coupled device camera (Bridgewater, New Jersey, USA) driven by Openlab software (Improvision, Coventry, UK). Photographs were taken at 0, 30, 60, 120, and 240 min.","[{'offsets': [[46, 56]], 'text': ['GATA-3-GFP'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[35, 45]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T2'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
58,PMC-1942070-00-TIAB,"Protein kinase D enzymes are dispensable for proliferation, survival and antigen receptor-regulated NFkappaB activity in vertebrate B-cells
To investigate the importance of protein kinase D (PKD) enzymes we generated a PKD-null DT40 B-lymphocyte cell line. Previously we have shown that PKDs have an essential role in regulating class II histone deacetylases in DT40 B-cells [Matthews, S.A., Liu, P., Spitaler, M., Olson, E.N., McKinsey, T.A., Cantrell, D.A. and Scharenberg, A.M. (2006) Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol. Cell Biol. 26, 1569-1577]. We now show that PKDs are also required to regulate HSP27 phosphorylation in DT40 B-cells. However, in contrast to previous observations in other cell types, PKD enzymes do not regulate basic cellular processes such as proliferation or survival responses, nor NFkappaB transcriptional activity downstream of the B cell antigen receptor. Thus, PKDs have a selective role in DT40 B-cell biology.","[{'offsets': [[692, 697]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[671, 679]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T2'}, {'offsets': [[683, 691]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T3'}, {'offsets': [[698, 713]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T4'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T3', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T4', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
59,PMC-3359311-16-Materials_and_Methods,"NF-kappaB/AP-1 Activity Assay
Supernatants from THP-1 reporter cells were incubated with Quanti-Blue substrate (Invivogen) at 37degreesC and allowed to develop for 16-18 hours. Quanti-Blue contains a substrate for alkaline phosphatase and changes in the amount of NF-kappaB/AP-1 activity were quantified by optical density (lambda = 655) measured using a SpectraMax 384 Plus plate reader and SoftMax Pro software (Molecular Devices).","[{'offsets': [[214, 234]], 'text': ['alkaline phosphatase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
60,PMC-3333881-03-MATERIALS_AND_METHODS,"Cells, transfection, treatments and luciferase assay
HeLa, p50-/-p65-/- mouse embryonic fibroblasts (MEFs) (52) and 293T cells were cultured in Dulbecco's modified Eagle's medium; Jurkat, U937 cells and human peripheral blood mononuclear cells (PBMCs) were cultured in RPMI 1640. PBMCs were isolated as previously described (53). Media were supplemented with 10% heat-inactivated fetal calf serum and 2 mM l-glutamine (Lonza Cologne AG, Germany). HeLa, p50-/-p65-/- MEFs and 293T were transfected with DNA by using FuGENE HD (Roche Diagnostic GmbH, Mannheim, Germany), according to the manufacturer's protocol; total DNA amounts were equalized by transfection of pRc/CMV empty vector (Invitrogen, Carlsbad, CA, USA). For pulse-stimulation, HeLa cells were treated with phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) (20 ng/ml) for 5 min, or tumor necrosis factor-alpha (TNF-alpha; Sigma-Aldrich) (20 ng/ml) for 30 min, washed twice in complete culture medium and then returned to culture. For luciferase assays, pSV-beta-Gal was co-transfected with pkappaBluc to monitor the transfection efficiency. Forty-eight-hour post-transfection, cells were lysed in lysis buffer of Dual Light Luciferase System (Tropix, Bedford, MA, USA) and the luciferase and beta-galactosidase activities were evaluated by using Dual Light Luciferase System (Tropix) in a bioluminometer (Turner Biosystem, Sunnyvale, CA, USA). The ratio of firefly luciferase activity to beta-galactosidase activity was expressed as relative light units.","[{'offsets': [[36, 46]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[59, 62]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[65, 68]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[453, 456]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[459, 462]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[866, 893]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[895, 904]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1018, 1028]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1041, 1049]], 'text': ['beta-Gal'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1208, 1218]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1261, 1271]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1276, 1294]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1449, 1459]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1472, 1490]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T14'}]",[],[],"[{'id': '*', 'ref_ids': ['T6', 'T7']}]",[],[]
61,PMC-3062687-12-Methods,"Cells and Reagents
Jurkat E6.1, HEK293T and HeLa cells were cultured in RPMI 1640 and DMEM supplemented with 10% fetal calf serum, 2 mM glutamine, and 100 U/ml each of penicillin and streptomycin, respectively. IkappaBalpha (C-21, sc-371), p65 (C-20, sc-372), and phospho-threonine (H-2, sc-5267) antibodies were from Santa Cruz Biotechnology; beta-actin (AC-15, A5441), Flag (M2, F3165), HA (HA-7, H3663), importin-alpha (IM-75, I1784), and importin-beta (31H4, I2534) antibodies were from Sigma; PARP (C2-10, 556362), IKKalpha (B78-1, 556532), and IKKbeta (24, 611254) antibodies were from BD Pharmingen; CK2alpha (31, 611610) and Hsp90 (68, 610418) antibodies were from BD Transduction Laboratories; phospho-IkappaBalpha (5A5, 9246S) and phospho-IKKalpha/beta (16A6, 2697S) antibodies were from Cell Signaling Technology; phospho-serine (AB1603) and phospho-tyrosine (4G10, 05-777) antibodies were from Millipore. The rabbit polyclonal RPS3 antiserum was as described previously6. The rabbit polyclonal antibody specific for S209 phosphorylated RPS3 was generated and affinity purified by Primm Biotech using the peptide NH2-CKPLPDHV(Sp)IVE-COOH.",[],[],[],[],[],[]
62,PMC-2222968-27-Caption-Figure_3,"Th2- or IL-4-Producing Cells Lack FOXP3
(A) FACS analysis of intracellular FOXP3 and IL-4 expression following PMA/Ionomycin stimulation. CD4+ T cells were gated on the basis of CD45RO and CD25 surface expression (upper panel), and gated cells are shown below for the CD45RO+CD25- (A, left panel), the CD45RO+CD25+ (right panel), and the CD45RO-CD25- subsets (central panel). A statistical analysis of eight independent donors after subtraction of the isotype control are shown in (B). The dotted gray line indicates the IC background level. The error bars show the error of the mean. (C) Similarly, a Th2 clone (BR8), CRTH2+ Th2 cells, IL-4-secreting cells, and memory T cells (CD45RO) were stained for FOXP3 and IL-4. Data are representative of three independent experiments.","[{'offsets': [[8, 12]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 39]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[75, 80]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[85, 89]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[138, 141]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[178, 184]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[189, 193]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[268, 274]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[275, 279]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[302, 308]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[309, 313]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[338, 344]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[345, 349]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[619, 624]], 'text': ['CRTH2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[637, 641]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[679, 685]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[704, 709]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[714, 718]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[13, 22]], 'text': ['Producing'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[29, 33]], 'text': ['Lack'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[90, 100]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[202, 212]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[642, 651]], 'text': ['secreting'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[692, 699]], 'text': ['stained'], 'type': 'Gene_expression', 'id': 'T24'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T20', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T21', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T21', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T22', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T22', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T23', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T24', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
63,PMC-1920263-13-RESULTS,"Sp1 and Sp3 transcription factors bind to the GC-box at position -87/-78 of the A3G promoter
To investigate whether the GC-box represents a binding site for the transcription factors Sp1 and Sp3, we performed EMSA analyses with nuclear extracts isolated from A3.01 T cells. As probes, we radioactively labeled the unmodified E2 sequence (nucleotides -92/-63 of the A3G promoter, probe designated APO-Sp1/3) or the same region carrying the two point mutations described above (probe designated APO-Sp1/3mut). As control, we used a commercially available Sp1 consensus oligonucleotide (Sp1cons), which is known to be recognized by Sp1 transcription factors. Four DNA-protein complexes were observed in the presence of the APO-Sp1/3 probe (Figure 6A). The upper two complexes were specific since they disappeared in the presence of a 30-fold molar excess of unlabeled APO-Sp1/3 probe (Figure 6A, lane 7). Further confirmation of the specificity of these DNA-protein complexes was demonstrated by the inability of the unlabeled APO-Sp1/3mut probe to abolish binding (Figure 6A, lanes 12 and 13). As expected, the two specific complexes were also present in the case of the Sp1cons control probe (Figure 6A, lanes 2 and 3). In contrast, none of these specific complexes was observed when the mutated probe was used (Figure 6A, lanes 10 and 11), confirming that protein binding was dependent on the identified GC-box. In order to characterize the complexes, we performed supershift experiments using Sp1- and Sp3-specific antibodies. The upper of the complexes that appeared in combination with the Sp1cons or APO-Sp1/3 probes, shifted in the presence of the Sp1 antibody (Figure 6B, lanes 3 and 7), whereas the lower complex shifted in the presence of the Sp3 antibody (Figure 6B, lanes 4 and 8). Taken together, the EMSA demonstrated that the GC-box located on the A3G core promoter serves as a binding site for Sp1 and Sp3.
To show binding of Sp1 and Sp3 factors also in the context of the endogenous A3G promoter, a chromatin immunoprecipitation (ChIP) assay was performed. Sp1 and Sp3 antibodies, but not an actin antibody, immunoprecipitated the A3G promoter in A3.01 T cells (Figure 6C, upper panel). In contrast, no PCR signal was received with a primer pair recognizing a region in the A3G gene ~4000 bp downstream of the Sp1/Sp3-binding site (Figure 6C, lower panel). Only the positive controls showed a DNA band, with an A3G expression plasmid or the sheared and cross-linked input DNA used as template. This demonstrates the binding of Sp1 and Sp3 transcription factors to the endogenous A3G promoter.","[{'offsets': [[0, 3]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 11]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[80, 83]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[183, 186]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[191, 194]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[365, 368]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[629, 632]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1494, 1497]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1503, 1506]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1653, 1656]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1751, 1754]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1861, 1864]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1908, 1911]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1916, 1919]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1940, 1943]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1948, 1951]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1998, 2001]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2072, 2075]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2080, 2083]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2107, 2112]], 'text': ['actin'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2146, 2149]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2289, 2292]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2426, 2429]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2542, 2545]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2550, 2553]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2594, 2597]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[34, 38]], 'text': ['bind'], 'type': 'Binding', 'id': 'T27'}, {'offsets': [[46, 52]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T28'}, {'offsets': [[120, 126]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T29'}, {'offsets': [[127, 152]], 'text': ['represents a binding site'], 'type': 'Binding', 'id': 'T30'}, {'offsets': [[615, 625]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T31'}, {'offsets': [[1839, 1845]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T32'}, {'offsets': [[1879, 1903]], 'text': ['serves as a binding site'], 'type': 'Binding', 'id': 'T33'}, {'offsets': [[1929, 1936]], 'text': ['binding'], 'type': 'Binding', 'id': 'T34'}, {'offsets': [[2002, 2010]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T35'}, {'offsets': [[2430, 2440]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[2531, 2538]], 'text': ['binding'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[2598, 2606]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T38'}]","[{'trigger': 'T27', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T1', 'T3', 'T28']}}, {'trigger': 'T27', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T2', 'T3', 'T28']}}, {'trigger': 'T30', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T3', 'T4', 'T29']}}, {'trigger': 'T30', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T3', 'T5', 'T29']}}, {'trigger': 'T31', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T33', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T12', 'T13', 'T32']}}, {'trigger': 'T33', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T12', 'T14', 'T32']}}, {'trigger': 'T34', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T15', 'T17', 'T35']}}, {'trigger': 'T34', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T16', 'T17', 'T35']}}, {'trigger': 'T36', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T37', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T24', 'T26', 'T38']}}, {'trigger': 'T37', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T25', 'T26', 'T38']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
64,PMC-3333881-00-TIAB,"Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65
Nuclear factor (NF)-kappaB is a master regulator of pro-inflammatory genes and is upregulated in human immunodeficiency virus 1 (HIV-1) infection. Mechanisms underlying the NF-kappaB deregulation by HIV-1 are relevant for immune dysfunction in AIDS. We report that in single round HIV-1 infection, or single-pulse PMA stimulation, the HIV-1 Tat transactivator activated NF-kappaB by hijacking the inhibitor IkappaB-alpha and by preventing the repressor binding to the NF-kappaB complex. Moreover, Tat associated with the p65 subunit of NF-kappaB and increased the p65 DNA-binding affinity and transcriptional activity. The arginine- and cysteine-rich domains of Tat were required for IkappaB-alpha and p65 association, respectively, and for sustaining the NF-kappaB activity. Among an array of NF-kappaB-responsive genes, Tat mostly activated the MIP-1alpha expression in a p65-dependent manner, and bound to the MIP-1alpha NF-kappaB enhancer thus promoting the recruitment of p65 with displacement of IkappaB-alpha; similar findings were obtained for the NF-kappaB-responsive genes CSF3, LTA, NFKBIA and TLR2. Our results support a novel mechanism of NF-kappaB activation via physical interaction of Tat with IkappaB-alpha and p65, and may contribute to further insights into the deregulation of the inflammatory response by HIV-1.","[{'offsets': [[31, 34]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[85, 98]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[103, 106]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[448, 451]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[514, 527]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[604, 607]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[628, 631]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[671, 674]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[769, 772]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[791, 804]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[809, 812]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[929, 932]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[953, 964]], 'text': [' MIP-1alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[981, 984]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1020, 1030]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1084, 1087]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1109, 1122]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1190, 1194]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1196, 1199]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1201, 1207]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1212, 1216]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1308, 1311]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1317, 1330]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1335, 1338]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[68, 79]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T26'}, {'offsets': [[490, 499]], 'text': ['hijacking'], 'type': 'Binding', 'id': 'T27'}, {'offsets': [[535, 545]], 'text': ['preventing'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[546, 559]], 'text': ['the repressor'], 'type': 'Anaphora', 'id': 'T25'}, {'offsets': [[560, 567]], 'text': ['binding'], 'type': 'Binding', 'id': 'T29'}, {'offsets': [[608, 618]], 'text': ['associated'], 'type': 'Binding', 'id': 'T30'}, {'offsets': [[657, 666]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[679, 686]], 'text': ['binding'], 'type': 'Binding', 'id': 'T32'}, {'offsets': [[778, 786]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[813, 824]], 'text': ['association'], 'type': 'Binding', 'id': 'T34'}, {'offsets': [[911, 921]], 'text': ['responsive'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[940, 949]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[965, 975]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[985, 994]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1007, 1012]], 'text': ['bound'], 'type': 'Binding', 'id': 'T39'}, {'offsets': [[1031, 1049]], 'text': ['NF-kappaB enhancer'], 'type': 'Entity', 'id': 'T40'}, {'offsets': [[1055, 1064]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1069, 1080]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T42'}, {'offsets': [[1093, 1105]], 'text': ['displacement'], 'type': 'Binding', 'id': 'T43'}, {'offsets': [[1293, 1304]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T44'}]","[{'trigger': 'T26', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T2']}}, {'trigger': 'T27', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T4', 'T5']}}, {'trigger': 'T28', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T4']}}, {'trigger': 'T29', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T30', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T6', 'T7']}}, {'trigger': 'T31', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T6']}}, {'trigger': 'T32', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T33', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T33', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T34', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T9', 'T10']}}, {'trigger': 'T35', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T36', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T12']}}, {'trigger': 'T38', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'T14']}}, {'trigger': 'T37', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T39', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T12', 'T15', 'T40']}}, {'trigger': 'T41', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T42', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T15', 'T16', 'T40']}}, {'trigger': 'T41', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E15']}}, {'trigger': 'T43', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T44', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T22', 'T23']}}]","[{'id': 'R1', 'head': {'ref_id': 'T25', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}]",[]
65,PMC-1920263-17-Caption-Figure_2,5'-RACE analysis of the A3G cDNA. Agarose gel electrophoresis of size marker and A3G 5'-RACE products after nested PCR with primer RACE-APO3Gnest (see Figure 1 for primer details). Arrowheads indicate the three resulting DNA bands which were cloned and sequenced.,"[{'offsets': [[24, 27]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[81, 84]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
66,PMC-1942070-04-Results,"3.1Loss of HSP27 phosphorylation in DT40 B cells lacking expression of PKD family kinases
DT40 B cells express two PKD isoforms, PKD1 and PKD3, and as previously described we have recently generated DT40 B cell lines that lack expression of either PKD1 or PKD3 or both enzymes [1]. In generating the double knockout cell lines we targeted the PKD1 loci in a PKD3-/- cell line that expressed a Flag-PKD3 transgene under the control of a doxycycline-inducible promoter. Hence, in the presence of doxycycline, Flag-PKD3 expression in PKD1/3 double knockout cells is comparable to endogenous PKD3 present in wild-type DT40 cells and removal of doxycycline from the culture media for 5 days results in a completely null PKD phenotype (Fig. 1A).
Previously, we have demonstrated that phosphorylation and nuclear exclusion of class II histone deacetylases (HDACs) during BCR engagement is defective in PKD1/3-/- B cells and can restored upon re-expression of a single PKD isoform [1]. The small heat shock protein HSP27 has recently been proposed as a PKD1 substrate [24] and we accordingly assessed whether PKD-null DT40 cells have defective phosphorylation of HSP27 on serine 82, the proposed PKD1 substrate sequence. We initially investigated the regulation of HSP27 phosphorylation in single knockout DT40 B cells lacking either PKD1 or PKD3. As shown in Fig. 1B, activation of the BCR or treatment with the DAG-mimetic PdBu increased the levels of HSP27 phosphorylation at S82 in wild-type DT40 B cells. BCR and phorbol ester signals were also able to increase HSP27 phosphorylation in PKD1 or PKD3 single knockout DT40 B cells (Fig. 1B). However, BCR- and phorbol ester-induced phosphorylation of HSP27 on S82 was abolished in B cells that lacked both PKD1 and PKD3 (Fig. 1C). Significantly, doxycycline-induced expression of the Flag-PKD3 transgene in the double knockout cells was sufficient to restore normal regulation of HSP27 phosphorylation (Fig. 1C). In contrast, expression of a kinase-deficient PKD3 mutant protein in the double knockout cells was not able to restore BCR- or phorbol ester-induced HSP27 phosphorylation (Fig. 1D). Hence, PKD3 as well as PKD1 can regulate HSP27 phosphorylation and in DT40 B cells they are functionally redundant as HSP27 kinases.","[{'offsets': [[11, 16]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[129, 133]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[138, 142]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[248, 252]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[256, 260]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[343, 347]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[358, 362]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[398, 402]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[512, 516]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[531, 535]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[536, 537]], 'text': ['3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[588, 592]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[895, 899]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[900, 901]], 'text': ['3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1007, 1012]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1045, 1049]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1155, 1160]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1188, 1192]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1257, 1262]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1326, 1330]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1334, 1338]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1446, 1451]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1559, 1564]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1584, 1588]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1592, 1596]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1696, 1701]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1751, 1755]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1760, 1764]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1834, 1838]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1925, 1930]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2004, 2008]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2107, 2112]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2147, 2151]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2163, 2167]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2181, 2186]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2258, 2263]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3, 7]], 'text': ['Loss'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[17, 32]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T39'}, {'offsets': [[103, 110]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[111, 127]], 'text': ['two PKD isoforms'], 'type': 'Anaphora', 'id': 'T37'}, {'offsets': [[222, 226]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T41'}, {'offsets': [[227, 237]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T42'}, {'offsets': [[381, 390]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[517, 527]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[538, 553]], 'text': ['double knockout'], 'type': 'Negative_regulation', 'id': 'T45'}, {'offsets': [[1126, 1135]], 'text': ['defective'], 'type': 'Negative_regulation', 'id': 'T46'}, {'offsets': [[1136, 1151]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T47'}, {'offsets': [[1164, 1173]], 'text': ['serine 82'], 'type': 'Entity', 'id': 'T48'}, {'offsets': [[1243, 1253]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T49'}, {'offsets': [[1263, 1278]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T50'}, {'offsets': [[1311, 1318]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[1422, 1431]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[1452, 1467]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[1471, 1474]], 'text': ['S82'], 'type': 'Entity', 'id': 'T54'}, {'offsets': [[1550, 1558]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[1565, 1580]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T56'}, {'offsets': [[1604, 1612]], 'text': ['knockout'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[1669, 1676]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[1677, 1692]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T59'}, {'offsets': [[1705, 1708]], 'text': ['S82'], 'type': 'Entity', 'id': 'T60'}, {'offsets': [[1713, 1722]], 'text': ['abolished'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1739, 1745]], 'text': ['lacked'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[1803, 1810]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[1811, 1821]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[1882, 1903]], 'text': ['sufficient to restore'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[1911, 1921]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T66'}, {'offsets': [[1931, 1946]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T67'}, {'offsets': [[1971, 1981]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T68'}, {'offsets': [[1994, 2003]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[2069, 2076]], 'text': ['restore'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[2099, 2106]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[2113, 2128]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T72'}, {'offsets': [[2172, 2180]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[2187, 2202]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T74'}]","[{'trigger': 'T38', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T40', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T42', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T41', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T42', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T43', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T44', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T45', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T45', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T46', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T47', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T17', 'T48']}}, {'trigger': 'T49', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T50', 'id': 'E16', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T51', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T52', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T53', 'id': 'E20', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T22', 'T54']}}, {'trigger': 'T55', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T56', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T57', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T58', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T59', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T26', 'T60']}}, {'trigger': 'T61', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E28']}}, {'trigger': 'T62', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T61', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E30']}}, {'trigger': 'T62', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T63', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T64', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T65', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E31']}}, {'trigger': 'T66', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T67', 'id': 'E35', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T68', 'id': 'E36', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T69', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T70', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E36']}}, {'trigger': 'T71', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T72', 'id': 'E40', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T73', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T33']}}, {'trigger': 'T74', 'id': 'E42', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T73', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T34']}}]","[{'id': 'R1', 'head': {'ref_id': 'T37', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T37', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E15', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E38', 'value': ''}]",[]
67,PMC-3333881-09-MATERIALS_AND_METHODS,"Real-time PCR
Total RNA was extracted from cells by using the TRIzol reagent (Invitrogen); RNA aliquots (200 ng) were reverse transcribed using Random Examers (Roche) and Superscript III Reverse Transcriptase (Invitrogen), according to the manufacturer's protocol. Real-time PCR was performed with the iQ Green Super mix (Bio-Rad Laboratories) and carried out with the iCycler iQ Real-Time detection system (Bio-Rad Laboratories) under the following conditions: 95degreesC, 1 min; (94degreesC, 10 s; 60degreesC, 30 s) x40. Primers for Tat and MIP-1alpha are listed in Supplementary Data. Real-time PCR of CSF3, LTA, NFKBIA, TLR2, GAPDH and ACTB was performed using the RT2 profiler PCR Array-Human NF-kappaB signaling pathway (QIAGEN Sciences, MD, USA). Reactions were carried out in triplicate, and gene expression levels were calculated relative to GAPDH mRNA levels as endogenous control. Relative expression was calculated as 2(Ct gene under investigation - Ct GAPDH).","[{'offsets': [[535, 538]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[543, 553]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[605, 609]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[611, 614]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[616, 622]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[624, 628]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[630, 635]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[640, 644]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[851, 856]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[965, 970]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[862, 868]], 'text': ['levels'], 'type': 'Transcription', 'id': 'T11'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}]",[],[],[],[]
68,PMC-3062687-18-Methods,"Subcellular Fractionation
Subcellular fractionation was performed by differential centrifugation as previously described6. Briefly, cells were resuspended in ice-cold Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 0.4 % NP-40, 0.5 mM PMSF, complete protease inhibitor cocktail) at 4 degreesC for 5 min. Lysates were centrifuged at 4 degreesC, 500 x g for 3 min, and supernatants were collected as cytosolic fractions. Pellets were incubated in Buffer C (20 mM HEPES pH7.9, 420 mM NaCl, 1.5 mM MgCl2, 25% glycerol, 0.5 mM PMSF, 0.2 mM EDTA, 0.5 mM DTT, complete protease inhibitor cocktail) at 4 degreesC for 10 min. Supernatants were collected as nuclear fractions following a centrifuge at 4 degreesC, 13,800 x g for 10 min.",[],[],[],[],[],[]
69,PMC-2806624-19-MATERIALS_AND_METHODS,"Western blotting.
For human RUNX1 and RUNX3 analysis on the protein level, 106 cells were lysed and loaded next to a protein-mass ladder (Invitrogen) on a NuPAGE 4-12% Bis-Tris gel (Invitrogen). The proteins were electroblotted onto a PVDF membrane (GE Healthcare). Unspecific binding was blocked with 3% milk in TBS Tween, and the membranes were subsequently incubated with a 1:1,000 dilution of rabbit anti-RUNX1 (ab11903; Abcam) or 1:200 dilution of rabbit anti-RUNX3 (H-50; Santa Cruz Biotechnology, Inc.) in blocking buffer containing 3% milk in TBS Tween overnight at 4degreesC. The blots were developed using an anti-rabbit IgG HRP-labeled mAb (Cell Signaling Technology) and visualized with a LAS-1000 gel documentation system (Fujifilm). To confirm sample loading and transfer membranes were incubated in stripping buffer and reblocked for 1 h and reprobed using anti-GAPDH (6C5; Ambion) and developed using an anti-mouse IgG HRP-labeled mAb (Cell Signaling Technology).","[{'offsets': [[28, 33]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[38, 43]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[409, 414]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[465, 470]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[877, 882]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[60, 73]], 'text': ['protein level'], 'type': 'Gene_expression', 'id': 'T6'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],[],[]
70,PMC-2222968-16-Materials_and_Methods,"RNA isolation and cDNA synthesis.
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. Reverse transcription of human samples was performed with TaqMan reverse-transcription reagents (Applied Biosystems) with random hexamers according to the manufacturer's protocol.",[],[],[],[],[],[]
71,PMC-3359311-22-Caption-Figure_4,"PBMCs from CF patients and controls show similar increases in caspase-1 activity upon inflammasome activation.
PBMCs from CF patients (n = 6) and healthy controls (n = 6) were primed with LPS (10 ng/ml) for 5 hours prior to stimulation with ATP (5 mM) for 1 hour or Poly(dA:dT) (1 microg/ml) for 3 hours. PBMCs were stimulated with P. aeruginosa strain PAO1 for 3 hours. A representative histogram of the % caspase-1-active cells is shown in (A) with the averaged values shown in (B).",[],[],[],[],[],[]
72,PMC-1134658-01-Background,"Members of the transforming growth factor beta (TGF-beta) superfamily play central roles in controlling cellular proliferation, differentiation, migration and apoptosis [1]. These cytokines can be divided into three subgroups: TGF-beta, the activins/inhibins, and the bone morphogenetic proteins (BMPs), of which the latter constitute the largest family. BMPs are 30-38 kDa hetero- or homodimeric proteins originally identified by their ability to induce ectopic cartilage and bone formation [2,3]. Several studies have demonstrated an essential role of these proteins during embryogenesis, and more recently, also in adult tissues [1]. TGF-beta has been intensively studied in normal and malignant haematopoietic cells and is one of the most potent endogenous negative regulators known to date. [4]. In contrast, the effect of BMPs in the immune system has not been widely investigated. In that respect, BMP- 2, -4 and -7 have been found to control differentiation of hematopoietic stem cells [5] and early T cell development [6,7]. BMP-6 has been reported to reduce the number of cobblestone-area-forming cells of normal human haematopoietic cells [8]. Furthermore, BMP-2, -4, 6 and -7 had an antiproliferative and a proapoptotic effect on multiple myeloma cells [9-11]. In addition, by gene expression profiling, BMP-6 significantly increased the predictive value for a multi-gene signature test and was associated with a poor outcome in diffuse large B cell lymphomas (DLBCL) [12].
BMP-6, like the other BMP members, signals through ligation and heterodimerzation of BMP type I [activin-like-kinase (ALK)] and type II serine-threonine kinase receptors, which subsequently propagates the signal downstream by phosphorylating Smad proteins. BMP-6 can signal through the ligation of the type I receptors Act-RIA, BMP-RIA, and BMP-RIB and the type II receptors BMP-RII, Act-RIIA and Act-RIIB, which lead to the phosphorylation of the receptor Smads (Smad-1, Smad-5, and Smad-8). The R- Smads then form complexes with the co-Smad (Smad4) and are translocated into the nucleus where they exert gene regulation [1,13].
Given the reported role of BMP-6 in B-cell malignancies and haematopoietic progenitor cells, we wanted to explore its potential role in normal human B cells. We studied the effects of BMP-6 on proliferation and apoptosis on resting and stimulated B cells. Furthermore, the expression of BMP receptors and BMP-6 induced activation of the Smad signalling pathway with subsequent regulation of the target genes Id1-Id4, were resolved. Finally, we investigated whether B cells also were capable of producing BMP-6.","[{'offsets': [[15, 46]], 'text': ['transforming growth factor beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[48, 56]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 236]], 'text': ['TGF-beta,'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[637, 645]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[905, 911]], 'text': ['BMP- 2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[913, 915]], 'text': ['-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[920, 922]], 'text': ['-7'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1034, 1039]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1168, 1173]], 'text': ['BMP-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1175, 1177]], 'text': ['-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1179, 1180]], 'text': ['6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1185, 1187]], 'text': ['-7'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1316, 1321]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1486, 1491]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1743, 1748]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1805, 1812]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1814, 1821]], 'text': ['BMP-RIA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1827, 1834]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1861, 1868]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1870, 1878]], 'text': ['Act-RIIA'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1883, 1891]], 'text': ['Act-RIIB'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1950, 1956]], 'text': ['Smad-1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1958, 1964]], 'text': ['Smad-5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1970, 1976]], 'text': ['Smad-8'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2030, 2035]], 'text': ['Smad4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2143, 2148]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2300, 2305]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2421, 2426]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2524, 2527]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2528, 2531]], 'text': ['Id4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2620, 2625]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1336, 1345]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1537, 1545]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T36'}, {'offsets': [[1550, 1567]], 'text': ['heterodimerzation'], 'type': 'Binding', 'id': 'T37'}, {'offsets': [[1772, 1780]], 'text': ['ligation'], 'type': 'Binding', 'id': 'T38'}, {'offsets': [[1899, 1903]], 'text': ['lead'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1911, 1926]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T40'}, {'offsets': [[1930, 1948]], 'text': ['the receptor Smads'], 'type': 'Anaphora', 'id': 'T32'}, {'offsets': [[1979, 1991]], 'text': ['The R- Smads'], 'type': 'Anaphora', 'id': 'T33'}, {'offsets': [[1997, 2011]], 'text': ['form complexes'], 'type': 'Binding', 'id': 'T41'}, {'offsets': [[2045, 2057]], 'text': ['translocated'], 'type': 'Localization', 'id': 'T42'}, {'offsets': [[2067, 2074]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T43'}, {'offsets': [[2389, 2399]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T44'}, {'offsets': [[2427, 2434]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[2493, 2503]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T46'}, {'offsets': [[2507, 2523]], 'text': ['the target genes'], 'type': 'Anaphora', 'id': 'T34'}, {'offsets': [[2610, 2619]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T47'}]","[{'trigger': 'T35', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T36', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T37', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T38', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T16']}}, {'trigger': 'T38', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T17']}}, {'trigger': 'T38', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T18']}}, {'trigger': 'T38', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T19']}}, {'trigger': 'T38', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T20']}}, {'trigger': 'T38', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T21']}}, {'trigger': 'T39', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E4']}}, {'trigger': 'T40', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T39', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E5']}}, {'trigger': 'T39', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E6']}}, {'trigger': 'T39', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E7']}}, {'trigger': 'T39', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E8']}}, {'trigger': 'T39', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E9']}}, {'trigger': 'T39', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E4']}}, {'trigger': 'T40', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T39', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E5']}}, {'trigger': 'T39', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E6']}}, {'trigger': 'T39', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E7']}}, {'trigger': 'T39', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E8']}}, {'trigger': 'T39', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E9']}}, {'trigger': 'T39', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E4']}}, {'trigger': 'T40', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T39', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E5']}}, {'trigger': 'T39', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E6']}}, {'trigger': 'T39', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E7']}}, {'trigger': 'T39', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E8']}}, {'trigger': 'T39', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E9']}}, {'trigger': 'T41', 'id': 'E31', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T22', 'T25']}}, {'trigger': 'T41', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T23', 'T25']}}, {'trigger': 'T41', 'id': 'E33', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T42', 'id': 'E34', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T22', 'T43']}}, {'trigger': 'T42', 'id': 'E35', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T23', 'T43']}}, {'trigger': 'T42', 'id': 'E36', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T43']}}, {'trigger': 'T44', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T45', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E37']}}, {'trigger': 'T46', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T45', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'E37']}}, {'trigger': 'T46', 'id': 'E41', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T47', 'id': 'E42', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}]","[{'id': 'R1', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T32', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T34', 'role': 'Subject'}, 'tail': {'ref_id': 'T29', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T34', 'role': 'Subject'}, 'tail': {'ref_id': 'T30', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E42', 'value': ''}]",[]
73,PMC-2800179-22-Caption-Figure_2,"Degraded CGN stimulated TNF secretion from monocytes.
Levels of TNF released from peripheral blood monocytes (A-B) and THP-1 cells (C-D) after stimulation with dCGN. A: TNF release induced by native CGN (open bars), 10 kDa dCGN (grey bars), or 40 kDa dCGN (black bars). B: Kinetics of TNF release induced by nothing (control; black diamonds), 0.1 mg/ml 10 kDa dCGN (black triangles), 0.1 mg/ml 40 kDa dCGN (black squares), or 10 microg/ml LPS (open squares). C: TNF release induced by nothing (control; open bars), 10 microg/ml LPS (hatched bars), or increasing concentrations of 10 kDa dCGN (grey bars), or 40 kDa dCGN (black bars). D: Kinetics of TNF release induced by nothing (control; black diamonds), 0.1 mg/ml 10 kDa dCGN (black triangles), 0.1 mg/ml 40 kDa dCGN (black squares), or 10 microg/ml LPS (open squares).","[{'offsets': [[24, 27]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[64, 67]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[169, 172]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[285, 288]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[462, 465]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[649, 652]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[13, 23]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[28, 37]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T8'}, {'offsets': [[68, 76]], 'text': ['released'], 'type': 'Localization', 'id': 'T9'}, {'offsets': [[173, 180]], 'text': ['release'], 'type': 'Localization', 'id': 'T10'}, {'offsets': [[181, 188]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[289, 296]], 'text': ['release'], 'type': 'Localization', 'id': 'T12'}, {'offsets': [[297, 304]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[466, 473]], 'text': ['release'], 'type': 'Localization', 'id': 'T14'}, {'offsets': [[474, 481]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[653, 660]], 'text': ['release'], 'type': 'Localization', 'id': 'T16'}, {'offsets': [[661, 668]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T17'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T9', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T12', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T13', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T16', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T17', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}]",[],[],[],[]
74,PMC-3359311-02-Results,"Airway epithelial cells do not produce significant amounts of IL-1beta in response to inflammasome stimulation
The inflammasomes and their respective activators examined in this study are listed in Table 1. Cells were stimulated in accordance with the schedule in Figure 1. In CF, airway epithelial cells have been shown to possess a hyper-inflammatory phenotype and produce an exaggerated pro-inflammatory cytokine response [4], [5]. To determine if airway epithelial cells contribute to the increased IL-1beta production in patients with CF, CF and control bronchial epithelial cell lines were stimulated with the inflammasome inducers P. aeruginosa strain PAO1 (PAO1) and LPS followed by ATP. IL-1beta levels in cell culture supernatants were not greatly increased in either the CF or control cell lines (Fig. 2a-d), although a small increase in IL-1beta production was detected in NuLi-1 and CuFi-1 cells, but not in S9 and IB3-1 cells, by 24 hours. In contrast, these airway cells were highly responsive to other inflammatory stimuli, such as recombinant IL-1beta, producing large quantities of IL-8 (Fig. 2a-d inserts).","[{'offsets': [[62, 70]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[503, 511]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[696, 704]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[849, 857]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1060, 1068]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[31, 38]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[71, 85]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[475, 485]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T8'}, {'offsets': [[493, 502]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[512, 522]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[758, 767]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[837, 845]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[858, 868]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T13'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T9', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T11', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T13', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}]",[]
75,PMC-2674207-02-Materials_and_Methods,"Participants and Study Design
We studied patients with mild asthma who were not treated with inhaled corticosteroids who had been included in a previously reported double-blind, placebo-controlled, crossover study with FP [34]. Seven patients with mild asthma entered the study and were randomized to receive a single inhalation of FP (100 and 500 microg) or a matched placebo control via a spacer chamber, and the other treatment was given after a wash-out period of at least 6 d. Blood was taken for preparation of PBMCs at 1 and 2 h after drug administration. All patients gave informed consent and the study was approved by the Ethics Committee of the Royal Brompton and Harefield Hospitals NHS Trust. The clinical study was conducted before the requirement for Clinical Trial Registration.",[],[],[],[],[],[]
76,PMC-2674207-16-Results,"The Effect of Corticosteroids on GATA-3 Nuclear Translocation and IL-4 mRNA
Corticosteroids are effective in inhibiting GATA-3-regulated IL-4 gene expression in vitro and in vivo [32]. We therefore investigated whether corticosteroids affect anti-CD3/CD28-stimulated nuclear import of GATA-3. Stimulation of cells with anti-CD3/CD28 resulted in a rapid cytoplasmic/nuclear GATA-3 translocation (Figure 1A), confirming our previous results [12]. We also confirmed a clear separation of nuclear and cytosolic fractions as indicated by histone H1 and MEK-1 markers (Figure 1B). The potent topical corticosteroid FP caused sustained loss of nuclear GATA-3 expression and cytoplasmic retention of GATA-3 at concentrations ranging from 10-12 to 10-8 M, which cover the therapeutic range [37]. This effect was concentration- and time-dependent, with a peak effect of 11.6-fold at 30 min at a concentration of 10-8 M (Figure 1C) and was associated with marked reductions in anti-CD3/CD28-stimulated IL-4 and IL-5 mRNA expression (Figure 1D) and a loss of GATA-3 binding to the native IL-5 promoter (Figure 1E).","[{'offsets': [[33, 39]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[66, 70]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[120, 126]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[137, 141]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[285, 291]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[373, 379]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[548, 553]], 'text': ['MEK-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[645, 651]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[692, 698]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[991, 995]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1000, 1004]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1047, 1053]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1076, 1080]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[4, 10]], 'text': ['Effect'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[40, 47]], 'text': ['Nuclear'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[48, 61]], 'text': ['Translocation'], 'type': 'Localization', 'id': 'T16'}, {'offsets': [[96, 105]], 'text': ['effective'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[109, 119]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[127, 136]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T19'}, {'offsets': [[147, 157]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[235, 241]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[256, 266]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[267, 274]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T23'}, {'offsets': [[275, 281]], 'text': ['import'], 'type': 'Localization', 'id': 'T24'}, {'offsets': [[333, 341]], 'text': ['resulted'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[365, 372]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T26'}, {'offsets': [[380, 393]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T27'}, {'offsets': [[612, 618]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T28'}, {'offsets': [[629, 633]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[637, 644]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T30'}, {'offsets': [[652, 662]], 'text': ['expression'], 'type': 'Localization', 'id': 'T31'}, {'offsets': [[667, 678]], 'text': ['cytoplasmic'], 'type': 'Entity', 'id': 'T32'}, {'offsets': [[679, 688]], 'text': ['retention'], 'type': 'Localization', 'id': 'T33'}, {'offsets': [[787, 798]], 'text': ['This effect'], 'type': 'Regulation', 'id': 'T34'}, {'offsets': [[827, 836]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T35'}, {'offsets': [[929, 939]], 'text': ['associated'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[952, 962]], 'text': ['reductions'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[980, 990]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1005, 1020]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T39'}, {'offsets': [[1039, 1043]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1054, 1061]], 'text': ['binding'], 'type': 'Binding', 'id': 'T41'}, {'offsets': [[1081, 1089]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T42'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T15']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T3']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T22', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T24', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T23']}}, {'trigger': 'T25', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T27', 'id': 'E12', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T26']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T28', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T33', 'id': 'E16', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T9', 'T32']}}, {'trigger': 'T31', 'id': 'E17', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T30']}}, {'trigger': 'T34', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T36', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T34', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T36', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T34', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T36', 'id': 'E23', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T35', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T35', 'id': 'E25', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T35', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T37', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T37', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T40', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E34']}}, {'trigger': 'T38', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T38', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T39', 'id': 'E32', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T39', 'id': 'E33', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T41', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T12', 'T13', 'T42']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}]",[]
77,PMC-2800179-03-Materials_and_Methods,"Animals, Chemicals and Diet
Male Wistar rats (150 g average weight) were housed under standard conditions and fed ad libitum with standard rodent laboratory chow. Degraded iota-carrageenans were administered in the drinking water (5% w/v) for 55 days to 2 groups of six animals each. The first group received the low molecular weight carrageenan (10 kDa dCGN) and the second received the medium molecular weight carrageenan (40 kDa dCGN). An additional group of four rats were maintained on regular tap water (control group). To increase palatability 0.2% sucrose was added to the drinking water of all groups (Van der Waaji et al., [23]). Fresh carrageenan solutions were prepared daily.",[],[],[],[],[],[]
78,PMC-2800179-17-Results,"ICAM-1 Expression Is Induced by Degraded CGN and Is Responsible for Monocytes Aggregation In Vitro
In order to study the effect of dCGN on the expression of cell surface antigens, PBM and THP-1 cells were incubated for 36 h in the presence and absence of dCGN. The expression of various cell surface molecules was analyzed by flow cytometry as described in materials and methods. Both forms of dCGN clearly stimulated expression of ICAM-1 (CD54) on PBM and THP-1 cells (Fig. 4A). The increase in ICAM-1 expression was higher on THP-1 cells treated with 40 kDa dCGN (Fig. 4B). Another surface antigen, the lymphocyte function-associated antigen 3 (CD58) was slightly reduced on PBM after treatment with 40 kDa dCGN (Fig. 4B). Interestingly, expression of major histocompatibility complex molecules of class I (HLA-ABC) and of class II (HLA-DR), as well as the monocyte marker CD14, seemed to be reduced by treatment with dCGN (Fig. 4B). However, these differences were not statistically significant.
Treatment with dCGN also induced a strong aggregation of monocytes, detected by phase contrast inverse microscopy (Fig. 5). Although this effect was easily observed in monocytes incubated with the 10 kDa dCGN (Fig. 5B), a more robust cell aggregation was observed in monocytes incubated with the 40 kDa dCGN (Fig. 5C). ICAM-1 has been proposed to be the main adhesion molecule responsible for monocyte aggregation. To confirm this, monocytes were incubated with both types of dCGN in the presence of an anti-ICAM-1 antibody, an anti-CD58 antibody and an isotype control IgG1 antibody. The anti-ICAM-1 antibody effectively blocked the cell aggregates induced by dCGN (Fig. 5D, 5E), strongly suggesting that indeed ICAM-1 is responsible for monocyte aggregation. Both the control IgG1 and the anti-CD58 antibody did not modify monocyte aggregation (data not shown).","[{'offsets': [[0, 6]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[432, 438]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[440, 444]], 'text': ['CD54'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[496, 502]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[605, 645]], 'text': ['lymphocyte function-associated antigen 3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[647, 651]], 'text': ['CD58'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[859, 874]], 'text': ['monocyte marker'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[875, 879]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1318, 1324]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1712, 1718]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[7, 17]], 'text': ['Expression'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[21, 28]], 'text': ['Induced'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[407, 417]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[418, 428]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[484, 492]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[503, 513]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[666, 673]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[740, 750]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[894, 901]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T19'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T14', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T15', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T16', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T19', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}, {'id': '*', 'ref_ids': ['T5', 'T6']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}]",[]
79,PMC-2222968-26-Caption-Figure_2,"Th2 Cells Do Not Express FOXP3
(A) Intracellular FACS analysis of FOXP3 expression in Th1, Th2, or iTreg-differentiated cells (two rounds, phenotype see Figure S1), rested or activated, with or without TGF-beta. FOXP3 expression was measured after 5 d in culture. The dot blots are representative of three independent experiments.
(B) Shows the same experimental setup, but naturally occurring Th2 cells were analyzed. Data are representative of three independent experiments.","[{'offsets': [[25, 30]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[66, 71]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[202, 210]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[212, 217]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[17, 24]], 'text': ['Express'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[72, 82]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[218, 228]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
80,PMC-3333881-10-MATERIALS_AND_METHODS,"Chromatin immunoprecipitation assay
Cells were fixed by adding formaldehyde (Sigma-Aldrich) at the final concentration of 1%. After 10 min, ice-cold PBS plus 0.125 M glycine was added, and plates were transferred on ice, washed extensively with PBS, and scraped. After centrifugation, cells were 10 min lysed in lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40) supplemented with 1x Complete Protease Inhibitor (Roche Diagnostic GmbH). Nuclei were pelletted (1000 x g, 5 min), and resuspended in sonication buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 10 mM EDTA). Chromatin was sonicated using Bandelin Sonoplus GM70 (Bandelin Electronic, Berlin, Germany), centrifuged (14 000 x g, 15 min), and supernatant was 10-fold diluted in dilution buffer (0.01% SDS, 16.7 mM Tris-HCl pH 8.0, 1.1% Triton X-100, 167 mM NaCl, 1.2 mM EDTA). Samples were pre-cleared by 3-h incubation with 20 microl of protein G agarose beads followed by incubation with antibodies against the analysed proteins. Primary antibodies were: anti-p65 (sc-372), anti-IkappaBalpha (sc-203) and rabbit IgG (sc-2027) from Santa Cruz Biotechnology; anti-FLAG M2 from Sigma-Aldrich. Immunoprecipitations were carried out at 4degreesC overnight and immune complexes were collected with protein G agarose beads, washed five times with low salt buffer (20 mM Tris-HCl pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl), four times with high salt buffer (20 mM Tris-HCl pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl), once with TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA), and extracted in TE buffer containing 2% SDS. Protein-DNA cross-links were reverted by heating at 65degreesC overnight. DNA was further purified by QIAquick PCR purification kit (QIAGEN) and eluted in 50 microl sterile distilled water. Specific enrichment in NF-kappaB enhancer sequences was measured by real-time PCR of chromatin immunoprecipitation (ChIP) eluates using SYBR GreenER Master Mix (Invitrogen). Reactions were carried out with the iCycler iQ Real-Time detection system (Bio-Rad Laboratories) using the following conditions: 95degreesC, 1 min; (94degreesC, 10 s; 60degreesC, 30 s) x40. Primers used for MIP-1alpha, GAPDH and ACTB are listed in Supplementary Data. Real-time PCR of CSF3, LTA, NFKBIA and TLR2 were performed using the Custom ChIP array (QIAGEN). For each sample, values were normalized to input DNA and reported as % of input over the rabbit IgG control.","[{'offsets': [[891, 900]], 'text': ['protein G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1247, 1256]], 'text': ['protein G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[2169, 2179]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[2181, 2186]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[2191, 2195]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2247, 2251]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2253, 2256]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2258, 2264]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2269, 2273]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
81,PMC-2222968-04-Results,"IL-4 Inhibits TGF-beta-Mediated iTreg Commitment
IL-4 induces differentiation of naive T cells, upon antigen encounter, into the Th2 cell lineage. We therefore asked whether IL-4 is able to inhibit TGF-beta induction of FOXP3 during the priming of naive T cells. Human CD4+CD45RA+ T cells were activated with plate-bound anti-CD3/CD28 in the presence of TGF-beta and/or IL-4 and harvested after 5 d. IL-4 efficiently repressed the TGF-beta-mediated induction of FOXP3 expression (Figure 5A) in a concentration-dependent manner (Figure 5B). Low levels of GATA3 were induced also in the absence of IL-4, as it was previously observed [3]. However, at low concentration, IL-4 was able to marginally induce FOXP3 expression. Of note, GATA3 was also induced in the presence of TGF-beta at high IL-4 concentration (Figure 5A and 5B). The IL-4-mediated prevention of FOXP3 expression was not caused by interferences of the receptor signaling, because the phosphorylation of SMAD2 or STAT6 was not affected by the addition of IL-4 and/or TGF-beta, which demonstrates that IL-4 as well as TGF-beta signaling were functional under these conditions (Figure 5C). Increasing amounts of IL-4 increase intracellular GATA3, whereas FOXP3 decreased, which is consistent with the mRNA analysis (Figure 5D). Furthermore, injection of IL-4 into wild-type B6 mice decreased the inducible or natural Treg number in vivo. A distinction of the Treg subsets is not possible, because recently activated iTreg cells also express surface CD25. We used complexes of recombinant mouse IL-4 (rmIL-4) plus anti-IL-4 monoclonal antibodies (mAbs), which have been shown to dramatically increase the potency of the cytokine in vivo [19]. In these mice, the percentage of CD4+CD25+ and FOXP3+ T cells dramatically decreased when the antibody-cytokine immune complexes were injected (Figure S2). Upon administration of rmIL-4 plus anti-IL-4 mAb complexes, the total number of CD4+CD25+ T cell, as well as the Foxp3+ T cells diminished by half (Figure S2G and S2H), confirming that the lower percentage was not due to an increase in the CD4+CD25- cells, but a real decrease of CD4+CD25+ T cells. In conclusion, IL-4 negatively regulates the natural or inducible Treg cell turnover not only in vitro but also in vivo. To study the effects of IL-4 on already-existing human natural or inducible Treg cells, we exposed sorted CD25+ T cells (nTreg cells) to IL-4 and analyzed FOXP3 expression and suppressive capacity. In already-existing Treg cells, IL-4 failed to inhibit FOXP3 expression (Figure S3A), and the suppressive capacity was not altered (Figure S3C). Similarly pre-existing iTreg cells did not decrease FOXP3 expression upon IL-4 exposure (Figure S3B).","[{'offsets': [[0, 4]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 22]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 53]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[174, 178]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[198, 206]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[220, 225]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[269, 272]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[273, 279]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[326, 329]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[330, 334]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[354, 362]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[370, 374]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[400, 404]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[431, 439]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[462, 467]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[554, 559]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[596, 600]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[668, 672]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[703, 708]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[730, 735]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[772, 780]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[789, 793]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[832, 836]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[860, 865]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[967, 972]], 'text': ['SMAD2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[976, 981]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1018, 1022]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1030, 1038]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1064, 1068]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1080, 1088]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1173, 1177]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1201, 1206]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1216, 1221]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1315, 1319]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1510, 1514]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1555, 1559]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1561, 1567]], 'text': ['rmIL-4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1579, 1583]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1736, 1739]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1740, 1744]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1750, 1755]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1882, 1888]], 'text': ['rmIL-4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1899, 1903]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1939, 1942]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1943, 1947]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1972, 1977]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2099, 2102]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2103, 2107]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2139, 2142]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2143, 2147]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2173, 2177]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2303, 2307]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2385, 2389]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2416, 2420]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2434, 2439]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2509, 2513]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2532, 2537]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2674, 2679]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2696, 2700]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[190, 197]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[207, 216]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[417, 426]], 'text': ['repressed'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[449, 458]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[468, 478]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[565, 572]], 'text': ['induced'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[585, 592]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T67'}, {'offsets': [[696, 702]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[709, 719]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T69'}, {'offsets': [[745, 752]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[846, 856]], 'text': ['prevention'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[866, 876]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[885, 891]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[948, 963]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T74'}, {'offsets': [[990, 998]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T75'}, {'offsets': [[1151, 1169]], 'text': ['Increasing amounts'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[1178, 1186]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[1222, 1231]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T78'}, {'offsets': [[1494, 1501]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[2440, 2450]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T80'}, {'offsets': [[2455, 2475]], 'text': ['suppressive capacity'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[2524, 2531]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[2538, 2548]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T83'}, {'offsets': [[2567, 2591]], 'text': ['the suppressive capacity'], 'type': 'Anaphora', 'id': 'T60'}, {'offsets': [[2600, 2607]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T84'}, {'offsets': [[2665, 2673]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[2680, 2690]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T86'}]","[{'trigger': 'T61', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T4']}}, {'trigger': 'T62', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T5']}}, {'trigger': 'T63', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T13']}}, {'trigger': 'T64', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T14']}}, {'trigger': 'T65', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T66', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T16', 'E7']}}, {'trigger': 'T67', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T68', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T18']}}, {'trigger': 'T69', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T70', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T21']}}, {'trigger': 'T70', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T22']}}, {'trigger': 'T71', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T23']}}, {'trigger': 'T72', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T73', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T74', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T74', 'id': 'E16', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T75', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T27']}}, {'trigger': 'T75', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T28']}}, {'trigger': 'T75', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T27']}}, {'trigger': 'T75', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T28']}}, {'trigger': 'T76', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T77', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T32', 'E21']}}, {'trigger': 'T78', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'E21']}}, {'trigger': 'T79', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T80', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T81', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T54']}}, {'trigger': 'T82', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T56']}}, {'trigger': 'T83', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T84', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T85', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T59']}}, {'trigger': 'T86', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}]","[{'id': 'R1', 'head': {'ref_id': 'T60', 'role': 'Subject'}, 'tail': {'ref_id': 'T82', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T36', 'T37']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E18', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E26', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E27', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E29', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}]",[]
82,PMC-2806624-20-MATERIALS_AND_METHODS,"Pull-down assay.
HEK293T cells were transfected with RUNX1 or RUNX3 using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instruction. Cells were lysed by sonication in HKMG buffer (10 mM Hepes, pH 7.9, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 1 mM DTT, 0.5% Nonidet P-40) containing a protease inhibitor cocktail (Roche Diagnostics). The cell lysate was precleared using streptavidin-agarose beads (GE Healthcare), incubated with biotinylated double-stranded oligonucleotides containing the wild-type or mutated RUNX binding sites, and polydeoxyinosinicdeoxycytidylic acid (Sigma-Aldrich). A combination of all three oligonucleotides containing the mutated or the wild-type binding sites was used in the assay. DNA-bound proteins were collected with streptavidin-agarose beads, washed with HKMG buffer, and finally resuspended in NuPAGE loading buffer (Invitrogen Life Technologies), heated to 70degreesC for 10 min, and separated on a NuPAGE 4-12% Bis-Tris gel (Invitrogen Life Technologies). The proteins were electroblotted onto a PVDF membrane (GE Healthcare) and detected using RUNX1 or RUNX3 antibodies described in the previous section.","[{'offsets': [[53, 58]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 67]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1109, 1114]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1118, 1123]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[36, 47]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T5'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],[],[]
83,PMC-1920263-07-MATERIALS_AND_METHODS,"Chromatin immunoprecipitation (ChIP) assay
A3.01 cells were treated with RPMI culture medium containing 1% formaldehyde for 10 min. at 37degreesC. Cells were washed twice with ice-cold PBS and incubated for 10 min. on ice after resuspension in SDS lysis buffer (ChIP Assay Kit, Upstate). After centrifugation, pellets were resuspended in MNase reaction buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 3 mM MgCl2, 1 mM CaCl2, 4% NP-40). DNA digestion was performed using 50 U Micrococcal Nuclease (Fermentas) and 1 x 107 cells per tube in a volume of 1.5 ml. After 2 min, reaction was stopped by adding 30 microl 200 mM EGTA. Further steps were performed using the Chromatin Immunoprecipitation Assay Kit (Upstate) according to the manufacturer's instructions. 1 x 107 cells and 2 microg antibody (Sp1(Pep2) sc-59, Sp3(D-20) sc-644 or actin(H-196) sc-7210, Santa Cruz Biotechnology) were used for each immunoprecipitation. All buffers were freshly supplied with protease inhibitors. After phenol/chloroform extraction and ethanol precipitation, DNA was resolved in 16 microl H2O. Immunoprecipitated DNA was detected by nested PCR using 4 microl of the resolved DNA in the first PCR, and 1 microl for the nested PCR. For amplification of the A3G promoter, the following primers were used: ChIP3Gplus 5'-ccacggtggcctccgagggtga-3' and ChIP3Gminus: 5'-ctctccaccatcaagacagac-3' (1. PCR); ChIP3G2plus: 5'-tactctccctccctgtcccca-3' and ChIP3G nested minus: 5'-aggctgatgcctccgcag-3' (nested PCR). Taq polymerase (Qiagen) was used together with the following cycle conditions: one cycle 94degreesC for 2 min; 30 cycles 94degreesC for 30 s, 60degreesC for 60 s, 72degreesC for 2 min; one cycle 72degreesC for 10 min. As a negative control, a region in the A3G gene was targeted using the primers ChIP3Gneg_plus: 5'-taagtaccacccagagatgag-3' and ChIP3Gneg_minus: 5'-catgatcttcatggtggcacg-3' for both PCR steps. PCR conditions were the same as for the A3G promoter sequence, with the exception that annealing temperature was decreased to 55degreesC.","[{'offsets': [[470, 490]], 'text': ['Micrococcal Nuclease'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[792, 795]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[809, 812]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[829, 834]], 'text': ['actin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1235, 1238]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1482, 1496]], 'text': ['Taq polymerase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1739, 1742]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1932, 1935]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
84,PMC-3359311-27-Caption-Table_1,Inflammasome Activators.,[],[],[],[],[],[]
85,PMC-2674207-11-Materials_and_Methods,"GATA-3-GFP Construct
The GATA-3 clone (BC003070) complete cDNA was obtained from Invitrogen Life Technologies as a 5'- EcoRI/3'-XhoI insert of GATA-3 in the pOTB7 vector. GATA-3 was excised from pOTB7 using XhoI digestion and pEGFP-C2 (Clontech, Saint-Germain-en-Laye, France) was digested with BamHI. DNA was recovered by phenol extraction and ethanol precipitation, and both the GATA-3 fragment and the pEGFP-C2 vector blunt-ended by incubation with Klenow (Bioline Bio-27029) for 30 min at 37degreesC. Klenow was inactivated by incubation for 10 min at 75degreesC. DNA was recovered by phenol extraction and ethanol precipitation, and both the blunt-ended GATA-3 fragment and the GFP vector were subsequently digested with EcoRI before the 5'-EcoRI/3'-blunt end GATA-3 fragment was inserted into the 5'-EcoRI/3'-blunt ended GFP vector. Positive clones were confirmed by digestion and size analysis by 1% agarose gel electrophoresis and by sequencing.","[{'offsets': [[0, 6]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[7, 10]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[25, 31]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[143, 149]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[171, 177]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[207, 211]], 'text': ['XhoI'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[295, 300]], 'text': ['BamHI'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[381, 387]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[659, 665]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[683, 686]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[726, 731]], 'text': ['EcoRI'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[765, 771]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[827, 830]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T13'}]",[],[],[],[],[]
86,PMC-3062687-03-Results,"RPS3 and IKKbeta interaction
The activation of the inhibitor of kappaB kinase (IKK), consisting of a regulatory subunit IKKgamma and two catalytic subunits, IKKalpha and IKKbeta, is critical for the phosphorylation and dispatch of the inhibitory IkappaBs and the liberation of NF-kappaB20-22. Given that RPS3 can be found in the cytoplasmic p65-p50-IkappaBalpha inhibitory complex in resting cells6, we hypothesized that activated IKKbeta might also bind to and phosphorylate RPS3. First, we found that ectopically expressed IKKbeta and RPS3 interacted (Fig. 1c). We next examined resting Jurkat cells and detected a modest endogenous IKKbeta-RPS3 interaction (Fig. 1d), potentially accounting for the basal NF-kappaB transcription required for cell proliferation and survival. RPS3-IKKbeta association was clearly augmented upon TNF stimulation, peaking at 10 min. (Fig. 1d), following similar kinetics to RPS3 serine phosphorylation (Fig. 1b). By contrast, there was no detectable interaction between RPS3 and IKKalpha (Fig. 1d).","[{'offsets': [[0, 4]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[9, 16]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[120, 128]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[157, 165]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[170, 177]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[304, 308]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[341, 344]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[345, 348]], 'text': ['p50'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[349, 361]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[431, 438]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[476, 480]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[525, 532]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[537, 541]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[635, 642]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[643, 647]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[778, 782]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[783, 790]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[907, 911]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1003, 1007]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1012, 1020]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[17, 28]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T21'}, {'offsets': [[421, 430]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[450, 454]], 'text': ['bind'], 'type': 'Binding', 'id': 'T23'}, {'offsets': [[462, 475]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T24'}, {'offsets': [[515, 524]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[542, 552]], 'text': ['interacted'], 'type': 'Binding', 'id': 'T26'}, {'offsets': [[648, 659]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T27'}, {'offsets': [[791, 802]], 'text': ['association'], 'type': 'Binding', 'id': 'T28'}, {'offsets': [[815, 824]], 'text': ['augmented'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[877, 886]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[912, 918]], 'text': ['serine'], 'type': 'Entity', 'id': 'T31'}, {'offsets': [[919, 934]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T32'}, {'offsets': [[983, 994]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T33'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T2']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T10', 'T11']}}, {'trigger': 'T24', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T25', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T26', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T12', 'T13']}}, {'trigger': 'T27', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T14', 'T15']}}, {'trigger': 'T28', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T29', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T30', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E9']}}, {'trigger': 'T32', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T18', 'T31']}}, {'trigger': 'T33', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T19', 'T20']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}]",[]
87,PMC-1134658-14-Methods,"Western-blot analysis
B cells from peripheral blood or cultured cell-lines were lysed in lysis buffer (glycerol 10%, beta-mercaptoethanol 5%, 0.0625 M Tris-HCL [pH 6.8], sodium dodecyl sulphate [SDS] 2.5%w/vol). Total protein (30-100 mug) from each sample was run on 10% or 12% SDS/polyacrylamide (SDS/PAGE) gels and blotted onto nitrocellulose filters (Protran; Schleicher &Schuell GmbH, Dassel, Germany). Blocking, washing and incubation of the filters with primary antibodies were done according to the manufacturer's protocols at room temperature (RT). After washing with TBS/0.1% Tween-20 (TBS-T), the filters were incubated with horseradish peroxidase (HRP) coupled to relevant secondary antibodies (see above) for 60 minutes at RT. Enzyme activity was visualised by the enhanced chemiluminescence system, ECL+PLUS (Amersham, Buckinghamshire, UK). Densitometric analysis was performed by scanning hyperfilms on a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA). Quantification of Id1, Id2 and Id3 protein was calculated by normalizing the specific protein bands to beta-actin using Image Quant 5.5 software (Molecular Dynamics).","[{'offsets': [[999, 1002]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1004, 1007]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1012, 1015]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1084, 1094]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
88,PMC-3359311-14-Materials_and_Methods,"Immunoblotting
1x106 cells were seeded in 12-well plates, stimulated as indicated, and lysed in RIPA buffer supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific). Protein concentrations were determined by Bradford assay (Thermo Scientific). Lysates were resolved by electrophoreses on 10% SDS-polyacrylamide gels and transferred onto PVDF membranes (Millipore). Blots were blocked for 1 hour at room temperature and probed overnight at 4degreesC for pro-IL-1beta (Santa Cruz), IkappaBalpha (Cell Signaling), or beta-actin (Cell Signaling). Blots were subsequently probed with fluorescently-labeled secondary antibodies, IRDye(R) 680 or 800CW (LI-COR Biosciences) for 1 hour. Both blocking and probing steps were carried out in tris-buffered saline (G Biosciences) containing 5% bovine serum albumin and 0.1% TWEEN 20 (Calbiochem). Blots were imaged on a LI-COR Odyssey infrared imaging system (LI-COR Biosciences) and quantified using the included analysis software.","[{'offsets': [[510, 522]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[544, 554]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
89,PMC-2800179-12-Materials_and_Methods,"Analysis of NF-kappaB Activation by Flow Cytometry
Nuclear activation of NF-kappabeta by flow cytometry was performed as described [31].",[],[],[],[],[],[]
90,PMC-3333881-19-Caption-Figure_2,"Tat enhances the NF-kappaB activity following PMA stimulation by associating with IkappaB-alpha and counteracting the NF-kappaB repression. HeLa cells (5 x 106) were transfected with p3xFLAG-Tat or p3xFLAG empty vector (5 microg), and 48 h later were stimulated with PMA (5 min, 20 ng/ml) or left unstimulated, washed twice with DMEM and harvested at the indicated times. Nuclear and cytosolic extracts were prepared for further analysis. (A) Nuclear extracts were analysed for the p65, p50 and FLAG-Tat binding to the NF-kappaB double-stranded oligonucleotide using the NF-kappaB Transcription Factor ELISA assay kit (Cayman). (B) Nuclear and cytosolic extracts (20 microg) were separated by 12% SDS-PAGE and analysed by western blotting using the anti-p65, anti-FLAG, anti-Histone H1, anti-IkappaB-alpha and anti-Hexokinase-II antibodies. Densitometry values (D) of the bands were expressed as fold increase above the control (lane 1). (C) IKK activity was measured in cytosolic extracts (100 microg) by using HTScan IKK kinase assay (Cell Signaling Technology). (D) HeLa cells (5 x 106) were transfected with or without p3xFLAG-Tat (5 microg); 48 h later, cells were stimulated with PMA (5 min, 20 ng/ml) or left unstimulated, washed twice with DMEM, and harvested after 240 min. Whole cell extracts (1 mg) were immunoprecipitated with protein G-Sepharose-coupled anti-IkappaB-alpha antibody. Immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-p65, anti-FLAG and anti-IkappaB-alpha antibodies. Densitometry values (D) of the bands were expressed as fold increase above the control (lane 1). Values (mean +/- SE, n = 3) are shown.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[82, 95]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[191, 194]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[482, 485]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[487, 490]], 'text': ['p50'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[495, 503]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1131, 1134]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1339, 1348]], 'text': ['protein G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[65, 76]], 'text': ['associating'], 'type': 'Binding', 'id': 'T9'}, {'offsets': [[504, 511]], 'text': ['binding'], 'type': 'Binding', 'id': 'T10'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T10', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
91,PMC-1134658-07-Results,"BMP-6 production in B cells
The fact that BMP-6 has been reported to act as an autocrine stimulator in chondrocytes [18] and ovarium [19], prompted us to investigate whether normal human B cells could produce BMP-6 upon stimulation. Ramos cells, which have been described to express BMP-6 mRNA endogenously [20], and the T cell line Jurkat, served as positive and negative controls, respectively. Endogenous BMP-6 mRNA levels in normal B cells were quantified by real-time RT-PCR after stimulation with anti-IgM for different time points. Interestingly, the up-regulation of BMP-6 mRNA was characteristic of an early-to intermediate inducible gene with maximal upregulation four hours after the addition of anti-IgM. The level of BMP-6 mRNA was back to baseline after 24 hours upon stimulation (Figure 10). Furthermore, both FCS and human AB-serum induced significant upregulation of BMP-6 mRNA (Figure 11). Interestingly, in a separate study we have found that normal human T cells do not express BMP-6 mRNA after activation (Sivertsen et al, manuscript in preparation). Next, we wanted to detect BMP-6 protein in normal B-cells and tested various commercially available antibodies. However, in our hands these anti-BMP-6 antibodies did only recognize the recombinant BMP-6 protein and not the native protein.","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[42, 47]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[209, 214]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[283, 288]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[408, 413]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[575, 580]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[730, 735]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[884, 889]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[998, 1003]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1098, 1103]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1217, 1222]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1269, 1274]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[6, 16]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[201, 208]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[275, 282]], 'text': ['express'], 'type': 'Transcription', 'id': 'T16'}, {'offsets': [[558, 571]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[661, 673]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[745, 761]], 'text': ['back to baseline'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[848, 855]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[868, 880]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[990, 997]], 'text': ['express'], 'type': 'Transcription', 'id': 'T22'}, {'offsets': [[1243, 1252]], 'text': ['recognize'], 'type': 'Binding', 'id': 'T23'}, {'offsets': [[1291, 1309]], 'text': ['the native protein'], 'type': 'Anaphora', 'id': 'T13'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T22', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T23', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]","[{'id': 'R1', 'head': {'ref_id': 'T13', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}]",[]
92,PMC-2806624-11-MATERIALS_AND_METHODS,"Immunohistochemistry.
Human tonsils were obtained from tonsillectomy samples of hypertrophic and obstructive tonsils without a current infection. Ethical permission was obtained from Cantonal Ethics Commission, and informed consent was obtained from patients. Paraformaldehyde-fixed tonsil cryosections were stained with unconjugated rabbit IgG polyclonal antibody to human RUNX1 (Santa Cruz Biotechnology, Inc.) or unconjugated mouse IgG1 mAb to human RUNX3 (Abcam). After a washing step, the sections were stained with the corresponding secondary antibodies. RUNX1-binding antibodies were detected by using Alexa Fluor 633-conjugated goat anti-rabbit IgG and RUNX3-binding antibodies were detected by using Alexa Fluor 532-conjugated goat anti-mouse IgG1. Afterward, the sections were washed and in the case of RUNX3 staining a blocking step with an unconjugated mouse IgG1 mAb was used. Finally, the sections were stained with Alexa Fluor 488-conjugated mouse IgG1 mAb to human FOXP3 (eBioscience) or the corresponding isotype control. Tissue sections were stained with DAPI for the demonstration of nuclei and mounted with Prolong antifade (Invitrogen). Images were acquired and analyzed using the confocal microscope DMI 4000B and the TCS SPE system (both from Leica).","[{'offsets': [[374, 379]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[453, 458]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[561, 566]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[661, 666]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[813, 818]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[981, 986]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[567, 574]], 'text': ['binding'], 'type': 'Binding', 'id': 'T7'}, {'offsets': [[667, 674]], 'text': ['binding'], 'type': 'Binding', 'id': 'T8'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
93,PMC-3359311-26-Caption-Figure_8,"Disruption of CFTR activity does not increase IL-1beta production in PBMCs or macrophages.
PBMCs from CF patients (n = 15) and controls (n = 13) were treated with CFTRinh172 (10 microM) for 18 hours prior to stimulation with live PAO1 (MOI = 1). (A) IL-1beta and (B) IL-8 production was measured at 24 hours. (C) Monocytes from controls (n = 3) were differentiated into macrophages. Macrophages were treated with CFTRinh172, stimulated as per monocytes, and measured for IL-1beta production at 24 hours. THP-1 reporter cells were treated with CFTRinh172 24 hours prior to stimulation with PAO1 and measured for (D) IL-1beta secretion, (E) IL-8, and (F) NF-kappaB/AP-1 activity at 24 hours (n = 4).","[{'offsets': [[46, 54]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[250, 258]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[471, 479]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[615, 623]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[37, 45]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[55, 65]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[272, 282]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[480, 490]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[624, 633]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T9'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
94,PMC-2800179-26-Caption-Figure_6,"Degraded CGN stimulated ICAM-1 and TNF-alpha gene expression in monocytes.
Representative samples of RT-PCR analysis showing over expression of ICAM-1 and TNF-alpha after stimulation of monocytes with 1 g/l of degraded CGN. beta-actin expression was used as normalization gene.","[{'offsets': [[24, 30]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[35, 44]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[144, 150]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[155, 164]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[224, 234]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[13, 23]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[50, 60]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[130, 140]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[235, 245]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T9'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T7', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T9', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]",[],[],[],[]
95,PMC-3333881-15-RESULTS,"Tat activates the p65-dependent expression of NF-kappaB-responsive genes, occupies the NF-kappaB enhancers and promotes the p65 recruitment with IkappaB-alpha displacement
We analysed the action of Tat on the expression of NF-kappaB-responsive genes in vivo. To this end, HeLa cells were transfected with FLAG-Tat, FLAG-Tat C(22,25,27)A or FLAG-Tat R(49-57)A, and 48 h later the expression of a number of NF-kappaB-dependent genes was analysed by real-time PCR. Tat significantly increased the expression of MIP-1alpha, CSF3, LTA, NFKBIA and TLR2, while the mutants Tat C(22,25,27)A and Tat R(49-57)A were ineffective (Figure 5A-E). The Tat-dependent transactivation of the NF-kappaB-dependent genes was abolished when cells were transfected with siRNA p65, indicating that the Tat transcriptional activation was mediated by p65 (Figure 5A-E). Differently, the expression of the NF-kappaB-independent genes GAPDH and ACTB was unaffected by wild-type and Tat mutants (Figure 5F and G). These results were consistent with the requirement of both the cysteine-rich and arginine-rich domains of Tat to enhance the NF-kappaB activity, suggesting that the up-regulation of NF-kappaB-responsive genes by Tat might occur through physical interaction of the viral protein with p65 and IkappaB-alpha.
MIP-1alpha, which was the mostly activated gene by Tat, encodes for a chemokine that promotes the recruitment of pro-inflammatory cells (56). Consistently with our findings, MIP-1alpha expression was increased in glial cells and lymph nodes of AIDS patients (57,58); moreover, MIP-1alpha production was induced by HIV-1 infection (59,60) and Tat protein (57,61,62). The transcriptional regulation of MIP-1alpha has been poorly characterized. Jaspar-based analysis (http://jaspar.genereg.net/) predicted three putative NF-kappaB enhancers in the proximal promoter region of the MIP-1alpha gene: NF-kappaB1, -1023/-1014 nucleotides; NF-kappaB2, -661/-652 nucleotides; NF-kappaB3, +370/+379 nucleotides (Supplementary Figure S3A). To validate the predicted NF-kappaB binding sites of the MIP-1alpha promoter, we stimulated HeLa cells with TNF-alpha, a well-known NF-kappaB inducer, and measured the expression levels of MIP-1alpha by real-time PCR, and the p65 occupancy of the NF-kappaB sites by ChIP. TNF-alpha activated the expression of MIP-1alpha and induced the p65 recruitment to the NF-kappaB1 site of MIP-1alpha without affecting the occupancy of the putative NF-kappaB2 and NF-kappaB3 sites (Supplementary Figure S3B and S3C). Tat also promoted the recruitment of p65 to the NF-kappaB1 site of MIP-1alpha, while it did not affect the putative NF-kappaB2 and NF-kappaB3 sites (Supplementary Figure S3D). Altogether these results indicated that the NF-kappaB1 site was the only effective NF-kappaB enhancer of the MIP-1alpha promoter in response to TNF-alpha and Tat.
Similarly to MIP-1alpha, Tat increased the recruitment of p65 to the NF-kappaB enhancers of CSF3, LTA, NFKBIA and TLR2, while it was ineffective at the promoters of GAPDH and ACTB (Figure 5H). By ChIP, Tat bound to the NF-kappaB-responsive promoters, and not to the GAPDH and ACTB promoters, with loss of binding following p65 RNA interference (Figure 5I), suggesting that Tat occupancy occurred via p65 interaction. As additional findings, IkappaB-alpha was chromatin-immunoprecipitated at the NF-kappaB enhancers in absence of Tat, and it was significantly removed in presence of Tat, or following IkappaB-alpha RNA interference (Figure 5J), indicating that Tat displaced IkappaB-alpha from promoters.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 21]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[124, 127]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[145, 158]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[198, 201]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[305, 313]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 336]], 'text': ['FLAG-Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[340, 358]], 'text': ['FLAG-Tat R(49-57)A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[462, 465]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[508, 518]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[520, 524]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[526, 529]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[531, 537]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[542, 546]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[566, 582]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[587, 600]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[637, 640]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[747, 756]], 'text': ['siRNA p65'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[778, 781]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[825, 828]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[907, 912]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[917, 921]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[954, 957]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1091, 1094]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1197, 1200]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1268, 1271]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1276, 1289]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1291, 1301]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1342, 1345]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1465, 1475]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1568, 1578]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1633, 1636]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1691, 1701]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1868, 1878]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2076, 2086]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2127, 2136]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2208, 2218]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2245, 2248]], 'text': ['p65'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2291, 2300]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2329, 2339]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2356, 2359]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2398, 2408]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2525, 2528]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2562, 2565]], 'text': ['p65'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2592, 2602]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2810, 2820]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2845, 2854]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2859, 2862]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2877, 2887]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2889, 2892]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2922, 2925]], 'text': ['p65'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2956, 2960]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2962, 2965]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2967, 2973]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2978, 2982]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3029, 3034]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3039, 3043]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3066, 3069]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3130, 3135]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3140, 3144]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3187, 3190]], 'text': ['p65'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3237, 3240]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3264, 3267]], 'text': ['p65'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[3305, 3318]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[3393, 3396]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[3446, 3449]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[3464, 3477]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[3524, 3527]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3538, 3551]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[74, 82]], 'text': ['occupies'], 'type': 'Binding', 'id': 'T76'}, {'offsets': [[111, 119]], 'text': ['promotes'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[128, 139]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T78'}, {'offsets': [[159, 171]], 'text': ['displacement'], 'type': 'Binding', 'id': 'T79'}, {'offsets': [[480, 489]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[494, 504]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[554, 565]], 'text': ['the mutants'], 'type': 'Anaphora', 'id': 'T70'}, {'offsets': [[606, 617]], 'text': ['ineffective'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[1230, 1241]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T83'}, {'offsets': [[1245, 1262]], 'text': ['the viral protein'], 'type': 'Anaphora', 'id': 'T71'}, {'offsets': [[1303, 1308]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T72'}, {'offsets': [[1324, 1333]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T84'}, {'offsets': [[1476, 1486]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T85'}, {'offsets': [[1491, 1500]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[1579, 1589]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[1594, 1601]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[1661, 1676]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T89'}, {'offsets': [[1677, 1687]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T90'}, {'offsets': [[2187, 2197]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T91'}, {'offsets': [[2249, 2258]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T92'}, {'offsets': [[2266, 2281]], 'text': ['NF-kappaB sites'], 'type': 'Entity', 'id': 'T93'}, {'offsets': [[2301, 2310]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[2315, 2325]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[2344, 2351]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[2360, 2371]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T97'}, {'offsets': [[2379, 2394]], 'text': ['NF-kappaB1 site'], 'type': 'Entity', 'id': 'T98'}, {'offsets': [[2417, 2426]], 'text': ['affecting'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[2431, 2440]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T100'}, {'offsets': [[2534, 2542]], 'text': ['promoted'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[2547, 2558]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T102'}, {'offsets': [[2573, 2588]], 'text': ['NF-kappaB1 site'], 'type': 'Entity', 'id': 'T103'}, {'offsets': [[2610, 2612]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T73'}, {'offsets': [[2893, 2902]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[2907, 2918]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T105'}, {'offsets': [[2933, 2952]], 'text': ['NF-kappaB enhancers'], 'type': 'Entity', 'id': 'T106'}, {'offsets': [[2990, 2992]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T74'}, {'offsets': [[2997, 3008]], 'text': ['ineffective'], 'type': 'Positive_regulation', 'id': 'T107'}, {'offsets': [[3016, 3025]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T108'}, {'offsets': [[3070, 3075]], 'text': ['bound'], 'type': 'Binding', 'id': 'T109'}, {'offsets': [[3145, 3154]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T110'}, {'offsets': [[3161, 3165]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[3169, 3176]], 'text': ['binding'], 'type': 'Anaphora', 'id': 'T75'}, {'offsets': [[3195, 3207]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T112'}, {'offsets': [[3241, 3250]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T113'}, {'offsets': [[3260, 3263]], 'text': ['via'], 'type': 'Positive_regulation', 'id': 'T114'}, {'offsets': [[3268, 3279]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T115'}, {'offsets': [[3323, 3351]], 'text': ['chromatin-immunoprecipitated'], 'type': 'Binding', 'id': 'T116'}, {'offsets': [[3423, 3430]], 'text': ['removed'], 'type': 'Negative_regulation', 'id': 'T117'}, {'offsets': [[3482, 3494]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T118'}, {'offsets': [[3528, 3537]], 'text': ['displaced'], 'type': 'Negative_regulation', 'id': 'T119'}, {'offsets': [[3552, 3556]], 'text': ['from'], 'type': 'Binding', 'id': 'T120'}]","[{'trigger': 'T76', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T77', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T1']}}, {'trigger': 'T78', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T77', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T1']}}, {'trigger': 'T79', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T3', 'T4']}}, {'trigger': 'T80', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T9']}}, {'trigger': 'T81', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T80', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T9']}}, {'trigger': 'T81', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T80', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T9']}}, {'trigger': 'T81', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T80', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T9']}}, {'trigger': 'T81', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T80', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T9']}}, {'trigger': 'T81', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T82', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T15']}}, {'trigger': 'T82', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T16']}}, {'trigger': 'T82', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T15']}}, {'trigger': 'T82', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T16']}}, {'trigger': 'T82', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T15']}}, {'trigger': 'T82', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T16']}}, {'trigger': 'T82', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T15']}}, {'trigger': 'T82', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T16']}}, {'trigger': 'T82', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T15']}}, {'trigger': 'T82', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T16']}}, {'trigger': 'T83', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T25', 'T26']}}, {'trigger': 'T84', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T29']}}, {'trigger': 'T85', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T86', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T87', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T88', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T32']}}, {'trigger': 'T89', 'id': 'E32', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T90', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T91', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T92', 'id': 'E35', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T37', 'T38', 'T93']}}, {'trigger': 'T94', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'T39']}}, {'trigger': 'T95', 'id': 'E37', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T96', 'id': 'E38', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'T39']}}, {'trigger': 'T97', 'id': 'E39', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T41', 'T42', 'T98']}}, {'trigger': 'T99', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'T39']}}, {'trigger': 'T100', 'id': 'E41', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T101', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'T43']}}, {'trigger': 'T102', 'id': 'E43', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T44', 'T45', 'T103']}}, {'trigger': 'T104', 'id': 'E44', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T50']}}, {'trigger': 'T105', 'id': 'E45', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T51', 'T52', 'T106']}}, {'trigger': 'T104', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'T50']}}, {'trigger': 'T105', 'id': 'E47', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T51', 'T53', 'T106']}}, {'trigger': 'T104', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E49', 'T50']}}, {'trigger': 'T105', 'id': 'E49', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T51', 'T54', 'T106']}}, {'trigger': 'T104', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'T50']}}, {'trigger': 'T105', 'id': 'E51', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T51', 'T55', 'T106']}}, {'trigger': 'T107', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T56', 'T50', 'T108']}}, {'trigger': 'T107', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T57', 'T50', 'T108']}}, {'trigger': 'T109', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T58', 'T59', 'T110']}}, {'trigger': 'T111', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'E56']}}, {'trigger': 'T112', 'id': 'E56', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T113', 'id': 'E57', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T114', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E57', 'E59']}}, {'trigger': 'T115', 'id': 'E59', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T62', 'T63']}}, {'trigger': 'T116', 'id': 'E60', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T117', 'id': 'E61', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'T66']}}, {'trigger': 'T117', 'id': 'E62', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E63']}}, {'trigger': 'T118', 'id': 'E63', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T119', 'id': 'E64', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E65', 'T68']}}, {'trigger': 'T120', 'id': 'E65', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}]","[{'id': 'R1', 'head': {'ref_id': 'T70', 'role': 'Subject'}, 'tail': {'ref_id': 'T15', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T70', 'role': 'Subject'}, 'tail': {'ref_id': 'T16', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T71', 'role': 'Subject'}, 'tail': {'ref_id': 'T25', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T72', 'role': 'Subject'}, 'tail': {'ref_id': 'T28', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T73', 'role': 'Subject'}, 'tail': {'ref_id': 'T43', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T74', 'role': 'Subject'}, 'tail': {'ref_id': 'T50', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T75', 'role': 'Subject'}, 'tail': {'ref_id': 'T109', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E18', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E21', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E34', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E35', 'value': ''}, {'id': 'M14', 'type': 'Negation', 'ref_id': 'E40', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E52', 'value': ''}, {'id': 'M16', 'type': 'Negation', 'ref_id': 'E53', 'value': ''}, {'id': 'M17', 'type': 'Negation', 'ref_id': 'E54', 'value': ''}, {'id': 'M18', 'type': 'Speculation', 'ref_id': 'E58', 'value': ''}, {'id': 'M19', 'type': 'Speculation', 'ref_id': 'E59', 'value': ''}]",[]
96,PMC-1920263-19-Caption-Figure_4,"A3G promoter activities after coexpression of HIV-1 proteins or treatment with TPA or interferons. (A) A3.01 T cells were cotransfected with pGL3-Basic reporter plasmid containing the 1025 bp A3G promoter and 1 microg of Vif expression plasmid, 1 microg Tat expression plasmid or increasing amounts of HIV-1NL4-3 (0.1, 0.5 and 1 microg). After 48 h, cells were harvested for luciferase assay. Firefly luciferase activities were normalized to coexpressed renilla luciferase activities. (B) A3.01 T cells were transiently transfected with pGL3-Basic reporter plasmid containing the 1025 bp A3G promoter or with empty vector. Fifteen hour before harvesting for luciferase assay, a subset of the cell culture was stimulated with 20 ng/ml TPA. Forty-eight hour after transfection, luciferase assay was performed. Firefly luciferase activities were normalized to coexpressed renilla luciferase activities and the values for the empty vectors (untreated and TPA-stimulated) were set as 1. (C) A3.01 T cells were transiently transfected with the A3G promoter constructs or with the interferon-responsive reporter plasmid pGL2-CVX (GAS). Fifteen hour before harvesting for luciferase assay, a subset of the cell culture was stimulated with 30 ng/ml IFN-alpha or IFN-gamma. Forty-eight hour after transfection, luciferase assay was performed. Firefly luciferase activities were normalized to coexpressed renilla luciferase activities. (D) HepG2 cells were used for transfection. The experiment was performed as described in (C). Mean values (+/-SD) of representative experiments performed in triplicate are shown.","[{'offsets': [[0, 3]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[192, 195]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[221, 224]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[254, 257]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[375, 385]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[401, 411]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[462, 472]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[588, 591]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[658, 668]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[776, 786]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[816, 826]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[877, 887]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1038, 1041]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1074, 1084]], 'text': ['interferon'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1164, 1174]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1240, 1249]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1253, 1262]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1301, 1311]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1341, 1351]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1402, 1412]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[442, 453]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[857, 868]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[1382, 1393]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T23', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}]",[],[],[],[]
97,PMC-2806624-30-Caption-Figure_6,"CbfbF/F CD4-cre mouse cells and iT reg cells generated from human naive CD4+ T cells undergoing siRNA-mediated RUNX1 and RUNX3 knock down show a diminished suppressive activity. Experimental setup (A) and results of the mouse suppression assay (B), FACS-purified naive CD4+8- T cells from CbfbF/F CD4-cre (left) and control CbfbF/+ CD4-cre mice (Cd45.2; right) were activated in vitro with anti-CD3/28 mAb, 50 U/ml IL-2, and 2.5 ng/ml TGF-beta. After 3 d, Foxp3-GFP+ cells were FACS-sorted and mixed with CFSE-loaded naive CD45.1+ CD4+ cells at the indicated ratios. These were then incubated with inactivated splenocytes and anti-CD3 mAb. After a further 4 d, CD45.1+ cells were analyzed for CFSE dilution. (C) As a control, CbfbF/+ CD4-cre CD4+ T cells activated in absence of TGF-beta were mixed with CFSE-loaded naive CD45.1+ CD4+ cells at the indicated ratios. Four days later CD45.1+ cells were analyzed for CFSE dilution. The median division number (of the naive CD45.1+ CD4+ cells in the cultures containing Foxp3-GFP+ cells) is indicated in each of the histograms. One of three experiments is shown. (D) Human naive CD4+ T cells, transfected with RUNX1 and RUNX3 siRNA and cultured under iT reg differentiating conditions were used in an in vitro suppression assay, cultured together with autologous CFSE-labeled CD4+ T cells, and stimulated with anti-CD3 mAb. The CFSE dilution of the CD4+ T cell responder cells was analyzed after 5 d by flow cytometry. The T reg/responder CD4+ T cell ratios used were 1:20, 1:10, and 1:5. One of two experiments is shown.","[{'offsets': [[0, 4]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 15]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[72, 75]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[111, 116]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[121, 126]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[269, 272]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[273, 274]], 'text': ['8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[289, 293]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[297, 304]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[324, 328]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[332, 339]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[346, 352]], 'text': ['Cd45.2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[395, 398]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[399, 401]], 'text': ['28'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[415, 419]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[435, 443]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[456, 465]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[523, 529]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[531, 534]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[631, 634]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[661, 667]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[726, 730]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[734, 741]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[742, 745]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[779, 787]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[822, 828]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[830, 833]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[882, 888]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[970, 976]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[978, 981]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1016, 1025]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1125, 1128]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1156, 1161]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1166, 1171]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1322, 1325]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1361, 1364]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1395, 1398]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1485, 1488]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[102, 110]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[127, 137]], 'text': ['knock down'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1172, 1177]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T41'}]","[{'trigger': 'T39', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T40', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T39', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T41', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}]",[],[],[],[]
98,PMC-2800179-20-Discussion,"Inflammation of the intestinal tract is usually associated with infiltration and activation of intestinal macrophages [17]. These macrophages are able to initiate immune responses and can be induced to differentiate into cells that either exacerbate or inhibit the inflammation. Accumulation of different types of leukocytes, including monocytes/macrophages, neutrophils, and lymphocytes in the intestinal mucosa during inflammation, is normally followed by secretion of pro-inflammatory cytokines [33]. Several stimuli can induce these leukocytes to produce and secrete cytokines during inflammation. One of the most potent and known stimuli for leukocyte activation is LPS from Gram-negative bacteria [34]. In addition, other factors are also able to stimulate cytokine secretion from various leukocytes [35], [36]. One such factor is CGN, a high molecular weight sulphated polysaccharide (>200 kDa) derived from red algae (Rhodophyceae) [1], [2]. Native CGN is widely used as a food additive (E 407) to improve texture. It is also used in cosmetics and pharmaceuticals. Although native form CGN (200-800 kDa) has been declared harmless to humans [8], its degraded forms (<50 kDa), also known as poligeenan, are widely used to induce colitis in rodents [3]-[5]. These degraded CGN may also have a possible carcinogenic effect [4], [6]-[8]; however this is still controversial.
Although acid treatment at high temperature (80degreesC) is required for CGN hydrolysis in vitro to lower molecular weight dCGN, it is probable that some dCGN are produced by acid hydrolysis during gastric digestion [9], [10] or interaction with intestinal bacteria [11], [12]. Thus, understanding the mechanisms of dCGN-induced bowel inflammation is of great importance. In this report, we have analyzed the role of human monocytes (PBM and THP-1) in dCGN-induced inflammation.
Preliminary in vivo studies in rats treated with dCGN revealed significant shortening of the large intestine associated with an inflammatory state, i.e. strong infiltration of macrophages to the intestinal mucosa similar to DSS-induced inflammation [20]. Using two fractions of dCGN (10 and 40 kDa), we observed a strong correlation between the severity of the inflammation and the dCGN molecular size, thus confirming the size related inflammation in vivo. This macrophage accumulation was not due to cell proliferation because dCGN inhibited THP-1 monocytes proliferation in vitro. These results are similar to those obtained with human colonic epithelial cells (NCM460 cell line) exposed to native CGN for 1-8 days [37]. Thus, it seems that dCGN promote macrophage infiltration by recruiting new cells to the inflamed intestinal mucosa and not by inducing cell proliferation. In addition, very few polymorphonuclear cells were detected in the mucosa at the time point analyzed as demonstrated by a very low level of MPO in the intestinal tissue.
These results suggest that monocytes might produce cytokines associated with activation into macrophages in response to dCGN. Thus, we analyzed the production of TNF by both PBM and THP-1 cells in response to dCGN. Degraded CGN induced a robust production of TNF by monocytes. The 40 kDa form of dCGN was more potent for monocyte stimulation than the 10 kDa or the native ones. Surprisingly, monocyte activation by dCGN to produce TNF was much stronger than the activation induced by LPS, an inflammatory factor considered to be among the most potent stimuli for leukocyte activation. These results underline the fact that partially degraded forms of CGN have important cellular effects. The amount of TNF secreted by PBM induced with LPS was much larger than the one secreted by THP-1 monocytes. Since monocyte activation by LPS is associated with the presence of the CD14 and TLR4 receptors [38]-[40], the different response observed could be due to the different expression of these receptors in PBM and THP-1 cells. CD14 is not expressed by THP-1 monocytes, but it is expressed by PBM. This fact could explain why THP-1 cells produced a much smaller response to LPS than PBM and also the difference of kinetics in the LPS induced TNF secretion. The peak of TNF response was observed after 8 h stimulation followed by a rapid decrease to baseline at 10 h, whereas on THP-1 cells the peak was not reached until after 56 h. Moreover, the amount of TNF secreted by monocytes induced with dCGN was much larger than the one induced by LPS. On the other hand, LPS and dCGN displayed a very different TNF secretion curve in THP-1 cells. These differences suggest that dCGN and LPS could use different activation mechanisms. It is noteworthy that neutralizing antibody to CD14 only partially (<40%) inhibited dCGN-induced TNF secretion (not shown). TLR4 has been recently identified as a surface membrane receptor for CGN in human colonic epithelial cells [41]. Thus, it is possible that TLR4 is activated by dCGN to induce cytokine secretion by monocytes. We can only speculate that TLR4 may have a higher affinity-binding site for dCGN than for LPS, however, this hypothesis remains to be tested.
Another indicator that dCGN stimulate monocytes leading to a more active phenotype is the fact that surface expression of the adhesion molecule ICAM-1 was enhanced in both PBM and THP-1 cells. The over expression of ICAM-1 caused the activated monocytes to form cell aggregates that were more abundant among cells treated with the 40 kDa dCGN. This correlates with the higher expression of ICAM-1 induced by the 40 kDa dCGN, suggesting that the partially degraded CGN is more biologically active. In addition, the cell aggregates are reminiscent of monocyte aggregates, which form multinucleated giant cells (MGC) in patients with Crohn's disease [42]. These giant cells were not observed in healthy individuals or in patients with ulcerative colitis [42]. Moreover, increased expression levels of ICAM-1 and LFA-3 (CD58) were also detected in monocytes from patients with Crohn's disease [43], [44]. Thus, degraded CGN clearly can activate monocytes to express an increased number of ICAM-1 adhesion molecules, therefore being capable of creating the conditions characteristic of Crohn's disease symptomatology, i.e. PBM accumulation and MGC formation [45], [46].
The NF-kappaB pathway regulates genes responsible for ICAM-1 and TNF-alpha expression. NF-kappaB activation is associated with the degradation of the inhibitor protein IkappaB [47]. Indeed, dCGN induced NF-kappaB activation as shown by degradation of IkappaBalpha, translocation of p65 and p50 sub-units to the nucleus and by activation of an NF-kappaB-responsive luciferase reporter plasmid. Again, a stronger activation of NF-kappaB was induced by the 40 kDa dCGN compared to 10 kDa dCGN, suggesting that the partially degraded CGN is more biologically active. Our data are in agreement with a previous study showing that native CGN also induced activation of NF-kappaB in human colonic epithelial cells [48].
NF-kappaB pathway is often associated to promote cell survival and cancer cell growth, however it has been sometimes reported to behave as a tumor suppressor, arresting cell proliferation [49]. Such relationship between NF-kB activation and cell cycle regulation has been reported in normal human epidermal cells [50]. Indeed, it has been shown that NF-kappaB activation suppressed cdk4 expression, which is necessary for the transition to S phase. Finally, NF-kappaB activation was reported to induce growth arrest in normal human keratinocytes by a mechanims involving the cdk inhibitor p21 [51]. The effects of dCGN on p21 and cdk4 expression remain to be studied.
In these studies, we have demonstrated a direct action of dCGN on monocytes. Monocytes exposed to dCGN acquired an inflammatory phenotype that included higher expression of the adhesion molecule ICAM-1 and TNF-alpha production, via the NF-kappaB pathway. This higher expression of ICAM-1 resulted in formation of cell aggregates similar to those observed in patients with Crohn's disease. We presume that the differential effects of 10 and 40 kDa dCGN to induce these effects on monocytes are tightly linked to their capacity to induce inflammation in vivo. However, in vivo, macrophages do not come in direct contact with the intestinal lumen and are separated by the epithelial barrier. The way by which dCGN may leave the intestinal lumen and cross the epithelial barrier to reach the macrophages is an intriguing open question. One possible explanation resides in the potential of dCGN to ""induce"" cellular and paracellular injurious effects at the intestinal epithelial cell monolayer [48].
In conclusion, dCGN inhibited THP-1 cell proliferation in vitro, accumulating the cells in the G1 phase of the cell cycle, increased ICAM-1 expression, stimulated ICAM-1-dependent monocyte aggregation in vitro, and stimulated TNF-alpha expression and secretion. These responses were more pronounced following 40 kDa dCGN, and were all linked to NF-kappaB activation. These results suggest that, although CGN is widely used as a food additive, its degraded forms have an important effect on monocytes characteristic of an inflammatory phenotype.","[{'offsets': [[3069, 3072]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[3166, 3169]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[3338, 3341]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[3609, 3612]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[3776, 3780]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[3785, 3799]], 'text': ['TLR4 receptors'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3927, 3931]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[4141, 4144]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[4168, 4171]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[4356, 4359]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[4504, 4507]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[4724, 4727]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[4751, 4755]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[4807, 4815]], 'text': ['receptor'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[4890, 4894]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[4986, 4990]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[5227, 5244]], 'text': ['adhesion molecule'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5245, 5251]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5317, 5323]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5491, 5497]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5899, 5905]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5910, 5915]], 'text': ['LFA-3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5917, 5921]], 'text': ['CD58'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[6086, 6092]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[6093, 6111]], 'text': ['adhesion molecules'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[6320, 6326]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[6331, 6340]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6517, 6529]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6548, 6551]], 'text': ['p65'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6556, 6559]], 'text': ['p50'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[6630, 6640]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[7360, 7364]], 'text': ['cdk4'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[7567, 7570]], 'text': ['p21'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[7600, 7603]], 'text': ['p21'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[7608, 7612]], 'text': ['cdk4'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[7841, 7847]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[7852, 7861]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7927, 7933]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[8775, 8781]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[8805, 8811]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[8868, 8877]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[3055, 3065]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[3101, 3115]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T21'}, {'offsets': [[3135, 3142]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[3152, 3162]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[3330, 3337]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T24'}, {'offsets': [[3613, 3621]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T25'}, {'offsets': [[3629, 3636]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[3671, 3674]], 'text': ['one'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[3675, 3683]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T27'}, {'offsets': [[3760, 3768]], 'text': ['presence'], 'type': 'Localization', 'id': 'T28'}, {'offsets': [[3873, 3883]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[3887, 3902]], 'text': ['these receptors'], 'type': 'Anaphora', 'id': 'T18'}, {'offsets': [[3939, 3948]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[3973, 3975]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T19'}, {'offsets': [[3979, 3988]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[4133, 4140]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[4145, 4154]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T33'}, {'offsets': [[4172, 4180]], 'text': ['response'], 'type': 'Regulation', 'id': 'T34'}, {'offsets': [[4236, 4244]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T35'}, {'offsets': [[4360, 4368]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T36'}, {'offsets': [[4382, 4389]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[4508, 4517]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T38'}, {'offsets': [[4701, 4710]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[4716, 4723]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[4728, 4737]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T41'}, {'offsets': [[4898, 4907]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[5209, 5219]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[5256, 5264]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[5303, 5313]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[5477, 5487]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[5498, 5505]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[5868, 5877]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[5878, 5888]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T64'}, {'offsets': [[6055, 6062]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[6066, 6075]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[6288, 6297]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T67'}, {'offsets': [[6304, 6315]], 'text': ['responsible'], 'type': 'Regulation', 'id': 'T68'}, {'offsets': [[6341, 6351]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T69'}, {'offsets': [[6502, 6513]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T70'}, {'offsets': [[6531, 6544]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T71'}, {'offsets': [[6577, 6584]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T72'}, {'offsets': [[6592, 6602]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[6619, 6629]], 'text': ['responsive'], 'type': 'Regulation', 'id': 'T74'}, {'offsets': [[7349, 7359]], 'text': ['suppressed'], 'type': 'Negative_regulation', 'id': 'T87'}, {'offsets': [[7365, 7375]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T88'}, {'offsets': [[7581, 7588]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[7613, 7623]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[7798, 7804]], 'text': ['higher'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[7805, 7815]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T92'}, {'offsets': [[7819, 7840]], 'text': ['the adhesion molecule'], 'type': 'Anaphora', 'id': 'T85'}, {'offsets': [[7862, 7872]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T93'}, {'offsets': [[7906, 7912]], 'text': ['higher'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[7913, 7923]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T95'}, {'offsets': [[8101, 8107]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[8108, 8121]], 'text': ['these effects'], 'type': 'Anaphora', 'id': 'T86'}, {'offsets': [[8765, 8774]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[8782, 8792]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T98'}, {'offsets': [[8857, 8867]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[8878, 8888]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T100'}, {'offsets': [[8893, 8902]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T101'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T23', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T24', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T25', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T26', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T27', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T28', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T28', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T29', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T30', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T33', 'id': 'E16', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T34', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T35', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T36', 'id': 'E19', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T37', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T38', 'id': 'E21', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T39', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T40', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T41', 'id': 'E24', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T42', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T58', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T59', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T60', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T61', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T62', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T63', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T64', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T63', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E34']}}, {'trigger': 'T64', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T65', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T66', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T67', 'id': 'E37', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T68', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T67', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T68', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T69', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T69', 'id': 'E42', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T70', 'id': 'E43', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T71', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T55', 'T72']}}, {'trigger': 'T71', 'id': 'E45', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T56', 'T72']}}, {'trigger': 'T73', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E47']}}, {'trigger': 'T74', 'id': 'E47', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T87', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T88', 'id': 'E49', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T89', 'id': 'E50', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T90', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T77']}}, {'trigger': 'T89', 'id': 'E52', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E53']}}, {'trigger': 'T90', 'id': 'E53', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T91', 'id': 'E54', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E55']}}, {'trigger': 'T92', 'id': 'E55', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T91', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T93', 'id': 'E57', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T94', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T95', 'id': 'E59', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T96', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T97', 'id': 'E61', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E62']}}, {'trigger': 'T98', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T82']}}, {'trigger': 'T99', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E64']}}, {'trigger': 'T100', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T99', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E66']}}, {'trigger': 'T101', 'id': 'E66', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}]","[{'id': 'R1', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T18', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T18', 'role': 'Subject'}, 'tail': {'ref_id': 'T6', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T19', 'role': 'Subject'}, 'tail': {'ref_id': 'T7', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T86', 'role': 'Subject'}, 'tail': {'ref_id': 'T94', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T48', 'T49']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E50', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E52', 'value': ''}]",[]
99,PMC-1920263-03-MATERIALS_AND_METHODS,"Plasmids
For cloning of an APOBEC3G promoter-driven reporter plasmid, genomic DNA was prepared from the T cell line PM1 using the DNeasy Kit (Qiagen). The DNA sequence ranging from positions -959 to +66 relative to the identified transcription start was amplified via PCR using the primers 3Gprom1025 (5'-TGTGAACGCGTTGCTGCAGGCCATCTGGATGTATATG-3') and 3Gpromreverse (5'-ACAGCAGATCTAGGGACCTCTGATAAAGACAGG-3'). PCR reactions were performed with Pwo DNA Polymerase (Roche) using the following cycle conditions: one cycle 94degreesC for 2 min; 30 cycles 94degreesC for 30 s, 58degreesC for 60 s, 72degreesC for 60 s; one cycle 72degreesC for 7 min. The amplicon was ligated into the promoterless luciferase reporter plasmid pGL3-Basic (Promega) via MluI and BglII restriction sites, which were introduced by the primers. The resulting construct contained 1025 bp of the A3G promoter and was designated pGL3-APOprom1025. Reporter plasmids containing shorter fragments of the APOBEC3G promoter were constructed using pGL3-APOprom1025 as template and the following forward primers: for plasmid pGL3-APOprom502 (containing sequence -436/+66): 3Gprom502 (5'-TGTGAACGCGTTCCATAACATGGGGACAAGA-3'); for plasmid pGL3-APOprom225 (containing sequence -159/+66): 3Gprom225 (5'-TGTGAACGCGTCGAGGGCAGGATCCGGGAGT-3'); for plasmid pGL3-APOprom180 (containing sequence -114/+66): 3Gprom180 (5'-TGTGAACGCGTTCTTGATGGTGGAGAGGAGG-3'); for plasmid pGL3-APOprom150 (containing sequence -84/+66): 3Gprom150 (5'-TGTGAACGCGTGCGGGACCACCAGGGGAGGGGCTT-3'); for plasmid pGL3-APOprom120 (containing sequence -54/+66): 3Gprom120 (5'-TGTGAACGCGTTGCTGGCTCAGCCTGGTGTG-3'); for plasmid pGL3-APOprom60 (containing sequence +7/+66): 3Gprom60 (5'-TGTGAACGCGTCCCTTTGCAATTGCCTTG-3'); each in combination with the reverse primer 3Gpromreverse (described above). PCR reactions were performed with Pfu Ultra Hotstart (Stratagene) using the following cycle conditions: one cycle 94degreesC for 2 min; 30 cycles 94degreesC for 45 s, 58degreesC for 45 s, 72degreesC for 60 s; one cycle 72degreesC for 7 min. As for pGL3-APOprom1025, MluI and BglII restriction sites were introduced via the primers and PCR products were ligated into pGL3-Basic (Promega) via these restriction sites. pGL3-APOprom180mut carries two point mutations (bold) and was generated using the primer 3GProm180mut (5'-TGTGAACGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGTTCGGGACCACCAG-3') in combination with primer 3Gpromreverse. This PCR was performed with an annealing temperature of 65degreesC. pGL3promE1 (containing nucleotides -114/-85) and pGL3promE2 (containing nucleotides -92/-63) were constructed by annealing the following single-stranded oligonucleotides: 114_85Plus (5'- CGCGTTCTTGATGGTGGAGAGGAGGCTCCAGCTGGA-3') and 114_85Minus (5'- GATCTCCAGCTGGAGCCTCCTCTCCACCATCAAGAA-3') or 92-63Plus (5'-CGCGTCCAGCTGGGCGGGACCACCAGGGGAGGGGCA-3') and 92_63Minus (5'-GATCTGCCCCTCCCCTGGTGGTCCCGCCCAGCTGGA-3'). After annealing, the double-stranded oligonucleotides which contained the respective 30 bp of the APOBEC3G promoter and sticky ends compatible with MluI and BglII restriction sites were ligated into the pGL3-Promoter (Promega) vector. The sequences of all constructed plasmids were verified by sequence analysis. Nucleotide -219 of the cloned APOBEC3G promoter differs from the sequence in the database (GenBank(TM) accession number DQ147772). An A-to-C substitution is present at this position. Numbering is relative to the major transcriptional start site we identified.
The reporter plasmids pGL3-Control and phRG-TK were purchased from Promega. pGL2-CVX contains two repeats of the IFN-responsive GAS (gamma activated sequence) elements (GATCTGGATTTAGAGTAATATGAAACTGAAAGTACTTCG) of the guanylate-binding protein (GBP) gene in front of a CMV minimal promoter and was kindly provided by Ute Pagelow and Mario Koster from the Helmholtz-Zentrum fur Infektionsforschung. Plasmid pNL4-3 (NIBSC, UK) contains the full-length HIV-1NL4-3 genome and has been described previously (34). pcDNA3.1Vif was generously provided by Nathaniel R. Landau from the Salk Institute, La Jolla. It was generated by amplifying the Vif gene from pNL4-3 and ligating it into the pcDNA3.1 vector via BamHI and XhoI restriction sites. A 3'-WPRE element was included into the XhoI site. pBS-kRSPA-TatHIV-1(NL4-3) was constructed by amplifying the two exons of Tat via PCR reaction using the molecular clone pNL4-3 as template and the following primer sets: exon1, 5UXho1HIV-Tat1Plus (5'-GCATGCTCGAGATGGAGCCAGTAGATCCTAG-3') and HIV-Tat1Minus (5'-TGCTTTGATAGAGAAGCTTGATG-3'); exon2, 15FHIV-Tat2Plus (5'-TTCTCTATCAAAGCAACCCACCTCCCAATCCCG-3') and 5USpe1HIV-Tat2Minus (5'-GACGTACTAGTCTATTCCTTCGGGCCTGTC-3'). XhoI and SpeI restriction sites were introduced via the primers. The sense-primer of exon2 starts with a 15-mer which is homologous to the 3' end of exon1 and necessary for fusion of both exons. PCRs were performed with Expand High Fidelity PCR System (Roche) using the following conditions: one cycle 94degreesC for 3 min; 35 cycles 94degreesC for 45 s, 55degreesC for 45 s, 68degreesC for 45 s; one cycle 68degreesC for 7 min. For fusion of both exons, the following PCR conditions were applied: one cycle 94degreesC for 3 min; 35 cycles 94degreesC for 45 s, 58degreesC for 45 s, 68degreesC for 60 s. After 10 cycles without primers, the sense-primer of exon1 and the antisense-primer of exon2 were added for the remaining cycles. The resulting amplicon was ligated into the pBS-kRSPA vector (35) via XhoI and SpeI restriction sites.","[{'offsets': [[27, 35]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[442, 445]], 'text': ['Pwo'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[691, 701]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[865, 868]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[969, 977]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1847, 1850]], 'text': ['Pfu'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3011, 3019]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[3256, 3264]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[3703, 3728]], 'text': ['guanylate-binding protein'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[3730, 3733]], 'text': ['GBP'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[4122, 4125]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[4283, 4286]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[4346, 4349]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[4460, 4463]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[4517, 4520]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[4574, 4577]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[4639, 4642]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}]",[],[],"[{'id': '*', 'ref_ids': ['T9', 'T10']}]",[],[]
100,PMC-3359311-10-Materials_and_Methods,"Ethics Statement
Blood samples were obtained with informed written consent from control subjects and CF patients at the BC Children's Hospital. Consent was obtained for children by their parent or legal guardian. Subjects 7 years of age and older were required to provide informed assent as well. Protocols were approved by the Clinical Research Ethics Board (H09-01192).",[],[],[],[],[],[]
101,PMC-2806624-03-RESULTS,"RUNX1 and RUNX3 bind to the FOXP3 promoter
Transcription element search system analysis of the human FOXP3 promoter predicted 3 putative RUNX binding sites at 333, 287, and 53 bp upstream of the transcription start site (TSS). All three binding sites are conserved between human, mouse, and rat (Fig. S4). To verify the putative binding sites in the FOXP3 promoter, we transiently transfected HEK293T cells with RUNX1 and RUNX3. After the pull-down with oligonucleotides containing the wild-type binding sequences, but not mutant sequences, RUNX binding to the FOXP3 promoter oligonucleotides was detected by Western blot (Fig. 3 A). To confirm these results and test the ability of single binding site sequences to bind either RUNX1 or RUNX3, we used the promoter enzyme immunoassay. Cell lysates were obtained from HEK293T cells that had been transiently transfected with RUNX1 or RUNX3 expression vectors. The biotinylated FOXP3 promoter oligonucleotides were linked to a streptavidin-coated microtiter plate, and bound RUNX1 or RUNX3 was detected by using anti-RUNX antibodies and a peroxidase-labeled secondary antibody. We showed binding of RUNX1 and RUNX3 to the mixture of all three oligonucleotides containing the binding sites, whereas there was no binding detectable when a combination of the mutated oligonucleotides was used in the assay (Fig. 3 B). Although there was a similar and high degree of binding to the -333 and -287 sites, a lower degree of binding was detected when the oligonucleotide containing the -53 site in the Foxp3 promoter was used. This effect was observed both for binding to RUNX1 and RUNX3 (Fig. 3 B). The binding to the two single binding sites at -333 and -287 was comparable to the mixture of all three oligonucleotides. Chromatin immunoprecipitation (ChIP) assay results confirmed the binding of RUNX1 and RUNX3 complexes containing CBFbeta to FOXP3 promoter during the differentiation of naive T cells toward T reg cells. Here, naive CD4+ T cells were cultured with IL-2, anti-CD2/3/28 mAb, and TGF-beta as a Foxp3-inducing stimulation. Amplification of PCR products from the FOXP3 promoter region with the predicted RUNX binding sites showed that RUNX1, RUNX3, and CBFbeta were immunoprecipitated together with the FOXP3 promoter (Fig. 3 C). Negative control primer targeting open reading frame-free intergenic DNA, IGX1A did not show any significant change in site occupancy.","[{'offsets': [[0, 5]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[10, 15]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[28, 33]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[101, 106]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[350, 355]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[412, 417]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[422, 427]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[541, 545]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[561, 566]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[728, 733]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[737, 742]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[874, 879]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[883, 888]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[926, 931]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1023, 1028]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1032, 1037]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1065, 1069]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1147, 1152]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1157, 1162]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1542, 1547]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1612, 1617]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1622, 1627]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1838, 1843]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1848, 1853]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1875, 1882]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1886, 1891]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1977, 1980]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2009, 2013]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2020, 2023]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2024, 2025]], 'text': ['3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2026, 2028]], 'text': ['28'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2038, 2046]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2052, 2057]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2119, 2124]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2191, 2196]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2198, 2203]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2209, 2216]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2259, 2264]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[16, 20]], 'text': ['bind'], 'type': 'Binding', 'id': 'T39'}, {'offsets': [[34, 42]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T40'}, {'offsets': [[381, 392]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[546, 553]], 'text': ['binding'], 'type': 'Binding', 'id': 'T42'}, {'offsets': [[567, 575]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T43'}, {'offsets': [[690, 702]], 'text': ['binding site'], 'type': 'Entity', 'id': 'T44'}, {'offsets': [[716, 720]], 'text': ['bind'], 'type': 'Binding', 'id': 'T45'}, {'offsets': [[857, 868]], 'text': ['transfected'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[889, 899]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[932, 940]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T48'}, {'offsets': [[1017, 1022]], 'text': ['bound'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[1136, 1143]], 'text': ['binding'], 'type': 'Binding', 'id': 'T50'}, {'offsets': [[1223, 1236]], 'text': ['binding sites'], 'type': 'Entity', 'id': 'T51'}, {'offsets': [[1259, 1266]], 'text': ['binding'], 'type': 'Binding', 'id': 'T52'}, {'offsets': [[1411, 1418]], 'text': ['binding'], 'type': 'Binding', 'id': 'T53'}, {'offsets': [[1426, 1430]], 'text': ['-333'], 'type': 'Entity', 'id': 'T54'}, {'offsets': [[1435, 1445]], 'text': ['-287 sites'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[1465, 1472]], 'text': ['binding'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[1526, 1534]], 'text': ['-53 site'], 'type': 'Entity', 'id': 'T57'}, {'offsets': [[1601, 1608]], 'text': ['binding'], 'type': 'Binding', 'id': 'T58'}, {'offsets': [[1644, 1651]], 'text': ['binding'], 'type': 'Binding', 'id': 'T59'}, {'offsets': [[1670, 1683]], 'text': ['binding sites'], 'type': 'Entity', 'id': 'T60'}, {'offsets': [[1827, 1834]], 'text': ['binding'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1892, 1900]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[2058, 2066]], 'text': ['inducing'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[2222, 2249]], 'text': ['immunoprecipitated together'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[2265, 2273]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T65'}]","[{'trigger': 'T39', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T1', 'T3', 'T40']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T2', 'T3', 'T40']}}, {'trigger': 'T41', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T41', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T42', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T8', 'T9', 'T43']}}, {'trigger': 'T45', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T9', 'T10', 'T44']}}, {'trigger': 'T45', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T9', 'T11', 'T44']}}, {'trigger': 'T46', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T47', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T46', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T47', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T49', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T14', 'T15', 'T48']}}, {'trigger': 'T49', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T14', 'T16', 'T48']}}, {'trigger': 'T50', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T14', 'T18', 'T51']}}, {'trigger': 'T50', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T14', 'T19', 'T51']}}, {'trigger': 'T52', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T52', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T53', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T54']}}, {'trigger': 'T53', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T55']}}, {'trigger': 'T56', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T57']}}, {'trigger': 'T58', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T58', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T59', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T60']}}, {'trigger': 'T61', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T23', 'T26', 'T62']}}, {'trigger': 'T61', 'id': 'E25', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T24', 'T26', 'T62']}}, {'trigger': 'T61', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T25', 'T26', 'T62']}}, {'trigger': 'T63', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'T28']}}, {'trigger': 'T63', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T33', 'T32']}}, {'trigger': 'T64', 'id': 'E29', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T35', 'T38', 'T65']}}, {'trigger': 'T64', 'id': 'E30', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T36', 'T38', 'T65']}}, {'trigger': 'T64', 'id': 'E31', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T37', 'T38', 'T65']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}]",[]
102,PMC-2800179-24-Caption-Figure_4,"Degraded CGN stimulated ICAM-1 expression in monocytes.
Peripheral blood monocytes (PBM) or THP-1 cells were incubated in the presence or absence of carrageenan for 24 h before being stained for various cell surface antigens. Antigen expression was then analyzed by flow cytometry. A: Histograms of ICAM-1 expression in cells treated with medium only (control), 10 kDa dCGN (C10), or 40 kDa dCGN (C40). B: Fluorescence intensity for expression of the antigens HLA-ABC, HLA-DR, CD14, ICAM-1, and CD58 in cells treated with medium only (control), 10 kDa dCGN (C10), or 40 kDa dCGN (C40). Data are mean +/- SEM.","[{'offsets': [[24, 30]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[299, 305]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[477, 481]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[483, 489]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[495, 499]], 'text': ['CD58'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[13, 23]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[31, 41]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[306, 316]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[433, 443]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[447, 459]], 'text': ['the antigens'], 'type': 'Anaphora', 'id': 'T6'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T9', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T10', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}]","[{'id': 'R1', 'head': {'ref_id': 'T6', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T6', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T6', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]",[],[],[]
103,PMC-1134658-10-Methods,"Cell culture
If not specified, all cells were cultured in X-VIVO 15(TM) (BioWhittaker, Verviers, Belgium) serum-free medium at 37degreesC and 5% CO2 in air.
Peripheral blood was provided by the Blood Bank at Buskerud Regional Hospital with formal agreement by the patients, and approval by the regional ethics committee. Highly purified resting human B-lymphocytes (CD19+ cells) were isolated from the peripheral blood by rosetting with immunomagnetic beads (Dynabeads M450; Dynal, Oslo, Norway) as described [55]. This procedure yields less than 0.5% T cells, 0.1% NK cells, and 0.5% monocytes as judged by indirect immunofluorescence staining.
The following cell lines from human lymphoid malignancies were maintained in RPMI 1640 (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% foetal bovine serum (FCS), 100 units/ml penicillin G, and 100 units/ml of streptomycin sulphate, but serum-starved for at least four hours and cultured in X-VIVO 15(TM) when included in experiments: EBV-negative BL cell lines Ramos (ECACC 85030802), HL60 (JCRB0085).","[{'offsets': [[366, 370]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
104,PMC-1134658-03-Results,"BMP-6 induces cell death in human memory B cells and Ramos cells
Next, we wanted to establish whether BMP-6 also could affect the viability of normal B cells. Cell viability was determined by propidium iodide (PI) staining after culture with or without BMP-6 for 48 hours. Interestingly, BMP-6 showed a small, but reproducible mean increase of cell death from 17 to 23% (n = 5; p <= 0,003) in anti-IgM stimulated CD27+ memory B cells. Furthermore, Ramos cells showed a mean increase in cell death from 20 to 50% (n = 3, p < 0,001, figure 3) after BMP-6 treatment. In contrast, cell death of total CD19+ cells (n = 6; p <= 0,32; data not shown) or CD27-IgG- naive B cells was not significantly affected (n = 5; p <= 0,65, figure 2).","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[102, 107]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[253, 258]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[288, 293]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[413, 417]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[547, 552]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[597, 601]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[647, 651]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
105,PMC-1942070-03-Materials_and_methods,"2.2sIgM staining
DT40 B cells (2 x 106 cells per point) were resuspended in 200 mul buffer (RPMI 1640 media, 1% foetal calf serum) containing anti-chicken M1 monoclonal antibody conjugated to FITC for 20 min on ice. The cells were washed twice and fluorescent intensity was analysed by flow cytometry.
All results shown are representative of at two to four independent experiments unless otherwise indicated.",[],[],[],[],[],[]
106,PMC-1920263-15-DISCUSSION,"Shortly after the discovery of APOBEC3G, it became clear that this human gene plays an important role in antiretroviral defense (4). Originally identified as a restriction factor of HIV-1 infection, expression of APOBEC3G was found in human peripheral blood lymphocytes and macrophages, which represent the main target cells for HIV-1 (32). In addition, the protein was detected in lung, liver, spleen, testis and ovary, but little is known about its transcriptional regulation (29,32,47). To address this question, we cloned the human APOBEC3G promoter and analyzed its regulation in T cells. Applying 5'-RACE, we identified multiple start sites for transcription of the A3G gene. This observation is consistent with the fact that the gene appears to lack canonical CCAAT and TATA boxes (32), a condition often associated with multiple transcriptional start sites (49-51). However, one single start site was detected in 6 of 19 clones and was designated as +1. This TSS is located 66 bp upstream of the start of the published mRNA sequence (GenBank(TM) NM021822).
We cloned a 1025 bp promoter, which ranges from position -959/+66 relative to the identified TSS. Luciferase reporter assays showed that this promoter was transcriptionally active in A3.01 T cells. Treatment with the phorbol ester TPA did not further enhance transcriptional activity, although upregulation of A3G mRNA levels in T cells by TPA has been described (33). Rose et al. used actinomycin D to block further transcription and did not find evidence for enhanced mRNA stability. Therefore, the authors suggested that an enhanced transcription rate could be responsible for the increased amount of A3G mRNA after TPA treatment. However, the promoter analysis we performed indicates a different mechanism that is independent of transcriptional regulation. In addition, we observed that the A3G promoter was not inducible by IFN-alpha or IFN-gamma in A3.01 T cells, whereas in the hepatic cell line HepG2, a moderate induction was measured. It has been described previously that A3G gene expression is upregulated by interferons in hepatocytes and macrophages (46-48, 52). In this context, two interferon-responsive elements have been identified at the positions -6/+9 and +1/+15 relative to the TSS (48). Consistent with this data, we observed an interferon induction in hepatocytes for the fragments ranging between 1025 and 120 bp length. The activity of the 60 bp fragment that does not contain these motifs was not affected. Thus, the induction we observed was most likely mediated by the described interferon-responsive elements. However, according to our results, these motifs can enhance transcription in hepatic cells, but not in T cells. This is surprising, since IFN-alpha-inducible signaling cascades are present in A3.01 T cells: we showed that the control plasmid harboring interferon-responsive GAS elements was markedly induced by IFN-alpha treatment. In contrast, the GAS element was not responsive to IFN-gamma treatment in these cells, suggesting that our T cell line was not able to mediate IFN-gamma-induced signals. So far, enhanced A3G promoter activity by interferons is clearly described in hepatocytes and macrophages, whereas the situation in T cells is still unclear. A recent study found no influence of IFN-alpha or IFN-gamma on A3G expression in resting primary blood lymphocytes (52). Another publication describes an enhanced expression of A3G after IFN-alpha treatment in resting primary CD4 T cells, but not in activated T cells (53). This observation is not contradictory to our results since T cell lines are mitotically active and therefore rather in an activated than in a resting state. In conclusion, the current data suggests that regulation of the A3G promoter activity by interferons is dependent on the cell type and possibly also from the cellular activation status.
We additionally analyzed the influence of HIV-1 proteins on A3G promoter activity. The HIV-1 Vif protein is neutralizing the antiviral function of A3G by a multitude of ways. Targeting the A3G protein for proteasomal degradation is considered to be the main mode of action (37-41), but it becomes more and more clear that other mechanisms are also involved. There is evidence that Vif also promotes exclusion of A3G from the virus particles and an influence on the A3G translation process is discussed (8,42,43). The question whether Vif alters transcription controlled by the A3G promoter has not been analyzed so far. Our analysis indicates that transcription from the A3G promoter is unaffected by Vif or other HIV-1 proteins. Taken together, in T cell lines, the A3G promoter appears constitutively active.
By generating a series of 5' deletions, we showed that the core promoter is located within the region -114/+66 relative to the TSS. This 180 bp promoter was transcriptionally active in the lymphoid, myeloid and hepatic cell lines we tested, indicating that ubiquitous transcription factors are involved in regulation of A3G gene transcription. A GC-box with the sequence TGGGCGGGAC was identified at position -87/-78 of the A3G promoter. This GC-box is essential for basal promoter activity, since changing the motif to TGTTCGGGAC by introducing two point mutations strongly reduced A3G promoter activity. The transcriptional potency of the GC-box was further demonstrated by cloning it upstream of an SV40 promoter. This resulted in a 4-fold enhanced transcription rate. The hypothesis that a general transcription factor is involved in regulation of A3G transcription was confirmed by EMSA. Supershift analysis showed that the transcription factors Sp1 and Sp3 which are ubiquitously expressed in mammalian cells, bind specifically to the identified motif. In addition, the binding of Sp1 and Sp3 to the endogenous A3G promoter was demonstrated by a chromatin immunoprecipitation assay. This observation is consistent with the results of the 5'-RACE, since Sp1 is known to play an important role for RNA polymerase II to bind to the transcription initiation site in TATA-boxless promoters and is associated with multiple transcription initiation sites (54-56). We also tested whether overexpression of Sp1 or Sp3 proteins had an influence on A3G promoter activity. Luciferase assays revealed that A3G promoter activities remained unchanged (data not shown), most probably due to the high basal expression level of the endogenous Sp1 and/or Sp3 proteins. The Sp family of transcription factors is involved in transcriptional regulation of many housekeeping, tissue-specific, viral and inducible genes (57). Whereas Sp1 typically acts as an activator, Sp3 can serve as a repressor or activator (57). However, in the context of the A3G promoter, both transcription factors serve as activators, as shown by siRNA-mediated silencing of the single factors. Although siRNAs directed against Sp1 or Sp3 significantly reduced transcription controlled by the 180 bp promoter, transcriptional activity was not reduced to the level of the 150 bp fragment. This can be explained by the remaining low amounts of Sp1/Sp3 proteins which can be seen in the western blot analysis. Alternatively, other transcription factors could be involved in A3G regulation.
Our results also provide information about the regulation of APOBEC3F (A3F), another member of the human APOBEC3 family. A3F is expressed in many human tissues that also express A3G and both proteins have been shown to form heteromultimers, which are most likely generated through binding to an RNA intermediate (26,29,30). A3F only differs in 16 nt from the 560 nt upstream of the TSS of A3G (GenBank(TM) DQ146365 and DQ147772). The 180-bp core promoter region, which we identified for A3G has 100% identity with the A3F sequence. Therefore, Sp1/Sp3 transcription factors are most likely also mediating basal transcription of the A3F gene.
Our study revealed that the human A3G gene is controlled by a promoter with multiple transcriptional start sites. In A3.01 T cells, the A3G promoter appears constitutively active and is not inducible by TPA, type I or II interferons or by HIV-1 proteins. The core promoter is located within a region of 180 bp at position -114/+66 relative to the TSS. A GC-box is crucial to the function of the core promoter and represents a binding site for Sp1 and Sp3 transcription factors. Our results can serve as a basis for future studies aimed at understanding how A3G and A3F expression is controlled in different tissues and how these restriction factors can be used to develop novel therapeutic strategies against HIV-1 infection.","[{'offsets': [[31, 39]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[213, 221]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[536, 544]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[672, 675]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1163, 1173]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1375, 1378]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1669, 1672]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1860, 1863]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1894, 1903]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1907, 1916]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2048, 2051]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2743, 2752]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2916, 2925]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2988, 2997]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3080, 3089]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3124, 3127]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3302, 3311]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3315, 3324]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3328, 3331]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3442, 3445]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3452, 3461]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3491, 3494]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3760, 3763]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3942, 3945]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3975, 3978]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[4029, 4032]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4071, 4074]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4263, 4266]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4294, 4297]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4347, 4350]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4416, 4419]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4459, 4462]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4553, 4556]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4583, 4586]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4649, 4652]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[5013, 5016]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5117, 5120]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5213, 5223]], 'text': ['TGTTCGGGAC'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5276, 5279]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[5545, 5548]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[5644, 5647]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[5652, 5655]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[5780, 5783]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5788, 5791]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5810, 5813]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5952, 5955]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5995, 6012]], 'text': ['RNA polymerase II'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[6197, 6200]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[6204, 6207]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[6237, 6240]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[6260, 6270]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[6292, 6295]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[6424, 6427]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6435, 6438]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6609, 6612]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6645, 6648]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[6724, 6727]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[6879, 6882]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[6886, 6889]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[7093, 7096]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[7097, 7100]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[7222, 7225]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[7299, 7307]], 'text': ['APOBEC3F'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[7309, 7312]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[7359, 7362]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[7416, 7419]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[7562, 7565]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[7627, 7630]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[7725, 7728]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[7756, 7759]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[7781, 7784]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[7785, 7788]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[7869, 7872]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[7913, 7916]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[8015, 8018]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[8322, 8325]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[8330, 8333]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[8436, 8439]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[8444, 8447]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[199, 209]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T86'}, {'offsets': [[354, 365]], 'text': ['the protein'], 'type': 'Anaphora', 'id': 'T80'}, {'offsets': [[370, 378]], 'text': ['detected'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[545, 553]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T88'}, {'offsets': [[567, 570]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T81'}, {'offsets': [[571, 581]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T89'}, {'offsets': [[651, 664]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T90'}, {'offsets': [[1316, 1323]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[1324, 1339]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T92'}, {'offsets': [[1359, 1371]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T93'}, {'offsets': [[1468, 1473]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T94'}, {'offsets': [[1482, 1495]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T95'}, {'offsets': [[1592, 1600]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[1601, 1614]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T97'}, {'offsets': [[1649, 1658]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[1864, 1872]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T99'}, {'offsets': [[1881, 1890]], 'text': ['inducible'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[2057, 2067]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T101'}, {'offsets': [[2071, 2082]], 'text': ['upregulated'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[2086, 2097]], 'text': ['interferons'], 'type': 'Anaphora', 'id': 'T82'}, {'offsets': [[2317, 2327]], 'text': ['interferon'], 'type': 'Anaphora', 'id': 'T83'}, {'offsets': [[2431, 2445]], 'text': ['60 bp fragment'], 'type': 'Entity', 'id': 'T103'}, {'offsets': [[2489, 2497]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T104'}, {'offsets': [[2559, 2603]], 'text': ['the described interferon-responsive elements'], 'type': 'Entity', 'id': 'T105'}, {'offsets': [[2640, 2652]], 'text': ['these motifs'], 'type': 'Anaphora', 'id': 'T84'}, {'offsets': [[2657, 2664]], 'text': ['enhance'], 'type': 'Positive_regulation', 'id': 'T106'}, {'offsets': [[2665, 2678]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T107'}, {'offsets': [[3289, 3298]], 'text': ['influence'], 'type': 'Regulation', 'id': 'T108'}, {'offsets': [[3332, 3342]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T109'}, {'offsets': [[3419, 3427]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T110'}, {'offsets': [[3428, 3438]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T111'}, {'offsets': [[4057, 4066]], 'text': ['Targeting'], 'type': 'Positive_regulation', 'id': 'T112'}, {'offsets': [[4087, 4110]], 'text': ['proteasomal degradation'], 'type': 'Protein_catabolism', 'id': 'T113'}, {'offsets': [[4420, 4426]], 'text': ['alters'], 'type': 'Regulation', 'id': 'T114'}, {'offsets': [[4427, 4440]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T115'}, {'offsets': [[4441, 4451]], 'text': ['controlled'], 'type': 'Regulation', 'id': 'T116'}, {'offsets': [[4463, 4471]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T117'}, {'offsets': [[4530, 4543]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T118'}, {'offsets': [[4544, 4548]], 'text': ['from'], 'type': 'Positive_regulation', 'id': 'T119'}, {'offsets': [[4557, 4565]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T120'}, {'offsets': [[4569, 4579]], 'text': ['unaffected'], 'type': 'Regulation', 'id': 'T121'}, {'offsets': [[4653, 4661]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T122'}, {'offsets': [[4685, 4691]], 'text': ['active'], 'type': 'Positive_regulation', 'id': 'T123'}, {'offsets': [[4999, 5009]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T124'}, {'offsets': [[5022, 5035]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T125'}, {'offsets': [[5531, 5541]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T126'}, {'offsets': [[5549, 5562]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T127'}, {'offsets': [[5679, 5688]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T128'}, {'offsets': [[5709, 5713]], 'text': ['bind'], 'type': 'Binding', 'id': 'T129'}, {'offsets': [[5769, 5776]], 'text': ['binding'], 'type': 'Binding', 'id': 'T130'}, {'offsets': [[5814, 5822]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T131'}, {'offsets': [[5968, 5990]], 'text': ['play an important role'], 'type': 'Positive_regulation', 'id': 'T132'}, {'offsets': [[6016, 6020]], 'text': ['bind'], 'type': 'Binding', 'id': 'T133'}, {'offsets': [[6179, 6193]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T134'}, {'offsets': [[6389, 6399]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T135'}, {'offsets': [[6728, 6736]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T136'}, {'offsets': [[6738, 6764]], 'text': ['both transcription factors'], 'type': 'Anaphora', 'id': 'T85'}, {'offsets': [[6765, 6785]], 'text': ['serve as activators,'], 'type': 'Positive_regulation', 'id': 'T137'}, {'offsets': [[6813, 6822]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T138'}, {'offsets': [[6904, 6911]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T139'}, {'offsets': [[6912, 6925]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T140'}, {'offsets': [[6926, 6936]], 'text': ['controlled'], 'type': 'Regulation', 'id': 'T141'}, {'offsets': [[6944, 6959]], 'text': ['180 bp promoter'], 'type': 'Entity', 'id': 'T142'}, {'offsets': [[6961, 6976]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T143'}, {'offsets': [[6994, 7001]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T144'}, {'offsets': [[7226, 7236]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T145'}, {'offsets': [[7285, 7295]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T146'}, {'offsets': [[7366, 7375]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T147'}, {'offsets': [[7408, 7415]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T148'}, {'offsets': [[7457, 7477]], 'text': ['form heteromultimers'], 'type': 'Binding', 'id': 'T149'}, {'offsets': [[7832, 7841]], 'text': ['mediating'], 'type': 'Positive_regulation', 'id': 'T150'}, {'offsets': [[7848, 7861]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T151'}, {'offsets': [[7925, 7935]], 'text': ['controlled'], 'type': 'Regulation', 'id': 'T152'}, {'offsets': [[7941, 7991]], 'text': ['promoter with multiple transcriptional start sites'], 'type': 'Entity', 'id': 'T153'}, {'offsets': [[8019, 8027]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T154'}, {'offsets': [[8051, 8057]], 'text': ['active'], 'type': 'Positive_regulation', 'id': 'T155'}, {'offsets': [[8069, 8078]], 'text': ['inducible'], 'type': 'Positive_regulation', 'id': 'T156'}, {'offsets': [[8233, 8239]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T157'}, {'offsets': [[8243, 8250]], 'text': ['crucial'], 'type': 'Positive_regulation', 'id': 'T158'}, {'offsets': [[8274, 8287]], 'text': ['core promoter'], 'type': 'Entity', 'id': 'T159'}, {'offsets': [[8305, 8312]], 'text': ['binding'], 'type': 'Binding', 'id': 'T160'}, {'offsets': [[8448, 8458]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T161'}, {'offsets': [[8462, 8472]], 'text': ['controlled'], 'type': 'Regulation', 'id': 'T162'}]","[{'trigger': 'T86', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T87', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T89', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T88']}}, {'trigger': 'T90', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T91', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T92', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T93', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T94', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T95', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T96', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T97', 'id': 'E11', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T98', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'E10']}}, {'trigger': 'T100', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T8', 'T9', 'T99']}}, {'trigger': 'T100', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T8', 'T10', 'T99']}}, {'trigger': 'T101', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T102', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T9']}}, {'trigger': 'T102', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T10']}}, {'trigger': 'T104', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T8', 'T9', 'T103']}}, {'trigger': 'T104', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T8', 'T10', 'T103']}}, {'trigger': 'T106', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E21', 'T8', 'T105']}}, {'trigger': 'T107', 'id': 'E21', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T108', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T17']}}, {'trigger': 'T109', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T108', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T18']}}, {'trigger': 'T110', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T21']}}, {'trigger': 'T111', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T112', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T25']}}, {'trigger': 'T113', 'id': 'E28', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T114', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T31']}}, {'trigger': 'T116', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E31', 'T32', 'T117']}}, {'trigger': 'T115', 'id': 'E31', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T118', 'id': 'E32', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T119', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T33', 'T120']}}, {'trigger': 'T121', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T34']}}, {'trigger': 'T123', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T35', 'T122']}}, {'trigger': 'T124', 'id': 'E36', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E37']}}, {'trigger': 'T125', 'id': 'E37', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T126', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T127', 'id': 'E39', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T128', 'id': 'E40', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T128', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T129', 'id': 'E42', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T129', 'id': 'E43', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T130', 'id': 'E44', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T43', 'T45', 'T131']}}, {'trigger': 'T130', 'id': 'E45', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T44', 'T45', 'T131']}}, {'trigger': 'T132', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'T46']}}, {'trigger': 'T133', 'id': 'E47', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T134', 'id': 'E48', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T134', 'id': 'E49', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T135', 'id': 'E50', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T135', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T54']}}, {'trigger': 'T137', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T57', 'T55', 'T136']}}, {'trigger': 'T137', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T57', 'T56', 'T136']}}, {'trigger': 'T138', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T138', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T139', 'id': 'E56', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T140', 'id': 'E57', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T141', 'id': 'E58', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E57', 'T57', 'T142']}}, {'trigger': 'T143', 'id': 'E59', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T144', 'id': 'E60', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T145', 'id': 'E61', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T146', 'id': 'E62', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T147', 'id': 'E63', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T148', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T149', 'id': 'E65', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T65', 'T66']}}, {'trigger': 'T150', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'T71']}}, {'trigger': 'T151', 'id': 'E67', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T150', 'id': 'E68', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'T72']}}, {'trigger': 'T152', 'id': 'E69', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['T74', 'T74', 'T153']}}, {'trigger': 'T155', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T75', 'T154']}}, {'trigger': 'T156', 'id': 'E71', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T75', 'T154']}}, {'trigger': 'T158', 'id': 'E72', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E73', 'T75', 'T157']}}, {'trigger': 'T160', 'id': 'E73', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T75', 'T76', 'T159']}}, {'trigger': 'T158', 'id': 'E74', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E75', 'T75', 'T157']}}, {'trigger': 'T160', 'id': 'E75', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T75', 'T77', 'T159']}}, {'trigger': 'T161', 'id': 'E76', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T78']}}, {'trigger': 'T161', 'id': 'E77', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T79']}}, {'trigger': 'T162', 'id': 'E78', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E76']}}, {'trigger': 'T162', 'id': 'E79', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E77']}}]","[{'id': 'R1', 'head': {'ref_id': 'T80', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T81', 'role': 'Subject'}, 'tail': {'ref_id': 'T88', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T82', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T82', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T83', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T83', 'role': 'Subject'}, 'tail': {'ref_id': 'T10', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T84', 'role': 'Subject'}, 'tail': {'ref_id': 'T105', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T55', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T85', 'role': 'Subject'}, 'tail': {'ref_id': 'T56', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T63', 'T64']}]","[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E18', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E19', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E29', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E35', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E60', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E66', 'value': ''}, {'id': 'M15', 'type': 'Speculation', 'ref_id': 'E68', 'value': ''}, {'id': 'M16', 'type': 'Negation', 'ref_id': 'E71', 'value': ''}, {'id': 'M17', 'type': 'Speculation', 'ref_id': 'E78', 'value': ''}, {'id': 'M18', 'type': 'Speculation', 'ref_id': 'E79', 'value': ''}]",[]
107,PMC-3359311-24-Caption-Figure_6,"NF-kappaB activation potentiates the degree of IL-1beta production and secretion upon inflammasome activation.
THP-1 reporter cells were primed overnight with heat-killed P. aeruginosa and stimulated the next day with live P. aeruginosa or additional heat-killed P. aeruginosa for the times indicated. Cell culture supernatants were assayed for (A) NF-kappaB/AP-1 activity, (B) IL-8, and (C) IL-1beta secretion (n = 3-6 experiments). Using the same stimulation method, THP-1 reporter cells were treated with Bay11-7082 (20 microM) for 1 hour prior to priming with heat-killed PAO1 or live PAO1. Supernatants were assayed at 24 hours for (D) NF-kappaB/AP-1 activity, (E) IL-8, and (F) IL-1beta secretion (n = 3-5). PBMCs from CF patients (n = 11-15) and controls (n = 10-13) were treated with z-YVAD-fmk (20 microM) or Bay11-7082 (10 microM) and stimulated with live PAO1 (MOI = 1), ATP (5 mM), or Poly(dA:dT) (1 microg/ml) according to the schedule in Figure 1. (G) IL-1beta and (H) IL-8 levels were measured at 24 hours. Statistical analysis was performed using two way ANOVA with Bonferroni correction for multiple comparisons. *, **, and *** signify P<0.05, 0.01, and 0.001.","[{'offsets': [[47, 55]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[392, 400]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[684, 692]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[966, 974]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[21, 32]], 'text': ['potentiates'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[56, 66]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[71, 80]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T7'}, {'offsets': [[81, 85]], 'text': ['upon'], 'type': 'Positive_regulation', 'id': 'T8'}, {'offsets': [[401, 410]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T9'}, {'offsets': [[693, 702]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T10'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T7', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T8', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T9', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T10', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}]",[]
108,PMC-3359311-06-Results,"NF-kappaB activation is required for IL-1beta and IL-8 responses to P. aeruginosa
We confirmed the dependence of PAO1-induced IL-1beta and IL-8 production on NF-kappaB activation using THP-1 cells expressing a reporter driven by NF-kappaB and AP-1 response elements. We found that stimulation of primed THP-1 reporter cells with heat-killed PAO1 produced the highest levels of NF-kappaB/AP-1 activation (Fig. 6a) and this correlated with IL-8 secretion (Fig. 6b) but negligible amounts of IL-1beta were secreted (Fig. 6c). Stimulation of primed THP-1 reporter cells with live PAO1 did not significantly increase NF-kappaB/AP-1 activity (Fig. 6a) or IL-8 secretion (Fig. 6b) over priming alone. However, IL-1beta production was greatly augmented over primed cells stimulated with heat-killed PAO1 or unprimed cells stimulated with live PAO1 (Fig. 6c). This confirmed that NF-kappaB activation alone is not sufficient for maximal IL-1beta secretion, but increased priming of NF-kappaB is capable of augmenting IL-1beta production and secretion upon inflammasome stimulation. Dependency of these responses on NF-kappaB was confirmed by pharmacologic inhibition of NF-kappaB using the Bay11-7082 inhibitor of IkappaBalpha phosphorylation, which significantly reduced NF-kappaB/AP-1 activation (P<0.001) (Fig. 6d) and the subsequent production of IL-8 (P<0.01) (Fig. 6e) and IL-1beta (P<0.001) (Fig. 6f) in response to both heat-killed and live PAO1. These results were also verified in CF and control PBMCs for each inflammasome examined (P<0.001) (Fig. 6g-h). Overall these results confirm that NF-kappaB is an important modulator of IL-1beta production and that increased activation of NF-kappaB augments inflammasome-mediated production of IL-1beta.","[{'offsets': [[37, 45]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[126, 134]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[489, 497]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[703, 711]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[928, 936]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1008, 1016]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1205, 1217]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1370, 1378]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1631, 1639]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1739, 1747]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[24, 32]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[55, 64]], 'text': ['responses'], 'type': 'Regulation', 'id': 'T13'}, {'offsets': [[99, 109]], 'text': ['dependence'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[118, 125]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[144, 154]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[503, 511]], 'text': ['secreted'], 'type': 'Localization', 'id': 'T17'}, {'offsets': [[712, 722]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[735, 744]], 'text': ['augmented'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[905, 915]], 'text': ['sufficient'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[937, 946]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[1192, 1201]], 'text': ['inhibitor'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1218, 1233]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T23'}, {'offsets': [[1235, 1240]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T11'}, {'offsets': [[1255, 1262]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T24'}, {'offsets': [[1328, 1338]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[1399, 1413]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[1618, 1627]], 'text': ['modulator'], 'type': 'Regulation', 'id': 'T27'}, {'offsets': [[1640, 1650]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1694, 1702]], 'text': ['augments'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[1716, 1724]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[1725, 1735]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T31'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T15', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T17', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T18', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T19', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T20', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T23', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T24', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E11']}}, {'trigger': 'T26', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T25', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T27', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E17']}}, {'trigger': 'T28', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T29', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T30', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T31', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]","[{'id': 'R1', 'head': {'ref_id': 'T11', 'role': 'Subject'}, 'tail': {'ref_id': 'T22', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E6', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}]",[]
109,PMC-2222968-12-Materials_and_Methods,"Inducible murine Treg culture.
Naive CD4+ T cells (CD4+, CD62L+, and CD25-) were isolated from pooled lymph nodes and spleens by FACS (FACS Aria, BD Biosciences). 5 x 105 T cells were co-cultured with 2.5 x 104 bone marrow-derived dendritic cells [62] and 0.01 mug/ml OVA323-339 peptide (Ansynth) in the presence or absence of 20-ng/mul rhTGF-ss1 (Peprotech) in 48-well plates. After 4 d, cells were harvested and analyzed for intracellular FOXP3 expression by FACS or gene expression by quantitative RT-PCR.","[{'offsets': [[37, 40]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 54]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[57, 62]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[69, 73]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[339, 346]], 'text': ['TGF-ss1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[441, 446]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[447, 457]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
110,PMC-2674207-06-Materials_and_Methods,"Cell Fractionation, Immunoprecipitation, and Western Blot Analysis
Nuclear and cytoplasmic fractions were prepared as previously described [35]. Whole cell lysates were prepared in NP-40 lysis buffer (0.5% Nonidet P-40, 20 mM Tris-HCl [pH 7.5], 150 mM NaCl) in the presence of complete protease cocktail inhibitor. Lysates were centrifuged at 4degreesC for 10 min at 12,000 rpm in an Eppendorf microcentrifuge to remove cellular debris. Samples were then immunoprecipitated with either 10 microl of antibody against GATA-3 or importin-alpha using A/G agarose slurry in the presence of protease inhibitor using the Catch and Release methodology (Upstate Biotechnology, Lake Placid, New York, USA). Western blot analysis was performed using anti-GATA-3, anti-importin-alpha, anti-GR, anti-p-p38 MAP kinase, anti-p-ATF-2, and anti-p-serine. Immunoreactive proteins were detected using an enhanced chemiluminescence ECL kit (Amersham Biosciences).","[{'offsets': [[516, 522]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
111,PMC-3359311-00-TIAB,"Inflammasome-Mediated IL-1beta Production in Humans with Cystic Fibrosis
Background
Inflammation and infection are major determinants of disease severity and consequently, the quality of life and outcome for patients with cystic fibrosis (CF). Interleukin-1 beta (IL-1beta) is a key inflammatory mediator. Secretion of biologically active IL-1beta involves inflammasome-mediated processing. Little is known about the contribution of IL-1beta and the inflammasomes in CF inflammatory disease. This study examines inflammasome-mediated IL-1beta production in CF bronchial epithelial cell lines and human patients with CF.
Results
Bronchial epithelial cell lines were found to produce negligible amounts of basal or stimulated IL-1beta compared to hematopoeitic cells and they did not significantly upregulate caspase-1 activity upon inflammasome stimulation. In contrast, peripheral blood mononuclear cells (PBMCs) from both CF and healthy control subjects produced large amounts of IL-1beta and strongly upregulated caspase-1 activity upon inflammasome stimulation. PBMCs from CF patients and controls displayed similar levels of caspase-1 activation and IL-1beta production when stimulated with inflammasome activators. This IL-1beta production was dependent on NF-kappaB activity and could be enhanced by priming with LPS. Finally, chemical inhibition of CFTR activity in control PBMCs and THP-1 cells did not significantly alter IL-1beta or IL-8 production in response to P. aeruginosa.
Conclusion
Hematopoeitic cells appear to be the predominant source of inflammasome-induced pro-inflammatory IL-1beta in CF. PBMCs derived from CF subjects display preserved inflammasome activation and IL-1beta secretion in response to the major CF pathogen Pseudomonas aeruginosa. However, our data do not support the hypothesis that increased IL-1beta production in CF subjects is due to an intrinsic increase in NF-kappaB activity through loss of CFTR function.","[{'offsets': [[22, 30]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[244, 262]], 'text': ['Interleukin-1 beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[264, 272]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[339, 347]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[433, 441]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[534, 542]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[724, 732]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[981, 989]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1154, 1162]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1225, 1233]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1431, 1439]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1597, 1605]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1690, 1698]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1832, 1841]], 'text': [' IL-1beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[13, 21]], 'text': ['Mediated'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[31, 41]], 'text': ['Production'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[306, 315]], 'text': ['Secretion'], 'type': 'Localization', 'id': 'T17'}, {'offsets': [[348, 356]], 'text': ['involves'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[525, 533]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[543, 553]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[674, 681]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[713, 723]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[955, 963]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[1034, 1038]], 'text': ['upon'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[1163, 1173]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[1179, 1189]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[1425, 1430]], 'text': ['alter'], 'type': 'Regulation', 'id': 'T27'}, {'offsets': [[1448, 1458]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1459, 1473]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[1572, 1579]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[1652, 1661]], 'text': ['preserved'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[1699, 1708]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T32'}, {'offsets': [[1823, 1832]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[1842, 1852]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T34'}, {'offsets': [[1871, 1874]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T35'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T17', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T24', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T25', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T26', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T27', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T29', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T28', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T30', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T31', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T32', 'id': 'E18', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T33', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T34', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T35', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}]",[]
112,PMC-2800179-07-Materials_and_Methods,"Cell Surface Antigen Expression Analysis
Peripheral Blood Monocytes or THP-1 cells were exposed to complete medium in the presence or absence of carrageenan for 36 h. After two washes in PBS without Ca2+ and Mg2+, cells were incubated in PBS containing 0.1% gelatin and 8% AB human serum to prevent binding to Fc receptors. Then, 5x105 cells were incubated with primary antibodies at 4degreesC for 30 min. Two other washes in PBS preceded incubation with FITC-conjugated goat antibody anti-mouse IgG diluted 1/1000 at 4degreesC for 30 min (Tebu). After two additional washes, analysis of stained cells was performed on an EPICS XL2 (Beckman-Coulter). The cell population was gated according to its forward and wide-angle light scattering. Data were expressed as mean relative fluorescence intensity (MFI) of 3000 cells.",[],[],[],[],[],[]
113,PMC-2222968-28-Caption-Figure_4,"FOXP3 Induction During the Differentiation Process
(A) Human CD4+CD45RA+ T cells were activated with plate-bound anti-CD3/CD28 in the presence of TGF-beta (5 ng/ml) or IL-4 (25 ng/ml). The cells were harvested at different time points, and mRNA was quantified by real-time PCR for FOXP3 and GATA3 expression. Bars show the mean +/- SD of three independent experiments.
(B) Intracellular GATA3 and FOXP3 staining is shown after exposure of CD4+CD45RA+ T cells to differentiating conditions as in part A of the figure. Data are representative of three independent experiments.","[{'offsets': [[0, 5]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[61, 64]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[65, 71]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[118, 121]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[122, 126]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[146, 154]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[168, 172]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[281, 286]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[291, 296]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[387, 392]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[397, 402]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[439, 442]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[443, 449]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[6, 15]], 'text': ['Induction'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[297, 307]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T15'}, {'offsets': [[403, 411]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T16'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T16', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
114,PMC-3062687-23-Methods,"ELISA
The amount of IL-8 present in supernatants collected from Jurkat cell culture was measured using a Human Interleukin-8 ELISA Ready-SET-Go kit (eBioscience) according to the manufacturer's instructions.","[{'offsets': [[20, 24]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[111, 124]], 'text': ['Interleukin-8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[144, 147]], 'text': ['kit'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
115,PMC-2806624-24-MATERIALS_AND_METHODS,"Online supplemental material.
Fig. S1 shows the induction of RUNX1, RUNX3, and FOXP3 mRNA in human CD4+ T cells after anti-CD2/3/28 mAb and TGF-beta stimulation. Fig. S2 shows decreased RUNX1 and RUNX3 mRNA and protein expression after siRNA-mediated knockdown and decreased FOXP3 expression in human CD4+ T cells after RUNX1 and RUNX3 knockdown. Fig. S3 shows the quantification of IL-4, IL-5, IL-10, IL-13, and IFN-gamma levels in control siRNA transfected or RUNX1 and RUNX3 siRNA transfected human CD4+ T cells. Fig. S4 shows the putative RUNX binding sites in the FOXP3 core promoter sequence of human, mouse, and rat. Fig. S5 shows the induction of FOXP3 protein after overexpression of RUNX1 and RUNX3 in human CD4+ T cells. Fig. S6 shows that endogenous IL-4 and IFN-gamma do not effect Foxp3 expression in naive CD4+ T cells of CbfbF/F CD4-cre and CbfbF/F control mice, which were stimulated with anti-CD3 and anti-CD28 mAbs, IL-2 and TGF-beta in the absence or presence of anti-IL-4 and anti-IFN-gamma neutralizing mAbs. Fig. S7 shows similar cell death (A) and proliferation (B) of Foxp3+ and Foxp3- cells in CbfbF/F CD4-cre and CbfbF/F control mice cultures. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20090596/DC1.","[{'offsets': [[61, 66]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[68, 73]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[79, 84]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[99, 102]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[123, 126]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[127, 128]], 'text': ['3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[129, 131]], 'text': ['28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[140, 148]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[186, 191]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[196, 201]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[275, 280]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[301, 304]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[320, 325]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[330, 335]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[383, 387]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[389, 393]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[395, 400]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[402, 407]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[413, 422]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[462, 467]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[472, 477]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[502, 505]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[569, 574]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[655, 660]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[693, 698]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[703, 708]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[718, 721]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[762, 766]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[771, 780]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[795, 800]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[821, 824]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[837, 841]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[845, 852]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[857, 861]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[911, 914]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[924, 928]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[935, 939]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[944, 952]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[988, 992]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1002, 1011]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1093, 1098]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1104, 1109]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1120, 1124]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1128, 1131]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1132, 1135]], 'text': ['cre'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1140, 1144]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[48, 57]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[85, 89]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T48'}, {'offsets': [[176, 185]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[202, 206]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T50'}, {'offsets': [[242, 250]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[251, 260]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T52'}, {'offsets': [[265, 274]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[281, 291]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[336, 345]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[478, 483]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[642, 651]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[675, 689]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[788, 794]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T59'}, {'offsets': [[801, 811]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T60'}]","[{'trigger': 'T47', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T48', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T47', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T48', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T47', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T48', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T49', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E9']}}, {'trigger': 'T50', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T52', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T49', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E11']}}, {'trigger': 'T53', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E20']}}, {'trigger': 'T49', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E13']}}, {'trigger': 'T53', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E21']}}, {'trigger': 'T49', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E9']}}, {'trigger': 'T50', 'id': 'E15', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E11']}}, {'trigger': 'T49', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T54', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T55', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T55', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T56', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T56', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T24', 'E25']}}, {'trigger': 'T58', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T57', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T24', 'E27']}}, {'trigger': 'T58', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T59', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T28']}}, {'trigger': 'T60', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T59', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T29']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}]",[]
116,PMC-3359311-20-Caption-Figure_2,"Airway epithelial cells do not significantly contribute to IL-1beta production in response to inflammasome stimuli.
Control cell lines ((A) S9, (C) NuLi-1) and their corresponding CF cell lines ((B) IB3-1, and (D) CuFi-1) cells were stimulated with P. aeruginosa (MOI = 10), ATP (5 mM), or IL-1beta (10 ng/ml), for the indicated times (n = 3 individual experiments). Cells were primed with LPS (100 ng/ml) for 4 hours where appropriate. Cell culture supernatants were assayed for IL-1beta and IL-8 production by ELISA. Insert shows IL-8 secretion in response to stimulation with IL-1beta (10 ng/ml).","[{'offsets': [[59, 67]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[290, 298]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[480, 488]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[579, 587]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[45, 55]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T5'}, {'offsets': [[68, 78]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T6'}, {'offsets': [[79, 93]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[498, 508]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T6', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}]",[]
117,PMC-3333881-17-DISCUSSION,"This study reports a novel mechanism of NF-kappaB activation by the HIV-1 Tat transactivator. Based on the evidence that Tat enhanced the transcriptional activity of the p65 subunit of NF-kappaB (49,63,64), and physically interacted with the IkappaB-alpha repressor (50,51), we investigated the possibility that Tat could activate NF-kappaB via direct interaction with IkappaB-alpha and p65. To this end, the NF-kappaB activity was monitored in single round HIV-1 infection using RNA interference to silence the Tat expression. By this approach, we avoided the perpetuation of NF-kappaB activation signaling due to subsequent rounds of viral entry in cell culture propagation (30,31). Upon HIV-1 infection, the early NF-kappaB activation occurred concomitantly with IKK activation and IkappaB-alpha degradation in the absence of Tat. Soon after the shut off of IKK activity and new synthesis of IkappaB-alpha, the NF-kappaB activity was kept elevated in the presence of Tat, while it was down regulated upon silencing of the Tat gene. These findings indicate that in single round HIV-1 infection, Tat enhanced the NF-kappaB activity without affecting the IKK activity and the half-life of IkappaB-alpha. Similar kinetic of NF-kappaB activation occurred upon short-pulse of PMA in Tat-transfected HeLa cells, where Tat inhibited the post-activation turn off of NF-kappaB in presence of newly synthesized IkappaB-alpha.
The Tat-dependent activation of NF-kappaB correlated with the association of the viral protein with IkappaB-alpha, which interfered with the generation of the IkappaB-alpha/p65 complex. This evidence demonstrated that Tat competed for the binding of IkappaB-alpha to p65 and prevented the IkappaB-alpha repression of p65. As additional mechanism of NF-kappaB activation, Tat associated with p65 and increased the p65 binding affinity to the NF-kappaB enhancer; this evidence was obtained with recombinant proteins indicating that the stronger binding of p65 to DNA was a consequence of direct association with Tat, which likely caused a conformational change of p65. We also demonstrated that the Tat cysteine-rich sequence (C22,25,27) was involved in the binding to the RHD of p65 and NF-kappaB activation. Differently, the Tat arginine-rich sequence (R49,52,53,55,56,57) was required for the binding to the sixth ankyrin of IkappaB-alpha (50,51), and for releasing p65 from the IkappaB-alpha inhibition. Altogether these results demonstrated that Tat abolished the negative feedback regulation of NF-kappaB by hijacking the IkappaB-alpha repressor, shielding p65 from the IkappaB-alpha embrace, and enforcing the p65 binding to DNA.
Further evidence of Tat activation of NF-kappaB showed that wild-type Tat, and not the Tat mutants lacking the arginine- or cysteine-rich domains, up-regulated in vivo the expression of a number of NF-kappaB-responsive genes, including MIP-1alpha, CSF3, LTA, NFKBIA and TLR2. By ChIP analysis, we observed that Tat increased the recruitment of p65 to the NF-kappaB enhancers of the activated genes, and was recovered at the same sites. RNA interference of p65 abolished the Tat occupancy of the NF-kappaB enhancers indicating that the Tat binding to the NF-kappaB sites was mediated by p65. These results were consistent with the evidence that Tat displaced p65 from the binding to IkappaB-alpha (Figures 2D and 3C), and increased the p65 DNA binding affinity through association (Figure 4E and F). Thus, Tat likely increased the recruitment of p65 to the NF-kappaB-dependent promoters by associating with p65 and by interfering with the assembly of p65 with the repressor IkappaB-alpha.
Of interest, IkappaB-alpha was found associated to the NF-kappaB enhancers in absence of Tat, where it was displaced in presence of Tat. These results suggest a negative regulatory role of IkappaB-alpha in gene regulation through occupancy of specific promoters. Indeed, IkappaB-alpha was found associated with hystone deacetylases at the hes1 promoter, from where it was removed following TNF-alpha stimulation causing histone acetylation and hes1 transcriptional activation (65). A similar mechanism of gene regulation could apply to the NF-kappaB-dependent genes analysed in this study, where Tat could activate the gene expression by removing IkappaB-alpha and promoting the p65 loading (Figure 7).
The physiological relevance of Tat cross talk with NF-kappaB was demonstrated in the HIV-1 infection of human monocytes, where HIV-1-encoded Tat protein counteracted post-activation turn off of NF-kappaB, as shown by: (i) sustained NF-kappaB activity by Tat in presence of newly synthesized IkappaB-alpha; (ii) coimmunoprecipitation of Tat with IkappaB-alpha and p65; (iii) induction of MIP-1alpha expression dependent on Tat and p65; (iv) Tat occupancy of the MIP-1alpha NF-kappaB enhancer associated with increased recruitment of p65.
This study supports the pro-inflammatory action of Tat through physical interaction with p65 and IkappaB-alpha. Several inflammatory cytokines under the transcriptional control of NF-kappaB are hyper-expressed in HIV-1 infected individuals, including IL-6 (66,67), TNF-alpha (68), and MIP-1alpha (57-62,69-71). In the case of TNF-alpha and IL-6, Tat activated the cytokine expression by binding to the TAR-like stem loop of the 5' transcript, thus likely promoting the transcriptional elongation (33,37,47). Here, we have shown that the Tat-dependent transcriptional activation of a number of pro-inflammatory genes required the assembly of Tat with p65 at the NF-kappaB enhancer together with the displacement of IkappaB-alpha (Figure 5). Thus, in the set of distinct NF-kappaB-responsive genes, Tat acted as a component of the transcriptional initiation complex, which is consistent with previous reports on Tat promoting the transcription via DNA motifs (72,73).
Overproduction of pro-inflammatory cytokines is considered a major mechanism of immune deregulation (26) and neuron dysfunction in AIDS (74,75). In this scenario, inhibition of NF-kappaB activity could lead to a therapeutic strategy for counteracting the abnormal production of pro-inflammatory cytokines and chemokines in HIV-1 infection. NF-kappaB inhibitors, such as anti-oxidants, proteasome and IKK inhibitors, significantly reduced the HIV-1 replication and the associated inflammatory response (76,77); however, these NF-kappaB inhibitors acted indiscriminately in both HIV-1-infected and uninfected cells. The evidence that Tat activates NF-kappaB through direct interaction with IkappaB-alpha and p65 may lead to specific inhibitors to counteract the Tat pro-inflammatory action.","[{'offsets': [[74, 77]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[121, 124]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[170, 173]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[242, 255]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[312, 315]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[369, 382]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[387, 390]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[512, 515]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[785, 798]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[829, 832]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[895, 908]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[970, 973]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1025, 1028]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1097, 1100]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1189, 1202]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1280, 1283]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1314, 1317]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1403, 1416]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1422, 1425]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1518, 1531]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1577, 1590]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1591, 1594]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1636, 1639]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1668, 1681]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1685, 1688]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1707, 1720]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1735, 1738]], 'text': ['p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1789, 1792]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1809, 1812]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1831, 1834]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1972, 1975]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2028, 2031]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2080, 2083]], 'text': ['p65'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2115, 2118]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2196, 2199]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2243, 2246]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2344, 2357]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2385, 2388]], 'text': ['p65'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2398, 2411]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2467, 2470]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2544, 2557]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2579, 2582]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2592, 2605]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2633, 2636]], 'text': ['p65'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2673, 2676]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[2723, 2726]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[2740, 2751]], 'text': ['Tat mutants'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[2889, 2899]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[2901, 2905]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[2907, 2910]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[2912, 2918]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[2923, 2927]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[2964, 2967]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[2997, 3000]], 'text': ['p65'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[3109, 3112]], 'text': ['p65'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[3127, 3130]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[3188, 3191]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[3239, 3242]], 'text': ['p65'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[3297, 3300]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[3311, 3314]], 'text': ['p65'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[3335, 3348]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[3388, 3391]], 'text': ['p65'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[3458, 3461]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[3498, 3501]], 'text': ['p65'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[3559, 3562]], 'text': ['p65'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[3603, 3606]], 'text': ['p65'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[3626, 3639]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[3654, 3667]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[3730, 3733]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[3773, 3776]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[3830, 3843]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[3912, 3925]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[3980, 3984]], 'text': ['hes1'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[4031, 4040]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[4085, 4089]], 'text': ['hes1'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[4237, 4240]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[4288, 4301]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[4320, 4323]], 'text': ['p65'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[4375, 4378]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T157'}, {'offsets': [[4485, 4488]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T158'}, {'offsets': [[4598, 4601]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T159'}, {'offsets': [[4635, 4648]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T160'}, {'offsets': [[4680, 4683]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T161'}, {'offsets': [[4689, 4702]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T162'}, {'offsets': [[4707, 4710]], 'text': ['p65'], 'type': 'Protein', 'id': 'T163'}, {'offsets': [[4731, 4741]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T164'}, {'offsets': [[4766, 4769]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T165'}, {'offsets': [[4774, 4777]], 'text': ['p65'], 'type': 'Protein', 'id': 'T166'}, {'offsets': [[4784, 4787]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T167'}, {'offsets': [[4805, 4815]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T168'}, {'offsets': [[4876, 4879]], 'text': ['p65'], 'type': 'Protein', 'id': 'T169'}, {'offsets': [[4932, 4935]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T170'}, {'offsets': [[4970, 4973]], 'text': ['p65'], 'type': 'Protein', 'id': 'T171'}, {'offsets': [[4978, 4991]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T172'}, {'offsets': [[5132, 5136]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T173'}, {'offsets': [[5146, 5155]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T174'}, {'offsets': [[5166, 5176]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T175'}, {'offsets': [[5207, 5216]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T176'}, {'offsets': [[5221, 5225]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T177'}, {'offsets': [[5227, 5230]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T178'}, {'offsets': [[5418, 5421]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T179'}, {'offsets': [[5522, 5525]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T180'}, {'offsets': [[5531, 5534]], 'text': ['p65'], 'type': 'Protein', 'id': 'T181'}, {'offsets': [[5595, 5608]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T182'}, {'offsets': [[5678, 5681]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T183'}, {'offsets': [[5791, 5794]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T184'}, {'offsets': [[6479, 6482]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T185'}, {'offsets': [[6535, 6548]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T186'}, {'offsets': [[6553, 6556]], 'text': ['p65'], 'type': 'Protein', 'id': 'T187'}, {'offsets': [[6607, 6610]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T188'}, {'offsets': [[222, 232]], 'text': ['interacted'], 'type': 'Binding', 'id': 'T48'}, {'offsets': [[352, 363]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[500, 507]], 'text': ['silence'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[516, 526]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T51'}, {'offsets': [[799, 810]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T52'}, {'offsets': [[818, 825]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[882, 891]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[1008, 1017]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[1141, 1150]], 'text': ['affecting'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[1391, 1402]], 'text': ['synthesized'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[1480, 1491]], 'text': ['association'], 'type': 'Binding', 'id': 'T58'}, {'offsets': [[1495, 1512]], 'text': ['the viral protein'], 'type': 'Anaphora', 'id': 'T45'}, {'offsets': [[1533, 1538]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T46'}, {'offsets': [[1539, 1549]], 'text': ['interfered'], 'type': 'Negative_regulation', 'id': 'T59'}, {'offsets': [[1559, 1569]], 'text': ['generation'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[1640, 1648]], 'text': ['competed'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1657, 1664]], 'text': ['binding'], 'type': 'Binding', 'id': 'T62'}, {'offsets': [[1693, 1702]], 'text': ['prevented'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1721, 1731]], 'text': ['repression'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[1793, 1803]], 'text': ['associated'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[1817, 1826]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[1835, 1842]], 'text': ['binding'], 'type': 'Binding', 'id': 'T67'}, {'offsets': [[1952, 1960]], 'text': ['stronger'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1961, 1968]], 'text': ['binding'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[1989, 2000]], 'text': ['consequence'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[2011, 2022]], 'text': ['association'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[2033, 2038]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T47'}, {'offsets': [[2046, 2052]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[2070, 2076]], 'text': ['change'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[2119, 2141]], 'text': ['cysteine-rich sequence'], 'type': 'Entity', 'id': 'T74'}, {'offsets': [[2158, 2166]], 'text': ['involved'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[2174, 2181]], 'text': ['binding'], 'type': 'Binding', 'id': 'T76'}, {'offsets': [[2189, 2192]], 'text': ['RHD'], 'type': 'Entity', 'id': 'T77'}, {'offsets': [[2247, 2269]], 'text': ['arginine-rich sequence'], 'type': 'Entity', 'id': 'T78'}, {'offsets': [[2295, 2303]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[2312, 2319]], 'text': ['binding'], 'type': 'Binding', 'id': 'T80'}, {'offsets': [[2327, 2340]], 'text': ['sixth ankyrin'], 'type': 'Entity', 'id': 'T81'}, {'offsets': [[2375, 2384]], 'text': ['releasing'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[2412, 2422]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T83'}, {'offsets': [[2530, 2539]], 'text': ['hijacking'], 'type': 'Binding', 'id': 'T84'}, {'offsets': [[2569, 2578]], 'text': ['shielding'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[2606, 2613]], 'text': ['embrace'], 'type': 'Binding', 'id': 'T86'}, {'offsets': [[2619, 2628]], 'text': ['enforcing'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[2637, 2644]], 'text': ['binding'], 'type': 'Binding', 'id': 'T88'}, {'offsets': [[2968, 2977]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T124'}, {'offsets': [[2982, 2993]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T125'}, {'offsets': [[3060, 3069]], 'text': ['recovered'], 'type': 'Binding', 'id': 'T126'}, {'offsets': [[3093, 3105]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T127'}, {'offsets': [[3113, 3122]], 'text': ['abolished'], 'type': 'Negative_regulation', 'id': 'T128'}, {'offsets': [[3131, 3140]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T129'}, {'offsets': [[3192, 3199]], 'text': ['binding'], 'type': 'Binding', 'id': 'T130'}, {'offsets': [[3227, 3235]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T131'}, {'offsets': [[3301, 3310]], 'text': ['displaced'], 'type': 'Negative_regulation', 'id': 'T132'}, {'offsets': [[3324, 3331]], 'text': ['binding'], 'type': 'Binding', 'id': 'T133'}, {'offsets': [[3374, 3383]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T134'}, {'offsets': [[3396, 3403]], 'text': ['binding'], 'type': 'Binding', 'id': 'T135'}, {'offsets': [[3421, 3432]], 'text': ['association'], 'type': 'Binding', 'id': 'T136'}, {'offsets': [[3469, 3478]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T137'}, {'offsets': [[3483, 3494]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T138'}, {'offsets': [[3542, 3553]], 'text': ['associating'], 'type': 'Binding', 'id': 'T139'}, {'offsets': [[3570, 3581]], 'text': ['interfering'], 'type': 'Negative_regulation', 'id': 'T140'}, {'offsets': [[3591, 3599]], 'text': ['assembly'], 'type': 'Binding', 'id': 'T141'}, {'offsets': [[3672, 3677]], 'text': ['found'], 'type': 'Negative_regulation', 'id': 'T142'}, {'offsets': [[3678, 3688]], 'text': ['associated'], 'type': 'Binding', 'id': 'T143'}, {'offsets': [[3719, 3726]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T144'}, {'offsets': [[3871, 3880]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T145'}, {'offsets': [[3936, 3946]], 'text': ['associated'], 'type': 'Binding', 'id': 'T146'}, {'offsets': [[3973, 3975]], 'text': ['at'], 'type': 'Binding', 'id': 'T147'}, {'offsets': [[3985, 3993]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T148'}, {'offsets': [[4006, 4008]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T123'}, {'offsets': [[4013, 4020]], 'text': ['removed'], 'type': 'Binding', 'id': 'T149'}, {'offsets': [[4021, 4030]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T150'}, {'offsets': [[4053, 4060]], 'text': ['causing'], 'type': 'Positive_regulation', 'id': 'T151'}, {'offsets': [[4090, 4116]], 'text': ['transcriptional activation'], 'type': 'Positive_regulation', 'id': 'T152'}, {'offsets': [[4276, 4278]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T153'}, {'offsets': [[4279, 4287]], 'text': ['removing'], 'type': 'Binding', 'id': 'T154'}, {'offsets': [[4306, 4315]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T155'}, {'offsets': [[4324, 4331]], 'text': ['loading'], 'type': 'Binding', 'id': 'T156'}, {'offsets': [[4379, 4389]], 'text': ['cross talk'], 'type': 'Regulation', 'id': 'T191'}, {'offsets': [[4655, 4676]], 'text': ['coimmunoprecipitation'], 'type': 'Binding', 'id': 'T192'}, {'offsets': [[4718, 4727]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T193'}, {'offsets': [[4742, 4752]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T194'}, {'offsets': [[4753, 4762]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T195'}, {'offsets': [[4788, 4797]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T196'}, {'offsets': [[4816, 4834]], 'text': ['NF-kappaB enhancer'], 'type': 'Entity', 'id': 'T197'}, {'offsets': [[4851, 4860]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T198'}, {'offsets': [[4861, 4872]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T199'}, {'offsets': [[4953, 4964]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T200'}, {'offsets': [[5231, 5240]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T201'}, {'offsets': [[5241, 5253]], 'text': ['the cytokine'], 'type': 'Anaphora', 'id': 'T189'}, {'offsets': [[5254, 5264]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T202'}, {'offsets': [[5268, 5275]], 'text': ['binding'], 'type': 'Binding', 'id': 'T203'}, {'offsets': [[5305, 5322]], 'text': [""the 5' transcript""], 'type': 'Anaphora', 'id': 'T190'}, {'offsets': [[5336, 5345]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T204'}, {'offsets': [[5350, 5376]], 'text': ['transcriptional elongation'], 'type': 'Transcription', 'id': 'T205'}, {'offsets': [[5510, 5518]], 'text': ['assembly'], 'type': 'Binding', 'id': 'T206'}, {'offsets': [[5579, 5591]], 'text': ['displacement'], 'type': 'Binding', 'id': 'T207'}, {'offsets': [[6518, 6529]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T208'}, {'offsets': [[6578, 6588]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T209'}, {'offsets': [[6592, 6602]], 'text': ['counteract'], 'type': 'Negative_regulation', 'id': 'T210'}]","[{'trigger': 'T48', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T2', 'T4']}}, {'trigger': 'T49', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T5', 'T6']}}, {'trigger': 'T50', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T51', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T52', 'id': 'E5', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T53', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T54', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T55', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T56', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T15', 'T14']}}, {'trigger': 'T57', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T58', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T19', 'T20']}}, {'trigger': 'T59', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E11']}}, {'trigger': 'T60', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T21', 'T22']}}, {'trigger': 'T61', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T23']}}, {'trigger': 'T62', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T63', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T23']}}, {'trigger': 'T64', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T27', 'T26']}}, {'trigger': 'T65', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T28', 'T29']}}, {'trigger': 'T66', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T28']}}, {'trigger': 'T67', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T68', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T69', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T70', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E24']}}, {'trigger': 'T71', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T31', 'T32']}}, {'trigger': 'T72', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'E24']}}, {'trigger': 'T73', 'id': 'E26', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T75', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E28', 'T34', 'T74']}}, {'trigger': 'T76', 'id': 'E28', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T34', 'T35', 'T77']}}, {'trigger': 'T79', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E30', 'T36', 'T78']}}, {'trigger': 'T80', 'id': 'E30', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T36', 'T37', 'T81']}}, {'trigger': 'T79', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T36', 'T78']}}, {'trigger': 'T82', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T36']}}, {'trigger': 'T83', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T84', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T40', 'T41']}}, {'trigger': 'T85', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T40']}}, {'trigger': 'T86', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T42', 'T43']}}, {'trigger': 'T87', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'T40']}}, {'trigger': 'T88', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T124', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'T97']}}, {'trigger': 'T125', 'id': 'E40', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T98']}}, {'trigger': 'T126', 'id': 'E41', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T97']}}, {'trigger': 'T127', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T99']}}, {'trigger': 'T128', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E42']}}, {'trigger': 'T129', 'id': 'E44', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T100']}}, {'trigger': 'T130', 'id': 'E45', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T101']}}, {'trigger': 'T131', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T102']}}, {'trigger': 'T132', 'id': 'E47', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'E49']}}, {'trigger': 'T133', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T104', 'T105']}}, {'trigger': 'T136', 'id': 'E49', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T103', 'T106']}}, {'trigger': 'T134', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'E49']}}, {'trigger': 'T135', 'id': 'E51', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T106']}}, {'trigger': 'T137', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E53', 'E54']}}, {'trigger': 'T138', 'id': 'E53', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T108']}}, {'trigger': 'T139', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T107', 'T109']}}, {'trigger': 'T137', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E53', 'E56']}}, {'trigger': 'T140', 'id': 'E56', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E57', 'T107']}}, {'trigger': 'T141', 'id': 'E57', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T110', 'T111']}}, {'trigger': 'T142', 'id': 'E58', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E59', 'E60']}}, {'trigger': 'T143', 'id': 'E59', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T112']}}, {'trigger': 'T144', 'id': 'E60', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T113']}}, {'trigger': 'T145', 'id': 'E61', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T115']}}, {'trigger': 'T146', 'id': 'E62', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T116']}}, {'trigger': 'T147', 'id': 'E63', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T117', 'T148']}}, {'trigger': 'T149', 'id': 'E64', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T116']}}, {'trigger': 'T150', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E64', 'T118']}}, {'trigger': 'T151', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'E64']}}, {'trigger': 'T152', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T119']}}, {'trigger': 'T153', 'id': 'E68', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E69', 'T120']}}, {'trigger': 'T154', 'id': 'E69', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T121']}}, {'trigger': 'T153', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E71', 'T120']}}, {'trigger': 'T155', 'id': 'E71', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E72']}}, {'trigger': 'T156', 'id': 'E72', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T122']}}, {'trigger': 'T191', 'id': 'E73', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T157', 'T157']}}, {'trigger': 'T192', 'id': 'E74', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T161', 'T162']}}, {'trigger': 'T193', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E76']}}, {'trigger': 'T194', 'id': 'E76', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T164']}}, {'trigger': 'T195', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E75', 'T165']}}, {'trigger': 'T195', 'id': 'E78', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E75', 'T166']}}, {'trigger': 'T196', 'id': 'E79', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T167', 'T168', 'T197']}}, {'trigger': 'T198', 'id': 'E80', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E81']}}, {'trigger': 'T199', 'id': 'E81', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T168', 'T169', 'T197']}}, {'trigger': 'T200', 'id': 'E82', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T170', 'T171']}}, {'trigger': 'T201', 'id': 'E83', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E84', 'E85']}}, {'trigger': 'T202', 'id': 'E84', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T176']}}, {'trigger': 'T203', 'id': 'E85', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T178']}}, {'trigger': 'T201', 'id': 'E86', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E84', 'E87']}}, {'trigger': 'T204', 'id': 'E87', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E94', 'E85']}}, {'trigger': 'T201', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E84', 'E89']}}, {'trigger': 'T204', 'id': 'E89', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E95', 'E85']}}, {'trigger': 'T201', 'id': 'E90', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E91', 'E85']}}, {'trigger': 'T202', 'id': 'E91', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T177']}}, {'trigger': 'T201', 'id': 'E92', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E91', 'E87']}}, {'trigger': 'T201', 'id': 'E93', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E91', 'E89']}}, {'trigger': 'T205', 'id': 'E94', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T176']}}, {'trigger': 'T205', 'id': 'E95', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T177']}}, {'trigger': 'T206', 'id': 'E96', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T180', 'T181']}}, {'trigger': 'T207', 'id': 'E97', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T181', 'T182']}}, {'trigger': 'T208', 'id': 'E98', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T185', 'T186']}}, {'trigger': 'T208', 'id': 'E99', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T185', 'T187']}}, {'trigger': 'T209', 'id': 'E100', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E101']}}, {'trigger': 'T210', 'id': 'E101', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T188']}}]","[{'id': 'R1', 'head': {'ref_id': 'T45', 'role': 'Subject'}, 'tail': {'ref_id': 'T19', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T46', 'role': 'Subject'}, 'tail': {'ref_id': 'T58', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T47', 'role': 'Subject'}, 'tail': {'ref_id': 'T71', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T123', 'role': 'Subject'}, 'tail': {'ref_id': 'T116', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T189', 'role': 'Subject'}, 'tail': {'ref_id': 'T176', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T189', 'role': 'Subject'}, 'tail': {'ref_id': 'T177', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T190', 'role': 'Subject'}, 'tail': {'ref_id': 'T189', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E25', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E52', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E55', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E58', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E64', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E69', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E87', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E89', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E97', 'value': ''}]",[]
118,PMC-3062687-07-Results,"Phosphorylation of RPS3 and its NF-kappaB function
We next examined whether S209 phosphorylation plays a role in the nuclear translocation of RPS3 during NF-kappaB activation. Subcellular fractions from either wild-type or S209A mutant RPS3-transfected cells were prepared and blotted for heat-shock protein 90 (hsp90), a cytoplasmic protein, and poly (ADP-ribose) polymerase (PARP), a nuclear protein, confirming a clean separation (Fig. 5a). As expected, PMA+I stimulation triggered wild-type Flag-RPS3 nuclear translocation (Fig. 5a). However, RPS3 (S209A) nuclear translocation was attenuated (Fig. 5a). We also tested the impact of activating NF-kappaB by overexpressing IKKbeta on RPS3 nuclear translocation. IKKbeta overexpression activated NF-kappaB measured by luciferase assays (Supplementary Fig. 7), and also induced the nuclear translocation of wild-type, but not S209A, RPS3 (Fig. 5b). These data suggest that S209 phosphorylation is critical for the NF-kappaB activation-induced RPS3 nuclear translocation.
To examine the role of S209 phosphorylation of RPS3 to its NF-kappaB function6, 7, 30, we silenced endogenous RPS3 expression using an siRNA that targets the 3' untranslated region (3' UTR) of RPS3 mRNA, followed by complementation with either wild-type or S209A mutant RPS3 via transfection. As expected, RPS3 siRNA severely reduced endogenous RPS3 abundance compared to NS siRNA, but did not affect the robust expression of Flag-tagged RPS3 from a transfected construct lacking the 3' UTR (Fig. 5c). We also found that RPS3 knockdown reduced TNF-induced expression of an Ig kappaB-driven luciferase construct6 (Fig. 5d). The impaired luciferase signal caused by RPS3 deficiency was completely restored by transfecting wild-type, but not by S209A RPS3 (Fig. 5d), despite equivalent expression (Fig. 5c). Moreover, the failure of S209A RPS3 to restore luciferase activity did not result from defective translation because the transient overexpression of green fluorescent protein (GFP) was comparable in cells complemented with wild-type or S029A RPS3 (Supplementary Fig. 8). Taken together, these data suggest that RPS3 S209 phosphorylation is critical for NF-kappaB activity involving the canonical Ig kappaB site.
We next used chromatin immunoprecipitation to determine whether S209 phosphorylation affects RPS3 and p65 recruitment to specific kappaB sites in intact chromatin during NF-kappaB activation. In RPS3 knockdown cells, PMA+I stimulated the recruitment of ectopically expressed, Flag-tagged wild-type, but not S209A RPS3 to the kappaB sites of the NFKBIA and IL8 promoters (Fig. 5e). While expressing RPS3 S209A had no impact on p65 nuclear translocation, it substantially attenuated p65 recruitment (Fig. 5e). Additional experiments revealed that p65 attraction to RPS3-independent NF-kappaB target gene promoters such as CD25 was increased (Supplementary Fig. 9), consistent with our previous observations6. There was no significant Flag-RPS3 or p65 recruitment to ACTB promoter lacking kappaB sites (Fig. 5e), suggesting the recruitment was kappaB site-specific. Thus, the recruitment of RPS3 as well as the contingent recruitment of p65 to key promoters depended on S209.
Interleukin 8 (IL-8) secretion induced by either T cell receptor (TCR) agonist stimulation or PMA+I was decreased as a consequence of reduced RPS3/p65 recruitment to the IL8 kappaB sites in the presence of S209A mutant compared to wild-type RPS3 (Supplementary Fig. 10). However, cell surface CD25 expression was comparable between the wild-type and S209A RPS3 transfected cells (Supplementary Fig. 11). Therefore, RPS3 S209 phosphorylation by IKKbeta is apparently required for RPS3 in directing NF-kappaB to a specific subset of target genes.","[{'offsets': [[19, 23]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[142, 146]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[236, 240]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[495, 504]], 'text': ['Flag-RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[547, 551]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[676, 683]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[687, 691]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[715, 722]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[770, 780]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[884, 888]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[994, 998]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1069, 1073]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1132, 1136]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1215, 1219]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1292, 1296]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1328, 1338]], 'text': ['RPS3 siRNA'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1367, 1371]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1448, 1464]], 'text': ['Flag-tagged RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1543, 1547]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1612, 1622]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1658, 1668]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1686, 1690]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1770, 1774]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1976, 2001]], 'text': ['green fluorescent protein'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2003, 2006]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2069, 2073]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2138, 2142]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2332, 2336]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2341, 2344]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2434, 2438]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2552, 2556]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2584, 2590]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2595, 2598]], 'text': ['IL8'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2637, 2641]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2665, 2668]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2720, 2723]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2784, 2787]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2802, 2806]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2859, 2863]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2971, 2980]], 'text': ['Flag-RPS3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2984, 2987]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3003, 3007]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3127, 3131]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3173, 3176]], 'text': ['p65'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3212, 3225]], 'text': ['Interleukin 8'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3227, 3231]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3354, 3358]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3359, 3362]], 'text': ['p65'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3382, 3385]], 'text': ['IL8'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3453, 3457]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3505, 3509]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3568, 3572]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3627, 3631]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3656, 3663]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3691, 3695]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[0, 15]], 'text': ['Phosphorylation'], 'type': 'Phosphorylation', 'id': 'T58'}, {'offsets': [[76, 80]], 'text': ['S209'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[81, 96]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T60'}, {'offsets': [[97, 109]], 'text': ['plays a role'], 'type': 'Regulation', 'id': 'T61'}, {'offsets': [[117, 124]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[125, 138]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T63'}, {'offsets': [[223, 228]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[229, 235]], 'text': ['mutant'], 'type': 'Regulation', 'id': 'T65'}, {'offsets': [[475, 484]], 'text': ['triggered'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[505, 512]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[513, 526]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T68'}, {'offsets': [[553, 558]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T69'}, {'offsets': [[560, 567]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[568, 581]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T71'}, {'offsets': [[586, 596]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[627, 633]], 'text': ['impact'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[661, 675]], 'text': ['overexpressing'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[692, 699]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T75'}, {'offsets': [[700, 713]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T76'}, {'offsets': [[821, 828]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[833, 840]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T78'}, {'offsets': [[841, 854]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T79'}, {'offsets': [[924, 928]], 'text': ['S209'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[929, 944]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T81'}, {'offsets': [[948, 956]], 'text': ['critical'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[986, 993]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[999, 1006]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T84'}, {'offsets': [[1007, 1020]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T85'}, {'offsets': [[1045, 1049]], 'text': ['S209'], 'type': 'Entity', 'id': 'T86'}, {'offsets': [[1050, 1065]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T87'}, {'offsets': [[1112, 1120]], 'text': ['silenced'], 'type': 'Negative_regulation', 'id': 'T88'}, {'offsets': [[1137, 1147]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T89'}, {'offsets': [[1301, 1313]], 'text': ['transfection'], 'type': 'Gene_expression', 'id': 'T90'}, {'offsets': [[1348, 1355]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T91'}, {'offsets': [[1416, 1422]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[1434, 1444]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T93'}, {'offsets': [[1548, 1557]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T94'}, {'offsets': [[1558, 1565]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T95'}, {'offsets': [[1570, 1577]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[1578, 1588]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T97'}, {'offsets': [[1605, 1611]], 'text': ['driven'], 'type': 'Positive_regulation', 'id': 'T98'}, {'offsets': [[1649, 1657]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[1676, 1682]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[1691, 1701]], 'text': ['deficiency'], 'type': 'Negative_regulation', 'id': 'T101'}, {'offsets': [[1729, 1741]], 'text': ['transfecting'], 'type': 'Gene_expression', 'id': 'T102'}, {'offsets': [[1958, 1972]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T103'}, {'offsets': [[2143, 2147]], 'text': ['S209'], 'type': 'Entity', 'id': 'T104'}, {'offsets': [[2148, 2163]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T105'}, {'offsets': [[2303, 2307]], 'text': ['S209'], 'type': 'Entity', 'id': 'T106'}, {'offsets': [[2308, 2323]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T107'}, {'offsets': [[2324, 2331]], 'text': ['affects'], 'type': 'Regulation', 'id': 'T108'}, {'offsets': [[2345, 2356]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T109'}, {'offsets': [[2439, 2448]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T110'}, {'offsets': [[2462, 2472]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T111'}, {'offsets': [[2477, 2488]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T112'}, {'offsets': [[2504, 2513]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T113'}, {'offsets': [[2546, 2551]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T114'}, {'offsets': [[2564, 2576]], 'text': ['kappaB sites'], 'type': 'Entity', 'id': 'T115'}, {'offsets': [[2642, 2647]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T116'}, {'offsets': [[2655, 2661]], 'text': ['impact'], 'type': 'Regulation', 'id': 'T117'}, {'offsets': [[2669, 2676]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T118'}, {'offsets': [[2677, 2690]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T119'}, {'offsets': [[2692, 2694]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T56'}, {'offsets': [[2709, 2719]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T120'}, {'offsets': [[2724, 2735]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T121'}, {'offsets': [[2788, 2798]], 'text': ['attraction'], 'type': 'Localization', 'id': 'T122'}, {'offsets': [[2841, 2850]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T123'}, {'offsets': [[2868, 2877]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T124'}, {'offsets': [[2988, 2999]], 'text': ['recruitment'], 'type': 'Localization', 'id': 'T125'}, {'offsets': [[3008, 3016]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T126'}, {'offsets': [[3060, 3075]], 'text': ['the recruitment'], 'type': 'Anaphora', 'id': 'T57'}, {'offsets': [[3092, 3100]], 'text': ['specific'], 'type': 'Regulation', 'id': 'T127'}, {'offsets': [[3112, 3123]], 'text': ['recruitment'], 'type': 'Localization', 'id': 'T128'}, {'offsets': [[3158, 3169]], 'text': ['recruitment'], 'type': 'Localization', 'id': 'T129'}, {'offsets': [[3184, 3193]], 'text': ['promoters'], 'type': 'Entity', 'id': 'T130'}, {'offsets': [[3194, 3202]], 'text': ['depended'], 'type': 'Regulation', 'id': 'T131'}, {'offsets': [[3206, 3210]], 'text': ['S209'], 'type': 'Entity', 'id': 'T132'}, {'offsets': [[3233, 3242]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T133'}, {'offsets': [[3243, 3250]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T134'}, {'offsets': [[3291, 3302]], 'text': ['stimulation'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[3316, 3325]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T136'}, {'offsets': [[3346, 3353]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T137'}, {'offsets': [[3363, 3374]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T138'}, {'offsets': [[3386, 3398]], 'text': ['kappaB sites'], 'type': 'Entity', 'id': 'T139'}, {'offsets': [[3418, 3423]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T140'}, {'offsets': [[3510, 3520]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T141'}, {'offsets': [[3573, 3584]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T142'}, {'offsets': [[3632, 3636]], 'text': ['S209'], 'type': 'Entity', 'id': 'T143'}, {'offsets': [[3637, 3652]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T144'}, {'offsets': [[3653, 3655]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T145'}]","[{'trigger': 'T58', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T60', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T59']}}, {'trigger': 'T61', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'E2']}}, {'trigger': 'T63', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T62']}}, {'trigger': 'T65', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T64']}}, {'trigger': 'T66', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T68', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T67']}}, {'trigger': 'T71', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T70']}}, {'trigger': 'T72', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T5', 'T69']}}, {'trigger': 'T73', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T76', 'id': 'E11', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T75']}}, {'trigger': 'T74', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T77', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T79', 'id': 'E14', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T10', 'T78']}}, {'trigger': 'T81', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T80']}}, {'trigger': 'T82', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T83', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T85', 'id': 'E18', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T11', 'T84']}}, {'trigger': 'T87', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T12', 'T86']}}, {'trigger': 'T88', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T89', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T90', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T91', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T17', 'T16']}}, {'trigger': 'T92', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T16']}}, {'trigger': 'T93', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T94', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T95', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'E26']}}, {'trigger': 'T96', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T97', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T98', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T99', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T100', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E33']}}, {'trigger': 'T101', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T102', 'id': 'E34', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T103', 'id': 'E35', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T105', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T27', 'T104']}}, {'trigger': 'T107', 'id': 'E37', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T106']}}, {'trigger': 'T108', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E37']}}, {'trigger': 'T109', 'id': 'E39', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T108', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'E37']}}, {'trigger': 'T109', 'id': 'E41', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T110', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T111', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T112', 'id': 'E44', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site', 'Site2'], 'ref_id': ['T31', 'T32', 'T114', 'T115']}}, {'trigger': 'T111', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T112', 'id': 'E46', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T31', 'T32', 'T115']}}, {'trigger': 'T111', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E48']}}, {'trigger': 'T112', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site', 'Site2'], 'ref_id': ['T31', 'T33', 'T114', 'T115']}}, {'trigger': 'T111', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E50']}}, {'trigger': 'T112', 'id': 'E50', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T31', 'T33', 'T115']}}, {'trigger': 'T113', 'id': 'E51', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T117', 'id': 'E52', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E53', 'T34', 'T116']}}, {'trigger': 'T119', 'id': 'E53', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T35', 'T118']}}, {'trigger': 'T120', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E55', 'T34', 'T116']}}, {'trigger': 'T121', 'id': 'E55', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T122', 'id': 'E56', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T37', 'T123']}}, {'trigger': 'T124', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T125', 'id': 'E58', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T40', 'T126']}}, {'trigger': 'T125', 'id': 'E59', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T41', 'T126']}}, {'trigger': 'T127', 'id': 'E60', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E56']}}, {'trigger': 'T128', 'id': 'E61', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T43', 'T130']}}, {'trigger': 'T129', 'id': 'E62', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T44', 'T130']}}, {'trigger': 'T131', 'id': 'E63', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E61', 'T43', 'T132']}}, {'trigger': 'T131', 'id': 'E64', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E62', 'T43', 'T132']}}, {'trigger': 'T133', 'id': 'E65', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T134', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E65', 'E67']}}, {'trigger': 'T135', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T136', 'id': 'E68', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E66', 'E69']}}, {'trigger': 'T137', 'id': 'E69', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E70', 'T50', 'T140']}}, {'trigger': 'T138', 'id': 'E70', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T47', 'T49', 'T139']}}, {'trigger': 'T141', 'id': 'E71', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T142', 'id': 'E72', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T144', 'id': 'E73', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T53', 'T143']}}, {'trigger': 'T145', 'id': 'E74', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'T54']}}]","[{'id': 'R1', 'head': {'ref_id': 'T56', 'role': 'Subject'}, 'tail': {'ref_id': 'T116', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T57', 'role': 'Subject'}, 'tail': {'ref_id': 'T122', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T24', 'T25']}, {'id': '*', 'ref_ids': ['T45', 'T46']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E38', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E40', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E43', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E49', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E52', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E58', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E59', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E60', 'value': ''}]",[]
119,PMC-3333881-05-MATERIALS_AND_METHODS,"Pseudotyped virions and single round infection
293T cells (1 x 107) were transfected with pNL4-3.Luc.R-E- or pNL4-3.FLAG-Tat.R-E- (10 microg) together with pHXB2 Env (10 microg), and 48-h post-transfection cell supernatant was collected. Enzyme-linked immunosorbent assay (ELISA) using anti-p24 antibody measured virion concentration. PBMCs, Jurkat or U937 cells (5 x 107) were infected with HXB2 Env-pseudotyped virions (500 ng of p24) by spinoculation, as previously described (50).","[{'offsets': [[121, 124]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[162, 165]], 'text': ['Env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[397, 400]], 'text': ['Env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[432, 435]], 'text': ['p24'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
120,PMC-3359311-18-Materials_and_Methods,"Statistics
All graphs display the mean +/- SEM and were generated with Prism 5 (Graphpad). Statistical significance was determined by performing one or two-way ANOVA and the Bonferroni post-test where applicable.",[],[],[],[],[],[]
121,PMC-2222968-21-Materials_and_Methods,"Western blotting.
For FOXP3 analysis on the protein level, 1 x 106 CD4+CD25- cells were lysed and loaded next to a protein-mass ladder (Magicmark, Invitrogen) on a NuPAGE 4-12% bis-tris gel (Invitrogen). The proteins were electroblotted onto a PVDF membrane (Amersham Life Science). Unspecific binding was blocked with BSA, and the membranes were subsequently incubated with an 1:200 dilution of goat anti-FOXP3 in blocking buffer (Abcam) overnight at 4 degreesC. The blots were developed using an anti-goat HRP-labeled mAb (Amersham Biosciences) and visualized with a LAS 1000 camera (Fuji). Membranes were incubated in stripping buffer and re-blocked for 1 h. The membranes were re-probed using anti-GATA3 (HG3-31; Santa Cruz Biotechnology), anti-T-bet (4B10, Santa Cruz Biotechnology), anti-GAPDH (6C5, Ambion), anti-phospho-SMAD2 (138D4), anti-phospho-STAT6 (5A4), and anti-STAT6 (Cell Signaling Technology),","[{'offsets': [[22, 27]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[67, 70]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 75]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[406, 411]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[702, 707]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[749, 754]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[794, 799]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[828, 833]], 'text': ['SMAD2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[856, 861]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[878, 883]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
122,PMC-1134658-18-Methods,"Statistical analysis
The statistical significance of differences between groups was determined using the paired two-tailed Wilcoxon nonparametric test, by applying SPSS10.1 software (SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered significant.",[],[],[],[],[],[]
123,PMC-2674207-15-Materials_and_Methods,"Statistical Analysis
Data from three or more independent experiments are presented as the mean+/-standard error of the mean (SEM), except where stated and were compared using GraphPad Prism 4 (GraphPad Software, http://www.graphpad.com). Results were analysed using one-way ANOVA with Newman-Keuls post test except for the data from the in vivo inhaled FP study, which was analysed by Friedman's test with subsequent Wilcoxson matched pair signed rank sum test. Data from this analysis are presented as a box-and-whiskers plot. Friedman's test was used as three matched measures were obtained using placebo, 100 microg, and 500 microg of inhaled FP, which had variable baseline levels. We did not assume a Gaussian distribution of the data due to the limited numbers of participants analysed (seven).The null hypothesis was rejected at p<0.05.",[],[],[],[],[],[]
124,PMC-3062687-14-Methods,"32P in vivo Labeling
HEK 293T cells were labeled with 2 mCi/ml 32P-orthophosphate (Perkin Elmer) in phosphate-free medium (Invitrogen) for 2 h. Cells were then left untreated or treated with TNF (50 ng/ml, R&D Systems) for indicated periods. Cell lysates were prepared and used for immunoprecipitations with RPS3 antibody.",[],[],[],[],[],[]
125,PMC-2806624-15-MATERIALS_AND_METHODS,"RNA interference.
CD4+ or naive CD4+ T cells were resuspended in 100 microl of Nucleofector solution (Lonza) and electroporated with 2 microM siRNA using the Nucleofector technology program U-14 (Lonza). Five different Silencer or Silencer Select Pre-designed siRNAs for RUNX1 (Applied Biosystems) and three Silencer Pre-designed siRNAs for RUNX3 (Applied Biosystems) were tested, and the best was selected for all further experiments. The Silencer Negative Control #1 siRNA (Applied Biosystems) was used for normalization. Cells were then left unstimulated or were stimulated after 12 h with anti-CD2, anti-CD3, and anti-CD28. Cells were cultured in serum-free AIM-V medium with the addition of 1 nmol/l IL-2 (Roche). Cells were harvested for mRNA detection of the target genes after 24 h and for protein detection after 48 h.","[{'offsets': [[18, 21]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[32, 35]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[271, 276]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[341, 346]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[598, 601]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[608, 611]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[622, 626]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[662, 667]], 'text': ['AIM-V'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[705, 709]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[260, 266]], 'text': ['siRNAs'], 'type': 'Negative_regulation', 'id': 'T10'}, {'offsets': [[330, 336]], 'text': ['siRNAs'], 'type': 'Negative_regulation', 'id': 'T11'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
126,PMC-3333881-08-MATERIALS_AND_METHODS,"Immunoprecipitation assay and GST-pull down
Immunoprecipitation, GST-pull down, and production of GST proteins in Escherichia coli strain BL21 were performed as previously reported (50). Details are described in Supplementary Data.","[{'offsets': [[30, 33]], 'text': ['GST'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[65, 68]], 'text': ['GST'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[98, 101]], 'text': ['GST'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
127,PMC-1920263-12-RESULTS,"A GC-box located at position -87/-78 of the A3G promoter is important for transcriptional activity
The reporter studies shown in Figure 3 had demonstrated a drop in luciferase activity after deletion of the 30 nt at the 5' end of the 180 bp core promoter. We therefore inspected the 30 bp sequence deleted in the 150 bp fragment and identified a GC-box at position -87/-78 (see Figure 1). The sequence TGGGCGGGAC, which is interrupted in the 150 bp fragment, represents a variant of the (G/T)GGGCGG(G/A)(G/A)(C/T) consensus motif recognized by Sp1 and Sp3 transcription factors. To analyze whether this putative Sp1/Sp3-binding site mediates transcriptional activity of the 180 bp core promoter, we introduced two point mutations which changed the sequence from TGGGCGGGAC to TGTTCGGGAC (mutations shown in bold). This resulted in a 71% reduction of the transcriptional activity compared to the unmodified 180 bp promoter (Figure 5A) and this value was only marginally higher than the luciferase activity of the 150 bp fragment, indicating that the identified motif is essential for basal activity of the A3G core promoter. To further examine the transcriptional potency of the 30 nt present in the 180 bp promoter, we cloned the region -114/-85 (containing all nucleotides which are deleted in the 150 bp fragment, designated E1) or the region -92/-63 (containing the putative Sp1/Sp3 motif, designated E2) into the vector pGL3-Promoter (see Figure 1). This vector contains a luciferase reporter gene under the control of an SV40 promoter without enhancer sequences, and putative transcriptionally active sequences can be cloned upstream of the SV40 promoter. Luciferase assays showed that the E1 element increased SV40 promoter activity only by ~2-fold (Figure 5B). In contrast, the 30 nt of E2 enhanced the transcriptional activity of the SV40 promoter by ~4.3-fold, indicating that the intact GC-box present in the E2 element was responsible for the strongly enhanced transcriptional activity of the SV40 promoter.","[{'offsets': [[44, 47]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[165, 175]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[544, 547]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[552, 555]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[985, 995]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1105, 1108]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1477, 1487]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1661, 1671]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[483, 529]], 'text': ['the (G/T)GGGCGG(G/A)(G/A)(C/T) consensus motif'], 'type': 'Entity', 'id': 'T9'}, {'offsets': [[530, 540]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T10'}, {'offsets': [[1502, 1519]], 'text': ['under the control'], 'type': 'Regulation', 'id': 'T11'}, {'offsets': [[1785, 1790]], 'text': ['30 nt'], 'type': 'Entity', 'id': 'T12'}, {'offsets': [[1797, 1805]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[1810, 1834]], 'text': ['transcriptional activity'], 'type': 'Transcription', 'id': 'T14'}, {'offsets': [[1934, 1945]], 'text': ['responsible'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[1963, 1971]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[1972, 1996]], 'text': ['transcriptional activity'], 'type': 'Positive_regulation', 'id': 'T17'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T1', 'T3', 'T9']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T1', 'T4', 'T9']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E5', 'T6', 'T12']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T17', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],[],[]
128,PMC-2222968-24-Materials_and_Methods,"Pull-down assay.
CD4+ T cells were stimulated with PMA and ionomycin for 2 h at 37degreesC. The cells were pelleted, resuspended in buffer C (20 mM HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, protease inhibitors [Sigma]. and 0.1% NP-40) and lysed on ice for 15 min. Insoluble material was removed by centrifugation. The supernatant was diluted 1:3 with buffer D (as buffer C, but without NaCl). The lysates were incubated with 10 mug of poly(dI-dC) (Sigma) and 70 mul of streptavidin-agarose (Amersham Biosciences) carrying biotinylated oligonucleotides, for 3 h at 4 degreesC. The beads were washed twice with buffer C:D (1:3) and resuspended in DTT-containing loading buffer (NuPAGE; Invitrogen), heated to 70 degreesC for 10 min, and the eluants on a NuPAGE 4-12% bis-tris gel (Invitrogen). The proteins were electroblotted onto a PVDF membrane (Amersham Biosciences) and detected using an anti-GATA3 mAb (Santa Cruz Biotechnology). Accumulated signals were analyzed using AIDA software (Raytest).","[{'offsets': [[17, 20]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[920, 925]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
129,PMC-2674207-00-TIAB,"Suppression of GATA-3 Nuclear Import and Phosphorylation: A Novel Mechanism of Corticosteroid Action in Allergic Disease
Background
GATA-3 plays a critical role in regulating the expression of the cytokines interleukin (IL)-4, IL-5, and IL-13 from T helper-2 (Th2) cells and therefore is a key mediator of allergic diseases. Corticosteroids are highly effective in suppressing allergic inflammation, but their effects on GATA-3 are unknown. We investigated the effect of the corticosteroid fluticasone propionate on GATA-3 regulation in human T-lymphocytes in vitro and in vivo.
Methods and Findings
In a T lymphocyte cell line (HuT-78) and peripheral blood mononuclear cells stimulated by anti-CD3 and anti-CD28 in vitro we demonstrated that fluticasone inhibits nuclear translocation of GATA-3 and expression of Th2 cytokines via a mechanism independent of nuclear factor-kappaB and is due, in part, to competition between GATA-3 and the ligand-activated glucocorticoid receptor for nuclear transport through the nuclear importer importin-alpha. In addition, fluticasone induces the expression of mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1), the endogenous inhibitor of p38 MAPK, which is necessary for GATA-3 nuclear translocation. These inhibitory effects of fluticasone are rapid, potent, and prolonged. We also demonstrated that inhaled fluticasone inhibits GATA-3 nuclear translocation in peripheral blood lymphocytes of patients with asthma in vivo.
Conclusions
Corticosteroids have a potent inhibitory effect on GATA-3 via two interacting mechanisms that potently suppress Th2 cytokine expression. This novel mechanism of action of corticosteroids may account for the striking clinical efficacy of corticosteroids in the treatment of allergic diseases.
Please see later in the article for Editors' Summary","[{'offsets': [[15, 21]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[132, 138]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[207, 225]], 'text': ['interleukin (IL)-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[227, 231]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[237, 242]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[421, 427]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[516, 522]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[789, 795]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[925, 931]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[957, 980]], 'text': ['glucocorticoid receptor'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1099, 1152]], 'text': ['mitogen-activated protein kinase (MAPK) phosphatase-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1154, 1159]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1223, 1229]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1382, 1388]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1539, 1545]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[0, 11]], 'text': ['Suppression'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[22, 29]], 'text': ['Nuclear'], 'type': 'Entity', 'id': 'T18'}, {'offsets': [[30, 36]], 'text': ['Import'], 'type': 'Localization', 'id': 'T19'}, {'offsets': [[41, 56]], 'text': ['Phosphorylation'], 'type': 'Phosphorylation', 'id': 'T20'}, {'offsets': [[164, 174]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T21'}, {'offsets': [[179, 189]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[193, 206]], 'text': ['the cytokines'], 'type': 'Anaphora', 'id': 'T16'}, {'offsets': [[461, 467]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[523, 533]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T24'}, {'offsets': [[755, 763]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T25'}, {'offsets': [[764, 771]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T26'}, {'offsets': [[772, 785]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T27'}, {'offsets': [[905, 916]], 'text': ['competition'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[947, 956]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[985, 992]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T30'}, {'offsets': [[993, 1002]], 'text': ['transport'], 'type': 'Localization', 'id': 'T31'}, {'offsets': [[1073, 1080]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T32'}, {'offsets': [[1085, 1095]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[1209, 1218]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1230, 1237]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T35'}, {'offsets': [[1238, 1251]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T36'}, {'offsets': [[1373, 1381]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[1389, 1396]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T38'}, {'offsets': [[1397, 1410]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T39'}, {'offsets': [[1518, 1535]], 'text': ['inhibitory effect'], 'type': 'Negative_regulation', 'id': 'T40'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T18']}}, {'trigger': 'T17', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T21', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T2']}}, {'trigger': 'T22', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T2']}}, {'trigger': 'T22', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T2']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T24', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T25', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T27', 'id': 'E14', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T26']}}, {'trigger': 'T28', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T31', 'id': 'E16', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T9', 'T30']}}, {'trigger': 'T28', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T31', 'id': 'E18', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T10', 'T30']}}, {'trigger': 'T29', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T32', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T33', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T34', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T36', 'id': 'E23', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T13', 'T35']}}, {'trigger': 'T37', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T39', 'id': 'E25', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T14', 'T38']}}, {'trigger': 'T40', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}]","[{'id': 'R1', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T16', 'role': 'Subject'}, 'tail': {'ref_id': 'T5', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T11', 'T12']}]",[],[]
130,PMC-2806624-18-MATERIALS_AND_METHODS,"Flow cytometry.
For analysis of human FOXP3 expression on the single-cell level, cells were first stained with the monoclonal CD4 mAb (Beckman Coulter), and after fixation and permeabilization, they were incubated with anti-human Foxp3-Alexa Fluor 488 antibody (BioLegend) based on the manufacturer's recommendations and subjected to FACS (EPICS XL-MCL; Beckman Coulter). A mouse IgG1 antibody (BioLegend) was used as an isotype control. Data were analyzed with the CXP software (Beckman Coulter). Cells were cultured with IL-2, and then left unstimulated or stimulated with anti-CD2/-CD3/-CD28 mAb.
Flow cytometry analyses of the mouse cells were performed on an LSRII (BD) and cell sorting was performed on a FACSAria (BD). All antibodies for these experiments were purchased from eBioscience or BD.","[{'offsets': [[38, 43]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[126, 129]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[230, 235]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[523, 527]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[580, 583]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[585, 588]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[590, 594]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[44, 54]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
131,PMC-3062687-17-Methods,"RNAi and Transfection
The siRNA (sense-strand sequence) IKKalpha, 5'-AUGACAGAGAAUGAUCAUGUUCUGC -3'; IKKbeta, 5'-GCAGCAAGGAGAACAGAGGUUAAUA -3'; IkappaBalpha, 5'-GAGCUCCGAGACUUUCGAGGAAAUA -3'; RPS3-3' UTR, 5'-GGAUGUUGCUCUCUAAAGACC -3' (Invitrogen). Transient transfection of siRNA and DNA constructs into Jurkat cells and 293T cells was described previously6.","[{'offsets': [[56, 64]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[100, 107]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[143, 155]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[191, 195]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
132,PMC-1920263-21-Caption-Figure_6,"Sp1 and Sp3 bind to the GC-box present in the A3G promoter. (A) Nuclear extracts of A3.01 T cells were incubated with a 32P-labeled commercial Sp1 oligonucleotide probe (Sp1cons) or labeled probes homologous to the unmodified or mutated E2 region (see Figure 1) of the A3G promoter (APO-Sp1/3 and APO-Sp1/3mut). Protein-DNA complexes were separated by polyacrylamide electrophoresis and detected by autoradiography. EMSA was performed with a 1- or 30-fold molar excess of unlabeled APO-Sp1/3 probe (competitor, lanes 6 and 7) or APO-Sp1/3mut probe (competitor mut., lanes 12 and 13). (B) Sp1- and Sp3-specific antibodies were added to the EMSA reactions resulting in a supershift (ss) of the respective antibody-protein-oligo complexes (lanes 3, 4, 7, 8, 11, 12). (C) ChIP assay was performed with DNA from A3.01 T cells. Immunoprecipitation was performed with antibodies against Sp1, Sp3 or actin. PCR primer pairs specific for the A3G promoter (upper panel) or the A3G gene (lower panel) were used. As positive controls, the sheared and cross-linked DNA before the immunoprecipitation step (input) or a plasmid carrying the target sequence (plasmid) was used as template.","[{'offsets': [[0, 3]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 11]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[46, 49]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[143, 146]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[269, 272]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[287, 290]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[291, 292]], 'text': ['3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[301, 304]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[305, 306]], 'text': ['3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[486, 489]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[490, 491]], 'text': ['3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[533, 536]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[537, 538]], 'text': ['3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[588, 591]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[597, 600]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[880, 883]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[885, 888]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[892, 897]], 'text': ['actin'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[933, 936]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[967, 970]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[12, 16]], 'text': ['bind'], 'type': 'Binding', 'id': 'T21'}, {'offsets': [[24, 30]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T22'}]","[{'trigger': 'T21', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T1', 'T3', 'T22']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T2', 'T3', 'T22']}}]",[],[],[],[]
133,PMC-2806624-00-TIAB,"Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+inducible regulatory T cells
Forkhead box P3 (FOXP3)+CD4+CD25+ inducible regulatory T (iT reg) cells play an important role in immune tolerance and homeostasis. In this study, we show that the transforming growth factor-beta (TGF-beta) induces the expression of the Runt-related transcription factors RUNX1 and RUNX3 in CD4+ T cells. This induction seems to be a prerequisite for the binding of RUNX1 and RUNX3 to three putative RUNX binding sites in the FOXP3 promoter. Inactivation of the gene encoding RUNX cofactor core-binding factor-beta (CBFbeta) in mice and small interfering RNA (siRNA)-mediated suppression of RUNX1 and RUNX3 in human T cells resulted in reduced expression of Foxp3. The in vivo conversion of naive CD4+ T cells into Foxp3+ iT reg cells was significantly decreased in adoptively transferred CbfbF/F CD4-cre naive T cells into Rag2-/- mice. Both RUNX1 and RUNX3 siRNA silenced human T reg cells and CbfbF/F CD4-cre mouse T reg cells showed diminished suppressive function in vitro. Circulating human CD4+ CD25high CD127- T reg cells significantly expressed higher levels of RUNX3, FOXP3, and TGF-beta mRNA compared with CD4+CD25- cells. Furthermore, FOXP3 and RUNX3 were colocalized in human tonsil T reg cells. These data demonstrate Runx transcription factors as a molecular link in TGF-beta-induced Foxp3 expression in iT reg cell differentiation and function.","[{'offsets': [[22, 27]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[32, 37]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 88]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[118, 133]], 'text': ['Forkhead box P3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[135, 140]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[142, 145]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[146, 150]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[282, 313]], 'text': ['transforming growth factor-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[315, 323]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[390, 395]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[400, 405]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[409, 412]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[484, 489]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[494, 499]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[544, 549]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[594, 598]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[608, 632]], 'text': ['core-binding factor-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[634, 641]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[709, 714]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[719, 724]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[776, 781]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[815, 818]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[833, 838]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[907, 911]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[915, 918]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[919, 922]], 'text': ['cre'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[942, 946]], 'text': ['Rag2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[961, 966]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[971, 976]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1014, 1018]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1022, 1025]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1026, 1029]], 'text': ['cre'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1115, 1118]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1120, 1124]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1129, 1134]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1189, 1194]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1196, 1201]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1207, 1215]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1235, 1238]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1239, 1243]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1265, 1270]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1275, 1280]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1350, 1354]], 'text': ['Runx'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1400, 1408]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1417, 1422]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[325, 332]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[337, 347]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[452, 464]], 'text': ['prerequisite'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[473, 480]], 'text': ['binding'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[518, 536]], 'text': ['RUNX binding sites'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[560, 572]], 'text': ['Inactivation'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[685, 693]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[694, 705]], 'text': ['suppression'], 'type': 'Negative_regulation', 'id': 'T53'}, {'offsets': [[754, 761]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[762, 772]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[977, 982]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[1162, 1171]], 'text': ['expressed'], 'type': 'Transcription', 'id': 'T57'}, {'offsets': [[1286, 1297]], 'text': ['colocalized'], 'type': 'Localization', 'id': 'T58'}, {'offsets': [[1314, 1325]], 'text': ['T reg cells'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[1392, 1396]], 'text': ['link'], 'type': 'Regulation', 'id': 'T60'}, {'offsets': [[1409, 1416]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[1423, 1433]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T62'}]","[{'trigger': 'T46', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T9']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T46', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T9']}}, {'trigger': 'T47', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T48', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T49', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T13', 'T15', 'T50']}}, {'trigger': 'T48', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T49', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T14', 'T15', 'T50']}}, {'trigger': 'T51', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T52', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T53', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T52', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T53', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T54', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E9']}}, {'trigger': 'T55', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T54', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E11']}}, {'trigger': 'T54', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T56', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T56', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T57', 'id': 'E20', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T57', 'id': 'E21', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T57', 'id': 'E22', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T58', 'id': 'E23', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T41', 'T59']}}, {'trigger': 'T58', 'id': 'E24', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T42', 'T59']}}, {'trigger': 'T60', 'id': 'E25', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T43']}}, {'trigger': 'T61', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T44']}}, {'trigger': 'T62', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}]",[],"[{'id': '*', 'ref_ids': ['T4', 'T5']}, {'id': '*', 'ref_ids': ['T9', 'T8']}, {'id': '*', 'ref_ids': ['T17', 'T18']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}]",[]
134,PMC-1134658-00-TIAB,"BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
Background
Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily and are secreted proteins with pleiotropic roles in many different cell types. A potential role of BMP-6 in the immune system has been implied by various studies of malignant and rheumatoid diseases. In the present study, we explored the role of BMP-6 in normal human peripheral blood B cells.
Results
The B cells were found to express BMP type I and type II receptors and BMP-6 rapidly induced phosphorylation of Smad1/5/8. Furthermore, Smad-phosphorylation was followed by upregulation of Id1 mRNA and Id1 protein, whereas Id2 and Id3 expression was not affected. Furthermore, we found that BMP-6 had an antiproliferative effect both in naive (CD19+CD27-) and memory B cells (CD19+CD27+) stimulated with anti-IgM alone or the combined action of anti-IgM and CD40L. Additionally, BMP-6 induced cell death in activated memory B cells. Importantly, the antiproliferative effect of BMP-6 in B-cells was completely neutralized by the natural antagonist, noggin. Furthermore, B cells were demonstrated to upregulate BMP-6 mRNA upon stimulation with anti-IgM.
Conclusion
In mature human B cells, BMP-6 inhibited cell growth, and rapidly induced phosphorylation of Smad1/5/8 followed by an upregulation of Id1.","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[101, 104]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[165, 173]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[285, 290]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[432, 437]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[559, 564]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[600, 605]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[606, 607]], 'text': ['5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[608, 609]], 'text': ['8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[624, 628]], 'text': ['Smad'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[677, 680]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[690, 693]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[711, 714]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[719, 722]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[779, 784]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[832, 836]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[837, 841]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[864, 868]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[869, 873]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[946, 951]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[967, 972]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1066, 1071]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1137, 1143]], 'text': ['noggin'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1198, 1203]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1277, 1282]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1345, 1350]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1351, 1352]], 'text': ['5'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1353, 1354]], 'text': ['8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1386, 1389]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[85, 97]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[573, 580]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[581, 596]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T32'}, {'offsets': [[629, 644]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T33'}, {'offsets': [[649, 657]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[661, 673]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[723, 733]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[742, 750]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T37'}, {'offsets': [[1187, 1197]], 'text': ['upregulate'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1318, 1325]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1326, 1341]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T40'}, {'offsets': [[1355, 1363]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1370, 1382]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T42'}]","[{'trigger': 'T30', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T31', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T6']}}, {'trigger': 'T32', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T31', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T6']}}, {'trigger': 'T32', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T31', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T6']}}, {'trigger': 'T32', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T33', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T34', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E8']}}, {'trigger': 'T35', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T34', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E8']}}, {'trigger': 'T35', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T36', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T36', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T37', 'id': 'E15', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E8']}}, {'trigger': 'T37', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E8']}}, {'trigger': 'T38', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T39', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T25']}}, {'trigger': 'T40', 'id': 'E19', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T39', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'T25']}}, {'trigger': 'T40', 'id': 'E21', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T39', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T25']}}, {'trigger': 'T40', 'id': 'E23', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T41', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E19']}}, {'trigger': 'T42', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T41', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E21']}}, {'trigger': 'T41', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E23']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E16', 'value': ''}]",[]
135,PMC-3359311-01-Introduction,"Cystic fibrosis is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which functions as a chloride ion channel. CF remains one of the most common lethal genetic diseases in populations of European descent with the current average lifespan of CF patients approximately 40 years of age [1], [2]. Recurrent inflammatory pulmonary exacerbation is the primary cause of lung disease progression and ultimately, death in CF. Controlled inflammation is important for fighting infection, but in excess, it becomes destructive to host cells and to the architecture of the lungs [2], [3]. In CF, airway epithelial cells have been shown to produce an exaggerated pro-inflammatory cytokine response to stimulation [4], [5]. It is unclear whether this heightened inflammatory response is intrinsic to cells lacking CFTR or whether it is a result of chronic polymicrobial infection [6], [7]. Regardless of this controversy, identifying and targeting relevant inflammatory mediators is a critical step in developing more specific therapeutic approaches to control inflammation and improve health outcomes in CF [8].
Interleukin-1 beta (IL-1beta) is a major inflammatory mediator. Its physiological effects are diverse and potentially important to the pathogenesis of lung exacerbations in CF, including the generation of fever, the recruitment of inflammatory effector cells, the induction of other pro-inflammatory cytokines such as IL-6 and IL-8, and the shaping of T cell responses [9], [10]. Following initiation of the NF-kappaB signaling cascade, IL-1beta is produced in the cytosol as a biologically inactive full-length pro-IL-1beta. Pro-IL-1beta is subsequently converted into its active form by cytosolic protein complexes termed ""inflammasomes."" Inflammasomes assemble in response to certain cellular danger signals and mediate the auto-activation of caspase-1 [9], [11], which cleaves pro-IL-1beta and pro-IL-18 into their biologically active forms for secretion. Four distinct inflammasomes have been recognized. These are the NLRP1 [12], NLRP3 [13], [14], NLRC4 [15], [16], and AIM2 inflammasomes [17], [18], which respond to a variety of different microbial signatures and danger signals [11].
P. aeruginosa, one of the most common and clinically relevant pathogens among CF patients, activates the NLRC4 inflammasome [19], [20]. Infection with P. aeruginosa triggers an increase in levels of IL-1beta, IL-6, and IL-8 in bronchoalveolar lavage fluid (BALF) from patients with CF [21]. Inflammasome responses depend on NF-kappaB signaling, where NF-kappaB is important in both the upregulation of specific inflammasome components [22], [23], as well as IL-1beta expression [24], [25].
Previous studies support a role for IL-1beta in the pathogenesis of CF inflammatory lung disease. Levels of IL-1beta are increased in BALF from CF patients with infection [21], [26], [27], [28] and this increase has been temporally associated with a clinical response to treatment [21]. Polymorphisms in the IL1B gene have also been associated with varying degrees of disease severity in CF patients [29]. Murine models of CFTR dysfunction have exhibited significant increases in IL-1beta expression or secretion in macrophages [30], [31], and support the hypothesis that the loss of CFTR increases NF-kappaB activation under basal and stimulatory conditions [4], [5], [32], [33]. Finally, replacement of chloride ions with glutamate or gluconate in cell culture media increases secretion of IL-1beta in response to NLRP3 stimulation by adenosine triphosphate (ATP) [34], implying an inhibitory role for extracellular chloride in NLRP3 activation. Taken together, these data implicate the involvement of IL-1beta and consequently, the inflammasomes, in CF inflammatory disease.","[{'offsets': [[1168, 1186]], 'text': ['Interleukin-1 beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1188, 1196]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1486, 1490]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1605, 1613]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[2460, 2468]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2470, 2474]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2719, 2727]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2787, 2795]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2859, 2867]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[3059, 3063]], 'text': ['IL1B'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[3231, 3239]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[3543, 3551]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3755, 3763]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1981, 1986]], 'text': ['their'], 'type': 'Anaphora', 'id': 'T14'}, {'offsets': [[2426, 2434]], 'text': ['triggers'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[2438, 2446]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[2625, 2634]], 'text': ['important'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[2728, 2738]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T18'}, {'offsets': [[2872, 2881]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[3218, 3227]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[3240, 3250]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[3254, 3263]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T22'}, {'offsets': [[3520, 3529]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[3530, 3539]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T24'}]","[{'trigger': 'T15', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T16', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T16', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T17', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T18', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T20', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T23', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T24', 'id': 'E13', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}]",[],[]
136,PMC-2806624-09-MATERIALS_AND_METHODS,"Isolation of PBMCs, CD4+ T cells, and culture conditions.
Human PBMCs were isolated by Ficoll (Biochrom) density gradient centrifugation and CD4+ T cells were then isolated using the Dynal CD4+ Isolation kit (Invitrogen) according to the manufacturer's instructions. The purity of CD4+ T cells was initially tested by flow cytometry and was >=95%. Cells were stimulated with the following combination of mAbs to T cell surface molecules (Meiler et al., 2008): anti-CD2 (clone 4B2 and 6G4; 0.5 microg/ml), anti-CD3 (clone OKT3; 0.5 microg/ml), and anti-CD28 mAb (clone B7G5; 0.5 microg/ml; all from Sanquin) and cultured in serum-free AIM-V medium (Life Technologies) with the addition of 1 nmol/liter IL-2 (Roche). TGF-beta (R&D Systems) was used at 5 ng/ml, if not stated otherwise. A combination of PMA (25 ng/ml) and ionomycin (1 mg/ml; Sigma-Aldrich) was used.
Human CD4+ CD127- CD25high and CD4+ CD127+ CD25neg cells were purified by flow cytometry using anti-CD127, anti-CD25-PC5 (Beckman Coulter), and anti-CD4-FITC antibodies (Dako).
Mouse naive (CD62Lhi44lo25-) CD4+ T cells were purified by flow cytometry and activated in vitro with 5 microg/ml plate-bound anti-CD3 and 1 microg/ml soluble anti-CD28 antibodies (eBioscience) in RPMI supplemented with 10% FCS, 5 mM beta-mercaptoethanol, and antibiotics. Neutralizing anti-IFN-gamma and anti-IL-4 mAbs (BD) were used at 1 microg/ml concentrations when indicated.","[{'offsets': [[20, 23]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[141, 144]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[189, 192]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[204, 207]], 'text': ['kit'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[281, 284]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[465, 468]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[510, 513]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[552, 556]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[701, 705]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[715, 723]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[871, 874]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[876, 881]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[883, 887]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[896, 899]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[901, 906]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[908, 912]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[965, 970]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[977, 981]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1014, 1017]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1055, 1060]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1062, 1064]], 'text': ['44'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1066, 1068]], 'text': ['25'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1071, 1074]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1173, 1176]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1206, 1210]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1333, 1342]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1352, 1356]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T27'}]",[],[],[],[],[]
137,PMC-2222968-15-Materials_and_Methods,"Transfections and reporter gene assays.
T cells were rested in serum-free AIM-V medium (Life Technologies) overnight. 3.5 mug of the FOXP3 promoter luciferase reporter vector and 0.5 mug phRL-TK were added to 3 x 106 CD4+ T cells resuspended in 100 muL of Nucleofector solution (Amaxa Biosystems) and electroporated using the U-15 program of the Nucleofector. After a 24-h culture in serum-free conditions and stimuli as indicated in the figures, luciferase activity was measured by the dual luciferase assay system (Promega Biotech) according to the manufacturer's instructions. Data were normalized by the activity of renilla luciferase.","[{'offsets': [[133, 138]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 158]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[217, 220]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[447, 457]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[492, 502]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[628, 638]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
138,PMC-2674207-09-Materials_and_Methods,"NF-kappaB Activation
NF-kappaB binding activity in nuclear extracts was determined using an ELISA-based kit (Trans-AM p65, Active Motif, Rixensart, Belgium). In brief, 5 microg of nuclear extracts were incubated with a plate coated with an NF-kappaB consensus oligonucleotide. Plates were washed before addition of an anti-p65 antibody. Antibody binding was detected with a secondary HRP-conjugated antibody and developed with TMB substrate. The intensity of the reaction was measured at 450 nm.","[{'offsets': [[118, 121]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
139,PMC-2674207-21-Caption-Figure_1,"Fluticasone propionate down-regulates Th2 cytokine gene expression and inhibits GATA-3 nuclear import.
(A) Anti-CD3/CD28 treatment of HuT-78 cells results in translocation of GATA-3 from the cytoplasm to the nucleus within 30 min. (B) Histone H1 and MEK-1 were used to confirm distinct separation of cytoplasmic and nuclear extracts in three separate experiments. (C) Western blot analysis of FP-treated HuT-78 cells demonstrated impaired nuclear localization of GATA-3 induced by anti-CD3/CD28 co-stimulation in a time- (at 10-8 M FP) and concentration- (at 60 min after stimulation) dependent manner. Cells were pretreated with FP for 30 min prior to stimulation. MEK1 and histone H1 were used to demonstrate equal cytoplasmic and nuclear loading respectively. Results are presented graphically below as mean+/-SEM of at least three independent experiments. *** p<0.001 compared to t = 0. (D) RT-PCR showing that FP inhibits IL-4 and IL-5 mRNA expression in CD3/CD28-costimulated cells. GAPDH was used as a loading control. Lower panels show graphical analysis of results presented as mean+/-SEM of at least three independent experiments. ###p<0.001 compared to control, ***p<0.001 compared to anti-CD3/CD28-stimulated. (E) FP (10 nM) reduces the ability of anti-CD3/CD28-stimulated GATA-3 to associate with the native IL-5 promoter 60 min after stimulation. Data are also shown graphically as mean+/-SEM of three independent experiments. All data were analysed by ANOVA followed by Newman-Keuls post-test.","[{'offsets': [[80, 86]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[175, 181]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[250, 255]], 'text': ['MEK-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[463, 469]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[666, 670]], 'text': ['MEK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[927, 931]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[936, 940]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[960, 963]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[964, 968]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1285, 1291]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1321, 1325]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[71, 79]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T12'}, {'offsets': [[87, 94]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[95, 101]], 'text': ['import'], 'type': 'Localization', 'id': 'T14'}, {'offsets': [[158, 171]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T15'}, {'offsets': [[208, 215]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T16'}, {'offsets': [[439, 446]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[447, 459]], 'text': ['localization'], 'type': 'Localization', 'id': 'T18'}, {'offsets': [[470, 477]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[918, 926]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[941, 956]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T21'}, {'offsets': [[969, 981]], 'text': ['costimulated'], 'type': 'Regulation', 'id': 'T22'}, {'offsets': [[1237, 1244]], 'text': ['reduces'], 'type': 'Negative_regulation', 'id': 'T23'}, {'offsets': [[1274, 1284]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[1295, 1304]], 'text': ['associate'], 'type': 'Binding', 'id': 'T25'}, {'offsets': [[1326, 1334]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T26'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T13']}}, {'trigger': 'T15', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T16']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T17']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T20', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T21', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T23', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T25', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T10', 'T11', 'T26']}}, {'trigger': 'T24', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]",[],[],[],[]
140,PMC-2800179-16-Results,"Effect of Native and Degraded CGN on THP-1 Proliferation and Cell Cycle
Preliminary observations by enumeration of THP-1 cells exposed to different concentrations of native and dCGN (10 and 40 kDa) during 2, 5 and 7 days, showed a decline in cell number (data not shown). This suggested that dCGN might cause an alteration in the cell cycle. Cell cycle analysis using flow cytometry showed an accumulation of THP-1 cells in G0/G1 phase, which was associated with a decrease number of cells in the S phase (Fig. 3A). The percentage of cells in the G0/G1 phase was 45.2% for control cells, 62.6% for C10 dCGN (at 2 mg/ml), and 64.2% for C40 dCGN-treated cells (at 2 mg/ml) (Fig. 3B). The effect of dCGN on cell cycle was dose-dependent (Fig. 3B). Neither native nor dCGN had an effect on the number of cells in the G2/M phase (Fig. 3). This effect is not due to cytotoxicity of dCGN even at the highest concentration (i.e. 2 mg/ml) since cell viability was not affected (data not shown).",[],[],[],[],[],[]
141,PMC-1920263-06-MATERIALS_AND_METHODS,"Electrophoretic mobility shift assay (EMSA)
For preparation of nuclear extracts, 5 x 106 A3.01 T cells were washed in cold PBS and resuspended in 500 microl buffer A (10 mM HEPES pH7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF). After incubation for 15 min on ice, swollen cells were pressed 10 times through a syringe with a 26G needle and centrifuged at 5000 r.p.m. for 5 min. Pellets contained the nuclei and were washed in buffer A for two times and resuspended in 50 microl buffer C (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA 1 mM DTT, 1 mM PMSF). After shaking for 30 min at 4degreesC and centrifugation for 10 min at 13 000 r.p.m., supernatants were used as nuclear extracts.
EMSA probes were generated by annealing the following complementary oligonucleotides: APO-Sp1/3, 5'- CCAGCTGGGCGGGACCACCAGGGGAGGGGC-3' and 5'-GCCCCTCCCCTGGTGGTCCCGCCCAGCTGG-3'; APO-Sp1/3mut, 5'- CCAGCTGTTCGGGACCACCAGGGGAGGGGC-3' and 5'- GCCCCTCCCCTGGTGGTCCCGAACAGCTGG-3' according to standard procedures. Nucleotides differing from the original promoter sequence are shown in bold type. A commercially available Sp1 probe (sc-2502, referred to as Sp1cons) was purchased from Santa Cruz Biotechnology. The double-stranded oligonucleotides were 5' end-labeled using T4 polynucleotide kinase (New England Biolabs) and [gamma-32P]ATP (3000 Ci/mmol, Amersham) and purified by using Nick G50 columns (Amersham).
For EMSA, 5 microg of nuclear proteins were preincubated on ice with 2 microg of poly(dI-dC) (Roche) as an unspecific competitor and 1 microg of bovine serum albumin in band shift buffer (50 mM Tris, 150 mM KCl, 5 mM EDTA, 2.5 mM dithiothreitol, 20% Ficoll) for 15 min. 32P-labeled oligonucleotides (50 000 c.p.m.) were added in a total volume of 20 microl, incubated on ice for 20 min and loaded onto 5% native polyacrylamide gels in 0.5xTris-borate-EDTA buffer. Upon fractionation, gels were dried and exposed for autoradiography. For competition experiments, 1- or 30-fold molar excess of the unlabeled APO-Sp1/3 or APO-Sp1/3mut oligonucleotides was added to the preincubation mixture. For supershift experiments, 2 microg Sp1 antibody (sc-59x, Santa Cruz Biotechnology) or Sp3 antibody (sc-644x, Santa Cruz Biotechnology) were added to the preincubation mixture and preincubation time was extended to 30 min.","[{'offsets': [[803, 806]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[894, 897]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1125, 1128]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1277, 1301]], 'text': ['T4 polynucleotide kinase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1564, 1584]], 'text': ['bovine serum albumin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2029, 2032]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2042, 2045]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2145, 2148]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2196, 2199]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
142,PMC-2222968-30-Caption-Figure_6,"IL-4 Inhibits TGF-beta-Mediated iTreg Commitment
CFSE-labeled CD4+CD45RA+ cells were activated with plate-bound anti-CD3/CD28, TGF-beta, and IL-4, as indicated. After 5 d, cells were analyzed by flow cytometry (A) and results of six independent experiments are shown in the bar graph below (B). Statistical significance (one-way Anova, Newman-Keuls) is indicated by asterisks (**p <= 0.01, ***p <= 0.001). (C) Kinetic analysis of intracellular GATA3 and FOXP3 staining is shown in panel C following exposure of CD4+CD45RA+ T cells to anti-CD3/28, IL-4 and TGF-beta. Data are representative of three independent experiments.","[{'offsets': [[0, 4]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 22]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[62, 65]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[66, 72]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[117, 120]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[121, 125]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[127, 135]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[141, 145]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[444, 449]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[454, 459]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[511, 514]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[515, 521]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[539, 542]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[543, 545]], 'text': ['28'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[547, 551]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[556, 564]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[460, 468]], 'text': ['staining'], 'type': 'Gene_expression', 'id': 'T17'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}]",[]
143,PMC-2222968-03-Results,"FOXP3 and GATA3 Kinetics in Differentiating Cells
The limited capacity of differentiated effector cells to induce FOXP3 expression suggests that iTreg induction has to occur before effector T cell differentiation occurs. Therefore, we analyzed the expression of FOXP3 and GATA3 during the differentiation of naive CD4 T cells into Th0 (neutral, anti-IL-4, anti-IFN-gamma, and anti IL-12), Th2, and iTreg phenotypes. After initiation of the differentiation process, FOXP3 and GATA3 showed a similar expression kinetic within the first 3 d, which are considered to be critical in T cell commitment [18]. Under Th2 differentiation conditions, FOXP3 mRNA expression increased only marginally (Figure 4A, left panel). Thus, although GATA3 and FOXP3 showed similar kinetics, their expression polarizes at the end of the differentiation process when cells were cultured towards Th2 or iTreg cells, respectively (Figure 4A and 4B). Interestingly, the Th0 cells were expressing more FOXP3 than the Th2 cells, but expressed low levels of GATA3; however, the protein expression slightly differed from mRNA expression, suggesting also posttranslational regulation and degradation as potential additional mechanisms in the differentiation process. The phenotype of iTreg cells included an anergic phenotype upon anti-CD3 re-stimulation (Figure S1A), CD103, CTLA-4, GITR, and PD-1 surface expression (Figure S1B). On the single-cell level, it can be seen that cells progress through a transition phase, where GATA3 and FOXP3 expression coexist to some degree in the same cells, which is resolved in iTreg cells after 7 d (Figure 4B). Taken together, these data demonstrated that Th2 cells have lost their capacity to express FOXP3 and showed that Th2 and iTreg cells arise from two different differentiation pathways.","[{'offsets': [[0, 5]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[10, 15]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[114, 119]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[262, 267]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[272, 277]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[314, 317]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[350, 354]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[361, 370]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[381, 386]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[465, 470]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[475, 480]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[640, 645]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[728, 733]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[738, 743]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[974, 979]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1028, 1033]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1304, 1307]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1337, 1342]], 'text': ['CD103'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1344, 1350]], 'text': ['CTLA-4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1352, 1356]], 'text': ['GITR'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1362, 1366]], 'text': ['PD-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1495, 1500]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1505, 1510]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1711, 1716]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[107, 113]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[120, 130]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T27'}, {'offsets': [[248, 258]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[498, 508]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[646, 661]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T30'}, {'offsets': [[662, 671]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[769, 774]], 'text': ['their'], 'type': 'Anaphora', 'id': 'T25'}, {'offsets': [[775, 785]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T32'}, {'offsets': [[958, 968]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T33'}, {'offsets': [[969, 973]], 'text': ['more'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1004, 1013]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[1014, 1017]], 'text': ['low'], 'type': 'Positive_regulation', 'id': 'T36'}, {'offsets': [[1375, 1385]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T37'}, {'offsets': [[1511, 1521]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T38'}, {'offsets': [[1573, 1581]], 'text': ['resolved'], 'type': 'Negative_regulation', 'id': 'T39'}, {'offsets': [[1680, 1684]], 'text': ['lost'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1703, 1710]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T41'}]","[{'trigger': 'T26', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T27', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T28', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T28', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T29', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T29', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T30', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T31', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T32', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T32', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T33', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T34', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T35', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T36', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T37', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T37', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T37', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T37', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T38', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T38', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T39', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T39', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T40', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T41', 'id': 'E24', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}]","[{'id': 'R1', 'head': {'ref_id': 'T25', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T25', 'role': 'Subject'}, 'tail': {'ref_id': 'T14', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}]",[]
144,PMC-2800179-02-Materials_and_Methods,"Preparation of Degraded Carrageenan
Two preparations of degraded carrageenan with low, (~10 kDa; C10), and medium, (~40 kDa; C40) molecular weight were prepared from native iota-carrageenan extracted from Euchema spinosum (generously provided by Sanofi Biosystems Industry, Boulogne-Billancourt, France). Native carrageenan was dissolved in distilled water (5% w/v) under vigorous stirring and heated to 60degreesC. Then, the carrageenan solution was submitted to two different treatments to obtain both low and medium molecular weight fractions. Briefly, for the low molecular weight fraction, carrageenan solution was hydrolyzed with 0.3% (v/v) concentrated sulphuric acid for 15 min at 80degreesC. After neutralization with NaOH 4N, the solution was ultra filtered through a hollow fibre cartridge with MW cut-off 5 kDa, (Amicon Inc, Beverly, USA). For the medium molecular weight fraction, the carrageenan solution was hydrolyzed with 0.3% (v/v) concentrated sulphuric acid for 30 min at 60degreesC. After neutralization, the supernatant was ultra filtered (MW cut-off 100 kDa). The filtrate was submitted to a second ultra filtration (MW cut-off 5 kDa). Both preparations of dCGN were precipitated with 4 volumes of 95% ethanol, dried at room temperature and ground to small particles (1 mm in diameter). Using gel-permeation chromatography in combination with light scattering measurements (see Viebke et al. [21]), it was confirmed that the low fraction had an average molecular weight of 10 kDa, and the medium fraction of 40 kDa. The sulphate content of polysaccharides in both fractions was measured following the method of Quemener et al. [22]. Finally, the absence of polysaccharide structure modifications in the two fractions was confirmed using 2H-NMR spectroscopy. The absence of LPS contamination in the two fractions was confirmed using the e-Toxate(R) kit (Sigma, St Quentin Fallavier, France). Before use in cell culture, the two fractions were dissolved in complete medium during 30 min at 56degreesC.",[],[],[],[],[],[]
145,PMC-1134658-06-Results,"BMP-6 induces upregulation of Id1
Next, we wanted to explore whether the BMP-6 induced phosphorylation of Smad 1/5/8 also could induce transcriptional changes of target genes. In this regard, the inhibitors of DNA binding proteins (Ids) are considered to be some of the major target genes for Smad-signalling [17]. Thus, B cells were pre-incubated over night in X-VIVO 15, and then cultured in medium alone or in the presence of BMP-6 for various time points before preparation of total RNA. The amount of Id1-Id4 mRNA was quantified by real-time RT-PCR. Interestingly, we observed a specific four-fold upregulation of Id1 mRNA in BMP-6-treated B cells (Figure 7). The up-regulation of Id1 mRNA was characteristic of an early inducible gene, with maximal upregulation two hours after the addition of BMP-6 and returned to baseline after 24 hours. In contrast, no significant changes were observed for Id2 and Id3 mRNA, whereas Id4-transcripts were not detectable (Figure 7, data not shown).
Western blot analysis revealed that the BMP-6-induced upregulation of Id1 mRNA also was correlated with upregulation of Id1 protein as well. The increase in Id1 protein level was detectable after one hour and increased until 24 hours after BMP-6 addition, showing a 16-fold upregulation compared with t0 (p <= 0.020, n = 4) (Figure 8 and 9). In line with the mRNA data, no consistent change in the amounts of Id2 and Id3 protein could be observed (Figure 8 and 9). We were able to block the Id1 specific band with a blocking peptide (data not shown). Taken together, these data suggest that Id1 could be a possible target gene for mediating the effects of BMP-6 in human B cells, whereas Id2 and Id3 not seem to be involved.","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[30, 33]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[73, 78]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[106, 112]], 'text': ['Smad 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[113, 114]], 'text': ['5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[115, 116]], 'text': ['8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[429, 434]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[506, 509]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[510, 513]], 'text': ['Id4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[619, 622]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[631, 636]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[686, 689]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[800, 805]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[901, 904]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[909, 912]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[927, 930]], 'text': ['Id4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1031, 1036]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1061, 1064]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1111, 1114]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1148, 1151]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1231, 1236]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1400, 1403]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1408, 1411]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1482, 1485]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1582, 1585]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1647, 1652]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1679, 1682]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1687, 1690]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[6, 13]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[14, 26]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T30'}, {'offsets': [[79, 86]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[87, 102]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T32'}, {'offsets': [[603, 615]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[669, 682]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[755, 767]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[875, 882]], 'text': ['changes'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[952, 962]], 'text': ['detectable'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[1037, 1044]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[1045, 1057]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T39'}, {'offsets': [[1079, 1089]], 'text': ['correlated'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[1095, 1107]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T41'}, {'offsets': [[1136, 1144]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[1200, 1209]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[1265, 1277]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[1375, 1381]], 'text': ['change'], 'type': 'Regulation', 'id': 'T45'}, {'offsets': [[1389, 1396]], 'text': ['amounts'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[1472, 1477]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T47'}]","[{'trigger': 'T29', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T30', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T3']}}, {'trigger': 'T32', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T31', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T3']}}, {'trigger': 'T32', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T31', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T3']}}, {'trigger': 'T32', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T33', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T10', 'T11']}}, {'trigger': 'T34', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T12', 'T13']}}, {'trigger': 'T35', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T12', 'T13']}}, {'trigger': 'T36', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T14', 'T13']}}, {'trigger': 'T36', 'id': 'E13', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T15', 'T13']}}, {'trigger': 'T37', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T16', 'T13']}}, {'trigger': 'T38', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T17']}}, {'trigger': 'T39', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T40', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E16']}}, {'trigger': 'T41', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T42', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T21']}}, {'trigger': 'T43', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T21']}}, {'trigger': 'T44', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T21']}}, {'trigger': 'T45', 'id': 'E22', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T21']}}, {'trigger': 'T46', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T45', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T21']}}, {'trigger': 'T46', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T47', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E13', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}]",[]
146,PMC-3062687-02-Results,"RPS3 phosphorylation in response to NF-kappaB activation
To test whether RPS3 is phosphorylated during NF-kappaB activation, we performed 32P-labeling experiments in tumor necrosis factor (TNF)-stimulated HEK 293T cells. While RPS3 was scarcely phosphorylated in unstimulated cells, we observed a marked increase in 32P-incorporation after TNF stimulation despite no increase in RPS3 protein (Fig. 1a). To determine which RPS3 residues were phosphorylated, we immunoprecipitated RPS3 from either resting or stimulated cells and performed immunoblotting with phosphorylation-specific antibodies. Both TNF and phorbol myristate acetate/ionomycin (PMA+I) stimulated rapid phosphorylation and degradaion of IkappaBalpha within 5 min which was accompanied by RPS3 phosphorylation on serine residues (Fig. 1b and data not shown), similar to the in vivo labeling. We did not detect tyrosine- or threonine-phosphorylation of RPS3 (Fig. 1b).","[{'offsets': [[0, 4]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[73, 77]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 231]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[379, 383]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[422, 426]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[479, 483]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[703, 715]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[754, 758]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[917, 921]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[5, 20]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[21, 35]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[81, 95]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T12'}, {'offsets': [[245, 259]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T13'}, {'offsets': [[304, 312]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[316, 333]], 'text': ['32P-incorporation'], 'type': 'Phosphorylation', 'id': 'T15'}, {'offsets': [[367, 375]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[427, 435]], 'text': ['residues'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[441, 455]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T18'}, {'offsets': [[652, 662]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[669, 684]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T20'}, {'offsets': [[689, 699]], 'text': ['degradaion'], 'type': 'Protein_catabolism', 'id': 'T21'}, {'offsets': [[759, 774]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T22'}, {'offsets': [[778, 793]], 'text': ['serine residues'], 'type': 'Entity', 'id': 'T23'}, {'offsets': [[875, 883]], 'text': ['tyrosine'], 'type': 'Entity', 'id': 'T24'}, {'offsets': [[888, 897]], 'text': ['threonine'], 'type': 'Entity', 'id': 'T25'}, {'offsets': [[898, 913]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T26'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T18', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T5', 'T17']}}, {'trigger': 'T19', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T20', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T21', 'id': 'E12', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T22', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T8', 'T23']}}, {'trigger': 'T26', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T24']}}, {'trigger': 'T26', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T25']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E15', 'value': ''}]",[]
147,PMC-2806624-06-RESULTS,"CBFbeta, RUNX1, and RUNX3 are important for the suppressive activity of CD25+ Foxp3+ T reg cells
Even though Cbfb-deficient CD4+ T cells had impaired induction of Foxp3 after stimulation with anti-CD3/28 mAbs and TGF-beta, sufficient numbers of Foxp3+ cells could be generated to permit analysis of their suppressive activity. Purified naive CD4+ T cells from CbfbF/F CD4-cre and control CbfbF/+ CD4-cre mice (Cd45.2) harboring a Foxp3-ires-GFP allele (Bettelli et al., 2006) were stimulated in vitro with anti-CD3/28 mAbs, IL-2, and TGF-beta. After 3 d, Foxp3+-GFP+ cells were sorted by flow cytometry and mixed with CFSE-labeled naive CD45.1+ CD4+ cells at ratios of 1:4, 1:2, and 1:1. The cells were then incubated with inactivated splenocytes and stimulated with anti-CD3 mAb for four more days. CD45.1+ cells were analyzed for CFSE dilution (Fig. 6 A). CbfbF/+ CD4-cre CD4+ T cells activated in the presence of TGF-beta showed a clear suppression of T cell proliferation that became even more apparent when an increased ratio of FOXP3+/CD25- cells was used (Fig. 6 B). The suppression was significantly reduced when cells from CbfbF/F CD4-cre mice were used, demonstrating that TGF-beta-induced Runx complexes are important for the suppressive activity of Foxp3+ T reg cells (Fig. 6 B). As a control, CbfbF/+ CD4-cre CD4+ T cells activated in absence of TGF-beta were mixed with CFSE-labeled naive CD45.1+ CD4+ cells. No suppression could be observed in all control groups without TGF-beta at all tested ratios (Fig. 6 C). The decreased suppression capacity of CbfbF/F CD4-cre iT reg cells was unlikely to be caused by decreased survival or proliferation. Foxp3+ and Foxp3- cells generated from both CbfbF/F CD4-cre and control cells all displayed similar proliferation rates and cell death as measured by CFSE dilution and annexin V staining, respectively (Fig. S7, A and B).
In addition, we tested the requirement of RUNX1 and RUNX3 for the development of the suppressive capacity in human iT reg cells. We isolated human naive CD4+ T cells and transfected them with a combination of RUNX1 and RUNX3 siRNA, or with a scrambled control siRNA. Cells were cultured under T reg conditions, and then mixed with CFSE-labeled autologous CD4+ T cells and stimulated with anti-CD3 mAb. Cells in which RUNX1 and RUNX3 were knocked down showed markedly lower suppressive activity compared with control iT reg cells at a T reg/CD4+ T responder cell ratio of 1:20, but not when the T reg/CD4+ T responder cell ratio was increased to 1:5 (Fig. 6 D). These results demonstrate the important role of RUNX1 and RUNX3 not only for the induction of FOXP3, but also for the suppressive capacity of iT reg cells both in humans and in mice. The data suggest both quantity and quality of T reg cells are hampered. Reduced intrinsic suppressive capacity of iT reg cells was demonstrated in mice, because Foxp3-GFP+ cells were FACS sorted and same numbers of iT reg cells are included in control experiments. In the suppression experiment with human cells, reduced suppressive activity was caused by reduced FOXP3 expression in T cells by siRNA inhibition of RUNX1 and RUNX3.","[{'offsets': [[0, 7]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[9, 14]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[20, 25]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[72, 76]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[78, 83]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[109, 113]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[124, 127]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[163, 168]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[197, 200]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[201, 203]], 'text': ['28'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[213, 221]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[245, 250]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[342, 345]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[360, 364]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[368, 375]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[388, 392]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[396, 403]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[410, 416]], 'text': ['Cd45.2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[430, 435]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[441, 444]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[511, 514]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[515, 517]], 'text': ['28'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[524, 528]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[534, 542]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[555, 560]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[562, 565]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[637, 643]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[645, 648]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[772, 775]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[800, 806]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[858, 862]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[866, 873]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[874, 877]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[916, 924]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1034, 1039]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1041, 1045]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1132, 1136]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1140, 1147]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1183, 1191]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1261, 1266]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1306, 1310]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1314, 1321]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1322, 1325]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1359, 1367]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1403, 1409]], 'text': ['CD45.1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1411, 1414]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1486, 1494]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1566, 1570]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1574, 1581]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1661, 1666]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[1672, 1677]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[1705, 1709]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[1713, 1720]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[1829, 1838]], 'text': ['annexin V'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[1924, 1929]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[1934, 1939]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2035, 2038]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2091, 2096]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2101, 2106]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2237, 2240]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2275, 2278]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2299, 2304]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2309, 2314]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2422, 2425]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[2482, 2485]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[2591, 2596]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[2601, 2606]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[2637, 2642]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[2887, 2896]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3090, 3095]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3141, 3146]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3151, 3156]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[114, 123]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[141, 149]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T74'}, {'offsets': [[150, 159]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[2107, 2112]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T76'}, {'offsets': [[2320, 2332]], 'text': ['knocked down'], 'type': 'Negative_regulation', 'id': 'T77'}, {'offsets': [[2573, 2582]], 'text': ['important'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[2624, 2633]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T79'}, {'offsets': [[3082, 3089]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T80'}, {'offsets': [[3096, 3106]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T81'}, {'offsets': [[3127, 3137]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T82'}]","[{'trigger': 'T73', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T74', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E1']}}, {'trigger': 'T75', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T76', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T76', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T77', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T77', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T78', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T66']}}, {'trigger': 'T79', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T78', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T67']}}, {'trigger': 'T80', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E13']}}, {'trigger': 'T81', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}, {'trigger': 'T82', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T80', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'E15']}}, {'trigger': 'T82', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}]",[],[],[],[]
148,PMC-3333881-23-Caption-Figure_6,"In HIV-1 infection Tat sustains the NF-kappaB activity and enhances the MIP-1alpha expression via interaction with IkappaB-alpha and p65. U937 cells (5 x 107) were transfected with siRNA Tat, siRNA control (2 nmol), or left untransfected; 24 h later cells were infected with HXB2-pseudotyped NL4-3.FLAG-Tat.R-E- virions (500 ng of p24) and harvested at the indicated time. (A) Real-time PCR of total RNA measured the Tat expression; ELISA measured the amount of p24 in whole cell extracts. (B) The binding of p65 to the NF-kappaB double-stranded oligonucleotide was measured in nuclear extracts (10 microg) using the NF-kappaB Transcription Factor ELISA assay kit (Cayman). (C) The IkappaB-alpha content was analysed by 12% SDS-PAGE and western blotting of cytosolic extracts (20 microg) using anti-IkappaB-alpha antibody. Densitometry values (D) of the bands were expressed as fold increase above the control (mock). (D) IKK activity was measured in cytosolic cell extracts (100 microg) using HTScan IKK Kinase Assay (Cell Signaling Technology). (E) U937 cells (5 x 107) were infected with HXB2-pseudotyped NL4-3.FLAG-Tat.R-E- virions, or left uninfected. Twenty-four-hour post-infection, cell extracts (1 mg) were immunoprecipitated with protein G-Sepharose-coupled anti-FLAG antibody. Immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-p65, anti-FLAG and anti-IkappaB-alpha antibodies. (F) U937 cells (5 x 107) were transfected with siRNA Tat, siRNA p65, siRNA control (2 nmol), or left untransfected; 24 h later, cells were infected with HXB2-pseudotyped NL4-3.FLAG-Tat.R-E- virions, or left uninfected. Twenty-four-hour post-infection, total RNA was analysed for MIP-1alpha expression by real-time PCR. (G and H) U937 cells (5 x 107) were transfected with siRNA Tat or siRNA control (2 nmol), or left untransfected; 24 h later, cells were infected with HXB2-pseudotyped NL4-3.FLAG-Tat.R-E- virions, or left uninfected. Twenty-four-hour post-infection, ChIP was performed with anti-p65 (G) or anti-FLAG (H). Real-time PCR was performed with primers specific for MIP-1alpha and GAPDH promoters. Values (mean +/- SE, n = 3) are shown. The asterisks indicate statistically significant differences compared to the control (mock), according to the Student's t-test (P < 0.05).","[{'offsets': [[19, 22]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[72, 82]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[115, 128]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[133, 136]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[181, 190]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[298, 306]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[331, 334]], 'text': ['p24'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[417, 420]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[462, 465]], 'text': ['p24'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[509, 512]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[682, 695]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1114, 1122]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1240, 1249]], 'text': ['protein G'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1475, 1484]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1486, 1495]], 'text': ['siRNA p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1604, 1612]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1707, 1717]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1800, 1809]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1920, 1928]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2105, 2115]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2120, 2125]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[59, 67]], 'text': ['enhances'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[83, 93]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}, {'offsets': [[98, 109]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T24'}, {'offsets': [[421, 431]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[498, 505]], 'text': ['binding'], 'type': 'Binding', 'id': 'T26'}, {'offsets': [[1718, 1728]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T27'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'E3']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T24', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T3']}}, {'trigger': 'T25', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T27', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}]",[]
149,PMC-1134658-13-Methods,"Cell sorting
Highly purified CD19+CD27- or CD19+CD27+ cells were obtained by staining CD19+ cells with anti-CD27 PE and CD19 PC5 mAbs for 30 minutes at 4degreesC, followed by washing with PBS and sorting on FACS DiVa from Becton Dickinson.","[{'offsets': [[29, 33]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 38]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[43, 47]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[48, 52]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[86, 90]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[108, 112]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[120, 124]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
150,PMC-2806624-27-Caption-Figure_3,"Binding of RUNX1 and RUNX3 proteins to the predicted binding sites in the FOXP3 promoter. (A) Mutated and wild-type oligonucleotides are shown. The predicted RUNX binding sites are accentuated (boxed and in green letters) and stars mark mutations introduced into the binding site of the control oligonucleotides. Nuclear extracts from HEK293T cells were incubated with biotinylated oligonucleotides. The precipitated oligonucleotide-transcription factor complexes were separated by SDS-PAGE and identified by Western blotting with anti-RUNX1 and anti-RUNX3 antibodies. A mixture of all three oligonucleotides with the predicted binding sites or with the inserted mutation into the predicted sites was used. Data shown are one representative of three independent experiments with similar results. (B) Promoter enzyme immunoassay using wild-type and mutated oligonucleotides within the FOXP3 promoter. Bars show mean +/- SE of three independent experiments. (C) Chromatin immunoprecipitation assay results show binding of RUNX1 and RUNX3 complexes containing CBFbeta to the human FOXP3 promoter in naive CD4+ T cells that were cultured with IL-2 together with anti-CD2/3/28 and TGF-beta. There was no change in site occupancy in all immunoprecipitations when IGX1A negative control primers were used. The results are normalized to input and isotype control antibody. Bars show mean +/- SE of three independent experiments. Statistical differences were verified by the paired Student's t test. *, P < 0.05","[{'offsets': [[11, 16]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 26]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 79]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[536, 541]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[551, 556]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[884, 889]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1020, 1025]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1030, 1035]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1057, 1064]], 'text': ['CBFbeta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1078, 1083]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1102, 1105]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1139, 1143]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1163, 1166]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1167, 1168]], 'text': ['3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1169, 1171]], 'text': ['28'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1176, 1184]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[0, 7]], 'text': ['Binding'], 'type': 'Binding', 'id': 'T17'}, {'offsets': [[53, 66]], 'text': ['binding sites'], 'type': 'Entity', 'id': 'T18'}, {'offsets': [[1009, 1016]], 'text': ['binding'], 'type': 'Binding', 'id': 'T19'}, {'offsets': [[1084, 1092]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T20'}]","[{'trigger': 'T17', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T1', 'T3', 'T18']}}, {'trigger': 'T17', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T2', 'T3', 'T18']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T7', 'T10', 'T20']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T8', 'T10', 'T20']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T9', 'T10', 'T20']}}]",[],[],[],[]
151,PMC-2806624-10-MATERIALS_AND_METHODS,"In vitro T cell differentiation.
CD4+ CD45RA+ magnetically sorted (CD45RO depletion with AutoMACS; Miltenyi Biotec) cells were stimulated with immobilized plate-bound anti-CD3 (1 microg/ml; OKT3; IgG1) and anti-CD28 (2 microg/ml). For Th1 differentiation conditions, cells were stimulated with the following: 40 ng/ml IL-2, 5 microg/ml anti-IL-4, and 25 ng/ml IL-12 (R&D Systems). For Th2 conditions, cells were stimulated with the following: 40 ng/ml IL-2, 25 ng/ml IL-4, and 5 microg/ml anti-IL-12 (R&D Systems). For T reg cell conditions, cells were stimulated with the following: 40 ng/ml IL-2, 5 ng/ml TGF-beta, 5 microg/ml anti-IL-12, 5 microg/ml anti-IL-4. For Th17 conditions, cells were stimulated with the following: 40 ng/ml IL-2, 20 ng/ml IL-6, 5 ng/ml TGF-beta, 20 ng/ml IL-23 (Alexis Biochemicals Corp.), 10 ng/ml IL-1beta, 5 microg/ml anti-IL-4, and 5 microg/ml anti-IL-12 were used. Proliferating cells were expanded in medium containing IL-2. The cytokine profile of these cells demonstrated that IFN-gamma is the predominant cytokine in Th1 cells, IL-4 and IL-13 in Th2 cells, and IL-17 in Th17 cells (Akdis et al., 2000; Burgler et al., 2009).","[{'offsets': [[33, 36]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[38, 44]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[67, 73]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 175]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[211, 215]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[318, 322]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[341, 345]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[360, 365]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[452, 456]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[467, 471]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[494, 499]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[593, 597]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[607, 615]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[634, 639]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[658, 662]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[736, 740]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[751, 755]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[765, 773]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[784, 789]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[828, 836]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[855, 859]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[882, 887]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[954, 958]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1014, 1023]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1066, 1070]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1075, 1080]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1099, 1104]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[74, 83]], 'text': ['depletion'], 'type': 'Negative_regulation', 'id': 'T28'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],[],[]
152,PMC-2674207-25-Caption-Figure_5,"Fluticasone propionate does not affect GATA-3 nuclear export.
(A) Western blot analysis showing that the nuclear export inhibitor leptomycin B (2 nM) does not affect the ability of FP (10-8 M) to prevent anti-CD3/CD28-stimulated GATA-3 nuclear localization measured at 60 min. ***p<0.001 compared to unstimulated cells, ###p<0.001 compared to anti-CD3/CD28-stimulated cells. (B) Western blot analysis showing that FP (10-8 M) does not affect whole-cell GATA-3 degradation over 17 h. (C) GFP-tagged GATA-3 is overexpressed and cells stimulated (b-j) or not (a) with anti-CD3/CD28. The effect of treating cells with FP (10-8 M, f-j) after 30 min stimulation with anti-CD3/CD28 is also shown. (D) FP (10-8 M) does not prevent anti-CD3/CD28-stimulated p65 nuclear translocation at 60 min after stimulation. **p<0.01 compared to unstimulated cells. All results are representative of at least four independent experiments and are shown as mean+/-SEM. Results were analysed by ANOVA followed by Newman-Keuls test.","[{'offsets': [[39, 45]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[229, 235]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[453, 459]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[498, 504]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[748, 751]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[32, 38]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T6'}, {'offsets': [[54, 60]], 'text': ['export'], 'type': 'Localization', 'id': 'T7'}, {'offsets': [[159, 165]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T8'}, {'offsets': [[196, 203]], 'text': ['prevent'], 'type': 'Negative_regulation', 'id': 'T9'}, {'offsets': [[218, 228]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[236, 243]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T11'}, {'offsets': [[244, 256]], 'text': ['localization'], 'type': 'Localization', 'id': 'T12'}, {'offsets': [[435, 441]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T13'}, {'offsets': [[460, 471]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T14'}, {'offsets': [[715, 722]], 'text': ['prevent'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[737, 747]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[752, 759]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[760, 773]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T18'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T9', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T12', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T11']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T13', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T17']}}, {'trigger': 'T16', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E7', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}]",[]
153,PMC-3333881-14-RESULTS,"Tat increases the p65 affinity binding to DNA through association with p65
We tested whether Tat physically interacted with p65. HeLa cells were transfected with the expression vectors of HA-p65 and FLAG-Tat, and 24 h later Tat was immunoprecipitated from cell extracts. The p65 protein was coimmunoprecipitated with wild-type Tat or the mutants Tat T,N(23,24)A, Tat K(50,51)A and Tat R(49-57)A at similar levels, while a significant decrease in coimmunoprecipitation was observed for Tat C(22,25,27)A (Figure 4A). Consistently, GST-pull down of in vitro translated proteins showed the direct binding of p65 to wild-type Tat, or the mutants Tat T,N(23,24)A, Tat K(50,51)A and Tat R(49-57)A, and lack of binding to Tat C(22,25,27)A (Figure 4B). These results indicated that Tat associated with p65 through the cysteine-rich domain and ruled-out the requirement of bridging proteins to mediate such interaction.
To identify the p65 domain required for binding to Tat, HeLa cells were transfected with FLAG-Tat together with HA-p65 mutants, which were deleted of the transactivation domain [p65deltaC (1-318)], or the RHD [p65deltaN (122-551)] (Figure 4C). Tat coimmunoprecipitated with p65deltaC (1-318), and not with p65deltaN (122-551) (Figure 4D), indicating that the RHD of p65 was involved in the physical interaction with Tat.
To address the effect of Tat on the p65 DNA-binding affinity, purified recombinant p65 protein was incubated with 32P-labeled-NF-kappaB double-stranded oligonucleotide in presence or absence of wild-type Tat or Tat C(22,25,27)A, and p65 DNA-binding was analysed by EMSA. Whereas wild-type Tat significantly increased the binding of p65 to DNA, the mutant Tat C(22,25,27)A, lacking the binding site for p65, was ineffective (Figure 4E). The p65 binding to DNA was evaluated by competition with increasing amounts of cold competitor NF-kappaB oligonucleotide, which showed that Tat significantly enhanced the p65 affinity binding to DNA (Figure 4E and F).","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 21]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 74]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[93, 96]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[124, 127]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[188, 194]], 'text': ['HA-p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[199, 207]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[224, 227]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[275, 278]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[327, 330]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[346, 361]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[363, 376]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[381, 394]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[485, 501]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[529, 532]], 'text': ['GST'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[604, 607]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[621, 624]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[641, 656]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[658, 671]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[676, 689]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[714, 730]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[773, 776]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[793, 796]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[926, 929]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[961, 964]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[999, 1007]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1022, 1028]], 'text': ['HA-p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1088, 1105]], 'text': ['p65deltaC (1-318)'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1120, 1139]], 'text': ['p65deltaN (122-551)'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1154, 1157]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1184, 1201]], 'text': ['p65deltaC (1-318)'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1216, 1235]], 'text': ['p65deltaN (122-551)'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1276, 1279]], 'text': ['p65'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1326, 1329]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1356, 1359]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1367, 1370]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1414, 1417]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1535, 1538]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1542, 1558]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1564, 1567]], 'text': ['p65'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1620, 1623]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1663, 1666]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1686, 1702]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1733, 1736]], 'text': ['p65'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1771, 1774]], 'text': ['p65'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1907, 1910]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1938, 1941]], 'text': ['p65'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4, 13]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[31, 38]], 'text': ['binding'], 'type': 'Binding', 'id': 'T52'}, {'offsets': [[54, 65]], 'text': ['association'], 'type': 'Binding', 'id': 'T53'}, {'offsets': [[108, 118]], 'text': ['interacted'], 'type': 'Binding', 'id': 'T54'}, {'offsets': [[232, 250]], 'text': ['immunoprecipitated'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[291, 311]], 'text': ['coimmunoprecipitated'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[334, 345]], 'text': ['the mutants'], 'type': 'Anaphora', 'id': 'T48'}, {'offsets': [[434, 442]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[446, 467]], 'text': ['coimmunoprecipitation'], 'type': 'Binding', 'id': 'T58'}, {'offsets': [[593, 600]], 'text': ['binding'], 'type': 'Binding', 'id': 'T59'}, {'offsets': [[629, 640]], 'text': ['the mutants'], 'type': 'Anaphora', 'id': 'T49'}, {'offsets': [[703, 710]], 'text': ['binding'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[777, 787]], 'text': ['associated'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[809, 829]], 'text': ['cysteine-rich domain'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[884, 891]], 'text': ['mediate'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[892, 908]], 'text': ['such interaction'], 'type': 'Anaphora', 'id': 'T50'}, {'offsets': [[930, 936]], 'text': ['domain'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[937, 945]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T65'}, {'offsets': [[950, 957]], 'text': ['binding'], 'type': 'Binding', 'id': 'T66'}, {'offsets': [[1049, 1056]], 'text': ['deleted'], 'type': 'Negative_regulation', 'id': 'T67'}, {'offsets': [[1064, 1086]], 'text': ['transactivation domain'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[1115, 1118]], 'text': ['RHD'], 'type': 'Entity', 'id': 'T69'}, {'offsets': [[1158, 1178]], 'text': ['coimmunoprecipitated'], 'type': 'Binding', 'id': 'T70'}, {'offsets': [[1269, 1272]], 'text': ['RHD'], 'type': 'Entity', 'id': 'T71'}, {'offsets': [[1309, 1320]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T72'}, {'offsets': [[1346, 1352]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[1375, 1382]], 'text': ['binding'], 'type': 'Binding', 'id': 'T74'}, {'offsets': [[1572, 1579]], 'text': ['binding'], 'type': 'Binding', 'id': 'T75'}, {'offsets': [[1638, 1647]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[1652, 1659]], 'text': ['binding'], 'type': 'Binding', 'id': 'T77'}, {'offsets': [[1704, 1711]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T78'}, {'offsets': [[1716, 1723]], 'text': ['binding'], 'type': 'Binding', 'id': 'T79'}, {'offsets': [[1724, 1728]], 'text': ['site'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[1742, 1753]], 'text': ['ineffective'], 'type': 'Positive_regulation', 'id': 'T81'}, {'offsets': [[1775, 1782]], 'text': ['binding'], 'type': 'Binding', 'id': 'T82'}, {'offsets': [[1925, 1933]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[1951, 1958]], 'text': ['binding'], 'type': 'Binding', 'id': 'T84'}]","[{'trigger': 'T51', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'E3']}}, {'trigger': 'T52', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T53', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T3']}}, {'trigger': 'T54', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T4', 'T5']}}, {'trigger': 'T55', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T56', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T9', 'T10']}}, {'trigger': 'T57', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T14']}}, {'trigger': 'T58', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T9', 'T14']}}, {'trigger': 'T59', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T17']}}, {'trigger': 'T60', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T16', 'T21']}}, {'trigger': 'T61', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T22', 'T23', 'T62']}}, {'trigger': 'T63', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T65', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T24', 'T64']}}, {'trigger': 'T66', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T67', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T68']}}, {'trigger': 'T67', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T69']}}, {'trigger': 'T70', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T30', 'T31']}}, {'trigger': 'T72', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T33', 'T34', 'T71']}}, {'trigger': 'T73', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T35']}}, {'trigger': 'T74', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T75', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T76', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T41']}}, {'trigger': 'T77', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T78', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T41', 'T80']}}, {'trigger': 'T79', 'id': 'E25', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T41', 'T44', 'T80']}}, {'trigger': 'T81', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T43']}}, {'trigger': 'T82', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T83', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T46']}}, {'trigger': 'T84', 'id': 'E29', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}]","[{'id': 'R1', 'head': {'ref_id': 'T48', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T48', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T48', 'role': 'Subject'}, 'tail': {'ref_id': 'T13', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T19', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T20', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T50', 'role': 'Subject'}, 'tail': {'ref_id': 'T61', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E19', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E26', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E27', 'value': ''}]",[]
154,PMC-2800179-11-Materials_and_Methods,"Western Blot Analysis
THP-1 cells were stimulated for various lengths of time with 0.1 mg/ml C10 or C40, or 10 microg/ml LPS. Cells were then pelleted, washed and homogenised in lysis buffer (10 mM Hepes, pH 7.9, 150 mM NaCl, 1 mM EDTA, 0.6% NP-40, and 0.5 mM PMSF) on ice. Homogenates were sonicated, centrifuged at 10,000 rpm to remove cellular debris, and supernatant collected. Protein concentration was determined using the DC Protein Assay (Bio-Rad). Proteins in samples (15 microg total proteins) were resolved in a denaturing 12% polyacrylamide gel and transferred to a nitrocellulose membrane. I-kappaBalpha protein was detected using a rabbit polyclonal antibody (Santa Cruz Biotechnology, CA) followed by a horseradish peroxidase-coupled goat polyclonal antibody against rabbit Ig (Caltag Laboratories). Finally, IkappaB bands were revealed using the ECL(TM) detection system (Amersham Pharmacia Biotech, Les Ullis, France) according to the manufacturers' instruction. Antibody to alpha-Tubulin (Santa Cruz) was use as loading control.
For nuclear NF-kappaB, THP-1 cells were stimulated with 1 mg/ml C10 or C40 for 30 minutes at 37degreesC. Cells were then pelleted and nuclei separated as described [31]. Nuclei were washed and homogenized directly in loading (Laemli) buffer and heated for 5 minutes at 100degreesC. Proteins in samples were resolved in a denaturing 8% polyacrylamide gel and transferred to a polyvinylidine fluoride (PVDF) membrane (Immobilon-P; Millipore, Bedford, MA). Membranes were incubated in blocking buffer (1% BSA, in PBS) for two hours at room temperature. Membranes were subsequently probed with the corresponding antibody in blocking buffer, overnight. Rabbit polyclonal antibody anti-NF-kappaB p50 subunit (# sc-114) or anti-NF-kappaB p65 subunit (# sc-109) from Santa Cruz Biotechnology were used. Membranes were washed six times in PBS with 0.05% Tween 20, 5 minutes each time, and incubated with a 1/3000 dilution of HRP-conjugated F(ab')2 goat anti-rabbit IgG in 5% nonfat dry milk and 0.05% Tween 20 in PBS for 1 hour at room temperature. After washing six more times in PBS with 0.05% Tween 20, antibody-reactive proteins were detected using a chemiluminescence substrate (SuperSignal; Pierce, Rockford, IL) according to the manufacturer's instructions. To confirm that equivalent amounts of protein were loaded in each line, membranes were also Western blotted for ERK as described [32].","[{'offsets': [[603, 616]], 'text': ['I-kappaBalpha'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
155,PMC-2674207-10-Materials_and_Methods,"Immunofluorescence Staining
Immunofluorescence staining was performed as previously described [34]. All staining was performed at room temperature and under humidification. Cells were collected and cytospins prepared in a cytocentrifuge (Shandon II, Shandon, Runcorn, UK). Cells were permeabilized, blocked, and then incubated with GR (1:50 E-20 Santa Cruz Biotechnology) or anti-GATA-3 (H-48; Santa Cruz Biotechnology) antibody for 1 h at room temperature. After three washes in phosphate-buffered saline (PBS), cells were incubated with tetrarhodamine isothiocyanate-conjugated goat anti-rabbit antibody (Dako). Cytospins were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI), a fluorescent blue nuclear indole chromatin stain, and mounted in PBS:glycerol (50:50). The immunopositive signal was characterised using laser scanning confocal microscopy on a Leica TCS NT/SP interactive laser cytometer equipped with confocal optics (Leica Microsystems, Wetzlar, Germany). To determine the specificity of the antibodies, rabbit serum immunoglobulin (Dako) and secondary antibodies without the primary were used as controls. Positively stained nuclei and total cells were counted (500) on each slide with the observer blinded to the treatment.","[{'offsets': [[332, 334]], 'text': ['GR'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
156,PMC-3359311-13-Materials_and_Methods,"Cell stimulation and cytokine quantification
Bronchial epithelial cells were plated and allowed to adhere overnight prior to stimulation. Bronchial epithelial cells were rested or primed with LPS for 5 hours and stimulated with live P. aeruginosa PAO1 or ATP for the times indicated. PBMCs and THP-1 reporter cells were either rested or primed with LPS (Invivogen) or heat-killed PAO1 overnight (16 hours). The next day the cells were challenged with live PAO1, PAO1deltaexsA, ATP (Invivogen), or Poly(dA:dT) (Sigma Aldrich) for the times indicated (see Fig. 1). For stimulations with Poly(dA:dT), lipofectamine LTX was used at a 1:1 (w:v) ratio of microg of DNA to microl of lipofectamine and was mixed 30 minutes prior to stimulation. The NF-kappaB inhibitor Bay11-7082 (Invivogen) was added to cultures 1 hour prior to priming. If no priming was involved, inhibitor was added 1 hour prior to inflammasome stimulation. The CFTR inhibitor CFTRinh172 (Sigma Aldrich) was added to cultures 18 hours prior to inflammasome stimulation. The caspase-1 inhibitor z-YVAD-fmk (Biovision) was added to cultures 1 hour prior to inflammasome stimulation. Supernatants were collected and stored at -20degreesC. Cytokines released into supernatants from PBMCs stimulated with inflammasome activators were quantified using sandwich ELISA (eBioscience).",[],[],[],[],[],[]
157,PMC-3333881-01-INTRODUCTION,"Nuclear factor (NF)-kappaB transcription factors regulate the transcription of genes that are involved in the immune and inflammatory response (1). The NF-kappaB family includes RelA/p65, c-Rel, RelB, p50 and p52 that share a highly conserved 300-amino acid Rel homology domain (RHD) for homo- or hetero-dimerization and DNA-binding. The transcriptional activity of the NF-kappaB complex depends on dimer composition since C-terminal unrelated transcriptional activation domains are present exclusively in p65, RelB and c-Rel (2).
Inhibitors of NF-kappaB (IkappaB) associate with the NF-kappaB complex and interfere with its binding to DNA (3). In the canonical pathway of NF-kappaB activation, the activated IkappaB kinase (IKK) phosphorylates IkappaB at specific serine residues that target the protein to ubiquitination and proteasomal degradation, which releases the functional NF-kappaB complex in the nucleus. IkappaB-alpha, the most abundant inhibitor of NF-kappaB (4), is phosphorylated by IKK at Ser32 and Ser36 (5), and subsequently ubiquitylated at Lys21 and Lys22 to be degraded by the 26S proteasome (6). The NF-kappaB activity is enhanced by phosphorylation of p65 at Ser276 by PKA and MSK1 (7,8), Ser311 by PKCzeta (9) and Ser536 by IKKalpha (10,11). Acetylation of p65 at Lys218 and Lys221 increases the DNA binding and impairs the association with IkappaB-alpha, and acetylation at Lys310 enhances the p65 transcriptional activity (12,13). Post-activation turn off of NF-kappaB is regulated by negative feedback loop through inhibitors under the transcriptional control of NF-kappaB, such as IkappaB-alpha and ubiquitin-editing protein A20 (14-20). Deacetylation of p65 by histone deacetylase-3 or SIRT1, or acetylation of p65 at Lys122 and Lys123 down-regulate the NF-kappaB activity (12,21,22).
Persistent activation of NF-kappaB occurs in human immunodeficiency virus-1 (HIV-1)-infected monocytes, macrophages and microglia, and enhances the expression of NF-kappaB-responsive genes, including pro-inflammatory cytokines, cell adhesion molecules and chemokines (23-25). Chronic inflammation is a major cause of immune and neuron dysfunction in AIDS (26,27). Consistently, non-human primate hosts for simian immunodeficiency virus, such as African green monkeys and sooty mangabey, lack aberrant immune activation and do not develop AIDS despite high virus replication (28,29). Thus, understanding the mechanisms of NF-kappaB deregulation by HIV-1 may provide further insights into AIDS pathogenesis.
In HIV-1 entry, the binding of the gp120 viral envelope to CD4 induces the NF-kappaB activity by activation of IKK (30) and procaspase 8 (31). Following viral integration, the early encoded HIV-1 Tat protein interacts with the HIV-1 RNA and host cell factors to sustain the viral replication. Tat binds to RNA stem-loop structures generated by the 5' end of target transcripts, including the HIV-1 transactivation-responsive element (TAR) (32), tumor necrosis factor beta (TNFbeta) (33) and interleukin-6 (IL-6) (34) to activate gene transcription. Indeed, Tat promotes the transcriptional initiation and elongation by interacting with transacting factors and cofactors, such as Sp1 (35), TFIID (36), E2F-4 (37), C/EBPbeta (38), cyclin T1/CDK9 (39,40) and the histone acetyltransferases p300/CBP and P/CAF (41-43). When released from HIV-1-infected cells, Tat deregulates the cell signaling by binding to cell receptors, such as integrins (44), Flk1/KDR receptor (45) and chemokine receptors (46).
We first reported that NF-kappaB was constitutively active in Jurkat cells that stably expressed the Tat gene (47). Following gene transfection or protein transduction, Tat induced the IKK activity and proteasomal degradation of IkappaB-alpha (48), and increased the p65 transcriptional activity by inhibiting the SIRT-1-mediated deacetylation of p65 Lys310 (49). These findings suggested that Tat modulates crucial enzymes involved in NF-kappaB signaling; however, it was unclear how Tat could subvert the negative feedback of NF-kappaB, which is mainly dependent on de novo synthesis of IkappaB-alpha (15,17). We previously found that IkappaB-alpha binds to Tat and promotes the nuclear export of the viral transactivator (50,51). In this study, we report that Tat counteracts the post-activation turn off of NF-kappaB through direct interaction with IkappaB-alpha and p65, which enhances the DNA binding and transcriptional activity of the NF-kappaB complex. The new mechanism of NF-kappaB deregulation here described may provide further insights into the chronic immune activation of HIV-1 infection.","[{'offsets': [[178, 182]], 'text': ['RelA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 186]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[188, 193]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[195, 199]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[201, 204]], 'text': ['p50'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[209, 212]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[506, 509]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[511, 515]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[520, 525]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[916, 929]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1175, 1178]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1200, 1204]], 'text': ['MSK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1222, 1229]], 'text': ['PKCzeta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1248, 1256]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1281, 1284]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1365, 1378]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1419, 1422]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1609, 1622]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1653, 1656]], 'text': ['A20'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1683, 1686]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1690, 1711]], 'text': ['histone deacetylase-3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1715, 1720]], 'text': ['SIRT1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1740, 1743]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2555, 2560]], 'text': ['gp120'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2579, 2582]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2644, 2656]], 'text': ['procaspase 8'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2716, 2719]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2813, 2816]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2965, 2991]], 'text': ['tumor necrosis factor beta'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2993, 3000]], 'text': ['TNFbeta'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3011, 3024]], 'text': ['interleukin-6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3026, 3030]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3077, 3080]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3199, 3202]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3209, 3214]], 'text': ['TFIID'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3221, 3226]], 'text': ['E2F-4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3233, 3242]], 'text': ['C/EBPbeta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3249, 3258]], 'text': ['cyclin T1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3259, 3263]], 'text': ['CDK9'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3307, 3311]], 'text': ['p300'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3312, 3315]], 'text': ['CBP'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3320, 3325]], 'text': ['P/CAF'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3376, 3379]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3465, 3482]], 'text': ['Flk1/KDR receptor'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3619, 3622]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3687, 3690]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3747, 3760]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3785, 3788]], 'text': ['p65'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3832, 3838]], 'text': ['SIRT-1'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3865, 3868]], 'text': ['p65'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3912, 3915]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4003, 4006]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4107, 4120]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4155, 4168]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4178, 4181]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4281, 4284]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4371, 4384]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4389, 4392]], 'text': ['p65'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[258, 277]], 'text': ['Rel homology domain'], 'type': 'Entity', 'id': 'T62'}, {'offsets': [[284, 287]], 'text': ['for'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[304, 316]], 'text': ['dimerization'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[325, 332]], 'text': ['binding'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[980, 994]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T66'}, {'offsets': [[1005, 1010]], 'text': ['Ser32'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[1015, 1020]], 'text': ['Ser36'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[1043, 1056]], 'text': ['ubiquitylated'], 'type': 'Ubiquitination', 'id': 'T69'}, {'offsets': [[1060, 1065]], 'text': ['Lys21'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[1070, 1075]], 'text': ['Lys22'], 'type': 'Entity', 'id': 'T71'}, {'offsets': [[1082, 1090]], 'text': ['degraded'], 'type': 'Protein_catabolism', 'id': 'T72'}, {'offsets': [[1091, 1093]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[1156, 1171]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T74'}, {'offsets': [[1182, 1188]], 'text': ['Ser276'], 'type': 'Entity', 'id': 'T75'}, {'offsets': [[1189, 1191]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[1212, 1218]], 'text': ['Ser311'], 'type': 'Entity', 'id': 'T77'}, {'offsets': [[1219, 1221]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[1238, 1244]], 'text': ['Ser536'], 'type': 'Entity', 'id': 'T79'}, {'offsets': [[1245, 1247]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1266, 1277]], 'text': ['Acetylation'], 'type': 'Acetylation', 'id': 'T81'}, {'offsets': [[1288, 1294]], 'text': ['Lys218'], 'type': 'Entity', 'id': 'T82'}, {'offsets': [[1299, 1305]], 'text': ['Lys221'], 'type': 'Entity', 'id': 'T83'}, {'offsets': [[1306, 1315]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T84'}, {'offsets': [[1324, 1331]], 'text': ['binding'], 'type': 'Binding', 'id': 'T85'}, {'offsets': [[1336, 1343]], 'text': ['impairs'], 'type': 'Negative_regulation', 'id': 'T86'}, {'offsets': [[1348, 1359]], 'text': ['association'], 'type': 'Binding', 'id': 'T87'}, {'offsets': [[1384, 1395]], 'text': ['acetylation'], 'type': 'Acetylation', 'id': 'T88'}, {'offsets': [[1399, 1405]], 'text': ['Lys310'], 'type': 'Entity', 'id': 'T89'}, {'offsets': [[1666, 1679]], 'text': ['Deacetylation'], 'type': 'Deacetylation', 'id': 'T90'}, {'offsets': [[1725, 1736]], 'text': ['acetylation'], 'type': 'Deacetylation', 'id': 'T91'}, {'offsets': [[1747, 1753]], 'text': ['Lys122'], 'type': 'Entity', 'id': 'T92'}, {'offsets': [[1758, 1764]], 'text': ['Lys123'], 'type': 'Entity', 'id': 'T93'}, {'offsets': [[2540, 2547]], 'text': ['binding'], 'type': 'Binding', 'id': 'T94'}, {'offsets': [[2583, 2590]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T95'}, {'offsets': [[2617, 2627]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[2728, 2737]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T97'}, {'offsets': [[2817, 2822]], 'text': ['binds'], 'type': 'Binding', 'id': 'T98'}, {'offsets': [[3040, 3048]], 'text': ['activate'], 'type': 'Positive_regulation', 'id': 'T99'}, {'offsets': [[3054, 3067]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T100'}, {'offsets': [[3139, 3150]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T101'}, {'offsets': [[3156, 3189]], 'text': ['transacting factors and cofactors'], 'type': 'Anaphora', 'id': 'T59'}, {'offsets': [[3276, 3306]], 'text': ['the histone acetyltransferases'], 'type': 'Anaphora', 'id': 'T60'}, {'offsets': [[3340, 3348]], 'text': ['released'], 'type': 'Localization', 'id': 'T102'}, {'offsets': [[3414, 3421]], 'text': ['binding'], 'type': 'Binding', 'id': 'T103'}, {'offsets': [[3605, 3614]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T104'}, {'offsets': [[3691, 3698]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T105'}, {'offsets': [[3732, 3743]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T106'}, {'offsets': [[3817, 3827]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T107'}, {'offsets': [[3839, 3847]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[3848, 3861]], 'text': ['deacetylation'], 'type': 'Deacetylation', 'id': 'T109'}, {'offsets': [[3869, 3875]], 'text': ['Lys310'], 'type': 'Entity', 'id': 'T110'}, {'offsets': [[4094, 4103]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T111'}, {'offsets': [[4169, 4174]], 'text': ['binds'], 'type': 'Binding', 'id': 'T112'}, {'offsets': [[4354, 4365]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T113'}, {'offsets': [[4394, 4399]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T61'}]","[{'trigger': 'T63', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T1', 'T62']}}, {'trigger': 'T64', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T63', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T1', 'T62']}}, {'trigger': 'T64', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T63', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E8', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T1', 'T62']}}, {'trigger': 'T64', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T63', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E14', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E20', 'T1', 'T62']}}, {'trigger': 'T64', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T63', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E20', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E20', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E20', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E20', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T1', 'T62']}}, {'trigger': 'T64', 'id': 'E26', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T63', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T1', 'T62']}}, {'trigger': 'T65', 'id': 'E32', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T63', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E36', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E32', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E38', 'T1', 'T62']}}, {'trigger': 'T65', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T63', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E38', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E38', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E38', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E38', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E44', 'T1', 'T62']}}, {'trigger': 'T65', 'id': 'E44', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T63', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E44', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E44', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E44', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E44', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E50', 'T1', 'T62']}}, {'trigger': 'T65', 'id': 'E50', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T63', 'id': 'E51', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E50', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E50', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E50', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E54', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E50', 'T6', 'T62']}}, {'trigger': 'T63', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E56', 'T1', 'T62']}}, {'trigger': 'T65', 'id': 'E56', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T63', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E56', 'T3', 'T62']}}, {'trigger': 'T63', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E56', 'T4', 'T62']}}, {'trigger': 'T63', 'id': 'E59', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E56', 'T5', 'T62']}}, {'trigger': 'T63', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E56', 'T6', 'T62']}}, {'trigger': 'T66', 'id': 'E61', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T67']}}, {'trigger': 'T66', 'id': 'E62', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T68']}}, {'trigger': 'T69', 'id': 'E63', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T70']}}, {'trigger': 'T69', 'id': 'E64', 'type': 'Ubiquitination', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T10', 'T71']}}, {'trigger': 'T72', 'id': 'E65', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T73', 'id': 'E66', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E65']}}, {'trigger': 'T74', 'id': 'E67', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T75']}}, {'trigger': 'T74', 'id': 'E68', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T77']}}, {'trigger': 'T74', 'id': 'E69', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T11', 'T79']}}, {'trigger': 'T76', 'id': 'E70', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'T12']}}, {'trigger': 'T78', 'id': 'E71', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'T13']}}, {'trigger': 'T80', 'id': 'E72', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E67', 'T14']}}, {'trigger': 'T81', 'id': 'E73', 'type': 'Acetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T15', 'T82']}}, {'trigger': 'T81', 'id': 'E74', 'type': 'Acetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T15', 'T83']}}, {'trigger': 'T84', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'E73']}}, {'trigger': 'T85', 'id': 'E76', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T84', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'E74']}}, {'trigger': 'T86', 'id': 'E78', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E79', 'E73']}}, {'trigger': 'T87', 'id': 'E79', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T15', 'T16']}}, {'trigger': 'T86', 'id': 'E80', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E79', 'E74']}}, {'trigger': 'T88', 'id': 'E81', 'type': 'Acetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T15', 'T89']}}, {'trigger': 'T90', 'id': 'E82', 'type': 'Deacetylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T21']}}, {'trigger': 'T90', 'id': 'E83', 'type': 'Deacetylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T20', 'T22']}}, {'trigger': 'T91', 'id': 'E84', 'type': 'Deacetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T23', 'T92']}}, {'trigger': 'T91', 'id': 'E85', 'type': 'Deacetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T23', 'T93']}}, {'trigger': 'T94', 'id': 'E86', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T95', 'id': 'E87', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E88', 'E86']}}, {'trigger': 'T96', 'id': 'E88', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T97', 'id': 'E89', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T98', 'id': 'E90', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T99', 'id': 'E91', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E92', 'E90']}}, {'trigger': 'T100', 'id': 'E92', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T99', 'id': 'E93', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E94', 'E90']}}, {'trigger': 'T100', 'id': 'E94', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T101', 'id': 'E95', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T34']}}, {'trigger': 'T101', 'id': 'E96', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T35']}}, {'trigger': 'T101', 'id': 'E97', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T36']}}, {'trigger': 'T101', 'id': 'E98', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T37']}}, {'trigger': 'T101', 'id': 'E99', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T38']}}, {'trigger': 'T101', 'id': 'E100', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T39']}}, {'trigger': 'T101', 'id': 'E101', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T40']}}, {'trigger': 'T101', 'id': 'E102', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T41']}}, {'trigger': 'T101', 'id': 'E103', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T33', 'T42']}}, {'trigger': 'T102', 'id': 'E104', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T103', 'id': 'E105', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T104', 'id': 'E106', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T105', 'id': 'E107', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E108', 'T46']}}, {'trigger': 'T106', 'id': 'E108', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T107', 'id': 'E109', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E110', 'T46']}}, {'trigger': 'T108', 'id': 'E110', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E111', 'T49']}}, {'trigger': 'T109', 'id': 'E111', 'type': 'Deacetylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T50', 'T110']}}, {'trigger': 'T111', 'id': 'E112', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T112', 'id': 'E113', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T54', 'T55']}}, {'trigger': 'T113', 'id': 'E114', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T56', 'T57']}}]","[{'id': 'R1', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T34', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T35', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T36', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T37', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T38', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T59', 'role': 'Subject'}, 'tail': {'ref_id': 'T39', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T60', 'role': 'Subject'}, 'tail': {'ref_id': 'T40', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T60', 'role': 'Subject'}, 'tail': {'ref_id': 'T41', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T60', 'role': 'Subject'}, 'tail': {'ref_id': 'T42', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T61', 'role': 'Subject'}, 'tail': {'ref_id': 'T113', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T1', 'T2']}, {'id': '*', 'ref_ids': ['T29', 'T30']}, {'id': '*', 'ref_ids': ['T31', 'T32']}]",[],[]
158,PMC-1920263-02-MATERIALS_AND_METHODS,"Cell culture
The human T cell lines A3.01 and PM1 (NIBSC, UK) and the human myeloid cell line U937 (NIBSC, UK) were grown in complete RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine and 100 U/ml penicillin-streptomycin. The human hepatic cell lines HepG2 and Huh7 (kindly provided by Dr Thomas Pietschmann, Department of Molecular Virology, University of Heidelberg) as well as HeLa cells were maintained in Dulbecco's high glucose modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM l-glutamine and 100 U/ml penicillin-streptomycin. Cells lines were incubated at 37degreesC with 100% humidity in 5-7% CO2 and passaged using standard cell culture techniques.",[],[],[],[],[],[]
159,PMC-3359311-19-Caption-Figure_1,"Cell stimulation and inhibitor schedule.
Schedule outlines the timing of inhibitor addition and priming in relation to inflammasome stimulation (t = 0) for THP-1 reporter and PBMC cytokine quantification experiments. Inhibitor treatments and stimulations were carried out as described in the Materials and Methods section.",[],[],[],[],[],[]
160,PMC-3062687-00-TIAB,"IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function duringEscherichia coliO157:H7 infection
NF-kappaB is a major gene regulator in immune responses and ribosomal protein S3 (RPS3) is an NF-kappaB subunit that directs specific gene transcription. However, it is unknown how RPS3 nuclear translocation is regulated. Here we report that IKKbeta phosphorylation of serine 209 (S209) was crucial for RPS3 nuclear localization in response to activating stimuli. Moreover, the foodborne pathogen Escherichia coli O157:H7 virulence protein NleH1 specifically inhibited RPS3 S209 phosphorylation and blocked RPS3 function, thereby promoting bacterial colonization and diarrhea but decreasing mortality in a gnotobiotic piglet infection model. Thus, the IKKbeta-dependent modification of a specific amino acid in RPS3 promotes specific NF-kappaB functions that underlie the molecular pathogenetic mechanisms of E. coli O157:H7.","[{'offsets': [[0, 7]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 38]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[184, 204]], 'text': ['ribosomal protein S3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[206, 210]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[305, 309]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[366, 373]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[427, 431]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[564, 569]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[593, 597]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[631, 635]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[776, 783]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[835, 839]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[8, 23]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T13'}, {'offsets': [[24, 33]], 'text': ['regulates'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[39, 46]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[47, 60]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T16'}, {'offsets': [[310, 317]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[318, 331]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T18'}, {'offsets': [[335, 344]], 'text': ['regulated'], 'type': 'Regulation', 'id': 'T19'}, {'offsets': [[374, 389]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T20'}, {'offsets': [[393, 403]], 'text': ['serine 209'], 'type': 'Entity', 'id': 'T21'}, {'offsets': [[415, 422]], 'text': ['crucial'], 'type': 'Positive_regulation', 'id': 'T22'}, {'offsets': [[432, 439]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T23'}, {'offsets': [[440, 452]], 'text': ['localization'], 'type': 'Localization', 'id': 'T24'}, {'offsets': [[453, 467]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T25'}, {'offsets': [[468, 478]], 'text': ['activating'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[583, 592]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[598, 602]], 'text': ['S209'], 'type': 'Entity', 'id': 'T28'}, {'offsets': [[603, 618]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T29'}, {'offsets': [[623, 630]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T30'}, {'offsets': [[784, 793]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T31'}, {'offsets': [[794, 806]], 'text': ['modification'], 'type': 'Protein_modification', 'id': 'T32'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T14', 'id': 'E2', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E1']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T15']}}, {'trigger': 'T18', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T17']}}, {'trigger': 'T19', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T6', 'T21']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'E6']}}, {'trigger': 'T25', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'E10']}}, {'trigger': 'T24', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T23']}}, {'trigger': 'T26', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T27', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T8']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T9', 'T28']}}, {'trigger': 'T30', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T10', 'E11']}}, {'trigger': 'T31', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'T11']}}, {'trigger': 'T32', 'id': 'E15', 'type': 'Protein_modification', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}]",[],"[{'id': '*', 'ref_ids': ['T3', 'T4']}]","[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
161,PMC-2806624-25-Caption-Figure_1,"RUNX1 and RUNX3 are involved in the induction of Foxp3 in iT reg cells. (A) RUNX1, RUNX3, and FOXP3 mRNA induction in human naive CD4+ T cells after alone or combined anti-CD2/3/28 mAb and TGF-beta stimulation in the presence of IL-2. Real-time PCR of human naive CD4+ T cells after 48 h of culture. Bars show the mean +/- SE of three independent experiments. (B) FOXP3 mRNA induction by anti-CD2/3/28 mAb and TGF-beta in human naive CD4+ T cells is reduced after siRNA-mediated RUNX1/3 knockdown. Real-time PCR of RNA from human naive CD4+ T cells, transfected with RUNX1 and/or RUNX3 siRNA or with a control siRNA and cultured with anti-CD2/3/28, TGF-beta and IL-2. Bars show the mean +/- SD of three independent experiments. (C) FOXP3 mRNA is down-regulated in iT reg cells after siRNA-mediated knockdown of RUNX1 and RUNX3. Real-time PCR for FOXP3, T-bet, GATA3, and RORC2 from human naive CD4+ T cells, transfected with RUNX1 and RUNX3 siRNA or with scrambled siRNA (control) and cultured under iT reg, Th1, Th2, or Th17-driving conditions for 12 d. Bars show the mean +/- SD of three independent experiments. (D) FOXP3 protein induction in iT reg cells is reduced after siRNA-mediated RUNX1/3 knockdown. Human naive CD4+ T cells were transfected with RUNX1 and/or RUNX3 siRNA or with a control siRNA and stimulated with anti-CD2/3/28 and TGF-beta in the presence of IL-2. CD4 and intracellular FOXP3 analysis by flow cytometry after 72 h. One of three independent experiments is shown. Statistical differences were verified by the paired Student's t test. *, P < 0.05; **, P < 0.01.","[{'offsets': [[0, 5]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[10, 15]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 54]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[76, 81]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[83, 88]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[94, 99]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[130, 133]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[172, 175]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[176, 177]], 'text': ['3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[178, 180]], 'text': ['28'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[189, 197]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[229, 233]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[264, 267]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[364, 369]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[393, 396]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[397, 398]], 'text': ['3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[399, 401]], 'text': ['28'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[410, 418]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[434, 437]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[479, 484]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[485, 486]], 'text': ['3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[536, 539]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[567, 572]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[580, 585]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[639, 642]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[643, 644]], 'text': ['3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[645, 647]], 'text': ['28'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[649, 657]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[662, 666]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[732, 737]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[811, 816]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[821, 826]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[846, 851]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[853, 858]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[860, 865]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[871, 876]], 'text': ['RORC2'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[894, 897]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[925, 930]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[935, 940]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1000, 1006]], 'text': ['iT reg'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1021, 1025]], 'text': ['Th17'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1119, 1124]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1191, 1196]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1197, 1198]], 'text': ['3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1222, 1225]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1257, 1262]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1270, 1275]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1331, 1334]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1335, 1336]], 'text': ['3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1337, 1339]], 'text': ['28'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[1344, 1352]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[1372, 1376]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[1378, 1381]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[1400, 1405]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[20, 28]], 'text': ['involved'], 'type': 'Regulation', 'id': 'T55'}, {'offsets': [[36, 45]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[100, 104]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T57'}, {'offsets': [[105, 114]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[370, 374]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T59'}, {'offsets': [[375, 384]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[450, 457]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[470, 478]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T62'}, {'offsets': [[487, 496]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[586, 591]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T64'}, {'offsets': [[738, 742]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T65'}, {'offsets': [[746, 760]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[789, 797]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[798, 807]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T68'}, {'offsets': [[941, 946]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[1133, 1142]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T70'}, {'offsets': [[1162, 1169]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[1182, 1190]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[1199, 1208]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[1276, 1281]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T74'}]","[{'trigger': 'T55', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T56', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T55', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T2']}}, {'trigger': 'T57', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T57', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T57', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T58', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T12']}}, {'trigger': 'T58', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T12']}}, {'trigger': 'T58', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T12']}}, {'trigger': 'T59', 'id': 'E10', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T60', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T18']}}, {'trigger': 'T61', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E13']}}, {'trigger': 'T63', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T61', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'E15']}}, {'trigger': 'T63', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T62', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T62', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T64', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T64', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T65', 'id': 'E20', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T66', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E22']}}, {'trigger': 'T68', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T66', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E24']}}, {'trigger': 'T68', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T67', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T67', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E24']}}, {'trigger': 'T69', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T69', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T70', 'id': 'E29', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T71', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E31']}}, {'trigger': 'T73', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T71', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E33']}}, {'trigger': 'T73', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T72', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T72', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T74', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T74', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}]",[],[],[],[]
162,PMC-2674207-23-Caption-Figure_3,"Fluticasone propionate-mediated inhibition of p38 MAP kinase phosphorylation and activation is associated with a marked down-regulation of GATA-3 serine phosphorylation.
(A) Western blot analysis shows that FP (10-8 M, 30 min) treatment reduced dual phosphorylation (threonine-180 and tyrosine-182) of p38 MAPK in anti-CD3/CD28-co-stimulated HuT-78 cells. (B) Time course of the effect of FP (10-8 M) on phosphorylation of activated transcription factor 2 (ATF-2), a measure of p38 MAPK activity. (C) FP-induced inhibition of p38 MAPK activity is associated with the decrease of anti-CD3/CD28 co-stimulation-induced serine phosphorylation (P-Ser) of GATA-3. For (A-C), quantification of the densitometry data is also shown. Each bar represents mean+/-SEM of at least three independent experiments. ###p<0.001 compared to control, ***p<0.001 compared to alphaCD3/CD28-stimulated cells. (D) FP induced MKP-1 mRNA in a concentration-dependent manner. All results are representative of at least three independent experiments and where appropriate expressed as means+/-SEM, *p<0.05. (E) FP induces MKP-1 mRNA in a time-dependent manner. Results are representative of two independent experiments. All data except (E) were analysed by ANOVA followed by Newman-Keuls post-test.","[{'offsets': [[139, 145]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[423, 455]], 'text': ['activated transcription factor 2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[457, 462]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[650, 656]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[900, 905]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1093, 1098]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[95, 105]], 'text': ['associated'], 'type': 'Regulation', 'id': 'T7'}, {'offsets': [[120, 135]], 'text': ['down-regulation'], 'type': 'Negative_regulation', 'id': 'T8'}, {'offsets': [[146, 152]], 'text': ['serine'], 'type': 'Entity', 'id': 'T9'}, {'offsets': [[153, 168]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T10'}, {'offsets': [[379, 385]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T11'}, {'offsets': [[404, 419]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T12'}, {'offsets': [[567, 575]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[608, 615]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[616, 622]], 'text': ['serine'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[623, 638]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T16'}, {'offsets': [[892, 899]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[930, 939]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T18'}, {'offsets': [[1085, 1092]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[1114, 1123]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T20'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T10', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T9']}}, {'trigger': 'T11', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T12', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T13', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T15']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T17', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T19', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T20', 'id': 'E12', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}]",[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]",[],[]
163,PMC-1134658-02-Results,"BMP-6 inhibits anti-IgM induced proliferation of human B cells
The effects of BMP-6 on normal and neoplastic hematopoietic cells prompted us to investigate the effects of BMP-6 on normal human B cells. All experiments in this study were performed under serum-free conditions as FCS has been shown to interfere with BMP-signalling [14](own observations). To study the effect of BMP-6 on proliferation, B-cells from healthy volunteers were stimulated with anti-IgM and/or CD40L in the presence or absence of BMP-6 for three days. We found that BMP-6 led to a 35% mean reduction of anti-IgM- induced DNA synthesis (n = 8; p <= 0.0002, Figure 1A). Similar results were obtained for B cells treated with anti-IgM and CD40L (26% mean reduction, n = 6; p <= 0.023). The BMP-6-induced inhibition of proliferation was dose-dependent in both peripheral B cells (Figure 1B) and the Burkitt lymphoma cell line Ramos (40% reduction of DNA synthesis, Figure 1C). The BMP-6 effects could be reversed by addition of the extracellular inhibitor Noggin (Figure 1D). Similarly, a combination of the soluble BMP receptors BMP-RIB-Fc and BMP-RII-Fc also neutralized the effects of BMP-6 (data not shown). Next, we wanted to test whether BMP-6 had different effect on naive and memory B cells. Naive (CD19+CD27-) and memory (CD19+CD27+) B cells were isolated from peripheral blood by cell sorting of immunobead-isolated CD19+ B cells [15], and tested for their capacity to proliferate in the presence of BMP-6. However, BMP-6 inhibited anti-IgM induced DNA synthesis in the two subpopulations to a similar extent, with a mean reduction of DNA-synthesis of 45% (n = 5; p <= 0,004) for naive B cells and 48% (n = 5; p <= 0,001) for memory B cells (Figure 1E).","[{'offsets': [[0, 5]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[78, 83]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[171, 176]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[377, 382]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[470, 475]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[506, 511]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[542, 547]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[712, 717]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[763, 768]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[953, 958]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1028, 1034]], 'text': ['Noggin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1102, 1109]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1117, 1124]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1160, 1165]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1216, 1221]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1279, 1283]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1284, 1288]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1303, 1307]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1308, 1312]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1398, 1402]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1482, 1487]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1498, 1503]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
164,PMC-2806624-02-RESULTS,"The role of RUNX1 and RUNX3 transcription factors in TGF-beta-mediated iT reg cell generation
To investigate the role of RUNX transcription factors in the development of iT reg cells, we cultured naive CD4+ T cells, isolated from human PBMCs, in conditions that enable the development of iT reg cells. Stimulation with anti-CD2/3/28 mAbs or TGF-beta alone resulted in a minimal up-regulation of RUNX1 and RUNX3 mRNA (Fig. 1 A). In contrast, the combination of both TGF-beta and anti-CD2/3/28 mAbs induced RUNX1 and RUNX3 mRNAs, as well as FOXP3 mRNA, within 48 h in naive CD4+ T cells. This result suggested further experiments to investigate whether the up-regulation of RUNX1 and RUNX3 might be a feature of iT reg cells during their development or even a prerequisite for their induction.
To test this hypothesis, RUNX1 and RUNX3 expression was knocked down in human naive CD4+ T cells by transfection of small interfering RNAs (siRNAs; Fig. 1 B). Deficiency of RUNX1 or RUNX3 resulted in markedly reduced TGF-beta-mediated induction of FOXP3 mRNA in naive CD4+ T cells compared with control cells transfected with scrambled siRNA. The level of FOXP3 mRNA was further reduced when both RUNX1 and RUNX3 were knocked down in naive CD4+ T cells during their differentiation to iT reg cells (Fig. 1 B).
The influence of RUNX1 and RUNX3 on the development of other T cell subsets and their specific transcription factor expression was further investigated. Naive CD4+ T cells were cultured under Th1, Th2, T reg cell, and Th17 differentiation conditions and the mRNA expression of the predominant transcription factor for each cell type was subsequently analyzed. We observed no change in GATA3 expression in Th2 cells, T-bet expression in Th1 cells, or RORC2 mRNA expression in Th17 cells in which RUNX1 and RUNX3 were knocked down compared with control cells. On the contrary, FOXP3 mRNA was significantly decreased in RUNX1- and RUNX3-deficient T reg cells compared with control cells (Fig. 1 C).
The effect of RUNX silencing on the expression level of intracellular FOXP3 during naive CD4+ T cell differentiation to iT reg was evaluated by flow cytometry. FOXP3 was only slightly reduced after RUNX1 silencing. Transfection of siRNA for RUNX3 had a stronger effect. The most striking FOXP3 reduction was observed when RUNX1 and RUNX3 were silenced together (Fig. 1 D). Similar results were obtained in total CD4+ T cells (Fig. S1 and Fig. S2). The increased impact of combined RUNX1 and RUNX3 knockdown implies that RUNX1 and RUNX3 might have redundant functions in the induction of FOXP3. In addition, the levels of IL-4, IL-5, IL-10, IL-13, and IFN-gamma in control siRNA-transfected or RUNX1 and RUNX3 siRNA-transfected CD4+ T cells that were cultured with or without anti-CD2/3/28 mAb and TGF-beta did not show any significant difference (Fig. S3).
To determine whether RUNX1 and RUNX3 are also expressed in human T reg cells in vivo, we isolated peripheral blood CD4+ CD127- CD25high T reg cells and compared them with CD4+ CD127+ CD25- T cells. Circulating T reg cells expressed significantly higher levels of RUNX3 mRNA compared with CD4+CD25- cells. As expected, IL-10, TGF-beta, and FOXP3 mRNAs are also expressed in circulating T reg cells (Fig. 2 A). There was no difference in RUNX1 mRNA expression between these two cell subsets. We also performed an analysis of human tonsils, which contain high numbers of FOXP3+ T reg cells (Verhagen et al., 2006). Staining of tonsil sections for FOXP3 and RUNX3 demonstrated in vivo coexpression of these two molecules in a subset of T reg cells, whereas there was low RUNX1 expression in all tonsil cells (Fig. 2 B).","[{'offsets': [[12, 17]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[22, 27]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 61]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[121, 125]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[202, 205]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[324, 327]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[328, 329]], 'text': ['3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[330, 332]], 'text': ['28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[341, 349]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[395, 400]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[405, 410]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[465, 473]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[483, 486]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[487, 488]], 'text': ['3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[489, 491]], 'text': ['28'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[505, 510]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[515, 520]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[539, 544]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[572, 575]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[672, 677]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[682, 687]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[817, 822]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[827, 832]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[876, 879]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[965, 970]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[974, 979]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1009, 1017]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1040, 1045]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1060, 1063]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1148, 1153]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1189, 1194]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1199, 1204]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1232, 1235]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1319, 1324]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1329, 1334]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1461, 1464]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1687, 1692]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1718, 1723]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1752, 1757]], 'text': ['RORC2'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1797, 1802]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1807, 1812]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1877, 1882]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1919, 1924]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1930, 1935]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2012, 2016]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2068, 2073]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2087, 2090]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2158, 2163]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2196, 2201]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2239, 2244]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2286, 2291]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2320, 2325]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2330, 2335]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2410, 2413]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2479, 2484]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2489, 2494]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[2518, 2523]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[2528, 2533]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[2585, 2590]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[2619, 2623]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[2625, 2629]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[2631, 2636]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[2638, 2643]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[2649, 2658]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[2691, 2696]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[2701, 2706]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[2725, 2728]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[2778, 2781]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[2782, 2783]], 'text': ['3'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[2784, 2786]], 'text': ['28'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[2795, 2803]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[2876, 2881]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[2886, 2891]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[2970, 2973]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[2975, 2980]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[2982, 2986]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[3026, 3029]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[3031, 3036]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[3038, 3042]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[3118, 3123]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[3143, 3146]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[3147, 3151]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[3173, 3178]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[3180, 3188]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[3194, 3199]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[3291, 3296]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[3423, 3428]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[3499, 3504]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[3509, 3514]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[3622, 3627]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[378, 391]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T92'}, {'offsets': [[411, 415]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T93'}, {'offsets': [[497, 504]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T94'}, {'offsets': [[521, 526]], 'text': ['mRNAs'], 'type': 'Transcription', 'id': 'T95'}, {'offsets': [[545, 549]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T96'}, {'offsets': [[655, 668]], 'text': ['up-regulation'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[833, 843]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T98'}, {'offsets': [[848, 860]], 'text': ['knocked down'], 'type': 'Negative_regulation', 'id': 'T99'}, {'offsets': [[951, 961]], 'text': ['Deficiency'], 'type': 'Negative_regulation', 'id': 'T100'}, {'offsets': [[1001, 1008]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T101'}, {'offsets': [[1018, 1026]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[1027, 1036]], 'text': ['induction'], 'type': 'Transcription', 'id': 'T103'}, {'offsets': [[1154, 1158]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T104'}, {'offsets': [[1171, 1178]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T105'}, {'offsets': [[1210, 1222]], 'text': ['knocked down'], 'type': 'Negative_regulation', 'id': 'T106'}, {'offsets': [[1677, 1683]], 'text': ['change'], 'type': 'Regulation', 'id': 'T107'}, {'offsets': [[1693, 1703]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T108'}, {'offsets': [[1724, 1734]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T109'}, {'offsets': [[1758, 1773]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T110'}, {'offsets': [[1818, 1830]], 'text': ['knocked down'], 'type': 'Negative_regulation', 'id': 'T111'}, {'offsets': [[1883, 1887]], 'text': ['mRNA'], 'type': 'Transcription', 'id': 'T112'}, {'offsets': [[1906, 1915]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T113'}, {'offsets': [[1936, 1945]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T114'}, {'offsets': [[2002, 2008]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T115'}, {'offsets': [[2017, 2026]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T116'}, {'offsets': [[2034, 2044]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[2182, 2189]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T118'}, {'offsets': [[2202, 2211]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T119'}, {'offsets': [[2213, 2234]], 'text': ['Transfection of siRNA'], 'type': 'Negative_regulation', 'id': 'T120'}, {'offsets': [[2251, 2266]], 'text': ['stronger effect'], 'type': 'Negative_regulation', 'id': 'T121'}, {'offsets': [[2292, 2301]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T122'}, {'offsets': [[2341, 2349]], 'text': ['silenced'], 'type': 'Negative_regulation', 'id': 'T123'}, {'offsets': [[2495, 2504]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[2555, 2564]], 'text': ['functions'], 'type': 'Regulation', 'id': 'T125'}, {'offsets': [[2572, 2581]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T126'}, {'offsets': [[2609, 2615]], 'text': ['levels'], 'type': 'Gene_expression', 'id': 'T127'}, {'offsets': [[2707, 2724]], 'text': ['siRNA-transfected'], 'type': 'Negative_regulation', 'id': 'T128'}, {'offsets': [[2812, 2843]], 'text': ['show any significant difference'], 'type': 'Regulation', 'id': 'T129'}, {'offsets': [[2901, 2910]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T130'}, {'offsets': [[3077, 3086]], 'text': ['expressed'], 'type': 'Transcription', 'id': 'T131'}, {'offsets': [[3215, 3224]], 'text': ['expressed'], 'type': 'Transcription', 'id': 'T132'}, {'offsets': [[3277, 3287]], 'text': ['difference'], 'type': 'Regulation', 'id': 'T133'}, {'offsets': [[3297, 3312]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T134'}, {'offsets': [[3536, 3548]], 'text': ['coexpression'], 'type': 'Gene_expression', 'id': 'T135'}, {'offsets': [[3552, 3571]], 'text': ['these two molecules'], 'type': 'Anaphora', 'id': 'T91'}, {'offsets': [[3618, 3621]], 'text': ['low'], 'type': 'Negative_regulation', 'id': 'T136'}, {'offsets': [[3628, 3638]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T137'}]","[{'trigger': 'T92', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T9']}}, {'trigger': 'T93', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T92', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T9']}}, {'trigger': 'T93', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T94', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T12']}}, {'trigger': 'T95', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T94', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T12']}}, {'trigger': 'T95', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T94', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T12']}}, {'trigger': 'T96', 'id': 'E10', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T97', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T97', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T98', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T98', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T99', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T99', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T100', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T100', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T101', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E17']}}, {'trigger': 'T103', 'id': 'E20', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T101', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E18']}}, {'trigger': 'T102', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T27']}}, {'trigger': 'T104', 'id': 'E23', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T105', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'E25']}}, {'trigger': 'T106', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T105', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'E27']}}, {'trigger': 'T106', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T107', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E30']}}, {'trigger': 'T108', 'id': 'E29', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T111', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T107', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'E32']}}, {'trigger': 'T111', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T107', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E30']}}, {'trigger': 'T109', 'id': 'E34', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T107', 'id': 'E35', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E32']}}, {'trigger': 'T107', 'id': 'E36', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'E30']}}, {'trigger': 'T110', 'id': 'E37', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T107', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E37', 'E32']}}, {'trigger': 'T112', 'id': 'E39', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T113', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E41']}}, {'trigger': 'T114', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T113', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E39', 'E43']}}, {'trigger': 'T114', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T115', 'id': 'E44', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'E46']}}, {'trigger': 'T117', 'id': 'E45', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T116', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T118', 'id': 'E47', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T48', 'E48']}}, {'trigger': 'T119', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T49']}}, {'trigger': 'T120', 'id': 'E49', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T121', 'id': 'E50', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T48', 'E49']}}, {'trigger': 'T122', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T51', 'E52']}}, {'trigger': 'T123', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T122', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T51', 'E54']}}, {'trigger': 'T123', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T53']}}, {'trigger': 'T124', 'id': 'E55', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T124', 'id': 'E56', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T125', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E58', 'T57']}}, {'trigger': 'T126', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T125', 'id': 'E59', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E58', 'T58']}}, {'trigger': 'T127', 'id': 'E60', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T127', 'id': 'E61', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T127', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T127', 'id': 'E63', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T127', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T128', 'id': 'E65', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T128', 'id': 'E66', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T129', 'id': 'E67', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E65']}}, {'trigger': 'T129', 'id': 'E68', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'E66']}}, {'trigger': 'T129', 'id': 'E69', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E60', 'T71']}}, {'trigger': 'T129', 'id': 'E70', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E61', 'E65']}}, {'trigger': 'T129', 'id': 'E71', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E61', 'E66']}}, {'trigger': 'T129', 'id': 'E72', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E61', 'T71']}}, {'trigger': 'T129', 'id': 'E73', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'E65']}}, {'trigger': 'T129', 'id': 'E74', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'E66']}}, {'trigger': 'T129', 'id': 'E75', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E62', 'T71']}}, {'trigger': 'T129', 'id': 'E76', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E63', 'E65']}}, {'trigger': 'T129', 'id': 'E77', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E63', 'E66']}}, {'trigger': 'T129', 'id': 'E78', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E63', 'T71']}}, {'trigger': 'T129', 'id': 'E79', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E64', 'E65']}}, {'trigger': 'T129', 'id': 'E80', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E64', 'E66']}}, {'trigger': 'T129', 'id': 'E81', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E64', 'T71']}}, {'trigger': 'T130', 'id': 'E82', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T130', 'id': 'E83', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T73']}}, {'trigger': 'T131', 'id': 'E84', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T80']}}, {'trigger': 'T132', 'id': 'E85', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T132', 'id': 'E86', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T132', 'id': 'E87', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T85']}}, {'trigger': 'T133', 'id': 'E88', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E89']}}, {'trigger': 'T134', 'id': 'E89', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T86']}}, {'trigger': 'T135', 'id': 'E90', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T88']}}, {'trigger': 'T135', 'id': 'E91', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T136', 'id': 'E92', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E93']}}, {'trigger': 'T137', 'id': 'E93', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T90']}}]","[{'id': 'R1', 'head': {'ref_id': 'T91', 'role': 'Subject'}, 'tail': {'ref_id': 'T88', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T91', 'role': 'Subject'}, 'tail': {'ref_id': 'T89', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E28', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E33', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E35', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E36', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E38', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E44', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E57', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E59', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E67', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E68', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E69', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E70', 'value': ''}, {'id': 'M14', 'type': 'Negation', 'ref_id': 'E71', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E72', 'value': ''}, {'id': 'M16', 'type': 'Negation', 'ref_id': 'E73', 'value': ''}, {'id': 'M17', 'type': 'Negation', 'ref_id': 'E74', 'value': ''}, {'id': 'M18', 'type': 'Negation', 'ref_id': 'E75', 'value': ''}, {'id': 'M19', 'type': 'Negation', 'ref_id': 'E76', 'value': ''}, {'id': 'M20', 'type': 'Negation', 'ref_id': 'E77', 'value': ''}, {'id': 'M21', 'type': 'Negation', 'ref_id': 'E78', 'value': ''}, {'id': 'M22', 'type': 'Negation', 'ref_id': 'E79', 'value': ''}, {'id': 'M23', 'type': 'Negation', 'ref_id': 'E80', 'value': ''}, {'id': 'M24', 'type': 'Negation', 'ref_id': 'E81', 'value': ''}, {'id': 'M25', 'type': 'Speculation', 'ref_id': 'E82', 'value': ''}, {'id': 'M26', 'type': 'Speculation', 'ref_id': 'E83', 'value': ''}, {'id': 'M27', 'type': 'Negation', 'ref_id': 'E88', 'value': ''}]",[]
165,PMC-3359311-05-Results,"PBMCs from CF patients do not produce increased amounts of IL-1beta upon inflammasome stimulation
Previous studies have shown that the loss of CFTR results in increased NF-kappaB activity and pro-inflammatory cytokine secretion [4], [5], [32], [36], [37]. To further examine this relationship, PBMCs from CF patients and healthy adult controls were stimulated with PAO1, LPS+ATP, and LPS+Poly(dA:dT), to activate the NLRC4, NLRP3, and AIM2 inflammasomes, respectively. By 24 hours of stimulation, CF PBMCs did not produce increased amounts of IL-1beta (Fig. 5a) or IL-8 (Fig. 5b) when compared to healthy controls. However, we did notice a transient decrease (P<0.001) in the amount of IL-1beta produced by CF cells in response to LPS+ATP at 6 hours (data not shown). Stimulation of PBMCs with P. aeruginosa that lacks exsA (PAO1deltaexsA), a key regulator of type III secretion, produced three-fold less IL-1beta compared to the parental PAO1 strain by 24 hours (Fig. 5a). Inflammasome stimulation without priming did not result in any IL-1beta production in either CF or control PBMCs. Contrary to our hypothesis, these results indicate that PBMCs from CF patients do not display increased production of IL-1beta or IL-8 with inflammasome activation nor do they suggest any increased basal or induced NF-kappaB activity. These results are consistent with our observation that caspase-1 activity is not different between CF and control PBMCs (Fig. 4).","[{'offsets': [[59, 67]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[543, 551]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[686, 694]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[819, 823]], 'text': ['exsA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[905, 913]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1037, 1045]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1206, 1214]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1218, 1222]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[30, 37]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T9'}, {'offsets': [[38, 47]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[514, 521]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[522, 531]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[650, 658]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T13'}, {'offsets': [[695, 703]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[716, 730]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[880, 888]], 'text': ['produced'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[900, 904]], 'text': ['less'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[1023, 1029]], 'text': ['result'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[1046, 1056]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[1182, 1191]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[1192, 1202]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T21'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T16', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T17', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T18', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T19', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T20', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T21', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T20', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T21', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}]",[]
166,PMC-1942070-02-Materials_and_methods,"2.1Cell culture, transient transfections and cell stimulation
The generation, culture and activation of PKD1-/-, PKD3-/- and PKD1/3-/- knockout DT40 B cell lines have been described previously [1]. Cells were lysed and protein extracts were analysed in Western blotting experiments as previously described [1]. Chloramphenicol acetyl transferase assays have been described previously [29].","[{'offsets': [[104, 108]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[113, 117]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[125, 129]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[130, 131]], 'text': ['3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[135, 143]], 'text': ['knockout'], 'type': 'Negative_regulation', 'id': 'T5'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T5', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
167,PMC-3333881-21-Caption-Figure_4,"Tat associates with p65 increasing its DNA-affinity binding. (A) HeLa cells were transfected with pRc/CMV-3xHA-p65 (5 microg) in presence or absence of p3xFLAG-Tat, p3xFLAG-Tat T,N(23,24)A, p3xFLAG-Tat K(50,51)A, p3xFLAG-Tat R(49-57)A, or p3xFLAG-Tat C(22,25,27)A (5 microg). FLAG-Tat proteins were immunoprecipitated with anti-FLAG antibody; immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-FLAG or anti-HA antibodies. (B) In vitro translated p65 (5 microl) was incubated with GST-Tat, GST-Tat T,N(23,24)A, GST-Tat K(50,51)A, GST-Tat R(49-57)A, GST-Tat C(22,25,27)A, or GST (5 microg) conjugated with Glutathione-Sepharose. Protein complexes were recovered by GST-pull down, separated by 12% SDS-PAGE, and analysed by western blotting with anti-p65 or anti-GST antibodies. (C) Schematic representation of wild-type and mutant p65 proteins. (D) HeLa cells were transfected with p3xFLAG-Tat (5 microg) in the presence or absence of pRc/CMV-3xHA-p65, pRc/CMV-3xHA-p65deltaC (1-318), or pRc/CMV-3xHA-p65deltaN (122-551) (5 microg). Wild-type and mutant HA-p65 proteins were immunoprecipitated with anti-HA antibody; immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-FLAG or anti-HA antibodies. (E) Recombinant p65 protein (100 ng; Active Motif Carlsbad, CA, USA) was 20 min incubated with 32P-labeled NF-kappaB double-stranded oligonucleotide in presence or absence of in vitro translated FLAG-Tat or FLAG-Tat C(22,25,27)A (5 microl); competitions were performed with 1.25- up to 40-fold molar excess of unlabeled oligonucleotide. DNA/protein complexes were separated by 6% PAGE in 0.5 x TBE buffer and analysed by autoradiography. (F) Densitometry of band-shifts shown in E.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[20, 23]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[106, 114]], 'text': ['3xHA-p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[160, 163]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[173, 188]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[198, 211]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[221, 234]], 'text': ['Tat R(49-57)A'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[247, 263]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[276, 284]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[485, 488]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[519, 526]], 'text': ['GST-Tat'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[528, 547]], 'text': ['GST-Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[549, 566]], 'text': ['GST-Tat K(50,51)A'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[568, 585]], 'text': ['GST-Tat R(49-57)A'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[587, 607]], 'text': ['GST-Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[612, 615]], 'text': ['GST'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[702, 705]], 'text': ['GST'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[868, 871]], 'text': ['p65'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[927, 930]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[980, 988]], 'text': ['3xHA-p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[998, 1012]], 'text': ['3xHA-p65deltaC'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1033, 1047]], 'text': ['3xHA-p65deltaN'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1091, 1097]], 'text': ['HA-p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1288, 1291]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1467, 1475]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1479, 1500]], 'text': ['FLAG-Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4, 14]], 'text': ['associates'], 'type': 'Binding', 'id': 'T28'}, {'offsets': [[24, 34]], 'text': ['increasing'], 'type': 'Positive_regulation', 'id': 'T29'}, {'offsets': [[35, 38]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T27'}, {'offsets': [[52, 59]], 'text': ['binding'], 'type': 'Binding', 'id': 'T30'}]","[{'trigger': 'T28', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T2']}}, {'trigger': 'T29', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E1']}}, {'trigger': 'T30', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]","[{'id': 'R1', 'head': {'ref_id': 'T27', 'role': 'Subject'}, 'tail': {'ref_id': 'T2', 'role': 'Object'}, 'type': 'Coreference'}]",[],[],[]
168,PMC-2222968-19-Materials_and_Methods,"Intracellular cytokine staining.
T cells were stimulated with 2 x 10-7 M PMA and 1 mug/ml of ionomycin (Sigma Chemicals) for 4 h. The following mAb was used: anti-IL-4-PE (8D4-8, BD). Matched isotype controls were used at the same protein concentration as the respective antibodies. Four-color FACS was performed using an EPICS XL-MCL (Beckman Coulter) using the software Expo32 version for data acquisition and evaluation.","[{'offsets': [[163, 167]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
169,PMC-2222968-32-Caption-Figure_8,"GATA3 Represses the Human FOXP3 Promoter
(A) Jurkat, Th2 cells, and human primary CD4 cells were transfected with an empty vector (pGL3 basic) or a vector containing the putative FOXP3 promoter region fused to the luciferase reporter gene. Bars show the mean +/- SD of arbitrary light units normalized for renilla luciferase of four independent experiments; samples were measured in triplicates.
(B) Naive CD4 T cells were transfected with the FOXP3 promoter reporter construct together with a GATA3 expression vector or an empty vector. Bars show the mean +/- SD of three independent experiments.
(C) Naive (left panel) or memory (right panel) CD4 T cells were transfected with wild-type or a GATA3 mutated 511-FOXP3 promoter reporter construct and activated with PMA and ionomycin. Bars show the mean +/- SD of arbitrary light units normalized for renilla luciferase of eight independent experiments; samples were measured in triplicates.
(D) Nuclear extracts were prepared from HEK cells transfected with GATA3 or an empty vector, (E) Th1, Th2, or iTreg cells and binding factors precipitated using biotinylated oligonucleotides. The oligonucleotides-transcription factor complexes were separated on a SDS-PAGE gel. The amounts of GATA3 protein in the precipitates were assessed by immunoblotting with anti-GATA3 mAb. Total nuclear extracts were also run as controls. Data are representative of three different experiments.
(F) iTreg or Th2 cells were analyzed by ChIP for GATA3 binding to the FOXP3 promoter. The ""input"" represents PCR amplification of the total sample, which was not subjected to any precipitation. Results are representative of three independent experiments.","[{'offsets': [[0, 5]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[26, 31]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[82, 85]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[179, 184]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[214, 224]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[314, 324]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[406, 409]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[444, 449]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[494, 499]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[645, 648]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[694, 699]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[712, 717]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[858, 868]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1008, 1013]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1234, 1239]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1310, 1315]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1476, 1481]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1497, 1502]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[6, 15]], 'text': ['Represses'], 'type': 'Negative_regulation', 'id': 'T19'}, {'offsets': [[32, 40]], 'text': ['Promoter'], 'type': 'Entity', 'id': 'T20'}, {'offsets': [[500, 510]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[1223, 1230]], 'text': ['amounts'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[1482, 1489]], 'text': ['binding'], 'type': 'Binding', 'id': 'T23'}, {'offsets': [[1503, 1511]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T24'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T2', 'T1', 'T20']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T23', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T17', 'T18', 'T24']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
170,PMC-2674207-19-Results,"The Inhibitory Effect of Corticosteroids on GATA-3 Nuclear Localization in Primary T Lymphocytes Ex Vivo and In Vivo
Treatment with FP ex vivo demonstrated a concentration-dependent decrease in the direct interaction between phospho-GATA-3 and importin-alpha in PBMCs from patients with asthma (Figure 6A and 6B), which was significantly inhibited at 10-12 M FP (p<0.001, ANOVA and Newman-Keuls test) and completely attenuated by 10-8 M FP (p<0.001, ANOVA and Newman-Keuls test).
Our previous T cell line studies indicated that 10-12 M FP suppresses IL-4 and -5 gene expression and attenuated the interaction of GATA-3 with importin-alpha (see Figures 1D and 2). This concentration is close to peak plasma levels obtained from asthmatic patients treated with inhaled FP (500 microg) [27]. Inhaled FP (500 microg) treatment of seven steroid-naive asthma patients significantly reduced GATA-3-importin-alpha interaction in vivo in a time-dependent manner. This produced a >90% decrease in GATA-3-importin-alpha association at 2 h (median [95% CI], 13,494 [6,828-17,829] versus 879 [597-1,165]; p<0.05 Friedman's analysis). However, this did not reach significance using Wilcoxon's post-test analysis (W = 6.00) probably due to low numbers of participants. Similar results were observed when GATA-3-importin-alpha association was measured (Figure 6C and 6D). The lower dose of FP (100 microg) was not effective. The attenuated interaction of GATA-3 did not result from the defective recycling of importin-alpha, as a significant decrease in the abundance of importin-alpha in the cytoplasmic pool was not detected (Figure 6E).
We further examined whether inhaled FP could affect cellular localization of GATA-3 in peripheral blood T cells. Treatment with inhaled FP (500 microg) for 2 h significantly increased GR nuclear translocation (Figure 7A) and concomitantly decreased the number of nuclear GATA-3 immunoreactive peripheral blood T cells (37%+/-4.2% versus 58.2%+/-4.95%, p = 0.016, W = 28.0, Wilcoxon's rank test) compared with placebo as measured by immunocytochemistry (Figure 7A and 7B). This was confirmed by Western blotting, which also indicated that this effect was both time- and dose-dependent (Figure 7C and 7D). Thus, inhaled FP (500 microg) induced significant loss in nuclear GATA-3 at 2 h (median [95% CI], 0.40 [0.27-0.53] versus 0.14 [0.11-0.19], p<0.05, W = 21.00, Wilcoxon's rank test) (Figure 7C) and cytoplasmic GATA-3 levels were enhanced by inhaled FP in a dose-dependent manner (median [95% CI], 0.0032 [0.0026-0.0039] versus 0.658 [0.592-0.720], p<0.05, W = -21.00, Wilcoxon's rank test) (Figure 7D). In addition, FP (500 microg) inhibited p38 MAPK phosphorylation in primary T cells in vivo at 2 h in samples from two patients (Figure 7E).
Taken together, our data suggest that inhaled FP reduces nuclear localization of GATA-3 in vivo by acutely inhibiting phospho-GATA-3-importin association. This effect may be direct, through competition for importin-alpha or associated molecules, or secondary to an effect on p38 MAPK-mediated GATA-3 phosphorylation via rapid induction of MKP-1. The combination of these two interacting effects can result in complete suppression of GATA-3 nuclear import and thus Th2 cytokine gene expression.","[{'offsets': [[44, 50]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[233, 239]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[550, 554]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[559, 561]], 'text': ['-5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[612, 618]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[884, 890]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[987, 993]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1289, 1295]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1439, 1445]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1701, 1707]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1808, 1810]], 'text': ['GR'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1895, 1901]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2294, 2300]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2437, 2443]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2851, 2857]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2896, 2902]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3063, 3069]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3109, 3114]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3203, 3209]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[4, 14]], 'text': ['Inhibitory'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[51, 58]], 'text': ['Nuclear'], 'type': 'Entity', 'id': 'T21'}, {'offsets': [[59, 71]], 'text': ['Localization'], 'type': 'Localization', 'id': 'T22'}, {'offsets': [[172, 181]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T23'}, {'offsets': [[182, 190]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T24'}, {'offsets': [[205, 216]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T25'}, {'offsets': [[225, 232]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T26'}, {'offsets': [[338, 347]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[416, 426]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[539, 549]], 'text': ['suppresses'], 'type': 'Negative_regulation', 'id': 'T29'}, {'offsets': [[567, 577]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T30'}, {'offsets': [[582, 592]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T31'}, {'offsets': [[597, 608]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T32'}, {'offsets': [[876, 883]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[906, 917]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T34'}, {'offsets': [[936, 945]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T35'}, {'offsets': [[959, 967]], 'text': ['produced'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[975, 983]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[1009, 1020]], 'text': ['association'], 'type': 'Binding', 'id': 'T38'}, {'offsets': [[1311, 1322]], 'text': ['association'], 'type': 'Binding', 'id': 'T39'}, {'offsets': [[1413, 1423]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T40'}, {'offsets': [[1424, 1435]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T41'}, {'offsets': [[1669, 1675]], 'text': ['affect'], 'type': 'Regulation', 'id': 'T42'}, {'offsets': [[1685, 1697]], 'text': ['localization'], 'type': 'Localization', 'id': 'T43'}, {'offsets': [[1798, 1807]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T44'}, {'offsets': [[1811, 1818]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T45'}, {'offsets': [[1819, 1832]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T46'}, {'offsets': [[2258, 2265]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[2278, 2282]], 'text': ['loss'], 'type': 'Localization', 'id': 'T48'}, {'offsets': [[2286, 2293]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[2425, 2436]], 'text': ['cytoplasmic'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[2444, 2450]], 'text': ['levels'], 'type': 'Localization', 'id': 'T51'}, {'offsets': [[2456, 2464]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T52'}, {'offsets': [[2489, 2498]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T53'}, {'offsets': [[2819, 2826]], 'text': ['reduces'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[2827, 2834]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[2835, 2847]], 'text': ['localization'], 'type': 'Localization', 'id': 'T56'}, {'offsets': [[2877, 2887]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T57'}, {'offsets': [[2912, 2923]], 'text': ['association'], 'type': 'Binding', 'id': 'T58'}, {'offsets': [[3054, 3062]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[3070, 3085]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T60'}, {'offsets': [[3096, 3105]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[3157, 3164]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T62'}, {'offsets': [[3188, 3199]], 'text': ['suppression'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[3210, 3217]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[3218, 3224]], 'text': ['import'], 'type': 'Localization', 'id': 'T65'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T22', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T21']}}, {'trigger': 'T23', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T24', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T25', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T26', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T27', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T28', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T29', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T30', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T29', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T30', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T31', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T32', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T33', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T34', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T35', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T36', 'id': 'E18', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T37', 'id': 'E19', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T38', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T39', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T40', 'id': 'E22', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T41', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T42', 'id': 'E24', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T43', 'id': 'E25', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T44', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T46', 'id': 'E27', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T11', 'T45']}}, {'trigger': 'T47', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T48', 'id': 'E29', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T13', 'T49']}}, {'trigger': 'T51', 'id': 'E30', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T14', 'T50']}}, {'trigger': 'T52', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T53', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E31']}}, {'trigger': 'T54', 'id': 'E33', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E34', 'E35']}}, {'trigger': 'T56', 'id': 'E34', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T15', 'T55']}}, {'trigger': 'T57', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T58', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T59', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T60', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T61', 'id': 'E39', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T62', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T63', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T65', 'id': 'E42', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T19', 'T64']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E24', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E29', 'value': ''}]",[]
171,PMC-2806624-23-MATERIALS_AND_METHODS,"Quantification of cytokine levels.
IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, and IFN-gamma secretion was assessed using fluorescent bead-based technology. The Bio-Plex-hu Cytokine Panel, 17-Plex Group 1 was used according to the manufacturer's instructions (Bio-Rad Laboratories). Fluorescent signals were read and analyzed using the Bio-Plex 200 System (Bio-Rad Laboratories).","[{'offsets': [[35, 39]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 45]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[47, 51]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[53, 58]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[60, 65]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[67, 72]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[78, 87]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[88, 97]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T8'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T8', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T8', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T8', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}]",[]
172,PMC-2800179-06-Materials_and_Methods,"Cell Cycle Analysis
THP-1 cells in exponential growth phase were exposed to complete medium in the presence or absence of carrageenans for 24 h before being stained with propidium iodide using the DNA-Prep Coulter kit according to the manufacturer's instruction (Beckman-Coulter, Villepinte, France). Cell DNA content was then analyzed by flow cytometry using an EPICS XL2 (Beckman-Coulter). Raw data for the distribution of DNA content of 30,000 cells retrieved from the cytometer were expressed as the percentage of G0/G1 through G2/M populations. Multicycle AV software (Phoenix Flow Systems, San Diego, CA) was used to generate DNA content frequency histograms and facilitate data analysis.",[],[],[],[],[],[]
173,PMC-3062687-22-Methods,"Immunoprecipitation and immunoblot
The cells were harvested and lysed on ice by 0.4 ml of the modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF) supplemented with 1 x protease inhibitor cocktail (Roche) and 1 x phosphatase inhibitor cocktail set I (EMD Biosciences) for 30 min. The lysates were centrifuged at 10,000 x g at 4 degreesC for 10 min to remove insoluble material. After normalizing protein concentrations, lysates were subjected to immunoprecipitation by adding 10 mg/ml appropriate antibody plus 30 ml of protein G-agarose (Roche), and rotated for at least 2 h at 4degreesC. The precipitates were washed at least five times with cold lysis buffer followed by separation by SDS-PAGE under reduced and denaturing conditions. Nitrocellulose membranes were blocked in 5 % nonfat milk in 0.1 % PBS-Tween 20 (PBS-T), probed with specific antibodies as described previously6. For immunoblotting of phosphorylated proteins, gels were transferred to methanol-treated polyvinylidene chloride membranes, retreated with methanol, and dried for 30 min. Blots were blocked in 5 % bovine serum albumin in 0.1 % Tris buffered saline-Tween 20 (TBS-T), and probed with specific antibodies as described previously46. Bands were imaged by the Super Signaling system (Pierce) according to the manufacturer's instructions.","[{'offsets': [[1179, 1186]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
174,PMC-2222968-07-Results,"GATA3 Represses the FOXP3 Promoter
To investigate the molecular mechanism of GATA3-mediated repression of human FOXP3, the human FOXP3 promoter was studied and a palindromic binding site for GATA3 was discovered. The GATA-binding site is located 303 bp upstream from the transcription start site (TSS) [24]. This site is highly conserved between humans, mice, and rats (Figure S4) and may therefore play an important role in FOXP3 regulation. The functional relevance of this site was studied using a FOXP3-promoter construct [24]. We transfected human primary CD4+ T cells, in vitro differentiated Th2 cells, and Jurkat cells (Jurkat cells are known to constitutively express GATA3 [25,26]), and we measured FOXP3 promoter activity. The promoter was not active in the GATA3-expressing cell line Jurkat or in the in vitro-differentiated Th2 cells, whereas the construct was active in the CD4 cells, which express a lower amount of GATA3 (Figure 8A). Overexpression of GATA3 in naive T cells diminished luciferase activity of the FOXP3 promoter compared with the control vector (Figure 8B). To further address the function of the GATA3 site, we inserted a site-specific mutation deleting the GATA3-binding site. This mutation increased luciferase activity by 3-fold in memory CD4+CD45RO+ T cells, whereas no difference was observed in naive (GATA3-) CD4+CD45RA+ T cells, revealing a repressor activity of GATA3 on the FOXP3 promoter (Figure 8C). Furthermore GATA3 binds directly to the FOXP3 promoter as investigated by pull-down assay. HEK cells were transiently transfected with GATA3 or a control vector, and increasing amounts of lysates were incubated with oligonucleotides containing the GATA3 site of the FOXP3 promoter or a control oligonucleotide with a mutated GATA3-binding site. After the pull-down, GATA3 binding was detected by Western blot. Similarly, GATA3-expressing Th2 cells and iTreg cells were subjected to this approach. Only HEK cells overexpressing GATA3 and Th2 cells showed GATA3-binding activity (Figure 8D and 8E). These experiments demonstrated that GATA3 binds the palindromic FOXP3 promoter. To gain insights into the in vivo situation, we performed a chromatin immunoprecipitation (ChIP) using an anti-GATA3 antibody and showed that GATA3 binds to the FOXP3 promoter region in Th2 cells, but not in iTreg cells (Figure 7F). Taken together these data demonstrate that the GATA3-binding to the FOXP3 promoter is repressing FOXP3 expression.","[{'offsets': [[0, 5]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[20, 25]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[77, 82]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[112, 117]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[129, 134]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[191, 196]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[425, 430]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[501, 506]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[561, 564]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[677, 682]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[709, 714]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[769, 774]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[888, 891]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[931, 936]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[968, 973]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1029, 1034]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1275, 1278]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1279, 1285]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1341, 1346]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1349, 1352]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1353, 1359]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1404, 1409]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1417, 1422]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1457, 1462]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1485, 1490]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1580, 1585]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1711, 1716]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1811, 1816]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1866, 1871]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1972, 1977]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1999, 2004]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2078, 2083]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2106, 2111]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2233, 2238]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2264, 2269]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2283, 2288]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2402, 2407]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2423, 2428]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2452, 2457]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[6, 15]], 'text': ['Represses'], 'type': 'Negative_regulation', 'id': 'T42'}, {'offsets': [[26, 34]], 'text': ['Promoter'], 'type': 'Entity', 'id': 'T43'}, {'offsets': [[92, 102]], 'text': ['repression'], 'type': 'Negative_regulation', 'id': 'T44'}, {'offsets': [[217, 234]], 'text': ['GATA-binding site'], 'type': 'Entity', 'id': 'T45'}, {'offsets': [[308, 317]], 'text': ['This site'], 'type': 'Anaphora', 'id': 'T40'}, {'offsets': [[399, 421]], 'text': ['play an important role'], 'type': 'Regulation', 'id': 'T46'}, {'offsets': [[431, 441]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T47'}, {'offsets': [[669, 676]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[715, 723]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[775, 785]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[856, 869]], 'text': ['the construct'], 'type': 'Anaphora', 'id': 'T41'}, {'offsets': [[874, 880]], 'text': ['active'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[905, 912]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[950, 964]], 'text': ['Overexpression'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[1178, 1186]], 'text': ['deleting'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[1191, 1209]], 'text': ['GATA3-binding site'], 'type': 'Entity', 'id': 'T55'}, {'offsets': [[1382, 1391]], 'text': ['repressor'], 'type': 'Negative_regulation', 'id': 'T56'}, {'offsets': [[1423, 1431]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T57'}, {'offsets': [[1463, 1468]], 'text': ['binds'], 'type': 'Binding', 'id': 'T58'}, {'offsets': [[1491, 1499]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[1817, 1824]], 'text': ['binding'], 'type': 'Binding', 'id': 'T60'}, {'offsets': [[1872, 1882]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[1957, 1971]], 'text': ['overexpressing'], 'type': 'Gene_expression', 'id': 'T62'}, {'offsets': [[2005, 2012]], 'text': ['binding'], 'type': 'Binding', 'id': 'T63'}, {'offsets': [[2084, 2089]], 'text': ['binds'], 'type': 'Binding', 'id': 'T64'}, {'offsets': [[2112, 2120]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T65'}, {'offsets': [[2270, 2275]], 'text': ['binds'], 'type': 'Binding', 'id': 'T66'}, {'offsets': [[2289, 2304]], 'text': ['promoter region'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[2408, 2415]], 'text': ['binding'], 'type': 'Binding', 'id': 'T68'}, {'offsets': [[2441, 2451]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[2458, 2468]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T70'}]","[{'trigger': 'T42', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T2', 'T1', 'T43']}}, {'trigger': 'T44', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T4', 'T3']}}, {'trigger': 'T46', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E4', 'T5', 'T45']}}, {'trigger': 'T47', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T48', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T50', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T51', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T11', 'E8', 'T49']}}, {'trigger': 'T52', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T53', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T54', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T16', 'T55']}}, {'trigger': 'T56', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T23', 'T22', 'T57']}}, {'trigger': 'T58', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T24', 'T25', 'T59']}}, {'trigger': 'T60', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T61', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T62', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T63', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T64', 'id': 'E17', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T32', 'T33', 'T65']}}, {'trigger': 'T66', 'id': 'E18', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T35', 'T36', 'T67']}}, {'trigger': 'T68', 'id': 'E19', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T37', 'T38']}}, {'trigger': 'T69', 'id': 'E20', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E21', 'E19']}}, {'trigger': 'T70', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}]","[{'id': 'R1', 'head': {'ref_id': 'T40', 'role': 'Subject'}, 'tail': {'ref_id': 'T45', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T41', 'role': 'Subject'}, 'tail': {'ref_id': 'T49', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}]",[]
175,PMC-2674207-05-Materials_and_Methods,"Reverse Transcription PCR
Total RNA was extracted using lysis buffer (RNeasy kit; Qiagen, Crawley, UK). During RNA purification, genomic DNA was digested with RNase-free DNase (Amersham Biosciences). Next, 0.5 microg of total RNA was reversed transcribed using the avian myeloblastosis virus RT (Promega, Southampton, UK). For relative quantification, RT-PCR was carried out using cDNA probes. Primers for IL-4 were from Sigma-Genosys (Cambridge, UK). Sequences of GADPH used are as follows: forward 5'-CCACCCATGGCAAATTCCATGGC, reverse 3'-TCTAGACGGCAGGTCAGGTCCAC.","[{'offsets': [[406, 410]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
176,PMC-2222968-11-Materials_and_Methods,"Quantitative real-time PCR.
The PCR primers and probes were designed based on the sequences reported in GenBank with the Primer Express software version 1.2 (Applied Biosystems) as follows: FOXP3 forward primer 5'-GAA ACA GCA CAT TCC CAG AGT TC-3'; FOXP3 reverse primer 5'-ATG GCC CAG CGG ATG AG-3'; EF-1alpha forward primer and reverse primer as described [61]; GATA3 forward primer 5'-GCG GGC TCT ATC ACA AAA TGA-3' and rwd 5'-GCT CTC CTG GCT GCA GAC AGC-3'. The prepared cDNAs were amplified using SYBR-PCR mastermix (Biorad) according to the recommendations of the manufacturer in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems).
Quantitative PCR of murine samples was performed with Brilliant SYBR Green QPCR master mix (Stratagene) and the following primers: Ubiquitin C, 5'- AGG TCA AAC AGG AAG ACA GAC GTA-3' and 5'-TCACACCCAAGAACAAGCACA-3'; Smad-7, 5'-GAA ACC GGG GGA ACG AAT TAT-3' and 5'-CGC GAG TCT TCT CCT CCC A-3'; TGF-ss1, 5'-TGA CGT CAC TGG AGT TGT ACG G-3' and 5'-GGT TCA TGT CAT GGA TGG TGC-3'. Primer pairs were evaluated for integrity by analysis of the amplification plot, dissociation curves, and efficiency of PCR amplification. PCR conditions were 10 min at 95 degreesC, followed by 40 cycles of 15 s at 95 degreesC and 60 degreesC for 1 min using an 7300 real-time PCR system (Applied Biosystems). PCR amplification of the housekeeping gene encoding ubiquitin C was performed during each run for each sample to allow normalization between samples. Relative quantification and calculation of the range of confidence was performed using the comparative deltadeltaCT method.","[{'offsets': [[190, 195]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[249, 254]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[300, 309]], 'text': ['EF-1alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[363, 368]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[782, 793]], 'text': ['Ubiquitin C'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[867, 873]], 'text': ['Smad-7'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[946, 953]], 'text': ['TGF-ss1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1392, 1403]], 'text': ['ubiquitin C'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
177,PMC-3062687-13-Methods,"Plasmid Constructs
The Flag-IKKbeta (SSEE), Flag-IKKbeta (SSAA), and HA-IkappaBalpha (SSAA) constructs were provided by C. Wu (NCI, Bethesda) and U. Siebenlist (NIAID, Bethesda), respectively. The HA-IkappaBalpha and IKKbeta (K44A)-Flag plasmids were purchased from Addgene44, 45. The Flag-RPS3, GST-RPS3, HA-RPS3, VN-HA, NleH1-HA plasmids were described previously6, 9. The point mutants of RPS3 were generated by site-directed mutagenesis using the Quick Change Kit (Stratagene) with primers forward 5'-CTGCCTGACCACGTGGCCATTGTGGAACCCAAA-3' and reverse 5'-TTTGGGTTCCACAATGGCCACGTGGTCAGGCAG-3' for S209A. All mutants were verified by DNA sequencing.","[{'offsets': [[23, 42]], 'text': ['Flag-IKKbeta (SSEE)'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[44, 63]], 'text': ['Flag-IKKbeta (SSAA)'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[69, 91]], 'text': ['HA-IkappaBalpha (SSAA)'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[197, 212]], 'text': ['HA-IkappaBalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[217, 236]], 'text': ['IKKbeta (K44A)-Flag'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[285, 294]], 'text': ['Flag-RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[296, 304]], 'text': ['GST-RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[306, 313]], 'text': ['HA-RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[315, 320]], 'text': ['VN-HA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[322, 330]], 'text': ['NleH1-HA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[392, 396]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
178,PMC-3062687-06-Results,"IKKbeta phosphorylates RPS3 at serine 209
Although originally defined as the kinase that phosphorylates IkappaB19, IKKbeta also phosphorylates unrelated substrates including 14-3-3beta and Bcl10, which lack the IKK consensus motif (DpSGYXpS/T)28. We therefore hypothesized that IKKbeta could directly phosphorylate RPS3. By in vitro kinase assays using recombinant IKK and RPS3 proteins, we observed strong incorporation of 32P in autophosphorylatd IKKalpha and IKKbeta (Fig. 4a, lanes 2-7) as well as phosporylated GST-IkappaBalpha (1-54) (Supplementary Fig. 4), but not the GST protein alone (Fig. 4a, lanes 3 and 6), when either IKKalpha or IKKbeta was used. We discovered that GST-RPS3 could be phosphorylated by IKKbeta, but not IKKalpha, in vitro (Fig. 4a, compare lanes 4 and 7).
To identify the RPS3 amino acid residue(s) phosphorylated by IKKbeta, we performed liquid chromatography-tandem mass spectrometry analyses using in vitro phosphorylated RPS3. The results indicated that IKKbeta phosphorylated S209, located in the RPS3 C-terminus (Fig. 4b). RPS3 amino acid sequence alignment revealed that S209 is conserved in many species throughout phylogeny with the exception of Caenorhabditis elegans and Schizosaccharomyces pombe, two organisms that do not possess the NF-kappaB signal pathway (Supplementary Fig. 5).
To verify biochemically that S209 is an IKKbeta substrate, we performed 32P-labeling in vitro kinase assays with recombinant wild-type or S209A mutant RPS3 proteins. Compared with the wild-type protein, the S209A mutation reduced IKKbeta-mediated RPS3 phosphorylation (Fig. 4c). There might be alternative phosphorylation site(s) under these conditions given modest residual phosphorylated RPS3 (Fig. 4c). RPS3 S209 does not fall within a conventional IKK recognition motif, but rather resides in a sequence motif (XXXpS/TXXE), potentially recognized by casein kinase II (CK2). Although IKKbeta kinase can display a CK2-like phosphorylation specificity29, no CK2 protein was detectable in our recombinant IKK proteins (Supplementary Fig. 6). Thus, RPS3 S209 phosphorylation was due to the alternate specificity of the IKKbeta kinase rather than any trace amount of CK2 bound to IKKs. To determine whether S209 is the critical site at which IKKbeta phosphorylates RPS3 in living cells, we transfected the wild-type or S209A mutant Flag-RPS3 alone, or together with IKKbeta into cells. Indeed, we observed that overexpressing IKKbeta enhanced Flag-RPS3 phosphorylation, but phosphorylation was effectively eliminated by alanine substitution indicating that S209 is the predominant target site for IKKbeta phosphorylation (Fig. 4d). We next generated a phospho-S209 RPS3 antibody and confirmed that endogenous RPS3 was phosphorylated at S209 in a time-dependent manner upon TNF stimulation (Fig. 4e). Thus, the RPS3 C-terminal tail potentially contains an important regulatory site.","[{'offsets': [[0, 7]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[23, 27]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[115, 122]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[174, 184]], 'text': ['14-3-3beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[189, 194]], 'text': ['Bcl10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[278, 285]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 319]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[373, 377]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[449, 457]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[462, 469]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[516, 532]], 'text': ['GST-IkappaBalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[576, 579]], 'text': ['GST'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[632, 640]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[644, 651]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[681, 689]], 'text': ['GST-RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[717, 724]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[734, 742]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[803, 807]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[848, 855]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[956, 960]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[989, 996]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1033, 1037]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1060, 1064]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1367, 1374]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1421, 1427]], 'text': ['kinase'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1478, 1482]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1557, 1564]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1574, 1578]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1717, 1721]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1733, 1737]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1914, 1921]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2075, 2079]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2145, 2152]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2267, 2274]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2290, 2294]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2357, 2366]], 'text': ['Flag-RPS3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2391, 2398]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2451, 2458]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2468, 2477]], 'text': ['Flag-RPS3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2622, 2629]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2677, 2703]], 'text': ['phospho-S209 RPS3 antibody'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2734, 2738]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2835, 2839]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[8, 22]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T45'}, {'offsets': [[31, 41]], 'text': ['serine 209'], 'type': 'Entity', 'id': 'T46'}, {'offsets': [[128, 142]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T47'}, {'offsets': [[301, 314]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T48'}, {'offsets': [[407, 427]], 'text': ['incorporation of 32P'], 'type': 'Phosphorylation', 'id': 'T49'}, {'offsets': [[431, 448]], 'text': ['autophosphorylatd'], 'type': 'Phosphorylation', 'id': 'T50'}, {'offsets': [[502, 515]], 'text': ['phosporylated'], 'type': 'Phosphorylation', 'id': 'T51'}, {'offsets': [[699, 713]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T52'}, {'offsets': [[808, 829]], 'text': ['amino acid residue(s)'], 'type': 'Entity', 'id': 'T53'}, {'offsets': [[830, 844]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T54'}, {'offsets': [[941, 955]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T55'}, {'offsets': [[997, 1011]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T56'}, {'offsets': [[1012, 1016]], 'text': ['S209'], 'type': 'Entity', 'id': 'T57'}, {'offsets': [[1465, 1470]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[1471, 1477]], 'text': ['mutant'], 'type': 'Regulation', 'id': 'T59'}, {'offsets': [[1534, 1539]], 'text': ['S209A'], 'type': 'Entity', 'id': 'T60'}, {'offsets': [[1540, 1548]], 'text': ['mutation'], 'type': 'Regulation', 'id': 'T61'}, {'offsets': [[1549, 1556]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[1565, 1573]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[1579, 1594]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T64'}, {'offsets': [[1702, 1716]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T65'}, {'offsets': [[1826, 1840]], 'text': ['sequence motif'], 'type': 'Entity', 'id': 'T66'}, {'offsets': [[1867, 1877]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T67'}, {'offsets': [[2080, 2084]], 'text': ['S209'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[2085, 2100]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T69'}, {'offsets': [[2105, 2108]], 'text': ['due'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[2232, 2236]], 'text': ['S209'], 'type': 'Entity', 'id': 'T71'}, {'offsets': [[2244, 2252]], 'text': ['critical'], 'type': 'Positive_regulation', 'id': 'T72'}, {'offsets': [[2275, 2289]], 'text': ['phosphorylates'], 'type': 'Phosphorylation', 'id': 'T73'}, {'offsets': [[2315, 2326]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[2436, 2450]], 'text': ['overexpressing'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[2459, 2467]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[2478, 2493]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T77'}, {'offsets': [[2499, 2514]], 'text': ['phosphorylation'], 'type': 'Anaphora', 'id': 'T44'}, {'offsets': [[2531, 2541]], 'text': ['eliminated'], 'type': 'Negative_regulation', 'id': 'T78'}, {'offsets': [[2545, 2565]], 'text': ['alanine substitution'], 'type': 'Regulation', 'id': 'T79'}, {'offsets': [[2582, 2586]], 'text': ['S209'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[2630, 2645]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T81'}, {'offsets': [[2743, 2757]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T82'}, {'offsets': [[2761, 2765]], 'text': ['S209'], 'type': 'Entity', 'id': 'T83'}, {'offsets': [[2776, 2785]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T84'}, {'offsets': [[2793, 2797]], 'text': ['upon'], 'type': 'Positive_regulation', 'id': 'T85'}]","[{'trigger': 'T45', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T2', 'T1', 'T46']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T4', 'T3']}}, {'trigger': 'T47', 'id': 'E3', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T5', 'T3']}}, {'trigger': 'T48', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'T6']}}, {'trigger': 'T49', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T49', 'id': 'E6', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T50', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T50', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T51', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T51', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T52', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T15', 'T16']}}, {'trigger': 'T52', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T15', 'T17']}}, {'trigger': 'T54', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T18', 'T19', 'T53']}}, {'trigger': 'T55', 'id': 'E14', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T56', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T22', 'T21', 'T57']}}, {'trigger': 'T59', 'id': 'E16', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T26', 'T58']}}, {'trigger': 'T61', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T60']}}, {'trigger': 'T62', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E17']}}, {'trigger': 'T63', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T27']}}, {'trigger': 'T64', 'id': 'E20', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T65', 'id': 'E21', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T67', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T30', 'T66']}}, {'trigger': 'T69', 'id': 'E23', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T32', 'T68']}}, {'trigger': 'T70', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'T33']}}, {'trigger': 'T72', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E26', 'T35', 'T71']}}, {'trigger': 'T73', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T35', 'T34']}}, {'trigger': 'T74', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T36']}}, {'trigger': 'T74', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T75', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T76', 'id': 'E30', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E29']}}, {'trigger': 'T77', 'id': 'E31', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T78', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'E33']}}, {'trigger': 'T79', 'id': 'E33', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T39', 'T80']}}, {'trigger': 'T81', 'id': 'E34', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T39', 'T80']}}, {'trigger': 'T82', 'id': 'E35', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T42', 'T83']}}, {'trigger': 'T84', 'id': 'E36', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E35']}}, {'trigger': 'T85', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}]","[{'id': 'R1', 'head': {'ref_id': 'T44', 'role': 'Subject'}, 'tail': {'ref_id': 'T77', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E9', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E24', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E25', 'value': ''}]",[]
179,PMC-2674207-27-Caption-Figure_7,"Inhaled fluticasone propionate impairs GATA-3 nuclear localization in PBMCs.
(A) Representative immunocytochemistry of showing the effect of inhaled FP (500 microg) on GR and GATA-3 nuclear localisation. (B) Nuclear GATA-3 immunoreactivity in PBMCs from seven steroid-naive asthma patients 2 h following inhaled FP treatment (100 or 500 microg via spacer). The median and interquartile ranges for each treatment are presented as a box-and-whiskers plot (n = 7); * p<0.05 Wilcoxon's rank test compared with placebo. (C) Immunoblotting analyses of PBMCs demonstrated a time-dependent decrease in nuclear expression of GATA-3, and increased cytoplasmic GATA-3 expression after inhalation of FP. (D) Immunoblotting analyses of PBMCs demonstrated a dose-dependent decrease in nuclear expression of GATA-3, and increased cytoplasmic GATA-3 expression 2 h after inhalation of FP. Histone H1 and MEK-1 immunoblotting confirmed equivalent total protein loading for the nuclear and cytoplasmic fractions respectively. Quantification of the densitometry data in (C) and (D) is shown as a box-and-whiskers plot of results from n = 6 participants for which data were available. *p<0.05 compared to control. (E) Western blot analyses of PBMCs demonstrated a time-dependent decrease in dual phosphorylation (threonine-180 and tyrosine-182) of p38 MAPK after inhalation of FP (500 microg). The results shown in (E) are representative of samples from two participants.","[{'offsets': [[39, 45]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[168, 170]], 'text': ['GR'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[175, 181]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[216, 222]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[616, 622]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[650, 656]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[793, 799]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[827, 833]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[888, 893]], 'text': ['MEK-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[31, 38]], 'text': ['impairs'], 'type': 'Negative_regulation', 'id': 'T10'}, {'offsets': [[46, 53]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T11'}, {'offsets': [[54, 66]], 'text': ['localization'], 'type': 'Localization', 'id': 'T12'}, {'offsets': [[182, 189]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[190, 202]], 'text': ['localisation'], 'type': 'Localization', 'id': 'T14'}, {'offsets': [[572, 581]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T15'}, {'offsets': [[582, 590]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T16'}, {'offsets': [[594, 601]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T17'}, {'offsets': [[602, 612]], 'text': ['expression'], 'type': 'Localization', 'id': 'T18'}, {'offsets': [[628, 637]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[638, 649]], 'text': ['cytoplasmic'], 'type': 'Entity', 'id': 'T20'}, {'offsets': [[657, 667]], 'text': ['expression'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[759, 767]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[771, 778]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T23'}, {'offsets': [[779, 789]], 'text': ['expression'], 'type': 'Localization', 'id': 'T24'}, {'offsets': [[815, 826]], 'text': ['cytoplasmic'], 'type': 'Entity', 'id': 'T25'}, {'offsets': [[834, 844]], 'text': ['expression'], 'type': 'Localization', 'id': 'T26'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T1', 'T11']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T13']}}, {'trigger': 'T14', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T3', 'T13']}}, {'trigger': 'T15', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T16', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T19', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T18', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T17']}}, {'trigger': 'T21', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T20']}}, {'trigger': 'T22', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T24', 'id': 'E12', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T23']}}, {'trigger': 'T26', 'id': 'E13', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T25']}}]",[],[],[],[]
180,PMC-2806624-29-Caption-Figure_5,"Diminished capacity of Cbfb-deficient CD4-cre mice T cells in the generation of Foxp3+ CD4+ T cells. (A) FACS-purified naive CD4+ CD8- T cells from CbfbF/F CD4-cre and control CbfbF/+ CD4-cre mice were activated in vitro with anti-CD3/28 mAb, 50 U/ml IL-2, +/- 10 nM retinoic acid (RA), and increasing concentrations of TGF-beta. After 3 d in culture, the cells were restimulated with PMA + ionomycin, and then analyzed for intracellular Foxp3 and IFN-gamma expression. One of five experiments is shown. (B) Naive CD4+ T cells from Cbfb CD4-cre or control mice (harboring a Foxp3-IRES-GFP allele) were adoptively transferred into Rag-deficient mice (5 x 106 cells per transfer). 6 wk later, TCRbeta+CD4+ cells from the spleen, mesenteric lymph node (MLN), and lamina propria of the small intestine (LP) were analyzed for Foxp3-GFP expression. Results from one of four CbfbF/F CD4-cre and control CbfbF/+ CD4-cre mice with same findings are shown. The data from four sets of mice is shown in C. Statistical analysis was performed with Mann-Whitney U test. *, P < 0.05 between groups.","[{'offsets': [[23, 27]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[38, 45]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[80, 85]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[87, 90]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[125, 128]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[130, 133]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[148, 152]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[156, 163]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[176, 180]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[184, 191]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[231, 234]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[235, 237]], 'text': ['28'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[251, 255]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[320, 328]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[438, 443]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[448, 457]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[514, 517]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[532, 536]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[537, 544]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[574, 579]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[585, 588]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[630, 633]], 'text': ['Rag'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[691, 698]], 'text': ['TCRbeta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[699, 702]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[821, 830]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[868, 872]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[876, 883]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[896, 900]], 'text': ['Cbfb'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[904, 911]], 'text': ['CD4-cre'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[28, 37]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T30'}, {'offsets': [[458, 468]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T31'}, {'offsets': [[634, 643]], 'text': ['deficient'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[831, 841]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T33'}]","[{'trigger': 'T30', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T31', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T31', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T32', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T33', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
181,PMC-1134658-17-Methods,"Determination of cell death
Cell death was measured by vital dye exclusion test by staining cells with 5 mug/ml propidium iodide ([PI]; Calbiochem Corp.; La Jolla, CA; 5 mg/ml) for one minute on ice. At least 1,000 cells per sample were run on a BD FACSCalibur flow cytometer.",[],[],[],[],[],[]
182,PMC-1134658-08-Discussion,"Recent studies have demonstrated an important role for BMP superfamily members in hematopoietic stem cells, early thymocytes [6,7] and B-cell malignancies [8,11,12], but a role for BMPs in normal human B cells has previously not been reported. The present study demonstrated a significant antiproliferative effect of BMP-6 in peripheral blood CD19+ B cells. Additionally, BMP-6 induced cell death in CD27+ memory B cells as well as in a Burkitt lymphoma cell line (Ramos). Importantly, BMP-6 induced a rapid and marked increase in Smad-1/5/8 phosphorylation. Furthermore, the BMP-6 induced Smad phosphorylation was followed by a selective upregulation of Id1 mRNA and subsequent Id1 protein.
In the present study, the demonstrated antiproliferative effect of BMP-6 in anti-IgM treated B cells was significant and dose-dependent. Importantly, the anti-proliferative effect of BMP-6 could be completely neutralized by the use of a natural inhibitor, Noggin. This is in line with others, showing that Noggin can function as a BMP-6 antagonist [21,22]. In addition, the combination of soluble BMP-RIB-Fc and BMP-RII-Fc fusion proteins also neutralized the anti-proliferative effect of BMP-6 in human B cells. Interestingly, as for other TGF family members, bifunctional effects have also been demonstrated for BMPs. Whereas several of the BMPs have been shown to promote proliferation in various cell types including condrocytes [23], liver [24] and granulosa cells [25], antiproliferative effects and induction of apoptosis has been reported for B and T lineage cells. Similar effects as demonstrated for BMP-6 on human B cells in the present study, were demonstrated for BMP-2, 4, 6 and -7 in human myeloma cells [9-11]. Other members of the BMP-family have also been reported to induce apoptosis, including in mouse B lineage cells [26]. Additionally, BMP-4 inhibits thymocyte proliferation [6]. Taken together, these data suggest that the role of BMPs in the regulation of proliferation and apoptosis is highly cell type dependent.
To examine how BMP-6 exerts its functional effects in B cells, we analysed BMP receptor expression by western blot analysis. Human peripheral B cells were found to express the BMP type I receptors Act-RIA and BMP-RIB, and the type II-receptors BMP-RII and Act-RIIb, which signal after binding of several BMPs, including BMP-6 [16,13]. To further explore BMP-6 induced signalling, activation of several pathways is possible. The major signalling pathway known to date, is activation of R-Smads [13,27]. In that respect, BMPs have been shown to exert antiproliferative effects in B lineage cells via phosphorylation of R-Smad [11,28]. Furthermore, BMP-2 has been shown to induce activation of STAT3 in myeloma cells [9]. However, phosphorylation of R-Smad was not investigated in that study. BMP-2 has also been shown to induce phosphorylation of p38 [29]. Thus, phosphorylation of p38, STAT3 and Smad1/5/8 represent important BMP-signalling pathways that mediated the effects of BMPs and even cross-talk between these pathways has been reported [29,30]. In the present study, we were not able to detect BMP-6-induced changes in the phosphorylation status of STAT3 or p38 in human peripheral B cells. Instead, a rapid and marked phosphorylation of Smad1/5/8 was revealed. In a parallel study, we have found that other BMPs also induced phosphorylation of Smad1/5/8 in peripheral B cells (data not shown). We are currently pursuing microarray studies to identify the signalling pathways and target genes that are differently regulated by the various BMPs in human B cells.
Upregulation of Id1 via Smad1/5/8 phosphorylation is a known mechanism for BMP-6 signalling in other cell systems [31,32] and regulation of Id-proteins is thought to be an important mechanism for Smad-signalling [17]. In the present study, real-time RT-PCR experiments revealed a specific four-fold upregulation for Id1 in BMP-6-treated B cells, while the amount of Id2-Id4 remained unchanged. In agreement with this, western blot analysis demonstrated an upregulation of Id1 protein, while the amount of Id2 and Id3 protein levels remained unchanged. Previously, Id1 has been considered not to be expressed in later developmental stages than pro-B cells [33,34], and its constitutive expression has been reported to impair mouse B cell development [35]. Therefore, our demonstration of the time-dependent upregulation of Id1 mRNA and protein in mature normal human B cells is of particular interest. In that respect, it is noteworthy that TGF-beta signalling in early and mature B cells induces both Id2 and Id3 expression [36,37], but not Id1 (data not shown). Interestingly, these results show that various members of the TGF-beta family regulate Id proteins differently. Id2 and Id3 are considered to be the Id proteins mainly expressed in mature B cells [38]. The present study also found Id2 and Id3 protein in B cells to be more highly expressed than Id1 in resting B cells. However, BMP-6 did not induce significant changes in the protein expression of Id2 and Id3. It is believed that Id proteins block differentiation and promote proliferation in various cell types [39,33]. Id proteins act as dominant-negative inhibitors of E-proteins and Pax5 function by forming dimers with these proteins, making them unable to bind DNA. It has been proposed that the balance among E-proteins, Pax5 and Id proteins might have an important role in activated B cells [38]. In that respect, E-proteins have been implicated in both the promotion and inhibition of cell survival and growth at different points in lymphocyte development [40]. The antiproliferative and death inducing effect of BMP-6 in B cells with concomitant upregulation of Id1 protein is therefore in line with the view that Id proteins are required for the induction of growth arrest and apoptosis in B-lymphocyte progenitors by TGF-beta [40].
Furthermore, Id proteins are known as important parts of signalling pathways involved in development, cell cycle and tumorigenesis [32]. It is well established that various members of the Id family are overexpressed in a range of human tumours and generally, Id1 appears to be the family member most widely overexpressed in a variety of human malignancies [41], including multiple myeloma [42,32]. Additionally, our findings that BMP-6 activates intracellular signalling pathways in human B cells might be of potential pathophysiological significance in lymphoma and inflammation. High BMP-6 mRNA expression in DLBCL has been shown to correlate to unfavourable outcome [12]. In this respect, it is of interest that targeted expression of Id1 to B-lymphocytes resulted in aberrant B cell development, massive apoptosis, and subsequent development of B cell lymphomas [35]. Moreover, BMP-6 has been suggested to play a role in rheumatoid arthritis (RA) [43,44] and elevated levels of Id1 and Id3 have been found in the synovia of RA-patients [45]. Altogether, these results point to an important role for Id proteins in the regulation of normal B cell homeostasis and in diseases, where B cells are involved. It will therefore be important to further elucidate the role of Id-1 in human B cells by selective over expression or inhibition of Id-1 gene expression.
Given the role of BMP-6 in mature human B cells demonstrated here, identification of BMP-6 producing cells in vivo with possibility of interaction with naive and memory B cells might contribute to the understanding of mature B cell biology. High BMP-6 mRNA expression in DLBCL has been detected by gene expression profiling [12]. Furthermore, production of BMP-6 transcripts in normal activated B cells was detected in the same study. Of note, an autocrine BMP-6 loop has been reported by others in chondrocytes and in the ovarium [46,19,18]. Therefore, we wanted to explore the possibility for an autocrine BMP-6 loop in human B cells. We analysed the expression BMP-6 mRNA in peripheral blood B cells by real-time PCR, and report here the upregulation of endogenous BMP-6 transcripts after stimulation with FCS, human AB-serum and, most importantly, anti-IgM. However, our attempts to study BMP-6 protein levels were unsuccessful due to problems with unspecific binding of the anti-BMP-6 antibodies tested, and lack of specific staining in control cells known to express BMP-6 mRNA. In contrast, the recombinant protein was readily detected. In that respect, few investigators have detected BMP-6 protein in humans, especially in non-pathogenic tissue. The possibility of BMP-6 production in human B-cells is in line with a recent work that reported the production of BMP-6 in mouse B cells, infiltrating the bone marrow of mice with inflammatory arthritis [43]. In this study, a role for BMPs in the inflammatoric process of arthritis was suggested. The upregulation of the BMP-6-transcripts after IgM-crosslinking is of pathophysiologic interest [12]. A loss of TGF-beta-responsiveness has been suggested to be a critical contribution to malignant transformation [47,48] and similar oncogenic mechanisms have been postulated for BMPs. Lines of evidence suggest [49] that at early stages of carcinogenesis, BMP-6 is not a tumour promoter, but suppresses benign and malignant tumour outgrowth. These findings are in good agreement with previous findings for other TGF-beta family members, including TGF-beta1 and BMP-4 [50], indicating that cellular context of the BMP target cell might define the various observed effects. In contrast to the upregulation of BMP-6 transcript in B cells, we were not able to detect BMP-6 transcripts in human peripheral blood CD4+ or CD8+ T cells (resting or stimulated with anti-CD3 and anti-CD28; data not shown), consistent with the findings in T cell lines [20] and T cells in mice [43]. Other potential BMP-6 sources for mature B cells in vivo might be other cells of the immune system or tissue with contact to the hematopoietic system. One well recognized source for BMP-6 production is the human bone and bone marrow stroma [51,8]. Furthermore, it is noteworthy that human umbilical vein endothelial cells (HUVEC) highly express BMP-6 mRNA [52], and vascular endothelium has been reported to produce BMP-6 [53]. These studies might imply a role for BMP-6 in transendothelial migration of B cells. BMP-6 mRNA has been demonstrated in murine macrophage cell lines, but not in humans [54]. In accordance with these findings, other human cell lines of neutrophil and monocytic origin have been described to be negative for the BMP-6 transcript [20]. To our knowledge, there is currently no report about BMP-6 production of human dendritic cells.","[{'offsets': [[317, 322]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[343, 347]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[372, 377]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[400, 404]], 'text': ['CD27'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[486, 491]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[531, 537]], 'text': ['Smad-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[538, 539]], 'text': ['5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[540, 541]], 'text': ['8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[576, 581]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[590, 594]], 'text': ['Smad'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[655, 658]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[679, 682]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[759, 764]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[875, 880]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[948, 954]], 'text': ['Noggin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[998, 1004]], 'text': ['Noggin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1023, 1028]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1089, 1096]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1104, 1111]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1181, 1186]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1602, 1607]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1669, 1674]], 'text': ['BMP-2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1676, 1677]], 'text': ['4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1679, 1680]], 'text': ['6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1685, 1687]], 'text': ['-7'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1851, 1856]], 'text': ['BMP-4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2047, 2052]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2229, 2236]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2241, 2248]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2276, 2283]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2288, 2296]], 'text': ['Act-RIIb'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2352, 2357]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2386, 2391]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2678, 2683]], 'text': ['BMP-2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2723, 2728]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2822, 2827]], 'text': ['BMP-2'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2917, 2922]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2927, 2932]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2933, 2934]], 'text': ['5'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2935, 2936]], 'text': ['8'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3134, 3139]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3189, 3194]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3278, 3283]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3284, 3285]], 'text': ['5'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3286, 3287]], 'text': ['8'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3385, 3390]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3391, 3392]], 'text': ['5'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3393, 3394]], 'text': ['8'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3618, 3621]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3626, 3631]], 'text': ['Smad1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3632, 3633]], 'text': ['5'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3634, 3635]], 'text': ['8'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3677, 3682]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3918, 3921]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3925, 3930]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3968, 3971]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3972, 3975]], 'text': ['Id4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4074, 4077]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4107, 4110]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4115, 4118]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4166, 4169]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4424, 4427]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4542, 4550]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4603, 4606]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4611, 4614]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4643, 4646]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4727, 4735]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4777, 4780]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4785, 4788]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4896, 4899]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4904, 4907]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4960, 4963]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4993, 4998]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5063, 5066]], 'text': ['Id2'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5071, 5074]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5253, 5257]], 'text': ['Pax5'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5394, 5398]], 'text': ['Pax5'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[5688, 5693]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[5738, 5741]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[5895, 5903]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[6169, 6172]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[6340, 6345]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[6496, 6501]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[6648, 6651]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[6792, 6797]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[6892, 6895]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[6900, 6903]], 'text': ['Id3'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[7181, 7185]], 'text': ['Id-1'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[7249, 7253]], 'text': ['Id-1'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[7289, 7294]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[7356, 7361]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[7517, 7522]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[7628, 7633]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[7728, 7733]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[7879, 7884]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[7935, 7940]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[8039, 8044]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[8164, 8169]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[8344, 8349]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[8464, 8469]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[8545, 8550]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[8641, 8646]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[8848, 8853]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[8937, 8945]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[9181, 9186]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[9337, 9345]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[9372, 9381]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[9386, 9391]], 'text': ['BMP-4'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[9532, 9537]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[9588, 9593]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[9632, 9635]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[9640, 9643]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[9686, 9689]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[9699, 9703]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[9814, 9819]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[9980, 9985]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[10143, 10148]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[10214, 10219]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[10263, 10268]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[10311, 10316]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[10537, 10542]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[10613, 10618]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[492, 499]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T132'}, {'offsets': [[519, 527]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T133'}, {'offsets': [[542, 557]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T134'}, {'offsets': [[582, 589]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T135'}, {'offsets': [[595, 610]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T136'}, {'offsets': [[615, 623]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T137'}, {'offsets': [[639, 651]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T138'}, {'offsets': [[1029, 1039]], 'text': ['antagonist'], 'type': 'Negative_regulation', 'id': 'T139'}, {'offsets': [[2196, 2203]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T140'}, {'offsets': [[2204, 2228]], 'text': ['the BMP type I receptors'], 'type': 'Anaphora', 'id': 'T123'}, {'offsets': [[2254, 2275]], 'text': ['the type II-receptors'], 'type': 'Anaphora', 'id': 'T124'}, {'offsets': [[2298, 2303]], 'text': ['which'], 'type': 'Anaphora', 'id': 'T125'}, {'offsets': [[2317, 2324]], 'text': ['binding'], 'type': 'Binding', 'id': 'T141'}, {'offsets': [[2328, 2340]], 'text': ['several BMPs'], 'type': 'Anaphora', 'id': 'T126'}, {'offsets': [[2702, 2708]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T142'}, {'offsets': [[2709, 2719]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T143'}, {'offsets': [[2893, 2908]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T144'}, {'offsets': [[3140, 3147]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T145'}, {'offsets': [[3148, 3155]], 'text': ['changes'], 'type': 'Regulation', 'id': 'T146'}, {'offsets': [[3163, 3178]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T147'}, {'offsets': [[3259, 3274]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T148'}, {'offsets': [[3358, 3365]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T149'}, {'offsets': [[3366, 3381]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T150'}, {'offsets': [[3602, 3614]], 'text': ['Upregulation'], 'type': 'Positive_regulation', 'id': 'T151'}, {'offsets': [[3636, 3651]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T152'}, {'offsets': [[3663, 3672]], 'text': ['mechanism'], 'type': 'Regulation', 'id': 'T153'}, {'offsets': [[3901, 3913]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T154'}, {'offsets': [[3958, 3964]], 'text': ['amount'], 'type': 'Gene_expression', 'id': 'T155'}, {'offsets': [[3976, 3994]], 'text': ['remained unchanged'], 'type': 'Positive_regulation', 'id': 'T156'}, {'offsets': [[4058, 4070]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T157'}, {'offsets': [[4097, 4103]], 'text': ['amount'], 'type': 'Gene_expression', 'id': 'T158'}, {'offsets': [[4134, 4152]], 'text': ['remained unchanged'], 'type': 'Positive_regulation', 'id': 'T159'}, {'offsets': [[4200, 4209]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T160'}, {'offsets': [[4270, 4273]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T127'}, {'offsets': [[4287, 4297]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T161'}, {'offsets': [[4408, 4420]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T162'}, {'offsets': [[4590, 4597]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T163'}, {'offsets': [[4615, 4625]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T164'}, {'offsets': [[4810, 4825]], 'text': ['the Id proteins'], 'type': 'Anaphora', 'id': 'T128'}, {'offsets': [[4833, 4842]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T165'}, {'offsets': [[4945, 4954]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T166'}, {'offsets': [[5007, 5013]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T167'}, {'offsets': [[5026, 5033]], 'text': ['changes'], 'type': 'Regulation', 'id': 'T168'}, {'offsets': [[5049, 5059]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T169'}, {'offsets': [[5224, 5234]], 'text': ['inhibitors'], 'type': 'Negative_regulation', 'id': 'T170'}, {'offsets': [[5270, 5284]], 'text': ['forming dimers'], 'type': 'Binding', 'id': 'T171'}, {'offsets': [[5290, 5304]], 'text': ['these proteins'], 'type': 'Anaphora', 'id': 'T129'}, {'offsets': [[5306, 5312]], 'text': ['making'], 'type': 'Positive_regulation', 'id': 'T172'}, {'offsets': [[5313, 5317]], 'text': ['them'], 'type': 'Anaphora', 'id': 'T130'}, {'offsets': [[5328, 5332]], 'text': ['bind'], 'type': 'Binding', 'id': 'T173'}, {'offsets': [[5722, 5734]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T174'}, {'offsets': [[6187, 6204]], 'text': ['the family member'], 'type': 'Anaphora', 'id': 'T131'}, {'offsets': [[6217, 6230]], 'text': ['overexpressed'], 'type': 'Positive_regulation', 'id': 'T175'}, {'offsets': [[6491, 6495]], 'text': ['High'], 'type': 'Positive_regulation', 'id': 'T176'}, {'offsets': [[6502, 6517]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T177'}, {'offsets': [[6634, 6644]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T178'}, {'offsets': [[6873, 6881]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T179'}, {'offsets': [[6882, 6888]], 'text': ['levels'], 'type': 'Gene_expression', 'id': 'T180'}, {'offsets': [[7216, 7220]], 'text': ['over'], 'type': 'Positive_regulation', 'id': 'T181'}, {'offsets': [[7221, 7231]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T182'}, {'offsets': [[7235, 7245]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T183'}, {'offsets': [[7259, 7269]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T184'}, {'offsets': [[7362, 7371]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T185'}, {'offsets': [[7512, 7516]], 'text': ['High'], 'type': 'Positive_regulation', 'id': 'T186'}, {'offsets': [[7523, 7538]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T187'}, {'offsets': [[7614, 7624]], 'text': ['production'], 'type': 'Transcription', 'id': 'T188'}, {'offsets': [[7718, 7727]], 'text': ['autocrine'], 'type': 'Regulation', 'id': 'T189'}, {'offsets': [[7869, 7878]], 'text': ['autocrine'], 'type': 'Regulation', 'id': 'T190'}, {'offsets': [[7924, 7934]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T191'}, {'offsets': [[8012, 8024]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T192'}, {'offsets': [[8336, 8343]], 'text': ['express'], 'type': 'Transcription', 'id': 'T193'}, {'offsets': [[8455, 8463]], 'text': ['detected'], 'type': 'Gene_expression', 'id': 'T194'}, {'offsets': [[8551, 8561]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T195'}, {'offsets': [[8627, 8637]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T196'}, {'offsets': [[8828, 8840]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T197'}, {'offsets': [[9516, 9528]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T198'}, {'offsets': [[9581, 9587]], 'text': ['detect'], 'type': 'Transcription', 'id': 'T199'}, {'offsets': [[9986, 9996]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T200'}, {'offsets': [[10128, 10134]], 'text': ['highly'], 'type': 'Positive_regulation', 'id': 'T201'}, {'offsets': [[10135, 10142]], 'text': ['express'], 'type': 'Transcription', 'id': 'T202'}, {'offsets': [[10206, 10213]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T203'}, {'offsets': [[10331, 10343]], 'text': ['demonstrated'], 'type': 'Transcription', 'id': 'T204'}, {'offsets': [[10520, 10528]], 'text': ['negative'], 'type': 'Transcription', 'id': 'T205'}, {'offsets': [[10619, 10629]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T206'}]","[{'trigger': 'T132', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T5']}}, {'trigger': 'T133', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T132', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T5']}}, {'trigger': 'T133', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T132', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T5']}}, {'trigger': 'T133', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T134', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T134', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T134', 'id': 'E9', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T135', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T9']}}, {'trigger': 'T136', 'id': 'E11', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T137', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E11']}}, {'trigger': 'T138', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T137', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E11']}}, {'trigger': 'T138', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T139', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T17', 'T16']}}, {'trigger': 'T140', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T140', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T140', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T140', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T141', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T28', 'T32']}}, {'trigger': 'T141', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T29', 'T32']}}, {'trigger': 'T141', 'id': 'E23', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T30', 'T32']}}, {'trigger': 'T141', 'id': 'E24', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T31', 'T32']}}, {'trigger': 'T142', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T34']}}, {'trigger': 'T143', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T144', 'id': 'E27', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T144', 'id': 'E28', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T144', 'id': 'E29', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T144', 'id': 'E30', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T145', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E32', 'T41']}}, {'trigger': 'T146', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T147', 'id': 'E33', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T148', 'id': 'E34', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T148', 'id': 'E35', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T148', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T149', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T150', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T149', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T150', 'id': 'E40', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T47']}}, {'trigger': 'T149', 'id': 'E41', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T150', 'id': 'E42', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T151', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T49', 'E44']}}, {'trigger': 'T152', 'id': 'E44', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T50']}}, {'trigger': 'T151', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T49', 'E46']}}, {'trigger': 'T152', 'id': 'E46', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T51']}}, {'trigger': 'T151', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T49', 'E48']}}, {'trigger': 'T152', 'id': 'E48', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T153', 'id': 'E49', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E43', 'T53']}}, {'trigger': 'T153', 'id': 'E50', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T53']}}, {'trigger': 'T153', 'id': 'E51', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E47', 'T53']}}, {'trigger': 'T154', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T54', 'T55']}}, {'trigger': 'T155', 'id': 'E53', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T56']}}, {'trigger': 'T155', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T57']}}, {'trigger': 'T156', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E53', 'T55']}}, {'trigger': 'T156', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'T55']}}, {'trigger': 'T157', 'id': 'E57', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T158', 'id': 'E58', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T158', 'id': 'E59', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T159', 'id': 'E60', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E58']}}, {'trigger': 'T159', 'id': 'E61', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T160', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T161', 'id': 'E63', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T162', 'id': 'E64', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T163', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E66']}}, {'trigger': 'T164', 'id': 'E66', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T163', 'id': 'E67', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E68']}}, {'trigger': 'T164', 'id': 'E68', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T65']}}, {'trigger': 'T163', 'id': 'E69', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T165', 'id': 'E70', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}, {'trigger': 'T165', 'id': 'E71', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T69']}}, {'trigger': 'T166', 'id': 'E72', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T72']}}, {'trigger': 'T166', 'id': 'E73', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T70']}}, {'trigger': 'T166', 'id': 'E74', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T71']}}, {'trigger': 'T167', 'id': 'E75', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E76', 'T73']}}, {'trigger': 'T168', 'id': 'E76', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E79']}}, {'trigger': 'T167', 'id': 'E77', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E78', 'T73']}}, {'trigger': 'T168', 'id': 'E78', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E80']}}, {'trigger': 'T169', 'id': 'E79', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T74']}}, {'trigger': 'T169', 'id': 'E80', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T75']}}, {'trigger': 'T170', 'id': 'E81', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T76', 'E82']}}, {'trigger': 'T171', 'id': 'E82', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T172', 'id': 'E83', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E84', 'E82']}}, {'trigger': 'T173', 'id': 'E84', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T76']}}, {'trigger': 'T174', 'id': 'E85', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T79', 'T78']}}, {'trigger': 'T175', 'id': 'E86', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T81']}}, {'trigger': 'T176', 'id': 'E87', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E88']}}, {'trigger': 'T177', 'id': 'E88', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T83']}}, {'trigger': 'T178', 'id': 'E89', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T84']}}, {'trigger': 'T179', 'id': 'E90', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E91']}}, {'trigger': 'T180', 'id': 'E91', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T86']}}, {'trigger': 'T179', 'id': 'E92', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E93']}}, {'trigger': 'T180', 'id': 'E93', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T87']}}, {'trigger': 'T181', 'id': 'E94', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E95']}}, {'trigger': 'T182', 'id': 'E95', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T183', 'id': 'E96', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E97']}}, {'trigger': 'T184', 'id': 'E97', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T89']}}, {'trigger': 'T185', 'id': 'E98', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T91']}}, {'trigger': 'T186', 'id': 'E99', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E100']}}, {'trigger': 'T187', 'id': 'E100', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T92']}}, {'trigger': 'T188', 'id': 'E101', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T93']}}, {'trigger': 'T189', 'id': 'E102', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T94', 'T94']}}, {'trigger': 'T190', 'id': 'E103', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T95', 'T95']}}, {'trigger': 'T191', 'id': 'E104', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T96']}}, {'trigger': 'T192', 'id': 'E105', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T97']}}, {'trigger': 'T193', 'id': 'E106', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T99']}}, {'trigger': 'T194', 'id': 'E107', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T100']}}, {'trigger': 'T195', 'id': 'E108', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T101']}}, {'trigger': 'T196', 'id': 'E109', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T102']}}, {'trigger': 'T197', 'id': 'E110', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T103']}}, {'trigger': 'T198', 'id': 'E111', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T109']}}, {'trigger': 'T199', 'id': 'E112', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T110']}}, {'trigger': 'T200', 'id': 'E113', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T116']}}, {'trigger': 'T201', 'id': 'E114', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E115']}}, {'trigger': 'T202', 'id': 'E115', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T117']}}, {'trigger': 'T203', 'id': 'E116', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T118']}}, {'trigger': 'T204', 'id': 'E117', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T120']}}, {'trigger': 'T205', 'id': 'E118', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T121']}}, {'trigger': 'T206', 'id': 'E119', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T122']}}]","[{'id': 'R1', 'head': {'ref_id': 'T123', 'role': 'Subject'}, 'tail': {'ref_id': 'T28', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T123', 'role': 'Subject'}, 'tail': {'ref_id': 'T29', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T124', 'role': 'Subject'}, 'tail': {'ref_id': 'T30', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T124', 'role': 'Subject'}, 'tail': {'ref_id': 'T31', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T125', 'role': 'Subject'}, 'tail': {'ref_id': 'T123', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T125', 'role': 'Subject'}, 'tail': {'ref_id': 'T124', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R7', 'head': {'ref_id': 'T126', 'role': 'Subject'}, 'tail': {'ref_id': 'T32', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R8', 'head': {'ref_id': 'T127', 'role': 'Subject'}, 'tail': {'ref_id': 'T61', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R9', 'head': {'ref_id': 'T128', 'role': 'Subject'}, 'tail': {'ref_id': 'T68', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R10', 'head': {'ref_id': 'T128', 'role': 'Subject'}, 'tail': {'ref_id': 'T69', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R11', 'head': {'ref_id': 'T129', 'role': 'Subject'}, 'tail': {'ref_id': 'T76', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R12', 'head': {'ref_id': 'T130', 'role': 'Subject'}, 'tail': {'ref_id': 'T76', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R13', 'head': {'ref_id': 'T131', 'role': 'Subject'}, 'tail': {'ref_id': 'T81', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E55', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E56', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E60', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E61', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E62', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E62', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E69', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E70', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E71', 'value': ''}, {'id': 'M11', 'type': 'Negation', 'ref_id': 'E75', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E77', 'value': ''}, {'id': 'M13', 'type': 'Negation', 'ref_id': 'E84', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E86', 'value': ''}, {'id': 'M15', 'type': 'Speculation', 'ref_id': 'E103', 'value': ''}, {'id': 'M16', 'type': 'Speculation', 'ref_id': 'E104', 'value': ''}, {'id': 'M17', 'type': 'Negation', 'ref_id': 'E107', 'value': ''}, {'id': 'M18', 'type': 'Speculation', 'ref_id': 'E108', 'value': ''}, {'id': 'M19', 'type': 'Negation', 'ref_id': 'E112', 'value': ''}, {'id': 'M20', 'type': 'Negation', 'ref_id': 'E117', 'value': ''}, {'id': 'M21', 'type': 'Negation', 'ref_id': 'E118', 'value': ''}, {'id': 'M22', 'type': 'Negation', 'ref_id': 'E119', 'value': ''}, {'id': 'M23', 'type': 'Speculation', 'ref_id': 'E119', 'value': ''}]",[]
183,PMC-2806624-14-MATERIALS_AND_METHODS,"Transfections and reporter gene assays.
T cells were rested in serum-free AIM-V medium overnight. 3.5 microg of the FOXP3 promoter luciferase reporter vector or a combination together with the RUNX1, RUNX3 pEGFPN1 vector, and 0.5 microg phRL-TK were added to 3 x 106 CD4+ T cells resuspended in 100 microl of Nucleofector solution (Lonza) and electroporated using the program U-15. After a 24-h culture in serum-free conditions and stimuli as indicated in the figures, luciferase activity was measured by the dual luciferase assay system (Promega) according to the manufacturer's instructions. PMA/ionomycin was used to stimulate the cells, because the transfection was only transient and the luciferase assay required a strong and fast stimulation of the cells. To evaluate the effect of overexpression of RUNX1 or RUNX3 on FOXP3 protein levels, CD4+ T cells were preactivated with 2 microg/ml phytohemagglutinin (Sigma-Aldrich) in serum-free AIM-V medium in the presence of 1 nmol/liter IL-2 (Roche) for 12 h, and then transfected with the vector pEGFPN1 containing the RUNX1 or RUNX3 fragment using the Nucleofector system (Amaxa Biosystems) and the program T-23. FOXP3 expression was evaluated by flow cytometry after 48 h of culture in AIM-V medium containing 1 nmol/liter IL-2.","[{'offsets': [[116, 121]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[131, 141]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[193, 198]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[200, 205]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[267, 270]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[469, 479]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[514, 524]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[693, 703]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[807, 812]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[816, 821]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[825, 830]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[847, 850]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[895, 913]], 'text': ['phytohemagglutinin'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[989, 993]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1072, 1077]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1081, 1086]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1167, 1172]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1278, 1282]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[779, 785]], 'text': ['effect'], 'type': 'Regulation', 'id': 'T19'}, {'offsets': [[789, 803]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[1021, 1032]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[1173, 1183]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T11', 'E2']}}, {'trigger': 'T20', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T11', 'E4']}}, {'trigger': 'T20', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T21', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T21', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T22', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}]",[]
184,PMC-3333881-04-MATERIALS_AND_METHODS,"RNA interference
Jurkat or U937 cells were transfected by electroporation using a Bio-Rad apparatus (Bio-Rad Laboratories, Hercules, CA, USA). Briefly, aliquots (5 x 106 cells) were suspended in 0.3 ml of RPMI 1640 supplemented with 20% fetal calf serum and subjected to a double electrical pulse (0.22 V, 960 microF) in the presence of annealed siRNA (200 pmol); electroporated cells were washed and cultured in complete medium. RNA interference was performed with: siRNA Tat sense, CUGCUUGUACCAAUUGCUAUU and siRNA Tat antisense, UAGCAAUUGGUACAAGCAGUU; siRNA control sense, CUGCUUGUCACA AUUGCUAUU and siRNA control antisense, UAGCAAUUGUGACAAGCAGUU. RNA interference of p65 and IkappaB-alpha was performed with SMART pool siRNA p65 and IkappaB-alpha (Dharmacon, Chicago, IL, USA).","[{'offsets': [[467, 482]], 'text': ['siRNA Tat sense'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[510, 529]], 'text': ['siRNA Tat antisense'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[670, 673]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[678, 691]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[722, 731]], 'text': ['siRNA p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[736, 749]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[654, 666]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T7'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
185,PMC-3359311-17-Materials_and_Methods,"Bacterial strains
P. aeruginosa laboratory strains PAO1 and the PAO1deltaexsA mutant were obtained from Dr. Robert Hancock. P. aeruginosa strains PAO1 and PAO1deltaexsA were grown from overnight cultures in Luria Bertani (LB) broth and LB+streptomycin (150 microg/ml) until mid-logarithmic phase. Cells were washed once in PBS and resuspended in PBS to an optical density of 0.5 (lambda = 600 nm). To prepare heat-killed bacteria, live PAO1 was resuspended in PBS to an optical density of 0.5 and heated at 60degreesC for 1 hour. For stimulations, live PAO1 was resuspended to an optical density of 0.5 in PBS and further diluted in culture medium prior to stimulation to achieve the desired multiplicity of infection. Heat-killed PAO1 was added in a volume equivalent to that used to achieve an MOI of 1 for live PAO1.",[],[],[],[],[],[]
186,PMC-2674207-14-Materials_and_Methods,"Densitometric Analysis
Densitometry of ECL immunoblots was performed using Gelworks ID intermediate software (Ultraviolet Products, Cambridgeshire, UK). Briefly, immunoblots were scanned and gates were drawn tightly around each band. Background values from each lane were subtracted to normalize each measurement. The bands were quantified using the Gelworks software. All Western blots were exposed to film for varying lengths of time, and only films generating subsaturating levels of intensity were selected for densitometric evaluation.",[],[],[],[],[],[]
187,PMC-2222968-20-Materials_and_Methods,"Flow cytometry.
For analysis of FOXP3 expression at the single-cell level, cells were first stained with the monoclonal antibody CD25 (Beckman Coulter), and after fixation and permeabilization, cells were incubated with PE-conjugated monoclonal antibody PCH101 (anti-human FOXP3; eBioscience) based on the manufacturer's recommendations and subjected to FACS (EPICS XL-MCL). For cell surface marker staining, cells were incubated for 20 min at 4degreesC in staining buffer with the following antibodies: anti-CD152-PE (CTLA-4; BD), anti-PD-1 (eBiosciences), anti-GITR (R & D Systems), anti-CD69 (Beckman Coulter), anti-CD103 (DakoCytomation), anti-CD62L (Beckman Coulter), or anti-HLA-DR (Beckman Coulter). The controls were FITC, PE, or ECD-conjugated mouse IgG1 or rat IgG2a. For staining of mouse cells, the following mAbs from BD Biosciences were used following standard techniques as described above: anti-CD3, anti-CD4, and anti-CD25. Anti-FcgammaRII/III antibody (2.4G2, ATCC) was included in all stainings to reduce nonspecific antibody binding. To isolate naive murine CD4 T cells from murine DO11.10 or DO11.10xCD2-GATA3 T cells, cells were stained with anti-CD25-FITC, anti-CD62L-PE, and anti-CD4-APC prior to sorting. Dead cells were excluded with 4'',6-Diamidino-2-phenylindole (DAPI). To analyze murine Foxp3 expression in inducible Treg cultures, cells were stained intracellularly with anti-Foxp3-PE according to manufacturer's instruction, in conjunction with anti-CD4-APC and LIVE/DEAD fixable dead cell stain kit (Invitrogen) to discriminate live cells. All monoclonal antibodies for murine cell stainings were purchased from eBioscience or BD Biosciences.","[{'offsets': [[32, 37]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[129, 133]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[273, 278]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[509, 514]], 'text': ['CD152'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[537, 541]], 'text': ['PD-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[563, 567]], 'text': ['GITR'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[590, 594]], 'text': ['CD69'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[619, 624]], 'text': ['CD103'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[648, 653]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[911, 914]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[921, 924]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[935, 939]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1078, 1081]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1121, 1124]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1125, 1130]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1169, 1173]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1185, 1190]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1204, 1207]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1317, 1322]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1407, 1412]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1482, 1485]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[38, 48]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}, {'offsets': [[1323, 1333]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T22', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T23', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}]",[]
188,PMC-2674207-22-Caption-Figure_2,"Fluticasone propionate reduces GATA-3 association with importin-alpha and GATA-3 nuclear import.
(A) Western blot analysis demonstrates a time- (at 10-8 M FP) and concentration- (at 60 min after stimulation) dependent induction of FP-activated GR interaction with importin-alpha (Imp-alpha). A positive control for GR association with importin is shown. Quantification of the densitometry data is shown below. Each bar represents mean+/-SEM of at least three independent experiments. *** p<0.001 compared to control, ### p<0.001. (B) Western blot analysis demonstrated a time- (at 10-8 M FP) and concentration- (at 60 min after stimulation) dependent induction of FP-activated GR nuclear translocation measured by IP. Quantification of the densitometry data is shown below. Each bar represents mean+/-SEM of at least three independent experiments. ***p<0.001 compared to control. (C) Western blot analysis of HuT-78 cells treated with FP and anti-CD3/CD28 co-stimulation demonstrated a concentration-dependent decrease in GATA-3-importin-alpha association at 20 min. Quantification of the densitometry data is shown below. Each bar represents mean+/-SEM of at least three independent experiments. ###p<0.001 compared to control, ***p<0.001 compared to alphaCD3/CD28-stimulated cells. (D) GFP-tagged GATA-3 was overexpressed and cells stimulated (b, c) or not (a) for 30 min with anti-CD3/CD28. The effect of 30 min pretreatment of cells with FP (10-8 M, c) is also shown. All data were analysed by ANOVA followed by Newman-Keuls post-test.","[{'offsets': [[31, 37]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[74, 80]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 246]], 'text': ['GR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[315, 317]], 'text': ['GR'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[677, 679]], 'text': ['GR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1022, 1028]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1299, 1305]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[23, 30]], 'text': ['reduces'], 'type': 'Negative_regulation', 'id': 'T8'}, {'offsets': [[38, 49]], 'text': ['association'], 'type': 'Binding', 'id': 'T9'}, {'offsets': [[81, 88]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T10'}, {'offsets': [[89, 95]], 'text': ['import'], 'type': 'Localization', 'id': 'T11'}, {'offsets': [[208, 217]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T12'}, {'offsets': [[218, 227]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T13'}, {'offsets': [[234, 243]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T14'}, {'offsets': [[247, 258]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T15'}, {'offsets': [[318, 329]], 'text': ['association'], 'type': 'Binding', 'id': 'T16'}, {'offsets': [[641, 650]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T17'}, {'offsets': [[651, 660]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[667, 676]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[680, 687]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T20'}, {'offsets': [[688, 701]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T21'}, {'offsets': [[1000, 1009]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T22'}, {'offsets': [[1010, 1018]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T23'}, {'offsets': [[1044, 1055]], 'text': ['association'], 'type': 'Binding', 'id': 'T24'}, {'offsets': [[1310, 1323]], 'text': ['overexpressed'], 'type': 'Gene_expression', 'id': 'T25'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T9', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T11', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T10']}}, {'trigger': 'T12', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T13', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T16', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T17', 'id': 'E10', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T18', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T21', 'id': 'E12', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T20']}}, {'trigger': 'T19', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T22', 'id': 'E14', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}, {'trigger': 'T23', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T24', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T25', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]",[],[],[],[]
189,PMC-1920263-14-RESULTS,"Silencing of Sp1 and Sp3 reduces A3G promoter activity
To confirm the role of Sp1 and Sp3 in regulation of A3G promoter activity, we silenced their translation via RNA interference. Functionality of the siRNAs directed against Sp1 or Sp3 was confirmed by western blot analysis: protein levels of Sp1 as well as the long and short isoforms of Sp3 were strongly reduced in the presence of 150 or 300 ng specific siRNA (Figure 7A). An unspecific control siRNA had no influence (Figure 7A). We then cotransfected the luciferase reporter plasmid containing the 180 bp A3G promoter together with 100 ng siRNA using an optimized protocol for the cotransfection of plasmid plus siRNA. This resulted in a 31-43% reduction of luciferase activity in the presence of Sp1- or Sp3-specific siRNA compared to the control siRNA. In contrast, no influence on transcriptional activity of the 150 bp fragment, which does not contain the Sp1/Sp3-binding motif, was observed. Thus, both Sp1 and Sp3 factors are mediating transcriptional activity of the A3G promoter.","[{'offsets': [[13, 16]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 24]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[33, 36]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[78, 81]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[86, 89]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[107, 110]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[227, 230]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[234, 237]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[296, 299]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[342, 345]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[513, 575]], 'text': ['luciferase reporter plasmid containing the 180 bp A3G promoter'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[755, 758]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[763, 766]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[966, 969]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[974, 977]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1032, 1035]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[0, 9]], 'text': ['Silencing'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[278, 292]], 'text': ['protein levels'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[360, 367]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[495, 508]], 'text': ['cotransfected'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[703, 712]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[716, 726]], 'text': ['luciferase'], 'type': 'Anaphora', 'id': 'T17'}, {'offsets': [[776, 781]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T23'}]","[{'trigger': 'T18', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T18', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T21', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T22', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T11', 'E9']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T11', 'E11']}}, {'trigger': 'T23', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}]","[{'id': 'R1', 'head': {'ref_id': 'T17', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}]",[],[],[]
190,PMC-3333881-20-Caption-Figure_3,"Tat relieves p65 from the IkappaB-alpha inhibition. (A) Schematic representation of wild-type and mutant Tat proteins. (B) HA-IkappaB-alpha (5 microl) was incubated in presence or absence of FLAG-Tat, FLAG-Tat T,N(23,24)A, FLAG-Tat K(50,51)A, FLAG-Tat R(49-57)A or FLAG-Tat C(22,25,27)A (10 microl) using in vitro translated proteins. Wild-type and mutant Tat proteins were immunoprecipitated with anti-FLAG antibody; immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-HA and anti-FLAG antibodies. (C) 35S-methionine-labeled p65 (5 microl) was incubated with in vitro translated HA-IkappaB-alpha (5 microl) in presence or absence of FLAG-Tat or FLAG-Tat R(49-57)A (5, 10 or 20 microl). HA-IkappaB-alpha was immunoprecipitated with anti-HA antibody; immunocomplexes were separated by 12% SDS-PAGE and analysed by western blotting with anti-HA and anti-FLAG antibodies, or autoradiography (35S-Met-p65). Densitometry values (D) of the bands were expressed as fold increase above the control (lane 1). (D) The p65 DNA binding activity was analysed by EMSA using in vitro translated proteins. 32P-labeled-NF-kappaB double-stranded oligonucleotide was incubated with p65 (0.5 microl) in presence or absence of HA-IkappaB-alpha (1 microl), FLAG-Tat or FLAG-Tat R(49-57)A (5 and 10 microl); competition of DNA binding was performed with 10 - up to 100-fold molar excess of unlabeled NF-kappaB double-stranded oligonucleotide. DNA/protein complexes were run on 6% PAGE-TBE and analysed by autoradiography. (E) p50-/-p65-/-MEFs (3 x 105 cells) were transfected with pkappaBLuc (0.5 microg) and pSV-beta-Gal (0.1 microg) with or without pRc/CMV-p65 (0.5 microg), pCMV4-HA-IkappaB-alpha (0.5 microg), p3xFLAG-Tat or p3xFLAG-Tat R(49-57)A (0.5, 1 and 2 microg). The luciferase activity was measured in cell extracts 48-h post-transfection and normalized to beta-galactosidase activity. Fold activation was calculated relative to transfection of the pkappaBLuc plasmid alone. Values (mean +/- SE, n = 3) are shown. As control of protein expression, aliquots of cell extracts (20 microg) were analysed by western blotting with anti-p65, anti-HA, anti-FLAG and anti-gamma-tubulin antibodies.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[13, 16]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[26, 39]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[105, 108]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[123, 139]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[191, 199]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[201, 221]], 'text': ['FLAG-Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[223, 241]], 'text': ['FLAG-Tat K(50,51)A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[243, 261]], 'text': ['FLAG-Tat R(49-57)A'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[265, 286]], 'text': ['FLAG-Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[356, 359]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[564, 567]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[618, 634]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[672, 680]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[684, 702]], 'text': ['FLAG-Tat R(49-57)A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[725, 741]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[935, 938]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1046, 1049]], 'text': ['p65'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1201, 1204]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1244, 1260]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1273, 1281]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1285, 1303]], 'text': ['FLAG-Tat R(49-57)A'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1541, 1544]], 'text': ['p50'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1547, 1550]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1628, 1636]], 'text': ['beta-Gal'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1674, 1677]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1698, 1714]], 'text': ['HA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1737, 1740]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1752, 1755]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1793, 1803]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1884, 1902]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4, 12]], 'text': ['relieves'], 'type': 'Negative_regulation', 'id': 'T32'}, {'offsets': [[40, 50]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T33'}, {'offsets': [[1054, 1061]], 'text': ['binding'], 'type': 'Binding', 'id': 'T34'}, {'offsets': [[1323, 1334]], 'text': ['competition'], 'type': 'Negative_regulation', 'id': 'T35'}, {'offsets': [[1342, 1349]], 'text': ['binding'], 'type': 'Binding', 'id': 'T36'}]","[{'trigger': 'T32', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T33', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T2', 'T3']}}, {'trigger': 'T34', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T20']}}, {'trigger': 'T36', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
191,PMC-3062687-19-Methods,"Luciferase Reporter Gene Assays
Luciferase reporter gene assays were performed as previously described6. Briefly, cells were cotransfected at a ratio of 10:1 with various promoter-driven firefly luciferase constructs to the Renilla luciferase pTKRL plasmid, together with indicated plasmids. Cells were cultured for 1-2 days and then stimulated in triplicate before harvest. Lysates were analyzed using the Dual-Luciferase Kit (Promega).","[{'offsets': [[195, 205]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[232, 242]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
192,PMC-1942070-05-Results,"3.2Cellular proliferation and survival in DT40 B cells lacking expression of PKD family kinases
PKD enzymes have previously been linked to the regulation of cell proliferation and survival (reviewed in [20]). To investigate the effect that loss of PKD kinases had on B cell survival and/or proliferation we cultured wild-type and PKD-null cells in the presence (PKD1/3-/-: Flag-PKD3+ve) or absence (PKD1/3-/-) of doxycycline and monitored exponential growth. As shown in Fig. 2A, PKD1/3-/- cells proliferated exponentially and re-expression of Flag-PKD3 in these cells had no impact on the rate of proliferation. Furthermore, the viability of PKD1/3-/- B cells during routine culturing was not significantly different from that of wild-type B cells (data not shown). It was noted that the population doubling time of PKD1/3-/- cells was slightly slower than that of wild type DT40 cells (12.7 +/- 2.8 h versus 10.2 +/- 0.4 h) but the failure of PKD3 re-expression to modify the proliferation rate of PKD1/3-/- cells suggests that these small differences were most likely the result of clonal variation and were not caused specifically by loss of PKD enzymes. Thus, PKD family enzymes are not essential for regulating basal survival and proliferation of DT40 B cells.
PKD enzymes, specifically PKD1 and PKD2, have previously been linked to a protective role against oxidative stress-induced injury in 3T3 fibroblast, HeLa and epithelial cell lines [17,30-32]. We therefore addressed the role of PKD family kinases in regulating B cell survival in response to oxidative stress and other stress stimuli. As shown in Fig. 2B, loss of PKD1/3 expression had no significant impact on the survival of DT40 B cells in response to mitochondrial stress stimuli (H2O2 or serum deprivation); DNA damaging agents (etoposide or doxorubicin); ER pathway stress due to calcium overload (thapsigargin) or following prolonged treatment with phorbol esters or Trichostatin A, an inhibitor of class I/II HDACs. Thus, PKD kinases do not play an essential role in regulating B cell survival in response to a range of different stress stimuli.","[{'offsets': [[362, 366]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[367, 368]], 'text': ['3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[378, 382]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[399, 403]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[404, 405]], 'text': ['3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[480, 484]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[485, 486]], 'text': ['3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[549, 553]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[643, 647]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[648, 649]], 'text': ['3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[817, 821]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[822, 823]], 'text': ['3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[945, 949]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1000, 1004]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1005, 1006]], 'text': ['3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1293, 1297]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1302, 1306]], 'text': ['PKD2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1630, 1634]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1635, 1636]], 'text': ['3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[527, 540]], 'text': ['re-expression'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[950, 963]], 'text': ['re-expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[1622, 1626]], 'text': ['loss'], 'type': 'Negative_regulation', 'id': 'T22'}, {'offsets': [[1637, 1647]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T23'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T23', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T22', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T23', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],[],[]
193,PMC-2800179-01-Introduction,"Carrageenan (CGN) is a high molecular weight sulphated polysaccharide (>200 kDa) derived from red algae (Rhodophyceae). Three main forms of CGN have been identified: kappa, iota, and lambda. They differ from each other in sulphation degree and solubility [1], [2]. Native CGN is thought to be harmless and is widely used as a food additive to improve texture. It is also used in cosmetics and pharmaceuticals. However, acid treatment at high temperature (80degreesC) triggers CGN hydrolysis to lower molecular weight (<50 kDa) compounds known as poligeenan or degraded CGN (dCGN). These dCGNs induce inflammation and have been widely used as models of colitis in several species, including rats [3], rabbits [4] and guinea pigs [5]. The role of dCGN as a tumor-promoting factor remains controversial [4], [6]-[8].
Although the native form is thought to be harmless for human consumption, small amounts of dCGN are probably produced by acid hydrolysis during gastric digestion [9], [10] or interaction with intestinal bacteria [11], [12]. Whereas the effects of native and dCGN on intestinal inflammation have been extensively analyzed in animal models, only few studies have been conducted using human cell lines. Recent studies have shown a link between exposure to native form CGN and IL-8 production by the human intestinal epithelial cell line, NCM460, via Nuclear Factor-kappaB (NF-kappaB) activation [13], [14]. NF-kappaB is a transcription factor that regulates the expression of genes associated with inflammation [15], [16].
Macrophage infiltration and accumulation is a common characteristic of intestinal diseases [17]. Macrophages represent 10% of total lamina propria cells, secrete a wide range of biologically active compounds and express cell-adhesion molecules. The immune cell response to an inflammatory stimulus seems to be amplified or directly generated by cells exposed to sulphated polysaccharides such as carrageenans. Indeed, inflammation induced by dCGN was associated with recruitment of macrophages to inflammation sites [18], [19]. Also, inflammation induced by Dextran Sulphate Sodium (DSS), another sulphated compound, was directly associated with macrophages recruitment [20], since DSS still provoked inflammation after T-lymphocyte and NK cell depletion [20]. Although inflammation can be induced by dCGN, there are no data on human monocyte responses to dCGN exposure. Therefore, to investigate the effects of dCGN on human monocytes, normal Peripheral Blood Monocytes (PBM) and tumoral monocyte/macrophage THP-1 cells were exposed to 10 kDa and 40 kDa dCGN. We found that dCGN inhibited THP-1 cell proliferation in vitro, increased ICAM-1 expression, stimulated ICAM-1-dependent monocyte aggregation, and stimulated TNF-alpha expression and secretion. These responses were more pronounced after 40 kDa dCGN exposure and were linked to NF-kappaB activation. In addition, the 40 kDa dCGN, but not the 10 kDa dCGN induced in vivo colitis as shown by the inflammatory response in the rat colon. These results suggest that the degraded forms of CGN have an important effect on monocytes resulting in an inflammatory phenotype.","[{'offsets': [[1287, 1291]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[2669, 2675]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[2699, 2705]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[2753, 2762]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1292, 1302]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[1357, 1360]], 'text': ['via'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[2659, 2668]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[2676, 2686]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T8'}, {'offsets': [[2742, 2752]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[2763, 2773]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T10'}, {'offsets': [[2778, 2787]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T11'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T7', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T9', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T11', 'id': 'E8', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
194,PMC-1920263-22-Caption-Figure_7,"Silencing of Sp1 and Sp3 reduces A3G promoter activity. (A) HeLa cells were transfected with 150 and 300 ng of unspecific, Sp1-specific or Sp3-specific siRNA. After 48 h, cells were harvested and Sp1 and Sp3 proteins were detected by western blot analysis. As loading control, protein levels of tubulin are shown. (B) HeLa cells were cotransfected with reporter plasmid pGL3-Basic containing 180 or 150 bp of the A3G promoter and siRNA. Hundred nanogram of unspecific siRNA (control), Sp1-specific siRNA (Sp1), Sp3-specific siRNA (Sp3) or a mixture of 50 ng Sp1-specific plus 50 ng Sp3-specific siRNA (Sp1+Sp3) were used. Firefly luciferase activities after 48 h were normalized to coexpressed renilla luciferase activities. Mean values (+/-SD) of a representative experiment performed in triplicate are shown.","[{'offsets': [[13, 16]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 24]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[33, 36]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[123, 126]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[139, 142]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[196, 199]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[204, 207]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[295, 302]], 'text': ['tubulin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[413, 416]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[485, 488]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[505, 508]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[511, 514]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[531, 534]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[558, 561]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[582, 585]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[602, 605]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[606, 609]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[630, 640]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[702, 712]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[0, 9]], 'text': ['Silencing'], 'type': 'Negative_regulation', 'id': 'T20'}, {'offsets': [[682, 693]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T21'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T20', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T21', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T21', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],[],[]
195,PMC-2222968-17-Materials_and_Methods,"Recombinant TAT proteins.
The cDNAs encoding GATA3 protein or the truncated GATA3 (lacking the two zinc fingers) were cloned in frame into an expression vector along with the TAT sequence as previously described [63]. Proteins were expressed in BL21 Star (DE3)pLysS (Invitrogen) and lysates were purified by Ni2+-chelate column chromatography. Both TAT-linked proteins were more than 95% pure, based on Coomassie blue staining of sodium disulfate acrylamide gels.","[{'offsets': [[12, 15]], 'text': ['TAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[45, 50]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[76, 81]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[175, 178]], 'text': ['TAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[349, 352]], 'text': ['TAT'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[83, 90]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T6'}, {'offsets': [[95, 111]], 'text': ['two zinc fingers'], 'type': 'Entity', 'id': 'T7'}]","[{'trigger': 'T6', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T3', 'T7']}}]",[],[],[],[]
196,PMC-3359311-03-Results,"Airway epithelial cells do not significantly upregulate caspase-1 activity in response to inflammasome stimulation
To examine if inflammasome activation occurs in these airway cells, caspase-1 activity was quantified by flow cytometry. There was no significant increase upon stimulation with live PAO1 or LPS+ATP at the times examined (Fig. 3a-b). Because previous studies have indicated a role for caspase-1 in the activation of NF-kappaB through Toll-like receptor (TLR) signaling [35], we examined whether chemical inhibition of caspase-1 altered NF-kappaB-dependent IL-6 production in response to P. aeruginosa. However, treatment with the caspase-1 inhibitor z-YVAD-fmk (YVAD) did not decrease IL-6 secretion by airway epithelial cells (Fig. 3c).","[{'offsets': [[570, 574]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[699, 703]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[542, 549]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T3'}, {'offsets': [[560, 569]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T4'}, {'offsets': [[575, 585]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T5'}, {'offsets': [[586, 600]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T6'}, {'offsets': [[690, 698]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T7'}, {'offsets': [[704, 713]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T8'}]","[{'trigger': 'T3', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T4', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T5', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T7', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T8', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}]",[]
197,PMC-2800179-18-Results,"Degraded CGN Induce an Increase in ICAM-1 and TNF-alpha mRNA Expression
The increase in surface ICAM-1 expression and TNF-alpha production by monocytes correlated with an upregulation of mRNA for these molecules. Both 10 kDa and 40 kDa dCGN induced a robust increase in mRNA for both ICAM-1 and TNF-alpha (Fig. 6). beta-actin mRNA levels were not affected by dCGN treatment.","[{'offsets': [[35, 41]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[46, 55]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[96, 102]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[118, 127]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[284, 290]], 'text': ['ICAM-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[295, 304]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 325]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[13, 19]], 'text': ['Induce'], 'type': 'Positive_regulation', 'id': 'T9'}, {'offsets': [[23, 31]], 'text': ['Increase'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[56, 71]], 'text': ['mRNA Expression'], 'type': 'Transcription', 'id': 'T11'}, {'offsets': [[76, 84]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[103, 113]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[128, 138]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[171, 183]], 'text': ['upregulation'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[196, 211]], 'text': ['these molecules'], 'type': 'Anaphora', 'id': 'T8'}, {'offsets': [[241, 248]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T16'}, {'offsets': [[258, 266]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[347, 355]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T18'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T9', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T10', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T11', 'id': 'E5', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T11', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T12', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T13', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T14', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T15', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T16', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T17', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T16', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T17', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T18', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}]","[{'id': 'R1', 'head': {'ref_id': 'T8', 'role': 'Subject'}, 'tail': {'ref_id': 'T3', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T8', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}]",[]
198,PMC-1920263-08-MATERIALS_AND_METHODS,"RNA interference and western blot analysis
Sp1 and Sp3 translation was silenced in HeLa cells using the siRNA duplexes Hs_SP1_1_HP and Hs_SP3_1_HP (Qiagen). A nonspecific siRNA (Qiagen) was used as control. HeLa cells were transfected with 150 or 300 ng siRNA per 6-well, using the HiPerfect transfection reagent (Qiagen) according to the manufacturer's protocol for reverse transfection of adherent cells in 6-well plates.
Forty-eight hours after transfection, HeLa cells were harvested for detection of Sp1 and Sp3 proteins. Cells were washed in PBS, lysed in RIPA (25 mM Tris pH 8.0, 137 mM NaCl, 1% Glycerol, 0.5% sodium deoxycholate, 1% NP-40, 2 mM EDTA pH 8, 0.1% SDS and protease inhibitors) and lysates were cleared by centrifugation. After boiling with Laemmli's buffer, samples were subjected to SDS-polyacrylamide gel electrophoresis followed by transfer to a nitrocellulose membrane. Sp1 and Sp3 proteins were detected using alpha-Sp1(Pep2) antibody (sc-59, Santa Cruz) or alpha-Sp3(D-20) antibody (sc-644, Santa Cruz) followed by incubation with alpha-rabbit-HRP (Amersham Biosciences). For detection of tubulin, alpha-tubulin (B5-1-2, Sigma) and alpha-mouse-HRP (Amersham Biosciences) antibodies were used. Signals were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences).","[{'offsets': [[43, 46]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 54]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[505, 508]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[513, 516]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[896, 899]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[904, 907]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[943, 946]], 'text': ['Sp1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[991, 994]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1117, 1124]], 'text': ['tubulin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1132, 1139]], 'text': ['tubulin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[492, 501]], 'text': ['detection'], 'type': 'Gene_expression', 'id': 'T11'}, {'offsets': [[922, 930]], 'text': ['detected'], 'type': 'Gene_expression', 'id': 'T12'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}]",[]
199,PMC-2806624-21-MATERIALS_AND_METHODS,"Promoter enzyme immuno assay.
As performed in the pull-down assay, HEK293T cells were transfected with RUNX1 or RUNX3 and subsequently lysed. Insoluble material was removed by centrifugation. 384-well plates, precoated with streptavidin (Thermo Fisher Scientific) were washed 3 times with washing buffer (PBS and 0.05% Tween 20). Biotinylated FOXP3 promoter/oligonucleotides probes containing the RUNX binding sites were added (1 pmol per well; 50 fmol/microl) and incubated for 1 h at room temperature. Either a combination of all three oligonucleotides containing the mutated or the wild-type binding sites was used or single oligonucleotides were used in the assay. After 3 washing steps with washing buffer, the nuclear extract was added (concentration > 0.2 microg/microl) and incubated overnight at 4degreesC. The lysates were incubated with 10 microg of poly-deoxyinosinic-deoxycytidylic acid (Sigma-Aldrich). The plate was washed with HKMG buffer and incubated with a 1:1000 dilution of rabbit anti-RUNX1 (ab11903, Abcam) or 1:200 dilution of rabbit anti-RUNX3 (H-50, Santa Cruz Biotechnology, Inc.) at 4degreesC for 2 h. After three washing steps with HKMG buffer, a secondary antibody (anti-rabbit IgG-HRP, 1:3,000 in HKMG buffer, Cell Signaling Technology) was added, and the plate was incubated for 1 h at 4degreesC. The wells were washed 4 times with HKMG buffer before adding the substrate reagent (R&D Systems). The colorimetric reaction was stopped by adding 2 M H2SO4. Absorbance at 450 nm was measured using a microplate reader (Berthold Technologies).","[{'offsets': [[67, 80]], 'text': ['HEK293T cells'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[103, 108]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[112, 117]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[343, 348]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1007, 1012]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1063, 1068]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[86, 97]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T7'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],[],[]
200,PMC-3333881-11-MATERIALS_AND_METHODS,"Statistical analysis
Statistical analysis was performed by two-tail unpaired Student's t-test. Data were reported as means +/- SE. Differences between the means were considered as statistically significant at the 95% level (P < 0.05).",[],[],[],[],[],[]
201,PMC-2674207-17-Results,"Ligand-Activated GR Competes with GATA-3 for Importin-alpha
We confirmed and extended previous data [20] to show that ligand-activated GR as well as GATA-3 uses importin-alpha for its nuclear import (Figure 2A and 2B). This interaction between GR and importin-alpha was significant at concentrations as low as 10-12 M and was maximal with 10-8 M FP. Subsequent GR nuclear translocation was rapid and sustained at significant levels for at least 14 h (Figure 2B). Using IP-Western blotting we showed that FP at 10-12-10-8 M decreased the association between GATA-3 and importin-alpha induced by anti-CD3/CD28 stimulation in a concentration-dependent manner (Figure 2C). In addition, using GFP-labelled GATA-3 and confocal microscopy we demonstrated that GATA-3 nuclear import following anti-CD3/CD28 stimulation for 30 min was attenuated by pretreatment with FP (10-8 M) (Figure 2D).","[{'offsets': [[17, 19]], 'text': ['GR'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 40]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[135, 137]], 'text': ['GR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[149, 155]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[244, 246]], 'text': ['GR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[361, 363]], 'text': ['GR'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[557, 563]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[688, 707]], 'text': ['GFP-labelled GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[753, 759]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[41, 44]], 'text': ['for'], 'type': 'Binding', 'id': 'T10'}, {'offsets': [[125, 134]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[156, 160]], 'text': ['uses'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[184, 191]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[192, 198]], 'text': ['import'], 'type': 'Localization', 'id': 'T14'}, {'offsets': [[364, 371]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T15'}, {'offsets': [[372, 385]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T16'}, {'offsets': [[523, 532]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[537, 548]], 'text': ['association'], 'type': 'Binding', 'id': 'T18'}, {'offsets': [[583, 590]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T19'}, {'offsets': [[639, 648]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T20'}, {'offsets': [[760, 767]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T21'}, {'offsets': [[768, 774]], 'text': ['import'], 'type': 'Localization', 'id': 'T22'}, {'offsets': [[775, 784]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T23'}, {'offsets': [[826, 836]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T24'}]","[{'trigger': 'T10', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T11', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T14', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T3', 'T13']}}, {'trigger': 'T12', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T14', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T13']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T6', 'T15']}}, {'trigger': 'T17', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T18', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T19', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T20', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T22', 'id': 'E12', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T9', 'T21']}}, {'trigger': 'T23', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T24', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}]",[],[],[],[]
202,PMC-2806624-28-Caption-Figure_4,"Regulation of FOXP3 promoter activity by RUNX1 and RUNX3. (A) Human primary CD4+ cells were transfected with an empty vector (pGL3 Basic), a vector containing the wild-type or mutated FOXP3 promoter region (FOXP3 -511/+176) fused to the luciferase reporter gene together with a GFP, RUNX1, or RUNX3 expression vector. Bars show the mean luciferase activity +/- SE measured as arbitrary light units of three independent experiments. (B) Human primary CD4+ cells were transfected with an empty vector (pGL3 Basic), a vector containing the putative FOXP3 promoter region (FOXP3 -511/+176) fused to the luciferase reporter gene, or with a vector containing the putative FOXP3 promoter region (FOXP3 -511/+176) with single RUNX binding sites mutated (53, 287, or 333) or with the combination of two or three RUNX binding sites mutated (53, 287, or 333) fused to the luciferase reporter gene. Bars show the mean luciferase activity +/- SD measured as arbitrary light units of three independent experiments.","[{'offsets': [[14, 19]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 46]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[51, 56]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[76, 79]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[184, 189]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[207, 212]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[237, 247]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[278, 281]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[283, 288]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[293, 298]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[337, 347]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[450, 453]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[546, 551]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[569, 574]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[599, 609]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[666, 671]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[861, 871]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[906, 916]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[92, 103]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T19'}, {'offsets': [[466, 477]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T20'}]","[{'trigger': 'T19', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T19', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T19', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T19', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T20', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T20', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}]",[],[],[],[]
203,PMC-2674207-26-Caption-Figure_6,"Fluticasone propionate impairs GATA-3 interaction with importin-alpha and GATA-3 nuclear localization in vivo and ex vivo.
(A and B) Co-immunoprecipitation analysis of PBMCs from steroid-naive asthma patients treated with FP in vitro demonstrated impaired interaction between GATA-3 and importin-alpha measured at 60 min. Each bar represents the mean+/-SEM of at least three independent experiments; *** p<0.001 compared with control as determined by ANOVA/Newman-Keuls analysis. (C and D) Co-immunoprecipitation analyses of PBMCs from steroid-naive asthma patients treated with inhaled FP (500 microg via a spacer) in vivo demonstrated decreased association between GATA-3 and importin-alpha. The individual values for each treatment are presented graphically. (E) Representative Western blot showing that importin-alpha expression was unaffected by inhalation of FP. Blot is representative of gels from three participants.","[{'offsets': [[31, 37]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[74, 80]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[276, 282]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[667, 673]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[23, 30]], 'text': ['impairs'], 'type': 'Negative_regulation', 'id': 'T5'}, {'offsets': [[38, 49]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T6'}, {'offsets': [[81, 88]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T7'}, {'offsets': [[89, 101]], 'text': ['localization'], 'type': 'Localization', 'id': 'T8'}, {'offsets': [[247, 255]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T9'}, {'offsets': [[256, 267]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T10'}, {'offsets': [[637, 646]], 'text': ['decreased'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[647, 658]], 'text': ['association'], 'type': 'Binding', 'id': 'T12'}]","[{'trigger': 'T5', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T6', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T5', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T7']}}, {'trigger': 'T9', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T10', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T11', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T12', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}]",[],[],[],[]
204,PMC-2222968-05-Results,"The Role of TGF-beta in T Cell Differentiation
Although TGF-beta-reduced CD25, IL-4 expression, and CD25 expression (Figure 6B), IL-4 significantly inhibited TGF-beta-mediated induction of FOXP3 in naive T cells driven toward FOXP3+ T cells, as shown by FACS analysis (Figure 6A). It is known that IL-4 is a potent growth factor and may therefore favor the proliferation of FOXP3- cells and thus decrease the relative percentage of FOXP3+ cells. However, analysis of cell division kinetics by CFSE-labeling demonstrated that IL-4 did not differentially promote cell growth of FOXP3+ over that of FOXP3-. In fact both populations showed similarly enhanced proliferation (Figure 6A). Furthermore the TGF-beta-mediated induction of FOXP3 expression was not caused by overgrowth of a CD25-FOXP3+ minority, since the number of FOXP3+ cells was low/absent in the purified CD4+CD45RA+ T cells (between 0% and 1%), and the FOXP3+ cells were not confined to the highly divided cells. CD25 was down-regulated in TGF-beta-treated cells compare to activated T cells, which was even more pronounced in cells cultured with TGF-beta and IL-4.
The addition of IL-4 to iTreg-driving conditions decreased the number of FOXP3+ cells (Figure 6B). In line with the previous findings, the IL-4-producing cells and the FOXP3 expressing cells are nonoverlapping populations. Since FOXP3 is known to act as a repressor of cytokine expression [20], we therefore analyzed GATA3 and FOXP3 expression. The expression kinetic of naive T cells exposed to IL-4 and TGF-beta demonstrated that GATA3 and FOXP3 are initially found in separate populations (day 2), but transiently co-express both factors (days 4-8), before establishing separate populations at the end of the differentiation process (day 10; Figure 6C), suggesting that GATA3 inhibits the development of iTreg cells by repressing FOXP3.
These results showed that IL-4 acts in vitro as an inhibitor of FOXP3 expression, without interfering with TGF-beta signaling, probably acting at the level of transcription factors, and possibly by a GATA3-dependent mechanism.","[{'offsets': [[12, 20]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[56, 64]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[73, 77]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[79, 83]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[100, 104]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[129, 133]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[158, 166]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[189, 194]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[226, 231]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[298, 302]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[374, 379]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[432, 437]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[525, 529]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[576, 581]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[596, 601]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[698, 706]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[729, 734]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[780, 784]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[785, 790]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[822, 827]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[866, 869]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[870, 876]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[915, 920]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[975, 979]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1002, 1007]], 'text': ['TGF-b'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1109, 1117]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1122, 1126]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1144, 1148]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1201, 1206]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1267, 1271]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1296, 1301]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1357, 1362]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1445, 1450]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1455, 1460]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1524, 1528]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1533, 1541]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1560, 1565]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1570, 1575]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1801, 1806]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1861, 1866]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1894, 1898]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1932, 1937]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1975, 1983]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2068, 2073]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[65, 72]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T46'}, {'offsets': [[84, 94]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[105, 115]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[148, 157]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[176, 185]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T50'}, {'offsets': [[716, 725]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[735, 745]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T52'}, {'offsets': [[754, 760]], 'text': ['caused'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[984, 998]], 'text': ['down-regulated'], 'type': 'Negative_regulation', 'id': 'T54'}, {'offsets': [[1075, 1085]], 'text': ['pronounced'], 'type': 'Positive_regulation', 'id': 'T55'}, {'offsets': [[1272, 1281]], 'text': ['producing'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[1302, 1312]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T57'}, {'offsets': [[1461, 1471]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T58'}, {'offsets': [[1542, 1554]], 'text': ['demonstrated'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1645, 1655]], 'text': ['co-express'], 'type': 'Gene_expression', 'id': 'T60'}, {'offsets': [[1656, 1668]], 'text': ['both factors'], 'type': 'Anaphora', 'id': 'T45'}, {'offsets': [[1850, 1860]], 'text': ['repressing'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1899, 1928]], 'text': ['acts in vitro as an inhibitor'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[1938, 1948]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T63'}, {'offsets': [[2004, 2010]], 'text': ['acting'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[2074, 2083]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T65'}]","[{'trigger': 'T46', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T2']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T46', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T2']}}, {'trigger': 'T47', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T46', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T2']}}, {'trigger': 'T48', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T49', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E8', 'T6']}}, {'trigger': 'T50', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T8', 'T7']}}, {'trigger': 'T51', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T16']}}, {'trigger': 'T52', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T53', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T54', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T55', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T27']}}, {'trigger': 'T56', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T57', 'id': 'E15', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T58', 'id': 'E16', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T58', 'id': 'E17', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T34']}}, {'trigger': 'T59', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T35']}}, {'trigger': 'T60', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T59', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T36']}}, {'trigger': 'T59', 'id': 'E21', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T35']}}, {'trigger': 'T60', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T59', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T36']}}, {'trigger': 'T61', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T40', 'T39']}}, {'trigger': 'T62', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'T41']}}, {'trigger': 'T63', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T64', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E28']}}, {'trigger': 'T65', 'id': 'E28', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T44', 'T41']}}]","[{'id': 'R1', 'head': {'ref_id': 'T45', 'role': 'Subject'}, 'tail': {'ref_id': 'T37', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T45', 'role': 'Subject'}, 'tail': {'ref_id': 'T38', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E11', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E16', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E17', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E24', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E27', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E28', 'value': ''}]",[]
205,PMC-3062687-11-Discussion,"RPS3 was previously demonstrated to function as an integral subunit conferring NF-kappaB regulatory specificity6. Here we sought to elucidate how NF-kappaB activation signaling triggers RPS3 to translocate and participate in NF-kappaB function in the nucleus. We demonstrate that IKKbeta-mediated RPS3 S209 phosphorylation represents a critical determinant in governing its nuclear import thus unveiling a novel mechanism behind NF-kappaB regulatory specificity. IKKbeta is the major kinase that phosphorylates IkappaBs in the classical NF-kappaB pathway, leading to their subsequent degradation40. Strikingly, RPS3 possesses not any consensus IKK motif; instead, S209 is centered in a consensus CK2 motif. The recent observation that human IKKbeta displayed CK2-like phosphorylation specificity29 coincides with our evidence that recombinant IKKbeta, but not IKKalpha, phosphorylated RPS3. We found this phosphorylation is a critical modulation for RPS3 nuclear translocation (via importin-alpha) and engagement in specific NF-kappaB transcription. CK2 was previously shown to phosphorylate p65 and to bind to and phosphorylate IKKbeta41-43, however, we ruled out the possibility that the IKKbeta-bound CK2 could account for the observed RPS3 phosphorylation because no CK2 was detected in the IKKbeta preparations used for the in vitro kinase assay. Because RPS3 only harbors the CK2 motif and not a traditional IKK motif, this RPS3 regulatory function could explain why IKK harbors the alternative substrate phosphorylation capability.
More importantly, our study has elucidated how RPS3 is biochemically integrated into NF-kappaB activation signaling in a manner that is pivotal for the pathogenesis of foodborne pathogen E. coli O157:H7. IKKbeta-mediated RPS3 S209 phosphorylation is a critical target modulated by this pathogen to subvert host NF-kappaB signaling. The bacterial effector NleH1 specifically binds to RPS3 once injected into host cells and profoundly suppresses NF-kappaB and its attendant protective immune responses9. Our data now show that NleH1 selectively inhibits RPS3 phosphorylation, thus retarding its nuclear translocation and subsequent NF-kappaB function, without altering other NF-kappaB signaling. Although NleH1 did not directly phosphorylate IKKbeta, its kinase activity was required to inhibit IKKbeta-mediated RPS3 S209 phosphorylation. Many bacteria pathogens have products that target key kinases to inactivate them in host cells, whereas E. coli O157:H7 employed NleH1 to steer the substrate specificity of IKKbeta thus specifically fine-tuning host NF-kappaB signaling. This could represent a novel strategy to fine-tune host NF-kappaB signaling that could be shared by other pathogens. These data provide new insights into the poorly understood action mechanism for most T3SS effectors.
NleH1 attenuates the transcription of RPS3-dependent, but not all, NF-kappaB target genes, in particular those genes associated with acute proinflammatory responses, including IL8 and TNF. In contrast, NleH1 does not block NF-kappaB p65 nuclear translocation, which suggests that certain p65-dependent but RPS3-independent NF-kappaB target genes might thus be beneficial for E. coli O157:H7 to replicate and disseminate in the host. By selectively inhibiting RPS3 and its attendant NF-kappaB function with NleH1, the pathogen achieves the ability to increase colonization and diarrhea yet limiting the mortality of the host. This seemingly paradoxical combination of effects make sense when one considers that increased bacterial load and diarrhea together with survival of the infected host would promote the spreading of the bacteria among a population of susceptible individuals. Such complex and paradoxical pathological effects that influence the spread of disease are often poorly understood at the molecular level. Our data elucidate how alterations in selective NF-kappaB function, achieved by impeding RPS3, but not altering p65 nuclear translocation, can influence specific cytokines that affect bacterial colonization, diarrhea diseases and mortality. It may be fruitful in attempting to understand other infectious and autoimmune diseases involving NF-kappaB to consider selective effects of subunits such as RPS3 in addition to global NF-kappaB inhibition.","[{'offsets': [[0, 4]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[186, 190]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[280, 287]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[297, 301]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[463, 470]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[611, 615]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[741, 748]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[843, 850]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[860, 868]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[885, 889]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[950, 954]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1092, 1095]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1129, 1136]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1190, 1197]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1239, 1243]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1295, 1302]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1360, 1364]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1586, 1590]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1743, 1750]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1760, 1764]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1894, 1899]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1922, 1926]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2064, 2069]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2091, 2095]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2242, 2247]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2279, 2286]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2332, 2339]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2349, 2353]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2505, 2510]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2549, 2556]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2831, 2836]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2869, 2873]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3007, 3010]], 'text': ['IL8'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3033, 3038]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3064, 3067]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3119, 3122]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3137, 3141]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3290, 3294]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3337, 3342]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3942, 3946]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3965, 3968]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4252, 4256]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[177, 185]], 'text': ['triggers'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[194, 205]], 'text': ['translocate'], 'type': 'Localization', 'id': 'T47'}, {'offsets': [[251, 258]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T48'}, {'offsets': [[288, 296]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[302, 306]], 'text': ['S209'], 'type': 'Entity', 'id': 'T50'}, {'offsets': [[307, 322]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T51'}, {'offsets': [[336, 344]], 'text': ['critical'], 'type': 'Regulation', 'id': 'T52'}, {'offsets': [[370, 373]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T43'}, {'offsets': [[374, 381]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T53'}, {'offsets': [[382, 388]], 'text': ['import'], 'type': 'Localization', 'id': 'T54'}, {'offsets': [[870, 884]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T55'}, {'offsets': [[900, 920]], 'text': ['this phosphorylation'], 'type': 'Anaphora', 'id': 'T44'}, {'offsets': [[935, 945]], 'text': ['modulation'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[955, 962]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T57'}, {'offsets': [[963, 976]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T58'}, {'offsets': [[978, 981]], 'text': ['via'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1078, 1091]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T60'}, {'offsets': [[1103, 1107]], 'text': ['bind'], 'type': 'Binding', 'id': 'T61'}, {'offsets': [[1115, 1128]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T62'}, {'offsets': [[1198, 1203]], 'text': ['bound'], 'type': 'Binding', 'id': 'T63'}, {'offsets': [[1214, 1225]], 'text': ['account for'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[1244, 1259]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T65'}, {'offsets': [[1751, 1759]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[1765, 1769]], 'text': ['S209'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[1770, 1785]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T68'}, {'offsets': [[1807, 1816]], 'text': ['modulated'], 'type': 'Regulation', 'id': 'T69'}, {'offsets': [[1913, 1918]], 'text': ['binds'], 'type': 'Binding', 'id': 'T70'}, {'offsets': [[2082, 2090]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T71'}, {'offsets': [[2096, 2111]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T72'}, {'offsets': [[2118, 2127]], 'text': ['retarding'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[2128, 2131]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T45'}, {'offsets': [[2132, 2139]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T74'}, {'offsets': [[2140, 2153]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T75'}, {'offsets': [[2265, 2278]], 'text': ['phosphorylate'], 'type': 'Phosphorylation', 'id': 'T76'}, {'offsets': [[2324, 2331]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T77'}, {'offsets': [[2340, 2348]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[2354, 2358]], 'text': ['S209'], 'type': 'Entity', 'id': 'T79'}, {'offsets': [[2359, 2374]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T80'}, {'offsets': [[2514, 2519]], 'text': ['steer'], 'type': 'Regulation', 'id': 'T81'}, {'offsets': [[3048, 3053]], 'text': ['block'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[3068, 3075]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T83'}, {'offsets': [[3076, 3089]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T84'}, {'offsets': [[3279, 3289]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[3933, 3941]], 'text': ['impeding'], 'type': 'Negative_regulation', 'id': 'T86'}, {'offsets': [[3956, 3964]], 'text': ['altering'], 'type': 'Regulation', 'id': 'T87'}, {'offsets': [[3969, 3976]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T88'}, {'offsets': [[3977, 3990]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T89'}, {'offsets': [[4224, 4231]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T90'}]","[{'trigger': 'T46', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T48']}}, {'trigger': 'T49', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E4', 'T3']}}, {'trigger': 'T51', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T4', 'T50']}}, {'trigger': 'T52', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'E3']}}, {'trigger': 'T54', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T53']}}, {'trigger': 'T55', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T10', 'T8']}}, {'trigger': 'T55', 'id': 'E8', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T10', 'T9']}}, {'trigger': 'T56', 'id': 'E9', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E7']}}, {'trigger': 'T58', 'id': 'E10', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T11', 'T57']}}, {'trigger': 'T56', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'E8']}}, {'trigger': 'T59', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T60', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T61', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T62', 'id': 'E15', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T63', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T64', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'E16']}}, {'trigger': 'T65', 'id': 'E18', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T66', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'T19']}}, {'trigger': 'T68', 'id': 'E20', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T20', 'T67']}}, {'trigger': 'T69', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T70', 'id': 'E22', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T21', 'T22']}}, {'trigger': 'T71', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'T23']}}, {'trigger': 'T72', 'id': 'E24', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T73', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E26', 'E23']}}, {'trigger': 'T75', 'id': 'E26', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T74']}}, {'trigger': 'T76', 'id': 'E27', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T77', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T78', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E30', 'T27']}}, {'trigger': 'T80', 'id': 'E30', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T79']}}, {'trigger': 'T81', 'id': 'E31', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T30', 'T29']}}, {'trigger': 'T82', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T34']}}, {'trigger': 'T84', 'id': 'E33', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T35', 'T83']}}, {'trigger': 'T85', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T38', 'T39']}}, {'trigger': 'T86', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T87', 'id': 'E36', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E37']}}, {'trigger': 'T89', 'id': 'E37', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T41', 'T88']}}, {'trigger': 'T90', 'id': 'E38', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}]","[{'id': 'R1', 'head': {'ref_id': 'T43', 'role': 'Subject'}, 'tail': {'ref_id': 'T4', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T44', 'role': 'Subject'}, 'tail': {'ref_id': 'T55', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T45', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E8', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E17', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E27', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E32', 'value': ''}]",[]
206,PMC-3062687-20-Methods,"Chromatin Immunoprecipitation (ChIP)
ChIP assays was performed as previously described6. The primers used to amplify the promoter region adjacent to the kappaB sites of IL8 and NFKBIA, as well as ACTB have been described6.","[{'offsets': [[169, 172]], 'text': ['IL8'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[177, 183]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[196, 200]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
207,PMC-2674207-03-Materials_and_Methods,"Antibodies and Reagents
The monoclonal antibodies against human CD3, CD28, GR, and importin-alpha were purchased from BD Biosciences (Oxford, United Kingdom). Rabbit antibodies against human GATA-3 (H-48) and GR (E-20, sc-1003) were obtained from Santa Cruz Biotechnology (Santa Cruz, California, United States), polyclonal rabbit antibodies against phospho-p38 MAP kinase and phospho-ATF-2 from Cell Signaling Technology (New England Biolabs, Hertford, UK), monoclonal antibody against phosphoserine (clone 4H4) from Affiniti Research Products (Exeter, UK), and antibodies against rabbit IgG-conjugated TRITC from Dako Cytomation (Cambridge, UK). The anti-GR antibody (Clone 41) from BD Transduction Laboratories (Oxford, UK) was used for Western blot analysis. All other reagents were purchased from Sigma (Poole, UK).","[{'offsets': [[64, 67]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[69, 73]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[75, 77]], 'text': ['GR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[191, 197]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[209, 211]], 'text': ['GR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[385, 390]], 'text': ['ATF-2'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
208,PMC-3333881-24-Caption-Figure_7,"Model of MIP-1alpha transcriptional activation by HIV-1 Tat. (A) In absence of Tat, IkappaB-alpha occupies the NF-kappaB enhancer of the MIP-1alpha promoter and likely interacts with transcriptional repressors, such as HDACs (65), to inhibit gene transcription. (B) Tat activates the MIP-1alpha expression by removing the IkappaB-alpha repressor from the NF-kappaB enhancer, and by increasing the binding of p65 NF-kappaB complex to the NF-kappaB enhancer.","[{'offsets': [[9, 19]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[56, 59]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[79, 82]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[84, 97]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[137, 147]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[266, 269]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[284, 294]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[322, 335]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[20, 35]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T9'}, {'offsets': [[36, 46]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[68, 75]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T11'}, {'offsets': [[98, 106]], 'text': ['occupies'], 'type': 'Binding', 'id': 'T12'}, {'offsets': [[111, 129]], 'text': ['NF-kappaB enhancer'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[168, 177]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T14'}, {'offsets': [[270, 279]], 'text': ['activates'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[295, 305]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[309, 317]], 'text': ['removing'], 'type': 'Negative_regulation', 'id': 'T17'}, {'offsets': [[382, 392]], 'text': ['increasing'], 'type': 'Positive_regulation', 'id': 'T18'}, {'offsets': [[397, 404]], 'text': ['binding'], 'type': 'Binding', 'id': 'T19'}, {'offsets': [[437, 455]], 'text': ['NF-kappaB enhancer'], 'type': 'Entity', 'id': 'T20'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'T2']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T4', 'T5', 'T13']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T6']}}, {'trigger': 'T16', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T17', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T8', 'T6']}}, {'trigger': 'T18', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T6']}}, {'trigger': 'T19', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T20']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}]",[]
209,PMC-2800179-04-Materials_and_Methods,"Evaluation of Colitis
Body weight, liquid and food consumption, diarrhea and rectal bleeding (detected by eye inspection) were recorded throughout the feeding period. After 55 days, animals were sacrificed by cervical dislocation. The length of the colon was measured as described by Okayashu et al. [24]. Then, each colon was ligated in sections of 2 cm and 1 to 2 ml of 10% formalin was infused into the intestinal lumen. The moderately distended segment was sectioned and fixed in 10% formalin. The following day, the intestinal content was removed by vortexing. The fixed segment was kept in 10% formalin at 4degreesC until the paraffin embedding procedure. To evaluate the degree of inflammation, this segment of colon was opened longitudinally and macroscopic and histological scores of inflammation were recorded as previously described [25], [26]. The toluidine blue staining was used for identification of sulphated polysaccharides in the intestinal mucosa. On the day of sacrifice, a fresh sample of each colon (50 mg) was collected for myeloperoxidase (MPO) assay according to Krawisz et al., [27]. The level of MPO, mainly expressed by neutrophils, indicates the rate of recruitment of neutrophils to the intestinal mucosa. One unit of MPO activity corresponds to the degradation of 1 micromol of peroxide per minute at 25degreesC.","[{'offsets': [[1047, 1062]], 'text': ['myeloperoxidase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1064, 1067]], 'text': ['MPO'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1123, 1126]], 'text': ['MPO'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1135, 1144]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T4'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],"[{'id': '*', 'ref_ids': ['T1', 'T2']}]",[],[]
210,PMC-1134658-15-Methods,"Analysis of BMP-6 messenger RNA (mRNA) expression
Endogenous expression of the BMP-6 gene was examined by reverse transcription-polymerase chain reaction. Total RNA was isolated using Absolutely RNA(TM) RT-PCR Miniprep Kit (Stratagene Europe, Amsterdam, Netherland) according to the manufacturers instructions. Quantification of the isolated total RNA was achieved by using spectrophotometric OD260 measurements. Equal amounts of RNA were then reverse transcribed to cDNA with TaqMan(R) Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, U.S.A). To measure mRNA expression of BMP6, Id1-Id4 and PGK1 PCR were carried out with TaqMan(R) universal master mix. Primers and probes were provided by Assay-on-Demand (Applied Biosystems). PCR reactions were carried out in a final volume of 25 mul (BMP-6) or 20 mul (ID1). The cDNA added to each reaction was equivalent to the input of 20 ng of total RNA. The gene expression was quantified using the standard curve method (BMP6), or the comparative CT method (Id1) as described in ABI7700 User Bulletin 2 (Applied Biosystems). The expression was then normalized to the expression level of PGK1. PGK1 was chosen, because it has been shown to have low expression variability among lymphocyte specimens [56]. Expression levels in B cells were then related to the expression levels in Ramos cells.","[{'offsets': [[12, 17]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 84]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[594, 598]], 'text': ['BMP6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[600, 603]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[604, 607]], 'text': ['Id4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[612, 616]], 'text': ['PGK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[809, 814]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[984, 988]], 'text': ['BMP6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1021, 1024]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1150, 1154]], 'text': ['PGK1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1156, 1160]], 'text': ['PGK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[39, 49]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T13'}, {'offsets': [[61, 71]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[575, 590]], 'text': ['mRNA expression'], 'type': 'Transcription', 'id': 'T15'}, {'offsets': [[925, 935]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T16'}, {'offsets': [[1130, 1140]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T17'}, {'offsets': [[1181, 1183]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T12'}, {'offsets': [[1202, 1221]], 'text': ['have low expression'], 'type': 'Gene_expression', 'id': 'T18'}]","[{'trigger': 'T13', 'id': 'E1', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T13', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T13', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T14', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T15', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T15', 'id': 'E7', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T15', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T15', 'id': 'E9', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T16', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T16', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T17', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T18', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]","[{'id': 'R1', 'head': {'ref_id': 'T12', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E5', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M10', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M12', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}]",[]
211,PMC-3062687-04-Results,"IKKbeta is required for RPS3 nuclear translocation
To examine whether the RPS3-IKKbeta interaction is required for RPS3 nuclear translocation, we knocked down IKKalpha or IKKbeta expression with siRNAs (Supplementary Fig. 1) and then observed stimulation-induced RPS3 nuclear migration by confocal microscopy. Both TNF and PMA+I triggered RPS3 nuclear translocation in Jurkat cells transfected with a scrambled nonspecific (NS) siRNA (Fig. 2a)6. RPS3 nuclear translocation was only slightly, if at all, impaired by IKKalpha-silencing. Conversely, knockdown of IKKbeta attenuated 60-70% of RPS3 nuclear accumulation following stimulation (Fig. 2a). Immunoblotting of nuclear fractions confirmed that full expression of IKKbeta, but not IKKalpha, was necessary for activation-induced RPS3 nuclear translocation (Fig. 2b). Control immunoblots revealed that p65 nuclear translocation was blocked under the same conditions (Fig. 2b).
We next examined the nuclear translocation of RPS3 in cells ectopically expressing either kinase-dead (SSAA) or constitutively-active (SSEE) mutant IKKbeta proteins. As expected, the SSEE, but not SSAA, mutant of IKKbeta induced NF-kappaB-dependent luciferase reporter activity (Fig. 2c, left). Whereas RPS3 remained cytosolic in IKKbeta (SSAA)-expressing cells (Fig. 2c, right), a substantial proportion of RPS3 translocated to the nucleus in cells expressing IKKbeta (SSEE) (Fig. 2c, right). The percentage of cells containing detectable nuclear RPS3 increased 5-fold in IKKbeta (SSEE)-expressing cells, but not in IKKbeta (SSAA)-expressing ones (Fig. 2d and Supplementary Fig. 2). Thus, IKKbeta activity is necessary and sufficient for RPS3 nuclear translocation in response to NF-kappaB activating stimuli.","[{'offsets': [[0, 7]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[24, 28]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 78]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[79, 86]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[115, 119]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[159, 167]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[171, 178]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[263, 267]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[339, 343]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[446, 450]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[515, 523]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[560, 567]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[589, 593]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[718, 725]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[735, 743]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[782, 786]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[854, 857]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[975, 979]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1077, 1084]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1142, 1149]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1178, 1188]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1232, 1236]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1259, 1266]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1337, 1341]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1390, 1397]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1477, 1481]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1502, 1509]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1546, 1553]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1619, 1626]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1668, 1672]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[11, 19]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[29, 36]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T32'}, {'offsets': [[37, 50]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T33'}, {'offsets': [[87, 98]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T34'}, {'offsets': [[102, 110]], 'text': ['required'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[120, 127]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T36'}, {'offsets': [[128, 141]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T37'}, {'offsets': [[146, 158]], 'text': ['knocked down'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[179, 189]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[255, 262]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[268, 275]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[276, 285]], 'text': ['migration'], 'type': 'Localization', 'id': 'T42'}, {'offsets': [[329, 338]], 'text': ['triggered'], 'type': 'Positive_regulation', 'id': 'T43'}, {'offsets': [[344, 351]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T44'}, {'offsets': [[352, 365]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T45'}, {'offsets': [[451, 458]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T46'}, {'offsets': [[459, 472]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T47'}, {'offsets': [[503, 511]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T48'}, {'offsets': [[524, 533]], 'text': ['silencing'], 'type': 'Negative_regulation', 'id': 'T49'}, {'offsets': [[547, 556]], 'text': ['knockdown'], 'type': 'Negative_regulation', 'id': 'T50'}, {'offsets': [[568, 578]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T51'}, {'offsets': [[594, 601]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T52'}, {'offsets': [[602, 614]], 'text': ['accumulation'], 'type': 'Localization', 'id': 'T53'}, {'offsets': [[615, 624]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[704, 714]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[749, 758]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T56'}, {'offsets': [[774, 781]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[787, 794]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[795, 808]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T59'}, {'offsets': [[858, 865]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T60'}, {'offsets': [[866, 879]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T61'}, {'offsets': [[884, 891]], 'text': ['blocked'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[950, 957]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T63'}, {'offsets': [[958, 971]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T64'}, {'offsets': [[1001, 1011]], 'text': ['expressing'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[1019, 1030]], 'text': ['kinase-dead'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[1041, 1062]], 'text': ['constitutively-active'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[1112, 1116]], 'text': ['SSEE'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1126, 1130]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[1150, 1157]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[1168, 1177]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T71'}, {'offsets': [[1237, 1245]], 'text': ['remained'], 'type': 'Localization', 'id': 'T72'}, {'offsets': [[1246, 1255]], 'text': ['cytosolic'], 'type': 'Entity', 'id': 'T73'}, {'offsets': [[1256, 1258]], 'text': ['in'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[1268, 1272]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[1342, 1354]], 'text': ['translocated'], 'type': 'Localization', 'id': 'T76'}, {'offsets': [[1362, 1369]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T77'}, {'offsets': [[1370, 1372]], 'text': ['in'], 'type': 'Positive_regulation', 'id': 'T78'}, {'offsets': [[1399, 1403]], 'text': ['SSEE'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[1458, 1468]], 'text': ['detectable'], 'type': 'Localization', 'id': 'T80'}, {'offsets': [[1469, 1476]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T81'}, {'offsets': [[1482, 1491]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[1511, 1515]], 'text': ['SSEE'], 'type': 'Positive_regulation', 'id': 'T83'}, {'offsets': [[1555, 1559]], 'text': ['SSAA'], 'type': 'Negative_regulation', 'id': 'T84'}, {'offsets': [[1639, 1648]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T85'}, {'offsets': [[1673, 1680]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T86'}, {'offsets': [[1681, 1694]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T87'}, {'offsets': [[1695, 1709]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T88'}]","[{'trigger': 'T31', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T33', 'id': 'E2', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T2', 'T32']}}, {'trigger': 'T34', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T3', 'T4']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'E3']}}, {'trigger': 'T37', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T36']}}, {'trigger': 'T38', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T39', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T38', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T39', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T40', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T42', 'id': 'E11', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T41']}}, {'trigger': 'T43', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T45', 'id': 'E13', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T9', 'T44']}}, {'trigger': 'T47', 'id': 'E14', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T10', 'T46']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'E16']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T50', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T51', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E17']}}, {'trigger': 'T54', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T53', 'id': 'E20', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T13', 'T52']}}, {'trigger': 'T55', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T55', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T56', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E21']}}, {'trigger': 'T57', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T56', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E24', 'E22']}}, {'trigger': 'T59', 'id': 'E26', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T16', 'T58']}}, {'trigger': 'T61', 'id': 'E27', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T17', 'T60']}}, {'trigger': 'T62', 'id': 'E28', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T64', 'id': 'E29', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T18', 'T63']}}, {'trigger': 'T65', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T66', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T67', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T68', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T69', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T70', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'E33']}}, {'trigger': 'T71', 'id': 'E36', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T70', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'E34']}}, {'trigger': 'T72', 'id': 'E38', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T22', 'T73']}}, {'trigger': 'T74', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E38', 'E40']}}, {'trigger': 'T75', 'id': 'E40', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T76', 'id': 'E41', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T77']}}, {'trigger': 'T78', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E41', 'E43']}}, {'trigger': 'T79', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T80', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T26', 'T81']}}, {'trigger': 'T82', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E46']}}, {'trigger': 'T83', 'id': 'E46', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T82', 'id': 'E47', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E48']}}, {'trigger': 'T84', 'id': 'E48', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T85', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E50', 'T29']}}, {'trigger': 'T88', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T87', 'id': 'E51', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T30', 'T86']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E25', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E29', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E35', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E37', 'value': ''}, {'id': 'M8', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M9', 'type': 'Negation', 'ref_id': 'E47', 'value': ''}]",[]
212,PMC-3333881-02-MATERIALS_AND_METHODS,"Plasmids
The plasmids pcDNA-3xHA-IkappaB-alpha, p3xFLAG-CMV-Tat, p3xFLAG-CMV-Tat C(22,25,27)A, p3xFLAG-CMV-Tat R(49,52,53,55,56,57)A, pGEX-2T-Tat, pGEX-2T-Tat C(22,25,27)A and pGEX-2T-Tat R(49,52,53,55,56,57)A were previously described (50). The plasmids pNL4-3.Luc.R-E- and pHXB2-env were obtained from the AIDS Research & Reference Reagent Program, Division of AIDS, NIAID, NIH, USA; pkappaBluc and pSV-beta-Gal were purchased from Promega (Madison, WI, USA). The plasmids pRc/CMV-3xHA-p65, pRc/CMV-3xHA-p65deltaC(1-318), pRc/CMV-3xHA-p65deltaN(122-551), p3xFLAG-CMV-Tat T,N(23,24)A, p3xFLAG-CMV-Tat K(50,51)A, pGEX-2T-Tat T,N(23,24)A, pGEX-2T-Tat K(50,51)A and pNL4-3.FLAG-Tat.R-E- were generated as described in Supplementary Data.","[{'offsets': [[28, 46]], 'text': ['3xHA-IkappaB-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[60, 63]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[77, 93]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[107, 132]], 'text': ['Tat R(49,52,53,55,56,57)A'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[142, 145]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[155, 171]], 'text': ['Tat C(22,25,27)A'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[184, 209]], 'text': ['Tat R(49,52,53,55,56,57)A'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[281, 284]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[405, 413]], 'text': ['beta-Gal'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[483, 491]], 'text': ['3xHA-p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[501, 515]], 'text': ['3xHA-p65deltaC'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[532, 546]], 'text': ['3xHA-p65deltaN'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[569, 584]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[598, 611]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[621, 636]], 'text': ['Tat T,N(23,24)A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[646, 659]], 'text': ['Tat K(50,51)A'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[676, 679]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}]",[],[],[],[],[]
213,PMC-3359311-15-Materials_and_Methods,"Quantification of caspase-1 activity
Bronchial epithelial cells were plated in 6-well plates at 5x105 cells/well overnight. Cells were primed with LPS for 5 hours and stimulated with ATP for 1 hour or stimulated with live PAO1 for 3 hours. PBMCs were stimulated the same day as blood donation. PBMCs were seeded in a 96-well plate at a density of 4.5x105 cells/well (2.5x106 cells/ml), primed with LPS for 5 hours and then stimulated with ATP for 1 hour or Poly(dA:dT) for 3 hours or stimulated with live PAO1 for 3 hours. Caspase-1 activity was measured using FLICA (Immunochemistry Technologies), a cell-permeable fluorescent probe (FAM-YVAD-fmk) that binds active caspase-1. Cells were incubated 1 hour with FLICA at 37degreesC and stained with PE-Cy7-conjugated anti-CD14 antibodies (eBioscience) to identify monocytes. The gating strategy consisted of including live cells that were CD14 positive which were subsequently analyzed for the frequency of FLICA positive cells.","[{'offsets': [[888, 892]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
214,PMC-3333881-16-RESULTS,"In HIV-1-infected monocytes Tat sustains the NF-kappaB activity and promotes the transcriptional activation of MIP-1alpha by interacting with IkappaB-alpha and p65
We next analysed whether Tat affected the NF-kappaB activity and the expression of MIP-1alpha in the course of HIV-1 infection. To detect the Tat protein, we produced HXB2 Env-pseudotyped NL4-3.FLAG-Tat.R-E- virions, which were used in single-round infection of U937, a human monocytic cell line. Cells were transfected with siRNA Tat, siRNA control or left untransfected to modulate the Tat expression, and then analysed for the kinetic of NF-kappaB activation following viral infection. The expression of Tat and p24 was detected at 3- to 12-h post-infection, while it was barely detected in siRNA Tat-transfected cells (Figure 6A).
The NF-kappaB activity, as measured by p65 DNA binding, was induced at 3-h post-infection in both Tat-positive (no siRNA and siRNA control) and Tat-negative cells (siRNA Tat), and increased at 12 h only in Tat-positive cells (Figure 6B). Degradation of IkappaB-alpha was observed at 3-h post-infection, and was followed by de novo synthesis of IkappaB-alpha at 12 h independently of the Tat presence (Figure 6C). Consistently, the IKK activity was induced at 3-h post-infection and turned off at 12 h independently of the Tat presence (Figure 6D). These results agreed with the kinetic of NF-kappaB activation in single-round HIV-1 infection of Jurkat cells (Figure 1), and further supported the requirement of viral expression to counteract the post-activation turn off of NF-kappaB.
In HIV-1-infected U937 cells, the endogenous Tat was coimmunoprecipitated with IkappaB-alpha and p65 (Figure 6E), and activated the MIP-1alpha expression in a p65-dependent manner, as shown by the lack of effect following RNA interference of Tat or p65 (Figure 6F). Moreover, Tat and p65 were both recruited to the NF-kappaB enhancer of MIP-1alpha, while the p65 occupancy was abolished by siRNA Tat (Figure 6G and H). Altogether these results indicated that in single round HIV-1 infection Tat associated with IkappaB-alpha and p65, and induced the p65-dependent activation of MIP-1alpha expression through occupancy of the MIP-1alpha promoter and increased recruitment of p65.","[{'offsets': [[28, 31]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[111, 121]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[142, 155]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[160, 163]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[189, 192]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[247, 257]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[306, 309]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[336, 339]], 'text': ['Env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[358, 366]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[489, 498]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[552, 555]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[671, 674]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[679, 682]], 'text': ['p24'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[758, 767]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[838, 841]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[897, 900]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[943, 946]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[963, 972]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1005, 1008]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1052, 1065]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1143, 1156]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1186, 1189]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1321, 1324]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1629, 1632]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1663, 1676]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1681, 1684]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1716, 1726]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1743, 1746]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1826, 1829]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1833, 1836]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1860, 1863]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1868, 1871]], 'text': ['p65'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1921, 1931]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1943, 1946]], 'text': ['p65'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1974, 1983]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2075, 2078]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2095, 2108]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2113, 2116]], 'text': ['p65'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2134, 2137]], 'text': ['p65'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2162, 2172]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2209, 2219]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2258, 2261]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[68, 76]], 'text': ['promotes'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[81, 96]], 'text': ['transcriptional'], 'type': 'Transcription', 'id': 'T46'}, {'offsets': [[97, 107]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T47'}, {'offsets': [[122, 124]], 'text': ['by'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[125, 136]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T49'}, {'offsets': [[193, 201]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T50'}, {'offsets': [[233, 243]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T51'}, {'offsets': [[539, 547]], 'text': ['modulate'], 'type': 'Regulation', 'id': 'T52'}, {'offsets': [[556, 566]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[657, 667]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[732, 734]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T43'}, {'offsets': [[746, 754]], 'text': ['detected'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[846, 853]], 'text': ['binding'], 'type': 'Binding', 'id': 'T56'}, {'offsets': [[859, 866]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[979, 988]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T58'}, {'offsets': [[1037, 1048]], 'text': ['Degradation'], 'type': 'Protein_catabolism', 'id': 'T59'}, {'offsets': [[1110, 1118]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[1130, 1139]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[1165, 1178]], 'text': ['independently'], 'type': 'Regulation', 'id': 'T62'}, {'offsets': [[1637, 1657]], 'text': ['coimmunoprecipitated'], 'type': 'Binding', 'id': 'T63'}, {'offsets': [[1702, 1711]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[1727, 1737]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[1747, 1756]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[1781, 1785]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T67'}, {'offsets': [[1789, 1795]], 'text': ['effect'], 'type': 'Anaphora', 'id': 'T44'}, {'offsets': [[1796, 1805]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T68'}, {'offsets': [[1882, 1891]], 'text': ['recruited'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[1899, 1917]], 'text': ['NF-kappaB enhancer'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[1947, 1956]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T71'}, {'offsets': [[1961, 1970]], 'text': ['abolished'], 'type': 'Negative_regulation', 'id': 'T72'}, {'offsets': [[2079, 2089]], 'text': ['associated'], 'type': 'Binding', 'id': 'T73'}, {'offsets': [[2122, 2129]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T74'}, {'offsets': [[2148, 2158]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[2173, 2183]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[2192, 2201]], 'text': ['occupancy'], 'type': 'Binding', 'id': 'T77'}, {'offsets': [[2220, 2228]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T78'}, {'offsets': [[2233, 2242]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[2243, 2254]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T80'}]","[{'trigger': 'T45', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T47', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E3']}}, {'trigger': 'T46', 'id': 'E3', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T48', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E5']}}, {'trigger': 'T49', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T3']}}, {'trigger': 'T50', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T5']}}, {'trigger': 'T51', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T52', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T53', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T54', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T54', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T55', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T14']}}, {'trigger': 'T55', 'id': 'E13', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E11', 'T14']}}, {'trigger': 'T56', 'id': 'E14', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T57', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T58', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E14', 'T19']}}, {'trigger': 'T59', 'id': 'E17', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T60', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'E17']}}, {'trigger': 'T61', 'id': 'E19', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T62', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E19', 'T22']}}, {'trigger': 'T63', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T24', 'T25']}}, {'trigger': 'T64', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T28', 'T24']}}, {'trigger': 'T65', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T66', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E23', 'E22']}}, {'trigger': 'T67', 'id': 'E25', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T68', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T69', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T31', 'T33', 'T70']}}, {'trigger': 'T71', 'id': 'E28', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T33', 'T34', 'T70']}}, {'trigger': 'T72', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T35']}}, {'trigger': 'T73', 'id': 'E30', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T36', 'T37']}}, {'trigger': 'T74', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T75', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T39']}}, {'trigger': 'T76', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T77', 'id': 'E34', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T36', 'T41', 'T78']}}, {'trigger': 'T79', 'id': 'E35', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T36']}}, {'trigger': 'T80', 'id': 'E36', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T41', 'T42', 'T78']}}]","[{'id': 'R1', 'head': {'ref_id': 'T43', 'role': 'Subject'}, 'tail': {'ref_id': 'T54', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T44', 'role': 'Subject'}, 'tail': {'ref_id': 'T64', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E6', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E20', 'value': ''}]",[]
215,PMC-2674207-12-Materials_and_Methods,"Transfection
HuT-78 cells were transfected with either EP8 or GFP vector only DNA using solution R, programme V-001 at a ratio of 3x106 cells/4 microg DNA for 7-8 h in complete medium (10% bovine serum in RPMI1640+15 L-glutamine) according to the general Amaxa protocol for nucleofection. The medium was subsequently changed to 1% RPMI for 24 h before transfected cells were added to anti-CD3/CD28 treated wells and live cell videomicroscopy performed.",[],[],[],[],[],[]
216,PMC-2222968-31-Caption-Figure_7,"GATA3 Acts as a Negative Regulator of FOXP3 Expression
(A) Human naive CD4+CDRA+ T cells were transduced with 0, 20, 100, and 500 nM of TAT-GATA3 protein, and intracellular presence of GATA3 was analyzed using FACS following anti-CD3/CD28 activation of the cells. GFP-positive cells were gated and analyzed for intracellular FOXP3 expression following a 2-d incubation period (lower panel). Data are representative of four independent experiments.
(B) CD4+CD25- T cells were isolated from D011.10 and D011.10xCD2-GATA3 mice and treated with OVA and TGF-beta for 96 h. Surface CD4 and intracellular FOXP3 were measured by FACS. These data are representative of three independent experiments.
(C) The cells treated as in (B) were harvested and mRNA was quantified by real-time PCR for SMAD7 and TGF-beta expression. Bars show the mean +/- SD of three independent experiments.","[{'offsets': [[0, 5]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[38, 43]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 74]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[75, 79]], 'text': ['CDRA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[136, 145]], 'text': ['TAT-GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[185, 190]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[230, 233]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[234, 238]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[264, 267]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[325, 330]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[452, 455]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[456, 460]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[509, 512]], 'text': ['CD2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[513, 518]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[549, 557]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[576, 579]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[598, 603]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[783, 788]], 'text': ['SMAD7'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[793, 801]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[173, 181]], 'text': ['presence'], 'type': 'Gene_expression', 'id': 'T20'}, {'offsets': [[331, 341]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T21'}, {'offsets': [[802, 812]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T22'}]","[{'trigger': 'T20', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T21', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T22', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T22', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E4', 'value': ''}]",[]
217,PMC-2806624-12-MATERIALS_AND_METHODS,"In vitro suppression assays.
Mouse Foxp3+ CD4+ CD8- T cells were FACS purified based on GFP expressed from a Foxp3-IRES-GFP knock-in allele (Foxp3GFP). Naive (CD62Lhi44lo25-) CD4+ T cells (effectors) were FACS-purified from Cd45.1 mice, then loaded with 5 microM CFSE (Invitrogen). Total splenocytes from C57BL/6 mice inactivated with 50 microg/ml mitomycin C (Sigma-Aldrich) for 45 min were used as APCs. A total of 4 x 105 CD4+ cells (CFSE-loaded CD25- plus Foxp3-GFP+) was mixed with 105 APCs + 1 microg/ml anti-CD3 mAb per well of a 96 well round bottom plate. Proliferation of the effector cells was analyzed by CFSE dilution. Apoptosis of the cells was investigated by annexin V staining and flow cytometry. Positive and negative control gates were made according to T cells cultured only in the presence of IL-2 without anti-CD3/28 stimulation.
Human naive CD4+ T cells were isolated by negative selection by MACS from PBMCs and either transfected with a scrambled siRNA or with a combination of RUNX1 and RUNX3 siRNA. Cells were then cultured under iT reg cell differentiating conditions and mixed with 2 x 105 autologous irradiated PBMCs that were used as APCs and autologous CFSE-labeled CD4+ T cells. T reg cell to responder cell ratio was 1:20, 1:10, and 1:5. To check the proliferation of the CD4+ T cells without suppression, no T reg cells were added in a control group. Cells were stimulated with 2.5 microg/ml anti-CD3 mAb, cultured in a 96-well plate and the proliferation of the effector cells was determined by analyzing the CFSE dilution by flow cytometry after 5 d of culture. Gating on the CD4+CFSE+ T cells enabled the exclusion of APCs and T reg cells.","[{'offsets': [[35, 40]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[42, 45]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[47, 50]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[88, 91]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[109, 114]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[120, 123]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[141, 146]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[146, 149]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[159, 164]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[166, 168]], 'text': ['44'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[170, 172]], 'text': ['25'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[175, 178]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[224, 230]], 'text': ['Cd45.1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[425, 428]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[449, 453]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[460, 469]], 'text': ['Foxp3-GFP'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[515, 518]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[675, 684]], 'text': ['annexin V'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[814, 818]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[832, 835]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[836, 838]], 'text': ['28'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[864, 867]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1003, 1008]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1013, 1018]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1198, 1201]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1306, 1309]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1432, 1435]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1613, 1616]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[92, 101]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[1019, 1024]], 'text': ['siRNA'], 'type': 'Negative_regulation', 'id': 'T30'}]","[{'trigger': 'T29', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T30', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T30', 'id': 'E3', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}]",[],[],[],[]
218,PMC-2800179-13-Materials_and_Methods,"Statistical Analysis
The results were expressed as the mean value +/- S.E.M. of individual experiments. The statistical significance of the differences between mean values was assessed by the Student's t-test and analysis of variance (ANOVA).",[],[],[],[],[],[]
219,PMC-3359311-09-Discussion,"Levels of IL-1beta are increased in the BALF of CF patients but the cellular source of this cytokine and its production in the context of targeted inflammasome activation are still unclear. We first studied airway epithelial cells due to their role in barrier function, proximity to infection, and ability to produce high levels of pro-inflammatory cytokines. However, we found that bronchial epithelial cells do not produce significant amounts of IL-1beta and do not show a significant increase in caspase-1 activation in response to PAO1 and LPS+ATP, in comparison to hematopoeitic mononuclear cells. Hematopoeitically-derived cells, such as monocytes and macrophages, appear to be a principal source of IL-1beta. CFTR is expressed in alveolar macrophages [32], [39] as well as in PBMCs at both the mRNA and protein level [40], [41], and its loss is frequently associated with an augmented inflammatory phenotype.
Despite our findings indicating that bronchial epithelial cells when grown in vitro are unlikely to be significantly involved in the direct production of IL-1beta (Fig. 2a-d), others have shown their capacity to respond to alveolar macrophage-derived IL-1beta and to amplify the inflammatory response through the induction of chemokines and recruitment of inflammatory effector cells [42]. This interaction may constitute a critical component to effective host defense and diminishing the capacity of host cells to respond to IL-1beta may leave the host susceptible to infections by pathogens such as P. aeruginosa [43]. Conversely, overproduction of IL-1beta can also play a key role in chronic inflammatory responses and cause damage to the lung parenchyma [44], [45].
Although we hypothesized that CF cells would secrete increased amounts of IL-1beta, we found that IL-1beta production in CF PBMCs was not increased upon inflammasome stimulation as compared to controls (Fig. 5a-b). This was in contrast to a previous study from our group, which showed increased IL-1beta production by CF PBMCs in response to LPS [46], although this difference may be accounted for by technical issues in stimulation time and dose. Moreover, IL-1beta production was not increased in CF PBMCs with inflammasome stimulation alone as would be anticipated if there were basal levels of NF-kappaB activation. Cells deficient in CFTR are thought to exhibit an increased basal level of NF-kappaB activity, which leads to increased pro-inflammatory cytokine production including an increased availability of pro-IL-1beta for cleavage and secretion. This amplification of IL-1beta secretion was shown by priming THP-1 monocytes and PBMCs with heat-killed P. aeruginosa or LPS prior to stimulation with live P. aeruginosa. This dramatically increased IL-1beta secretion over stimulation with live P. aeruginosa without priming (Fig. 6c). Similarly, if CF PBMCs expressed increased basal NF-kappaB activity, there would be an increase in IL-1beta secretion in the absence of LPS priming. However, no increase in IL-1beta was observed under basal or primed conditions. Studies investigating the production of IL-1beta have been somewhat inconsistent. A study by Reininger et al. [43] provided evidence that human bronchial epithelial cells possessing the deltaF508 CFTR mutation had a slightly reduced capacity to produce IL-1beta and lacked the ability to induce an early NF-kappaB activation in response to P. aeruginosa. Conversely, a study by Kotrange et al. [31] found that murine bone marrow-derived macrophages expressing deltaF508-CFTR produced increased amounts of IL-1beta when compared to macrophages expressing normal CFTR in response to Burkholderia cenocepacia K56-2. The differentiation of monocytes into macrophages may partly account for the differences observed with the study by Kotrange. Inflammasome-mediated IL-1beta production by monocytes and PBMCs does differ from macrophages [47], [48], [49] and macrophages are found to have higher expression of CFTR over monocytes [50]. However, as monocytes and other PBMCs express CFTR [50], [51] and produce large amounts of IL-1beta, they are adequate models to examine the effects of CFTR function on IL-1beta production. Other hematopoeitic cells may also contribute to IL-1beta production. For example, neutrophil counts can be significantly increased in the lungs of CF patients [52], [53], [54] and may produce mature IL-1beta through caspase-1 independent mechanisms [55].
The role of NF-kappaB activation in inflammasome activation and IL-1beta secretion is not straightforward. Studies have revealed an essential role for NF-kappaB activation in the production of pro-IL-1beta and inflammasome components such as NLRP3 [22], [23]. In contrast, deletion of IKKbeta, a kinase essential in NF-kappaB activation, increases IL-1beta secretion in murine macrophages [56], [57] and demonstrates a dual role for NF-kappaB in regulation of IL-1beta. To address this uncertainty in our experiments we also quantified IL-8, an important CF cytokine and marker of NF-kappaB activation [58], and found no differences between CF and control subjects. Similarly, levels of intracellular pro-IL-1beta in THP-1 cells were dependent on NF-kappaB activity and did not increase with CFTRinh172 treatment. Subsequent treatment of THP-1 cells and PBMCs with the NF-kappaB inhibitor Bay11-7082 significantly inhibited both IL-1beta and IL-8 secretion (Fig. 6d-h). Therefore, the IL-1beta and IL-8 responses observed were both dependent upon NF-kappaB activation. Priming with heat-killed P. aeruginosa, like LPS, is unable to induce a strong IL-1beta response as compared to live P. aeruginosa (Fig. 6c), but generated greater NF-kappaB/AP-1 activation (Fig. 6a) and IL-8 secretion (Fig. 6b) than live bacteria despite stimulation at equivalent MOIs. This may be indicative of the different degree and quality of the inflammatory response generated by live as opposed to dead bacteria [59].
Potential shortcomings of these experiments include its translatability to lung disease and issues related to the hypermutability of P. aeruginosa during the evolution of chronic infection. Although the responses measured in peripheral blood cells may not completely reflect the responses occurring in the CF lung, PBMCs have a number of useful advantages: (i) PBMCs are not subject to alterations that may emerge from long-term cell culture, cloning and immortalization, and (ii) PBMCs express a large repertoire of innate immune receptors and secrete a broad array of cytokines and chemokines allowing comprehensive analysis of the modulation of inflammatory responses by CFTR. Consideration must also be given to the nature of P. aeruginosa infection and genotypic changes in P. aeruginosa as infection progresses. P. aeruginosa mediates inflammasome activation through its type III secretion system (T3SS) and the NLRC4 inflammasome [19], [20]. However, clones of P. aeruginosa established during chronic infection may accumulate mutations in virulence factors such as exsA [60]. By employing a deletion mutant in exsA, the key regulator in T3SS transcription, we confirmed that the T3SS is important for IL-1beta secretion (Fig. 5a-b), and that depending on the adaptation in type III secretion, the host IL-1beta response may be up or downregulated [19], [60], [61].
In conclusion, our data are consistent with a role for hematopoietic cells, not airway epithelial cells, as the major source of inflammasome-mediated IL-1beta production in the lungs in response to ATP and P. aeruginosa. Furthermore, we find little evidence to support an increased IL-1beta inflammatory response to NF-kappaB/Inflammasome stimulation in CF patients. Further studies are warranted to determine if adaptations of P. aeruginosa during the course of chronic lung infection alters inflammasome activation, and whether this can be correlated with disease severity in CF.","[{'offsets': [[10, 18]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[448, 456]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[706, 714]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1070, 1078]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1167, 1175]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1442, 1450]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1567, 1575]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1761, 1769]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1785, 1793]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1982, 1990]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2145, 2153]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2566, 2574]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2744, 2752]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2930, 2938]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3004, 3012]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3100, 3108]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3313, 3321]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3821, 3829]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[4082, 4090]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[4160, 4168]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[4230, 4238]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[4381, 4389]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[4501, 4509]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4785, 4793]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4897, 4905]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5366, 5374]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5422, 5430]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5585, 5593]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[7052, 7056]], 'text': ['exsA'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[7143, 7151]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[7244, 7252]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[7457, 7465]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[7589, 7597]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[23, 32]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[105, 108]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T23'}, {'offsets': [[109, 119]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[138, 146]], 'text': ['targeted'], 'type': 'Regulation', 'id': 'T26'}, {'offsets': [[417, 424]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T27'}, {'offsets': [[1056, 1066]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[1549, 1563]], 'text': ['overproduction'], 'type': 'Gene_expression', 'id': 'T29'}, {'offsets': [[1732, 1739]], 'text': ['secrete'], 'type': 'Localization', 'id': 'T30'}, {'offsets': [[1740, 1749]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T31'}, {'offsets': [[1794, 1804]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T32'}, {'offsets': [[1825, 1834]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T33'}, {'offsets': [[1972, 1981]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[1991, 2001]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T35'}, {'offsets': [[2154, 2164]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T36'}, {'offsets': [[2173, 2182]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T37'}, {'offsets': [[2544, 2562]], 'text': ['This amplification'], 'type': 'Positive_regulation', 'id': 'T38'}, {'offsets': [[2575, 2584]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T39'}, {'offsets': [[2734, 2743]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T40'}, {'offsets': [[2753, 2762]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T41'}, {'offsets': [[2918, 2926]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[2939, 2948]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T43'}, {'offsets': [[2956, 2963]], 'text': ['absence'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[2992, 3000]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[3086, 3096]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[3285, 3292]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T47'}, {'offsets': [[3305, 3312]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[3812, 3820]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[3830, 3840]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[4057, 4064]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T51'}, {'offsets': [[4132, 4139]], 'text': ['effects'], 'type': 'Regulation', 'id': 'T52'}, {'offsets': [[4169, 4179]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[4216, 4226]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T54'}, {'offsets': [[4239, 4249]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T55'}, {'offsets': [[4366, 4373]], 'text': ['produce'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[4408, 4419]], 'text': ['independent'], 'type': 'Regulation', 'id': 'T57'}, {'offsets': [[4441, 4445]], 'text': ['role'], 'type': 'Regulation', 'id': 'T69'}, {'offsets': [[4510, 4519]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T70'}, {'offsets': [[4775, 4784]], 'text': ['increases'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[4794, 4803]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T72'}, {'offsets': [[4856, 4865]], 'text': ['dual role'], 'type': 'Regulation', 'id': 'T73'}, {'offsets': [[4883, 4893]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T74'}, {'offsets': [[5351, 5360]], 'text': ['inhibited'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[5384, 5393]], 'text': ['secretion'], 'type': 'Localization', 'id': 'T76'}, {'offsets': [[5440, 5449]], 'text': ['responses'], 'type': 'Regulation', 'id': 'T77'}, {'offsets': [[5469, 5478]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[5569, 5575]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T79'}, {'offsets': [[5594, 5602]], 'text': ['response'], 'type': 'Regulation', 'id': 'T80'}, {'offsets': [[7033, 7041]], 'text': ['deletion'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[7184, 7193]], 'text': ['depending'], 'type': 'Regulation', 'id': 'T82'}, {'offsets': [[7253, 7261]], 'text': ['response'], 'type': 'Regulation', 'id': 'T83'}, {'offsets': [[7269, 7271]], 'text': ['up'], 'type': 'Positive_regulation', 'id': 'T84'}, {'offsets': [[7275, 7288]], 'text': ['downregulated'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[7448, 7456]], 'text': ['mediated'], 'type': 'Positive_regulation', 'id': 'T86'}, {'offsets': [[7466, 7476]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T87'}, {'offsets': [[7490, 7504]], 'text': ['in response to'], 'type': 'Positive_regulation', 'id': 'T88'}, {'offsets': [[7579, 7588]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T89'}, {'offsets': [[7611, 7619]], 'text': ['response'], 'type': 'Regulation', 'id': 'T90'}]","[{'trigger': 'T24', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T25', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T26', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T27', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T28', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T29', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T30', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T31', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T32', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T33', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T34', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T35', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T36', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T37', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T38', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E16']}}, {'trigger': 'T39', 'id': 'E16', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T40', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E18']}}, {'trigger': 'T41', 'id': 'E18', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T42', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E20']}}, {'trigger': 'T43', 'id': 'E20', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T44', 'id': 'E21', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T45', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T46', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T47', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E25']}}, {'trigger': 'T48', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T49', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E27']}}, {'trigger': 'T50', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T51', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T52', 'id': 'E29', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E30']}}, {'trigger': 'T53', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T54', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E32']}}, {'trigger': 'T55', 'id': 'E32', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T56', 'id': 'E33', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T57', 'id': 'E34', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E33']}}, {'trigger': 'T69', 'id': 'E35', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E36']}}, {'trigger': 'T70', 'id': 'E36', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T58']}}, {'trigger': 'T71', 'id': 'E37', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E38']}}, {'trigger': 'T72', 'id': 'E38', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T59']}}, {'trigger': 'T73', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E40']}}, {'trigger': 'T74', 'id': 'E40', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T60']}}, {'trigger': 'T75', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E42']}}, {'trigger': 'T76', 'id': 'E42', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T61']}}, {'trigger': 'T77', 'id': 'E43', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T62']}}, {'trigger': 'T78', 'id': 'E44', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E43']}}, {'trigger': 'T79', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E46']}}, {'trigger': 'T80', 'id': 'E46', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T63']}}, {'trigger': 'T81', 'id': 'E47', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T64']}}, {'trigger': 'T82', 'id': 'E48', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T84', 'id': 'E49', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E52']}}, {'trigger': 'T82', 'id': 'E50', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T85', 'id': 'E51', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E52']}}, {'trigger': 'T83', 'id': 'E52', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T66']}}, {'trigger': 'T86', 'id': 'E53', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E54']}}, {'trigger': 'T87', 'id': 'E54', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T67']}}, {'trigger': 'T88', 'id': 'E55', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E53']}}, {'trigger': 'T89', 'id': 'E56', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E57']}}, {'trigger': 'T90', 'id': 'E57', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T68']}}]","[{'id': 'R1', 'head': {'ref_id': 'T23', 'role': 'Subject'}, 'tail': {'ref_id': 'T1', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E4', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E10', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E21', 'value': ''}, {'id': 'M7', 'type': 'Negation', 'ref_id': 'E22', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E29', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E31', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E34', 'value': ''}, {'id': 'M12', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M13', 'type': 'Speculation', 'ref_id': 'E49', 'value': ''}, {'id': 'M14', 'type': 'Speculation', 'ref_id': 'E51', 'value': ''}, {'id': 'M15', 'type': 'Negation', 'ref_id': 'E57', 'value': ''}, {'id': 'M16', 'type': 'Speculation', 'ref_id': 'E57', 'value': ''}]",[]
220,PMC-2222968-01-Introduction,"Effective immune responses are characterized by T cell activation, which directs adaptive and innate immune responses to kill pathogens efficiently. Dependent on the pathogen, T cells differentiate into different subtypes, such as Th1 or Th2 cells, which are most efficient in defeating microbial or parasitic invaders respectively. A hallmark of Th1 and Th2 differentiation pathways is the exclusiveness of the individual phenotype leading to either Th1 or Th2, but not to mixed populations. The exclusiveness of this mechanism is provided by a polarization process, where Th2 differentiation inhibits Th1 commitment and vice versa. Specifically interleukin 4 (IL-4)-induced STAT6 and GATA3 inhibit differentiation into Th1 cells in the early phase of commitment [1,2]. GATA3 is sufficient to induce a Th2 phenotype [3] and acts not only through the induction of IL-4, IL-5 and IL-13, the Th2 cytokines, but also through the inhibition of Th1 cell-specific factors [3]. Recently, it was shown that T-bet directly modulates GATA3 function, suggesting that transcription factors compete in the early differentiation phase of T cells, potentially integrating environmental signals to finally imprint the T cell phenotype [4,5]. A GATA3-dominated immune response has been shown to be essential in airway hyperresonsiveness [6] and IL-4-dominated responses can break antigen-specific immune tolerance [7]. Overexpression of a dominant negative form of GATA3 [8] or treatment with antisense-mediated GATA3 blockade [9] decreased the severity of the allergic airway hyper-responsiveness.
The discovery of regulatory T (Treg) cells highlights another phenotype of T cells, which is essential for tolerance against self-antigens. Naturally occurring, thymus-derived Treg (nTreg) cells are generated in the thymus and are assumed to protect against the activity of autoreactive T cells in the periphery. These cells express the forkhead transcription factor FOXP3 and constitutively express CD25 on their surface, but they lack expression of Th1 or Th2 cytokines. Particularly interesting are those Treg cells that are generated in the periphery and thus are potential targets for therapeutic interventions. These induced Treg (iTreg) cells were reported to express FOXP3 [10]. The exact mechanisms of iTreg generation are unclear, but T cell receptor (TCR) triggering has been shown to induce FOXP3 expression and suppressive cells in human [11,12], however the phenotype appears to be of transient nature [13,14]. TGF-beta has been demonstrated to be important for the persistent induction of these cells in vitro and in vivo, since animals lacking the TGF-betaRII on T cells have fewer peripherally iTreg cells [15] and suffer from a T cell-dependent multiorgan inflammatory disease [16]. Although the effect of TGF-beta on natural and inducible Treg cell induction has been demonstrated repeatedly [15,17], its molecular mechanisms remain to be identified.
The current study provides evidence that GATA3 and FOXP3 play a competitive role in iTreg cell commitment as T-bet and GATA3 for Th1 and Th2 differentiation, respectively. We show that GATA3 inhibits FOXP3 induction and that IL-4 limits FOXP3 expression in a GATA3-mediated way, both in vitro and in vivo. We also show that GATA3 directly binds to the FOXP3 promoter and thereby prevents the induction of this gene, demonstrating that Th2 differentiation overrules iTreg induction.","[{'offsets': [[647, 660]], 'text': ['interleukin 4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[662, 666]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[676, 681]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[686, 691]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[771, 776]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[864, 868]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[870, 874]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[879, 884]], 'text': ['IL-13'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[999, 1004]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1024, 1029]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1228, 1233]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1328, 1332]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1448, 1453]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1495, 1500]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1949, 1954]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1982, 1986]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2257, 2262]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2385, 2390]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2507, 2515]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2646, 2657]], 'text': ['TGF-betaRII'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2806, 2814]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2993, 2998]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3003, 3008]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3061, 3066]], 'text': ['T-bet'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3071, 3076]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3137, 3142]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3152, 3157]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3177, 3181]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3189, 3194]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3211, 3216]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3276, 3281]], 'text': ['GATA3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3304, 3309]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[668, 675]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T34'}, {'offsets': [[851, 860]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T35'}, {'offsets': [[1014, 1023]], 'text': ['modulates'], 'type': 'Regulation', 'id': 'T36'}, {'offsets': [[1402, 1444]], 'text': ['Overexpression of a dominant negative form'], 'type': 'Negative_regulation', 'id': 'T37'}, {'offsets': [[1501, 1509]], 'text': ['blockade'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1907, 1914]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[1974, 1981]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T40'}, {'offsets': [[2249, 2256]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T41'}, {'offsets': [[2378, 2384]], 'text': ['induce'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[2391, 2401]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2634, 2641]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T44'}, {'offsets': [[3143, 3151]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T45'}, {'offsets': [[3158, 3167]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[3182, 3188]], 'text': ['limits'], 'type': 'Negative_regulation', 'id': 'T47'}, {'offsets': [[3195, 3205]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T48'}, {'offsets': [[3217, 3229]], 'text': ['mediated way'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[3291, 3296]], 'text': ['binds'], 'type': 'Binding', 'id': 'T50'}, {'offsets': [[3310, 3318]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T51'}, {'offsets': [[3331, 3339]], 'text': ['prevents'], 'type': 'Negative_regulation', 'id': 'T52'}, {'offsets': [[3344, 3353]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[3357, 3366]], 'text': ['this gene'], 'type': 'Anaphora', 'id': 'T33'}]","[{'trigger': 'T34', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T1']}}, {'trigger': 'T34', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T4', 'T1']}}, {'trigger': 'T35', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T6', 'T5']}}, {'trigger': 'T35', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T7', 'T5']}}, {'trigger': 'T35', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T8', 'T5']}}, {'trigger': 'T36', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T10', 'T9']}}, {'trigger': 'T37', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T38', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T39', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T40', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T41', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T42', 'id': 'E12', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T43', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T44', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T45', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T26']}}, {'trigger': 'T46', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T47', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E18', 'T28']}}, {'trigger': 'T48', 'id': 'E18', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T29']}}, {'trigger': 'T49', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'T30']}}, {'trigger': 'T50', 'id': 'E20', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T31', 'T32', 'T51']}}, {'trigger': 'T52', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'E20']}}, {'trigger': 'T53', 'id': 'E22', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}]","[{'id': 'R1', 'head': {'ref_id': 'T33', 'role': 'Subject'}, 'tail': {'ref_id': 'T32', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T1', 'T2']}]",[],[]
221,PMC-1920263-04-MATERIALS_AND_METHODS,"5'-Rapid amplification of cDNA ends analysis (RACE)
Total RNA was isolated from A3.01 T cells using RNeasy mini kit (Qiagen). The transcriptional start sites of A3G were identified using the 5'/3' RACE Kit, 2nd Generation (Roche) according to the manufacturer's instructions. The following primers were used: RACE-APO3G1 (5'-TATCCCTTGTACACTTTGT-3') for cDNA synthesis, RACE-APO3G2 (5'-CATACTCCTGGTCACGAT-3') for the first PCR and RACE-APO3Gnest (5'-GAATACACCTGGCCTCGAA-3') for the nested PCR. Reaction products were analyzed by agarose gel electrophoresis, purified using QIAquick gel extraction kit (Qiagen), T/A-cloned into vector pCR4-TOPO (Invitrogen) and sequenced.","[{'offsets': [[161, 164]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
222,PMC-2800179-14-Results,"Degraded CGN Induce Colonic Inflammation
All rats developed diarrhea during degraded carrageenan administration and gross evidence of blood was frequently detected in the stools. Colon length dramatically decreased in all treated rats with a more pronounced effect being observed in the 40 kDa dCGN treated group (Fig. 1A). Furthermore, prolonged exposure to 40 kDa dCGN resulted in high macroscopic and histological scores of inflammation (Fig. 1B, C). Only weak myeloperoxidase activity was detected in both control and dCGN-treated groups (Fig. 1D), indicating that granulocytes did not play a major role in the inflammation at that stage. Histological examination revealed various degrees of mucosal inflammation. Rats treated with 10 kDa dCGN showed edema, epithelium atrophy and slight lymphocyte infiltration (data not shown). These symptoms were totally absent in the colon of control rats (Fig. 1E). More severe mucosal injuries including ulceration, hyperplastic epithelium, crypt distortion and a strong macrophage infiltration, were observed in the 40 kDa dCGN-treated rats (Fig. 1F). No sulphated polysaccharides were detected by toluidine blue staining of colon mucosa from rats treated with either the 10 or 40 kDa dCGN (not shown). Although we cannot exclude that dCGN mat not have retained in the section during the histology procedure, this indicates that these polymers may not have been phagocytosed.","[{'offsets': [[464, 479]], 'text': ['myeloperoxidase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
223,PMC-3333881-22-Caption-Figure_5,"Tat activates the p65-dependent expression of NF-kappaB-responsive genes by occupying the NF-kappaB enhancers and promoting the p65 recruitment with IkappaB-alpha displacement. HeLa cells (5 x 106) were transfected with p3xFLAG-Tat, p3xFLAG-Tat C(22,25,27), p3xFLAG-Tat R(49-57) or empty vector (10 microg); for p65 RNA interference, cells (5 x 106) were transfected with p3xFLAG-Tat (10 microg) and siRNA p65 or siRNA control (200 pmol). Twenty-four-hour post-transfection, total RNA was extracted and analysed by real-time PCR to evaluate the expression of MIP-1alpha (A), CSF3 (B), LTA (C), NFKBIA (D), TLR2 (E), GAPDH (F), ACTB (G) genes. (H) HeLa cells (5 x 106) were transfected with p3xFLAG-Tat, or empty vector (10 microg) and 48 h later ChIP was performed with anti-p65 antibody. Real-time PCR was performed with primers specific for the indicated promoters. (I) HeLa cells (5 x 106) were transfected with empty vector, or p3xFLAG-Tat (10 microg) in presence or absence of siRNA p65, or siRNA control (200 pmol); 48 h later, ChIP was performed with anti-FLAG antibody. Real-time PCR was performed with primers specific for the indicated promoters. (J) HeLa cells (5 x 106) were transfected with empty vector, p3xFLAG-Tat (10 microg), or empty vector plus siRNA IkappaB-alpha or siRNA control (200 pmol); 48 h later, ChIP was performed with anti-IkappaB-alpha antibody. Real-time PCR was performed with primers specific for the indicated promoters. Values (mean +/- SE, n = 3) are shown. The asterisks indicate statistically significant differences compared to the control (empty vector) according to the Student's t-test (P < 0.05).","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 21]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[128, 131]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[149, 162]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[228, 231]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[241, 256]], 'text': ['Tat C(22,25,27)'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[266, 278]], 'text': ['Tat R(49-57)'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[312, 315]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[380, 383]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[400, 409]], 'text': ['siRNA p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[559, 569]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[575, 579]], 'text': ['CSF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[585, 588]], 'text': ['LTA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[594, 600]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[606, 610]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[616, 621]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[627, 631]], 'text': ['ACTB'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[698, 701]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[940, 943]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[982, 991]], 'text': ['siRNA p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1226, 1229]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1264, 1283]], 'text': ['siRNA IkappaB-alpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[76, 85]], 'text': ['occupying'], 'type': 'Binding', 'id': 'T23'}, {'offsets': [[114, 123]], 'text': ['promoting'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[132, 143]], 'text': ['recruitment'], 'type': 'Binding', 'id': 'T25'}, {'offsets': [[163, 175]], 'text': ['displacement'], 'type': 'Binding', 'id': 'T26'}, {'offsets': [[320, 332]], 'text': ['interference'], 'type': 'Negative_regulation', 'id': 'T27'}, {'offsets': [[545, 555]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T28'}]","[{'trigger': 'T23', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T24', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T1']}}, {'trigger': 'T25', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T24', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T1']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T3', 'T4']}}, {'trigger': 'T27', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T28', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T28', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T28', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T28', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T28', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T28', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E7', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E8', 'value': ''}, {'id': 'M4', 'type': 'Speculation', 'ref_id': 'E9', 'value': ''}, {'id': 'M5', 'type': 'Speculation', 'ref_id': 'E10', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E13', 'value': ''}]",[]
224,PMC-2674207-24-Caption-Figure_4,"Fluticasone propionate competes with phospho-GATA-3 for importin-alpha.
(A) schematic representation of the in vitro binding competition assay. (B) GR isolated from FP (10-8 M) stimulated cells enhances GR-importin-alpha binding in the presence (*) and absence (==blacksquare, square, filled==) of activated GATA-3. * p<0.05 compared to no activated GR. (C) GATA-3 isolated from anti-CD3/CD28-stimulated cells does not attenuate GR-importin-alpha association. *p<0.05 compared to control. (D) Activated GR blocks the ability of purified phospho-GATA-3 isolated from anti-CD3/CD28-stimulated cells interacting with immobilised importin-alpha in an in vitro binding assay. *p<0.05 compared to GATA-3 isolated from unstimulated cells. #p<0.05 compared to stimulated GATA-3-importin binding. (E) The effect of activated (*) versus unstimulated (o) GR on attenuation of GATA-3-importin-alpha association was concentration-dependent. *p<0.05, **p<0.01 between groups. All results are expressed as mean+/-SEM of three independent experiments and analysed by ANOVA followed by Newman-Keuls post-test.","[{'offsets': [[45, 51]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 150]], 'text': ['GR'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[203, 205]], 'text': ['GR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[308, 314]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[350, 352]], 'text': ['GR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[358, 364]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[429, 431]], 'text': ['GR'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[503, 505]], 'text': ['GR'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[545, 551]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[691, 697]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[763, 769]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[844, 846]], 'text': ['GR'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[865, 871]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[37, 44]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T14'}, {'offsets': [[194, 202]], 'text': ['enhances'], 'type': 'Positive_regulation', 'id': 'T15'}, {'offsets': [[221, 228]], 'text': ['binding'], 'type': 'Binding', 'id': 'T16'}, {'offsets': [[340, 349]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T17'}, {'offsets': [[419, 428]], 'text': ['attenuate'], 'type': 'Negative_regulation', 'id': 'T18'}, {'offsets': [[447, 458]], 'text': ['association'], 'type': 'Binding', 'id': 'T19'}, {'offsets': [[493, 502]], 'text': ['Activated'], 'type': 'Positive_regulation', 'id': 'T20'}, {'offsets': [[506, 512]], 'text': ['blocks'], 'type': 'Negative_regulation', 'id': 'T21'}, {'offsets': [[537, 544]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T22'}, {'offsets': [[597, 608]], 'text': ['interacting'], 'type': 'Binding', 'id': 'T23'}, {'offsets': [[752, 762]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T24'}, {'offsets': [[779, 786]], 'text': ['binding'], 'type': 'Binding', 'id': 'T25'}, {'offsets': [[806, 815]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[827, 839]], 'text': ['unstimulated'], 'type': 'Positive_regulation', 'id': 'T27'}, {'offsets': [[850, 861]], 'text': ['attenuation'], 'type': 'Negative_regulation', 'id': 'T28'}, {'offsets': [[887, 898]], 'text': ['association'], 'type': 'Binding', 'id': 'T29'}, {'offsets': [[917, 926]], 'text': ['dependent'], 'type': 'Regulation', 'id': 'T30'}]","[{'trigger': 'T14', 'id': 'E1', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T15', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'T2']}}, {'trigger': 'T16', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T17', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T18', 'id': 'E5', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E6', 'T6']}}, {'trigger': 'T19', 'id': 'E6', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T20', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T21', 'id': 'E8', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E9', 'T8']}}, {'trigger': 'T23', 'id': 'E9', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T22', 'id': 'E10', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T24', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T25', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T26', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T27', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T28', 'id': 'E15', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E16', 'T12']}}, {'trigger': 'T29', 'id': 'E16', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T30', 'id': 'E17', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E15']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E5', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E14', 'value': ''}]",[]
225,PMC-2806624-26-Caption-Figure_2,"RUNX1 and RUNX3 expression in Foxp3+ T reg cells and in human CD4+, CD127-, CD25high cells. (A) Real-time PCR analysis of CD4+, CD127-, and CD25high T reg cells and CD4+, CD127+, and CD25neg T cells isolated from human peripheral blood showed an increased expression of IL-10, TGF-beta, FOXP3, and RUNX3 mRNA in CD25+ compared with CD25- cells. Bars show the mean +/- SE of three independent experiments. (B) Human tonsil sections were analyzed by confocal microscopy. Tissue sections were stained for FOXP3, RUNX1, RUNX3, and DAPI or isotype controls. HEK cells RUNX1-transfected or not transfected served as additional control for RUNX1 staining. Data shown are representative from one of the three tissue samples with similar results. Bars, 5 microm. Statistical differences were verified by the paired Student's t test. *, P < 0.05; **, P < 0.01.","[{'offsets': [[0, 5]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[10, 15]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[30, 35]], 'text': ['Foxp3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[62, 65]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[68, 73]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[76, 80]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[122, 125]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[128, 133]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[140, 144]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[165, 168]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[171, 176]], 'text': ['CD127'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[183, 187]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[270, 275]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[277, 285]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[287, 292]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[298, 303]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[312, 316]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[332, 336]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[502, 507]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[509, 514]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[516, 521]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[553, 562]], 'text': ['HEK cells'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[563, 568]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[633, 638]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[16, 26]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T25'}, {'offsets': [[246, 255]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T26'}, {'offsets': [[256, 266]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T27'}, {'offsets': [[569, 580]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T28'}, {'offsets': [[588, 599]], 'text': ['transfected'], 'type': 'Gene_expression', 'id': 'T29'}]","[{'trigger': 'T25', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T25', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T26', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T27', 'id': 'E4', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T26', 'id': 'E5', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E6']}}, {'trigger': 'T27', 'id': 'E6', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T26', 'id': 'E7', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T27', 'id': 'E8', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T26', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T27', 'id': 'E10', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T28', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T29', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}]",[],[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E12', 'value': ''}]",[]
226,PMC-1942070-07-Discussion,"4Protein kinase D serine kinases have been proposed to regulate diverse cellular functions including the phosphorylation and nuclear localisation of class II HDACs and the phosphorylation of HSP27. It has also been suggested that PKDs act as mitochondrial sensors for oxidative stress and play a role in regulating NFkappaB transcription factors [41]. Most of the data about the function of PKDs has come from experiments that ectopically express active or inhibitory PKD mutants or that use RNAi to reduce PKD expression. We have used gene targeting to specifically delete PKD alleles in DT40 chicken B cells and can thus use PKD-null DT40 cells to assess the relative contribution of individual PKD isoforms in class II HDAC control versus oxidative stress responses and NFkappaB regulation in lymphocytes. We have previously used these PKD-null DT40 cells to define an essential role for PKDs in regulation of class II HDACs, the present report now describes an indispensable role for PKDs in regulating the phosphorylation of HSP27 on serine 82, a site previously identified as a target for the p38-MAPKAPK2 signalling cascade [42]. However, studies of PKD-null DT40 cells reveal that PKD family kinases are not essential for oxidative stress survival responses nor are they required for activation of NFkappaB transcription factors. These latter findings are in striking contrast to previous observations in HeLa and epithelial cell lines where overexpression/RNAi approaches have implicated PKD1/2 in the control of proliferation, survival and NFkappaB activation [20,23]. Hence, the present report shows that the proposed roles for PKDs as key sensors that modulate survival pathways in response to oxidative stress and regulate cell survival and proliferation are not ubiquitous and may be restricted to certain cell lineages. Taken together, these data indicate that loss of expression of PKD family members does not globally impact on early BCR-regulated signalling pathways.","[{'offsets': [[191, 196]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1030, 1035]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1103, 1111]], 'text': ['MAPKAPK2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1497, 1501]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1502, 1503]], 'text': ['2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[18, 24]], 'text': ['serine'], 'type': 'Entity', 'id': 'T7'}, {'offsets': [[55, 63]], 'text': ['regulate'], 'type': 'Regulation', 'id': 'T8'}, {'offsets': [[64, 90]], 'text': ['diverse cellular functions'], 'type': 'Anaphora', 'id': 'T6'}, {'offsets': [[172, 187]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T9'}, {'offsets': [[996, 1006]], 'text': ['regulating'], 'type': 'Regulation', 'id': 'T10'}, {'offsets': [[1011, 1026]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T11'}, {'offsets': [[1039, 1048]], 'text': ['serine 82'], 'type': 'Entity', 'id': 'T12'}, {'offsets': [[1084, 1090]], 'text': ['target'], 'type': 'Regulation', 'id': 'T13'}]","[{'trigger': 'T8', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T9', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T7']}}, {'trigger': 'T10', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T11', 'id': 'E4', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T12']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T2', 'T12']}}]","[{'id': 'R1', 'head': {'ref_id': 'T6', 'role': 'Subject'}, 'tail': {'ref_id': 'T9', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}]",[]
227,PMC-1134658-04-Results,"Human B cells express BMP-6 receptors
Detailed knowledge regarding expression of different BMP receptors in B cells is currently not available. To further elucidate the role of BMPs in human B cells, we performed western blot analysis for type I and type II BMP receptors. This analysis revealed that the type I receptors Act-RIA, BMP-RIB and the type II receptors BMP-RII and Act-RIIb are expressed on resting human B-cells (Figure 4). Ramos cells expressed the type I receptors Act-RIA, weakly BMP-RIB and the type II receptor BMP-RII, but more weakly than normal B cells (Figure 4). HL60 cells were used for comparison and weakly expressed Act-RIA and BMP-RII.
Taken together, these data show that normal human B cells and Ramos cells express a set of BMP receptors, previously shown to bind BMP-6 [16].","[{'offsets': [[22, 27]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[322, 329]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[331, 338]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[365, 372]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[377, 385]], 'text': ['Act-RIIb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[480, 487]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[496, 503]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[529, 536]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[643, 650]], 'text': ['Act-RIA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[655, 662]], 'text': ['BMP-RII'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[795, 800]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[390, 399]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T12'}, {'offsets': [[449, 458]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T13'}, {'offsets': [[633, 642]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T14'}, {'offsets': [[790, 794]], 'text': ['bind'], 'type': 'Binding', 'id': 'T15'}]","[{'trigger': 'T12', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T12', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T13', 'id': 'E6', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T13', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T14', 'id': 'E8', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T14', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T15', 'id': 'E10', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}]",[],[],[],[]
228,PMC-1134658-11-Methods,"Growth factors/supplements
The following reagents were used at indicated concentrations: recombinant human (rhu) BMP-6 (1 mug/ml, if not specified otherwise), rhu BMP-RIB/ALK-6/Fc Chimera (5 mug/ml), rhu BMPR-II/Fc Chimera (5 mug/ml), and recombinant mouse Noggin (5 mug/ml) were purchased from R&D Systems (Abingdon, UK); Anti-IgM F(ab)2 fragments of rabbit polyclonal antibodies to human IgM heavy chain (37.5 mug/ml) was obtained from Dako, Copenhagen, Denmark and rhu CD40 ligand (CD40L, 10 ng/ml) was a gift from Immunex Corp. (Seattle, WA).","[{'offsets': [[113, 118]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[163, 170]], 'text': ['BMP-RIB'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[171, 176]], 'text': ['ALK-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[204, 211]], 'text': ['BMPR-II'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[257, 263]], 'text': ['Noggin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[472, 483]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[485, 490]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
229,PMC-1134658-09-Conclusion,"In conclusion, our results show that BMP-6 induces activation of intracellular Smad signalling in mature human B-cells with consecutive production of Id1 protein. Furthermore, we report that BMP-6 has an antiproliferative effect in B cells stimulated with anti-IgM alone or the combined action of anti-IgM and CD40L. Additionally, BMP-6 induces cell death in activated memory B cells and Ramos cells. Taken together, these results provide a rationale to further examine the role of BMP-6 signalling in normal B cell biology as well as in pathologic conditions like B cell malignancies and autoimmune disorders.","[{'offsets': [[37, 42]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[150, 153]], 'text': ['Id1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[191, 196]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[310, 315]], 'text': ['CD40L'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[331, 336]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[482, 487]], 'text': ['BMP-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[124, 135]], 'text': ['consecutive'], 'type': 'Positive_regulation', 'id': 'T7'}, {'offsets': [[136, 146]], 'text': ['production'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T8', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}]",[],[],[],[]
230,PMC-2806624-04-RESULTS,"Regulation of FOXP3 promoter activity and FOXP3 protein expression by RUNX1 and RUNX3
To investigate the effect of RUNX1 and RUNX3 binding to the RUNX binding sites in the FOXP3 promoter, we transfected human peripheral blood CD4+ T cells with a FOXP3 promoter luciferase reporter vector and RUNX1 or RUNX3 expression vectors. An increase in luciferase activity was observed only when the FOXP3 promoter (-511 to +176) luciferase construct was cotransfected with RUNX1 or RUNX3 expression vectors (Fig. 4 A). The increase in promoter activity was greater upon cotransfection of RUNX3 compared with RUNX1. Luciferase expression was abrogated when the Runx binding sites in the FOXP3 promoter (-511 to +176) luciferase construct were mutated (Fig. 4 A). In these experiments, the overexpression of RUNX1 and RUNX3 eliminated the need of TGF-beta for FOXP3 promoter activation and PMA/ionomycin stimulation was sufficient.
To examine the role of each of the three RUNX binding sites for the FOXP3 promoter activity, we mutated each individually or in combination. No reduction in luciferase activity was observed when the -53 site was mutated and only a slight reduction when either the -287 or -333 site was mutated (Fig. 4 B). However, mutating the -53 site in combination with one of the other two sites led to a significant decrease in luciferase activity, with the greatest reduction observed when all three binding sites were mutated (Fig. 4 B), suggesting that the identified binding sites have redundant functions and RUNX binding to more than one site is necessary for the full activation of the FOXP3 promoter. Supporting these findings, the overexpression of RUNX1 in human primary CD4+ T cells resulted in significantly elevated levels of FOXP3 protein measured by flow cytometry after 48 h. This was achieved without any requirement for anti-CD3, anti-CD28 stimulation, or the presence of TGF-beta. Although there was a trend, the transfection of CD4+ T cells with RUNX3 did not lead to statistically significant increase in FOXP3 (Fig. S5).","[{'offsets': [[14, 19]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[42, 47]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[70, 75]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[80, 85]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[115, 120]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[125, 130]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[172, 177]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[226, 229]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[246, 271]], 'text': ['FOXP3 promoter luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[292, 297]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[301, 306]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[342, 352]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[389, 429]], 'text': ['FOXP3 promoter (-511 to +176) luciferase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[463, 468]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[472, 477]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[578, 583]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[598, 603]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[605, 615]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[676, 681]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[706, 716]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[796, 801]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[806, 811]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[835, 843]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[848, 853]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[988, 993]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1077, 1087]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1337, 1347]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1523, 1527]], 'text': ['RUNX'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1602, 1607]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1667, 1672]], 'text': ['RUNX1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1690, 1693]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1748, 1753]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1852, 1855]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1862, 1866]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1899, 1907]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1957, 1960]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1975, 1980]], 'text': ['RUNX3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2035, 2040]], 'text': ['FOXP3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[0, 10]], 'text': ['Regulation'], 'type': 'Regulation', 'id': 'T40'}, {'offsets': [[20, 28]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T41'}, {'offsets': [[29, 37]], 'text': ['activity'], 'type': 'Positive_regulation', 'id': 'T42'}, {'offsets': [[56, 66]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[131, 138]], 'text': ['binding'], 'type': 'Binding', 'id': 'T44'}, {'offsets': [[146, 164]], 'text': ['RUNX binding sites'], 'type': 'Entity', 'id': 'T45'}, {'offsets': [[191, 202]], 'text': ['transfected'], 'type': 'Positive_regulation', 'id': 'T46'}, {'offsets': [[307, 317]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T47'}, {'offsets': [[330, 338]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T48'}, {'offsets': [[444, 457]], 'text': ['cotransfected'], 'type': 'Positive_regulation', 'id': 'T49'}, {'offsets': [[478, 488]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T50'}, {'offsets': [[513, 521]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[525, 533]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T52'}, {'offsets': [[560, 574]], 'text': ['cotransfection'], 'type': 'Gene_expression', 'id': 'T53'}, {'offsets': [[616, 626]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T54'}, {'offsets': [[631, 640]], 'text': ['abrogated'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[778, 792]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T56'}, {'offsets': [[827, 831]], 'text': ['need'], 'type': 'Positive_regulation', 'id': 'T57'}, {'offsets': [[854, 862]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[863, 873]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T59'}, {'offsets': [[1064, 1073]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T60'}, {'offsets': [[1158, 1167]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T61'}, {'offsets': [[1325, 1333]], 'text': ['decrease'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[1376, 1385]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T63'}, {'offsets': [[1480, 1493]], 'text': ['binding sites'], 'type': 'Entity', 'id': 'T64'}, {'offsets': [[1528, 1535]], 'text': ['binding'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[1561, 1570]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[1584, 1594]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[1608, 1616]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T68'}, {'offsets': [[1649, 1663]], 'text': ['overexpression'], 'type': 'Gene_expression', 'id': 'T69'}, {'offsets': [[1729, 1737]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T70'}, {'offsets': [[1801, 1805]], 'text': ['This'], 'type': 'Anaphora', 'id': 'T39'}, {'offsets': [[1831, 1842]], 'text': ['requirement'], 'type': 'Positive_regulation', 'id': 'T71'}, {'offsets': [[1941, 1953]], 'text': ['transfection'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[2023, 2031]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T73'}]","[{'trigger': 'T40', 'id': 'E1', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T3']}}, {'trigger': 'T42', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T1', 'T41']}}, {'trigger': 'T40', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T4']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T3']}}, {'trigger': 'T43', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T40', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T4']}}, {'trigger': 'T44', 'id': 'E7', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T5', 'T7', 'T45']}}, {'trigger': 'T44', 'id': 'E8', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T6', 'T7', 'T45']}}, {'trigger': 'T46', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T47', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T46', 'id': 'E11', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E12']}}, {'trigger': 'T47', 'id': 'E12', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T46', 'id': 'E13', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E14']}}, {'trigger': 'T47', 'id': 'E14', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T48', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T12', 'E16']}}, {'trigger': 'T49', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T48', 'id': 'E17', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T12', 'E18']}}, {'trigger': 'T49', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T48', 'id': 'E19', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T12', 'E20']}}, {'trigger': 'T49', 'id': 'E20', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E23']}}, {'trigger': 'T50', 'id': 'E21', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T50', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T14']}}, {'trigger': 'T50', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T51', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T7', 'E25', 'T52']}}, {'trigger': 'T53', 'id': 'E25', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T51', 'id': 'E26', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'Site'], 'ref_id': ['T7', 'E27', 'T52']}}, {'trigger': 'T53', 'id': 'E27', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T54', 'id': 'E28', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T55', 'id': 'E29', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T56', 'id': 'E30', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T21']}}, {'trigger': 'T56', 'id': 'E31', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T57', 'id': 'E32', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T23']}}, {'trigger': 'T59', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T24', 'T58']}}, {'trigger': 'T60', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T61', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T62', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T63', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T65', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T28', 'T29', 'T64']}}, {'trigger': 'T66', 'id': 'E39', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'E38']}}, {'trigger': 'T67', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T29', 'T68']}}, {'trigger': 'T69', 'id': 'E41', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T70', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T32', 'E41']}}, {'trigger': 'T71', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T35']}}, {'trigger': 'T72', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T73', 'id': 'E45', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T38', 'E44']}}]","[{'id': 'R1', 'head': {'ref_id': 'T39', 'role': 'Subject'}, 'tail': {'ref_id': 'T70', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E34', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E39', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E43', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}]",[]
231,PMC-2674207-20-Discussion,"Here we have demonstrated, to our knowledge for the first time, that corticosteroids may inhibit GATA-3 function and therefore the transcription of Th2 genes via two distinct but interacting molecular mechanisms. Firstly, corticosteroid-activated GR appears to compete with activated GATA-3 for nuclear import via importin-alpha, which is required for the nuclear transport of both GATA-3 and GR. Secondly, corticosteroids at higher concentrations increase the expression of MKP-1, a potent inhibitor of p38 MAPK activity and thereby prevent T cell receptor/co-receptor activation of p38 MAPK to prevent the phosphorylation of GATA-3 that is necessary for interaction with importin-alpha and subsequent nuclear import.
We have previously shown that translocation of GATA-3 from the cytoplasm to the nucleus involves the nuclear transporter protein importin-alpha, which interacts with phosphorylated GATA-3 [12]. We have also previously reported that GATA-3 knockdown using siRNA results in suppression of anti-CD3/CD28-stimulated IL-4/IL-5 mRNA induction, thus implicating an essential role for GATA-3 in the transcription of these genes [12]. We now confirm, in human T cells, that GR also uses the same nuclear import mechanism as GATA-3 [22]. We therefore propose that there is competition between ligand-activated GR and phospho-GATA-3 for nuclear import. Furthermore, we have shown that there is preferential binding of importin-alpha to activated GR over phospho-GATA-3, so that corticosteroids would preferentially reduce GATA-3 entry and thus rapidly switch off Th2 gene transcription without any need for any intermediate steps. Furthermore, there was some degree of specificity for GATA-3, as nuclear translocation of the p65 subunit of NF-kappaB was not affected by corticosteroid exposure.
We tested some alternative explanations for this effect of FP on GATA-3 nuclear exclusion and failed to show that FP either enhances GATA-3 nuclear export directly or induces GATA-3 degradation. The evidence from the in vitro competition assays does, however, suggest that purified activated GR can clearly attenuate purified phospho-GATA-3-importin-alpha association and that the converse does not occur. Furthermore, we have shown that only phospho-GATA-3 can associate with importin-alpha. This mechanism is sensitive to very low concentrations of corticosteroid and would be rapid in onset as no changes in protein synthesis are required. This acute mechanism may also contribute to the reduction in GATA-3 nuclear import and may play a major role at low corticosteroid concentrations and/or at early time points prior to MKP-1 induction.
Corticosteroids can modulate p38 MAPK activity through the induction of MKP-1, a potent endogenous inhibitor of MAPK function [38],[39]. We report here a rapid induction of MKP-1 mRNA following stimulation of cells with relatively high concentrations of FP. We hypothesize that this rapid induction of MKP-1 can reduce GATA-3 nuclear import by attenuating p38 MAPK activity and subsequent GATA-3 phosphorylation, thus preventing nuclear translocation. The location of the serine residue(s) of GATA-3 that are phosphorylated by p38 MAPK are currently unknown, but a bioinformatics search (Motif Scanner, http://scansite.mit.edu/motifscan_seq.phtml) indicates at least three potential p38 MAPK-sensitive serine residues.
As predicted from these in vitro data, impairment of GATA-3 nuclear import by FP may, at least in part, underlie the efficacy of corticosteroids in suppressing allergic inflammation. Although we did not assess the acute inhibitory effect of FP on the expression of IL-4 mRNA in vivo, a single inhalation of FP (500 microg) may have comparable effects, as it provides plasma levels within a relevant range of concentrations used to suppress IL-4 transcription in our in vitro system [37]. A lower dose of inhaled FP (100 microg) was not effective, but plasma concentrations may be below those required for GATA-3 inhibition. However, it is likely that the higher concentrations of FP in the airways after inhaled administration would be effective in inhibiting GATA-3 in airway T cells of asthma patients. The study of PBMCs from asthma patients treated with inhaled corticosteroid therapy clearly demonstrates that these molecular mechanisms are likely to also occur in patients at therapeutic doses of inhaled corticosteroids. In addition, previous studies have shown that corticosteroids can suppress IL-4 and IL-5 release from peripheral blood cells of asthma patients in vitro and in vivo [40]-[42].
In summary, our data provide evidence for a novel action of corticosteroids: suppression of allergic inflammation through a rapid inhibitory effect on GATA-3 nuclear translocation by preferential binding to the shared nuclear import protein importin-alpha and by a second mechanism involving increased synthesis of MKP-1, which inhibits p38 MAPK, thus preventing the phosphorylation of GATA-3 that is necessary for nuclear translocation of GATA-3. These two mechanisms are likely to be synergistic, accounting for the rapid and potent effect of corticosteroids on allergic inflammation. This is exemplified by the rapid inhibitory effect of topical corticosteroids on nasal Th2 cytokine release after allergen provocation in individuals with seasonal allergic rhinitis (hay fever) [43]. Prevention of phospho-GATA-3 interaction with importin-alpha may provide a new approach for the development of novel therapies for the treatment of allergic diseases.","[{'offsets': [[97, 103]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[247, 249]], 'text': ['GR'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[284, 290]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[382, 388]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[393, 395]], 'text': ['GR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[475, 480]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[627, 633]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[766, 772]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[900, 906]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[951, 957]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1031, 1035]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1036, 1040]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1096, 1102]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1184, 1186]], 'text': ['GR'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1234, 1240]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1319, 1321]], 'text': ['GR'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1334, 1340]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1454, 1456]], 'text': ['GR'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1470, 1476]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1530, 1536]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1693, 1699]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1733, 1736]], 'text': ['p65'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1868, 1874]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1936, 1942]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1978, 1984]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2095, 2097]], 'text': ['GR'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2137, 2143]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2254, 2260]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2507, 2513]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2629, 2634]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2718, 2723]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2819, 2824]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2948, 2953]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2965, 2971]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3035, 3041]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3139, 3145]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3418, 3424]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3630, 3634]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3805, 3809]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3970, 3976]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4125, 4131]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4468, 4472]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4477, 4481]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4720, 4726]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4884, 4889]], 'text': ['MKP-1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4955, 4961]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5009, 5015]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5378, 5384]], 'text': ['GATA-3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[237, 246]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T51'}, {'offsets': [[261, 268]], 'text': ['compete'], 'type': 'Negative_regulation', 'id': 'T52'}, {'offsets': [[274, 283]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T53'}, {'offsets': [[295, 302]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T54'}, {'offsets': [[303, 309]], 'text': ['import'], 'type': 'Localization', 'id': 'T55'}, {'offsets': [[310, 313]], 'text': ['via'], 'type': 'Regulation', 'id': 'T56'}, {'offsets': [[339, 347]], 'text': ['required'], 'type': 'Regulation', 'id': 'T57'}, {'offsets': [[356, 363]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T58'}, {'offsets': [[364, 373]], 'text': ['transport'], 'type': 'Localization', 'id': 'T59'}, {'offsets': [[448, 456]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T60'}, {'offsets': [[461, 471]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T61'}, {'offsets': [[596, 603]], 'text': ['prevent'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[608, 623]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T63'}, {'offsets': [[634, 638]], 'text': ['that'], 'type': 'Anaphora', 'id': 'T49'}, {'offsets': [[642, 651]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T64'}, {'offsets': [[656, 667]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T65'}, {'offsets': [[692, 702]], 'text': ['subsequent'], 'type': 'Positive_regulation', 'id': 'T66'}, {'offsets': [[703, 710]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T67'}, {'offsets': [[711, 717]], 'text': ['import'], 'type': 'Localization', 'id': 'T68'}, {'offsets': [[749, 762]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T69'}, {'offsets': [[799, 806]], 'text': ['nucleus'], 'type': 'Entity', 'id': 'T70'}, {'offsets': [[807, 815]], 'text': ['involves'], 'type': 'Regulation', 'id': 'T71'}, {'offsets': [[870, 879]], 'text': ['interacts'], 'type': 'Binding', 'id': 'T72'}, {'offsets': [[885, 899]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T73'}, {'offsets': [[958, 967]], 'text': ['knockdown'], 'type': 'Gene_expression', 'id': 'T74'}, {'offsets': [[991, 1002]], 'text': ['suppression'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[1020, 1030]], 'text': ['stimulated'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[1046, 1055]], 'text': ['induction'], 'type': 'Transcription', 'id': 'T77'}, {'offsets': [[1087, 1091]], 'text': ['role'], 'type': 'Regulation', 'id': 'T78'}, {'offsets': [[1110, 1123]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T79'}, {'offsets': [[1127, 1138]], 'text': ['these genes'], 'type': 'Anaphora', 'id': 'T50'}, {'offsets': [[1206, 1213]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T80'}, {'offsets': [[1214, 1220]], 'text': ['import'], 'type': 'Localization', 'id': 'T81'}, {'offsets': [[1282, 1293]], 'text': ['competition'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[1326, 1333]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T83'}, {'offsets': [[1345, 1352]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T84'}, {'offsets': [[1353, 1359]], 'text': ['import'], 'type': 'Localization', 'id': 'T85'}, {'offsets': [[1415, 1422]], 'text': ['binding'], 'type': 'Binding', 'id': 'T86'}, {'offsets': [[1444, 1453]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1462, 1469]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T88'}, {'offsets': [[1523, 1529]], 'text': ['reduce'], 'type': 'Negative_regulation', 'id': 'T89'}, {'offsets': [[1537, 1542]], 'text': ['entry'], 'type': 'Localization', 'id': 'T90'}, {'offsets': [[1704, 1711]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T91'}, {'offsets': [[1712, 1725]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T92'}, {'offsets': [[1766, 1774]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T93'}, {'offsets': [[1847, 1858]], 'text': ['this effect'], 'type': 'Negative_regulation', 'id': 'T94'}, {'offsets': [[1875, 1882]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T95'}, {'offsets': [[1883, 1892]], 'text': ['exclusion'], 'type': 'Localization', 'id': 'T96'}, {'offsets': [[1927, 1935]], 'text': ['enhances'], 'type': 'Positive_regulation', 'id': 'T97'}, {'offsets': [[1943, 1950]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T98'}, {'offsets': [[1951, 1957]], 'text': ['export'], 'type': 'Localization', 'id': 'T99'}, {'offsets': [[1970, 1977]], 'text': ['induces'], 'type': 'Positive_regulation', 'id': 'T100'}, {'offsets': [[1985, 1996]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T101'}, {'offsets': [[2085, 2094]], 'text': ['activated'], 'type': 'Positive_regulation', 'id': 'T102'}, {'offsets': [[2110, 2119]], 'text': ['attenuate'], 'type': 'Negative_regulation', 'id': 'T103'}, {'offsets': [[2129, 2136]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T104'}, {'offsets': [[2159, 2170]], 'text': ['association'], 'type': 'Binding', 'id': 'T105'}, {'offsets': [[2246, 2253]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T106'}, {'offsets': [[2265, 2274]], 'text': ['associate'], 'type': 'Binding', 'id': 'T107'}, {'offsets': [[2476, 2486]], 'text': ['contribute'], 'type': 'Positive_regulation', 'id': 'T108'}, {'offsets': [[2494, 2503]], 'text': ['reduction'], 'type': 'Negative_regulation', 'id': 'T109'}, {'offsets': [[2514, 2521]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T110'}, {'offsets': [[2522, 2528]], 'text': ['import'], 'type': 'Localization', 'id': 'T111'}, {'offsets': [[2550, 2554]], 'text': ['role'], 'type': 'Regulation', 'id': 'T112'}, {'offsets': [[2635, 2644]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T113'}, {'offsets': [[2705, 2714]], 'text': ['induction'], 'type': 'Positive_regulation', 'id': 'T114'}, {'offsets': [[2806, 2815]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T115'}, {'offsets': [[2830, 2839]], 'text': ['following'], 'type': 'Positive_regulation', 'id': 'T116'}, {'offsets': [[2935, 2944]], 'text': ['induction'], 'type': 'Gene_expression', 'id': 'T117'}, {'offsets': [[2958, 2964]], 'text': ['reduce'], 'type': 'Negative_regulation', 'id': 'T118'}, {'offsets': [[2972, 2979]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T119'}, {'offsets': [[2980, 2986]], 'text': ['import'], 'type': 'Localization', 'id': 'T120'}, {'offsets': [[2990, 3001]], 'text': ['attenuating'], 'type': 'Negative_regulation', 'id': 'T121'}, {'offsets': [[3024, 3034]], 'text': ['subsequent'], 'type': 'Regulation', 'id': 'T122'}, {'offsets': [[3042, 3057]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T123'}, {'offsets': [[3064, 3074]], 'text': ['preventing'], 'type': 'Negative_regulation', 'id': 'T124'}, {'offsets': [[3075, 3082]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T125'}, {'offsets': [[3083, 3096]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T126'}, {'offsets': [[3118, 3132]], 'text': ['serine residue'], 'type': 'Entity', 'id': 'T127'}, {'offsets': [[3155, 3169]], 'text': ['phosphorylated'], 'type': 'Phosphorylation', 'id': 'T128'}, {'offsets': [[3404, 3414]], 'text': ['impairment'], 'type': 'Negative_regulation', 'id': 'T129'}, {'offsets': [[3425, 3432]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T130'}, {'offsets': [[3433, 3439]], 'text': ['import'], 'type': 'Localization', 'id': 'T131'}, {'offsets': [[3585, 3602]], 'text': ['inhibitory effect'], 'type': 'Negative_regulation', 'id': 'T132'}, {'offsets': [[3616, 3626]], 'text': ['expression'], 'type': 'Transcription', 'id': 'T133'}, {'offsets': [[3796, 3804]], 'text': ['suppress'], 'type': 'Negative_regulation', 'id': 'T134'}, {'offsets': [[3810, 3823]], 'text': ['transcription'], 'type': 'Transcription', 'id': 'T135'}, {'offsets': [[3977, 3987]], 'text': ['inhibition'], 'type': 'Negative_regulation', 'id': 'T136'}, {'offsets': [[4114, 4124]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T137'}, {'offsets': [[4459, 4467]], 'text': ['suppress'], 'type': 'Negative_regulation', 'id': 'T138'}, {'offsets': [[4482, 4489]], 'text': ['release'], 'type': 'Localization', 'id': 'T139'}, {'offsets': [[4699, 4716]], 'text': ['inhibitory effect'], 'type': 'Negative_regulation', 'id': 'T140'}, {'offsets': [[4727, 4734]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T141'}, {'offsets': [[4735, 4748]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T142'}, {'offsets': [[4765, 4772]], 'text': ['binding'], 'type': 'Binding', 'id': 'T143'}, {'offsets': [[4861, 4870]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T144'}, {'offsets': [[4871, 4880]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T145'}, {'offsets': [[4921, 4931]], 'text': ['preventing'], 'type': 'Negative_regulation', 'id': 'T146'}, {'offsets': [[4936, 4951]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T147'}, {'offsets': [[4970, 4979]], 'text': ['necessary'], 'type': 'Positive_regulation', 'id': 'T148'}, {'offsets': [[4984, 4991]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T149'}, {'offsets': [[4992, 5005]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T150'}, {'offsets': [[5356, 5366]], 'text': ['Prevention'], 'type': 'Negative_regulation', 'id': 'T151'}, {'offsets': [[5370, 5377]], 'text': ['phospho'], 'type': 'Phosphorylation', 'id': 'T152'}, {'offsets': [[5385, 5396]], 'text': ['interaction'], 'type': 'Binding', 'id': 'T153'}]","[{'trigger': 'T51', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T52', 'id': 'E2', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T3', 'T2']}}, {'trigger': 'T53', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T55', 'id': 'E4', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T3', 'T54']}}, {'trigger': 'T56', 'id': 'E5', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T57', 'id': 'E6', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E7']}}, {'trigger': 'T59', 'id': 'E7', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T58']}}, {'trigger': 'T57', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T59', 'id': 'E9', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T5', 'T58']}}, {'trigger': 'T60', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E11']}}, {'trigger': 'T61', 'id': 'E11', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T62', 'id': 'E12', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E13']}}, {'trigger': 'T63', 'id': 'E13', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T64', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T65', 'id': 'E15', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T7']}}, {'trigger': 'T64', 'id': 'E16', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E13']}}, {'trigger': 'T68', 'id': 'E17', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T7', 'T67']}}, {'trigger': 'T66', 'id': 'E18', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E15']}}, {'trigger': 'T69', 'id': 'E19', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T8', 'T70']}}, {'trigger': 'T71', 'id': 'E20', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E19']}}, {'trigger': 'T72', 'id': 'E21', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T73', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T9']}}, {'trigger': 'T74', 'id': 'E23', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T75', 'id': 'E24', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'E23']}}, {'trigger': 'T76', 'id': 'E25', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E28']}}, {'trigger': 'T75', 'id': 'E26', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'E23']}}, {'trigger': 'T76', 'id': 'E27', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E29']}}, {'trigger': 'T77', 'id': 'E28', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T77', 'id': 'E29', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T78', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T13']}}, {'trigger': 'T79', 'id': 'E31', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T78', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T13']}}, {'trigger': 'T79', 'id': 'E33', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T81', 'id': 'E34', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T14', 'T80']}}, {'trigger': 'T82', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E36', 'T16']}}, {'trigger': 'T85', 'id': 'E36', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T17', 'T84']}}, {'trigger': 'T83', 'id': 'E37', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T86', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T86', 'id': 'E39', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T87', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T18']}}, {'trigger': 'T88', 'id': 'E41', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T89', 'id': 'E42', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E43']}}, {'trigger': 'T90', 'id': 'E43', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T92', 'id': 'E44', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T22', 'T91']}}, {'trigger': 'T93', 'id': 'E45', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E44']}}, {'trigger': 'T94', 'id': 'E46', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E47']}}, {'trigger': 'T96', 'id': 'E47', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T23', 'T95']}}, {'trigger': 'T97', 'id': 'E48', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E49']}}, {'trigger': 'T99', 'id': 'E49', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T98']}}, {'trigger': 'T100', 'id': 'E50', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E51']}}, {'trigger': 'T101', 'id': 'E51', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T25']}}, {'trigger': 'T102', 'id': 'E52', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T103', 'id': 'E53', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E54', 'T26']}}, {'trigger': 'T105', 'id': 'E54', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T104', 'id': 'E55', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T106', 'id': 'E56', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T107', 'id': 'E57', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T28']}}, {'trigger': 'T108', 'id': 'E58', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E59']}}, {'trigger': 'T109', 'id': 'E59', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E60']}}, {'trigger': 'T111', 'id': 'E60', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T29', 'T110']}}, {'trigger': 'T112', 'id': 'E61', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E62']}}, {'trigger': 'T113', 'id': 'E62', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T114', 'id': 'E63', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T31']}}, {'trigger': 'T115', 'id': 'E64', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T32']}}, {'trigger': 'T116', 'id': 'E65', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E64']}}, {'trigger': 'T117', 'id': 'E66', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T118', 'id': 'E67', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E68', 'E69']}}, {'trigger': 'T120', 'id': 'E68', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T34', 'T119']}}, {'trigger': 'T121', 'id': 'E69', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E70', 'E66']}}, {'trigger': 'T122', 'id': 'E70', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E71']}}, {'trigger': 'T123', 'id': 'E71', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T124', 'id': 'E72', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E73', 'E69']}}, {'trigger': 'T126', 'id': 'E73', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T34', 'T125']}}, {'trigger': 'T128', 'id': 'E74', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T36', 'T127']}}, {'trigger': 'T129', 'id': 'E75', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E76']}}, {'trigger': 'T131', 'id': 'E76', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T37', 'T130']}}, {'trigger': 'T132', 'id': 'E77', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E78']}}, {'trigger': 'T133', 'id': 'E78', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T38']}}, {'trigger': 'T134', 'id': 'E79', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E80']}}, {'trigger': 'T135', 'id': 'E80', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T136', 'id': 'E81', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T40']}}, {'trigger': 'T137', 'id': 'E82', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T41']}}, {'trigger': 'T138', 'id': 'E83', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E84']}}, {'trigger': 'T139', 'id': 'E84', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T138', 'id': 'E85', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E86']}}, {'trigger': 'T139', 'id': 'E86', 'type': 'Localization', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T140', 'id': 'E87', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E88', 'E89']}}, {'trigger': 'T142', 'id': 'E88', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T44', 'T141']}}, {'trigger': 'T143', 'id': 'E89', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T140', 'id': 'E90', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E88', 'E91']}}, {'trigger': 'T144', 'id': 'E91', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E92']}}, {'trigger': 'T145', 'id': 'E92', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T146', 'id': 'E93', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E94', 'E91']}}, {'trigger': 'T147', 'id': 'E94', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T46']}}, {'trigger': 'T148', 'id': 'E95', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E96']}}, {'trigger': 'T150', 'id': 'E96', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T47', 'T149']}}, {'trigger': 'T151', 'id': 'E97', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E98']}}, {'trigger': 'T153', 'id': 'E98', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}, {'trigger': 'T152', 'id': 'E99', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T48']}}]","[{'id': 'R1', 'head': {'ref_id': 'T49', 'role': 'Subject'}, 'tail': {'ref_id': 'T63', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T50', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T50', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E23', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E35', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E42', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E48', 'value': ''}, {'id': 'M6', 'type': 'Negation', 'ref_id': 'E50', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E58', 'value': ''}, {'id': 'M8', 'type': 'Speculation', 'ref_id': 'E61', 'value': ''}, {'id': 'M9', 'type': 'Speculation', 'ref_id': 'E72', 'value': ''}, {'id': 'M10', 'type': 'Negation', 'ref_id': 'E77', 'value': ''}, {'id': 'M11', 'type': 'Speculation', 'ref_id': 'E77', 'value': ''}]",[]
232,PMC-3333881-12-RESULTS,"Tat enhances the NF-kappaB activity by hijacking IkappaB-alpha and inhibiting the post-activation turn off of NF-kappaB
We analysed the kinetic of NF-kappaB activation in single round HIV-1 infection by modulating the expression of Tat with RNA interference. Jurkat cells were transfected with siRNA Tat, siRNA control, or left untransfected, and 24 h later cells were infected with HXB2 Env-pseudotyped NL4-3.Luc.R-E- virions. By cytofluorimetric analysis, ~40% of cells was siRNA-transfected and HIV-1-infected at 12-h post-infection (Supplementary Figure S1). The expression of Tat was detected at 1-h post-infection and progressively increased up to 12 h in untransfected and siRNA control-transfected cells, while it was barely detected in siRNA Tat-transfected cells (Figure 1A). The LTR-dependent luciferase expression was also progressively induced at 1- to 12-h post-infection in untransfected and siRNA control-transfected cells, while it was barely observed in siRNA Tat-transfected cells, as expected for the Tat-dependent transactivation of the HIV-1 LTR (Figure 1A).
The progressive increase in NF-kappaB activity, as measured by p65-p50 binding to an NF-kappaB consensus oligonucleotide (Figure 1B) and nuclear p65 (Figure 1C, nucleus), was observed at 1- to 3-h post-infection in both Tat-positive (no siRNA or siRNA control) and Tat-negative (siRNA Tat) cells; however, at 12-h post-infection, the p65 DNA binding and nuclear p65 persisted elevated in presence of Tat (no siRNA and siRNA control), while they dropped in absence of Tat (siRNA Tat) (Figure 1B and C). IkappaB-alpha was degraded in the cytosol within 3-h post-infection and de novo synthesized at 6 h with full replenishment at 12-h post-infection in both Tat-positive and Tat-negative cells (Figure 1C, cytosol). Consistently, the IKK activity was induced at 1-h post-infection, and decreased at 3-h post-infection independently of the presence of Tat (Figure 1D). Similar kinetics of NF-kappaB activity, IKK activation and IkappaB-alpha degradation/re-synthesis were observed in single-round HIV-1 infection of PBMCs using a cocktail of Azidothymidine (AZT) and Lamivudine (3TC) as reverse transcriptase inhibitors (Supplementary Figure S2). These results indicated that in single-round HIV-1 infection the NF-kappaB activation initially correlated with the IKK activation and IkappaB-alpha degradation independently of the presence of Tat, and it was kept elevated in presence of Tat following the decay of the IKK activity and new synthesis of IkappaB-alpha.
Next, we tested the single action of Tat on the kinetic of NF-kappaB activity induced by PMA. To this end, HeLa cells were transfected with p3x-FLAG-Tat, or empty vector, stimulated with PMA for 5 min, and extensively washed to avoid the oscillatory kinetic of NF-kappaB activation (17,18). In un-stimulated cells, the p65 DNA binding (Figure 2A) and nuclear p65 (Figure 2B, nucleus) were slightly enhanced by Tat, while the IkappaB-alpha content was not significantly affected (Figure 2B, cytosol). Transient stimulation with PMA increased the NF-kappaB DNA binding activity and nuclear p65 at 5 min peaking at 60-120 min independently of the presence of Tat (Figure 2A and B); however, while the p65 DNA binding and nuclear p65 persisted elevated at 240-min post-treatment in Tat-positive cells, they dropped in Tat-negative cells (Figure 2A and B). In addition, Tat bound to the NF-kappaB oligonucleotide in un-stimulated cells and its binding increased following PMA stimulation (Figure 2A), suggesting that the viral protein was a component of the NF-kappaB complex bound to DNA. Degradation of IkappaB-alpha was progressively induced at 5-30 min, followed by de novo synthesis at 60 min with full replenishment at 240 min in both Tat-positive and negative cells (Figure 2B, cytosol). Consistently, the IKK activation started at 5 min, and turned off at 30 min independently of the presence of Tat (Figure 2C). These results indicated that Tat enhanced the NF-kappaB activity in un-stimulated and PMA-stimulated cells without affecting the IKK activity and IkappaB-alpha content.
As we previously found that Tat binds to the sixth ankyrin of IkappaB-alpha (50,51), we tested whether Tat counteracted the generation of the IkappaB-alpha/NF-kappaB complex. To this end, the association of IkappaB-alpha with p65 was analysed in vivo at 0 and 240 min after short-pulse PMA, which corresponded to the time of un-stimulated condition and post-activation de novo synthesis of IkappaB-alpha, respectively. Coimmunoprecipitation of IkappaB-alpha with p65 was detected at 0- and 240-min post-treatment in Tat-negative cells (Figure 2D, lanes 1 and 3), and was halved in Tat-positive cells, where Tat coimmunoprecipitated with IkappaB-alpha (Figure 2D, lanes 2 and 4), indicating that Tat competed the IkappaB-alpha binding to p65.","[{'offsets': [[0, 3]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[49, 62]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[232, 235]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[294, 303]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[388, 391]], 'text': ['Env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[581, 584]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[745, 754]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[804, 814]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[972, 981]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1021, 1024]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1144, 1147]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1148, 1151]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1226, 1229]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1301, 1304]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1346, 1349]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1360, 1369]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1415, 1418]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1443, 1446]], 'text': ['p65'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1481, 1484]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1548, 1551]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1553, 1562]], 'text': ['siRNA Tat'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1583, 1596]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1737, 1740]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1754, 1757]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1930, 1933]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2006, 2019]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2360, 2373]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2419, 2422]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2464, 2467]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2529, 2542]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2581, 2584]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2693, 2696]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2863, 2866]], 'text': ['p65'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2903, 2906]], 'text': ['p65'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2954, 2957]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2969, 2982]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3132, 3135]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3200, 3203]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3242, 3245]], 'text': ['p65'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3270, 3273]], 'text': ['p65'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3322, 3325]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3358, 3361]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3409, 3412]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3644, 3657]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3780, 3783]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3943, 3946]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3989, 3992]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4106, 4119]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4157, 4160]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4191, 4204]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4232, 4235]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4271, 4284]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4336, 4349]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4355, 4358]], 'text': ['p65'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4519, 4532]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4573, 4586]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4592, 4595]], 'text': ['p65'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4645, 4648]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4710, 4713]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4736, 4739]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4766, 4779]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4824, 4827]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4841, 4854]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4866, 4869]], 'text': ['p65'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[39, 48]], 'text': ['hijacking'], 'type': 'Binding', 'id': 'T69'}, {'offsets': [[203, 213]], 'text': ['modulating'], 'type': 'Regulation', 'id': 'T70'}, {'offsets': [[218, 228]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T71'}, {'offsets': [[567, 577]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T72'}, {'offsets': [[638, 647]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T73'}, {'offsets': [[719, 721]], 'text': ['it'], 'type': 'Anaphora', 'id': 'T65'}, {'offsets': [[726, 741]], 'text': ['barely detected'], 'type': 'Negative_regulation', 'id': 'T74'}, {'offsets': [[794, 803]], 'text': ['dependent'], 'type': 'Positive_regulation', 'id': 'T75'}, {'offsets': [[815, 825]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T76'}, {'offsets': [[849, 856]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T77'}, {'offsets': [[1152, 1159]], 'text': ['binding'], 'type': 'Binding', 'id': 'T78'}, {'offsets': [[1423, 1430]], 'text': ['binding'], 'type': 'Binding', 'id': 'T79'}, {'offsets': [[1457, 1465]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T80'}, {'offsets': [[1521, 1525]], 'text': ['they'], 'type': 'Anaphora', 'id': 'T66'}, {'offsets': [[1526, 1533]], 'text': ['dropped'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[1537, 1544]], 'text': ['absence'], 'type': 'Negative_regulation', 'id': 'T82'}, {'offsets': [[1601, 1609]], 'text': ['degraded'], 'type': 'Protein_catabolism', 'id': 'T83'}, {'offsets': [[1663, 1674]], 'text': ['synthesized'], 'type': 'Gene_expression', 'id': 'T84'}, {'offsets': [[2020, 2031]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T85'}, {'offsets': [[2032, 2044]], 'text': ['re-synthesis'], 'type': 'Gene_expression', 'id': 'T86'}, {'offsets': [[2050, 2058]], 'text': ['observed'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[2374, 2385]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T88'}, {'offsets': [[2516, 2525]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T89'}, {'offsets': [[2871, 2878]], 'text': ['binding'], 'type': 'Binding', 'id': 'T90'}, {'offsets': [[2942, 2950]], 'text': ['enhanced'], 'type': 'Positive_regulation', 'id': 'T91'}, {'offsets': [[3013, 3021]], 'text': ['affected'], 'type': 'Regulation', 'id': 'T92'}, {'offsets': [[3075, 3084]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T93'}, {'offsets': [[3167, 3180]], 'text': ['independently'], 'type': 'Regulation', 'id': 'T94'}, {'offsets': [[3250, 3257]], 'text': ['binding'], 'type': 'Binding', 'id': 'T95'}, {'offsets': [[3284, 3292]], 'text': ['elevated'], 'type': 'Positive_regulation', 'id': 'T96'}, {'offsets': [[3342, 3346]], 'text': ['they'], 'type': 'Anaphora', 'id': 'T67'}, {'offsets': [[3347, 3354]], 'text': ['dropped'], 'type': 'Negative_regulation', 'id': 'T97'}, {'offsets': [[3362, 3370]], 'text': ['negative'], 'type': 'Negative_regulation', 'id': 'T98'}, {'offsets': [[3413, 3418]], 'text': ['bound'], 'type': 'Binding', 'id': 'T99'}, {'offsets': [[3479, 3482]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T68'}, {'offsets': [[3483, 3490]], 'text': ['binding'], 'type': 'Binding', 'id': 'T100'}, {'offsets': [[3491, 3500]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T101'}, {'offsets': [[3629, 3640]], 'text': ['Degradation'], 'type': 'Protein_catabolism', 'id': 'T102'}, {'offsets': [[3676, 3683]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T103'}, {'offsets': [[3697, 3705]], 'text': ['followed'], 'type': 'Positive_regulation', 'id': 'T104'}, {'offsets': [[3717, 3726]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T105'}, {'offsets': [[4075, 4084]], 'text': ['affecting'], 'type': 'Regulation', 'id': 'T106'}, {'offsets': [[4161, 4166]], 'text': ['binds'], 'type': 'Binding', 'id': 'T107'}, {'offsets': [[4174, 4187]], 'text': ['sixth ankyrin'], 'type': 'Entity', 'id': 'T108'}, {'offsets': [[4236, 4248]], 'text': ['counteracted'], 'type': 'Negative_regulation', 'id': 'T109'}, {'offsets': [[4253, 4263]], 'text': ['generation'], 'type': 'Binding', 'id': 'T110'}, {'offsets': [[4321, 4332]], 'text': ['association'], 'type': 'Binding', 'id': 'T111'}, {'offsets': [[4506, 4515]], 'text': ['synthesis'], 'type': 'Gene_expression', 'id': 'T112'}, {'offsets': [[4548, 4569]], 'text': ['Coimmunoprecipitation'], 'type': 'Binding', 'id': 'T113'}, {'offsets': [[4700, 4706]], 'text': ['halved'], 'type': 'Negative_regulation', 'id': 'T114'}, {'offsets': [[4740, 4760]], 'text': ['coimmunoprecipitated'], 'type': 'Binding', 'id': 'T115'}, {'offsets': [[4828, 4836]], 'text': ['competed'], 'type': 'Negative_regulation', 'id': 'T116'}, {'offsets': [[4855, 4862]], 'text': ['binding'], 'type': 'Binding', 'id': 'T117'}]","[{'trigger': 'T95', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T39']}}, {'trigger': 'T69', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T1', 'T2']}}, {'trigger': 'T70', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E4']}}, {'trigger': 'T71', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T72', 'id': 'E5', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}, {'trigger': 'T73', 'id': 'E6', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T74', 'id': 'E7', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'T7']}}, {'trigger': 'T75', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E9']}}, {'trigger': 'T76', 'id': 'E9', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T77', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E8']}}, {'trigger': 'T78', 'id': 'E11', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T11']}}, {'trigger': 'T78', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T79', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T17']}}, {'trigger': 'T80', 'id': 'E14', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T19']}}, {'trigger': 'T80', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T18', 'T19']}}, {'trigger': 'T81', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'E17']}}, {'trigger': 'T82', 'id': 'E17', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T81', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T18', 'E17']}}, {'trigger': 'T83', 'id': 'E19', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T84', 'id': 'E20', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T22']}}, {'trigger': 'T85', 'id': 'E21', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T86', 'id': 'E22', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T87', 'id': 'E23', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E21']}}, {'trigger': 'T87', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E22']}}, {'trigger': 'T88', 'id': 'E25', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T89', 'id': 'E26', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T30']}}, {'trigger': 'T90', 'id': 'E27', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T33']}}, {'trigger': 'T91', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E27', 'T35']}}, {'trigger': 'T91', 'id': 'E29', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T34', 'T35']}}, {'trigger': 'T92', 'id': 'E30', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T36', 'T35']}}, {'trigger': 'T93', 'id': 'E31', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T37']}}, {'trigger': 'T94', 'id': 'E32', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E31', 'T38']}}, {'trigger': 'T96', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'T41']}}, {'trigger': 'T96', 'id': 'E34', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T40', 'T41']}}, {'trigger': 'T97', 'id': 'E35', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E1', 'E36']}}, {'trigger': 'T98', 'id': 'E36', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T42']}}, {'trigger': 'T97', 'id': 'E37', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T40', 'E36']}}, {'trigger': 'T99', 'id': 'E38', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T100', 'id': 'E39', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T43']}}, {'trigger': 'T101', 'id': 'E40', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E39']}}, {'trigger': 'T102', 'id': 'E41', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T103', 'id': 'E42', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E41']}}, {'trigger': 'T104', 'id': 'E43', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E44', 'E42']}}, {'trigger': 'T105', 'id': 'E44', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T44']}}, {'trigger': 'T106', 'id': 'E45', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['T48', 'T47']}}, {'trigger': 'T107', 'id': 'E46', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site2'], 'ref_id': ['T49', 'T50', 'T108']}}, {'trigger': 'T109', 'id': 'E47', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E48', 'T51']}}, {'trigger': 'T110', 'id': 'E48', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T52']}}, {'trigger': 'T111', 'id': 'E49', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T53', 'T54']}}, {'trigger': 'T112', 'id': 'E50', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T55']}}, {'trigger': 'T113', 'id': 'E51', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T56', 'T57']}}, {'trigger': 'T114', 'id': 'E52', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E51', 'T59']}}, {'trigger': 'T115', 'id': 'E53', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T60', 'T61']}}, {'trigger': 'T116', 'id': 'E54', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E55', 'T62']}}, {'trigger': 'T117', 'id': 'E55', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T63', 'T64']}}]","[{'id': 'R1', 'head': {'ref_id': 'T65', 'role': 'Subject'}, 'tail': {'ref_id': 'T72', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T66', 'role': 'Subject'}, 'tail': {'ref_id': 'T79', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T66', 'role': 'Subject'}, 'tail': {'ref_id': 'T18', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R5', 'head': {'ref_id': 'T67', 'role': 'Subject'}, 'tail': {'ref_id': 'T40', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R6', 'head': {'ref_id': 'T68', 'role': 'Subject'}, 'tail': {'ref_id': 'T43', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E11', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E12', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M4', 'type': 'Negation', 'ref_id': 'E32', 'value': ''}, {'id': 'M5', 'type': 'Negation', 'ref_id': 'E45', 'value': ''}, {'id': 'M6', 'type': 'Speculation', 'ref_id': 'E47', 'value': ''}, {'id': 'M7', 'type': 'Speculation', 'ref_id': 'E49', 'value': ''}]",[]
233,PMC-3359311-07-Results,"Bay11-7082 inhibits pro-IL-1beta production in response to P. aeruginosa
In addition to inhibition of NF-kappaB activity, Bay11-7082 can also directly inhibit the NLRP3 inflammasome [38]. To validate its use in this study as an NF-kappaB inhibitor, western blots for pro-IL-1beta were performed alongside inhibition of CFTR activity by CFTRinh172 in response to PAO1 at 4 hours after stimulation (Fig. 7a). Our results indicate that Bay11-7082 prevents production of pro-IL-1beta whereas CFTRinh172 does not seem to affect it. This was further corroborated by the ability Bay11-7082 to inhibit IkappaBalpha degradation at 0.5, 1, and 1.5 hours post PAO1 stimulation (Fig. 7b).","[{'offsets': [[594, 606]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[586, 593]], 'text': ['inhibit'], 'type': 'Negative_regulation', 'id': 'T2'}, {'offsets': [[607, 618]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T3'}]","[{'trigger': 'T2', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}, {'trigger': 'T3', 'id': 'E2', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}]",[],[],[],[]
234,PMC-3359311-11-Materials_and_Methods,"Cell Culture
CF (IB3-1 and CuFi-1) and control (S9 and NuLi-1) cells were obtained from the American Type Culture Collection. IB3-1 cells were derived from a patient expressing the deltaF508 and W1282X mutations and CuFi-1 were derived from a deltaF508 homozygous patient. S9 cells are IB3-1 cells that have been transfected with CFTR using an adeno-associated viral vector and NuLi-1 cells were derived from a patient possessing a wild-type CFTR genotype. THP1-XBlue cells stably express a secreted embryonic alkaline phosphatase (SEAP) reporter inducible by NF-kappaB and AP-1 (Invivogen). Cells were cultured as recommended by their respective suppliers using standard protocols. S9 and IB3-1 cells were cultured in basal LHC-8 (Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM L-glutamine, and 1 mM sodium pyruvate. NuLi-1/CuFi-1 cells were cultured in BEBM serum-free medium (Lonza) with supplement bullet kit (EGF, hydrocortisone, bovine pituitary extract, transferrin, bovine insulin, triiodothyronine, epinephrine, retinoic acid), 2 mM L-glutamine, and 1 mM sodium pyruvate. PBMCs from CF patients and controls were cultured in RPMI-1640 (Hyclone) supplemented with 10% FBS, 2 mM L-glutamine, and 1 mM sodium pyruvate (complete RPMI). THP1-XBlue cells were cultured in complete RPMI with the addition of zeocin (100 microg/ml) to select for cells expressing the SEAP NF-kappaB/AP-1 reporter. Prior to stimulation, bronchial epithelial cell lines were plated in coated [62] 96-well plates (BD Biosciences) at 3x104 cells/well unless indicated, and allowed to adhere overnight. Plates for S9 and IB3-1 stimulations were coated in a mixture of bovine serum albumin (100 microg/ml), fibronectin (10 microg/ml), and bovine collage type I (30 microg/ml) (BD Biosciences). Plates for NuLi-1 and CuFi-1 were coated with collagen type IV (60 microg/ml) (Sigma Aldrich). PBMCs were plated in 96-well plates at a density of 1.5x105 cells/well in 200 microl (7.5x105 cells/mL). THP-1 reporter cells were differentiated into a macrophage-like phenotype using 50 ng/ml of phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich) for 24 hours at a density of 1x105 cells/well in 200 microl (5x105 cells/ml). Cells were washed with PBS and allowed to rest a further 42 hours prior to stimulation.","[{'offsets': [[985, 996]], 'text': ['transferrin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1005, 1012]], 'text': ['insulin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1678, 1691]], 'text': ['serum albumin'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
235,PMC-1920263-09-RESULTS,"Characterization of the transcriptional start sites of APOBEC3G by 5'-RACE
To identify the transcriptional start sites (TSS) of APOBEC3G (A3G) in A3.01 T cells, we performed 5'-rapid amplification of cDNA ends analysis (RACE) with A3G-specific primers (see Figure 1). Agarose gel electrophoresis resolved the nested PCR products into three bands of different electrophoretic mobility with a dominant middle band (Figure 2). For each band, the DNA was cloned and sequence analysis of six or seven individual transformants was performed. We observed that the transcriptional start sites of the A3G gene were located between 58 and 361 nt upstream of the ATG start codon (Figure 1). Although TSS were variable and most sites were only detected once among the 19 clones analyzed, one TSS was identified in six individual clones. This TSS was located 66 nt upstream of the start of the published A3G mRNA sequence (GenBank(TM) accession number NM021822) and we defined this position as the major transcriptional start site of the A3G gene.","[{'offsets': [[55, 63]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[128, 136]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[138, 141]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[231, 234]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[592, 595]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[891, 894]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1025, 1028]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T7'}]",[],[],"[{'id': '*', 'ref_ids': ['T2', 'T3']}]",[],[]
236,PMC-1920263-20-Caption-Figure_5,"A GC-box mediates transcriptional activity of the 180 bp core promoter. (A) A3.01 T cells were transfected with reporter plasmid pGL3-Basic containing 180, 150 or 120 bp of the A3G promoter. The two G-to-T substitutions introduced into the GC-box of the 180 bp fragment (180mut) are specified. After 48 h, cells were harvested for luciferase assay. Firefly luciferase activities were normalized to coexpressed renilla luciferase activities. Mean values (+/-SD) of a representative experiment performed in triplicate are shown. (B) pGL3-Promoter reporter plasmids containing the regions E1 or E2 (see Figure 1) upstream of the SV40 promoter were transfected into A3.01 T cells. Firefly luciferase activities after 48 h were normalized to coexpressed renilla luciferase activities. Mean values (+/-SD) of a representative experiment performed in triplicate are shown.","[{'offsets': [[177, 180]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[331, 341]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[357, 367]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[418, 428]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[685, 695]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[757, 767]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[398, 409]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T7'}, {'offsets': [[737, 748]], 'text': ['coexpressed'], 'type': 'Gene_expression', 'id': 'T8'}]","[{'trigger': 'T7', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}, {'trigger': 'T7', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T8', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T8', 'id': 'E4', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],[],[]
237,PMC-3062687-24-Methods,"Cell Infections
HeLa cells were infected with E. coli O157:H7 or C. rodentium strains as described previously9.",[],[],[],[],[],[]
238,PMC-2674207-07-Materials_and_Methods,"Chromatin Immunoprecipitation
Chromatin immunoprecipitation (IP) was performed as previously described [12] in HuT-78 T-cells with 2 microg of anti-GATA-3 (Santa Cruz Biotechnology), or isotypic immunoglobulin G as a non-specific control (Santa Cruz Biotechnology) overnight at 4degreesC. Promoter sequences were detected with PCR primers for the IL-5 promoter (-445 to +4): forward 5'-TTAATCTAGCCACAGTCATAG-3' and reverse: 5'-TCATGGCTCTGAAACGTTCTG-3'. PCR was performed using a Hybaid Omnigene thermal cycler (Hybaid, Ashford, UK) with cycling parameters of 72degreesC for 10 min, 35 cycles at 94degreesC for 45 s, 52degreesC for 45 s, 72degreesC for 45 s.","[{'offsets': [[347, 351]], 'text': ['IL-5'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
239,PMC-2222968-13-Materials_and_Methods,"In vitro T cell differentiation.
CD4+ CD45RA+ magnetically-sorted (CD45RO depletion, MACS, according to the protocol of the manufacturer) cells were stimulated with immobilized plate-bound anti-CD3 (1 mug/ml, Okt3, IgG1) and anti-CD28 (2 mug/ml) in Th1 conditions: 25 ng/ml IL-12, 5 mug/ml anti-IL-4 (R&D systems); in Th2 conditions: 25 ng/ml IL-4, 5 mug/ml anti-IFN-gamma, 5 mug/ml anti-IL-12 (R&D systems); or in Treg conditions: 10 ng/ml TGF-beta, 5 mug/ml anti-IFN-gamma, 5 mug/ml anti-IL-12, 5 mug/ml anti-IL-4. Proliferating cells were expanded in medium containing IL-2 (30 ng/ml).","[{'offsets': [[33, 36]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[38, 44]], 'text': ['CD45RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[67, 73]], 'text': ['CD45RO'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[194, 197]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[230, 234]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[274, 279]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[295, 299]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[343, 347]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[363, 372]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[388, 393]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[441, 449]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[465, 474]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[490, 495]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[511, 515]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[572, 576]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[74, 83]], 'text': ['depletion'], 'type': 'Negative_regulation', 'id': 'T16'}]","[{'trigger': 'T16', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],[],[]
240,PMC-1920263-01-INTRODUCTION,"The recently discovered APOBEC3 family of cytidine deaminases is considered to play an important role in antiviral intrinsic immunity (1,2). In primates, the seven paralogs APOBEC3A, B, C, DE, F, G, H (A3A-H) have been described (3), and they appear to fulfill individual functions. Human APOBEC3G (A3G), the most prominent member of the APOBEC3 family has been identified as the cellular restriction factor that is responsible for inhibition of virion infectivity factor (Vif)-deleted human immunodeficiency virus-1 (HIV-1) replication in non-permissive cells (4). A3G is packaged into HIV-1deltavif particles and causes C-to-U deaminations on the single-stranded viral DNA during reverse transcription (5-8). This leads to degradation of the uracile-containing DNA by cellular repair mechanisms or to hypermutation of the viral genome (5,6). As a result, only a marginal fraction of the A3G-containing HIV-1 particles is able to complete the replication cycle. In addition to the inhibition of HIV-1, A3G restricts replication of other lentiviruses, gammaretroviruses, deltaretroviruses, spumaviruses, long-terminal-repeat (LTR)-retrotransposons, orthohepadnaviruses and avihepadnaviruses (9-21). Interestingly, deamination seems not to be the only A3G-mediated antiviral mechanism; in the case of hepatitis B virus (HBV) and human T cell leukemia virus type 1 (HTLV-1), A3G was shown to restrict virus replication by deamination-independent mechanisms (12, 13, 19, 22-25). Another member of the APOBEC3 family, APOBEC3F (A3F), appears to have similar activities like A3G (26,27). A3F is also packaged into HIV-1deltavif particles and induces similar C-to-U deaminations, although the proteins differ in their target sequences specificity (26,28). Furthermore, A3F proteins were detected in many tissues that express A3G and are able to form heteromultimers with A3G (26,29,30). Both proteins localize to mRNA processing (P) bodies, cytoplasmic compartments involved in the degradation and storage of non-translating mRNAs (30,31).
A3G has been shown to be expressed in T cells, a relevant cell target for HIV-1 in vivo, but little is known about its regulation (4,29,32). There is a report describing that mitogenic stimulation of T cells upregulates A3G mRNA levels, but this was not analyzed on the transcriptional level (33). Since the A3G promoter has not been systematically analyzed so far, our aim was to clone the A3G promoter and characterize its regulation in T cells. In our study, we observed that A3G uses multiple transcriptional start sites (TSS). By generating a series of 5' deletions of the A3G promoter, we identified a 180 bp region that mediated basal transcription. In T cells, transcriptional activity of this core promoter was not inducible by mitogenic stimulation or interferon treatment, but was dependent on a GC-box which was recognized by Sp (specificity protein) 1 and Sp3 transcription factors.","[{'offsets': [[173, 181]], 'text': ['APOBEC3A'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 184]], 'text': ['B'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[186, 187]], 'text': ['C'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[189, 191]], 'text': ['DE'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[193, 194]], 'text': ['F'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[196, 197]], 'text': ['G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[199, 200]], 'text': ['H'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[289, 297]], 'text': ['APOBEC3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[299, 302]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[446, 471]], 'text': ['virion infectivity factor'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[473, 476]], 'text': ['Vif'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[566, 569]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[597, 600]], 'text': ['vif'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[889, 892]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1003, 1006]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1251, 1254]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1373, 1376]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1514, 1522]], 'text': ['APOBEC3F'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1524, 1527]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1570, 1573]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1583, 1586]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1619, 1622]], 'text': ['vif'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1763, 1766]], 'text': ['A3F'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1819, 1822]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1865, 1868]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2034, 2037]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2254, 2257]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2342, 2345]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2425, 2428]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2513, 2516]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2612, 2615]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2796, 2806]], 'text': ['interferon'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2872, 2898]], 'text': ['Sp (specificity protein) 1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2903, 2906]], 'text': ['Sp3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[478, 485]], 'text': ['deleted'], 'type': 'Negative_regulation', 'id': 'T38'}, {'offsets': [[1811, 1818]], 'text': ['express'], 'type': 'Gene_expression', 'id': 'T39'}, {'offsets': [[1839, 1859]], 'text': ['form heteromultimers'], 'type': 'Binding', 'id': 'T40'}, {'offsets': [[1881, 1894]], 'text': ['Both proteins'], 'type': 'Anaphora', 'id': 'T35'}, {'offsets': [[1895, 1903]], 'text': ['localize'], 'type': 'Localization', 'id': 'T41'}, {'offsets': [[1907, 1933]], 'text': ['mRNA processing (P) bodies'], 'type': 'Entity', 'id': 'T42'}, {'offsets': [[2059, 2068]], 'text': ['expressed'], 'type': 'Gene_expression', 'id': 'T43'}, {'offsets': [[2149, 2152]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T36'}, {'offsets': [[2153, 2163]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T44'}, {'offsets': [[2242, 2253]], 'text': ['upregulates'], 'type': 'Positive_regulation', 'id': 'T45'}, {'offsets': [[2258, 2269]], 'text': ['mRNA levels'], 'type': 'Gene_expression', 'id': 'T46'}, {'offsets': [[2429, 2437]], 'text': ['promoter'], 'type': 'Entity', 'id': 'T47'}, {'offsets': [[2455, 2458]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T37'}, {'offsets': [[2459, 2469]], 'text': ['regulation'], 'type': 'Regulation', 'id': 'T48'}, {'offsets': [[2841, 2847]], 'text': ['GC-box'], 'type': 'Entity', 'id': 'T49'}, {'offsets': [[2858, 2868]], 'text': ['recognized'], 'type': 'Binding', 'id': 'T50'}]","[{'trigger': 'T38', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T10']}}, {'trigger': 'T39', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T23']}}, {'trigger': 'T39', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T24']}}, {'trigger': 'T40', 'id': 'E4', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T23', 'T25']}}, {'trigger': 'T41', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T23', 'T42']}}, {'trigger': 'T41', 'id': 'E6', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T24', 'T42']}}, {'trigger': 'T43', 'id': 'E7', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T44', 'id': 'E8', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T26']}}, {'trigger': 'T45', 'id': 'E9', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E10']}}, {'trigger': 'T46', 'id': 'E10', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T27']}}, {'trigger': 'T48', 'id': 'E11', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T29', 'T47']}}, {'trigger': 'T50', 'id': 'E12', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T31', 'T33', 'T49']}}, {'trigger': 'T50', 'id': 'E13', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2', 'Site'], 'ref_id': ['T31', 'T34', 'T49']}}]","[{'id': 'R1', 'head': {'ref_id': 'T35', 'role': 'Subject'}, 'tail': {'ref_id': 'T23', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T35', 'role': 'Subject'}, 'tail': {'ref_id': 'T24', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R3', 'head': {'ref_id': 'T36', 'role': 'Subject'}, 'tail': {'ref_id': 'T26', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R4', 'head': {'ref_id': 'T37', 'role': 'Subject'}, 'tail': {'ref_id': 'T47', 'role': 'Object'}, 'type': 'Coreference'}]","[{'id': '*', 'ref_ids': ['T8', 'T9']}, {'id': '*', 'ref_ids': ['T10', 'T11']}, {'id': '*', 'ref_ids': ['T18', 'T19']}]",[],[]
241,PMC-2800179-08-Materials_and_Methods,"TNF Activity Bioassay
Monocytes or THP-1 cells were cultured with or without different concentrations of CGNs or LPS (Salmonella typhosa, Sigma) for 24 h or the indicated time. Biologically active TNF-alpha/beta in tissue culture supernatant was measured using the WEHI 164 clone 13-cell killing assay [29]. TNF concentrations are expressed as pg/ml.","[{'offsets': [[0, 3]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[197, 206]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[207, 211]], 'text': ['beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[308, 311]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
242,PMC-3062687-15-Methods,"In Vitro Kinase Assay
Kinase-active recombinant IKKbeta and IKKalpha proteins were purchased from Active Motif and Millipore, respectively. Bacterially purified glutathione S-transferase (GST), GST-IkappaBalpha (1-54), wild type, mutant GST-RPS3, or RPS3 proteins were used as substrates. The in vitro kinase assay was performed as previously described29. Briefly, enzyme (100 ng) and substrate (2 mug) were co-incubated in IKK reaction buffer (25 mM Tris-HCl [pH 8.0], 50 mM KCl, 10 mM MgCl2, 1 mM DTT, 1 mM Na3VO4, 1 mM ATP) or NleH1 reaction buffer (50 mM Tris-HCl [pH 7.6], 5 mM MgCl2, 1 mM DTT, 1 mM ATP) with 0.5 muCi 32P-gamma-ATP (GE Healthcare) added at 37 degreesC for 30 min. The reactions were resolved by SDS-PAGE and visualized by autoradiography.","[{'offsets': [[48, 55]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[60, 68]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[237, 245]], 'text': ['GST-RPS3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[250, 254]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
243,PMC-3062687-08-Results,"NleH1 inhibits RPS3 phosphorylation in vitro
EHEC pathogens are important causative agents of both foodborne disease and pediatric renal failure31. EHEC utilize T3SS to inject effector proteins directly into intestinal epithelial cells32, a subset of which inhibit NF-kappaB-dependent innate responses9, 33-38. The E. coli O157:H7 EDL933 effector protein NleH1 binds to and attenuates RPS3 nuclear translocation, thus impairing RPS3-dependent NF-kappaB signaling9. We therefore hypothesized that NleH1 may function by inhibiting RPS3 S209 phosphorylation. As expected, transfecting increasing amounts of NleH1-HA plasmid blocked TNFalpha-induced NF-kappaB activation in a dose-dependent manner (Fig. 6a-b)9. Remarkably, NleH1 reduced both TNF-induced, as well as basal RPS3 phosphorylation to roughly 20% of vehicle control (Fig. 6c). Expressing NleH1 does not interfere with either TNF-induced IKK activation or IkappaBalpha degradation, consistent with the lack of NleH1 impact on p65 nuclear translocation9 (Fig. 6c).
To determine if NleH1 inhibits RPS3 phosphorylation, we infected HeLa cells with E. coli O157:H7 strains possessing or lacking either nleH1 (deltanleH1) or with a strain lacking a functional T3SS unable to inject NleH1 into mammalian cells (deltaescN). In uninfected cells, TNF-treatment stimulated a ~7-fold increase in RPS3 S209 phosphorylation, peaking at 30 minutes (Fig. 6d). By contrast, RPS3 S209 phosphorylation was substantially impaired in cells infected with wild-type E. coli O157:H7 (Fig. 6d). However, TNF-induced RPS3 S209 phosphorylation was unimpaired in cells infected with either deltanleH1 or deltaescN (Fig. 6d). We showed previously that wild-type, but not deltanleH1 or deltaescN E. coli O157:H7 significantly attenuated TNF-induced RPS3 nuclear translocation9. The parallel between RPS3 phosphorylation and its nuclear translocation during E. coli infection provides evidence in the context of an NF-kappaB-dependent disease process that RPS3 S209 phosphorylation is important for nuclear translocation.
Our discovery that NleH1 inhibits RPS3 S209 phosphorylation suggested that it should also blocks RPS3-dependent NF-kappaB target gene transcription (e.g. IL8, NFKBIA, and TNFAIP3). Indeed, these genes were only modestly upregulated in cells infected with wild-type E. coli O157:H7, but significantly induced in cells infected with either deltanleH1 or deltaescN strains (Fig. 6e). In contrast, deleting nleH1 had no impact on the expression of RPS3-independent genes, including CD25 and TNFSF13B (Supplementary Fig. 12). Together these results demonstrate that NleH1 specifically inhibits the protective immune response by directly blocking RPS3 S209 phosphorylation and thereby impairing critical RPS3-dependent NF-kappaB target genes.","[{'offsets': [[0, 5]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[15, 19]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[355, 360]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[385, 389]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[428, 432]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[496, 501]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[529, 533]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[604, 612]], 'text': ['NleH1-HA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[629, 637]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[720, 725]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[739, 742]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[769, 773]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[846, 851]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[883, 886]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[913, 925]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[967, 972]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[983, 986]], 'text': ['p65'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1037, 1042]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1052, 1056]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1155, 1160]], 'text': ['nleH1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1162, 1172]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1234, 1239]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1262, 1271]], 'text': ['deltaescN'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1295, 1298]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1342, 1346]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1415, 1419]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1537, 1540]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1549, 1553]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1620, 1630]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1634, 1643]], 'text': ['deltaescN'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1700, 1710]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1714, 1723]], 'text': ['deltaescN'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1765, 1768]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1777, 1781]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1827, 1831]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1983, 1987]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2068, 2073]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2083, 2087]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2146, 2150]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2203, 2206]], 'text': ['IL8'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2208, 2214]], 'text': ['NFKBIA'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2220, 2227]], 'text': ['TNFAIP3'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2387, 2397]], 'text': ['deltanleH1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2401, 2410]], 'text': ['deltaescN'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2452, 2457]], 'text': ['nleH1'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2527, 2531]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2536, 2544]], 'text': ['TNFSF13B'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2610, 2615]], 'text': ['NleH1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2690, 2694]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2747, 2751]], 'text': ['RPS3'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[6, 14]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T52'}, {'offsets': [[20, 35]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T53'}, {'offsets': [[361, 366]], 'text': ['binds'], 'type': 'Binding', 'id': 'T54'}, {'offsets': [[374, 384]], 'text': ['attenuates'], 'type': 'Negative_regulation', 'id': 'T55'}, {'offsets': [[390, 397]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T56'}, {'offsets': [[398, 411]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T57'}, {'offsets': [[518, 528]], 'text': ['inhibiting'], 'type': 'Negative_regulation', 'id': 'T58'}, {'offsets': [[534, 538]], 'text': ['S209'], 'type': 'Entity', 'id': 'T59'}, {'offsets': [[539, 554]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T60'}, {'offsets': [[582, 592]], 'text': ['increasing'], 'type': 'Positive_regulation', 'id': 'T61'}, {'offsets': [[726, 733]], 'text': ['reduced'], 'type': 'Negative_regulation', 'id': 'T62'}, {'offsets': [[743, 750]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T63'}, {'offsets': [[774, 789]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T64'}, {'offsets': [[835, 845]], 'text': ['Expressing'], 'type': 'Gene_expression', 'id': 'T65'}, {'offsets': [[861, 870]], 'text': ['interfere'], 'type': 'Negative_regulation', 'id': 'T66'}, {'offsets': [[899, 909]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T67'}, {'offsets': [[926, 937]], 'text': ['degradation'], 'type': 'Protein_catabolism', 'id': 'T68'}, {'offsets': [[959, 963]], 'text': ['lack'], 'type': 'Negative_regulation', 'id': 'T69'}, {'offsets': [[973, 979]], 'text': ['impact'], 'type': 'Regulation', 'id': 'T70'}, {'offsets': [[987, 994]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T71'}, {'offsets': [[995, 1008]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T72'}, {'offsets': [[1043, 1051]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T73'}, {'offsets': [[1057, 1072]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T74'}, {'offsets': [[1140, 1147]], 'text': ['lacking'], 'type': 'Negative_regulation', 'id': 'T75'}, {'offsets': [[1330, 1338]], 'text': ['increase'], 'type': 'Positive_regulation', 'id': 'T76'}, {'offsets': [[1347, 1351]], 'text': ['S209'], 'type': 'Entity', 'id': 'T77'}, {'offsets': [[1352, 1367]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T78'}, {'offsets': [[1420, 1424]], 'text': ['S209'], 'type': 'Entity', 'id': 'T79'}, {'offsets': [[1425, 1440]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T80'}, {'offsets': [[1459, 1467]], 'text': ['impaired'], 'type': 'Negative_regulation', 'id': 'T81'}, {'offsets': [[1541, 1548]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T82'}, {'offsets': [[1554, 1558]], 'text': ['S209'], 'type': 'Entity', 'id': 'T83'}, {'offsets': [[1559, 1574]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T84'}, {'offsets': [[1579, 1589]], 'text': ['unimpaired'], 'type': 'Negative_regulation', 'id': 'T85'}, {'offsets': [[1754, 1764]], 'text': ['attenuated'], 'type': 'Negative_regulation', 'id': 'T86'}, {'offsets': [[1769, 1776]], 'text': ['induced'], 'type': 'Positive_regulation', 'id': 'T87'}, {'offsets': [[1782, 1789]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T88'}, {'offsets': [[1790, 1803]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T89'}, {'offsets': [[1832, 1847]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T90'}, {'offsets': [[1852, 1855]], 'text': ['its'], 'type': 'Anaphora', 'id': 'T51'}, {'offsets': [[1856, 1863]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T91'}, {'offsets': [[1864, 1877]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T92'}, {'offsets': [[1988, 1992]], 'text': ['S209'], 'type': 'Entity', 'id': 'T93'}, {'offsets': [[1993, 2008]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T94'}, {'offsets': [[2012, 2021]], 'text': ['important'], 'type': 'Regulation', 'id': 'T95'}, {'offsets': [[2026, 2033]], 'text': ['nuclear'], 'type': 'Entity', 'id': 'T96'}, {'offsets': [[2034, 2047]], 'text': ['translocation'], 'type': 'Localization', 'id': 'T97'}, {'offsets': [[2074, 2082]], 'text': ['inhibits'], 'type': 'Negative_regulation', 'id': 'T98'}, {'offsets': [[2088, 2092]], 'text': ['S209'], 'type': 'Entity', 'id': 'T99'}, {'offsets': [[2093, 2108]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T100'}, {'offsets': [[2443, 2451]], 'text': ['deleting'], 'type': 'Negative_regulation', 'id': 'T101'}, {'offsets': [[2681, 2689]], 'text': ['blocking'], 'type': 'Negative_regulation', 'id': 'T102'}, {'offsets': [[2695, 2699]], 'text': ['S209'], 'type': 'Entity', 'id': 'T103'}, {'offsets': [[2700, 2715]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T104'}]","[{'trigger': 'T52', 'id': 'E1', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E2', 'T1']}}, {'trigger': 'T53', 'id': 'E2', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T54', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme', 'Theme2'], 'ref_id': ['T3', 'T4']}}, {'trigger': 'T55', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E5', 'E3']}}, {'trigger': 'T57', 'id': 'E5', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T4', 'T56']}}, {'trigger': 'T58', 'id': 'E6', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E7', 'T6']}}, {'trigger': 'T60', 'id': 'E7', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T7', 'T59']}}, {'trigger': 'T61', 'id': 'E8', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}, {'trigger': 'T62', 'id': 'E9', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E10', 'T10']}}, {'trigger': 'T63', 'id': 'E10', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T11']}}, {'trigger': 'T62', 'id': 'E11', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E12', 'T10']}}, {'trigger': 'T64', 'id': 'E12', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T12']}}, {'trigger': 'T65', 'id': 'E13', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T13']}}, {'trigger': 'T66', 'id': 'E14', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E15', 'E13']}}, {'trigger': 'T67', 'id': 'E15', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E13', 'T14']}}, {'trigger': 'T66', 'id': 'E16', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E17', 'E13']}}, {'trigger': 'T68', 'id': 'E17', 'type': 'Protein_catabolism', 'arguments': {'role': ['Theme'], 'ref_id': ['T15']}}, {'trigger': 'T69', 'id': 'E18', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T16']}}, {'trigger': 'T70', 'id': 'E19', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E20', 'E18']}}, {'trigger': 'T72', 'id': 'E20', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T17', 'T71']}}, {'trigger': 'T73', 'id': 'E21', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E22', 'T18']}}, {'trigger': 'T74', 'id': 'E22', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T19']}}, {'trigger': 'T75', 'id': 'E23', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T20']}}, {'trigger': 'T76', 'id': 'E24', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E25', 'T24']}}, {'trigger': 'T78', 'id': 'E25', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T25', 'T77']}}, {'trigger': 'T80', 'id': 'E26', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T26', 'T79']}}, {'trigger': 'T81', 'id': 'E27', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E26']}}, {'trigger': 'T82', 'id': 'E28', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E29', 'T27']}}, {'trigger': 'T84', 'id': 'E29', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T28', 'T83']}}, {'trigger': 'T85', 'id': 'E30', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T29']}}, {'trigger': 'T85', 'id': 'E31', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E28', 'T30']}}, {'trigger': 'T86', 'id': 'E32', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T31']}}, {'trigger': 'T87', 'id': 'E33', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E35', 'T33']}}, {'trigger': 'T86', 'id': 'E34', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E33', 'T32']}}, {'trigger': 'T89', 'id': 'E35', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T34', 'T88']}}, {'trigger': 'T90', 'id': 'E36', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T35']}}, {'trigger': 'T92', 'id': 'E37', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T35', 'T91']}}, {'trigger': 'T94', 'id': 'E38', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T36', 'T93']}}, {'trigger': 'T95', 'id': 'E39', 'type': 'Regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E40', 'E38']}}, {'trigger': 'T97', 'id': 'E40', 'type': 'Localization', 'arguments': {'role': ['Theme', 'ToLoc'], 'ref_id': ['T36', 'T96']}}, {'trigger': 'T98', 'id': 'E41', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E42', 'T37']}}, {'trigger': 'T100', 'id': 'E42', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T38', 'T99']}}, {'trigger': 'T101', 'id': 'E43', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T45']}}, {'trigger': 'T102', 'id': 'E44', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E45', 'T48']}}, {'trigger': 'T104', 'id': 'E45', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme', 'Site'], 'ref_id': ['T49', 'T103']}}]","[{'id': 'R1', 'head': {'ref_id': 'T51', 'role': 'Subject'}, 'tail': {'ref_id': 'T35', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E21', 'value': ''}, {'id': 'M2', 'type': 'Negation', 'ref_id': 'E30', 'value': ''}, {'id': 'M3', 'type': 'Negation', 'ref_id': 'E31', 'value': ''}]",[]
244,PMC-1942070-01-Introduction,"1The protein kinase D (PKD) serine/threonine kinase family has three members: PKD1, PKD2 and PKD3. Most cell types express at least two PKD isoforms but PKD enzymes are especially highly expressed in haematopoietic cells, where they are activated in response to antigen receptors stimulation [2,3]. A conserved signalling pathway linking antigen receptors to PKDs involves the activation of PLCgamma and the subsequent production of diacylglycerol (DAG) which stimulates classical and/or novel protein kinase Cs (PKC) that phosphorylate two key regulatory serine residues in the activation loop of PKD kinases [3-6]. The N-terminal regulatory region of PKD enzymes contains a DAG binding domain and direct binding of DAG also contributes to PKD1 activation [7] as well as regulating the spatial location of PKD enzymes within cells [8-12].
PKD enzymes have been proposed to regulate numerous cellular functions, including cell proliferation [13-16], anti-apoptotic signals [17,18] and thymocyte development [19]. Expression of mutant catalytically inactive and constitutively activated PKDs can also modify Golgi function, cell adhesion and cell motility (reviewed in [20]). In particular, PKDs have been widely linked to the activation of the NFkappaB transcription factor and in regulating cell survival during oxidative stress [17,21-23]. Another recently proposed PKD1 substrate is HSP27 [24], a small heat shock protein involved in regulating cell migration and cell survival [25]. An essential role for PKD enzymes in regulating class II histone deacetylases (HDACs), enzymes that repress MEF2-dependent gene transcription, has also been demonstrated [1,26-28].
To investigate the biological role of PKDs we have generated DT40 B cell lines that lack expression of one or more members of the PKD family [1], allowing us to investigate the function(s) of PKD isoforms following B cell antigen receptor (BCR) stimulation, as well addressing the issue of functional redundancy between the different PKD family members. Previous studies have shown that PKDs are indispensable for HDAC regulation in B cells [1]. Herein we show that PKDs are also indispensable for HSP27 phosphorylation in B cells. However, PKD-null DT40 B cells are viable and proliferate normally. Moreover, loss of the entire cellular pool of PKD does not critically affect oxidative stress responses in B cells nor do PKD kinases play an essential role in regulating NFkappaB transcriptional activity. Together, these findings reveal that in B lymphocytes, PKD kinases are not critical regulators of many of the cellular processes previously ascribed to them in other cellular systems.","[{'offsets': [[78, 82]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[84, 88]], 'text': ['PKD2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[93, 97]], 'text': ['PKD3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[741, 745]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1368, 1372]], 'text': ['PKD1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1386, 1391]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1595, 1599]], 'text': ['MEF2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2166, 2171]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[706, 713]], 'text': ['binding'], 'type': 'Binding', 'id': 'T9'}, {'offsets': [[726, 737]], 'text': ['contributes'], 'type': 'Positive_regulation', 'id': 'T10'}, {'offsets': [[746, 756]], 'text': ['activation'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[2148, 2161]], 'text': ['indispensable'], 'type': 'Positive_regulation', 'id': 'T12'}, {'offsets': [[2172, 2187]], 'text': ['phosphorylation'], 'type': 'Phosphorylation', 'id': 'T13'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T10', 'id': 'E2', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause'], 'ref_id': ['E3', 'E1']}}, {'trigger': 'T11', 'id': 'E3', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T12', 'id': 'E4', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E5']}}, {'trigger': 'T13', 'id': 'E5', 'type': 'Phosphorylation', 'arguments': {'role': ['Theme'], 'ref_id': ['T8']}}]",[],[],[],[]
245,PMC-2222968-22-Materials_and_Methods,"Administration of cytokines and antibodies in vivo.
Age- and gender-matched normal B6 mice received every other day intraperitoneal (ip) injections of PBS, 1.5 mug rmIL-4, 50 mug anti-IL-4 mAb (11B11 or MAB404), or a mixture of 1.5 mug rmIL-4 plus 50 mug anti-IL-4 mAb (11B11 or MAB404) for 7 d. Thereafter, spleen and lymph node cells were analyzed by flow cytometry for CD3, CD4, and CD25 expression. The anti-mouse IL-4 mAb MAB404 was obtained from R&D Systems, the second anti-mouse IL-4 mAb 11B11 was purchased from eBioscience.","[{'offsets': [[184, 188]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[238, 242]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[260, 264]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[372, 375]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[377, 380]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[386, 390]], 'text': ['CD25'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[418, 422]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[487, 491]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[391, 401]], 'text': ['expression'], 'type': 'Gene_expression', 'id': 'T9'}]","[{'trigger': 'T9', 'id': 'E1', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T4']}}, {'trigger': 'T9', 'id': 'E2', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T9', 'id': 'E3', 'type': 'Gene_expression', 'arguments': {'role': ['Theme'], 'ref_id': ['T6']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
246,PMC-3333881-06-MATERIALS_AND_METHODS,"Cell extracts, western blotting, IKK activity and NF-kappaB DNA binding
Total, nuclear and cytosolic extracts were performed as previously described (54); details are reported in Supplementary Data. Western blotting analysis was performed by resuspending protein aliquots in loading buffer (125 mM Tris-HCl, pH 6.8, 5% SDS, 1% bromophenol blue, 10% beta-mercaptoethanol, 25% glycerol), resolved on 12% SDS-PAGE, transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA) and incubated with primary antibodies (1:1000) followed by incubation with horseradish-peroxidase-linked mouse or rabbit IgG (1:2000) (GE Healthcare Amersham, Little Chalfont, Buckinghamshire, UK) in PBS containing 5% non-fat dry milk (Bio-Rad Laboratories). Proteins were detected by chemiluminescence using the ECL System (GE Healthcare Amersham). Primary antibodies were purchased from: Santa Cruz Biotechnology, Santa Cruz, CA, USA (anti-HA F7, anti-IkappaB-alpha C15, anti-Histone H1, anti-Hexokinase-II); Sigma-Aldrich (anti-FLAG M2, anti-gamma-Tubulin); Upstate, Lake Placid, NY, USA (anti-p65). Densitometry of single bands was analysed by ImageJ software package (NIH, USA). IKK activity was evaluated in cytosolic extracts using the HTScan IKK kinase assay kit (Cell Signaling Technology, Danvers, MA, USA). Binding of p65, p50 and FLAG-Tat to the double-stranded NF-kappaB oligonucleotide was measured using NF-kappaB Combo Transcription Factor Assay kit (Cayman Chemical Company, Ann Arbor, MI, USA). Electrophoretic Mobility Shift Assay (EMSA) was performed as previously described (55); details are described in Supplementary Data.","[{'offsets': [[1321, 1324]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1326, 1329]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1334, 1342]], 'text': ['FLAG-Tat'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1310, 1317]], 'text': ['Binding'], 'type': 'Binding', 'id': 'T4'}]","[{'trigger': 'T4', 'id': 'E1', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T1']}}, {'trigger': 'T4', 'id': 'E2', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T2']}}, {'trigger': 'T4', 'id': 'E3', 'type': 'Binding', 'arguments': {'role': ['Theme'], 'ref_id': ['T3']}}]",[],[],"[{'id': 'M1', 'type': 'Speculation', 'ref_id': 'E1', 'value': ''}, {'id': 'M2', 'type': 'Speculation', 'ref_id': 'E2', 'value': ''}, {'id': 'M3', 'type': 'Speculation', 'ref_id': 'E3', 'value': ''}]",[]
247,PMC-1920263-10-RESULTS,"The core promoter of A3G is located within the region -114/+66 relative to the TSS
For characterization of the A3G promoter, we cloned the 1025 bp located at position -959/+66 relative to the identified transcription start into the promoterless pGL3-Basic luciferase reporter plasmid and designated the plasmid pGL3-Basic-APOprom1025. Similarly, pGL3-APOprom502 (containing sequence -436/+66), pGL3-APOprom225 (containing sequence -159/+66) and further 5' deletion reporter constructs containing 180, 150, 120 or 60 bp upstream of position +65 were generated (Figure 3A). In order to analyze transcriptional activity, the luciferase reporter plasmids were transiently transfected into A3.01 T cells. Luciferase assays revealed a ~20-fold increased transcriptional activity of the 1025 bp sequence as compared to the empty vector, indicating that we had identified an active A3G promoter sequence (Figure 3B). This transcription rate was not significantly altered by the 5' deletions leading to the 502, 225 and 180 bp fragments (Figure 3B). In contrast, a drop in luciferase activity was observed in the case of the 150 bp fragment. This construct only retained 28% of the transcriptional activity of the 180 bp promoter in A3.01 T cells and activity of the 120 bp fragment was further reduced. Comparable reductions relative to the activity of 180 bp fragment were observed in the myeloid cell line U937 and the hepatic cell lines HepG2 and Huh7 (Figure 3C), indicating that the core promoter of A3G is located within the region -114/+66 relative to the TSS.","[{'offsets': [[21, 24]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[111, 114]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[256, 266]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[622, 632]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[700, 710]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[874, 877]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1064, 1074]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1497, 1500]], 'text': ['A3G'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[738, 747]], 'text': ['increased'], 'type': 'Positive_regulation', 'id': 'T11'}, {'offsets': [[748, 772]], 'text': ['transcriptional activity'], 'type': 'Transcription', 'id': 'T12'}, {'offsets': [[780, 796]], 'text': ['1025 bp sequence'], 'type': 'Entity', 'id': 'T13'}, {'offsets': [[909, 932]], 'text': ['This transcription rate'], 'type': 'Anaphora', 'id': 'T9'}, {'offsets': [[955, 962]], 'text': ['altered'], 'type': 'Regulation', 'id': 'T14'}, {'offsets': [[1056, 1060]], 'text': ['drop'], 'type': 'Negative_regulation', 'id': 'T15'}, {'offsets': [[1075, 1083]], 'text': ['activity'], 'type': 'Anaphora', 'id': 'T10'}]","[{'trigger': 'T11', 'id': 'E1', 'type': 'Positive_regulation', 'arguments': {'role': ['Theme', 'Cause', 'CSite'], 'ref_id': ['E2', 'T6', 'T13']}}, {'trigger': 'T12', 'id': 'E2', 'type': 'Transcription', 'arguments': {'role': ['Theme'], 'ref_id': ['T5']}}, {'trigger': 'T14', 'id': 'E3', 'type': 'Regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E1']}}, {'trigger': 'T15', 'id': 'E4', 'type': 'Negative_regulation', 'arguments': {'role': ['Theme'], 'ref_id': ['E2']}}]","[{'id': 'R1', 'head': {'ref_id': 'T9', 'role': 'Subject'}, 'tail': {'ref_id': 'T11', 'role': 'Object'}, 'type': 'Coreference'}, {'id': 'R2', 'head': {'ref_id': 'T10', 'role': 'Subject'}, 'tail': {'ref_id': 'T12', 'role': 'Object'}, 'type': 'Coreference'}]",[],"[{'id': 'M1', 'type': 'Negation', 'ref_id': 'E3', 'value': ''}]",[]
248,PMC-2806624-16-MATERIALS_AND_METHODS,"RNA isolation and cDNA synthesis.
RNA was isolated using the RNeasy Mini kit (QIAGEN) according to the manufacturer's protocol. Reverse transcription of human samples was performed with reverse-transcription reagents (Fermentas) with random hexamers according to the manufacturer's protocol.",[],[],[],[],[],[]
0,PMC-3585731-22-Materials_and_Methods,"Stable Infection of Myr-Akt1
To generate MSCV retroviruses, HEK293FT cells (Invitrogen) were transfected with 2 microg of viral DNA and 1 microg of gal/pol and VSV-G accessory plasmids in 6 well plates using GenJet transfection reagent (Signagen Labs). Virus-containing media was collected 72 hr later, filtered through 0.45 microm filter and applied to L929 cells with 8 microg/ml polybrene. Cells were selected and maintained in 10 microg/ml puromycin.","[{'offsets': [[20, 28]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
1,PMC-3320587-08-Materials_and_Methods,"siRNA transfection of MDM
An siRNA was constructed (Ambion Inc., www.ambion.com) to target a sequence unique to the NFAT5 transcript: 5'-CAACATGCCTGGAATTCAA-3' (nt 335 to 353) [31]. As described, a control for non-specific siRNA effects, we used an siRNA targeting the green fluorescent protein (GFP), 5'- GGCTACGTCCAGGAGCGCACC-3'. MDM were transfected in 6-well plates using 1 microM of the indicated siRNA in siPORT NeoFX transfection reagent (Ambion Inc., www.ambion.com), prepared as recommended by the manufacturer, in a final volume of 750 microl in Macrophage-SFM medium plus 5% heat-inactivated human AB serum. The cultures were left at 37degreesC overnight after which cells were washed and incubated in fresh medium. MDM were transfected two times for efficient knock down of NFAT5 expression before infection experiments were performed [31].","[{'offsets': [[116, 121]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[269, 294]], 'text': ['green fluorescent protein'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[296, 299]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[786, 791]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
2,PMC-3218875-10-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"microRNAs
miRNAs are recently discovered regulators of gene expression and represent a class of noncoding RNA molecules essential in many cellular and developmental processes, including immune responses and inflammation. They bind the 3'-UTR of target mRNAs leading to the repression of protein expression and the promotion of target mRNA degradation [77].
miR-146a/b and miR-155 are of particular interest for inflammatory signalling to NF-kappaB, since these miRNAs can be induced by inflammatory stimuli such as IL-1beta, TNF and TLRs [78,79]. In addition, miR-146a is an NF-kappaB-dependent gene, and the NF-kappaB signalling molecules IRAK1 and TRAF6 were identified as target genes of miR-146a [78] (Figure 1). Similarly, miR-155 was shown to target transcripts for the NF-kappaB signalling molecules IKKepsilon and RIP1 [79,80]. Notably, both miR-146 and miR-155 are expressed at higher levels in RA synovial fibroblasts and synovial tissue [81,82], as well as in peripheral blood mononuclear cells of RA patients [83]. miR-146a is also overexpressed in CD4+ and IL-17-producing T cells from RA patients [84,85]. Interestingly, a polymorphism in the 3'-UTR of the miR-146a target gene was recently shown to be associated with RA susceptibility [86]. miR-155 overexpression in synovial fibroblasts was able to prevent the TLR and cytokine-inducible expression of specific matrix metalloproteinases that mediate tissue destruction in RA [81]. Moreover, miR-155 was shown to promote TNF production, a key process in the pathogenesis of RA [87]. miR-146 and miR-155 may therefore be important negative regulators of inflammation in RA and their potential for the development of new treatments is substantial. In addition, their increased expression in RA patients is potentially useful as a marker for disease diagnosis, progression, or treatment efficacy [88], but this will require confirmation using a large and well-defined cohort.
Besides miR-146 and miR-155, a number of other miRNAs with a potential role in the control of NF-kappaB-dependent inflammatory responses in RA pathology were recently identified. In this context, miR-124a - a key regulator of the chemokine monocyte chemoattractant protein 1 - was shown to be decreased in synoviocytes from RA patients [89]. Similarly, elevated levels of miR-203 - leading to increased secretion of matrix metalloproteinase-1 and IL-6 - were detected in RA synovial fibroblasts [90]. Finally, miR-16, miR-132, and miR-223 were also shown to have an altered expression in RA patients, indicating their potential as diagnostic biomarkers for pathogenesis [83,88,91].","[{'offsets': [[357, 365]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[366, 367]], 'text': ['b'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[372, 379]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[515, 523]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[525, 528]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[560, 568]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[640, 645]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[650, 655]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[691, 699]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[728, 735]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[807, 817]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[822, 826]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[862, 869]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1027, 1035]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1061, 1064]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1070, 1075]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1171, 1179]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1257, 1264]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1458, 1465]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1487, 1490]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1561, 1568]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1959, 1966]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2135, 2143]], 'text': ['miR-124a'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2179, 2213]], 'text': ['monocyte chemoattractant protein 1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2311, 2318]], 'text': ['miR-203'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2355, 2381]], 'text': ['matrix metalloproteinase-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2386, 2390]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2449, 2455]], 'text': ['miR-16'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2457, 2464]], 'text': ['miR-132'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2470, 2477]], 'text': ['miR-223'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
3,PMC-1359074-16-Materials_and_Methods,"Antibodies.
Sox6 antibodies used in this study were either kindly provided by Dr. Enzo Lalli (Universite Louis Pasteur, France [7]) or commercially obtained (Catalog No. sc-17332 X, Santa Cruz Biotechnology, Santa Cruz, California, United States). All Sox6 antibodies generated similar results. c-Myc antibody was purchased from Invitrogen. Normal rabbit IgG antibody was obtained from Upstate Biotechnology (Lake Placid, New York, United States).","[{'offsets': [[12, 16]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[252, 256]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[295, 300]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
4,PMC-3312845-01-Background,"Status epilepticus (SE) is a medical emergency with significant mortality [1]. SE has been defined as continuous seizure activity, which causes neuronal cell death, epileptogenesis and learning impairment [2,3]. Some brain regions vulnerable to SE play a role in the generation and propagation of paroxysmal activity in experimental epilepsy models. The piriform cortex (PC) is one of the most susceptible brain regions to seizure-induced damage in the kainate, pilocarpine and other models of temporal lobe epilepsy (TLE) [4-6]. Pilocarpine, a cholinergic agonist, induces SE in rodents. This pilocarpine-induced SE, similar to human TLE, shows massive neuronal loss in the hippocampus followed by glial proliferation. This neuronal damage in the pilocarpine model is not restricted to the hippocampus, but often extends to extrahippocampal limbic structures. Indeed, pilocarpine-induced SE results in acute neuronal damages within layers II and III of the PC [5,6].
SE also induces severe vasogenic edema in the PC accompanied by neuronal and astroglial damages [5-8]. Brain edema proceeds in two phases, early cytotoxic edema phase and late vasogenic edema phase. Early cytotoxic osmotic edema is due to excess stimulation of glutamatergic pathways during SE, which increases intracellular Na+ and Ca2+ concentrations. The vasogenic edema results from dysfunction of endothelial cells and the blood-brain barrier (BBB). Many studies have reported increased permeability of the BBB during epileptic activity [9-13]. A fast and significant increase in systemic blood pressure, particularly shown during tonic epileptic seizures, induces a marked vasodilation of the large cerebral arteries and an increase in blood pressure in capillaries, small arteries, and veins leading to leakage of the BBB [9]. Loss of BBB integrity is not only due to an abrupt increase in the intraluminal pressure but also influenced by the properties of cerebral tissue. Indeed, an acute increase in blood pressure or epileptic activity causes an increase in pinocytosis at the level of the cerebral endothelium [11-13].
Recently, reports have also emphasized that seizure or epilepsy is a prolonged inflammatory condition, and that seizure activity rapidly increases the synthesis and release of various interleukins in rodent brain areas involved in seizure onset and their generalization. Cytokines act on endothelial cells and change the permeability of the BBB, which exerts significant effects on neuronal viability and excitability [14,15]. Indeed, Sztriha [16] reported that dexamethasone pretreatment reduces vasogenic edema in thalamus following kainic acid-induced seizure. Among cytokines, tumor necrosis factor-alpha (TNF-alpha) is a 17 kDa protein that is produced mainly by activated macrophages and T cells in the immune system. TNF-alpha is expressed at low levels in normal brain and is rapidly upregulated in glia, neurons and endothelial cells in various pathophysiological conditions, including SE [17,18]. TNF-alpha shows various effects on brain function depending on its local tissue concentration, the type of target cells, and especially the specific receptor subtype: TNF receptor I, or p55 receptor (TNFp55R); and TNF receptor II, or p75 receptor (TNFp75R) [19]. Furthermore, TNF-alpha induces macrophage inflammatory protein-2 (MIP-2) that recruits neutrophils under pathological conditions, including SE [14,20]. Neurons, microglia, and astrocytes produce MIP-2 when incubated with pro-inflammatory cytokines such as TNF-alpha and/or interleukin-1beta (IL-1beta) or after injury [21-23]. Indeed, we have recently reported that SE-mediated MIP-2 expression is relevant to leukocyte infiltrations following SE in an IL-1beta-independent manner [20]. However, the relationship between the TNF-alpha system and BBB disruption/neutrophil infiltration during vasogenic edema formation induced by epileptogenic insults has not been fully clarified. Therefore, in the present study, we investigated the roles of TNF-alpha in vasogenic edema and its related events in rat epilepsy models provoked by pilocarpine-induced SE.","[{'offsets': [[2680, 2707]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[2709, 2718]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[2823, 2832]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[3006, 3015]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[3173, 3187]], 'text': ['TNF receptor I'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[3192, 3204]], 'text': ['p55 receptor'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3206, 3213]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[3220, 3235]], 'text': ['TNF receptor II'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[3240, 3252]], 'text': ['p75 receptor'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[3254, 3261]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[3282, 3291]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[3300, 3333]], 'text': ['macrophage inflammatory protein-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3335, 3340]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3464, 3469]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3525, 3534]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3542, 3559]], 'text': ['interleukin-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3561, 3569]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3647, 3652]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3722, 3730]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3794, 3803]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[4012, 4021]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
5,PMC-3585731-09-Results,"Expression of Constitutively Active Akt, Rescues Necroptosis Under Serum Free Conditions
We used L929 cells stably expressing constitutively active wild type Akt1 (Myr-Akt) or the catalytically inactive mutant K179M in order to further understand the contribution of growth factors and RIP1 kinase to Akt activation during necroptosis. Constitutively active Akt1 (Myr-Akt) was generated as previously described [37] by the addition of a myristoylation signal which provides constitutive localization to the plasma membrane and by the deletion of the auto-inhibitory PH domain (Fig. 7A) resulting in an Akt that is active under serum free. It is important to note that the cells expressing Myr-Akt were viable, grew in a manner indistinguishable from the empty vector control cells, and were not triggered to induce necroptosis by serum starvation (Fig. 7B). This indicates that active Akt alone is not sufficient to induce necroptotic cell death. Under serum free conditions Myr-Akt, but not the K179M mutant, fully restored zVAD.fmk-induced necroptosis (Fig. 7A,B). Nec-1 prevented both Myr-Akt dependent cell death and the necroptosis-specific delayed increase in Akt Thr308 phosphorylation (Fig. 7B,C). Myr-Akt also allowed other zVAD.fmk-dependent events, including activation of JNK and c-Jun phosphorylation (Fig. 7C) and upregulation of TNFalpha mRNA (Fig. 7D) to occur under serum free conditions, confirming an important role for Akt at the apex of necroptotic signaling. These data demonstrated that the presence of active and membrane localized Akt is sufficient to uncouple Akt activation during necroptosis from growth factor signaling. RIP1 kinase was still able to regulate Akt activation during necroptosis, suggesting that growth factors and RIP1 kinase provide two independent inputs required for Akt changes during necroptosis.
RIP1 kinase-dependent Thr308 phosphorylation of Myr-Akt during necroptosis increased Myr-Akt activity as it did with endogenous Akt (Fig. 5). Phosphorylation of many previously described Akt substrates was increased upon the expression of Myr-Akt, but not the K179M mutant, confirming that these molecules are Akt substrates in L929 cells (Fig. 7C). The effect of zVAD.fmk on their phosphorylation varied, likely due to the increased basal activity of Myr-Akt. Some substrates, including p70S6K, S6, GSK-3 and FoxO4, were fully phosphorylated even in the absence of zVAD.fmk. On the other hand, phosphorylation of FoxO1 and MDM2 was significantly increased in the presence of zVAD.fmk, indicating that necroptotic Thr308 phosphorylation of Myr-Akt still promoted its activity.
Under serum free conditions all zVAD.fmk-induced downstream events (cell death, JNK activation, TNFalpha production) were dependent on the over expressed Myr-Akt. This allowed us to examine the effects of other Akt mutations on necroptosis. First, we found that membrane localization of Akt is required. Full length Akt or a mutant lacking both the PH domain and the Myr tag did not support the activation of cell death or increased Thr308 phosphorylation following zVAD.fmk addition under serum free conditions (Fig. S8A,B). Second, we found a specific and critical role for Thr308 phosphorylation in the regulation of the necroptotic functions of Akt. It has been reported that Ala mutations at Thr308 and Ser473 cause a reduction in the catalytic activity of Akt, while Asp mutants increase activity [38]. We examined the effect of Ala and Asp mutants at both sites during necroptosis. In our hands, both Asp mutants displayed activity comparable to wild type Akt, while both Ala mutants displayed comparable decreases in activity (Fig. S8C). Despite similar catalytic activities, Thr308 and Ser473 mutants displayed major differences in their ability to promote necroptotic changes (Fig. 7E,F,G). As expected, the S473D mutant, which was phosphorylated on Thr308 after the addition of zVAD, displayed only slightly reduced activity, while S473A was significantly less active in all aspects of necroptosis. S473A was unable to be efficiently phosphorylated on Thr308 possibly due to the inability of the Ala mutated 473 site to be phosphorylated and provide a docking site for PDK1 to phosphorylate Thr308 [39]. Strikingly, both Ala and Asp mutants of Thr308 were significantly less active in promoting cell death, phosphorylation of JNK and c-Jun, and TNFalpha mRNA. This suggests that T308D, in spite of being an active Akt construct, may not be a perfect mimic of phosphorylation and this mutant form of the kinase may not have sufficient activity to phosphorylate the entire repertoire of substrates in the cells. When tested, T308D did not support the downstream phosphorylation of several substrates that were phosphorylated by the Myr-Akt construct in the presence of zVAD including FoxO1, Foxo4, MDM2, and p70S6K (Fig. S8D). Our model, based on these results, is that necroptosis-specific Thr308 phosphorylation provides a critical link between necroptotic machinery and Akt kinase, allowing Akt to phosphorylate substrates during necroptosis, promote TNFalpha synthesis, JNK activation and eventual cell death.","[{'offsets': [[158, 162]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[164, 171]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[210, 215]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[286, 290]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[358, 362]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[364, 371]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[689, 696]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[975, 982]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[996, 1001]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1088, 1095]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1292, 1297]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1344, 1352]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1650, 1654]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1759, 1763]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1847, 1851]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1895, 1902]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1932, 1939]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2086, 2093]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2107, 2112]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2299, 2306]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2335, 2341]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2343, 2345]], 'text': ['S6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2357, 2362]], 'text': ['FoxO4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2461, 2466]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2471, 2475]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2587, 2594]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2720, 2728]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2778, 2785]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3386, 3389]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3842, 3854]], 'text': ['S473D mutant'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3967, 3972]], 'text': ['S473A'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4034, 4039]], 'text': ['S473A'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4204, 4208]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4369, 4374]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4380, 4388]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4414, 4419]], 'text': ['T308D'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4658, 4663]], 'text': ['T308D'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4765, 4772]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4817, 4822]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4824, 4829]], 'text': ['Foxo4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4831, 4835]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4841, 4847]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[5087, 5095]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T60'}]",[],[],[],[],[]
6,PMC-3585731-29-Caption-Figure_4,"Late Thr308 phosphorylation of Akt contributes to necroptosis.
(A) L929 cells were treated with zVAD.fmk and bFGF or PDGF, with or without Nec-1, for the indicated periods of time. (B,C) L929 cells were stimulated by zVAD.fmk or TNFalpha (B) or bFGF/zVAD.fmk under serum free conditions (C). Akt inh. VIII was added 15 min before necroptotic stimulation (Pre) or at indicated times after stimulation. Viability was measured 24 hr after activation of necroptosis. (D) L929 cells were stimulated with bFGF/zVAD under serum free conditions. PD173074 was added 15 min before or 1 hr after FGF/zVAD. Samples for western blot were collected at 15 min and 9 hr time points. (E) Cells were pretreated with PD173074 or it was added 1 hr after bFGF/zVAD.fmk, followed by viability assessment at 24 hr. In all graphs, average+/-SD was plotted.","[{'offsets': [[109, 113]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[229, 237]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[245, 249]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[499, 503]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[734, 738]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
7,PMC-1064873-07-Materials_and_methods,"Isolation of mRNA and real-time PCR
Total cellular RNA was extracted from PB CD4+ T cells using an RNA isolation kit (RNeasy Mini kit; Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. cDNA was synthesized from total RNA with Molony murine leukemia virus reverse transcriptase (US Biochemical, Cleveland, OH, USA) and oligo-(dT)15 primers (Promega, Madison, WI, USA). Real-time PCR was performed with the LightCycler Instrument (Roche Diagnostics, Penzberg, Germany) in glass capillaries. The reaction mix containing Taq DNA polymerase and DNA double-strand-specific SYBR Green I dye (Lightcycler FastStart DNA Master SYBR Green I; Roche Diagnostics) and specific primers were added to cDNA dilutions.
The cDNA samples were denatured at 95degrees C for 10 min, and were then amplified for 40-50 cycles: at 95degrees C (10 s), at 65degrees C (15 s), and 72degrees C (22 s) for beta-actin; at 95degrees C (10 s), at 62degrees C (15 s), and at 72degrees C (10 s) for SOCS1; and at 96degrees C (10 s), at 68degrees C (15 s), and at 72degrees C (15 s) for SOCS3. Amplification curves of the fluorescence values versus cycle number were obtained, and a melting curve analysis was then performed. The levels of SOCS1 and SOCS3 expression were determined by normalizing relative to beta-actin expression. The forward and reverse primers were as follows: for beta-actin, 5'-GTGGGGCGCCCCAGGCACCA-3' and 5'-CTCCTTAATGTCACGCACGATTTC-3' ; for SOCS1, 5'-AGACCCCTTCTCACCTCTTG-3' and 5'-GCACAGCAGAAAAATAAAGC-3' ; and for SOCS3, 5'-CCCGCCGGCACCTTTCTG-3' and 5'-AGGGGCCGGCTCAACACC-3'.","[{'offsets': [[77, 80]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[541, 544]], 'text': ['Taq'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[900, 910]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[988, 993]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1075, 1080]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1228, 1233]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1238, 1243]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1298, 1308]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1374, 1384]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1454, 1459]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1529, 1534]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
8,PMC-3317373-00-TIAB,"The Absence of Nrf2 Enhances NF-kappaB-Dependent Inflammation following Scratch Injury in Mouse Primary Cultured Astrocytes
It has been proved that Nrf2 depletion enhances inflammatory process through activation of NF-kappaB in the brain after TBI, but little is known about the relationship between Nrf2 and NF-kappaB in astrocytes after TBI. Hence, we used primary cultured astrocytes from either Nrf2 wildtype or knockout mice to study the influence of Nrf2 on the activation of NF-kappaB and expression of proinflammatory cytokines in a model of TBI in vitro. Primary cultured astrocytes were scratched to mimic the traumatic injury in vitro. Then the DNA-binding activity of NF-kappaB was evaluated by EMSA. The mRNA and protein levels of TNF-alpha, IL-1beta, IL-6, and MMP9 were also evaluated. Gelatin zymography was performed to detect the activity of MMP9. The activity of NF-kappaB and expression of proinflammatory cytokines mentioned above were upregulated at 24 h after scratch. The expression and activity of MMP9 were also elevated. And such tendency was much more prominent in Nrf2 KO astrocytes than that in WT astrocytes. These results suggest that the absence of Nrf2 may induce more aggressive inflammation through activation of NF-kappaB and downstream proinflammatory cytokines in astrocytes.","[{'offsets': [[755, 763]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[765, 769]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[775, 779]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[860, 864]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1023, 1027]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
9,PMC-1064895-17-Results,"Activation of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3
To determine downstream effector molecules of the PI3K pathway, we evaluated the activation of Akt by western blotting. As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 mug/ml) or LY294002 (20 muM), no difference in the amounts of phosphorylated Akt was observed. However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120-240 min. In contrast, non-phosphorylated Akt and beta-actin remained unchanged regardless of incubation time. PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3, which was an inhibition by wortmannin and PDTC as well as by LY294002 (data not shown).","[{'offsets': [[19, 22]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 59]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[178, 181]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[342, 345]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[412, 415]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 571]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[576, 586]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[637, 640]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[661, 666]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[719, 722]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
10,PMC-3589482-20-Results,"C/EBP-beta Binds the Murine SerpinB2 Proximal Promoter in vivo in an LPS-inducible Manner
We investigated the temporal dynamics of C/EBP-beta recruitment to the murine SerpinB2 promoter in response to LPS in vivo by chromatin immunoprecipitation (ChIP). RAW 264.7 cells were stimulated with LPS for up to 8 hrs, soluble chromatin was immunoprecipitated with antibodies against DNA binding proteins, and the enriched DNA amplified by both semi-quantitative and qPCR using SerpinB2 proximal promoter specific primers (illustrated in fig. 4A). The results showed that C/EBP-beta is constitutively present at the SerpinB2 promoter as demonstrated by its association with the promoter in unstimulated macrophages and increased temporally in response to LPS reaching as much as 10-fold over unstimulated cells after 8 hrs (Fig. 7). Since changes in C/EBP-beta phosphorylation states can affect C/EBP-beta's ability to transactivate target genes [38]; [63]; [64], we investigated recruitment to the SerpinB2 proximal promoter of the T217 phosphorylated C/EBP-beta isoform (p-C/EBP-betaT217), which has been associated with cell survival [65]. p-C/EBP-betaT217 was constitutively bound to the SerpinB2 proximal promoter and also present after 1 hr of LPS stimulation (Fig. 7). In contrast to total C/EBP-beta, the binding affinity of p-C/EBP-betaT217 for the SerpinB2 proximal promoter diminished with LPS stimulation at later timepoints (4 and 8 hrs)(Fig. 7). These data show an inverse relationship between C/EBP-beta and p-C/EBP-betaT217 recruitment, and indicate that T217-phosphorylated C/EBP-beta may not be responsible for increased transcription from the SerpinB2 promoter in response to LPS.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 36]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[131, 141]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[168, 176]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[471, 479]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[565, 575]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[609, 617]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[843, 853]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[888, 898]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[992, 1000]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1046, 1056]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1066, 1082]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1136, 1152]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1185, 1193]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1290, 1300]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1326, 1342]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1351, 1359]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1501, 1511]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1516, 1532]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1584, 1594]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1655, 1663]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
11,PMC-3342329-20-Caption-Figure_3,"Induction of apoptotic cell death in tumor tissues of CCR5 -/- mice.
A, Apoptotic cells in tumor sections were examined by fluorescence microscopy after DAPI and TUNEL staining as described in material and methods. The apoptotic index was determined as the number of DAPI-stained, TUNEL-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. B and C, Apoptotic protein (cleaved caspase-3 and Bax) in tumor sections were detected by immunofluorescence assay. The reactive cell number was determined as the number of DAPI-stained, Specific antibody (cleaved caspase-3 and Bax)-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. D, The expression of apoptotic proteins was detected by Western blotting using specific antibodies; cleaved caspase-3, cleaved caspase-9, cleaved PARP, Bax, Bcl-2 and c-IAP1 in the tumor tissues. The beta-actin protein was used as an internal control. Each band is representative of three independent experimental results. Data are means +/- S.D. of three experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05).","[{'offsets': [[54, 58]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[435, 439]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[861, 865]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1073, 1079]], 'text': ['c-IAP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1106, 1116]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1324, 1328]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
12,PMC-1064895-03-Materials_and_methods,"Reagents
Recombinant IL-17, IL-18, IL-15, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, IL-6 and IL-8 were purchased from R & D systems (Minneapolis, MN, USA). Recombinant transforming growth factor (TGF)-beta was purchased from Peprotech (London, UK). Recombinant TNF-alpha and IL-1 were purchased from Endogen Inc. (Cambridge, MA, USA). Cyclosporin A was provided by Sandos Ltd. (Basel, Switzerland). Phytohemagglutinin (PHA), pyrrolidine dithiocarbamate (PDTC), rapamycin, dexamethasone and curcumin were all obtained from the Sigma Chemical Co. (St Louis, MA, USA). Anti-CD3 monoclonal antibody and anti-CD28 monoclonal antibody were obtained from BD Biosciences (San Diego, CA, USA). LY294002, SB203580, FK506, wortmannin and PD98059 were obtained from Calbiochem (Schwalbach, Germany).","[{'offsets': [[21, 26]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 33]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[35, 40]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[42, 76]], 'text': ['monocyte chemoattractant protein-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[78, 83]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[86, 130]], 'text': ['macrophage inflammatory protein (MIP)-1alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[132, 141]], 'text': ['MIP-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[143, 147]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[152, 156]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[227, 264]], 'text': ['transforming growth factor (TGF)-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[320, 329]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[334, 338]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[458, 476]], 'text': ['Phytohemagglutinin'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[478, 481]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[663, 667]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
13,PMC-3585731-13-Materials_and_Methods,"Reagents and Chemicals
Necrostatin analogs were synthesized as previously described [23], [24]. The following reagents and final concentrations (unless otherwise specified in the text/figures) were used in the experiments: Akt inhibitor VIII (10 microM, Calbiochem), MK-2206 (10 microM, Selleck Chem), Triciribine (100 microM, National Cancer Institute), SP600125 (10 microM, Calbiochem), JNK inhibitor VIII (10 microM, Calbiochem), UO126 (10 mM, Cayman Chem), PD169316 (10 microM, Calbiochem), LiCl (10 mM, Sigma), SB216763 (10 microM, Calbiochem), BX912 (10 microM, Axon Med Chem), PF-4706871 (Sigma), rapamycin (100 nM, Santa Cruz), PI-103 (10 microM, Calbiochem), Torin-1 (500 nM, gift of Dr. Nathanael Grey (Harvard Medical School), LY249002 (10 microM, Cell Signaling), PD173074 (2 microM, Cayman Chem), PD166866 (20 microM, Calbiochem), 4EGI-1 (50 microM, Calbiochem). Pan-caspase inhibitor zVAD.fmk (20-30 microM) was purchased from Bachem. Human and mouse TNFalpha (10 ng/ml), human bFGF (25 ng/ml), EGF (50 ng/ml), PDGF-BB (20 ng/ml), and IGF-1 (50 ng/ml) were from Cell Sciences or Peprotech. All other reagents were from Sigma.","[{'offsets': [[965, 973]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[992, 996]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1009, 1012]], 'text': ['EGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1049, 1054]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
14,PMC-3342329-11-Materials_and_Methods,"Western Blotting
Tumor tissues were homogenized with protein extraction solution (PRO-PREPTM, Intron Biotechnology, Seoul, Korea), and lysed by 60 min incubation on ice. The tissue lysate centrifuged at 15,000 rpm for 15 min at 4degreesC. Equal amounts of proteins (40 microg) were separated on a SDS/12%-polyacrylamide gel, and then transferred to a polyvinylidene difluoride (PVDF) membrane (GE Water and Process technologies, Trevose, PA, USA). Blots were blocked for 1 h at room temperature with 5% (w/v) non-fat dried milk in Tris-Buffered Saline Tween-20 [TBST: 10 mM Tris (pH 8.0) and 150 mM NaCl solution containing 0.05% Tween-20]. After a short washing in TBST, the membranes were immunoblotted with the following primary antibodies: mouse monoclonal antibodies directed against p65 and p50 (1:500 dilutions; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal antibodies directed against Bax and PARP (1:500 dilutions; Santa Cruz Biotechnology), and against caspase-3, caspase-9, Bcl-2 and c-IAP-1 (1:1000 dilutions; Cell Signaling Technology, Beverly, MA). The blots were incubated with the respective horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:4000 dilutions; Santa Cruz Biotechnology). Immunoreactive proteins were detected with the ECL detection system.","[{'offsets': [[789, 792]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[797, 800]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1010, 1017]], 'text': ['c-IAP-1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
15,PMC-3589482-12-Experimental_Procedures,"Statistical Analysis
Data are presented as mean +/- SEM per group. Results were analyzed using the analysis of variance (ANOVA) or Student's t test where relevant. P-values <0.05 were considered significant.",[],[],[],[],[],[]
16,PMC-3586680-08-Conflict_of_Interest_Statement,The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.,[],[],[],[],[],[]
17,PMC-3589482-19-Results,"C/EBP-beta Mediates both Constitutive and LPS-induced SerpinB2 mRNA Expression in MEFs and Inflammatory Primary Macrophages
To investigate the importance of C/EBP-beta to endogenous SerpinB2 mRNA expression in response to LPS, we utilized C/EBP-beta-null (Cebpb-/-) and wild-type MEFs (Cebpb+/+), since RAW264.7 cells constitutively express endogenous C/EBP-beta. Wild-type MEFs express low levels of endogenous SerpinB2 and the absence of C/EBP-beta attenuated endogenous SerpinB2 mRNA expression. LPS stimulated an increase in SerpinB2 mRNA expression in wild-type MEFs (Fig. 6A), whereas LPS-stimulated SerpinB2 mRNA expression was significantly dampened in Cebpb-/- MEFs as compared to wild-type. We next tested if similar effects could be seen in thioglycollate-elicited inflammatory macrophages in which C/EBP-beta expression was knocked down using species-specific lentiviral shRNAs (Fig. 6B, left). As was observed in MEFs, both constitutive and LPS-induced SerpinB2 mRNA expression was significantly decreased in C/EBP-beta-deficient inflammatory macrophages (Fig. 6B, right). These data show that C/EBP-beta is critical for mediating constitutive and LPS-inducible transcription of endogenous SerpinB2 mRNA.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 62]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[157, 167]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[182, 190]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[239, 249]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[256, 261]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[286, 291]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[352, 362]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[412, 420]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[440, 450]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[473, 481]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[529, 537]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[606, 614]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[661, 666]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[810, 820]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[966, 974]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1022, 1032]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1107, 1117]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1203, 1211]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
18,PMC-3291650-05-Discussion,"In the present study we have investigated the contribution of A20 expression in myeloid cells in the innate immune response to IAV lung infection. In the pulmonary environment, macrophages populate both lung parenchyma and the alveolar lumen where they are referred to as alveolar macrophages. Under naive conditions, alveolar macrophages exert important immunomodulatory functions [65], [66]. However, alveolar macrophages are also crucial in the innate immune response against IAV as they are one of the first cells that encounter infectious IAV particles [67], [68]. They are an important source of proinflammatory cytokines and chemokines that attract innate immune cells to the lung during the primary phase of infection [69], and they are the primary producers of type I IFNs [70]. Alveolar macrophages are also known to phagocytose virus infected apoptotic cells and antibody coated viral particles, further contributing to viral clearance. We could show that BMDM or alveolar macrophages derived from A20myel-KO mice express higher amounts of chemokines, cytokines and type I IFNs compared to wild type mice in response to in vitro infection. Similarly, in vivo infection with IAV resulted in higher levels of primarily neutrophil attracting chemokines such as KC and MIP-2 and several proinflammatory cytokines such as IL-6, TNF and IL-1beta in the lungs of A20myel-KO mice compared to wild type mice. This was associated with a selective enhancement of neutrophil recruitment to the bronchoalveolar compartment, and resulted in improved viral clearance later on during infection. Although the role of neutrophils during viral infection is still under debate, recent evidence supports a protective function of these cells during IAV infection [71], [72]. MCP-1 levels were not affected by the absence of A20 in myeloid cells, which is consistent with the notion that airway epithelial cells are the primary source of MCP-1 production during IAV infection [73]. Mice deficient for the MCP-1 receptor CCR2, which is expressed on a subset of circulating monocytes, are protected against IAV infection and display reduced signs of immunopathology [74]-[76]. During IAV infection these monocytes develop into inflammatory dendritic cells or proinflammatory macrophages [77] and are considered major contributors to IAV-induced immunopathology [78]. A20myel-KO mice were protected against a lethal IAV infection, which is rather surprising since an excessive proinflammatory cytokine response and an excessive influx of inflammatory cells is generally believed to be associated with increased lethality [64], [79]. However, the selective effect of A20 deficiency on neutrophil recruitment, without altering inflammatory monocyte (Ly6C+ CD11b+) recruitment, further support the idea that monocytes and not neutrophils are major contributors to IAV-associated immunopathology and lethality [78].
We show that A20 deficient BMDM display enhanced NF-kappaB and IRF3 activation in response to RIG-I stimulation by synthetic LMW double stranded RNA. RIG-I has previously been shown to play a key role in the innate immune response to IAV [13], suggesting that the increased immune response of A20myel-KO mice to IAV lung infection reflects enhanced RIG-I signaling. We propose that A20 inhibits IAV-induced proinflammatory gene expression (as shown in our manuscript for TNF, IL-6, KC, MIP-2, and IFNbeta) by negatively regulating NF-kappaB and IRF3 activation, which are the major pathways controlling these genes. However, this does not exclude an additional effect of A20 on other signaling pathways that may contribute to proinflammatory gene expression. A20 is believed to exert its NF-kappaB and IRF3 inhibitory functions by modulating the ubiquitination status of different signaling proteins [80]. In this context, it was recently shown that A20 cooperates with the ubiquitin-binding proteins TAX1BP1 and ABIN1 to to disrupt the TRAF3-TBK1-IKKepsilon complex, thereby negatively affecting K63-polyubiquitination of TBK1 and IKKepsilon, and their ability to activity IRF3 [81], [82]. Whether similar mechanisms are involved in the regulation of RIG-I induced NF-kappaB activation is still unclear. So far we were unable to clearly detect ubiquitination of TBK1 and IKKepsilon in primary macrophages, preventing us from studying the effect of A20 deficiency on their ubiquitination status. It cannot be excluded however that A20 also targets other substrates that mediate NF-kappaB and IRF3 activation in myeloid cells. The identification of these substrates will be the topic of future investigations in our laboratory. Multiple other deubiquitinating enzymes (DUBs), such as DUBA [28], CYLD [29], [30], OTUB1/2 [31], and A20 [49]-[52] have been shown to negatively regulate RIG-I signaling to NF-kappaB and IRF-3, implicating possible redundancy. However, evidence so far was limited to in vitro data and was obtained under non-physiological conditions. The clear protective phenotype of A20myel-KO mice that we here describe indicates that A20 expression in myeloid cells is a central gatekeeper of RIG-I induced signaling in response to IAV infection and that other DUBs cannot substitute for A20 deficiency under physiological conditions. If A20 has a similar non-redundant role in other cell types that are implicated in the response to IAV, such as lung epithelial cells, remains to be investigated.
Understanding and controlling the activation of innate antiviral immune responses is an important step toward novel therapies. About a fifth of world's population is infected by IAV annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. The high mutation rate of IAV turns all attempts of vaccine and antiviral design into a never ending battle. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism [83]. Our results suggest that not only siRNA targeting IAV components, but boosting the antiviral immune response by intranasal administration of siRNA against A20 might be a valid therapeutic approach. Also small compound inhibitors of A20 might be an interesting alternative. Finally, similar targeting of A20 might be of interest in the battle against other viral infections including RSV and SARS coronavirus.","[{'offsets': [[1269, 1271]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1276, 1281]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1328, 1332]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1334, 1337]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1342, 1350]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1764, 1769]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1926, 1931]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2960, 2964]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2991, 2996]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3047, 3052]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3246, 3251]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3368, 3371]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3373, 3377]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3379, 3381]], 'text': ['KC'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3383, 3388]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3394, 3401]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3442, 3446]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3699, 3703]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3910, 3915]], 'text': ['ABIN1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[4020, 4024]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[4029, 4039]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[4071, 4075]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4149, 4154]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4260, 4264]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4269, 4279]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4489, 4493]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4691, 4695]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4779, 4784]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4812, 4817]], 'text': ['IRF-3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[5105, 5110]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
19,PMC-1064873-13-Results,"IL-6-mediated STAT3 phosphorylation and inhibition of IL-10 effect in normal CD4+ T cells
STAT3 is activated by many cytokines and growth factors such as the IL-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor, and oncostatin M), platelet-derived growth factor, and epidermal growth factor, in addition to IL-10 [4], but previous studies have demonstrated that IL-6 is the major factor in RA synovial fluid that induces constitutive activation of STAT3 in mononuclear cells [31]. Since IL-6 is also abundant in sera of active RA patients, frequently detected at > 1 ng/ml [27], we examined whether persistent exposure of CD4+ T cells to high concentrations of IL-6 in the blood circulation was responsible for their sustained STAT3 activation and resistance to IL-10 inhibition in active RA. Both STAT1 and STAT3 phosphorylation was activated by IL-6 in normal CD4+ T cells (data not shown), in agreement with previous observations [4]. Normal CD4+ T cells were thus incubated for 20 min with culture medium containing 30% serum from active RA patients and neutralizing anti-IL-6 antibody or control antibody, and STAT phosphorylation was examined by western blot analysis. RA serum was able to induce tyrosine phosphorylation of STAT3 but not STAT1, and this STAT3 activation was mostly abolished by neutralization of IL-6 activity (Fig. 5a). These results indicate that IL-6 is the dominant STAT3-activating factor contained in sera of active RA patients. The lack of STAT1 activation by RA serum suggests that much higher concentrations of IL-6 may be required for STAT1 activation as compared with STAT3 activation, or that inhibitors of STAT1 signaling may be present in RA serum.
We next examined whether IL-6 could suppress the effect of IL-10 to inhibit IFN-gamma production by CD4+ T cells. After preincubation with or without 10 ng/ml IL-6 for 36 hours, normal CD4+ T cells were stimulated by CD3 and CD28 costimulation in the presence or absence of 1 ng/ml IL-10 for 36 hours, and the IFN-gamma production was measured by ELISA. IL-6 pretreatment of normal cells reduced IL-10-mediated inhibition of IFN-gamma production (Fig. 5b), indicating that high concentrations of IL-6 could modulate T-cell responsiveness to IL-10. Taken together, these findings suggest that persistent exposure to serum IL-6 may have a role in both the induction of STAT3 activation and the resistance to the inhibitory effect of IL-10 in RA CD4+ T cells.","[{'offsets': [[0, 4]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 19]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[54, 59]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[77, 80]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[90, 95]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[184, 188]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[190, 195]], 'text': ['IL-11'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[197, 223]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[229, 241]], 'text': ['oncostatin M'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[244, 274]], 'text': ['platelet-derived growth factor'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[280, 303]], 'text': ['epidermal growth factor'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[320, 325]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[375, 379]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[461, 466]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[500, 504]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[635, 638]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[674, 678]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[740, 745]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[775, 780]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[811, 816]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[821, 826]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[860, 864]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[875, 878]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[958, 961]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1089, 1093]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1244, 1249]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1258, 1263]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1274, 1279]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1333, 1337]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1386, 1390]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1407, 1412]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1484, 1489]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1557, 1561]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1582, 1587]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1616, 1621]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1656, 1661]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1725, 1729]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1759, 1764]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1776, 1785]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1800, 1803]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1859, 1863]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1885, 1888]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1925, 1929]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1982, 1987]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2010, 2019]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2054, 2058]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2096, 2101]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2125, 2134]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2196, 2200]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2241, 2246]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2321, 2325]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2367, 2372]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2431, 2436]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2443, 2446]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T54'}]",[],[],[],[],[]
20,PMC-1064895-20-Conclusions,"We have detected a more pronounced production of IL-17 from RA PBMC in response to IL-15 and MCP-1 as well as stimulation by anti-CD3/anti-CD28. We have also shown that upregulation of IL-17 by activated T cells in patients with RA could be the result of activation via the PI3K/Akt pathway with resultant NF-kappaB activation. Our data provide insights into cellular mechanisms of the regulation of IL-17 production in RA, and highlight the role of T cells, which has hitherto been neglected in RA pathogenesis. Together with recent data on the successful introduction of anti-IL-17 in RA, our results have added information for the future molecular targeting of new therapeutic applications in RA.","[{'offsets': [[49, 54]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 88]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[93, 98]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 143]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[185, 190]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[279, 282]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[400, 405]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[578, 583]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
21,PMC-1472690-11-Methods,"Stimulation conditions
For induction of transcription factors and cytokines, PBMC were cultured in a volume of 4 ml in sterile pyrogen-free 6-well culture plates (Falcon, Heidelberg, Germany). Cultures were stimulated for 1 h (EMSA) or from 0 h to 48 h (ELISA) with 1 or 100 mug per 106 cells of GP, with 250 ng/106 cells TSST-1 (Toxin Technologies, Sarasota, FL, USA) or with 250 ng/106 cells wild-type LPS from Escherichia coli serotype 0111:B4 (Sigma, Munich, Germany). In costimulatory experiments, PBMC were supplemented simultaneously with a combination of GP and TSST-1 or with a combination of GP and LPS.","[{'offsets': [[322, 328]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[570, 576]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
22,PMC-3585731-10-Results,"Akt Controls TNFalpha Production in Other Cell Types
After establishing the role of RIP1 kinase-dependent signaling to Akt in L929 cells, we sought to expand our study to other cell types that are known to undergo necroptotic cell death. Fas-associated protein with death domain (FADD)-deficient Jurkat T lymphocytes and the macrophage cell lines (J774A.1 and RAW264.7) are other models of necroptosis, which can be induced by stimulation with TNFalpha or zVAD.fmk, respectively [17]. Similar to L929 cells, a RIP1 kinase dependent increase in the phosphorylation of Thr308 on Akt occurred during necroptosis (Fig. 8B,D,F) in these cell types. Furthermore, TNFalpha mRNA levels were increased in each of these cell types during necroptosis and efficiently inhibited by both RIP1 and Akt inhibitors (Fig. 8A,C,E). However, inhibition of Akt did not protect these cells from death (Fig. S9A,B,C). These results indicate that regulation of autocrine TNFalpha synthesis and necroptosis-associated inflammatory signaling may be a more important function of Akt pathway activation by RIP1 kinase in multiple cell types compared to its contribution to cell death.
We next chose to look at the role of Akt in necroptosis in mouse lung fibroblasts. Lung fibroblasts selected to survive after deletion of all three Akt isoforms [40] were resistant to cell death induced by the addition of TNFalpha and zVAD.fmk. Expression of catalytically active Akt (Myr-Akt) in these cells restored TNFalpha mRNA production in response to TNFalpha and zVAD.fmk (Fig. 8G) without re-establishing cell death (Fig. S9D). Consistent with our earlier Akt knockdown data, lung fibroblasts expressing endogenous Akt1 or Akt2 were phosphorylated on Thr308 in response to TNFalpha and zVAD.fmk (Fig. S9E) and in both cases robust RIP1-dependent TNFalpha mRNA upregulation occurred under necroptotic conditions (Fig. 8H). These data further support the notion that Akt activity is critical for autocrine TNFalpha synthesis, even in the absence of necroptotic cell death, indicating an unexpected differentiation between Akt-mediated inflammatory signaling under necroptotic conditions and cell death per se.","[{'offsets': [[13, 21]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[84, 88]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 278]], 'text': ['Fas-associated protein with death domain'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[280, 284]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[444, 452]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[510, 514]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[657, 665]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[774, 778]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[947, 955]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1078, 1082]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1379, 1387]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1475, 1483]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1515, 1523]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1681, 1685]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1689, 1693]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1739, 1747]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1797, 1801]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1812, 1820]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1970, 1978]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
23,PMC-3312845-05-Methods,"Tissue processing
At designated time points (non-SE: 12 hr, 1 day, 2 days, 3 days, 4 days and 1 week after SE; n = 5, for each time point), animals were perfused transcardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) under urethane anesthesia (1.5 g/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO). The brains were removed, and postfixed in the same fixative for 4 hr. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight. Thereafter, the entire hippocampus was frozen and sectioned with a cryostat at 30 mum and consecutive sections were contained in six-well plates containing PBS. For stereological study, every sixth section in the series throughout the entire hippocampus was used in some animals.",[],[],[],[],[],[]
24,PMC-3320587-14-Results,"MTb increases HIV-1 LTR activity of HIV-1 subtypes B, C, and E
To compare the functional impact of MTb stimulation on subtype-specific HIV-1 LTR activity, we first constructed reporter plasmids containing viral subtype B, C, and E LTRs (-208 to + 64 nt relative to the transcription start site) linked to the firefly luciferase reporter gene. After transfection of the monocytic THP-1 cell line with these plasmids, cells were stimulated with an irradiated whole cell lysate of MTb (H37Rv). We note that MTb lysate induces inflammatory responses in monocytes that resemble those induced in response to live MTb (see for example, [35]-[37]). Upon stimulation, the B, C, and E LTR-driven reporters demonstrated a significant enhancement in luciferase activity (Figure 1A) and the magnitude of this effect was subtype-specific. Subtype C LTRs displayed the strongest activity, while the LTRs from subtype E isolates consistently showed the weakest activity (Figure 1A), consistent with previous studies demonstrating subtype-specific LTR activity that used TNF as a stimulus [38], [39].","[{'offsets': [[317, 327]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[738, 748]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1054, 1057]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
25,PMC-3291650-11-Materials_and_Methods,"Cells and transfection
HEK293T and MDCK cells were grown in DMEM (Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics. HEK293T cells were transfected using the calcium phosphate precipitate transfection method with specific expression vectors (pCAGGS-E-hA20 (LMBP 3778), pCAGGS-E-RIG-I-CARD (LMBP 6517), pEF-HA-IRF-7 (kindly provided by T. Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo)), NF-kappaB, IRF3, IRF7 reporter plasmids (respectively pConLuc (LMBP3248), pISRE-luc (LMBP4011), pGL3-IFNalpha4-luc (kindly provided by J. Hiscott, McGill University, Montreal, Quebec, Canada), and pACTbetagal (LMBP4341) for transfection efficiency normalization. Details of plasmids are presented along with detailed sequence maps at the BCCM-LMBP plasmid databank http://bccm.belspo.be/index.php.
For the generation of BMDM, bone marrow cells were cultured 7 days in RPMI 1640 (Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate, antibiotics and 40 ng/ml recombinant M-CSF. BMDM were of >=95% purity as measured by flow cytometry using F4/80 and CD11b specific antibodies. For the isolation of alveolar macrophages, the trachea was canulated and the lung was flushed 4 times with HBSS containing 1 mM EDTA. Alveolar macrophages were cultured in RPMI 1640 (Gibco) supplemented with 1% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics.","[{'offsets': [[477, 481]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[483, 487]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
26,PMC-2817507-02-2._Methods,"2.1. Animals
Ninety Wister rats (male, body weight: 250 g to 300 g) were provided by Experimental Animal Center, China Medical University. The rats were assigned randomly to three groups: normal group (N, n = 10, without any treatment), normal saline control (S, n = 40, intra-cerebral injection of normal saline as control) and intra-cerebral hemorrhage group (ICH, n = 40). The experimental protocol used for animals was approved by the Animal Care and Use Committee, China Medical University. The rats were subjected to intra-cerebral injection of normal saline or autologous whole blood and were sacrificed on 6 hours, 1 day, 3 days and 7 days after the injection, respectively. Five rats in each group at each time point were sacrificed by transcardially perfusion of normal saline followed by 4% buffered Para formaldehyde (pH = 7.4). The brains were removed, postfixed, embedded in paraffin, and cut into sections (7 mum) as described previously [8]. Five rats in each group at each time point were sacrificed by over dose injection of Ketamine. The brains were removed and stored at minus 80degreesC for RT-PCR and Western Blots.",[],[],[],[],[],[]
27,PMC-3218875-03-Basic_principles_of_NF-+%A6B_signalling,"NF-kappaB proteins are sequestered in the cytoplasm as latent complexes by inhibitory proteins referred to as inhibitor of NF-kappaB (IkappaB) proteins, which prevent NF-kappaB nuclear translocation and DNA binding [19]. Whereas the majority of IkappaBs (IkappaBalpha, IkappaBbeta, IkappaBepsilon, p105 (also known as NF-kappaB1), p100 (also known as NF-kappaB2)) serve as inhibitors of NF-kappaB, IkappaBxi and Bcl-3 instead potentiate NF-kappaB transactivation in the nucleus. p100 and p105 are precursors of the p52 and p50 NF-kappaB subunits, respectively. There are two unique NF-kappaB signalling pathways, termed canonical (or classical) and noncanonical (or alternative) NF-kappaB pathways.
The canonical NF-kappaB pathway plays a major role in innate and adaptive immunity, and is triggered by many stimuli including proinflammatory cytokines (for example, TNF, IL-1), antigens, RANKL, and TLR ligands. NF-kappaB signalling initiated by different receptors requires the formation of proximal protein-protein interactions that are often receptor specific, but ultimately converge in the activation of the IkappaB kinase (IKK) complex, which mediates phosphorylation of the inhibitory IkappaB protein leading to its K48-polyubiquitination and degradation by the proteasome [20]. The IKK complex is comprised of the two catalytic subunits IKK1 and IKK2 (also known as IKKalpha and IKKbeta) and the regulatory subunit NF-kappaB essential modulator (NEMO - also known as IKKgamma) (Figure 1). Gene targeting experiments showed that IKK2 and NEMO, but not IKK1, are required for canonical NF-kappaB activation [21].
One of the best studied NF-kappaB signalling pathways is the TNF pathway. TNF stimulation results in the recruitment of TNF receptor-1-associated death domain (TRADD) protein and of receptor interacting protein 1 (RIP1), which function as adaptor proteins for the E3 ubiquitin ligases TNF receptor-associated factor (TRAF) 2 and TRAF5, which in turn bind the E3 ubiquitin ligases cellular inhibitor of apoptosis (cIAP) 1 and cIAP2 (Figure 1). On TNF stimulation, TNF-receptor bound RIP1 is rapidly modified by K63-linked polyubiquitin chains. TRAF2/5 and cIAP1/2 are good candidates for RIP1 ubiquitination, but the specific role of each is still unclear. The polyubiquitin chains on RIP1 are believed to create a scaffold to recruit the IKK and TAK1 complex via the ubiquitin-binding proteins NEMO and TAB1/2, respectively. The recent identification of a distinct E2/E3 enzyme complex that modifies NEMO with linear polyubiquitin chains and is essential for TNF-activated NF-kappaB signalling adds further complexity [22]. The exact role of protein-anchored polyubiquitin chains remains unclear, as it was recently suggested that unanchored polyubiquitin chains can directly activate the TAK1 complex [23].
Similar signalling principles apply to other receptors. For example, TLR4 stimulation by lipopolysaccharide induces the recruitment of Toll/IL-1 receptor adaptor protein (also referred to as Mal) and TRIF-related adaptor molecule (TRAM), which most probably serve as bridging factors to recruit myeloid differentiation primary response gene 88 (MyD88) and TIR domain-containing adaptor-inducing IFNbeta (TRIF), respectively. MyD88 in turn recruits members of the IL-1R-associated kinase (IRAK) family and TRAF6, leading to oligomerisation and selfubiquitination of TRAF6 [24]. TRIF also recruits TRAF6 [25] and RIP1 [26] via a direct interaction. Both pathways then activate TAK1 and IKK in a ubiquitination-dependent manner similar to the TNF pathway (Figure 1).
The noncanonical NF-kappaB pathway can be activated by the lymphotoxin beta receptor, BAFF receptor, CD40, and RANK (Figure 2). In this pathway, p100 is processed by the proteasome to p52, which together with the RelB NF-kappaB subunit regulates a distinct set of target genes that control B-cell development, secondary lymphoid organ development, and osteoclastogenesis [27] The noncanonical NF-kappaB pathway is strictly dependent on IKK1, which is activated upon phosphorylation by NF-kappaB inducing kinase (NIK). NIK is predominantly regulated at the post-translational level and is present at extremely low levels in most cell types. In unstimulated cells, NIK occurs in a cytoplasmic complex with TRAF2, TRAF3, and cIAP1/2, which K48-polyubiquitinates NIK, leading to its continuous degradation by the proteasome. Receptor ligation has been shown not only to remove TRAF3 from this complex by recruiting it to the receptor, but also to attract TRAF2 and cIAP1/2, which are essential for subsequent TRAF3 degradation. All this contributes to releasing NIK from its constitutive degradation, resulting in NIK accumulation and IKK1 phosphorylation [28,29] (Figure 2).
It should be mentioned that CD40, lymphotoxin beta receptor and RANK mediate the activation of both canonical and noncanonical NF-kappaB signalling pathways. Upon binding of their ligand, CD40 and RANK interact with several TRAF members, including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6, and this leads to the proteolysis of both TRAF2 and TRAF3, which represents an important step in the activation of the noncanonical pathway as described above. Specific TRAF molecules are associated with overlapping and distinct CD40-mediated functions. For example, in B cells TRAF6 is required for CD40-mediated JNK activation and IL-6 production, while TRAF2 is required for activation of NF-kappaB, and TRAF3 serves as a negative regulator of CD40 signalling [30,31].","[{'offsets': [[255, 267]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[269, 280]], 'text': ['IkappaBbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[282, 296]], 'text': ['IkappaBepsilon'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[298, 302]], 'text': ['p105'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[318, 328]], 'text': ['NF-kappaB1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[331, 335]], 'text': ['p100'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[351, 361]], 'text': ['NF-kappaB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[398, 407]], 'text': ['IkappaBxi'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[412, 417]], 'text': ['Bcl-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[479, 483]], 'text': ['p100'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[488, 492]], 'text': ['p105'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[515, 518]], 'text': ['p52'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[523, 526]], 'text': ['p50'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[866, 869]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[888, 893]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1345, 1349]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1354, 1358]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1374, 1382]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1387, 1394]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1423, 1452]], 'text': ['NF-kappaB essential modulator'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1454, 1458]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1475, 1483]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1536, 1540]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1545, 1549]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1559, 1563]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1680, 1683]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1693, 1696]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1739, 1777]], 'text': ['TNF receptor-1-associated death domain'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1779, 1784]], 'text': ['TRADD'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1801, 1831]], 'text': ['receptor interacting protein 1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1833, 1837]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1904, 1943]], 'text': ['TNF receptor-associated factor (TRAF) 2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1948, 1953]], 'text': ['TRAF5'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1999, 2039]], 'text': ['cellular inhibitor of apoptosis (cIAP) 1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2044, 2049]], 'text': ['cIAP2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2065, 2068]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2101, 2105]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2162, 2167]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2168, 2169]], 'text': ['5'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2174, 2179]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2180, 2181]], 'text': ['2'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2206, 2210]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2303, 2307]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2365, 2369]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2413, 2417]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2422, 2426]], 'text': ['TAB1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2427, 2428]], 'text': ['2'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2519, 2523]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2578, 2581]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2808, 2812]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2896, 2900]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[2962, 2996]], 'text': ['Toll/IL-1 receptor adaptor protein'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3018, 3020]], 'text': ['Ma'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3027, 3056]], 'text': ['TRIF-related adaptor molecule'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3058, 3062]], 'text': ['TRAM'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3122, 3170]], 'text': ['myeloid differentiation primary response gene 88'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[3172, 3177]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[3183, 3229]], 'text': ['TIR domain-containing adaptor-inducing IFNbeta'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[3231, 3235]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[3252, 3257]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[3332, 3337]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[3392, 3397]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[3404, 3408]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[3423, 3428]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[3438, 3442]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[3502, 3506]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[3567, 3570]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[3650, 3675]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[3677, 3690]], 'text': ['BAFF receptor'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[3692, 3696]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[3702, 3706]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[3736, 3740]], 'text': ['p100'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[3775, 3778]], 'text': ['p52'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[3804, 3808]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[4027, 4031]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[4076, 4101]], 'text': ['NF-kappaB inducing kinase'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[4103, 4106]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[4109, 4112]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[4254, 4257]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[4295, 4300]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[4302, 4307]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[4313, 4318]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[4319, 4320]], 'text': ['2'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[4350, 4353]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[4464, 4469]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[4542, 4547]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[4552, 4557]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[4558, 4559]], 'text': ['2'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[4596, 4601]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[4649, 4652]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[4701, 4704]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[4722, 4726]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[4791, 4795]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4797, 4822]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4827, 4831]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4951, 4955]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4960, 4964]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[5011, 5016]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[5018, 5023]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[5025, 5030]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[5032, 5037]], 'text': ['TRAF5'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[5043, 5048]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[5092, 5097]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[5102, 5107]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[5279, 5283]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[5328, 5333]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[5350, 5354]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[5383, 5387]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[5406, 5411]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[5457, 5462]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[5497, 5501]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T127'}]",[],[],[],[],[]
28,PMC-1472690-04-Results,"Role of NFkappaB, NFIL-6 and NFAT binding in LPS-, TSST-1-, GP-, GP + LPS- and GP + TSST-1-induced IL-1RA expression by human PBMC
Because GP induced band shifts to NFkappaB, NFIL-6 and NFAT sites, but no TNFalpha, IL-6 or IFNgamma, we hypothesized that the activated transcription factors might bind to sites in the IL-1RA promoter. We investigated previoulsy described and newly discovered transcription factor binding sites of the IL-1RA promoter (Table 1) using the program OMIGA (v.1.1.3, Oxford Molecular, Oxford, UK). The LPS responsive kappaB consensus site of LRE-1 (between -84 and -93) [30] displayed band shifts, but no significant alterations of its binding activity, irrespective of the treatment (data not shown). A new kappaB3 site (-100 and -130) within the LRE-1 [30] showed increased binding induced by TSST-1 (+30% vs. control), but GP co-treatment up-regulated the LPS (+65% vs. control)- and the TSST-1 (+110% vs. control)-induced binding in a superadditive synergistic fashion, when compared to medium control as well as to LPS, TSST-1 or GP or the theoretical values of GP/LPS calc. or GP/TSST-1 calc. (all p < 0.05; Fig. 4). Binding to a new kappaB consensus site (between -266 and -280) was significantly elevated for GP + TSST-1 (p < 0.05; data not shown). The LPS-, TSST-1- and GP + LPS-induced binding to the new kappaB2/3 site (-288 and -302) was down-regulated by about 20-35% in comparison with medium control (p < 0.05; data not shown). The NFIL-6 site (-147 and -170) close to LRE-2 [31,32] showed an up-regulation of binding for all compounds and combinations vs. medium control, ranging from 25-110% (p < 0.05). Further, GP + TSST-1 induced an increased binding to the NFIL-6 site in comparison with TSST-1 (1.3fold) or GP (1.6fold; p < 0.05), (data not shown). A new binding site for NFATP2/3 was found more distal of the transcription start site, between -471 and -490, displaying again a substantial increase of binding for all compounds and combinations, when compared to medium control (p < 0.05). In addition, binding to the NFATP2/3 site following both, GP + LPS (1.4fold of GP) and GP + TSST-1 (1.5fold of GP, 1.25fold of TSST-1) was elevated (p < 0.05; Fig. 5), but only in an additive synergistic manner, i.e. the experimental results were not different from the theoretical values (calc.).","[{'offsets': [[18, 24]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[29, 33]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[51, 57]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[84, 90]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[99, 105]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[205, 213]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[215, 219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[223, 231]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[317, 323]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[434, 440]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[822, 828]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[918, 924]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1052, 1058]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1113, 1119]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1249, 1255]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1294, 1300]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1662, 1668]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1736, 1742]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2131, 2137]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2166, 2172]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
29,PMC-3218875-09-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"TNF receptor-associated factor 1
TRAF1 is a unique member of the TRAF protein family because it lacks a RING finger domain and therefore lacks ubiquitin ligase activity. Accumulating data support a role for TRAF1 as both a negative and a positive modulator of NF-kappaB signalling by certain TNF family receptors, possibly in a cell-type-dependent manner [71,72]. Expression of TRAF1 is inducible by TNF and overexpression of TRAF1 inhibits TNF-induced NF-kappaB activation. TRAF1-deficient T cells are hyper-responsive to TNF, with enhanced proliferation and activation of the NF-kappaB signalling pathway. TRAF1 also functions as a negative regulator of CD40-induced NF-kappaB activation. TRAF1-deficient dendritic cells, however, show attenuated responses to secondary stimulation by TRAF2-dependent factors, suggesting a positive regulatory role in these cells. The mechanism by which TRAF1 modulates NF- kappaB activation is still unclear. Most probably, TRAF1 competes with TRAF family members for binding to the receptor or other signalling proteins. Alternatively, TRAF1 might recruit A20 with which it can physically interact [73]. A genome-wide association study examining more than 300,000 SNPs among approximately 1,500 autoantibody-positive RA cases and 1,800 controls identified a genetic variation at the TRAF1-complement component 5 locus as an important RA risk locus [74]. Subsequent work indicates that TRAF1 is more likely to be the causative locus [75]. Recent work in a Korean population also demonstrates genetic association of the TRAF1 region with RA [76].","[{'offsets': [[0, 32]], 'text': ['TNF receptor-associated factor 1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[33, 38]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[143, 152]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[207, 212]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[378, 383]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[400, 403]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[426, 431]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[441, 444]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[475, 480]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[523, 526]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[608, 613]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[656, 660]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[691, 696]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[787, 792]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[889, 894]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[960, 965]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1073, 1078]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1093, 1096]], 'text': ['A20'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1320, 1325]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1422, 1427]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1555, 1560]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
30,PMC-3585731-01-Introduction,"Necroptosis is a form of regulated cell death that displays all the major hallmarks of necrosis [1]. A growing number of studies have implicated necroptosis in a wide range of animal models of human disease, including brain, heart and retinal ischemia-reperfusion injury, acute pancreatitis, brain trauma, retinal detachment, and Huntington's disease [2], [3]. Importantly, several recent studies have linked necroptosis to models of inflammation including intestinal inflammation and systemic inflammatory response syndrome (SIRS) [4], [5], [6]. The discovery of a regulated form of necrotic death could uncover molecular targets amenable to pharmacological intervention for the treatment of various conditions.
A complex consisting of two related Ser/Thr kinases, RIP1 and RIP3, plays a critical role in the initiation of necroptosis in multiple systems [7], [8], [9]. A recent genome wide siRNA screen for mediators of necroptosis induced by the pan-caspase inhibitor zVAD.fmk in mouse fibrosarcoma L929 cells, revealed a broad and diverse cellular network of 432 genes that may regulate this process [10]. These data provided important confirmation of the highly regulated nature of necroptosis and revealed the first insight into the full repertoire of mediators of this form of cell death. However, the specific signaling pathways activated during necroptosis and their connections to RIP1 and RIP3 remain poorly understood. Several recent studies [10], [11], [12], [13], [14] have suggested that JNK kinase activation plays an important role during necroptosis in L929 cells downstream from RIP1 kinase. For example, the transcription factor c-Jun, a key cellular target of JNK activity, was one of the hits in the genome wide siRNA screen [10]. Activation of JNK in L929 cells has been linked to autocrine TNFalpha synthesis, activation of oxidative stress and induction of autophagy, all of which contribute to necroptosis. Importantly, RIP1 kinase dependent activation of JNK and TNFalpha production has recently been described to be independent of its role in necroptosis [15]. Curiously, Akt kinase, a key pro-survival molecule and a well-established inhibitor of apoptotic cell death, has also recently been linked to necroptosis in L929 cells [16], where insulin-dependent activation of Akt was suggested to promote necroptosis by suppressing autophagy. This conclusion was unexpected, since several reports from different groups, including ours, have established that autophagy promotes, rather than suppresses, zVAD.fmk-induced necroptosis in L929 cells [11], [14], [17]. This raised the possibility that Akt controls more general mechanisms that contribute to the execution of necroptosis. Furthermore, the key question of whether insulin-dependent Akt activity solely provides an environment conducive for necroptosis or if Akt activation is an intrinsic component of necroptosis signaling that is linked to RIP1 kinase has not been explored.
In this study, we expanded these observations to delineate the specific contributions and molecular ordering of the Akt and JNK pathways downstream from RIP1 kinase during necroptosis. Our data reveal that Akt is activated through RIP1 kinase-dependent Thr308 phosphorylation during necroptosis in multiple cell types. Furthermore, we found that downstream Akt signaling through mTORC1 and S6 contributes to the activation of necroptosis and TNFalpha production. We found that the Akt pathway serves as a critical link between RIP1 kinase and JNK activation in L929 cells. Further data suggested that in multiple other cell types including FADD deficient Jurkat cells, RAW and J774.1 macrophage cell lines, and mouse lung fibroblasts Akt provides a key link to TNFalpha production, but is dispensible for cell death per se. Overall, our results reveal a specific and novel role for the Akt pathway in regulated necrosis and necrosis-associated inflammatory signaling.","[{'offsets': [[766, 770]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[775, 779]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1391, 1395]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1400, 1404]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1598, 1602]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1649, 1654]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1814, 1822]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1946, 1950]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1990, 1998]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2269, 2276]], 'text': ['insulin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2748, 2755]], 'text': ['insulin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2926, 2930]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3114, 3118]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3192, 3196]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3351, 3353]], 'text': ['S6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3403, 3411]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3488, 3492]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3601, 3605]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3722, 3730]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
31,PMC-3586680-10-Caption-Figure_2,"p53 and WWOX in GBM cell apoptosis. (A) Full-length p53 possesses two N-terminal transactivation acidic domains, a proline-rich domain, a central DNA-binding region, and a C-terminal domain, containing a nuclear localization signal, an oligomerization domain, and a basic region. N-terminal deletion mutants of p53 are also shown. (B) Three likely scenarios are proposed for WWOX and p53 to regulate GBM cell death. First, ectopic WWOX fails to induce apoptosis of GBM cells expressing endogenous wild type p53. It appears that ectopic WWOX binds and functionally antagonizes p53, and both proteins nullify each other's function in inducing apoptosis. Second, no physical interactions between mutant p53 proteins and WWOX are expected in GBM cells. Thus, ectopic WWOX induce apoptosis in mutant p53-expressing cells. Finally, whether WWOX binds p53 isoforms is unknown. Also, whether ectopic WWOX induction of apoptosis in GBM cells expressing p53 isoforms remains to be established. TAD, transactivation domain; PrD, proline domain; NLS, nuclear localization signal; OD, oligomerization domain; BR, basic region.","[{'offsets': [[0, 3]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 12]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[52, 55]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[311, 314]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[375, 379]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[384, 387]], 'text': ['p53'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[431, 435]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[507, 510]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[536, 540]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[576, 579]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[700, 703]], 'text': ['p53'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[717, 721]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[763, 767]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[795, 798]], 'text': ['p53'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[834, 838]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[845, 848]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[892, 896]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[944, 947]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
32,PMC-3312845-16-Results,"Neutrophil infiltration
Recent studies have reported that neutrophils infiltrate the brain under certain pathological conditions [26]. Indeed, we have reported massive neutrophil infiltration in layer III/IV of the PC 1 day after SE [20]. In the present study, 1 day-post-SE animals of the saline-infused group showed infiltration of MPO-positive neutrophils into the PC. Similarly, 1 day-post-SE animals of the sTNFp55R-infused group showed neutrophil infiltration into the PC 1 day after SE (Figure 6A). The number of neutrophils/area in the PC region (including the vasogenic edema region and the non-vasogenic edema region) of sTNFp55R-infused animals was significantly lower than that of the saline-infused group (Figure 6D, p < 0.05). However, there was no difference in neutrophil infiltration per unit area of vasogenic edema between the saline- and sTNFp55R-infused groups (Figure 6D). Furthermore, neutrophil infiltration showed a direct proportion to the area of vasogenic edema, with a linear coefficient of correlation of 0.8631 (p < 0.05, Figure 6E). Therefore, our findings indicate that SE-induced neutrophil infiltration into the PC may be correlated to TNF-alpha-mediated vasogenic edema formation.","[{'offsets': [[413, 420]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[632, 639]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[859, 866]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1171, 1180]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
33,PMC-3589482-03-Experimental_Procedures,"Real-time Quantitative PCR (qPCR)
The RNeasy Mini Kit (Qiagen) was used to isolate total RNA from cells. For cDNA synthesis, 1 microg of total RNA was reverse transcribed using TaqMan(R) Reverse Transcription Reagents (Applied Biosystems). qPCR was performed using TaqMan(R) Gene Expression 20X primers for Serpinb2/SerpinB2 (Mm00440905_m1), Cebpb (Mm00843434_s1) and beta-actin (Mm00607939_s1) (Applied Biosystems).","[{'offsets': [[307, 315]], 'text': ['Serpinb2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[316, 324]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[342, 347]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[368, 378]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
34,PMC-1359074-04-Results,"EMSA and ChIP Assays Show that Sox6 Directly Binds to the epsilony Promoter
Sox6 might repress the epsilony promoter, either through direct physical contact with the promoter or by regulating intermediates affecting the epsilony promoter. To investigate whether Sox6 is directly associated with the epsilony promoter, we first performed electrophoretic mobility shift assays (EMSA) using a c-Myc-tagged Sox6 in a reticulocyte lysate-based transcription/translation in vitro system. The probes used are listed in Figure 3A. The 36-base pair (bp) WT probe corresponds to the critical region of the epsilony promoter defined in our promoter deletion analyses. This probe contains two consensus Sox/Sox6 binding sites. Also included in our EMSA are three mutated probes that are, either truncated (M1), or mutated (M2 and M3) in Sox/Sox6 binding sites (Figure 3A). Sox6 is able to physically associate with the 36-bp region (Figure 3B) within the epsilony promoter defined by the deletion analysis experiments (Figure 2C). The 36-bp probe was shifted by the tagged Sox6 protein. Moreover, both c-Myc and Sox6 antibodies supershift the band, indicating that the binding is Sox6-specific. To rule out the possibility that the c-Myc tag itself binds to the probe, an HA-tagged Sox6 was used in another EMSA that confirmed these results (Figure 3C).
Next, nuclear extracts from MEL cells were used in EMSA employing the same 36-bp probe. MEL cells, a murine erythroleukemic cell line, express adult beta globins, but not epsilony [33]. Sox6 directly binds to this DNA sequence in MEL cells (Figure 3D). The intact consensus Sox/Sox6 binding sites of the DNA probe are required for the binding, as shown in the competition assay (Figure 3E). Ablation of putative Sox/Sox6 binding sites (M1 and M3) abolish their ability to compete in EMSA (Figure 3E). The M2 mutant probe may compete partially with WT binding.
To investigate the functional significance of the intact Sox/Sox6 binding sites, the epsilony promoter reporter constructs with mutagenized Sox/Sox6 binding sites were co-transfected with the Sox6 overexpression vector into GM979 cells. Consistent with the EMSA results, the mutant epsilony promoter reporter constructs (with either one or both Sox/Sox6 binding sites mutagenized) do not result in significant promoter repression in transfection studies (Figure 3F). Thus, both sites are required for maximal repression of epsilony by Sox6, but not to the same degree.
We also tested whether Sox6 binds to the epsilony promoter in vivo using chromatin immunoprecipitation (ChIP) (Figure 4). The Sox6-containing complex was immunoprecipitated from MEL cells or from liver cells of 15.5 dpc WT mice using Sox6 antibody. Figure 4 shows that the epsilony proximal promoter is readily immunoprecipitated with Sox6 antibody in both MEL cells and liver cells. Normal IgG was used as a negative control (Figure 4A). The above data (Figures 3 and 4) clearly indicate that Sox6 acts as a repressor of the epsilony gene by directly binding to the epsilony promoter, probably as a dimer.","[{'offsets': [[31, 35]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[58, 66]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[76, 80]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[99, 107]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[220, 228]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[262, 266]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[299, 307]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[390, 395]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[403, 407]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[596, 604]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[861, 865]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[943, 951]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1061, 1065]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1090, 1095]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1100, 1104]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1168, 1172]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1220, 1225]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1260, 1262]], 'text': ['HA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1270, 1274]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1491, 1503]], 'text': ['beta globins'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1513, 1521]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1528, 1532]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1987, 1995]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2094, 2098]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2184, 2192]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2425, 2433]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2437, 2441]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2494, 2498]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2512, 2520]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2597, 2601]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2705, 2709]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2744, 2752]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2806, 2810]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2965, 2969]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2997, 3005]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3038, 3046]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T36'}]",[],[],[],[],[]
35,PMC-3317373-02-2._Methods_and_Materials,"2.1. Primary Culture and Identification of Mouse Astrocytes
Nrf2 knockout ICR mice were kindly provided by Dr. Thomas W. Kensler (Johns Hopkins University, Baltimore, MD, USA). Primary astrocytes were obtained from postnatal 2-day-old Nrf2 wide type (WT) and knockout (KO) mice (6 mice for each genotype). Following decapitation, the cortices were dissected out, and the meninges and associated blood vessels were removed. The tissue was roughly chopped with a scalpel blade, incubated in 0.5% trypsin for 10 minutes at 37degreesC, and agitated every few minutes. After digestion, the tissue was rinsed twice in DMEM with 10% FBS, followed by a mechanical dissociation in DMEM with 20% FBS and 5 units/mL penicillin, 5 mug/mL streptomycin (complete culture medium). After incubation for 1 h, the supernatant was transferred to a new flask or dish (Costar, USA) for depleting the residual epithelial cells. Then the cells were cultivated at 37degreesC with 5% CO2. And the complete culture medium was half-changed twice a week. Astrocytes expanded for about 7 days to reach confluence. Then the flasks or dishes were shaken at 150 rpm for 4 h to deplete the microglia and less adherent cells from the cultures. After shaking, the resulting cultures were mainly astrocytes, which were determined by immunoreactivity for GFAP (sc-166481, Santa Cruz Biotechnology, CA, USA). Cells passaged for 2-3 generations were used in the following studies.",[],[],[],[],[],[]
36,PMC-3291650-19-Caption-Figure_3,"A20 deficiency in myeloid cells protects against IAV lung infection.
A20myel-WT and A20myel-KO mice were infected intranasally with a sublethal dose of IAV and weight loss was monitored (A). At day 4, 7 and 10 post infection (p.i.) viral titers in the lung were measured and expressed as mean TCID50 (B). The dashed line represents the detection limit. ND, not detectable. BAL was isolated from IAV infected mice at 4, 7 and 10 days p.i. and KC, MIP-2, MCP-1, IL-6 and IFNalpha protein levels were analyzed by ELISA and multiplexing technologies (C). Absolute numbers of resident alveolar macrophages, neutrophils and monocytes in BAL were analyzed by flow cytometry at 4, 7 and 10 days p.i. (D). Numbers are averages +/- SEM of at least 5 mice per group and are representative of 2 independent experiments. *p<0.05; **p<0.01.","[{'offsets': [[442, 444]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[446, 451]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[453, 458]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[460, 464]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
37,PMC-1472690-18-Caption-Figure_1,"A, GP led to DNA binding of NFAT, NFkappaB and NFIL-6. Human PBMC were incubated with medium control or GP (1 and 100 mug) for 1 h at 37degreesC. Nuclear extracts were incubated with a 32P-labeled NFAT, NFkappaB, NFIL-6 or NFkappaB-IL-8 oligonucleotide probe corresponding to the IFNgamma, TNFalpha, IL-6 and IL-8 gene promoters (Table 1). Arrows with the black head indicate migrational location of the NFAT-DNA, NFkappaB-DNA, NFIL-6-DNA or NFkappaB-IL-8-DNA complex compared to free probe (no shift). Arrow with the open head indicates a supershift of NFkappaB-IL-8-DNA-anti-p65 and -p50, respectively. An autoradiogram from a representative experiment is shown (n = 7). B, Decreased DNA binding of NFkappaB following GP + TSST-1, compared to TSST-1, GP, or TSST-1/GP. Human PBMC were incubated with medium control, LPS, TSST-1, GP (100 mug), GP + TSST-1 and GP + LPS for 1 h at 37degreesC. An autoradiogram from a representative experiment is shown. Schematic representation of NFkappaB-DNA binding activity following GP (1 and 100 mug) or TSST-1 treatment (250 ng) as well as simultaneous administration of both compounds and the theoretical value (GP/TSST-1 calc.). Medium control levels were set equal to 1+/- SEM and significances (* = p < 0.05) are shown with respect to medium control (n = 4).","[{'offsets': [[28, 32]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 53]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[197, 201]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[213, 219]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[232, 236]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[280, 288]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[290, 298]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[300, 304]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[309, 313]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[404, 408]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[428, 434]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[451, 455]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[563, 567]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[577, 580]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[586, 589]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[725, 731]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[745, 751]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[760, 766]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[823, 829]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[850, 856]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1043, 1049]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
38,PMC-2817507-12-3._Results,"3.4. Activation of TLR4-Mediated NF-Kappa-B Signaling
Activation of TLR4 induces the phosphorylation of inhibitor of kappa-B (IkappaB), which dissociates IkappaB with NF-kappa-B (NFkappaB). Then, NFkappaB translocates into the nucleus and activates and regulates the transcription of genes related to inflammatory responses. To detectd the activation of TLR4-mediated NFkappaB signaling, the phosphorylation of inhibitor of kappa-B (p-IkappaB) and activity of NFkappaB were measured by methods of Western Blots and EMSA. Results showed that the p-IkappaB increased at 6 hours after ICH (P < .05), peaked on 3 days after ICH, and maintained a high level on 7 days after ICH (P < .05, Figure 5). As expected, the activity of NFkappaB was also increased in the same manner as that of the p-IkappaB (Figure 4).","[{'offsets': [[19, 23]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[68, 72]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[354, 358]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
39,PMC-1064895-19-Discussion,"IL-17 was first described as a T cell product with proinflammatory properties [5,22]. RA is characterized by hyperplasia of synovial lining cells and an intense infiltration by mononuclear cells [23]. Proinflammatory cytokines such as IL-1 and TNF-alpha are abundant in rheumatoid synovium, whereas the T cell-derived cytokines, especially IL-4 and interferon-gamma, have often proved difficult to detect in RA synovium [24]. Although T cells may have a role in the augmentation of rheumatoid synovial inflammation, the lack of T cell-derived cytokines has limited its importance. In this respect, IL-17 is appealing because it has been described as a T cell-derived cytokine with proinflammatory properties.
In our studies, we tried to evaluate how IL-17 production is regulated in RA PBMC, and which signaling pathway it used. Levels of IL-17 were found to be higher in RA synovial fluid than in OA synovial fluid [15]. However, there are few data available on the agents that stimulate IL-17 production in RA, although the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25]. In our experiments, PHA as mitogens, as well as anti-CD3/anti-CD28 for signaling through the T cell receptor, increased IL-17 production from RA PBMC in a dose-dependent manner. We found, by a cell proliferation assay (data not shown), that this upregulation of IL-17 might be due to increased cellular activity rather than to cellular proliferation.
IL-17 is produced mainly by activated CD4+ T cells, especially for Th1/Th0 cells, not the Th2 phenotype [26]. However, it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14]. In addition, IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [27]. A complex interaction between cells in inflamed RA joints might produce a variety of proinflammatory cytokines and chemokines, which also activate other cells in the joints. For example, IL-17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL-6, IL-8 and tumor necrosis factor-stimulated gene 6 as well as prostaglandin E2 in vitro [12,28,29]. There are as yet few data available on the agents that stimulate IL-17 production in RA, although some cytokines (IL-15 and IL-23) have been known to regulate IL-17 production [13,14]. We therefore investigated the in vitro production of IL-17 in RA PBMC responding to a variety of cytokines/chemokines and mitogens as well as T cell receptor (TCR) ligation using anti-CD3/anti-CD28. Our studies demonstrated that IL-15 and MCP-1 as well as TCR ligation significantly increased the production of IL-17 in RA PBMC. Adding IL-15 or MCP-1 to TCR ligation augmented IL-17 production more markedly. In contrast, IL-1 and TNF-alpha, which are known to have proinflammatory properties and to be increased in RA joints, did not affect IL-17 production. Our data were consistent with a recent report that IL-15 triggered in vitro IL-17 production in PBMC, but TNF-alpha did not do so [13]. Although there were no data that MCP-1 directly induces T cell activation, it might exert effects indirectly on T cells through the activation of monocytes/macrophages in PBMC cultures. As reported for normal individuals [25], T cell activation through anti-CD3/anti-CD28 also increases IL-17 induction in RA PBMC.
Although the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31], no data have been available on how IL-17 production can be regulated by certain signaling pathways. By using signal transduction inhibitors, we therefore examined which signaling pathway was mainly involved in the induction of IL-17 in RA PBMC.
We identified that anti-CD3-induced IL-17 production in RA PBMC was significantly hampered by the PI3K inhibitor LY294002 and the NF-kappaB inhibitor PDTC to comparable levels of basal production without stimulation. We also found that anti-CD3-induced IL-17 production was downregulated by the addition of SB203580, a p38 MAPK inhibitor. It is interesting that a series of evidence supports crosstalk between NF-kappaB and p38. In myocytes, IkappaB kinase-beta is activated by p38 [32], and the activated p38 can stimulate NF-kappaB by a mechanism involving histone acetylase p300/CREB-binding protein [33]. Our results revealed that p38 MAPK activation was not affected by LY294002, whereas NF-kappaB binding activity was decreased by LY294002, which provided the evidence for a p38 MAPK pathway independent of PI3K activation. The direct relationship between p38 and NF-kappaB for IL-17 production needs to be studied in future experiments.
The search for a downstream pathway of PI3K seemed to have a maximal response of Akt activation at 1 hour and a gradual loss of activity at 2 hours. The fact that Akt is phosphorylated upon anti-CD3 stimulation suggests the possible involvement of PI3K in the induction of IL-17 in RA. In view of the fact that NF-kappaB was also activated by anti-CD3/anti-CD28, IL-15 or mitogens in our experiments, it is most likely that the NF-kappaB pathway is also actively involved in the induction of IL-17 in RA PBMC. In contrast, the AP-1 signal transduction pathway, another important signaling pathway for cytokines/chemokines, was not activated in our experiments (data not shown). Although PI3K and its downstream kinase Akt in association with NF-kappaB have been reported to deliver activating signals in many cell types, the data on the signal inducing IL-17 are lacking. Our data clearly demonstrated that PI3K/Akt and resultant NF-kappaB activation could be an important arbitrator of the upregulation of IL-17 in RA, on the basis of our experiments showing simultaneous blocking of NF-kappaB binding activity in the IL-17 promoter by PDTC and LY294002. Considering its proinflammatory activities and successful induction of anti-IL-17 for ameliorating arthritis in animal models [2,6,34-36], understanding the IL-17 signaling pathway is an important element of developing new targeted therapies in RA.","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[235, 239]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 253]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[340, 344]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[349, 365]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[598, 603]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[750, 755]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[839, 844]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[989, 994]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1043, 1048]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1093, 1097]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1159, 1162]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1201, 1205]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1259, 1264]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1401, 1406]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1490, 1495]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1528, 1531]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1636, 1639]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1656, 1661]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1739, 1744]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2055, 2060]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2133, 2137]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2139, 2143]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2148, 2187]], 'text': ['tumor necrosis factor-stimulated gene 6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2302, 2307]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2351, 2356]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2361, 2366]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2396, 2401]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2475, 2480]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2615, 2619]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2651, 2656]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2661, 2666]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2733, 2738]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2758, 2763]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2767, 2772]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2799, 2804]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2844, 2848]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2853, 2862]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2964, 2969]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3033, 3038]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3058, 3063]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3088, 3097]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3151, 3156]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3385, 3389]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3405, 3410]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3509, 3514]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3588, 3593]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3780, 3785]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3822, 3825]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3834, 3839]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4051, 4056]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4240, 4259]], 'text': ['IkappaB kinase-beta'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4375, 4379]], 'text': ['p300'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4380, 4400]], 'text': ['CREB-binding protein'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4682, 4687]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4823, 4826]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4905, 4908]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5015, 5020]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5099, 5103]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[5105, 5110]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5234, 5239]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5269, 5273]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5460, 5463]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[5595, 5600]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[5654, 5657]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5749, 5754]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5861, 5866]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5974, 5979]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6055, 6060]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T69'}]",[],[],[],[],[]
40,PMC-3589482-15-Results,"Sequence Conservation within the Human and Murine SerpinB2 Proximal Promoters
To look for potential cis-acting elements that might mediate transcription of the murine SerpinB2 gene and the response to LPS, we aligned the murine and human SerpinB2 5' flanking regions. We reasoned that the presence of evolutionarily conserved, potential transcription factor binding sites in this region might play a role in the regulation of SerpinB2 gene expression [52]. The presence of several repetitive sequence elements delineated five broadly homologous regions (A-E) between the human and murine promoters (Fig. 2C). The proximal promoter (Region E), which contains the essential LPS response element, exhibited the greatest homology. Further analysis of Region E revealed that several of the cis-acting regulatory elements defined in the human SerpinB2 proximal promoter are conserved in the murine SerpinB2 promoter (Fig. 3). Specifically, a TATA consensus sequence is located 23 to 29bp upstream from the transcription initiation site, similar to the position of the TATA box of the human SERPINB2 gene [53]; [54]. A putative CCAAT enhancer binding protein (C/EBP) site is present at -192/-203, two potential activator protein 1 (AP-1) binding sites are found at nucleotides -88/-94 and -100/-106, and a putative cyclic AMP response element (CRE) is present at -172/-177. Both of the AP-1 sites are identical in sequence to those identified in the human SERPINB2 promoter, and the CRE differs in the identity of a single central nucleotide [37]; [55]. A consensus E box (-538/-533), as well as potential binding sites for PU.1 (-412/-407) and Oct-1 (-296/-288) were also identified within the proximal promoter region (Fig. S2). Further upstream, a retinoic acid response element at -1349/-1340, a PAUSE-1 silencer element at -1540/-1528 and a NF-kappaB p65 binding site at -1342/-1351 (Fig. S2) are also well conserved [16]; [30]; [56].","[{'offsets': [[50, 58]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[167, 175]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 246]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[426, 434]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[837, 845]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[892, 900]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1084, 1092]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1449, 1457]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1617, 1621]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1638, 1643]], 'text': ['Oct-1'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
41,PMC-3342329-03-Results,"Decrease of NF-kappaB Activity in Tumor Tissue of CCR5-/- Mice
The activation of NF-kappaB plays a critical role in cancer cell survival, especially melanoma cancer cells and in CCR5 expression. To evaluate whether the tumor inhibition was related with the inactivation of NF-kappaB in melanoma, the DNA binding activity of NF-kappaB was determined by electromobility shift assay (EMSA) in melanoma tissue. The constitutively activated DNA binding activity was reduced in the CCR5-/- mice tumor tissue (Figure 2A). Moreover, the translocation of p50 and p-p65 into the nucleus through the inhibition of phosphorylation of IkappaB was also prevented in the tumor tissues of CCR5-/- mice (Figure 2B). Immunofluorescence analysis also confirmed that the intensity of nuclear staining for p50 had decreased in the tumor tissues of CCR5-/- mice (Figure 2C).","[{'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[178, 182]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[476, 480]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[546, 549]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[556, 559]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[673, 677]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[785, 788]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[827, 831]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
42,PMC-3589482-31-Caption-Figure_8,"C/EBP-beta is necessary for SerpinB2 proximal promoter activity.
(A) The SerpinB2 proximal promoter is significantly activated in LPS-stimulated Cebpb+/+ MEFs and not in Cebpb-/- MEFs. Murine SerpinB2 gene promoter activity measured in Cebpb+/+ and Cebpb-/- MEFs expressing the pGLmP-539 SerpinB2 promoter-luciferase reporter in the presence or absence of LPS (100 ng/mL). Cells were co-transfected with the pGLmP-539 SerpinB2 promoter-luciferase reporter and beta-galactosidase reporter plasmids, and luciferase units normalized to beta-galactosidase activity. (B) C/EBP-beta gene schematic depicting gene structure and phospho-acceptor sites. (C) Phosphorylation of C/EBP-beta at Serine 64 negatively regulates LPS-stimulated SerpinB2 promoter activity. Cebpb-/- MEFs were co-transfected with expression plasmids encoding wild-type C/EBP-beta or the indicated C/EBP-beta phospho-acceptor mutants, along with the pGLmP-539 SerpinB2 promoter-luciferase reporter and beta-galactosidase reporter plasmids, and stimulated with LPS for 4 hrs. Luciferase activity was quantified and normalized to beta-galactosidase activity. The western blot (below the graphs) confirms the expression of the respective C/EBP-beta phospho-acceptor mutants. The C/EBP-betaT217A -transfected MEFs express both the 38 kDa and 35 kDa isoforms of C/EBP-beta. The results represent the mean and SEM of at least three independent experiments performed in triplicate. (*, p<0.05, one-way ANOVA).","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 36]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[73, 81]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[145, 150]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[170, 175]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[192, 200]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[236, 241]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[249, 254]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[288, 325]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[418, 455]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[460, 487]], 'text': ['beta-galactosidase reporter'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[502, 512]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[533, 551]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[566, 576]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[668, 678]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[728, 736]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[756, 761]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[834, 844]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[862, 897]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[924, 961]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[966, 993]], 'text': ['beta-galactosidase reporter'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1039, 1049]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1092, 1110]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1199, 1234]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1240, 1255]], 'text': ['C/EBP-betaT217A'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1321, 1331]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
43,PMC-3317373-11-3._Results,"3.1. Depletion of Nrf2 Aggravated the Cell Death in Astrocytes after Scratch Injury
Cell death was detected by microscope and CCK-8 analysis at 24 h after scratch. The detachment from culture plate, cell lost, and cytoplasmic process distortion were mostly observed in both sides of scratch line in group KO TBI. CCK-8 assay also showed lower OD value of group KO TBI (0.38 +/- 0.064) than that of group WT TBI (0.98 +/- 0.098) (P < 0.01), which also suggested more cell death in group KO TBI (Figure 1). There was no difference between two sham-operated groups.",[],[],[],[],[],[]
44,PMC-3312845-10-Methods,"Quantification of data
The fluorescence intensities of SMI-71/p65-Thr435 phosphorylation or GFPA/p65-Thr435 phosphorylation were measured using a computer-assisted image analysis program (The University of Texas ImageTool program V. 3.0 and AxioVision Rel. 4.8 software). After regions were outlined, 30 areas/rat (300 mum2/area) were randomly selected within the PC, and double immunofluorescent merge images were captured from the PC (15 sections from each animal). Merge images were digitally separated to red or green image, and converted to grayscale images, respectively (n = 36 per region examined, in non-SE, 12 hr post-SE and 1 day post-SE). The range of intensity values was obtained from the selected images. Based on the mean range of intensity values, each image was normalized by adjusting the black and white range of the image. Manipulation of the images was restricted to threshold and brightness adjustments to the whole image. Intensity measurements are represented as the mean number of a 256 gray scale (NIH Image 1.59 software and AxioVision Rel. 4.8 software). Values for background staining were obtained from the corpus callosum. Optical density values were then corrected by subtracting the average values of background noise obtained from 15 image inputs.","[{'offsets': [[62, 65]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 100]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
45,PMC-3218875-05-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"A20 protein
A20 (also known as TNFAIP3) is a ubiquitin-editing protein that negatively regulates NF-kappaB-dependent gene expression in response to different immune-activating stimuli, including TNF, IL-1 and antigens, and the triggering of TLRs and the nucleotide-binding oligomerisation domain-containing 2 receptor (reviewed in [37]). A20 is believed to inhibit NF-kappaB function by deubiquitinating specific NF-kappaB signalling molecules, such as RIP1, RIP2, TRAF6 and MALT1, which disrupts specific protein-protein interactions [38-41] (Figure 1). Recently, the disruption of interactions between E2 ubiquitin conjugating enzymes (Ubc13 and Ubc5hc) and E3 ubiquitin ligases (TRAF6, TRAF2 and cIAP1/2) were described as another important mechanism used by A20 to downregulate NF-kappaB signalling [42]. The association of A20 with its targets requires specific ubiquitin-binding adaptor proteins, including A20-binding inhibitor of NF-kappaB (ABIN) 1 and Tax1-binding protein 1 [43-46].
Next to its role in suppressing NF-kappaB activation, A20 is also a strong inhibitor of apoptosis, at least in some cell types. The mechanisms by which A20 regulates apoptotic signalling, however, are still elusive. A20-deficient mice spontaneously develop multiorgan inflammation and cachexia and die within 2 weeks of birth, illustrating the potent anti-inflammatory function of this molecule [46]. A20-deficient cells are also more susceptible to TNF-mediated apoptosis, confirming its role as an antiapoptotic protein. We recently showed that mice specifically lacking A20 in intestinal epithelial cells exhibit increased susceptibility to experimental colitis due to the hypersensitivity of their intestinal epithelial cells to TNF-induced apoptosis, confirming A20 as a major antiapoptotic protein in the intestinal epithelium [47]. Two independent studies showed that mice lacking A20 in B cells develop autoimmunity due to hyperactive NF-kappaB responses in B cells leading to unrestricted B-cell survival [48,49].
A20 expression has been observed in several cell types that play important roles in the pathophysiology of RA, such as fibroblasts, synoviocytes and lymphocytes. Interestingly, A20 expression is itself regulated by NF-kappaB [50], implicating A20 in the negative feedback regulation of NF-kappaB signalling. Recently, intra-articular injection of an A20-expressing adenovirus was shown to reduce the severity of synovial inflammation and joint destruction in a mouse model of collagen-induced arthritis, even in untreated joints, in both a prophylactic and therapeutic setting. A20 expression in synovial tissue was associated with inhibition of NF-kappaB activity and decreased levels of TNF, IL-1beta, IL-6, soluble RANKL, monocyte chemo-attractant protein 1, and IL-17, suggesting that A20 induces a protective effect in collagen-induced arthritis mice through suppression of NF-kappaB activation and NF- kappaB-dependent gene expression [51]. Because TNF and IL-1beta are known to mediate synovitis, pannus formation, and erosion of cartilage and bone in RA, the decreased serum levels of TNF and IL-1beta in A20-transduced mice might explain the beneficial effects in the clinical, pathological, and radiological findings. This study also demonstrated that A20 overexpression leads to a decrease in the number of activated osteoclasts in joint tissue. A20 might therefore minimise joint destruction through decreasing the osteoclast number and activity. It will be interesting to analyse in future the susceptibility of conditional knockout mice that lack A20 in specific cell types such as synovial fibroblasts, macrophages, dendritic cells, B cells or T cells.
Importantly, several SNPs in the human A20 locus have been associated with increased susceptibility to development of autoimmune pathologies (reviewed in [52]). Several genome-wide association studies also revealed a clear association between mutations in the A20 locus in the 6q23 chromosome and susceptibility to RA [52]. Although the identified variants are not located in a gene, they are thought to influence A20 as its nearest gene (~150 kb downstream of A20), probably by the presence of potential regulatory DNA elements in this region. As A20 is required for termination of TNF-induced signals, and TNF is the primary inflammatory cytokine in RA, these findings reveal A20 as a candidate susceptibility locus for RA. How these variants affect normal A20 activity and how they cause RA, however, remain unclear. Recently, Elsby and colleagues functionally evaluated in vitro the regulatory ability of RA-associated SNP variants on A20 promoter activity, and could show repressed A20 transcription for some of the SNPs investigated [53]. It will be of interest to identify the actual causal variants and to elucidate the functional consequences of these variants. In this context, knockin mice for the corresponding A20 SNPs, combined with mouse models for RA, will be very valuable tools.","[{'offsets': [[0, 3]], 'text': ['A20'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[12, 15]], 'text': ['A20'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[31, 38]], 'text': ['TNFAIP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[45, 70]], 'text': ['ubiquitin-editing protein'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[97, 106]], 'text': ['NF-kappaB'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[195, 198]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[338, 341]], 'text': ['A20'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[453, 457]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[459, 463]], 'text': ['RIP2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[465, 470]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[475, 480]], 'text': ['MALT1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[638, 643]], 'text': ['Ubc13'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[648, 654]], 'text': ['Ubc5hc'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[682, 687]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[689, 694]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[699, 704]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[705, 706]], 'text': ['2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[762, 765]], 'text': ['A20'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[828, 831]], 'text': ['A20'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[913, 956]], 'text': ['A20-binding inhibitor of NF-kappaB (ABIN) 1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[961, 983]], 'text': ['Tax1-binding protein 1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1047, 1050]], 'text': ['A20'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1145, 1148]], 'text': ['A20'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1209, 1212]], 'text': ['A20'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1394, 1397]], 'text': ['A20'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1443, 1446]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1566, 1569]], 'text': ['A20'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1726, 1729]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1760, 1763]], 'text': ['A20'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1881, 1884]], 'text': ['A20'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2016, 2019]], 'text': ['A20'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2193, 2196]], 'text': ['A20'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2259, 2262]], 'text': ['A20'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2366, 2369]], 'text': ['A20'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2594, 2597]], 'text': ['A20'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2705, 2708]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2710, 2718]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2720, 2724]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2734, 2739]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2741, 2776]], 'text': ['monocyte chemo-attractant protein 1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2805, 2808]], 'text': ['A20'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2971, 2974]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2979, 2987]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3109, 3112]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3117, 3125]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3129, 3132]], 'text': ['A20'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3278, 3281]], 'text': ['A20'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3373, 3376]], 'text': ['A20'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3577, 3580]], 'text': ['A20'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3723, 3726]], 'text': ['A20'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3944, 3947]], 'text': ['A20'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4098, 4101]], 'text': ['A20'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4145, 4148]], 'text': ['A20'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4232, 4235]], 'text': ['A20'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4267, 4270]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4292, 4295]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4324, 4332]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4362, 4365]], 'text': ['A20'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4443, 4446]], 'text': ['A20'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4623, 4626]], 'text': ['A20'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4671, 4674]], 'text': ['A20'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4907, 4910]], 'text': ['A20'], 'type': 'Protein', 'id': 'T62'}]",[],[],[],[],[]
46,PMC-3291650-17-Caption-Figure_1,"A20 inhibits NF-kappaB and IRF3 activation in response to RIG-I stimulation.
(A) HEK293T cells were transfected with NF-kappaB (left), IRF3 (middle) or IRF7 dependent luciferase reporter (right) plasmids, together with plasmids expressing RIG-I (2CARD), IRF7 (right) and increasing amounts of A20. Luciferase activity in cell extracts was analyzed in a luminometer. Numbers are averages +/- SD of 3 samples per set-up. (B-D) A20myel-KO and wild type (A20myel-WT) BMDM were transfected with LMW poly(I:C) and analyzed at different time points (minutes) after the start of transfection for IkappaBalpha phosphorylation and degradation, and IRF3 phosphorylation by immunoblotting of total cell extracts (B). The band that is non-specifically recognized by the anti-IkappaBalpha antibody (indicated by an asterisk) can be used as a loading control. Nuclear translocation of NF-kappaB (p65) and IRF3 was analyzed by immunoblotting of cytoplasmic or nuclear fractions (C). Quantification of band density for nuclear p65 and IRF3 is shown in bar graphs (expressed as relative density compared to the first lane;  = time 0). IL-6, TNF and IFNbeta levels in the supernatant of cells used in (B) were determined by bioassay (IL-6) and ELISA (TNF and IFNbeta) as described in the 'materials and methods' section (D). Data are representative of 2 independent experiments.","[{'offsets': [[27, 31]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[58, 63]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[135, 139]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[152, 156]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[167, 177]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[254, 258]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[588, 600]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[638, 642]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[881, 884]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[890, 894]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1010, 1013]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1018, 1022]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1117, 1121]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1123, 1126]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1131, 1138]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1215, 1219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1232, 1235]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1240, 1247]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
47,PMC-2817507-01-1._Introduction,"Intracerebral hemorrhage (ICH) represents 10%-15% of all strokes and occurs with increasing frequency as a complication of the thrombolytic treatment of ischemic stroke, which is associated with high mortality and severe disability in survivors [1, 2]. Local brain tissue deformation induces primary brain damage after ICH; more importantly, the excitotoxicity and inflammatory responses in the brain tissue induced by ICH result in further brain damage following ICH [3]. Both innate and adaptive immunological/inflammatory mechanisms have been clearly shown to participate in the progression of brain injury after ischemic stroke. Nevertheless, how the inflammatory responses in ICH are triggered and regulated remains to be elucidated.
TLRs are a family of transmembrane proteins and act as signal transduction molecules [4]. Activation of TLRs recruits downstream signaling proteins and results in transcription of genes encoding inflammation-associated molecules and cytokines [5, 6]. For example, combined with specific ligand, the activation of TLR4 induces the phosphorylation of inhibitor of kappa-B (IkappaB) and dissociates IkappaB from NF-kappa-B (NFkappaB). Then, NFkappaB trans-locates into the nucleus and activates and regulates the transcription of genes related to inflammatory responses [5, 6]. TLRs play a critical role in the induction of immunological/inflammatory responses and are implicated in several CNS diseases, such as infectious disease, autoimmune disease, and ischemic brain injury [7, 8]. Accumulating evidences demonstrate that TLR4, the first mammalian TLR recognized, contributes to the neuronal death, blood brain barrier damage, brain edema, and inflammatory responses in the brain injury induced by ischemia [8, 9]. However, little is known about TLR4 in the brain after ICH. In the present study, we detected the transcription of TLR4 gene and the activation of TLR4-mediated signaling in the rat brains subjected to experimental ICH. Our data firstly provided the knowledge about the distribution of TLR4 and the temporal profile of the activation of TLR4-mediated signaling in rat brain tissue after ICH.","[{'offsets': [[1052, 1056]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1563, 1567]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1787, 1791]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1871, 1875]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1903, 1907]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2042, 2046]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2093, 2097]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
48,PMC-3342329-22-Caption-Figure_5,"Induction of the infiltration of CD8+ T cells and NK cells into tumor, and increase in spleen of CCR5-/- mice.
A and B, Immunolfluorescence analysis was used to determine the expression levels of CD8 (CD8+ cytotoxic T-cell surface marker) and CD57 (NK cell marker) in tumor and spleen sections. The images shown are representative of three separate experiments performed in triplicate. Scale bars indicate 50 microm (A) and 100 microm (B). C and D, Analysis of lymphocyte phenotypes. The tumor and spleen tissues were separated at study termination (Day 31). Flow cytometry analysis was performed using FACSAria flow cytometry, and represent data were shown. Data are means +/- S.D. of four experimental animals.","[{'offsets': [[97, 101]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
49,PMC-3312845-12-Results,"TNF-alpha, and TNF receptor expression
In non-SE induced animals of the saline-infused groups, TNF-alpha immunoreactivity was weakly detected in PC neurons (data not shown). In 12 hr-post SE animals of the saline-infused group, most of the activated microglia showed strong TNF-alpha immunoreactivity (Figure 1A). This expression pattern was maintained up to 1 week after SE. In non-SE-induced animals of the saline-infused groups, TNFp55R and TNFp75R immunoreactivities were also weakly observed in astrocytes (data not shown). In 12 hr-post SE animals of the saline-infused group, TNFp55R immunoreactivity was observed in astrocytes (Figure 1B). Unlike TNFp55R, TNFp75R immunoreactivity was detected in endothelial cells as well as astrocytes (Figures 1C-E). One day to 1 week after SE, both TNFp55R and TNFp75R immunoreactivities were significantly reduced in astrocytes, not in endothelial cells, due to massive astroglial loss (data not shown) [5,7,8,20].","[{'offsets': [[0, 9]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[95, 104]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[274, 283]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[432, 439]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[444, 451]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[583, 590]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[655, 662]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[664, 671]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[794, 801]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[806, 813]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
50,PMC-1064895-07-Materials_and_methods,"Quantification of IL-17 mRNA by semiquantitative reverse transcription-polymerase chain reaction
PBMC were incubated with various concentrations of anti-CD3 in the presence or absence of inhibitors (LY294002, PDTC). After 16 hours of incubation, mRNA was extracted with RNAzol B (Biotex Laboratories, Houston, TX, USA) in accordance with the manufacturer's instructions. Reverse transcription of 2 mug of total mRNA was performed at 42degreesC using the Superscript(TM) reverse transcription system (Takara, Shiga, Japan). PCR amplification of cDNA aliquots was performed by adding 2.5 mM dNTPs, 2.5 U of Taq DNA polymerase (Takara) and 0.25 muM of sense and antisense primers. The reaction was performed in PCR buffer (1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl, pH 8.3) in a total volume of 25 mul. The following sense and antisense primers for each molecules were used: IL-17 sense, 5'-ATG ACT CCT GGG AAG ACC TCA TTG-3'; IL-17 antisense, 5'-TTA GGC CAC ATG GTG GAC AAT CGG-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense, 5'-CGA TGC TGG GCG TGA GTA C-3'; GAPDH antisense, 5'-CGT TCA GCT CAG GGA TGA CC-3'. Reactions were processed in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT, USA) through cycles for 30 s of denaturation at 94degreesC, 1 min of annealing at 56degreesC for GAPDH and IL-17, followed by 1 min of elongation at 72degreesC. PCR rounds were repeated for 25 cycles each for both GAPDH and IL-17; this was determined as falling within the exponential phase of amplification for each molecule. The level of mRNA expression was presented as a ratio of IL-17 PCR product over GAPDH product.","[{'offsets': [[18, 23]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[605, 608]], 'text': ['Taq'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[870, 875]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[978, 1018]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1020, 1025]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1067, 1072]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1298, 1303]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1308, 1313]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1415, 1420]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1425, 1430]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1585, 1590]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1608, 1613]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
51,PMC-3320587-01-Introduction,"Mycobacterium tuberculosis (MTb), the causative agent of tuberculosis (TB), is the most common co-infection and cause of death in patients infected with human immunodeficiency virus type 1 (HIV-1) [1], [2]. Direct engagement of pathogen recognition receptors (PRRs) by MTb on mononuclear phagocytes activates signaling cascades that directly induce transcription from the proviral LTR (reviewed in [3]). Furthermore, inflammatory cytokines and chemokines produced by the human host in response to MTb infection activate signal transduction pathways in CD4 T cells and monocytic cells that also result in transcriptional activation of the HIV-1 LTR [4]-[6]. Activation of HIV-1 replication via these MTb-induced pathways ultimately leads to higher viral loads and, in turn, expedited CD4 T cell loss and progression to AIDS ([7], reviewed in [8]-[10]). Furthermore, the progressive immune compromise associated with HIV-1 infection itself is a major cause of latent MTb reactivation, as well as increased susceptibility to primary TB infection ([11]-[15], reviewed in [8]).
The primary PRR on monocytic cells triggered by MTb infection is toll-like receptor (TLR) 2 [16]-[20]. Engagement of TLR2 results in engagement of the adaptor protein MyD88 and the subsequent recruitment of several kinases, including IRAK1 and IRAK4, and the ubiquitin ligase TRAF6 ([21]-[23], reviewed in [10], [24]). TRAF6 activates IkappaB kinase (IKK) and mitogen-activated protein (MAP) kinases that, in turn, ultimately induce activation of specific transcription factor families, including the NF-kappaB and AP-1 families, which have been shown to associate with the HIV-1 LTR and to drive its transcription ([22], [25]-[27], reviewed in [10]).
Notably, HIV-1 comprises several subtypes, and the LTR of each subtype is unique with respect to the number and organization of activator binding sites. For example, HIV-1 subtype B, the most highly characterized viral subtype and the primary cause of infection in the Americas, Europe, Japan, and Australia, has two tandem NF-kappaB motifs in its LTR. By contrast, HIV-1 subtypes C and E, which have spread disproportionately in TB-burdened sub-Saharan Africa and southeast Asia, have three and one NF-kappaB binding sites, respectively [1], [28]-[30].
We previously showed that the most primordial member of the nuclear factor of activated T cells (NFAT) family, NFAT5 (also known as TonEBP), binds to a site within the HIV-1 LTR that is highly conserved across all HIV-1 subtypes, and is also conserved in HIV-2 and SIV LTRs. This NFAT5 site overlaps the core NF-kappaB binding motifs in the LTR and is required for constitutive replication of representative HIV-1 subtype B, C, and E isolates in human primary monocyte-derived macrophages (MDM) [31]. Given that NFAT5 has previously been shown to be transcriptionally activated by the MAP kinase p38, which is downstream of MyD88 signaling, [32], we speculated that NFAT5 may also be involved in MTb-induced activation of HIV-1 replication via a TLR-mediated pathway in monocytes and peripheral blood mononuclear cells (PBMC).
Here, we show that NFAT5 and its cognate binding site are of crucial importance for efficient MTb-induced stimulation of HIV-1 replication in human MDM and PBMC. Moreover, we demonstrate that MTb infection increases NFAT5 gene expression in human monocytes in a MyD88-dependent manner. Thus, these results expand the known stimuli of NFAT5 expression to the PRR-mediated innate immune response, and demonstrate that NFAT5 is a critical modulator of MTb-induced enhancement of HIV-1 replication.","[{'offsets': [[552, 555]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[783, 786]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1138, 1164]], 'text': ['toll-like receptor (TLR) 2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1190, 1194]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1240, 1245]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1307, 1312]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1317, 1322]], 'text': ['IRAK4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1349, 1354]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1392, 1397]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2390, 2395]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2411, 2417]], 'text': ['TonEBP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2791, 2796]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2903, 2908]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2945, 2950]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3125, 3130]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3322, 3327]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3368, 3373]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3440, 3445]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3522, 3527]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
52,PMC-3585731-17-Materials_and_Methods,"Cell Lines
L929 and FADD-deficient Jurkat cells were obtained from ATCC. Lung fibroblasts were a generous gift of Dr. Philip Tsichlis (Tufts University) [53]. J774A.1 (ATCC) cells and RAW264.7 (ATCC) cells were generous gifts of Junying Yuan (Harvard University) and Alexander Poltorak (Tufts University), respectively. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic mixture (Invitrogen). The mouse lung fibroblast media was additionally supplemented with L-glutamine, non-essential amino acids, and sodium pyruvate. Jurkat cells were maintained in RPMI1640, supplemented with 10% FetalPlex (Gemini) and 1% antibiotic-antimycotic.","[{'offsets': [[20, 24]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
53,PMC-3291650-03-Results,"A20 negatively regulates IAV-induced gene expression in BMDM
To investigate the role of A20 in the IAV-induced proinflammatory and antiviral innate immune responses, we infected A20 deficient and control BMDM with IAV X-47 (H3N2). A20 mRNA levels were rapidly induced in wild type BMDM, but not in A20 deficient BMDM, upon viral infection (figure 2A). Furthermore, A20myel-KO BMDM show enhanced expression of IL-6 and IFNbeta mRNA after IAV infection compared to control cells (figure 2A). In accordance with these data, cell culture supernatant collected from these cells contained higher levels of TNF and IFNbeta (figure 2B).
Upon host infection with IAV, alveolar macrophages are an important source of cytokines and chemokines, attracting innate immune cells to the lung during the primary phase of infection. To test whether A20 directly controls IAV-induced gene expression in alveolar macrophages, we isolated these cells from lungs of A20myel-KO and control littermates and infected them in vitro with IAV X-47. Expression and secretion of the proinflammatory cytokines IL-6 and TNF, the type-I IFN IFNbeta and IFNalpha4 and the chemokines MCP-1 (ccl2) and KC (cxcl1) was significantly higher in IAV infected cells lacking A20 compared to infected wild type cells (figure 2C and figure S1). Taken together these results demonstrate that A20 negatively regulates IAV-induced proinflammatory and antiviral gene expression in alveolar macrophages, consistent with the inhibitory effect of A20 seen on RIG-I-induced NF-kappaB and IRF3 activation.","[{'offsets': [[409, 413]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[418, 425]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[600, 603]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[608, 615]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1079, 1083]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1088, 1091]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1108, 1115]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1120, 1129]], 'text': ['IFNalpha4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1149, 1154]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1156, 1160]], 'text': ['ccl2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1166, 1168]], 'text': ['KC'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1170, 1175]], 'text': ['cxcl1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1507, 1512]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1535, 1539]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
54,PMC-3585731-05-Results,"Late Increase in Akt Thr308 Phosphorylation Contributes to the Induction of Necroptotic Cell Death
We next investigated if the delayed RIP1 kinase-dependent increase in Akt Thr308 phosphorylation functionally contributes to the execution of necroptotic cell death. Firstly, PDGF/zVAD.fmk, which cannot induce necroptosis (Fig. 2A), triggered only the initial, rapid Akt and JNK phosphorylation changes and not the delayed activation (Fig. 4A), indicating that late, rather than early Akt phosphorylation correlates with necroptosis. Secondly, we saw that the ability of the Akt inhibitor to protect cells from necroptosis rapidly declined after 6 hrs of stimulation with zVAD.fmk, TNFalpha or bFGF/zVAD.fmk and no protection was observed when the inhibitor was added at 9 hrs (Fig. 4B,C). This time frame coincides with the timing of the secondary Akt Thr308 phosphorylation. Finally, we terminated the bFGF signal one hour after addition of bFGF by the addition of PD173074. This allowed us to retain early Akt activation, but to suppress the secondary increase (Fig. 4D). Both pre-addition and delayed addition of PD173074 fully prevented necroptosis (Fig. 4E). Overall, these data, while correlative, indicate that early Akt activation is insufficient to promote necroptosis and are strongly supportive of an important role for the delayed activation of Akt in the induction of necroptotic cell death.","[{'offsets': [[135, 139]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[681, 689]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[693, 697]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[903, 907]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[942, 946]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
55,PMC-3342329-15-Materials_and_Methods,"Flow Cytometric Analysis
Lymphocytes were obtained from tumor and spleen tissues for phenotype analysis. Spleen and tumor lymphocytes were isolated from fresh spleen and tumor biopsies obtained from three mice per group. Spleen and tumor biopsies were briefly homogenized mechanically in PBS, filtered (100 microm cell strainer; BD PharMingen) and then placed in lysis buffer (ACK lysing buffer, LONZA) to remove red blood cells. One million splenocytes were washed once in PBS containing 1% bovine serum albumin (BSA) and re-suspended in 100 microl of PBS/BSA buffer. Meanwhile, one million cells obtained from tumor tissues were placed in RPMI medium, incubated to obtain suspension cell for 1hour at 37degreesC, centrifuged (1200 rpm, 3 min) and then washed in PBS. Next, the lymphocytes were incubated with various conjugated monoclonal antibodies, including CD4-APC, CD8-FITC and CD19-PE for 20min at 4degreesC, washed twice in PBS, and re-suspended in 400 microl of PBS. A flow cytometric analysis was performed on a FACSAria flow cytometry (BD Biosciences), and the data were analyzed using the WinMDI statistical software (Scripps, La Jolla, CA, USA). Forward and side scatter parameters were used to gate on lymphocytes.","[{'offsets': [[863, 866]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[885, 889]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
56,PMC-3585731-12-Discussion,"Altogether, our results suggest that Akt kinase is specifically engaged in the signaling downstream from RIP1 kinase, which exerts its activity through promoting a selective increase in Akt phosphorylation on Thr308. This provides a link connecting RIP1 kinase to downstream signaling and execution events during necroptosis in L929 cells, including JNK activation, autocrine TNFalpha synthesis and eventual cell death. According to our model, phosphorylation of Akt requires two distinct signals. The first input, which is induced by growth factors, leads to the plasma membrane localization of Akt. Expression of constitutively active membrane-targeted Myr-Akt overcomes this requirement. At the same time, expression of Myr-Akt is not sufficient for the induction of necroptosis or efficient activation of JNK and TNFalpha synthesis. A second, RIP1 kinase-dependent input is required for Thr308 phosphorylation of Akt, which in turn is required for necroptotic signaling. Necroptotic phosphorylation of Thr308 of Akt is sufficient to increase its activity towards a number of known substrates in L929 cells and our data reveal that the Akt effector pathway downstream of mTORC1 contributes to necroptosis, thereby identifying a new mediator of this form of cell death.
Our results raise some important mechanistic questions relevant to the specific regulation of Akt during necroptosis. First, what is the mechanism of the RIP1-dependent increase in Akt Thr308 phosphorylation? One possibility is that RIP1 kinase inhibits a phosphatase that targets Thr308. To our knowledge, PP2A is the only enzyme established to specifically dephosphorylate this residue [45]. However, we did not observe any effect of the PP2A inhibitor, okadaic acid, on Thr308 phosphorylation or activation of necroptosis in L929 cells. Another possibility is that the increase in Thr308 results from RIP1 kinase targeting PDK1, Akt or scaffolding factors that bring these two kinases together. Interestingly, we observed phosphorylation of Akt by recombinant RIP1 kinase in vitro on Thr146, 195/197, and 435 and Ser381 residues. Furthermore, mutating these residues to Ala in Myr-Akt leads to the loss of its ability to promote necroptosis. However, we were not able to confirm phosphorylation of these residues on endogenous Akt in L929 cells using either mass spectrometry or western blotting with a phospho-specific antibody raised against Thr435 peptide, suggesting that direct phosphorylation of Akt by RIP1 likely represents an in vitro artifact and does not reflect endogenous regulation. Second, what are the key substrates of Akt that promote necrotic death and TNFalpha synthesis? On the one hand, our data suggest new roles for Akt effector pathways mediated by mTORC1 in necroptotic control. On the other hand, we have observed only modest changes in mTORC1 activity under necroptotic conditions, suggesting that additional Akt substrates are likely to be involved. This warrants a re-evaluation of the roles of additional Akt substrates in necroptotic death, since no such connections have been established. Similarly, the mechanisms connecting mTORC1 to JNK remain to be elucidated. While there are some recent examples of mTORC1-dependent regulation of JNK, e.g. following ER stress [46], the exact mechanisms during necroptosis remain to be established. Given the activation of JNK by TNFalpha and the importance of mTORC1-dependent translational control in necroptosis, one possibility is that mTORC1 contributes to the translation of TNFalpha and forms a positive feed forward loop with JNK.
Akt's role as a key inhibitor of apoptosis is well documented, however, evidence of its contribution as a mediator of cell death under various circumstances has begun to emerge as well [45], [47]. Our data demonstrates a new mode of necrosis-specific regulation of Akt by RIP1 kinase. Importantly, while it is possible that necroptosis-specific targets of Akt exist, this regulation clearly involves a number of well established Akt targets including mTORC1, and potentially, GSK-3, FoxO1/4, and MDM2. Therefore, it may no longer be safe to assume that activation of Akt universally reflects pro-survival signaling nor that its inhibition will lead to more cell death. It is tempting to speculate that rather than serving a universally pro-survival role, the Akt pathway may function to promote cell fates alternative to apoptosis, ranging from survival to non-apoptotic cell death. The final decision between survival and death may depend on additional, Akt-independent inputs, such as the status of RIP1 kinase, expression of particular oncogenic factors [45] or excessive metabolic stress [47].
Another mechanism that should be considered in conjunction with the regulation of cell death by Akt is autophagy. Akt activation leads to the inhibition of autophagy through activation of mTOR [48]. The role of autophagy in cell death in general is very complex and it can both promote and inhibit necroptosis in various situations. Several studies suggested that activation of autophagy promotes necroptosis induced by zVAD.fmk in L929 cells [11], [14]. Others, including ourselves in unpublished data, have found that inihibition of autophagy promotes necroptosis by TNFalpha [49]. This suggests that the inhibition of autophagy by Akt or mTOR in our system may contribute to necroptosis induced by TNFalpha, however, it is more difficult to reconcile with the positive role of these proteins in zVAD-induced death. Clearly, further identification of the factors differentiating between pro-death and pro-survival autophagy in mammalian cells is required to better understand its role in the regulation necroptosis by Akt pathway.
Importantly, our data revealed that RIP1 kinase signaling to Akt is a general feature of necroptotic signaling that is observed in multiple cell types. At the same time, the significance of this connection varies in a cell type specific fashion. Importantly, in mouse lung fibroblasts, FADD-deficient Jurkat cells, and macrophages, Akt signaling contributed more prominently to an increase in TNFalpha synthesis, rather than cell death per se, unlike its role in L929 cells. A recent study [15] has demonstrated that, in addition to its role in necroptosis, RIP1 plays an important role in mediating the production of TNFalpha. These data emphasize the emerging complexity of necroptotic signaling mechanisms and highlight the major contribution of Akt to increased inflammatory signaling, specifically accompanying this form of regulated necrosis [5], [6], [10].
Robust inflammation is one of the most important consequences of necrotic cell death as well as its regulated subtype, necroptosis, both in vitro and in vivo [1], [5], [6], [50], [51]. Our results highlight an important notion that inflammation not only passively accompanies necroptosis in a variety of cellular systems by the virtue of rapid loss of plasma membrane integrity characteristic for necrotic cell death, but also that it is an intrinsic and regulated component of necroptosis due to the specific activation of TNFalpha synthesis by RIP1/Akt kinases. Therefore, this pathway may represent a new molecular target for the inhibition of pathologic inflammatory signaling. Initial in vivo data appears to support this notion. Two recent papers showed that the loss of control over RIP1/RIP3 kinase activities by FADD and caspase-8 in epithelial cells unleashes a feed forward cycle of necroptosis and TNFalpha production, resulting in the development of intestinal inflammation in mice and, possibly, in patients with Crohn's disease [4], [5]. This increased production of TNFalpha during necroptosis may also be important for acute necrotizing diseases, such as necrotizing pancreatitis and acute bacterial infections, where hyper-acute inflammation accompanying necrotic cell death is the primary cause of multiple organ failure and patient death. Along these lines, another recent paper by Duprez et al. has shown that RIP1 and RIP3 mediate the cellular damage introduced by TNF-induced SIRS [6]. The role of RIP1 kinase in acute and chronic inflammatory diseases warrants further investigation, as efficient and specific RIP1 kinase inhibitors may offer therapeutic benefit for treating these conditions.","[{'offsets': [[105, 109]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[249, 253]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[376, 384]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[655, 662]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[723, 730]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[817, 825]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[847, 851]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1426, 1430]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1505, 1509]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1876, 1880]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1898, 1902]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2035, 2039]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2152, 2159]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2484, 2488]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2647, 2655]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3377, 3385]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3528, 3536]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3858, 3862]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4069, 4074]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4075, 4076]], 'text': ['4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4082, 4086]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4587, 4591]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5253, 5261]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5385, 5393]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5753, 5757]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[6003, 6007]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[6110, 6118]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[6275, 6279]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[6335, 6343]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[7105, 7113]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[7127, 7131]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[7371, 7375]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[7376, 7380]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[7402, 7406]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[7411, 7420]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[7491, 7499]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[7663, 7671]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[8012, 8016]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[8021, 8025]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[8102, 8106]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[8215, 8219]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T56'}]",[],[],[],[],[]
57,PMC-1064873-03-Materials_and_methods,"Isolation of CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were prepared from heparinized blood samples by centrifugation over Ficoll-Hypaque density gradients (Pharmacia, Uppsala, Sweden). CD4+ T cells were purified from PBMC by positive selection using anti-CD4 mAb-coated magnetic beads (Miltenyi Biotec, Gladbach, Germany), according to the manufacturer's instructions. CD4+ T cells were isolated from ST samples, as previously described [27]. Briefly, fresh ST samples were fragmented and digested with collagenase and DNase for 1 hour at 37degreesC. After removing tissue debris, ST cell suspensions in culture medium (RPMI 1640 medium; Life Technologies, Gaithersburg, MD, USA) supplemented with 25 mM HEPES (2 mM L-glutamine, 2% nonessential amino acids, 100 IU/ml penicillin, and 100 mg/ml streptomycin; Life Technologies) with 10% heat-inactivated FCS (Life Technologies) were incubated at 37degreesC in six-well plates (Coster, Cambridge, MA, USA) for 45 min. Non-adherent cells were harvested and CD4+ T cells were purified by positive selection as already described.","[{'offsets': [[13, 16]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[199, 202]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[269, 272]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[383, 386]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1018, 1021]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
58,PMC-1064895-13-Results,"Increased IL-17 production in PBMC of patients with RA by anti-CD3 and/or anti-CD28, and PHA
Because IL-17 was already known from earlier reports to be produced mainly by activated T cells, we investigated the effect of different concentrations of anti-CD3 (1, 5 and 10 mug/ml) as a T cell activation, which showed a dose-dependent increase in IL-17 levels (data not shown). On the basis of this, we chose 10 mug/ml as a stimulation concentration for anti-CD3. As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold, and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone. Furthermore, when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 +/- 85 versus 211 +/- 1 pg/ml; P < 0.05).","[{'offsets': [[10, 15]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 83]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[89, 92]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[101, 106]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[344, 349]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[517, 522]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[578, 582]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[610, 615]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[723, 726]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[738, 743]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[803, 807]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
59,PMC-3589482-00-TIAB,"The Transcription Factor C/EBP-beta Mediates Constitutive and LPS-Inducible Transcription of Murine SerpinB2
SerpinB2 or plasminogen activator inhibitor type 2 (PAI-2) is highly induced in macrophages in response to inflammatory stimuli and is linked to the modulation of innate immunity, macrophage survival, and inhibition of plasminogen activators. Lipopolysaccharide (LPS), a potent bacterial endotoxin, can induce SerpinB2 expression via the toll-like receptor 4 (TLR4) by ~1000-fold over a period of 24 hrs in murine macrophages. To map the LPS-regulated SerpinB2 promoter regions, we transfected reporter constructs driven by the ~5 kb 5'-flanking region of the murine SerpinB2 gene and several deletion mutants into murine macrophages. In addition, we compared the DNA sequence of the murine 5' flanking sequence with the sequence of the human gene for homologous functional regulatory elements and identified several regulatory cis-acting elements in the human SERPINB2 promoter conserved in the mouse. Mutation analyses revealed that a CCAAT enhancer binding (C/EBP) element, a cyclic AMP response element (CRE) and two activator protein 1 (AP-1) response elements in the murine SerpinB2 proximal promoter are essential for optimal LPS-inducibility. Electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrated that LPS induces the formation of C/EBP-beta containing complexes with the SerpinB2 promoter. Importantly, both constitutive and LPS-induced SerpinB2 expression was severely abrogated in C/EBP-beta-null mouse embryonic fibroblasts (MEFs) and primary C/EBP-beta-deficient peritoneal macrophages. Together, these data provide new insight into C/EBP-beta-dependent regulation of inflammation-associated SerpinB2 expression.","[{'offsets': [[25, 35]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[100, 108]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[109, 117]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[121, 159]], 'text': ['plasminogen activator inhibitor type 2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[161, 166]], 'text': ['PAI-2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[419, 427]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[447, 467]], 'text': ['toll-like receptor 4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[469, 473]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[561, 569]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[676, 684]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[970, 978]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1189, 1197]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1393, 1403]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1434, 1442]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1500, 1508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1546, 1556]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1609, 1619]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1700, 1710]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1759, 1767]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
60,PMC-1472690-25-Caption-Table_1,Sense strand of oligonucleotides used in EMSAs.,[],[],[],[],[],[]
61,PMC-3291650-06-Materials_and_Methods,"Ethics statement
All experiments on mice were conducted according to the national (Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 06/04/2010) and European (EU Directives 2010/63/EU, 86/609/EEG) animal regulations. Animal protocols were approved by the ethics committee of Ghent University (permit number LA1400091, approval ID 2010/001). All efforts were made to ameliorate suffering of animals. Mice were anesthetized by intraperitoneal (i.p.) injection of a mixture of ketamine (12 mg/kg) and xylazine (60 mg/kg).",[],[],[],[],[],[]
62,PMC-3312845-18-Discussion,"The major findings in the present study are that TNF-alpha signaling showed cellular specific responses of NF-kappaB phosphorylation in the PC following SE, which may be related to vasogenic edema formation followed by neutrophil infiltration. BBB disruption has been reported in experimental and human epilepsy [12,13,15,16,28]. Leakage of serum-derived components into the extracellular space is associated with hyperexcitability and seizure onset [12,13,15,16,28]. Furthermore, dysfunction of the BBB leads to epileptogenesis and contributes to progression of epilepsy [12,13,15,16,28]. In the present study, TNF-alpha immunoreactivity was obviously observed in microglia in the PC following SE. TNF receptor expressions were also up-regulated in astrocytes (TNFp55R and TNFp75R) and endothelial cells (TNFp75R). Furthermore, blockade of TNF-alpha signaling by sTNFp55 infusion effectively (but not completely) reduced volumes of SE-induced vasogenic edema and neuronal damage in the PC. These findings indicate that TNF-alpha may participate in astroglial and endothelial responses to SE, which are relevant to SE-induced vasogenic edema formation [5-8]. Indeed, TNF-alpha signaling increases BBB permeability in various experimental disease models [29]. In the present study, sTNFp55 infusion could not completely prevent SE-induced vasogenic edema and neuronal damage in the PC. Therefore, our findings suggest that TNF-alpha signaling may not be a unique upstream event in vasogenic edema development.
p65 phosphorylation of NF-kappaB enhances its transactivation potential, and p65 phosphorylation occurs in either the cytoplasm or the nucleus [30]. In the present study, p65-Thr435 immunoreactivity was detected in endothelial cells, and its immunoreactivity showed an inverse correlation to the degree of SMI-71 expression. SMI-71, an endothelial barrier antigen, is a protein expressed by endothelial cells of rat BBB [31]. Under pathological conditions, SMI-71 expression is lost in endothelial cells [5,7,8,30,32]. Acute phases of the above pathological conditions are accompanied by opening of the BBB and development of vasogenic edema [33]. Indeed, neutralization of SMI-71 in vivo leads to widening of intercellular junctions between endothelial cells and swelling of perivascular astrocytic processes [34], although SMI-71 is not localized at endothelial cell junctions [35-38]. In the present study, SMI-71 immunoreactivity was significantly reduced in blood vessels 1 day after SE when vasogenic edema and neuronal damage were observed. Furthermore, sTNFp55R infusion effectively prevented SE-induced SMI-71 down-regulation. With respect to the phosphorylation of p65-Thr435 by TNF-alpha [39], our findings indicate that TNF-alpha-mediated p65-Thr435 phosphorylation in endothelial cells may play an important role in vasogenic edema induction via SMI-71 degradation or its posttranslational dysfunction influencing BBB permeability.
In our previous studies [5,8], dystrophin (an actin-binding protein [40]) immunoreactivity was detected in blood vessels and in astrocytic perivascular end-feet, and was down-regulated 12 hrs after SE prior to the appearance of vasogenic edema and down-regulation of SMI-71 immunoreactivity. With respect to this previous report, changes in SMI immunoreactivity would be causes/results of interaction between endothelial cells and perivascular astrocytes. In the present study, p65-Ser276, p65-Ser311, p65-Ser529, and p65-Ser536 phosphorylation was observed in astrocytes following SE. Furthermore, sTNFp55R infusion effectively inhibited p65-Ser276 and p65-Ser311phosphorylation in astrocytes following SE. Therefore, it is likely that enhanced p65-Ser276 and p65-Ser311 phosphorylation may be involved in TNF-alpha-mediated BBB disruption. However, sTNFp55R infusion could not prevent p65-Ser529 and p65-Ser536 phosphorylations from SE insults. Since p65-Ser529 and p65-Ser536 are phosphorylated by TNF-alpha and IL-1beta [41], it is likely that IL-1beta-mediated p65-Ser529/Ser536 phosphorylation may also play a role in SE-induced vasogenic edema. Therefore, our findings indicate that both TNF-alpha and IL-1beta may be synergists to play either a direct (by endothelial cells) or indirect (by astrocytes) role in the maintenance of BBB permeability.
Neutrophil infiltration into brain parenchyma is transiently observed during the acute phase of SE (4 - 36 hr after SE) and disappears thereafter [20]. SE rapidly increases synthesis and release of chemokines in various areas of the rodent brain [42]. Among them, MIP-2 is required for efficient neutrophil or lymphocyte recruitment to brain parenchyma [43]. In our previous study [20], neutrophil infiltration in the frontoparietal cortex was regulated by P2X7 receptor-mediated MIP-2 expression. In the PC, however, neither a P2X7 receptor agonist/antagonist nor IL-1Ra (an IL-1beta antagonist) infusion could not affect leukocyte infiltration. In the present study, sTNFp55R infusion effectively inhibited neutrophil infiltration in the PC by reducing vasogenic edema formation in a MIP-2-independent manner. With respect to the present and our previous reports, it is therefore likely that vasogenic edema induced by TNF-alpha can induce neutrophil infiltration and press injury to evoke neuronal-astroglial loss in the PC, unlike other brain regions.
In conclusion, our findings reveal that impairments of endothelial cell function via TNF-alpha mediated p65-Thr 435 NF-kappaB phosphorylation may be involved in SE-induced vasogenic edema, which is relevant to neutrophil infiltration and neuronal-astroglial loss.","[{'offsets': [[49, 58]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[612, 621]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[762, 769]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[774, 781]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[806, 813]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[841, 850]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[865, 871]], 'text': ['TNFp55'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1020, 1029]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1167, 1176]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1282, 1288]], 'text': ['TNFp55'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1422, 1431]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1509, 1512]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1586, 1589]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1680, 1683]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2571, 2578]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2684, 2687]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2698, 2707]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2741, 2750]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2760, 2763]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2985, 2995]], 'text': ['dystrophin'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3000, 3021]], 'text': ['actin-binding protein'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3432, 3435]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3444, 3447]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3456, 3459]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3472, 3475]], 'text': ['p65'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3554, 3561]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3593, 3596]], 'text': ['p65'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3608, 3611]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3700, 3703]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3715, 3718]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3761, 3764]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3806, 3813]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3841, 3844]], 'text': ['p65'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3856, 3859]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3907, 3910]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3922, 3925]], 'text': ['p65'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3955, 3964]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3969, 3977]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4002, 4010]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4020, 4023]], 'text': ['p65'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4149, 4158]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4163, 4171]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4574, 4579]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4767, 4780]], 'text': ['P2X7 receptor'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4790, 4795]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4875, 4881]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4886, 4905]], 'text': ['IL-1beta antagonist'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4980, 4987]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5096, 5101]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5231, 5240]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5451, 5460]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5470, 5473]], 'text': ['p65'], 'type': 'Protein', 'id': 'T59'}]",[],[],[],[],[]
63,PMC-3320587-13-Materials_and_Methods,"Statistical analysis
Where applicable, results are expressed as mean +/- SEM. Comparison between two groups was performed using the paired Student t-Test with the aid of Microsoft Excel software. p<=0.05 was considered significant.",[],[],[],[],[],[]
64,PMC-2817507-13-4._Discussion,"Intra-cerebral hemorrhage (ICH) represents 10-15% of all strokes, and occurs with increasing frequency as a complication of the thrombolytic treatment of ischemic stroke [1]. The mortality of ICH is higher than that of ischemic stroke. Only 31% are functionally independent at 3 months. Only 38% of the patients survive the 1st year [10]. Unfortunately, the method for treatment of this disease and protection of the brain tissue after ICH are not effective. Mass effect, ischemia, and toxicity of blood components after ICH induce brain tissue damage. In addition, there is increasing evidence that inflammatory processes are involved in cerebrovascular events. After ICH, inflammatory mediators from the blood might enter to the brain and induce an inflammatory reaction and the brain cells itself are also capable of producing many of these agents [11]. The inflammatory responses are responsible for the ICH induced brain injury, which could provide new therapeutic targets for ICH. Various constituents of the inflammatory response, including adhesion molecules, cytokines, leukocytes, immunoglobulins, and complement, may be important in the pathogenesis of ICH. However, how the inflammatory responses is activated and regulated in the brain tissue after ICH is unclear.
Transcription factor nuclear factor-kappa-B (NFkappaB) is an important nuclear transcription factor, which initiates transcription of genes associated with immune responses and inflammation [12, 13] and also plays a key role in regulating inflammation in brain pathologies. It has been reported that NFkappaB increased in the region of perihematoma after ICH [14]. NFkappaB activation occurs within minutes and persists for at least a week in response to ICH, which is associated with the expression of selected target genes [15]. Activation of NFkappaB initiates inflammatory responses and contributes to the pathobiology of perilesional cell death after ICH [16]. Inhibition of NFkappaB activity has been shown to have a therapeutic effect on experimental ICH, such as reduce inflammation, behavioral dysfunction, and neuronal damage produced by ICH [17]. The knowledge about how NFkappaB is activated in the brain subjected to ICH is critical for seeking a new neuroprotective method for ICH.
Toll-like receptors (TLRs) are a family of signal transduction molecules and play a critical role in the induction of innate and adaptive immunity [4]. TLR-mediated signaling pathways mainly stimulate the activation of NFkappaB [12, 13]. TLR4, the first mammalian TLR recognized, has been reported to be involved in several central nervous (CNS) system diseases, such as inflammatory or autoimmune CNS diseases and cerebral ischemic injury [7, 8]. Although previous reports indicated that the activation of NFkappaB was attributed to the oxidative stress or glutamate receptor activation induced by red blood cells and/or plasma constituents [17], very few studies have been directed to investigate the role and the relationship between TLR4-mediated NFkappaB signaling and ICH.
In the present study, we established the rat model of experimental ICH and detected the TLR4 mRNA and protein. Our data showed that transcription of TLR4 as well as the expression of TLR4 protein after ICH significantly elevated in brain tissue. These changes started as early as 6 hours after the ICH insult and maintained at a high level for 7 days afterward. The TLR4 protein, detected by immunohistochemistry, was consistently distributed in peri-hemorrhage areas, the hippocampus, cortex, thalamic nuclei, and some white matter tracts. These data indicated that increased expression of TLR4 may be related to the triggering of the inflammatory responses in the brain tissue after ICH.
Recent studies demonstrated that ICH initiates inflammatory responses, which are associated with secondary growth of hemorrhage and cell death [18]. It is now believed that TLR4-mediated-NFkappaB pathway activates and regulates immunological and inflammatory responses. To investigate the mechanisms underlying the increased inflammatory responses in the brain after ICH, in the present study, we evaluated the activation of TLR4-mediated NFkappaB signaling by detecting the p-IkappaB and the activity of NFkappaB in hemorrhagic brains. NFkappaB is an important transcription factor downstream in the TLR4-mediated signaling pathway. Activation of TLR4 stimulates IkappaBalpha phosphorylation and degradation, resulting in nuclear translocation of NFkappaB, which initiates transcription of genes associated with innate immune responses and inflammation [5, 6]. We observed that the levels of phosphorylation of IkappaB and the activity of NFkappaB were significantly increased in brain tissue after ICH. The temporal profile of the expression of p-IkappaB and the activation of NFkappaB was similar to that of the expression of TLR4. Our data suggest that ICH stimulates activation of the TLR4/NFkappaB signaling pathway, which is consistent with previous reports that activation of NFkappaB is regulated through the TLR4-mediated signaling pathway. TLR4 plays an important role in the recognition of microbial components [19, 20] and can also recognize endogenous molecules such as the degradation products of macromolecules, products of proteolytic cascades, intracellular components of ruptured cells, and products of genes that are activated by inflammation. For instance, HSP70, HSP32, HSP27, and enzymes involved in oxidative stress are found to be upregulated in the brain after ICH, which may be produced by injured neuronal cells or blood cells [21]. It may be speculated that these molecules produced in damaged brain or came from blood cells and constituents of plasma server as endogenous TLR4 ligands, activate TLR4-mediated NFkappaB signaling, and initiate the inflammatory responses in IHC brain. However, the specific endogenous ligands for TLR4 in hemorrhagic brain have not been determined and need to be identified through further research.
In conclusion, the present study demonstrated the temporal profile of the activation of TLR4-mediated NFkappaB signaling in brain tissue in a rat model of experimental ICH, which suggests that TLR4-mediated NFkappaB signaling participates in the pathogenesis of ICH, which may be a therapeutic target for the prevention of ICH-induced brain damage.","[{'offsets': [[2512, 2516]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[3011, 3015]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[3141, 3145]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[3202, 3206]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[3236, 3240]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[3419, 3423]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3644, 3648]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[3916, 3920]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[4168, 4172]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[4344, 4348]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[4391, 4395]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[4407, 4419]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[4872, 4876]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[4933, 4937]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[5061, 5065]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[5094, 5098]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[5421, 5426]], 'text': ['HSP70'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[5428, 5433]], 'text': ['HSP32'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[5435, 5440]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[5745, 5749]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[5768, 5772]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[5901, 5905]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[6092, 6096]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[6197, 6201]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
65,PMC-3585731-27-Caption-Figure_2,"Akt contributes to necroptosis induced by zVAD.fmk and TNFalpha.
(A,B) Necroptosis was induced by zVAD.fmk or TNFalpha (full serum, A) or growth factors/zVAD.fmk (serum free, B) in the presence of inhibitors of Akt (Akt inhibitor VIII), JNK (SP600125), p38 (PD169316), and Erk (UO126). Cell viability was determined after 24 hrs. (C) L929 cells transfected with Akt1, Akt2, and Akt3 siRNAs for 72 hrs were treated with zVAD.fmk or TNFalpha for 9 hrs. Cell viability and Akt expression levels were determined after 24 hrs. In all graphs, average+/-SD was plotted.","[{'offsets': [[55, 63]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[110, 118]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[362, 366]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[368, 372]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[378, 389]], 'text': ['Akt3 siRNAs'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 439]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
66,PMC-1472690-15-Methods,"Cytokine measurements
Supernatants of cell cultures were harvested 3, 6, 9, 12, 18, 24, 30, 36 and 48 hours after stimulation and stored at -80 degreesC until used and thawed only once. IFNgamma, TNFalpha, IL-1 and IL-6 were determined using an ELISA from Bender Systems (Vienna, Austria), IL-1RA and IL-8 by an ELISA from R&D Systems (Wiesbaden-Nordenstadt, Germany), and TGFbeta 1 using an ELISA as previously described [57]. Quantification of IL-2 as an indicator for the bioactivity of IL-1 was done as previously described [46]. Samples were diluted in the same buffer as that used for the standards. All cytokines were quantified using an ELISA plate reader (Anthos Labotec, Salzburg, Austria or Microplate Reader, BioRad). Cytokine amounts were all within the range of the standard curve. Only stimulation of PBMC observed in donors showing no spontaneous cytokine release was included in the statistics.","[{'offsets': [[186, 194]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[196, 204]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[206, 210]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[215, 219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[290, 296]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[301, 305]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[373, 382]], 'text': ['TGFbeta 1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[446, 450]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[490, 494]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
67,PMC-2817507-06-2._Methods,"2.5. Western Blots
Cellular proteins were prepared from ICH cerebral hemispheres, electrophoresed with SDS-polyacrylamide gel and transferred onto Hybond ECL membranes (Amersham Pharmacia, Piscataway, NJ). The ECL membranes were incubated with the appropriate primary antibody (WuHan, BA1717) followed by incubation with peroxidase-conjugated secondary antibodies (Golden Bridge, PV-6001). The signals were detected with the ECL system (Amersham Pharmacia). The same membranes were probed with anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase, Biodesign, Saco, Maine) after being washed with stripping buffer. The signals were quantified by scanning densitometry and computer-assisted image analysis.","[{'offsets': [[499, 504]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[506, 546]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
68,PMC-3586680-06-Perspectives,"Whether WWOX affects TMZ sensitivity has never been determined. Binding proteins for WWOX and/or p53 are likely to affect apoptosis and TMZ sensitivity in GBM cells. WWOX binds MEK, and that PMA dissociates this complex for causing apoptosis of T leukemia cells (Lin et al., 2011). Thus, appropriate chemicals, which break apart the WWOX/MEK complex, are expected to cause GBM cell death. Preliminary studies from our screening of chemicals have selected certain small molecules that induce apoptosis of many types of cancer cells (Lu et al., unpublished). Indeed, specific inhibition of MEK by selumetinib enhances TMZ-induced cancer cell death in vivo (Holt et al., 2012). Serum factors can be utilized for blocking cancer growth. For example, serum complement C1q induces apoptosis of prostate cancer and neuroblastomas cells without participation of downstream proteins in the classical activation pathway (Hong et al., 2009). In this event, ectopic WWOX is activated for inducing apoptosis.
Failure of ectopic WWOX in inducing apoptosis of glioma cells possessing wild type p53 is unusual (Chiang et al., 2012). In most cases, we have shown that p53 functionally interacts with WWOX, and both proteins induce apoptosis in a synergistic manner (Chang et al., 2001, 2003, 2005a,b, 2007, 2010, 2012; Su et al., 2012). A likely scenario is that p53-binding proteins, which are present in GBMs, may interfere with the apoptotic function of WWOX and p53. Functional antagonism among tumor suppressors has never been documented in the literature. However, it is not surprising to find that many tumor suppressor proteins, e.g., p53, WWOX, Smad4, PTEN, PP2A, and etc., are significantly upregulated during the early stage of cancer progression (Lai et al., 2005; Chang et al., unpublished). Do these proteins act synergistically in blocking cancer progression but lose control eventually? Or, do they counteract each other's function, thus allowing cancer growth? Whether endogenous WWOX counteracts with the function of endogenous p53 is unknown and remains to be established.
One of the unique characteristics for malignant gliomas is their diffuse infiltration into distant brain tissue. Signal pathways, involving PI3K, Akt, mTOR, NF-kappaB, and autophagy, are believed to confer these migrating cells resistant to apoptotic death (Lefranc et al., 2005). Glioma cells possess CD44 as a receptor for interacting with brain matrix hyaluronan (Murai et al., 2004; Yoshida et al., 2012), and secrete hyaluronidases and metalloproteinases to facilitate their migration (Delpech et al., 2002; Junker et al., 2003; Hagemann et al., 2012). Also, lack of WWOX expression is expected to enhance cell migration. For example, loss of WWOX facilitates migration of ovarian cancer and osteosarcoma cells (Gourley et al., 2009; Del Mare et al., 2011). Ectopic expression of TIAF1 (TGF-beta-induced antiapoptotic factor), p53, and WWOX suppresses anchorage-independent growth and cell migration and causes apoptosis in cancer cells (Chang et al., 2012). We believe that glioma cells, with stem cell-like properties, migrate individually rather than collectively. This assumption is based upon our observations that mouse Wwox gene knockout cells (e.g., embryonic fibroblasts) migrate individually and aggressively. In contrast, wild type cells migrate collectively (Chou et al., unpublished). While a portion of WWOX is anchored on the cell membrane/cytoskeleton, WWOX-negative cells lose recognition by parental WWOX-positive cells, and this increases the mobility of WWOX-negative cells to move away from the WWOX-positive cells. Conceivably, WWOX-negative glioma cells migrate individually and turn away from WWOX-expressing brain cells to low WWOX expression areas. Apparently, the migratory behavior of WWOX-negative glioma cells may account for the diffuse invasion into distant brain tissue (Chou et al., unpublished).
Metabolic alterations have been shown in Wwox knockout mice, including postnatal lethality, bone metabolism defects, ataxia, steroidogenesis, and generation of osteosarcomas (Del Mare et al., 2011; Salah et al., 2012). In a Drosophila model, Wwox is shown to participate in pathways involving aerobic metabolism and oxidative stress for generation of ROS (O'Keefe et al., 2011). Under UV stress, functional Wwox gene expression induces ROS production in Drosophila. Cancer cells are known to overly utilize glycolysis for growth advantage - the so-called Warburg (Moncada et al., 2012). Conceivably, WWOX is likely to override glucose consumption in cancer cells and exerts generation of ROS to curb the cancer cell growth and invasion.
In summary, in this perspective article we have discussed the potential role of tumor suppressors p53 and WWOX in regulating TMZ sensitivity in GBM cells. We have shown the role of WWOX in controlling cell migration and metabolic alterations, and discussed the effects of WWOX deficiency and TMZ resistance in cancer cells.","[{'offsets': [[8, 12]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[85, 89]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[97, 100]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[166, 170]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[954, 958]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1015, 1019]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1079, 1082]], 'text': ['p53'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1151, 1154]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1183, 1187]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1346, 1349]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1440, 1444]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1449, 1452]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1626, 1629]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1631, 1635]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1637, 1642]], 'text': ['Smad4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1644, 1648]], 'text': ['PTEN'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1980, 1984]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2029, 2032]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2221, 2224]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2226, 2230]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2377, 2381]], 'text': ['CD44'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2647, 2651]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2723, 2727]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2860, 2865]], 'text': ['TIAF1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2907, 2910]], 'text': ['p53'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2916, 2920]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3206, 3210]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3397, 3401]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3449, 3453]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3498, 3502]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3554, 3558]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3596, 3600]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3630, 3634]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3697, 3701]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3732, 3736]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3793, 3797]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3952, 3956]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4153, 4157]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4318, 4322]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4511, 4515]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4746, 4749]], 'text': ['p53'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4754, 4758]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4829, 4833]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4920, 4924]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T44'}]",[],[],[],[],[]
69,PMC-3320587-04-Materials_and_Methods,"Viruses
HIV-1Bal, HIV-1Lai, HIV-193TH64, HIV-192TH51, HIV-192TH53, HIV-198CH01, and HIV-198IN22 were obtained from The Centralized Facility for AIDS Reagents, National Institute for Biological Standard and Control (NIBSC), United Kingdom. HIV-1KR25 was isolated in our laboratory as described before [33].",[],[],[],[],[],[]
70,PMC-1064873-15-Discussion,"CD4+ T cells orchestrate the Th1-type cell-mediated immune response in RA [22]. Activated CD4+ T cells stimulate macrophages, synovial fibroblasts, B cells, and osteoclasts through the expression of cell surface molecules and Th1 cytokines, thereby contributing to both the chronic inflammation and the joint destruction. CD4+ T cells require two signals to be activated; antigen receptor occupancy and CD28-mediated costimulation. In the ST lesion, the CD28 ligands, both CD80 and CD86, together with MHC class II antigens, are substantially expressed by antigen-presenting cells such as macrophages and dendritic cells [18-20]. The significance of CD28 engagement in the T-cell-mediated disease process has recently been proven by the clinical efficacy of its blocker cytotoxic T-cell-associated antigen 4 (CD152)-IgG in RA patients [23].
IL-10 plays a predominant role in limiting immune and inflammatory responses by regulating the function of both macrophages and Th1 cells [1]. IL-10 inhibits the tyrosine phosphorylation of the CD28 molecule and the subsequent phosphatidylinositol 3-kinase binding in T cells, and thereby directly acts on T cells [24]. In the present study, we found that PB CD4+ T cells from patients with active RA, in the presence of IL-10, are able to produce higher levels of IFN-gamma after CD3 and CD28 costimulation than normal CD4+ T cells. Despite high-level IL-10R1 expression and constitutive STAT3 activation, IL-10-induced tyrosine phosphorylation of STAT3 is suppressed in RA CD4+ T cells, in contrast to normal CD4+ T cells, where STAT3 phosphorylation is dose-dependently inducible by IL-10. Serum IL-6 from RA patients induces STAT3 but not STAT1 phosphorylation in normal CD4+ T cells, and exogenous IL-6 induces the resistance to IL-10 inhibition of IFN-gamma production. RA CD4+ T cells contain higher levels of SOCS1 but contain lower levels of SOCS3 transcripts in comparison with normal CD4+ T cells. These findings indicate that CD4+ T cells become resistant to the inhibitory effect of IL-10 before migration into the inflamed ST, and suggest that this resistance may be attributable to impaired IL-10-dependent STAT3 activation, in association with sustained STAT3 phosphorylation and SOCS1 induction.
IL-10-mediated inhibition of CD4+ T-cell cytokine production is principally dependent on its inhibition of macrophage antigen-presenting cell function [1]. However, this indirect inhibitory effect is thought to be restricted at the site of T-cell activation in RA, because macrophages in the ST express high levels of cytokines, CD80 and CD86 molecules, and MHC class II antigens [10,18-20]. More recently, IL-10 has been shown to induce the antigen-specific T-cell unresponsiveness by inhibiting CD28 tyrosine phosphorylation [33]. This direct effect also may be limited in active RA patients, because their PB CD4+ T cells showed a defective IL-10 inhibition of CD28-costimulated production of both IFN-gamma and IL-2.
Numerous cytokines, both proinflammatory and anti-inflammatory, have been detected in the ST of RA, and the balance between these opposing cytokine activities regulates disease severity [10]. Endogenous IL-10, produced mainly by macrophages and T cells, inhibits proinflammatory cytokine production by ST cells [12]. However, this regulatory activity seems to be restricted during chronic inflammation. The activation of both the extracellular stimulus-regulated kinase and p38 kinase pathways, induced by TNF-alpha and IL-1, inhibits the Jak1-STAT3 signaling pathway shared by IL-10 and IL-6 in adhered macrophages [13]. More importantly, IL-10-mediated STAT3 activation is mostly undetectable in RA synovial macrophages. This impaired IL-10 signaling is probably induced by chronic exposure to immune complexes in vivo, because both cell surface IL-10R1 expression and IL-10-induced Jak1 activation are suppressed in IFN-gamma-primed macrophages by a protein kinase C-dependent pathway following ligation of the IgG Fc gamma receptor [14]. Furthermore, dendritic cells from RA synovial fluids are resistant to the immunoregulatory effect of IL-10 due to decreased transport of intracellular IL-10R1 in the presence of proinflammatory cytokine stimuli such as TNF-alpha, IL-1, and granulocyte-macrophage colony-stimulating factor [15]. We have demonstrated that the resistance of RA CD4+ T cells to IL-10 may be associated with defective IL-10-dependent STAT3 activation, but not with IL-10R1 expression. Inhibitory effects of IL-10 on these inflammatory cell types are therefore differentially modulated at the signal transduction level under the inflammatory environment in RA.
In association with impaired IL-10-mediated STAT3 activation, STAT3 was found to be tyrosine phosphorylated persistently (up to 6 hours) in freshly isolated PB and ST CD4+ T cells from RA patients. STAT3 is activated by a variety of cytokines, notably the IL-6 family of cytokines (e.g. IL-6, IL-11, leukemia inhibitory factor, and oncostatin M) and growth factors, in addition to IL-10 [4]. Of these cytokines, IL-6 plays a predominant role in eliciting a systemic reaction such as the acute phase response in active RA, due mainly to its abundance in the blood circulation [27]. Consistent with this notion, IL-6 was the major STAT3-activating factor contained in the serum of active RA patients, and the responsiveness to IL-10 was suppressed in normal CD4+ T cells after 36 hours of incubation with IL-6. These results suggest that both the sustained STAT3 activation and the resistance to IL-10 inhibition found in RA CD4+ T cells may be induced after chronic exposure in vivo to high concentrations of serum IL-6. However, it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10, because RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34].
CD4+ T cells isolated from the ST of RA also showed a defect in the IL-10-induced STAT3 signaling pathway. It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST, because IL-6 is highly concentrated compared with the blood level [27]. In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-gamma inhibition in CD4+ T cells was reduced by pretreatment with IL-1beta and TNF-alpha, although less effectively than by IL-6 (data not shown). Furthermore, IFN-gamma and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST, because T-cell infiltrates produce both cytokines [34,35]. In an autocrine fashion, IL-10 may persistently stimulate STAT3 activation and IFN-gamma can induce SOCS1 protein as a crosstalk inhibitor of IL-10 signaling [32]. The T-cell-inhibitory effect of IL-10 may therefore be modulated complicatedly upon exposure to an inflammatory environment in RA joints, where many cytokines are present substantially [10].
STAT3 activation has been implicated in the pathogenesis of RA. Active STAT3 is constitutively expressed in synovial fluid mononuclear cells from RA patients [36]. IL-6 is the major STAT3-activating factor present in synovial fluid, which has a crucial role in the activation of monocyte functions such as gene expression of the Fc gamma receptor type I and type III and of HLA-DR [31]. More recently, high levels of activated STAT3, thought to be induced mainly by IL-6, have been detected in the ST, and STAT3 activation has been shown to be involved in synovial fibroblast proliferation and IL-6 production [37]. In this regard, STAT3 is critical in the survival and expansion of growth factor-dependent synovial fibroblasts [38]. Furthermore, the significance of persistent STAT3 signaling in Th1-cell-dominated autoimmune arthritis has been suggested by studies of the gp130F759/F759 mice, in which the Src homology phosphatase-2 binding site of gp130 (the transmembrane glycoprotein beta subunit of the IL-6 family cytokine receptor), tyrosine 759, was mutated to phenylalanine [39]. In the gp130F759/F759 mice, T cells, particularly the CD4+ T-cell subset, are chronically activated and resistant to activation-induced cell death through gp130-mediated STAT3 activation.
The longevity of cytokine signals transduced by the JAK-STAT pathway is regulated by the SOCS family proteins [7]. We found that CD4+ T cells from patients with active RA expressed higher levels of SOCS1, but lower levels of SOCS3, compared with normal CD4+ T cells. SOCS1 prevents activation of JAK by directly binding to JAK, and SOCS3 inhibits the action of JAK by binding to the Src homology phosphatase-2-binding domain of receptors such as gp130 [40]. SOCS1 and SOCS3 are induced by various cytokines, including IL-6 and IL-10, as mediators of negative feedback and crosstalk inhibition [7]. Recent studies with mice lacking SOCS3 or SOCS1 revealed that SOCS3 is a negative regulator of IL-6 signaling but not of IL-10 signaling. Studies of conditional SOCS3-deficient mice have shown that SOCS3 deficiency, but not SOCS1 deficiency, results in sustained activation of STAT3 in response to IL-6 [8,41]. The analysis of SOCS3-deficient macrophages has indicated that SOCS3 is a crucial inhibitor of the IL-6-induced transcriptional response [42]. However, SOCS3 is dispensable for both the negative feedback inhibition and the immunoregulatory action of IL-10 in macrophages [41]. On the contrary, SOCS1 was found to directly inhibit IL-10-mediated signaling [43]. Increased SOCS1 expression in RA CD4+ T cells may therefore be associated with both the impaired responsiveness to IL-10 and to IL-10-mediated STAT3 activation, and defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6.
There is a possibility that SOCS1 induction may be associated with the ability of CD4+ T cells to produce IFN-gamma, because CD4+ T cells from active RA could produce high levels of IFN-gamma in the presence of IL-10, and because IFN-gamma has been known as a potent inducer of SOCS1 [32]. It is of interest in this regard to indicate that polarized Th1 and Th2 cells express high levels of SOCS1 and SOCS3 mRNA, respectively [44]. IL-12-induced STAT4 activation is inhibited by SOCS3 induction in Th2 cells, whereas IL-4-induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells. SOCS1 and SOCS3 may thus have important roles as Th1-specific and Th2-specific, mutually exclusive, cross-talk repressors of the IL-4-STAT6 and the IL-12-STAT4 signaling pathways, respectively. Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts, and the SOCS3 expression correlates well with serum IgE levels and disease pathology [45]. Higher SOCS1 expression with lower SOCS3 expression in PB CD4+ T cells from RA patients, compared with healthy controls, is therefore probably consistent with their systemic bias towards a Th1 phenotype, as has previously been demonstrated [46-49].","[{'offsets': [[0, 3]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[90, 93]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[322, 325]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[403, 407]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[454, 458]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[473, 477]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[482, 486]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[650, 654]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[770, 819]], 'text': ['cytotoxic T-cell-associated antigen 4 (CD152)-IgG'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[841, 846]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[984, 989]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1035, 1039]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1200, 1203]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1262, 1267]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1306, 1315]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1330, 1334]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1361, 1364]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1394, 1401]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1430, 1435]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1448, 1453]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1490, 1495]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1516, 1519]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1552, 1555]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1572, 1577]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1627, 1632]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1640, 1644]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1670, 1675]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1684, 1689]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1716, 1719]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1744, 1748]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1775, 1780]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1795, 1804]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1820, 1823]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1858, 1863]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1892, 1897]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1936, 1939]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1979, 1982]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2037, 2042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2147, 2152]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2163, 2168]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2211, 2216]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2237, 2242]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2254, 2259]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2283, 2286]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2583, 2587]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2592, 2596]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2661, 2666]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2751, 2755]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2866, 2869]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2898, 2903]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2918, 2922]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2955, 2964]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2969, 2973]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3178, 3183]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[3481, 3490]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[3495, 3499]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[3514, 3518]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[3519, 3524]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[3553, 3558]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[3563, 3567]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[3615, 3620]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[3630, 3635]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[3712, 3717]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[3823, 3830]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[3846, 3851]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[3860, 3864]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[3894, 3903]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4118, 4123]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4168, 4175]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4236, 4245]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4247, 4251]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[4257, 4305]], 'text': ['granulocyte-macrophage colony-stimulating factor'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[4359, 4362]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[4375, 4380]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[4414, 4419]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[4430, 4435]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[4461, 4468]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[4503, 4508]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[4685, 4690]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[4700, 4705]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[4718, 4723]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[4823, 4826]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[4854, 4859]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[4943, 4947]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[4949, 4954]], 'text': ['IL-11'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[4956, 4982]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T128'}, {'offsets': [[4988, 5000]], 'text': ['oncostatin M'], 'type': 'Protein', 'id': 'T129'}, {'offsets': [[5037, 5042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T130'}, {'offsets': [[5068, 5072]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T131'}, {'offsets': [[5266, 5270]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T132'}, {'offsets': [[5285, 5290]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T133'}, {'offsets': [[5381, 5386]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T134'}, {'offsets': [[5412, 5415]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T135'}, {'offsets': [[5459, 5463]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T136'}, {'offsets': [[5511, 5516]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T137'}, {'offsets': [[5550, 5555]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T138'}, {'offsets': [[5579, 5582]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T139'}, {'offsets': [[5670, 5674]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T140'}, {'offsets': [[5710, 5715]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T141'}, {'offsets': [[5760, 5763]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T142'}, {'offsets': [[5786, 5791]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T143'}, {'offsets': [[5851, 5856]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T144'}, {'offsets': [[5869, 5872]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T145'}, {'offsets': [[5939, 5944]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T146'}, {'offsets': [[5951, 5954]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T147'}, {'offsets': [[6019, 6024]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T148'}, {'offsets': [[6033, 6038]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T149'}, {'offsets': [[6101, 6104]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T150'}, {'offsets': [[6117, 6122]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T151'}, {'offsets': [[6191, 6195]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T152'}, {'offsets': [[6409, 6414]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T153'}, {'offsets': [[6424, 6433]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T154'}, {'offsets': [[6448, 6451]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T155'}, {'offsets': [[6494, 6502]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T156'}, {'offsets': [[6507, 6516]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T157'}, {'offsets': [[6552, 6556]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T158'}, {'offsets': [[6588, 6597]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T159'}, {'offsets': [[6602, 6607]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T160'}, {'offsets': [[6620, 6623]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T161'}, {'offsets': [[6678, 6683]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T162'}, {'offsets': [[6789, 6794]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T163'}, {'offsets': [[6822, 6827]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T164'}, {'offsets': [[6843, 6852]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T165'}, {'offsets': [[6864, 6869]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T166'}, {'offsets': [[6906, 6911]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T167'}, {'offsets': [[6960, 6965]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T168'}, {'offsets': [[7119, 7124]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T210'}, {'offsets': [[7190, 7195]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T211'}, {'offsets': [[7283, 7287]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T212'}, {'offsets': [[7301, 7306]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T213'}, {'offsets': [[7448, 7472]], 'text': ['Fc gamma receptor type I'], 'type': 'Protein', 'id': 'T214'}, {'offsets': [[7477, 7485]], 'text': ['type III'], 'type': 'Protein', 'id': 'T215'}, {'offsets': [[7546, 7551]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T216'}, {'offsets': [[7585, 7589]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T217'}, {'offsets': [[7625, 7630]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T218'}, {'offsets': [[7713, 7717]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T219'}, {'offsets': [[7751, 7756]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T220'}, {'offsets': [[7897, 7902]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T221'}, {'offsets': [[7993, 7998]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T222'}, {'offsets': [[8070, 8075]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T223'}, {'offsets': [[8081, 8157]], 'text': ['transmembrane glycoprotein beta subunit of the IL-6 family cytokine receptor'], 'type': 'Protein', 'id': 'T224'}, {'offsets': [[8216, 8221]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T225'}, {'offsets': [[8263, 8266]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T226'}, {'offsets': [[8364, 8369]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T227'}, {'offsets': [[8379, 8384]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T228'}, {'offsets': [[8526, 8529]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T229'}, {'offsets': [[8595, 8600]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T230'}, {'offsets': [[8622, 8627]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T231'}, {'offsets': [[8650, 8653]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T232'}, {'offsets': [[8664, 8669]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T233'}, {'offsets': [[8729, 8734]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T234'}, {'offsets': [[8843, 8848]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T235'}, {'offsets': [[8855, 8860]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T236'}, {'offsets': [[8865, 8870]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T237'}, {'offsets': [[8915, 8919]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T238'}, {'offsets': [[8924, 8929]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T239'}, {'offsets': [[9028, 9033]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T240'}, {'offsets': [[9037, 9042]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T241'}, {'offsets': [[9057, 9062]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T242'}, {'offsets': [[9090, 9094]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T243'}, {'offsets': [[9116, 9121]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T244'}, {'offsets': [[9156, 9161]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T245'}, {'offsets': [[9193, 9198]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T246'}, {'offsets': [[9219, 9224]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T247'}, {'offsets': [[9272, 9277]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T248'}, {'offsets': [[9293, 9297]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T249'}, {'offsets': [[9322, 9327]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T250'}, {'offsets': [[9369, 9374]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T251'}, {'offsets': [[9405, 9409]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T252'}, {'offsets': [[9458, 9463]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T253'}, {'offsets': [[9556, 9561]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T254'}, {'offsets': [[9600, 9605]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T255'}, {'offsets': [[9636, 9641]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T256'}, {'offsets': [[9677, 9682]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T257'}, {'offsets': [[9700, 9703]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T258'}, {'offsets': [[9782, 9787]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T259'}, {'offsets': [[9795, 9800]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T260'}, {'offsets': [[9810, 9815]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T261'}, {'offsets': [[9842, 9847]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T262'}, {'offsets': [[9893, 9898]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T263'}, {'offsets': [[9931, 9935]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T264'}, {'offsets': [[9965, 9970]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T265'}, {'offsets': [[10019, 10022]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T266'}, {'offsets': [[10043, 10052]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T267'}, {'offsets': [[10062, 10065]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T268'}, {'offsets': [[10119, 10128]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T269'}, {'offsets': [[10148, 10153]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T270'}, {'offsets': [[10167, 10176]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T271'}, {'offsets': [[10215, 10220]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T272'}, {'offsets': [[10328, 10333]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T273'}, {'offsets': [[10338, 10343]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T274'}, {'offsets': [[10369, 10374]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T275'}, {'offsets': [[10383, 10388]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T276'}, {'offsets': [[10416, 10421]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T277'}, {'offsets': [[10454, 10458]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T278'}, {'offsets': [[10467, 10472]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T279'}, {'offsets': [[10500, 10505]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T280'}, {'offsets': [[10530, 10535]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T281'}, {'offsets': [[10540, 10545]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T282'}, {'offsets': [[10659, 10663]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T283'}, {'offsets': [[10664, 10669]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T284'}, {'offsets': [[10678, 10683]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T285'}, {'offsets': [[10684, 10689]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T286'}, {'offsets': [[10838, 10843]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T287'}, {'offsets': [[10865, 10870]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T288'}, {'offsets': [[10955, 10960]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T289'}, {'offsets': [[10983, 10988]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T290'}, {'offsets': [[11006, 11009]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T291'}]",[],[],[],[],[]
71,PMC-3320587-18-Results,"NF-kappaB and NFAT5 binding to the HIV-1 LTR can be specifically disrupted
To demonstrate that the impact of NFAT5 silencing on MTb-induced viral replication was a direct effect due to modulation of recruitment of NFAT5 to the HIV-1 LTR and not due to secondary, NFAT5-regulated effects, we set out to disrupt NFAT5 binding to the viral LTR in the context of HIV-1/MTb co-infection. This series of experiments also allowed us to dissect the relative importance of NFAT5 and NF-kappaB binding to the HIV-1 LTR in MTb regulation of HIV-1 replication.
To perform these experiments, we constructed a panel of infectious HIV-1Lai/Bal-env molecular clones where either the NFAT5 site was specifically disrupted or the two NF-kappaB binding sites were either individually or dually disrupted (Figure 3A). Specifically, we constructed a clone in which the NFAT5 binding site was mutated (named HIV-1Lai/Bal-env-N5-Mut) by changing the CC dinucleotide to TT in the core NFAT5 binding site and introduced substitution mutations into the NF-kappaB/NFAT5 shared binding element that we predicted would disrupt NF-kappaB binding but preserve NFAT5 binding. Specifically, we mutated two guanines (GG) in the kappaB I site and changed them to thymine and adenine (TA) (HIV-1Lai/Bal-env-kappaB I-mut) and also introduced the same GG to TA change in the second, more distal NF-kappaB site (kappaB II) in HIV-1Lai/Bal-env (HIV-1Lai/Bal-env-kappaB II-Mut). We also created a double NF-kappaB site mutant virus (HIV-1Lai/Bal-env-kappaB I+II-Mut) in order to test the impact of complete disruption of NF-kappaB binding to the HIV-1 LTR on MTb regulation.
To determine the specificity of these substitutions upon NFAT5 and NF-kappaB p50/p65 binding to the LTR, we performed a quantitative DNase I footprinting analysis using the wild-type LTR or mutant LTRs in combination with increasing concentrations of recombinant NFAT5 or NF-kappaB p50/p65 proteins. As shown in Figure 3B, the N5-Mut LTR could not bind NFAT5 (compare lanes 12-15 and lanes 17-20), but p50/p65 binding was not impaired (compare lanes 2-5 with lanes 7-10). By contrast, changing the GG dinucleotide to TA in either NF-kappaB binding motif, as predicted, inhibited p50/p65 binding at each site (compare lanes 2-5 with lanes 7-10 and lanes 12-15 of Figure 3C). As expected, mutation of both NF-kappaB sites (kappaB I+II-Mut) resulted in abrogation of p50/p65 binding to the LTR. However, recombinant NFAT5 binding to the single and the double NF-kappaB mutant LTRs was not impaired and indeed appeared enhanced (compare lanes 2-5 to lanes 7-20 of Figure 3D). Thus, binding of NFAT5 or NF-kappaB p50/p65 to their respective motifs can be specifically disrupted within an overlapping or shared binding site.","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[109, 114]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[214, 219]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[263, 268]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[310, 315]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[464, 469]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[629, 632]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[899, 902]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1129, 1134]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1267, 1270]], 'text': ['env'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1400, 1403]], 'text': ['env'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1418, 1421]], 'text': ['env'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1505, 1508]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1691, 1696]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1711, 1714]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1715, 1718]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1767, 1774]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1897, 1902]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1916, 1919]], 'text': ['p50'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1920, 1923]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1987, 1992]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2036, 2039]], 'text': ['p50'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2040, 2043]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2213, 2216]], 'text': ['p50'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2217, 2220]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2398, 2401]], 'text': ['p50'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2402, 2405]], 'text': ['p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2447, 2452]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2623, 2628]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2642, 2645]], 'text': ['p50'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2646, 2649]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
72,PMC-3312845-09-Methods,"Volumetric analysis and cell counts
To measure vasogenic edema, the volume of anti-rat IgG positive region in PC was estimated according to the formula based on the modified Cavalieri method: V = sigmaa x tnom x 1/ssf, where a is area of the region of the delineated subfield measured by AxioVision Rel. 4.8 software, tnom is the nominal section thickness (of 30 mum in this study), and ssf is the fraction of the sections sampled or section sampling fraction (of 1/6 in this study). The subfield areas were delineated with a 2.5 x objective lens [5,7,8,18,25]. The volumes are reported as mm3. An optical fractionator was used to estimate cell numbers. The optical fractionator (a combination of performing counting with the optical dissector, with fractionator sampling) is a stereological method based on a properly designed systematic random sampling method that by definition yields unbiased estimates of population number. The sampling procedure is accomplished by focusing through the depth of the tissue (the optical dissector height, h; 15 mum in all cases for this study). The number of each cell type (C) in each of the subregions is estimated as: C = sigmaQ- x t/h x 1/asf x 1/ssf, where Q- is the number of cells actually counted in the dissectors that fell within the sectional profiles of the subregion seen on the sampled sections, and Asf is the areal sampling fraction calculated by the area of the counting frame of the dissector, a(frame) (of 50 x 50 mum2 in this study) and the area associated with each x, y movement, grid (x, y step) (of 250 x 250 mum2 in this study) {asf = (a(frame)/a(x, y step))}. The immunoreactive cells were counted with a 40x objective lens. The immunoreactive cells were counted with a 40x objective lens. All immunoreactive cells were counted regardless the intensity of labeling. Cell counts were performed by two different investigators who were blind to the classification of tissues. SE-induced PC atrophy is evident [8], so changes in cell number may be caused by an alterations in the volume of the PC. Therefore, the total number of cells was corrected by multiplying with appropriate correction factors (CF) representing the degree of shrinkage (or swelling) compared with the Non-SE.",[],[],[],[],[],[]
73,PMC-3291650-15-Materials_and_Methods,"RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted using Aurum Total RNA mini kit (BioRad) and reverse transcribed into cDNA with iScript cDNA synthesis kit (BioRad) according to the manufacturer's instructions. qPCR was performed by using SYBR Green I master mix I (Roche) in the Lightcycler 480 detection system (Roche) with the following primers: HPRT: 5'-AGTGTTGGATACAGGCCAGAC-3' and 5'CGTGATTCAAATCCCTGAAGT-3'; IL-6: 5'-GAGGATACCACTCCCAACAGACC-3' and 5'-AAGTGCATCATCGTTGTTCATACA-3'; IFNbeta: 5'-TCAGAATGAGTGGTGGTTGC-3' and 5'-GACCTTTCAAATGCAGTAGATTCA-3'; A20: 5'-AAACCAATGGTGATGGAAACTG-3' and 5'-GTTGTCCCATTCGTCATTCC-3'; CCL2: 5'-TTAAAAACCTGGATCGGAACCAA-3' and 5'-GCATTAGCTTCAGATTTACGGGT-3'; CXCL1: 5'-GAGCCTCTAACCAGTTCCAG-3' and 5'-TGAGTGTGGCTATGACTTCG-3' and IFNalpha4: 5'-TGATGAGCTACTACTGGTCAGC-3' and 5'-GATCTCTTAGCACAAGGATGGC-3'. Primers were designed with PerlPrimer (http://perlprimer.sourceforge.net). Quantification was performed using the comparative CT method (deltadeltaCT). Results are expressed relative to HPRT values.","[{'offsets': [[428, 432]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[500, 507]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[572, 575]], 'text': ['A20'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[638, 642]], 'text': ['CCL2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[709, 714]], 'text': ['CXCL1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[778, 787]], 'text': ['IFNalpha4'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
74,PMC-1359074-12-Materials_and_Methods,"Histology.
18.5-dpc embryos were exsanguinated and peripheral blood smears were prepared from both mutant and WT mice. The slides were Wright-stained and read by DAF. For whole mount analysis, 14.5-dpc WT and mutant embryos, and postnatal day-10.5 mice were fixed in 10% formalin, paraffin-embedded, sectioned at 5 mum, and stained with hematoxylin and eosin. Liver samples (at 14.5 dpc and 18.5 dpc) were prepared in a similar manner. Images were obtained with Nikon Labophot-2 microscope. Objectives used were E Plan 40/0.65 160/0.17 Nikon (40x objective), E Plan 100/1.25 oil 160/0.17 Nikon (100x objective). The camera was a Nikon Coolpix 4300. Original images are available.",[],[],[],[],[],[]
75,PMC-3317373-06-2._Methods_and_Materials,"2.5. RT-PCR
Total RNA was isolated with Trizol (Invitrogen, CA, USA), and single-stranded cDNA was synthesized from 2 mug of total RNA with BU-Script RT-Kit (Biunique, Jiangsu, China) according to the manufacturer's protocol. The cDNA was stored in -20degreesC. Reverse transcription was conducted with GoTaq Green Master Mix (Promega, WI, USA) according to the manufacturer's protocol. Table 1 shows the primers and PCR parameters. PCR products were detected by agarose gel electrophoresis. The intensity of the bands was analyzed by ImageJ program. The level of beta-actin was used as an internal standard.","[{'offsets': [[564, 574]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
76,PMC-3589482-07-Experimental_Procedures,"Transient Transfection and Luciferase Assays (RAW264.7 Macrophages)
RAW 264.7 cells (2x107) growing in log phase were transfected with the indicated luciferase reporter plasmid (20 microg) along with the pRL-thymidine kinase (TK) (Promega) internal control reporter plasmid (2 microg) by electroporation using a Bio-Rad Gene Pulser with a Capacitance Extender (0.25 kV, 960 microFd). pGL3 control plasmid which encodes the SV40 promoter and enhancer was included as a positive control for transfection efficiency, and as an internal standard for promoter and enhancer activities. Transfected cells were transferred to 10 ml of pre-warmed media in 6-well tissue culture plates, divided into two identical cell pools and incubated 16 hrs in a 5% CO2 and 95% humidified air atmosphere at 37degreesC either in the presence or absence of 100 ng/ml LPS. Luciferase activity was measured using a Dual-Luciferase Reporter Assay System kit (Promega). Measurements represent the results of at least three independent experiments. Promoter activity is expressed as the number of firefly luciferase light units normalized either to pRL-TK renilla luciferase light units or to cellular protein concentration (where co-transfected C/EBP-beta or LPS affected pRL-TK activity). Protein concentration was determined using the Bio-Rad protein microassay reagent.","[{'offsets': [[27, 37]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[149, 159]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[208, 224]], 'text': ['thymidine kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[226, 228]], 'text': ['TK'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[848, 858]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[894, 904]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1076, 1086]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1124, 1126]], 'text': ['TK'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1135, 1145]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1217, 1227]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1248, 1250]], 'text': ['TK'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
77,PMC-3291650-01-Introduction,"Viruses are a class of highly diverse pathogens which depend on the host cell for their replication. The initiation of a protective innate antiviral immune response involves the action of specialized pattern recognition receptors (PRR), which detect conserved molecular structures of the invading pathogen. Triggering of PRRs induces the production of host proinflammatory cytokines (e.g. TNF, IL-6 and IL-1) and type I interferons (interferon-alpha (IFN-alpha) and IFN-beta) through activation of downstream signaling pathways that control various transcription factors such as NF-kappaB, AP-1, IRF3 and IRF7 [1], [2]. The presence of viral nucleic acids, such as viral RNA and DNA, viral replication intermediates and viral transcription products, can be sensed by specific intracellular PRRs [3]. Endosomal Toll-like receptors (TLRs) and cytoplasmic RNA helicase RIG-I-like receptors (RLRs) or Nod-like receptors (NLRs) detect the presence of viral single stranded (TLR7, TLR8, Nod2) or double stranded RNA (TLR3, RIG-I, MDA5). Intracellular DNA sensors that mediate antiviral immune responses to DNA viruses include TLR9, DAI [4] and the PYHIN domain containing proteins AIM2 [5], [6], [7] and IFI16 [8]. TLR mediated antiviral responses are restricted to specialized type I IFN producing plasmacytoid dendritic cells (pDC), while most other cell types, including conventional DC (cDC), macrophages and fibroblasts, depend on the cytosolic RNA and DNA sensors for the production of antiviral proteins [9].
Influenza A virus (IAV) is the etiological agent of a contagious acute respiratory disease that causes considerable mortality, which is generally believed to be due to an excessive host inflammatory response. Emergence of drug-resistant strains of influenza viruses with pandemic potential underscores the importance of developing novel antiviral strategies. In this context, understanding of the mechanisms that regulate IAV-induced immune responses is critical. IAV infection leads to the exposure in the host cell of single-stranded genomic RNA and double stranded RNA, the latter being an intermediate of viral replication. TLR3 and RIG-I have been implicated as sensors of IAV infection [10]-[12]. Both receptors contribute to the proinflammatory response to IAV, but the initiation of the innate antiviral immune response largely depends on RIG-I mediated signaling [13]. Interestingly, RIG-I deficient mice are highly susceptible to IAV [14], [15], whereas TLR3 deficient mice have a survival advantage to acute infection [16]. These results indicate that an imbalance between the beneficial and harmful effects of mediators released by immune cells is likely to contribute to the pathogenesis of influenza.
RIG-I contains a C-terminal DExD/H box helicase domain, which is required for ligand recognition, and two N-terminal CARD domains. Upon ligand binding, the CARD domains of RIG-I associate with the CARD domain of the MAVS (also termed IPS-1, VISA, Cardif) adaptor protein, which subsequently translocates to and inserts in the outer mitochondrial membrane via its C-terminal transmembrane domain [17]-[20]. Signaling downstream of MAVS requires the action of various ubiquitin modifying enzymes, which both positively and negatively regulate RIG-I mediated signal transduction [21]. K63-specific ubiquitin ligases (E3s), such as TRIM25 [22] and Riplet [23], [24], have been shown to directly promote RIG-I activation. In addition, well characterized ubiquitin ligases such as TRAF6 [25], [26] and TRAF3 [27] mediate respectively NF-kappaB and IRF3 activation upon RIG-I stimulation. On the other hand, deubiquitinating enzymes (DUBs), such as DUBA [28], CYLD [29], [30] and OTUB1/2 [31] have been shown to negatively regulate RLR signaling by specifically removing K63-linked polyubiquitin chains from several signaling molecules. Furthermore, various K48-specific ubiquitin ligases, such as AIP4 [32] and TRIAD3A [33] mark respectively MAVS and TRAF3 for proteasome mediated degradation, thus inhibiting further downstream signaling. Additionally, the attachment of K48-specific polyubiquitin chains to the IRF3 and IRF7 transcription factors by E3s such as RAUL [34], TRIM21 [35] and RBCK1 [36] further dampens antiviral signal transduction.
A20 is an ubiquitin-editing enzyme belonging to the OTU-domain family of DUBs. Interestingly, A20 also harbors atypical zinc finger dependent K48-specific E3 ubiquitin ligase activity. Both catalytic and noncatalytic mechanisms were previously shown to be involved in the negative regulation of proinflammatory signaling by A20 in response to multiple receptors such as TNF receptor I [37]-[39], TLR4 [40], and IL-1R [41]. The anti-inflammatory role of A20 is clearly demonstrated by the fact that A20 deficient mice die early after birth due to severe multi-organ inflammation and cachexia [37]. More recently, gene targeting of A20 in specific cell types was shown to be associated with autoimmunity and chronic inflammation [42]-[48], further illustrating that A20 is an important brake on the inflammatory response. The relevance of these findings for human disease has recently been illustrated through the identification of polymorphisms in the A20 locus that are associated with several autoimmune diseases and chronic inflammation [45]. In contrast to its well established function in the regulation of proinflammatory responses, the role of A20 in the regulation of antiviral immune responses is less well described and limited to a number of in vitro studies using overexpression or silencing in specific cell lines, indicating that A20 may regulate RIG-I- and TLR3-induced signaling to NF-kappaB and IRF-3 [49]-[52]. However, the precise in vivo role of A20 in the response to viral infection remains to be clarified. Using myeloid cell specific A20 knockout mice (A20myel-KO) that were recently generated in our lab and primary cells derived of these mice, we here provide evidence that A20 is a crucial negative regulator of IAV-induced proinflammatory and antiviral signaling in macrophages. Interestingly, A20myel-KO mice show enhanced survival and reduced morbidity in response to IAV lung infection compared to wild type mice. Protection against IAV in A20myel-KO mice is associated with increased cytokine and chemokine production, augmented recruitment of innate immune cells such as neutophils and alveolar macrophages, and enhanced viral clearance. These results suggest that boosting the innate immune response to IAV by targeting A20 activity in myeloid cells might have therapeutic potential.","[{'offsets': [[389, 392]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[394, 398]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[403, 407]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[433, 449]], 'text': ['interferon-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[451, 460]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[466, 474]], 'text': ['IFN-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[596, 600]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[605, 609]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[969, 973]], 'text': ['TLR7'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[975, 979]], 'text': ['TLR8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[981, 985]], 'text': ['Nod2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1011, 1015]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1017, 1022]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1024, 1028]], 'text': ['MDA5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1120, 1124]], 'text': ['TLR9'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1126, 1129]], 'text': ['DAI'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1175, 1179]], 'text': ['AIM2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1198, 1203]], 'text': ['IFI16'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2138, 2142]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2147, 2152]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2357, 2362]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2403, 2408]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2474, 2478]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2725, 2730]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2897, 2902]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2941, 2945]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2959, 2964]], 'text': ['IPS-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2966, 2970]], 'text': ['VISA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2972, 2978]], 'text': ['Cardif'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3155, 3159]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3266, 3271]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3353, 3359]], 'text': ['TRIM25'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3369, 3375]], 'text': ['Riplet'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3424, 3429]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3500, 3505]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3521, 3526]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3567, 3571]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3588, 3593]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3667, 3671]], 'text': ['DUBA'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3678, 3682]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3750, 3753]], 'text': ['RLR'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3916, 3920]], 'text': ['AIP4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3930, 3937]], 'text': ['TRIAD3A'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3961, 3965]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3970, 3975]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4132, 4136]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4141, 4145]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4183, 4187]], 'text': ['RAUL'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4194, 4200]], 'text': ['TRIM21'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4210, 4215]], 'text': ['RBCK1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4638, 4652]], 'text': ['TNF receptor I'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4664, 4668]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4679, 4684]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5628, 5633]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5639, 5643]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5679, 5684]], 'text': ['IRF-3'], 'type': 'Protein', 'id': 'T58'}]",[],[],[],[],[]
78,PMC-3342329-21-Caption-Figure_4,"Upregulation of IL-1Ra in the tumor and spleen of CCR5-/- mice.
A, Figure 4A indicates mouse cytokine array panel coordinates. Nitrocellulose membranes contain 40 different anti-cytokine antibodies printed in duplicate. B, Mouse cytokine array panel indicate the cytokine expression difference in tumor tissues of CCR5+/+ mice and CCR5-/- mice, especially IL-1Ra. Representative blot from three independent experiments is shown. Positive controls show the manufacturer's internal positive control samples on the membrane. C, Protein immune-arrays were performed using Mouse cytokine array in spleen tissues. There were differences in cytokines between CCR5+/+ mice and CCR5-/- mice, especially IL-1Ra. Representative blot from three independent experiments is shown. Positive controls show the manufacturer's internal positive control samples on the membrane. D and E, Immunolfluorescence analysis was used to determine the expression levels of IL-1Ra in tumor and spleen tissues. The reactive cell number was determined as the number of DAPI-stained, IL-1Ra antibody-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. F and G, Expression of IL-1Ra was analyzed by western blotting in tumor and spleen tissues. Each band is representative of three independent experimental results. Data are means +/- S.D. of three experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05).","[{'offsets': [[16, 22]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[314, 318]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[331, 335]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[356, 362]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[652, 656]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[669, 673]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[694, 700]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[945, 951]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1216, 1220]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1284, 1290]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1519, 1523]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
79,PMC-3585731-24-Materials_and_Methods,"TNFalpha ELISA
Mouse TNFalpha Quantikine ELISA assays (R&D Systems) were performed according to manufacturer's descriptions. Cell lysates were prepared from 3x106 cells plated and treated in a 10 cm2 dish.","[{'offsets': [[0, 8]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 29]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
80,PMC-3589482-13-Results,"The SerpinB2 Gene is Highly Responsive to LPS
When RAW264.7 macrophages were exposed to LPS, SerpinB2 mRNA was detectable as early as 30 min following LPS challenge, reaching maximal levels at 24 hrs (Fig. 1A). A similar strong induction of LPS-inducible SerpinB2 mRNA expression has been reported previously in murine peritoneal macrophages and human peripheral blood mononuclear cells [4]; [32]. LPS-induced SerpinB2 expression involves both an increase in gene transcription and stabilization of the mRNA [5]; [29]; [42]-[44]. SerpinB2 protein expression was also induced as has been reported in other cell types [31], and detectable after 8 hrs of LPS treatment (Fig. 1).","[{'offsets': [[4, 12]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[93, 101]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[255, 263]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[410, 418]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[530, 538]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
81,PMC-1359074-18-Materials_and_Methods,"ChIP assay.
As described by Nouzova [53], in brief: Cells from MEL cells (4 x 107) or fetal liver cells from three 15.5-dpc WT mice were treated with 1% formaldehyde for 10 min at 37 degreesC, rinsed in ice-cold 1x Hanks' balanced salt solution with 0.1% EDTA containing protease inhibitors, collected by centrifugation at 4 degreesC, resuspended in a SDS lysis buffer containing protease inhibitors, and incubated on ice for 10 min. DNA-protein complexes were sonicated to 200 and 600 bp. One-tenth of the sample was set aside for input control, and the remaining sample was precleared with protein A-Sepharose (Amersham Biosciences, Piscataway, New Jersey, United States). Following preclearing, the samples were split into thirds: one sample treated with anti-Sox6, a second treated with normal rabbit IgG, and the third sample without Ab. The last two were used as negative controls. The chromatin-antibody complexes were eluted, and the DNA protein cross-links were reversed with 5 M NaCl at 65 degreesC for 4 h. Input DNA or immunoprecipitated DNA was used as a template in the PCR reaction. PCR amplification of the epsilony promoter was performed and yielded a 172-bp amplicon, corresponding to nucleotides -31 to +140 of the epsilony promoter (primers MHB1688, 5'CGAAGAATAAAAGGCCACCA3'; and MHB1689, 5'GCTTCACCACCAACCTCTTC3'). PCR was performed under the following conditions: 95 degreesC for 15 min followed by 30 cycles at 95 degreesC for 30 s, 60 degreesC for 30 s, and 72 degreesC for 45 s, ending with a final extension at 72 degreesC for 5 min.","[{'offsets': [[592, 601]], 'text': ['protein A'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[763, 767]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1123, 1131]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1234, 1242]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
82,PMC-1064873-09-Materials_and_methods,"Statistical analysis
Data are expressed as the mean value +/- standard error of the mean or box plots. The statistical significance of differences between two groups was determined by the Mann-Whitney U test or the Wilcoxon signed rank test. P < 0.05 was considered significant.",[],[],[],[],[],[]
83,PMC-3589482-30-Caption-Figure_7,"Differential recruitment of C/EBP-beta and C/EBP-betaT217 to the murine SerpinB2 promoter in vivo.
Transcription factor occupancy on the SerpinB2 proximal promoter in vivo was determined by chromatin immunoprecipitation (ChIP) assay. RAW264.7 macrophages were treated in the presence or absence of LPS for the indicated times and chromatin immunoprecipitation performed using antibodies against C/EBP-beta or p-C/EBP-beta (T217). Soluble chromatin (600-700 ng) was immunoprecipitated with antibodies against C/EBP-beta, p-C/EBP-beta (T217), RNA Polymerase II (RNAPII), or a rabbit IgG (rIgG) control. (A) Typical PCR pattern obtained in ChIP assays using murine SerpinB2 proximal promoter-specific primers, 338/-315 and -5/+19, as diagrammed in top. Recruitment of RNAPII to the SerpinB2 promoter suggests active transcription following LPS stimulation. Minimal background was detected using the rabbit IgG control, indicative of the specificity of the ChIP reaction. (B) qPCR analysis of chromatin immunoprecipitated with antibodies against C/EBP-beta, p-C/EBP-beta (T217), and the rIgG control. The data are represented relative to rIgG signal using the 2-deltadeltaCt method.","[{'offsets': [[28, 38]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[72, 80]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 145]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 405]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[409, 428]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[508, 518]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[520, 539]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[662, 670]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[779, 787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1042, 1052]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1054, 1073]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1134, 1138]], 'text': ['rIgG'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
84,PMC-1359074-00-TIAB,"Sox6 Directly Silences Epsilon Globin Expression in Definitive Erythropoiesis
Sox6 is a member of the Sox transcription factor family that is defined by the conserved high mobility group (HMG) DNA binding domain, first described in the testis determining gene, Sry. Previous studies have suggested that Sox6 plays a role in the development of the central nervous system, cartilage, and muscle. In the Sox6-deficient mouse, p100H, epsilony globin is persistently expressed, and increased numbers of nucleated red cells are present in the fetal circulation. Transfection assays in GM979 (erythroleukemic) cells define a 36-base pair region of the epsilony proximal promoter that is critical for Sox6 mediated repression. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrate that Sox6 acts as a repressor by directly binding to the epsilony promoter. The normal expression of Sox6 in wild-type fetal liver and the ectopic expression of epsilony in p100H homozygous fetal liver demonstrate that Sox6 functions in definitive erythropoiesis. The present study shows that Sox6 is required for silencing of epsilony globin in definitive erythropoiesis and suggests a role for Sox6 in erythroid cell maturation. Thus, Sox6 regulation of epsilony globin might provide a novel therapeutical target in the treatment of hemoglobinopathies such as sickle cell anemia and thalassemia.","[{'offsets': [[0, 4]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[23, 37]], 'text': ['Epsilon Globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[78, 82]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[261, 264]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[303, 307]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[401, 405]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[430, 445]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[645, 653]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[693, 697]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[828, 832]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[880, 888]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[924, 928]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[984, 992]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1042, 1046]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1116, 1120]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1150, 1165]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1219, 1223]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1260, 1264]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1279, 1294]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
85,PMC-1359074-09-Materials_and_Methods,"Plasmid construction.
The epsilony promoter deletion reporter plasmid (E-luc) was generated by PCR amplification of the epsilony proximal promoter. A 2.2-kb fragment upstream of the epsilony globin initiation codon (ATG) was used, because it has been shown that all sequences required for epsilon gene silencing are located within a 3.7-kb EcoRI fragment containing about 2 kb of sequence upstream of the epsilon globin gene cap site [50]. Nucleotide numbering is relative to the transcription start site. The transcriptional start site is based on the longest cDNA in the Fantom (Functional Annotation of Mouse) database. The PCR primers contained XhoI and HindIII sites that were used to clone the epsilony promoter fragment upstream of the firefly luciferase gene in pGL3 Basic (Promega, Madison, Wisconsin, United States). A 2.5-kb SstI/XhoI fragment of muLCRbeta 9.3 (micro LCR; [31]) was then inserted upstream of the epsilony promoter in the above pGL3 Basic plasmid, resulting in a reporter construct in which luciferase expression is driven by the epsilony promoter. A series of deletion constructs of the epsilony promoter were generated similarly. Forward primers with an XhoI site include: MHB1457, 5'CCGCTCGAGTGCTAGGCAAACACTCA3' (-2077 to -2052); MHB1503, 5'CCGCTCGAGTCTCTACACTGTCACTCCCTG3' (-634 to -605); MHB1505, 5'CCGCTCGAGGGAGCCAAAAAAAGAATGC3' (-197 to -169); MHB1506, 5'CCGCTCGAGCTGACCAATGGCTTCAAAG3' (-85 to -58); MHB1532, 5'CCGCTCGAGAATGCAGAACAAAGGGTCAGA3' (-63 to -34); and MHB1507, 5'CCGCTCGAGGTCTGCGAAGAATAAAAGGC 3' (-37 to -9). All forward primers were used in combination with the reverse primer HindIII site: MHB1477, 5'CGGAAGCTTGGGAGGTTGCTGGTGA3' (+45 to +20).
Sox6-pcDNA3.1 [15] was used to overexpress Sox6. A truncated version of the Sox6 overexpression construct (Sox6-deltaHMG-pcDNA3.1) that lacks the HMG domain was generated, as described by others [32]. Mutagenesis of Sox/Sox6 consensus binding sites of the epsilony promoter were done by PCR. Forward primers used to generate these mutagenized epsilony promoter reporter constructs include: MHB1661, 5'CCGCTCGAGAATGCAGTGCCAAGGGTCAGAACATTGTCTGCGAAG3' (-63 to -19); MHB1662, 5'CCGCTCGAGAATGCAGAACAAAGGGTCAGATGAGTGTCTGCGAAGAA3' (-63 to -16); and MHB1663, 5'CCGCTCGAGAATGCATGCCAAGGGTCAGATGAGTGTCTGCGAAGAA 3' (-63 to -18).","[{'offsets': [[26, 34]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 128]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[182, 197]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[289, 296]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[405, 419]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[700, 708]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[751, 761]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[924, 932]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1018, 1028]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1057, 1065]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1115, 1123]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1689, 1693]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1732, 1736]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1765, 1769]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1796, 1800]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1945, 1953]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
86,PMC-3585731-15-Materials_and_Methods,"Antibodies
The following antibodies were used: phospho-Akt (Thr308) (clone C31E5E) rabbit mAb, phospho-Akt (Ser473) (clone D9E) XP rabbit mAb, Akt (pan) (clone C67E7) rabbit mAb, Akt1 (clone C73H10) rabbit mAb, Akt2 (clone D6G4) rabbit mAb, Akt3 (clone 62A8) rabbit mAb, phospho-JNK (Thr183/Tyr185) (81E11) rabbit mAb, SAPK/JNK rabbit pAb, phospho-c-Jun (Ser63) II rabbit pAb, c-Jun (60A8) rabbit mAb, alpha-tubulin (clone DM1A) mouse mAb, phospho-FoxO1 (Thr24)/FoxO3a (Thr32) rabbit pAb, FoxO1 (L27) rabbit pAb, phospho-FoxO4 (Ser193) rabbit pAb, FoxO4 rabbit pAb, phospho-MDM2 (Ser166) rabbit pAb, phospho-GSK-3alpha/beta (Ser21/9) rabbit pAb, phospho-p70 S6 Kinase (Thr389) (clone 108D2) rabbit mAb, phospho-S6 Ribosomal Protein (Ser235/236) (clone D57.2.2E) XP rabbit mAb, S6 Ribosomal Protein (clone 54D2) mouse mAb, phospho-4E-BP1 (Thr37/46) rabbit pAb, mTOR (clone 7C10) rabbit mAb, PDK1 rabbit pAb (all Cell Signaling), MDM2 rabbit pAb (Bioworlde).",[],[],[],[],[],[]
87,PMC-3589482-22-Results,"Phosphorylation of C/EBP-beta at Serine 64 negatively Regulates LPS-stimulated SerpinB2 Promoter Activity
Phosphorylation of C/EBP-beta is well recognized to modulate its transactivation potential [63]. To investigate C/EBP-beta phosphorylation sites that may be important for LPS-stimulated SerpinB2 proximal promoter activity (Fig. 8B), we co-expressed several C/EBP-beta phospho-acceptor mutants in which the critical threonine or serine residue was mutated to an alanine, along with the pGLmP-539 murine SerpinB2 luciferase reporter in Cebpb-/- MEFs. Re-expression of wild-type C/EBP-beta in Cebpb-/- MEFs significantly stimulated SerpinB2 luciferase reporter gene expression in the presence of LPS by ~3 fold (Fig. 8C, left), confirming the importance of C/EBP-beta to LPS-induced SerpinB2 gene transcription. Expression of the C/EBP-beta phospho-acceptor mutant, C/EBPbetaT217A, in Cebpb-/- MEFs did not significantly increase SerpinB2 promoter activity above that of wild-type C/EBP-beta (Fig. 8C, right); confirming that phosphorylation of C/EBP-beta at T217 is not a major factor in the regulation of SerpinB2 promoter activity in response to LPS.
C/EBP-beta contains additional phosphorylation sites, C/EBP-betaT188 and C/EBP-betaS64 (Fig. 8B), which may be involved in modulating C/EBP-beta-dependent SerpinB2 gene transcription. C/EBP-betaT188 is implicated in regulating DAPK1, an IFNgamma-inducible gene involved in the regulation of cell cycle and apoptosis [38], processes with which SerpinB2 has also been associated [17]. C/EBP-betaS64 is important for LPS-induced transcription of the cytokines IL-6 and MCP-1 [64]. Similarly, SerpinB2 is induced by LPS and regulated in a manner similar to cytokines [29]. Given the similarities in the functional significance of these phospho-specific isoforms of C/EBP-beta and SerpinB2, we investigated whether these phospho-acceptor sites may play a role in SerpinB2 gene expression. C/EBP-betaT188A-transfected MEFs exhibited SerpinB2 promoter activity similar to that of wild-type C/EBP-beta-transfected MEFs, whereas the expression of C/EBP-betaS64A potentiated SerpinB2 promoter activity in response to LPS (Fig. 8C, right). These data suggest that phosphorylation of C/EBP-beta at S64 acts to negatively regulate SerpinB2 proximal promoter activity.","[{'offsets': [[19, 29]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 87]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[125, 135]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[218, 228]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[292, 300]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[363, 398]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[508, 536]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[540, 545]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[582, 592]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[596, 601]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[635, 663]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[760, 770]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[786, 794]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[833, 867]], 'text': ['C/EBP-beta phospho-acceptor mutant'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[869, 883]], 'text': ['C/EBPbetaT217A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[888, 893]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[933, 941]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[984, 994]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1048, 1058]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1110, 1118]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1157, 1167]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1291, 1301]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1312, 1320]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1384, 1389]], 'text': ['DAPK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1394, 1402]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1413, 1417]], 'text': ['gene'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1500, 1508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1614, 1618]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1623, 1628]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1646, 1654]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1818, 1828]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1833, 1841]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1915, 1923]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1941, 1956]], 'text': ['C/EBP-betaT188A'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1984, 1992]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2040, 2050]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2095, 2109]], 'text': ['C/EBP-betaS64A'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2122, 2130]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2229, 2239]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2275, 2283]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T40'}]",[],[],[],[],[]
88,PMC-3218875-02-Pathological_triggers_of_NF-+%A6B_signalling_in_RA,"Since NF-kappaB is central to the process of inflammation in RA, much research deals with the identification of the molecular triggers that activate NF-kappaB in RA. It is well accepted that proinflammatory cytokines such as TNF and IL-1 play an important role, and administration of TNF antagonists is an effective treatment for severe RA (reviewed in [9]). TNF and IL-1 are both very potent activators of NF-kappaB and it can be expected that NF-kappaB activation by these cytokines mediates most of their pro-inflammatory activities in RA (reviewed in [3]).
NF-kappaB activation by receptor activator of NF-kappaB (RANK), a TNF receptor family member, is important for osteoclastogenesis, and defects in proper RANK-NF-kappaB signalling are likely to be involved in RA pathology and other diseases associated with bone loss [7]. CD40 is another TNF receptor family member that is functionally expressed on a variety of cell types, including smooth muscle fibroblasts from normal and RA patients and RA synovial cells, B cells, macrophages, and dendritic cells, and can be upregulated by proinflammatory cytokines including TNF [10]. Binding of the CD40 ligand (CD154), which is transiently expressed on the surface of activated CD4+ T cells, triggers NF-kappaB activation resulting in fibroblast proliferation and secretion of proinflammatory cytokines and chemokines, which contributes to joint destruction. However, studies with antagonistic anti-CD40 or anti-CD154 antibodies led to the conclusion that CD40 signals may be important at the initial stages of arthritis induction, but are not required once disease is established and pathogenic antibodies are already present [11,12]. Enhanced expression of the TNF receptor family member B-cell activating factor (BAFF), allowing the survival of autoantibody- producing B lymphocytes, is also characteristic for RA, and antagonists of BAFF have been developed to counter RA [13]. Finally, lymphotoxin beta receptor signalling has been implicated in tertiary lymphoid organ formation at sites of chronic inflammation including RA [13].
Toll-like receptors (TLRs) have been implicated in a variety of autoimmune diseases and are potential candidates for inducing NF-kappaB-dependent inflammation in RA. In addition to microbial ligands, an increasing number of endogenous ligands - a group of proteins derived from host tissues and cells - have been reported as candidate activators of TLRs inducing so-called sterile inflammation (reviewed in [14,15]). TLRs are expressed in RA synovial tissues and various endogenous ligands are present within the inflamed joints of RA patients. Moreover, animal models using TLR knockout mice or strategies to block TLR signalling clearly identify TLR-dependent inflammation as being important in the pathogenesis of the disease.
High mobility group box chromosomal protein 1 (HMGB1), a highly conserved chromatin component that can be actively secreted by macrophages or passively released by necrotic cells, is one of the most putative endogenous TLR4 ligands involved in RA pathology. HMGB1 is increased in RA synovial tissue and HMGB1 neutralising antibodies or the antagonistic BoxA domain of HMGB1 protect against collagen-induced arthritis in mice [16]. Myeloid-related protein 8 and myeloid-related protein 14, damage-associated molecular pattern molecules belonging to the S100 family of calcium-binding proteins, are also abundantly present in RA synovial fluid, and have been suggested to be involved in TLR4-induced chronic inflammation in RA [17,18]. Other endogenous TLR ligands that may be involved in RA pathology are extracellular matrix components such as fibrinogen, fibronectin, biglycan, tenascin C, and hyal-uronic acid fragments (reviewed in [14,15]). Together, these studies suggest that several TLR ligands in the inflamed joint tissue may contribute to NF-kappaB activation and inflammatory gene expression in RA.","[{'offsets': [[225, 228]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[284, 287]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[359, 362]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[585, 616]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[618, 622]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[714, 718]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[832, 836]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[848, 874]], 'text': ['TNF receptor family member'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1126, 1129]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1151, 1162]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1164, 1169]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1231, 1234]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1509, 1513]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1743, 1767]], 'text': ['B-cell activating factor'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1769, 1773]], 'text': ['BAFF'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1890, 1894]], 'text': ['BAFF'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1944, 1969]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2820, 2865]], 'text': ['High mobility group box chromosomal protein 1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2867, 2872]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2894, 2913]], 'text': ['chromatin component'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3039, 3051]], 'text': ['TLR4 ligands'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3078, 3083]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3123, 3128]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3188, 3193]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3251, 3276]], 'text': ['Myeloid-related protein 8'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3281, 3307]], 'text': ['myeloid-related protein 14'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3505, 3509]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3676, 3687]], 'text': ['fibronectin'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3689, 3697]], 'text': ['biglycan'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3699, 3709]], 'text': ['tenascin C'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
89,PMC-1064895-05-Materials_and_methods,"CD4+ T-cell isolation by MACS
Anti-CD4 microbeads were used essentially as recommended by the manufacturer (Miltenyi) [19]. PBMC were resuspended in 80 mul of FBS staining buffer. Anti-CD4 microbeads (20 mul) were added and incubated for 15 min at 6-12degreesC. Saturating amounts of fluorochrome-conjugated antibodies were added for a further 10 min. Cells were diluted in 2.5 ml of FBS staining buffer, pelleted, resuspended in 500 mul and magnetically separated, usually on an AutoMACS magnet fitted with a MACS MS column. Flow-through and two 1 ml washes were collected as the negative fraction. Enriched cells were collected in two 0.5 ml aliquots from the column after removal from the magnet. Alternatively, cells stained with anti-CD4-phycoerythrin were washed, magnetically labeled with anti-phycoerythrin microbeads (20 mul added to 80 mul of cell suspension; 15 min, 6-12degreesC), and magnetically separated as described above. The purity of cells was assessed by flow cytometric analysis of stained cells on a FACS Vantage sorter. Most (more than 97%) of the isolated cells had the CD4 T cell marker.","[{'offsets': [[0, 3]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[35, 38]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[185, 188]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[739, 742]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1095, 1098]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
90,PMC-1064873-00-TIAB,"Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+T cells from patients with rheumatoid arthritis
IL-10 has been shown to block the antigen-specific T-cell cytokine response by inhibiting the CD28 signaling pathway. We found that peripheral blood CD4+ T cells from patients with active rheumatoid arthritis (RA) were able to produce greater amounts of interferon gamma after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 than were normal control CD4+ T cells, although their surface expression of the type 1 IL-10 receptor was increased. The phosphorylation of signal transducer and activator of transcription 3 was sustained in both blood and synovial tissue CD4+ T cells of RA, but it was not augmented by the presence of 1 ng/ml IL-10. Sera from RA patients induced signal transducer and activator of transcription 3 phosphorylation in normal CD4+ T cells, which was mostly abolished by neutralizing anti-IL-6 antibody. Preincubation of normal CD4+ T cells with IL-6 reduced IL-10-mediated inhibition of interferon gamma production. Blood CD4+ T cells from RA patients contained higher levels of suppressor of cytokine signaling 1 but lower levels of suppressor of cytokine signaling 3 mRNA compared with control CD4+ T cells, as determined by real-time PCR. These results indicate that RA CD4+ T cells become resistant to the immunosuppressive effect of IL-10 before migration into synovial tissue, and this impaired IL-10 signaling may be associated with sustained signal transducer and activator of transcription 3 activation and suppressor of cytokine signaling 1 induction.","[{'offsets': [[14, 19]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 50]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[80, 114]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[118, 121]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[170, 175]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[264, 268]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[319, 322]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[424, 440]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[455, 459]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[501, 506]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[532, 535]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[587, 608]], 'text': ['type 1 IL-10 receptor'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[647, 697]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[746, 749]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[818, 823]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[855, 905]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[932, 935]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[994, 998]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1033, 1036]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1051, 1055]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1064, 1069]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1093, 1109]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1128, 1131]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1185, 1219]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1240, 1274]], 'text': ['suppressor of cytokine signaling 3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1302, 1305]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1379, 1382]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1444, 1449]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1507, 1512]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1556, 1606]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1622, 1656]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
91,PMC-3342329-01-Introduction,"Chemokines are small soluble molecules that are best known for their potent ability to induce cancer cell growth by inflammation. Many types of cancer cells express chemokines and chemokine receptors [1]. The accumulated evidence indicates that the chemokine (C-C motif) ligand 5 (CCL5) and C-C chemokine receptor (CCR5), which are potent chemotactic factors for inflammatory cells, may be significantly involved in the proliferation and metastasis of several cancers. Intermediate and strong CCR5 expression is significantly associated with nonmetastatic development of colorectal cancer [2], melanoma [3], hepatoma [4], glioblastoma, Hodgkin lymphoma [5], as well as oral and prostate cancer cells [6]. Local production of the CCL5 is also important in the progression of breast cancer [7], and also correlates with poor prognosis [8]. Meanwhile, CCR5 disruption has been demonstrated to inhibit experimental tumor growth and metastasis of pancreatic cancer [9]. In addition, host absence of CCR5 potentiates the delay of tumor growth [10], and CCR5 inhibitors prevented cancer cell growth, such as prostate cancer [11], breast cancer, hepatoma cells [4], and lung cancer [12]. These data suggest that the deficiency of inflammatory chemokine receptor CCR5 may function as a suppressive receptor in cancer progression. However, more studies are required to describe how CCR5 deficiency acts in the inhibition of tumor development.
Interleukin-1 receptor antagonist (IL-1Ra), a member of the IL-1 family, is a naturally occurring cytokine that competitively blocks the IL-1 receptor [13]. Because IL-1Ra has been shown to inhibit tumor progression by promoting antitumor immune responses and by enhancing the activity of chemotherapy, numerous studies have examined the ability of IL-1Ra to block tumor progression. IL-1Ra expression was reduced in prostate [14], breast [15], and skin cancer [16]. It was also reported that endogenous IL-1Ra deficient mice developed aggressive tumors following exposure to carcinogens [17]. Meanwhile, proliferation of the melanoma cells that were transduced with IL-1Ra gene was reduced and inhibited melanoma development [18]. IL-1R blockade also reduced hepatic tumor growth [19]. Moreover, it has also been reported that IL-1Ra reduces fibrosarcoma development [20], B16 melanoma growth and metastasis [21], colon adenocarcinoma growth [22], and skin cancer development [23]. IL-1 knockout mice injected with melanoma failed to develop solid tumors [24]. It was also found that IL-1Ra, combined with temozolomide and docetaxel chemotherapy, demonstrated more significant antitumor activity against B16 melanoma cells in vivo [25]. These data indicate that IL-1Ra is important as a tumor growth suppressing cytokine.
NF-kappaB plays a crucial role in the suppression of apoptosis, as well as the induction of cell proliferation and inflammation, and is closely associated with cancer development [26]. Constitutive activation of NF-kappaB has been described in a great number of cancers including colon cancers, prostate cancers and melanoma [27], and was found to up-regulate anti-apoptotic genes and/or down regulate apoptotic gene expression [28]. Although NF-kappaB promotes tumor growth, it is required for the immune system to function normally [29]. Studies on c-Rel-deficient mice demonstrated that c-Rel is essential for IL-2, IL-3, GM-CSF, and IFNgamma expression in T lymphocytes [30]. C-Rel-deficient mice also have a tissue-specific deficiency of various cytokines and growth factors in T cells and macrophages affecting both innate and humoral immune responses in the host [31]. Therefore, NF-kappaB can be specially targeted to prevent cancer cell growth by (1) directly affecting apoptotic cancer cell death, (2) stimulating tumor killing lymphocytes infiltration or (3) increasing the production of tumor killing lymphokines. Activation of NF-kappaB is important in the regulation of CCR-mediated tumor growth and metastasis. It was reported that inhibition of NF-kappaB by dehydroxymethyl-epoxyquinomicin (DHMEQ) induces cell death of primary effusion lymphoma by inhibition of CCR5 expression [32]. Activation of NF-kappaB also increases CCL5-mediated oral cancer motility (5) and lung metastasis [33]. Thus, it is possible that inhibition of NF-kappaB could be involved in CCR5 mediated tumor development.
NF-kappaB transcription factor binding sites are present in the promoter region of proinflammatory cytokine genes, such as IL-1alpha, IL-6, GM-CSF, and KC [34]. On the other hand, the IL-1Ra is a negative regulator of the inflammatory response. Several studies have demonstrated the ability of IL-1Ra to abrogate the proinflammatory effects of IL-1. Smith et al. suggested that the regulation of IL-1Ra gene expression is a complex event involving the interactions of three different transcription factors; NF-kappaB/PU.1/GA-binding protein binding site [35]. Nuclear translocation of NF-kappaB (p65) was significantly enhanced and prolonged in IL-1Ra-deficient mice, compared to that in wild type mice [36]. Intracellular IL-1Ra (icIL-1Ra) was found to inhibit IL-1 by blocking NF-kappaB signal transduction pathways in inflammatory responses [37]. Because IL-1 has been shown to be an inducer of NF-kappaB activation [38], we hypothesized that the expression of IL-1Ra could play an important role in the autocrine activation of transcription factors NF-kappaB or vice versa. Thus, the aim of this study was to evaluate the roles of NF-kappaB and IL-1Ra in the chemokine receptor CCR5-mediated suppression of tumor development.","[{'offsets': [[249, 279]], 'text': ['chemokine (C-C motif) ligand 5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[281, 285]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[291, 313]], 'text': ['C-C chemokine receptor'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[315, 319]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[493, 497]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[729, 733]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[849, 853]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[994, 998]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1047, 1051]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1254, 1258]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1372, 1376]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1433, 1466]], 'text': ['Interleukin-1 receptor antagonist'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1468, 1474]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1531, 1539]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1598, 1604]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1782, 1788]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1817, 1823]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1937, 1943]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2100, 2106]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2261, 2267]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2518, 2524]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2696, 2702]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2746, 2754]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3307, 3312]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3346, 3351]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3369, 3373]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3375, 3379]], 'text': ['IL-3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3381, 3387]], 'text': ['GM-CSF'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4135, 4139]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4196, 4200]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4332, 4336]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4488, 4497]], 'text': ['IL-1alpha'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4499, 4503]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4505, 4511]], 'text': ['GM-CSF'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4517, 4519]], 'text': ['KC'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4549, 4555]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4659, 4665]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4761, 4767]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4882, 4886]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4961, 4964]], 'text': ['p65'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5010, 5016]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5074, 5094]], 'text': ['Intracellular IL-1Ra'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5096, 5104]], 'text': ['icIL-1Ra'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[5329, 5335]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5514, 5520]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5528, 5546]], 'text': ['chemokine receptor'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5547, 5551]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T58'}]",[],[],[],[],[]
92,PMC-1472690-00-TIAB,"beta-(1->3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio
Background
beta-1 to 3-D-glucans represent a pathogen-associated molecular pattern and are able to modify biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells mediated by a fungal beta-1 to 3-D-glucan, i.e. glucan phosphate, in the presence of lipopolysaccharide (LPS) or toxic shock syndrome toxin 1 (TSST-1).
Results
Despite an activation of nuclear factor (NF)kappaB, NFinterleukin(IL)-6 and NFAT similar to LPS or TSST-1, we observed no significant production of IL-1beta, IL-6, tumor necrosis factor alpha or interferon gamma induced by glucan phosphate. Glucan phosphate-treated leukocytes induced a substantial amount of IL-8 (peak at 18 h: 5000 pg/ml), likely due to binding of NFkappaB to a consensus site in the IL-8 promoter. An increase in IL-1receptor antagonist(RA) production (peak at 24 h: 12000 pg/ml) by glucan phosphate-treated cells positively correlated with IL-8 levels. Glucan phosphate induced significant binding to a known NFIL-6 site and a new NFAT site within the IL-1RA promoter, which was confirmed by inhibition experiments. When applied in combination with either LPS or TSST-1 at the same time points, we detected that glucan phosphate elevated the LPS- and the TSST-1-induced DNA binding of NFkappaB, NFIL-6 and NFAT, leading to a synergistic increase of IL-1RA. Further, glucan phosphate modulated the TSST-1-induced inflammatory response via reduction of IL-1beta and IL-6. As a consequence, glucan phosphate shifted the TSST-1-induced IL-1beta/IL-1RA ratio towards an anti-inflammatory phenotype. Subsequently, glucan phosphate decreased the TSST-1-induced, IL-1-dependent production of IL-2.
Conclusion
Thus, beta-1 to 3-D-glucans may induce beneficial effects in the presence of pro-inflammatory responses, downstream of receptor binding and signaling by switching a pro- to an anti-inflammatory IL-1RA-mediated reaction. Our results also offer new insights into the complex regulation of the IL-1RA gene, which can be modulated by a beta-1 to 3-D-glucan.","[{'offsets': [[77, 81]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[127, 135]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[136, 160]], 'text': ['IL-1 receptor antagonist'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[585, 613]], 'text': ['toxic shock syndrome toxin 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[615, 621]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[684, 703]], 'text': ['NFinterleukin(IL)-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[708, 712]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[731, 737]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[780, 788]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[790, 794]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[796, 823]], 'text': ['tumor necrosis factor alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[827, 843]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[941, 945]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1035, 1039]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1065, 1088]], 'text': ['IL-1receptor antagonist'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1089, 1091]], 'text': ['RA'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1193, 1197]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1305, 1311]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1416, 1422]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1508, 1514]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1548, 1554]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1559, 1563]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1602, 1608]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1650, 1656]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1704, 1712]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1717, 1721]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1770, 1776]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1785, 1793]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1794, 1800]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1892, 1898]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1908, 1912]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1937, 1941]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2148, 2154]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2245, 2251]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
93,PMC-3585731-03-Results,"RIP1 Kinase-dependent Activation of Akt Contributes to Necroptosis
Given our observation that growth factors are important for zVAD.fmk induced death, we examined the contribution of several pathways, including MAPK pathways and Akt, which are known to be activated following growth factor receptor activation (Fig. 2A). Inhibition of Akt (Akt inhibitor VIII) strongly protected the cells from growth factor-sensitive necroptosis induced by zVAD.fmk [16] as well as cell death triggered by bFGF or IGF-1/zVAD.fmk under serum free conditions (Fig. 2B). Inhibition of Akt also protected the cells from growth-factor insensitive death by caused by TNFalpha (Fig. 2A). Consistent with previous reports, the JNK inhibitor SP600125 protected the cells from both zVAD.fmk and TNFalpha induced death (Fig. 2A,B and Fig. S2A) [12], [14]. In contrast, inhibition of two other MAPKs, p38 and ERK, previously reported not to be activated during necroptosis [14], did not protect from either zVAD.fmk or TNFalpha induced death (Fig. 2A).
Next, we used two approaches to further validate the role of Akt in necroptotic cell death. First, two additional Akt inhibitors, a highly specific, allosteric kinase inhibitor MK-2206 [25] and triciribine (TCN) [26], which blocks membrane translocation of Akt, both attenuated cell death (Fig. S2B). Secondly, simultaneous knockdown of Akt isoforms Akt1 and Akt2 using siRNAs protected cells from necroptosis induced by both zVAD.fmk and TNFalpha (Fig. 2C). No expression of Akt3 was seen in L929 cells (Fig. S2C) and, consistently, Akt3 siRNA had no additional effect on necroptosis. Our results confirmed that Akt plays a key role in necroptosis induced by multiple stimuli in L929 cells.
To understand the activation of Akt and JNK under necroptotic conditions, we examined the changes in Akt and JNK phosphorylation at 9 hrs post zVAD.fmk and TNFalpha stimulation. This time point was chosen because it reflects the early stage of cell death in our system (Fig. S3A, B). Following stimulation with either zVAD.fmk or TNFalpha we observed a robust increase in Akt phosphorylation at a known major activation site, Thr308 (Fig. 3A). Interestingly, we did not observe concomitant phosphorylation changes in the second major activation site of Akt, Ser473. We also observed an increase in the phosphorylation of both the p46 and p54 isoforms of JNK and its major substrate c-Jun (Fig. 3A). These data indicate that both Akt and JNK are activated under necroptotic conditions.
The RIP1 kinase inhibitor, Nec-1, completely prevented the increase in Thr308 Akt phosphorylation, while Nec-1i did not (Fig. 3A, Fig. S1D). Similarly, Nec-1 prevented the induction of JNK phosphorylation in response to zVAD.fmk and substantially reduced this change after TNFalpha addition. We observed some changes in total protein levels of JNK and c-Jun following necroptotic stimulation. Some of these changes, e.g. zVAD.fmk-induced increase in c-Jun, were also attenuated by Nec-1. Importantly, Nec-1 did not alter the basal phosphorylation levels of either Akt or JNK (Fig. 3A). This established that Akt Thr308 and JNK phosphorylation during necroptosis is RIP1 dependent.
Interestingly, we discovered that the phosphorylation of Akt Thr308, JNK and Jun are late events following zVAD.fmk stimulation (Fig. 3B) that coincide with the onset of necroptosis at 6 hr post-stimulation (Fig. S3A). To better understand the contributions of growth factors and RIP1 kinase to necroptotic regulation of Akt, we next analyzed the time course of these phosphorylation changes under serum free conditions. We found that the addition of bFGF alone or in combination with zVAD.fmk led to a substantial rapid and transient increase in both Thr308 and Ser473 phosphorylation of Akt as well as JNK and c-Jun at 15 minutes, reflecting the expected response to growth factor stimulation (Fig. 3C). Significantly, the combination of bFGF/zVAD.fmk, but not bFGF alone, also caused a robust, second, delayed increase in the phosphorylation of Thr308, but not Ser473, of Akt as well as a delayed increase in the phosphorylation of JNK and Jun. Furthermore, Nec-1 had no significant effect on the early increase in both Akt and JNK/c-Jun phosphorylation triggered by both bFGF and bFGF/zVAD, while Nec-1, but not its inactive analog Nec-1i (Fig. S1E), efficiently blocked the bFGF/zVAD increase at 6-9 hr (Fig. 3D), suggesting that only the delayed activation of Akt and JNK is specific for necroptosis and dependent on RIP1 kinase activity. Similarly, IGF/zVAD, which also promoted cell death under serum free conditions, produced a delayed increase in Thr308 phosphorylation on Akt, while IGF alone caused solely an early, transient increase in phosphorylation (Fig. S3C). We confirmed the kinetics of the Akt Thr308 and Ser473 phosphorylation changes using a quantitative ELISA assay, which also showed a robust delayed necroptosis-specific RIP1-dependent increase in Akt Thr308 phosphorylation (Fig. S3D, E). Taken together, these results indicate that the observed delayed increases in Akt and JNK phosphorylation, preceding the onset of cell death, represent specific consequences of necroptotic signaling downstream from RIP1 kinase.","[{'offsets': [[0, 4]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[490, 494]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[498, 503]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[645, 653]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[769, 777]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[991, 999]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1375, 1379]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1384, 1388]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1464, 1472]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1501, 1505]], 'text': ['Akt3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1559, 1569]], 'text': ['Akt3 siRNA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1873, 1881]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2047, 2055]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2347, 2350]], 'text': ['p46'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2355, 2358]], 'text': ['p54'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2399, 2404]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2506, 2510]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2580, 2583]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2775, 2783]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2854, 2859]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2952, 2957]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3167, 3171]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3463, 3467]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3634, 3638]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3795, 3800]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3923, 3927]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3946, 3950]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4218, 4223]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4258, 4262]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4267, 4271]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4362, 4366]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4506, 4510]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4930, 4934]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5214, 5218]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T37'}]",[],[],[],[],[]
94,PMC-1472690-19-Caption-Figure_2,"NFkappaB p65/p50 and NFATc2/c1 were involved in GP-induced DNA binding. In order to determine whether the DNA binding proteins activated by GP were related to NFkappaB and NFAT, an immuno(dot) blot was performed. A representative dot blot showing staining of negative and positive controls (recombinant proteins NFkappaB p52, c-rel; nuclear extracts of PMA-treated Jurkat cells positive for NFkappaB p50, p65 and for NFATc1, c2) in the upper panel and staining of nuclear extracts of GP-treated PBMC (positive for NFkappaB p65, p50 and NFAT c2, c1) in the lower panel is shown (n = 3).","[{'offsets': [[9, 12]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[13, 16]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[21, 27]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[28, 30]], 'text': ['c1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[172, 176]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[321, 324]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[326, 331]], 'text': ['c-rel'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[400, 403]], 'text': ['p50'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[405, 408]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[417, 423]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[425, 427]], 'text': ['c2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[523, 526]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[528, 531]], 'text': ['p50'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[536, 543]], 'text': ['NFAT c2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[545, 547]], 'text': ['c1'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
95,PMC-3342329-13-Materials_and_Methods,"Immunofluorescence
Sections were treated with 10% bovine serum albumin in PBS for 1 h at room temperature, incubated overnight at 4degreesC with p50 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA), p65 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA), Bax (1:200 dilution), cleaved caspase-3 (1:100), CD8 (1:10), CD57 (1:50) and IL-1Ra (1:500) antibodies, followed by incubation in anti-mouse IgG conjugated with Alexa 488 (1:100 dilution, Molecular Probes, Eugene, OR, USA) and anti-rabbit IgG conjugated with Alexa 568 (1:100 dilution, Molecular Probes) for 40 min at room temperature. Finally, the sections were rinsed, mounted on slides, and cover-slipped for fluorescence microscopy and photography using ApoTome microscopy (Carl Zeiss, Thornwood, NY, USA).","[{'offsets': [[145, 148]], 'text': ['p50'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[200, 203]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[332, 338]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
96,PMC-3320587-11-Materials_and_Methods,"Western blot
Whole cell extracts were collected with lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Triton, 10% glycerol, and 1 tablet of Complete EDTA-free Protease Inhibitor Cocktail (Roche) per 25 ml of buffer. Extracts were boiled for 5 min in 1x Laemmli sample buffer with 5% v/v 2-mercaptoethanol and proteins were separated by SDS-PAGE. The gel was transferred to a nitrocellulose Trans-Blot Transfer Membrane (BioRad). The blot was then blocked for 1 h at 37degreesC in a solution of 4% BSA (Sigma) and 0.1% Tween-20 (BioRad) in a buffer containing 50 mM Tris and 150 mM NaCl at pH 7.6 (BSA/TBST). Primary incubation was carried out with a1:200 dilution of rabbit anti-NFAT5 antibody (H-300) (Santa Cruz Biotechnology) and a 1:500 dilution of goat anti-Lamin-B1 antibody (sc-6217; Santa Cruz Biotechnology) in BSA/TBST for 2 h at room temperature. The blot was washed 3x5 min in TBST and incubated in 1:6000 donkey anti-goat-HRP (Santa Cruz Biotechnology) or goat anti-rabbit-HRP (BioRad) as appropriate for 1 h. The blot was again washed 3x5 min in TBST and developed with SuperSignal West Pico Chemiluminescent Reagent (Pierce).","[{'offsets': [[512, 515]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[835, 838]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
97,PMC-3317373-04-2._Methods_and_Materials,"2.3. Cell Death Measurement by CCK-8 Assay
1 x 103/well cells were seeded to 96-well culture plates and cultivated for 24 h to adhere. Then the cell was scrated as mentioned above. Astrocyte cell death was assessed by cell counting kit-8 (CCK-8) (Dojindo, Japan) assay 24 h after scratch according to the manufacturer's protocol. Briefly, 10 muL CCK-8 was added into every well and incubated for 1 h. Then OD value was read at 450 nm using a Bio-Rad ELISA microplate reader (Bio-Rad Laboratories, CA, USA). All measurements were performed in sextuplicate. Results were expressed as mean of OD value at 450 nm +/- SD.",[],[],[],[],[],[]
98,PMC-1472690-13-Methods,"Preparation of nuclear extracts and electrophoretic mobility shift assays (EMSA)
Nuclear extracts of purified PBMCs were prepared according to a technique described by Trede et al. [27] and modified for our experimental setup [56]. The intensity of shifted bands was normalized to bands of unstimulated controls. Competition experiments with labeled and unlabeled mutated oligos of the cytokine promoter binding sites (see above) were carried out in order to prevent non-specific binding to nuclear proteins. For such experiments, an excess (5-50x) of unlabeled oligos was added to the nuclear extracts. For specificity of binding, supershift assays for NFkappaB with a combined p65/50 antibody were performed (data not shown). To exclude non-specific reactions, a 30-fold molar excess of Oct-1 DNA (unrelated DNA, Table 1) was used, which did not compete with specific binding.","[{'offsets': [[679, 682]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[683, 685]], 'text': ['50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[789, 794]], 'text': ['Oct-1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
99,PMC-1359074-10-Materials_and_Methods,"Quantitation of globin mRNA.
RNA was first reverse transcribed to cDNA. Primers for cDNA PCR amplification of globin genes were obtained from Primerbank [51]. All primers were searched against the NCBI database to confirm specificity. For epsilony globin: MHB1666, 5'TGGCCTGTGGAGTAAGGTCAA3'; and MHB1667, 5'GAAGCAGAGGACAAGTTCCCA3'. For zeta globin: MHB1668, 5'CTACCCCCAGACGAAGACCTA3'; and MHB1669, 5'CTTAACCGCATCCCCTACGG3'. For betaH1 globin: MHB1672, 5'TGGACAACCTCAAGGAGACC3'; and MHB1673, 5'ACCTCTGGGGTGAATTCCTT3'. For betamaj/min globin: MHB1674: 5'ATGGCCTGAATCACTTGGAC3'; and MHB1675, 5'ACGATCATATTGCCCAGGAG3'. Using the SYBR green supermix kit with ROX (Bio-Rad, Hercules, California, United States), PCR amplification was run on an ABI7000 (Applied Biosystems, Foster City, California, United States) at the University of Arizona core facility. All PCR was performed in a 25-mul reaction with 12.5 mul SYBR green supermix. GAPDH mRNA levels were used as control for input RNA. Standard curve analyses were performed to test the efficiency of the amplifications. Triplicates were done for each PCR reaction. Relative quantitative values were calculated in the ABI Prism 7000 SDS Software (Applied Biosystems) and normalized to GAPDH in Microsoft Excel (Redmond, Washington, United States).","[{'offsets': [[239, 254]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[336, 347]], 'text': ['zeta globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[428, 441]], 'text': ['betaH1 globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[521, 528]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[529, 539]], 'text': ['min globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[929, 934]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1232, 1237]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
100,PMC-3291650-13-Materials_and_Methods,"Flow cytometry
Lungs were dissected and incubated with collagenase type IV (1 mg/ml; Sigma) and DNAse (100 U/ml; Roche) at 37degreesC for 30 min. Subsequently, samples were filtered through a 70 microm and 40 microm nylon mesh. For the preparation of BAL, trachea were canulated and airway lumen was flushed 4 times with HBSS with 1 mM EDTA. Cells were stained with monoclonal antibodies directed against MHC-II (I-A/I-E) FITC (M5/114.15.2), CD11c PerCP-Cy5.5 (N418), F4/80 APC (BM8), CD62L PE (MEL-14), Granzyme B FITC (NGZB) from eBiosciences and CD3 Molecular Complex Horizon v450 (17A2), Ly6C Horizon v450 (AL-21), Ly6G PE (1A8), CD11b APC-Cy7 (M1/70), CD8alpha PerCP (53-6.7), IFNgamma Alexa 647 (XMG1.2) and CD16/32 (2.4G2) from BD Pharmingen. Samples were acquired on a LSRII Cytometer and analyzed using FACSDiva software (BD Biosciences). Propidium iodide was used to discriminate between live and dead cells.","[{'offsets': [[55, 74]], 'text': ['collagenase type IV'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[485, 490]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[504, 514]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[549, 552]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[619, 623]], 'text': ['Ly6G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[657, 665]], 'text': ['CD8alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[682, 690]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[714, 718]], 'text': ['CD16'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
101,PMC-3320587-02-Materials_and_Methods,"Ethics statement
In our studies we used unidentified human discarded blood cells (peripheral blood mononuclear cells, PBMC), which we obtained from the Blood Bank of Children's Hospital in Boston.",[],[],[],[],[],[]
102,PMC-1472690-06-Results,"Inhibition of transcription factors led to reduced IL-1RA levels
Pharmacological inhibitors were used to demonstrate that the transcription factor sites within the IL-1RA promoter are relevant for the induction of IL-1RA by GP. As expected, an inhibition of NFkappaB via CAPE [35] and CyA, NFAT via CyA and NFIL-6 via CHX [36] could not be overruled by GP, leading to a down-regulated binding activity of the transcription factors to the IL-1RA sites, and a reduction of IL-1RA mRNA and IL-1RA protein levels (Fig. 7). The extent of reduction in NFATP2/3 binding is exemplarily shown in an autoradiogram (Fig. 7A, left side) and graphically summarized (n = 4, Fig. 7A, right side). The results for the NFkappaB and NFIL-6 binding sites were similar (data not shown). Because the highest IL-1RA amount was found at 24 h, mRNA was examined following 1 h inhibition and 18 h of GP. A representative gel demonstrating a decrease in IL-1RA mRNA after inhibition with CAPE, CyA and CHX is displayed in Fig. 7B (n = 4). In addition, corresponding IL-1RA protein levels after 24 h of GP are shown in Fig. 7C (n = 3). Altogether, NFkappaB inhibition by CAPE was more pronounced at the binding activity and the transcription, whereas CyA and CHX mainly led to a decreased IL-1RA release.","[{'offsets': [[51, 57]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[164, 170]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[214, 220]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[290, 294]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 313]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[438, 444]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[471, 477]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[487, 493]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[787, 793]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[928, 934]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1040, 1046]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1262, 1268]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
103,PMC-3585731-26-Caption-Figure_1,"bFGF and IGF-1 promote necroptosis in concert with zVAD.fmk.
(A) L929 cells were treated with TNFalpha or zVAD.fmk under normal serum (10% FBS) or serum free conditions. Cell viability was determined after 24 hr using the CellTiter-Glo Viability assay. The concentrations of all necroptosis-inducing agents are listed in the Materials and Methods section or indicated in the figures. (B) Cells were treated with zVAD.fmk, the indicated growth factors, and Nec-1 under serum free conditions for 24 hrs followed by measurement of cell viability. (C) Cells under serum free conditions were treated with FGF, zVAD.fmk, or both for 24 hrs followed by viability assay. (D) Cell death was induced by zVAD.fmk or TNFalpha under full serum condition in the presence of 2 microM PD173074 and 20 microM PD166866. In all graphs, average+/-SD was plotted.","[{'offsets': [[0, 4]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[9, 14]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[94, 102]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[705, 713]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
104,PMC-3312845-07-Methods,"Double immunofluorescence study
Sections were incubated with 3% bovine serum albumin in PBS for 30 min at room temperature. Sections were then incubated in a mixture of goat anti-TNF-alpha IgG (1:1000, R&D systems, Minneapolis, MN)/mouse anti-OX-42 IgG (1:100, Serotec, Cambridge, UK), mouse anti-GFAP IgG (1:1000, an astroglial marker, Millipore Corporation, Billerica, MA)/rabbit anti-TNFp55R IgG (1:1000, Abcam, Cambridge, UK), mouse anti-GFAP IgG/rabbit anti-TNFp75R IgG (1:1000, Abcam, Cambridge, UK), mouse anti-SMI-71 IgM (1:1000, Covance, Berkeley, CA)/rabbit anti-TNFp75R IgG, mouse anti-GFAP IgG/rabbit anti-NF-kappaB (p65-Ser276, p65-Ser311, p65-Ser529, and p65-Thr435) IgG (1:100, Abcam, Cambridge, UK), mouse anti-SMI-71 IgM/rabbit anti-p65-Thr435 NF-kappaB IgG, mouse anti-SMI-71 IgM/rabbit anti-GLUT-1 IgG (1:100, Abcam, Cambridge, UK), or mouse anti-GFAP IgG/rabbit anti-MIP-2 IgG (1:100) in PBS containing 0.3% triton X-100 overnight at room temperature. After washing three times for 10 minutes with PBS, sections were also incubated in a mixture of FITC- and Cy3-conjugated secondary antisera (Amersham, San Francisco, CA), diluted 1:200, for 2 hr at room temperature. The sections were washed three times for 10 min with PBS, and mounted on gelatin-coated slides. For nuclei counterstaining, we used Vectashield mounting medium with DAPI (Vector, Burlingame, CA). All images were captured using an AxioImage M2 microscope and AxioVision Rel. 4.8 software.","[{'offsets': [[71, 84]], 'text': ['serum albumin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
105,PMC-3320587-16-Results,"MTb increases NFAT5 mRNA levels in human MDM
Given that macrophages, which are the primary target of MTb infection, are also a major reservoir of HIV-1 as infection progresses [40], we next investigated whether MTb is able to directly enhance NFAT5 mRNA expression in primary human MDM. We prepared MDM from five normal donors, stimulated the cells with the MTb lysate or left them unstimulated, and measured NFAT5 gene expression levels by quantitative real-time PCR at 24 and 48 hours. We also investigated whether HIV-1 infection is capable of inducing NFAT5 mRNA synthesis by infecting MDM with live or heat-inactivated R5-tropic representatives of subtype B (HIV-1Bal), C (HIV-198IN22), or E (HIV-192TH64). As shown in Figure 2A, stimulation with MTb lysate significantly increased NFAT5 mRNA levels at 24 (p<0.05) and 48 (p<0.01) hours, whereas infection with viable or heat-inactivated HIV-1 isolates did not increase NFAT5 mRNA levels (Figure 2A). Thus, MTb specifically enhances NFAT5 mRNA expression in human MDM, and this response continues to increase for at least 48 hours post-stimulation (Figure 2A).","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[243, 248]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[409, 414]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[556, 561]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[787, 792]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[925, 930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[988, 993]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
106,PMC-3589482-05-Experimental_Procedures,"Western Blot Assays
Whole cell lysates were prepared in RIPA buffer (10 mM Tris, 150 mM NaCl, 1%Triton X-100, 0.5% NP-40, 0.5% deoxycholate, 0.1% SDS), proteins were separated on 4-12% Bis-Tris NuPAGE gels (Invitrogen), and transferred to PVDF membranes. Membranes were subsequently blocked with 5% milk in PBS-T (1X PBS, 0.1% Tween-20), and incubated with primary antibodies overnight. Affinity purified rabbit anti-mouse SerpinB2 antibodies were prepared after immunization with a purified recombinant GST-murine SerpinB2 fusion protein produced in E. coli as in [35]. Other antibodies used for western blot assays include: C/EBP-beta (sc-150) (Santa Cruz Biotechnologies), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alpha/beta tubulin (Cell Signaling Technology, Inc.).","[{'offsets': [[504, 538]], 'text': ['GST-murine SerpinB2 fusion protein'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[626, 636]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[676, 716]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[718, 723]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
107,PMC-2817507-04-2._Methods,"2.3. Detection of TLR4 mRNA by the Method of RT-PCR
Briefly, total RNA samples were isolated from peri-hemorrhage regions in left basal ganglia using Simply P Total RNA isolation Kit (BioFlux, HZ, China) according to the manufacturer's instructions. The quantity of total RNA was determined on a Nanodrop (ND-1000 Spectrophotometer) by measuring optical density at A260 and A280 nm wavelength. Then, the concentrations of mRNA were adjusted to 1.0 g/mL. RNA was reverse-transcribed into cDNA in 20 muL reaction system using Superscript First-Strand Synthesis Kit for RT-PCR (promega Inc) under conditions described by the supplier. One microliter of cDNA was used to amplify the TLR4 gene fragment with 1x PCR buffer, 1.5 mM MgCl2, 200 muM of each dNTP, 200 muM of primers, and 2u Taq DNA polymerase. The house keep gene (beta-actin) was used as an internal control. The PCR primer sequences were designed according to the TLR4 and beta-actin gene sequences reported in GenBank. TLR4 (145 bp): forward: 5'-AGCTTTGGTCAGTTGGCTCT-3'; reverse: 5'-CAGGATGACACCATTGAAGC-3'; beta-actin (701 bp): forward: 5'-GCCAACCGTGAAAAAGATG-3'; reverse: 5'-CCAGGATAGAGCCACCAAT-3'. Reaction cycles were performed at the following condition: 94degreesC 2 min, 94degreesC 40 s, 55degreesC 40 s, and 72degreesC 60 s. The reaction was stopped after 31 cycles. PCR products were electrophoresed through agarose gel. Image Acquisition and Analysis software were used to determine band densities. The abundance of TLR4 mRNA was expressed as the ratio of TLR4 mRNA to beta-actin mRNA.","[{'offsets': [[18, 22]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[679, 683]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[781, 799]], 'text': ['Taq DNA polymerase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[801, 820]], 'text': ['The house keep gene'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[822, 832]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[923, 927]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[932, 942]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[979, 983]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1068, 1078]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1486, 1490]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1526, 1530]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1539, 1549]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
108,PMC-3342329-07-Discussion,"In the present study, we found that tumor weight and volume were much smaller in the CCR5-/- mice compared to the CCR5+/+ mice inoculated with B16 melanoma cells (Figure 1A and 1B). The tumor growth inhibition in the CCR5-/- mice was associated with the inhibition of constitutively activated NF-kappaB and elevation of IL-1Ra in the tumor tissue. This anti-tumor activity was also associated with decreased expression of NF-kappaB target anti-apoptotic, cell proliferative, and tumor promoting genes (Bcl-2 and C-IAP1) but with increased expression of their target apoptotic genes; cleaved caspase-3 and 9, and Bax (Figure 3A-D). In the tumor and the spleen, the number of cytotoxic CD8+ T cells, CD57+ natural killer cells, and the levels of IL-1Ra were increased (Figure 4 and 5). These findings suggest that melanoma growth was inhibited in the CCR5-/- mice, and that the elevation of IL-1Ra, accompanied with decreased NF-kappaB, is significant in the inhibition of melanoma growth in CCR5-/- mice.
NF-kappaB regulates the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]. Because of its abilities to induce the expression of a large array of inflammatory mediators and its roles as core transcription factors in diverse immune responses, NF-kappaB has been recognized as a major factor responsible for cytokine-associated cancer development or anti-tumor immunity. In the melanoma tumor tissues of the CCR5-/- mice, the expression of NF-kappaB target cell death genes (Bax, caspase-3 and 9) and the DNA binding activity of NF-kappaB, were significantly inhibited, but the expression of cell death inhibitory NF-kappaB target genes, such as Bcl-2 and cIAP were enhanced. In addition, CCR5-/- prevented the phosphorylation of IkappaB, accompanied with the inhibition of the p50 and p65 translocation into the nucleus (Figure 2A-C). Many tumors, including melanoma, have increased levels of NF-kappaB [40], which is likely acting as a survival factor for melanoma growth. Thus, the inhibitions of NF-kappaB activity and the expression of target genes are critical in the inhibition of tumor growth in CCR5-/- mice. Although the mechanism is not clear as to how CCR5-/- downregulates NF-kappaB, it is noteworthy that NF-kappaB is activated or inactivated by many cytokines.
Numerous studies showed that cytokine affect tumor growth by regulating NF-kappaB. Inflammatory cytokines, including IL-1, IL-6 and IL-8, activate NF-kappaB pathways in tumor cells [41]. The interleukin 10 (IL-10) is well known as an anti-tumor factor as well as an anti-inflammatory factor [42], [43]. IL-10 inhibits constitutively activated NF-kappaB both in vitro [44] and in vivo [45]. Inhibition of NF-kappaB by the IL-10 contributes to the anti-tumor effects through the activation of caspase-3 and apoptosis in Colon26-bearing mice [43]. Similarly, several studies have demonstrated the ability of IL-1Ra to abrogate the proinflammatory effects of IL-1 [46]. It has been reported that IL-1 induces the activation of NF-kappaB in several cancers, and increases cell cycle progression, and the suppression of apoptotic cell death leading to tumor promotion. The results of various studies over the past 10 years indicate that the major function of IL-1Ra is to regulate the pleiotropic effects of IL-1 by competitively blocking its functions [47]. The ability of IL-1 to induce its own antagonist is of interest in understanding the regulation and dysregulation of IL-1 signaling in normal and diseased tissue. Up-regulation of the receptor antagonist represents a mechanism for turning off IL-1 signaling and creating a temporary state of refractoriness. The elevated expression of IL-1Ra, without any change of IL-1 in tumors, suggests that the IL-1-signaling system may be dysregulated by IL-1Ra in tumors. IL-1Ra has been shown to inhibit tumor progression in prostate, breast, and skin cancer [14], [15], [16]. Intracellular IL-1Ra (icIL-1Ra) inhibits IL-6 and IL-8 production in Caco-2 cells by blocking NF-kappaB pathways [37]. We found that the levels of IL-1Ra were significantly elevated in the tumor tissues of CCR5-/- mice inoculated with B16 melanoma cells. Taken together, these data indicate IL-1Ra could be critically involved in the tumor growth inhibition of CCR5-/- mice through the inactivation of NF-kappaB in the present study.
CCR5 increases tumor growth in a local model and inhibits the efficacy of a dendrite cell vaccine in CCR5+/+ mice compared with CCR5-/- mice [10]. Cheng J and Sung RS examined the effect of CCR5 on the immune response to adenovirus vectors and graft function in an islet transplant model. They found that CCR5 absence does not prevent the local immune response to adenovirus transduction [48]. Additionally, Tan MC et al. suggested that disruption of CCR5/CCL5 signaling, either by reducing CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor (TAK-779), reduced Treg (regulatory T cells) migration to tumors so that tumors are smaller in control mice [9]. These data support the important premise that inhibition of tumor growth in CCR5-/- mice could be related with the inhibition of immune escape. Similar to this finding, we found that the CCR5+/+ mice injected with melanoma cells apparently have a lower number of cytotoxic T cells (CD8+positive T Lymphocytes cells) and natural killer cells (CD57 positive NK cells), as well as dendrite cells, in spleen tissues compared to those without melanoma cells. But the lymphocytes of the CCR5-/- mice did not decrease when injected with melanoma cells. These differences of the immune response between the CCR5+/+ mice and the CCR5-/- mice, involving tumor immune tolerance, may be connected with the inhibition of cancer progression. Taken together, in the cytokine array experiment, the level of MIP-1alpha (which has a potent activity of T cell and B cell migration) was increased in the CCR5-/- mice compared with those in the CCR5+/+ mice. Thus, relatively increased tumor associated cytotoxic lymphocytes could play an important role in inhibiting the tumor growth in CCR5-/- mice.
Activation of NF-kappaB could modulate subcellular localization of NK cells and pathogenesis [49]. Inhibition of NF-kappaB activity prevented NK cell depletion, and thus increased anti-tumor activity by decreasing IL-6 production [50]. Thus, the decreased NF-kappaB and elevated IL-1Ra could also be associated in the infiltration of cytotoxic lymphocytes into tumor, resulting in tumor growth inhibition. In contrast, IL-23, a tumor growth promoting cytokine, increased NF-kappaB and immune cell infiltration in oral tumor [51]. These data indicate that NF-kappaB could be involved in the cytokine mediated anti-tumor activities of immune cells. It is also noteworthy that IL-1Ra inhibited melanoma tumor growth by increasing the number of myeloid suppressor cells in tumor [25]. The 3-methylcholatrene-induced tumor incidence was reduced in IL-1alpha knockout mice, but increased in IL-1Ra mice with concomitant maturation of NK cells and anti-tumor immunity [52]. These data indicate that the decrease of NF-kappaB, and thus increase of IL-1Ra could be significant in tumor growth inhibition of CCR5-/- mice.
Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein-coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-kappaB/IL-1Ra pathways in CCR5-/- mice.","[{'offsets': [[85, 89]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[114, 118]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[217, 221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[320, 326]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[512, 518]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[744, 750]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[849, 853]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[889, 895]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[990, 994]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1461, 1465]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1742, 1746]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1831, 1834]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1839, 1842]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2157, 2161]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2217, 2221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2452, 2456]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2520, 2534]], 'text': ['interleukin 10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2536, 2541]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2632, 2637]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2750, 2755]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2934, 2940]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3282, 3288]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3717, 3723]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3826, 3832]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3950, 3970]], 'text': ['Intracellular IL-1Ra'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3972, 3980]], 'text': ['icIL-1Ra'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3991, 3995]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4097, 4103]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4156, 4160]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4241, 4247]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4311, 4315]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4384, 4388]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4485, 4489]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4512, 4516]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4574, 4578]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4689, 4693]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4835, 4839]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4840, 4844]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4875, 4879]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4941, 4945]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5145, 5149]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5256, 5260]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5550, 5554]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[5668, 5672]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[5689, 5693]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5860, 5870]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5953, 5957]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5993, 5997]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6136, 6140]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[6364, 6368]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[6429, 6435]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[6824, 6830]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[6993, 7002]], 'text': ['IL-1alpha'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[7035, 7041]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[7190, 7196]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[7248, 7252]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[7318, 7322]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[7332, 7336]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[7437, 7441]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[7583, 7587]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7745, 7751]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7764, 7768]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T82'}]",[],[],[],[],[]
109,PMC-3218875-01-Introduction,"Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting up to 1% of the adult population. RA is characterised by a symmetrical polyarthritis in which chronic inflammation of joints is associated with a progressive destruction of cartilage and bone, leading to functional decline and disability. Infiltration of cells of the innate and adaptive immune system into the joint space drives the local production of proinflammatory T-helper type 1 and T-helper type 17 cytokines, chemokines, and matrix metalloproteinases by infiltrating monocytes and synovial cells. Proliferation of synovial fibroblasts leads to the formation of pannus tissue, which invades and degrades articular cartilage and subchondral bone.
The aetiology of RA is still not understood, but it is well accepted that activation of NF-kappaB-dependent gene expression plays a key role in the development of RA and many other autoimmune diseases. NF-kappaB represents a family of structurally related and evolutionarily conserved proteins (p100 or NF-kappaB2, p105 or NF-kappaB1, p65 or RelA, RelB, c-Rel) that function as homodimers or heterodimers [1], and that regulate the expression of a large number of genes - such as TNF, IL-1, IL-6, cyclo-oxygenase-2, chemokines, inducible nitric oxide synthase, and matrix metalloproteinases - that are involved in RA. In addition, TNF and IL-1 are themselves very potent activators of NF-kappaB (reviewed in [2,3]).
NF-kappaB activation can be detected in cultured synovial fibroblasts and synovial tissue from RA patients, and animal models of inflammatory arthritis also demonstrate the active role of NF-kappaB in the development and progression of RA (reviewed in [4]). The time course of NF-kappaB activation appears to precede the onset of disease, and blockade of NF-kappaB by different means decreases disease severity [5,6].
Next to its role in proinflammatory gene expression, NF-kappaB is also essential for osteoclastogenesis, mainly by mediating the effects of receptor activator of NF-kappaB ligand (RANKL). Defects in the regulation of osteoclastogenesis are the major cause of bone erosion in osteolytic diseases such as RA [7].
Finally, recent discoveries revealing a genetic association with several genes relevant to NF-kappaB signalling, including CD40, TRAF1, TNFAIP3, and c-REL, further highlight the importance of NF-kappaB activation in RA pathogenesis [8].","[{'offsets': [[1028, 1032]], 'text': ['p100'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1036, 1046]], 'text': ['NF-kappaB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1048, 1052]], 'text': ['p105'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1056, 1066]], 'text': ['NF-kappaB1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1068, 1071]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1075, 1079]], 'text': ['RelA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1081, 1085]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1087, 1092]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1213, 1216]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1224, 1228]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1230, 1247]], 'text': ['cyclo-oxygenase-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1261, 1292]], 'text': ['inducible nitric oxide synthase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1364, 1367]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2007, 2045]], 'text': ['receptor activator of NF-kappaB ligand'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2047, 2052]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2301, 2305]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2307, 2312]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2314, 2321]], 'text': ['TNFAIP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2327, 2332]], 'text': ['c-REL'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
110,PMC-1359074-06-Results,"The Expression Pattern of Sox6 Suggests a Role in Definitive Erythropoiesis
The observation that Sox6-deficient mice ectopically express epsilony globin in liver, where definitive erythroid cells mature, suggests that Sox6 is an important regulator in definitive erythropoiesis. To determine the temporal and spatial expression pattern of Sox6, Northern blot and in situ hybridization assays were employed. As shown in Figure 6A, Sox6 is detectable by Northern blot beginning at 10.5 dpc, coincident with the temporal onset of definitive erythropoiesis in the liver. Furthermore, in situ hybridization shows that Sox6 is highly transcribed in 12.5-dpc liver, but not in yolk sac blood islands at 7.5 dpc (Figure 6B). Therefore, Sox6 expression is temporally and spatially coincident with definitive, but not primitive, erythropoiesis. These data, taken together with the observation that epsilony globin is highly expressed in the liver cells of 14.5-dpc p100H mutant mice (Figure 5), demonstrate that Sox6 functions in definitive erythropoiesis.","[{'offsets': [[26, 30]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 101]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 152]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[218, 222]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[339, 343]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[430, 434]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[613, 617]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[728, 732]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[888, 903]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1002, 1006]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
111,PMC-3317373-13-3._Results,"3.3. Expression of Proinflammatory Cytokines Was Elevated in Nrf2 Knockout Astrocytes after Scratch Injury
As we all know, TNF-alpha, IL-1beta, and IL-6 are regulated by NF-kappaB and reflect the endogenous activity of NF-kappaB. It has been revealed that these proinflammatory cytokines are increased after TBI in animals [2, 8]. And our previous study has proved that higher levels of such proinflammatory cytokines were observed in the brain of Nrf2-deficient mice after TBI [5]. But it is still ambiguous about the relationship between these cytokines and Nrf2 in astrocytes after TBI. Here, we tested the levels of TNF-alpha, IL-1beta, and IL-6 in cultured astrocytes at 24 h after scratch injury by RT-PCR and ELISA. It was shown that the mRNA levels of TNF-alpha, IL-1beta, and IL-6 were increased after scratch in both WT and KO astrocytes when compared with their sham counterparts, respectively. Moreover, the mRNA levels of these cytokines in group KO TBI were much higher than those in group WT TBI (1.66 +/- 0.085 versus 1.39 +/- 0.110 for TNF-alpha, 1.34 +/- 0.064 versus 0.73 +/- 0.088 for IL-1beta, and 1.28 +/- 0.102 versus 0.99 +/- 0.073 for IL-6. P < 0.01) (Figures 3(a)-3(d)). The results of ELISA revealed that the protein level of TNF-alpha was upregulated after scratch injury in WT and KO astrocytes when compared with their sham counterparts. And it was also higher in group KO TBI than in group WT TBI (3.67 +/- 0.156 versus 2.31 +/- 0.087, P < 0.01) (Figure 4(a)). Similar tendency was observed in protein level of IL-6 and IL-1beta. For IL-6, it was 36.07 +/- 0.786 for group KO TBI while 25.76 +/- 0.536 for group WT TBI (P < 0.01) (Figure 4(b)). For IL-1beta, it was 190.75 +/- 6.339 for group KO TBI while 154.50 +/- 5.348 for group WT TBI (P < 0.01) (Figure 4(c)).","[{'offsets': [[134, 142]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 152]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[631, 639]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[645, 649]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[771, 779]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[785, 789]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1105, 1113]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1160, 1164]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1542, 1546]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1551, 1559]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1565, 1569]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1680, 1688]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
112,PMC-3589482-10-Experimental_Procedures,"Electrophoretic Mobility Shift Assays
Radiolabelled, double-stranded oligonucleotide probes for gel shift assays were prepared using T4 polynucleotide kinase and [gamma-32P]-ATP. RAW 264.7 nuclear extracts were prepared by the detergent lysis method [41]. DNA binding reactions (25 microl) containing 10 mM HEPES pH 7.9, 10 microg/ml BSA, 2 mM DTT, 30% glycerol, 20% Ficoll-400, 1 microg poly (dI-dC), 6 microg of nuclear extracts and 10,000 to 20,000 cpm (0.05 to 0.2 ng) of radiolabelled probe were performed for 20 minutes at room temperature. Binding reaction products were resolved by electrophoresis at room temperature on 5% polyacrylamide gels (29:1 acrylamide:bis-acrylamide (Bio-Rad)) in 1x TBE at 10V/cm. For supershift assays, nuclear extracts were pre-incubated 2 hrs on ice with 4 microg of specific C/EBP antibody. Antibodies were purchased from Santa Cruz: anti-C/EBP-alpha (sc-61), anti-C/EBP-beta (sc-150), anti-C/EBP-delta (sc-151) and anti-C/EBP-epsilon (sc-158).","[{'offsets': [[133, 157]], 'text': ['T4 polynucleotide kinase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
113,PMC-3586680-04-p53_Isoforms,"At least nine isoforms of p53 have been identified due to alternative mRNA splicing, multiple gene promoters, and alternative initiation sites of translation (Ghosh et al., 2004; Ray et al., 2006; Figure 2). In cancers, aberrant expression of p53 isoforms occurs frequently (Bourdon et al., 2005; Bourdon, 2007). Full-length p53, delta133p53, and p53beta are localized mainly in the nucleus, and only few of them are in cytoplasm. p53gamma and delta133p53beta are localized in the nucleus and cytoplasm. delta133p53gamma is localized in the cytoplasm (Bourdon et al., 2005). Co-transfection of p53 and p53beta increases p53-mediated apoptosis, whereas co-expression of p53 with delta133p53 suppresses p53-mediated apoptosis (Bourdon et al., 2005). delta133p53 differentially regulates gene expression in p53-dependent and -independent manners (Aoubala et al., 2011). Co-expression of delta133p53beta or delta133p53gamma with p53 does not affect p53 transcriptional activity on p21 and Bax promoters, as well as apoptosis.","[{'offsets': [[26, 29]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[243, 246]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[325, 328]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[330, 341]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[347, 354]], 'text': ['p53beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 439]], 'text': ['p53gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[444, 459]], 'text': ['delta133p53beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[504, 520]], 'text': ['delta133p53gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[594, 597]], 'text': ['p53'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[602, 609]], 'text': ['p53beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 623]], 'text': ['p53'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[669, 672]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[678, 689]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[701, 704]], 'text': ['p53'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[748, 759]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[804, 807]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[884, 899]], 'text': ['delta133p53beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[903, 919]], 'text': ['delta133p53gamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[925, 928]], 'text': ['p53'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[945, 948]], 'text': ['p53'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[977, 980]], 'text': ['p21'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[985, 988]], 'text': ['Bax'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
114,PMC-3342329-05-Results,"Upregulation of IL-1Ra in the Tumor and Spleen of CCR5-/- Mice
To investigate the difference in the cytokine levels between the tumor and spleen tissues of the CCR5+/+ and CCR5-/- mice, we conducted a cytokine array assay using a Mouse Proteome Array (Figure 4A). Among 40 tested cytokines, the levels of IL-1Ra, MIG, MIP-1alpha increased about 686, 9 and 25-fold respectively, in CCR5-/- mice compared to CCR5+/+ mice. Using this technique, no other cytokines were found to be different between the CCR5-/- mice and the CCR5+/+ mice (Figure 4B). Similar altered cytokine levels were found in the spleens of CCR5-/- mice (Figure 4C). Since the IL-1Ra level was the most significantly elevated, the expression of IL-1Ra in tumor and spleen tissues was analyzed by immunofluorescence and western blotting. The expression of IL-1Ra was upregulated in tumor and spleen tissues of the CCR5-/- mice (Figure 4D-G).","[{'offsets': [[16, 22]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[160, 164]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 176]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[305, 311]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[313, 316]], 'text': ['MIG'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[318, 328]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[381, 385]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[406, 410]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[500, 504]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[521, 525]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[608, 612]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[644, 650]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[712, 718]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[822, 828]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[880, 884]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
115,PMC-3312845-19-Caption-Figure_1,Expression of TNF-alpha and TNF receptor in the PC 12 hr-post SE. (A) TNF-alpha immunoreactivity in Ox-42-positive microglia (arrows). (B) TNFp55R expression in astrocytes (arrows). (C-D) TNFp75R expression in astrocytes as well as endothelial cells (arrows). Bar = 25 (A-D) mum.,"[{'offsets': [[14, 23]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 79]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[139, 146]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[188, 195]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
116,PMC-3589482-17-Results,"The C/EBP Element is Bound by an LPS-induced Nuclear Factor from RAW 264.7 Macrophages
Nuclear factor binding to the putative C/EBP element (-203/-192) was investigated by electrophoretic mobility shift assay (EMSA) using nuclear extracts from untreated and LPS-treated RAW 264.7 macrophages. Three different double stranded oligonucleotide probes were used for EMSA, representing (1) the putative SerpinB2 C/EBP element (-203/-192), (2) a mutant SerpinB2 element containing the same mutation as in pGLmP-539mC/EBP and (3) the rat albumin promoter distal element 1 (DEI) region containing a high affinity C/EBP binding site. Four bands of different mobilities, representing DNA-nuclear protein complexes were detected (Fig. 5A). Three of these bands (I, II, III) represent complexes with single stranded DNA (Fig. 5A) while the uppermost (slowest migrating) complex was induced by LPS. The LPS-inducible complex was not detected using the mutant C/EBP oligonucleotide probe and could be abolished by an excess of unlabeled double-stranded oligonucleotide, carrying either the same sequence (Fig. 5B, lanes 4 and 5) or the sequence of a known C/EBP binding site from the rat albumin promoter (Fig. 5B, lanes 8 and 9), but not by the mutated oligonucleotide (Fig. 5B, lanes 6 and 7). Together these data indicate that the putative SerpinB2 C/EBP site at -203/-192 binds a LPS-inducible complex that is likely to contain a member of the C/EBP family of transcription factors.","[{'offsets': [[398, 406]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[447, 455]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[531, 538]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1174, 1181]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1329, 1337]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
117,PMC-1064873-11-Results,"Increased expression of cell surface IL-10R1 on RA CD4+ T cells
The functional receptor complex of IL-10 consists of two subunits, the primary ligand-binding component IL-10R1 and the accessory component type 2 IL-10R [1]. IL-10R1 expression plays a critical role in cellular responses to IL-10 [29]. To examine whether the resistance to IL-10 inhibition in RA CD4+ T cells was due to limited receptor expression, the cell surface expression of IL-10R1 on PB CD4+ T cells from active RA patients and from healthy controls was determined by flow cytometric analysis. As shown in Fig. 3a,3b, the intensity of IL-10R1 expression on CD4+ T cells was significantly increased in RA patients compared with in healthy controls. These results suggest that the intracellular signal transduction pathway of IL-10 may be impaired in CD4+ T cells of active RA.","[{'offsets': [[37, 44]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 54]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[99, 104]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[168, 175]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[204, 217]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[223, 230]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[289, 294]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[338, 343]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[361, 364]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[445, 452]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[459, 462]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[607, 614]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[629, 632]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[796, 801]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[821, 824]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
118,PMC-3320587-21-Results,"MTb induces NFAT5 gene expression via the MyD88-dependent signaling cascade
To begin to decipher the cellular mechanisms underlying NFAT5-dependent, MTb-induced HIV-1 replication, we next investigated the requirement for specific signaling molecules in the TLR pathway that are required for MTb stimulation of NFAT5 gene expression. We began by examining the requirement of TLR2 ligation in enhancing NFAT5 mRNA levels. When THP-1 cells were treated with the TLR2-specific agonist Pam3Cys for 16 hours, NFAT5 mRNA levels were significantly increased in Pam3Cys-stimulated cells as compared to mock-stimulated control cells (Figure 7A). As a positive control for this experiment we also infected THP-1 cells with CDC1551 (Figure 7A). Notably, MTb infection enhanced NFAT5 mRNA levels to a greater extent than Pam3Cys stimulation, suggesting that additional PRRs may be triggered during actual MTb infection, augmenting its stimulatory effect on NFAT5 gene expression (Figure 7A).
The adaptor molecule MyD88 transmits signals upon TLR2 ligation (reviewed in [53]). To confirm that this protein and, therefore, that this TLR-dependent pathway is important for MTb induction of NFAT5 gene expression, we constructed a THP-1 cell line that constitutively expresses a lentivirally-delivered short hairpin (sh)RNA targeting MyD88. Real-time PCR analysis demonstrated that MyD88 mRNA levels in these cells were constitutively and significantly reduced in comparison to control THP-1 cells transduced with a lentivirus expressing control GFP shRNA (data not shown). These MyD88 knockdown THP-1 cells were then infected with MTb (CDC1551) and NFAT5 mRNA levels were examined. Since TNF is a MyD88-dependent gene [21], [54], [55], as a positive control we measured TNF mRNA levels. For a negative control, we measured mRNA levels of the MyD88-independent gene CD86 [55], [56]. As shown in Figure 7B, knockdown of MyD88 specifically inhibited MTb-induced NFAT5 and TNF mRNA levels and had no impact on CD86 mRNA levels. Thus, MTb regulation of NFAT5 is dependent upon MyD88.
To futher dissect the pathway mediating MTb upregulation of NFAT5 transcription, we also constructed THP-1 cells transduced with lentivirally-delivered shRNAs targeting IRAK1 or TRAF6, two signaling molecules downstream of MyD88. As shown in Figures 7C and 7D, knockdown of both IRAK1 and TRAF6 significantly inhibited MTb induced NFAT5 mRNA levels. As expected, MTb-induced TNF gene expression was also significantly reduced (Figures 7C-7D), consistent with a role for IRAK1 and TRAF6 in TNF gene expression secondary to MTb infection as previously reported. Although CD86 gene expression did not depend on MyD88 (Figure 7B), abrogation of IRAK1 and TRAF6 gene expression significantly reduced CD86 mRNA levels, indicating that CD86 expression is IRAK1- and TRAF6-dependent, but MyD88-independent in MTb-infected monocytes (Figures 7C-7D). Taken together, these results clearly demonstrate that MTb upregulation of NFAT5 gene expression in human monocytic cells requires activation of MyD88 and the MyD88-associated adaptor molecules IRAK1 and TRAF6.","[{'offsets': [[12, 17]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[42, 47]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[132, 137]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[310, 315]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[374, 378]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[401, 406]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[459, 463]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[503, 508]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[765, 770]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[944, 949]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1000, 1005]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1029, 1033]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1174, 1179]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1285, 1306]], 'text': ['short hairpin (sh)RNA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1317, 1322]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1365, 1370]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1529, 1538]], 'text': ['GFP shRNA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1563, 1568]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1633, 1638]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1672, 1675]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1681, 1686]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1754, 1757]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1826, 1831]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1849, 1853]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1902, 1907]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1943, 1948]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1953, 1956]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1990, 1994]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2032, 2037]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2056, 2061]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2123, 2128]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2232, 2237]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2241, 2246]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2286, 2291]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2342, 2347]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2352, 2357]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2394, 2399]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2438, 2441]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2533, 2538]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2543, 2548]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2552, 2555]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2632, 2636]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2671, 2676]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2704, 2709]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2714, 2719]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2758, 2762]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2792, 2796]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2811, 2816]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2822, 2827]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2843, 2848]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2979, 2984]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3049, 3054]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3063, 3068]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3098, 3103]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3108, 3113]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T55'}]",[],[],[],[],[]
119,PMC-3291650-18-Caption-Figure_2,"A20 negatively regulates IAV-induced gene expression in BMDM and alveolar macrophages.
(A-B) BMDM isolated from A20myel-WT and A20myel-KO animals were infected with IAV (moi 1). At different hours post infection (hours p.i.) cells were lysed and IL-6, IFNbeta and A20 mRNA expression was analyzed by qPCR (A). 18 hours post infection cell culture supernatant was analyzed for TNF and IFNbeta protein levels by ELISA and multiplexing technologies (B). (C-D) Alveolar macrophages were mock treated or infected with IAV (moi 1) for 18 hours. IL-6 and IFNbeta mRNA expression was determined by qPCR (C). Cell culture supernatant was analyzed for IL-6 and IFNbeta protein levels by ELISA and multiplexing technologies (D). Error bars represent mean values (+/- SEM) of 2-3 samples. Results are representative for 2 independent experiments. ***p<0,001.","[{'offsets': [[246, 250]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[252, 259]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[376, 379]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[384, 391]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 543]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[548, 555]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[642, 646]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[651, 658]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
120,PMC-1064895-00-TIAB,"Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor ?B-dependent pathway in patients with rheumatoid arthritis
Inflammatory mediators have been recognized as being important in the pathogenesis of rheumatoid arthritis (RA). Interleukin (IL)-17 is an important regulator of immune and inflammatory responses, including the induction of proinflammatory cytokines and osteoclastic bone resorption. Evidence for the expression and proinflammatory activity of IL-17 has been demonstrated in RA synovium and in animal models of RA. Although some cytokines (IL-15 and IL-23) have been reported to regulate IL-17 production, the intracellular signaling pathways that regulate IL-17 production remain unknown. In the present study, we investigated the role of the phosphoinositide 3-kinase (PI3K)/Akt pathway in the regulation of IL-17 production in RA. Peripheral blood mononuclear cells (PBMC) from patients with RA (n = 24) were separated, then stimulated with various agents including anti-CD3, anti-CD28, phytohemagglutinin (PHA) and several inflammatory cytokines and chemokines. IL-17 levels were determined by sandwich enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction. The production of IL-17 was significantly increased in cells treated with anti-CD3 antibody with or without anti-CD28 and PHA (P < 0.05). Among tested cytokines and chemokines, IL-15, monocyte chemoattractant protein-1 and IL-6 upregulated IL-17 production (P < 0.05), whereas tumor necrosis factor-alpha, IL-1beta, IL-18 or transforming growth factor-beta did not. IL-17 was also detected in the PBMC of patients with osteoarthritis, but their expression levels were much lower than those of RA PBMC. Anti-CD3 antibody activated the PI3K/Akt pathway; activation of this pathway resulted in a pronounced augmentation of nuclear factor kappaB (NF-kappaB) DNA-binding activity. IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively. However, inhibition of activator protein-1 and extracellular signal-regulated kinase 1/2 did not affect IL-17 production. These results suggest that signal transduction pathways dependent on PI3K/Akt and NF-kappaB are involved in the overproduction of the key inflammatory cytokine IL-17 in RA.","[{'offsets': [[10, 24]], 'text': ['interleukin-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[68, 71]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[263, 282]], 'text': ['Interleukin (IL)-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[494, 499]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[590, 595]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[600, 605]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[638, 643]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[707, 712]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[827, 830]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[860, 865]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1034, 1038]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1040, 1058]], 'text': ['phytohemagglutinin'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1060, 1063]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1116, 1121]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1262, 1267]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1357, 1361]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1366, 1369]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1421, 1426]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1428, 1462]], 'text': ['monocyte chemoattractant protein-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1467, 1471]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1484, 1489]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1521, 1548]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1550, 1558]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1560, 1565]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1569, 1600]], 'text': ['transforming growth factor-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1610, 1615]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1783, 1786]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1920, 1925]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2074, 2077]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2150, 2169]], 'text': ['activator protein-1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2174, 2213]], 'text': ['extracellular signal-regulated kinase 1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2214, 2215]], 'text': ['2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2231, 2236]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2323, 2326]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2409, 2414]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T35'}]",[],[],[],[],[]
121,PMC-2817507-10-3._Results,"3.2. Expression of TLR4 Protein Increased in Brain Tissue after ICH
To investigate the increased TLR4 at the protein level, the expression of TLR4 protein was measured in brain tissue by the method of Western Blots using specific antibodies for TLR4. Our results showed that a low level of TLR4 protein was detectable in the saline control group. The expression of TLR4 significantly increased starting from 6 hours after ICH (P < .05), peaked on the 3rd day after ICH, and then decreased but still maintained at a high level on the 7th day after ICH (P < .05, Figure 2). This observation of TLR4 protein was consistent with the temporal profile of the TLR4 mRNA after ICH.","[{'offsets': [[19, 23]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 101]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[142, 146]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[245, 249]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[290, 294]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[365, 369]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[592, 596]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[653, 657]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
122,PMC-1472690-02-Results,"Binding activities of NFkappaB, NFIL-6 and NFAT from human PBMC to the TNFalpha, IL-6 and IFNgamma promoters following an in vitro stimulation (1 h) with LPS, TSST-1, GP, GP + LPS and GP + TSST-1
GP induced band shifts, indicating binding of NFkappaB as well as of NFIL-6 to the corresponding DNA oligonucleotides (kappa consensus, kappa1, kappa2, kappa3 sites from the TNFalpha promoter; kappa consensus from the IL-8 promoter; NFIL-6consensus from the IL-6 promoter; Table 1; Fig. 1A). The extent of the band shifts induced by GP was not statistically different when compared to LPS or TSST-1 (Fig. 1B). A supershift, conducted for an NFkappaB consensus site from the IL-8 promoter, demonstrated a GP-induced predominant binding of NFkappaB p65 and to a lesser degree of p50 (Fig. 1A). Accordingly, an immunoblot of nuclear extracts from GP-treated PBMC showed a strong binding of NFkappaB p65 and a weaker reaction of p50, whereas p52 was negative (Fig. 2). Simultaneous co-treatment of PBMC with GP did not change the LPS-induced NFkappaB binding to oligos from the TNFalpha promoter significantly (Fig. 1B), but substantially decreased the TSST-1-induced NFkappaB binding when compared to TSST-1 or GP (100 mug) and thus differed completely from the theoretical value of GP/TSST-1 calc. (n = 4; p < 0.05 vs. GP/TSST-1 calc. and p = 0.07 vs. TSST-1; Fig. 1B). GP was also able to induce band shifts indicative of binding of particular variants of NFAT to an oligo from the IFNgamma promoter (Fig. 1A). An immunoblot for two NFAT subunits demonstrated a GP-induced binding of NFATc2 and to a lesser degree of NFATc1 (Fig. 2).","[{'offsets': [[32, 38]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[43, 47]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 79]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[81, 85]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[90, 98]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[159, 165]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[189, 195]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[265, 271]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[370, 378]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[414, 418]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[454, 458]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[588, 594]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[670, 674]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[743, 746]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[773, 776]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[892, 895]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[921, 924]], 'text': ['p50'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[934, 937]], 'text': ['p52'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1070, 1078]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1145, 1151]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1194, 1200]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1279, 1285]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1316, 1322]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1346, 1352]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1451, 1455]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1477, 1485]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1528, 1532]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1579, 1585]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1612, 1618]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T29'}]",[],[],[],[],[]
123,PMC-3312845-03-Methods,"Intracerebroventricular drug infusion
Rats were divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor (sTNFp55R, 50 mug/ml; Sigma-Aldrich Co., St. Louis, MO)-treated groups. The dosage of sTNFp55R was determined as the highest dose that induced SE of comparable severity in 100% of animals with 5% mortality in the preliminary study. Animals were anesthetized (Zolretil, 50 mg/kg, i.m.; Virbac Laboratories, France) and placed in a stereotaxic frames. For the osmotic pump implantation, holes were drilled through the skull to introduce a brain infusion kit 1 (Alzet, Cupertino, CA) into the right lateral ventricle (1 mm posterior; 1.5 mm lateral; - 3.5 mm depth; flat skull position with bregma as reference), according to the atlas of Paxinos and Watson [24]. The infusion kit was sealed with dental cement and connected to an osmotic pump (1007D, Alzet, Cupertino, CA). The pump was placed in a subcutaneous pocket in the dorsal region. Animals received 0.5 mul/hr of vehicle or compound for 1 week. Therefore, the dose of sTNFp55R was 0.6 mug/day per each animal. The compounds began to be immediately infused after surgery. Since the volume of vasogenic edema peaked at 2-3 days after SE in our previous studies [5-8,20], we chose this time point. Thus, our experimental schedules at least inhibit the function of TNF-alpha from 3 days prior to SE to 4 days after SE when the volume of vasogenic edema peaked.","[{'offsets': [[110, 125]], 'text': ['TNFp55 receptor'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[128, 135]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[213, 220]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1052, 1059]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1344, 1353]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
124,PMC-3218875-07-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Cylindromatosis protein
Cylindromatosis (CYLD) protein was originally identified as a tumour suppressor involved in familial cylindromatosis [63]. CYLD is also involved, however, in diverse physiological processes ranging from immunity and inflammation to cell cycle progression, spermatogenesis, and osteoclastogenesis (reviewed in [64]). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB signalling initiated by TNFR, RANK and T-cell receptor stimulation (reviewed in [64]) (Figure 1), by deubiquitina-ting several NF-kappaB signalling proteins including NEMO, TRAF2, TRAF6, TRAF7, RIP1 and TAK1. Many of these are also targeted by A20 and it is still not clear why the cell needs A20 as well as CYLD to control NF-kappaB activation. As A20 is only expressed in many cell types upon stimulation, it has been suggested that this protein mainly regulates later phases of NF-kappaB signalling, whereas CYLD would regulate constitutive and early signalling. In addition, their relative activity might also be cell-type dependent [64].
Interestingly, CYLD has been shown to negatively regulate RANK signalling and osteoclastogenesis in mice [65]. Mice with a genetic deficiency of CYLD have aberrant osteoclast differentiation and develop severe osteoporosis. Osteoclast precursors of these mice are hyper-responsive to RANKL-induced differentiation and produce more and larger osteoclasts. CYLD expression is markedly upregulated under conditions of RANKL-induced osteoclastogenesis and is recruited to ubiquitinated TRAF6 via the ubiquitin-binding adaptor protein p62 (also known as sequestosome 1) [65], followed by the CYLD-mediated deubiquitination of TRAF6. In this context, it is worth mentioning that transgenic mice expressing a mutated form of p62 also display abnormal osteoclastogenesis and develop progressive bone loss [66]. These findings suggest that CYLD-mediated inhibi-tion of RANK-induced NF-kappaB signalling plays a key role in the negative regulation of osteoclastogenesis and indicate CYLD as a potential genetic factor involved in the pathology of bone disorders such as RA.","[{'offsets': [[0, 15]], 'text': ['Cylindromatosis'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[24, 39]], 'text': ['Cylindromatosis'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 45]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[147, 151]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[340, 344]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[350, 373]], 'text': ['deubiquitinating enzyme'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[440, 444]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[577, 581]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[583, 588]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[590, 595]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[597, 602]], 'text': ['TRAF7'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[604, 608]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[613, 617]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[654, 657]], 'text': ['A20'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[703, 706]], 'text': ['A20'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[718, 722]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[759, 762]], 'text': ['A20'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[921, 925]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1068, 1072]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1111, 1115]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1198, 1202]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1337, 1342]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1408, 1412]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1468, 1473]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1535, 1540]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1549, 1558]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1583, 1586]], 'text': ['p62'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1602, 1616]], 'text': ['sequestosome 1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1640, 1644]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1674, 1679]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1771, 1774]], 'text': ['p62'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1884, 1888]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1913, 1917]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2026, 2030]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T35'}]",[],[],[],[],[]
125,PMC-3585731-19-Materials_and_Methods,"siRNA Knockdown
siRNAs were purchased from Dharmacon. Mouse ribosomal S6 protein (L-040893-00 and L-045791-00), mouse Akt1 (L-040709-00), mouse Akt2 (L-040782-00), mouse Akt3 (L-040891-00), mouse mTOR (L-065427-00), mouse PDK1 (L-040658-00), non-coding control (D-001810-10-05), mouse Mapk8 (J-040128-05), mouse Mapk9 (J-040134-05), mouse Jun (L-043776-00). siRNA were transfected using RNAiMAX reagent (Invitrogen), according to manufacturer's recommendations. After 72 hr, cells were treated with zVAD.fmk or TNFalpha for 9 hr (RNA or Western blot) or 24 hr (cell viability).","[{'offsets': [[118, 122]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[144, 148]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[170, 174]], 'text': ['Akt3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[222, 226]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[285, 290]], 'text': ['Mapk8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[312, 317]], 'text': ['Mapk9'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[511, 519]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
126,PMC-3312845-14-Results,"NF-kappaB phosphorylation
It is well established that TNF-alpha is one of the major stimuli toward phosphorylation of NF-kappaB. To confirm TNF-alpha-mediated signaling following SE, we performed an immunohistochemical study using five phospho-NF-kappaB antibodies. Compared to non-SE animals (data not shown), 12 hr-post SE animals of the saline-infused group showed p65-Ser276, p65-Ser311, p65-Ser529, and p65-Ser536 phosphorylation in astrocytes (not endothelial cells). sTNFp55R infusion effectively reduced p65-Ser276 and p65-Ser311 phosphorylation (p < 0.05, respectively), while it could not affect p65-Ser529 or p65-Ser536 phosphorylation (Figures 3 and 4A). In contrast, p65-Thr435 phosphorylation was increased in endothelial cells (not astrocytes) within the PC of saline-infused animals 12 hr after SE (Figure 5A). In addition, sTNFp55R infusion effectively alleviated SE-induced p65-Thr435 phosphorylation in endothelial cells, compared to saline infusion (p < 0.05, Figure 5B).","[{'offsets': [[54, 63]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[140, 149]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[368, 371]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[380, 383]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[392, 395]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[408, 411]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[475, 482]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[512, 515]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[527, 530]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[606, 609]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 623]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[680, 683]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[841, 848]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[892, 895]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
127,PMC-1064895-09-Materials_and_methods,"Gel mobility-shift assay of NF-kappaB binding site
Nuclear proteins were extracted from about 5 x 106 PBMC. Oligonucleotide probes encompassing the NF-kappaB binding site of the human IL-17 promoter (5'-ATG ACC TGG AAA TAC CCA AAA TTC-3') were generated by 5'-end labeling of the sense strand with [gamma-32P]dATP (Amersham Pharmacia) and T4 polynucleotide kinase (TaKaRa). Unincorporated nucleotides were removed by NucTrap probe purification columns (Stratagene, La Jolla, CA, USA). Nuclear extracts (2 mug of protein) were incubated with radiolabeled DNA probes (10 ng; 100,000 c.p.m.) for 30 min at room temperature in 20 mul of binding buffer consisting of 20 mM Tris-HCl, pH 7.9, 50 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 5% glycerol, 1 mg/ml BSA, 0.2% Nonidet P40 and 50 ng/mul poly(dI-dC). Samples were subjected to electrophoresis on nondenaturing 5% polyacrylamide gels in 0.5 x Tris-borate-EDTA buffer (pH 8.0) at 100 V. Gels were dried under vacuum and exposed to Kodak X-OMAT film at -70degreesC with intensifying screens. Rabbit polyclonal antibodies against NF-kappaB subunits p50, p65 and c-Rel were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).","[{'offsets': [[184, 189]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1095, 1098]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1100, 1103]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1108, 1113]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
128,PMC-1064873-16-Conclusion,"CD4+ T cells from active RA patients are characterized by their resistance to IL-10 inhibition of IFN-gamma production, due to constitutive STAT3 phosphorylation and impaired IL-10-mediated STAT3 activation. The defective STAT3 signaling is possibly associated with SOCS1 predominance over SOCS3. These abnormalities in active RA are thought to be induced mainly after chronic exposure to high concentrations of IL-6. The limited efficacy of IL-10 treatment of RA patients [50] may be explained in part by the unresponsiveness to IL-10 of inflammatory cells, including T cells. On the contrary, the therapeutic efficacy of anti-IL-6 receptor antibody has been reported in RA patients [51], and one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation. More specific therapy targeting STAT3 activation will be awaited; for example, the induction of the SOCS3 gene, the efficacy of which has been demonstrated in animal models [37].","[{'offsets': [[1, 3]], 'text': ['D4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[78, 83]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[98, 107]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[140, 145]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[175, 180]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[190, 195]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[222, 227]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[266, 271]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[290, 295]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[412, 416]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[442, 447]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[530, 535]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[628, 641]], 'text': ['IL-6 receptor'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[783, 787]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[798, 803]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[848, 853]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[916, 921]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T17'}]",[],[],[],[],[]
129,PMC-1359074-02-Results,"Persistent Expression of the Embryonic Globin, epsilony, in Sox6-Deficient Mice
The epsilony globin gene was initially identified as an upregulated transcript in the p100H mouse using subtractive hybridization to identify Sox6 downstream targets. This initial observation was confirmed in an independent knock-out allele of Sox6 [13] using real-time polymerase chain reaction (PCR) (unpublished data). Real-time PCR was used to quantitate the expression levels of other globin genes in p100H mutant and WT mouse livers at two developmental stages, 15.5 dpc and 18.5 dpc. As shown in Figure 1, the epsilony gene is expressed at high levels at both time points in mutant mice, in contrast to the decline in expression observed in WT mice. No difference was seen between WT and heterozygous mice (unpublished data). Interestingly, the expression levels of the other two embryonic globin genes (zeta and betah1) are also higher in p100H homozygous mice, compared with WT mice, but to a much lesser extent than seen for epsilony globin at 18.5 dpc (Figure 1). Moreover, the expression level of adult beta globin is also somewhat higher in p100H homozygous mice than in WT mice at 18.5 dpc (Figure 1). Perinatal lethality of mutant mice (presumably from the heart defect [14]) precludes us from evaluating postnatal globin expression. The graphs in Figure 1 illustrate real time PCR results that were performed in triplicate (standard deviation of the data is shown by error bars). Because all of the assays were performed at the same time with the same internal control, the levels shown are relative levels and are thus comparable across all samples and are in agreement with previously published results for WT fetal mice [29]. We note that the level of epsilony expression in the livers of 15.5 dpc and 18.5 dpc homozygous mutant mice is statistically equivalent to the level of betamaj/min expression in the livers of 15.5 dpc and 18.5 dpc homozygous WT mice.","[{'offsets': [[39, 45]], 'text': ['Globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 55]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[60, 64]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[84, 99]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[222, 226]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[324, 328]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[597, 605]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[891, 895]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[900, 906]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1015, 1030]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1095, 1106]], 'text': ['beta globin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1751, 1759]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1877, 1884]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1885, 1888]], 'text': ['min'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
130,PMC-3291650-08-Materials_and_Methods,"Viral infection and determination of viral titers
Mouse adapted IAV X-47 (H3N2; PR8xA/Victoria/3/75) was propagated in MDCK cells. For viral inoculation, mice were anesthetized by i.p. injection with ketamine (12 mg/kg) and xylazine (60 mg/kg) and 50 microl X-47 diluted in PBS was administered intranasally. For lethal and sublethal infection, mice received respectively 2-LD50 or 0.05-LD50 X-47. To determine pulmonary viral titers, median tissue culture infectious dose (TCID50) was measured as follows: lungs were homogenized with a Polytron homogenizer (Kinematica) in PBS. Eight-fold serial dilutions of lung homogenates were incubated on MDCK cells for 5 days in DMEM supplemented with trypsin (1 microg/ml), 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics. For read-out, 0.5% chicken red blood cells (RBC) were added and end-point dilution of hemagglutination was monitored. TCID50 titers were then calculated according to the method of Reed and Muench [85].",[],[],[],[],[],[]
131,PMC-2817507-09-3._Results,"3.1. TLR4 mRNA Increased in Brain Tissue after ICH
TLR4 mRNA levels were detected by Rt-PCR. The low level of TLR4 mRNA was observed in normal rat brain tissue. In the saline control group, the TLR4 mRNA slightly increased, but was not significantly different from normal group. However, the TLR4 mRNA after ICH significantly increased starting from 6 hours after ICH (P < .05), peaked on the 3rd day after ICH, and then decreased on the 7th day after ICH (P < .05), but still maintained a higher level compared with saline control (P < .05, Figure 1).","[{'offsets': [[5, 9]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 55]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[110, 114]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[194, 198]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[292, 296]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
132,PMC-1064873-05-Materials_and_methods,"Flow cytometric analysis for IL-10R1 expression
A sample of 5 x 105 cells of PBMC was resuspended in PBS with 1% FCS. PBMC were incubated with saturating concentrations of anti-IL-10R1 mAb (IgG1; R&D systems, Minneapolis, MN, USA) or with isotype-matched control mAb (Immunotech), followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Cells were then incubated with phycoerythrin-conjugated anti-CD4 mAb (Becton Dickinson). Cells were washed well with 1% FCS/PBS between incubations. Analysis was performed on a FACScan flow cytometer (Becton Dickinson).","[{'offsets': [[29, 36]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[177, 184]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[478, 481]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
133,PMC-3585731-07-Results,"Akt and mTORC1 Control the Activation of JNK during Necroptosis
JNK is a well-established regulator of TNFalpha synthesis in a variety of systems [13], [14], [15], [34]. Therefore, the ability of Akt and mTORC1 inhibitors to block the increase in TNFalpha mRNA lead us to examine their role in the activation of JNK during necroptosis. Knockdown of Akt isoforms Akt1 and Akt2 or inhibition of Akt prominently suppressed the necroptosis dependent increase in JNK and c-Jun phosphorylation (Fig. 6E, S6D,E) suggesting that Akt may provide a link between RIP1 and JNK activation. Importantly, inhibition of Akt only inhibited the delayed, but not the early, increase in bFGF/zVAD.fmk induced JNK and c-Jun phosphorylation (Fig. S6F). Knockdown of mTOR, rapamycin and the p70S6K inhibitor PF-4708671 also attenuated the necroptosis-associated increase in JNK and c-Jun phosphorylation (Fig. 6F, S6E,G, Fig. S5D). Overall, these data suggested that the Akt-mTORC1-S6K axis, acting downstream from RIP1 kinase, is required for the increase in JNK activity during necroptosis in L929 cells.","[{'offsets': [[103, 111]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[247, 255]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[362, 366]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[371, 375]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[466, 471]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[552, 556]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[667, 671]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[697, 702]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[768, 774]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[859, 864]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[959, 962]], 'text': ['S6K'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[992, 996]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
134,PMC-1064895-15-Results,"Inhibition of IL-17 production by signal transduction inhibitors and anti-rheumatic drugs
Having observed the increased IL-17 production in RA PBMC, it was important to know which signal transduction pathways were involved. As illustrated in Fig. 3, an significant decrease in anti-CD3-induced IL-17 production was observed when co-incubated with NF-kappaB inhibitor, PDTC and dexamethasone in comparison with anti-CD3 alone (38 +/- 5 and 54 +/- 11 versus 98 +/- 19 pg/ml, respectively; P < 0.05).
LY294002 and wortmannin, as an inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC (98 +/- 19 versus 38 +/- 10 pg/ml [P < 0.005] and 48 +/- 4 pg/ml [P < 0.05], respectively).
The calcineurin inhibitors cyclosporin A and FK506 also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor SB203580 did, whereas rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3). To evaluate the possibility of non-specific inhibition by the drug at high concentrations, we observed the dose response of PDTC and LY294002 for the inhibition of IL-17 production in PBMC. There were dose-dependent inhibitions of IL-17 production with chemical inhibitors (Fig. 4a). The other inhibitors in addition to PDTC and LY294002 showed the same pattern of inhibition. Cytotoxic effects on PBMC by the chemical inhibitors at experimental concentrations were not observed (Fig. 4b).","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 125]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[294, 299]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[593, 598]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[717, 728]], 'text': ['calcineurin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[787, 792]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[933, 938]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1120, 1125]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1187, 1192]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
135,PMC-1359074-08-Discussion,"In this report, we show that Sox6 is a novel factor in the complicated regulation mechanism of globin genes. In the Sox6 null mouse, there is a transient effect on the embryonic globin genes, zeta and betaH1, and a persistent upregulation of the epsilony globin gene. Sox6 directly regulates and binds to the proximal promoter of epsilony gene and represses the epsilony-globin gene in definitive erythropoiesis.
Sox6 belongs to group D of the Sox family of proteins that includes Sox5, 12, 13, and 23 [34]. Group D Sox proteins contain a coiled-coiled domain that mediates homo- and heterodimerization [6,35]. Functionally, dimerization of Sox5 and Sox6 has been shown to greatly increase the binding efficiency of the two Sox proteins to DNA that contains adjacent Sox sites [6]. In addition, Sox6 binds more strongly to an HMG-box dimer motif than to a single HMG-box motif [5]. Therefore, it appears that target genes for group D Sox proteins, such as Sox6, probably harbor pairs of HMG binding sites with a configuration compatible with binding of D-Sox protein dimers. Indeed, in the present study, the defined Sox6 target sequence of the epsilony promoter contains two Sox/Sox6 consensus sites (Figure 3A). Functionally, both sites are essential for Sox6 binding to the epsilony promoter and repression of its activity (Figure 3E and 3F). These observations suggest that Sox6 binds to this sequence of the epsilony promoter either as a homodimer or as a heterodimer with other Sox proteins. Because Sox proteins recognize a short 6-bp core-binding sequence that allows for considerable degeneracy, the specificity of their actions is thought to rely upon interactions with other transcription factors [36]. In our EMSAs, we had to run the electrophoresis on a 4%-6% gel for at least 4-8 h to detect the Sox6-associated band, suggesting that Sox6 is part of a high molecular weight complex. A few other epsilony globin repressors have been reported to bind to DNA sequences near the Sox/Sox6 consensus sites, including the DRED complex [37] and COUP-TF [38]. Sox6 might interact with these factors and form a large repression complex. Identification of other components of the Sox6-containing complex associated with the epsilony promoter will shed light on its mechanism of repression.
Sox proteins bind and bend linear DNA by partial intercalation in the minor groove, and can also bind to four-way junctions [2-4]. Therefore, one attractive model to explain how Sox6 proteins control gene expression is that they function as architectural factors bound to DNA, influencing local chromatin structure by bending DNA and by assembling multiprotein transcriptional complexes. By changing the local chromatin structure, Sox6 could either interfere with binding of other activators to the promoter or facilitate binding of other repressors. Another example of a repressor that interferes with an activator on the epsilony promoter is DRED. DRED interferes with EKLF, an activator, in binding to the epsilony promoter [39]. Two HMG architectural proteins (distantly related to the Sox family of transcription factors), HMG-I and HMG-Y, were demonstrated to bind to the human adult beta globin silencers (silencers I and II) and cause bending of the DNA, facilitating the binding of other repressors [40].
Sox6 expression is temporally and spatially coincident with definitive (but not primitive) erythropoiesis (Figure 6), and Sox6 represses epsilony globin expression both in vivo (Figure 1) and in vitro (Figure 2). Moreover, in situ hybridization clearly shows that the persistent expression of epsilony globin in p100H mutant mice is due to defects in the silencing mechanism of definitive erythropoiesis that takes place in the liver (Figure 5). Taken together, these data demonstrate that Sox6 functions in definitive erythropoiesis to silence epsilony globin expression.
The expression level of epsilony globin in homozygous Sox6 null mice at 15.5 dpc and 18.5 dpc is statistically equivalent to the level of betamaj/min expression in the livers of 15.5-dpc and 18.5-dpc homozygous WT mice (Figure 1). This demonstrates that ectopic expression of the epsilony globin gene is quite robust in homozygous mutant mice. The expression levels of two other embryonic globin genes (zeta and betah1) are also higher in p100H homozygotes, compared with WT. Like epsilony, levels of zeta and betah1 are dramatically higher in mutant mice at 15.5 dpc. However, unlike epsilony globin, zeta and betah1 decline in expression by day 18.5 dpc (Figure 1), suggesting that epsilony is regulated differently than zeta and betah1. It is possible that Sox6 has a general effect on embryonic globin genes (and erythrocyte maturation) in addition to a specific role in silencing epsilony.
Although most p100H mutant mice die just after being born, a rare few survive longer. None have been observed to live longer than 2 wk after birth [14]. We examined a single archived sample of liver RNA from a mutant mouse on postnatal day 13.5 for globin gene expression and detected high levels of epsilony globin in this RNA sample, compared with undetectable epsilony RNA in WT control mice. At this point in development, the levels of zeta and betah1 RNA were undetectable both in mutant and WT; however, adult beta-like globin RNA levels were moderately elevated in the mutant RNA compared with WT (unpublished data), similar to what we observe at 18.5 dpc (Figure 1). These findings suggest that Sox6 continues to function postnatally to silence epsilony globin expression and has a unique function in the regulation of epsilony-globin. The mechanism by which Sox6 regulates the other embryonic globin genes remains to be elucidated.
Sox6 has other effects in erythropoiesis, including a delay in enucleation/maturation in p100H mutant mice. This may be the result of indirect effects, such as stress-induced proliferation (resulting from cardiac defects) and/or anemia. Severe anemia can lead to rapid premature release of red cells, prior to their complete maturation. However, the hematocrit of 18.5-dpc mutant mice is only 20% lower than that of WT (unpublished data), and this mild anemia is probably not sufficient to explain the extent of nucleated red cells. Alternatively, Sox6 itself may play a role in red cell terminal differentiation, as it has been shown to be an important factor in cardiac [15], neuronal [10], astrocytic [11], and cartilage differentiation programs [32,41-44].
The restoration of normal enucleation of red cells in Sox6-deficient mouse by postnatal day 10.5 may result from functional compensation of other Sox proteins (expressed at later developmental stages), since functional redundancy is a recurring theme with Sox proteins [13,45,46]. Moreover, erythropoiesis has already shifted from fetal liver to bone marrow by postnatal day 10.5. The accompanying change in the microenvironment of red cell production may permit normal enucleation. Identification of Sox6 downstream target genes and its interacting proteins will shed light on the role of Sox6 in red cell terminal differentiation and the enucleation process.
Recently, in vivo and in vitro analyses suggest that reactivation of human epsilon-globin would be therapeutically beneficial to adults with sickle cell disease [47], providing a rationale for detailed investigations into the molecular basis of epsilon-globin gene silencing. The present study identifies a novel repressor, Sox6, which binds to the epsilony proximal promoter, potentially as part of a larger repression complex. Because murine Sox6 and its human counterpart are 94% identical at the amino acid level [48], it is possible that human Sox6 may also be important in human epsilon globin silencing. There is significant sequence homology between the human and mouse epsilon promoter regions, and the human promoter contains at least two potential Sox6 binding sites. Indeed, the existence of a silencer of the human epsilon globin gene has been proposed [49,50]. Thus, elucidation of the Sox6 repression mechanism and identification of other components of the Sox6-containing complex may further our understanding of epsilon globin regulation and potentially reveal additional molecular targets for the treatment of sickle cell anemia and beta thalassemias.","[{'offsets': [[29, 33]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[116, 120]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[192, 196]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[201, 207]], 'text': ['betaH1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[246, 261]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[268, 272]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[330, 343]], 'text': ['epsilony gene'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[362, 377]], 'text': ['epsilony-globin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[413, 417]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[481, 485]], 'text': ['Sox5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[487, 489]], 'text': ['12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[491, 493]], 'text': ['13'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[499, 501]], 'text': ['23'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[641, 645]], 'text': ['Sox5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[650, 654]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[795, 799]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[956, 960]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1117, 1121]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1145, 1153]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1257, 1261]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1277, 1285]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1378, 1382]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1413, 1421]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1810, 1814]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1848, 1852]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1909, 1924]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2029, 2033]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2051, 2055]], 'text': ['COUP'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2056, 2058]], 'text': ['TF'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2065, 2069]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2183, 2187]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2227, 2235]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2471, 2475]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2724, 2728]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2916, 2924]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2937, 2941]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2943, 2947]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2964, 2968]], 'text': ['EKLF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3002, 3010]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3121, 3126]], 'text': ['HMG-I'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3131, 3136]], 'text': ['HMG-Y'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3206, 3217]], 'text': ['silencers I'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3222, 3224]], 'text': ['II'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3307, 3311]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3429, 3433]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3444, 3459]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3600, 3615]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3797, 3801]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3852, 3867]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3904, 3919]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3934, 3938]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4018, 4025]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4026, 4029]], 'text': ['min'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4160, 4175]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4283, 4287]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4292, 4298]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4361, 4369]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4381, 4385]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4390, 4396]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4465, 4480]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4482, 4486]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4491, 4497]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4564, 4572]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4603, 4607]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4612, 4618]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4640, 4644]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4765, 4773]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5075, 5090]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5138, 5146]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5215, 5219]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5224, 5230]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5291, 5307]], 'text': ['beta-like globin'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5478, 5482]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5528, 5543]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5602, 5617]], 'text': ['epsilony-globin'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5642, 5646]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5716, 5720]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[6264, 6268]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[6531, 6535]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[6978, 6982]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7067, 7071]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7213, 7227]], 'text': ['epsilon-globin'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[7383, 7397]], 'text': ['epsilon-globin'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[7462, 7466]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[7487, 7495]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[7582, 7586]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[7687, 7691]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[7723, 7737]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[7816, 7823]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[7966, 7980]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[8038, 8042]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[8110, 8114]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[8167, 8181]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T93'}]",[],[],[],[],[]
136,PMC-3342329-17-Materials_and_Methods,"Statistical Analysis
The data were analyzed using the GraphPad Prism 4 ver. 4.03 software (GraphPad Software, La Jolla, CA). Data are presented as mean +/- SD. Difference between CCR5-/- mice and CCR5+/+ mice were compared using t test. A value of p<0.05 was considered to be statistically significant. Survival data were presented by Kaplan-Meier survival estimates and compared and calculated by Log-rank (Mantel-Cox) Test in GraphPad Prism.","[{'offsets': [[179, 183]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[196, 200]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
137,PMC-1359074-14-Materials_and_Methods,"Cell culture and transfection.
GM979 cells (Coriell Cell Repositories, Camden, New Jersey, United States) were cultured in Ham's F12 with 2 mM L-glutamine supplemented with heat-inactivated 10% fetal calf serum (Ivitrogen, Carlsbad, California, United States), penicillin (100 units/ml), streptomycin 100 mug/ml), and L-glutamine (2 mM). MEL cells were cultured in DMEM supplemented as above (without heat inactivating the serum). GM979 cells (4 x 105) in log phase of growth were transfected with plasmids by FuGENE6 (Roche, Indianapolis, Indiana, United States). Cells were transfected with epsilony promoter reporter constructs (500 ng) along with either empty vector or Sox6 overexpression vector (1000 ng). In assays of dosage effect, we used 200 ng, 500 ng, and 1000 ng). pRL-CMV 15ng (Promega) was used as a control for transfection efficiency.","[{'offsets': [[593, 601]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[674, 678]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
138,PMC-1472690-17-Methods,"Statistical analysis
The Kolmogorow-Smirnov test was used to evaluate, whether cytokine amounts and binding activities to transcription factors were normally distributed. Correlation coefficients and corresponding significances were analyzed by the Pearson test (normal distribution) or the Spearman test (non-normal distribution). To compare experimental data to a theoretical value (for example GP + TSST-1 vs GP/TSST-1 calc.) we calculated the sum of the individual effects and added these values into Fig. 1B, 3, 4, 5, and 6. Significances of differences between experimental data (for example GP vs LPS) as well as between experimental data and theoretical values (for example GP + TSST-1 vs GP/TSST-1 calc.) were analysed using the Student's t-test (normal distribution) or the Wilcoxon Signed-Rank test (non-normal distribution), (SPSS for Windows; SPSS Science Software, Erkrath, Germany).","[{'offsets': [[402, 408]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[415, 421]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[687, 693]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[700, 706]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
139,PMC-3317373-08-2._Methods_and_Materials,"2.7. Enzyme-Linked Immunosorbent Assay (ELISA)
Cells of four groups were homogenized as mentioned above. The supernatant was collected, and total protein was determined by Coomassie Plus Protein Assay Reagent (Pierce, IL, USA). Levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6) protein were quantified using ELISA kits specific for mouse according to the manufacturer's instructions (Bender MedSystems Inc. CA, USA). Briefly, prepared the standard and created the standard dilution for building standard curve. Then samples and biotinconjugate were added to microwell strips. After incubated for 2 h at room temperature, the microwell strips were washed 3 times with wash buffer, and streptavidin-HRP were added to all wells. After incubated for 1 h, microwell strips were washed 3 times followed by adding TMB substrate. After incubated for about 10-30 min, the stop solution was added. The colour intensity was measured at 450 nm using a Bio-Rad ELISA microplate reader (Bio-Rad Laboratories, CA, USA). The concentration of protein was determined according to the standard curve and expressed as pg/mg of total protein.","[{'offsets': [[279, 297]], 'text': ['interleukin-1 beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[299, 307]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[314, 327]], 'text': ['interleukin-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[329, 333]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
140,PMC-3586680-03-p53_and_Functions,"Activated p53 mediates apoptosis, cell cycle arrest, senescence, DNA repair, or metabolism (Lane and Levine, 2010). The primary structures of p53 and its isoforms are depicted (Figure 2). p53 induces cell cycle arrest by transactivating genes such as cyclin-dependent kinase inhibitor p21, or microRNA miR34. p53 induces apoptosis by transactivating proapoptotic genes such as BAX, PUMA, SCOTIN, and FAS, and inhibiting the antiapoptotic gene BCL-2 (Lane and Levine, 2010). p53 triggers pro-survival or cell death response, depending upon cell types, the intensity of the stress signal, and the extent of cellular damage (Menendez et al., 2009). Also, p53 plays a role in controlling cell motility via regulating the expression of smooth muscle alpha-actin (Comer et al., 1998), collagens IIalpha1 and VIalpha1 (Sun et al., 1999), and many others.","[{'offsets': [[10, 13]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[142, 145]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[188, 191]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[285, 288]], 'text': ['p21'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[302, 307]], 'text': ['miR34'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[309, 312]], 'text': ['p53'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[377, 380]], 'text': ['BAX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[382, 386]], 'text': ['PUMA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[388, 394]], 'text': ['SCOTIN'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[400, 403]], 'text': ['FAS'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[443, 448]], 'text': ['BCL-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[474, 477]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[652, 655]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[731, 756]], 'text': ['smooth muscle alpha-actin'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[779, 797]], 'text': ['collagens IIalpha1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[802, 810]], 'text': ['VIalpha1'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
141,PMC-3320587-06-Materials_and_Methods,"Quantitative DNase I footprinting
Recombinant NFAT5 (amino acids 175-471) with an N-terminal 6x His tag was expressed in E. coli BL21(DE3) cells (Stratagene; www.stratagene.com) and purified under native conditions using Ni-NTA agarose (Qiagen). Recombinant p50 and p65 were purchased (Active Motif, www.activemotif.com). Quantitative DNase I footprinting was performed as previously described [31].","[{'offsets': [[13, 20]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[46, 51]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[258, 261]], 'text': ['p50'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[266, 269]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[335, 342]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
142,PMC-3589482-09-Experimental_Procedures,"Transient Transfection and Luciferase Assays (MEF Cells)
Cebpb-/- MEFs (1x105) [34] were transfected with the indicated luciferase reporter plasmid (400 ng) along with a beta-actin-beta-galactosidase reporter plasmid (200 ng) by electroporation using the Invitrogen Neon(TM) system (1 pulse, 1350 V, 30 msec). Transfected cells were transferred to pre-warmed media in 24 well plates and incubated for 48 hrs prior to incubation with LPS (100 ng/ml) for 4 hrs where indicated. In some experiments, plasmids encoding C/EBP-beta or C/EBP-beta phospho-acceptor mutants (T188A, T217A, S64A) [38]-[40] or control vector were co-transfected (0.6-1.0 microg total DNA). Luciferase activity was determined and normalized to that of beta-galactosidase [38] using the Luciferase Assay System and beta-Galactosidase Enzyme Assay System Kits, respectively (Promega). Each experiment was repeated at least three times, and triplicate samples were employed for each sample. Expression of the C/EBP-beta phospho-acceptor mutant proteins was checked for equal expression by western blot.","[{'offsets': [[27, 37]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 62]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[120, 130]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[170, 180]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[181, 199]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[515, 525]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[529, 564]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[566, 571]], 'text': ['T188A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[573, 578]], 'text': ['T217A'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[580, 584]], 'text': ['S64A'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[662, 672]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[723, 741]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[757, 767]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[785, 803]], 'text': ['beta-Galactosidase'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[977, 1011]], 'text': ['C/EBP-beta phospho-acceptor mutant'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
143,PMC-3342329-08-Materials_and_Methods,"Ethics Statement
All experiments were approved and carried out according to the Guide for the Care and Use of Animals [Animal Care Committee of Chungbuk National University, Korea (CBNUA-045-0902-01)].",[],[],[],[],[],[]
144,PMC-3585731-20-Materials_and_Methods,"Western Blot
For Western blot, 4x105 adherent cells (1x106 Jurkat cells) were seeded into 35 mm2 dishes. After 24-48 hr, cells were stimulated with 30 microM zVAD.fmk or 10 ng/ml mouse TNFalpha. For treatments under serum free conditions, cells were serum starved for 24 hr prior to the addition of growth factors, 20 microM zVAD.fmk or 10 ng/ml mouse TNFalpha. Cells were harvested in 1xRIPA buffer (Cell Signaling) supplemented with 50 microg/ml phenylmethanesulfonylfluoride. After brief sonication, cell lysates were spun down for 15 min at 14,000xrpm. Protein concentrations were measured using the Pierce 660 nm Assay Reagent (Pierce). Equal amounts of proteins were boiled for 5 min at 95degreesC. Western blotting was performed according to standard protocols. Briefly, SDS-PAGE gels were transferred to PVDF membrane, blocked in 3% milk or 5% bovine serum albumin (BSA) in TBST buffer for 30 min at room temperature. Primary antibodies were incubated in 5%BSA/TBST overnight at 4degreesC. Secondary antibodies were incubated in TBST for 30 min at room temperature. Luminata (Millipore) ECL reagents were used to develop the signals. In some cases, membranes were stripped using OneMinute stripping buffer (GM Biosciences) and reprobed with new antibodies.","[{'offsets': [[185, 193]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[352, 360]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
145,PMC-1472690-26-Caption-Figure_8,"Cartoon of the sense strand of the IL-1RA promoter. Relative locations of previously (LRE-1) [30-33] and newly described (boxed), positively (black) and negatively (gray) regulatory transcription factor binding sites are depicted.","[{'offsets': [[35, 41]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
146,PMC-2817507-08-2._Methods,"2.7. Statistical Analysis
All data were presented as mean +/- SEM. The measurements were analyzed by one-way analysis of variance (ANOVA) or Student's t-test. The P < .05 level of probability was used as the criteria of significance.",[],[],[],[],[],[]
147,PMC-1064895-10-Materials_and_methods,"Cell viability (Trypan blue dye exclusion assay)
For cell viability assays, the trypan blue dye exclusion method was used to evaluate the potential of direct cytotoxic effect of inhibitors on cells. After incubation for 24 hours, the cells were harvested and the percentage cell viability was calculated with the formula 100 x (number of viable cells/number of both viable and dead cells) [21].",[],[],[],[],[],[]
148,PMC-3585731-28-Caption-Figure_3,"RIP1 kinase-dependent phosphorylation of Akt and JNK during necroptosis.
(A) L929 cells were treated with zVAD.fmk or TNFalpha for 9 hr, followed by western blotting with indicated antibodies. (B,C) L929 cells were treated with zVAD.fmk (B) or bFGF/zVAD.fmk (serum free conditions, C) and samples were collected at the indicated time points for western blot. (D) Nec-1 was added to the cells stimulated with bFGF or bFGF/zVAD (serum free conditions) for 15 min or 9 hr followed by western blot with the indicated antibodies.","[{'offsets': [[0, 4]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[118, 126]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 248]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[408, 412]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[416, 420]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
149,PMC-3317373-01-1._Introduction,"Brain damage following traumatic injury is a result of direct (primary injury) and indirect (secondary or delayed injury) mechanisms. The secondary injury mechanism involves the initiation of an acute inflammatory response, including breakdown of blood-brain barrier (BBB), brain edema, infiltration of peripheral blood cells, and activation of resident immunocompetent cells, as well as the release of numerous immune mediators such as interleukins and chemotactic factors [1]. And the subsequent inflammation leads to secondary damage not only in brain but also in other organs [2-4].
Nuclear factor erythroid 2-related factor2 (Nrf2) is a transcription factor that regulates many kinds of antioxidant genes. Several studies have demonstrated that Nrf2 regulates the inflammation in the brain after traumatic brain injury (TBI). It was also showed that TBI could induce more aggravated damage in Nrf2 knockout mice than in wildtype mice [5]. On the contrary, such inflammation can be extenuated through elevating the level of Nrf2 by its inducers, such as sulforaphane (SFN) [6]. It is well documented that astrocytes play a critical role in maintaining normal brain physiology and responding to injury or disease. In fact, all the aforementioned studies are performed in vivo. Little is known about the relationship between Nrf2 and inflammation in astrocytes after TBI. Therefore, here we analysed the influence of Nrf2 on the expression of proinflammatory cytokines in primary cultured astrocytes from transgenic mice after scratch injury.",[],[],[],[],[],[]
150,PMC-3589482-25-Caption-Figure_2,"Deletion reporter gene analysis of LPS and PMA-responsive regions in the murine SerpinB2 promoter.
(A) Schematic representation of the murine SerpinB2 promoter and 5' deletion luciferase reporter constructs. The murine 5' flanking region from -4480 to +92 was inserted upstream of the luciferase reporter gene and 5' deletions were generated using restriction enzyme sites or with specific oligonucleotide PCR primers. Construct names indicate the most 5' nucleotide of murine SerpinB2 5' flanking sequence. (B) RAW 264.7 macrophages were transiently transfected with the indicated murine SerpinB2 promoter-luciferase reporter constructs and control plasmids. Cells were either left untreated or treated with 100 ng/ml LPS or 40 ng/ml PMA for 16 hrs. Shown is the relative luciferase reporter gene activity following treatment. The results represent the mean and SEM of four independent experiments. (C) DNA sequence conservation between the human and murine SerpinB2 5' flanking regions. Schematic representation of the human and murine SerpinB2 5' flanking regions with regions of nucleotide sequence identity indicated by the same colored boxes. Homologous regions are interrupted by repetitive sequence elements in both 5' flanking regions. Alu = Alu repeat, ID4 =  ID4 short interspersed nuclear repeat (SINE), L1 =  L1 long interspersed nuclear element (LINE), L2 =  L2 LINE, MIR = MIR SINE, MLT1L = MLT1L long terminal repeat (LTR), (TATG)n = TATG tetranucleotide repeat, tis = transcription initiation site.","[{'offsets': [[80, 88]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[142, 195]], 'text': [""SerpinB2 promoter and 5' deletion luciferase reporter""], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[285, 295]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[477, 485]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[589, 626]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[773, 783]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[959, 967]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1038, 1046]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
151,PMC-3312845-21-Caption-Figure_3,"Effect of sTNFp55R infusion on NF-kappaB phosphorylation in astrocytes 12 hr after SE. In 12 hr-post SE animals of the saline-infused group (A, C, E and G), astrocytes show p65-Ser276 (A), p65-Ser311 (C), p65-Ser529 (E), and p65-Ser536 (G) phosphorylation (arrows). sTNFp55R infusion (B, D, F and H) effectively reduces p65-Ser276 (B) and p65-Ser311 (D) phosphorylation, while it does not affect p65-Ser529 (F) and p65-Ser536 (H) phosphorylation (arrows). Bar = 12.5 mum.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[173, 176]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[189, 192]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[205, 208]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[225, 228]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[267, 274]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[320, 323]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[339, 342]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[396, 399]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[415, 418]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
152,PMC-1359074-17-Materials_and_Methods,"EMSA.
Single-stranded complementary oligonucleotides were annealed and end-labeled with [gamma-32P] ATP with T4 polynucleotide kinase. EMSA was performed with 5 mug of nuclear proteins from MEL cells or 3 mul of in vitro-translated Sox6 along with the reticulocyte lysate in binding buffer: 100 mM NaCl, 10% glycerol, 200 ng/mul BSA, 50 ng/mul poly (dI-dC) or poly (dG-dC), 10 mM HEPES (pH 7), 0.1 mM EDTA, 0.25 mM DTT, 0.6 mM MgCl2. For competition or supershift assays, the indicated unlabelled oligonucleotide competitor (200-fold molar excess) or antibody (3 mul) was added 30 min to 60 min prior to addition of radiolabeled probe. Following addition of the radiolabeled probe, the samples were incubated for 30 min or 60 min at room temperature and loaded on a 4% or 6% (w/v) polyacrylamide gel. Electrophoresis was performed at a constant 19 mAmp for 4-8 h at room temperature, and the gels were dried prior to autoradiography. Antibodies used for supershift analyses included c-Myc, HA, and Sox6 antibodies (described as above). The DNA sequences of the oligonucleotides are as follows (only forward oligos are listed): For the 36-bp WT probe: 5'AATGCAGAACAAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1556); for mutant probe 1 (M1): 5'AACAAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1644); for mutant probe 2 (M2): 5'AATGCAGAACAAAGGGTCAGAtgagTGTCTGCGAAG3' (MHB1648); for mutant probe 3 (M3): 5'AATGCAGtgccAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1650).","[{'offsets': [[109, 133]], 'text': ['T4 polynucleotide kinase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[232, 236]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[329, 332]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[983, 988]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[990, 992]], 'text': ['HA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[998, 1002]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
153,PMC-3291650-20-Caption-Figure_4,"A20 deficiency in myeloid cells protects against lethal IAV infection.
A20myel-WT (n = 11) and A20myel-KO (n = 11) mice were intranasally infected with a lethal dose of IAV and survival (p<0.001) (A) and weight loss +/- SEM (B) was monitored for respectively 21 and 15 days p.i. BAL fluid was collected from wild type (A20myel-WT) and A20myel-KO mice 6 days following infection with a lethal dose IAV and KC, MIP-2, MCP-1, IL-6 and IFNalpha protein levels were determined (C). Absolute numbers of alveolar macrophages, neutrophils and monocytes in BAL were analyzed by flow cytometry at 6 days p.i. (D). Numbers are averages +/- SEM of at least 5 mice per group. Data are representative of 2 independent experiments. *p<0.05; **p<0.01, ***p<0.001.","[{'offsets': [[405, 407]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[409, 414]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[416, 421]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[423, 427]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[432, 440]], 'text': ['IFNalpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
154,PMC-3320587-09-Materials_and_Methods,"Stable THP-1 cells expressing shRNA
The lentiviral plasmid pLKO.1 expressing shRNA targeting human MyD88 was purchased from Open Biosystems (www.openbiosystems.com) and was validated in our laboratory. shRNA targeting human IRAK1 (forward primer 5'-CCGGAGCAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGCTGCTCCTTTTTG-3', reverse primer 5'-AATTCAAAAAGGAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGACAGCTGCT-3' mRNA (IRAK1 mRNA target sequence is underlined) and human TRAF6 (forward primer 5'-CCGGAGAAACCTGTTGTGATTCGTCTCATAAATCACAACAGGTTTCTCCTTTTTG-3', reverse primer 5'-AATTCAAAAAGGAGAAACCTGTTGTGATTTATGAGACGAATCACAACAGGTTTCT-3' (TRAF6 mRNA target sequence is underlined) were designed in our laboratory and were cloned into the pLKO.1 plasmid. Lentiviruses encoding shRNA sequences were generated by transfecting the packaging cell line HEK-293T with the shRNA-encoding pLKO.1 plasmids in combination with the packaging plasmid psPAX2 and the envelope plasmid pMD2.G using Effectene transfection reagent (Qiagen, www.qiagen.com). Supernatants were collected 48 hours post-transfection, clarified by centrifugation, and stored at -80degreesC. THP-1 cells were transduced with the lentiviral particles by culturing the cells with supernatants from the virus-producing cells in the presence of 8 microg/ml polybrene (Millipore, www.millipore.com) and spinoculation for two hours at 2000 RPM. Successfully transduced cells were selected and expanded by treatment with 0.8 microg/ml puromycin.","[{'offsets': [[30, 35]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[77, 82]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[99, 104]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[224, 229]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[392, 397]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[444, 449]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[607, 612]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
155,PMC-3585731-34-Caption-Figure_9,"Model of RIP1, Akt and JNK dependent signaling in necroptotic L929 cells.
Akt phosphorylation at Thr308 during necroptosis requires inputs from both growth factors and RIP1 kinase. Downstream from Akt, JNK activation leads to TNFalpha synthesis. Activation of Akt during necroptosis also leads the phosphorylation of several known Akt substrates, such as mTOR, which contribute to the execution of necroptotic death in L929 cells.","[{'offsets': [[9, 13]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[168, 172]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[226, 234]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
156,PMC-3585731-23-Materials_and_Methods,"ELISAOne Assay
ELISAOne assays (TGRBio, Hindmarsh, Australia) were performed according to manufacturer's protocol with the following modifications. Cell lysates were prepared in RIPA buffer as described for Western blots. Five microliters of samples were diluted in 45 microL of ELISAOne lysis buffer prior to analysis. Primary antibodies to phopsho-Thr308 and phopsho-Ser473 were incubated with the samples for 2 hr at room temperature. Primary antibody to pan-Akt was incubated overnight at 4degreesC. Signals for phospho-antibodies were normalized based on pan-Akt values.",[],[],[],[],[],[]
157,PMC-1064895-18-Results,"Activation of the NF-kappaB and activator protein-1 (AP-1) pathway in the IL-17 promoter region
To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-kappaB recognition sites in the promoters of IL-17. As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-kappaB to IL-17 promoters in comparison with that of controls (lane 1). A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5). In normal PBMC the same pattern was observed, but the degree of NF-kappaB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b). To confirm the link between PI3K activity and NF-kappaB, we performed EMSA to determine the NF-kappaB binding activity after treatment with both LY294002 and PDTC. Both agents block NF-kappaB DNA-binding activity in the IL-17 promoter (Fig. 7c). Western blotting for IkappaB-alpha showed inhibition of degradation of IkappaB-alpha by LY294002 and PDTC at the same time (Fig. 7c). In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-kappaB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.","[{'offsets': [[32, 51]], 'text': ['activator protein-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[53, 57]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 79]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[187, 191]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[209, 212]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[217, 222]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[253, 258]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[382, 387]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[475, 479]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[536, 541]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[647, 650]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[655, 658]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[682, 687]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[805, 809]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1079, 1084]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1126, 1139]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1176, 1189]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1256, 1260]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1326, 1330]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1425, 1430]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
158,PMC-3585731-14-Materials_and_Methods,"DNA
Cloning of Myr-Akt1, containing c-terminal FLAG tag, has been described [52]. Myr-Akt1-FLAG was amplified by PCR and subcloned into the BglII and EcoRI sites of pMSCV-puro retroviral vector (Invitrogen). Mutant versions of Myr-Akt1 were generated using the same strategy.","[{'offsets': [[15, 23]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[82, 95]], 'text': ['Myr-Akt1-FLAG'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 235]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
159,PMC-1064895-04-Materials_and_methods,"Production of IL-17 by T cell receptor activation, cytokines or chemokines
PBMC were prepared from heparinized blood by Ficoll-Hypaque (SG1077) density-gradient centrifugation. Cell cultures were performed as described previously [18]. In brief, the cell suspensions were adjusted to a concentration of 106/ml in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Cell suspension (1 ml) was dispensed into 24-well multi-well plates (Nunc, Roskilde, Denmark), and incubated for 24 hours at 37degreesC in 5% CO2. Subsequently, various concentrations of cyclosporin A (10-500 ng/ml) were added to the medium and cells were incubated for 24 hours. To each well was added FK506, rapamycin, curcumin, PDTC, LY294002, SB203580, PD98059, dexamethasone or wortmannin. After incubation for 24 hours (unless otherwise stated), cell-free media were collected and stored at -20degreesC until assayed. All cultures were set up in triplicate, and results are expressed as means +/- SEM.","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
160,PMC-3320587-00-TIAB,"Regulation ofMycobacterium tuberculosis-Dependent HIV-1 Transcription Reveals a New Role for NFAT5 in the Toll-Like Receptor Pathway
Tuberculosis (TB) disease in HIV co-infected patients contributes to increased mortality by activating innate and adaptive immune signaling cascades that stimulate HIV-1 replication, leading to an increase in viral load. Here, we demonstrate that silencing of the expression of the transcription factor nuclear factor of activated T cells 5 (NFAT5) by RNA interference (RNAi) inhibits Mycobacterium tuberculosis (MTb)-stimulated HIV-1 replication in co-infected macrophages. We show that NFAT5 gene and protein expression are strongly induced by MTb, which is a Toll-like receptor (TLR) ligand, and that an intact NFAT5 binding site in the viral promoter of R5-tropic HIV-1 subtype B and subtype C molecular clones is required for efficent induction of HIV-1 replication by MTb. Furthermore, silencing by RNAi of key components of the TLR pathway in human monocytes, including the downstream signaling molecules MyD88, IRAK1, and TRAF6, significantly inhibits MTb-induced NFAT5 gene expression. Thus, the innate immune response to MTb infection induces NFAT5 gene and protein expression, and NFAT5 plays a crucial role in MTb regulation of HIV-1 replication via a direct interaction with the viral promoter. These findings also demonstrate a general role for NFAT5 in TLR- and MTb-mediated control of gene expression.","[{'offsets': [[93, 98]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[436, 473]], 'text': ['nuclear factor of activated T cells 5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[475, 480]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[621, 626]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1045, 1050]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1052, 1057]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1063, 1068]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1105, 1110]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1186, 1191]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1225, 1230]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1392, 1397]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
161,PMC-1064873-08-Materials_and_methods,"Western blot analysis
CD4+ T cells were stimulated for 20 min by the indicated concentrations of IL-10 and IL-6 at a density of 5 x 105 cells in 0.5 ml culture medium with 10% FCS. To examine the effect of serum IL-6 on STAT phosphorylation, normal CD4+ T cells were stimulated for 20 min with 30% active RA serum in culture medium with 40 mug/ml neutralizing goat anti-IL-6 polyclonal antibody (IgG; Techne, Princeton, NJ, USA) or control goat IgG (Techne). Whole cell lysates were prepared by placing cells in 100 mul SDS lysing buffer (62.5 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% bromphenol blue). Then 20 mul protein samples were fractionated on 10% SDS-polyacrylamide gels and were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK), and the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20.
Tyrosine phosphorylation of STAT1 and STAT3 was detected using commercial available kits (Cell Signaling Technology, Beverly, MA, USA) according to the manufacturer's instructions. Briefly, the membrane was incubated with the antibodies (rabbit IgG) anti-STAT1 antibody, anti-phosphorylated tyrosine 701 of STAT1 antibody, anti-STAT3 antibody, and anti-phosphorylated tyrosine 705 of STAT3 antibody, diluted as recommended at 1/2000 with Tris-buffered saline with 0.1% Tween 20 with 5% BSA. Antibody binding was detected by horseradish peroxidase-conjugated anti-rabbit IgG antibody diluted at 1/4000 with Tris-buffered saline with 0.1% Tween 20 with 5% BSA, and was revealed using the chemiluminescence system. Protein bands were quantified by densitometry using NIH-Image analysis, and STAT phosphorylation was compared with the total amount of STAT protein. IFN-gamma-stimulated Hela cells were used as a positive control for STAT1 phosophorylation.","[{'offsets': [[22, 25]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 102]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[107, 111]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[212, 216]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[249, 252]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[370, 374]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[911, 916]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[921, 926]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1138, 1143]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1190, 1195]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1211, 1216]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1267, 1272]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1671, 1675]], 'text': ['STAT'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1744, 1753]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1812, 1817]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
162,PMC-3589482-21-Results,"C/EBP-beta Promotes LPS-inducible Murine SerpinB2 Proximal Promoter Activity
Since C/EBP-beta binds to the SerpinB2 proximal promoter in an LPS-inducible manner both in vitro and in vivo, we wanted to address the question of whether C/EBP-beta was an essential factor for driving transcription from the SerpinB2 promoter in cells in response to LPS. The ability of endogenous C/EBP-beta to direct transcription from the SerpinB2 proximal promoter was examined by transfection of the pGLmP-539 murine SerpinB2 luciferase reporter construct into Cebpb+/+ and Cebpb-/- MEFs. We found that LPS-stimulated SerpinB2 promoter activity was significantly increased in Cebpb+/+ MEFs and abrogated in Cebpb-/- MEFs (Fig. 8A), indicating that endogenous C/EBP-beta is required for LPS-induced SerpinB2 proximal promoter activity.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 49]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 93]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[107, 115]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[233, 243]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[303, 311]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[376, 386]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[420, 428]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[500, 528]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[544, 549]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[557, 562]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[601, 609]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[659, 664]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 695]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[742, 752]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[781, 789]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
163,PMC-3320587-22-Discussion,"The transcription factor NFAT5 is the most evolutionarily divergent member of the Rel family of NFAT proteins [57]. Unlike the other NFAT proteins (NFATp, NFATc, NFAT3, and NFAT4), NFAT5 binds DNA as an obligate dimer in a fashion resembling NF-kappaB proteins [58], is calcineurin independent, and does not cooperate with the basic region-leucine zipper proteins Fos and Jun in gene activation ([59], [60], reviewed in [61]-[63]). To date, osmotic stress, integrin activation, and T cell-stimulation have been shown to regulate NFAT5 activity [59], [64], [65]. Based on our demonstration here that the host innate immune response to MTb infection induces MyD88-dependent upregulation of NFAT5 gene expression, we have expanded this list to include MTb as an additional stimulus. We have linked this observation to MTb-stimulated HIV-1 gene expression by showing that MTb enhances the replication of HIV-1 subtypes B and C via a direct interaction between NFAT5 and the viral promoter. Thus, HIV-1 has co-opted NFAT5, which is induced as part of the innate immune response to TB, for enhanced viral transcription/replication.
NF-kappaB is activated after MTb engagement of PRRs [20], [66]. Multiple studies of HIV-1 activation have shown that initial recruitment of the NF-kappaB p50/p65 heterodimer to the HIV-1 proviral enhancer region is crucial for HIV gene transcription (reviewed in [67], [68]). Upon interaction with the viral LTR, NF-kappaB rapidly induces hyperacetylation of histones associated with nucleosome 1 (nuc-1) at the HIV-1 transcription start site, resulting in recruitment of the pTEFb complex, which is required for RNA pol II processivity ([69], reviewed in [68], [70]).
In this report we directly examined the relative roles of NFAT5 and NF-kappaB p50/p65 in HIV-1 replication under conditions of activation by MTb co-infection, when NF-kappaB levels in the nucleus are elevated. We found that specific disruption of the NFAT5 binding site(s) in R5-tropic subtype B or subtype C infectious molecular clones significantly reduced virus replication in PBMC or MDM co-infected with a clinical isolate of MTb. Thus, NF-kappaB binding to the viral LTR is not sufficient to compensate for the loss of NFAT5 binding to the LTR under conditions of MTb co-infection. Reciprocally, an intact NFAT5 site could not compensate for disruption of the two NF-kappaB sites. Thus, both factors are required for MTb-induced HIV-1 replication.
Intriguingly, both in the absence and presence of MTb co-infection, disruption of NF-kappaB site II consistently resulted in greater suppression of virus replication than disruption of NF-kappaB site I. Consistent with these findings, synthetic reporter assays have previously shown that these two sites have distinct roles in driving transcription. The downstream NF-kappaB site I binding site, which is directly upstream of three highly conserved Sp binding sites, appears to enhance Sp protein recruitment to the LTR [71]-[73]. Because NF-kappaB site I overlaps the NFAT5 binding site, it is possible that loss of NF-kappaB binding to this site is mitigated, at least in part, by increased NFAT5 binding to the mutated site. This hypothesis is consistent with our quantitative DNase I footprinting analysis that shows that specific disruption of NF-kappaB site I results in enhanced binding of NFAT5 to the LTR.
HIV-1 subtype C now makes up greater than 50% of all HIV-1 infections worldwide, and its prevalence is especially high in regions of endemic TB [1], [2], [28], [52], Most HIV-1 subtype C isolates possess three NF-kappaB binding sites in the LTR [30]. Our analysis of MTb whole lysate-stimulated, LTR-driven reporter gene expression from representative B, C, and E LTRs showed that LTRs derived from subtype C isolates were superior in driving reporter gene expression as compared to LTRs derived from subtype B or E isolates. Other studies have found that, in response to TNF, subtype C LTRs drive reporter gene transcription more strongly than other subtype LTRs [38], [39]. In the co-infection model utilized in this report, in which clinical isolates of both MTb and HIV-1 subtype C were used to infect freshly prepared human peripheral blood cells, we found that specific disruption of NFAT5 binding to the LTR significantly impaired viral replication during MTb co-infection, indicating that even the presence of three intact NF-kappaB binding sites, which is typical for HIV-1 subtype C isolates [30], cannot compensate for loss of NFAT5 recruitment to the viral LTR in the context of MTb co-infection.
Given that the NF-kappaB and NFAT5 binding motifs overlap, how do NF-kappaB and NFAT5 function at this overlapping or shared site in the LTR to drive viral transcription in response to MTb infection? Because NFAT5 expression continues to rise for at least 48 hours post-MTb infection (Figure 2A), one possibility is that the host factors NF-kappaB and NFAT5 associate with the LTR at different stages after viral activation. While NF-kappaB presence in the nucleus declines in the hours post MTb infection [74], [75], NFAT5 levels escalate. Thus, NFAT5, which is pivotal for HIV-1 transcription in unstimulated cells [31], may, after Mtb infection, perpetuate viral transcriptional initiation begun by NF-kappaB and, with Tat levels also elevated, promote high levels of sustained HIV-1 transcription. Indeed, in response to hypertonic stress, NFAT5 binds to the aldose reductase (AR) promoter and induces rapid hyperacetylation of histones H3 and H4 [76]. Furthermore, hypertonic stress of mouse renal collecting duct epithelial cells results in NFAT5 and NF-kappaB complex formation at NF-kappaB-dependent gene promoters [77]. Thus, there are precedents for imagining that NFAT5 could function at the HIV-1 LTR by inducing histone remodeling in a manner similar to NF-kappaB ([69], reviewed in [68], [70]) or by directly interacting with NF-kappaB in a cooperative manner.
In conclusion, we have demonstrated that NFAT5 is required for the replication of R5-tropic subtype B and subtype C HIV-1 isolates in response to MTb-co-infection of human PBMC and MDM. Functional NF-kappaB interaction with the viral LTR is also required, but fully intact NF-kappaB binding elements are unable to compensate for the loss of NFAT5 recruitment to the viral promoter. In addition, we have demonstrated that MTb infection or stimulation with the TLR2 ligand PAM3Cys, induces NFAT5 gene expression in human monocytes. Furthermore, we have shown that MTb stimulation of NFAT5 depends on TLR pathway signaling molecules, including MyD88, IRAK1, and TRAF6. Taken together, the findings presented here enhance the general understanding of the innate immune response to MTb infection by showing that NFAT5 is a major mediator of TLR-dependent gene expression; its importance for gene regulation is likely applicable to other MTb- and TLR-regulated genes. Moreover, these data provide molecular insights into MTb regulation of HIV-1 transcription, thereby elucidating several new targets for therapeutic interventions aimed at controlling TB/HIV-1 co-infection.","[{'offsets': [[25, 30]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 153]], 'text': ['NFATp'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[155, 160]], 'text': ['NFATc'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[162, 167]], 'text': ['NFAT3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[173, 178]], 'text': ['NFAT4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[181, 186]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[270, 281]], 'text': ['calcineurin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[364, 367]], 'text': ['Fos'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[372, 375]], 'text': ['Jun'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[529, 534]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[656, 661]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[688, 693]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[956, 961]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1011, 1016]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1280, 1283]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1284, 1287]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1753, 1758]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1773, 1776]], 'text': ['p50'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1777, 1780]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2220, 2225]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3142, 3147]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3229, 3236]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3346, 3351]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3936, 3939]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4254, 4259]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4502, 4507]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4653, 4658]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4781, 4786]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4925, 4930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[5091, 5096]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5120, 5125]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5295, 5298]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5417, 5422]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5436, 5452]], 'text': ['aldose reductase'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5454, 5456]], 'text': ['AR'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5620, 5625]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5748, 5753]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5989, 5994]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[6145, 6154]], 'text': ['NF-kappaB'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[6289, 6294]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6407, 6411]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6436, 6441]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6529, 6534]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[6589, 6594]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[6596, 6601]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[6607, 6612]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[6755, 6760]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T60'}]",[],[],[],[],[]
164,PMC-1472690-23-Caption-Figure_6,"Decreased IL-1beta/IL-1RA ratio following GP + TSST-1 when compared to TSST-1. Time course (48 h) of the IL-1beta/IL-1RA ratio following incubation of human PBMC with LPS, TSST-1, GP + LPS, GP/LPS calc., GP + TSST-1 or GP/TSST-1 calc. LPS and GP + LPS treatments resulted in generating more IL-1beta than IL-1RA up to 24 h. When comparing LPS or GP/LPS calc. vs GP + LPS we did not find significant alterations in the IL-1beta/IL-1RA ratio over 48 h. With respect to TSST-1 or GP/TSST-1 calc. vs GP + TSST-1 we observed a pronounced anti-inflammatory action of GP, as demonstrated by an about 10-100 fold reduced ratio at 18 h and 24 h, i.e. a higher production of IL-1RA than of IL-1beta (* = p < 0.05). Data are shown as mean +/- SEM (n = 3).","[{'offsets': [[10, 18]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[19, 25]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[47, 53]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[71, 77]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[105, 113]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[114, 120]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[172, 178]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[209, 215]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[222, 228]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[291, 299]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[305, 311]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[418, 426]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[427, 433]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[467, 473]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[480, 486]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[501, 507]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[665, 671]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[680, 688]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
165,PMC-3218875-13-Caption-Figure_2,"Noncanonical NF-kappaB signalling. CD40 and RANK can activate the noncanonical NF-kappaB pathway that is dependent on NF-kappaB inducing kinase (NIK) expression levels. In unstimulated cells NIK forms a cytosolic complex with the ubiquitin ligases TRAF2, TRAF3 and cIAP1/2, which facilitates the K48-linked polyubiquitination and proteasomal degradation of NIK, keeping NIK levels low. Upon ligand binding, TRAF3 is recruited to the receptor, where TRAF2 directs nondegradative K63-linked polyubiquitination of cIAP1/2, resulting in their activation. Subsequently cIAP1/2 directs its K48-linked polyubiquitination to TRAF3, rather than NIK. As a result, TRAF3 is degraded and NIK is stabilised, resulting in increased NIK levels in the cell. NIK then phosphorylates and activates IKK1, which mediates NF-kappaB p100 phosphorylation. This is followed by K48-linked polyubiquitination and partial proteasomal degradation of p100 to p52, which forms a heterodimer with RelB to activate transcription. Next to TRAF3, TRAF1 has also been identified as a negative regulator of this pathway, most probably by competing with other TNF receptor-associated factors. cIAP, cellular inhibitor of apoptosis; IKK, IkappaB kinase; NF, nuclear factor; RANK, receptor activator of NF-kappaB; TRAF, TNF receptor-associated factor; TNF, tumour necrosis factor.","[{'offsets': [[35, 39]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[44, 48]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[118, 143]], 'text': ['NF-kappaB inducing kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[145, 148]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[191, 194]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[248, 253]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[255, 260]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[265, 270]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[271, 272]], 'text': ['2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[357, 360]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[370, 373]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[407, 412]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[449, 454]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[511, 516]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[517, 518]], 'text': ['2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[564, 569]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[570, 571]], 'text': ['2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[617, 622]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[636, 639]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[654, 659]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[676, 679]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[718, 721]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[742, 745]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[780, 784]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[811, 815]], 'text': ['p100'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[922, 926]], 'text': ['p100'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[930, 933]], 'text': ['p52'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[966, 970]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1006, 1011]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1013, 1018]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1236, 1240]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1242, 1273]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1313, 1316]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1318, 1340]], 'text': ['tumour necrosis factor'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
166,PMC-3589482-29-Caption-Figure_6,"C/EBP-beta is essential for constitutive and LPS-induced SerpinB2 mRNA expression.
(A) Endogenous SerpinB2 mRNA expression is abrogated in Cebpb-/- MEFs compared to Cebpb+/+ MEFs in the absence and presence of LPS. qPCR analysis of murine SerpinB2 mRNA expression in untreated Cebpb+/+ and Cebpb-/- MEFs, and after simulation with LPS (100 ng/ml) for the indicated times. (B) Endogenous SerpinB2 expression is abrogated in C/EBP-beta-deficient inflammatory macrophages. Thioglycollate-elicited peritoneal macrophages (TG macs) were infected with human and murine specific lentiviral shRNAs. Human CEBPB shRNA serves as the non-silencing control since it does not target the murine Cebpb sequence [38]. Lentiviral transduced macrophages were stimulated with LPS (100 ng/ml) for 4 hrs. Left: Western blot analysis shows effective knockdown of endogenous C/EBP-beta following infection with murine Cebpb shRNA and not human CEBPB shRNA. Right: qPCR analysis of murine SerpinB2 mRNA expression in the lentiviral transduced peritoneal macrophages. The results represent the mean and SEM of two independent experiments performed in duplicate or triplicate. (*, p<0.05, two-way ANOVA).","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 65]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[98, 106]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 144]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[165, 170]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[239, 247]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[277, 282]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[290, 295]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[387, 395]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[423, 433]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[681, 686]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[852, 862]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[965, 973]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}]",[],[],[],[],[]
167,PMC-3317373-03-2._Methods_and_Materials,"2.2. In Vitro Model of TBI Established by Scratch Injury
Astrocyte scratch injury was performed as in a previous report [7]. Astrocytes were planted in 6-well plates and grown to confluence. The cell monolayer was scratched with a sterile 26G syringe needle, resulting in the formation of a 0.5 mm wide gap. Immediately after scratch, cells were washed twice with sterile PBS, cultured with complete culture medium, and named as TBI group. Cells, which did not received scratch, were used as blank control and named as sham group.",[],[],[],[],[],[]
168,PMC-2817507-03-2._Methods,"2.2. Induction of Intracerebral Hemorrhage
Since most intracerebral hemorrhages occur in the basal ganglia clinically, in the present study, rat model of ICH was induced in left basal ganglia. Rats were anesthetized with intra-peritoneal sodium pentobarbital (60 mg/kg). The body (rectal) temperature was maintained at 37degreesC during the surgery using a feedback-controlled heating system. The rats were positioned in a stereotactic frame, and the scalp was incised along the midline. Using a sterile technique, a 1 mm burr hole was opened in the skull on the left coronal suture 3 mm lateral to the midline. A blunt 26-gauge needle was inserted into the left basal ganglia under stereotactic guidance (coordinates: 0.2 mm anterior, 6.0 mm ventral, and 3.0 mm lateral to the midline). Then, a 75 muL of autologous whole blood was infused at a rate of 20 muL/min with the use of a microinfusion pump. After the completion of the infusion, the needle was withdrawn quickly, cyanoacrylate glue was placed around the burr hole, and the skin incision was closed with sutures. For the normal saline control rats, only 75 muL normal saline was injected.",[],[],[],[],[],[]
169,PMC-3585731-02-Results,"Basic Fibroblast Growth Factor Promotes Necroptosis in L929 Cells
It has been established that mouse fibrosarcoma L929 cells undergo necroptotic cell death following stimulation with TNFalpha [10], [17]. In addition, inhibition of caspase-8 activity alone, either through siRNA knockdown or by using the pan-caspase inhibitor, zVAD.fmk, is sufficient to trigger necroptosis in these cells [10], [14]. Interestingly, while necroptosis was initially identified as a back-up form of cell death triggered by pro-apoptotic stimuli in the presence of apoptosis inhibitors [17], recent analysis of physiological cell death during mouse development has suggested that the loss of apoptotic regulators, such as caspase-8 and FADD [18], [19], [20], leads to robust induction of necroptosis and death of E10.5 embryos even though apoptosis is not normally induced in wild type embryos. These data are reminiscent of the observations in L929 cells where the loss of caspase activity in healthy cells is sufficient to trigger necroptosis and prompted us to explore the extrinsic or intrinsic cellular factors that promote necroptosis once caspase-8 activity, which cleaves and inactivates RIP1 kinase and the RIP1 deubiquitinase CYLD [21], [22], is removed in L929 cells. Consistent with a previous report [16], we found that serum starvation of L929 cells prevented necroptosis in response to zVAD.fmk (Fig. 1A). The addition of growth factors, such as bFGF, restored zVAD.fmk induced death under serum free conditions (Fig. 1B). Interestingly, this does not reflect a generic requirement for growth factor signaling, as only some growth factors (bFGF and IGF-1, but not EGF and PDGF) promoted death (Fig. 1B). Furthermore, growth factor-dependent necroptosis required the inhibition of caspase activity, as bFGF alone did not induce cell death (Fig. 1C). In contrast, TNFalpha triggered necroptosis equally efficiently in the absence of serum (Fig. 1A), suggesting that either growth factors and zVAD.fmk or TNFalpha are required for necroptotic death in L929 cells.
Previously we described the development of 7-Cl-O-Nec-1 (Nec-1) as a potent and selective inhibitor of RIP1 kinase and necroptosis (Fig. S1A) [23], [24]. Recently, its selectivity has been further validated against a panel of more than 400 human kinases [15]. This inhibitor efficiently blocked growth factor/zVAD.fmk-induced necroptosis under serum free conditions in L929 cells and both zVAD.fmk and TNFalpha-induced necroptosis under full serum conditions (Fig. 1B, S1B). To further validate the role of RIP1, we used an inactive analog, 7-Cl-O-Nec-1i (Nec-1i) (Fig. S1A), which contains an extra N-methyl group that leads to almost complete loss of RIP1 kinase inhibitory activity in vitro [23]. Nec-1i was unable to protect L929 cell death under serum condtions treated with zVAD.fmk or TNFalpha (Fig. S1B) or serum free conditions treated with bFGF/zVAD.fmk (Fig. S1C). This confirms that RIP1 kinase is responsible for necroptosis in L929 cells under both serum and serum free conditions.
We next examined whether bFGF contributes to zVAD.fmk-induced necroptosis under normal serum conditions (10% FBS). We used two bFGF receptor tyrosine kinase inhibitors (PD173074 and PD166866), and determined that inhibition of bFGF signaling strongly inhibited zVAD.fmk-induced necroptosis under normal serum conditions (Fig. 1D). In contrast, neither bFGF receptor inhibitor was able to attenuate TNFalpha-induced necroptosis (Fig. 1D), consistent with growth factors being dispensable for this pathway (Fig. 1A). Overall, these data suggest that the induction of necroptosis by zVAD.fmk is promoted by bFGF under both serum and serum free conditions. The induction of necroptosis, however, is not a simple consequence of growth factor signaling since not all growth factors allowed death to occur. Instead, specific signaling events mediated by particular growth factors appear to contribute to necroptotic death.","[{'offsets': [[0, 30]], 'text': ['Basic Fibroblast Growth Factor'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 191]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[231, 240]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[702, 711]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[716, 720]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1126, 1135]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1176, 1180]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1196, 1215]], 'text': ['RIP1 deubiquitinase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1216, 1220]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1441, 1445]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1635, 1639]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1644, 1649]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1659, 1662]], 'text': ['EGF'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1796, 1800]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1857, 1865]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1997, 2005]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2159, 2163]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2458, 2466]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2563, 2567]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2709, 2713]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2848, 2856]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2906, 2910]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2951, 2955]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3077, 3081]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3179, 3208]], 'text': ['bFGF receptor tyrosine kinase'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3279, 3283]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3404, 3417]], 'text': ['bFGF receptor'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3450, 3458]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3656, 3660]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T29'}]",[],[],[],[],[]
170,PMC-3320587-10-Materials_and_Methods,"MTb culture
The MTb clinical strain CDC1551 was prepared by adding 100 microl of frozen bacteria stock into 10 ml of Middlebrook 7H9 medium (Difco BD, www.bd.com) supplemented with albumin dextrose complex (ADC) and 0.05% Tween 80 (Sigma-Aldrich, www.sigmaaldrich.com). The cultures were grown to an OD650 of 0.4 at 37degreesC to ensure that they were in the logarithmic growth phase. Bacteria were then plated, washed with PBS, resuspended in PBS, and passed through a 5 microm filter to ensure that the bacteria were in a single cell suspension. Bacterial cell numbers were determined by measurement of OD650 before further dilution with RPMI 1640 medium for cell infection studies at 10:1 PBMC: bacilli or 1:1 MDM: bacilli and THP-1:bacilli. Colony-forming unit (CFU) analysis was performed and on days 4 and 7 the average CFU counts were 6x103 and 5x104, respectively, confirming that mycobacteria levels increased over the course of infection of primary MDM.",[],[],[],[],[],[]
171,PMC-3342329-12-Materials_and_Methods,"Immunohistochemistry
All specimens were fixed in formalin and embedded in paraffin for examination. Sections (4 microm thick) were stained with H&E and analyzed by immunohistochemistry. The paraffin-embedded sections were deparaffinized and rehydrated, washed in distilled water, and then subjected to heat-mediated antigen retrieval. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in methanol for 15 min, followed by clearing in PBS for 5 min. The sections were blocked for 30 min with 3% normal horse serum diluted in PBS, blotted, and incubated with primary mouse anti-mouse proliferating cell nuclear antigen (PCNA, 1:200 dilution) monoclonal antibodies in blocking serum for 4 h at room temperature. Thereafter, the slides were washed three times for 5 min each in PBS and incubated with biotinylated anti-mouse and anti-rabbit antibodies for 2 h. The slides were washed in PBS, followed by the addition of the avidin biotin peroxidase complex (ABC kit; Vector Laboratories, Burlingame, CA, USA). The slides were washed and the peroxidase reaction was developed with diaminobenzidine (DAB) and peroxide, followed by counterstaining with hematoxylin, mounting in aqua-mount, and evaluation under a light microscope (magnificationx200; Olympus, Tokyo, Japan). A negative control was included in all experiments by omitting the primary antibody. For the detection of apoptotic cell death in the tumor tissues, the paraffin-embedded sections were incubated in a mixture of the labeling solution (540 microl) and enzyme solution (60 microl) for 1 h at 37degreesC, and then washed three times in 0.1 M PBS for 5 min each, according to the manufacturer's instructions. Next, the sections were incubated with 4',6-diamidino-2-phenylindole (DAPI) for 15 min at 37degreesC. Finally, the sections were rinsed, mounted on slides, and cover-slipped for fluorescence microscopy (DAS microscope).",[],[],[],[],[],[]
172,PMC-1064873-14-Results,"High expression of SOCS1 mRNA in RA CD4+ T cells
IL-6 induces two potent inhibitors of JAKs (SOCS1 and SOCS3 proteins) that not only act as mediators of negative feedback inhibition, but also play a major role in crosstalk inhibition by opposing other cytokine-signaling pathways [7]. SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL-6 but not by IL-10, thereby regulating the divergent action of IL-6 and IL-10 [8,9]. On the contrary, SOCS1 is able to partially inhibit IL-10-mediated STAT3 activation and cellular responses, as well as IFN-gamma-mediated STAT1 activation [32]. To determine whether SOCSs were involved in the defective IL-10-induced STAT3 activation of RA CD4+ T cells, the levels of SOCS1 and SOCS3 mRNA expression in PB CD4+ T cells from active RA patients and from healthy controls were compared by semiquantitative real-time PCR. The RA CD4+ T cells contained higher levels of SOCS1 but lower levels of SOCS3 transcripts than did control CD4+ T cells (Fig. 6a). Constitutive expression of SOCS1 mRNA in RA CD4+ T cells was comparable with the expression in normal CD4+ T cells stimulated by 10 ng/ml IL-6 (Fig. 6b), supporting its functional significance. Defective IL-10-induced STAT3 activation therefore appears to be due at least in part to an abundance of SOCS1 in RA CD4+ T cells.","[{'offsets': [[19, 24]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 39]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 53]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[93, 98]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[103, 108]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[285, 290]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[339, 344]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[367, 371]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[383, 388]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[433, 437]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[442, 447]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[472, 477]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[507, 512]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[522, 527]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[574, 583]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[593, 598]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[674, 679]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[688, 693]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[711, 714]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[739, 744]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[749, 754]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[777, 780]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[896, 899]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[936, 941]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[962, 967]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[997, 1000]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1048, 1053]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1065, 1068]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1123, 1126]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1159, 1163]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1225, 1230]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1239, 1244]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1320, 1325]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1332, 1335]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
173,PMC-3320587-15-Results,"Specific disruption of NFAT5 binding impairs LTR-driven transcription in THP-1 cells in response to MTb stimulation
Although the transcription factor NFAT5 binds to a core NF-kappaB binding motif in the HIV-1 LTR enhancer region of subtype B, when two thymines (TT) are changed to cytosines (CC) in the proximal NF-kappaB binding motif (named N5-Mut) (bottom of Figure 1B), the binding of NFAT5 can be disrupted while leaving binding of NF-kappaB unperturbed [31]. We examined the requirement of NFAT5 for MTb-induced LTR activity by transfecting a wild-type and NFAT5 mutant LTR reporter construct into THP-1 cells, followed by stimulation with an MTb lysate. As shown in Figure 1B, in the absence of MTb lysate stimulation the activity of the NFAT5 binding site-mutant LTR was significantly reduced (p<0.05) in comparison to the wild-type LTR. When the NFAT5 binding site-mutant LTR was examined in THP-1 cells stimulated with the MTb lysate, its activity was reduced to an even more significant extent (p<0.01).
To determine whether MTb lysate stimulation directly enhances NFAT5 expression in THP-1 cells, we stimulated cells for 8 or 24 hours or left them unstimulated and examined NFAT5 protein levels by western blot. As shown in Figure 1C, we found that NFAT5 protein levels steadily increased in response to MTb lysate stimulation, revealing that TLR engagement by MTb results in enhanced levels of NFAT5, consistent with its playing a role in MTb-induced activation of the HIV-1 LTR.","[{'offsets': [[23, 28]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[150, 155]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[389, 394]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[496, 501]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1077, 1082]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1187, 1192]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1262, 1267]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1408, 1413]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
174,PMC-3312845-06-Methods,"Immunohistochemistry
Free-floating sections were first incubated with 10% normal goat serum for 30 min at room temperature. They were then incubated in rabbit anti-MPO IgG (1:100, Thermo fisher scientific) or rabbit anti-MIP-2 IgG (1:200, Invitrogen, Carlsbad, CA) in PBS containing 0.3% Triton X-100 (Sigma-Aldrich Co., St. Louis, MO) and 2% normal goat serum(Sigma-Aldrich Co., St. Louis, MO) overnight at room temperature. After washing three times for 10 min with PBS, the sections were incubated sequentially, in goat anti-rabbit or horse anti-mouse IgG (Vector, Burlingame, CA) and ABC complex (Vector, Burlingame, CA), diluted 1:200 in the same solution as the primary antiserum. Between the incubations, the tissues were washed with PBS three times for 10 min each. To confirm vasogenic edema, some tissue sections were reacted for serum-proteins using horse anti-rat IgG (Vector, Burlingame, CA) as a primary antibody. The sections were visualized with 3,3'-diaminobenzidine (DAB, Sigma-Aldrich Co., St. Louis, MO) in 0.1 M Tris buffer and mounted on the gelatin-coated slides. The immunoreactions were observed under the Axioscope microscope (Carl Zeiss, Munchen-Hallbergmoos). For negative controls, rat hippocampal tissues were incubated with 1 mug of the antibody that was preincubated with 1 mug of purified peptide for 1 hr at room temperature or incubated with pre-immune serum instead of the primary antibody. For negative controls, tissues were incubated with pre-immune serum instead of primary antibody.",[],[],[],[],[],[]
175,PMC-1472690-05-Results,"GP modulated the TSST-1-induced IL-1beta/IL-1RA ratio towards an anti-inflammatory phenotype
In a simplified approach, IL-1beta and IL-1RA might represent two sides of a coin, i.e. pro- or anti-inflammatory action. Therefore, we applied the IL-1beta/IL-1RA ratio as an indicator of the degree of inflammation. Both, LPS and GP + LPS treatments resulted in generating more IL-1beta than IL-1RA at early time points, i.e. up to 24 h. Comparing LPS vs. GP + LPS, we did not find substantial alterations over a time course of 48 h in the IL-1beta/IL-1RA ratio, only a - non-significant - 2.5fold higher ratio at 6 h. With respect to TSST-1 or the theoretical value of GP/TSST-1 calc. vs. GP + TSST-1, we observed a pronounced anti-inflammatory action of GP, as demonstrated by an about 10-100 fold reduced ratio at 18 h and 24 h of incubation, i.e. a higher production of IL-1RA than of IL-1beta (n = 3; both p < 0.05; Fig. 6). A biological relevance of this result was suggested by a decrease of the IL-1 dependent release of IL-2 from murine EL-4 cells following GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc. (data not shown in detail, n = 4; p < 0.07).","[{'offsets': [[17, 23]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[32, 40]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 47]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[119, 127]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[132, 138]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[241, 249]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[250, 256]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[372, 380]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[386, 392]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[534, 542]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[543, 549]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[629, 635]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[667, 673]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[689, 695]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[868, 874]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[883, 891]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[997, 1001]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1023, 1027]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1066, 1072]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1090, 1096]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1103, 1109]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
176,PMC-3320587-26-Caption-Figure_4,"MTb-induced HIV-1 replication in PBMC depends on binding of NFAT5 and NF-kappaB to the LTR.
Specific disruption of the NF-kappaB or NFAT5 binding sites in the HIV-1 subtype B LTR inhibits R5-tropic virus replication in human PBMC after co-infection with MTb. PBMC from four normal donors were infected with 1000 TCID50 HIV-1Lai/Bal-env-WT or the mutants HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut and either; (A) left untreated, or (B) co-infected with MTb isolate CDC1551 (10:1 cells:bacilli). Viral p24 levels in culture supernatants were measured at days 4, 7 and 12 post-infection. (C) Histograms show viral p24 levels at day 12 in the MTb uninfected (grey bars) and MTb co-infected (black bars) PBMC cultures. Replication of the mutant viruses was compared to wild-type virus replication under the same experimental conditions (without and with MTb co-infection, respectively). *, p<0.05; **, p<0.01, as compared to HIV-1Lai/Bal-Env-WT.","[{'offsets': [[60, 65]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[332, 335]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[367, 370]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[398, 401]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[430, 433]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[467, 470]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[582, 585]], 'text': ['p24'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[693, 696]], 'text': ['p24'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
177,PMC-3585731-30-Caption-Figure_5,"mTORC1 contributes to the regulation of necroptosis.
(A) L929 cells were treated with zVAD.fmk or TNFalpha for 9 hr and harvested for western blot. (B) Cell under serum free condition were treated with bFGF or bFGF/zVAD.fmk for the indicated amounts of time, followed by western blotting using the indicated antibodies. (C) Necroptosis was induced by zVAD.fmk or TNFalpha in L929 cell in the presence of inhibitors of Akt(Akt inh. VIII) and mTOR (rapamycin, Torin-1 and PI-103). (D) L929 cells with mTOR siRNA knockdown were harvested for western blot or treated with zVAD.fmk or TNFalpha for 24 hrs. Cell viability was determined 24 hr after activation of necroptosis. In all graphs, average+/-SD was plotted.","[{'offsets': [[98, 106]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[202, 206]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[210, 214]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[363, 371]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[580, 588]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
178,PMC-3585731-11-Results,"Model of RIP1, Akt and JNK Dependent Signaling in Necroptotic L929 Cells
In this study we investigated RIP1 kinase-dependent signaling pathways using mouse fibrosarcoma L929 cells that die by necroptosis when treated with the pan-caspase inhibitor zVAD.fmk. Altogether, our results suggest that Akt kinase is specifically engaged in signaling downstream from RIP1 kinase, which leads to a selective increase in its phosphorylation on Thr308, but not Ser473. According to our model (Fig. 9), necroptosis-associated phosphorylation of Akt requires two distinct signals. The first input, which is induced by growth factors, leads to the plasma membrane localization of Akt. Expression of a constitutively membrane-targeted Akt construct, Myr-Akt, overcomes the requirement for growth factors. At the same time, expression of Myr-Akt alone is not sufficient for the induction of necroptosis. A second, RIP1 kinase-dependent input is required for Thr308 phosphorylation of Akt in response to caspase inhibition and is essential for the propagation of the necroptotic signal.
Using Akt inhibitors, knockdown of Akt isoforms, and the expression of Akt mutants, we showed that necroptotic activation of Akt is indispensable for this form of cell death in L929 cells. We also investigated downstream Akt-dependent pathways that contribute to necroptosis. First, we demonstrated that selective necroptotic phosphorylation of Thr308 of Akt is sufficient to increase its activity towards a number of known substrates and Akt effector pathways such as the mTORC1 pathway, which, in turn, contributes to cell death. Second, our data suggested that Akt activation provides a pivotal link connecting RIP1 kinase to known downstream signaling and execution events in necroptotic L929 cells, namely, JNK activation and autocrine TNFalpha synthesis, a critical event in necroptosis in L929 cells [15].
In order to further test our model, we examined Akt phosphorylation after inhibition of a downstream kinase in the pathway, JNK. However, we found that SP600125, which protected L929 cells from death and inhibited TNFalpha production (Fig. 2A,B S2A S10A), inhibited both basal and post-treatment phosphorylation levels of Akt at both Ser473 and Thr308 (Fig. S10B). It has been published that SP600125 is a somewhat non-specific inhibitor that may inhibit the p110delta subunit of PI3K [41] and PDK1 [42]. Both of these off-target effects could inhibit basal Akt phosphorylation levels, precluding the use of SP600125 in this system.
Therefore, to examine the role of JNK, we switched to a more specific JNK inhibitor, JNK inhibitor VIII [43], and siRNAs against JNK1 and JNK2 (Fig. S10B-G). As expected, specific inhibition or knockdown of JNK1/2 allowed phosphorylation of Akt on Thr308 while inhibiting the phosphorylation of c-Jun at Ser63 (Fig. S10B,E), agreeing with our model. It did not, however, lead to a reduction in TNFalpha production or cell death (Fig. S10C,D,F,G), suggesting that earlier data with SP600125 protection (Fig. 2) could reflect off-target effects of this molecule, rather than JNK inhibition. Previous reports also suggested a critical role for c-Jun in necroptosis and autocrine TNFalpha synthesis [13], [14], [15] and we confirmed these conclusions using c-Jun siRNA knockdown (Fig. S10H-J). Notably, in this case, Thr308 phosphorylation was reduced after the induction of necroptosis. Thus, autocrine TNFalpha production, dependent on c-Jun, may create a feedback loop that contributes to the delayed activation of Akt. It is also important to note that we observed an overall increase in the protein level of c-Jun after treatment of L929 cells with zVAD.fmk or TNFalpha, which was both Akt and mTOR-dependent (Fig. 6E,F). These new data led us to an unexpected, but important conclusion that c-Jun is critical for necroptosis, while JNK activity may serve as a useful marker of pathway activation, but may be either redundant (e.g. phosphorylation of c-Jun on a site other than Ser63 may occur [44]) or dispensable functionally. In addition, researchers need to use caution when using SP600125 due to potantial off-target effects.","[{'offsets': [[9, 13]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[103, 107]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[359, 363]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[735, 742]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[822, 829]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[898, 902]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1684, 1688]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1811, 1819]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2097, 2105]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2342, 2359]], 'text': ['p110delta subunit'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2377, 2381]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2645, 2649]], 'text': ['JNK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2654, 2658]], 'text': ['JNK2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2723, 2727]], 'text': ['JNK1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2728, 2729]], 'text': ['2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2811, 2816]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2910, 2918]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3157, 3162]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3192, 3200]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3269, 3274]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3416, 3424]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3450, 3455]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3625, 3630]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3678, 3686]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3809, 3814]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3968, 3973]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
179,PMC-1472690-12-Methods,"Oligonucleotides (Oligos) and 5'-32-P-Labeling
The complementary double-stranded (ds) oligonucleotides (oligos) from the TNFalpha, IL-8, IFNgamma and IL-6 promoters were synthesised from single stranded (ss) oligos (illustrated in Table 1), (TIB Molbiol, Berlin, Germany) and 32P-labeled with 5'gamma-P-ATP (3,000 Ci/mmol, Amersham, Braunschweig, Germany) using the Ready-To-Go-Polynucleotide-Kinase Kit (PNK Kit, Pharmacia LKB, Freiburg, Germany) according to the manufacturer's instructions. To test the binding specificity of the oligos, mutated oligos were used as an additional control. Mutations in the P2 site of the IFNgamma promoter [29] and in the kappa consensus sequence of the TNFalpha promoter [55] have been reported to interfere with sequences, which seem to be crucial for the binding of NFAT and NFkappaB proteins, respectively. Afterwards, the ds oligos were purified via gel filtration using Probe Quant G-50 Micro Columns (Pharmacia) according to the manufacturer's instructions.","[{'offsets': [[121, 129]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[131, 135]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 145]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[150, 154]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[624, 632]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[690, 698]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[805, 809]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
180,PMC-3586680-00-TIAB,"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.","[{'offsets': [[17, 21]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[26, 29]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[96, 99]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[242, 277]], 'text': ['WW domain-containing oxidoreductase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[278, 282]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[284, 287]], 'text': ['FOR'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[291, 295]], 'text': ['WOX1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[372, 376]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[567, 571]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[650, 653]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[655, 659]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[712, 715]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[775, 778]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[783, 787]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[849, 852]], 'text': ['p53'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[902, 906]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[935, 939]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[978, 981]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
181,PMC-1359074-05-Results,"The Persistent Expression of epsilony Globin in Sox6-Deficient Mice Is Due to a Defect in the epsilony-Gene-Silencing Mechanism in Definitive Erythroid Cells
Normally, the epsilony globin gene is exclusively expressed in primitive erythrocytes and silenced in definitive erythrocytes. To determine whether the persistent expression of epsilony globin is due to residual primitive erythrocytes or is due to ectopic expression of epsilony globin in definitive erythrocytes, we examined the spatial pattern of epsilony globin transcripts in mouse embryos by in situ hybridization (Figure 5). As expected, epsilony globin is not expressed in the WT 14.5-dpc liver, the site of definitive erythropoiesis in the fetus. In contrast, abundant ectopic epsilony mRNA expression is seen in the liver of 14.5-dpc mutants (Figure 5 A-D). However, the expression of betamaj/min globin is equally abundant in both WT and p100H mutant mice (Figure 5 E and F). These data demonstrate that the persistent high levels of epsilony are due to ectopic expression in the definitive erythroid cells that mature in the fetal liver, suggesting that there is an intrinsic defect of the epsilony silencing mechanism in Sox6-null mice.","[{'offsets': [[29, 44]], 'text': ['epsilony Globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[48, 52]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[94, 102]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 187]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[335, 350]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[428, 443]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[507, 522]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[602, 617]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[743, 751]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[852, 859]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[860, 870]], 'text': ['min globin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1002, 1010]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1159, 1167]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1191, 1195]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
182,PMC-3589482-04-Experimental_Procedures,"DNA Sequence Analysis
The DNA sequence of the murine SerpinB2 promoter was determined by sequencing the pUC-based plasmids pDB9406, pDB9402-41 and pDB9402-42, in addition to plasmids prepared from pDB9402-41 and pDB9402-42 containing deletions introduced by exonuclease III digestion. Plasmids pDB9406, pDB9402-41 and pDB9402-42 containing genomic DNA isolated from a lambdaFIXII (Stratagene) genomic library prepared from a 129 mouse strain, were kindly provided by Dr. Dominique Belin, University of Geneva. pDB9406 contains a 4.4 kb EcoRI/SpeI genomic fragment spanning the transcription initiation site; pDB9402-41 and pDB9402-42 contain a 1.2 kb EcoRI genomic fragment, located immediately upstream of the pDB9406 EcoRI fragment, cloned in opposite orientations. Subcloned inserts were verified by restriction enzyme digestion and DNA sequencing. The nucleotide sequence of the 4480 bp murine SerpinB2 gene 5' flanking region was determined using the ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin-Elmer) and a PE 373A sequencer (Perkin-Elmer). This sequence was deposited in GenBank/EMBL/DDBJ Data Bank with Accession No. AF339731.","[{'offsets': [[53, 61]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[258, 273]], 'text': ['exonuclease III'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[898, 906]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
183,PMC-1064895-01-Introduction,"Rheumatoid arthritis (RA) is characterized by infiltrations of macrophages and T cells into the joint, and synovial hyperplasia. Proinflammatory cytokines released from these cells are known to be important in the destruction of joints in RA [1]. The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-alpha) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2].
A little over a decade ago, the primacy of T cells in the pathogenesis of autoimmune disease such as RA was undisputed because they are the largest cell population infiltrating the synovium. However, a series of studies demonstrated paucity of T cell-derived cytokines such as IL-2 and interferon-gamma in the joints of RA, whereas macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-alpha were abundant in rheumatoid synovium. This paradox has questioned the role of T cells in the pathogenesis of RA [3]. Because we have already demonstrated the enhanced proliferation of antigen specific T cells, especially to type II collagen, and the skewing of T helper type 1 (Th1) cytokines in RA [4], the role of T cells needs to be elucidated in different aspects.
IL-17 is one of the inflammatory cytokines secreted mainly by activated T cells, which can induce IL-6 and IL-8 by fibroblasts [5]. This cytokine is of interest for two major reasons: first, similarly to TNF-alpha and IL-1, IL-17 has proinflammatory properties; second, it is produced by T cells [6]. Recent observations demonstrated that IL-17 can also activate osteoclastic bone resorption by the induction of RANKL (receptor activator of nuclear factor kappaB [NF-kappaB] ligand), which is involved in bony erosion in RA [7]. It also stimulates the production of IL-6 and leukemia inhibitory factor by synoviocytes, and of prostaglandin E2 and nitric oxide by chondrocytes, and has the ability to differentiate and activate the dendritic cells [8-10]. Levels of IL-17 in synovial fluids were significantly higher in patients with RA than in patients with osteoarthritis (OA), and it was produced by CD4+ T cells in the synovium [11,12].
IL-15, secreted from activated macrophages, has been reported to be an important trigger of IL-17 production in RA peripheral blood mononuclear cells (PBMC) by cyclosporine and steroid sensitive pathways [13]. Recently, Happel and colleagues also showed that IL-23 could be an efficient trigger of IL-17 production from both CD4+ and CD8+ T cells [14].
Although the contribution of IL-17 in joint inflammation in RA has been documented in earlier studies [12,15,16], the intracellular signal transduction pathway for IL-17 production remains uncertain. In the present study we used various stimuli to investigate IL-17 production in PBMC of patients with RA and its signaling transduction pathway.
We found that the intracellular signaling pathway involving phosphoinositide 3-kinase (PI3K)/Akt and NF-kappaB might be involved in the overproduction of the key inflammatory cytokine IL-17 in RA. These results might provide new insights into the pathogenesis of RA and future directions for new therapeutic strategies in RA.","[{'offsets': [[307, 340]], 'text': ['tumor necrosis factor (TNF)-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[346, 364]], 'text': ['interleukin (IL)-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[783, 787]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[792, 808]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[884, 888]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[890, 894]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[896, 901]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[903, 908]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[913, 922]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1292, 1297]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1390, 1394]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1399, 1403]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1496, 1505]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1510, 1514]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1516, 1521]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1631, 1636]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1704, 1709]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1711, 1773]], 'text': ['receptor activator of nuclear factor kappaB [NF-kappaB] ligand'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1858, 1862]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1867, 1893]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2057, 2062]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2194, 2197]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2232, 2237]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2324, 2329]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2491, 2496]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2530, 2535]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2557, 2560]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2566, 2569]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2614, 2619]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2749, 2754]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2845, 2850]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3023, 3026]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3114, 3119]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}]",[],[],[],[],[]
184,PMC-3312845-17-Results,"MIP-2 expression
MIP-2 is a powerful chemokine that contributes to recruitment of neutrophils [27]. MIP-2 is undetectable or present at low levels under physiological conditions, and shows transient increases under pathological conditions via TNF-alpha and/or interleukin-1beta (IL-1beta)-dependent mechanisms [14]. Thus, it would be plausible that TNF-alpha-mediated MIP-2 expression may provoke SE-induced neutrophil infiltrations. To confirm this hypothesis, we investigated MIP-2 expression in the PC. Consistent with our previous study [20], some MIP-2-positive astrocytes were observed in the core and periphery of the vasogenic edema lesions, but not in the non-vasogenic edema region (Figure 6B and 6C). Although the number of MIP-2 positive cells per unit area in the PC region of sTNFp55R-infused animals was significantly lower than that of the saline-infused group due to reduction of the area of vasogenic edema, there was no difference in the number of MIP-2 positive cells per unit area of vasogenic edema between sTNFp55R-infused animals and saline-infused animals (Figure 6F). Furthermore, the number of MIP-2-positive cells showed a direct proportion to the unit area of vasogenic edema with a linear coefficient of correlation of 0.682 (p < 0.05, Figure 6G). Therefore, together with reduction in neutrophil infiltration in the PC region of sTNFp55R-infused animals, our findings provide evidence that TNF-alpha may regulate SE-induced neutrophil infiltration at least in the PC via vasogenic edema formation and not via direct TNF-alpha-mediated MIP-2 expression in astrocytes.","[{'offsets': [[0, 5]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 22]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[37, 46]], 'text': ['chemokine'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[100, 105]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[243, 252]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[260, 277]], 'text': ['interleukin-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[279, 287]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[349, 358]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[368, 373]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[478, 483]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[552, 557]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[735, 740]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[791, 798]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[967, 972]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1030, 1037]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1121, 1126]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1361, 1368]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1421, 1430]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1547, 1556]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1566, 1571]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
185,PMC-3218875-11-Conclusions,"The NF-kappaB family of transcription factors plays crucial roles in the inflammatory processes in RA leading to cartilage and bone destruction. Keeping NF-kappaB activation under control can thus be very important for the design of specific therapeutics. The existence of multiple negative regulators ensuring a tight regulation of the NF-kappaB pathway, however, raises the question of the specific role of each of these regulators and the relationship between them. In addition, given the number of miRNAs in humans and the multiple mRNAs they target, intense complexity can be expected. How all these regulatory signals are themselves regulated will be an important question in order to clarify how NF-kappaB signalling is organised, and, more importantly, how this knowledge may lead to new treatments for inflammatory diseases such as RA.",[],[],[],[],[],[]
186,PMC-3291650-12-Materials_and_Methods,"Western blotting
For total lysates, cells were lysed at 4degreesC for 15 min in lysis buffer (200 mM NaCl, 1% NP-40, 10 mM Tris-HCl pH 7.5, 5 mM EDTA, 2 mM DTT) supplemented with protease and phosphatase inhibitors. Nuclear and cytoplasmic lysates were prepared by resuspending cells in B1 (10 mM Hepes pH 7.5, 10 mM KCl, 1 mM MgCl2, 5% glycerol, 0.5 mM EDTA and 0.1 mM EGTA supplemented with protease and phosphatase inhibitors) for 15 min at 4degreesC. Next, NP-40 detergent was added to a final concentration of 0.65% and cells were centrifuged at 500 g for 5 min. The nuclear fraction containing pellet was lyzed in B2 (20 mM Hepes pH 7.5, 1% NP-40, 400 mM NaCl, 10 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM EDTA and 0.1 mM EGTA supplemented with protease and phosphatase inhibitors) for 15 min at 4degreesC. The lysates were subsequently separated by SDS-PAGE and analyzed by western blotting and ECL detection (Perkin Elmer Life Sciences). Immunoblots were revealed with anti-A20, anti-IkappaBalpha, anti-p65, and anti-histon H1 (Santa Cruz), anti-IRF3 (Invitrogen), anti-phospho-IRF3 and anti-phospho-IkappaBalpha (Cell Signaling) and anti-actin (MP Biomedicals). The density of the bands was quantified (fold induction) with the ImageJ (http://rsbweb.nih.gov/ij) Gel analyzer tool. All intensities were calculated relative to the first lane ( = time 0).",[],[],[],[],[],[]
187,PMC-3312845-11-Methods,"Data analysis
Data obtained from volumetric analysis, cell counts, and quantitative measurements were analyzed using Student's t-test to determine statistical significance. Linear regression analysis was also performed to determine correlations with SMI-71/p65-Thr435 phosphorylation, and the number of MPO cells/vasogenic edema areas.","[{'offsets': [[257, 260]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
188,PMC-3312845-23-Caption-Figure_5,"Effect of sTNFp55R infusion on p65-Thr435 phosphorylation in endothelial cells following SE. (A-B) Inhibition of p65-Thr435 phosphorylation by sTNFp55R infusion 12 hr after SE. p65-Thr435 phosphorylation is rarely observed in astrocytes (arrows). (C) Endothelial p65-Thr435 phosphorylation in non-SE animals. (D-E) Endothelial p65-Thr435 phosphorylation in saline-infused animals 1 day after SE. p65-Thr435 phosphorylation is enhanced, while SMI-71 expression is reduced in GLUT-1-positive endothelial cells (arrows). (F-G) Endothelial p65-Thr435 phosphorylation in sTNFp55R-infused animal 1 day after SE. sTNFp55R infusion effectively reduces p65-Thr435 and preserves SMI-71 expression in GLUT-1-positive endothelial cells (arrows). Bars = 12.5 (A-D) and 25 (E-G) mum.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[31, 34]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[113, 116]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[144, 151]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[177, 180]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[263, 266]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[327, 330]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[396, 399]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[474, 480]], 'text': ['GLUT-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[536, 539]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[567, 574]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[607, 614]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[644, 647]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 696]], 'text': ['GLUT-1'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
189,PMC-3320587-20-Results,"NFAT5 is important for enhancement of HIV-1 subtype C replication in response to MTb infection
As shown in Figure 1, the subtype C LTR was the most active of the HIV-1 LTR subtypes in the reporter assays. Subtype C LTRs generally have three functional NF-kappaB sites in their LTRs, and subtype C is the predominant viral subtype in the African and Asian HIV-1 epidemics where MTb co-infection is extremely common [1], [2], [28], [52]. We thus next extended our analysis of the role of NFAT5 in MTb/HIV-1 co-infection to a subtype C isolate. We first constructed an infectious molecular clone of the HIV-1 subtype C primary isolate HIV-198IN22, which has two NFAT5 binding sites in its LTR and three NF-kappaB sites (Figure 6A). We disrupted the two NFAT5 binding sites by changing the TT of each site to CC to create a mutant virus that we named HIV-198IN22-N5-Mut. Bulk PBMC from four normal donors were infected overnight with 1000 TCID50 of wild-type HIV-198IN22 or HIV-198IN22-N5-Mut and the cultures were then co-infected with MTb CDC1551 or left infected with virus alone. At day 11 post-viral infection, wild-type HIV-198IN22 replication was greater, but not significantly so, as compared to replication of HIV-198IN22 NFAT5-Mut (Figure 6B). However, in the context of MTb co-infection, wild-type HIV-198IN22 replication was significantly increased (p<0.05) at day 11 over HIV-198IN22 NFAT5-Mut replication (Figure 6C), indicating that the absence of NFAT5 binding sites was particularly detrimental to virus replication in the presence of MTb co-infection. Thus, even when three functional NF-kappaB binding sites are present in the LTR, as in the HIV-1 subtype C infectious clone studied here, disruption of NFAT5 binding to the LTR impairs virus replication in response to MTb co-infection.","[{'offsets': [[0, 5]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[486, 491]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1718, 1723]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
190,PMC-3589482-27-Caption-Figure_4,"Identification of cis-acting elements required for the LPS-responsiveness of the murine SerpinB2 promoter.
(A) Schematic representation of the -539/+92 region of the murine SerpinB2 promoter with the location of candidate cis-acting regulatory elements indicated with boxes. The location of the 5' ends of the -539, -189 and -87 reporter constructs is also shown. Positions of murine SerpinB2 proximal promoter-specific primers, 338/-315 and -5/+19 used in ChIP assays are indicated. (B) RAW 264.7 macrophages were transiently transfected with the indicated murine SerpinB2 promoter-luciferase reporter constructs and either left untreated or treated with 100 ng/ml LPS for 16 hrs. The results show relative luciferase activity following LPS treatment and represent the mean and SEM of 4-7 independent experiments.","[{'offsets': [[88, 96]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[173, 181]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[384, 392]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[565, 602]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[708, 718]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
191,PMC-1064873-10-Results,"Resistance to IL-10 inhibition of IFN-gamma production in RA CD4+ T cells
The CD28 costimulatory pathway is crucial for effective antigen-specific T-cell cytokine production, and IL-10 can directly suppress this response by inhibiting CD28 tyrosine phosphorylation and binding of phosphatidylinositol 3-kinase [24]. To evaluate the responsiveness of RA CD4+ T cells to IL-10, purified PB CD4+ T cells from three patients with active RA and from three healthy controls were stimulated by immobilized anti-CD3 antibody and anti-CD28 antibody with or without diluted concentrations of IL-10 for 36 hours, and IFN-gamma production was measured by ELISA. As shown in Fig. 1, IFN-gamma production by activated normal CD4+ T cells was mostly inhibited at concentrations as low as 1 ng/ml IL-10. However, RA CD4+ T cells were able to produce significant amounts of IFN-gamma in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10-100 ng/ml.
We thus compared the levels of IFN-gamma production by CD4+ T cells after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 in RA patients with active disease (multiple inflammatory joints, CRP level >= 10 mg/l) and inactive disease (in remission, CRP level < 10 mg/l) [26] and in healthy controls. There were no statistically significant differences in IFN-gamma production without IL-10 among these three groups (Fig. 2a), but the inhibitory effect of IL-10 on IFN-gamma production was significantly limited in the active RA group as compared with the inactive RA group and healthy controls (percentage decrease: active RA, 2.9 +/- 14.4%; inactive RA, 45.6 +/- 14.4%; controls, 65.8 +/- 7.9%) (Fig. 2b). As a consequence, CD4+ T cells from active RA patients produced higher levels of IFN-gamma in the presence of 1 ng/ml IL-10 than did normal CD4+ T cells (Fig. 2a).
In addition, we compared IL-2 production by CD4+ T cells after CD3 and CD28 costimulation in the presence of IL-10 in active RA patients and in healthy controls. Similarly, IL-2 production was not affected by 1 ng/ml IL-10 in RA patients (percentage decrease, -2.1 +/- 13.8%), while it was significantly reduced in healthy controls (61.1 +/- 13.7%; P < 0.05). Taken together, these results indicate that RA CD4+ T cells become less susceptible to the immunoregulatory effect of IL-10 during the active phase.","[{'offsets': [[14, 19]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 43]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[61, 64]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[78, 82]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[179, 184]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[235, 239]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[353, 356]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[369, 374]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[388, 391]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[504, 507]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[526, 530]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[582, 587]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[606, 615]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[670, 679]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[711, 714]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[781, 786]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[800, 803]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[857, 866]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[894, 899]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[948, 953]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1015, 1024]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1039, 1042]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1058, 1061]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1066, 1070]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1112, 1117]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1348, 1357]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1377, 1382]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1448, 1453]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1457, 1466]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1718, 1721]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1781, 1790]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1818, 1823]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1840, 1843]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1889, 1893]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1908, 1911]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1935, 1939]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1973, 1978]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2037, 2041]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2081, 2086]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2271, 2274]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2342, 2347]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T41'}]",[],[],[],[],[]
192,PMC-1472690-21-Caption-Figure_4,"GP modulated LPS- and TSST-1-induced binding to a new NFkappaB3 site in the IL-1RA promoter. Binding was enhanced for GP + LPS and GP + TSST-1, when compared to LPS, TSST-1, GP, GP/LPS calc. or GP/TSST-1 calc., respectively (* = p < 0.05; ** = p < 0.01). Medium control levels were set equal to 1 +/- SEM (n = 6). DNA binding was assessed by EMSA (see methods).","[{'offsets': [[22, 28]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[76, 82]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[136, 142]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[166, 172]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[197, 203]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
193,PMC-3589482-16-Results,"A C/EBP, CRE and Two AP-1 Sites in the Murine SerpinB2 Gene Proximal Promoter are Essential for Optimal LPS-inducible Transcription
To investigate regulatory elements between -539 and -189 essential for LPS-inducible transcription, several candidate binding sites for transcription factors previously reported to mediate LPS-inducible transcription in other genes [57] were targeted by nucleotide substitution designed to disrupt transcription factor binding to the pGLmP-539 murine SerpinB2 promoter-luciferase reporter gene construct (Fig. 4A). As shown in Fig. 4B, mutation of the consensus E box (-538/-533), PU.1 (-412/-407), or the variant Oct-1 (-296/-288) site did not decrease LPS-induced promoter activity. In contrast, mutation of the C/EBP site (-203/-192) completely eliminated promoter activity, similar to the levels observed for the -189 SerpinB2 promoter deletion construct. Others have also recently implicated this C/EBP site in LPS-induced activation of the SerpinB2 gene [58].
Considering the conserved sequence and position of the CRE and two AP-1 sites in the murine SerpinB2 promoter and their demonstrated involvement in the PMA-responsiveness of the human SERPINB2 promoter [37], these sites were also mutated by nucleotide substitution to investigate whether they played a role in the LPS response of the murine SerpinB2 promoter. As shown in Fig. 4B, mutation of the CRE at -177/-172 or either of the two AP-1 sites at -106/-100 and -94/-88, completely or significantly reduced LPS-inducible luciferase activity from the murine SerpinB2 promoter. These data show that the C/EBP element, as well as the CRE and both AP-1 cis-acting elements are critical for LPS-inducible transcription from the SerpinB2 proximal promoter.","[{'offsets': [[46, 54]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[483, 525]], 'text': ['SerpinB2 promoter-luciferase reporter gene'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[854, 862]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[978, 986]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1090, 1098]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1182, 1190]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1339, 1347]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1520, 1530]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1556, 1564]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1722, 1730]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
194,PMC-3218875-06-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"A20-binding inhibitors of NF-kappaB
ABIN-1, ABIN-2 and ABIN-3 (also known as TNIP-1, TNIP-2, and TNIP-3) were identified as ubiquitously expressed A20 interacting proteins and were shown to inhibit NF-kappaB activation by TNF and several other inflammatory stimuli upon overexpression. Because ABINs contain a specific ubiquitin-binding motif, they have been proposed to target A20 to polyubiquitinated substrates [43,44]. Similar to A20, ABIN-1 and ABIN-3 expression is NF-kappaB dependent, implicating a potential role for the A20/ABIN complex in the negative feedback regulation of NF-kappaB activation (reviewed in [54]). Unexpectedly, both ABIN-1-deficient and ABIN-2-deficient mice exhibit only slightly increased or normal NF-kappaB responses, respectively, possibly reflecting redundant NF-kappaB inhibitory activities of multiple ABINs [55,56]. Functional ABIN-3 is expressed in humans, but mice only express a truncated and inactive form lacking the crucial ubiquitin-binding domain [57]. As for A20, ABIN-1 also strongly inhibits TNF-induced apoptosis [58], and ABIN-1 deficient mice die embryonically due to TNF-dependent foetal liver apoptosis [56].
Using oligonucleotide microarray analysis, ABIN-1 was identified among TNF-induced genes in human synoviocytes, and high levels of ABIN-1 mRNA were detected in RA tissue biopsies, indicating a potential role for ABIN-1, together with A20, in the negative feedback regulation of NF-kappaB signalling and the pathogenesis of RA [59]. In a recent study, inhibition of TLR responses by immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors was shown to depend on the expression of the NF-kappaB inhibitory proteins ABIN-3 and A20. Moreover, this protective effect of the ITAM was strongly suppressed in inflammatory arthritis synovial macrophages [60]. Interestingly, ABIN-1 polymorphisms have been associated with psoriasis and systemic lupus erythematosus in humans [61,62]. A high degree of overlap between systemic lupus erythematosus and RA susceptibility loci might be expected as the two diseases show some clinical overlap in joint involvement, autoantibody production, systemic features and response to treatments such as B-cell depletion (rituximab). It will therefore be interesting to investigate whether SNPs that have been reported to be associated with systemic lupus erythematosus are also associated with RA.","[{'offsets': [[0, 3]], 'text': ['A20'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 42]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[44, 50]], 'text': ['ABIN-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[55, 61]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[77, 83]], 'text': ['TNIP-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[85, 91]], 'text': ['TNIP-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[97, 103]], 'text': ['TNIP-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[147, 150]], 'text': ['A20'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[222, 225]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[378, 381]], 'text': ['A20'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[434, 437]], 'text': ['A20'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[439, 445]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[450, 456]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[529, 532]], 'text': ['A20'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[645, 651]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[666, 672]], 'text': ['ABIN-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[865, 871]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[920, 947]], 'text': ['truncated and inactive form'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1006, 1009]], 'text': ['A20'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1011, 1017]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1041, 1044]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1073, 1079]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1120, 1123]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1206, 1212]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1234, 1237]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1294, 1300]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1375, 1381]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1397, 1400]], 'text': ['A20'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1692, 1698]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1703, 1706]], 'text': ['A20'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1845, 1851]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
195,PMC-3342329-04-Results,"Induction of Apoptotic Cell Death and Inhibition of the Expression of Anti-apoptotic Proteins in CCR5-/- Mice
To see whether inhibition of NF-kappaB activity results in the induction of apoptotic cell death and expression of NF-kappaB target apoptotic cell death regulatory protein, the levels of apoptotic cell death and expression of apoptotic cell death regulatory proteins were assessed. Apoptotic cell death in the tumor sections were evaluated in the CCR5+/+ and CCR5-/- mice that were inoculated with melanoma cells. TUNEL staining revealed a higher frequency of apoptotic cell death in the tumor tissues of the CCR5-/- mice than that of the CCR5+/+ mice (Figure 3A). Immunohistochemical and immunofluorescence showed that high levels of cleaved caspase-3 and Bax were found more frequently in the CCR5-/- mice than in the CCR5+/+ mice (Figure 3B and 3C). Consistent with the immunohistochemical data, Western blot analysis of tumor proteins showed greater increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP and Bax, whereas the levels of Bcl-2 and C-IAP1 were significantly decreased in CCR5-/- mice tissues (Figure 3D).","[{'offsets': [[97, 101]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[457, 461]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[469, 473]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[619, 623]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[649, 653]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[805, 809]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[830, 834]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1076, 1082]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1115, 1119]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
196,PMC-3312845-02-Methods,"Experimental animals
This study utilized progeny of Sprague-Dawley (SD) rats (male, 9 - 11 weeks old) obtained from Experimental Animal Center, Hallym University, Chunchon, South Korea. The animals were provided with a commercial diet and water ad libitum under controlled temperature, humidity and lighting conditions (22 +/- 2degreesC, 55 +/- 5% and a 12:12 light/dark cycle with lights). Animal protocols were approved by the Institutional Animal Care and Use Committee of Hallym University. Procedures involving animals and their care were conducted in accord with our institutional guidelines that comply with NIH Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, 1996). In addition, we have made all efforts to minimize the number of animals used and their suffering.",[],[],[],[],[],[]
197,PMC-3585731-18-Materials_and_Methods,"Cell Viability Experiments
Cells were seeded into white clear bottom 96 well plates at the density of 1x104 cells/well and treated as described for western blot experiments. Cell viability was determined using CellTiter-Glo Cell Viability Assay (Promega). Experiments were performed in duplicate or triplicate. Viability of the control untreated cells was set as 100%. Relative viability of cells, induced to undergo necroptosis and treated with the compound relative to the control compound-treated cells, was determined and plotted to exclude the possible effects of non-specific toxicity of the small molecules.",[],[],[],[],[],[]
198,PMC-3589482-23-Discussion,"Macrophages are key mediators of the innate immune response, and consequently provide the first line of defense against pathogens. Pro-inflammatory stimuli, such as the bacterial endotoxin LPS, stimulate macrophages to mount an anti-pathogenic response which involves massive induction of the pro-survival factor SerpinB2. SerpinB2 is transcriptionally induced by cross talk between the IKKbeta/NF-kappaB and p38MAPK signaling modules in response to LPS [16]. Here we report that SerpinB2 gene transcription in response to LPS is conferred by the SerpinB2 proximal promoter and is greatly dependent upon C/EBP-beta. LPS-induced C/EBP-beta was shown to specifically bind the C/EBP response element in the SerpinB2 proximal promoter in vitro and in vivo, and loss of C/EBP-beta abrogates constitutive SerpinB2 gene transcription and the response to LPS.
The murine SerpinB2 proximal promoter region between nucleotides -539 and +92 mediated both PMA- and LPS-inducible gene transcription, with induction by PMA being less intense and more transient than that by LPS. Inspection of the murine SerpinB2 proximal promoter sequence shows that a CRE and two AP-1-like elements, demonstrated to mediate PMA-stimulated transcription of the human SERPINB2 gene [37], also are present in the murine SerpinB2 proximal promoter between nucleotides -189 and -87. These sites may therefore also play a role in mediating PMA-inducible transcription of the murine SerpinB2 gene. In contrast to the pattern of incremental increases in PMA-induced transcriptional activity conferred by regions of the murine SerpinB2 promoter containing these sites, most of the LPS-inducible response is dependent upon cis-acting regulatory sequences in the region between nucleotides -189 and -539. LPS responsiveness absolutely required the C/EBP binding site located in the region between nucleotides -189 and -539, with the downstream CRE and AP-1-like elements also being critical. Of note, there are previous reports of combinatorial interactions between C/EBP-beta and CRE binding proteins (CREB) and AP-1 [63], and C/EBP-beta has been reported to physically interact with AP-1, and NF-kappaB to promote gene expression of inflammatory mediators [63]; [66]. Additionally, CREB has been shown to control transcription of the C/EBP-beta gene [67].
In this study, C/EBP-beta was found to be a major requirement for both constitutive and LPS-induced SerpinB2 gene transcription. In a previous microarray expression profiling study, SerpinB2 was identified as gene whose induction in C/EBP-beta-deficient peritoneal macrophages by LPS and IFNgamma was severely impaired compared to wild-type macrophages [68]. Our qPCR results validate this finding, as we found that both constitutive and LPS-inducible SerpinB2 mRNA expression is significantly abrogated in C/EBP-beta-shRNA transduced peritoneal macrophages, emphasizing the link between C/EBP-beta and SerpinB2 gene transcription. While C/EBP proteins can act as either homodimers or heterodimers [63], we identified C/EBP-beta as the only LPS-inducible C/EBP isoform to bind the SerpinB2 C/EBP response element, suggesting a predominant role for C/EBP-beta in LPS-induced SerpinB2 gene expression. C/EBP-beta, like SerpinB2, plays an important role in inflammation, as it is upregulated by LPS and a host of other inflammatory cytokines [59]; [62]. Furthermore, C/EBP-beta-null mice are susceptible to bacterial infection [69]; [70] and SerpinB2 has been demonstrated to protect from bacterial and viral-induced cell death [14]-[16]; [25]. Thus the regulation of SerpinB2 gene expression by C/EBP-beta is consistent with its functional role in inflammation.
Phosphorylation of C/EBP-beta at several different amino acid residues has been shown to modulate transactivation of its target genes [63]; . C/EBP-beta phosphorylated on T217 has been reported to rescue macrophages from apoptosis induced by Bacillus anthracis lethal toxin (LT) [65], an activity that has also been attributed to SerpinB2 [16]. However, expression of a C/EBP-beta phospho-acceptor site mutant, C/EBPbetaT217A, in Cebpb-/- MEFs did not increase SerpinB2 proximal promoter activity over that of wild-type C/EBP-beta, even though recruitment of C/EBP-betaT217 to the SerpinB2 promoter was observed to decrease following LPS stimulation of RAW264.7 cells. These data indicate that the T217 phospho-acceptor site is not important for the regulation of SerpinB2 gene expression. Similarly, expression of the C/EBP-beta phospho-acceptor site mutant, C/EBP-betaT188A, did not affect SerpinB2 promoter activity differently from that of wild-type. In contrast, expression of C/EBP-betaS64A significantly enhanced LPS-induced SerpinB2 promoter activity, indicating that phosphorylation of C/EBP-beta at S64 negatively regulates LPS-induced SerpinB2 promoter activity. Since C/EBP-beta S64 is constitutively phosphorylated in both RAW264.7 cells and MEFs [73], it is likely that dephosphorylation at this site may be a critical event during LPS-induced transcription of SerpinB2 to increase its promoter activity. Roy and colleagues demonstrated that Mixed lineage kinase-3 (MLK3)-driven dephosphorylation of C/EBP-beta S64 was important for IFNgamma-regulated signaling pathways [73]. Our data suggest that MLK3-driven dephosphorylation of S64 may also be involved in LPS-signaling pathways.
In recent years it has become apparent that persistent infection is integrally linked to chronic inflammation and cancer, and immune cells such as macrophages can either promote or attenuate cancer progression [2]; [74]-[76]. SerpinB2 expression has been associated with both inflammation and cancer, and is a favorable or unfavorable prognostic indicator depending on cancer type [77]. The presence of SerpinB2 has been shown to modulate cytokine profiles which can affect immune cell polarization [27]; [28]; [77]; [78]. Interestingly C/EBP-beta has also been shown to modulate cytokine secretion from immune cells, thereby modifying their phenotype [27]; [79]-[81]. Our study has demonstrated that C/EBP-beta plays an important role in mediating both constitutive and LPS-induced transcription of the SerpinB2 gene, which may have implications for the inflammatory phenotype of infiltrating immune cells in the tumor microenvironment.
In summary, our studies show that the C/EBP site (-203/-195) in the murine SerpinB2 proximal promoter is necessary to support both constitutive and LPS-induced SerpinB2 gene expression. Importantly, we were able to uncover a previously unknown role for C/EBP-betaS64 in negatively regulating SerpinB2 promoter activity. Taken together these data provide new insight into the regulation of inflammation-associated SerpinB2 gene expression.","[{'offsets': [[313, 321]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[323, 331]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[387, 394]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[480, 488]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[547, 555]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[604, 614]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[628, 638]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[704, 712]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[765, 775]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[799, 807]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[863, 871]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1090, 1098]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1237, 1245]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1288, 1296]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1447, 1455]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1589, 1597]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2026, 2036]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2088, 2098]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2296, 2306]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2333, 2343]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2418, 2426]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2500, 2508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2527, 2531]], 'text': ['gene'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2551, 2561]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2606, 2614]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2770, 2778]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2906, 2916]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2921, 2929]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3036, 3046]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3099, 3107]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3166, 3176]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3192, 3200]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3218, 3228]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3235, 3243]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3382, 3392]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3457, 3465]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3583, 3591]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3611, 3621]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3697, 3707]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[3820, 3830]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[4008, 4016]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[4048, 4087]], 'text': ['C/EBP-beta phospho-acceptor site mutant'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[4089, 4103]], 'text': ['C/EBPbetaT217A'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[4108, 4113]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[4139, 4147]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[4198, 4208]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[4259, 4267]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[4442, 4450]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4497, 4536]], 'text': ['C/EBP-beta phospho-acceptor site mutant'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4538, 4553]], 'text': ['C/EBP-betaT188A'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4570, 4578]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4660, 4674]], 'text': ['C/EBP-betaS64A'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[4710, 4718]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[4773, 4783]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[4824, 4832]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[4858, 4868]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[5053, 5061]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[5134, 5156]], 'text': ['Mixed lineage kinase-3'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[5158, 5162]], 'text': ['MLK3'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[5192, 5202]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[5225, 5233]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[5291, 5295]], 'text': ['MLK3'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[5602, 5610]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[5779, 5787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[5913, 5923]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[6077, 6087]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[6180, 6188]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T128'}, {'offsets': [[6389, 6397]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T129'}, {'offsets': [[6474, 6482]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T130'}, {'offsets': [[6606, 6614]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T131'}, {'offsets': [[6727, 6735]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T132'}]",[],[],[],[],[]
199,PMC-3317373-12-3._Results,"3.2. Disruption of Nrf2 Enhanced Upregulation of NF-kappaB DNA-Binding Activity after Scratch Injury
It has been reported that NF-kappaB is activated in brain after TBI [2]. Here, we studied the DNA-binding activity of NF-kappaB of astrocytes from Nrf2 WT or KO mice by EMSA at 24 h after scratch injury. Scratch injury induced activation of NF-kappaB in astrocytes of both genotypes, while higher NF-kappaB activity was observed in group KO TBI than in group WT TBI (2.67 +/- 0.173 versus 2.28 +/- 0.072, P < 0.01) (Figure 2).",[],[],[],[],[],[]
200,PMC-3342329-18-Caption-Figure_1,"Inhibition of tumor development in CCR5-/- mice.
A-C, Tumor images, volumes, and weights. B16 melanoma cells (5x105 cells/mouse) were inoculated s.c. into CCR5+/+ mice and CCR5-/- mice (n = 20). Tumor volumes were measured every day and tumor weights were measured at study termination (Day 31). The CCR5-/- mice had a significant reduction in tumor growth and volume as compared to CCR5+/+ mice. The results are expressed as mean +/- SD. * indicates significant difference from CCR5+/+ mice (P<0.05). D, The CCR5-/- mice demonstrated significantly higher survival rates compared to CCR5+/+ mice (by Log-rank Test). E. Tumor sections were analyzed by H&E stain and expression of proliferating cell nuclear antigen (PCNA) by immunohistochemistry. Data are means +/- S.D. of four experimental animals. * indicates significant difference from CCR5+/+ mice (P<0.05). Scale bar indicates 50 m.","[{'offsets': [[35, 39]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[155, 159]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[172, 176]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[300, 304]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[383, 387]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[479, 483]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[509, 513]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[583, 587]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[840, 844]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
201,PMC-3586680-01-Mechanisms_of_Resistance_to_Temozolomide_in_Glioblastomas,"Glioblastoma multiforme afflicts 12,500 new patients in the U.S. annually (Friedman et al., 2000; Stupp et al., 2009; Silber et al., 2012). Glioblastoma (GBM) is highly lethal, and the average survival expectancy is 14.6 months, and the overall 5-year survival rate for GBM is only 9.8% (Friedman et al., 2000; Stupp et al., 2009). High levels of resistance to current therapeutic modalities and cancer relapse are frequently seen in patients (Haar et al., 2012; Happold et al., 2012). The current standard therapy for GBM mainly includes maximum debulking surgery, radiation, and treatment with the monofunctional alkylating agent temozolomide (TMZ) (Friedman et al., 2000; Nishikawa, 2010). Multiple mechanisms are involved in the TMZ resistance, which may include cancer stem cells, microRNAs, drug efflux, DNA damage repair, tumor cells under hypoxia, histone deacetylation, epithelial-mesenchymal transition, STAT3 kinase, and many others (Haar et al., 2012; Happold et al., 2012; Johannessen and Bjerkvig, 2012; Kitange et al., 2012; Kohsaka et al., 2012; Zhang et al., 2012b).
Temozolomide induces generation of DNA lesions, including O6-methylguanine, N3-methyladenine, and N7-methylguanine (Goellner et al., 2011; Zhang et al., 2012b). The O6-methylguanine lesion is known to trigger autophagy, rather than apoptosis, to cause cell death (Kanzawa et al., 2003). Also, inhibition of antiapoptotic Bcl-2 by a pan-Bcl-2 inhibitor (-)-gossypol leads to autophagic death in gliomas and enhances the action of TMZ (Voss et al., 2010). However, a recent study demonstrated that TMZ-induced autophagy is pro-survival, and may block the eventual apoptosis in GBM cells (Knizhnik et al., 2013). Also, MAPO2 (C1orf201) gene participates in the O6-methylguanine lesion-induced apoptosis (Fujikane et al., 2012). MAPO2 gene encodes a novel 37-kDa protein. It is not determined whether this gene is involved in autophagy.
The O6-methylguanine lesion is a substrate for direct repair by O6-methylguanine-DNA methyltransferase (MGMT) (Pollack et al., 2006; Hegi et al., 2008; Fukushima et al., 2009; Zhang et al., 2012b). Without MGMT repair, O6-methylguanine initiates activation of mismatch repair-deficient (MMR) proteins or Rad3-related protein kinase that ultimately leads to apoptotic cell death (Caporali et al., 2004; Wang and Edelmann, 2006; Roos et al., 2007). High expression of MGMT or loss of MMR contributes significantly to TMZ resistance in many clinical cases (Pollack et al., 2006; Hegi et al., 2008; Sarkaria et al., 2008). The initiation of apoptotic signaling fails in the absence of the MMR system.
Sensitivity to TMZ is significantly associated with the methylation status of MGMT gene promoter in cells committed to differentiation (Villalva et al., 2012). An increase in MGMT gene promoter methylation, which blocks MGMT protein expression, prolongs cancer patient survival. Intriguingly, overexpressed microRNA-21 reduces Bax/Bcl-2 ratio and caspase-3 activity, thereby blocking TMZ-induced apoptosis (Shi et al., 2010). MicroRNA-21 is considered as a pro-survival factor for cancer cells (Li et al., 2012). Integrins play a role in the resistance of advanced cancers to radiotherapy and chemotherapy. alpha5beta1 integrin negatively regulates p53 signaling, and the event induces glioma cell resistance to TMZ (Janouskova et al., 2012). alpha5beta1 integrin is considered as a therapeutic target for high-grade brain tumors. The base excision repair enzyme alkylpurine-DNA-N-glycosylase (APNG), which repairs the cytotoxic lesions N3-methyladenine and N7-methylguanine, also participates in the TMZ resistance (Agnihotri et al., 2012). Upregulation of mitochondrial respiratory chain coupling to suppress the production of reactive oxygen species (ROS) regulated by cytochrome c oxidase contributes in part to TMZ resistance in gliomas (Oliva et al., 2011).
Reversal of TMZ resistance may be achieved by MGMT pseudosubstrates, O6-benzylguanine and lomeguatrib to sensitize tumors to TMZ (Zhang et al., 2012b). Methoxyamine-blocker of base excision repair contributes significantly to TMZ cytotoxicity particularly when O6-methylguanine adducts are repaired or tolerated (Goellner et al., 2011; Zhang et al., 2012b). Dual targeting of base excision repair and NAD(+) biosynthesis may reverse TMZ resistance in patients with resistant and recurrent GBM (Goellner et al., 2011). Interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increase the sensitivity of TMZ through MGMT-dependent or -independent mechanisms (Nakada et al., 2012). Resveratrol, a natural polyphenol, reverses TMZ resistance via an NF-kappaB-dependent mechanism (Huang et al., 2012). STAT3 inhibitor or STAT3 knockdown potentiates TMZ efficacy in resistant GBM cell lines (Kohsaka et al., 2012). Intratumoral hypoxia is common in GBMs and may be associated with the development of TMZ resistance. Induced hyperoxia can be utilized to reverse TMZ resistance in GBMs (Sun et al., 2012). Cancer stem cells are probably the key to failure in TMZ treatment. The concept of cancer stem cell survival from treatment with TMZ and other chemotherapeutic drugs has been more complicated than previously thought (Beier et al., 2011; Chen et al., 2012). CD133-positive cancer stem cells are expressed in both normal stem cells and cancer stem cells (Donovan and Pilkington, 2012). However, the role of CD133 as a marker for glioma cancer stem cells relative to its biological function has yet to be established.","[{'offsets': [[1405, 1410]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1420, 1425]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1700, 1705]], 'text': ['MAPO2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1707, 1715]], 'text': ['C1orf201'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1809, 1814]], 'text': ['MAPO2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1981, 2019]], 'text': ['O6-methylguanine-DNA methyltransferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2021, 2025]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2123, 2127]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2383, 2387]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2692, 2696]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2789, 2793]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2834, 2838]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2921, 2932]], 'text': ['microRNA-21'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2941, 2944]], 'text': ['Bax'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2945, 2950]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2961, 2970]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3040, 3051]], 'text': ['MicroRNA-21'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3263, 3266]], 'text': ['p53'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3924, 3928]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[4396, 4411]], 'text': ['Interferon-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[4413, 4421]], 'text': ['IFN-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[4522, 4526]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4705, 4710]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4724, 4729]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[5263, 5268]], 'text': ['CD133'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[5411, 5416]], 'text': ['CD133'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
202,PMC-1064895-08-Materials_and_methods,"Western blot analysis of Akt, phosphorylated Akt and IkappaB-alpha
PBMC were incubated with anti-CD3 (10 mug/ml) in the presence or absence of LY294002 (20 muM). After incubation for 1 hour, whole cell lysates were prepared from about 107 cells by homogenization in the lysis buffer, and centrifuged at 14,000 r.p.m. (19,000 g) for 15 min. Protein concentrations in the supernatants were determined with the Bradford method (Bio-Rad, Hercules, CA, USA). Protein samples were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). For western hybridization, membrane was preincubated with 0.1% skimmed milk in TBS-T buffer (0.1% Tween 20 in Tris-buffered saline) at room temperature for 2 hours, then primary antibodies against Akt, phosphorylated Akt and IkappaB-alpha (Cell Signaling Technology Inc., Beverly, MA, USA), diluted 1:1000 in 5% BSA/TBS-T, were added and incubated overnight at 4degreesC. After washing four times with TBS-T, horseradish peroxidase-conjugated secondary antibodies were added and allowed to incubate for 1 hour at room temperature. After TBS-T washing, hybridized bands were detected with the enhanced chemiluminescence (ECL) detection kit and Hyperfilm-ECL reagents (Amersham Pharmacia).","[{'offsets': [[25, 28]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[45, 48]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 66]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[790, 793]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[810, 813]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[818, 831]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
203,PMC-3585731-00-TIAB,"Akt Regulates TNFalpha Synthesis Downstream of RIP1 Kinase Activation during Necroptosis
Necroptosis is a regulated form of necrotic cell death that has been implicated in the pathogenesis of various diseases including intestinal inflammation and systemic inflammatory response syndrome (SIRS). In this work, we investigated the signaling mechanisms controlled by the necroptosis mediator receptor interacting protein-1 (RIP1) kinase. We show that Akt kinase activity is critical for necroptosis in L929 cells and plays a key role in TNFalpha production. During necroptosis, Akt is activated in a RIP1 dependent fashion through its phosphorylation on Thr308. In L929 cells, this activation requires independent signaling inputs from both growth factors and RIP1. Akt controls necroptosis through downstream targeting of mammalian Target of Rapamycin complex 1 (mTORC1). Akt activity, mediated in part through mTORC1, links RIP1 to JNK activation and autocrine production of TNFalpha. In other cell types, such as mouse lung fibroblasts and macrophages, Akt exhibited control over necroptosis-associated TNFalpha production without contributing to cell death. Overall, our results provide new insights into the mechanism of necroptosis and the role of Akt kinase in both cell death and inflammatory regulation.","[{'offsets': [[14, 22]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 51]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[389, 419]], 'text': ['receptor interacting protein-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[421, 425]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[534, 542]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[597, 601]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[757, 761]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[923, 927]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[974, 982]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1103, 1111]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
204,PMC-1064873-01-Introduction,"IL-10 is a key cytokine in regulating inflammatory responses, mainly by inhibiting the production and function of proinflammatory cytokines. IL-10 binds to the IL-10 receptor (IL-10R) complex that is composed of two subunits, the primary ligand-binding component type 1 IL-10R (IL-10R1) and the accessory component type 2 IL-10R [1]. The interaction of IL-10 and IL-10R engages the Janus kinase (JAK) family tyrosine kinases Jak1 and Tyk2, which are constitutively associated with IL-10R1 and type 2 IL-10R, respectively [2]. IL-10 induces tyrosine phosphorylation and activation of the latent transcriptional factors signal transducer and activator of transcription (STAT) 3 and STAT1 [3]. Upon phosphorylation, STAT1 and STAT3 proteins form homodimers or heterodimers, rapidly translocate into the nucleus, and modulate gene transcription. Intriguingly, STAT3 is indispensable for both IL-10-derived anti-inflammatory and IL-6-derived proinflammatory responses [4]. Studies of cell-type-specific STAT3-deficient mice have shown that STAT3 activation is essential for IL-10-mediated anti-inflammatory reactions in macrophages and neutrophils [5], but is responsible for IL-6-mediated prevention of apoptosis in T cells [6]. The suppressor of cytokine signaling (SOCS) proteins have been identified as a family of endogenous JAK kinase inhibitors that can act in classic feedback inhibition loops, but their roles as the mediators of crosstalk inhibition by opposing cytokine signaling pathways have been clarified [7]. Recent studies indicate that SOCS3 plays a key role in regulating the divergent action of IL-10 and IL-6, by specifically blocking STAT3 activation induced by IL-6 but not that induced by IL-10 [8,9].
The synovial membrane of rheumatoid arthritis (RA) is characterized by an infiltrate of a variety of inflammatory cells, such as lymphocytes, macrophages, and dendritic cells, together with proliferation of synovial fibroblast-like cells. Numerous cytokines are overproduced in the inflamed joint, and macrophages and synovial fibroblasts are an important source of proinflammatory cytokines. Tumor necrosis factor alpha (TNF-alpha) and IL-1, two major macrophage products, are crucial in the process of chronic inflammation and joint destruction, and they give rise to effector components, including other inflammatory cytokines, chemokines, growth factors, matrix proteases, nitric oxide, and reactive oxygen species [10]. IL-6 is a pleiotropic cytokine produced substantially by activated fibroblasts, and its proinflammatory actions include simulating the acute-phase response, B-cell maturation into plasma cells, T-cell functions, and hematopoietic precursor cell differentiation [11].
However, anti-inflammatory cytokines and cytokine inhibitors are also present in large quantities in RA joints. IL-10, produced by macrophages and partly by T cells in the synovial tissue (ST), is best known as a negative regulator for macrophage and Th1 cells, but the expression level is insufficient to counterbalance the cascade of proinflammatory events [12]. In addition, the anti-inflammatory action of IL-10 appears to be modulated at the level of signal transduction during chronic inflammation. IL-10 signaling is impaired in macrophages upon chronic exposure to proinflammatory cytokines such as TNF-alpha and IL-1 and immune complexes [13,14]. Cell surface expression of IL-10R1 is decreased in synovial fluid dendritic cells due to the presence of TNF-alpha, IL-1, and granulocyte-macrophage colony-stimulating factor [15].
CD4+ T cells may be activated by arthritogenic antigens, in conjunction with CD28-mediated costimulatory signaling, in RA. The significance of this autoimmune process has been supported by the linkage of the MHC class II antigens HLA-DRB1*0404 and HLA-DRB1*0401 with disease susceptibility and severity [16,17], and by the high-level expression of MHC class II molecules and both CD28 ligands, CD80 and CD86, in the inflamed ST [18-20]. The continuing emergence of activated CD4+ T cells, even though few in number, may be crucial in sustaining the activation of macrophages and synovial fibroblasts through cell surface signaling by means of cell surface CD69 and CD11, as well as the release of proinflammatory Th1 cytokines such as interferon gamma (IFN)-gamma and IL-17 [21,22]. In addition, CD4+ T cells could stimulate B-cell production of autoantibodies such as rheumatoid factor and osteoclast-mediated bone destruction. Their obligatory role in RA synovitis was recently proved by successful treatment of active disease by selective inhibition of T-cell activation with fusion protein of cytotoxic T-cell-associated antigen 4 (CD152)-IgG, which can block the engagement of CD28 on T cells by binding to CD80 and CD86 with high avidity [23].
IL-10 efficiently blocks the antigen-specific T-cell cytokine response by inhibiting the CD28 signaling pathway [24], as well as indirectly by downregulating the function of antigen-presenting cells. To elucidate the resistance of CD4+ T cells to this direct inhibition in RA, we investigated the production of IFN-gamma after CD3 and CD28 costimulation in the presence of IL-10, the induction of STAT1 and STAT3 phosphorylation by IL-10, and the expression of SOCS1 and SOCS3 mRNA in peripheral blood (PB) CD4+ T cells from RA patients.","[{'offsets': [[1, 5]], 'text': ['L-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[141, 146]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[160, 174]], 'text': ['IL-10 receptor'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[176, 182]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[263, 276]], 'text': ['type 1 IL-10R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[278, 285]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 328]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[353, 358]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[363, 369]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[425, 429]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[434, 438]], 'text': ['Tyk2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[481, 488]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[493, 506]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[526, 531]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[618, 675]], 'text': ['signal transducer and activator of transcription (STAT) 3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[680, 685]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[713, 718]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[723, 728]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[856, 861]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[888, 893]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[924, 928]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[998, 1003]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1035, 1040]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1069, 1074]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1171, 1175]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1549, 1554]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1610, 1615]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1620, 1624]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1651, 1656]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1679, 1683]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1708, 1713]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2114, 2141]], 'text': ['Tumor necrosis factor alpha'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2143, 2152]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2158, 2162]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2446, 2450]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2456, 2476]], 'text': ['pleiotropic cytokine'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2825, 2830]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3123, 3128]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3218, 3223]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3320, 3329]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3334, 3338]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3396, 3403]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3474, 3483]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3485, 3489]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3495, 3543]], 'text': ['granulocyte-macrophage colony-stimulating factor'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3550, 3553]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3627, 3631]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3780, 3793]], 'text': ['HLA-DRB1*0404'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3798, 3811]], 'text': ['HLA-DRB1*0401'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3930, 3934]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3944, 3948]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3953, 3957]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4025, 4028]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4206, 4210]], 'text': ['CD69'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4215, 4219]], 'text': ['CD11'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4285, 4301]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4302, 4313]], 'text': ['(IFN)-gamma'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4318, 4323]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4346, 4349]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4647, 4696]], 'text': ['cytotoxic T-cell-associated antigen 4 (CD152)-IgG'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4732, 4736]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4762, 4766]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4771, 4775]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4800, 4805]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4889, 4893]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5031, 5034]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5111, 5120]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5135, 5139]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5173, 5178]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5197, 5202]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5207, 5212]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5232, 5237]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5261, 5266]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5271, 5276]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5307, 5310]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T75'}]",[],[],[],[],[]
205,PMC-3291650-04-Results,"A20 deficiency in myeloid cells protects against IAV lung infection
To determine the role of A20 expression in myeloid cells during an IAV infection in vivo, we intranasally inoculated both A20myel-KO mice and control littermates with a sublethal dose of the mouse adapted IAV X-47 (H3N2) strain and monitored morbidity in terms of weight loss. A20myel-KO mice showed reduced weight loss compared to wild type control littermates and recovered faster from the viral challenge (figure 3A). Also, total protein concentration in BAL fluid, which reflects lung damage and vascular leakage, was increased significantly at 7 and 10 days post infection in both wild type and A20myel-KO mice, and was slightly lower in A20myel-KO mice (data not shown). Next, we measured pulmonary viral titers at 4, 7 and 10 days post infection. No differences in viral titers were observed in A20myel-KO mice versus wild type mice at day 4 and 7 post infection. However, after 10 days, almost no virus could be detected in the lungs of A20myel-KO mice while abundant infectious viral particles could still be isolated from lungs of all wild type mice (figure 3B). This indicates that loss of A20 in myeloid cells does not affect early viral replication but contributes to viral clearance at later stages during infection.
To verify if A20 deficiency in myeloid cells affects IAV-induced gene expression in the lung, we analyzed the levels of several chemokines and cytokines in the bronchoalveolar lavage (BAL) at day 4, 7 and day 10 following infection. Levels of KC and MIP-2 chemokines, as well as IL-6 were significantly higher at day 7 p.i. in BAL from IAV infected A20myel-KO mice compared to IAV infected wild type mice (figure 3C). Unlike our observations with in vitro stimulated primary macrophages we could not detect a significant increase in MCP-1 or IFNalpha production in the lungs of A20myel-KO animals (figure 3C). KC is the murine orthologue of IL-8 and serves together with MIP-2 as a chemoattractant for neutrophils, while MCP-1 is mainly known as a chemoattractant for monocytes, which eventually develop into macrophages upon entering the alveolar lumen [60]. Consistent with the higher KC and MIP-2 levels in A20myel-KO mice, the number of neutrophils (CD11b+ Ly6C+ Ly6G+ F4/80-) that were recruited in the bronchoalveolar spaces upon IAV infection was clearly higher throughout infection in A20myel-KO mice compared to control animals (figure 3D). Although we could detect a significant increase in monocyte (CD11b+ Ly6C+) recruitment at day 4 post infection, this was not evident at later time points after infection (figure 3D), which is consistent with the equal expression of MCP-1 in both groups of mice. The number of resident alveolar macrophages (autofluorescent+ CD11c+ F4/80+ CD11b-) was also elevated in A20myel-KO mice but did not differ significantly between IAV infected or mock infected mice (figure 3D). Elimination of IAV infected cells depends on the clonal expansion of virus specific cytotoxic CD8+ T cells (CTL) [61], [62], [63]. To test whether A20 expression in myeloid cells regulates the antiviral CTL response, total CD8+ T cells and virus specific Granzyme B (GrB) and IFNgamma expressing CD8+ T cells were measured in BAL and lung parenchyma of wild type and A20myel-KO mice. A clear increase in CD8+ T cells could be detected at day 7 and 10 post infection, but no differences were observed between A20myel-KO and wild type mice (figure S2A and figure S2C). Also, the number of GrB and IFNgamma CD8+ T cells as well as IFNgamma expression levels in the lungs were not altered by the absence of A20 in myeloid cells (figure S2A-C).
Protection against IAV infection is also provided by the humoral immune response. To test whether loss of A20 in myeloid cells affects B cell mediated immunity, we determined hemagglutinin (HA) antibody titers in the serum of A20myel-KO and wild type littermates. However, no differences could be detected between wild type and A20myel-KO animals (figure S2D), indicating that humoral immunity is not affected by A20 expression in myeloid cells. Together, these data suggest that mechanisms other than adaptive immunity, such as an increased innate immune response, characterized by an increased influx of neutrophils and increased numbers of alveolar macrophages, contribute to the better viral clearance in A20myel-KO mice.
It is generally believed that IAV-induced mortality is due to an excessive proinflammatory response in the lung. We therefore analyzed whether the increased proinflammatory cytokine production and infiltration of proinflammatory cells in A20myel-KO mice affects mortality induced by intranasal infection with a lethal dose of IAV X-47. Surprisingly, almost all A20myel-KO mice survived (10/11), while all control mice succumbed (0/11) within 16 days after infection (figure 4A). A20myel-KO mice still showed significant weight loss and lung damage (as reflected by increased total protein concentration in the BAL; data not shown) during the course of infection but were able to recover, in contrast to wild type mice that succumbed (figure 4B). Similar to our observations with sublethal IAV infection, pulmonary KC and MIP-2 production was stronger in A20myel-KO animals compared to wild type mice following lethal IAV infection (figure 4C), which correlates with the increased numbers of neutrophils in the lungs of these mice (figure 4C). Also levels of the proinflammatory cytokines IL-6, TNF and IL-1beta, which are often associated with immunopathogenesis in humans [64], were increased in the lungs of A20myel-KO mice compared to control animals (figure 4C and figure S3A). Again, MCP-1 production was not increased and even lower in A20myel-KO mice (figure 4C), and also monocyte recruitment was not different between both groups of mice. We could also not detect any differences in viral clearance or antiviral adaptive immunity at 6 h post infection (figure S3B-F). Collectively these data indicate that A20 deficiency in myeloid cells is associated with an increased innate immune response and protection against a lethal IAV infection.","[{'offsets': [[1542, 1544]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1549, 1554]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1578, 1582]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1832, 1837]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1909, 1911]], 'text': ['KC'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1940, 1944]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1970, 1975]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2020, 2025]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2186, 2188]], 'text': ['KC'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2193, 2198]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2272, 2277]], 'text': ['F4/80'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2681, 2686]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2780, 2785]], 'text': ['F4/80'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3176, 3186]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3188, 3191]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3508, 3511]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[5201, 5203]], 'text': ['KC'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[5208, 5213]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[5475, 5479]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[5481, 5484]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[5489, 5497]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[5676, 5681]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T28'}]",[],[],[],[],[]
206,PMC-3320587-24-Caption-Figure_2,"MTb induces NFAT5 gene expression and knockdown of NFAT5 impairs HIV-1 replication during MTb co-infection.
(A) MTb but not HIV-1 increases NFAT5 mRNA synthesis in human macrophages. MDM were isolated from PBMC obtained from four normal donors. The cells were incubated for 24 or 48 hours with heat-inactivated or live R5-tropic HIV-1 subtype B, C, or E isolates, live MTb strain CDC1551 (1:1 MDM:bacilli), or left untreated. Quantitative real-time PCR analysis of NFAT5 mRNA expression levels revealed that the low, constitutively present level of NFAT5 mRNA expressed in untreated cells was not affected by exposure to live or inactivated HIV-1, but was significantly increased at both 24 (*, p<0.05) and 48 (**, p<0.01) hours following infection with MTb. (B) NFAT5-specific siRNA effectively suppresses NFAT5 expression in MDM in both the absence and presence of MTb co-infection. MDM (1x106 cells/well in a 6-well plate) from four normal donors were transfected with siRNA specific for NFAT5 or, as a control, GFP, and were then infected with MTb (1:1 MDM:bacilli) or left uninfected. In the cells transfected with control siRNA, MTb infection significantly increased NFAT5 expression in comparison to uninfected cells (open bars). When MDM were transfected with NFAT5-specific siRNA, both constitutively expressed (p = 0.048) and MTb-induced (p = 0.021) NFAT5 mRNA were significantly suppressed (grey bars). (C) HIV-1 subtype B replication is significantly suppressed in the presence of MTb co-infection when NFAT5 expression is abrogated in human MDM. MDM from four normal donors were transfected with NFAT5-specific and control siRNAs as described in 2B. Cells were then infected with HIV-1Lai/Bal-env followed by co-infection with MTb CDC1551. Virus replication was measured at days 6, 9, and 12 post-infection. At day 12, virus replication was significantly reduced in cells transfected with NFAT5-specific siRNA in comparison to cells transfected with control siRNA (*, p<0.05). We monitored the morphology of cells within the infected cultures and did not observe noticeable macrophage necrosis even at the final timepoint of viral harvest.","[{'offsets': [[12, 17]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 56]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[140, 145]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[465, 470]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[549, 554]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[763, 768]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[807, 812]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[991, 996]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1015, 1018]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1173, 1178]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1268, 1273]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1360, 1365]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1515, 1520]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1609, 1614]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1706, 1709]], 'text': ['env'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1902, 1907]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
207,PMC-1359074-01-Introduction,"Sry type HMG box (Sox6) is a member of the Sox transcription factor family characterized by the conserved high mobility group (HMG) domain, consisting of 79 amino acids involved in DNA recognition and binding [1]. Sox transcription factors bind to the minor groove of DNA and cause a 70degrees-85degrees bend of the DNA that leads to local conformational changes [2,3], while most other transcription factors target the major groove of DNA [4]. Therefore, Sox proteins may perform part of their function as architectural proteins by organizing local chromatin structure and assembling other DNA-bound transcription factors into biologically active, sterically defined multiprotein complexes. Sox6 has been reported to be able to act as either an activator or a repressor, depending on its interactors and its target promoter context [5,6]. Intriguingly, Sox6 has also been shown to act as a general splicing factor that participates in pre-mRNA splicing [7]. Depletion of Sox6 in HeLa cell extracts blocked splicing of multiple substrates, and expression of the HMG domain of either Sox6, Sox9, or Sry in the extracts restored splicing, indicating functional overlap of these proteins [7]. Regardless of how Sox6 functions in regulating gene expression, previous studies have demonstrated that Sox6 is an important regulatory molecule that plays a role in the development of the central nervous system [8-11], cartilage [6,12,13], and muscle [14,15]. A Sox6-null mutant mouse (p100H) has previously been identified in our laboratory [14]. Mice homozygous for p100H show delayed growth, develop myopathy and arterioventricular heart block, and die within 2 wk after birth [14]. The p100H mutant allele is associated with a Chromosome 7 inversion that disrupts both the p gene and the Sox6 gene (and no other gene within 50,000 nucleotides of the chromosomal breakpoints) [14]. Because the p gene functions solely in pigmentation [16], the Sox6 transcription factor is implicated in all other phenotypes.
Among the HMG box proteins distantly related to Sry (the first member identified of the Sox transcription factor family) that similarly bind to the minor groove and bend DNA, but without sequence specificity, are the ubiquitously expressed HMG1 and HMG2 proteins [17]. Modulation of DNA structure by these and other HMG proteins can mediate long-range enhancer function on both DNA and chromatin-assembled genes by bringing together distant regions of DNA and associated factors. Specifically, HMG proteins have been shown to modulate beta-globin genes [18-21].
The mouse beta-globin genes {epsilony, betah1, beta-major, and beta-minor} are clustered on Chromosome 7 and they are highly homologous to their human counterparts in organizational structure and function [22]. High-level expression of these genes requires a regulatory element, the locus control region that is characterized by a set of nuclease hypersensitive sites spread over 25 kb located 5' of the epsilony gene [23]. The beta-globin genes are expressed in a tissue- and development-specific fashion. In mice, erythropoiesis originates in the embryonic yolk sac where primitive erythroid cells express epsilony and betah-1 globins [22]. At 11.5 d post coitus (dpc), erythropoiesis shifts to the fetal liver where definitive erythroid cells express adult beta globins (beta major and minor) [22]. The epsilony gene is silenced in definitive erythroid cells. The mechanism of silencing of its human counterpart, epsilon globin, has been studied extensively. In definitive erythropoiesis, epsilon is activated and silenced autonomously [24,25], although in primitive erythropoiesis epsilon also appears to be regulated competitively [26]. The gamma-globin to adult beta-globin switch is controlled by promoter competition for the LCR [24,25].
All the elements responsible for silencing the epsilon globin gene are within the epsilon gene or in adjacent sequences [27], suggesting that silencing is primarily gene autonomous. Using promoter deletion analyses in transgenic mouse models and cell transfection assays, multiple DNA elements important to the silencing process have been previously identified in both the proximal and the distal epsilon gene promoter [27]. Their corresponding transcription factors, such as GATA-1, YY-1, COUP-TF, and DRED have been identified and shown to directly bind to these DNA elements (as part of protein complexes) to regulate epsilon silencing [27]. Thus, it appears that the silencing of the epsilon gene involves a complicated network of multiple cis elements and transacting proteins.
In addition to playing an important role in the development of the central nervous system [8-11], cartilage [6,12,13], and muscle [14,15], it was shown that Sox6 is upregulated in long-term hematopoiesis stem cells (LT-HSC) compared with multipotent progenitors of adult mouse bone marrow lineage [28]. In this study, we describe that Sox6 also exerts pleiotropic effects on erythropoiesis. These effects include delayed maturation of erythrocytes (that normally enucleate prior to entering the bloodstream [27]) and higher expression of embryonic globin genes. The most extreme effect is the persistence of high expression of the embryonic epsilony globin gene. Here we describe and characterize the effects of Sox6 on the epsilony globin gene. We show that Sox6 binds to the proximal promoter of epsilony globin and represses its transcription. In wild-type (WT) mice, Sox6 is not expressed in yolk sac blood islands, but is expressed in fetal liver, the opposite expression pattern of epsilony globin. In the absence of Sox6, epsilony globin is ectopically expressed in the fetal liver, demonstrating that Sox6 functions in definitive erythropoiesis.","[{'offsets': [[0, 3]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 22]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[692, 696]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[854, 858]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[972, 976]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1083, 1087]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1089, 1093]], 'text': ['Sox9'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1098, 1101]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1208, 1212]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1294, 1298]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1453, 1457]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1768, 1769]], 'text': ['p'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1783, 1787]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1888, 1889]], 'text': ['p'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1938, 1942]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2051, 2054]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2243, 2247]], 'text': ['HMG1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2252, 2256]], 'text': ['HMG2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2594, 2602]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2604, 2610]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2612, 2622]], 'text': ['beta-major'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2628, 2638]], 'text': ['beta-minor'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2969, 2977]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3173, 3181]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3186, 3201]], 'text': ['betah-1 globins'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3339, 3349]], 'text': ['beta major'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3354, 3359]], 'text': ['minor'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3371, 3379]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3481, 3495]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3557, 3564]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3650, 3657]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3711, 3723]], 'text': ['gamma-globin'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3733, 3744]], 'text': ['beta-globin'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3858, 3872]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3893, 3900]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4208, 4215]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4287, 4293]], 'text': ['GATA-1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4295, 4299]], 'text': ['YY-1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4301, 4308]], 'text': ['COUP-TF'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4314, 4318]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4432, 4439]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4499, 4506]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4751, 4755]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4929, 4933]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5235, 5250]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5306, 5310]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5318, 5333]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5353, 5357]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5392, 5407]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5465, 5469]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5582, 5597]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5617, 5621]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5623, 5638]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5703, 5707]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T54'}]",[],[],[],[],[]
208,PMC-3586680-07-Authors_Contribution,"Ming-Fu Chiang and Chun-I Sze wrote the sections dealing with TMZ; Pei-Yi Chou wrote the review sections for p53 and WWOX and designed graphs; Wan-Jen Wang managed citations; Nan-Shan Chang conceived ideas, wrote and thoroughly revised the manuscript, and discussed with coauthors.","[{'offsets': [[109, 112]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[117, 121]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
209,PMC-3312845-13-Results,"Effect of sTNFp55R infusion on SE-induced serum-protein extravasation and neuronal damage
In our previous [5,7,8,20] and preliminary data, vasogenic edema and neuronal damage were noticeable at 1 day and 3 days after SE, respectively. Therefore, we determined that 3 days after SE was the best time point to evaluate the effect of sTNFp55R infusion on both vasogenic edema and neuronal damages induced by SE. In saline-treated animals, the PC was stained diffusely with anti-rat IgG (Figure 2A). The volume of vasogenic edema was 17.1 +/- 1.5 mm3 (Figure 2E). The number of FJB-positive neurons in the PC was 236,145 +/- 49,469 (Figure 2B). In sTNFp55R-treated animals, SE-induced vasogenic edema was attenuated to 9.8 +/- 0.7 mm3 (Figures 2C and 2E). In addition, the number of FJB-positive neurons in the PC was 89,138 +/- 5,698 (Figures 2D-E). Thus, sTNFp55R infusion attenuated SE-induced vasogenic edema and neuronal damage compared to saline-infused animals (p < 0.05).","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[332, 339]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[645, 652]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[854, 861]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
210,PMC-3317373-07-2._Methods_and_Materials,"2.6. Western Blot
To obtain total protein lysates, cells were homogenized in RIPA buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 20 mM NaF, 0.5 mM DTT, 1 mM PMSF, and protease inhibitor cocktail in PBS pH 7.4) and centrifuged at 12,000 g for 15 min at 4degreesC. Protein concentrations were estimated by Coomassie Plus Protein Assay Reagent (Pierce, IL, USA). Fifty micrograms of the resulting cytosolic protein extracts were heat-denatured in Laemmli sample loading buffer, separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and electroblotted onto a nitrocellulose membrane. For immunoblotting, membranes were blocked with 5% nonfat dry milk in saline buffer overnight at 4degreesC, and the following antibodies were used: anti-beta-actin (sc-130657, Santa Cruz Biotechnology, CA, USA, 43 kDa) and anti-matrix metallopeptidase 9 (MMP9) (sc-6841, Santa Cruz Biotechnology, CA, USA, 92 kDa). Each primary antibody was diluted appropriately in blocking buffer and then added to the blots for 1 h at room temperature. The blots were washed three times in the washing buffer and covered with the horseradish peroxidase-linked secondary antibody at a 1 : 2000 dilution for 1 h. Blots were incubated with enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, Bucks, UK) and exposed to radiographic film (Fuji Hyperfilm, Tokyo, Japan). ImageJ was used to analyze the intensity of the blots. The level of beta-actin was used as internal standard.","[{'offsets': [[898, 902]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
211,PMC-2817507-07-2._Methods,"2.6. Electrophoretic Mobility Shift Assay (EMSA)
Nuclear proteins were isolated from brain tissue. Briefly, after removal of supernatant (cytoplasmic extract), the pellets were resuspended in nuclear extraction reagent. The tubes containing pellets were put on vortex for 15 seconds every 10 minutes, for a total of 40 minutes. The tubes were centrifuged at maximum speed (~16,000 x g) in a micro centrifuge for 10 minutes. The supernatants (nuclear extract) were transferred to a clean prechilled tube and stored at -80degreesC until use. EMSA was performed as described previously [8]. NFkappaB binding activity was examined in a 15 muL binding reaction mixture containing 15 mug of nuclear proteins and 35 fmol [gamma-32P] labeled double-stranded NFkappaB consensus oligonucleotide. A super shift assay using antibodies to P65 and P50 was performed to confirm NFkappaB binding specificity as previously described.","[{'offsets': [[826, 829]], 'text': ['P65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[834, 837]], 'text': ['P50'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
212,PMC-1064895-14-Results,"Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
Because RA PBMC include several cell types in addition to T cells, some inflammatory cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells. To evaluate the effects of inflammatory cytokines released by activated PBMC, we tested the effects of several cytokines and chemokines on IL-17 production. We detected an increase in IL-17 level after stimulation with IL-15 (10 ng/ml), whereas with IL-1beta (10 ng/ml), TNF-alpha (10 ng/ml), IL-18 (10 ng/ml) or TGF-beta (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a). When treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml), significant upregulations of IL-17 proteins were observed (62 +/- 42 and 50 +/- 10 versus 31 +/- 11 pg/ml, respectively; P < 0.05), whereas none was observed with IL-8 (10 ng/ml), MIP-1alpha (10 ng/ml) or MIP-1beta (10 ng/ml) (Fig. 2b).","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[264, 269]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[423, 428]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[468, 473]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[503, 508]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[534, 542]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[555, 564]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[577, 582]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[597, 605]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[631, 636]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[681, 686]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[701, 705]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[747, 752]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[881, 885]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[898, 908]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[923, 932]], 'text': ['MIP-1beta'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
213,PMC-3585731-06-Results,"The Akt Signaling Pathway Contributes to the Regulation of Necroptosis
We next determined whether the necroptosis-associated increase in Thr308 phosphorylation results in an increase in Akt kinase activity. Under necroptotic conditions, we observed an increase in the phosphorylation of multiple known Akt substrates (Forkhead box class O (FoxO) proteins, GSK-3 kinases and mouse double minute 2 (MDM2)) as well as downstream molecules (p70 ribosomal protein S6 Kinase (p70S6K), S6) (Fig. 5A). In some cases (FoxO1, FoxO4, MDM2), a robust increase was observed. In other cases (FoxO3a, GSK-3alpha/beta, p70S6K and its substrate S6), the changes were less pronounced (Fig. 5A). The timing of the phosphorylation changes paralleled the increase in Akt phosphorylation (Fig. 5B, S5A, B). In the case of pFoxO1 we occasionally observed a shift in migration rather than an increase in band intensity (e.g. comparing Fig. 5A and B), suggesting that phosphorylation events in addition to Thr24 take place during necroptosis. Notably, in all cases the necroptosis-associated increases in Akt substrates were abrogated by Nec-1 (Fig. 5A, Fig. S5A, B). Overall, these data suggested that a significant part of the ""canonical"" Akt signaling network is activated at the onset of necroptotic cell death in a RIP1 dependent fashion.
Akt kinase is considered to be a pro-survival protein that inhibits apoptosis through the control of multiple effectors including mTORC1, GSK-3 and others [28]. An important question is whether these same molecules reverse their pro-survival roles during necroptosis. We found that inhibition of mTORC1 by rapamycin, an inhibitor of the mTOR co-factor Raptor [29], protected cells from necroptosis (Fig. 5C). Similarly, the direct mTOR kinase inhibitor Torin1 [30] and the dual PI3K/mTOR inhibitor PI-103 [31] also efficiently inhibited necroptosis (Fig. 5C). Knockdown of mTOR using siRNA further validated the small-molecule inhibitor data indicating a role for mTOR in necroptosis by protecting cells from both zVAD.fmk and TNFalpha induced death (Fig. 5D).
mTORC1 regulates translation through activation of p70S6 kinase and, subsequently, ribosomal protein S6 [32]. Notably, a genome-wide siRNA screen [10] suggested an important role for protein translation in necroptosis. Consistently, we found that the small molecule inhibitor of p70S6K PF-4708671 [33] attenuated necroptosis at the concentrations required to block S6 phosphorylation (Fig. S5C, D). Partial siRNA knockdown of S6 protein attenuated necroptosis as well (Fig. S5E), suggesting that translational control by p70S6K/S6 may play a role in necroptosis. Overall, while the full repertoire of Akt targets during necroptosis remains to be fully explored, our data provide evidence that the activity of an anti-apoptotic branch of Akt signaling can promote necroptosis.
RIP1 kinase, Akt, mTORC1 and JNK control the upregulation of TNFalpha accompanying necroptosis. Hitomi et al. [10] have recently reported that the induction of necroptosis by zVAD.fmk in L929 cells is associated with increased synthesis of TNFalpha, which potentiates cell death. Therefore, we examined whether Akt and its effectors contribute to TNFalpha synthesis. Consistent with a RIP1-dependent increase in TNFalpha protein (Fig. S6A, B), we found that TNFalpha mRNA levels increased during necroptosis in L929 cells in a RIP1 (Fig. S6C. Under serum free conditions, bFGF alone triggered some induction of TNFalpha mRNA, while its combination with zVAD.fmk (but not zVAD.fmk alone) caused a pronounced further increase (Fig. 6A). Conversely, PDGF caused a modest upregulation of TNFalpha mRNA, which was not further increased in the presence of zVAD.fmk (Fig. 6A), demonstrating that activation of necroptosis is specifically accompanied by a marked increase in autocrine TNFalpha synthesis.
Further analysis suggested that both Akt and mTORC1 contribute to the upregulation of TNFalpha mRNA during necroptosis as both small-molecule inhibition and siRNA knockdown of Akt and mTOR reduced TNFalpha mRNA levels in necroptotic cells (Fig. 6B,C,D). Notably, RIP1 and Akt inhibitors had no effect on the levels of TNFalpha mRNA in control cells or in the cells stimulated with bFGF alone (Fig. 6A,B, Fig. S6C), suggesting that these kinases specifically mediate necroptosis-dependent increase in TNFalpha synthesis.","[{'offsets': [[380, 395]], 'text': ['double minute 2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[397, 401]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[437, 468]], 'text': ['p70 ribosomal protein S6 Kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[470, 476]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[479, 481]], 'text': ['S6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[509, 514]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[516, 521]], 'text': ['FoxO4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[523, 527]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[578, 584]], 'text': ['FoxO3a'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[586, 596]], 'text': ['GSK-3alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[597, 601]], 'text': ['beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[603, 609]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[628, 630]], 'text': ['S6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[800, 806]], 'text': ['pFoxO1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1295, 1299]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1671, 1677]], 'text': ['Raptor'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2046, 2054]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2131, 2143]], 'text': ['p70S6 kinase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2181, 2183]], 'text': ['S6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2359, 2365]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2445, 2447]], 'text': ['S6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2506, 2508]], 'text': ['S6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2601, 2607]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2608, 2610]], 'text': ['S6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2856, 2860]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2917, 2925]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3096, 3104]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3203, 3211]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3241, 3245]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3268, 3276]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3314, 3322]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3383, 3387]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3428, 3432]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3467, 3475]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3640, 3648]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3833, 3841]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3939, 3947]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4050, 4058]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4116, 4120]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4171, 4179]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4234, 4238]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4353, 4361]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T42'}]",[],[],[],[],[]
214,PMC-3342329-16-Materials_and_Methods,"Protein Immuno-arrays
The tumor and spleen tissues were excised and homogenized in PBS with protease inhibitor cocktail (Sigma-Aldrich, USA) and Triton X-100 (final concentration 1%). The samples were frozen at -70degreesC, thawed, and centrifuged at 10,000xg for 5 min to remove cellular debris. The tissue lysates were performed protein assay in the same way as for western blotting. 4.5 mg of proteins, collected from three samples per group, were used for Mouse cytokine array as the protocol provided by supplier (Proteome Profiler(TM), #ARY006, R&D Systems, USA).",[],[],[],[],[],[]
215,PMC-3291650-07-Materials_and_Methods,"Mice
A20fl/fl mice were generated as previously described [56]. A20fl/fl mice were crossed with LysM-Cre mice [84] (provided by I. Forster, Institute of Genetics, University of Cologne, Germany) to generate A20fl/fl LysMCre transgenes and are described in detail elsewhere [48]. Mice were housed in individually ventilated cages at the VIB Department of Molecular Biomedical Research in specific pathogen-free animal facilities. Influenza infections were performed on age- (between 7 and 9 weeks old) and sex-matched littermates. A20fl/fl LysM-Cre animals were backcrossed three times to the C57Bl/6 background. A20fl/fl mice expressing or lacking the LysM-Cre transgene were termed A20myel-KO and wild type (A20myel-WT) respectively.",[],[],[],[],[],[]
216,PMC-1064873-04-Materials_and_methods,"Culture of CD4+ T cells
PB CD4+ T-cell populations were resuspended at a density of 1 x 106 cells/ml in culture medium with 10% FCS, and 0.5 ml cell suspensions were dispensed into the wells of 24-well microtiter plates (Coster) coated with 1 mug/ml anti-CD3 mAb (Immunotech, Marseille, France). The cells were incubated with 1 mug/ml anti-CD28 mAb (Immunotech) in the presence or absence of the indicated concentrations of IL-10 (Becton Dickinson, San Jose, CA, USA) at 37degreesC in a humidified atmosphere containing 5% CO2 [28]. Culture supernatants were collected 36 hours later and cell-free samples were stored at -30degreesC until cytokine assay.
To examine the effect of IL-6 on T-cell responsiveness to IL-10, CD4+ T cells from healthy controls were incubated in culture medium with 10% FCS in the presence or absence of 10 ng/ml IL-6 (Becton Dickinson) for 36 hours. Cells were then stimulated for 36 hours with anti-CD3 mAb and anti-CD28 mAb in the presence or absence of 1 ng/ml IL-10. Culture supernatants were measured for IFN-gamma concentrations.","[{'offsets': [[11, 14]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[27, 30]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[340, 344]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[424, 429]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[680, 684]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[713, 718]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[720, 723]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[840, 844]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[945, 949]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[992, 997]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1038, 1047]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
217,PMC-3320587-19-Results,"NF-kappaB and NFAT5 binding play independent activating roles in MTb-mediated induction of HIV-1 replication
We next examined the functional impact of specifically disrupting NF-kappaB or NFAT5 binding on regulation of HIV-1 replication by infecting bulk PBMC from four normal donors with the wild-type or mutant HIV-1Lai/Bal-env molecular clones. After overnight infection, cells were co-infected with MTb (CDC1551) or mock-infected and free virus levels were detected by measuring p24 levels in culture supernatants at days 4, 7, and 12 post-HIV-1 infection.
Replication of each mutant virus was reduced in comparison to wild-type virus in mock- and MTb-co-infected cells at all timepoints examined (Figures 4A-4B). As depicted in the histograms displayed in Figure 4C, at day 12 post-HIV-1 infection in MTb-co-infected cells there was a significant reduction in levels of HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, and HIV-1Lai/Bal-env -N5-Mut in comparison to wild-type virus (Figure 4C). In the absence of MTb co-infection, p24 levels were also significantly lower in the PBMC cultures infected with HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut and HIV-1Lai/Bal-env-N5-Mut, but not HIV-1Lai/Bal-env-kappaB I-Mut, in comparison to wild-type virus (Figure 4C). None of the mutations completely abolished viral induction by MTb co-infection. However, the replication of each mutant virus was impaired to a more significant extent in the context of MTb co-infection, consistent with important roles for both NF-kappaB and NFAT5 in MTb-induced HIV-1 replication.
To specifically examine the functional impact of NF-kappaB and NFAT5 binding site usage in MDM, which are efficiently infected by both pathogens, we next isolated MDM from four normal donors and infected these cells with 1000 TCID50 of wild-type HIV-1Lai/Bal-env or with the mutant viral clones HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut. After overnight incubation, cell cultures were co-infected with MTb (CDC1551) or left infected with virus alone. Supernatants were collected at days 4, 7, and 12 post-HIV-1 infection and virus replication was measured. As shown in Figures 5A and 5C, in the absence of MTb co-infection, replication of mutant viral molecular clones (HIV-1Lai/Bal-env-kappaB I-Mut (p<0.05), HIV-1Lai/Bal-env-kappaB II-Mut (p<0.01), and HIV-1Lai/Bal-env-kappaB I+II-Mut (p<0.01) as well as HIV-1Lai/Bal-env-N5-Mut (p<0.01) were significantly reduced in comparison to the wild-type virus (Figures 5A-5C).
When the cultures were co-infected with MTb, p24 levels increased when the cells were infected with either the wild-type or, to lower levels, with the kappaB-I mutant virus (Figure 5B). However, p24 levels were significantly inhibited in cells infected with HIV-1Lai/Bal-env -N5-Mut (p<0.01) (Figure 5D). Moreover, p24 levels were significantly lower at day 12 in cultures infected with HIV-1Lai/Bal-env-kappaB II-Mut and HIV-1Lai/Bal-env-kappaB I+II-Mut as compared to infection of cells with wild-type virus (Figure 5D). Notably, although replication of the mutant virus with the single, proximal NF-kappaB binding site mutation in the shared NFAT5/NF-kappaB element (HIV-1Lai/Bal-env-kappaB I-Mut) was diminished, this was not significant at day 12 (Figures 5B-5D).
We note that overall p24 levels were noticeably lower in the cultures co-infected with MTb compared with those infected with HIV-1 alone. This is consistent with previous observations showing that MTb infection of human primary macrophage cultures ex vivo suppresses HIV-1 infection due to chemokine synthesis and the enhanced expression of cellular inhibitory factors [48]-[50]. Given that NF-kappaB is efficiently activated in primary MDM in response to TLR agonists [51] and as we have shown in Figure 2, NFAT5 gene expression is also induced by TLR agonists, MDM are a suitable experimental system to analyze the effect of NF-kappaB versus NFAT5 binding site mutations on virus replication in isolated MDM in the absence or presence of MTb co-infection. Taken together, the results from PBMC and MDM co-infection experiments demonstrate that the conserved NFAT5 binding site plays as important a transcriptional role in LTR regulation by MTb as do the NF-kappaB sites.","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[188, 193]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[326, 329]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[483, 486]], 'text': ['p24'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[888, 891]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[919, 922]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[951, 954]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[989, 992]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1083, 1086]], 'text': ['p24'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1172, 1175]], 'text': ['env'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1204, 1207]], 'text': ['env'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1241, 1244]], 'text': ['env'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1274, 1277]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1597, 1602]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1896, 1899]], 'text': ['env'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1945, 1948]], 'text': ['env'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1976, 1979]], 'text': ['env'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2008, 2011]], 'text': ['env'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2045, 2048]], 'text': ['env'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2402, 2405]], 'text': ['env'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2442, 2445]], 'text': ['env'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2487, 2490]], 'text': ['env'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2540, 2543]], 'text': ['env'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2686, 2689]], 'text': ['p24'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2836, 2839]], 'text': ['p24'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2912, 2915]], 'text': ['env'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2956, 2959]], 'text': ['p24'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3041, 3044]], 'text': ['env'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3076, 3079]], 'text': ['env'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3324, 3327]], 'text': ['env'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3431, 3434]], 'text': ['p24'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3918, 3923]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T32'}]",[],[],[],[],[]
218,PMC-3586680-02-WW_Domain-Containing_Oxidoreductase_WWOX,"Recently, tumor suppressors p53 and WWOX were shown to regulate the apoptosis of glioblastoma cells (Chiang et al., 2012). WW domain-containing oxidoreductase, known as WWOX, FOR, or WOX1, is encoded by human or mouse WWOX/Wwox gene. This gene is located in chromosome 16q23.3-24.1, an area known as the common fragile site FRA16D. The full-length WWOX protein is composed of two N-terminal WW domains, a C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, and a proapoptotic C-terminal tail D3 (Chang et al., 2001, 2007, 2010; Aqeilan et al., 2004, 2007; Hong et al., 2007; Salah et al., 2012) (Figure 1). WWOX may act as an alternative receptor for sex steroid hormones, since its SDR domain possesses an NSYK motif capable of interacting with androgen and estrogen (Chang et al., 2005a; Su et al., 2012).
Expression of WWOX is either altered or lost from epigenetic modification in multiple malignant cancers, such as non-small cell lung carcinoma (Donati et al., 2007), hematopoietic malignancies (Ishii and Furukawa, 2004), gastric carcinoma (Aqeilan et al., 2004), pancreatic carcinoma (Kuroki et al., 2004), breast carcinoma (Guler et al., 2004; Aqeilan et al., 2007), and glioblastoma multiforme (Kosla et al., 2011). Restoration of WWOX gene prevents the growth of lung cancer (Fabbri et al., 2005), pancreatic cancer (Nakayama et al., 2008), and prostate cancer (Hong et al., 2009).
The first WW domain of WWOX may interact with proteins possessing a PPxY motif(s) such as AP-2gamma, p73, ErbB4, Ezrin, SIMPLE, c-Jun, RUNX4, and many others (Chang et al., 2007; Salah et al., 2012; Su et al., 2012; Figure 1). Transiently overexpressed WWOX binds transcription factors AP-2, p73, and c-Jun and block their nuclear relocation in vitro, which suppresses cancer cell survival (Salah et al., 2012). In stark contrast, Wwox co-migrates with proapoptotic and pro-survival transcription factors to the nuclei of neurons upon sciatic nerve axotomy in rats (Li et al., 2009). No blocking of translocation of transcription factors to the nuclei by Wwox was observed.
Under stress conditions, WWOX is activated via phosphorylation at Tyr33, and binds proteins independently of the PPxY motif (Chang et al., 2001, 2003, 2005a,b, 2007, 2010). Activated WWOX physically interacts with serine 46-phosphorylated p53 (Figure 1), which stabilizes p53 and its apoptotic function (Chang et al., 2005b). Also, WWOX binds Disheveled proteins (Dvl), which are key components in Wnt/beta-catenin signaling pathway (Figure 1). No PPxY motif is in Dvl. Transiently overexpressed WWOX sequesters Dvl-2 in the cytoplasm and thereby blocks Dvl-2-mediated TCF transcriptional activity (Bouteille et al., 2009).
Overexpressed WWOX induces apoptosis and inhibits proliferation of human hepatic carcinoma cells (Hu et al., 2012) and many cancer cell types (Chang et al., 2007, 2010; Salah et al., 2012; Su et al., 2012). WWOX enhances the cytotoxic function of tumor necrosis factor by down-regulating apoptosis inhibitor Bcl-2 and Bcl-xL and up-regulating apoptotic p53 (Chang et al., 2001). Also, WWOX mediates cell death synergistically with p53. Upon exposure to chemicals or environmental stress, such as UV irradiation and chemotherapeutic drugs, WWOX undergoes phosphorylation in Tyr33 and probably others sites, followed by relocating to mitochondria or nuclei for inducing apoptosis (Chang et al., 2007, 2010).
WWOX binds MEK in Jurkat T cells (Lin et al., 2011). Phorbol myristate acetate (PMA) dissociates the MEK/WWOX complex and induces WWOX to translocate to the mitochondria to induce apoptosis, whereas MEK relocates to the lipid raft. Inhibition of MEK activity increases TMZ-induced suppression of cancer cell growth (Holt et al., 2012). Ectopic expression of WWOX in A549 cells induces procaspase-3 and procaspase-9 activation and induces cytochrome C releasing from the mitochondria (Zhang et al., 2012a). Complement C1q induces ectopic WWOX phosphorylation in Try33 and leads to cell apoptosis independently of the classical complement activation pathway (Hong et al., 2009). A portion of WWOX is anchored in the membrane/cytoskeleton area via binding with hyaluronidase Hyal-2 (Hsu et al., 2009) and Phospho-Ezrin (Jin et al., 2006). Transforming growth factor beta1 binds Hyal-2 as a cognate receptor to signal the formation of the WWOX/Hyal-2/Smad4 complex to relocate to the nucleus for enhancing the SMAD-driven promoter activity (Hsu et al., 2009).","[{'offsets': [[28, 31]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 40]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[123, 158]], 'text': ['WW domain-containing oxidoreductase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[169, 173]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[175, 178]], 'text': ['FOR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[183, 187]], 'text': ['WOX1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[218, 222]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[223, 227]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[348, 352]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[624, 628]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[839, 843]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1258, 1262]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1433, 1437]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1500, 1509]], 'text': ['AP-2gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1511, 1514]], 'text': ['p73'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1516, 1521]], 'text': ['ErbB4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1523, 1528]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1530, 1536]], 'text': ['SIMPLE'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1538, 1543]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1545, 1550]], 'text': ['RUNX4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1663, 1667]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1696, 1700]], 'text': ['AP-2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1702, 1705]], 'text': ['p73'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1711, 1716]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1841, 1845]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2065, 2069]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2109, 2113]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2267, 2271]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2323, 2326]], 'text': ['p53'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2356, 2359]], 'text': ['p53'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2416, 2420]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2486, 2498]], 'text': ['beta-catenin'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2580, 2584]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2596, 2601]], 'text': ['Dvl-2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2638, 2643]], 'text': ['Dvl-2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2722, 2726]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2915, 2919]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2955, 2976]], 'text': ['tumor necrosis factor'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3016, 3021]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3026, 3032]], 'text': ['Bcl-xL'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3061, 3064]], 'text': ['p53'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3093, 3097]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3139, 3142]], 'text': ['p53'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3247, 3251]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3414, 3418]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3544, 3548]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3772, 3776]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3799, 3811]], 'text': ['procaspase-3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3816, 3828]], 'text': ['procaspase-9'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3951, 3955]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4104, 4108]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4186, 4192]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4224, 4229]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4250, 4282]], 'text': ['Transforming growth factor beta1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4289, 4295]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T55'}]",[],[],[],[],[]
219,PMC-1472690-16-Methods,"Inhibition of transcription factors
To inhibit translocation and binding of transcription factors to the IL-1RA promoter, PBMC were incubated for 1 h with each of the following substances (concentrations were based upon 50% inhibition): 50 mug/ml of CAPE (caffeic-3,4-dihydroxycinnamic-acid-phenyl-ester), (Biomol, Hamburg, Germany); 400 ng/ml cyclosporin A (Calbiochem-Merck Biosciences, Bad Soden, Germany); 10 mug/ml cycloheximide (Santa Cruz Biotechnology) prior to incubation with GP. Band shifts were determined after 1 h incubation with GP as described before, including mutated oligos for NFIL-6 (TTA CAA CAG TGG ATT GCG ACA CTT AGT GGG) and NFATP2/3 (GGC GCA GAA AAG GTA AAA TAT TTA CTA TCT) binding sites within the IL-1RA promoter. PBMC RNA was isolated with an RNeasy kit (Qiagen, Germany) and messenger RNA was transcribed into cDNA with Reactin Ready First Strand kit (Biomol) and analysed for IL-1RA and GAPDH transcripts by PCR with a HotStart ""sweet"" PCR mastermix (Biomol) (95degreesC, 30 sec, 55degreesC, 30 sec, 72degreesC, 30 sec, 25 cycles for IL-1RA and 94degreesC for 30 sec, 50degreesC for 30 sec and 72degreesC for 45 sec, 25 cycles for GAPDH) following 18 h incubation with GP. IL-1RA protein was measured in the supernatant by ELISA after 24 h incubation with GP.","[{'offsets': [[105, 111]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[597, 603]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[650, 656]], 'text': ['NFATP2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[657, 658]], 'text': ['3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[726, 732]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[908, 914]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[919, 924]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1205, 1211]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
220,PMC-3320587-05-Materials_and_Methods,"LTR plasmid construction and reporter assay
LTR reporter plasmids were constructed by inserting nucleotides -208 to +64 relative to the transcriptional initiation site of HIV-1Lai, HIV-1Bal (B subtype), HIV-198IN17, HIV-198IN22, HIV-198CH01, HIV-1CM9 (C subtype), HIV-193TH64, HIV-192TH53, HIV-192TH51, and HIV-1KR25 (E subtype) into the reporter vector pGL3 (Promega BioSciences, www.promega.com) using Xho I and Hind III restriction enzyme sites. Sequences were aligned and analyzed with CLUSTAL W (www.ebi.ac.uk/clustalw/). The HIV-1Lai NFAT5 binding site-mutant (N5-Mut) reporter plasmid was created by standard PCR-based mutagenesis methods [34]. THP-1 cells (0.8x106/ml) were transfected with 0.3 microg/ml LTR wild-type (WT) or mutated reporter plasmids in combination with 0.03 microg/ml Renilla luciferase (pRL-TK) control vector using Effectene transfection reagent (Qiagen; www.qiagen.com). Cells were incubated at 37degreesC for 16 hours after which they were stimulated with 10 microg/ml MTb CDC1551 lysate or left unstimulated for 8 hours. Reporter gene expression was quantitated by dual-luciferase reporter assay according to the manufacturer's protocol (Promega; www.promega.com).","[{'offsets': [[804, 814]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1054, 1067]], 'text': ['Reporter gene'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1103, 1113]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
221,PMC-1472690-07-Discussion,"Animal models of sepsis and myocardial injury suggest that a beta-1 to 3-D-glucan like GP mediates its protective mechanisms, in part, via a rapid shift from NFkappaB- to PI3K-signaling [22,37]. Our study provides novel evidence that downstream of recognition and signaling pro-inflammatory transcription factor binding and cytokine expression of human leukocytes is switched to an anti-inflammatory phenotype by GP.
We confirmed and extended previous results [13-16] indicating that, in the absence of other stimuli, beta-1 to 3-D-glucans induced binding of NFkappaB-, NFIL-6- and NFAT-mers to cytokine promoters. Because of the multiple band shifts observed for NFAT binding (Fig. 1A), one could speculate that there is activation of several different NFAT isoforms, probably derived from alternative splicing [38]. Interestingly, the GP-induced transcription factor binding transformed only into a very limited cytokine response, namely IL-8 and IL-1RA (Fig. 3B). Hence, our data are in aggreement with the few reports describing a beta-1 to 3-D-glucan-mediated IL-8 [6,16,19] and IL-1RA production [17]. In addition, our EMSA/supershift and immunoblotting results demonstrated a GP-mediated predominant binding of NFkappaB p65 and to a lesser extent of p50 to a kappaB consensus site of the IL-8 promoter (Figs. 1A, 2). Results by Schulte and colleagues [28] pointed to an induction of IL-8 transcription depending on activation via an NFkappaB p65/65 homodimer, rather than via p65/50 heterodimers, which might be the case for the GP-mediated IL-8 transcription. A GP-mediated IL-8 transcription based upon a cooperation between transactivated NFkappaB p65 and NFIL-6 [13,39] or NFATc2 dimer binding to the IL-8kappaB site [38] seems also possible. The IL-8kappaB consensus site exhibits a preferentially p65 binding half site and thus differs from the kappaB half site described for TNFalpha and IL-1beta [27,40], supporting the idea of regulating NFkappaB binding through combinatorial associations of the subunits and the specific sequence of the decameric kappaB motif [41,42]. Unlike LPS or TSST-1, we found that GP did not induce IL-1beta, but it strongly induced IL-1RA, suggesting an immediate anti-inflammatory potential of GP. Analysing the IL-1RA promoter [34], we discovered four new binding sites (Fig. 8): an NFkappaB3 site (between -100 and -130), an NFkappaB consensus site (-266 and -280), another NFkappaB2/3 site (-288 and -302) and a more distal NFATP2/3 site (-471 and -490). Our data indicated that GP leads to production of IL-1RA primarily via induction of NFATP2/3 and NFIL-6 DNA binding, which might be due to differences in the binding motif or the composition of the activated transcription factors (NFAT) between the IFNgamma, IL-6 and IL-1RA promoter. The differential decrease of NFkappaB, NFAT and NFIL-6 binding to sites in the IL-1RA promoter as well as of IL-1RA mRNA and protein induced by selective inhibitors prior to GP treatment might suggest that these steps are linked to each other and necessary for induction of IL-1RA (Fig. 7). Regarding cellular sources, both, monocytes as well as neutrophils have been reported to produce IL-1RA [32]. Flow cytometric experiments seemed to confirm that monocytes and neutrophils were able to produce IL-8 just as IL-1RA in response to GP (data not shown). This GP-induced cytokine profile was substantially more restricted than that of LPS or TSST-1, which is likely due to differences in recognition and signaling between LPS, TSST-1 and GP. Recognition of LPS is mainly mediated through Toll-like receptor 4 and subsequent signaling via the NFkappaB pathway, leading to expression of pro-inflammatory mediators like TNFalpha [43]. A bacterial superantigen like TSST-1 acts through binding to MHC-II molecules and subsequently the T cell receptor, leading to release of mainly IFNgamma and TNFalpha, the latter via both, PI3K and p38 mitogen-activated kinase signaling [44,45]. Altogether, the induction of the neutrophil-attracting IL-8 and the anti-inflammatory IL-1RA by fungal carbohydrates (GP) may well fit to a benign PAMP response, mounting defensive mechanisms against a possible microbial attack.
Potentially even more relevant than the specific cytokine panel induced by GP, we found that, in the presence of other stimuli (LPS or TSST-1), GP ameliorated their pro-inflammatory immune reactions, similar to the effects in murine models of sepsis and inflammation [21-24]. Mainly, GP altered the TSST-1-induced IL-1beta/IL-1RA ratio from a pro- to an anti-inflammatory profile via down-regulation of IL-1beta and IL-6, at the same time there was a synergistic up-regulation of IL-1RA. In part, this change may be caused by GP-mediated modulations of the TSST-1 induced binding of NFkappaB, NFIL-6 and NFAT to known and up to now unknown sites within the IL-8 and IL-1RA promoter instead of the TNFalpha, IL-1beta, IL-6 or IFNgamma promoter. Accordingly, we found that the TSST-1-induced binding of NFkappaB to sites from the TNFalpha promoter negatively correlated with the GP-mediated enhancement of the TSST-1-induced IL-1RA production (r = -0.88; p < 0.01; data not shown in detail). Of the four examined NFkappaB sites from the IL-1RA promoter, mostly the TSST-1- and LPS-induced binding to the NFkappaB3 and the TSST-1-induced binding to the new NFkappaB consensus site seemed to be increased by GP. So, while we observed a GP-mediated down-regulation of the LPS- and the TSST-1-induced NFkappaB binding to sites of the TNFalpha promoter, there was an up-regulation to NFkappaB3 and NFkappaB consensus sites of the IL-1RA promoter. These seemingly contradictory data could be explained by differences in either NFkappaB subunits or conserved nucleotides (#1, 2, 3, 10) within the decameric NFkappaB binding motif between the TNFalpha and the IL-1RA promoter (for NFkappaB3 the IL-1RA motif contains a T on position 10 instead of the conserved C in the TNFalpha motif, see Table 1), probably leading to differences in binding [41,42]. Despite the location of the new NFkappaB consensus site (-266 and -280) in the inhibitory element (-250 and -294) of the IL-1RA promoter [30], we observed no inhibition. On the other side, we found an inhibitory NFkappaB2/3 site (-288 and -302) towards the end of the inhibitory element, demonstrating down-regulations of the LPS- and TSST-1-induced binding, which could not be altered by GP. In our opinion, this site may therefore represent at least a part of the previoulsy described inhibitory element [30]. The GP-modulated increase in TSST-1-induced binding to the new NFkappaB3 and NFkappaB consensus site, the NFIL-6 site [32] as well as to the novel NFATP2/3 site may explain the synergistic up-regulation of the TSST-1-induced IL-1RA production. We think that this GP-modulated activation of transcription was reflected by the decrease of the IL-1beta/IL-1RA ratio following GP + TSST-1 (Fig. 6). In this context, it has been postulated that in vitro a 100fold excess of IL-1RA over IL-1beta might control the biological effects of IL-1 [46,47]. Since, in fact, the IL-1beta/IL-1RA ratio following GP + TSST-1 is partially less than 0.01, it is not unreasonable to assume that IL-1beta bioactivity is inactivated in our system. Indeed, GP reduced the TSST-1-induced, IL-1-dependent IL-2 production of murine EL-4 cells (data not shown in detail).
The weaker modulating effects of GP on the LPS-induced immune response observed in this study, may be attributed to delicately balanced differences in signaling pathways between LPS and TSST-1 [43-45]. TSST-1 has been shown to use the PI3K pathway for signaling [44] and this effect may be sustained by GP treatment [22,37]. It has been demonstrated that in septic/LPS-adapted leukocytes the PI3K pathway selectively controls sIL-1RA but not IL-1beta production [48]. Signaling via PI3K has been reported to be involved in the activation of NFAT in T cells [49]. Activation of NFkappaB can also take place via PI3K [50], which may offer an explanation for a difference in signaling between GP (PI3K) and LPS (mitogen-activated kinase signaling). This idea may be supported by another study showing that despite the use of similar PRR, LPS and peptidoglycan activated the IL-1RA gene through different mechanisms/DNA-binding proteins and acted synergistically in combination, suggestive of signals which are not equivalent in all parts [51].","[{'offsets': [[570, 576]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[582, 586]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[664, 668]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[754, 758]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[940, 944]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[949, 955]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1065, 1069]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1084, 1090]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1227, 1230]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1257, 1260]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1295, 1299]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1390, 1394]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1449, 1452]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1453, 1455]], 'text': ['65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1483, 1486]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1487, 1489]], 'text': ['50'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1548, 1552]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1582, 1586]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1658, 1661]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1666, 1672]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1684, 1690]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1712, 1716]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1758, 1762]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1810, 1813]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1889, 1897]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1902, 1910]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2101, 2107]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2141, 2149]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2175, 2181]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2256, 2262]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2586, 2592]], 'text': ['NFATP2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2593, 2594]], 'text': ['3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2599, 2605]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2733, 2737]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2751, 2759]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2761, 2765]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2770, 2776]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2826, 2830]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2835, 2841]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2866, 2872]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2896, 2902]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3061, 3067]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3175, 3181]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3286, 3290]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3299, 3305]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3429, 3435]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3514, 3520]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3575, 3595]], 'text': ['Toll-like receptor 4'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3704, 3712]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3749, 3755]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3864, 3872]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3877, 3885]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3917, 3945]], 'text': ['p38 mitogen-activated kinase'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4020, 4024]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4051, 4057]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4329, 4335]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4493, 4499]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4508, 4516]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4517, 4523]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4597, 4605]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4610, 4614]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4674, 4680]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4751, 4757]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4787, 4793]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4798, 4802]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4851, 4855]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4860, 4866]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4891, 4899]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4901, 4909]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4911, 4915]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4919, 4927]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4969, 4975]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5022, 5030]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5102, 5108]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5117, 5123]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5229, 5235]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5257, 5263]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[5314, 5320]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[5474, 5480]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[5522, 5530]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[5617, 5623]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[5827, 5835]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[5844, 5850]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[6157, 6163]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[6371, 6377]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[6577, 6583]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[6758, 6764]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[6773, 6779]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[6889, 6897]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[6898, 6904]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[6926, 6932]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[7017, 7023]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[7029, 7037]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[7078, 7082]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[7112, 7120]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[7121, 7127]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[7149, 7155]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[7223, 7231]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[7297, 7303]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[7313, 7317]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[7328, 7332]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[7579, 7585]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[7595, 7601]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[7820, 7826]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[7835, 7843]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[7934, 7938]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[8264, 8270]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T107'}]",[],[],[],[],[]
222,PMC-3320587-28-Caption-Figure_6,"Disruption of the NFAT5 site in HIV-1 subtype C significantly impairs MTb-induced viral replication.
(A) Mutation of the NFAT5 binding site in an HIV-1 subtype C infectious molecular clone. NFAT5 binding site mutations were introduced into the LTR of subtype C HIV-198IN22-WT. The NFAT5 binding site mutant (HIV-198IN22 N5-Mut) LTR sequence is shown alongside that of HIV-198IN22-WT. The HIV-198IN22 isolate analyzed here contains three NF-kappaB and two NFAT5 binding sites. The unique 3' terminal adenine, which is important for NFAT5 binding to its site, is shown in blocks. Mutations were introduced into the 3' LTR of the HIV-198IN22-WT proviral sequence. PBMC from four normal donors were infected with 1000 TCID50 of HIV-198IN22-WT or HIV-198IN22-N5-Mut. Cells were then (B) left infected with virus alone or (C) co-infected with MTb strain CDC1551 (10:1 cells:bacilli). Culture supernatants were collected at days 3, 7 and 11 post-infection and viral p24 levels were measured. Replication of HIV-198IN22-N5-Mut was significantly reduced at day 11 post-infection in comparison to HIV-198IN22-WT (*, p<0.05) in the presence of MTb co-infection.","[{'offsets': [[531, 536]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[959, 962]], 'text': ['p24'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
223,PMC-3291650-16-Materials_and_Methods,"Statistics
Results are expressed as the mean +/- SEM. Statistical significance between groups was assessed using two-way ANOVA. The differences for in vivo experiments (at least 5 mice per group) were calculated using the Mann-Whitney U-test for unpaired data. Statistical significance of differences between survival rates was analyzed by comparing Kaplan-Meier curves using the log-rank test (GraphPad Prism version 5, GraphPad, San Diego, CA).",[],[],[],[],[],[]
224,PMC-3589482-08-Experimental_Procedures,"Lentiviral shRNAs, Packaging and Transduction
pLKO.1-puro lentiviral vectors carrying short hairpin RNAs (shRNA) specific for human and mouse cebpb were used in these studies. Because the human and mouse cebpb 3' untranslated regions are not identical, these species-specific shRNAs cannot knockdown expression of endogenous C/EBP-beta when used on cells of the other species; therefore we used the human CEBPB shRNA as a control in these experiments as in [38]. To produce lentiviral particles, HEK-293T cells were transfected with a mixture of plasmids: each shRNA expression plasmid (1 microg), pCMV-deltaR8.2dvpr packaging plasmid (0.75 microg), and pCMV-VSV-G envelope plasmid (0.25 microg) using Lipofectamine 2000 reagent (Invitrogen). The lentiviral supernatant was collected 48 hrs after transfection, cleared by centrifugation at 2,000 g for 10 mins and passed through a 0.45 microm filter. The target cells were treated with the lentiviral supernatant and 8 microg/ml Polybrene (American Bioanalytical) for 24 hrs. The lentiviral supernatant was replaced with fresh growth media and incubated further for 72 hrs to allow for effective gene knockdown. C/EBP-beta knockdown was confirmed by western blot analysis.","[{'offsets': [[142, 147]], 'text': ['cebpb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[204, 209]], 'text': ['cebpb'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[325, 335]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1162, 1172]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
225,PMC-1359074-13-Materials_and_Methods,"Northern blot.
A mouse embryonic tissue Northern blot filter (Seegene, Rockville, Maryland, United States) was hybridized with a Sox6 probe generated by RT-PCR (nucleotides 1353-1927) and labeled with [alpha-32P]dCTP, by random primer labeling (RediprimeII; Amersham Biosciences, Buckinghamshire, England, United Kingdom). The hybridization was performed in phosphate buffered 7% SDS hybridization solution. Blots were washed with 0.2x SSC, 1% SDS at 60 degreesC prior to exposure to X-ray film (Kodak, Rochester, New York, United States) at -80 degreesC for 6 d.","[{'offsets': [[129, 133]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
226,PMC-3585731-32-Caption-Figure_7,"Over expression of constitutively active Akt restores necroptosis under serum free conditions.
(A,B) L929 cells were stably infected with empty MSCV retrovirus or viruses encoding Myr-Akt or the catalytically inactive Myr-Akt K179M. Necroptosis was induced by the addition of zVAD.fmk under serum free conditions (A) or serum or serum free conditions with Nec-1 (B). Viability assays were performed after 24 hr. (C) Myr-Akt and Myr-Akt K179M cells were treated with zVAD.fmk and/or Nec-1 under serum free conditions for 9 hr, followed by western blot using the indicated antibodies. Endogenous Akt (~) and Myr-Akt (*) bands are indicated. (D) L929 cells, stably infected with Myr-Akt and Myr-Akt K179KM, were stimulated with zVAD.fmk for 9 hr under serum free conditions. TNFalpha mRNA levels were determined by qRT-PCR and normalized using mouse 18S RNA. (E-G) L929 cells expressing Myr-Akt and Ala and Asp mutants of Thr308 and Ser473 were treated with zVAD.fmk under serum free conditions, followed by viability assay at 24 hr (E), western blot at 9 hr (F), or evaluation of TNFalpha mRNA levels by qRT-PCR at 9 hrs (G). In all graphs, average+/-SD was plotted.","[{'offsets': [[772, 780]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[847, 850]], 'text': ['18S'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1078, 1086]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
227,PMC-3218875-04-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Since NF-kappaB activation is so crucial to many cellular processes, a tight regulation of the NF-kappaB signalling pathway and the genes it induces is an absolute requirement to fine-tune the inflammatory response. Moreover, terminating an NF-kappaB response is essential to prevent persistent NF-kappaB activation that may lead to chronic inflammation and/or tumorigenesis. To achieve this, cells employ different mechanisms, including the expression of inhibitory proteins that downregulate NF-kappaB signalling [32]. Below we give an overview of a number of proteins that are involved in the dampening or termination of the NF-kappaB response, some of them under the control of NF-kappaB itself and thus acting in a negative feedback loop. In addition, we discuss the potential role of these NF-kappaB inhibitory factors in the immunopathology of RA. Several other proteins involved in the negative regulation of NF-kappaB-dependent inflammatory responses, such as MyD88s, IRAK-M, and TOLLIP, have been described (reviewed in [33]). These proteins are not discussed here, since a link with RA pathology has not yet been reported.Although IKK1 is a critical component of the non-canonical NF-kappaB pathway, it should be mentioned that this kinase also plays a prominent role in the negative regulation of both canonical and noncanonical NF-kappaB pathways. Macrophages from IKK1-deficient mice or knockin mice expressing inactive IKK1 show increased production of proinflammatory cytokines as a result of enhanced IKK2 activation and IkappaBalpha degradation [34]. IKK1 has also been shown to inhibit nuclear NF-kappaB and to downregulate proinflammatory signalling by phosphorylating STAT1 [35]. Interestingly, a recent study has demonstrated that IKK1 phosphorylates NIK in negative feedback regulation of the noncanonical NF-kappaB pathway [36], supporting the idea that IKK1 plays important roles in terminating both canonical and noncanonical NF-kappaB pathways with possible implications for chronic inflammatory diseases like RA.","[{'offsets': [[969, 975]], 'text': ['MyD88s'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[977, 983]], 'text': ['IRAK-M'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[989, 995]], 'text': ['TOLLIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1142, 1146]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1378, 1382]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1434, 1438]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1518, 1522]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1538, 1550]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1569, 1573]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1689, 1694]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1753, 1757]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1773, 1776]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1878, 1882]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T13'}]",[],[],[],[],[]
228,PMC-1472690-01-Background,"beta-1 to 3-D-glucans occur as a principal component of microbial cell walls or can be secreted from both, non-pathogenic and pathogenic fungi such as S. cerevisae and C. albicans [1]. These beta-1 to 3-D-linked glucose polymers are characterized as a fungal pathogen-associated molecular pattern (PAMP) [2]. The primary cellular recognition of beta-1 to 3-D-glucans is mediated by several beta-1 to 3-D-glucan receptors on phagocytes [3,4] and other cells [5,6]. Human as well as murine Dectin-1 has been demonstrated to be the major pattern recognition receptor (PRR) for intact yeast and beta-1 to 3-D-glucan-containing particles (i.e. zymosan) on monocytes/macrophages as well as neutrophils and on primary cells [7-11]. In the murine system, binding of zymosan to Dectin-1 resulted in production of TNFalpha through Toll-like receptor 2 and the adaptor protein MyD88 [12]. Another water-soluble beta-1 to 3-D-glucan (PGG-glucan) has been described to activate NFkappaB and NFIL-6 in murine cell lines [13,14]. Similarly, it has been shown that beta-1 to 3-D-glucans activate NFkappaB in a human monocyte-like cell line [15] and in human polymorphonuclear neutrophils (PMN), in the latter case without secretion of pro-inflammatory cytokines (IL-1, IL-6, TNFalpha) [16]. One study proposed that the production of the anti-inflammatory IL-1RA, but not IL-1 by human monocytes may be a potentially protective mechanism induced by beta-1 to 3-D-glucan [17]. Three other investigations have reported that human leukocytes and human vascular endothelial cells produce IL-8 in response to zymosan [18] or a water-soluble beta-1 to 3-D-glucan [6,19].
In addition, beta-1 to 3-D-glucans seem to be able to modify the response to pro-inflammatory stimuli or even sepsis. In a murine polymicrobial sepsis model, beta-1 to 3-D-glucan [20] treatment resulted in decreased septic morbidity and mortality mediated via inhibition of NFkappaB and stimulation of the phosphoinositide-3-kinase (PI3K) pathway [21,22]. These and other animal studies [23,24] as well as a clinical trial [25] support a protective role of beta-1 to 3-D-glucan in certain pro-inflammatory conditions. The mechanisms underlying these beneficial effects of beta-1 to 3-D-glucan are only partially resolved, especially in humans. Thus, the aim of this study was to elucidate molecular and cellular mechanisms of beta-1 to 3-D-glucans on human leukocytes in pro-inflammatory conditions with special emphasis on the cytokine profile and its transcriptional regulation. For this purpose, peripheral blood mononuclear cells (PBMC) were exposed to a well-defined beta-1 to 3-D-glucan, i.e. glucan phosphate (GP) [20,26], alone or simultaneously with LPS from gram-negative bacteria or the superantigen TSST-1 from gram-positive bacteria over 48 h. Because of the potential effect of beta-1 to 3-D-glucan on cytokine production [12,16-19], TNFalpha, IL-1beta, IL-6, IL-8 and IL-1RA were measured as well as IFNgamma, IL-2, IL-4, IL-10, IL-12 and TGFbeta1. Correspondingly, four NFkappaB sites from the TNFalpha promoter (kappa consensus, kappa1, kappa2, kappa3) [27], a kappa consensus site from the IL-8 promoter [28], an NFAT site from the IFNgamma promoter (ATP2) [29] and a consensus NFIL-6 site from the IL-6 promoter [13] were examined. Because of the anti-inflammatory role of IL-1RA, we focused on binding of transcription factors to the IL-1RA promoter. An inhibitory element and three positive-acting LPS-response elements (LRE-1, LRE-2 and LRE-3) in the IL-1RA promoter, including NFkappaB, PU.1 and NFIL-6 sites, have been characterized previously [30-33]. Using computational analysis for homology search [34], we looked for new binding motifs in the IL-1RA promoter.","[{'offsets': [[488, 496]], 'text': ['Dectin-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[769, 777]], 'text': ['Dectin-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[804, 812]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[821, 841]], 'text': ['Toll-like receptor 2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[866, 871]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[978, 984]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1247, 1251]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1253, 1257]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1259, 1267]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1339, 1345]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1355, 1359]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1567, 1571]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2759, 2765]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2896, 2904]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2906, 2914]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2916, 2920]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2922, 2926]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2931, 2937]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2963, 2971]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2973, 2977]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2979, 2983]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2985, 2990]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2992, 2997]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3002, 3010]], 'text': ['TGFbeta1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3058, 3066]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3156, 3160]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3198, 3206]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3265, 3269]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3340, 3346]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3402, 3408]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3521, 3527]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3720, 3726]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T32'}]",[],[],[],[],[]
229,PMC-3342329-02-Results,"Inhibition of Tumor Development in CCR5-/- Mice
The effect of CCR5 in tumor development was investigated using CCR5+/+ and CCR5-/- mice. B16-F0 melanoma cells were inoculated subcutaneously into CCR5+/+ and CCR5-/- mice (n = 20). Tumor growth was monitored for 31 days. Tumor growth in the CCR5-/- mice was significantly lower than that in the CCR5+/+ mice. The tumor growth in the CCR5-/- mice was reduced to 19.1%, whereas the tumor growth in the CCR5+/+ mice was only reduced to 24.3%, in both tumor weight (Figure 1A and 1B) and tumor volume, respectively (Figure 1A and 1C). These results correlated with mice survival rates. There was a significant difference in survival rates between CCR5-/- mice (75% of starting time) and CCR5+/+ mice (15%) at the end of the experiment (Figure 1D). There was a significant difference in survival rates between CCR5-/- mice and CCR5+/+ mice. At the end of the experiment, 75% of the CCR5-/- mice survived while only 15% of the CCR5+/+ mice survived. Subcutaneous tumors were harvested from the sacrificed mice 31 days after inoculation. The immunohistochemical analysis of tumor sections, stained with H&E and for proliferation antigen PCNA, revealed greater inhibition of tumor cell growth in CCR5-/- mice. The histologic findings after H&E staining indicated that the tumor tissues of the CCR5-/- mice, but not those of the CCR5+/+ mice, contained large areas of necrosis. PCNA reactive cells were significantly reduced in the CCR5-/- mice (Figure 1E).","[{'offsets': [[35, 39]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 66]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[111, 115]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[123, 127]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[195, 199]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[207, 211]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[290, 294]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[344, 348]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[382, 386]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[449, 453]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[692, 696]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[732, 736]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[854, 858]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[871, 875]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[926, 930]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[970, 974]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1237, 1241]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1334, 1338]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1369, 1373]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1472, 1476]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
230,PMC-3589482-14-Results,"The SerpinB2 Proximal Promoter Confers LPS Responsiveness
To investigate cis-acting regulatory elements responsive to LPS in the 5' flanking region of the murine SerpinB2 gene, nucleotides -4480 to +92 and a series of generated deletion mutants of the 5' flanking region were cloned upstream of a promoter-less firefly luciferase reporter gene (pGL3 Basic) (Fig. 2A). The reporter constructs were then transiently transfected into sub-confluent RAW264.7 macrophages and assayed for luciferase activity in the presence and absence of LPS or PMA, for comparison. PMA-induced SerpinB2 gene regulation has been extensively studied in human macrophage cell lines [45]-[47], and has been shown to occur through several proximal and distal AP-1 responsive elements [30]; [37]; [47]-[51]. As shown in Fig. 2B, the SerpinB2 5' flanking region from -4480 to +92 directs both PMA- and LPS-inducible transcription, approximately 2-fold and 7-fold, respectively. Deletion of the murine SerpinB2 promoter from -1686 to -1341 increased LPS-inducibility to approximately 16-fold, indicating the presence of a silencer element in this region. Further deletion beyond -539 abolished the LPS-response of the promoter, indicating the presence of an essential LPS response element in the region between -539 and -189; however, the response of the murine SerpinB2 promoter to PMA is less affected by this deletion. While deletion of the SerpinB2 promoter from -189 to -87 eliminated the LPS response and marginally reduced the PMA response, the -87 murine SerpinB2 promoter construct was still partially responsive to PMA, indicating that cis-acting elements mediating the response of the murine SerpinB2 promoter to PMA also lie downstream of nucleotide -87.","[{'offsets': [[4, 12]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[162, 170]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[319, 329]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[482, 492]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[573, 581]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[806, 814]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[973, 981]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1333, 1341]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1415, 1423]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1534, 1542]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1674, 1682]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
231,PMC-3585731-25-Materials_and_Methods,"In vitro Akt Kinase Assay
Akt kinase activity was measured using the Akt kinase assay kit (nonradioactive) from Cell Signaling Technology. In brief, Myr-Akt was immunoprecipitated from L929 cells using anti-FLAG M2 magnetic beads (Sigma). The in vitro assay was performed in the presence of a GSK fusion protein substrate. Phosphorylation of the GSK fusion protein was visualized by western blot.","[{'offsets': [[149, 156]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
232,PMC-3320587-23-Caption-Figure_1,"NFAT5 interaction with the LTR is important for MTb-induced HIV-1 transcription.
(A) MTb stimulation increases activity of LTRs derived from HIV-1 subtypes B, C, and E. HIV-1 LTRs (-208 to +64 nt relative to the transcription start site) from representative subtype B, C, and E viral isolates were cloned into plasmid pGL3. THP-1 cells (0.8x106/ml) were transfected with each reporter plasmid (0.3 microg/ml) plus the Renilla luciferase control plasmid pRL-TK (0.03 microg/ml) and incubated at 37degreesC for 16 hours. Cells were then either left untreated or treated with 10 microg/ml MTb lysate for 8 hours before termination of the cultures. In the histogram, open bars represent individual LTR activities in untreated cells. Light grey bars represent mean values of LTR activities from each subtype in untreated cells. Black bars represent individual LTR activities in MTb lysate-treated cells, and dark grey bars represent mean values of LTR activities from each subtype in cells treated with MTb lysate. LTR transcriptional activity for all of the representative LTRs tested was significantly increased in cultures treated with MTb lysate in comparison to untreated cultures. Results are from three independent experiments performed in duplicate (*, p<0.05; **, p<0.01 as compared to unstimulated cultures). (B) Specific disruption of the NFAT5 binding site significantly reduces LTR-reporter gene activity in monocytic cells in response to MTb lysate treatment. THP-1 cells were transfected with luciferase expression vectors encoding nucleotides 208 to +64 of the wild-type HIV-1Lai LTR and an HIV-1Lai LTR containing the NFAT5 binding site mutations (N5-Mut). After 16 hours, the cells were left untreated or exposed to 10 microg/ml MTb lysate for 8 hours at 37degreesC. Disruption of NFAT5 binding to the enhancer region significantly suppressed LTR-driven reporter gene expression in comparison to the wild-type LTR when cells were treated with MTb lysate (p<0.01). LTR activity was also suppressed in the untreated cells but to a lesser extent (p<0.05). Results are from three independent experiments performed in duplicate and adjusted to Renilla luciferase control expression (*, p<0.05; **, p<0.01). Nucleotide sequences representing the wild-type and NFAT5 binding site-mutated HIV-1Lai LTRs are shown at the bottom of the figure. (C) MTb lysate increases NFAT5 protein levels in monocytic cells. THP-1 cells were left untreated (control) or exposed to 10 microg/ml MTb lysate for 8 or 24 hours at 37degreesC. Whole cell extracts were collected and analyzed by western blot with anti-NFAT5 antibody. An antibody directed against Lamin-B1 was used as a loading control. The histogram shows densitometric analysis of the NFAT5 bands from the western blot autoradiograph displayed and values represent mean band intensities at 0, 8, and 24 hours post-stimulation with MTb lysate.","[{'offsets': [[0, 5]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[426, 436]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1503, 1513]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1794, 1799]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[2160, 2170]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2372, 2377]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2645, 2653]], 'text': ['Lamin-B1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2735, 2740]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
233,PMC-2817507-00-TIAB,"Activation of TLR4-Mediated NFkappaB Signaling in Hemorrhagic Brain in Rats
Inflammation and immunity play a crucial role in the pathogenesis of Intracerebral hemorrhage (ICH). Toll-like receptor 4- (TLR4-) mediated nuclear factor kappa-B (NFkappaB) signaling plays critical roles in the activation and regulation of inflammatory responses in injured brain. However, the involvement of TLR4-mediated NFkappaB signaling in the pathogenesis of ICH remains unknown. The present study was to evaluate the temporal profile of the expression of TLR4 and the activation of TLR4-mediated NFkappaB signaling in brain tissues of Wistar rats after ICH. TLR4 mRNA and protein, the phosphorylation of inhibitors of kappa B (p-IkappaBalpha), and the activity of NFkappaB were examined in hemorrhagic cerebral tissue by Rt-PCR, Western blots, immunohistochemistry staining, and EMSA. Compared with saline control, the TLR4 mRNA and protein significantly increased starting at 6 hours after ICH, peaked on the 3rd day after ICH, and then decreased but still maintained at a higher level on the 7th day after ICH (P < .05). The level of p-IkappaBalpha and the activity of NFkappaB also increased in the brain after ICH compared with saline control. The present study firstly suggests that TLR4-mediated NFkappaB signaling participates in the pathogenesis of ICH, which may become a therapeutic target for ICH-induced brain damage.","[{'offsets': [[14, 18]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[177, 197]], 'text': ['Toll-like receptor 4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[200, 204]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[386, 390]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 543]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[566, 570]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[642, 646]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[688, 709]], 'text': ['inhibitors of kappa B'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[713, 725]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[903, 907]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1122, 1134]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1272, 1276]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
234,PMC-3312845-22-Caption-Figure_4,"Quantitative analyses of the effect of sTNFp55R infusion on NF-kappaB phosphorylation and SMI-71 expression. (A) Quantitative analysis of NF-kappaB phosphorylation 12 hr after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (B) Quantitative analysis of SMI-71 expression 1 day after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (C) Linear regression analysis between p65-Thr435 phosphorylation and SMI-71 in the PC following SE.","[{'offsets': [[40, 47]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[444, 447]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
235,PMC-1064895-06-Materials_and_methods,"Enzyme-linked immunosorbent assay of IL-17
IL-17 in culture supernatants was measured by sandwich enzyme-linked immunosorbent assay as described previously [20]. In brief, a 96-well plate (Nunc) was coated with 4 mug/ml monoclonal antibodies against IL-17 (R & D Systems) at 4degreesC overnight. After blocking with phosphate-buffered saline/1% bovine serum albumin (BSA)/0.05% Tween 20 for 2 hours at room temperature (22-25degreesC), test samples and the standard recombinant IL-17 (R & D Systems) were added to the 96-well plate and incubated at room temperature for 2 hours. Plates were washed four times with phosphate-buffered saline/Tween 20, and then incubated with 500 ng/ml biotinylated mouse monoclonal antibodies against IL-17 (R & D Systems) for 2 hours at room temperature. After washing, streptavidin-alkaline phosphate-horseradish peroxidase conjugate (Sigma) was incubated for 2 hours, then washed again and incubated with 1 mg/ml p-nitrophenyl phosphate (Sigma) dissolved in diethanolamine (Sigma) to develop the color reaction. The reaction was stopped by the addition of 1 M NaOH and the optical density of each well was read at 405 nm. The lower limit of IL-17 detection was 10 pg/ml. Recombinant human IL-17 diluted in culture medium was used as a calibration standard, ranging from 10 to 2000 pg/ml. A standard curve was drawn by plotting optical density against the log of the concentration of recombinant cytokines, and used for determination of IL-17 in test samples.","[{'offsets': [[37, 42]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[43, 48]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[250, 255]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[478, 483]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[733, 738]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1176, 1181]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1224, 1229]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1471, 1476]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
236,PMC-3589482-26-Caption-Figure_3,"Potential cis-acting regulatory elements in the LPS responsive region of the murine SerpinB2 promoter
-563/-1. Mouse and human nucleotide sequences were aligned using Clustal W software. Cis-acting elements conserved between the human and murine SerpinB2 promoters are boxed and labeled. AP-1 =  activator protein 1; C/EBP =  CCAAT enhancer binding protein; CRE = cAMP response element; Oct1 =  octamer transcription factor 1/POU2F1; PU.1 =  purine box binding protein 1. The putative transcription initiation site (tis) is indicated and exon 1 is presented in uppercase. The location of the 5' ends of the -539, -189 and -87 reporter constructs are also shown.","[{'offsets': [[84, 92]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[246, 254]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[387, 391]], 'text': ['Oct1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 425]], 'text': ['octamer transcription factor 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[426, 432]], 'text': ['POU2F1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[434, 438]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[442, 470]], 'text': ['purine box binding protein 1'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
237,PMC-1472690-20-Caption-Figure_3,"A, IL-1beta was down-regulated (12 h - 24 h) following GP + TSST-1 when compared to TSST-1. Time course (48 h) of IL-1beta production (pg/ml) by human PBMC incubated with medium control, 100 mug GP, 250 ng TSST-1, GP + TSST-1, 250 ng LPS and GP + LPS. At 18 h and 24 h there was a marked reduction in IL-1beta production following GP + TSST-1 when compared to TSST-1 (* = p < 0.05). Graphs depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are also shown. IL-1beta levels in the supernatnant were obtained by Elisa and are shown as mean +/- SEM (n = 3). B, IL-1RA was exaggerated following GP + TSST-1 (12 h - 48 h) when compared to TSST-1. Time course (48 h) of IL-1RA production (pg/ml) by human PBMC incubated with medium control, 100 mug GP, 250 ng TSST-1, GP + TSST-1, 250 ng LPS and GP + LPS. Between 18 h and 48 h a simultaneous treatment of PBMC with GP + TSST-1 led to a synergistic effect, i.e. a higher IL-1RA production when compared to an addition of the single values for TSST-1 and GP (* = p < 0.05). Graphs depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are included. IL-1RA levels in the supernatnant were obtained by Elisa and are shown as mean +/- SEM (n = 3).","[{'offsets': [[3, 11]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[60, 66]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[84, 90]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[114, 122]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[206, 212]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[219, 225]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[301, 309]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[336, 342]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[360, 366]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[447, 453]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[476, 484]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[577, 583]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[615, 621]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[653, 659]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[683, 689]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[773, 779]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[786, 792]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[884, 890]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[934, 940]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1006, 1012]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1100, 1106]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1127, 1133]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
238,PMC-3585731-16-Materials_and_Methods,"QPCR Primers
Mouse TNFalpha: forward 5'-CCCTCACACTCAGATCATCTTCT-3', reverse 5'-GCTACGACGTGGGCTACAG-3';mouse 18S: forward 5-' ATAACAGGTCTGTGATGCCCTTAG-3, reverse 5'-CTAAACCATCCAATCGGTAGTAGC-3';human TNFalpha: forward 5'- ATGAGCACTGAAAGCATGATCC-3', human TNFalpha: reverse 5'-GAGGGCTGATTAGAGAGAGGTC-3'; human 18S: forward 5'- CAGCCACCCGAGATTGAGCA -3, human 18S: reverse 5'-TAGTAGCGACGGGCGGTGTG-3'.","[{'offsets': [[19, 27]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[108, 111]], 'text': ['18S'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[198, 206]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[253, 261]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 310]], 'text': ['18S'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[355, 358]], 'text': ['18S'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
239,PMC-3291650-02-Results,"A20 inhibits RIG-I-induced NF-kappaB and IRF3 activation
RIG-I signaling induces the activation of NF-kappaB, IRF3 and IRF7 transcription factors, which promote the expression of proinflammatory cytokines and type I IFNs that restrict further viral propagation. Previous studies have shown that ectopically expressed A20 negatively regulates NF-kappaB and IRF3 activation upon RIG-I stimulation [50]-[52]. Similarly, we show that A20 overexpression in HEK293T cells prevents NF-kappaB- and IRF3-dependent luciferase reporter gene activation induced by transfection of a truncated constitutive active form of RIG-I [53], corresponding to only the two N-terminal CARD domains of RIG-I [RIG-I (2CARD)] (figure 1A, left and middle graph). We next investigated whether A20 also inhibits IRF7 activation. Unlike IRF3, IRF7 is not or weakly expressed under naive conditions and IRF7 protein levels are rapidly upregulated upon virus-induced IRF3 activation [54], [55]. To determine the effect of A20 on IRF7 activation, we therefore transfected minor amounts of an IRF7 expression plasmid together with plasmids encoding RIG-I (2CARD), A20 and an IRF7-specific IFNalpha4 luciferase reporter construct. RIG-I (2CARD) expression in the absence of IRF7 co-expression showed negligible IFNalpha4 promoter activation (grey bar, figure 1A, right graph), whereas significant reporter gene expression was observed in the presence of IRF7. Similar to its inhibitory effect on NF-kappaB and IRF3 activation, A20 also prevented RIG-I-induced IRF7 activation (figure 1A, right graph). These results demonstrate the potential of A20 to inhibit RIG-I-induced NF-kappaB and IRF3/7 activation.
To study the effect of endogenously expressed A20 on RIG-I-induced signaling in a more immunological relevant context, we performed further experiments in A20 deficient primary macrophages. Since A20 full knockout mice die prematurely as a result of severe multi-organ inflammation [37], we generated mice carrying a conditional A20 allele in which exon IV and exon V were flanked by two loxP sites [56]. Crossing these mice with transgenic mice expressing Cre recombinase under control of the lysozyme M promoter leads to specific deletion in myeloid cells and allowed us to generate myeloid cell specific A20 knockout mice [48]. To stimulate the RIG-I receptor, we transfected A20myel-KO BMDM and wild type control cells with minimal amounts of low molecular weight (LMW) poly(I:C), which is known to preferentially bind and activate RIG-I rather than MDA5 [57]. Of note, this concentration of poly(I:C) was unable to induce significant TLR3 dependent NF-kappaB and IRF3 activation or cytokine production (data not shown). As expected, poly(I:C) transfection induced the rapid expression of A20 in wild type, but not in A20myel-KO BMDM (figure 1B, upper panel). At early time points, slightly slower migrating forms of A20 were observed, indicating that A20 undergoes a yet unknown modification upon poly(I:C) transfection. Compared to wild type BMBM, A20 deficient cells showed enhanced NF-kappaB activation as indicated by increased phosphorylation and sustained degradation of IkappaBalpha (figure 1B). Furthermore, nuclear translocation of the p65 NF-kappaB subunit was enhanced in poly(I:C) transfected A20myel-KO BMDM, reaching a maximum at earlier time points compared to wild type cells (figure 1C). IRF3 is known to be activated upon phosphorylation of a series of carboxyl terminal serine residues by the IKK-like kinases TBK1 and IKKepsilon [58], leading to its dimerization and subsequent translocation to the nucleus [59]. Using immunoblotting with an antibody directed against phosphorylated Ser396, maximum IRF3 phosphorylation was detected at earlier time points in A20myel-KO BMDM compared to wild type BMDM (figure 1B). Similar to p65, IRF3 nuclear translocation reached its maximum at an earlier time point in A20 deficient BMDM compared to wild type cells (figure 1C). NF-kappaB controls the expression of IL-6 and TNF, and NF-kappaB and IRF3 control the expression of IFNbeta. In line with the enhanced activation of NF-kappaB and IRF3 as described above, A20myel-KO BMDM secreted increased amounts of IL-6, TNF and IFNbeta (figure 1D). Similar results were obtained using peritoneal macrophages (data not shown). Together, these results demonstrate that A20 plays an important role in the negative regulation of RIG-I-induced NF-kappaB and IRF3 activation in primary macrophages.","[{'offsets': [[13, 18]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 45]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[57, 62]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[110, 114]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[119, 123]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[356, 360]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[377, 382]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[490, 494]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[505, 515]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[570, 604]], 'text': ['truncated constitutive active form'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[608, 613]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[677, 682]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[782, 786]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[806, 810]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[812, 816]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[871, 875]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[934, 938]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[996, 1000]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1058, 1062]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1140, 1144]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1164, 1174]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1238, 1242]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1418, 1422]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1474, 1478]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1510, 1515]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1524, 1528]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1624, 1629]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1652, 1656]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1657, 1658]], 'text': ['7'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1724, 1729]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2319, 2324]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2507, 2512]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2525, 2529]], 'text': ['MDA5'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2610, 2614]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2639, 2643]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3153, 3165]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3221, 3224]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3381, 3385]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3505, 3509]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3514, 3524]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3695, 3699]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3822, 3825]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3827, 3831]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3999, 4003]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4008, 4011]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4031, 4035]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4062, 4069]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4125, 4129]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4196, 4200]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4202, 4205]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4210, 4217]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4407, 4412]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4435, 4439]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T53'}]",[],[],[],[],[]
240,PMC-1064895-12-Results,"IL-17 production in PBMC from patients with RA, patients with OA and normal individuals
PBMC were separated and cultured with PHA (5 mug/ml) from patients with RA, patients with OA, and age-matched normal controls; IL-17 levels were then determined in the culture supernatants (Fig. 1). Although the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 +/- 31, 43 +/- 19 and 43 +/- 10 pg/ml, respectively), the IL-17 production stimulated by PHA was significantly higher in RA PBMC than in those from OA and controls (768 +/- 295 versus 463 +/- 211 pg/ml [P < 0.05] and 241 +/- 29 pg/ml [P < 0.001]).","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[126, 129]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[215, 220]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[317, 322]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[449, 454]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[480, 483]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
241,PMC-3320587-12-Materials_and_Methods,"Quantitative PCR
The mRNA expression levels were determined by SYBR Green-based real-time PCR (Applied Biosystems, www.appliedbiosystems.com). The reaction conditions were 95degreesC for 10 min followed by 40 cycles of 95degreesC for 15 sec and 60degreesC for 1 min. The results were normalized using beta-actin mRNA as an internal control and expressed as relative values.","[{'offsets': [[301, 311]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
242,PMC-3585731-04-Results,"TNFalpha Induces Delayed Akt Thr308 Phosphorylation and Necroptosis Independent of Growth Factor Stimulation
Consistent with TNFalpha inducing necroptosis independently of growth factors (Fig. 1A), FGFR inhibitors did not attenuate TNFalpha-induced changes in Akt or JNK phosphorylation, while efficiently preventing these changes in response to zVAD.fmk (Fig. S4A). Furthermore, addition of TNFalpha led to comparable late activation of Akt p308 signal under both normal and serum free conditions (Fig. S4B, C), indicating that TNFalpha signaling to Akt Thr308 is growth factor-independent. In contrast, activation of JNK by TNFalpha followed different kinetics from zVAD.fmk-induced changes. TNFalpha treatment caused an early and robust increase in the phosphorylation of JNK and c-Jun. Nec-1 did not affect this early increase, however, it reduced levels of pJNK/Jun at the late, 9 hr time point (Fig. S4B, C). This again separated early RIP1-independent changes, which likely reflect the ability of additional upstream kinases, such as Ask1 to activate JNK [27], from the late RIP1 kinase-dependent necroptotic signaling.","[{'offsets': [[0, 8]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[125, 133]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[232, 240]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[392, 400]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[529, 537]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[626, 634]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[694, 702]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[783, 788]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[942, 946]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1041, 1045]], 'text': ['Ask1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1082, 1086]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
243,PMC-3320587-27-Caption-Figure_5,"Disruption of NF-kappaB or NFAT5 sites in the LTR inhibits MTb-induced HIV-1 replication in MDM.
MDM from four normal donors were infected with 1000 TCID50 of HIV-1Lai/Bal-env-WT or the mutants HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut, and were either (A) left infected with virus alone or (B) co-infected with MTb CDC1551 (1:1 MDM:bacilli). Viral p24 levels in the culture supernatants were measured at days 4, 7 and 12 post-infection. Presentation of viral p24 levels at day 12 in cultures infected with (C) HIV-1 alone or (D) co-infected with MTb are shown as histograms. (*, p<0.05; **, p<0.01, as compared to HIV-1Lai/Bal-env-WT).","[{'offsets': [[172, 175]], 'text': ['env'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[207, 210]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 241]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[270, 273]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 310]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 434]], 'text': ['p24'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[542, 545]], 'text': ['p24'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[710, 713]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
244,PMC-2817507-05-2._Methods,"2.4. Immunohistochemistry (IHC)
The IHC staining for TLR4 was performed as described previously [8]. The primary antibody employed was rabbit anti-TLR4 (WuHan, BA1717). The biotinylated secondary antibody and antibody-biotin-avidin-peroxidase complexes (ABC reagent, SC-2018) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Slides processed without primary antibodies served as negative controls.","[{'offsets': [[53, 57]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[225, 231]], 'text': ['avidin'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
245,PMC-1064873-02-Materials_and_methods,"Patients and samples
The total patient population consisted of 32 patients with RA (25 women and seven men; mean +/- standard deviation age, 52.8 +/- 12.4 years) diagnosed according to the revised 1987 criteria of the American College of Rheumatology (formally, the American Rheumatism Association) [25]. All patients were receiving prednisolone (<= 7.5 mg/day) and disease-modifying antirheumatic drugs. Clinical parameters in the study patients were as follows (mean +/- standard deviation): erythrocyte sedimentation rate, 55.9 +/- 35.4 mm/hour; serum C-reactive protein (CRP) level, 32.0 +/- 32.0 mg/l; and IgM class rheumatoid factor titer, 142 +/- 158 U/ml. Patients were divided into two groups: 24 patients with active disease, who had multiple tender and/or swollen joints and elevated serum CRP level (>= 10 mg/l); and eight patients with inactive disease, who satisfied the American College of Rheumatology preliminary criteria for clinical remission [26]. Sixteen healthy volunteers (11 women and five men; age, 45.8 +/- 11.2 years) served as controls. ST samples were obtained from three RA patients undergoing total knee replacement. All patients gave informed consent.",[],[],[],[],[],[]
246,PMC-3317373-05-2._Methods_and_Materials,"2.4. Electrophoretic Mobility Shift Assay (EMSA)
Monolayers of astrocytes were washed with PBS and harvested by scraping into cold PBS. The cell pellet obtained by centrifugation was resuspended in buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1.0 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride. Then 10% Nonidet P-40 was added and vortexed briefly, and the nuclei were pelleted by centrifugation. The nuclear proteins were extracted with buffer containing 20 mM HEPES (pH 7.9), 0.4 mM NaCl, 1.0 mM EDTA, 1.0 mM EGTA, 1.0 mM DTT, and 1.0 mM phenylmethylsulfonyl fluoride. Insoluble material was removed by centrifugation at 14000 rpm, and the supernatant containing the nuclear proteins was stored at -80degreesC until use. Protein concentration was determined using a bicinchoninic acid assay kit with bovine serum albumin as the standard (Pierce Biochemicals, Rockford, IL, USA). EMSA was performed using gel shift assay system (Promega, Madison, WI, USA). Consensus oligonucleotide probe (5'-AGTTGAGGGGACTTTCCCAGGG-3') was end-labeled by T4-polynucleotide kinase using [gamma-32P]-ATP (Free Biotech., Beijing, China). Nuclear protein (20 mug) was preincubated in 20 muL binding buffer containing 10 mM Tris-HCl (PH 7.5), 1 mM MgCl2, 0.5 mM NaCl, 4% glycerol, 0.5 mM EDTA, 0.5 mM DTT, and 2 mug poly dI-dC for 20 minutes on ice. After addition of the 1 muL 32P-labled oligonucleotide probe, the incubation was continued for 20 minutes on ice. The DNA-protein complexes were separated by electrophoresis on 4% nondenaturing polyacrylamide gel in 0.5 x TBE buffer (tris-borate-EDTA) at 390 V for 1 hour at 4degreesC. After electrophoresis, the gel was dried and exposed to X-ray film (Fuji Hyperfilm, Tokyo, Japan). Levels of NF-kappaB DNA binding activity were quantified by software ImageJ.",[],[],[],[],[],[]
247,PMC-3342329-14-Materials_and_Methods,"Gel Electromobility Shift Assay
A gel electromobility shift assay (EMSA) was performed according to the manufacturer's recommendations (Promega, Madison, WI). The tumor tissues were briefly homogenized in 200 microl of solution A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonylfluoride), vortexed vigorously, incubated on ice for 10 min, and then centrifuged at 15000 rpm for 15 min. The pelleted nuclei were resuspended in solution C (solution A supplemented with 420 mM NaCl and 20% glycerol), and incubated on ice for 20 min. The resuspended pellet was centrifuged at 15000 rpm for 15 min, and the resulting nuclear extracts supernatant were collected in a chilled Eppendorf tube. Consensus oligonucleotides were end-labeled using T4 polynucleotide kinase and [P32]-ATP for 10 min at 37degreesC. The gel shift reactions were assembled and incubated at room temperature. Subsequently, 1 ml of gel loading buffer was added to each reaction and loaded onto a 6% non-denaturating gel. The gel was subjected to electrophoresis until the dye was four-fifths of the way down the gel. The gel was dried for 1 h at 80degreesC and exposed to film overnight at -70degreesC.",[],[],[],[],[],[]
248,PMC-3585731-31-Caption-Figure_6,"Akt and mTORC1 control autocrine TNFalpha synthesis and JNK activation during necroptosis.
(A) Cells were treated under serum free conditions with bFGF or PDGF with or without zVAD.fmk for 9 hr, followed by qRT-PCR analysis of mTNFalpha. Data was normalized to mouse 18S RNA. (B) Necroptosis was induced by zVAD.fmk or TNFalpha in cells treated with Nec-1, rapamycin (rapa), or Akt inh. VIII inh. followed by qRT-PCR analysis of TNFalpha mRNA levels. (C-F) L929 cells with siRNA knockdown of Akt isoforms (C,E) or mTOR (D,F) were stimulated with zVAD.fmk or TNFalpha for 9 hr, followed by qRT-PCR analysis of mTNFalpha (C,D) or western blot (E,F). In all graphs, average+/-SD was plotted.","[{'offsets': [[33, 41]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[147, 151]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 236]], 'text': ['mTNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[267, 270]], 'text': ['18S'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[319, 327]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[429, 437]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[558, 566]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[609, 618]], 'text': ['mTNFalpha'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
249,PMC-3312845-08-Methods,"Fluoro-Jade B staining
Fluoro-Jade B (FJB) staining was used to identify degenerating neurons in tissues obtained from non-SE and 3 days post-SE animals in every group. In our previous [18,25] and preliminary data, neuronal damage was first detectable at 3 days after SE. Therefore, we determined 3 days after SE as the best time point to look FJB. Briefly, sections were rinsed in distilled water, and mounted onto gelatin-coated slides and then dried on a slide warmer. The slides were immersed in 100% ethanol for 3 min, followed by 70% ethanol for 2 min and distilled water for 2 min. The slides were then transferred to 0.06% potassium permanganate for 15 min and gently agitated. After rinsing in distilled water for 2 min, the slides were incubated for 30 min in 0.001% FJB (Histo-Chem Inc., Jefferson, AR), freshly prepared by adding 20 ml of a 0.01% stock FJB solution to 180 ml of 0.1% acetic acid, with gentle shaking in the dark. After rinsing for 1 min in each of three changes of distilled water, the slides were dried, dehydrated in xylene and coverslipped with DPX (Sigma-Aldrich Co., St. Louis, MO). For stereological study, every sixth section in the series throughout the entire PC was used (see below).",[],[],[],[],[],[]
250,PMC-3320587-17-Results,"RNAi directed against NFAT5 inhibits replication of subtype B HIV-1
To extend the results we obtained in the reporter assays to a physiological TB/HIV co-infection model, we next tested the effect of siRNA-mediated ablation of NFAT5 mRNA levels in MDM co-infected with a subtype B HIV-1Lai infectious molecular clone and a clinical isolate of MTb. To perform this experiment, we first constructed an HIV-1Lai clone bearing the CCR5-tropic envelope region of HIV-1Bal (HIV-1Lai/Bal-env) so that it would efficiently infect primary MDM. We used this approach to ensure that our analysis of the roles of NF-kappaB and NFAT5 in MTb-induced HIV-1 replication could be interpreted in the proper context of previous research findings that examined LTR regulation in the context of full-length viral replication [41]-[46]. The HIV-1Lai/Bal-Env infectious clone is isogenic for the entire sequence of the parental HIV-1Lai infectious clone except for the substitution of the HIV-1Bal envelope co-receptor binding region in place of the HIV-1Lai envelope co-receptor binding region. We note that we confirmed that HIV-1Lai/Bal-Env grew in PBMC at a similar rate to wild-type HIV-1Bal, indicating proper co-receptor engagement and internalization of this infectious clone (data not shown).
Next, we knocked down NFAT5 mRNA levels in MDM using an siRNA that suppresses both NFAT5 mRNA and NFAT5 protein levels [31]. As shown in Figure 2, transfection of the siRNA specific for NFAT5 reduces NFAT5 mRNA levels in both MTb-uninfected (p = 0.048) and MTb-infected (p = 0.021) MDM as compared to transfection of control GFP siRNA into MTb-uninfected or -infected MDM (Figure 2B). We note that although siRNA normally is effective for 48-72 hours in cell lines that divide rapidly, in human MDM, which are non-dividing cells, siRNA to host factors remains detectable and functional up to at least 15 days post-transfection [47].
MDM in which NFAT5 expression had been inhibited with NFAT5 siRNA or that were transfected with control GFP siRNA were then infected with 1000 TCID50 of HIV-1Lai/Bal-env. After overnight virus infection, the cells were then co-infected with the MTb clinical strain CDC1551. Free virus levels were then measured in culture supernatants from MDM transfected with NFAT5-specific siRNA or GFP control siRNA at days 6, 9 and 12 post-HIV-1 infection to measure the impact of NFAT5 inhibition on MTb-induced HIV replication.
As shown in Figure 2C, HIV-1 replication was suppressed at days 6 and 9 post-infection in the NFAT5 siRNA-treated cells as compared to cells treated with control siRNA, and it was significantly inhibited by day 12 post-infection (p<0.05) (Figure 2C). Thus, knock down of NFAT5 expression significantly impairs HIV-1 subtype B replication in MDM co-infected with MTb.","[{'offsets': [[22, 27]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[227, 232]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[427, 431]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[481, 484]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[615, 620]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[832, 835]], 'text': ['Env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[975, 983]], 'text': ['envelope'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1036, 1044]], 'text': ['envelope'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1117, 1120]], 'text': ['Env'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1301, 1306]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1362, 1367]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1377, 1382]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1465, 1470]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1479, 1484]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1604, 1607]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1925, 1930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1966, 1971]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2016, 2019]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2078, 2081]], 'text': ['env'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2273, 2278]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2297, 2300]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2381, 2386]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2524, 2529]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2701, 2706]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
251,PMC-1472690-24-Caption-Figure_7,"Inhibition of GP-induced NFkappaB, NFAT and NFIL-6 DNA binding to the IL-1RA promoter. A, A representative autoradiogram (lane 1: control, lane 2: GP, lane 3: GP + unlabeled mutated NFATP2/3 oligo, lane 4: GP + CAPE, lane 5: GP + CyA, lane 6: GP + CHX, lane 7: GP + unlabeled NFATP2/3 oligo, lane 8: water) as well as a graphical summary for the NFATP2/3 site, depicting a decrease in binding following inhibition when compared to GP is displayed (* = p < 0.05). Data are shown as mean +/- SEM (n = 4). B, Inhibition of NFkappaB, NFAT and NFIL-6 resulted in decreased IL-1RA mRNA following CHX, CAPE or CyA compared to GP. GAPDH is used as housekeeping control (representative gel, n = 4). C, Inhibition of NFkappaB, NFAT and NFIL-6 significantly reduced the production of IL-1RA by human PBMC following treatment with CHX, CAPE or CyA when compared to GP (* = p < 0.05; ** = p < 0.01). Data are shown as mean +/- SEM (n = 3).","[{'offsets': [[35, 39]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[44, 50]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[70, 76]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[530, 534]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 545]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 574]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[623, 628]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[717, 721]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[726, 732]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[773, 779]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
252,PMC-1472690-14-Methods,"Immuno (Dot) blot
To determine whether the DNA binding proteins were related to NFkappaB and NFAT, dot blots using a SRC96D SNS minifold I dot blotter (Schleicher & Schull, Dassel, Germany) were performed with the following positive controls and antibodies (all from Santa Cruz Biotechnology, Heidelberg, Germany): positive controls (10 ng/dot): NFkappaB p52 (80 kD) sc-4095WB, c-Rel (61 kD) sc-4030WB; Jurkat nuclear extract, PMA-stimulated; primary antibodies (1 mug/dot): anti-NFkappaB p50 (NLS) sc-114, anti-NFkappaB p65 (A) sc-109, anti-NFkappaB p52 (447) sc-848, a rabbit polyclonal IgG1 antiserum, anti-c-rel (N466) sc-272, anti-NFATc2 (M-20) sc-1151, anti-NFATc1 (K-18) sc-1149, two goat polyclonal IgG1 antisera; secondary antibodies (0.8 mug/dot): goat anti-rabbit IgG AP-conjugate sc-2007, and donkey anti-goat IgG AP-conjugate sc-2022. The nuclear proteins were blotted onto a nitrocellulose membrane (Bio-Rad). After blocking with PBS/3% BSA (Fluka, Deisenhofen, Germany), the blot was incubated overnight with the primary antibodies diluted 1:2000 in PBS/1% BSA, washed again and incubated with the alkaline phosphatase-conjugated secondary antibody (1:500 in PBS/1% BSA). The blot was developed using the Vectastain(R) staining kit (Vector Laboratories Inc. Burlingame, CA, USA).","[{'offsets': [[93, 97]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[355, 358]], 'text': ['p52'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[378, 383]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[489, 492]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[521, 524]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[551, 554]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[610, 615]], 'text': ['c-rel'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[636, 642]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[664, 670]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
253,PMC-1359074-11-Materials_and_Methods,"In situ hybridization.
Antisense probes were designed to murine epsilony globin nucleotides 509-584; betamaj globin nucleotides 458-549; and mouse Sox6 nucleotides 1353-1927. Embryos were fixed overnight by immersion in 4% paraformaldehyde, embedded in paraffin, sectioned at 5 mum, and adhered to charge modified slides (VWR, West Chester, Pennsylvania, United States). Slides were processed for in situ hybridization as described [52] using in vitro transcribed RNA probes labeled with 33P. Darkfield and brightfield images were obtained with a Nikon Optiphot microscope (Nikon, Melville, New York, United States) and SPOT RT-Slider digital camera (Diagnostic Instruments, Sterling Heights, Michigan, United States). Objectives used were 1x (NA = 0.04) and 10x (NA = 0.5). Images were processed, pseudocolored, and combined using Photoshop (Adobe, San Jose, California, United States) software with Fovea Pro (Reindeer Graphics, Asheville, North Carolina, United States) plugins. Original images are available.","[{'offsets': [[64, 79]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[101, 115]], 'text': ['betamaj globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[147, 151]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
254,PMC-3291650-14-Materials_and_Methods,"Cytokine quantification
For TNF ELISA, 96-well plates were coated with TNF coating (TN3-19, eBioscience) and detection (R4-6A2, eBioscience) antibodies. IFNalpha and IFNbeta protein levels were determined with an ELISA kit (PBL Biomedical Laboratories). For IFNgamma ELISA, 96-well plates were coated with IFNgamma coating (XMG1.2) and detection (R4-6A2) antibodies (eBiosciences). Detection of MCP-1, KC, TNF, IL-1beta and IL-6 in BAL fluid was performed using Bioplex (BioRad) technology according to the manufacturer's instructions. Milliplex technology (Millipore) was used for the detection of MIP-2 in BAL fluid.","[{'offsets': [[28, 31]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[71, 74]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[166, 173]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 400]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[402, 404]], 'text': ['KC'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[406, 409]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[411, 419]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[424, 428]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
255,PMC-1359074-07-Results,"Mutant p100H Mice Have Higher Numbers of Nucleated Red Cells
Among the other Sox6 effects in erythropoiesis, we have noticed that there are more nucleated red blood cells circulating in p100H mutant mice than in WT mice at 14.5 dpc and 18.5 dpc (Figure 7A). However, at postnatal day 10.5, we do not see circulating nucleated red cells in either WT or mutant mice, suggesting that this may be a transient effect. In addition, the mutant liver shows a significant increase in hematopoietic precursor cells including nucleated erythrocytes at 18.5 dpc (Figure 7B). This alteration is noted as early as 14.5 dpc. These observations suggest that besides silencing the epsilony globin gene, Sox6 may affect red cell maturation.","[{'offsets': [[77, 81]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[664, 679]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[686, 690]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
256,PMC-3320587-03-Materials_and_Methods,"Cell culture
PBMC from normal unidentified donors were isolated by Ficoll-Hypaque (Pharmacia Corporation, Peapack, NJ) density gradient centrifugation and were cultured in RPMI 1640 medium with 2 mM L-glutamine (BioWhittaker, Inc., Walkersville, MD) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gemini Bio-Products, www.gembio.com). Human monocytes were isolated from PBMC preparations by positive selection with CD14 microbeads from Miltenyi Biotec (www.miltenyibiotec.com) as described by the manufacturer, and were cultured at 1x106 cells per well in 6-well plates in Macrophage-SFM medium (Gibco, www.invitrogen.com) supplemented with 15 ng/ml recombinant human MCSF (R&D, www.rndsystems.com) and 5% heat-inactivated human AB serum (Nabi, Boca Raton, FL). The cell cultures were incubated at 37degreesC and 5% CO2 for 5 days, after which supernatant was replaced with fresh medium lacking MCSF before manipulation. More than 95% of the adherent cells obtained with this technique were CD14+ macrophages as verified by flow cytometry. THP-1 cells were obtained from ATCC (www.atcc.org) and cultured in RPMI 1640 medium supplemented with 10% FCS (BioWhittaker, www.lonzabio.com). 293T cells were obtained from ATCC (www.atcc.org) and were maintained in Dulbecco's Modified Eagle's medium (DMEM) (Gibco, www.invitrogen.com) supplemented with 10% FCS.","[{'offsets': [[431, 435]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[684, 688]], 'text': ['MCSF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[911, 915]], 'text': ['MCSF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1007, 1011]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
257,PMC-3589482-06-Experimental_Procedures,"Construction of SerpinB2 Reporter Gene Plasmids
The PCR primers DW5'LUC, containing a Kpn I restriction site, and DW3'LUC, containing an Xho I restriction site, were used to PCR amplify and clone the SerpinB2 promoter (-3261 to +92) from pDB9406 into the Kpn I/Xho I polylinker restriction sites of pGL3 Basic (Promega) to produce pGLmP-3261. The EcoR I insert of pDB9402-42 was sub-cloned immediately upstream of the SerpinB2 promoter EcoR I site (-3261) of pGLmP-3261 to produce pGLmP-4480. Additional murine SerpinB2 luciferase reporter constructs (pGLmP-2751, pGLmP-2614, pGLmP-1686, pGLmP-1341, pGLmP-694, pGLmP-539 and pGLmP-189) were generated by digesting pGLmP-3261 with EcoR I and a second restriction enzyme (Sfi I, Apa I, BstX I, Bsu36 I, Pac I, Hae III and Apo I respectively), blunt ending the resultant 5' or 3' overhangs with T4 DNA polymerase (NEB) and re-ligating the vector ends with T4 DNA ligase. The PCR primers BSPCR2 and DW3'LUC were used to subclone the murine SerpinB2 promoter regions -87 to +92 into the Kpn I/Xho I polylinker restriction sites of pGL3 Basic to produce pGLmP-87. The control empty vector was pGL3 Basic (Promega).
Luciferase reporter constructs containing mutations in the SerpinB2 promoter LPS-responsive regions E box, PU.1, Oct-1 and C/EBP (pGLmP-539mEbox, pGLmP-539mPU.1, pGLmP-539mOct and pGLmP-539mC/EBP respectively) were generated as described [36]. The mutant oligonucleotide PCR primer sequences are provided in Fig. S1, and were used as follows: pGLmP-539mEbox: mPAI2mEboxa and mPAI2mEboxb; pGLmP-539mPU.1: mPAI2mPU.1a and mPAI2mPU.1b; pGLmP-539mOct: mPAI2mOct-2a and mPAI2mOct-2b; pGLmP-539mC/EBP: mPAI2mCEBPa and mPAI2mCEBPb. The oligonucleotide PCR primers used to generate mutants, pGLmP-539mCRE, pGLmP-539mAP-1a, and pGLmP-539mAP-1b were reported previously [37]. The flanking oligonucleotide PCR primers were RVprimer3 (Promega) and GLprimer2 (Promega). pGLmP-539 was used as the template in each case. Recombinant PCR products were digested with EcoR I and Xho I and cloned between the EcoR I and Xho I restriction sites of pGLmP-539 in place of the -539/+92 region of the wild-type murine SerpinB2 promoter. Sequence verified constructs were used in the experiments.","[{'offsets': [[16, 38]], 'text': ['SerpinB2 Reporter Gene'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[200, 208]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[418, 426]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[511, 539]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[680, 686]], 'text': ['EcoR I'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[720, 725]], 'text': ['Sfi I'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[727, 732]], 'text': ['Apa I'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[734, 740]], 'text': ['BstX I'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[742, 749]], 'text': ['Bsu36 I'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[751, 756]], 'text': ['Pac I'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[758, 765]], 'text': ['Hae III'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[770, 775]], 'text': ['Apo I'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[842, 859]], 'text': ['T4 DNA polymerase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[903, 916]], 'text': ['T4 DNA ligase'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[986, 994]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1159, 1178]], 'text': ['Luciferase reporter'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1218, 1226]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2009, 2015]], 'text': ['EcoR I'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2020, 2025]], 'text': ['Xho I'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2153, 2161]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
258,PMC-3317373-15-4._Discussion,"The present study demonstrated that scratch injury induced the upregulation of NF-kappaB DNA binding activity and overexpression of TNF-alpha, IL-1beta, IL-6, and MMP9 in cultured astrocytes. Also we revealed that scratch injury induced higher activity of NF-kappaB and enhanced expression of proinflammatory cytokines in Nrf2 knockout cultured astrocytes than those in wildtype astrocytes for the first time.
It has been demonstrated that NF-kappaB is activated in brain and spinal cord after traumatic injury [2, 9]. As a transcript factor, NF-kappaB binds with DNA once it was activated and induces transcription of MMP9 and a battery of proinflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6, in brain tissues after TBI [3, 10, 11]. Our results also revealed that scratch injury induced elevation of NF-kappaB DNA binding activity, overexpression of MMP9, and proinflammatory mediators mentioned above in cultured astrocytes. It has been demonstrated that there is an autoregulatory loop among these proinflammatory mediators. For example, TNF-alpha and IL-1beta are potent stimulators for MMP9 in astrocytes [12, 13], and IL-6 induces overexpression of MMP9 in human colon carcinoma cells [14], and TNF-alpha and IL-1beta also can induce activation of NF-kappaB [15, 16]. This autoregulatory loop extremely aggravates the damaging effect of inflammation and induces secondary injury to brain. It is a good choice for targeting on an upstream factor to prevent such autoregulatory loop after TBI.
Nrf2-ARE pathway has been proved to be the key regulator in reducing oxidative stress, inflammatory damage, and accumulation of toxic metabolites, which are all involved in TBI. Our previous study has proved the augmentation of Nrf2 in brain tissue after TBI [17]. Enhanced level of Nrf2 activates transcription of a group of antioxidant genes, such as heme oxygenase-1 (HO-1) and NAD (P)H: quinone oxidoreductase-1 (NQO1), which would subsequently reduce the damage in brain [18]. Postinjury administration of SFN, an inducer of Nrf2, significantly improves spatial memory of rat and decreases the immunoreactivity for 4-Hydroxynonenal (4-HNE), a marker of lipid peroxidation, in the cortex and the CA3 subfield of hippocampus after TBI [19]. On the other hand, Nrf2-deficient mice appear more susceptible to TBI. Depletion of Nrf2 induces higher expression of proinflammatory mediators in brain after TBI [20]. Here, our results revealed that overexpression of TNF-alpha, IL-1beta, IL-6, and MMP9 after scratch injury was more aggravated in cultured Nrf2 knockout astrocytes than in wildtype astrocyetes for the first time, and overexpression of these proinflammatory mediators led to more astrocytes deaths.
Data obtained from animal studies suggest the possibility that antioxidant effect of Nrf2 may be achieved by suppression of proinflammatory pathways which are mediated by NF-kappaB signaling. Administration of SFN is found to be able to inhibit IKK/IkappaB phosphorylation and p65 NF-kappaB subunit nuclear translocation, consequently alleviating NF-kappaB signaling [21]. And NF-kappaB activation induced by lipopolysaccharide (LPS) could be attenuated by diverse Nrf2 activators, such as SFN and curcumin (CUR) [22]. Furthermore, our previous studies indicate that depletion of Nrf2 induces augmentation of NF-kappaB activity and inflammatory response in lung, brain, and intestine after TBI [4, 5, 23]. Results from this study further confirmed such relationship existed in cultured astrocytes after scratch injury. Enhanced activation of NF-kappaB is also discovered in lung, macrophages, and mouse embryonic fibroblasts of Nrf2-deficient mice after experimental sepsis [24]. Interestingly, it is reported that NF-kappaB can inhibit Nrf2 at transcriptional level. NF-kappaB p65 subunit repressed the Nrf2-ARE pathway at transcriptional level by competitive interaction with the CH1-KIX domain of CBP or local histone hypoacetylation [25]. All these findings indicate the potential complicate crosstalk between NF-kappaB and Nrf2, which may be regulated by the upstream mitogen-activated protein kinase (MAPKs) pathway [26].
It has been confirmed that Nrf2 is mainly detected in nucleus of astrocytes after TBI [18]. In view of the fact that Nrf2 is a transcription factor which should take function mainly in nucleus, it can be reasoned that astrocytes may be one kind of respondent cells in activation of Nrf2-ARE pathway after TBI. Previous study identified the expression of TNF-alpha, IL-1beta, and IL-6 in cultured astrocytes after treatment with LPS or oxyhemoglobin [27, 28]. Another study revealed that after middle cerebral artery occlusion, MMP9-positive astrocytes were observed in brain tissues by immunohistochemistry [29]. Those results indicate the role of astrocytes in inflammatory process after brain injury. But till now, there is no study focused on the relationship among astrocytes, Nrf2, and proinflammatory mediators after TBI. Our results demonstrated the upregulated expression of TNF-alpha, IL-1beta, IL-6, and MMP9 in Nrf2 knockout astrocytes after scratch injury for the first time.
In conclusion, depletion of Nrf2 induced the activation of NF-kappaB and the expression of TNF-alpha, IL-1beta, IL-6, and MMP9 resulting in more cell deaths in astrocytes after scratch injury. These results suggest that Nrf2 may be an important target for anti-inflammatory therapy after TBI.","[{'offsets': [[143, 151]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[153, 157]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[163, 167]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[619, 623]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[689, 697]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[703, 707]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[866, 870]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1070, 1078]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1106, 1110]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1139, 1143]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1170, 1174]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1230, 1238]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1866, 1882]], 'text': ['heme oxygenase-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1884, 1888]], 'text': ['HO-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2487, 2495]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2497, 2501]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2507, 2511]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3001, 3004]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3802, 3805]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4517, 4525]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4531, 4535]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4679, 4683]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[5046, 5054]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[5056, 5060]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5066, 5070]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5242, 5250]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5252, 5256]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[5262, 5266]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T40'}]",[],[],[],[],[]
259,PMC-2817507-11-3._Results,"3.3. Distribution of TLR4 in Brain Subjected to ICH
To explore the distribution of TLR4 protein, the TLR4 was detected by immunohistochemistry (IHC). Results showed that TLR4 immunoreactivity was not detectable in brain tissue from normal and sham control. However, immunoreactivity for TLR4 was consistently demonstrated in peri-hemorrhage areas, the hippocampus, cortex, thalamic nuclei, and some white matter tracts (Figure 3).","[{'offsets': [[21, 25]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 87]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[101, 105]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[170, 174]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[287, 291]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
260,PMC-3589482-11-Experimental_Procedures,"Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed using a commercially available Magna-ChIP(TM) kit (Millipore), as recommended by the manufacturer, with minor modifications. Briefly, after crosslinking the chromatin with 1% formaldehyde at room temperature for 10 min and neutralizing with glycine for 5 min at room temperature, cells were washed with cold PBS, scraped and collected on ice. Cells extracts were prepared using a commercially available kit (Millipore). Nuclear lysates were sonicated 5 times for 15 sec with 1 min intervals on ice using a Sonic Dismembrator (Fisher). An equal amount of chromatin was immunoprecipitated at 4degreesC overnight with at least 1 microg of the following antibodies: C/EBP-beta (sc-150X), p-C/EBP-beta (T217) (sc-16993X), normal rabbit IgG (sc-2027)(Santa Cruz Biotechnologies) and RNA polymerase II (Clone CTD4H8)(Millipore). Immunoprecipitated products were collected after incubation with Protein G coated magnetic beads (Millipore). The beads were washed, the bound chromatin was eluted in ChIP Elution Buffer (Millipore) and the proteins were digested with Proteinase K for 2 hrs at 62degreesC. The DNA was then purified using the QIAquick PCR Purification Kit (Qiagen). DNA was amplified by semi-quantitative PCR or by qPCR using the SYBR green method and primers specific for the SerpinB2 proximal promoter: forward (-338/-315) 5'AAGACTCCCACAGATGGTGGCTGT3'; reverse (-5/+19) 5'TTCTTGGAAAGCTGGCACTGTGTG3'.","[{'offsets': [[957, 966]], 'text': ['Protein G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1127, 1139]], 'text': ['Proteinase K'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1352, 1360]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
261,PMC-3320587-25-Caption-Figure_3,"Specific disruption of NFAT5 or NF-kappaB binding sites in the LTR of HIV-1 subtype B.
(A) Mutations introduced into a HIV-1Lai/Bal-env infectious molecular clone. NF-kappaB and NFAT5 binding site mutations were introduced into the LTR of the HIV-1Lai/Bal-env-wild type (WT) infectious molecular clone. The NF-kappaB binding site mutants (HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut), and NFAT5 binding site mutant (HIV-1Lai/Bal-env-N5-Mut) are shown along with the HIV-1Lai/Bal-env-WT sequence. Mutations were introduced into the 3' LTR of the HIV-1Lai/Bal-env-WT proviral sequence. (B) Specific mutation of the NFAT5 binding site abolishes NFAT5 binding to the viral LTR but does not affect NF-kappaB p50/p65 binding to the overlapping NF-kappaB binding site. Quantitative DNaseI footprinting analysis is shown using HIV-1 LTR fragments (-262 to +4 nt relative to the transcription start site) from HIV-1Lai/Bal-env-WT and HIV-1Lai/Bal-env-N5-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng), or NFAT5 (10 ng, 50 ng, and 250 ng). The regions that are protected from DNase I cleavage by the binding of NF-kappaB and NFAT5 are indicated with a bars. (C) Specific disruption of the HIV-1 subtype B NF-kappaB binding sites effectively abrogates recombinant p50/p65 binding. Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng). The regions that are protected from DNase I cleavage by the binding of recombinant NF-kappaB are indicated with a bars. (D) Specific disruption of the HIV-1 subtype B NF-kappaB binding site does not inhibit but enhances NFAT5 binding to this region. Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NFAT5 (10 ng, 50 ng, and 250 ng). The regions that are protected from DNase I cleavage by the binding of recombinant NFAT5 are indicated with a bars.","[{'offsets': [[132, 135]], 'text': ['env'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[256, 259]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[352, 355]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[383, 386]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[415, 418]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[481, 484]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[531, 534]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[610, 613]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[694, 699]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[755, 758]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[759, 762]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[827, 833]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[966, 969]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[990, 993]], 'text': ['env'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1057, 1060]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1061, 1064]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1098, 1103]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1168, 1175]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1217, 1222]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1355, 1358]], 'text': ['p50'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1359, 1362]], 'text': ['p65'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1385, 1391]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1467, 1470]], 'text': ['env'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1488, 1491]], 'text': ['env'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1519, 1522]], 'text': ['env'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1555, 1558]], 'text': ['env'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1631, 1634]], 'text': ['p50'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1635, 1638]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1705, 1712]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1889, 1894]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1932, 1938]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2014, 2017]], 'text': ['env'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2035, 2038]], 'text': ['env'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2066, 2069]], 'text': ['env'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2102, 2105]], 'text': ['env'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2167, 2172]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2237, 2244]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2284, 2289]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T38'}]",[],[],[],[],[]
262,PMC-3218875-08-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Single-immunoglobulin IL-1 receptor-related protein
Single-immunoglobulin IL-1 receptor-related (SIGIRR) protein, also known as TIR-8, is a member of the TLR/IL-1R family that has been extensively characterised as an inhibitor of IL-1R and TLR signalling, probably through direct interaction with these receptors, MyD88, IRAK1 or TRAF6 [67] (Figure 1). Given the important role of IL-1R and TLR signalling in the chronic inflammation observed in RA [68], a regulatory role for SIGIRR in RA is not unlikely. SIGIRR has a very restricted expression pattern, being expressed in epithelial cells, monocytes and immature dendritic cells, but not in mature macro-phages [69,70]. Recently, SIGIRR overexpression was shown to inhibit the spontaneous release of inflammatory cytokines by human RA synovial cells. This inhibitory function of SIGIRR was further confirmed in vivo, since SIGIRR-deficient mice developed a more severe disease in zymosan-induced arthritis, as well as collagen-induced arthritis mouse models [70]. It will be interesting to compare the expression of SIGIRR in RA patients with its expression in control patients, or to investigate whether the function of SIGIRR is compromised in RA patients. Because of its restricted expression pattern, SIGIRR may also be an interesting therapeutic target in RA.","[{'offsets': [[0, 43]], 'text': ['Single-immunoglobulin IL-1 receptor-related'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[52, 95]], 'text': ['Single-immunoglobulin IL-1 receptor-related'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[97, 103]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[128, 133]], 'text': ['TIR-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[230, 235]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[314, 319]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[321, 326]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[330, 335]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[381, 386]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[477, 483]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[507, 513]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[683, 689]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[832, 838]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[876, 882]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1069, 1075]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1174, 1180]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1258, 1264]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T17'}]",[],[],[],[],[]
263,PMC-1064873-12-Results,"Defective IL-10-mediated STAT3 phosphorylation in RA CD4+ T cells
The interaction of IL-10R with IL-10 induces tyrosine phosphorylation and activation of the latent transcription factors STAT1 and STAT3 [3]. Macrophage-specific STAT3-deficient mice demonstrated that STAT3 plays a dominant role in IL-10-mediated anti-inflammatory responses [5], which has recently been confirmed in human macrophages by studies of dominant-negative STAT3 overexpression [30]. The induction of STAT1 and STAT3 phosphorylation by IL-10 in PB CD4+ T cells from active RA patients and from healthy controls was examined using western blotting. STAT3 phosphorylation was dose-dependently induced after IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b). In contrast, STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients and this STAT3 phosphorylation was detectable for up to 6 hours. STAT3 phosphorylation was augmented only when activated by as much as 10 ng/ml IL-10. Both sustained STAT3 phosphorylation and defective IL-10-induced STAT3 phosphorylation were found in RA ST CD4+ T cells (Fig. 4c). On the other hand, IL-10-induced STAT1 phosphorylation was not detected in either RA CD4+ T cells or normal CD4+ T cells (Fig. 4a). These results indicate that STAT3 is the major IL-10-activated STAT in CD4+ T cells, and IL-10-induced STAT3 activation may be diminished in active RA, in association with sustained STAT3 phosphorylation.","[{'offsets': [[10, 15]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[25, 30]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 56]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[85, 91]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[97, 102]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[187, 192]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[197, 202]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[228, 233]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[267, 272]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[298, 303]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[433, 438]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[477, 482]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[487, 492]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[512, 517]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[524, 527]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[624, 629]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[681, 686]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[719, 722]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[759, 764]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[807, 810]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[844, 849]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[900, 905]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[979, 984]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1001, 1006]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1037, 1042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1051, 1056]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1093, 1096]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1136, 1141]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1150, 1155]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1202, 1205]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1225, 1228]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1277, 1282]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1296, 1301]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1320, 1323]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1338, 1343]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1352, 1357]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1431, 1436]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T37'}]",[],[],[],[],[]
264,PMC-3342329-10-Materials_and_Methods,"Tumor Inoculation and Tumor Monitoring
B16 melanoma cells were injected subcutaneously [5x105 tumor cells in 0.1 ml Phosphate buffered saline(PBS)/animal] using a 27 G needle into the right-lower flanks of the carrier mice as previously described [54]. The body weights and tumor volumes of the animals were monitored twice weekly. The tumor volumes were measured with Vernier calipers and calculated using the following formula: (AxB2)/2, where A is the larger and B is the smaller of the two dimensions. At the end of the experiment, the animals were sacrificed. The tumors were separated from the surrounding muscles and dermis.",[],[],[],[],[],[]
265,PMC-3589482-18-Results,"C/EBP-beta is a LPS-induced Nuclear Factor that Binds to the C/EBP Element of the SerpinB2 Proximal Promoter
The C/EBP family of basic leucine zipper transcription factors are known for their roles in cellular differentiation and inflammation [59]. Consisting of six members, the C/EBP transcription factors can homo-/heterodimerize and display similar DNA binding specificities [60]. Four family members, C/EBP-alpha, C/EBP-beta, C/EBP-delta and C/EBP-epsilon, are present in myeloid cells and play different roles in differentiating myeloid cells depending on the extracellular environment [61]. To determine which C/EBP proteins were involved in the formation of the different nucleo-protein complexes, and particularly of the LPS-inducible complex, EMSA was performed after incubating the nucleo-protein complexes with antibodies specific for C/EBP-alpha, C/EBP-beta, C/EBP-delta and C/EBP-epsilon. Each antibody detects the carboxy-terminal DNA-binding region of the respective protein, so that pre-incubation of antibody with nuclear extract is expected to abolish DNA binding by EMSA [62]. Only antibodies against C/EBP-beta abolished the formation of the LPS-inducible complex (Fig. 5C). Taken together these data show that the LPS-induced complex with the C/EBP element (-203/-192) contains C/EBP-beta.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[82, 90]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[406, 417]], 'text': ['C/EBP-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[419, 429]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[431, 442]], 'text': ['C/EBP-delta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[447, 460]], 'text': ['C/EBP-epsilon'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[847, 858]], 'text': ['C/EBP-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[860, 870]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[872, 883]], 'text': ['C/EBP-delta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[888, 901]], 'text': ['C/EBP-epsilon'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1121, 1131]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1300, 1310]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
266,PMC-3342329-06-Results,"Induction of CD8 T cells and NK Cell Infiltration into Tumor and Spleen of CCR5-/- Mice
To investigate whether the inhibition of tumor growth in CCR5-/- mice is related to tumor-specific immune responses, we analyzed the distribution patterns of CD8+ cytotoxic T cell and CD57+ Natural Killer cells in tumor and spleen tissues. By staining the tumor sections from CCR5-/- mice, we found that there was a significant influx of CD8+ cells into the tumor, as well as an increase in the number of infiltrating NK cells (Figure 5A). CD8+ T cells and CD57+ NK cells were spread diffusely throughout the entire sections. To further investigate the differences in the numbers of CD8+ T cells and CD57+ NK cells between CCR5+/+ mice and CCR5-/- mice in immunity-related organ, we also analyzed the CD8 and CD57 reactive cell number in spleen tissues. The number of CD8+ T cells and CD57+ NK cells were higher in the spleen of the CCR5-/- mice than in the spleen of the CCR5+/+ mice (Figure 5B). These data suggest that by promoting the infiltration of CD8 T cells and NK cells, which are potent cytotoxic effectors for tumors, could play a role in an anti-tumor effect in CCR5-/- mice.
To analyze the cell phenotype change in CCR5-/- mice and CCR5+/+ mice by inoculation of the melanoma cell, lymphocytes were isolated from the tumor and spleen tissues. The B, CD3 T, CD4 T, CD 8 T and NK cell portion of CCR5-/- mice tumor tissue were 7.2%, 48.2%, 16.9%, 32.1% and 7.8%, respectively, compared to 2.9%, 11.1%, 2.3%, 0.6% and 3.1% of CCR5+/+ mice (Figure 5C). The lymphocytes that infiltrated the tumor tissue of the CCR5-/- mice also had higher levels of CD19, CD3, CD4, CD8 and CD57 when compared to the CCR5+/+ mice. The B, CD3 T, CD4 T, CD 8 T and NK cell portion of the CCR5-/- mice spleen were 61.3%, 33.4%, 17.6%, 9.2% and 0.6%, respectively compared to 38.3%, 5.9%, 4.0%, 1.0% and 3.9% of the CCR5+/+ mice (Figure 5D). These data suggest that by promoting the infiltration of CD8 T cells and NK cells, which are potent cytotoxic effectors for tumors, could play a role in the inhibition of tumor growth in CCR5-/- mice.","[{'offsets': [[75, 79]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[145, 149]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[364, 368]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[711, 715]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[728, 732]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[921, 925]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[960, 964]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1163, 1167]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1217, 1221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1234, 1238]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1359, 1362]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1396, 1400]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1525, 1529]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1608, 1612]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1647, 1651]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1658, 1661]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1697, 1701]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1725, 1728]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1766, 1770]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1892, 1896]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2105, 2109]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
267,PMC-3342329-19-Caption-Figure_2,"Decrease of NF-kappaB activity in tumor tissue of CCR5-/- mice.
A, The DNA binding activity of NF-kappaB was determined in the nuclear extracts of the CCR5-/- mice and CCR5+/+ mice tumor tissues by EMSA described in material and methods. B, Expression of p50 and p65 phosphorylation in nuclear extracts (NE), and IkappaB and IkappaB phosphorylation in the cytosol (CE) determined by Western blotting. C, Immunolfluorescence analysis of p50 confirmed that the intensities of nuclear staining for p50 were decreased in the tumor tissues of CCR5-/- mice. Data are means +/- S.D. of four experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05). Scale bar indicates 50 microm.","[{'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[151, 155]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[168, 172]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[255, 258]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[263, 266]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[436, 439]], 'text': ['p50'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[495, 498]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[538, 542]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[646, 650]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
268,PMC-1472690-03-Results,"Cytokine profile of human PBMC following a 48 h in vitro stimulation with LPS, TSST-1, GP, GP + LPS and GP + TSST-1
Because of the GP-induced band shifts to seven sites from the TNFalpha, IL-8, IL-6 and IFNgamma promoters, it could be assumed that GP treatment of human PBMC would lead to production of TNFalpha, IL-8, IL-6, IFNgamma and other pro-inflammatory mediators. Previous studies reported that beta-1 to 3-D-glucans induced only a limited cytokine secretion of human blood cells [15-18]. Corroborating and extending these singular findings in terms of examining pro- (eight) as well as anti- (three) inflammatory cytokines over time (48 h) and six additional transcription factor binding sites, our comprehensive analysis revealed the following cytokine profile of human leukocytes in response to a highly purified water soluble beta-1 to 3-D-glucan and in comparison to two pro-inflammatory mediators (LPS, TSST-1):
(i) IL-1beta
There was no IL-1beta production detectable following PBMC treatment with 1 nor 100 mug GP. An insignificant up-regulation of IL-1beta production for GP + LPS was observed in comparison with LPS. For GP + TSST-1 we found a significant reduction in IL-1beta from 18 h - 24 h, for the latter by about 40% when compared to TSST-1 or the theoretical value of GP/TSST-1 calc. (n = 6; both p = 0.01). On the whole, GP mediated a reduction of the TSST-1-induced amount of IL-1beta by about 50% (Fig. 3A).
(ii) IL-6
GP induced only a small amount of IL-6 and there was no significant alteration of the LPS-induced IL-6 production by GP. On the contrary, we observed a decreased IL-6 production for GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc., especially at 24 h by about 40% (n = 5; both p = 0.02), (data not shown in detail).
(iii) IL-8
We found that GP induced a substantial IL-8 production, in comparison with medium control, especially at 24 h (n = 13; p < 0.01). A combination of GP and LPS resulted in a non-significant increase of IL-8 production when compared to LPS or GP/LPS calc. There was no significant alteration in IL-8 production following GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc. (data not shown in detail).
(iv) IL-1RA
Besides IL-8, IL-1RA was the only mediator which was produced in significant quantities following GP treatment, especially at 24 h (n = 14, p < 0.01). When compared to LPS stimulation or GP/LPS calc., GP + LPS did not alter the kinetic course of the IL-1RA production. However, following GP + TSST-1 we found a synergistic increase in IL-1RA production from 18 h to 48 h, when compared to TSST-1 (for instance at 24 h: n = 6; p = 0.01) or to the theoretical value of GP/TSST-1 calc. (from 18 h to 36 h). Over the time course of 48 h, GP elevated the TSST-1-induced amount of IL-1RA by approximately 200% (Fig. 3B).
Positive correlation between GP-induced IL-8 and IL-1RA productions. Following stimulation with GP (24 h), we observed a positive correlation between IL-8 and IL-1RA. Moreover, we found this correlation to be dose-dependent, since 100 mug of GP induced larger amounts of IL-8 and IL-1RA than 1 mug GP (n = 5, p <= 0.002, r = 0.9 and 0.98, respectively).
(v) TNFalpha
With respect to TNFalpha production, 100 mug of GP yielded minor, statistically not distinguishable amounts, when compared to medium control. GP + LPS did not change the TNFalpha production when compared to LPS supplementation or GP/LPS calc. When combined with TSST-1 or GP/TSST-1 calc., GP seemed to exert a synergistic effect on TNFalpha secretion after 36 h (n = 3; p < 0.05), but overall an enhancement of only 10% was observed (p > 0.05; data not shown in detail).
(vi) IFNgamma
No IFNgamma production was detectable following treatment of PBMC with 100 mug GP. There was a minor increase in IFNgamma production following GP + LPS at 36 h, when compared to LPS or GP/LPS calc., and a slight down-regulation following GP + TSST-1 at 24 h and 36 h, when compared to TSST-1 or GP/TSST-1 calc. (data not shown).
(vii) IL-2, IL-12, IL-4, IL-10, TGFbeta1
The production of IL-2, IL-12, IL-4, IL-10 and TGFbeta 1 was not induced by GP. There were also no significant differences between medium control, LPS, TSST-1, GP, GP + LPS, GP/LPS calc. and GP + TSST-1 or GP/TSST-1 calc. over 48 h (data not shown).","[{'offsets': [[79, 85]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[109, 115]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[178, 186]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[188, 192]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[194, 198]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[203, 211]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[303, 311]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[313, 317]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[319, 323]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[325, 333]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[917, 923]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[930, 938]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[952, 960]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1065, 1073]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1144, 1150]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1187, 1195]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1259, 1265]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1297, 1303]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1379, 1385]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1404, 1412]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1442, 1446]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1481, 1485]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1545, 1549]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1609, 1613]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1634, 1640]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1658, 1664]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1671, 1677]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1775, 1779]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1819, 1823]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1980, 1984]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2072, 2076]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2103, 2109]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2127, 2133]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2140, 2146]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2186, 2192]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2201, 2205]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2207, 2213]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2443, 2449]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2486, 2492]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2528, 2534]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2582, 2588]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2663, 2669]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2743, 2749]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2768, 2774]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2848, 2852]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2857, 2863]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2958, 2962]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2967, 2973]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3079, 3083]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3088, 3094]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3166, 3174]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3191, 3199]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3345, 3353]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3437, 3443]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3450, 3456]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3507, 3515]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3651, 3659]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3663, 3671]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3773, 3781]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3903, 3909]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3945, 3951]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3958, 3964]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3995, 3999]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4001, 4006]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4008, 4012]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4014, 4019]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4021, 4029]], 'text': ['TGFbeta1'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4048, 4052]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4054, 4059]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4061, 4065]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4067, 4072]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4077, 4086]], 'text': ['TGFbeta 1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4182, 4188]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4226, 4232]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4239, 4245]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T75'}]",[],[],[],[],[]
269,PMC-3218875-00-TIAB,"Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis
The transcription factor NF-kappaB plays crucial roles in the regulation of inflammation and mmune responses, and inappropriate NF-kappaB activity has been linked with many autoimmune and inflammatory diseases, including rheumatoid arthritis. Cells employ a multilayered control system to keep NF-kappaB signalling in check, including a repertoire of negative feedback regulators ensuring termination of NF-kappaB responses. Here we will review various negative regulatory mechanisms that have evolved to control NF-kappaB signalling and which have been implicated in the pathogenesis of rheumatoid arthritis.",[],[],[],[],[],[]
270,PMC-3312845-04-Methods,"Seizure induction
Three days after surgery, rats were treated with pilocarpine (380 mg/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO) at 20 min after methylscopolamine (5 mg/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO). Using this treatment paradigm, behavioral seizures typically began within 20-40 min. Approximately 80% of pilocarpine treated rats showed acute behavioral features of SE (including akinesia, facial automatisms, limbic seizures consisting of forelimb clonus with rearing, salivation, masticatory jaw movements, and falling). We applied the 2 hr-SE rat model, because > 90% of the rats that we monitored in our previous studies [25] displayed spontaneous, recurrent seizures within 1-3 months after pilocarpine-induced status epilepticus. Diazepam (10 mg/kg, i.p.; Hoffman Ia Roche, Neuilly sur-Seine) was administered 2 hours after onset of SE and repeated, as needed. The rats were then observed 3 - 4 hours a day in the vivarium for general behavior and occurrence of spontaneous seizures. Non-experienced SE (non-SE) rats (showing only acute seizure behaviors during 10 - 30 min, n = 8) and age-matched normal rats were used as controls (n = 7).",[],[],[],[],[],[]
271,PMC-1472690-10-Methods,"Isolation of human PBMC
Buffy coats were obtained from healthy blood donors in compliance with the Helsinki declaration and with the approval of the ethics committee of the University of Luebeck. The buffy coats were separated over a Ficoll-Hypaque (Biochrom, Berlin, Germany) gradient [54,55]. Following isolation, PBMC were cultured at a final concentration of 3 x 106 cells/ml (for ELISA measurements) or 5 x 106/ml (for gel shifts) or 1 x 106 cells/ml (for flow cytometry) in RPMI 1640 medium (BioWhittaker, Heidelberg, Germany, LPS-free), containing 10% heat-inactivated fetal calf serum (FCS, low-LPS, Invitrogen, Karlsruhe, Germany), 1% penicillin (10000 U/ml), 1% streptomycin (10000 mug/ml), and 1% 200 mM L-glutamine (BioWhittaker).",[],[],[],[],[],[]
272,PMC-1472690-08-Conclusion,"In summary, our data demonstrated that in vitro glucan phosphate induced a transcription factor binding and a subsequent cytokine profile different from LPS and also from TSST-1 and, moreover, switched a pro-inflammatory TSST-1-induced response to an IL-1RA-mediated anti-inflammatory reaction. Our results also generated new insights into a very complex interplay of transcription factor binding to various known and newly identified sites in the IL-1RA promoter (Fig. 8), which can be regulated differentially by a fungal carbohydrate. Together with the in vivo studies [22,37], our findings might support the concept of protective effects mediated by glucan phosphate in pro-inflammatory conditions, especially with a dysregulated IL-1beta/IL-1RA ratio [52,53].","[{'offsets': [[171, 177]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[221, 227]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[251, 257]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[448, 454]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[734, 742]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[743, 749]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
273,PMC-3291650-10-Materials_and_Methods,"In vivo intracellular GrB and IFNgamma staining of activated CD8+ T cells
Granzyme B (GrB) and IFNgamma expressing CD8+ T cells were determined by treating the mice intranasally with 50 microg Brefeldin A (Sigma) as previously described [86]. 6 h later, BAL and lungs were isolated and single cell suspensions were prepared from the lung in the presence of 3 microg/ml Brefeldin A. Cells were stained, fixed and permeabilized (Cytofix/Cytoperm, BD Biosciences) according to the manufacturer's instructions. Activated CD8+ T cells were analyzed by flow cytometry based on CD62lo CD3+ and CD8+ expression. Live/Dead fixable aqua dead cell stain kit (Molecular Probes) was used to discriminate live from dead cells.","[{'offsets': [[22, 25]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[61, 64]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 84]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[86, 89]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[115, 118]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[517, 520]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[578, 581]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[587, 590]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
274,PMC-3317373-10-2._Methods_and_Materials,"2.9. Statistical Analysis
Data were expressed as mean +/- SD and evaluated by ANOVA and LSD multiple comparison test. P values <0.05 were considered to be significant. All analyses were performed by using SPSS 18.0 software.",[],[],[],[],[],[]
275,PMC-3589482-28-Caption-Figure_5,"The LPS-inducible nuclear factor binding the murine SerpinB2 proximal promoter C/EBP site contains C/EBP-beta.
(A) EMSA with nuclear extracts from untreated (UN) and 10 hr LPS treated (LPS) RAW 264.7 cells incubated with either the murine SerpinB2 promoter -212/-185 probe containing an intact (SerpinB2 C/EBP) or mutated (mutant C/EBP) C/EBP site or with the rat albumin promoter DEI region C/EBP (rat albumin C/EBP) probe. (B) Cold competition EMSAs performed with the radiolabelled murine SerpinB2 promoter -212/-185 probe and a 100-fold molar excess of each of the double stranded oligonucleotides described in (A) demonstrate the specificity of the DNA-protein complexes. (C) Supershift assays were performed with the -212/-185 probe by after preincubation with the indicated specific C/EBP antibody. The LPS-inducible complex is indicated with an arrowhead.","[{'offsets': [[52, 60]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[99, 109]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[239, 247]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[295, 303]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[364, 371]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[403, 410]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[492, 500]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
276,PMC-1359074-03-Results,"Transfection Studies Using GM979 Cells Indicate That Sox6 Directly Represses the epsilony Gene Promoter at the Transcriptional Level
Real-time PCR assays (Figure 1) measure steady-state levels of epsilony mRNA, not transcriptional activity of the epsilony promoter. To investigate whether Sox6 directly acts on the epsilony gene promoter at the transcriptional level, we used an in vitro transient transfection assay and GM979 cells, a murine erythroleukemic cell line that expresses both epsilony and adult beta globins [30]. We generated an epsilony promoter reporter construct (E-Luc) by fusing a micro-LCR (muLCR) element (2.5 kb) [31] to the epsilony proximal promoter (2.2 kb), followed by the luciferase reporter gene, as shown in Figure 2A (detailed in Materials and Methods). Overexpression of Sox6 in GM979 cells by transient transfection leads to a dosage-dependent repression of E-Luc reporter activity (Figure 2B). In contrast, overexpression of a truncated Sox6 protein that lacks its HMG domain [32] (similar to the p100H mouse allele) fails to repress E-Luc activity (Figure 2B). These data indicate that Sox6 acts to repress the epsilony promoter at the transcriptional level.
Sox6 has been shown to act as a repressor and to interact with a widely expressed co-repressor, CtBP2, on the fgf-3 promoter [5]. CtBP2 is expressed in GM979 cells (unpublished data). To investigate whether the interaction with CtBP2 is required for Sox6 repression of the epsilony promoter, we introduced a point mutation (L386H) in the Sox6 protein that has been previously reported to be sufficient to abolish Sox6-CtBP2 interaction [5]. This amino acid change is not in the HMG DNA binding domain. However, this mutant version of Sox6 retains the ability to repress the epsilony promoter in the transfection assay (Figure 2B), indicating that Sox6 represses the epsilony promoter in a CtBP2-independent manner. Deletion analysis of the epsilony promoter, as shown in Figure 2C, defined a region (-63 to -37) within the epsilony proximal promoter that is critical for Sox6 repression. Analysis of this short region reveals two Sox/Sox6 consensus binding sites [5] (Figure 3A).","[{'offsets': [[53, 57]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[81, 89]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[196, 204]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[247, 255]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[289, 293]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[315, 323]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[489, 497]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[508, 520]], 'text': ['beta globins'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[543, 551]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[647, 655]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[700, 710]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[803, 807]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[971, 975]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1121, 1125]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1146, 1154]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1194, 1198]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1290, 1295]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1304, 1309]], 'text': ['fgf-3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1324, 1329]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1422, 1427]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1444, 1448]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1467, 1475]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1532, 1536]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1607, 1611]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1612, 1617]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1728, 1732]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1768, 1776]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1841, 1845]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1860, 1868]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1883, 1888]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1934, 1942]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2017, 2025]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2065, 2069]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}]",[],[],[],[],[]
277,PMC-3312845-24-Caption-Figure_6,"Effect of sTNFp55R infusion on neutrophil infiltration and MIP-2 expression following SE. (A) Neutrophil infiltration in vasogenic edema lesion 1 day after SE. (B) MIP-2 expression in the PC 1 day after SE. (C) Astroglial expression of MIP-2 (arrows). Bars = 12.5 (A and C) and 150 (B) mum. (D) Quantitative analysis of neutrophil infiltration 1 day after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (E) Linear regression analysis between the number of infiltrated neutrophils/area in the vasogenic edema region and the area of vasogenic edema in the PC. (F) Quantitative analysis of the number of MIP-2 positive cells per the unit area of vasogenic edema 1 day after SE (mean +/- S.E.M). There is no difference in the number of MIP-2-positive cells per unit area of vasogenic edema between sTNFp55R-infused animals and saline-infused animals. (G) Linear regression analysis between the number of MIP-2 positive cells per unit area in vasogenic edema region and the area of vasogenic edema in the PC.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[59, 64]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[164, 169]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[236, 241]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[639, 644]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[770, 775]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[833, 840]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[938, 943]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
278,PMC-1472690-22-Caption-Figure_5,"GP modulated TSST-1-induced DNA binding to a new NFATP2/3 site in the IL-1RA promoter. Binding was up-regulated for GP + LPS and GP + TSST-1, when compared to GP and, in the latter case, to both GP and TSST-1 (* = p < 0.05). Human PBMC were incubated with medium control, LPS, TSST-1, GP, GP + TSST-1 and GP + LPS for 1 h at 37degreesC. Schematic representation of the elevated NFAT-DNA binding activity to the site in the IL-1RA promoter. Bars depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are added. Medium control levels were set equal to 1 +/- SEM (n = 6). An autoradiogram of a representative experiment is shown in the lower panel (lane 1: water; lane 2: medium control; lane 3: GP; lane 4: LPS; lane 5: TSST-1, lane 6: GP + LPS; lane 7: GP + TSST-1).","[{'offsets': [[13, 19]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 76]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[134, 140]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[202, 208]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[277, 283]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[294, 300]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[378, 382]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[423, 429]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[502, 508]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[734, 740]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[773, 779]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
279,PMC-3312845-15-Results,"SMI-71 expression
Previously, we reported that SMI-71 (an endothelial barrier antigen) immunoreactivity decreased in the PC 1 day after SE [5]. Similarly, in 1 day-post SE animals of the saline-infused group, loss of SMI-71 immunoreactivity was detected in layer III/IV of the PC as compared to non-SE animals (Figures 4B and 5C-E, p < 0.05). Thus, loss of SMI-71 immunoreactivity correlated with volume of vasogenic edema following SE. This reduction in SMI-71 was accompanied by increased p65-Thr435 phosphorylation (Figures 5C-D). Therefore, the degree of SMI-71 immunoreactivity was inversely correlated to p65-Thr435 phosphorylation with a linear coefficient of correlation of -0.6324 (p < 0.05; Figure 4C). In addition, sTNFp55R infusion effectively alleviated p65-Thr435 phosphorylation and preserved SMI-71 immunoreactivity in endothelial cells following SE, as compared to saline infusion (p < 0.05; Figures 4A-B, 5D and 5F).","[{'offsets': [[491, 494]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[611, 614]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[727, 734]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[767, 770]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
280,PMC-3218875-12-Caption-Figure_1,"Canonical NF-kappaB signalling and negative regulators. Ligand engagement of specific membrane receptors such as TNFR1, CD40, RANK, and TLR4 trigger the recruitment of specific adaptor proteins (TNF receptor 1-associated death domain protein (TRADD), MyD88, MAL, TIR domain-containing adaptor-inducing IFNbeta (TRIF)), kinases (RIP1, IRAK1, IRAK4), and ubiquitin ligases (TRAF2, TRAF6, cIAP1, cIAP2) to the receptor. K63-linked polyubiquitination of TRAFs, RIP1 and IRAK1, is recognised by NEMO and TAB proteins, resulting in the recruitment and activation of respectively IKK2 and TAK1. TAK1 then phosphorylates and activates IKK2, which in turn phosphorylates IkappaBalpha, triggering its K48-linked ubiquitination and proteasomal degradation. This allows NF-kappaB (here shown as a heterodimer of p65 and p50) to translocate to the nucleus and promote target gene expression. TRAF1, which has no ubiquitin ligase activity, can negatively regulate NF-kappaB activation, most probably by competing with other TRAFs. A20 and CYLD are deubiquitinating enzymes that control NF-kappaB activation by targeting specific signalling proteins including RIP1 and TRAF6, to which they are recruited using specific ubiquitin-binding adaptor proteins such as ABIN-1 and p62. miR-146 is thought to negatively regulate TLR signalling by inhibiting expression of IRAK1 and TRAF6. Finally, TLR signalling can also be inhibited by the transmembrane protein SIGIRR, which has been proposed to compete with TLR4 for binding to IRAK1 and TRAF6. The expression of many of these negative regulatory molecules is NF-kappaB dependent, implicating them in the negative feedback regulation of NF-kappaB activation. ABIN, A20-binding inhibitor of NF-kappaB; cIAP, cellular inhibitor of apoptosis; CYLD, cylindromatosis; IKK, IkappaB kinase; IkappaB, inhibitor of NF-kappaB; IRAK, IL-1R-associated kinase; MyD88, myeloid differentiation primary response gene 88; NEMO, NF-kappaB essential modulator; NF, nuclear factor; RANK, receptor activator of NF-kappaB; RIP1, receptor interacting protein 1; SIGIRR, single-immunoglobulinIL-1 receptor-related; TIR, Toll-like receptor/IL-1R; TRAF, TNF receptor-associated factor; TLR, Toll-like receptor; TNF, tumour necrosis factor.","[{'offsets': [[113, 118]], 'text': ['TNFR1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 124]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[126, 130]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[136, 140]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[195, 241]], 'text': ['TNF receptor 1-associated death domain protein'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[243, 248]], 'text': ['TRADD'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[251, 256]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[258, 261]], 'text': ['MAL'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[263, 309]], 'text': ['TIR domain-containing adaptor-inducing IFNbeta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[311, 315]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[328, 332]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[334, 339]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[341, 346]], 'text': ['IRAK4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[372, 377]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[379, 384]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[386, 391]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[393, 398]], 'text': ['cIAP2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[457, 461]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[466, 471]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[490, 494]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[573, 577]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[582, 586]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[588, 592]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[627, 631]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[662, 674]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[800, 803]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[808, 811]], 'text': ['p50'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[879, 884]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1017, 1020]], 'text': ['A20'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1025, 1029]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1145, 1149]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1154, 1159]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1247, 1253]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1258, 1261]], 'text': ['p62'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1348, 1353]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1358, 1363]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1440, 1446]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1488, 1492]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1508, 1513]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1518, 1523]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1689, 1693]], 'text': ['ABIN'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1695, 1729]], 'text': ['A20-binding inhibitor of NF-kappaB'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1770, 1774]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1776, 1791]], 'text': ['cylindromatosis'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1878, 1883]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1885, 1933]], 'text': ['myeloid differentiation primary response gene 88'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1935, 1939]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1941, 1970]], 'text': ['NF-kappaB essential modulator'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1992, 1996]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1998, 2029]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2031, 2035]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2037, 2067]], 'text': ['receptor interacting protein 1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2069, 2075]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2077, 2119]], 'text': ['single-immunoglobulinIL-1 receptor-related'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2215, 2218]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2220, 2242]], 'text': ['tumour necrosis factor'], 'type': 'Protein', 'id': 'T56'}]",[],[],[],[],[]
281,PMC-3317373-14-3._Results,"3.4. Expression and Activity of MMP9 Were Greatly Enhanced in Nrf2 Knockout Astrocytes after Scratch Injury
MMP9 is an important gelatinase to induce or aggravate the inflammation process. In the present study, we elevated the mRNA, protein levels, and activity of MMP9 in astrocytes at 24 h after scratch injury by RT-PCR, western blot, and gelatine zymography. Expression of MMP9 was elevated after scratch injury in WT and KO astrocytes as compared with their sham counterparts. The mRNA level of MMP9 was higher in group KO TBI than in group WT TBI (1.36 +/- 0.090 versus 1.01 +/- 0.068, P < 0.01) (Figures 3(a) and 3(e)). Significant difference was also discovered in MMP9 protein level by western blot, as 1.44 +/- 0.076 for group KO TBI and 1.13 +/- 0.048 for group WT TBI (P < 0.01) (Figure 5). Gelatine zymography revealed higher MMP9 activity in group KO TBI than that in group WT TBI too (101.76 +/- 6.343 versus 76.32 +/- 3.388, P < 0.01) (Figure 6).","[{'offsets': [[32, 36]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[108, 112]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[265, 269]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[377, 381]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[500, 504]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[673, 677]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[839, 843]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
282,PMC-3589482-02-Experimental_Procedures,"Cell Culture
Murine macrophage RAW 264.7 cells (ATCC TIB-71) were maintained in RPMI 1640 media (Gibco BRL), supplemented with 2 mM L-glutamine (Gibco BRL), 10% serum supreme (BioWhittaker), 200 microg/ml penicillin, 100 microg/ml streptomycin, 25 mM N-2-hydroxyethylpiperazine-N-2-ethane sulphonic acid (HEPES) and 25 mM sodium bicarbonate, in 5% CO2 and 95% humidified air atmosphere at 37degreesC. Wild-type (Cebpb+/+) and knockout (Cebpb-/-) mouse embryonic fibroblasts (MEFs) [34] were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/glutamate solution (Cellgro). Primary peritoneal macrophages were obtained by injecting C57BL/6 mice with 3% thioglycollate broth followed by peritoneal lavage 3-5 days later, and maintained in 50% DMEM/F12 media (Gibco BRL). Precautions were taken to exclude bacterial lipopolysaccharide contamination from all cell cultures through the use of certified LPS-free serum. Cell viability was determined using the trypan blue (Sigma) dye exclusion method. All cultures were routinely checked to exclude Mycoplasma infection by nuclear staining using Hoechst stain 33258 (Sigma) and the MycoAlert Detection Kit (Lonza). Bacterial lipopolysaccharide (LPS) (Salmonella minnesota Strain Re595) was obtained from Sigma.","[{'offsets': [[412, 417]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[436, 441]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
283,PMC-3585731-33-Caption-Figure_8,"Akt signaling contributes to autocrine TNFalpha production in multiple cell types.
FADD deficient Jurkat cells were treated with TNFalpha followed by measurement of (A) human TNFalpha mRNA levels by qRT-PCR and normalized using human 18S RNA or (B) western blot at 9 hr. RAW 264.7 or J774A.1 cells were treated with zVAD.fmk (100 uM or 50 uM respectively) followed by (C,E) measurement of TNFalpha mRNA levels by qRT-PCR or (D,F) western blot at 9 hr. (G) Akt null mouse lung fibroblasts expressing Myr-Akt or K179M were treated with zVAD.fmk and TNFalpha followed by measurement of TNFalpha mRNA levels by qRT-PCR at 9 hr. (H) Mouse lung fibroblasts expressing only endogenous Akt1 or Akt2 were treated with zVAD.fmk and TNFalpha followed by measurement of TNFalpha mRNA levels by qRT-PCR at 9 hr.","[{'offsets': [[39, 47]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 87]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[129, 137]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[175, 183]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[234, 237]], 'text': ['18S'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[389, 397]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[547, 555]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[583, 591]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[678, 682]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[686, 690]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[722, 730]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[758, 766]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
284,PMC-1064895-16-Results,"IL-17 mRNA expression in RA PBMC
To see whether enhanced IL-17 production could be regulated at a transcriptional level, semi-quantatitive reverse transcription-polymerase chain reaction was performed. We observed a dose-dependent increase in IL-17 mRNA transcripts after stimulation with anti-CD3; this was inhibited by the PI3K inhibitor LY294002 and by the NF-kappaB inhibitor PDTC (Fig. 5).","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 62]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[243, 248]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
285,PMC-1064895-02-Materials_and_methods,"Patients
Informed consent was obtained from 24 patients (5 men and 19 women) with RA who fulfilled the 1987 revised criteria of the American College of Rheumatology (formerly the American Rheumatism Association) [17]. The age of the patients with RA was 50 +/- 8 (mean +/- SEM) years (range 23-71 years). All medications were stopped 48 hours before entry to the study. Comparisons were made with 14 patients with OA (3 men and 11 women) and with 14 healthy controls (3 men and 11 women) who had no rheumatic diseases. The mean ages of the patients with OA and the healthy controls were 50 +/- 8 years (range 34-68 years) and 30 +/- 6 years (range 24-57 years). Informed consent was obtained, and the protocol was approved by the Catholic University of Korea Human Research Ethics Committee.",[],[],[],[],[],[]
286,PMC-3586680-05-p53_and_WWOX_Alterations_in_GBMs,"p53 mutants are considered as unfavorable factors for the effectiveness in radiotherapy and TMZ treatment in glioma cells (Gjerset et al., 1995; Hirose et al., 2001; Squatrito et al., 2010; Blough et al., 2011). Loss of functional p53 confers sensitivity to TMZ in glioma cells, whereas wild type p53 increases the TMZ resistance (Blough et al., 2011). p53 mutants reduce TMZ sensitivity in gliomas (Blough et al., 2011).
Altered WWOX expression is shown in GBMs, in which downregulation of WWOX is associated with loss of heterozygosity and promoter methylation (Kosla et al., 2011). Recently, we demonstrated that overexpressed WWOX induces apoptosis of glioblastoma U373-MG cells harboring mutant p53 by causing hypoploidy and DNA fragmentation (Chiang et al., 2012). However, ectopic WWOX has no effect with U87-MG expressing wild type p53. Unlike TMZ, WWOX induces apoptosis of U373-MG cells via a mitochondria-independent and caspase-3-independent pathway (Chiang et al., 2012). While the underlying mechanisms are unknown, it is reasonable to assume that the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 mutants and WWOX. Activated WWOX binds wild type p53 with Ser46 phosphorylation (Chang et al., 2005b). UV irradiation enhances the binding interactions. Despite the presence of Ser46 in delta40p53, binding of this protein with WWOX remains to be determined. We postulate that in GBM cells, both wild type p53 and ectopic WWOX proteins appear to have a functional antagonism, thereby nullifying each other's function in inducing apoptosis (Figure 2). Mutant p53 proteins cannot bind ectopic WWOX in GBM cells, and WWOX is able to induce apoptosis. Whether WWOX causes apoptosis in GBM expressing p53 isoforms is unknown and remains to be established.","[{'offsets': [[0, 3]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[231, 234]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[297, 300]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[353, 356]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[430, 434]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[491, 495]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[630, 634]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[700, 703]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[788, 792]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[840, 843]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[857, 861]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[932, 941]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1161, 1164]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1177, 1181]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1193, 1197]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1214, 1217]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1351, 1361]], 'text': ['delta40p53'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1392, 1396]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1470, 1473]], 'text': ['p53'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1486, 1490]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1622, 1625]], 'text': ['p53'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1655, 1659]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1678, 1682]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1720, 1724]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1760, 1763]], 'text': ['p53'], 'type': 'Protein', 'id': 'T25'}]",[],[],[],[],[]
287,PMC-3312845-00-TIAB,"Tumor necrosis factor-alpha-mediated threonine 435 phosphorylation of p65 nuclear factor-kappaB subunit in endothelial cells induces vasogenic edema and neutrophil infiltration in the rat piriform cortex following status epilepticus
Background
Status epilepticus (SE) induces severe vasogenic edema in the piriform cortex (PC) accompanied by neuronal and astroglial damages. To elucidate the mechanism of SE-induced vasogenic edema, we investigated the roles of tumor necrosis factor (TNF)-alpha in blood-brain barrier (BBB) disruption during vasogenic edema and its related events in rat epilepsy models provoked by pilocarpine-induced SE.
Methods
SE was induced by pilocarpine in rats that were intracerebroventricularly infused with saline-, and soluble TNF p55 receptor (sTNFp55R) prior to SE induction. Thereafter, we performed Fluoro-Jade B staining and immunohistochemical studies for TNF-alpha and NF-kappaB subunits.
Results
Following SE, most activated microglia showed strong TNF-alpha immunoreactivity. In addition, TNF p75 receptor expression was detected in endothelial cells as well as astrocytes. In addition, only p65-Thr435 phosphorylation was increased in endothelial cells accompanied by SMI-71 expression (an endothelial barrier antigen). Neutralization of TNF-alpha by soluble TNF p55 receptor (sTNFp55R) infusion attenuated SE-induced vasogenic edema and neuronal damages via inhibition of p65-Thr435 phosphorylation in endothelial cells. Furthermore, sTNFp55R infusion reduced SE-induced neutrophil infiltration in the PC.
Conclusion
These findings suggest that impairments of endothelial cell functions via TNF-alpha-mediated p65-Thr 485 NF-kappaB phosphorylation may be involved in SE-induced vasogenic edema. Subsequently, vasogenic edema results in extensive neutrophil infiltration and neuronal-astroglial loss.","[{'offsets': [[0, 27]], 'text': ['Tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 73]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[462, 495]], 'text': ['tumor necrosis factor (TNF)-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[757, 773]], 'text': ['TNF p55 receptor'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[776, 783]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[892, 901]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[987, 996]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1028, 1044]], 'text': ['TNF p75 receptor'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1131, 1134]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1278, 1287]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1299, 1315]], 'text': ['TNF p55 receptor'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1318, 1325]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1413, 1416]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1476, 1483]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1632, 1641]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1651, 1654]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
288,PMC-3342329-00-TIAB,"Deficiency of C-C Chemokine Receptor 5 Suppresses Tumor DevelopmentviaInactivation of NF-?B and Upregulation of IL-1Ra in Melanoma Model
To evaluate the relevance of C-C chemokine receptor type 5 (CCR5) expression and tumor development, we compared melanoma growth in CCR5 knockout (CCR5-/-) mice and wild type (CCR5+/+) mice. CCR5-/- mice showed reduced tumor volume, tumor weight, and increased survival rate when compared to CCR5+/+ mice. We investigated the activation of NF-kappaB since it is an implicated transcription factor in the regulation of genes involving cell growth, apoptosis, and tumor growth. Significant inhibition of DNA binding activity of NF-kappaB, and translocation of p50 and p65 into the nucleus through the inhibition of phosphorylation of IkappaB was found in the melanoma tissues of CCR5-/- mice compared to melanoma tissues of CCR5+/+ mice. NF-kappaB target apoptotic protein expression, such as cleaved caspase-3, cleaved PARP, and Bax, was elevated, whereas the survival protein expression levels, such as Bcl-2, C-IAP1, was decreased in the melanoma tissues of CCR5-/- mice. Interestingly, we found that the level of IL-1Ra, a tumor growth suppressive cytokine, was significantly elevated in tumor tissue and spleen of CCR5-/- mice compared to the level in CCR5+/+ mice. Moreover, infiltration of CD8+ cytotoxic T cell and CD57+ natural killer cells was significantly increased in melanoma tumor and spleen tissue of CCR5-/- mice compared to that of CCR5+/+ mice. Therefore, these results showed that CCR5 deficiency caused apoptotic cell death of melanoma through inhibition of NF-kappaB and upregulation of IL-1Ra.","[{'offsets': [[14, 38]], 'text': ['C-C Chemokine Receptor 5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[112, 118]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[166, 195]], 'text': ['C-C chemokine receptor type 5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[197, 201]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[268, 272]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[283, 287]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[312, 316]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[327, 331]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[428, 432]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[694, 697]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[702, 705]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[813, 817]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[858, 862]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1046, 1052]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1095, 1099]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1151, 1157]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1253, 1257]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1291, 1295]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1451, 1455]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1484, 1488]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1535, 1539]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1643, 1649]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
289,PMC-3320587-29-Caption-Figure_7,"The MyD88-mediated signaling cascade is important for MTb induction of NFAT5 expression in human monocytes.
(A) Engagement of TLR2 significantly enhances NFAT5 mRNA synthesis in monocytes. THP-1 cells were incubated with the TLR2-specific ligand Pam3Cys (5 microg/ml), infected with MTb strain CDC1551 (1:1 cells:bacilli), or left untreated. After 16 hours, NFAT5 mRNA levels were measured. NFAT5 mRNA expression was significantly increased when the cells were incubated with Pam3Cys (*, p<0.05) or infected with MTb (**, p<0.01). (B) MyD88 is important for MTb induction of NFAT5 gene expression in human monocytes. THP-1 cells that constitutively express lentivirally-delivered shRNA targeting MyD88 or control shRNA targeting GFP were constructed as described in Materials and Methods. Cells were infected with MTb strain CDC1551 (1:1 cells:bacilli) or left uninfected for 16 hours at 37degreesC, and RNA was analyzed. NFAT5 mRNA levels were significantly inhibited in the cells transduced with MyD88-specific shRNA (black bars) compared with the cells transduced with control shRNA (open bars) in both, the absence or presence of MTb infection. TNF and CD86 mRNAs, the expression of which are MyD88-dependent and -independent, respectively, during MTb infection, were measured as controls. (C, D) IRAK1 and TRAF6 are required for MTb induction of NFAT5 gene expression in human monocytes. THP-1 cells that constitutively express lentivirally-delivered IRAK1- or TRAF6-specific shRNA were constructed as described in Materials and Methods. THP-1 cells expressing control shRNA were used as described in 7B. Cells were infected with MTb strain CDC1551 or left uninfected for 16 hours at 37degreesC, and RNA was analyzed. NFAT5 expression was significantly inhibited in the MTb-infected cells expressing either IRAK1 (C) or TRAF6 (D) shRNA (black bars) compared to cells expressing control shRNA (open bars). TNF and CD86 mRNAs, both of which require IRAK1 and TRAF6 to be induced by PRR activation, were measured as controls. (*, p<0.05; **, p<0.01).","[{'offsets': [[4, 9]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[71, 76]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[126, 130]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[154, 159]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[225, 229]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[358, 363]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[391, 396]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[535, 540]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[575, 580]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[696, 701]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[729, 732]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[922, 927]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[998, 1003]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1149, 1152]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1157, 1161]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1197, 1202]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1301, 1306]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1311, 1316]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1351, 1356]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1456, 1461]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1466, 1471]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1574, 1579]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1723, 1728]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1812, 1817]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1825, 1830]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1891, 1896]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1910, 1913]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1918, 1922]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1952, 1957]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1962, 1967]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
290,PMC-3585731-08-Results,"PI3-kinase and PDK1 Mediate the Increase in Akt Thr308 Phosphorylation Under Necroptotic Conditions
Typical regulation of Akt by growth factors involves its recruitment to the plasma membrane, which is mediated by the binding of the pleckstrin homology (PH) domain of Akt to the product of PI3K, phosphatidylinositol-3,4,5-triphosphate (PIP3). In the membrane, Akt is phosphorylated on Thr308 and Ser473 by 3-phosphoinositide dependent protein kinase-1 (PDK1) and mTORC2 (or DNA-PK), respectively [35]. Since our results showed that only Thr308 Akt phosphorylation is increased during necroptosis, we next examined whether it is still dependent on PI3K and PDK1. Inhibition of PI3K and PDK1 using the specific inhibitors LY249002 and BX912 [36] resulted in the efficient inhibition of cell death and Akt Thr308 phosphorylation (Fig. S7A-D). Likewise, siRNA knockdown of PDK1 protected cells from death and inhibited Akt Thr308 phosphorylation (Fig. S7E,F) Therefore, PI3K and PDK1 activity is still required for non-canonical Akt activation during necroptosis.","[{'offsets': [[15, 19]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[407, 452]], 'text': ['3-phosphoinositide dependent protein kinase-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[454, 458]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[657, 661]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[686, 690]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[870, 874]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[976, 980]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
291,PMC-1472690-09-Methods,"Materials
Water soluble phosphorylated beta-1 to 3-D-glucan (GP) was prepared as done before [20]. The physicochemical characteristics of GP were determined as reported previously [20,26]. GP was dissolved in aqueous media, filter-sterilized (0.2 mum) and screened for endotoxin contamination with the Endospecy assay (Seigakaku, Tokyo, Japan), which is specific for endotoxin but does not respond to beta-1 to 3-D-glucans.",[],[],[],[],[],[]
292,PMC-3317373-09-2._Methods_and_Materials,"2.8. Gelatine Zymography
Cells of four groups were homogenized in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM CaCl2, 0.2 mM NaN3, and 0.01% Triton. Soluble extracts were separated by centrifugation and stored at -20degreesC. Gelatin zymography was performed according to the manufacturer's instructions (Genmed Scientifics Inc, MA, USA). Briefly, 40 mug cytosolic protein extracts were separated by electrophoresis. Then the proteins were renatured by incubation in 2.5% Triton X-100 and then incubated in substrate buffer for 40 h at 37degreesC to enable the MMP9 to cleave the gelatin. After rinsing in water, each gel was stained with Coomassie blue for 1 h and destained in 50% methanol. Proteolytic activities were showed by clear bands in blue gel which indicates the lysis of the substrate. Quantification of MMP9 band density was performed with image analysis program ImageJ.","[{'offsets': [[583, 587]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[839, 843]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
293,PMC-1064873-06-Materials_and_methods,"Immunoassay for IFN-gamma and IL-2
Concentrations of IFN-gamma and IL-2 in culture supernatants of CD4+ T cells were measured in duplicate by the quantitative sandwich ELISA using cytokine-specific capture with biotinylated detection mAb and recombinant cytokine proteins (all from Becton Dickinson), according to the manufacturer's protocol. The detection limits for IFN-gamma and IL-2 were 15 pg/ml.","[{'offsets': [[16, 25]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[30, 34]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 62]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[67, 71]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[99, 102]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[368, 377]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[382, 386]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
294,PMC-3589482-01-Introduction,"The inflammatory response is a double-edged sword. Properly orchestrated, it results in the clearing of foreign molecules and invading pathogens from the body. Uncontrolled, it may lead to organ damage, sepsis, and even cancer [1]-[3]. Many of the pathological manifestations of the inflammatory response are mediated by cytokines and other inducible gene products expressed by macrophages upon exposure to the gram-negative bacterial cell wall component LPS. As macrophages are key effectors of pathogen-induced innate immune responses, their survival is critical for initial pathogen neutralization and subsequent development of adaptive immune responses. One of the most LPS-inducible macrophage gene products known is the ovalbumin-like serine protease inhibitor (ov-serpin) SerpinB2, a widely recognized macrophage survival factor [4]; [5]. SerpinB2 was first identified as an inhibitor of urokinase-type plasminogen activator (uPA)[6]-[8], a serine protease involved in the degradation and turnover of the extracellular matrix through the activation of plasminogen [7]; [9]. Such function requires SerpinB2 to be secreted from the cell yet SerpinB2 exists primarily as a nonglycosylated intracellular protein [10]. Over the past decade, intracellular roles for SerpinB2 in cell survival [11]-[17], proliferation and differentiation [18]-[21], signal transduction [15]; [22]; [23] and innate immunity [24]-[28], have been described.
The SerpinB2 gene is highly regulated in a cell type specific manner analogous to that of cytokines and oncogenes [29]; [30]. It is one of the most responsive genes known [31], and can be induced over 1000-fold by LPS [31]-[32], and is up-regulated by a range of inflammatory mediators [9]. LPS activates immune responses through multiple signalling pathways. The toll-like receptor 4 (TLR4) is responsible for the recognition of LPS and other microbial products and plays a central role in the initiation of innate immune responses, including cytokine release. The binding of LPS to TLR4 on the surface of macrophages leads to the recruitment of adaptor molecules and the activation of protein kinases, generating signals to the nuclear factor-kappaB (NF-kappaB), mitogen-activated protein kinase (MAPK) and/or phosphoinositide 3(PI3)-kinase pathways [33].
In studies aimed at identifying LPS-inducible pro-survival factors downstream of p38 MAPK, SerpinB2 was identified as a factor whose expression was upregulated by cooperation of the IKKbeta/NF-kappaB and p38 MAPK/CREB pathways [16]. Our previously published data indicated that SerpinB2 is distinctly regulated from other LPS-inducible genes in terms of kinetics, LPS dose response and sensitivity to IFN-gamma co-stimulation [4]; however, the cis-acting elements in the SerpinB2 promoter responsible for LPS-dependent transcription in macrophages and the specific LPS-responsive transcription factors that bind the SerpinB2 promoter were not defined. Here we show that LPS induction of SerpinB2 is dependent upon cis-acting regulatory sequences in the region between nucleotides -189 and -539 of the murine SerpinB2 promoter, and is critically dependent upon a C/EBP binding site at -203/-195. C/EBP-beta directly bound to this site in vivo and its deficiency abrogated constitutive SerpinB2 expression and SerpinB2 induction by LPS. Importantly, a C/EBP-beta phospho-acceptor site was found to negatively regulate LPS-induced SerpinB2 promoter activity. Together, these findings provide new insight into the transcriptional regulation of the SerpinB2 gene.","[{'offsets': [[779, 787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[846, 854]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[895, 931]], 'text': ['urokinase-type plasminogen activator'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[933, 936]], 'text': ['uPA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1059, 1070]], 'text': ['plasminogen'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1104, 1112]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1146, 1154]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1267, 1275]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1442, 1450]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1802, 1822]], 'text': ['toll-like receptor 4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1824, 1828]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2022, 2026]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2387, 2395]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2478, 2485]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2574, 2582]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2697, 2706]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2767, 2775]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2912, 2920]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2983, 2991]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3104, 3112]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3191, 3201]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3280, 3288]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3304, 3312]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3346, 3356]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3424, 3432]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3540, 3548]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
295,PMC-3291650-09-Materials_and_Methods,"Determination of HAI (hemagglutination inhibition) titers
To determine the HAI titers in infected mice, sera of these were treated with receptor-destroying enzyme (RDE/Cholera filtrate; Sigma) to remove sialic acids from serum proteins capable of aspecific inhibition of agglutination. After incubation overnight at 37degreesC, the RDE was inactivated by addition of 0.75% sodium citrate in PBS and heating to 56degreesC for 30 min. To remove sialic acid binding proteins, sera were cleared with 1/10 volume 50% chicken RBC. Titration was done by incubating a two-fold dilution series of sera with 4 HA units of X-47 virus for 1 hour at room temperature in 96-well U-bottom plates. Finally, an equal volume of 0.5% chicken RBC was added and titers were read 30 min later. Negative controls included PBS instead of immune serum (agglutination control) or PR8 instead of X-47 virus (control for agglutination effect of sera); as positive control, serum from a mouse infected twice with a sublethal dose of X-47 was used.",[],[],[],[],[],[]
296,PMC-3589482-24-Caption-Figure_1,"LPS induction of SerpinB2 mRNA and protein expression in murine macrophage cells.
RAW264.7 macrophages were treated for the indicated times with 100 ng/ml LPS. (A) qPCR analysis of murine SerpinB2 mRNA levels, relative to beta-actin. The plot is representative of at least two independent experiments performed in triplicate. (B) Immunoblot analysis of SerpinB2 protein expression in whole cell lysates. Blot was reprobed for GAPDH as a loading control.","[{'offsets': [[17, 25]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[188, 196]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[222, 232]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[353, 361]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[426, 431]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
297,PMC-3586680-09-Caption-Figure_1,"Schematic diagrams of WWOX structure and its role in signaling. WWOX contains two N-terminal WW domains, a C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, and a D3 region. A nuclear localization signal (NLS) is in between the WW domains (Chang et al., 2003, 2007; Del Mare et al., 2011; Salah et al., 2012; Su et al., 2012; reviews). The SDR domain possesses a mitochondria-binding region. There are two conserved tyrosine phosphorylation sites, Tyr33 and Tyr287. Other phosphorylation sites predicted by NetPhos 2.0 Server are Tyr6, Thr12, Ser14, Tyr61, Tyr293, and Thr3B3, respectively. Upon stress stimulation, WWOX is phosphorylated in Tyr33 and binds p53. The WWOX/p53 complex then translocates to mitochondria or nucleus to induce apoptosis. WWOX also binds PPxY motif-containing transcription factors, such as RUNX2, c-Jun, and ERBB4, via its first WW domain, and the binding blocks the activity of these proteins by retaining them in the cytoplasm. WWOX binds Tau via its SDR domain. WWOX participates in the Wnt/beta-catenin signal pathway by binding Dvl and inhibiting its nuclear import. Phorbol ester stimulates the dissociation of MEK/WWOX complex in Jurkat T cell, and the released WWOX translocates to the mitochondria for causing cell death. WWOX is recruited to the membrane area by association with Hyal-2 and phospho-Ezrin. Hyal-2 is an alternative receptor for TGF-beta1. In response to TGF-beta1, WWOX binds Hyal-2 and forms a complex, followed by relocating to the nucleus and enhancing the SMAD-driven promoter activity. Ack1, activated Cdc42-associated kinase 1; Hyal-2, hyaluronoglucosaminidase 2; CKI, casein kinase; GSK, glycogen synthase kinase; PKA, protein kinase A.","[{'offsets': [[22, 26]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[64, 68]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[635, 639]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[677, 680]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[769, 773]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[838, 843]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[845, 850]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[856, 861]], 'text': ['ERBB4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[978, 982]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[989, 992]], 'text': ['Tau'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1013, 1017]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1217, 1221]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1279, 1283]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1338, 1344]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1357, 1362]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1364, 1370]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1402, 1411]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1428, 1437]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1439, 1443]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1450, 1456]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1565, 1569]], 'text': ['Ack1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1571, 1606]], 'text': ['activated Cdc42-associated kinase 1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1608, 1614]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1616, 1642]], 'text': ['hyaluronoglucosaminidase 2'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
298,PMC-3312845-20-Caption-Figure_2,"Effect of sTNFp55R infusion on SE-induced serum-protein extravasation and neuronal damage. (A-D) Serum-protein extravasation and FJB-positive neuronal damages in the PC 3 days after SE. Compared to saline-infused animals, serum-protein extravasation and FJB-positive neuronal damage is markedly ameliorated in sTNFp55R-infused animals. Bars = 400 (A and C) and 50 (B and D) mum. (E) Quantitative analyses of serum-protein extravasation and FJB-positive neuronal damage in the PC 3 days after SE (mean +/- S.E.M). Significant differences from saline-treated animals, *p < 0.05.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[311, 318]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
299,PMC-1064895-11-Materials_and_methods,"Statistical analysis
Data are expressed as means +/- SEM. Statistical analysis was performed with Student's t-test for matched pairs. P values less than 0.05 were considered significant.",[],[],[],[],[],[]
300,PMC-3585731-21-Materials_and_Methods,"qRT-PCR
Cells were treated as described for Western blots. Total RNA was isolated using ZR Miniprep kit (Zymo Research). 1 microg of RNA was converted to cDNA using random primers (M-MuLV cDNA kit, New England Biolabs). 1 microL of cDNA was used with 500 pM primers in qPCR reactions. Reactions were performs using SYBRGreen 2xMaster mix (SABiosciences) in a LightCycler480 (Roche).",[],[],[],[],[],[]
301,PMC-3342329-09-Materials_and_Methods,"Animals
The CCR5 wild type (CCR5+/+) and CCR5 knockout (CCR5-/-) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine 04609 USA). The mice were housed and bred under specific pathogen free conditions at the Laboratory Animal Research Center of Chungbuk National University, Korea. The mice (n = 4/cage) were maintained in a room with a constant temperature of 22+/-1degreesC, relative humidity of 55+/-10%, and 12-h light/dark cycle, and fed standard rodent chow (Samyang, Korea) and purified tap water ad libitum. The CCR5+/+ mice (n = 20) and CCR5-/- mice (n = 20), that were used, had matched ages (10-11 weeks old) and weights (16-19 g). Control mice (B6129PF2/J) were F2 hybrid mice from the C57BL/6J-AW-J and 129P3/J parental strains. CCR5 mice (B6, 129P2-Ccr5tm1Kuz/J) have the entire coding region of the CCR5 gene deleted from the parental strains, B6;129P2-Ccr5tm1kuz and B6;129P2-Cmkbr5tm1Kuz.","[{'offsets': [[12, 16]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 32]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 45]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[56, 60]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[533, 537]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[559, 563]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[755, 759]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[827, 831]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
302,PMC-3291650-00-TIAB,"A20 (Tnfaip3) Deficiency in Myeloid Cells Protects against Influenza A Virus Infection
The innate immune response provides the first line of defense against viruses and other pathogens by responding to specific microbial molecules. Influenza A virus (IAV) produces double-stranded RNA as an intermediate during the replication life cycle, which activates the intracellular pathogen recognition receptor RIG-I and induces the production of proinflammatory cytokines and antiviral interferon. Understanding the mechanisms that regulate innate immune responses to IAV and other viruses is of key importance to develop novel therapeutic strategies. Here we used myeloid cell specific A20 knockout mice to examine the role of the ubiquitin-editing protein A20 in the response of myeloid cells to IAV infection. A20 deficient macrophages were hyperresponsive to double stranded RNA and IAV infection, as illustrated by enhanced NF-kappaB and IRF3 activation, concomitant with increased production of proinflammatory cytokines, chemokines and type I interferon. In vivo this was associated with an increased number of alveolar macrophages and neutrophils in the lungs of IAV infected mice. Surprisingly, myeloid cell specific A20 knockout mice are protected against lethal IAV infection. These results challenge the general belief that an excessive host proinflammatory response is associated with IAV-induced lethality, and suggest that under certain conditions inhibition of A20 might be of interest in the management of IAV infections.","[{'offsets': [[5, 12]], 'text': ['Tnfaip3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[373, 402]], 'text': ['pathogen recognition receptor'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[403, 408]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[936, 940]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
303,PMC-1359074-15-Materials_and_Methods,"Nuclear protein extract and in vitro translation of Sox6.
Nuclear extracts were prepared from MEL cells (2 x 107) using a kit (Active Motif, Carlsbad, California, United States). The Sox6 in vitro translation expression vector, tagged with c-Myc and HA, was described before [15]. The translation was performed in a reticulocyte lysate based in vitro translational system (TNT(R) Quick Coupled Transcription/Translation Systems, Promega). A vector without the Sox6 coding sequence was also translated as a negative control.","[{'offsets': [[52, 56]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 187]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[240, 245]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[250, 252]], 'text': ['HA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[460, 464]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
304,PMC-3320587-07-Materials_and_Methods,"HIV-1 infectious molecular clones
The plasmid encoding the full-length infectious molecular clone of HIV-1Lai was obtained from the NIH AIDS Reagent and Reference Program. The HIV-1Lai/Bal-Env infectious molecular clone was constructed by replacing the envelope (env) gp160 amino acids 103-717 of the HIV-1Lai (B subtype that utilizes CXCR4) molecular clone with the corresponding region of HIV-1Bal (B subtype that utilizes CCR5). The HIV-1Lai/Bal-Env chimeric virus uses CCR5 as a secondary receptor. The infectious molecular clone of HIV-198IN22 was constructed using DNA extracted from PBMC that were infected with a primary isolate of HIV-198IN22. HIV-1Lai/Bal-Env and HIV-198IN22 mutant viruses were constructed by introducing point mutations using standard PCR-based mutagenesis methods.","[{'offsets': [[268, 273]], 'text': ['gp160'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[335, 340]], 'text': ['CXCR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[425, 429]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
